PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Ballard, VLT; Sharma, A; Duignan, I; Holm, JM; Chin, A; Choi, R; Hajjar, KA; Wong, SC; Edelberg, JM				Ballard, Victoria L. T.; Sharma, Arti; Duignan, Inga; Holm, Jacquelyne M.; Chin, Andrew; Choi, Ruby; Hajjar, Katherine A.; Wong, Shing-Chiu; Edelberg, Jay M.			Vascular tenascin-C regulates cardiac endothelial phenotype and neovascularization	FASEB JOURNAL			English	Article						heart; bone marrow; angiogenesis; EPC	PROGENITOR CELLS; INTEGRIN ALPHA-8-BETA-1; EXTRACELLULAR-MATRIX; ADHESION; EXPRESSION; CARDIOPROTECTION; ANGIOGENESIS; REGENERATION; FIBRONECTIN; IMPAIRMENT	Microenvironmental cues mediate postnatal neovascularization via modulation of endothelial cell and bone marrow-derived endothelial progenitor cell (EPC) activity. Numerous signals regulate the activity of both of these cell types in response to vascular injury, which suggests that parallel mechanisms regulate angiogenesis in the vascular beds of both the heart and bone marrow. To identify mediators of such shared pathways, in vivo bone marrow/cardiac phage display biopanning was performed and led to the identification of tenascin-C as a candidate protein. Functionally, tenascin-C inhibits cardiac endothelial cell spreading and enhances migration in response to angiogenic growth factors. Analysis of human coronary thrombi revealed tenascin-C protein expression colocalized with the endothelial cell/EPC marker Tie-2 in intrathrombi vascular channels. Immunostains in the rodent heart demonstrated that tenascin-C also colocalizes with EPCs homing to sites of cardiac angiogenic induction. To determine the importance of tenascin-C in cardiac neovascularization, we used an established cardiac transplantation model and showed that unlike wild-type mice, tenascin-C-/- mice fail to vascularize cardiac allografts. This demonstrates for the first time that tenascin-C is essential for postnatal cardiac angiogenic function. Together, our data highlight the role of tenascin-C as a microenvironmental regulator of cardiac endothelial/EPC activity.	Cornell Univ, Weill Med Coll, Dept Med, Div Cardiol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Cell & Dev Biol, New York, NY 10021 USA	Cornell University; Cornell University	Edelberg, JM (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Cardiol, 520 E 70th St, New York, NY 10021 USA.	jme2002@med.cornell.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019738, R03AG020320, R01AG020918] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67839] Funding Source: Medline; NIA NIH HHS [AG19738, AG20918, AG20320] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8; Avecilla ST, 2004, NAT MED, V10, P64, DOI 10.1038/nm973; Cai DQ, 2003, AM J PHYSIOL-HEART C, V285, pH463, DOI 10.1152/ajpheart.00144.2003; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Choi K, 1998, DEVELOPMENT, V125, P725; Denda S, 1998, MOL BIOL CELL, V9, P1425, DOI 10.1091/mbc.9.6.1425; Edelberg JM, 1998, J CLIN INVEST, V102, P837, DOI 10.1172/JCI3058; Edelberg JM, 2002, CIRC RES, V90, pE89, DOI 10.1161/01.RES.0000020861.20064.7E; Edelberg JM, 2001, CIRC RES, V89, P117, DOI 10.1161/hh1401.093954; Edelberg JM, 2002, CIRCULATION, V105, P608, DOI 10.1161/hc0502.103672; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Graff J, 2002, J PHARMACOL EXP THER, V300, P952, DOI 10.1124/jpet.300.3.952; IMAI K, 1994, FEBS LETT, V352, P216, DOI 10.1016/0014-5793(94)00960-0; Imanaka-Yoshida K, 2001, LAB INVEST, V81, P1015, DOI 10.1038/labinvest.3780313; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Jallo GI, 1997, NEUROSURGERY, V41, P1052, DOI 10.1097/00006123-199711000-00007; Jones PL, 2000, MATRIX BIOL, V19, P581, DOI 10.1016/S0945-053X(00)00106-2; JOSHI P, 1993, J CELL SCI, V106, P389; Kajiwara K, 2004, CIRC J, V68, P198, DOI 10.1253/circj.68.198; Kale S, 2004, FASEB J, V18, P270, DOI 10.1096/fj.04-1604fje; Kalka C, 2000, ANN THORAC SURG, V70, P829, DOI 10.1016/S0003-4975(00)01633-7; Kiernan BW, 1996, MOL CELL NEUROSCI, V7, P322, DOI 10.1006/mcne.1996.0024; LAFLEUR DW, 1994, J BIOL CHEM, V269, P20757; Matsuda A, 1999, INVEST OPHTH VIS SCI, V40, P1071; Modarai B, 2005, CIRCULATION, V111, P2645, DOI 10.1161/CIRCULATIONAHA.104.492678; Moldovan NI, 2003, TRENDS CARDIOVAS MED, V13, P265, DOI 10.1016/S1050-1738(03)00108-7; Muller WA, 2002, LAB INVEST, V82, P521, DOI 10.1038/labinvest.3780446; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; NISHIDA M, 1993, AM J PHYSIOL, V264, pH639, DOI 10.1152/ajpheart.1993.264.2.H639; Ohta M, 1998, BLOOD, V91, P4074; Paganelli G, 2001, CANCER BIOTHER RADIO, V16, P227, DOI 10.1089/10849780152389410; Paik DC, 2004, EXP MOL MED, V36, P524, DOI 10.1038/emm.2004.67; Schenk S, 1999, MOL BIOL CELL, V10, P2933, DOI 10.1091/mbc.10.9.2933; SCHNAPP LM, 1995, J BIOL CHEM, V270, P23196, DOI 10.1074/jbc.270.39.23196; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; SRIRAMARAO P, 1993, J CELL SCI, V105, P1001; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; TAN SS, 1987, P NATL ACAD SCI USA, V84, P7977, DOI 10.1073/pnas.84.22.7977; VanderVeldeZimmermann D, 1997, EXP CELL RES, V230, P111, DOI 10.1006/excr.1996.3405; VARNUMFINNEY B, 1995, NEURON, V14, P1213, DOI 10.1016/0896-6273(95)90268-6; Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953; Walter DH, 2002, HERZ, V27, P579, DOI 10.1007/s00059-002-2427-y; Whitlon DS, 1999, J COMP NEUROL, V406, P361, DOI 10.1002/(SICI)1096-9861(19990412)406:3<361::AID-CNE5>3.0.CO;2-O; Xaymardan M, 2004, J EXP MED, V199, P797, DOI 10.1084/jem.20031639; Xaymardan M, 2004, CIRC RES, V94, pE39, DOI 10.1161/01.RES.0000122042.51161.B6; Zagzag D, 2002, HISTOL HISTOPATHOL, V17, P301, DOI 10.14670/HH-17.301; Ziegelhoeffer T, 2004, CIRC RES, V94, P230, DOI 10.1161/01.RES.0000110419.50982.1C	48	65	79	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					717	+		10.1096/fj.05-5131fje	http://dx.doi.org/10.1096/fj.05-5131fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16461331				2022-12-28	WOS:000237698700039
J	Drouineaud, V; Lagrost, L; Klein, A; Desrumaux, C; Le Guern, N; Athias, A; Menetrier, F; Moiroux, P; Sagot, P; Jimenez, C; Masson, D; Deckert, V				Drouineaud, Veronique; Lagrost, Laurent; Klein, Alexis; Desrumaux, Catherine; Le Guern, Naig; Athias, Anne; Menetrier, Franck; Moiroux, Philippe; Sagot, Paul; Jimenez, Clement; Masson, David; Deckert, Valerie			Phospholipid transfer protein (PLTP) deficiency reduces sperm motility and impairs fertility of mouse males.	FASEB JOURNAL			English	Article						alpha-tocopherol; vitamin E; reproductive biology	IN-VITRO FERTILIZATION; ALPHA-TOCOPHEROL; VITAMIN-E; HUMAN SPERMATOZOA; PLASMA; MICE; PATHOPHYSIOLOGY; CHOLESTEROL; INFERTILITY; METABOLISM	Vitamin E was discovered for its implication in reproductive biology, and its transport in mammalian plasma and brain was shown to be governed by plasma phospholipid transfer protein (PLTP). We show that PLTP deficiency is associated with hypofertility of mouse males but not mouse females, and it accounts for a significant decrease in total number of pups produced over a 2-month breeding period of PLTP knocked out mice (-32%, P < 0.03). PLTP is highly expressed in epididymis of mouse males, and alpha-tocopherol, the main vitamin E isomer in vivo, was significantly less abundant in cauda and caput epididymis of PLTP-deficient mice as compared with wild-type counterparts ( caput: -26%, P < 0.05; cauda: -21%, P < 0.05). Mature spermatozoa from PLTP- deficient epididymis were shown to retain an abnormal alpha-tocopherol content. PLTP deficiency tended to reduce sperm motility as shown by a 24% reduction in spermatozoa with progressive motility (P < 0.02), with no change in other sperm parameters as compared with wild-type males. Finally, in vitro fertilization rates of wild-type oocytes with spermatozoa from PLTP- deficient males were markedly reduced as compared with those measured with spermatozoa from wild-type males (-60%, P < 0.05). It is concluded that PLTP is a new, key factor that determines sperm motility and male fertility.	INSERM, U498, Fac Med, F-21079 Dijon, France; EA Genet & Reprod, Lab Biol Reprod, Dijon, France; Fac Med, IFR 100, Dijon, France; Hop Bocage, Serv Gynecol Obstet, Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Bourgogne; CHU Dijon Bourgogne	Lagrost, L (corresponding author), INSERM, U498, Fac Med, 7 Bd Jeanne Arc,BP87900, F-21079 Dijon, France.	laurent.lagrost@u-bourgogne.fr; valerie.deckert@u-bourgogne.fr	Desrumaux, Catherine/O-1925-2018; Masson, David/R-6633-2019; MASSON, David/AAC-8896-2022; MASSON, David/R-4557-2017	MASSON, David/0000-0003-1692-0699; MASSON, David/0000-0003-1692-0699; DECKERT, Valerie/0000-0001-5728-1710				Agarwal A, 2005, FERTIL STERIL, V84, P228, DOI 10.1016/j.fertnstert.2004.12.057; Agarwal A, 2003, FERTIL STERIL, V79, P829, DOI 10.1016/S0015-0282(02)04948-8; AHKONG QF, 1973, BIOCHEM J, V136, P147, DOI 10.1042/bj1360147; ALBERS JJ, 1995, BBA-LIPID LIPID MET, V1258, P27, DOI 10.1016/0005-2760(95)00091-P; Breininger E, 2005, THERIOGENOLOGY, V63, P2126, DOI 10.1016/j.theriogenology.2004.08.016; Christiansen-Weber TA, 2000, AM J PATHOL, V157, P1017, DOI 10.1016/S0002-9440(10)64614-7; Desrumaux C, 1999, FASEB J, V13, P883, DOI 10.1096/fasebj.13.8.883; Desrumaux C, 2004, FASEB J, V18, P296, DOI 10.1096/fj.04-2400fje; ELIASSON R, 1977, FERTIL STERIL, V28, P1257; Evans HM, 1922, SCIENCE, V56, P650, DOI 10.1126/science.56.1458.650; Gatti JL, 2004, ANIM REPROD SCI, V82-3, P321, DOI 10.1016/j.anireprosci.2004.05.011; Geva E, 1996, FERTIL STERIL, V66, P430, DOI 10.1016/S0015-0282(16)58514-8; INGOLD KU, 1987, LIPIDS, V22, P163, DOI 10.1007/BF02537297; Jiang XC, 2002, J BIOL CHEM, V277, P31850, DOI 10.1074/jbc.M205077200; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Jiang XC, 2001, NAT MED, V7, P847, DOI 10.1038/89977; Jishage K, 2001, J BIOL CHEM, V276, P1669, DOI 10.1074/jbc.C000676200; Kaempf-Rotzoll DE, 2003, CURR OPIN LIPIDOL, V14, P249, DOI 10.1097/00041433-200306000-00004; Katsanidis E, 1999, FREE RADICAL BIO MED, V27, P1137, DOI 10.1016/S0891-5849(99)00205-1; Keskes-Ammar L, 2003, ARCH ANDROLOGY, V49, P83, DOI 10.1080/713828100; KESSOPOULOU E, 1995, FERTIL STERIL, V64, P825, DOI 10.1016/S0015-0282(16)57861-3; Lagrost L, 1998, CURR OPIN LIPIDOL, V9, P203, DOI 10.1097/00041433-199806000-00004; LILFORD R, 1994, BMJ-BRIT MED J, V309, P570, DOI 10.1136/bmj.309.6954.570; Mardones P, 2002, J NUTR, V132, P443, DOI 10.1093/jn/132.3.443; Masson D, 2003, MOL HUM REPROD, V9, P457, DOI 10.1093/molehr/gag062; Miettinen HE, 2001, J CLIN INVEST, V108, P1717, DOI 10.1172/JCI13288; Neild DM, 2005, MOL REPROD DEV, V72, P230, DOI 10.1002/mrd.20322; Pena FJ, 2004, ZYGOTE, V12, P117, DOI 10.1017/S096719940400262X; Schlitt A, 2003, ARTERIOSCL THROM VAS, V23, P1857, DOI 10.1161/01.ATV.0000094433.98445.7F; Schlitt A, 2005, BBA-MOL CELL BIOL L, V1733, P187, DOI 10.1016/j.bbalip.2004.12.011; Schneider M, 2004, DIABETES, V53, P2633, DOI 10.2337/diabetes.53.10.2633; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; Therond P, 1996, MOL HUM REPROD, V2, P739, DOI 10.1093/molehr/2.10.739; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Vallee M, 2000, ANAL BIOCHEM, V287, P153, DOI 10.1006/abio.2000.4841; World Heath Organization (WHO), 2000, WHO LAB MAN EX HUM S; WYROBEK AJ, 1975, P NATL ACAD SCI USA, V72, P4425, DOI 10.1073/pnas.72.11.4425; Xian-Cheng J, 2005, J BIOL CHEM, V280, P18336, DOI 10.1074/jbc.M500007200; Yang XP, 2003, ARTERIOSCL THROM VAS, V23, P1601, DOI 10.1161/01.ATV.0000085841.55248.13	39	15	15	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					794	+		10.1096/fj.05-5385fje	http://dx.doi.org/10.1096/fj.05-5385fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16467369				2022-12-28	WOS:000237698700032
J	Farrar, CA; Zhou, WD; Lin, T; Sacks, SH				Farrar, Conrad A.; Zhou, Wuding; Lin, Tao; Sacks, Steven H.			Local extravascular pool of C3 is a determinant of postischemic acute renal failure	FASEB JOURNAL			English	Article						renal transplant; immune regulation; complement	COMPLEMENT COMPONENT C3; ISCHEMIA-REPERFUSION INJURY; P-SELECTIN; GENE-EXPRESSION; ACUTE REJECTION; FACTOR-B; BIOSYNTHESIS; KIDNEY; IMMUNOLOGY; ACTIVATION	The third complement component (C3) is an acute phase protein that plays a central role in reperfusion injury in several organ models. To investigate the contribution of local synthesis of C3 and distinguish it from that of circulating complement mainly produced by hepatic synthesis, we employed a mouse renal isograft model. Our model demonstrated a close relationship between the extent of intrarenal expression of C3 and cold-ischemia induced injury. Ischemic C3-positive donor kidneys transplanted into C3-positive or C3-negative recipients developed widespread tissue damage and severe acute renal failure. In contrast, ischemic C3-negative isografts exhibited only mild degrees of functional and structural disturbance, even when transplanted into normal C3-positive recipients. Thus local synthesis of C3, mostly identified in the tubular epithelium, was essential for complement-mediated reperfusion damage, whereas circulating C3 had a negligible effect. Our results suggest a two-compartment model for the pathogenic function of C3, in which the extravascular compartment is the domain of local synthesis of C3, and where the role of circulating C3 is redundant. Our data cast new light on the mechanism of complement-mediated tissue injury in nonimmunological disorders, and challenges the longstanding dogma that circulating components are the main complement effectors of extravascular tissue damage.	Kings Coll London, Dept Nephrol & Transplantat, Guys Hosp, Sch Med, London SE1 9RT, England; Kings Coll London, Dept Nephrol & Transplantat, Kings Coll Hosp, Sch Med, London SE1 9RT, England; Kings Coll London, Dept Nephrol & Transplantat, St Thomas Hosp, Sch Med, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Sacks, SH (corresponding author), Kings Coll London, Dept Nephrol & Transplantat, Guys Hosp, Sch Med, 5th Floor,Thomas Guy House, London SE1 9RT, England.	steven.sacks@kcl.ac.uk		Sacks, Steven/0000-0001-6361-9095	MRC [G0000771] Funding Source: UKRI; Medical Research Council [G0000771] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Bao LH, 2003, J AM SOC NEPHROL, V14, P670, DOI 10.1097/01.ASN.0000051597.27127.A1; BARTOK I, 1995, J IMMUNOL, V154, P5367; BIANCONE L, 1994, KIDNEY INT, V45, P451, DOI 10.1038/ki.1994.59; Bonventre JV, 2003, J AM SOC NEPHROL, V14, P2199, DOI 10.1097/01.ASN.0000079785.13922.F6; BOTTO M, 1992, J IMMUNOL, V149, P1348; BROOIMANS RA, 1991, J CLIN INVEST, V88, P379, DOI 10.1172/JCI115314; COLTEN HR, 1992, J APPL PHYSIOL, V72, P1; David S, 1997, NEPHROL DIAL TRANSPL, V12, P51, DOI 10.1093/ndt/12.1.51; de Vries B, 2003, J IMMUNOL, V170, P3883, DOI 10.4049/jimmunol.170.7.3883; Eppinger MJ, 1997, AM J PATHOL, V150, P1773; Farrar CA, 2004, AM J PATHOL, V164, P133, DOI 10.1016/S0002-9440(10)63104-5; Fischer MB, 1998, J IMMUNOL, V160, P2619; Fischer MB, 1996, J IMMUNOL, V157, P549; Gerritsma JSJ, 1996, MOL IMMUNOL, V33, P847, DOI 10.1016/0161-5890(96)84610-4; Heinzelmann M, 1999, AM J KIDNEY DIS, V34, P384, DOI 10.1016/S0272-6386(99)70375-6; Hoffmann S, 2004, KIDNEY INT, V66, P1686, DOI 10.1111/j.1523-1755.2004.00936.x; Ikai M, 1996, CLIN EXP IMMUNOL, V106, P156, DOI 10.1046/j.1365-2249.1996.d01-817.x; JAESCHKE H, 1993, AM J PHYSIOL, V264, pG801, DOI 10.1152/ajpgi.1993.264.4.G801; KALINA SL, 1993, AUST NZ J SURG, V63, P213, DOI 10.1111/j.1445-2197.1993.tb00521.x; Kelly KJ, 1996, J CLIN INVEST, V97, P1056, DOI 10.1172/JCI118498; MCPHADEN AR, 1993, IMMUNOL RES, V12, P213, DOI 10.1007/BF02918254; Moller-Kristensen M, 2005, SCAND J IMMUNOL, V61, P426, DOI 10.1111/j.1365-3083.2005.01591.x; MOLMENTI EP, 1993, J BIOL CHEM, V268, P14116; Morgan BP, 1997, CLIN EXP IMMUNOL, V107, P1, DOI 10.1046/j.1365-2249.1997.d01-890.x; Mulligan MS, 1999, J IMMUNOL, V162, P4952; PASSWELL J, 1988, J CLIN INVEST, V82, P1676, DOI 10.1172/JCI113780; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Pratt JR, 2003, AM J PATHOL, V163, P1457, DOI 10.1016/S0002-9440(10)63503-1; Pratt JR, 2002, NAT MED, V8, P582, DOI 10.1038/nm0602-582; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sheerin NS, 1997, KIDNEY INT, V51, P703, DOI 10.1038/ki.1997.101; Shoskes DA, 1998, TRANSPLANTATION, V66, P1697, DOI 10.1097/00007890-199812270-00022; Singbartl K, 2000, FASEB J, V14, P48, DOI 10.1096/fasebj.14.1.48; Springall T, 2001, NAT MED, V7, P801, DOI 10.1038/89923; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Takada M, 1997, J CLIN INVEST, V99, P2682, DOI 10.1172/JCI119457; Tang S, 1999, J AM SOC NEPHROL, V10, P69; Tang S, 1999, J IMMUNOL, V162, P4336; Thurman JM, 2003, J IMMUNOL, V170, P1517, DOI 10.4049/jimmunol.170.3.1517; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; Yasojima K, 1998, CIRC RES, V82, P1224, DOI 10.1161/01.RES.82.11.1224; Zhou WD, 2000, J CLIN INVEST, V105, P1363, DOI 10.1172/JCI8621; Zhou WD, 2001, KIDNEY INT, V59, P1227, DOI 10.1046/j.1523-1755.2001.0590041227.x	46	142	146	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					217	226		10.1096/fj.05-4747com	http://dx.doi.org/10.1096/fj.05-4747com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449793				2022-12-28	WOS:000237698700006
J	Maillard, P; Huby, T; Andreo, U; Moreau, M; Chapman, J; Budkowska, A				Maillard, Patrick; Huby, Thierry; Andreo, Ursula; Moreau, Martine; Chapman, John; Budkowska, Agata			The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/Cla1 is mediated by ApoB-containing lipoproteins	FASEB JOURNAL			English	Article						candidate receptors; VLDL; hepatoma cells	HIGH-DENSITY-LIPOPROTEIN; NEUTRALIZING ANTIBODIES; SR-BI; HYPERVARIABLE REGION-1; CANDIDATE RECEPTOR; ENVELOPE PROTEIN; PARTICLES; ENTRY; INFECTION; BINDING	The possible role of candidate receptors in the cellular penetration of HCV from serum of infected patients remains unclear. SR-BI/Cla1 interacts with plasma HDL, native and modified LDL, and VLDL, and facilitates cellular cholesterol efflux to lipoprotein acceptors. SR-BI/Cla1 binds HCV E2 protein and interacts with HCV pseudotypes via the HVR1 of the E2 envelope glycoprotein. Our data reveal that functional SR-BI/Cla1 expressed on the surface of CHO cells mediates the binding and uptake of HCV from the sera of infected patients. Interaction between HCV and SR-BI/Cla1 is not sensitive to either anti-E2 or anti-HVR1 antibodies but is effectively inhibited by anti-beta lipoprotein antibodies and competed out by apoB-containing lipoproteins and notably by VLDL. We interpret our data to indicate that VLDL associated with or incorporated into HCV plays a critical role in the primary interaction of HCV with SR-BI/Cla1, whereas the HCV E2 protein does not. In addition, our findings in hepatoma cell lines suggest that the interaction of HCV with human hepatocytes is equally mediated, at least in a part, by VLDL, and as such may represent an alternative pathway for infection. The association of HCV with ApoB-containing lipoproteins may promote cellular uptake of this virus in the presence of neutralizing antibodies.	Inst Pasteur, Hepacivirus Unit, F-75724 Paris 15, France; INSERM, U551, Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm)	Budkowska, A (corresponding author), Inst Pasteur, Hepacivirus Unit, 25 Rue Dr Roux, F-75724 Paris 15, France.	abudkow@pasteur.fr	HUBY, Thierry/N-4820-2019; Huby, Thierry/E-6768-2017	HUBY, Thierry/0000-0001-6634-551X; Huby, Thierry/0000-0001-6634-551X				Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Andre P, 2002, J VIROL, V76, P6919, DOI 10.1128/JVI.76.14.6919-6928.2002; Andre P, 2005, SEMIN LIVER DIS, V25, P93, DOI 10.1055/s-2005-864785; Bartosch B, 2005, J VIROL, V79, P8217, DOI 10.1128/JVI.79.13.8217-8229.2005; Bartosch B, 2003, J BIOL CHEM, V278, P41624, DOI 10.1074/jbc.M305289200; Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; Baumert TF, 1998, J VIROL, V72, P3827, DOI 10.1128/JVI.72.5.3827-3836.1998; BRADLEY D, 1991, J MED VIROL, V34, P206, DOI 10.1002/jmv.1890340315; BRADLEY DW, 1990, GASTROENTEROLOGY, V99, P1054, DOI 10.1016/0016-5085(90)90626-C; CHAPMAN MJ, 1981, J LIPID RES, V22, P339; Cormier EG, 2004, P NATL ACAD SCI USA, V101, P7270, DOI 10.1073/pnas.0402253101; Forns X, 2000, P NATL ACAD SCI USA, V97, P13318, DOI 10.1073/pnas.230453597; Germi R, 2002, J MED VIROL, V68, P206, DOI 10.1002/jmv.10196; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; Lambot M, 2002, J BIOL CHEM, V277, P20625, DOI 10.1074/jbc.M111020200; Lim SP, 2002, VIROLOGY, V303, P79, DOI 10.1006/viro.2002.1687; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; Lozach PY, 2003, J BIOL CHEM, V278, P20358, DOI 10.1074/jbc.M301284200; Maillard P, 2001, J VIROL, V75, P8240, DOI 10.1128/JVI.75.17.8240-8250.2001; Masciopinto F, 2004, EUR J IMMUNOL, V34, P2834, DOI 10.1002/eji.200424887; Monazahian M, 1999, J MED VIROL, V57, P223, DOI 10.1002/(SICI)1096-9071(199903)57:3<223::AID-JMV2>3.0.CO;2-4; MORRIS KM, 1982, SCIENCE, V215, P399, DOI 10.1126/science.7199205; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; Petit JM, 2003, AM J GASTROENTEROL, V98, P1150, DOI 10.1016/S0002-9270(03)00106-0; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; Prince AM, 1996, J VIRAL HEPATITIS, V3, P11, DOI 10.1111/j.1365-2893.1996.tb00075.x; Rhainds D, 2004, INT J BIOCHEM CELL B, V36, P39, DOI 10.1016/S1357-2725(03)00173-0; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Rodriguez E, 1996, J VIROL, V70, P3470; Scarselli E, 2002, EMBO J, V21, P5017, DOI 10.1093/emboj/cdf529; Serfaty L, 2001, J HEPATOL, V34, P428, DOI 10.1016/S0168-8278(00)00036-2; Shelness GS, 2001, CURR OPIN LIPIDOL, V12, P151, DOI 10.1097/00041433-200104000-00008; SHIMIZU YK, 1994, J VIROL, V68, P1494, DOI 10.1128/JVI.68.3.1494-1500.1994; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; THOMSSEN R, 1992, MED MICROBIOL IMMUN, V181, P293, DOI 10.1007/BF00198849; Trigatti BL, 2000, BBA-MOL CELL BIOL L, V1529, P276, DOI 10.1016/S1388-1981(00)00154-2; Triyatni M, 2002, J VIROL, V76, P9335, DOI 10.1128/JVI.76.18.9335-9344.2002; Voisset C, 2005, J BIOL CHEM, V280, P7793, DOI 10.1074/jbc.M411600200; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Yu MYW, 2004, P NATL ACAD SCI USA, V101, P7705, DOI 10.1073/pnas.0402458101; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102	42	117	123	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					735	+		10.1096/fj.05-4728fje	http://dx.doi.org/10.1096/fj.05-4728fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16476701				2022-12-28	WOS:000237698700022
J	Tatebayashi, Y; Planel, E; Chui, DH; Sato, S; Miyasaka, T; Sahara, N; Murayama, M; Kikuchi, N; Yoshioka, K; Rivka, R; Takashima, A				Tatebayashi, Yoshitaka; Planel, Emmanuel; Chui, De-Hua; Sato, Shinji; Miyasaka, Tomohiro; Sahara, Naruhiko; Murayama, Miyuki; Kikuchi, Naomi; Yoshioka, Katsuji; Rivka, Ravid; Takashima, Akihiko			c-jun N-terminal kinase hyperphosphorylates R406W tau at the PHF-1 site during mitosis	FASEB JOURNAL			English	Article						frontotemporal dementia and Parkinsonism linked to chromosome 17; glycogen synthase kinase	GLYCOGEN-SYNTHASE KINASE-3-BETA; FAMILIAL PRESENILE-DEMENTIA; MULTIPLE SYSTEM TAUOPATHY; PAIRED HELICAL FILAMENTS; ACTIVATED PROTEIN-KINASE; HAMSTER OVARY CELLS; ALZHEIMERS-DISEASE; TAU-PROTEIN; FRONTOTEMPORAL DEMENTIA; TRANSGENIC MICE	Tauopathies such as Alzheimer disease ( AD) probably involve a type of phosphorylation imbalance causing the accumulation of abnormally hyperphosphorylated tau in neurons and/or glias. Investigation of R406W tau mutation may provide insight into such abnormal tau hyperphosphorylation, since this mutation causes AD-like dementia and tauopathy in humans and because it has the unique ability to reduce tau phosphorylation in vitro and in cultured cells. Here we show that R406W mutation primarily disrupts tau phosphorylation at Ser404, a priming phosphorylation site of glycogen synthase kinase-3 beta (GSK-3 beta), thereby reducing subsequent GSK-3 beta-mediated phosphorylation at the PHF-1 site (mostly Ser396). In contrast, c-jun N-terminal kinase (JNK) as activated in the mitotic phase directly hyperphosphorylates R406W tau at the PHF-1 site. This was confirmed by PHF-1 hyperphosphorylation of R406W tau in mitotic cells, its association with cytoplasmic JNK activation, and its inhibition by a JNK inhibitor, SP600125. These data unveil the unknown mechanisms of physiological tau phosphorylation at the PHF-1 site and suggest that cytoplasmic JNK activation may play an important role in the abnormal tau hyperphosphorylation associated with R406W tau mutation and in AD.	RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Lab Alzheimres Dis, Wako, Saitama 3510198, Japan; Psychiat Res Inst Tokyo, Mood Disorder Res Team, Depress Project, Tokyo 156, Japan; NYU, Nathan S Kline Inst Psychiat Res, Ctr Dementia Res, New York, NY USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Lincoln, NE 68583 USA; Univ Tokyo, Fac Med, Dept Neuropathol, Tokyo, Japan; Canc Res Inst, Div Cell Cycle Regulat, Kanazawa, Ishikawa, Japan; Netherlands Brain Bank, Amsterdam, Netherlands; Peking Univ, Neurosci Res Inst, Beijing, Peoples R China	RIKEN; Tokyo Institute of Psychiatry; Nathan Kline Institute for Psychiatric Research; New York University; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska Medical Center; University of Tokyo; Peking University	Takashima, A (corresponding author), RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Lab Alzheimres Dis, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	kenneth@brain.riken.go.jp		Planel, Emmanuel/0000-0001-5128-0565				Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alonso AD, 2004, J BIOL CHEM, V279, P34873, DOI 10.1074/jbc.M405131200; Andorfer C, 2005, J NEUROSCI, V25, P5446, DOI 10.1523/JNEUROSCI.4637-04.2005; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; Connell JW, 2001, FEBS LETT, V493, P40, DOI 10.1016/S0014-5793(01)02267-0; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; Herrup K, 2002, J ALZHEIMERS DIS, V4, P243, DOI 10.3233/JAD-2002-4315; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Ikeda M, 2005, AM J PATHOL, V166, P521, DOI 10.1016/S0002-9440(10)62274-2; Ingram EM, 2002, TRENDS MOL MED, V8, P555, DOI 10.1016/S1471-4914(02)02440-1; IQBAL K, 1989, P NATL ACAD SCI USA, V86, P5646, DOI 10.1073/pnas.86.14.5646; Iqbal K, 1996, ANN NY ACAD SCI, V777, P132, DOI 10.1111/j.1749-6632.1996.tb34411.x; Ishiguro K, 1995, NEUROSCI LETT, V202, P81, DOI 10.1016/0304-3940(95)12206-0; Ito M, 1999, MOL CELL BIOL, V19, P7539; JORDAN MA, 1992, J CELL SCI, V102, P401; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kins S, 2003, AM J PATHOL, V163, P833, DOI 10.1016/S0002-9440(10)63444-X; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Krishnamurthy PK, 2004, J BIOL CHEM, V279, P7893, DOI 10.1074/jbc.M311203200; Matsumura N, 1999, AM J PATHOL, V154, P1649, DOI 10.1016/S0002-9440(10)65420-X; Mattson MP, 2002, J NEUROVIROL, V8, P539, DOI 10.1080/13550280290100978; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Merrick SE, 1996, J BIOL CHEM, V271, P5589, DOI 10.1074/jbc.271.10.5589; Miyasaka T, 2001, AM J PATHOL, V158, P373, DOI 10.1016/S0002-9440(10)63979-X; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; MunozMontano JR, 1997, FEBS LETT, V411, P183, DOI 10.1016/S0014-5793(97)00688-1; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Passant U, 2004, DEMENT GERIATR COGN, V17, P287, DOI 10.1159/000077156; Perez M, 2000, J NEUROCHEM, V74, P2583, DOI 10.1046/j.1471-4159.2000.0742583.x; Planel E, 2002, DRUG DEVELOP RES, V56, P491, DOI 10.1002/ddr.10100; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; POPE WB, 1994, EXP NEUROL, V126, P185, DOI 10.1006/exnr.1994.1057; PREUSS U, 1995, MOL BIOL CELL, V6, P1397, DOI 10.1091/mbc.6.10.1397; Reed LA, 1997, ANN NEUROL, V42, P564, DOI 10.1002/ana.410420406; Reed LA, 2001, NEUROBIOL AGING, V22, P89, DOI 10.1016/S0197-4580(00)00202-5; Rohn TT, 2001, AM J PATHOL, V158, P189, DOI 10.1016/S0002-9440(10)63957-0; Sahara N, 2000, J NEUROSCI RES, V60, P380, DOI 10.1002/(SICI)1097-4547(20000501)60:3<380::AID-JNR13>3.0.CO;2-5; Sahara N, 2004, J NEUROCHEM, V90, P829, DOI 10.1111/j.1471-4159.2004.02558.x; Sato S, 2002, J BIOL CHEM, V277, P42060, DOI 10.1074/jbc.M202241200; SEHIFF PB, 1980, P NATL ACAD SCI USA, V77, P1561; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; Spillantini MG, 1996, ACTA NEUROPATHOL, V92, P42, DOI 10.1007/s004010050487; Spillantini MG, 1997, P NATL ACAD SCI USA, V94, P4113, DOI 10.1073/pnas.94.8.4113; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; Tatebayashi Y, 1999, J NEUROSCI, V19, P5245; Tatebayashi Y, 2004, J CELL SCI, V117, P1653, DOI 10.1242/jcs.01018; Tatebayashi Y, 2002, P NATL ACAD SCI USA, V99, P13896, DOI 10.1073/pnas.202205599; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; van Swieten JC, 1999, ANN NEUROL, V46, P617, DOI 10.1002/1531-8249(199910)46:4<617::AID-ANA10>3.0.CO;2-I; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Zhang B, 2004, J NEUROSCI, V24, P4657, DOI 10.1523/JNEUROSCI.0797-04.2004; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	64	32	35	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					762	+		10.1096/fj.05-4362fje	http://dx.doi.org/10.1096/fj.05-4362fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16478768				2022-12-28	WOS:000237698700019
J	Brun, C; Philip-couderc, P; Raggenbass, M; Roatti, A; Baertschi, AJ				Brun, C; Philip-couderc, P; Raggenbass, M; Roatti, A; Baertschi, AJ			Intracellular targeting of truncated secretory peptides in the mammalian heart and brain	FASEB JOURNAL			English	Article						ANP; atrial myocyte; growth hormone; HL-1; hormones; hypothalamus; mitochondria; NPY; translation initiation	NEUROPEPTIDE-Y; GROWTH-HORMONE; TRANSLATION INITIATION; GRANULE BIOGENESIS; START SITES; PROTEIN; VESICLES; MEMBRANE; NEURONS; ATRIAL	Secretory polypeptides are vital for nervous system function, sleep, reproduction, growth, and metabolism. Ribosomes scanning the 5'-end of mRNA usually detect the first AUG site for initiating translation. The nascent propeptide chain is then directed via a signal-peptide into the endoplasmic reticulum, processed through the Golgi stacks, and packaged into secretory vesicles. By expressing prepropeptide-EGFP fusion proteins, we observed unusual destinations, mitochondria, nucleus, and cytoplasm, of neuropeptide Y (NPY), atrial natriuretic peptide, and growth hormone in living murine cardiac cells and hypothalamic slices. Subcellular expression was modulated by Zn++ or mutations of N-terminal prohormone sequences but was not due to overexpression in the trans-Golgi network. Mitochondrial targeting of NPY also occurred without the EGFP tag, was enhanced by site- directed mutagenesis of the first AUG initiation site, and abolished by mutation of the second AUG. Immunological methods indicated the presence of N-terminal truncated NPY in mitochondria. Imaging studies showed depolarization of NPY-containing mitochondria. P-SORT software correctly predicted the secondary intracellular destinations and suggested such destinations for many neuropeptides and peptide hormones known. Thus, mammalian cells may retarget secretory peptides from extracellular to intracellular sites by skipping the first translation-initiation codon and thereby alter mitochondrial function, gene expression, and secretion.	Ctr Med Univ Geneva, Dept Neurosci, CH-1211 Geneva 4, Switzerland	University of Geneva	Baertschi, AJ (corresponding author), Ctr Med Univ Geneva, Dept Neurosci, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	alex.baertschi@medecine.unige.ch						Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; Baertschi AJ, 2001, CIRC RES, V89, pE23, DOI 10.1161/hh1501.095715; Burke NV, 1997, NEURON, V19, P1095, DOI 10.1016/S0896-6273(00)80400-6; CANAFF L, 1993, P NATL ACAD SCI USA, V90, P7799; Casas F, 1999, MOL CELL BIOL, V19, P7913; Casas F, 2003, FASEB J, V17, P426, DOI 10.1096/fj.02-0732com; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; CUNNINGHAM BC, 1991, SCIENCE, V253, P545, DOI 10.1126/science.1907025; Deloche O, 2004, MOL CELL, V13, P357, DOI 10.1016/S1097-2765(04)00008-5; Dineley KE, 2003, J NEUROCHEM, V85, P563, DOI 10.1046/j.1471-4159.2003.01678.x; El Meskini R, 2001, ENDOCRINOLOGY, V142, P864, DOI 10.1210/endo.142.2.7929; Fiaschi-Taesch N, 2004, CIRCULATION, V110, P177, DOI 10.1161/01.CIR.0000134483.30849.B7; Guillemin R, 2004, ANN NY ACAD SCI, V1038, P131, DOI 10.1196/annals.1315.021; Gutierrez P, 2002, FEBS LETT, V517, P155, DOI 10.1016/S0014-5793(02)02610-8; Jacques D, 2003, CAN J PHYSIOL PHARM, V81, P288, DOI 10.1139/Y02-165; Kaipio K, 2005, BIOCHEM BIOPH RES CO, V337, P633, DOI 10.1016/j.bbrc.2005.09.093; Karniely S, 2005, EMBO REP, V6, P420, DOI 10.1038/sj.embor.7400394; Keeler C, 2004, J MOL NEUROSCI, V22, P43, DOI 10.1385/JMN:22:1-2:43; Kiss J, 2005, EUR J NEUROSCI, V21, P2111, DOI 10.1111/j.1460-9568.2005.04012.x; Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; Kuiper RP, 2000, BIOCHEM CELL BIOL, V78, P289, DOI 10.1139/bcb-78-3-289; Labrador V, 2004, CIRC RES, V95, pE98, DOI 10.1161/01.RES.0000150592.88464.ad; Magoulas C, 2000, ENDOCRINOLOGY, V141, P4681, DOI 10.1210/en.141.12.4681; McGuinness L, 2003, ENDOCRINOLOGY, V144, P720, DOI 10.1210/en.2002-220847; MIFUNE H, 1995, ANAT EMBRYOL, V192, P117; NAKAI K, 1998, P SORT PREDICTION PR; Nguyen MTA, 2001, ENDOCRINOLOGY, V142, P694, DOI 10.1210/en.142.2.694; Nichol H, 2002, INSECT BIOCHEM MOLEC, V32, P1699, DOI 10.1016/S0965-1748(02)00110-8; O'Donovan KJ, 1999, MOL CELL BIOL, V19, P4711; Paquet L, 1996, J NEUROSCI, V16, P964; Pierson PM, 2005, BRAIN RES, V1036, P50, DOI 10.1016/j.brainres.2004.12.020; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Rogol AD, 2004, J PEDIATR ENDOCR MET, V17, P1259; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Silva AP, 2005, BIOL CELL, V97, P457, DOI 10.1042/BC20040102; Silva-Filho MC, 2003, CURR OPIN PLANT BIOL, V6, P589, DOI 10.1016/j.pbi.2003.09.008; Swaab DF, 2004, INT REV CYTOL, V240, P305, DOI 10.1016/S0074-7696(04)40003-5; THIBAULT G, 1992, AM J PHYSIOL, V262, pC907, DOI 10.1152/ajpcell.1992.262.4.C907; Thiele C, 1998, SEMIN CELL DEV BIOL, V9, P511, DOI 10.1006/scdb.1998.0259; Tooze SA, 2001, TRENDS CELL BIOL, V11, P116, DOI 10.1016/S0962-8924(00)01907-3; Wojewodzka U, 2004, NEUROENDOCRINOL LETT, V25, P78	42	9	12	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					732	+		10.1096/fj.05-4338fje	http://dx.doi.org/10.1096/fj.05-4338fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16443679				2022-12-28	WOS:000235996000001
J	Charalampopoulos, I; Alexaki, VI; Lazaridis, I; Dermitzaki, E; Avlonitis, N; Tsatsanis, C; Calogeropoulou, T; Margioris, AN; Castanas, E; Gravanis, A				Charalampopoulos, I; Alexaki, VI; Lazaridis, I; Dermitzaki, E; Avlonitis, N; Tsatsanis, C; Calogeropoulou, T; Margioris, AN; Castanas, E; Gravanis, A			G protein-associated, specific membrane binding sites mediate the neuroprotective effect of dehydroepiandrosterone	FASEB JOURNAL			English	Article						apoptosis; neurosteroid; steroid membrane receptors	IN-VITRO MODEL; TESTOSTERONE RECEPTORS; ALZHEIMERS-DISEASE; CORTISOL-LEVELS; SULFATE DHEAS; ESTROGEN; CELLS; NEURONS; DIFFERENTIATION; ACTIVATION	The neurosteroid dehydroepiandrosterone (DHEA) at 1 nM protects NMDA-/GABA(A)-receptor negative neural crest-derived PC12 cells from apoptosis. We now report that membrane-impermeable DHEA-BSA conjugate replaces unconjugated DHEA in protecting serum-deprived PC12 cells from apoptosis (IC50=1.5 nM). Protection involves phosphorylation of the prosurvival factor Src and induction of the anti-apoptotic protein Bcl-2 and is sensitive to pertussis toxin. Binding assays of [H-3] DHEA on isolated PC12 cell membranes revealed saturation within 30 min and binding of DHEA with a K-d of 0.9 nM. A similar binding activity was detectable in isolated membranes from rat hippocampus and from normal human adrenal chromaffin cells. The presence of DHEA-specific membrane binding sites was confirmed by flow cytometry and confocal laser microscopy of DHEA-BSA-FITC stained cells. In contrast to estrogens and progestins, glucocorticoids and androgens displaced DHEA from its membrane binding sites but with a 10-fold lower affinity than DHEA (IC50= 9.3 and 13.6 nM, respectively). These agents acted as pure antagonists, blocking the antiapoptotic effect of DHEA as well as the induction of Bcl-2 proteins and Src kinase activation. In conclusion, our findings suggest that neural crest-derived cells possess specific DHEA membrane binding sites coupled to G proteins. Binding to these sites confers neuroprotection.	Univ Crete, Sch Med, Dept Pharmacol, Iraklion 71003, Greece; Univ Crete, Sch Med, Dept Expt Endocrinol, Iraklion 71003, Greece; Univ Crete, Sch Med, Dept Clin Chem, Iraklion 71003, Greece; Natl Hellen Res Fdn, Inst Organ & Pharmaceut Chem, GR-15258 Athens, Greece	University of Crete; University of Crete; University of Crete; National Hellenic Research Foundation	Gravanis, A (corresponding author), Univ Crete, Sch Med, Dept Pharmacol, POB 2208, Iraklion 71003, Greece.	gravanis@med.uoc.gr	Alexaki, Vasileia Ismini/K-5527-2019; Castanas, Elias/E-7007-2010; Avlonitis, Nicolaos/T-6053-2019; Tsatsanis, Christos/AAM-9362-2020; Charalampopoulos, Ioannis/I-6319-2012; Avlonitis, Nicolaos/A-5161-2009	Castanas, Elias/0000-0002-8370-1835; Tsatsanis, Christos/0000-0003-1214-4151; Charalampopoulos, Ioannis/0000-0003-3415-7332; Lazaridis, Iakovos/0000-0002-4578-2347; Alexaki, Vasileia Ismini/0000-0003-3935-8985				Alexaki VI, 2004, FASEB J, V18, P1594, DOI 10.1096/fj.04-1495fje; Baulieu EE, 1998, P NATL ACAD SCI USA, V95, P4089, DOI 10.1073/pnas.95.8.4089; BELANGER A, 1994, J CLIN ENDOCR METAB, V79, P1086; Benten WPM, 1999, FASEB J, V13, P123, DOI 10.1096/fasebj.13.1.123; Charalampopoulos I, 2005, ENDOCRINOLOGY, V146, P3309, DOI 10.1210/en.2005-0263; Charalampopoulos L, 2004, P NATL ACAD SCI USA, V101, P8209, DOI 10.1073/pnas.0306631101; Compagnone NA, 2000, FRONT NEUROENDOCRIN, V21, P1, DOI 10.1006/frne.1999.0188; Corre I, 1999, ONCOGENE, V18, P6335, DOI 10.1038/sj.onc.1203010; Dermitzaki E, 2002, J BIOL CHEM, V277, P12280, DOI 10.1074/jbc.M111236200; Falkenstein E, 1996, BIOCHEM BIOPH RES CO, V229, P86, DOI 10.1006/bbrc.1996.1761; GAETJENS E, 1980, J STEROID BIOCHEM, V13, P1001, DOI 10.1016/0022-4731(80)90177-6; Gametchu B, 1999, STEROIDS, V64, P107, DOI 10.1016/S0039-128X(98)00097-X; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; HALES TG, 1994, J NEUROSCI, V14, P5429; Hatzoglou A, 2005, J CLIN ENDOCR METAB, V90, P893, DOI 10.1210/jc.2004-0801; HATZOGLOU A, 1994, CLIN CHIM ACTA, V227, P97, DOI 10.1016/0009-8981(94)90139-2; Kampa M, 2002, FASEB J, V16, P1429, DOI 10.1096/fj.02-0131fje; Kimonides VG, 1998, P NATL ACAD SCI USA, V95, P1852, DOI 10.1073/pnas.95.4.1852; Levin ER, 2002, STEROIDS, V67, P471, DOI 10.1016/S0039-128X(01)00179-9; Liu DM, 2002, J BIOL CHEM, V277, P21379, DOI 10.1074/jbc.M200491200; Liu DM, 2004, STEROIDS, V69, P279, DOI 10.1016/j.steroids.2004.02.004; LUSTIG RH, 1994, J NEUROSCI, V14, P3945; LUSTIG RH, 1994, MOL CELL NEUROSCI, V5, P587, DOI 10.1006/mcne.1994.1072; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Marder K, 1996, NEUROLOGY, V47, P155, DOI 10.1212/WNL.47.1.155; MIGNON CJ, 1957, J CLIN ENDOCR METAB, V17, P1051; Mizota K, 2005, BRIT J PHARMACOL, V145, P545, DOI 10.1038/sj.bjp.0706213; ORENTREICH N, 1984, J CLIN ENDOCR METAB, V59, P551, DOI 10.1210/jcem-59-3-551; PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0; Saito Y, 2003, MOL BRAIN RES, V110, P159, DOI 10.1016/S0169-328X(02)00548-X; SAPOLSKY RM, 1986, ENDOCR REV, V7, P284, DOI 10.1210/edrv-7-3-284; SAPOLSKY RM, 1986, J NEUROSCI, V6, P2240; Swaab DF, 2005, AGEING RES REV, V4, P141, DOI 10.1016/j.arr.2005.03.003; SWAAB DF, 1994, J NEUROENDOCRINOL, V6, P681, DOI 10.1111/j.1365-2826.1994.tb00635.x; Umegaki H, 2000, BRAIN RES, V881, P241, DOI 10.1016/S0006-8993(00)02847-X; Weill-Engerer S, 2002, J CLIN ENDOCR METAB, V87, P5138, DOI 10.1210/jc.2002-020878; Widstrom RL, 2004, SEMIN REPROD MED, V22, P289, DOI 10.1055/s-2004-861546; Wooten MW, 2000, MOL CELL BIOL, V20, P4494, DOI 10.1128/MCB.20.13.4494-4504.2000; Yang SH, 2002, J APPL PHYSIOL, V92, P195, DOI 10.1152/jappl.2002.92.1.195; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100	41	56	62	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					577	+		10.1096/fj.05-5078fje	http://dx.doi.org/10.1096/fj.05-5078fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16407456				2022-12-28	WOS:000235996000023
J	Stagg, MA; Coppen, SR; Suzuki, K; Varela-Carver, A; Lee, J; Brand, NJ; Fukushima, S; Yacoub, MH; Terracciano, CMN				Stagg, MA; Coppen, SR; Suzuki, K; Varela-Carver, A; Lee, J; Brand, NJ; Fukushima, S; Yacoub, MH; Terracciano, CMN			Evaluation of frequency, type, and function of gap junctions between skeletal myoblasts overexpressing connexin43 and cardiomyocytes: relevance to cell transplantation	FASEB JOURNAL			English	Article						gap junctional conductance; electrophysiology	MYOCARDIAL-INFARCTION; STEM-CELLS; MUSCLE; FIBROBLASTS; EXPRESSION; CHANNELS; REPAIR; CONDUCTANCE	Cell transplantation of skeletal myoblasts (SMs) is one possible treatment for repairing cardiac tissue after myocardial injury. However, inappropriate electrical coupling between grafted SMs and host cardiomyocytes may be responsible for the arrhythmias observed in clinical trials of SM transplantation. Whether functional gap junctions occur between the two cell types remains controversial. We have studied the ability of SMs to electrically couple with isolated adult rat cardiomyocytes (CMs) and assessed whether connexin43 (Cx43) overexpression enhanced gap junctional conductance (G(j)). C2C12 myoblast lines overexpressing Cx43 were generated by gene transfection and clonal selection. CMs were cocultured with either SMs overexpressing Cx43 (CM-SMCx43) or control SMs (CM-SMWT) in vitro. G(j) between pairs of SMs and CMs was quantified with dual whole cell patch clamping. Formation of G(j) occurred between 22% of CM-SMWT pairs (n= 73) and 48% of CM-SMCx43 pairs (n= 71, P < 0.001). The G(j) of CM- SMCx43 pairs (29.7 +/- 4.3 nS, n=21) was greater than that of CM-SMWT pairs (14.8 +/- 2.0 nS, n=12, P < 0.05). The overexpression of Cx43 in SMs increased the formation of electrical communication and the steady-state conductance between SMs and CMs. Enhanced gap junctional conductance may be useful to promote the integration of transplanted SMs into the myocardium.	Univ London Imperial Coll Sci Technol & Med, Harefield Hosp, Heart Sci Ctr, Natl Heart & Lung Inst, London UB9 6JH, England	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital	Stagg, MA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Harefield Hosp, Heart Sci Ctr, Natl Heart & Lung Inst, London UB9 6JH, England.	m.stagg@imperial.ac.uk		Stagg, Mark/0000-0003-2306-8326	Medical Research Council [G116/158] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G116/158] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abraham MR, 2005, CIRC RES, V97, P159, DOI 10.1161/01.RES.0000174794.22491.a0; BEBLO DA, 1995, CIRC RES, V77, P813, DOI 10.1161/01.RES.77.4.813; Camelliti P, 2005, CARDIOVASC RES, V65, P40, DOI 10.1016/j.cardiores.2004.08.020; CARMELIET E, 2002, CELLULAR CARDIAC ELE, P95; CHIU RCJ, 1995, ANN THORAC SURG, V60, P12; Coppen SR, 1998, CIRC RES, V82, P232; Cottrell GT, 2001, AM J PHYSIOL-CELL PH, V281, pC1559, DOI 10.1152/ajpcell.2001.281.5.C1559; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; Evans WH, 2002, MOL MEMBR BIOL, V19, P121, DOI 10.1080/09687680210139839; Formigli L, 2005, AM J PHYSIOL-CELL PH, V288, pC795, DOI 10.1152/ajpcell.00345.2004; Gaudesius G, 2003, CIRC RES, V93, P421, DOI 10.1161/01.RES.0000089258.40661.0C; Herreros J, 2003, EUR HEART J, V24, P2012, DOI 10.1016/j.ehj.2003.09.012; Horackova M, 2004, AM J PHYSIOL-HEART C, V287, pH1599, DOI 10.1152/ajpheart.00965.2003; Iijima Y, 2003, FASEB J, V17, P1361, DOI 10.1096/fj.02-1048fje; Kizana E, 2005, CIRCULATION, V111, P394, DOI 10.1161/01.CIR.0000153812.64956.EF; Leobon B, 2003, P NATL ACAD SCI USA, V100, P7808, DOI 10.1073/pnas.1232447100; Menasche P, 2003, J AM COLL CARDIOL, V41, P1078, DOI 10.1016/S0735-1097(03)00092-5; Menasche P, 2004, CURR OPIN CARDIOL, V19, P154, DOI 10.1097/00001573-200403000-00016; MORENO AP, 2004, CARDIAC ELECTROPHYSI, P120, DOI DOI 10.1016/B0-7216-0323-8/50017-8; NEYTON J, 1985, NATURE, V317, P331, DOI 10.1038/317331a0; Ott HC, 2004, J PHYSIOL-LONDON, V558, P793, DOI 10.1113/jphysiol.2003.060186; Pouly J, 2004, CIRCULATION, V110, P1626, DOI 10.1161/01.CIR.0000142861.55862.15; RASBAND WS, 2005, IMAGEJ; Reinecke H, 2000, J CELL BIOL, V149, P731, DOI 10.1083/jcb.149.3.731; Reinecke H, 2004, HUM GENE THER, V15, P627, DOI 10.1089/1043034041361253; Reinecke H, 2004, CIRC RES, V94, pE56, DOI 10.1161/01.RES.0000125294.04612.81; Reinecke H, 2002, J MOL CELL CARDIOL, V34, P241, DOI 10.1006/jmcc.2001.1507; Siminiak T, 2004, AM HEART J, V148, P531, DOI 10.1016/j.ahj.2004.03.043; SRINIVAS M, 2004, CARDIAC ELECTROPHYSI, P158; Suzuki K, 2000, CIRCULATION, V102, P359; Suzuki K, 2001, J THORAC CARDIOV SUR, V122, P759, DOI 10.1067/mtc.2001.116210; Terracciano CMN, 1998, J PHYSIOL-LONDON, V512, P651, DOI 10.1111/j.1469-7793.1998.651bd.x; van den Bos EJ, 2004, J HEART LUNG TRANSPL, V23, P1217, DOI 10.1016/j.healun.2003.10.015; van Veen TAB, 2001, CARDIOVASC RES, V51, P217, DOI 10.1016/S0008-6363(01)00324-8; Veenstra RD, 2001, BIOPHYS J, V80, P2231, DOI 10.1016/S0006-3495(01)76196-6; Yao JA, 2003, CIRC RES, V93, P736, DOI 10.1161/01.RES.0000095977.66660.86; Yao JA, 2003, CIRC RES, V92, P437, DOI 10.1161/01.RES.0000059301.81035.06; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883	38	23	27	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					744	+		10.1096/fj.05-5088fje	http://dx.doi.org/10.1096/fj.05-5088fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16443678				2022-12-28	WOS:000235996000002
J	Yu, J; Lei, L; Liang, YX; Hinh, L; Hickey, RP; Huang, Y; Liu, DG; Yeh, JL; Rebar, E; Case, C; Spratt, K; Sessa, WC; Giordano, FJ				Yu, J; Lei, L; Liang, YX; Hinh, L; Hickey, RP; Huang, Y; Liu, DG; Yeh, JL; Rebar, E; Case, C; Spratt, K; Sessa, WC; Giordano, FJ			An engineered VEGF-activating zinc finger protein transcription factor improves blood flow and limb salvage in advanced-age mice	FASEB JOURNAL			English	Article						vascular endothelial growth factor	ENDOTHELIAL GROWTH-FACTOR; DNA RECOGNITION; MOUSE MODEL; ANGIOGENESIS; INDUCTION; ISOFORMS; CELLS; SELECTION; ISCHEMIA; SEQUENCE	Advances in understanding the relationship between protein structure and DNA binding specificity have made it possible to engineer zinc finger protein (ZFP) transcription factors to specifically activate or repress virtually any gene. To evaluate the potential clinical utility of this approach for peripheral vascular disease, we investigated the ability of an engineered vascular endothelial growth factor (VEGFa)-activating ZFP (MVZ+ 426b) to induce angiogenesis and rescue hindlimb ischemia in a murine model. Hindlimb ischemia was surgically induced in advanced-age C57/BL6 mice. Adenovirus ( Ad) encoding either MVZ+ 426b or the fluorescent marker dsRed was delivered to the adducter muscle of the ischemic hindlimb, and the effects on blood flow, limb salvage, and vascularization were assessed. Ad-MVZ+426b induced expression of VEGFa at the mRNA and protein levels and stimulated a significant increase in vessel counts in the ischemic limb. This was accompanied by significantly increased blood flow and limb salvage as measured serially for 4 wk. These data demonstrate that activation of the endogenous VEGFa gene by an engineered ZFP can induce angiogenesis in a clinically relevant model and further document the feasibility of designing ZFPs to therapeutically regulate gene expression in vivo.	Yale Univ, Sch Med, Dept Pharmacol, Sect Cardiovasc Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, New Haven, CT 06520 USA; Sangamo Biosci, Richmond, CA USA	Yale University; Yale University; Sangamo Therapeutics, Inc.	Giordano, FJ (corresponding author), BCMM 436C,295 Congress Ave, New Haven, CT 06443 USA.	Frank.Giordano@yale.edu	Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938	NHLBI NIH HHS [R01HL-63770, R01HL-64001] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063770, R01HL064001] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beerli RR, 2002, NAT BIOTECHNOL, V20, P135, DOI 10.1038/nbt0202-135; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Giordano FJ, 1997, CIRCULATION, V96, P400; Gratton JP, 2003, NAT MED, V9, P357, DOI 10.1038/nm835; Grunstein J, 2000, MOL CELL BIOL, V20, P7282, DOI 10.1128/MCB.20.19.7282-7291.2000; Huang Y, 2004, FASEB J, V18, P1138, DOI 10.1096/fj.04-1510fje; Jamieson AC, 2003, NAT REV DRUG DISCOV, V2, P361, DOI 10.1038/nrd1087; Jonca F, 1997, J BIOL CHEM, V272, P24203, DOI 10.1074/jbc.272.39.24203; Kato Y, 2001, BIOCHEM BIOPH RES CO, V287, P422, DOI 10.1006/bbrc.2001.5622; Kim I, 2001, CIRC RES, V89, P477, DOI 10.1161/hh1801.097034; KLUG A, 1987, COLD SPRING HARB SYM, V52, P473, DOI 10.1101/SQB.1987.052.01.054; Lee CW, 2004, J AM COLL CARDIOL, V43, P474, DOI 10.1016/j.jacc.2003.09.033; Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200; Luque A, 2003, J BIOL CHEM, V278, P23656, DOI 10.1074/jbc.M212964200; Maes C, 2004, J CLIN INVEST, V113, P188, DOI 10.1172/JCI200419383; Matthews JM, 2002, IUBMB LIFE, V54, P351, DOI 10.1080/15216540216035; Mattot V, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000013925.19218.7B; Oh H, 2002, P NATL ACAD SCI USA, V99, P383, DOI 10.1073/pnas.012074399; Pabo CO, 2001, ANNU REV BIOCHEM, V70, P313, DOI 10.1146/annurev.biochem.70.1.313; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Rebar EJ, 2002, NAT MED, V8, P1427, DOI 10.1038/nm795; Robinson CJ, 2001, J CELL SCI, V114, P853; Tuomisto TT, 2004, ATHEROSCLEROSIS, V174, P111, DOI 10.1016/j.atherosclerosis.2004.01.015; Urnov FD, 2002, BIOCHEM PHARMACOL, V64, P919, DOI 10.1016/S0006-2952(02)01150-4; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183	27	40	58	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					479	+		10.1096/fj.04-3670fje	http://dx.doi.org/10.1096/fj.04-3670fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16423874				2022-12-28	WOS:000235996000009
J	Turk, R; Sterrenburg, E; van der Wees, CGC; de Meijer, EJ; de Menezes, RX; Groh, S; Campbell, KP; Noguchi, S; van Ommen, GJB; den Dunnen, JT; 't Hoen, PAC				Turk, R; Sterrenburg, E; van der Wees, CGC; de Meijer, EJ; de Menezes, RX; Groh, S; Campbell, KP; Noguchi, S; van Ommen, GJB; den Dunnen, JT; 't Hoen, PAC			Common pathological mechanisms in mouse models for muscular dystrophies	FASEB JOURNAL			English	Article						microarray; dystrophin-glycoprotein complex; inflammation; extracellular matrix; biomarker	CDNA MICROARRAY ANALYSIS; GENE-EXPRESSION; SKELETAL-MUSCLE; SARCOGLYCAN COMPLEX; MEMBRANE REPAIR; SMOOTH-MUSCLE; MDX MICE; DYSFERLIN; DEGENERATION; DISRUPTION	Duchenne/Becker and limb-girdle muscular dystrophies share clinical symptoms like muscle weakness and wasting but differ in clinical presentation and severity. To get a closer view on the differentiating molecular events responsible for the muscular dystrophies, we have carried out a comparative gene expression profiling of hindlimb muscles of the following mouse models: dystrophin-deficient (mdx, mdx(3cv)), sarcoglycan-deficient (Sgca null, Sgcb null, Sgcg null, Sgcd null), dysferlin-deficient (Dysf null, SJL(Dysf)), sarcospan-deficient (Sspn null), and wild-type (C57B1/6, C57B1/10) mice. The expression profiles clearly discriminated between severely affected (dystrophinopathies and sarcoglycanopathies) and mildly or nonaffected models (dysferlinopathies, sarcospan-deficiency, wild-type). Dystrophin-deficient and sarcoglycan-deficient profiles were remarkably similar, sharing inflammatory and structural remodeling processes. These processes were also ongoing in dysferlin-deficient animals, albeit at lower levels, in agreement with the later age of onset of this muscular dystrophy. The inflammatory proteins Spp1 and S100a9 were up-regulated in all models, including sarcospan-deficient mice, which points, for the first time, at a subtle phenotype for Sspn null mice. In conclusion, we identified biomarker genes for which expression correlates with the severity of the disease, which can be used for monitoring disease progression. This comparative study is an integrating step toward the development of an expression profiling-based diagnostic approach for muscular dystrophies in humans.	Leiden Univ, Med Ctr, Ctr Human & Clin Genet, NL-2333 AL Leiden, Netherlands; Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA USA; Natl Inst Neurosci, Dept Neuromuscular Res, Tokyo, Japan	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Howard Hughes Medical Institute; National Center for Neurology & Psychiatry - Japan	't Hoen, PAC (corresponding author), Leiden Univ, Med Ctr, Ctr Human & Clin Genet, Wassenaarseweg 72, NL-2333 AL Leiden, Netherlands.	p.a.c.hoen@lumc.nl	dunnen, johan den/ABH-4228-2020; 't Hoen, Peter/A-4857-2012; Turk, Rolf/E-7832-2010; Hoen, Peter A 't/D-3950-2018	dunnen, johan den/0000-0002-6304-1710; Turk, Rolf/0000-0003-1283-9594; Hoen, Peter A 't/0000-0003-4450-3112; Campbell, Kevin/0000-0003-2066-5889				Abbas AR, 2005, GENES IMMUN, V6, P319, DOI 10.1038/sj.gene.6364173; Araishi K, 1999, HUM MOL GENET, V8, P1589, DOI 10.1093/hmg/8.9.1589; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; Bakay M, 2002, NEUROMUSCULAR DISORD, V12, pS125, DOI 10.1016/S0960-8966(02)00093-7; Bansal D, 2004, TRENDS CELL BIOL, V14, P206, DOI 10.1016/j.tcb.2004.03.001; Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bittner RE, 1999, NAT GENET, V23, P141, DOI 10.1038/13770; Brussee V, 1997, NEUROMUSCULAR DISORD, V7, P487, DOI 10.1016/S0960-8966(97)00115-6; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; Bushby KMD, 1999, BRAIN, V122, P1403, DOI 10.1093/brain/122.8.1403; Campanaro S, 2002, HUM MOL GENET, V11, P3283, DOI 10.1093/hmg/11.26.3283; CARPENTER S, 1979, BRAIN, V102, P147, DOI 10.1093/brain/102.1.147; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Cohn RD, 2001, J CLIN INVEST, V107, pR1, DOI 10.1172/JCI11642; Cohn RD, 2000, MUSCLE NERVE, V23, P1456, DOI 10.1002/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; COX GA, 1993, NAT GENET, V4, P87, DOI 10.1038/ng0593-87; Dalkilic I, 2003, CURR OPIN GENET DEV, V13, P231, DOI 10.1016/S0959-437X(03)00048-0; Diehn M, 2003, NUCLEIC ACIDS RES, V31, P219, DOI 10.1093/nar/gkg014; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; Durbeej M, 2000, MOL CELL, V5, P141, DOI 10.1016/S1097-2765(00)80410-4; Durbeej M, 2002, CURR OPIN GENET DEV, V12, P349, DOI 10.1016/S0959-437X(02)00309-X; Emery AEH, 2002, LANCET, V359, P687, DOI 10.1016/S0140-6736(02)07815-7; Haslett JN, 2002, P NATL ACAD SCI USA, V99, P15000, DOI 10.1073/pnas.192571199; Haslett JN, 2002, INT J DEV NEUROSCI, V20, P359, DOI 10.1016/S0736-5748(02)00041-2; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Inoue K, 2004, NAT GENET, V36, P361, DOI 10.1038/ng1322; Kuznetsov AV, 1998, MOL CELL BIOCHEM, V183, P87, DOI 10.1023/A:1006868130002; Lebakken CS, 2000, MOL CELL BIOL, V20, P1669, DOI 10.1128/MCB.20.5.1669-1677.2000; Lennon NJ, 2003, J BIOL CHEM, V278, P50466, DOI 10.1074/jbc.M307247200; Lim LE, 1998, CURR OPIN NEUROL, V11, P443, DOI 10.1097/00019052-199810000-00006; MCARDLE A, 1995, NEUROMUSCULAR DISORD, V5, P445, DOI 10.1016/0960-8966(95)00001-4; Nagy E, 1998, TRENDS BIOCHEM SCI, V23, P198, DOI 10.1016/S0968-0004(98)01208-0; Noguchi S, 2003, HUM MOL GENET, V12, P595, DOI 10.1093/hmg/ddg065; Ozawa E, 1998, MUSCLE NERVE, V21, P421, DOI 10.1002/(SICI)1097-4598(199804)21:4<421::AID-MUS1>3.3.CO;2-W; OZAWA E, 1995, HUM MOL GENET, V4, P1711, DOI 10.1093/hmg/4.suppl_1.1711; Porter JD, 2003, NEUROMUSCULAR DISORD, V13, P223, DOI 10.1016/S0960-8966(02)00242-0; Porter JD, 2003, HUM MOL GENET, V12, P1813, DOI 10.1093/hmg/ddg197; Porter JD, 2002, HUM MOL GENET, V11, P263, DOI 10.1093/hmg/11.3.263; *R DEV COR TEAM, 2004, R LANG ENV STAT COMP; Rouger K, 2002, AM J PHYSIOL-CELL PH, V283, pC773, DOI 10.1152/ajpcell.00112.2002; Sanoudou D, 2004, NEUROBIOL DIS, V15, P590, DOI 10.1016/j.nbd.2003.12.013; Sasaoka T, 2003, NEUROMUSCULAR DISORD, V13, P193, DOI 10.1016/S0960-8966(02)00220-1; Schafer R, 2005, NEUROMUSCULAR DISORD, V15, P57, DOI 10.1016/j.nmd.2004.09.011; Sharma U, 2003, MAGN RESON IMAGING, V21, P145, DOI 10.1016/S0730-725X(02)00646-X; Straub V, 1998, AM J PATHOL, V153, P1623, DOI 10.1016/S0002-9440(10)65751-3; 't Hoen PAC, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh038; 't Hoen PAC, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng020; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; Tsukahara T, 2002, MUSCLE NERVE, V25, P898, DOI 10.1002/mus.10085; Turk R, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-98; Turk R, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-57; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; Winokur ST, 2003, HUM MOL GENET, V12, P2895, DOI 10.1093/hmg/ddg327; Zhang B, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-16; [No title captured]	59	62	64	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					127	+		10.1096/fj.05-4678fje	http://dx.doi.org/10.1096/fj.05-4678fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16306063				2022-12-28	WOS:000234053100005
J	Basha, R; Murali, M; Siddiqi, HK; Ghosal, K; Siddiqi, OK; Lashuel, HA; Ge, YW; Lahiri, DK; Zawia, NH				Basha, R; Murali, M; Siddiqi, HK; Ghosal, K; Siddiqi, OK; Lashuel, HA; Ge, YW; Lahiri, DK; Zawia, NH			Lead (Pb) exposure and its effect on APP proteolysis and A beta aggregation	FASEB JOURNAL			English	Article						beta-amyloid; development; environmental factors; gene regulation; metals; secretases	AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; TRANSCRIPTIONAL REGULATION; TRANSGENIC MICE; ZINC; SECRETASE; IRON; BRAIN; EXPRESSION; ALUMINUM	Alzheimer's disease ( AD) is a progressive neurodegenerative disorder with clinical manifestations appearing in old age, however, the initial stages of this disease may begin early in life. AD is characterized by the presence of excessive deposits of aggregated beta-amyloid ( A beta) peptides, which are derived from the beta-amyloid precursor protein ( APP) following processing by beta-secretase and gamma-secretase. Recently, we have reported that developmental exposure of rats to Pb resulted in latent elevation of APP mRNA, APP, and A beta in old age. Here we examined whether latent up-regulation in APP expression and A beta levels is exacerbated by concurrent disturbances in APP processing or A beta aggregation. Among the environmental metals tested, only A beta solutions containing Pb promoted the formation of A beta aggregates at nanomolar concentrations. The lifetime profiles of alpha-, beta-, and gamma-secretases remained constant in adult and aging animals, and developmental exposure to Pb did not alter them. Furthermore, the addition of various concentrations of Pb ( 0.1 to 50 mu M) to cerebral cortical extracts derived from control animals also did not affect the proteolytic activities of these enzymes. Therefore, we propose that amyloidogenesis is promoted by a latent response to developmental reprogramming of the expression of the APP gene by early exposure to Pb, as well as enhancement of A beta aggregation in old age. In rodents, these events occur without Pb-induced disturbances to the enzymatic processing of APP. The aforementioned results provide further evidence for the developmental basis of amyloidogenesis and late-life disturbances in AD-associated proteins by environmental agents.	Univ Rhode Isl, Neurotoxicol & Epigenom Lab, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA; EPFL, Swiss Fed Inst Technol, Lab Neurobiol & Funct Neuroproteom, Integrat Biosci Inst, Lausanne, Switzerland; Indiana Univ, Sch Med, Dept Psychiat, Mol Neurogenet Lab,Inst Psychiat Res, Indianapolis, IN 46204 USA	University of Rhode Island; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Indiana University System; Indiana University-Purdue University Indianapolis	Zawia, NH (corresponding author), Univ Rhode Isl, Neurotoxicol & Epigenom Lab, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA.	nzawia@uri.edu	Lashuel, Hilal/M-3500-2017; Lahiri, Debomoy/AAZ-3322-2020; Siddiqi, Hasan/AAL-5217-2020	Siddiqi, Omar/0000-0001-7813-1623; Basha, Riyaz/0000-0002-4071-0993	NIA NIH HHS [AG18884, AG18379] Funding Source: Medline; NIEHS NIH HHS [ES08104, ES013022] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES008104, R21ES013022] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018379, R01AG018884] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Atwood CS, 1999, MET IONS BIOL SYST, V36, P309; Basha MR, 2003, INT J DEV NEUROSCI, V21, P1, DOI 10.1016/S0736-5748(02)00137-5; Basha MR, 2005, J NEUROSCI, V25, P823, DOI 10.1523/JNEUROSCI.4335-04.2005; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Campbell A, 2000, CELL MOL BIOL, V46, P721; Christensen MA, 2004, MOL CELL BIOL, V24, P865, DOI 10.1128/MCB.24.2.865-874.2004; CONNOR JR, 1992, J NEUROSCI RES, V31, P75, DOI 10.1002/jnr.490310111; Cuajungco MP, 1997, BRAIN RES REV, V23, P219, DOI 10.1016/S0165-0173(97)00002-7; DUNCAN MW, 1992, J NEUROSCI, V12, P1523, DOI 10.1523/jneurosci.12-04-01523.1992; Ge YW, 2004, FASEB J, V18, P1037, DOI 10.1096/fj.03-1379fje; GHOSAL KJ, 2002, TOXICOLOGIST, V66, P103; GIBBONS DL, 1995, J BIOL CHEM, V270, P7335, DOI 10.1074/jbc.270.13.7335; GOOD PF, 1992, ANN NEUROL, V31, P286, DOI 10.1002/ana.410310310; Goyer RA, 1996, CASARETT DOULLS TOXI, V5, P691; Guilarte TR, 2000, MOL BRAIN RES, V76, P299, DOI 10.1016/S0169-328X(00)00010-3; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; HERSHEY CO, 1983, NEUROLOGY, V33, P1350, DOI 10.1212/WNL.33.10.1350; Huang XD, 1997, J BIOL CHEM, V272, P26464, DOI 10.1074/jbc.272.42.26464; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; JOACHIM CL, 1992, ALZ DIS ASSOC DIS, V6, P7, DOI 10.1097/00002093-199205000-00003; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lee JY, 1999, J NEUROSCI, V19, DOI 10.1523/jneurosci.19-11-j0002.1999; Lee JY, 2002, P NATL ACAD SCI USA, V99, P7705, DOI 10.1073/pnas.092034699; Lopez-Toledano MA, 2004, J NEUROSCI, V24, P5439, DOI 10.1523/JNEUROSCI.0974-04.2004; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; MANTYH PW, 1993, J NEUROCHEM, V61, P1171, DOI 10.1111/j.1471-4159.1993.tb03639.x; Maynard CJ, 2002, J BIOL CHEM, V277, P44670, DOI 10.1074/jbc.M204379200; Pallitto MM, 2001, BIOPHYS J, V81, P1805, DOI 10.1016/S0006-3495(01)75831-6; Price DL, 1998, SCIENCE, V282, P1079, DOI 10.1126/science.282.5391.1079; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SILBERGELD EK, 1992, FASEB J, V6, P3201, DOI 10.1096/fasebj.6.13.1397842; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Smith MA, 1998, J NEUROCHEM, V70, P2212, DOI 10.1046/j.1471-4159.1998.70052212.x; TAKASHIMA S, 1990, BRAIN DEV-JPN, V12, P367, DOI 10.1016/S0387-7604(12)80066-0; WEISS B, 1991, NEUROTOXICOLOGY, V12, P379; Weisskopf MG, 2004, ENVIRON HEALTH PERSP, V112, P620, DOI 10.1289/ehp.6687; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang YX, 2003, EXP NEUROL, V184, P489, DOI 10.1016/S0014-4886(03)00272-3; Zawia NH, 1998, DEV BRAIN RES, V107, P291, DOI 10.1016/S0165-3806(98)00023-6	43	71	74	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2083	+		10.1096/fj.05-4375fje	http://dx.doi.org/10.1096/fj.05-4375fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16230335	Green Submitted			2022-12-28	WOS:000232991100016
J	Shukla, S; Mishra, A; Fu, PF; MacLennan, GT; Resnick, MI; Gupta, S				Shukla, S; Mishra, A; Fu, PF; MacLennan, GT; Resnick, MI; Gupta, S			Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice	FASEB JOURNAL			English	Article						insulin-like growth factor-I; insulin-like growth factor receptor-1; insulin receptor substrate-1	NECROSIS-FACTOR-ALPHA; PROSTATE-CANCER CELLS; I IGF-I; INCREASED EXPRESSION; DIETARY FLAVONOIDS; KAPPA-B; BREAST; INDUCTION; RISK; CHEMOPREVENTION	Epidemiological studies suggest that increased intake of fruits and vegetables may be associated with a reduced risk of prostate cancer. Apigenin (4', 5, 7,-trihydroxyflavone), a common dietary flavonoid abundantly present in fruits and vegetables, has shown remarkable anti-proliferative effects against various malignant cell lines. However, the mechanisms underlying these effects remain to be elucidated. We investigated the in vivo growth inhibitory effects of apigenin on androgen-sensitive human prostate carcinoma 22Rv1 tumor xenograft subcutaneously implanted in athymic male nude mice. Apigenin was administered to mice by gavage at doses of 20 and 50 mu g/mouse/day in 0.2 ml of a vehicle containing 0.5% methyl cellulose and 0.025% Tween 20 in two different protocols. In the first protocol, apigenin was administered for 2 wk before inoculation of tumor and was continued for 8 wk, resulting in significant inhibition of tumor volume by 44 and 59% ( P < 0.002 and 0.0001), and wet weight of tumor by 41 and 53% ( P < 0.05), respectively. In the second protocol, administration of apigenin began 2 wk after tumor inoculation and continued for 8 wk; tumor volume and wet weights of tumor were reduced by 39 and 53% ( P < 0.01 and 0.002) and 31 and 42% ( P < 0.05), respectively. The tumor inhibitory effect of apigenin was more pronounced in the first protocol of extended treatment, which was associated with increased accumulation of human IGFBP-3 in mouse serum along with significant increase in IGFBP-3 mRNA and protein expression in tumor xenograft. Apigenin intake by these mice also resulted in simultaneous decrease in serum IGF-I levels and induction of apoptosis in tumor xenograft. Importantly, tumor growth inhibition, induction of apoptosis, and accumulation of IGFBP-3 correlated with increasing serum and tumor apigenin levels. In both studies, animals did not exhibit any signs of toxicity or reduced food consumption. In cell culture studies, apigenin treatment resulted in cell growth inhibition and induction of apoptosis, which correlated with increased accumulation of IGFBP- 3 in culture medium and cell lysate. These effects were associated with significant reduction in IGF-I secretion; inhibition of IGF-I-induced cell cycle progression and insulin receptor substrate- 1 (IRS-1) tyrosine phosphorylation, along with an increase in sub-G1 peak by apigenin. Further, treatment of cells with IGFBP-3 antisense oligonucleotide reversed these effects and attenuated apigenin-mediated inhibition of IRS-1 phosphorylation conferring inhibitory effects of apigenin on IGF-signaling. This study presents the first evidence that the in vitro and in vivo growth inhibitory effects of apigenin involve modulation of IGF-axis signaling in prostate cancer.	Case Western Reserve Univ, Dept Urol, James & Eilleen Dicke Res Lab, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA USA	Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gupta, S (corresponding author), Case Western Reserve Univ, Dept Urol, James & Eilleen Dicke Res Lab, 10900 Euclid Ave, Cleveland, OH 44106 USA.	sanjay.gupta@case.edu	MISHRA, ANIL/S-7983-2017; Fu, Pingfu/O-5415-2019	MISHRA, ANIL/0000-0003-4266-4684; Fu, Pingfu/0000-0002-2334-5218; MacLennan, Gregory T./0000-0003-0089-449X; Gupta, Sanjay/0000-0002-9492-3249	NATIONAL CANCER INSTITUTE [R03CA099049, R03CA094248, R01CA108512, P30CA043703] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA43703, R03 CA094248, R03 CA099049, R01 CA108512] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adhami VM, 2004, CANCER RES, V64, P8715, DOI 10.1158/0008-5472.CAN-04-2840; Baxter RC, 2000, AM J PHYSIOL-ENDOC M, V278, pE967, DOI 10.1152/ajpendo.2000.278.6.E967; Birt DF, 1997, ANTICANCER RES, V17, P85; Brusselmans K, 2005, J BIOL CHEM, V280, P5636, DOI 10.1074/jbc.M408177200; Butt AJ, 2001, APOPTOSIS, V6, P199, DOI 10.1023/A:1011388710719; Caltagirone S, 2000, INT J CANCER, V87, P595, DOI 10.1002/1097-0215(20000815)87:4&lt;595::AID-IJC21&gt;3.0.CO;2-5; Chen J, 2003, J PHARMACOL EXP THER, V304, P1228, DOI 10.1124/jpet.102.046409; Cohen JH, 2000, JNCI-J NATL CANCER I, V92, P61, DOI 10.1093/jnci/92.1.61; Colston KW, 1998, J MOL ENDOCRINOL, V20, P157, DOI 10.1677/jme.0.0200157; Denis L, 1999, EUR UROL, V35, P377, DOI 10.1159/000019912; Devi GR, 2002, PROSTATE, V51, P141, DOI 10.1002/pros.10068; DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455; Djavan B, 2001, WORLD J UROL, V19, P225, DOI 10.1007/s003450100220; Engelmann C, 2002, PHYTOMEDICINE, V9, P489, DOI 10.1078/09447110260573100; Fang J, 2005, FASEB J, V19, P342, DOI 10.1096/fj.04-2175com; Franklin SL, 2003, J CLIN ENDOCR METAB, V88, P900, DOI 10.1210/jc.2002-020472; Gradolatto A, 2005, DRUG METAB DISPOS, V33, P49, DOI 10.1124/dmd.104.000893; Grimberg A, 2002, INT J ONCOL, V21, P327; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; Grzmil M, 2004, J PATHOL, V202, P50, DOI 10.1002/path.1492; Gucev ZS, 1996, CANCER RES, V56, P1545; Gupta S, 2002, ONCOGENE, V21, P3727, DOI 10.1038/sj.onc.1205474; Gupta S, 2001, BIOCHEM BIOPH RES CO, V287, P914, DOI 10.1006/bbrc.2001.5672; Hessenauer A, 2003, INT J ONCOL, V22, P1263; Hollman PCH, 1999, FOOD CHEM TOXICOL, V37, P937, DOI 10.1016/S0278-6915(99)00079-4; Hong J, 2002, J BIOL CHEM, V277, P10489, DOI 10.1074/jbc.M109604200; Huynh H, 1996, J BIOL CHEM, V271, P1016, DOI 10.1074/jbc.271.2.1016; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kim MH, 2003, J CELL BIOCHEM, V89, P529, DOI 10.1002/jcb.10543; Knowles LM, 2000, NUTR CANCER, V38, P116, DOI 10.1207/S15327914NC381_16; Kobayashi T, 2002, CANCER LETT, V176, P17, DOI 10.1016/S0304-3835(01)00738-8; Lee HY, 2002, CANCER RES, V62, P3530; Li L, 2003, CANCER CAUSE CONTROL, V14, P721, DOI 10.1023/A:1026383824791; Li SL, 1998, CELL TISSUE RES, V291, P469, DOI 10.1007/s004410051016; Liang YC, 1999, CARCINOGENESIS, V20, P1945, DOI 10.1093/carcin/20.10.1945; Mohan S, 2002, J ENDOCRINOL, V175, P19, DOI 10.1677/joe.0.1750019; Nickerson T, 1997, BIOCHEM BIOPH RES CO, V237, P690, DOI 10.1006/bbrc.1997.7089; Nickerson T, 2001, CANCER RES, V61, P6276; Pollak M, 1998, CANCER METAST REV, V17, P383, DOI 10.1023/A:1006154108619; Rajah R, 2002, CELL GROWTH DIFFER, V13, P163; Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957; Rozen F, 1998, INT J ONCOL, V13, P865; Shukla S, 2004, NEOPLASIA, V6, P390, DOI 10.1593/neo.04112; Shukla S, 2004, CLIN CANCER RES, V10, P3169, DOI 10.1158/1078-0432.CCR-03-0586; Singh RP, 2002, CANCER RES, V62, P3063; Sporn MB, 2002, NAT REV CANCER, V2, P537, DOI 10.1038/nrc844; Stattin P, 2000, J NATL CANCER I, V92, P1910, DOI 10.1093/jnci/92.23.1910; Tsao AS, 2004, CA-CANCER J CLIN, V54, P150, DOI 10.3322/canjclin.54.3.150; WANG W, MOL CARCINOG, V28, P102; Wang Y, 1999, BIOFACTORS, V9, P3, DOI 10.1002/biof.5520090102; Way TD, 2004, J BIOL CHEM, V279, P4479, DOI 10.1074/jbc.M305529200; Wolk A, 1998, J NATL CANCER I, V90, P911, DOI 10.1093/jnci/90.12.911; Yin F, 1999, THYROID, V9, P369, DOI 10.1089/thy.1999.9.369; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Zi XL, 2000, CANCER RES, V60, P5617	55	70	72	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2042	+		10.1096/fj.05-3740fje	http://dx.doi.org/10.1096/fj.05-3740fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16230333				2022-12-28	WOS:000232991100017
J	Cowan, KN; Leung, WCY; Mar, C; Bhattacharjee, R; Zhu, YH; Rabinovitch, M				Cowan, KN; Leung, WCY; Mar, C; Bhattacharjee, R; Zhu, YH; Rabinovitch, M			Caspases from apoptotic myocytes degrade extracellular matrix: a novel remodeling paradigm	FASEB JOURNAL			English	Article						apoptosis; smooth muscle; elastin	PROGRAMMED CELL-DEATH; TENASCIN-C; INHIBITORS; REGRESSION; ELASTASE; MICE; SUPPRESSION; MECHANISM; SURVIVAL; INTEGRIN	Induction of smooth muscle cell apoptosis is critical to the reversal of severe structural remodeling in hypertensive pulmonary arteries during disease regression (1, 2). This process involves coordinated resorption of pathologically deposited extracellular matrix, including elastin, and occurs in the presence of serine elastase and matrix metalloproteinase inhibitors (2). Here, we show that apoptotic smooth muscle cells exhibit extensive degradation of elastin coincident with cell surface immunolocalization and release of caspases. We further document that recombinant caspase-2, -3, and -7 are potently elastolytic. These enzymes are present in an active form on apoptotic cell surfaces and caspase inhibitors attenuate their elastolytic activity. Our results reveal a previously undescribed function for apoptotic cells and a novel paradigm whereby removal of cells is coordinated with degradation of excess extracellular matrix during remodeling in development and disease.	Stanford Univ, Sch Med, Wall Ctr Pulm Vasc Dis, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Univ Toronto, Hosp Sick Children, Div Cardiovasc Res, Dept Pediat,Lab Med & Pathobiol & Med, Toronto, ON, Canada	Stanford University; Stanford University; Stanford University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Rabinovitch, M (corresponding author), Stanford Univ, Sch Med, Wall Ctr Pulm Vasc Dis, CCSR-Room 2245B,269 Campus Dr, Stanford, CA 94305 USA.	marlener@stanford.edu	Bhattacharjee, Rakesh/ABC-8810-2021	Cowan, Kyle/0000-0003-0109-7716				AGGELER J, 1984, J CELL BIOL, V98, P1662, DOI 10.1083/jcb.98.5.1662; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Bratton DL, 1997, J BIOL CHEM, V272, P26159, DOI 10.1074/jbc.272.42.26159; Brooks Dennis E., 1999, Veterinary Ophthalmology, V2, P3; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Colussi PA, 1998, J BIOL CHEM, V273, P26566, DOI 10.1074/jbc.273.41.26566; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; Cowan KN, 2000, NAT MED, V6, P698, DOI 10.1038/76282; Cowan KN, 2000, J CLIN INVEST, V105, P21, DOI 10.1172/JCI6539; Cowan KN, 1999, CIRC RES, V84, P1223, DOI 10.1161/01.RES.84.10.1223; Edwards PD, 1997, J MED CHEM, V40, P1876, DOI 10.1021/jm960819g; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; TAKADA T, 1996, CEREBROVASC DIS, V2, P32; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zheng TS, 2000, EXP CELL RES, V256, P67, DOI 10.1006/excr.2000.4841	20	28	31	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1848	+		10.1096/fj.05-3706fje	http://dx.doi.org/10.1096/fj.05-3706fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16123172				2022-12-28	WOS:000231843700005
J	Dalakas, E; Newsome, PN; Harrison, DJ; Plevris, JN				Dalakas, E; Newsome, PN; Harrison, DJ; Plevris, JN			Hematopoietic stem cell trafficking in liver injury	FASEB JOURNAL			English	Review						migration; engraftment; SDF-1; MMP-9	CHRONIC HEPATITIS-C; BONE-MARROW-CELLS; STROMAL-DERIVED FACTOR-1; CHEMOKINE RECEPTOR CXCR4; PROGENITOR CELLS; MATRIX METALLOPROTEINASES; FACTOR-I; PERIPHERAL-BLOOD; ALCOHOLIC HEPATITIS; MESSENGER-RNA	Bone marrow ( BM) hematopoietic stem cells ( HSCs) have been shown to facilitate regeneration in multiple nonhematopoietic tissues by either generating epithelial cells or altering the inflammatory response. Depending on injury type, the predominant mechanism of epithelial lineage regeneration occurs by spontaneous cell fusion or transdifferentiation. Irrespective of the mechanism, mobilization from the BM is a prerequisite. Mechanisms by which HSCs mobilize into damaged organs are currently under scrutiny. Murine and human studies have shown that the chemokine SDF- 1 and its receptor CXCR4 participate in the mobilization of HSCs from BM and in the migration of HSCs to injured liver. SDF- 1 is a potent HSC chemoattractant and is produced by the liver. Production is increased during liver injury leading to increased HSC migration to the liver, a finding diminished by neutralizing anti- CXCR4 antibodies. Additional factors have been implicated in the control of hepatic migration of HSCs such as IL- 8, hepatocyte growth factor, and MMP- 9. Matriceal remodeling is an essential component in HSC engraftment, and MMP- 9 expression is increased in liver injury. This review focuses on the complex interaction of chemokines, adhesion molecules, and extracellular matrix factors required for successful migration and engraftment of HSCs into the liver.	Univ Edinburgh, Hepatol Unit, Edinburgh EH16 4SB, Midlothian, Scotland; Univ Edinburgh, Sch Med, MRC, Ctr Inflammat Res, Edinburgh, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Dalakas, E (corresponding author), Univ Edinburgh, Hepatol Unit, Chancellors Bldg,49 Little France Crescent, Edinburgh EH16 4SB, Midlothian, Scotland.	e.dalakas@ed.ac.uk	Plevris, John N/O-3517-2014; Newsome, Philip N/D-4495-2018	Newsome, Philip N/0000-0001-6085-3652				Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Alison M, 1998, CURR OPIN CELL BIOL, V10, P710, DOI 10.1016/S0955-0674(98)80111-7; ALISON MR, 1993, J PATHOL, V171, P291, DOI 10.1002/path.1711710410; Alison MR, 2001, LIVER, V21, P367, DOI 10.1034/j.1600-0676.2001.210601.x; Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; Austin TW, 2003, MECH DEVELOP, V120, P131, DOI 10.1016/S0925-4773(02)00339-8; Bajetto A, 1999, J NEUROCHEM, V73, P2348, DOI 10.1046/j.1471-4159.1999.0732348.x; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Bleul CC, 1998, J EXP MED, V187, P753, DOI 10.1084/jem.187.5.753; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Carion A, 2003, BRIT J HAEMATOL, V122, P918, DOI 10.1046/j.1365-2141.2003.04545.x; Casamayor-Palleja M, 2001, BLOOD, V97, P3992, DOI 10.1182/blood.V97.12.3992; Chung TW, 2004, J GASTROEN HEPATOL, V19, P565, DOI 10.1111/j.1440-1746.2004.03344.x; Dahlke MH, 2003, J HEPATOL, V39, P365, DOI 10.1016/S0168-8278(03)00264-2; Dalakas E, 2003, HEPATOLOGY, V38, p284A; DApuzzo M, 1997, EUR J IMMUNOL, V27, P1788, DOI 10.1002/eji.1830270729; De Silvestro G, 2004, HEPATO-GASTROENTEROL, V51, P805; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Fibbe WE, 1999, ANN NY ACAD SCI, V872, P71, DOI 10.1111/j.1749-6632.1999.tb08454.x; Fuchs E, 2000, CELL, V100, P143, DOI 10.1016/S0092-8674(00)81691-8; Geisler S, 1997, CELL TISSUE RES, V289, P173, DOI 10.1007/s004410050863; Goddard S, 2001, TRANSPLANTATION, V72, P1957, DOI 10.1097/00007890-200112270-00016; GODISKA R, 1995, J NEUROIMMUNOL, V58, P167, DOI 10.1016/0165-5728(95)00008-P; Grzelak I, 1998, EUR SURG RES, V30, P198, DOI 10.1159/000008577; Hanumegowda UM, 2003, TOXICOL SCI, V76, P237, DOI 10.1093/toxsci/kfg222; Haruyama T, 2000, BIOCHEM BIOPH RES CO, V272, P681, DOI 10.1006/bbrc.2000.2837; Hatch Heather M., 2002, Cloning and Stem Cells, V4, P339, DOI 10.1089/153623002321025014; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Hattori K, 2001, BLOOD, V97, P3354, DOI 10.1182/blood.V97.11.3354; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; HILL DB, 1993, HEPATOLOGY, V18, P576, DOI 10.1016/0270-9139(93)90358-T; Huang YS, 1996, J HEPATOL, V24, P377, DOI 10.1016/S0168-8278(96)80156-5; Ianus A, 2003, J CLIN INVEST, V111, P843, DOI 10.1172/JCI200316502; Idilman R, 2004, TRANSPLANTATION, V78, P1647, DOI 10.1097/01.TP.0000144055.78462.4F; Ishikawa F, 2003, ANN NY ACAD SCI, V996, P174, DOI 10.1111/j.1749-6632.2003.tb03245.x; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Janowska-Wieczorek A, 2000, EXP HEMATOL, V28, P1274, DOI 10.1016/S0301-472X(00)00532-4; JIANG W, 1994, EXP CELL RES, V215, P284, DOI 10.1006/excr.1994.1344; Kanazawa Y, 2003, P NATL ACAD SCI USA, V100, P11850, DOI 10.1073/pnas.1834198100; Kawabata T, 1999, P NATL ACAD SCI USA, V96, P5663, DOI 10.1073/pnas.96.10.5663; Kim CH, 1998, BLOOD, V91, P4434, DOI 10.1182/blood.V91.12.4434.412k45_4434_4443; Kim CH, 1998, BLOOD, V91, P100, DOI 10.1182/blood.V91.1.100.100_100_110; Kiss A, 2001, LIVER, V21, P237, DOI 10.1034/j.1600-0676.2001.021004237.x; Knittel T, 2000, HISTOCHEM CELL BIOL, V113, P443; Kollet O, 2003, J CLIN INVEST, V112, P160, DOI 10.1172/JCI200317902; Kollet O, 2002, BLOOD, V100, P2778, DOI 10.1182/blood-2002-02-0564; Korbling M, 2002, NEW ENGL J MED, V346, P738, DOI 10.1056/NEJMoa3461002; Kuyvenhoven JP, 2004, TRANSPLANTATION, V77, P1646, DOI 10.1097/01.TP.0000131170.67671.75; Kuyvenhoven JP, 2003, TRANSPL P, V35, P2967, DOI 10.1016/j.transproceed.2003.10.049; Kuyvenhoven JP, 2004, THROMB HAEMOSTASIS, V91, P506, DOI 10.1160/TH03-05-0272; Kwon Oh Sang, 2003, Taehan Kan Hakhoe Chi, V9, P222; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Lamming CED, 2003, J CLIN INVEST, V111, P811, DOI 10.1172/JCI200315956; Lapidot T, 2002, EXP HEMATOL, V30, P973, DOI 10.1016/S0301-472X(02)00883-4; Lataillade JJ, 2002, BLOOD, V99, P1117, DOI 10.1182/blood.V99.4.1117; Leroy V, 2004, AM J GASTROENTEROL, V99, P271, DOI 10.1111/j.1572-0241.2004.04055.x; Levesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Lichtinghagen R, 2003, CLIN SCI, V105, P373, DOI 10.1042/CS20030098; Mohle R, 2001, ANN NY ACAD SCI, V938, P26; Nagasawa T, 1999, Adv Immunol, V71, P211; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Netelenbos T, 2002, J LEUKOCYTE BIOL, V72, P353; Newsome PN, 2003, GASTROENTEROLOGY, V124, P1891, DOI 10.1016/S0016-5085(03)00401-3; Ng IOL, 2003, HEPATOLOGY, V38, P989, DOI 10.1053/jhep.2003.50395; Pablos JL, 1999, AM J PATHOL, V155, P1577, DOI 10.1016/S0002-9440(10)65474-0; Peled A, 2000, BLOOD, V95, P3289, DOI 10.1182/blood.V95.11.3289.011k33_3289_3296; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Pillarisetti K, 2001, INFLAMMATION, V25, P293, DOI 10.1023/A:1012808525370; Ponomaryov T, 2000, J CLIN INVEST, V106, P1331, DOI 10.1172/JCI10329; Pruijt JFM, 2002, P NATL ACAD SCI USA, V99, P6228, DOI 10.1073/pnas.092112999; Roland J, 2003, BLOOD, V101, P399, DOI 10.1182/blood-2002-03-0978; Sakaida I, 2004, HEPATOLOGY, V40, P1304, DOI 10.1002/hep.20452; Sell S, 2001, HEPATOLOGY, V33, P738, DOI 10.1053/jhep.2001.21900; SHERON N, 1993, HEPATOLOGY, V18, P41, DOI 10.1002/hep.1840180108; Shimoda K, 1998, HEPATOLOGY, V28, P108, DOI 10.1002/hep.510280116; Stumm RK, 2002, J NEUROSCI, V22, P5865; Sweeney EA, 2001, ANN NY ACAD SCI, V938, P48; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; ten Hove WR, 2003, LIVER TRANSPLANT, V9, P552, DOI 10.1053/jlts.2003.50116; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Terada R, 2003, LAB INVEST, V83, P665, DOI 10.1097/01.LAB.0000067498.89585.06; Theise ND, 2000, HEPATOLOGY, V32, P11, DOI 10.1053/jhep.2000.9124; Theise ND, 2000, HEPATOLOGY, V31, P235, DOI 10.1002/hep.510310135; Thorgeirsson SS, 1996, FASEB J, V10, P1249, DOI 10.1096/fasebj.10.11.8836038; TILG H, 1992, TRANSPLANTATION, V53, P800, DOI 10.1097/00007890-199204000-00019; VAN ZK, 1992, J IMMUNOL, V148, P1746; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wang JF, 2000, BLOOD, V95, P2505, DOI 10.1182/blood.V95.8.2505.008k24_2505_2513; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Wang XL, 2003, BLOOD, V101, P4201, DOI 10.1182/blood-2002-05-1338; Watanabe Y, 2003, BIOL PHARM BULL, V26, P564; Whetton AD, 1999, TRENDS CELL BIOL, V9, P233, DOI 10.1016/S0962-8924(99)01559-7; Wu T, 2003, AM J TRANSPLANT, V3, P1173, DOI 10.1046/j.1600-6143.2003.00137.x; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zaitseva M, 2002, J IMMUNOL, V168, P2609, DOI 10.4049/jimmunol.168.6.2609	97	91	101	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1225	1231		10.1096/fj.04-2604rev	http://dx.doi.org/10.1096/fj.04-2604rev			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16051689				2022-12-28	WOS:000231843700029
J	Shams, I; Nevo, E; Avivi, A				Shams, I; Nevo, E; Avivi, A			Erythropoietin receptor spliced forms differentially expressed in blind subterranean mole rats	FASEB JOURNAL			English	Article						EpoR spliced variants; hypoxia; Epo	SPALAX-EHRENBERGI; HUMAN CANCER; CELL-LINE; HYPOXIA; CALCIUM; BRAIN; MOTIF; IDENTIFICATION; PROLIFERATION; HEMOGLOBIN	Erythropoietin ( Epo) is the primary regulator of erythropoiesis, controlling the proliferation, maturation, and survival of erythroid progenitor cells. The functions of Epo are mediated through its specific receptor ( EpoR) expressed mainly on the surface of erythroid progenitor cells, and the expression of both responds to hypoxia. The subterranean mole rat ( Spalax) is a unique model system to study the molecular mechanisms for adaptation to hypoxia. Here, we cloned two forms of Spalax EpoR: a complete EpoR cDNA as well as a novel truncated bone marrow specific EpoR form. In the full- length Spalax EpoR ( sEpoR), two out of the eight conserved tyrosine- phosphorylation sites were substituted ( Y481F and Y499G), suggesting that Spalax Epo signaling pathways may be modulated. The level of the sEpoR mRNA in the spleen and in bone marrow was relatively low and similar in Spalax newborns and adults, with no significant response to hypoxia. The truncated sEpoR was not detected in the spleen and comprised only similar to 1% of the sEpoR expressed in the bone marrow. In Rattus, the truncated EpoR form was similar to 15% of the total expressed receptor. The level of Rattus EpoR in newborn spleens was three- to fourfold higher than in Spalax newborns and decreased toward adulthood. Severe hypoxia induces a significant increase in adult Rattus EpoR. Our data provide further insight into the adaptive mechanisms of Spalax to the extreme conditions of hypoxia in its subterranean environment.	Univ Haifa, Lab Anim Mol Evolut, Inst Evolut, IL-31905 Haifa, Israel	University of Haifa	Avivi, A (corresponding author), Univ Haifa, Lab Anim Mol Evolut, Inst Evolut, IL-31905 Haifa, Israel.	aaron@esti.haifa.ac.il		Shams, Imad/0000-0001-6496-2928				Arcasoy MO, 2003, BIOCHEM BIOPH RES CO, V307, P999, DOI 10.1016/S0006-291X(03)01303-2; Arcasoy MO, 2002, LAB INVEST, V82, P911, DOI 10.1097/01.LAB.0000020415.72863.40; ARIELI R, 1991, COMP BIOCHEM PHYS A, V100, P543, DOI 10.1016/0300-9629(91)90367-L; ARIELI R, 1986, EXPERIENTIA, V42, P441, DOI 10.1007/BF02118650; ARIELI R, 1977, PHYSIOL ZOOL, V50, P61, DOI 10.1086/physzool.50.1.30155716; Ashur-Fabian C, 2004, P NATL ACAD SCI USA, V101, P12236, DOI 10.1073/pnas.0404998101; Assandri R, 1999, J PHYSIOL-LONDON, V516, P343, DOI 10.1111/j.1469-7793.1999.0343v.x; Avivi A, 2005, CELL CYCLE, V4, P368, DOI 10.4161/cc.4.3.1534; Avivi A, 1999, FEBS LETT, V452, P133, DOI 10.1016/S0014-5793(99)00584-0; BARRON C, 1994, GENE, V147, P263, DOI 10.1016/0378-1119(94)90078-7; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Bittorf T, 1996, INT J BIOCHEM CELL B, V28, P175, DOI 10.1016/1357-2725(95)00128-X; Bouscary D, 2003, BLOOD, V101, P3436, DOI 10.1182/blood-2002-07-2332; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Chiba S, 1997, BLOOD, V90, P97; DANDREA A, 1990, INT J CELL CLONING, V8, P173, DOI 10.1002/stem.5530080716; EDOUTE Y, 1988, J COMP PHYSIOL B, V158, P575, DOI 10.1007/BF00692566; Farrell F, 2004, ONCOLOGIST, V9, P18, DOI 10.1634/theoncologist.9-90005-18; Flint-Ashtamker G, 2002, FEBS LETT, V518, P189, DOI 10.1016/S0014-5793(02)02691-1; GURNETT AM, 1984, J PROTEIN CHEM, V3, P445, DOI 10.1007/BF01025063; JACOBSON LO, 1957, NATURE, V179, P633, DOI 10.1038/179633a0; Joneja B, 1997, J BIOL CHEM, V272, P11176, DOI 10.1074/jbc.272.17.11176; KLEINSCHMIDT T, 1984, H-S Z PHYSIOL CHEM, V365, P531, DOI 10.1515/bchm2.1984.365.1.531; Lappin T, 2003, ONCOLOGIST, V8, P15, DOI 10.1634/theoncologist.8-suppl_1-15; Levin I, 1998, FEBS LETT, V427, P164, DOI 10.1016/S0014-5793(98)00414-1; Miller BA, 1999, J BIOL CHEM, V274, P20465, DOI 10.1074/jbc.274.29.20465; NAKAMURA Y, 1992, SCIENCE, V257, P1138, DOI 10.1126/science.257.5073.1138; Nevo, 1999, MOSAIC EVOLUTION SUB; NEVO E, 1989, HEREDITY, V62, P85, DOI 10.1038/hdy.1989.11; Nevo E., 1961, Mammalia Paris, V25, P127, DOI 10.1515/mamm.1961.25.2.127; NEVO E., 2001, ADAPTIVE RAD BLIND S; Seta KA, 2004, CELL CALCIUM, V36, P331, DOI 10.1016/j.ceca.2004.02.006; Shams I, 2004, P NATL ACAD SCI USA, V101, P9698, DOI 10.1073/pnas.0403540101; Shams Imad, 2005, FASEB J, V19, P307; Shimizu R, 1999, EXP HEMATOL, V27, P229, DOI 10.1016/S0301-472X(98)00048-4; Siren AL, 2001, ACTA NEUROPATHOL, V101, P271, DOI 10.1007/s004010000297; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Weisinger G, 1999, BBA-GENE STRUCT EXPR, V1446, P225, DOI 10.1016/S0167-4781(99)00091-3; Widmer HR, 1997, P NATL ACAD SCI USA, V94, P2062, DOI 10.1073/pnas.94.5.2062; Wright GL, 2004, FASEB J, V18, P1031, DOI 10.1096/fj.03-1289fje; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yamaji R, 1998, BBA-MOL CELL RES, V1403, P169, DOI 10.1016/S0167-4889(98)00037-8; YOSHIMURA A, 1992, J BIOL CHEM, V267, P11619; Yu XB, 2002, DEVELOPMENT, V129, P505; ZANJANI ED, 1977, J LAB CLIN MED, V89, P640	45	21	21	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1749	+		10.1096/fj.05-3975fje	http://dx.doi.org/10.1096/fj.05-3975fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16081499				2022-12-28	WOS:000231843700021
J	Carny, O; Gazit, E				Carny, O; Gazit, E			A model for the role of short self-assembled peptides in the very early stages of the origin of life	FASEB JOURNAL			English	Article						aromatic interactions; closed-cage nanostructures; molecular recognition; origin of life; peptides; self-association; pi-pi stacking	AMYLOID FIBRIL FORMATION; SURFACTANT-LIKE PEPTIDES; FORM NANOTUBES; AMINO-ACIDS; RNA; RECOGNITION; STACKING; ATP; EVOLUTION; STATE	The molecular basis of the origin of life is one of the most fundamental questions in modern biology. While the "RNA world" hypothesis offers a very sensible model for the evolvement of the current biochemical networks, there is a lack of knowledge about the early steps that led to the formation of the first RNA molecules. This issue is essential as it is practically impossible that complex molecules as functional RNA oligonucleotides had evolved spontaneously. It was recently demonstrated that peptide molecules as simple as dipeptides can self-assemble into well-ordered tubular, fibrilar, and closed-cage structures. Other studies have confirmed the ability of dipeptides to act as catalysts and the capability of other peptides, as short as tripeptides, to serve as a template for nucleotide binding and orientation. Unlike complex RNA molecules, the spontaneous formation of functional short peptides in the primordial earth conditions is very likely. We suggest a novel mechanism for the origin of life that is based on the ability of short peptides to form encapsulated structures, catalyst chemical reaction, and serve as highly ordered template for the assembly of nucleotides. This model may explain the early events that led to the formation of the current biochemical machinery that combines the elaborated and coordinated interaction between nucleic acids and proteins to allow the function of living systems.	Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, George S Wise Fac Life Sci, IL-69978 Tel Aviv, Israel	Tel Aviv University	Gazit, E (corresponding author), Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, George S Wise Fac Life Sci, IL-69978 Tel Aviv, Israel.		Gazit, Ehud/C-3715-2011; Gazit, Ehud/M-8026-2019; Gazit, Ehud/AHE-9332-2022	Gazit, Ehud/0000-0001-5764-1720; Gazit, Ehud/0000-0001-5764-1720; 				ANDERS E, 1989, NATURE, V342, P255, DOI 10.1038/342255a0; Arrhenius G, 2000, CHEM GEOL, V169, P69, DOI 10.1016/S0009-2541(00)00333-8; BAHADUR K, 1958, NATURE, V182, P1668, DOI 10.1038/1821668a0; Blakaj DM, 2001, J AM CHEM SOC, V123, P2548, DOI 10.1021/ja005538j; BOHLER C, 2002, NATURE, V376, P578; Butterfield SM, 2004, ANGEW CHEM INT EDIT, V43, P724, DOI 10.1002/anie.200352527; Butterfield SM, 2003, J AM CHEM SOC, V125, P9580, DOI 10.1021/ja0359254; Chiti F, 2001, PROTEIN SCI, V10, P2541, DOI 10.1110/ps.ps.10201; DEAMER DW, 1993, ORIGINS LIFE CTR CON, P9; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; GABRIELE V, 1998, ANNU REV BIOPH BIOM, V27, P407; Gazit E, 2002, FASEB J, V16, P77, DOI 10.1096/fj.01-0442hyp; Gazit E, 2002, ANGEW CHEM INT EDIT, V41, P257, DOI 10.1002/1521-3773(20020118)41:2<257::AID-ANIE257>3.0.CO;2-M; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kochavi E, 1997, J MOL EVOL, V45, P342, DOI 10.1007/PL00006239; Lai J, 2003, CURR OPIN NEUROBIOL, V13, P291, DOI 10.1016/S0959-4388(03)00074-6; LARRALDE R, 1995, P NATL ACAD SCI USA, V92, P8158, DOI 10.1073/pnas.92.18.8158; LAZCANO A, 1988, J MOL EVOL, V27, P283, DOI 10.1007/BF02101189; LAZCANO A, 1988, J MOL EVOL, V27, P365, DOI 10.1007/BF02101199; Levy M, 1998, P NATL ACAD SCI USA, V95, P7933, DOI 10.1073/pnas.95.14.7933; Lilley DMJ, 2003, TRENDS BIOCHEM SCI, V28, P495, DOI 10.1016/S0968-0004(03)00191-9; Lu K, 2003, J AM CHEM SOC, V125, P6391, DOI 10.1021/ja0341642; MAHER KA, 1988, NATURE, V331, P612, DOI 10.1038/331612a0; MAJI SK, 2001, CHEM COMMUN CAMBRIDG; McCleskey SC, 2003, J AM CHEM SOC, V125, P1114, DOI 10.1021/ja021230b; Meierhenrich UJ, 2004, P NATL ACAD SCI USA, V101, P9182, DOI 10.1073/pnas.0403043101; Mojzsis SJ, 1996, NATURE, V384, P55, DOI 10.1038/384055a0; Naito A, 2004, MAGN RESON CHEM, V42, P247, DOI 10.1002/mrc.1323; NORBERG J, 1995, J AM CHEM SOC, V117, P10832, DOI 10.1021/ja00149a006; Orgel LE, 2004, CRIT REV BIOCHEM MOL, V39, P99, DOI 10.1080/10409230490460765; Pizzarello S, 2004, ORIGINS LIFE EVOL B, V34, P25, DOI 10.1023/B:ORIG.0000009826.76353.de; Plankensteiner K, 2004, ANGEW CHEM INT EDIT, V43, P1886, DOI 10.1002/anie.200353135; Reches M, 2004, NANO LETT, V4, P581, DOI 10.1021/nl035159z; Reches M, 2003, SCIENCE, V300, P625, DOI 10.1126/science.1082387; Reches M, 2002, J BIOL CHEM, V277, P35475, DOI 10.1074/jbc.M206039200; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Rode BM, 1999, COORDIN CHEM REV, V190, P1085, DOI 10.1016/S0010-8545(99)00159-9; Rode BM, 1999, PEPTIDES, V20, P773, DOI 10.1016/S0196-9781(99)00062-5; Rode BM, 1999, PEPTIDES, V20, P1513, DOI 10.1016/S0196-9781(99)00163-1; Santoso S, 2002, NANO LETT, V2, P687, DOI 10.1021/n1025563i; Sazani PL, 2004, J AM CHEM SOC, V126, P8370, DOI 10.1021/ja049171k; Schneider SE, 2000, J AM CHEM SOC, V122, P542, DOI 10.1021/ja9935153; Shiels JC, 2002, NUCLEIC ACIDS RES, V30, P550, DOI 10.1093/nar/30.2.550; Song YJ, 2004, CHEM COMMUN, P1044, DOI 10.1039/b402126f; Sun LL, 2002, CHEM BIOL, V9, P619, DOI 10.1016/S1074-5521(02)00141-2; Takahashi Y, 2004, BIOORGAN MED CHEM, V12, P693, DOI 10.1016/j.bmc.2003.11.022; Tartaglia GG, 2004, PROTEIN SCI, V13, P1939, DOI 10.1110/ps.04663504; Tjernberg L, 2002, J BIOL CHEM, V277, P43243, DOI 10.1074/jbc.M205570200; Vauthey S, 2002, P NATL ACAD SCI USA, V99, P5355, DOI 10.1073/pnas.072089599; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107	51	83	82	0	37	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1051	1055		10.1096/fj.04-3256hyp	http://dx.doi.org/10.1096/fj.04-3256hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	15985527				2022-12-28	WOS:000230923000032
J	Pietri, M; Scheider, B; Mouillet-Richard, S; Ermonval, M; Mutel, V; Launay, JM; Kellermann, O				Pietri, M; Scheider, B; Mouillet-Richard, S; Ermonval, M; Mutel, V; Launay, JM; Kellermann, O			Reactive oxygen species-dependent TNF-alpha converting enzyme activation through stimulation of 5-HT2B and alpha(1D) autoreceptors in neuronal cells	FASEB JOURNAL			English	Article							TUMOR-NECROSIS-FACTOR; NADPH OXIDASE; SIGNAL-TRANSDUCTION; ALZHEIMERS-DISEASE; MYRISTATE ACETATE; RECEPTOR SUBTYPES; OXIDATIVE STRESS; LIPID RAFTS; EXPRESSION; SEROTONIN	A major determinant of neuronal homeostasis is the proper integration of cell signaling pathways recruited by a variety of neuronal and non-neuronal factors. By taking advantage of a neuroectodermal cell line (1C11) endowed with the capacity to differentiate into serotonergic (1C11(5-HT)) or noradrenergic (1C11(NE)) neurons, we identified serotonin (5-hydroxytryptamine, 5-HT)- and norepinephrine (NE)-dependent signaling cascades possibly involved in neuronal functions. First, we establish that 5-HT2B receptors and alpha(1D) adrenoceptors are functionally coupled to reactive oxygen species (ROS) synthesis through NADPH oxidase activation in 1C11(5-HT) and 1C11(NE) cells. This observation constitutes the prime evidence that bioaminergic autoreceptors take part in the control of the cellular redox equilibrium in a neuronal context. Second, our data identify TACE (TNF-alpha Converting Enzyme), a member of a disintegrin and metalloproteinase (ADAM) family, as a downstream target of the 5-HT2B and alpha(1D) receptor-NADPH oxidase signaling pathways. Upon 5-HT2B or alpha(1D) receptor stimulation, ROS fully govern TNF-alpha shedding in the surrounding milieu of 1C11(5-HT) or 1C11(NE) cells. Third, 5-HT2B and alpha(1D) receptor couplings to the NADPH oxidase-TACE cascade are strictly restricted to 1C11-derived progenies that have implemented a complete serotonergic or noradrenergic phenotype. Overall, these observations suggest that 5-HT2B and alpha(1D) autoreceptors may play a role in the maintenance of neuron- and neurotransmitter-associated functions. Eventually, our study may have implications regarding the origin of oxidative stress as well as upregulated expression of proinflammatory cytokines in neurodegenerative disorders, which may relate to the deviation of normal signaling pathways.	CNRS, Inst Andre Lwoff, UPR 1983, Inst Pasteur,Lab Differenciat Cellulaire & Pr, F-94801 Villejuif, France; F Hoffmann La Roche & Co Ltd, Pharma Res Dept, CH-4002 Basel, Switzerland; Univ Paris 05, Serv Biochim, Fac Pharm, Hop Lariboisiere EA3621, Paris, France	Centre National de la Recherche Scientifique (CNRS); Roche Holding; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	Scheider, B (corresponding author), CNRS, Inst Andre Lwoff, UPR 1983, Inst Pasteur,Lab Differenciat Cellulaire & Pr, 7 Rue Guy Moquet, F-94801 Villejuif, France.	bschneid@vjf.cnrs.fr	Mouillet, Sophie/E-4960-2017; Schneider, Benoit/AAF-3850-2019	Mouillet, Sophie/0000-0002-8950-1949; PIETRI, Mathea/0000-0002-1819-2878; Ermonval, Myriam/0000-0002-9685-9826; Schneider, Benoit/0000-0002-1377-2670				Alonso MA, 2001, J CELL SCI, V114, P3957; Amin JK, 2001, J MOL CELL CARDIOL, V33, P131, DOI 10.1006/jmcc.2000.1285; Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Audia JE, 1996, J MED CHEM, V39, P2773, DOI 10.1021/jm960062t; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Choi DS, 1996, FEBS LETT, V391, P45, DOI 10.1016/0014-5793(96)00695-3; Cussac D, 2002, N-S ARCH PHARMACOL, V365, P242, DOI 10.1007/s00210-001-0505-y; DUSI S, 1993, BIOCHEM J, V290, P173, DOI 10.1042/bj2900173; Duxon MS, 1997, NEUROSCIENCE, V76, P323, DOI 10.1016/S0306-4522(96)00480-0; Friedman JI, 1999, BIOL PSYCHIAT, V46, P1243, DOI 10.1016/S0006-3223(99)00232-2; Gaspar P, 2003, NAT REV NEUROSCI, V4, P1002, DOI 10.1038/nrn1256; Gaur U, 2003, BIOCHEM PHARMACOL, V66, P1403, DOI 10.1016/S0006-2952(03)00490-8; Goridis C, 2002, NAT REV NEUROSCI, V3, P531, DOI 10.1038/nrn871; Hayley S, 1999, J NEUROSCI, V19, P5654; HIGUCHI M, 1994, J IMMUNOL, V152, P3550; Hoyer D, 2002, PHARMACOL BIOCHEM BE, V71, P533, DOI 10.1016/S0091-3057(01)00746-8; Ignatowski TA, 1997, J NEUROIMMUNOL, V79, P84, DOI 10.1016/S0165-5728(97)00107-0; Jaffre F, 2004, CIRCULATION, V110, P969, DOI 10.1161/01.CIR.0000139856.20505.57; Jerman JC, 2001, EUR J PHARMACOL, V414, P23, DOI 10.1016/S0014-2999(01)00775-0; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kawakami N, 2000, BIOL PHARM BULL, V23, P1100; Kellermann O, 1996, BRIT J PHARMACOL, V118, P1161, DOI 10.1111/j.1476-5381.1996.tb15519.x; Kordek R, 1996, P NATL ACAD SCI USA, V93, P9754, DOI 10.1073/pnas.93.18.9754; Lee SL, 2001, AM J PHYSIOL-LUNG C, V281, pL646, DOI 10.1152/ajplung.2001.281.3.L646; LEE SL, 1994, AM J PHYSIOL, V266, pL46, DOI 10.1152/ajplung.1994.266.1.L46; LORIC S, 1995, MOL PHARMACOL, V47, P458; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; Manivet P, 2000, J BIOL CHEM, V275, P9324, DOI 10.1074/jbc.275.13.9324; Mattson MP, 2003, NEUROMOL MED, V4, P109, DOI 10.1385/NMM:4:1-2:109; MERRILL JE, 1992, DEV NEUROSCI-BASEL, V14, P1, DOI 10.1159/000111642; Mhatre M, 2004, J ALZHEIMERS DIS, V6, P147; Mouillet-Richard S, 2000, J BIOL CHEM, V275, P9186, DOI 10.1074/jbc.275.13.9186; Osborne PB, 2002, BRIT J PHARMACOL, V135, P226, DOI 10.1038/sj.bjp.0704453; Philipp M, 2004, PHARMACOL THERAPEUT, V101, P65, DOI 10.1016/j.pharmthera.2003.10.004; Porter RHP, 1999, BRIT J PHARMACOL, V128, P13, DOI 10.1038/sj.bjp.0702751; QUINN MT, 1993, J BIOL CHEM, V268, P20983; Scherzer JA, 1997, J IMMUNOL, V158, P913; Schneider B, 2003, P NATL ACAD SCI USA, V100, P13326, DOI 10.1073/pnas.2235648100; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Tournois C, 1998, J BIOL CHEM, V273, P17498, DOI 10.1074/jbc.273.28.17498; Vilhardt F, 2004, EMBO J, V23, P739, DOI 10.1038/sj.emboj.7600066; Viviani B, 2004, TOXICOL LETT, V149, P85, DOI 10.1016/j.toxlet.2003.12.022; Volgin DV, 2001, J CHEM NEUROANAT, V22, P157, DOI 10.1016/S0891-0618(01)00124-7; Williams A, 1997, BRAIN RES, V754, P171, DOI 10.1016/S0006-8993(97)00067-X; Xiao L, 2002, AM J PHYSIOL-CELL PH, V282, pC926, DOI 10.1152/ajpcell.00254.2001; Zhang ZL, 2001, FASEB J, V15, P303	51	36	37	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1078	1087		10.1096/fj.04-3631com	http://dx.doi.org/10.1096/fj.04-3631com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	15985531				2022-12-28	WOS:000230923000036
J	Cappai, R; Leck, SL; Tew, DJ; Williamson, NA; Smith, DP; Galatis, D; Sharples, RA; Curtain, CC; Ali, FE; Cherny, RA; Culvenor, JG; Bottomley, SP; Masters, CL; Barnham, KJ; Hill, AF				Cappai, R; Leck, SL; Tew, DJ; Williamson, NA; Smith, DP; Galatis, D; Sharples, RA; Curtain, CC; Ali, FE; Cherny, RA; Culvenor, JG; Bottomley, SP; Masters, CL; Barnham, KJ; Hill, AF			Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway	FASEB JOURNAL			English	Article						protein aggregation; Parkinson's disease; amyloid; circular dichroism	PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; SECONDARY STRUCTURE; A-BETA; PATHOGENESIS; MUTATIONS; FIBRILLIZATION; STABILIZATION; DEGRADATION; COMPONENT	Dopamine (DA) and alpha-synuclein (alpha-SN) are two key molecules associated with Parkinson's disease (PD). We have identified a novel action of DA in the initial phase of alpha-SN aggregation and demonstrate that DA induces alpha-SN to form soluble, SDS-resistant oligomers. The DA: alpha-SN oligomeric species are not amyloidogenic as they do not react with thioflavin T and lack the typical amyloid fibril structures as visualized with electron microscopy. Circular dichroism studies indicate that in the presence of lipid membranes DA interacts with alpha-SN, causing an alteration to the structure of the protein. Furthermore, DA inhibited the formation of iron-induced alpha-SN amyloidogenic aggregates, suggesting that DA acts as a dominant modulator of alpha-SN aggregation. These observations support the paradigm emerging for other neurodegenerative diseases that the toxic species is represented by a soluble oligomer and not the insoluble fibril.	Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia; Univ Melbourne, Ctr Neurosci, Melbourne, Vic 3010, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic 3010, Australia; Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic 3010, Australia; Mental Hlth Res Inst Victoria, Parkville, Vic 3052, Australia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia; Monash Univ, Sch Phys & Mat Engn, Clayton, Vic 3168, Australia	University of Melbourne; University of Melbourne; University of Melbourne; University of Melbourne; Monash University; Monash University	Cappai, R (corresponding author), Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia.	r.cappai@unimelb.edu.au	Hill, Andrew F./AAH-2854-2020; Williamson, Nicholas A/O-9812-2016; Hill, Andrew F./GZL-4124-2022; Cappai, Roberto/B-3347-2010; Hill, Andrew F/B-4527-2009	Williamson, Nicholas A/0000-0002-2173-3452; Hill, Andrew F./0000-0001-5581-2354; Cappai, Roberto/0000-0002-9505-8496; Hill, Andrew F/0000-0001-5581-2354; Smith, David/0000-0001-5177-8574				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Barnham KJ, 2004, FASEB J, V18, P1427, DOI 10.1096/fj.04-1890fje; Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; Chandra S, 2004, P NATL ACAD SCI USA, V101, P14966, DOI 10.1073/pnas.0406283101; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Culvenor JG, 1999, AM J PATHOL, V155, P1173, DOI 10.1016/S0002-9440(10)65220-0; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Der-Sarkissian A, 2003, J BIOL CHEM, V278, P37530, DOI 10.1074/jbc.M305266200; Du HN, 2003, BIOCHEMISTRY-US, V42, P8870, DOI 10.1021/bi034028+; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; GERARD C, 1994, POLYHEDRON, V13, P591, DOI 10.1016/s0277-5387(00)84736-1; Golts N, 2002, J BIOL CHEM, V277, P16116, DOI 10.1074/jbc.M107866200; Gotz ME, 2004, ANN NY ACAD SCI, V1012, P193, DOI 10.1196/annals.1306.017; Hoyer W, 2002, J MOL BIOL, V322, P383, DOI 10.1016/S0022-2836(02)00775-1; Hoyer WG, 2004, J MOL BIOL, V340, P127, DOI 10.1016/j.jmb.2004.04.051; Jo EJ, 2002, J MOL BIOL, V315, P799, DOI 10.1006/jmbi.2001.5269; Li J, 2004, FASEB J, V18, P962, DOI 10.1096/fj.03-0770fje; Lotharius J, 2002, HUM MOL GENET, V11, P2395, DOI 10.1093/hmg/11.20.2395; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Norris EH, 2005, J BIOL CHEM, V280, P21212, DOI 10.1074/jbc.M412621200; Perez RG, 2004, J NEUROCHEM, V89, P1318, DOI 10.1111/j.1471-4159.2004.02423.x; Perez RG, 2002, J NEUROSCI, V22, P3090, DOI 10.1523/JNEUROSCI.22-08-03090.2002; Recchia A, 2004, FASEB J, V18, P617, DOI 10.1096/fj.03-0338rev; Reixach N, 2004, P NATL ACAD SCI USA, V101, P2817, DOI 10.1073/pnas.0400062101; Rekas A, 2004, J MOL BIOL, V340, P1167, DOI 10.1016/j.jmb.2004.05.054; Sidhu A, 2004, FASEB J, V18, P637, DOI 10.1096/fj.03-1112rev; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509	40	213	219	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2005	19	8					1377	+		10.1096/fj.04-3437fje	http://dx.doi.org/10.1096/fj.04-3437fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15946991				2022-12-28	WOS:000230207800023
J	De Flora, S; Quaglia, A; Bennicelli, C; Vercelli, M				De Flora, S; Quaglia, A; Bennicelli, C; Vercelli, M			The epidemiological revolution of the 20th century	FASEB JOURNAL			English	Review						descriptive epidemiology; cardiovascular diseases; tumors; infectious diseases	CANCER MORTALITY	100 years ago the epidemiological scenario of human diseases had substantially remained unchanged. The 20th century has been characterized by a fantastic advance in life expectancy and by a shift from infectious to chronic degenerative diseases as prevailing causes of death. As an example of the epidemiological revolution in a developed country, we reconstructed, year by year from 1901 to 2000, the situation in Italy. Reference to the situation in other countries is also made. Both crude and age-adjusted mortality data were made available for males and females. A new turning point became evident in the second half of the 20th century with the decline of mortality for cardiovascular diseases and, more recently, for tumors. This review discusses the roots and rationale for these epidemiological changes. The discoveries made in the area of biomedical sciences, the progress in preventive and curative medicine, and the improvement of hygienic conditions have been so spectacular that 1 million lives are saved every year in Italy as compared with the late 19th century.	Univ Genoa, Dept Hlth Sci, I-16132 Genoa, Italy; Natl Inst Canc Res, Descript Epidemiol Unit, Genoa, Italy	University of Genoa; University of Genoa; IRCCS AOU San Martino IST	De Flora, S (corresponding author), Univ Genoa, Dept Hlth Sci, Via A Pastore 1, I-16132 Genoa, Italy.	sdf@unige.it		Vercelli, Marina/0000-0002-9757-2616				[Anonymous], 1992, INT STAT CLASS DIS R, V1-3; Cimons M, 1998, NAT MED, V4, P544, DOI 10.1038/nm0598-544; Crocetti Emanuele, 2004, Epidemiol Prev, V28, P1; DECARLI A, 1994, TUMORI, V80, P405, DOI 10.1177/030089169408000601; DeFlora S, 1996, MUTAT RES-REV GENET, V366, P197, DOI 10.1016/S0165-1110(96)00043-7; Istituto Nazionale di Statistica (ISTAT), 1958, CAUS DEATH 1887 1955; Levi F, 2002, INT J CANCER, V98, P636, DOI 10.1002/ijc.10235; Lopez A. D., 2000, ENCY EPIDEMIOLOGIC M, P617; Murphy S L, 2000, Natl Vital Stat Rep, V48, P1; Peto R, 1997, BRIT MED J, V315, P1030, DOI 10.1136/bmj.315.7115.1030; Pinnelli A, 1998, EUR J POPUL, V14, P333, DOI 10.1023/A:1006182029835; Taubenberger JK, 2000, VIROLOGY, V274, P241, DOI 10.1006/viro.2000.0495; Terada M, 1998, NAT MED, V4, P1221, DOI 10.1038/3198; *US DEP HHS, 1992, MMWR-MORBID MORTAL W, V41, P548	14	39	42	4	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					892	897		10.1096/fj.04-3541rev	http://dx.doi.org/10.1096/fj.04-3541rev			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15923399				2022-12-28	WOS:000230207800036
J	Penz, S; Reininger, AJ; Brandl, R; Goyal, P; Rabie, T; Bernlochner, I; Rother, E; Goetz, C; Engelmann, B; Smethurst, PA; Ouwehand, WH; Farndale, R; Nieswandt, B; Siess, W				Penz, S; Reininger, AJ; Brandl, R; Goyal, P; Rabie, T; Bernlochner, I; Rother, E; Goetz, C; Engelmann, B; Smethurst, PA; Ouwehand, WH; Farndale, R; Nieswandt, B; Siess, W			Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI	FASEB JOURNAL			English	Article						atherosclerotic plaques; ischemic stroke; thrombogenicity; arterial thrombus	FACTOR PATHWAY INHIBITOR; TISSUE-FACTOR; COLLAGEN; THROMBOGENICITY; DEPOSITION; AGGREGATION; RECEPTORS; ADHESION; DOMAINS; ANTIGEN	Lipid-rich atherosclerotic plaques are vulnerable, and their rupture can cause the formation of a platelet-and fibrin-rich thrombus leading to myocardial infarction and ischemic stroke. Although the role of plaque-based tissue factor as stimulator of blood coagulation has been recognized, it is not known whether plaques can cause thrombus formation through direct activation of platelets. We isolated lipid-rich atheromatous plaques from 60 patients with carotid stenosis and identified morphologically diverse collagen type I- and type III- positive structures in the plaques that directly stimulated adhesion, dense granule secretion, and aggregation of platelets in buffer, plasma, and blood. This material also elicited platelet-monocyte aggregation and platelet-dependent blood coagulation. Plaques exposed to flowing blood at arterial wall shear rate induced platelets to adhere to and spread on the collagenous structures, triggering subsequent thrombus formation. Plaque-induced platelet thrombus formation was observed in fully anticoagulated blood (i.e., in the absence of tissue factor-mediated coagulation). Mice platelets lacking glycoprotein VI ( GPVI) were unable to adhere to atheromatous plaque or form thrombi. Human platelet thrombus formation onto plaques in flowing blood was completely blocked by GPVI inhibition with the antibody 10B12 but not affected by integrin alpha(2)beta(1) inhibition with 6F1 mAb. Moreover, the initial platelet response, shape change, induced by plaque was blocked by GPVI inhibition but not with alpha(2)beta(1) antagonists (6F1 mAb or GFOGER-GPP peptide). Pretreatment of plaques with collagenase or anti-collagen type I and anti-collagen type III antibodies abolished plaque-induced platelet activation. Our results indicate that morphologically diverse collagen type I- and collagen type III- containing structures in lipid-rich atherosclerotic plaques stimulate thrombus formation by activating platelet GPVI. This platelet collagen receptor, essential for plaque-induced thrombus formation, presents a promising new anti-thrombotic target for the prevention of ischemic cardiovascular diseases.	Univ Munich, Inst Prevent Cardiovasc Dis, Munich, Germany; Univ Munich, Dept Transfus Med & Hemostaseol, Munich, Germany; Klinikum Munich Schwabing, Dept Vasc Surg, Munich, Germany; Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, Wurzburg, Germany; Univ Munich, Inst Clin Chem, Munich, Germany; Univ Cambridge, Dept Hematol, Cambridge, England	University of Munich; University of Munich; University of Wurzburg; University of Munich; University of Cambridge	Siess, W (corresponding author), Univ Munich, Klinikum Innenstadt, Inst Prophylaxe & Epidemiol Kreislaufkrankheiten, Pettenkoferstr 9, D-80336 Munich, Germany.	wsiess@med.uni-muenchen.de	Rabie, Tamer/C-7886-2013; Siess, Wolfgang/A-6430-2009; Goyal, Pankaj/C-3567-2012	Siess, Wolfgang/0000-0003-0698-6416; Rabie, Tamer/0000-0001-9060-8797				Abi-Younes S, 2000, CIRC RES, V86, P131, DOI 10.1161/01.RES.86.2.131; Ardissino D, 1997, LANCET, V349, P769, DOI 10.1016/S0140-6736(96)11189-2; Badimon JJ, 1999, CIRCULATION, V99, P1780, DOI 10.1161/01.CIR.99.14.1780; BADIMON L, 1987, J LAB CLIN MED, V110, P706; Barnes MJ, 1999, EXP GERONTOL, V34, P513, DOI 10.1016/S0531-5565(99)00038-8; Brandl R, 1997, CIRCULATION, V96, P3360; Cauwenberghs N, 2001, BLOOD, V98, P652, DOI 10.1182/blood.V98.3.652; CAZENAVE JP, 1993, CENTRIFUGATION TECHN; Chen J, 2001, ATHEROSCLEROSIS, V159, P289, DOI 10.1016/S0021-9150(01)00509-3; Clemetson KJ, 2001, THROMB HAEMOSTASIS, V86, P189; COLLER BS, 1989, BLOOD, V74, P182; Corti R, 2002, AM J MED, V113, P668, DOI 10.1016/S0002-9343(02)01344-X; De Meyer GRY, 1999, ARTERIOSCL THROM VAS, V19, P2524, DOI 10.1161/01.ATV.19.10.2524; FERNANDEZORTIZ A, 1994, J AM COLL CARDIOL, V23, P1562, DOI 10.1016/0735-1097(94)90657-2; Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4; Haseruck N, 2004, BLOOD, V103, P2585, DOI 10.1182/blood-2003-04-1127; Holtkotter O, 2002, J BIOL CHEM, V277, P10789, DOI 10.1074/jbc.M112307200; Kato K, 2003, BLOOD, V102, P1701, DOI 10.1182/blood-2003-03-0717; Katsuda Shogo, 2003, J Atheroscler Thromb, V10, P267; Knight CG, 1999, CARDIOVASC RES, V41, P450, DOI 10.1016/S0008-6363(98)00306-X; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Komorowicz E, 2002, THROMB HAEMOSTASIS, V88, P827, DOI 10.1055/s-0037-1613310; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Massberg S, 2003, FASEB J, V17, P397, DOI 10.1096/f.03-0464.fje; Merten M, 2001, CIRCULATION, V103, P2032; Moons AHM, 2002, CARDIOVASC RES, V53, P313, DOI 10.1016/S0008-6363(01)00452-7; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Nieswandt B, 2000, J BIOL CHEM, V275, P23998, DOI 10.1074/jbc.M003803200; Nieswandt B, 2001, J EXP MED, V193, P459, DOI 10.1084/jem.193.4.459; Rother E, 2003, CIRCULATION, V108, P741, DOI 10.1161/01.CIR.0000083715.37658.C4; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; Schulte V, 2001, J BIOL CHEM, V276, P364, DOI 10.1074/jbc.M007536200; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; Siljander PRM, 2004, J BIOL CHEM, V279, P47763, DOI 10.1074/jbc.M404685200; Siljander PRM, 2004, BLOOD, V103, P1333, DOI 10.1182/blood-2003-03-00869; Smethurst PA, 2004, BLOOD, V103, P903, DOI 10.1182/blood-2003-01-0308; Toschi V, 1997, CIRCULATION, V95, P594, DOI 10.1161/01.CIR.95.3.594; VANZANTEN GH, 1994, J CLIN INVEST, V93, P615, DOI 10.1172/JCI117014; Watson SP, 2001, THROMB HAEMOSTASIS, V86, P276; WEIDTMANN A, 1995, ARTERIOSCL THROM VAS, V15, P1131, DOI 10.1161/01.ATV.15.8.1131; Westrick RJ, 2001, CIRCULATION, V103, P3044, DOI 10.1161/hc2501.092492; Zillmann A, 2001, BIOCHEM BIOPH RES CO, V281, P603, DOI 10.1006/bbrc.2001.4399	42	119	127	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					898	909		10.1096/fj.04-2748com	http://dx.doi.org/10.1096/fj.04-2748com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15923400				2022-12-28	WOS:000230207800037
J	Hunt, JS; Petroff, MG; McIntire, RH; Ober, C				Hunt, JS; Petroff, MG; McIntire, RH; Ober, C			HLA-G and immune tolerance in pregnancy	FASEB JOURNAL			English	Review						human; placenta; immune privilege	LEUKOCYTE ANTIGEN-G; REGULATORY T-CELLS; INTERFERON-GAMMA CONTRIBUTES; MESSENGER-RIBONUCLEIC-ACID; CLASS-I MOLECULES; DENDRITIC CELLS; G EXPRESSION; DC-SIGN; INHIBITORY RECEPTOR; PRESENTING CELLS	Multiple mechanisms underlie the surprising willingness of mothers to tolerate genetically different fetal tissues during pregnancy. Chief among these is the choice of HLA-G, a gene with few alleles, rather than the highly polymorphic HLA-A and -B genes, for expression by the placental cells that interface directly with maternal blood and tissues. Novel aspects of this major histo compatibility complex class Ib gene include alternative splicing to permit production of membrane and soluble isoforms, deletions that dampen responses to interferons, and a shortened cytoplasmic tail that affects expression at the cell surface. Placental cells migrating into the maternal uterus synthesize both membrane and soluble isoforms, which interact with inhibitory receptors on leukocytes such as ILT2 and ILT4. Cytotoxic T lymphocytes either die or reduce production of one of their major coreceptor/activator cell surface molecules, CD8; natural killer cells are immobilized and mononuclear phagocytes are programmed into suppressive modes characterized by high production of anti-inflammatory cytokines. The idea that placental HILA-G proteins facilitate semiallogeneic pregnancy by inhibiting maternal immune responses to foreign (paternal) antigens via these actions on immune cells is now well established, and the postulate that the recombinant counterparts of these proteins may be used as powerful tools for preventing immune rejection of transplanted organs is gaining in popularity.	Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA; Univ Chicago, Chicago, IL 60637 USA	University of Kansas; University of Kansas Medical Center; University of Chicago	Hunt, JS (corresponding author), Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA.	jhunt@kumc.edu		Ober, Carole/0000-0003-4626-9809	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD045611] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD035859, R01HD021244, R01HD026429, P01HD039878] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016475] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR016475] Funding Source: Medline; NICHD NIH HHS [HD21244, HD26429, HD39878, HD045611, HD35859] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aldrich C, 2000, J REPROD IMMUNOL, V47, P41, DOI 10.1016/S0165-0378(00)00052-8; Aldrich CL, 2001, MOL HUM REPROD, V7, P1167, DOI 10.1093/molehr/7.12.1167; Allan DSJ, 2000, IMMUNOBIOLOGY, V202, P34, DOI 10.1016/S0171-2985(00)80050-9; Allan DSJ, 1999, J EXP MED, V189, P1149, DOI 10.1084/jem.189.7.1149; Aluvihare VR, 2004, NAT IMMUNOL, V5, P266, DOI 10.1038/ni1037; Ashkar AA, 1999, BIOL REPROD, V61, P493, DOI 10.1095/biolreprod61.2.493; Ashkar AA, 2000, J EXP MED, V192, P259, DOI 10.1084/jem.192.2.259; Avril T, 1999, J IMMUNOL, V162, P5902; Boyson JE, 2002, P NATL ACAD SCI USA, V99, P16180, DOI 10.1073/pnas.212643199; BULMER JN, 1988, REPROD NUTR DEV, V28, P1599, DOI 10.1051/rnd:19881006; Cantoni C, 1998, EUR J IMMUNOL, V28, P1980, DOI 10.1002/(SICI)1521-4141(199806)28:06<1980::AID-IMMU1980>3.0.CO;2-F; Cao W, 1999, MOL HUM REPROD, V5, P541, DOI 10.1093/molehr/5.6.541; Castro MJ, 2000, TISSUE ANTIGENS, V56, P232, DOI 10.1034/j.1399-0039.2000.560305.x; CHEN HL, 1991, AM J PATHOL, V139, P327; COLBERN GT, 1994, AM J OBSTET GYNECOL, V170, P1244, DOI 10.1016/S0002-9378(94)70134-2; Colonna M, 1997, J EXP MED, V186, P1809, DOI 10.1084/jem.186.11.1809; Contini P, 2003, EUR J IMMUNOL, V33, P125, DOI 10.1002/immu.200390015; Cupurdija K, 2004, AM J REPROD IMMUNOL, V51, P117, DOI 10.1046/j.8755-8920.2003.00128.x; FAULK WP, 1976, NATURE, V262, P799, DOI 10.1038/262799a0; Fournel S, 2000, J IMMUNOL, V164, P6100, DOI 10.4049/jimmunol.164.12.6100; FUJII T, 1994, J IMMUNOL, V153, P5516; Gangadharan D, 2004, CURR OPIN IMMUNOL, V16, P264, DOI 10.1016/j.coi.2004.03.015; Gardner L, 2003, BIOL REPROD, V69, P1438, DOI 10.1095/biolreprod.103.017574; Givan AL, 1997, AM J REPROD IMMUNOL, V38, P350; Goldman-Wohl DS, 2000, MOL HUM REPROD, V6, P88, DOI 10.1093/molehr/6.1.88; Grimsley C, 1997, HUM IMMUNOL, V52, P33, DOI 10.1016/S0198-8859(96)00241-8; Hara N, 1996, AM J REPROD IMMUNOL, V36, P349; HARRISON GA, 1993, HUM MOL GENET, V2, P2200, DOI 10.1093/hmg/2.12.2200-a; Heikkinen J, 2004, CLIN EXP IMMUNOL, V136, P373, DOI 10.1111/j.1365-2249.2004.02441.x; Heikkinen J, 2003, CLIN EXP IMMUNOL, V131, P498, DOI 10.1046/j.1365-2249.2003.02092.x; Hiby SE, 1999, TISSUE ANTIGENS, V53, P1, DOI 10.1034/j.1399-0039.1999.530101.x; Horuzsko A, 2001, INT IMMUNOL, V13, P385, DOI 10.1093/intimm/13.3.385; HSI BL, 1991, J REPROD IMMUNOL, V19, P209, DOI 10.1016/0165-0378(91)90036-P; Hunt J S, 1992, Curr Top Microbiol Immunol, V181, P39; HUNT JS, 1992, FASEB J, V6, P2344, DOI 10.1096/fasebj.6.6.1544544; Hunt JS, 2000, AM J OBSTET GYNECOL, V183, P682, DOI 10.1067/mob.2000.106762; HUNT JS, 1987, J IMMUNOL, V138, P2481; Hunt JS, 2003, MOL HUM REPROD, V9, P729, DOI 10.1093/molehr/gag087; Hunt JS, 1996, J REPROD IMMUNOL, V32, P1, DOI 10.1016/S0165-0378(96)88352-5; HUNT JS, 1994, BIOL REPROD, V50, P461, DOI 10.1095/biolreprod50.3.461; HUNT JS, 1989, J REPROD IMMUNOL, V16, P1, DOI 10.1016/0165-0378(89)90002-8; HUNT JS, 1992, BIOL REPROD, V47, P141, DOI 10.1095/biolreprod47.1.141; HUNT JS, 1990, PLACENTA, V11, P467, DOI 10.1016/S0143-4004(05)80192-4; HUNT JS, 2002, ENDOMETRIUM, P405; Hviid TVF, 2003, IMMUNOGENETICS, V55, P63, DOI 10.1007/s00251-003-0547-z; Hviid TVF, 1999, HUM IMMUNOL, V60, P1237, DOI 10.1016/S0198-8859(99)00130-5; Hviid TVF, 2001, IMMUNOGENETICS, V53, P48, DOI 10.1007/s002510100296; ISHITANI A, 1992, P NATL ACAD SCI USA, V89, P3947, DOI 10.1073/pnas.89.9.3947; Ishitani A, 2003, J IMMUNOL, V171, P1376, DOI 10.4049/jimmunol.171.3.1376; Kammerer U, 2000, AM J PATHOL, V157, P159, DOI 10.1016/S0002-9440(10)64527-0; Kammerer U, 2003, AM J PATHOL, V162, P887, DOI 10.1016/S0002-9440(10)63884-9; Kanai T, 2001, MOL HUM REPROD, V7, P195, DOI 10.1093/molehr/7.2.195; Kapasi K, 2000, IMMUNOLOGY, V101, P191, DOI 10.1046/j.1365-2567.2000.00109.x; Khalil-Daher I, 1999, J REPROD IMMUNOL, V43, P175, DOI 10.1016/S0165-0378(99)00032-7; Kikuchi-Maki A, 2003, J IMMUNOL, V171, P3415, DOI 10.4049/jimmunol.171.7.3415; King A, 2000, EUR J IMMUNOL, V30, P1623, DOI 10.1002/1521-4141(200006)30:6<1623::AID-IMMU1623>3.0.CO;2-M; Langat DK, 2002, IMMUNOGENETICS, V54, P164, DOI 10.1007/s00251-002-0454-8; Laupeze B, 1999, HUM IMMUNOL, V60, P591, DOI 10.1016/S0198-8859(99)00025-7; Le Bouteiller P, 1997, Rev Reprod, V2, P7; Le Friec G, 2003, HUM IMMUNOL, V64, P752, DOI 10.1016/S0198-8859(03)00091-0; Le Gal FA, 1999, INT IMMUNOL, V11, P1351, DOI 10.1093/intimm/11.8.1351; LEBOUTEILLER P, 1994, CRIT REV IMMUNOL, V14, P89, DOI 10.1615/CritRevImmunol.v14.i2.10; Lee N, 1998, J IMMUNOL, V160, P4951; Lee N, 1998, P NATL ACAD SCI USA, V95, P5199, DOI 10.1073/pnas.95.9.5199; LeMaoult J, 2004, P NATL ACAD SCI USA, V101, P7064, DOI 10.1073/pnas.0401922101; Lenfant F, 2003, J GEN VIROL, V84, P307, DOI 10.1099/vir.0.18735-0; Li XF, 2001, J CLIN ENDOCR METAB, V86, P1823, DOI 10.1210/jc.86.4.1823; Liang SY, 2002, EUR J IMMUNOL, V32, P2418, DOI 10.1002/1521-4141(200209)32:9<2418::AID-IMMU2418>3.0.CO;2-L; Lila N, 2002, CIRCULATION, V105, P1949, DOI 10.1161/01.CIR.0000015075.89984.46; Lim KH, 1997, AM J PATHOL, V151, P1809; Lozano JM, 2002, AIDS, V16, P347, DOI 10.1097/00002030-200202150-00005; LYSIAK JJ, 1995, PLACENTA, V16, P221, DOI 10.1016/0143-4004(95)90110-8; Marzi M, 1996, CLIN EXP IMMUNOL, V106, P127, DOI 10.1046/j.1365-2249.1996.d01-809.x; McIntire RH, 2004, J LEUKOCYTE BIOL, V76, P1220, DOI 10.1189/jlb.0604337; MEDAWAR PB, 1953, SYM SOC EXP BIOL, V7, P320; Menier C, 2000, HUM IMMUNOL, V61, P1118, DOI 10.1016/S0198-8859(00)00194-4; Miyazaki S, 2003, J LEUKOCYTE BIOL, V74, P514, DOI 10.1189/jlb.1102566; MIZUNO M, 1994, AM J REPROD IMMUNOL, V31, P180, DOI 10.1111/j.1600-0897.1994.tb00865.x; Moffett-King A, 2002, NAT REV IMMUNOL, V2, P656, DOI 10.1038/nri886; Morales PJ, 2003, J IMMUNOL, V171, P6215, DOI 10.4049/jimmunol.171.11.6215; Navarro F, 1999, EUR J IMMUNOL, V29, P277, DOI 10.1002/(SICI)1521-4141(199901)29:01<277::AID-IMMU277>3.0.CO;2-4; NEHEMIAH JL, 1981, AM J OBSTET GYNECOL, V140, P261, DOI 10.1016/0002-9378(81)90271-4; O'Brien M, 2001, CELL MOL LIFE SCI, V58, P1943, DOI 10.1007/PL00000828; Ober C, 2003, AM J HUM GENET, V72, P1425, DOI 10.1086/375501; Ober C, 1998, PLACENTA, V19, P127, DOI 10.1016/S0143-4004(98)90000-5; Ober C, 1997, J REPROD IMMUNOL, V36, P1, DOI 10.1016/S0165-0378(97)00062-4; Onno M, 2000, J IMMUNOL, V164, P6426, DOI 10.4049/jimmunol.164.12.6426; Onno M, 2000, HUM IMMUNOL, V61, P1086, DOI 10.1016/S0198-8859(00)00191-9; Palucka KA, 1998, J IMMUNOL, V160, P4587; Parham P, 1996, CURR BIOL, V6, P638, DOI 10.1016/S0960-9822(09)00436-9; PARHAR RS, 1988, CELL IMMUNOL, V116, P392, DOI 10.1016/0008-8749(88)90240-7; Park B, 2001, IMMUNITY, V15, P213, DOI 10.1016/S1074-7613(01)00179-0; Pende D, 1997, EUR J IMMUNOL, V27, P1875, DOI 10.1002/eji.1830270809; PerezVillar JJ, 1997, J IMMUNOL, V158, P5736; Petrie C, 2003, IEEE INTERNET COMPUT, V7, P68, DOI 10.1109/MIC.2003.1215662; Petroff MG, 2002, J REPROD IMMUNOL, V56, P3, DOI 10.1016/S0165-0378(02)00024-4; Pfeiffer KA, 2000, HUM IMMUNOL, V61, P559, DOI 10.1016/S0198-8859(00)00123-3; Pfeiffer KA, 2001, MOL HUM REPROD, V7, P373, DOI 10.1093/molehr/7.4.373; Phillips TA, 2003, J LEUKOCYTE BIOL, V74, P81, DOI 10.1189/jlb.0103033; Piccinni MP, 1998, NAT MED, V4, P1020, DOI 10.1038/2006; Polanczyk MJ, 2004, J IMMUNOL, V173, P2227, DOI 10.4049/jimmunol.173.4.2227; Rajagopalan S, 2001, J IMMUNOL, V167, P1877, DOI 10.4049/jimmunol.167.4.1877; Rajagopalan S, 1999, J EXP MED, V189, P1093, DOI 10.1084/jem.189.7.1093; Read S, 2001, CURR OPIN IMMUNOL, V13, P644, DOI 10.1016/S0952-7915(01)00273-4; Rebmann V, 2001, TISSUE ANTIGENS, V57, P15, DOI 10.1034/j.1399-0039.2001.057001015.x; Rebmann V, 1999, TISSUE ANTIGENS, V53, P14, DOI 10.1034/j.1399-0039.1999.530102.x; REDMAN CWG, 1984, IMMUNOLOGY, V52, P457; Riteau B, 2001, J IMMUNOL, V166, P5018, DOI 10.4049/jimmunol.166.8.5018; RouasFreiss N, 1997, P NATL ACAD SCI USA, V94, P11520, DOI 10.1073/pnas.94.21.11520; Rousseau P, 2003, HUM IMMUNOL, V64, P1005, DOI 10.1016/j.humimm.2003.08.347; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; Samaridis J, 1997, EUR J IMMUNOL, V27, P660, DOI 10.1002/eji.1830270313; SANDERS SK, 1991, J EXP MED, V174, P737, DOI 10.1084/jem.174.3.737; Sasaki H, 1999, TRANSPLANT P, V31, P953, DOI 10.1016/S0041-1345(98)01852-1; Sasaki Y, 2004, MOL HUM REPROD, V10, P347, DOI 10.1093/molehr/gah044; Sedlmayr P, 2002, AM J REPROD IMMUNOL, V48, P96, DOI 10.1034/j.1600-0897.2002.01116.x; Shiroishi M, 2003, P NATL ACAD SCI USA, V100, P8856, DOI 10.1073/pnas.1431057100; Simon C, 1995, HUM REPROD, V10, P43, DOI 10.1093/humrep/10.suppl_2.43; Sivori S, 2000, HUM IMMUNOL, V61, P1055, DOI 10.1016/S0198-8859(00)00201-9; Soderstrom K, 1997, J IMMUNOL, V159, P1072; Soilleux EJ, 2002, J LEUKOCYTE BIOL, V71, P445; Soilleux EJ, 2001, J PATHOL, V195, P586, DOI 10.1002/path.1026; Solier C, 2002, EUR J IMMUNOL, V32, P3576, DOI 10.1002/1521-4141(200212)32:12<3576::AID-IMMU3576>3.0.CO;2-M; STARKEY PM, 1988, IMMUNOLOGY, V65, P129; Suarez MB, 1997, IMMUNOGENETICS, V45, P464, DOI 10.1007/s002510050235; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Trundley A, 2004, TISSUE ANTIGENS, V63, P1, DOI 10.1111/j.1399-0039.2004.00170.x; van der Meer A, 2004, MOL HUM REPROD, V10, P189, DOI 10.1093/molehr/gah032; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; Vince GS, 1996, PLACENTA, V17, P191, DOI 10.1016/S0143-4004(96)90038-7; VINCE GS, 1990, J IMMUNOL METHODS, V132, P181, DOI 10.1016/0022-1759(90)90028-T; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; Yang YP, 1996, J IMMUNOL, V156, P4224; Zavazava N, 1998, MOL MED TODAY, V4, P116, DOI 10.1016/S1357-4310(97)01185-4; Zdravkovic M, 1999, PLACENTA, V20, P431, DOI 10.1053/plac.1999.0393	135	346	380	0	29	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					681	693		10.1096/fj.04-2078rev	http://dx.doi.org/10.1096/fj.04-2078rev			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15857883				2022-12-28	WOS:000229602600025
J	Chen, EI; Florens, L; Axelrod, FT; Monosov, E; Barbas, CF; Yates, JR; Felding-Habermann, B; Smith, JW				Chen, EI; Florens, L; Axelrod, FT; Monosov, E; Barbas, CF; Yates, JR; Felding-Habermann, B; Smith, JW			Maspin alters the carcinoma proteome	FASEB JOURNAL			English	Article						cancer proteomics; MudPIT; tumor suppressor; metastasis; protein profiling	MAJOR HISTOCOMPATIBILITY COMPLEX; MASS-SPECTRAL DATA; MULTICATALYTIC PROTEINASE; PLASMINOGEN-ACTIVATOR; PEPTIDASE ACTIVITIES; TUMOR PROGRESSION; SUBUNIT PATTERN; BREAST-CANCER; PROTEASOME; EXPRESSION	Maspin, a member of the serine protease inhibitor (serpin) family, is a tumor suppressor in breast and prostate cancer. To address molecular mechanisms underlying maspin's activity, we restored its expression in invasive carcinoma cells and analyzed the resulting changes by shotgun proteomics. Using a mass spectrometry-based multidimensional proteomic method, we observed changes to the expression of similar to 27% of the detectable proteome. In particular, we noted changes to the expression of proteins that regulate cytoskeletal architecture, cell death, and protein turnover. In each case, changes in protein expression were accompanied by measurable changes in tumor cell phenotype. Thus, maspin-expressing cells exhibit a more prominent actin cytoskeleton, a reduced invasive capacity, an increased rate of spontaneous apoptosis, and an altered proteasome function. These observations reveal for the first time the far reaching effects of maspin on multiple protein networks and a new hypothesis of maspin function based on the regulation of proteasome function.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Burnham Inst, Canc Res Ctr, Program Cell Adhes, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute; Sanford Burnham Prebys Medical Discovery Institute; Scripps Research Institute; Scripps Research Institute	Chen, EI (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	emilyc@scripps.edu		Florens, Laurence/0000-0002-9310-6650	NCI NIH HHS [CA30199, CA95458, CA69306, 5 R01 CA086258, CA82713] Funding Source: Medline; NCRR NIH HHS [M01 RR00833, U54 RR020843-01, M01 RR0083] Funding Source: Medline; NHLBI NIH HHS [T32 HL 07695] Funding Source: Medline; NIAID NIH HHS [R21AI53781] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA030199, R01CA095458, P01CA082713, R01CA086258, R01CA069306] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833, U54RR020843, M01RR000083] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI053781] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bass R, 2002, J BIOL CHEM, V277, P46845, DOI 10.1074/jbc.C200532200; Bennett RG, 2000, ENDOCRINOLOGY, V141, P2508, DOI 10.1210/en.141.7.2508; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; CARDOZO C, 1995, J BIOL CHEM, V270, P22645, DOI 10.1074/jbc.270.38.22645; Chang DD, 1998, ONCOGENE, V16, P1921, DOI 10.1038/sj.onc.1201715; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; Dahlmann B, 2000, J MOL BIOL, V303, P643, DOI 10.1006/jmbi.2000.4185; DEMARTINO GN, 1993, ENZYME PROTEIN, V47, P314, DOI 10.1159/000468689; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; GACZYNSKA M, 1994, P NATL ACAD SCI USA, V91, P9213, DOI 10.1073/pnas.91.20.9213; Gaczynska M, 1996, J BIOL CHEM, V271, P17275, DOI 10.1074/jbc.271.29.17275; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; HAASS C, 1989, EXP CELL RES, V180, P243, DOI 10.1016/0014-4827(89)90228-0; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hojo T, 2001, CANCER LETT, V171, P103, DOI 10.1016/S0304-3835(01)00569-9; Jager S, 1999, J MOL BIOL, V291, P997, DOI 10.1006/jmbi.1999.2995; Jiang N, 2002, ONCOGENE, V21, P4089, DOI 10.1038/sj.onc.1205507; Kisselev AF, 1999, MOL CELL, V4, P395, DOI 10.1016/S1097-2765(00)80341-X; KUCKELKORN U, 1995, EUR J IMMUNOL, V25, P2605, DOI 10.1002/eji.1830250930; Liu HB, 2004, ANAL CHEM, V76, P4193, DOI 10.1021/ac0498563; Liu JY, 2004, CANCER RES, V64, P1703, DOI 10.1158/0008-5472.CAN-03-2568; Maass N, 2001, J PATHOL, V195, P321; Maul RS, 2003, J CELL BIOL, V160, P399, DOI 10.1083/jcb.200212057; Maul RS, 1999, ONCOGENE, V18, P7838, DOI 10.1038/sj.onc.1203206; McGowen R, 2000, CANCER RES, V60, P4771; Meiners S, 2003, J BIOL CHEM, V278, P21517, DOI 10.1074/jbc.M301032200; Mohsin SK, 2003, J PATHOL, V199, P432, DOI 10.1002/path.1319; Ngamkitidechakul C, 2003, J BIOL CHEM, V278, P31796, DOI 10.1074/jbc.M302408200; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PARISH RW, 1987, J CELL SCI, P181; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; PRICE JE, 1990, CANCER RES, V50, P717; RIVETT AJ, 1989, J BIOL CHEM, V264, P12215; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Sadygov RG, 2003, ANAL CHEM, V75, P3792, DOI 10.1021/ac034157w; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Schweisguth F, 1999, P NATL ACAD SCI USA, V96, P11382, DOI 10.1073/pnas.96.20.11382; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; Sood AK, 2002, CLIN CANCER RES, V8, P2924; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Townson JL, 2003, CURR MOL MED, V3, P631, DOI 10.2174/1566524033479483; Van den Eynde BJ, 2001, CURR OPIN IMMUNOL, V13, P147, DOI 10.1016/S0952-7915(00)00197-7; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; Wu CC, 2003, NAT BIOTECHNOL, V21, P532, DOI 10.1038/nbt819; Yasumatsu R, 2001, HEAD NECK-J SCI SPEC, V23, P962, DOI 10.1002/hed.1139; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	56	30	33	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1123	+		10.1096/fj.04-2970fje	http://dx.doi.org/10.1096/fj.04-2970fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15857880				2022-12-28	WOS:000228865300005
J	Oka, S; Kato, J; Moss, J				Oka, S; Kato, J; Moss, J			Identification and characterization of a mammalian 39-kDa poly(ADP-ribose) glycohydrolase	FASEB JOURNAL			English	Meeting Abstract	Experimental Biology 2006 Meeting	APR 01-05, 2006	San Francisco, CA	Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut					NHLBI, PCCMB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Yodoi, Junji/F-6189-2011	Yodoi, Junji/0000-0001-6849-4914; Masutani, Hiroshi/0000-0001-7633-2827; Hirata, Hiromi/0000-0002-3769-7441					0	98	101	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR 6	2006	20	4	1				A45	A45		10.1096/fj.05-4439fje	http://dx.doi.org/10.1096/fj.05-4439fje			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	024OW	16254043				2022-12-28	WOS:000236206500217
J	Hui, AS; Bauer, AL; Striet, JB; Schnell, PO; Czyzyk-Krzeska, MF				Hui, Anna S.; Bauer, Amy L.; Striet, Justin B.; Schnell, Phillip O.; Czyzyk-Krzeska, Maria F.			Calcium signaling stimulates translation of HIF-alpha during hypoxia	FASEB JOURNAL			English	Article						protein kinase C; oxygen-sensitive cells; protein translation; carotid body; PC12 cells	TUMOR-SUPPRESSOR PROTEIN; TYROSINE-HYDROXYLASE; MESSENGER-RNA; GENE-EXPRESSION; INDUCIBLE FACTOR-1-ALPHA; MAMMALIAN TARGET; CHANNEL ACTIVITY; K+ CHANNEL; ACTIVATION; CELLS	Hypoxia-inducible factors (HIFs) are ubiquitous transcription factors that mediate adaptation to hypoxia by inducing specific sets of target genes. It is well accepted that hypoxia induces accumulation and activity of HIFs by causing stabilization of their alpha subunits. We have demonstrated that hypoxia stimulates translation of HIF-1 alpha and -2 alpha proteins by distributing HIF-alpha mRNAs to larger polysome fractions. This requires influx of extracellular calcium, stimulation of classical protein kinase C-alpha (cPKC-alpha), and the activity of mammalian target of rapamycin, mTOR. The translational component contributes to similar to 40-50% of HIF-alpha proteins accumulation after 3 h of 1% O-2. Hypoxia also inhibits general protein synthesis and mTOR activity; however, cPKC-alpha inhibitors or rapamycin reduce mTOR activity and total protein synthesis beyond the effects of hypoxia alone. These data show that during general inhibition of protein synthesis by hypoxia, cap-mediated translation of selected mRNAs is induced through the mTOR pathway. We propose that calcium-induced activation of cPKC-alpha hypoxia partially protects an activity of mTOR from hypoxic inhibition. These results provide an important physiologic insight into the mechanism by which hypoxia-stimulated influx of calcium selectively induces the translation of mRNAs necessary for adaptation to hypoxia under conditions repressing general protein synthesis.	Univ Cincinnati, Coll Med, Dept Genome Sci, Genome Res Inst, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Czyzyk-Krzeska, MF (corresponding author), Univ Cincinnati, Coll Med, Dept Genome Sci, Genome Res Inst, 2180 E Galbraith Rd, Cincinnati, OH 45267 USA.	maria.czyzykkrzeska@uc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066312, R01HL058687] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66312, HL58687] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKER H, 1989, ANNU REV PHYSIOL, V51, P835, DOI 10.1146/annurev.physiol.51.1.835; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Avila G, 2004, CELL MOL NEUROBIOL, V24, P317, DOI 10.1023/B:CEMN.0000022765.52109.26; Berchner-Pfannschmidt U, 2004, J BIOL CHEM, V279, P44976, DOI 10.1074/jbc.M313995200; Berjukow S, 1996, BRIT J PHARMACOL, V118, P748, DOI 10.1111/j.1476-5381.1996.tb15463.x; BLENIS J, 1986, P NATL ACAD SCI USA, V83, P1733, DOI 10.1073/pnas.83.6.1733; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Conforti L, 1997, J PHYSIOL-LONDON, V502, P293, DOI 10.1111/j.1469-7793.1997.293bk.x; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; CZYZYKKRZESKA MF, 1992, J NEUROCHEM, V58, P1538, DOI 10.1111/j.1471-4159.1992.tb11376.x; Fontainhas AM, 2005, NEUROSCIENCE, V133, P393, DOI 10.1016/j.neuroscience.2005.02.026; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Jiang B, 2002, MOL CELL BIOCHEM, V238, P69, DOI 10.1023/A:1019907104763; Kim W, 2003, CURR OPIN GENET DEV, V13, P55, DOI 10.1016/S0959-437X(02)00010-2; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Levites Y, 2003, FASEB J, V17, P952, DOI 10.1096/fj.02-0881fje; Liu LP, 2004, CANCER BIOL THER, V3, P492, DOI 10.4161/cbt.3.6.1010; Lopez-Barneo J, 2001, ANNU REV PHYSIOL, V63, P259, DOI 10.1146/annurev.physiol.63.1.259; Lopez-Barneo J, 1999, RESP PHYSIOL, V115, P215, DOI 10.1016/S0034-5687(99)00016-X; Maher P, 2001, J NEUROSCI, V21, P2929, DOI 10.1523/JNEUROSCI.21-09-02929.2001; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Millhorn DE, 1997, KIDNEY INT, V51, P527, DOI 10.1038/ki.1997.73; MochizukiOda N, 1997, J NEUROCHEM, V69, P377; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; Mottet D, 2003, J CELL PHYSIOL, V194, P30, DOI 10.1002/jcp.10176; Nakashima S, 2002, J BIOCHEM, V132, P669, DOI 10.1093/oxfordjournals.jbchem.a003272; NORRIS ML, 1995, J BIOL CHEM, V270, P23774, DOI 10.1074/jbc.270.40.23774; Page EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200; Premkumar DRD, 2000, J APPL PHYSIOL, V88, P1898, DOI 10.1152/jappl.2000.88.5.1898; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Schnell PO, 2003, J NEUROCHEM, V85, P483, DOI 10.1046/j.1471-4159.2003.01696.x; Schwab MS, 1999, MOL CELL BIOL, V19, P2485; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Shaw G, 2002, FASEB J, V16, P869, DOI 10.1096/fj.01-0995fje; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; Thomas G, 2000, NAT CELL BIOL, V2, pE71, DOI 10.1038/35010581; Tinton SA, 1999, FEBS LETT, V446, P55, DOI 10.1016/S0014-5793(99)00185-4; Weinreb O, 2004, FASEB J, V18, P1471, DOI 10.1096/fj.04-1916fje; Yu SP, 1998, J NEUROSCI RES, V52, P612, DOI 10.1002/(SICI)1097-4547(19980601)52:5<612::AID-JNR13>3.0.CO;2-3; Zakrzewska A, 2005, J NEUROCHEM, V94, P1288, DOI 10.1111/j.1471-4159.2005.03293.x; Zhu GY, 1998, J NEUROSCI METH, V81, P73, DOI 10.1016/S0165-0270(98)00019-3; Zhu WH, 1996, AM J PHYSIOL-CELL PH, V271, pC658, DOI 10.1152/ajpcell.1996.271.2.C658	50	100	103	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2006	20	3					466	475		10.1096/fj.05-5086com	http://dx.doi.org/10.1096/fj.05-5086com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	074LY	16507764				2022-12-28	WOS:000239815100010
J	Glezer, I; Lapointe, A; Rivest, S				Glezer, Isaias; Lapointe, Amelie; Rivest, Serge			Innate immunity triggers oligodendrocyte progenitor reactivity and confines damages to brain injuries	FASEB JOURNAL			English	Article						lipopolysaccharide; toll-like receptor 4; demyelination; Olig bHLH transcription factors; neuroprotection	CENTRAL-NERVOUS-SYSTEM; TOLL-LIKE RECEPTORS; ETHIDIUM-BROMIDE INJECTION; MULTIPLE-SCLEROSIS; GROWTH-FACTOR; IN-VIVO; INDUCED NEUROTOXICITY; SUBVENTRICULAR ZONE; PRECURSOR CELLS; FACTOR OLIG2	Regarded as a damaging reaction, innate immune response can either improve or worsen brain outcome after injury. Hence, inflammatory molecules might modulate cell susceptibility or healing events. The remyelination that follows brain lesions is dependent on the recruitment of oligodendrocyte progenitor cells (OPCs) and expression of genes controlling differentiation and myelin production, such as Olig1 and Olig2 bHLH transcription factors. We aimed to determine how innate immunity affects these processes. Here we report that lipopolysaccharide (LPS) infusion triggered OPC reactivity. Acute inflammation changed the distribution of Olig1- and Olig2-expressing cells following chemical demyelination, enhanced reappearance of transcription signals linked to remyelination and rapidly cleared myelin debris. Although cells expressing Olig1, Olig2, and proteolipid protein were attracted to demyelinated sites in the course of chronic inflammation, myelin loss was not associated with the effects of inflammation on OPC reactivity. In addition, the beneficial properties of brain immunity are broadened to an aggressive model of injury, wherein LPS through Toll-like receptor 4 (TLR4) reduced surfactant-mediated damage while anti-inflammatory treatment enlarged the lesion. In conclusion, TLR4 activation in microglia is a powerful mechanism for improving repair at the remyelination level and protecting the cerebral tissue in presence of agents with strong cytolytic properties.	Univ Laval, Lab Mol Endocrinol, CHUL Res Ctr, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Dept Anat & Physiol, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Rivest, S (corresponding author), Univ Laval, Lab Mol Endocrinol, CHUL Res Ctr, 2705,Boul Laurier, Quebec City, PQ G1V 4G2, Canada.	Serge.Rivest@crchul.ulaval.ca	Messier, Claude/A-2322-2008; Glezer, Isaias/D-2867-2013	Messier, Claude/0000-0002-4791-1763; Rivest, Serge/0000-0002-6082-770X; Glezer, Isaias/0000-0002-9799-1933				Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Arnett HA, 2004, SCIENCE, V306, P2111, DOI 10.1126/science.1103709; Baumann N, 2001, PHYSIOL REV, V81, P871, DOI 10.1152/physrev.2001.81.2.871; Beutler B, 2002, CURR OPIN HEMATOL, V9, P2, DOI 10.1097/00062752-200201000-00002; Blais V, 2004, J IMMUNOL, V172, P7043, DOI 10.4049/jimmunol.172.11.7043; Butzkueven H, 2002, NAT MED, V8, P613, DOI 10.1038/nm0602-613; Calver AR, 1998, NEURON, V20, P869, DOI 10.1016/S0896-6273(00)80469-9; Calza L, 1998, P NATL ACAD SCI USA, V95, P3209, DOI 10.1073/pnas.95.6.3209; Chen ZJ, 2002, J NEUROCYTOL, V31, P481, DOI 10.1023/A:1025791614468; Cockeran R, 2002, CURR OPIN INFECT DIS, V15, P235, DOI 10.1097/00001432-200206000-00004; Coin PG, 1996, J IMMUNOL, V156, P4797; Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X; Fancy SPJ, 2004, MOL CELL NEUROSCI, V27, P247, DOI 10.1016/j.mcn.2004.06.015; Felts PA, 2005, BRAIN, V128, P1649, DOI 10.1093/brain/awh516; Foote AK, 2005, BRAIN, V128, P528, DOI 10.1093/brain/awh417; Franklin RJM, 1997, J NEUROSCI RES, V50, P337, DOI 10.1002/(SICI)1097-4547(19971015)50:2<337::AID-JNR21>3.0.CO;2-3; Franklin RJM, 2002, NAT REV NEUROSCI, V3, P705, DOI 10.1038/nrn917; Gensert JM, 1997, NEURON, V19, P197, DOI 10.1016/S0896-6273(00)80359-1; Glezer I, 2004, NEUROSCIENTIST, V10, P538, DOI 10.1177/1073858404263494; Glezer I, 2003, NEUROPHARMACOLOGY, V45, P1120, DOI 10.1016/S0028-3908(03)00279-X; Glezer I, 2003, J NEUROSCI, V23, P11094; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; GRACA DL, 1986, NEUROPATH APPL NEURO, V12, P593, DOI 10.1111/j.1365-2990.1986.tb00162.x; Griffiths I, 1998, SCIENCE, V280, P1610, DOI 10.1126/science.280.5369.1610; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Hoshino K, 1999, J IMMUNOL, V162, P3749; Jalabi W, 2005, J NEUROSCI, V25, P2885, DOI 10.1523/JNEUROSCI.2748-04.2005; Johnstone RW, 2001, J BIOL CHEM, V276, P16667, DOI 10.1074/jbc.M010774200; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Kopp E, 2003, CURR OPIN IMMUNOL, V15, P396, DOI 10.1016/S0952-7915(03)00080-3; Kotter MR, 2005, NEUROBIOL DIS, V18, P166, DOI 10.1016/j.nbd.2004.09.019; Kuchroo VK, 2002, ANNU REV IMMUNOL, V20, P101, DOI 10.1146/annurev.immunol.20.081701.141316; Laflamme N, 2001, J NEUROCHEM, V79, P648, DOI 10.1046/j.1471-4159.2001.00603.x; Laflamme N, 1999, J NEUROSCI, V19, P10923, DOI 10.1523/JNEUROSCI.19-24-10923.1999; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Lehnardt S, 2002, J NEUROSCI, V22, P2478, DOI 10.1523/JNEUROSCI.22-07-02478.2002; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; Lu QR, 2002, CELL, V109, P75, DOI 10.1016/S0092-8674(02)00678-5; Lu QR, 2001, NAT NEUROSCI, V4, P973, DOI 10.1038/nn718; Mason JL, 2001, J NEUROSCI, V21, P7046, DOI 10.1523/JNEUROSCI.21-18-07046.2001; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nadeau S, 2003, J NEUROSCI, V23, P5536, DOI 10.1523/jneurosci.23-13-05536.2003; Nadeau S, 2002, J IMMUNOL, V169, P3370, DOI 10.4049/jimmunol.169.6.3370; Nguyen MD, 2002, NAT REV NEUROSCI, V3, P216, DOI 10.1038/nrn752; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; Paxino G, 2001, MOUSE BRAIN STEREOTA; PERRY VH, 1997, IMMUNOLOGY NERVOUS S, P155; Picard-Riera N, 2002, P NATL ACAD SCI USA, V99, P13211, DOI 10.1073/pnas.192314199; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PRINGLE NP, 1992, DEVELOPMENT, V115, P535; Rivest S, 2003, BRAIN BEHAV IMMUN, V17, P13, DOI 10.1016/S0889-1591(02)00055-7; Rowitch DH, 2004, NAT REV NEUROSCI, V5, P409, DOI 10.1038/nrn1389; Schwab JM, 2005, LANCET, V365, P2055, DOI 10.1016/S0140-6736(05)66699-8; Sim FJ, 2000, NEUROSCIENCE, V100, P131, DOI 10.1016/S0306-4522(00)00252-9; Soulet D, 2003, J CELL BIOL, V162, P257, DOI 10.1083/jcb.200301097; Sreedhar AS, 2003, J BIOL CHEM, V278, P35231, DOI 10.1074/jbc.M301371200; Sun T, 2001, CURR BIOL, V11, P1413, DOI 10.1016/S0960-9822(01)00441-9; Takebayashi H, 2002, CURR BIOL, V12, P1157, DOI 10.1016/S0960-9822(02)00926-0; Tsai HH, 2002, CELL, V110, P373, DOI 10.1016/S0092-8674(02)00838-3; VIGO C, 1985, J BIOL CHEM, V260, P3418; Wolswijk G, 1998, J NEUROSCI, V18, P601; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Xin M, 2005, J NEUROSCI, V25, P1354, DOI 10.1523/JNEUROSCI.3034-04.2005; YAJIMA K, 1979, LAB INVEST, V41, P385; Zamvil SS, 2003, NEURON, V38, P685, DOI 10.1016/S0896-6273(03)00326-X; Zhou Q, 2001, NEURON, V31, P791, DOI 10.1016/S0896-6273(01)00414-7; Zhou Q, 2002, CELL, V109, P61, DOI 10.1016/S0092-8674(02)00677-3	70	90	93	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					750	+		10.1096/fj.05-5234fje	http://dx.doi.org/10.1096/fj.05-5234fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16464958				2022-12-28	WOS:000237698700035
J	Kobayashi, S; Lackey, T; Huang, Y; Bisping, E; Pu, WT; Boxer, LM; Liang, QR				Kobayashi, Satoru; Lackey, Troy; Huang, Yuan; Bisping, Egbert; Pu, William T.; Boxer, Linda M.; Liang, Qiangrong			Transcription factor GATA4 regulates cardiac BCL2 gene expression in vitro and in vivo	FASEB JOURNAL			English	Article						cardiomyocyte; promoter; doxorubicin; cardiotoxicity	CELL-SURVIVAL; PROMOTER; PHOSPHORYLATION; ACTIVATION; APOPTOSIS; DEATH	The transcription factor GATA-4 protects cardiomyocytes against doxorubicin-induced cardiotoxicity. Here, we report the identification of Bcl2 as a direct target gene of GATA4 that may mediate the prosurvival function of GATA4 in cardiomyocytes. Bcl2 transcript and protein levels were reduced by doxorubicin in neonatal rat ventricular cardiomyocytes (NRVC) and in mouse heart as determined by RT-PCR and Western blot analysis. The reduction in Bcl2 was prevented by overexpression of GATA4 in NRVC and in transgenic mouse heart. Also, expression of GATA4 increased baseline Bcl2 levels by 30% in NRVC and 2.7-fold in transgenic heart, indicating the sufficiency of GATA4 to up-regulate Bcl2 gene expression. GATA4 knockdown by siRNA reduced Bcl2 levels by 48% in NRVC, suggesting that GATA4 is required for Bcl2 constitutive gene expression. Transfection of HEK cells with GATA4 plasmids activated Bcl2 promoter and elevated Bcl2 protein levels. Deletion and mutagenesis analysis revealed that a consensus GATA motif at base -266 on the promoter conserved across multiple species is partially responsible for the promoter activity. Electrophoretic mobility shift and chromatin immunoprecipitation assays demonstrate that GATA4 directly bound to this GATA site. Together, these results indicate that GATA4 positively regulates cardiac Bcl2 gene expression in vitro and in vivo.	Univ S Dakota, Sch Med, Cardiovasc Res Inst, S Dakota Hlth Res Fdn, Sioux Falls, SD 57105 USA; Childrens Hosp Boston, Dept Cardiol, Boston, MA USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	University of South Dakota; Harvard University; Boston Children's Hospital; Stanford University	Liang, QR (corresponding author), Univ S Dakota, Sch Med, Cardiovasc Res Inst, S Dakota Hlth Res Fdn, 1100 E 21st St, Sioux Falls, SD 57105 USA.	qliang@usd.edu	Pu, William/AAJ-8301-2020	Pu, William/0000-0002-4551-8079	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017662] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR-017662] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aries A, 2004, P NATL ACAD SCI USA, V101, P6975, DOI 10.1073/pnas.0401833101; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Brocheriou V, 2000, J GENE MED, V2, P326, DOI 10.1002/1521-2254(200009/10)2:5<326::AID-JGM133>3.0.CO;2-1; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; Chagnon F, 2005, CIRC RES, V96, P1095, DOI 10.1161/01.RES.0000168327.22888.4d; Charron F, 1999, SEMIN CELL DEV BIOL, V10, P85, DOI 10.1006/scdb.1998.0281; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Heckman CA, 2003, ONCOGENE, V22, P7891, DOI 10.1038/sj.onc.1206639; HEWITT SM, 1995, CANCER RES, V55, P5386; Imahashi K, 2004, CIRC RES, V95, P734, DOI 10.1161/01.RES.0000143898.67182.4c; ITO H, 1990, P NATL ACAD SCI USA, V87, P4275, DOI 10.1073/pnas.87.11.4275; Kalyanaraman B, 2002, MOL CELL BIOCHEM, V234, P119, DOI 10.1023/A:1015976430790; Kawamura T, 2004, CIRC RES, V94, P1492, DOI 10.1161/01.RES.0000129701.14494.52; Kim Y, 2003, MOL PHARMACOL, V63, P368, DOI 10.1124/mol.63.2.368; Kitta K, 2003, J BIOL CHEM, V278, P4705, DOI 10.1074/jbc.M211616200; Kumarapeli ARK, 2005, FASEB J, V19, P2051, DOI 10.1096/fj.05-3973fje; Ladas EJ, 2004, J CLIN ONCOL, V22, P517, DOI 10.1200/JCO.2004.03.086; LaVoie HA, 2004, ENDOCRINOLOGY, V145, P3122, DOI 10.1210/en.2003-1719; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; Liang QR, 2002, J MOL CELL CARDIOL, V34, P611, DOI 10.1006/jmcc.2002.2011; Liang QR, 2001, MOL CELL BIOL, V21, P7460, DOI 10.1128/MCB.21.21.7460-7469.2001; Maulik N, 1999, CIRCULATION, V100, P369; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Romero F, 1999, EMBO J, V18, P3419, DOI 10.1093/emboj/18.12.3419; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; Suzuki YJ, 2004, J MOL CELL CARDIOL, V37, P1195, DOI 10.1016/j.yjmcc.2004.09.009; Weisleder N, 2004, P NATL ACAD SCI USA, V101, P769, DOI 10.1073/pnas.0303202101	32	84	91	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					800	+		10.1096/fj.05-5426fje	http://dx.doi.org/10.1096/fj.05-5426fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16469847				2022-12-28	WOS:000237698700028
J	Roviezzo, F; Bucci, M; Delisle, C; Brancaleone, V; Di Lorenzo, A; Mayo, IP; Fiorucci, S; Fontana, A; Gratton, JP; Cirino, G				Roviezzo, Fiorentina; Bucci, Mariarosaria; Delisle, Chantal; Brancaleone, Vincenzo; Di Lorenzo, Annarita; Mayo, Inmaculada Posadas; Fiorucci, Stefano; Fontana, Angelo; Gratton, Jean-Philippe; Cirino, Giuseppe			Essential requirement for sphingosine kinase activity in eNOS-dependent NO release and vasorelaxation	FASEB JOURNAL			English	Article									[Roviezzo, Fiorentina; Bucci, Mariarosaria; Brancaleone, Vincenzo; Di Lorenzo, Annarita; Mayo, Inmaculada Posadas; Cirino, Giuseppe] Univ Naples Federico 2, Dipartimento Farmacol Sperimentale, I-80131 Naples, Italy; [Delisle, Chantal; Gratton, Jean-Philippe] Inst Rech Clin Montreal, Lab Endothelial Cell Biol, Montreal, PQ H2W 1R7, Canada; [Fontana, Angelo] CNR, Ist Chim Biomol, I-80125 Naples, Italy; [Fiorucci, Stefano] Dipartimento Med Sperimentale, Perugia, Italy	University of Naples Federico II; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR)	Cirino, G (corresponding author), Univ Naples Federico 2, Dipartimento Farmacol Sperimentale, Via Domenico Montesano 49, I-80131 Naples, Italy.	cirino@unina.it	Fontana, Angelo/C-3354-2012; Fiorucci, Stefano/I-1251-2012; Fontana, Angelo/AAO-2741-2021; Posadas, Inmaculada/M-1124-2014	Fontana, Angelo/0000-0002-5453-461X; Fontana, Angelo/0000-0002-5453-461X; Posadas, Inmaculada/0000-0003-1854-3372; Roviezzo, Fiorentina/0000-0003-1582-7396; Cirino, Giuseppe/0000-0003-3954-4083; Gratton, Jean-Philippe/0000-0001-9877-8520; brancaleone, vincenzo/0000-0002-0063-659X; Di Lorenzo, Annarita/0000-0003-1239-4222					0	32	33	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					340	342		10.1096/fj.05-4647fje	http://dx.doi.org/10.1096/fj.05-4647fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16322129				2022-12-28	WOS:000207915000014
J	Tinhofer, I; Biedermann, R; Krismer, M; Crazzolara, R; Greil, R				Tinhofer, I; Biedermann, R; Krismer, M; Crazzolara, R; Greil, R			A role of TRAIL in killing osteoblasts by myeloma cells	FASEB JOURNAL			English	Article							MALIGNANT PLASMA-CELLS; FAS-LIGAND GENE; MULTIPLE-MYELOMA; BONE-DISEASE; INDUCED APOPTOSIS; UP-REGULATION; TNF FAMILY; KAPPA-B; RECEPTOR; EXPRESSION	In multiple myeloma (MM), neoplastic plasma cells accumulate in the bone marrow where their survival, proliferation, and apoptosis are controlled at multiple levels by interaction with the bone marrow microenvironment. Myeloma cells actively control these interactions by activating stromal and endothelial cells for production of survival factors, such as interleukin-6, and suppressing other cell types such as erythroblasts, normal B cell progenitors, and T-cells. In the present study, we identified primary osteoblasts as additional potential targets for myeloma cell-mediated suppression which was partly dependent on the death receptor ligand TRAIL. Besides killing of osteoblasts, myeloma cell lines sensitized osteoblasts to cell death mediated by recombinant TRAIL, whereas primary osteoblasts protected myeloma cells from TRAIL-mediated apoptosis that was mediated by osteoprotegerin (OPG). Besides increase of osteoclastogenesis and osteoclast activity, suppression of bone-forming cells by myeloma cells might contribute to bone loss in MM patients. In addition, clinical development of recombinant TRAIL as anti-myeloma therapy should include evaluation of potential side effects on viability of normal bone cells.	Salzburg Gen Hosp, Med Dept Hematol Oncol Hemostaseol Rheumatol & In, Lab Immunol & Mol Canc Res, Salzburg, Austria; Private Paracelsus Med Univ, Salzburg, Austria; Univ Innsbruck, Tyrolean Canc Res Inst, A-6020 Innsbruck, Austria; Univ Innsbruck Hosp, Dept Orthoped Surg, A-6020 Innsbruck, Austria; Univ Innsbruck Hosp, Dept Pediat, A-6020 Innsbruck, Austria	Paracelsus Private Medical University; University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck	Tinhofer, I (corresponding author), Univ Hosp, Med Dept Hematol Oncol Hemostaseol Rheumatol & In, Lab Immunol & Mol Canc Res, Salzburg, Austria.	i.tinhofer@salk.at	Greil, Richard F/C-7673-2017; Biedermann, Rainer/AAF-2636-2020	Greil, Richard F/0000-0002-4462-3694; Tinhofer, Ingeborg/0000-0002-0512-549X				Atkins GJ, 2002, BONE, V31, P448, DOI 10.1016/S8756-3282(02)00858-X; Bureau F, 2002, BLOOD, V99, P3683, DOI 10.1182/blood.V99.10.3683; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Drexler HG, 2000, LEUKEMIA RES, V24, P681, DOI 10.1016/S0145-2126(99)00195-2; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; Formigli L, 2000, J CELL PHYSIOL, V182, P41, DOI 10.1002/(SICI)1097-4652(200001)182:1<41::AID-JCP5>3.0.CO;2-7; Gazitt Y, 1999, LEUKEMIA, V13, P1817, DOI 10.1038/sj.leu.2401501; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hjorth-Hansen H, 1999, J BONE MINER RES, V14, P256, DOI 10.1359/jbmr.1999.14.2.256; Kagawa S, 2001, CANCER RES, V61, P3330; Katavic V, 2003, J IMMUNOL, V170, P1540, DOI 10.4049/jimmunol.170.3.1540; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Lincz LF, 2001, LEUKEMIA, V15, P1650, DOI 10.1038/sj.leu.2402251; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; Meyer MA, 2004, NEW ENGL J MED, V350, P1464; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Munshi A, 2002, CANCER CHEMOTH PHARM, V50, P46, DOI 10.1007/s00280-002-0465-z; O'Connell J, 1999, IMMUNOL TODAY, V20, P46, DOI 10.1016/S0167-5699(98)01382-6; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Roodman GD, 1997, CANCER, V80, P1557, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1557::AID-CNCR5>3.0.CO;2-H; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shipman CM, 2003, CANCER RES, V63, P912; Silvestris F, 2004, BRIT J HAEMATOL, V126, P475, DOI 10.1111/j.1365-2141.2004.05084.x; Silvestris F, 2003, BRIT J HAEMATOL, V122, P39, DOI 10.1046/j.1365-2141.2003.04374.x; Silvestris F, 2002, BLOOD, V99, P1305, DOI 10.1182/blood.V99.4.1305; Silvestris F, 2001, BLOOD, V97, P1155, DOI 10.1182/blood.V97.5.1155; Smyth MJ, 2003, IMMUNITY, V18, P1, DOI 10.1016/S1074-7613(02)00502-2; SOBEL ES, 1993, INT IMMUNOL, V5, P1275, DOI 10.1093/intimm/5.10.1275; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; Tinhofer I, 2000, BLOOD, V95, P610, DOI 10.1182/blood.V95.2.610; Ursini-Siegel J, 2002, J IMMUNOL, V169, P5505, DOI 10.4049/jimmunol.169.10.5505; Villunger A, 1997, BLOOD, V90, P12; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	36	37	38	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					759	+		10.1096/fj.05-4329fje	http://dx.doi.org/10.1096/fj.05-4329fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16436464				2022-12-28	WOS:000235996000004
J	Sagun, KC; Carcamo, JM; Golde, DW				Sagun, KC; Carcamo, JM; Golde, DW			Vitamin C enters mitochondria via facilitative glucose transporter 1 (Glut1) and confers mitochondrial protection against oxidative injury	FASEB JOURNAL			English	Article						ROS; oxidative stress; DNA damage; antioxidants; cellular redox	MYELOID-LEUKEMIA CELLS; ASCORBIC-ACID; DEHYDROASCORBIC ACID; PERMEABILITY TRANSITION; GLUTATHIONE-PEROXIDASE; PROTEIN TRANSLOCATION; TARGETING SEQUENCES; LIVER-MITOCHONDRIA; MAMMALIAN-CELLS; DNA GLYCOSYLASE	Reactive oxygen species (ROS)-induced mitochondrial abnormalities may have important consequences in the pathogenesis of degenerative diseases and cancer. Vitamin C is an important antioxidant known to quench ROS, but its mitochondrial transport and functions are poorly understood. We found that the oxidized form of vitamin C, dehydroascorbic acid (DHA), enters mitochondria via facilitative glucose transporter 1 (Glut1) and accumulates mitochondrially as ascorbic acid (mtAA). The stereo-selective mitochondrial uptake of D-glucose, with its ability to inhibit mitochondrial DHA uptake, indicated the presence of mitochondrial Glut. Computational analysis of N-termini of human Glut isoforms indicated that Glut1 had the highest probability of mitochondrial localization, which was experimentally verified via mitochondrial expression of Glut1-EGFP. In vitro mitochondrial import of Glut1, immunoblot analysis of mitochondrial proteins, and cellular immunolocalization studies indicated that Glut1 localizes to mitochondria. Loading mitochondria with AA quenched mitochondrial ROS and inhibited oxidative mitochondrial DNA damage. mtAA inhibited oxidative stress resulting from rotenone-induced disruption of the mitochondrial respiratory chain and prevented mitochondrial membrane depolarization in response to a protonophore, CCCP. Our results show that analogous to the cellular uptake, vitamin C enters mitochondria in its oxidized form via Glut1 and protects mitochondria from oxidative injury. Since mitochondria contribute significantly to intracellular ROS, protection of the mitochondrial genome and membrane may have pharmacological implications against a variety of ROS-mediated disorders.	Mem Sloan Kettering Canc Ctr, Dept Clin Labs, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Chem, New York, NY 10021 USA; Cornell Univ, Dept Pharmacol, Weill Med Coll, New York, NY USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Carcamo, JM (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Clin Labs, Box 451,1275 York Ave, New York, NY 10021 USA.	jcarcamo@enzobio.com			NCI NIH HHS [CA 30388] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA030388, R01CA030388] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarraberes FA, 2001, BBA-BIOMEMBRANES, V1513, P1, DOI 10.1016/S0304-4157(01)00005-3; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Cline GW, 1998, AM J PHYSIOL-ENDOC M, V274, pE381, DOI 10.1152/ajpendo.1998.274.2.E381; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; Daruwala R, 1999, FEBS LETT, V460, P480, DOI 10.1016/S0014-5793(99)01393-9; de Souza-Pinto NC, 2001, CANCER RES, V61, P5378; DENQ RY, 1989, FREE RADICAL BIO MED, V6, P123, DOI 10.1016/0891-5849(89)90109-3; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Enzmann H, 1999, MUTAT RES-FUND MOL M, V425, P213, DOI 10.1016/S0027-5107(99)00044-5; Esworthy RS, 1997, ARCH BIOCHEM BIOPHYS, V340, P59, DOI 10.1006/abbi.1997.9901; Frankel EN, 1996, J AGR FOOD CHEM, V44, P131, DOI 10.1021/jf950374p; Frei B, 1999, P SOC EXP BIOL MED, V222, P196, DOI 10.1046/j.1525-1373.1999.d01-136.x; FREI B, 1991, AM J CLIN NUTR, V54, pS1113, DOI 10.1093/ajcn/54.6.1113s; Genova ML, 2004, ANN NY ACAD SCI, V1011, P86, DOI 10.1196/annals.1293.010; GIULIVI C, 1995, ARCH BIOCHEM BIOPHYS, V316, P909, DOI 10.1006/abbi.1995.1122; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668; Gruss-Fischer T, 2002, BIOCHEM PHARMACOL, V63, P1325, DOI 10.1016/S0006-2952(02)00863-8; Guaiquil VH, 1997, J BIOL CHEM, V272, P9915; Guaiquil VH, 2001, J BIOL CHEM, V276, P40955, DOI 10.1074/jbc.M106878200; HAYAKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P979, DOI 10.1016/0006-291X(92)92300-M; Henry TR, 1996, ARCH TOXICOL, V70, P482, DOI 10.1007/s002040050302; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; INGEBRETSEN OC, 1982, BIOCHIM BIOPHYS ACTA, V684, P21, DOI 10.1016/0005-2736(82)90044-X; Lemasters JJ, 1999, J BIOENERG BIOMEMBR, V31, P305, DOI 10.1023/A:1005419617371; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Li X, 2002, ARCH BIOCHEM BIOPHYS, V403, P103, DOI 10.1016/S0003-9861(02)00205-9; Li X, 2001, ARCH BIOCHEM BIOPHYS, V387, P143, DOI 10.1006/abbi.2000.2245; Lim MLR, 2001, FEBS LETT, V503, P69, DOI 10.1016/S0014-5793(01)02693-X; Liu Q, 2004, P NATL ACAD SCI USA, V101, P4302, DOI 10.1073/pnas.0400265101; Lutsenko EA, 2002, J BIOL CHEM, V277, P16895, DOI 10.1074/jbc.M201151200; Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; Minamikawa T, 1999, EXP CELL RES, V246, P26, DOI 10.1006/excr.1998.4290; MYER YP, 1980, J BIOL CHEM, V255, P9666; Orth M, 2001, AM J MED GENET, V106, P27, DOI 10.1002/ajmg.1425; PACKER JE, 1979, NATURE, V278, P737, DOI 10.1038/278737a0; PADH H, 1991, NUTR REV, V49, P65, DOI 10.1111/j.1753-4887.1991.tb07407.x; Perez-Cruz I, 2003, BLOOD, V102, P336, DOI 10.1182/blood-2002-11-3559; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; PHUNG CD, 1994, ARCH BIOCHEM BIOPHYS, V315, P479, DOI 10.1006/abbi.1994.1528; Ramanathan K, 2003, J NUTR BIOCHEM, V14, P416, DOI 10.1016/S0955-2863(03)00076-7; REBOUCHE CJ, 1991, AM J CLIN NUTR, V54, pS1147, DOI 10.1093/ajcn/54.6.1147s; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SIES H, 1978, EUR J BIOCHEM, V84, P377, DOI 10.1111/j.1432-1033.1978.tb12178.x; Small I, 2004, PROTEOMICS, V4, P1581, DOI 10.1002/pmic.200300776; Sureda FX, 1997, CYTOMETRY, V28, P74, DOI 10.1002/(SICI)1097-0320(19970501)28:1<74::AID-CYTO9>3.0.CO;2-H; Szarka A, 2004, ARCH BIOCHEM BIOPHYS, V428, P73, DOI 10.1016/j.abb.2004.05.011; Tan XZ, 1999, CARCINOGENESIS, V20, P2287, DOI 10.1093/carcin/20.12.2287; TOMKINSON AE, 1988, J BIOL CHEM, V263, P12532; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; VATASSERY GT, 1995, NEUROCHEM INT, V26, P527, DOI 10.1016/0197-0186(94)00147-M; Vatassery GT, 2004, J NEUROSCI RES, V75, P845, DOI 10.1002/jnr.20027; VERA JC, 1994, BLOOD, V84, P1628; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; Weber A, 2000, PLANT CELL, V12, P787, DOI 10.1105/tpc.12.5.787; WELLS WW, 1990, J BIOL CHEM, V265, P15361; Witenberg B, 1999, BIOCHEM PHARMACOL, V57, P823, DOI 10.1016/S0006-2952(98)00351-7; Xu DP, 1996, J BIOENERG BIOMEMBR, V28, P77; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173	67	169	173	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					1657	1667		10.1096/fj.05-4107com	http://dx.doi.org/10.1096/fj.05-4107com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16195374				2022-12-28	WOS:000232991100043
J	Singleton, PA; Dudek, SM; Chiang, ET; Garcia, JGN				Singleton, PA; Dudek, SM; Chiang, ET; Garcia, JGN			Regulation of sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P(1) receptor, PI3 kinase, Tiam1/Rac1, and alpha-actinin	FASEB JOURNAL			English	Article						cytoskeleton; S1P; S1P(1)/Edg1 receptor; Tiam1; PI3 kinase; alpha actinin	MYOSIN LIGHT-CHAIN; PROTEIN-COUPLED RECEPTOR; LIPID RAFTS; CD44 INTERACTION; ACTIVATION; CAVEOLAE; RHO; PHOSPHORYLATION; ADHESION; RAC	Endothelial cell (EC) barrier dysfunction results in increased vascular permeability observed in inflammation, tumor angiogenesis, and atherosclerosis. The platelet-derived phospholipid sphingosine-1-phosphate (S1P) decreases EC permeability in vitro and in vivo and thus has obvious therapeutic potential. We examined S1P-mediated human pulmonary artery EC signaling and barrier regulation in caveolin-enriched microdomains (CEM). Immunoblotting from S1P-treated EC revealed S1P-mediated rapid recruitment ( 1 mu M, 5 min) to CEMs of the S1P receptors S1P(1) and S1P(3), p110 PI3 kinase alpha and beta catalytic subunits, the Rac1 GEF, Tiam1, and alpha-actinin isoforms 1 and 4. Immunoprecipitated p110 PI3 kinase catalytic subunits from S1P-treated EC exhibited PIP3 production in CEMs. Immunoprecipitation of S1P receptors from CEM fractions revealed complexes containing Tiam1 and S1P1. PI3 kinase inhibition (LY294002) attenuated S1P-induced Tiam1 association with S1P1, Tiaml/Rac1 activation, alpha-actinin-1/4 recruitment, and EC barrier enhancement. Silencing of either S1P1 or Tiam1 expression resulted in the loss of S1P-mediated Rac1 activation and alpha-actinin-1/4 recruitment to CEM. Finally, silencing S1P1, Tiam1, or both alpha-actinin isoforms 1/4 inhibits S1P-induced cortical F-actin rearrangement and S1P-mediated barrier enhancement. Taken together, these results suggest that S1P-induced recruitment of S1P1 to CEM fractions promotes PI3 kinase-mediated Tiam1/Rac1 activation required for alpha-actinin-1/4-regulated cortical actin rearrangement and EC barrier enhancement.	Johns Hopkins Univ, Div Pulm & Crit Care Med, Ctr Translat Resp Med, Sch Med, Baltimore, MD 21224 USA	Johns Hopkins University	Garcia, JGN (corresponding author), Johns Hopkins Univ, Div Pulm & Crit Care Med, Ctr Translat Resp Med, Sch Med, Baltimore, MD 21224 USA.	drgarcia@jhmi.edu	Garcia, Joe GN/E-8862-2010					Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cascone I, 2003, J BIOL CHEM, V278, P50702, DOI 10.1074/jbc.M307234200; DeMali KA, 2003, J CELL SCI, V116, P2389, DOI 10.1242/jcs.00605; Djordjevic S, 2002, TRENDS BIOCHEM SCI, V27, P426, DOI 10.1016/S0968-0004(02)02136-9; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; FLEMING IN, 2001, BIOCHEM J, V382, P857; Foukas LC, 2003, ARCH BIOCHEM BIOPHYS, V414, P13, DOI 10.1016/S0003-9861(03)00177-2; FRELEY TS, 2005, IN PRESS J BIOL CHEM; Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Garcia JGN, 1999, AM J PHYSIOL-LUNG C, V276, pL989, DOI 10.1152/ajplung.1999.276.6.L989; Glebov OO, 2004, NAT CELL BIOL, V6, P238, DOI 10.1038/ncb1103; Gratton JP, 2004, CIRC RES, V94, P1408, DOI 10.1161/01.RES.0000129178.56294.17; HANADA, 2004, BIOCHIM BIOPHYS ACTA, V1697, P3; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Harris TJC, 2002, BIOESSAYS, V24, P996, DOI 10.1002/bies.10172; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Jacobson JR, 2004, AM J RESP CELL MOL, V30, P662, DOI 10.1165/rcmb.2003-0267OC; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Kawamura S, 2003, J BIOL CHEM, V278, P31111, DOI 10.1074/jbc.M300725200; Kos CH, 2003, J CLIN INVEST, V111, P1683, DOI 10.1172/JCI200317988; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Liu F, 2002, FASEB J, V16, P950, DOI 10.1096/fj.01-0870com; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Malliri A, 2004, J BIOL CHEM, V279, P30092, DOI 10.1074/jbc.M401192200; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; Mathew R, 2004, CIRCULATION, V110, P1499, DOI 10.1161/01.CIR.0000141576.39579.23; McVerry BJ, 2004, J CELL BIOCHEM, V92, P1075, DOI 10.1002/jcb.20088; Mertens AE, 2003, FEBS LETT, V546, P11, DOI 10.1016/S0014-5793(03)00435-6; Minshall RD, 2003, AM J PHYSIOL-LUNG C, V285, pL1179, DOI 10.1152/ajplung.00242.2003; O'Connell KMS, 2004, TRENDS CARDIOVAS MED, V14, P37, DOI 10.1016/j.tcm.2003.10.002; Okamoto H, 1999, BIOCHEM BIOPH RES CO, V260, P203, DOI 10.1006/bbrc.1999.0886; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Otey CA, 2004, CELL MOTIL CYTOSKEL, V58, P104, DOI 10.1002/cm.20007; PAVALKO FM, 1991, BIOCHEM SOC T, V19, P1065, DOI 10.1042/bst0191065; Pierce SK, 2004, NAT CELL BIOL, V6, P180, DOI 10.1038/ncb0304-180; Pyne S, 2000, PHARMACOL THERAPEUT, V88, P115, DOI 10.1016/S0163-7258(00)00084-X; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schaphorst KL, 2003, AM J PHYSIOL-LUNG C, V285, pL258, DOI 10.1152/ajplung.00311.2002; Schubert W, 2002, J BIOL CHEM, V277, P40091, DOI 10.1074/jbc.M205948200; Shikata Y, 2003, FASEB J, V17, P2240, DOI 10.1096/fj.03-0198com; Shikata Y, 2003, J APPL PHYSIOL, V94, P1193, DOI 10.1152/japplphysiol.00690.2002; Silvius JR, 2003, BBA-BIOMEMBRANES, V1610, P174, DOI 10.1016/S0005-2736(03)00016-6; Singleton PA, 2004, EXP CELL RES, V295, P102, DOI 10.1016/j.yexcr.2003.12.025; Spiegel S, 2002, LEUKEMIA, V16, P1596, DOI 10.1038/sj.leu.2402611; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; Waeber C, 2004, DRUG NEWS PERSPECT, V17, P365, DOI 10.1358/dnp.2004.17.6.829028; WOSCHOLSKI R, 1994, J BIOL CHEM, V269, P25067; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517	60	220	229	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					1646	1656		10.1096/fj.05-3928com	http://dx.doi.org/10.1096/fj.05-3928com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16195373				2022-12-28	WOS:000232991100042
J	Metzner, L; Kottra, G; Neubert, K; Daniel, H; Brandsch, M				Metzner, L; Kottra, G; Neubert, K; Daniel, H; Brandsch, M			Serotonin, L-tryptophan, and tryptamine are effective inhibitors of the amino acid transport system PAT1	FASEB JOURNAL			English	Article						membrane transport; proton gradient; nontransported inhibitors; Xenopus laevis oocytes; Caco-2 cells	CACO-2 CELL MONOLAYERS; LINE CACO-2; ABSORPTION; IDENTIFICATION; IMINO; PEPT1; HPAT1	The proton-coupled amino acid transporter PAT1, cloned recently from brain and intestine, mediates the uphill transport of L- and D-proline, L-alanine, glycine, taurine, D-serine, GABA, and many other related compounds and drugs. Here we describe the novel finding that L-tryptophan and its derivatives tryptamine, 5-hydroxy-L-tryptophan, serotonin, and indole-3-propionic acid strongly inhibit H+-dependent L-[H-3] proline uptake into Caco-2 cells with inhibition constants (K-i) of 0.9 to 6.1 mM. Uptake of L-[H-3] tryptophan into Caco-2 cells on the other hand was not inhibited by L-proline. Whereas PAT1 substrates produced significant changes in a membrane potential assay for electrogenic transport in Caco-2 cells, L-tryptophan, tryptamine, and 5-hydroxy-L-tryptophan failed to alter membrane voltage. When PAT1 was expressed in Xenopus laevis oocytes and analyzed by the two-electrode voltage clamp technique, glycine elicited high inward currents that were dependent on membrane potential but no currents were observed with L-tryptophan, tryptamine, 5-hydroxy-L-tryptophan, or serotonin. Although not transported electrogenically by PAT1, L-tryptophan and its derivatives inhibited glycine-evoked currents dose-dependently. We conclude that serotonin, L-tryptophan, and tryptamine bind to PAT1 with potencies similar to the prototype substrates, inhibit transport function but are not transported by this carrier protein. They may be considered as the carriers' naturally occurring inhibitors that may alter the transport function of PAT1.	Univ Halle Wittenberg, Biozentrum, Membrane Transport Grp, D-06120 Halle Saale, Germany; Tech Univ Munich, Ctr Life & Food Sci, Mol Nutr Unit, D-8050 Freising Weihenstephan, Germany; Univ Halle Wittenberg, Dept Biochem Biotechnol, Inst Biochem, Halle Saale, Germany	Martin Luther University Halle Wittenberg; Technical University of Munich; Martin Luther University Halle Wittenberg	Brandsch, M (corresponding author), Univ Halle Wittenberg, Biozentrum, Membrane Transport Grp, Weinbergweg 22, D-06120 Halle Saale, Germany.	brandsch@biozentrum.uni-halle.de	Daniel, Hannelore/B-8982-2009					Anderson CMH, 2004, GASTROENTEROLOGY, V127, P1410, DOI 10.1053/j.gastro.2004.08.017; Birdsall T C, 1998, Altern Med Rev, V3, P271; Boll M, 2004, PFLUG ARCH EUR J PHY, V447, P776, DOI 10.1007/s00424-003-1073-4; Boll M, 2003, MOL MEMBR BIOL, V20, P261, DOI 10.1080/0968768031000100759; Boll M, 2003, GENOMICS, V82, P47, DOI 10.1016/S0888-7543(03)00099-5; Boll M, 2002, J BIOL CHEM, V277, P22966, DOI 10.1074/jbc.M200374200; Brandsch M, 1998, J BIOL CHEM, V273, P3861, DOI 10.1074/jbc.273.7.3861; Chen Z, 2003, J PHYSIOL-LONDON, V546, P349, DOI 10.1113/jphysiol.2002.026500; Faria TN, 2004, MOL PHARMACEUT, V1, P67, DOI 10.1021/mp034001k; Foltz M, 2004, FASEB J, V18, P1758, DOI 10.1096/fj.03-1387fje; Knutter I, 2001, BIOCHEMISTRY-US, V40, P4454, DOI 10.1021/bi0026371; Metzner L, 2004, J PHARMACOL EXP THER, V309, P28, DOI 10.1124/jpet.103.059014; RANALDI G, 1994, ANTIMICROB AGENTS CH, V38, P1239, DOI 10.1128/AAC.38.6.1239; Sagne C, 2001, P NATL ACAD SCI USA, V98, P7206, DOI 10.1073/pnas.121183498; Takanaga H, 2005, J BIOL CHEM, V280, P8974, DOI 10.1074/jbc.M413027200; Theis S, 2002, J BIOL CHEM, V277, P7287, DOI 10.1074/jbc.M105028200; THWAITES DT, 1993, J BIOL CHEM, V268, P18438; THWAITES DT, 1993, FEBS LETT, V333, P78, DOI 10.1016/0014-5793(93)80378-8; Thwaites DT, 2000, BRIT J PHARMACOL, V129, P457, DOI 10.1038/sj.bjp.0703069; THWAITES DT, 1995, J MEMBRANE BIOL, V145, P245	20	49	52	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2005	19	11					1468	1473		10.1096/fj.05-3683com	http://dx.doi.org/10.1096/fj.05-3683com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16126914				2022-12-28	WOS:000232315700040
J	Park, YJ; Chang, LC; Liang, JF; Moon, C; Chung, CP; Yang, VC				Park, YJ; Chang, LC; Liang, JF; Moon, C; Chung, CP; Yang, VC			Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study	FASEB JOURNAL			English	Article						LMWP; PTD; TAT; gene therapy; medical imaging	ARGININE-RICH PEPTIDES; HIV-1 TAT PROTEIN; HEPARIN ANTAGONIST; MAMMALIAN-CELLS; CELLULAR UPTAKE; TRANSDUCTION; EFFICACY; INTERNALIZATION; TRANSPORTERS; ENDOCYTOSIS	Naturally derived, nontoxic peptides from protamine by the authors, termed low molecular weight protamines (LMWPs), possess high arginine content and carry significant sequence similarity to that of TAT, by far the most potent protein transduction domain peptide. Therefore, it was hypothesized that these LMWPs would also inherit the similar translocation activity across the cell membrane, which enables any impermeable species to be transduced into the cells. LMWPs were prepared by enzymatic digestion of protamine, examined their capability of transducing an impermeable protein toxin into the tumor cells by chemical conjugation, and determined cytotoxicity of transduced protein toxin ( e. g., gelonin) against cancer cell lines and a tumor-bearing mouse. In vitro results showed that LMWPs could indeed translocate themselves into several mammalian cell lines as efficiently as TAT, thereby transducing impermeable gelonin into the cells by chemical conjugation. In vivo studies further confirmed that LMWP could carry an impermeable gelonin across the tumor mass and subsequently inhibit the tumor growth. In conclusion, the presence of equivalent cell translocation potency, absence of toxicity of peptide itself, and the suitability for low-cost production by simple enzymatic digestion could expand the range of clinical applications of LMWPs, including medical imaging and gene/protein therapies.	Seoul Natl Univ, Sch Dent, Craniomaxillofacial Reconstruct Sci Major, Seoul 110749, South Korea; Seoul Natl Univ, Intellectual Biointerface Engn Ctr, Seoul 110749, South Korea; Seoul Natl Univ, Sch Dent, Dept Periodontol, Seoul 110749, South Korea; Natl Def Med Ctr, Sch Pharm, Taipei, Taiwan; Stevens Inst Technol, Dept Chem & Chem Biol, Hoboken, NJ 07030 USA; Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); National Defense Medical Center; Stevens Institute of Technology; University of Michigan System; University of Michigan	Park, YJ (corresponding author), Seoul Natl Univ, Sch Dent, Craniomaxillofacial Reconstruct Sci Major, 28-2 Yongon Dong, Seoul 110749, South Korea.	parkyj@snu.ac.kr		Moon, Cheol/0000-0003-2342-0860	NATIONAL CANCER INSTITUTE [R01CA114612] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA114612] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Byun Y, 1999, THROMB RES, V94, P53, DOI 10.1016/S0049-3848(98)00201-1; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; Chang LC, 2001, AAPS PHARMSCI, V3, part. no.; Chang LC, 2001, AAPS PHARMSCI, V3, part. no.; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; HEEREMANS JLM, 1992, BIOCHIM BIOPHYS ACTA, V1117, P258, DOI 10.1016/0304-4165(92)90022-M; JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864; Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h; Lee LM, 2001, AAPS PHARMSCI, V3, part. no.; Liang JF, 2003, BIOCHEMISTRY-MOSCOW+, V68, P116, DOI 10.1023/A:1022109905487; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; McGrath MS, 2003, CANCER RES, V63, P72; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Niesner U, 2002, BIOCONJUGATE CHEM, V13, P729, DOI 10.1021/bc025517+; Park YJ, 2003, J GENE MED, V5, P700, DOI 10.1002/jgm.402; Rosenblum MG, 1999, CLIN CANCER RES, V5, P865; Rothbard JB, 2002, J MED CHEM, V45, P3612, DOI 10.1021/jm0105676; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Selbo PK, 2001, INT J CANCER, V92, P761, DOI 10.1002/1097-0215(20010601)92:5<761::AID-IJC1238>3.0.CO;2-4; Snyder EL, 2001, CURR OPIN MOL THER, V3, P147; Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Tsui B, 2001, THROMB RES, V101, P417, DOI 10.1016/S0049-3848(00)00427-8; Tung CH, 2002, BIOORGAN MED CHEM, V10, P3609, DOI 10.1016/S0968-0896(02)00248-1; Veenendaal LM, 2002, P NATL ACAD SCI USA, V99, P7866, DOI [10.1073/pnas.122157899, 10.1073/pnas.162346299]; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Zaro JL, 2003, BIOCHEM BIOPH RES CO, V307, P241, DOI 10.1016/S0006-291X(03)01167-7	31	103	111	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1555	+		10.1096/fj.04-2322fje	http://dx.doi.org/10.1096/fj.04-2322fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16033808	Green Published			2022-12-28	WOS:000230923000016
J	Lakshmana, MK; Araki, W; Tabira, T				Lakshmana, MK; Araki, W; Tabira, T			Amyloid beta peptide binds a novel death-inducing protein, AB-DIP	FASEB JOURNAL			English	Article						Alzheimer's disease; apoptosis; protein interaction	ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; COGNITIVE DECLINE; PRECURSOR PROTEIN; APOPTOSIS; ACTIVATION; NEURONS; PLAQUES; NEURODEGENERATION; ACCUMULATION	Amyloid beta-peptide (A beta) plays a central role in the pathogenesis of Alzheimer's disease (AD). It is toxic toneurons, but the mechanism for its action remains largely unknown. Here, we have identified a novel death-inducing protein, A beta-related DIP (AB-DIP), by two-hybrid screening of the human brain cDNA library and confirmed the binding of A beta with AB-DIP by coimmunoprecipitation. Overexpression of AB-DIP-induced cell death and coexpression of A beta enhanced the cell death. During apoptosis, the 97-kDa AB-DIP was cleaved to a 62-kDa protein (AB-DIPp62) at the caspase cleavage site, LEKD. It is more important that cotransfection of A beta with AB-DIP produced the AB-DIP p62 fragment. Small interfering RNA-mediated knockdown of AB-DIP protein expression significantly protected neuroblastoma cells from A beta-induced neurotoxicity. AB-DIP may mediate the neurotoxicity of A beta, and therefore, AB-DIP may be a potential, therapeutic target for AD.	Natl Ctr Geriatr & Gerontol, Natl Inst Longev Sci, Dept Vasc Dementia Res, Aichi 4748522, Japan; Natl Inst Neurosci, Dept Demyelinating Dis & Aging, Tokyo, Japan	National Center for Geriatrics & Gerontology; National Center for Neurology & Psychiatry - Japan	Lakshmana, MK (corresponding author), Natl Ctr Geriatr & Gerontol, Natl Inst Longev Sci, Dept Vasc Dementia Res, 36-3 Gengo, Aichi 4748522, Japan.	laxman@nils.go.jp; tabira@nils.go.jp	Araki, Wataru/G-7913-2014	Araki, Wataru/0000-0001-8467-6937				Anderson AJ, 1996, J NEUROSCI, V16, P1710, DOI 10.1523/jneurosci.16-05-01710.1996; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Bouchier-Hayes L, 2002, EMBO REP, V3, P616, DOI 10.1093/embo-reports/kvf139; Buckig A, 2002, HISTOCHEM CELL BIOL, V118, P353, DOI 10.1007/s00418-002-0459-2; Casley CS, 2002, NEUROBIOL DIS, V10, P258, DOI 10.1006/nbdi.2002.0516; Casley CS, 2002, J NEUROCHEM, V80, P91, DOI 10.1046/j.0022-3042.2001.00681.x; Chan D, 2003, LANCET, V362, P1121, DOI 10.1016/S0140-6736(03)14469-8; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; D'Andrea MR, 2001, HISTOPATHOLOGY, V38, P120, DOI 10.1046/j.1365-2559.2001.01082.x; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; Fonte V, 2002, P NATL ACAD SCI USA, V99, P9439, DOI 10.1073/pnas.152313999; Fox NC, 1999, NEUROLOGY, V52, P1687, DOI 10.1212/WNL.52.8.1687; FOX NC, 2004, LANCET, V313, P92; FUKUTANI Y, 1995, NEUROSCI LETT, V200, P57, DOI 10.1016/0304-3940(95)12083-G; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; HYMAN BT, 1985, RES ADV ALZHEIMERS D, P453; Islam K, 1997, AM J PATHOL, V151, P265; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kienlen-Campard P, 2002, J BIOL CHEM, V277, P15666, DOI 10.1074/jbc.M200887200; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; Lauber K, 2001, J BIOL CHEM, V276, P29772, DOI 10.1074/jbc.M101524200; LIPPA CF, 1992, NEUROBIOL AGING, V13, P405, DOI 10.1016/0197-4580(92)90115-E; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Oddo S, 2004, NEURON, V43, P321, DOI 10.1016/j.neuron.2004.07.003; Ohyagi Y, 2005, FASEB J, V19, P255, DOI 10.1096/fj.04-2637fje; Rohn TT, 2002, NEUROBIOL DIS, V11, P341, DOI 10.1006/nbdi.2002.0549; Smith MA, 2002, LANCET, V359, P1864, DOI 10.1016/S0140-6736(02)08695-6; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; vanderMaarel SM, 1996, HUM MOL GENET, V5, P887, DOI 10.1093/hmg/5.7.887; Wilson C, 2004, NEUROPATH APPL NEURO, V30, P19, DOI 10.1046/j.0305-1846.2003.00496.x; Wirths O, 2001, NEUROSCI LETT, V306, P116, DOI 10.1016/S0304-3940(01)01876-6; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; Yan SD, 1997, NATURE, V389, P689; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	42	7	10	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1362	+		10.1096/fj.05-3672fje	http://dx.doi.org/10.1096/fj.05-3672fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15923395				2022-12-28	WOS:000229602600005
J	Maezawa, I; Nivison, M; Montine, KS; Maeda, N; Montine, TJ				Maezawa, Izumi; Nivison, Mary; Montine, Kathleen S.; Maeda, Nobuyo; Montine, Thomas J.			Neurotoxicity from innate immune response is greatest with targeted replacement of epsilon 4 allele of apolipoprotein E gene and is mediated by microglial p38MAPK	FASEB JOURNAL			English	Article						APOE; neurodegeneration	ACTIVATED PROTEIN-KINASE; NEURONAL OXIDATIVE DAMAGE; NITRIC-OXIDE SYNTHASE; ALZHEIMERS-DISEASE; BRAIN INFLAMMATION; IN-VIVO; LIPOPOLYSACCHARIDE; RECEPTOR; APOE; ALLELE	Inheritance of APOE alleles is associated with varying clinical outcomes in several neurodegenerative diseases that are associated with innate immune response in brain. We tested the hypothesis that inheritance of different APOE alleles would significantly modulate neurotoxicity arising from glial innate immune response. We first used dissociated cultures of wild-type (wt) murine neurons and glia derived from mice with targeted replacement (TR) of the epsilon 2, epsilon 3, or, epsilon 4 APOE allele. Our results showed that the vast majority of bystander damage to wt neurons derived from microglia was greatest with TR APOE4 glia, intermediate from TR APOE3 glia, and least from TR APOE2 glia and preceded detectable NO secretion. Microglial p38MAPK-dependent cytokine secretion followed a similar pattern of TR APOE dependence. In hippocampal slice cultures, innate immune activation had a similar pattern of TR APOE-dependence and produced postsynaptic neuronal damage in TR APOE4 and TR APOE3 but not TR APOE2 cultures that was p38MAPK dependent. These findings suggest a new mechanism by which inheritance of different APOE alleles may influence the outcome of neurodegenerative diseases associated with microglial innate immune response.	Univ Washington, Dept Pathol, Seattle, WA 98104 USA; Univ N Carolina, Dept Pathol, Chapel Hill, NC USA	University of Washington; University of Washington Seattle; University of North Carolina; University of North Carolina Chapel Hill	Montine, TJ (corresponding author), Univ Washington, Dept Pathol, Box 359791, Seattle, WA 98104 USA.	tmontine@u.washington.edu		Montine, Kathleen/0000-0003-2110-8363	NATIONAL INSTITUTE ON AGING [R01AG024011, P50AG005136] Funding Source: NIH RePORTER; NIA NIH HHS [AG-24011, AG-05136] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200; ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Barone FC, 2001, MED RES REV, V21, P129, DOI 10.1002/1098-1128(200103)21:2<129::AID-MED1003>3.0.CO;2-H; Bock HH, 2004, J BIOL CHEM, V279, P33471, DOI 10.1074/jbc.M401770200; Brecht WJ, 2004, J NEUROSCI, V24, P2527, DOI 10.1523/JNEUROSCI.4315-03.2004; Brendza RP, 2002, MOL PSYCHIATR, V7, P132, DOI 10.1038/sj.mp.4001006; Brown CM, 2002, FREE RADICAL BIO MED, V32, P1071, DOI 10.1016/S0891-5849(02)00803-1; Buttini M, 1999, J NEUROSCI, V19, P4867; Calon F, 2004, NEURON, V43, P633, DOI 10.1016/j.neuron.2004.08.013; Colton CA, 2002, NEUROBIOL AGING, V23, P777, DOI 10.1016/S0197-4580(02)00016-7; Corder EH, 1998, NAT MED, V4, P1182, DOI 10.1038/2677; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; Enzinger C, 2004, ANN NEUROL, V55, P563, DOI 10.1002/ana.20027; Fabrizi C, 2001, J BIOL CHEM, V276, P25692, DOI 10.1074/jbc.M100133200; Fassbender K, 2004, FASEB J, V18, P203, DOI 10.1096/fj.03-0364fje; Fiebich BL, 2001, J NEUROCHEM, V79, P950, DOI 10.1046/j.1471-4159.2001.00652.x; GEBICKEHAERTER PJ, 1989, J NEUROSCI, V9, P183; Giovannini MG, 2002, NEUROBIOL DIS, V11, P257, DOI 10.1006/nbdi.2002.0538; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Han IO, 2002, NEUROSCI LETT, V325, P9, DOI 10.1016/S0304-3940(02)00218-5; Hauss-Wegrzyniak B, 2002, EXP NEUROL, V176, P336, DOI 10.1006/exnr.2002.7966; Holtzman DM, 2004, J MOL NEUROSCI, V23, P247, DOI 10.1385/JMN:23:3:247; Imler JL, 2001, TRENDS CELL BIOL, V11, P304, DOI 10.1016/S0962-8924(01)02004-9; John U, 2003, ALCOHOL ALCOHOLISM, V38, P263, DOI 10.1093/alcalc/agg063; Johnson GB, 2003, CRIT REV IMMUNOL, V23, P15, DOI 10.1615/CritRevImmunol.v23.i12.20; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Li YJ, 2004, NEUROGENETICS, V5, P209, DOI 10.1007/s10048-004-0193-0; Li YJ, 2004, NEUROLOGY, V62, P2005, DOI 10.1212/01.WNL.0000128089.53030.AC; Liu B, 2002, ANN NY ACAD SCI, V962, P318, DOI 10.1111/j.1749-6632.2002.tb04077.x; Luk JM, 1995, ANAL BIOCHEM, V232, P217, DOI 10.1006/abio.1995.0010; Maezawa I, 2004, J NEUROCHEM, V91, P1312, DOI 10.1111/j.1471-4159.2004.02818.x; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Milatovic D, 2003, J NEUROCHEM, V87, P1518, DOI 10.1046/j.1471-4159.2003.02120.x; Milatovic D, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-20; MINGHETTI L, 1995, J NEUROCHEM, V65, P2690; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Moffatt OD, 1999, J IMMUNOL, V162, P6800; Montine TJ, 2002, J NEUROCHEM, V83, P463, DOI 10.1046/j.1471-4159.2002.01157.x; Nadeau S, 2002, J IMMUNOL, V169, P3370, DOI 10.4049/jimmunol.169.6.3370; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; NEWMAN MF, 1995, ANN THORAC SURG, V59, P1326, DOI 10.1016/0003-4975(95)00076-W; Piao CS, 2003, J NEUROSCI RES, V73, P537, DOI 10.1002/jnr.10671; Polazzi E, 2002, REV NEUROSCIENCE, V13, P221; Rivest S, 2003, BRAIN BEHAV IMMUN, V17, P13, DOI 10.1016/S0889-1591(02)00055-7; Scali C, 2003, NEUROSCIENCE, V117, P909, DOI 10.1016/S0306-4522(02)00839-4; Shie FS, 2005, GLIA, V52, P70, DOI 10.1002/glia.20220; Shie FS, 2005, AM J PATHOL, V166, P1163, DOI 10.1016/S0002-9440(10)62336-X; Stern EL, 2000, J NEUROIMMUNOL, V106, P114, DOI 10.1016/S0165-5728(00)00194-6; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Sullivan PM, 1998, J CLIN INVEST, V102, P130, DOI 10.1172/JCI2673; Wenk GL, 2004, J NEUROCHEM, V89, P484, DOI 10.1111/j.1471-4159.2004.02359.x; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Xie Z, 2004, GLIA, V45, P170, DOI 10.1002/glia.10314; Xie Z, 2003, EXP NEUROL, V182, P135, DOI 10.1016/S0014-4886(03)00057-8; Xie Z, 2002, J NEUROSCI, V22, P3484; Zhu XW, 2002, NEUROSIGNALS, V11, P270, DOI 10.1159/000067426	61	89	92	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					797	+		10.1096/fj.05-5423fje	http://dx.doi.org/10.1096/fj.05-5423fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16481366				2022-12-28	WOS:000237698700018
J	Dorschner, RA; Lopez-Garcia, B; Peschel, A; Kraus, D; Morikawa, K; Nizet, V; Gallo, RL				Dorschner, RA; Lopez-Garcia, B; Peschel, A; Kraus, D; Morikawa, K; Nizet, V; Gallo, RL			The mammalian ionic environment dictates microbial susceptibility to antimicrobial defense peptides	FASEB JOURNAL			English	Article						leukocyte recruitment; cathelicidin; AMP activity; dermatitis	STAPHYLOCOCCUS-AUREUS; SIGMA-FACTOR; ADAPTIVE RESPONSE; INNATE IMMUNITY; SKIN; EXPRESSION; VIRULENCE; MICE; BETA-DEFENSIN-1; NEUTROPHILS	Antimicrobial peptides (AMPs) have been shown in animal and human systems to be effective natural antibiotics. However, it is unclear how they convey protection; they often appear inactive when assayed under culture conditions applied to synthetic antibiotics. This inactivation has been associated with loss of function in physiological concentrations of NaCl or serum. In this study we show that the balance of host ionic conditions dictate microbial sensitivity to AMPs. Carbonate is identified as the critical ionic factor present in mammalian tissues that imparts the ability of AMPs such as cathelicidins and defensins to kill at physiological NaCl concentrations. After adapting to carbonate-containing solutions, global changes occur in Staphylococcus aureus and Escherichia coli structure and gene expression despite no change in growth rate. Our findings show that changes in cell wall thickness and Sigma factor B expression correspond to the increased susceptibility to the AMP LL-37. These observations provide new insight into the factors involved in enabling function of innate immune effector molecules, and suggest that discovery of new antimicrobials should specifically target pathogens as they exist in the host and not the distinctly different phenotype of bacteria grown in culture broth.-Dorschner, R. A., Lopez-Garcia, B., Peschel, A., Kraus, D., Morikawa, K., Nizet, V., Gallo, R. L. The mammalian ionic environment dictates microbial susceptibility to antimicrobial defense peptides.	Univ Calif San Diego, Dept Med, Div Dermatol, San Diego, CA 92103 USA; VA San Dieg Healthcare Ctr, San Diego, CA USA; Univ Calif San Diego, Dept Pediat, Div Infect Dis, San Diego, CA 92103 USA; Univ Tubingen, Cellular & Mol Microbiol Div, Med Microbiol & Hyg Dept, Tubingen, Germany; Univ Tsukuba, Inst Basic Med Sci, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 305, Japan	University of California System; University of California San Diego; University of California System; University of California San Diego; Eberhard Karls University of Tubingen; University of Tsukuba	Gallo, RL (corresponding author), Mail Code 9111B,3350 La Jolla Viallage Dr, La Jolla, CA 92161 USA.	rgallo@vapop.ucsd.edu	Gallo, Richard L/A-8931-2009; Nizet, Victor/AAF-3190-2019	Gallo, Richard L/0000-0002-1401-7861; Morikawa, Kazuya/0000-0002-1503-7151; Nizet, Victor/0000-0003-3847-0422	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI052453, R01AI052453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045676] Funding Source: NIH RePORTER; NIAID NIH HHS [AI052453] Funding Source: Medline; NIAMS NIH HHS [AR45676] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AOYAMA T, 1990, FEBS LETT, V263, P1, DOI 10.1016/0014-5793(90)80691-B; BORREGAARD N, 1984, J CLIN INVEST, V74, P455, DOI 10.1172/JCI111442; Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935; Di Nardo A, 2003, J IMMUNOL, V170, P2274, DOI 10.4049/jimmunol.170.5.2274; Dorschner RA, 2003, PEDIATR RES, V53, P566, DOI 10.1203/01.PDR.0000057205.64451.B7; Dorschner RA, 2001, J INVEST DERMATOL, V117, P91, DOI 10.1046/j.1523-1747.2001.01340.x; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; GALLO RL, 2005, ANTIMICROBIAL PEPTID; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Heuner K, 2002, INFECT IMMUN, V70, P1604, DOI 10.1128/IAI.70.3.1604-1608.2002; Johansson J, 1998, J BIOL CHEM, V273, P3718, DOI 10.1074/jbc.273.6.3718; Jonsson IM, 2004, INFECT IMMUN, V72, P6106, DOI 10.1128/IAI.72.10.6106-6111.2004; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Lee P, 2005, P NATL ACAD SCI USA, V102, P1906, DOI 10.1073/pnas.0409808102; MCKAY W, 1987, ANESTH ANALG, V66, P572; Morikawa K, 2001, BIOCHEM BIOPH RES CO, V288, P385, DOI 10.1006/bbrc.2001.5774; Moser C, 2002, INFECT IMMUN, V70, P3068, DOI 10.1128/IAI.70.6.3068-3072.2002; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Ouellette AJ, 1999, INFECT IMMUN, V67, P6643; Peschel A, 1999, J BIOL CHEM, V274, P8405, DOI 10.1074/jbc.274.13.8405; Peschel A, 2001, J EXP MED, V193, P1067, DOI 10.1084/jem.193.9.1067; Sahu SN, 2003, MOL CELL BIOCHEM, V253, P167, DOI 10.1023/A:1026028930203; Salzman NH, 2003, NATURE, V422, P522, DOI 10.1038/nature01520; Travis SM, 2000, INFECT IMMUN, V68, P2748, DOI 10.1128/IAI.68.5.2748-2755.2000; TURNBERG L A, 1970, Journal of Clinical Investigation, V49, P548, DOI 10.1172/JCI106265; Wang YQ, 1998, J BIOL CHEM, V273, P33115, DOI 10.1074/jbc.273.50.33115; Wu SW, 1996, J BACTERIOL, V178, P6036, DOI 10.1128/jb.178.20.6036-6042.1996; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Zaiou M, 2003, J INVEST DERMATOL, V120, P810, DOI 10.1046/j.1523-1747.2003.12132.x; Zasloff M, 2002, NEW ENGL J MED, V347, P1199, DOI 10.1056/NEJMe020106; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	34	150	155	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					35	42		10.1096/fj.05-4406com	http://dx.doi.org/10.1096/fj.05-4406com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16394265				2022-12-28	WOS:000235996000042
J	Guillemin, J				Guillemin, J			Biological weapons and secrecy	FASEB JOURNAL			English	Editorial Material									MIT, MIT Secur Studies Program, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Guillemin, J (corresponding author), MIT, MIT Secur Studies Program, 77 Massachusetts Ave, Cambridge, MA 02139 USA.							Guillemin J., 2005, BIOL WEAPONS INVENTI	1	4	4	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					1763	U974		10.1096/fj.05-1102ufm	http://dx.doi.org/10.1096/fj.05-1102ufm			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16260643				2022-12-28	WOS:000234053100026
J	Kanda, T; Wakino, S; Homma, K; Yoshioka, K; Tatematsu, S; Hasegawa, K; Takamatsu, I; Sugano, N; Hayashi, K; Saruta, T				Kanda, T; Wakino, S; Homma, K; Yoshioka, K; Tatematsu, S; Hasegawa, K; Takamatsu, I; Sugano, N; Hayashi, K; Saruta, T			Rho-kinase as a molecular target for insulin resistance and hypertension	FASEB JOURNAL			English	Article						obesity; skeletal muscle; IRS-1	NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE CELLS; DIABETIC DB/DB MICE; OBESE ZUCKER RATS; SKELETAL-MUSCLE; TNF-ALPHA; RECEPTOR SUBSTRATE-1; DISTINCT PATHWAYS; PROTEIN-KINASE; GLUCOSE-UPTAKE	Rho-kinase plays an important role in hypertension and is reported to interfere with insulin signaling through serine phosphorylation of insulin receptor substrate-1 (IRS-1) in cultured vascular smooth muscle cells. We therefore examined the role of Rho-kinase in the development of insulin resistance in Zucker obese rats. In skeletal muscles and aortic tissues of Zucker obese rats, activation of RhoA/Rho-kinase was observed. Long-term Rho-kinase inhibition by 4 wk treatment with fasudil (a Rho-kinase inhibitor) not only reduced blood pressure but corrected glucose and lipid metabolism, with improvement in serine phosphorylation of IRS-1 and insulin signaling in skeletal muscles. Direct visualization of skeletal muscle arterioles with an intravital CCD videomicroscope demonstrated that both acetylcholine- and sodium nitroprusside-induced vasodilations were blunted, which were restored by the fasudil treatment. Furthermore, both fasudil and Y-27632 prevented the serine phosphorylation of IRS-1 induced by insulin and/or tumor necrosis factor-alpha in skeletal muscle cells. Collectively, Rho-kinase is responsible for the impairment of insulin signaling and may constitute a critical mediator linking between metabolic and hemodynamic abnormalities in insulin resistance.	Keio Univ, Sch Med, Dept Internal Med, Shinjuku Ku, Tokyo 1608582, Japan	Keio University	Hayashi, K (corresponding author), Keio Univ, Sch Med, Dept Internal Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	khayashi@sc.itc.keio.ac.jp	Homma, Koichiro/J-3146-2015					Abe K, 2004, CIRC RES, V94, P385, DOI 10.1161/01.RES.0000111804.34509.94; BARON AD, 1995, J CLIN INVEST, V96, P786, DOI 10.1172/JCI118124; Begum N, 2002, J BIOL CHEM, V277, P6214, DOI 10.1074/jbc.M110508200; Bolz SS, 2003, CIRCULATION, V107, P3081, DOI 10.1161/01.CIR.0000074202.19612.8C; Cheung AT, 1998, ENDOCRINOLOGY, V139, P4928, DOI 10.1210/en.139.12.4928; Cusi K, 2000, J CLIN INVEST, V105, P311, DOI 10.1172/JCI7535; de Jongh RT, 2004, CIRCULATION, V109, P2529, DOI 10.1161/01.CIR.0000129772.26647.6F; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; Del Aguila LF, 1999, AM J PHYSIOL-ENDOC M, V276, pE849, DOI 10.1152/ajpendo.1999.276.5.E849; DOHM GL, 1988, J CLIN INVEST, V82, P486, DOI 10.1172/JCI113622; Dombrowski L, 1996, AM J PHYSIOL-ENDOC M, V270, pE667, DOI 10.1152/ajpendo.1996.270.4.E667; Duplain H, 2001, CIRCULATION, V104, P342, DOI 10.1161/01.CIR.104.3.342; Emilsson V, 1998, BIOCHEM BIOPH RES CO, V252, P450, DOI 10.1006/bbrc.1998.9667; Eto M, 2001, CIRC RES, V89, P583, DOI 10.1161/hh1901.097084; Fujiwara K, 1999, HYPERTENSION, V33, P1470, DOI 10.1161/01.HYP.33.6.1470; Gong MC, 1997, J BIOL CHEM, V272, P10704; Hanna AN, 2001, MOL BIOL CELL, V12, P3618, DOI 10.1091/mbc.12.11.3618; HAYASHI K, 1989, CIRC RES, V65, P1475, DOI 10.1161/01.RES.65.6.1475; Hori H, 2002, DIABETES, V51, P2387, DOI 10.2337/diabetes.51.8.2387; Jiang ZY, 1999, J CLIN INVEST, V104, P447, DOI 10.1172/JCI5971; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; Karnam P, 1997, J BIOL CHEM, V272, P6136, DOI 10.1074/jbc.272.10.6136; LEVIN BE, 1980, PHARMACOL BIOCHEM BE, V13, P107, DOI 10.1016/0091-3057(80)90128-8; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Masaki T, 2000, AM J PHYSIOL-REG I, V279, pR1305, DOI 10.1152/ajpregu.2000.279.4.R1305; Matsuda H, 1999, J AM SOC NEPHROL, V10, P2272; Mukai Yasushi, 2001, FASEB Journal, V15, P1062; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Plante GE, 2003, CARDIOVASC RES, V59, P963, DOI 10.1016/S0008-6363(03)00521-2; Rask-Madsen C, 2003, CIRCULATION, V108, P1815, DOI 10.1161/01.CIR.0000091406.72832.11; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Sandu OA, 2000, DIABETES, V49, P2178, DOI 10.2337/diabetes.49.12.2178; Shimokawa H, 1999, CARDIOVASC RES, V43, P1029, DOI 10.1016/S0008-6363(99)00144-3; Somlyo AV, 2003, FASEB J, V17, P223, DOI 10.1096/fj.02-0655com; Sordella R, 2002, DEV CELL, V2, P553, DOI 10.1016/S1534-5807(02)00162-4; Steinberg HO, 1996, J CLIN INVEST, V97, P2601, DOI 10.1172/JCI118709; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Valverde AM, 2003, J BIOL CHEM, V278, P10221, DOI 10.1074/jbc.M209363200; Wakino S, 2004, CIRC RES, V95, pE45, DOI 10.1161/01.RES.0000142313.68389.92; Wakino S, 2001, J BIOL CHEM, V276, P47650, DOI 10.1074/jbc.M108719200; Williams SB, 1996, J AM COLL CARDIOL, V27, P567, DOI 10.1016/0735-1097(95)00522-6; Yamamoto T, 2001, KIDNEY INT, V60, P364, DOI 10.1046/j.1523-1755.2001.00808.x; Zeng GY, 2000, CIRCULATION, V101, P1539, DOI 10.1161/01.CIR.101.13.1539; Zick Y, 2003, INT J OBESITY, V27, pS56, DOI 10.1038/sj.ijo.0802503	47	88	91	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					169	+		10.1096/fj.05-4197fje	http://dx.doi.org/10.1096/fj.05-4197fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16267124				2022-12-28	WOS:000234053100021
J	Schild, L; Jaroscakova, I; Lendeckel, U; Wolf, G; Keilhoff, G				Schild, L; Jaroscakova, I; Lendeckel, U; Wolf, G; Keilhoff, G			Neuronal nitric oxide synthase controls enzyme activity pattern of mitochondria and lipid metabolism	FASEB JOURNAL			English	Article						endogenous nitric oxide; citrate synthase; respiratory chain	CYTOCHROME-C; INHIBITION; COMPLEXES; MECHANISM; OXYGEN; CELLS; DNA	Mitochondria are affected by endogenous nitric oxide ( NO). Besides effects of NO on mitochondrial enzymes and the stimulation of mitochondrial H2O2 production, a NO-dependent increase in mitochondrial biogenesis in several tissues has been reported. It is still obscure whether NO generated by one specific or different NO synthase ( NOS) isoenzymes determine such effects. Therefore, we analyzed the amount of mitochondria, respiratory chain enzyme complexes, and citrate synthase in the brain, muscle, heart, kidney, and liver by comparing wildtype (WT) mice and mice lacking the neuronal nitric oxide synthase isoform (nNOS-KO). Our results show that the activities of NADH: cytochrome c oxidoreductase and succinate cytochrome c oxidoreductase differ between WT and nNOS-KO mice. However, similar quantities of mitochondria were found in the homogenates of tissues in WT and nNOS-KO animals. Most impressive, higher activities and protein of citrate synthase were found in the brain, muscle, heart, kidney, and liver of nNOS-KO mice. Additionally, higher contents of fatty acid synthase and lipids were determined in the livers of nNOS-KO mice but not in the heart and brain. Furthermore, liver mitochondria from nNOS-KO mice consumed pyruvate at a higher rate and released more citric acid. Our data document a previously unrecognized role of endogenous NO in the regulation of lipid metabolism.	Otto Von Guericke Univ, Fak Med, Inst Klin Chem & Pathol Biochem, Bereich Pathol Biochem, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Fak Med, Inst Med Neurobiol, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Fak Med, Inst Expt Innere Med, D-39120 Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University; Otto von Guericke University	Schild, L (corresponding author), Otto Von Guericke Univ, Fak Med, Inst Klin Chem & Pathol Biochem, Bereich Pathol Biochem, Leipziger Str 44, D-39120 Magdeburg, Germany.	Lorenz.Schild@Medizin.Uni-Magdeburg.de	Lendeckel, Uwe/Q-6922-2016	Lendeckel, Uwe/0000-0002-0684-9959				Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Bates TE, 1996, BIOCHEM BIOPH RES CO, V218, P40, DOI 10.1006/bbrc.1996.0008; BATES TE, 1995, BIOCHEM BIOPH RES CO, V213, P896, DOI 10.1006/bbrc.1995.2213; BIRCHMACHIN MA, 1994, BIOCHEM MED METAB B, V51, P35, DOI 10.1006/bmmb.1994.1004; Bodrova ME, 1998, FEBS LETT, V435, P269, DOI 10.1016/S0014-5793(98)01072-2; Brenman JE, 1997, DEV NEUROSCI-BASEL, V19, P224, DOI 10.1159/000111211; Brennan PA, 2002, ANN ROY COLL SURG, V84, P75; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; Brown GC, 1999, BIOCHEM SOC SYMP, V66, P17, DOI 10.1042/bss0660017; Brunori M, 2004, BBA-BIOENERGETICS, V1655, P365, DOI 10.1016/j.bbabio.2003.06.008; Carreras MC, 2004, HEPATOLOGY, V40, P157, DOI 10.1002/hep.20255; Cooper CE, 2002, TRENDS BIOCHEM SCI, V27, P33, DOI 10.1016/S0968-0004(01)02035-7; Cote HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035; Drapier JC, 1997, METHODS, V11, P319, DOI 10.1006/meth.1996.0426; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; Galli S, 2003, CANCER RES, V63, P6370; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; Haynes V, 2003, IUBMB LIFE, V55, P599, DOI 10.1080/15216540310001628681; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; Kim MM, 2004, CLIN CANCER RES, V10, P8512, DOI 10.1158/1078-0432.CCR-04-0734; King T.E., 1967, METHODS ENZYMOL, P216, DOI DOI 10.1016/0076-6879(67)10043-8; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; MOELLERING H, 1966, ANAL BIOCHEM, V17, P369, DOI 10.1016/0003-2697(66)90172-2; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; Ramachandran A, 2004, P NATL ACAD SCI USA, V101, P384, DOI 10.1073/pnas.0304653101; Ramachandran A, 2002, FREE RADICAL BIO MED, V33, P1465, DOI 10.1016/S0891-5849(02)01142-5; REYNAFARJE B, 1985, ANAL BIOCHEM, V145, P406, DOI 10.1016/0003-2697(85)90381-1; Roediger WE, 2004, IUBMB LIFE, V56, P35, DOI 10.1080/15216540310001649822; Sarti P, 2003, IUBMB LIFE, V55, P605, DOI 10.1080/15216540310001628726; Schild L, 1996, ACTA OPHTHALMOL SCAN, V74, P354; SHEN WQ, 1995, CIRCULATION, V92, P3505, DOI 10.1161/01.CIR.92.12.3505; Shiva S, 2004, BIOCHEM J, V379, P359, DOI 10.1042/BJ20031758; TORRES J, 1995, BIOCHEM J, V312, P169, DOI 10.1042/bj3120169; WIECHELMAN KJ, 1988, ANAL BIOCHEM, V175, P231, DOI 10.1016/0003-2697(88)90383-1	36	38	38	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					145	+		10.1096/fj.05-3898fje	http://dx.doi.org/10.1096/fj.05-3898fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16246868				2022-12-28	WOS:000232991100009
J	Komarova, EA; Krivokrysenko, V; Wang, KH; Neznanov, N; Chernov, MV; Komarov, PG; Brennan, ML; Golovkina, TV; Rokhlin, O; Kuprash, DV; Nedospasov, SA; Hazen, SR; Feinstein, E; Gudkov, AV				Komarova, EA; Krivokrysenko, V; Wang, KH; Neznanov, N; Chernov, MV; Komarov, PG; Brennan, ML; Golovkina, TV; Rokhlin, O; Kuprash, DV; Nedospasov, SA; Hazen, SR; Feinstein, E; Gudkov, AV			p53 is a suppressor of inflammatory response in mice	FASEB JOURNAL			English	Article						inflammation; nuclear factor kappa B; cytokines	NF-KAPPA-B; RHEUMATOID-ARTHRITIS SYNOVIUM; AGE-ASSOCIATED DIFFERENCES; OXIDE SYNTHASE EXPRESSION; NITRIC-OXIDE; INDUCED APOPTOSIS; HELICOBACTER-PYLORI; GENE-EXPRESSION; BLADDER-CANCER; TNF-ALPHA	Chronic inflammation is known to promote cancer, suggesting that negative regulation of inflammation is likely to be tumor suppressive. We found that p53 is a general inhibitor of inflammation that acts as an antagonist of nuclear factor kappa B (NF kappa B). We first observed striking similarities in global gene expression profiles in human prostate cancer cells LNCaP transduced with p53 inhibitory genetic element or treated with TNF, suggesting that p53 inhibits transcription of TNF-inducible genes that are largely regulated by NF kappa B. Consistently, ectopically expressed p53 acts as an inhibitor of transcription of NF kappa B-dependent promoters. Furthermore, suppression of inflammatory response by p53 was observed in vivo in mice by comparing wild-type and p53 null animals at molecular (inhibition of transcription of genes encoding cytokines and chemokines, reducing accumulation of reactive oxygen species and protein oxidation products), cellular (activation of macrophages and neutrophil clearance) and organismal (high levels of metabolic markers of inflammation in tissues of p53-deficient mice and their hypersensitivity to LPS) levels. These observations indicate that p53, acting through suppression of NF kappa B, plays the role of a general "buffer" of innate immune response in vivo that is well consistent with its tumor suppressor function and frequent constitutive activation of NF kappa B in tumors.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Quark Biotech Inc, Fremont, CA USA; Cleveland BioLabs Inc, Cleveland, OH USA; Jackson Lab, Bar Harbor, ME 04609 USA; Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Lab Mol Immunol, Moscow, Russia; NCI, Mol Immunoregulat Lab, Ctr Canc Res, Frederick, MD 21701 USA; SAIC Frederick Inc, Frederick, MD 21701 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Jackson Laboratory; University of Iowa; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Gudkov, AV (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	gudkov@ccf.org	Nedospasov, Sergei/Q-7319-2016; Nedospasov, Sergei/J-5936-2013; Nedospasov, Sergei/C-3043-2018; Nedospasov, Sergei/L-1990-2015; Kuprash, Dmitry/O-4899-2015	Kuprash, Dmitry/0000-0002-1488-4148; Gudkov, Andrei/0000-0003-2548-0154	NCI NIH HHS [N01-CO-12400, CA75179, CA88071] Funding Source: Medline; DIVISION OF BASIC SCIENCES - NCI [Z01BC010601] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA088071, R01CA075179] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambs S, 1998, P NATL ACAD SCI USA, V95, P8823, DOI 10.1073/pnas.95.15.8823; Badawi AF, 1996, CANCER LETT, V105, P123, DOI 10.1016/0304-3835(96)04284-X; Celli A, 1998, SEMIN LIVER DIS, V18, P177, DOI 10.1055/s-2007-1007153; Chompret A, 2002, BIOCHIMIE, V84, P75, DOI 10.1016/S0300-9084(01)01361-X; Chorinchath BB, 1996, J IMMUNOL, V156, P1525; Coleman WB, 2003, CURR MOL MED, V3, P573, DOI 10.2174/1566524033479546; CORREA P, 1992, CANCER RES, V52, P6735; Davis DW, 2000, J EXP MED, V192, P857, DOI 10.1084/jem.192.6.857; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Drane P, 2002, CELL DEATH DIFFER, V9, P527, DOI 10.1038/sj.cdd.4400983; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Firestein GS, 1997, P NATL ACAD SCI USA, V94, P10895, DOI 10.1073/pnas.94.20.10895; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; Ghosh S, 2002, AM J RESP CRIT CARE, V166, P890, DOI 10.1164/rccm.2109094; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Gu LB, 2004, J BIOL CHEM, V279, P52141, DOI 10.1074/jbc.M407915200; Gu LB, 2002, BLOOD, V99, P3367, DOI 10.1182/blood.V99.9.3367; Guevara NV, 1999, NAT MED, V5, P335, DOI 10.1038/6585; Hibi K, 1997, AM J CLIN PATHOL, V108, P26; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Komarova EA, 2003, J BIOL CHEM, V278, P15465, DOI 10.1074/jbc.C300011200; KOMAROVA EA, 2005, IN PRESS ONCOGENE; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Kuwano K, 1996, AM J RESP CRIT CARE, V154, P477, DOI 10.1164/ajrccm.154.2.8756825; Lang SM, 1997, AM J GASTROENTEROL, V92, P2166; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Lu T, 2004, ONCOGENE, V23, P2138, DOI 10.1038/sj.onc.1207332; Lu T, 2004, P NATL ACAD SCI USA, V101, P7112, DOI 10.1073/pnas.0402048101; Merched AJ, 2003, ARTERIOSCL THROM VAS, V23, P1608, DOI 10.1161/01.ATV.0000084825.88022.53; Neznanov N, 2001, J VIROL, V75, P10409, DOI 10.1128/JVI.75.21.10409-10420.2001; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; Ohkusu-Tsukada K, 1999, J IMMUNOL, V163, P1966; OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3; Okuda Y, 2003, J NEUROIMMUNOL, V135, P29, DOI 10.1016/S0165-5728(02)00428-9; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rokhlin OW, 2000, ONCOGENE, V19, P1959, DOI 10.1038/sj.onc.1203453; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P248; Saito H, 2001, J BIOL CHEM, V276, P29307, DOI 10.1074/jbc.M103740200; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Shanahan F, 2003, ALIMENT PHARM THER, V18, P6, DOI 10.1046/j.1365-2036.18.s2.5.x; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Tateda K, 1996, INFECT IMMUN, V64, P769, DOI 10.1128/IAI.64.3.769-774.1996; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; van Vlijmen BJM, 2001, CIRC RES, V88, P780, DOI 10.1161/hh0801.089261; von der Thusen JH, 2002, CIRCULATION, V105, P2064, DOI 10.1161/01.CIR.0000015502.97828.93; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; WANG L, 1995, J BIOL CHEM, V270, P23159, DOI 10.1074/jbc.270.39.23159; WARREN W, 1995, CARCINOGENESIS, V16, P1181, DOI 10.1093/carcin/16.5.1181; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wichmann MW, 1996, J SURG RES, V65, P109, DOI 10.1006/jsre.1996.0351; Winterbourn CC, 2000, CURR OPIN HEMATOL, V7, P53, DOI 10.1097/00062752-200001000-00010; WU CQ, 1994, J INTERFERON RES, V14, P357, DOI 10.1089/jir.1994.14.357; Yamanishi Y, 2002, P NATL ACAD SCI USA, V99, P10025, DOI 10.1073/pnas.152333199; Yamanishi Y, 2002, AM J PATHOL, V160, P123, DOI 10.1016/S0002-9440(10)64356-8; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	62	180	193	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2005	19	6					1030	+		10.1096/fj.04-3213fje	http://dx.doi.org/10.1096/fj.04-3213fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15811878				2022-12-28	WOS:000228865300027
J	Wood, KC; Hebbel, RP; Granger, DN				Wood, KC; Hebbel, RP; Granger, DN			Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice	FASEB JOURNAL			English	Article						inflammation; thrombogenesis; hypoxia/reoxygenation; leukocyte-endothelial cell adhesion	OXYGEN RADICAL GENERATION; SUPEROXIDE-DISMUTASE; PLATELET; AUTOXIDATION; GLUTATHIONE; HEMOGLOBIN; ADHESION; DISEASE; MODEL; IRON	Although blood cell-endothelial cell adhesion and oxidative stress have been implicated in the pathogenesis of sickle cell disease (SCD), the nature of the linkage between these vascular responses in SCD remains unclear. The objective of this study was to determine whether superoxide derived from endothelial cell-associated NADPH oxidase mediates the leukocyte-endothelial (L/E) and platelet-endothelial cell (P/E) adhesion that is observed in the cerebral microvasculature of sickle cell transgenic (Ps) mice. Intravital fluorescence microscopy was used to monitor L/E and P/E adhesion in brain postcapillary venules of wild-type (WT), SOD1 transgenic (SOD1-TgN), and gp91phox (NADPH oxidase)-deficient mice that were transplanted with bone marrow from beta(s) mice. Hypoxia/reoxygenation (H/R) yielded intense P/E and L/E adhesion responses in cerebral venules of beta(s)/WT chimeras that were significantly attenuated in both beta(s)/SOD1-TgN, and beta(s)/gp91phox(-/-) chimeras. Pretreatment of beta(s)/WT chimeras with the iron-chelator desferroxamine blunted the blood cell-endothelial cell adhesion responses to H/R, whereas pretreatment with the xanthine oxidase inhibitor allopurinol had no effect. These findings suggest that superoxide derived from endothelial cell NADPH-oxidase and catalytically active iron contribute to the proinflammatory and prothrombogenic responses associated with sickle cell disease.	Louisiana State Univ, Hlth Sci Ctr, Dept Cellular & Mol Physiol, Shreveport, LA 71130 USA; Univ Minnesota, Sch Med, Vasc Biol Ctr, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Div Hematol Oncol Transplantat, Minneapolis, MN 55455 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Granger, DN (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Cellular & Mol Physiol, 1501 Kings Highway, Shreveport, LA 71130 USA.	dgrang@lsuhsc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL055552] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK043785] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL055552, P01-HL55552] Funding Source: Medline; NIDDK NIH HHS [P01-DK43785] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akgur FM, 2000, AM J PHYSIOL-HEART C, V279, pH791, DOI 10.1152/ajpheart.2000.279.2.H791; Aslan M, 2001, P NATL ACAD SCI USA, V98, P15215, DOI 10.1073/pnas.221292098; Ballas SK, 1998, BAILLIERE CLIN HAEM, V11, P185, DOI 10.1016/S0950-3536(98)80075-9; Browne P, 1998, FREE RADICAL BIO MED, V24, P1040, DOI 10.1016/S0891-5849(97)00391-2; DAS SK, 1980, BRIT J HAEMATOL, V44, P87, DOI 10.1111/j.1365-2141.1980.tb01186.x; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; Faraci FM, 2004, ARTERIOSCL THROM VAS, V24, P1367, DOI 10.1161/01.ATV.0000133604.20182.cf; Fukui T, 1997, CIRC RES, V80, P45, DOI 10.1161/01.RES.80.1.45; Gorlach A, 2000, CIRC RES, V87, P26, DOI 10.1161/01.RES.87.1.26; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Gurkan E, 2005, ANN HEMATOL, V84, P71, DOI 10.1007/s00277-004-0935-y; Harrison DG, 2003, J RENIN-ANGIO-ALDO S, V4, P51, DOI 10.3317/jraas.2003.014; HEBBEL RP, 1988, P NATL ACAD SCI USA, V85, P237, DOI 10.1073/pnas.85.1.237; HEBBEL RP, 1982, J CLIN INVEST, V70, P1253, DOI 10.1172/JCI110724; HEBBEL RP, 1985, CLIN HAEMATOL, V14, P129; Inwald DP, 2000, BRIT J HAEMATOL, V111, P474, DOI 10.1046/j.1365-2141.2000.02353.x; Ishikawa M, 2004, CIRC RES, V94, P239, DOI 10.1161/01.RES.0000111524.05779.60; JARASCH ED, 1986, ACTA PHYSIOL SCAND, V126, P39; Jeon BR, 2001, SHOCK, V15, P112, DOI 10.1097/00024382-200115020-00006; Kaul DK, 2000, J CLIN INVEST, V106, P411, DOI 10.1172/JCI9225; Kaul DK, 2004, AM J PHYSIOL-HEART C, V287, pH293, DOI 10.1152/ajpheart.01150.2003; MARVA E, 1994, BLOOD, V83, P242; Massberg S, 1998, BLOOD, V92, P507, DOI 10.1182/blood.V92.2.507; Noguchi CT, 2001, BLOOD CELL MOL DIS, V27, P971, DOI 10.1006/bcmd.2001.0469; Prass K, 2002, J CEREBR BLOOD F MET, V22, P520, DOI 10.1097/00004647-200205000-00003; REPKA T, 1991, BLOOD, V78, P2753; Rey FE, 2002, CIRCULATION, V106, P2497, DOI 10.1161/01.CIR.0000038108.71560.70; SAAD STO, 1991, NOUV REV FR HEMATOL, V33, P11; Tailor A, 2003, ARTERIOSCL THROM VAS, V23, P675, DOI 10.1161/01.ATV.0000056742.97580.79; TOMITA Y, 1994, BLOOD, V83, P939; Tsujikawa A, 2000, HYPERTENSION, V36, P250, DOI 10.1161/01.HYP.36.2.250; Turhan A, 2002, P NATL ACAD SCI USA, V99, P3047, DOI 10.1073/pnas.052522799; Walder CE, 1997, STROKE, V28, P2252, DOI 10.1161/01.STR.28.11.2252; Wood KC, 2004, AM J PHYSIOL-HEART C, V286, pH1608, DOI 10.1152/ajpheart.01056.2003; Wun T, 2002, CLIN LAB HAEMATOL, V24, P81	35	89	93	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					989	+		10.1096/fj.04-3218fje	http://dx.doi.org/10.1096/fj.04-3218fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15923406				2022-12-28	WOS:000227901300009
J	Waghray, M; Cui, ZB; Horowitz, JC; Subramanian, IM; Martinez, FJ; Toews, GB; Thannickal, VJ				Waghray, M; Cui, ZB; Horowitz, JC; Subramanian, IM; Martinez, FJ; Toews, GB; Thannickal, VJ			Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts	FASEB JOURNAL			English	Article						TGF-1 beta fibrosis; oxidative stress; tissue repair; apoptosis	TRANSFORMING GROWTH-FACTOR-BETA-1; UP-REGULATION; MEDIATED APOPTOSIS; LUNG FIBROBLASTS; MESSENGER-RNA; FAS LIGAND; EXPRESSION; TYROSINE; BETA; TRANSFORMING-GROWTH-FACTOR-BETA-1	Cell-cell signaling roles for reactive oxygen species (ROS) generated in response to growth factors/ cytokines in nonphagocytic cells are not well defined. In this study, we show that fibroblasts isolated from lungs of patients with idiopathic pulmonary fibrosis (IPF) generate extracellular hydrogen peroxide (H2O2) in response to the multifunctional cytokine, transforming growth factor beta 1 (TGF-beta 1). In contrast, TGF-beta 1 stimulation of small airway epithelial cells (SAECs) does not result in detectable levels of extracellular H2O2. IPF fibroblasts independently stimulated with TGF-beta 1 induce loss of viability and death of overlying SAECs when cocultured in a compartmentalized Transwell system. These effects on SAECs are inhibited by the addition of catalase to the coculture system or by the selective enzymatic blockade of H2O2 production by IPF fibroblasts. IPF fibroblasts heterogeneously express alpha-smooth muscle actin stress fibers, a marker of myofibroblast differentiation. Cellular localization of H2O2 by a fluorescent-labeling strategy demonstrated that extracellular secretion of H2O2 is specific to the myofibroblast phenotype. Thus, myofibroblast secretion of H2O2 functions as a diffusible death signal for lung epithelial cells. This novel mechanism for intercellular ROS signaling may be important in physiological/ pathophysiological processes characterized by regenerating epithelial cells and activated myofibroblasts.	Univ Michigan, Med Ctr, Dept Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Thannickal, VJ (corresponding author), Univ Michigan, Med Ctr, Dept Med, Div Pulm & Crit Care Med, 6301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	vjt@umich.edu	Horowitz, Jeffrey/AAY-7238-2021	Horowitz, Jeffrey/0000-0002-1505-2837	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL074024, R01HL067967] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, P646, DOI DOI 10.1164/AJRCCM.161.2.ATS3-00; Denning TL, 2002, FREE RADICAL BIO MED, V33, P1641, DOI 10.1016/S0891-5849(02)01141-3; Fujita T, 2002, AM J RESP CELL MOL, V27, P542, DOI 10.1165/rcmb.4775; Garcia-Trevijano ER, 1999, HEPATOLOGY, V29, P960, DOI 10.1002/hep.510290346; Geiser T, 2004, AM J PHYSIOL-LUNG C, V287, pL448, DOI 10.1152/ajplung.00177.2003; Goldkorn T, 1998, J CELL SCI, V111, P3209; Hagimoto N, 2002, J IMMUNOL, V168, P6470, DOI 10.4049/jimmunol.168.12.6470; Horowitz JC, 2004, J BIOL CHEM, V279, P1359, DOI 10.1074/jbc.M306248200; Iglesias-de la Cruz MC, 2001, KIDNEY INT, V59, P87, DOI 10.1046/j.1523-1755.2001.00469.x; Jiang Z, 2003, BIOCHEM BIOPH RES CO, V309, P961, DOI 10.1016/j.bbrc.2003.08.102; Jones DP, 2004, FASEB J, V18, P1246, DOI 10.1096/fj.03-0971fje; Kamsler A, 2004, MOL NEUROBIOL, V29, P167, DOI 10.1385/MN:29:2:167; Kazzaz JA, 1996, J BIOL CHEM, V271, P15182, DOI 10.1074/jbc.271.25.15182; Krysko O, 2004, APOPTOSIS, V9, P495, DOI 10.1023/B:APPT.0000031452.75162.75; Kuwano K, 2002, LAB INVEST, V82, P1695, DOI 10.1097/01.LAB.0000045084.81853.76; Kuwano K, 1999, AM J RESP CELL MOL, V20, P53, DOI 10.1165/ajrcmb.20.1.2941; Larios JM, 2001, J BIOL CHEM, V276, P17437, DOI 10.1074/jbc.M100426200; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Li WQ, 2004, FREE RADICAL BIO MED, V37, P196, DOI 10.1016/j.freeradbiomed.2004.04.028; Maeyama T, 2001, EUR RESPIR J, V17, P180, DOI 10.1183/09031936.01.17201800; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Thannickal VJ, 1998, J BIOL CHEM, V273, P23611, DOI 10.1074/jbc.273.36.23611; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Thannickal VJ, 2000, FASEB J, V14, P1741, DOI 10.1096/fj.99-0878com; Thannickal VJ, 1998, BIOCHEM BIOPH RES CO, V251, P437, DOI 10.1006/bbrc.1998.9443; Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Uhal BD, 2003, EUR RESPIR J, V22, p7S, DOI 10.1183/09031936.03.00000303; Uhal Bruce D., 1998, American Journal of Physiology, V275, pL1192; Wang RG, 1999, AM J PHYSIOL-LUNG C, V277, pL1158, DOI 10.1152/ajplung.1999.277.6.L1158; Wang RQ, 1999, AM J PHYSIOL-LUNG C, V277, pL1245, DOI 10.1152/ajplung.1999.277.6.L1245; Ye JP, 1999, J BIOL CHEM, V274, P34974, DOI 10.1074/jbc.274.49.34974	34	190	205	1	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					854	+		10.1096/fj.04-2882fje	http://dx.doi.org/10.1096/fj.04-2882fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15857893	Green Published			2022-12-28	WOS:000227591900012
J	Adusumilli, PS; Stiles, BM; Chan, MK; Eisenberg, DP; Yu, ZK; Stanziale, SF; Huq, R; Wong, RJ; Rusch, VW; Fong, YM				Adusumilli, Prasad S.; Stiles, Brendon M.; Chan, Mei-Ki; Eisenberg, David P.; Yu, Zhenkun; Stanziale, Stephen F.; Huq, Rumana; Wong, Richard J.; Rusch, Valerie W.; Fong, Yuman			Real-time diagnostic imaging of tumors and metastases by use of a replication-competent herpes vector to facilitate minimally invasive oncological surgery	FASEB JOURNAL			English	Article						oncolytic viral therapy; gene therapy; HSV; endoscopy	GREEN FLUORESCENT PROTEIN; ONCOLYTIC VIRAL THERAPY; LIGHT-EMITTING PROTEINS; GENE-THERAPY; CANCER; VISUALIZATION; BACTERIA; ANIMALS; MICE; CELL	Current efforts on expanding minimally invasive techniques into the realm of oncological surgery are hindered by lack of accurate visualization of tumor margins and failure to detect micro metastases in real time. We used a systemic delivery of a herpes viral vector with cancer-selective infection and replication to precisely differentiate between normal and malignant tissue. NV1066 is a genetically modified, replication-competent herpes simplex virus carrying a transgene for enhanced green fluorescent protein (GFP). We tested the potential of NV1066 in delineating tumor tissue in vitro and in vivo in a wide range of cancers and whether NV1066-induced GFP expression can detect small foci of tumors and metastases in in vivo models using an operating endoscope with fluorescent filters. Our findings indicate that NV1066 can be used for real-time intraoperative imaging and enhanced detection of early cancers and metastases. We demonstrate that a single dose of NV1066, administered either locally (intratumoral or intracavitary) or systemically, will detect loco-regional and distant disease throughout the body. Such cancer selectivity is confirmed in 110 types of cancer cells from 16 different primary organs. Fluorescence-aided minimally invasive endoscopy revealed microscopic tumor deposits unrecognized by conventional laparoscopy/ thoracoscopy. Furthermore, NV1066 ability to transit and infect tumor and metastases is proven in syngenic and transplanted tumors in different animal models, both immunocompetent and immunodeficient. Cancer-selective GFP expression is confirmed by histology, immunohistochemistry, and qRT-PCR. These studies form the basis for real-time, intraoperative diagnostic imaging of tumor and metastases by minimally invasive endoscopic technology.	Mem Sloan Kettering Canc Ctr, Dept Surg, Murray F Brennan Chair Surg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Mol Cytol Core Facil, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Fong, YM (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, Murray F Brennan Chair Surg, 1275 York Ave, New York, NY 10021 USA.	fongy@mskcc.org		Rusch, Valerie/0000-0003-2345-6900	NATIONAL CANCER INSTITUTE [R01CA075416, R01CA080982] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA075416, R01 CA 75416, R01 CA/DK80982] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JY, 2002, NAT MED, V8, P891, DOI 10.1038/nm743; Adusumilli PS, 2005, ANN THORAC SURG, V80, P409, DOI 10.1016/j.athoracsur.2005.01.048; Akporiaye ET, 1999, CURR OPIN MOL THER, V1, P443; Bennett JJ, 2001, NAT MED, V7, P859, DOI 10.1038/89991; Bennett JJ, 2004, FASEB J, V18, P1001, DOI 10.1096/fj.02-1080fje; Buunen M, 2004, SURG ENDOSC, V18, P1022, DOI 10.1007/s00464-003-9169-7; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; D'Angelica M, 2003, ANN SURG ONCOL, V10, P183, DOI 10.1245/ASO.2003.03.091; Everts M, 2004, CURR GENE THER, V4, P337; Green NK, 2002, CANCER GENE THER, V9, P1036, DOI 10.1038/sj.cgt.7700541; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Hoffman RM, 2005, NAT REV CANCER, V5, P796, DOI 10.1038/nrc1717; Kooby DA, 1999, FASEB J, V13, P1325, DOI 10.1096/fasebj.13.11.1325; Lal DR, 2005, SURG CLIN N AM, V85, P105, DOI 10.1016/j.suc.2004.09.008; Paquin A, 2001, HUM GENE THER, V12, P13, DOI 10.1089/104303401450924; Paraskeva P A, 2004, Semin Laparosc Surg, V11, P27, DOI 10.1177/107155170401100106; Stanziale SF, 2004, HUM GENE THER, V15, P609, DOI 10.1089/104303404323142051; Stiles BM, 2006, CANCER GENE THER, V13, P53, DOI 10.1038/sj.cgt.7700860; Stiles BM, 2003, SURGERY, V134, P357, DOI 10.1067/msy.2003.244; TSIEN RY, 2003, NAT REV MOL CELL BIO, V4, pSS16; Umeoka T, 2004, CANCER RES, V64, P6259, DOI 10.1158/0008-5472.CAN-04-1335; Wong RJ, 2002, HUM GENE THER, V13, P1213, DOI 10.1089/104303402320138998; Yang M, 2000, P NATL ACAD SCI USA, V97, P12278, DOI 10.1073/pnas.97.22.12278; Yu YA, 2003, ANAL BIOANAL CHEM, V377, P964, DOI 10.1007/s00216-003-2065-0; Yu YA, 2004, NAT BIOTECHNOL, V22, P313, DOI 10.1038/nbt937	25	41	45	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					726	+		10.1096/fj.05-5316fje	http://dx.doi.org/10.1096/fj.05-5316fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16467372	Green Accepted			2022-12-28	WOS:000237698700031
J	Hanley, WD; Napier, SL; Burdick, MM; Schnaar, RL; Sackstein, R; Konstantopoulos, K				Hanley, William D.; Napier, Susan L.; Burdick, Monica M.; Schnaar, Ronald L.; Sackstein, Robert; Konstantopoulos, Konstantinos			Variant isoforms of CD44 are P- and L-selectin ligands on colon carcinoma cells	FASEB JOURNAL			English	Article									[Hanley, William D.; Napier, Susan L.; Konstantopoulos, Konstantinos] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21205 USA; [Konstantopoulos, Konstantinos] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD USA; [Schnaar, Ronald L.] Johns Hopkins Univ, Sch Med, Dept Pharmacol, Baltimore, MD 21205 USA; [Burdick, Monica M.; Sackstein, Robert] Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA; [Sackstein, Robert] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Burdick, Monica M.; Sackstein, Robert] Harvard Univ, Sch Med, Harvard Skin Dis Res Ctr, Boston, MA USA; [Sackstein, Robert] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Konstantopoulos, K (corresponding author), Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21205 USA.	rsackstein@rics.bwh.harvard.edu; kkonsta1@jhu.edu	Thomas, Susan/B-4592-2016; Schnaar, Ronald L/S-8967-2016; Thomas, Susan/A-9947-2009; Konstantopoulos, Konstantinos/A-7045-2011	Schnaar, Ronald L/0000-0002-7701-5484; Thomas, Susan/0000-0003-4651-232X; Burdick, Monica/0000-0003-3168-0072	NCI NIH HHS [R01 CA 101135] Funding Source: Medline; NHLBI NIH HHS [R01 HL60528, R01 HL073714] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA101135] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073714, R01HL060528] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))			0	96	105	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					337	339		10.1096/fj.05-4574fje	http://dx.doi.org/10.1096/fj.05-4574fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16352650				2022-12-28	WOS:000207915000013
J	Jin, LM; Foss, CE; Zhao, XY; Mills, TM; Wang, MH; McCluskey, LP; Yaddanapud, GSS; Falck, JR; Imig, JD; Webb, RC				Jin, LM; Foss, CE; Zhao, XY; Mills, TM; Wang, MH; McCluskey, LP; Yaddanapud, GSS; Falck, JR; Imig, JD; Webb, RC			Cytochrome P450 epoxygenases provide a novel mechanism for penile erection	FASEB JOURNAL			English	Article						erectile dysfunction; epoxyeicosatrienoic acids; corpus cavernosum; smooth muscle	NITRIC-OXIDE SYNTHASE; FLOW-INDUCED DILATION; HYPERPOLARIZING FACTOR; ARACHIDONIC-ACID; CALCIUM DOBESILATE; DEPENDENT HYPERPOLARIZATION; EPOXYEICOSATRIENOIC ACIDS; GENE-TRANSFER; DYSFUNCTION; RELAXATION	Erectile dysfunction (ED) is estimated to affect more than 30 million American men and 152 million men worldwide. Therapeutic agents targeting the nitric oxide/cyclic GMP signaling pathway have successfully treated patients with ED; however, the efficacies of these treatments are significantly lower in specific populations such as patients with diabetes. The goal of this study was to discover and identify new endothelium-derived relaxing factors involved in the regulation of erectile function, providing alternative therapeutic targets for treatment of ED. Immunoblotting results showed that protein expressions of epoxygenases from cytochrome P450 (CYP) 2B, 2C and 2J subfamilies, as well as NADPH CYP reductase were present in rat corpora cavernosa, which was confirmed by immunohistochemical analysis. Furthermore, CYP2C was localized in cavernosal endothelial cells using double immunolabeling. CYP epoxygenase activity was analyzed by reverse-phase high-pressure liquid chromatography; and the results showed that 11,12- epoxyeicosatrienoic acid (EET) was the major product metabolized by CYP epoxygenases in rat corpora cavernosa. Inhibition of EETs function by injection of an EETs antagonist into rat penis significantly decreased intracavernosal pressure-induced by electrical stimulation of the major pelvic ganglion in vivo. In conclusion, our results suggest that EETs, produced by CYP epoxygenases, in penile endothelial cells serve as vasodilators. Inhibition of this pathway attenuated erectile function, suggesting that EETs are required for normal erection.	Johns Hopkins Univ, Dept Urol, Baltimore, MD 21287 USA; Med Coll Georgia, Dept Physiol, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Surg, Urol Sect, Augusta, GA 30912 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	Johns Hopkins University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Jin, LM (corresponding author), Johns Hopkins Univ, Dept Urol, 600 N Wolfe St, Baltimore, MD 21287 USA.	ljin8@jhmi.edu	Falck, John R/B-3030-2011	Falck, John R/0000-0002-9219-7845; McCluskey, Lynnette/0000-0003-1765-6068; Imig, John/0000-0002-9668-2899	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071138, P01HL074167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038226] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-74167, HL-71138] Funding Source: Medline; NIDDK NIH HHS [DK38226] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angulo J, 2003, BIOCHEM BIOPH RES CO, V312, P1202, DOI 10.1016/j.bbrc.2003.11.034; Angulo J, 2003, BRIT J PHARMACOL, V139, P854, DOI 10.1038/sj.bjp.0705293; Archer SL, 2003, CIRCULATION, V107, P769, DOI 10.1161/01.CIR.0000047278.28407.C2; Bauersachs J, 1996, CIRCULATION, V94, P3341, DOI 10.1161/01.CIR.94.12.3341; Bivalacqua TJ, 2003, J UROLOGY, V169, P1911, DOI 10.1097/01.ju.0000051881.14239.4a; Brandes RP, 2000, P NATL ACAD SCI USA, V97, P9747, DOI 10.1073/pnas.97.17.9747; Burnett AL, 2004, INT J IMPOT RES, V16, pS15, DOI 10.1038/sj.ijir.3901209; Burnett AL, 2002, J ANDROL, V23, P92, DOI 10.1002/j.1939-4640.2002.tb02601.x; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; CAPDEVILA J, 1981, BIOCHEM BIOPH RES CO, V101, P1357, DOI 10.1016/0006-291X(81)91597-7; Champion HC, 1999, P NATL ACAD SCI USA, V96, P11648, DOI 10.1073/pnas.96.20.11648; Chitaley K, 2001, NAT MED, V7, P119, DOI 10.1038/83258; DAIKH BE, 1994, J PHARMACOL EXP THER, V271, P1427; de Tejada IS, 2002, DIABETES CARE, V25, P2159; DROLLER MJ, 1993, JAMA-J AM MED ASSOC, V270, P83; DUBE S, 2004, AM J PHYSIOL-HEART C, V280, pH2581; Fisslthaler B, 2001, HYPERTENSION, V38, P1427, DOI 10.1161/hy1201.096532; Gauthier KM, 2002, CIRC RES, V90, P1028, DOI 10.1161/01.RES.0000018162.87285.F8; Goldstein I, 2003, DIABETES CARE, V26, P777, DOI 10.2337/diacare.26.3.777; Gonzalez-Cadavid NF, 2004, EXP GERONTOL, V39, P1705, DOI 10.1016/j.exger.2004.06.022; Gonzalgo ML, 2003, J UROLOGY, V170, P503, DOI 10.1097/01.ju.0000071478.69480.fd; Huang A, 2005, CIRC RES, V96, P376, DOI 10.1161/01.RES.0000155332.17783.26; Huang A, 2004, CIRC RES, V94, P245, DOI 10.1161/01.RES.0000111525.96232.46; Huang A, 2001, AM J PHYSIOL-HEART C, V280, pH2462, DOI 10.1152/ajpheart.2001.280.6.H2462; Jin LM, 2004, AM J PHYSIOL-HEART C, V287, pH1495, DOI 10.1152/ajpheart.01006.2003; Lin CS, 2002, BJU INT, V89, P955, DOI 10.1046/j.1464-410X.2002.02792.x; McKinlay JB, 2000, INT J IMPOT RES, V12, pS6, DOI 10.1038/sj.ijir.3900567; Miura H, 2001, CIRCULATION, V103, P1992; Mizusawa H, 2001, BRIT J PHARMACOL, V132, P1333, DOI 10.1038/sj.bjp.0703938; Nishikawa Y, 2000, AM J PHYSIOL-HEART C, V279, pH459, DOI 10.1152/ajpheart.2000.279.2.H459; Podlasek CA, 2001, J UROLOGY, V166, P746, DOI 10.1016/S0022-5347(05)66054-5; Popp R, 1998, CIRC RES, V82, P696, DOI 10.1161/01.RES.82.6.696; Price DE, 1998, DIABETIC MED, V15, P821, DOI 10.1002/(SICI)1096-9136(199810)15:10<821::AID-DIA697>3.0.CO;2-P; Rendell MS, 1999, JAMA-J AM MED ASSOC, V281, P421, DOI 10.1001/jama.281.5.421; Roman RJ, 2002, PHYSIOL REV, V82, P131, DOI 10.1152/physrev.00021.2001; Rota R, 2004, EUR J PHARMACOL, V495, P217, DOI 10.1016/j.ejphar.2004.05.019; Ruiz E, 1997, BRIT J PHARMACOL, V121, P711, DOI 10.1038/sj.bjp.0701184; Shimokawa H, 1996, J CARDIOVASC PHARM, V28, P703, DOI 10.1097/00005344-199611000-00014; Stanarius A, 2001, UROL RES, V29, P168, DOI 10.1007/s002400100181; Udosen IT, 2003, AM J PHYSIOL-HEART C, V285, pH2054, DOI 10.1152/ajpheart.00075.2003; Urakami-Harasawa L, 1997, J CLIN INVEST, V100, P2793, DOI 10.1172/JCI119826; Vickers MA, 2002, INT J IMPOT RES, V14, P466, DOI 10.1038/sj.ijir.3900910; Wang H, 2003, J PHARMACOL EXP THER, V307, P753, DOI 10.1124/jpet.103.052787; Wang MH, 1998, J PHARMACOL EXP THER, V284, P966	44	18	18	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					539	+		10.1096/fj.05-4341fje	http://dx.doi.org/10.1096/fj.05-4341fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16415108				2022-12-28	WOS:000235996000016
J	Leger, B; Vergani, L; Soraru, G; Hespel, P; Derave, W; Gobelet, C; D'Ascenzio, C; Angelini, C; Russell, AP				Leger, B; Vergani, L; Soraru, G; Hespel, P; Derave, W; Gobelet, C; D'Ascenzio, C; Angelini, C; Russell, AP			Human skeletal muscle atrophy in amyotrophic lateral sclerosis reveals a reduction in Akt and an increase in atrogin-1	FASEB JOURNAL			English	Article						E3 ligase; neurodegenerative disease	TRANSCRIPTION FACTORS; UBIQUITIN LIGASES; MESSENGER-RNAS; EXPRESSION; INSULIN; ACTIVATION; PATHWAY; KINASE; GROWTH; GENES	The molecular mechanisms influencing muscle atrophy in humans are poorly understood. Atrogin-1 and MuRF1, two ubiquitin E3-ligases, mediate rodent and cell muscle atrophy and are suggested to be regulated by an Akt/Forkhead (FKHR) signaling pathway. Here we investigated the expression of atrogin-1, MuRF1, and the activity of Akt and its catabolic (FKHR and FKHRL1) and anabolic (p70(s6k) and GSK-3 beta) targets in human skeletal muscle atrophy. The muscle atrophy model used was amyotrophic lateral sclerosis (ALS). All measurements were performed in biopsies from 22 ALS patients and 16 healthy controls as well as in G93A ALS mice. ALS patients had a significant increase in atrogin-1 mRNA and protein content, which was associated with a decrease in Akt activity. There was no difference in the mRNA and protein content of FKHR, FKHRL1, p70(s6k), and GSK-3 beta. Similar observations were made in the G93A ALS mice. Human skeletal muscle atrophy, as seen in the ALS model, is associated with an increase in atrogin-1 and a decrease in Akt. The transcriptional regulation of human atrogin-1 may be controlled by an Akt-mediated transcription factor other than FKHR or via another signaling pathway.	Clin Romande Readaptat SuvaCare, CH-1951 Sion, Switzerland; Univ Padua, Dipartimento Sci Neurol, Ist Veneto Med Mol, I-35129 Padua, Italy; Katholieke Univ Leuven, Fac Kinesiol & Rehabil Sci, Res Ctr Exercise & Hlth, B-3001 Heverlee, Belgium	University of Padua; Veneto Institute Molecular Medicine; KU Leuven	Russell, AP (corresponding author), Clin Romande Readaptat SuvaCare, Av Gd Champsec 90, CH-1951 Sion, Switzerland.	aaron.russell@crr-suva.ch	Léger, Bertrand/AAK-4356-2020; Derave, Wim/B-2554-2014; Sorarù, Gianni/AAB-8891-2019; Angelini, Corrado I/J-3655-2019	Derave, Wim/0000-0002-2225-5587; Angelini, Corrado I/0000-0002-9554-8794; Soraru, Gianni/0000-0001-9691-6328; Leger, Bertrand/0000-0003-2782-1442; Hespel, Peter/0000-0003-1283-2229; Russell, Aaron/0000-0002-7323-9501	Telethon [GTF02009] Funding Source: Medline	Telethon(Fondazione Telethon)		Blough E, 1999, BIOTECHNIQUES, V26, P202, DOI 10.2144/99262bm05; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629; Cartoni R, 2005, J PHYSIOL-LONDON, V567, P349, DOI 10.1113/jphysiol.2005.092031; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Dehoux M, 2004, ENDOCRINOLOGY, V145, P4806, DOI 10.1210/en.2004-0406; Dehoux MJM, 2003, FEBS LETT, V544, P214, DOI 10.1016/S0014-5793(03)00505-2; Derave W, 2003, NEUROBIOL DIS, V13, P264, DOI 10.1016/S0969-9961(03)00041-X; Di Giovanni S, 2004, ANN NEUROL, V55, P195, DOI 10.1002/ana.10811; Dubowitz V., 1985, MUSCLE BIOPSY PRACTI; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Jefferson LS, 1999, INT J BIOCHEM CELL B, V31, P191, DOI 10.1016/S1357-2725(98)00141-1; Jones SW, 2004, FASEB J, V18, P1025, DOI 10.1096/fj.03-1228fje; Kumamoto T, 2000, ACTA NEUROPATHOL, V100, P595, DOI 10.1007/s004010000229; Lai KMV, 2004, MOL CELL BIOL, V24, P9295, DOI 10.1128/MCB.24.21.9295-9304.2004; Latres E, 2005, J BIOL CHEM, V280, P2737, DOI 10.1074/jbc.M407517200; Lecker SH, 1999, J NUTR, V129, p227S, DOI 10.1093/jn/129.1.227S; Lee SW, 2004, J AM SOC NEPHROL, V15, P1537, DOI 10.1097/01.ASN.0000127211.86206.E1; Li YP, 2005, FASEB J, V19, P362, DOI 10.1096/fj.04-2364com; Li YP, 2003, AM J PHYSIOL-CELL PH, V285, pC806, DOI 10.1152/ajpcell.00129.2003; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; Lynch G S, 2001, Exerc Sport Sci Rev, V29, P141, DOI 10.1097/00003677-200110000-00002; McGee SL, 2003, DIABETES, V52, P926, DOI 10.2337/diabetes.52.4.926; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; Nikawa T, 2004, FASEB J, V18, P522, DOI 10.1096/fj.03-0419fje; Pallafacchina G, 2002, P NATL ACAD SCI USA, V99, P9213, DOI 10.1073/pnas.142166599; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; RUSSELL AP, 2005, FASEB J; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; SWASH M, 1999, CLIN FEATURES DIAGNO; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; Welsh GI, 1997, FEBS LETT, V410, P418, DOI 10.1016/S0014-5793(97)00579-6; Zinna EM, 2003, CURR OPIN CLIN NUTR, V6, P87, DOI 10.1097/00075197-200301000-00013	41	109	115	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					583	+		10.1096/fj.05-5249fje	http://dx.doi.org/10.1096/fj.05-5249fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16507768				2022-12-28	WOS:000235996000015
J	Soteriades, ES; Rosmarakis, ES; Paraschakis, K; Falagas, ME				Soteriades, ES; Rosmarakis, ES; Paraschakis, K; Falagas, ME			Research contribution of different world regions in the top 50 biomedical journals (1995-2002)	FASEB JOURNAL			English	Article						research productivity; world regions; top journals; publications' quality	EUROPEAN-UNION; IMPACT FACTORS; PUBLICATIONS; GEOGRAPHY; SCIENCE; INDEXES	We evaluated all articles published by different world regions in the top 50 biomedical journals in the database of the Journal Citation Reports-Institute for Scientific Information for the period between 1995 and 2002. The world was divided into 9 regions [United States of America (the U. S.), Western Europe, Japan, Canada, Asia, Oceania, Latin America, and the Caribbean, Eastern Europe, and Africa] based on a combination of geographic, economic and scientific criteria. The number of articles published by each region, the mean impact factor, and the product of the above two parameters were our main indicators. The above numbers were also adjusted for population size, gross national income per capita of each region, and other factors. Articles published from the U. S. made up about two-thirds of all scientific papers published in the top 50 biomedical journals between 1995 and 2002. Western Europe contributed approximately a quarter of the published papers while the remaining one-tenth of articles came from the rest of the world. Canada, however, ranked second when number of articles was adjusted for population size. The U. S. is by far the highest-ranking country/region in publications in the top 50 biomedical journals even after adjusting for population size, gross national product, and other factors. Canada and Western Europe share the second place while the rest of the world is far behind. Soteriades, E. S., Rosmarakis, E. S., Paraschakis, K., Falagas, M. E. Research contribution of different world regions in the top 50 biomedical journals (1995-2002).	Alfa Inst Biomed Sci, Maroussi 15123, Greece; Cyprus Int Inst Environm & Publ Hlth, Nicosia, Cyprus; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA	Alfa Institute Of Biomedical Sciences; Cyprus International Institute for Environmental & Public Health; Tufts University	Falagas, ME (corresponding author), Alfa Inst Biomed Sci, 9 Neapoleos St, Maroussi 15123, Greece.	matthew.falagas@tufts.edu						Benner Mats, 2004, Aust Health Rev, V28, P161; BENZER A, 1993, LANCET, V341, P247, DOI 10.1016/0140-6736(93)90116-X; Coates R, 2002, CARDIOVASC RES, V53, P279, DOI 10.1016/S0008-6363(01)00530-2; Gallagher EJ, 1998, ANN EMERG MED, V31, P83, DOI 10.1016/S0196-0644(98)70286-0; GARFIELD E, 1955, SCIENCE, V122, P108, DOI 10.1126/science.122.3159.108; Hefler L, 1999, LANCET, V353, P1856, DOI 10.1016/S0140-6736(99)01278-7; *I SCI INF, 2004, SCI CIT IND J CIT RE; Keiser J, 2004, BMJ-BRIT MED J, V328, P1229, DOI 10.1136/bmj.38069.518137.F6; LUUKKONEN T, 1990, ANN MED, V22, P145, DOI 10.3109/07853899009147259; Mela GS, 2003, EUR RADIOL, V13, P657, DOI 10.1007/s00330-002-1640-7; *NAT LIB MED, 2004, IND MED DAT PUBM; Neuberger J, 2002, EUR J GASTROEN HEPAT, V14, P209, DOI 10.1097/00042737-200203000-00001; Rahman M, 2003, PUBLIC HEALTH, V117, P274, DOI 10.1016/S0033-3506(03)00068-4; Rosmarakis ES, 2005, INT J CARDIOL, V100, P443, DOI 10.1016/j.ijcard.2004.11.005; Saravia NG, 2004, B WORLD HEALTH ORGAN, V82, P608; Seglen PO, 1997, BRIT MED J, V314, P498; Thompson DF, 1999, NEW ENGL J MED, V340, P817, DOI 10.1056/NEJM199903113401020; Ugolini D, 2003, EUR J CANCER, V39, P1888, DOI 10.1016/S0959-8049(03)00431-3; VERGIDIS PI, 2005, IN PRESS EUR J CLIN; Whitehouse GH, 2002, EUR RADIOL, V12, P715, DOI 10.1007/s00330-001-1212-2; *WORLD BANK, 2004, WORLD DEV IND 2002; 2004, UN STAT YB	22	44	46	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					29	34		10.1096/fj.05-4711lsf	http://dx.doi.org/10.1096/fj.05-4711lsf			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16394264				2022-12-28	WOS:000235996000041
J	Yang, G; Wu, LY; Wang, R				Yang, G; Wu, LY; Wang, R			Pro-apoptotic effect of endogenous H2S on human aorta smooth muscle cells	FASEB JOURNAL			English	Article						cystathionine gamma-lyase; proliferation; MAPK; cell cycle protein	CYSTATHIONINE-GAMMA-LYASE; HYDROGEN-SULFIDE; RAT; INHIBITION; EXPRESSION; KINASES; PROLIFERATION; HYPERTENSION; PATHOGENESIS; MODULATION	Cystathionine gamma-lyase (CSE) is a key enzyme in the trans-sulfuration pathway, which uses L-cysteine to produce hydrogen sulfide (H2S). The CSE/H2S system has been shown to play an important role in regulating cellular functions in different systems. In the present study, we overexpressed CSE in human aorta smooth muscle cells (HASMCs) using a recombinant defective adenovirus containing CSE gene (Ad-CSE). Infection of HASMCs with Ad-CSE resulted in a significant increase in the expression of CSE protein and H2S production. Ad-CSE transfection inhibited cell growth and stimulated apoptosis, as evidenced by cell viability assay, Hoechst 33258 staining, TUNEL, and caspase 3 activation. CSE-mediated apoptosis was associated with an increased ERK and p38 MAPK activation, up-regulation of p21(Cip/WAK-1), and down-regulation of cyclin D1 expression. After inhibiting endogenous background CSE gene expression, direct administration of H2S at 100 mu M induced apoptosis of HASMCs. The other two endproducts of CSE-catalyzed enzymatic reaction, ammonium and pyruvate, failed to do so. These results demonstrate that overexpression of CSE stimulates SMC apoptosis due to an increased endogenous production of H2S. Adenovirus-mediated transfer of CSE gene may provide a novel therapeutic approach in treating vascular diseases linked to abnormal cellular proliferation and vascular remodeling.	Univ Saskatchewan, Coll Med, Dept Physiol, Saskatoon, SK S7N 0W0, Canada; Univ Saskatchewan, Coll Med, Dept Pharmacol, Saskatoon, SK S7N 0W0, Canada	University of Saskatchewan; University of Saskatchewan	Wang, R (corresponding author), Lakehead Univ, 955 Oliver Rd, Thunder Bay, ON P7B 5E1, Canada.	rwang@lakeheadu.ca	Wang, Rui/C-7824-2012; Yang, Guangdong/G-4129-2011	Wang, Rui/0000-0003-3825-3620; 				Barber T, 1999, J NUTR, V129, P928, DOI 10.1093/jn/129.5.928; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Deplancke B, 2003, FASEB J, V17, P1310, DOI 10.1096/fj.02-0883fje; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; ERICKSON PF, 1990, BIOCHEM J, V269, P335, DOI 10.1042/bj2690335; Eto K, 2002, J NEUROCHEM, V83, P80, DOI 10.1046/j.1471-4159.2002.01097.x; Geng B, 2004, BIOCHEM BIOPH RES CO, V318, P756, DOI 10.1016/j.bbrc.2004.04.094; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hershenson MB, 1997, CAN J PHYSIOL PHARM, V75, P898, DOI 10.1139/cjpp-75-7-898; Hou YZ, 2004, EUR J PHARMACOL, V499, P85, DOI 10.1016/j.ejphar.2004.07.107; Hui Y, 2003, J INFECTION, V47, P155, DOI 10.1016/S0163-4453(03)00043-4; Ishii I, 2004, BIOCHEM J, V381, P113, DOI 10.1042/BJ20040243; KERY V, 1994, J BIOL CHEM, V269, P25283; Kobayashi T, 2004, BIOL PHARM BULL, V27, P587, DOI 10.1248/bpb.27.587; Mason DP, 1999, CIRC RES, V85, P1179; Mok YYP, 2004, BRIT J PHARMACOL, V143, P881, DOI 10.1038/sj.bjp.0706014; NISHI N, 1994, J BIOL CHEM, V269, P1015; Park WH, 2003, INT J ONCOL, V23, P197; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sun XF, 2004, BIOCHEM PHARMACOL, V67, P147, DOI 10.1016/j.bcp.2003.08.041; Todd DE, 2004, ONCOGENE, V23, P3284, DOI 10.1038/sj.onc.1207467; Ullmannova V, 2003, LEUKEMIA RES, V27, P1115, DOI 10.1016/S0145-2126(03)00103-6; Wang R, 2003, ANTIOXID REDOX SIGN, V5, P493, DOI 10.1089/152308603768295249; Wang R, 2002, FASEB J, V16, P1792, DOI 10.1096/fj.02-0211hyp; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yan H, 2004, BIOCHEM BIOPH RES CO, V313, P22, DOI 10.1016/j.bbrc.2003.11.081; Yang GD, 2004, FASEB J, V18, P1782, DOI 10.1096/fj.04-2279fje; Yang GD, 2004, J BIOL CHEM, V279, P49199, DOI 10.1074/jbc.M408997200; Zhang CY, 2003, BIOCHEM BIOPH RES CO, V302, P810, DOI 10.1016/S0006-291X(03)00256-0; Zhao WM, 2003, CAN J PHYSIOL PHARM, V81, P848, DOI 10.1139/Y03-077; Zhao WM, 2002, AM J PHYSIOL-HEART C, V283, pH474, DOI 10.1152/ajpheart.00013.2002; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008; Zhong GZ, 2003, J HYPERTENS, V21, P1879, DOI 10.1097/00004872-200310000-00015	35	263	281	1	35	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					553	+		10.1096/fj.05-4712fje	http://dx.doi.org/10.1096/fj.05-4712fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16507767				2022-12-28	WOS:000235996000014
J	Zhang, JP; Wang, Y; Chu, YW; Su, LP; Gong, YP; Zhang, RH; Xiong, SD				Zhang, JP; Wang, Y; Chu, YW; Su, LP; Gong, YP; Zhang, RH; Xiong, SD			Agrin is involved in lymphocytes activation that is mediated by alpha-dystroglycan	FASEB JOURNAL			English	Article						agrin; alpha-dystroglycan; immunological synapse; lymphocyte activation	IMMUNOLOGICAL SYNAPSE FORMATION; T-CELL-ACTIVATION; DYSTROPHIN-ASSOCIATED GLYCOPROTEINS; TORPEDO ELECTRIC ORGAN; BETA-DYSTROGLYCAN; ACETYLCHOLINE-RECEPTORS; EXTRACELLULAR-MATRIX; MUTANT MICE; COSTIMULATION; IDENTIFICATION	It is well established that agrin, an extracellular matrix protein, plays a crucial role in the formation of neuromuscular junctions. Recent evidence indicates that agrin also contributes to immunological synapse formation. However, little is known about how agrin induces the activation of lymphocytes and whose receptors mediate its regulatory effects on these cells. In the present study, agrin was detected in lymphocytes. Up-regulation of agrin expression was involved in lymphocyte activation whereas down-regulation of its expression led to inhibition of both antigen-specific and nonspecific lymphocyte activation, indicating an intrinsic role for agrin in the activation of lymphocytes. Unexpectedly, unlike that found in muscle cells where there is coexpression of muscle-specific kinase (MuSK) and alpha-dystroglycan receptors for agrin, only alpha-dystroglycan could be detected in lymphocytes. Confocal examination showed that alpha-dystroglycan colocalized with agrin in forming the immunological synapse. Down-regulation of alpha-dystroglycan expression inhibited lymphocyte activation even in the presence of agrin. However, agrin involved in down-regulation of alpha-dystroglycan receptors did not increase the inhibitory effect on lymphocytes activation. The anti-alpha-dystroglycan antibody also induced lymphocytes activation. Taken together, these findings strongly indicate that agrin and alpha-dystroglycan mediate lymphocyte activation. Furthermore, agrin-involved lymphocyte activation is mediated by alpha-dystroglycan.-Zhang, J., Wang, Y., Chu, Y., Su, L., Gong, Y., Zhang, R., Xiong, S. Agrin is involved in lymphocytes activation that is mediated by alpha-dystroglycan.	Fudan Univ, Shanghai Med Coll, Dept Immunol, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China; Fudan Univ, Shanghai Med Coll, Key Lab Mol Med, Minist Educ, Shanghai 200032, Peoples R China; Shanghai Univ E Inst, Div Immunol, Shanghai, Peoples R China	Fudan University; Fudan University	Xiong, SD (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Immunol, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China.	sdxiongfd@126.com						Andres PG, 2004, J IMMUNOL, V172, P5880, DOI 10.4049/jimmunol.172.10.5880; Bezakova G, 2003, NAT REV MOL CELL BIO, V4, P295, DOI 10.1038/nrm1074; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; Bromley SK, 2002, IMMUNOLOGY, V106, P289, DOI 10.1046/j.1365-2567.2002.01441.x; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Bromley SK, 2001, NAT IMMUNOL, V2, P1159, DOI 10.1038/ni737; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; Cote PD, 1999, NAT GENET, V23, P338, DOI 10.1038/15519; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Friedl P, 2004, TRENDS CELL BIOL, V14, P557, DOI 10.1016/j.tcb.2004.09.005; Friedl P, 2002, IMMUNOL REV, V186, P83, DOI 10.1034/j.1600-065X.2002.18608.x; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; Gingras J, 2002, J CELL BIOL, V158, P1109, DOI 10.1083/jcb.200203012; GODFREY EW, 1984, J CELL BIOL, V99, P615, DOI 10.1083/jcb.99.2.615; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Hailman E, 2002, IMMUNITY, V16, P839, DOI 10.1016/S1074-7613(02)00326-6; Herbst R, 2002, DEVELOPMENT, V129, P5449, DOI 10.1242/dev.00112; Huppa JB, 2003, NAT REV IMMUNOL, V3, P973, DOI 10.1038/nri1245; IBRAGHIMOVBESKROVNAYA O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Ilsley JL, 2001, CELL SIGNAL, V13, P625, DOI 10.1016/S0898-6568(01)00188-7; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Jacobson C, 1998, J NEUROSCI, V18, P6340; James M, 2000, J CELL SCI, V113, P1717; Kahl J, 2003, J NEUROSCI, V23, P392, DOI 10.1523/JNEUROSCI.23-02-00392.2003; Khan AA, 2001, SCIENCE, V292, P1681, DOI 10.1126/science.1056594; Kiefer F, 2002, TRANSPL IMMUNOL, V9, P69, DOI 10.1016/S0966-3274(02)00009-6; Krogsgaard M, 2003, SEMIN IMMUNOL, V15, P307, DOI 10.1016/j.smim.2003.09.002; Lee KH, 2002, SCIENCE, V295, P1539, DOI 10.1126/science.1067710; Maldonado RA, 2004, NATURE, V431, P527, DOI 10.1038/nature02916; Miceli MC, 2001, SEMIN IMMUNOL, V13, P115, DOI 10.1006/smim.2000.0303; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; OPENSHAW P, 1995, J EXP MED, V182, P1357, DOI 10.1084/jem.182.5.1357; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Phillips WD, 1995, CLIN EXP PHARMACOL P, V22, P961, DOI 10.1111/j.1440-1681.1995.tb02333.x; Richie LI, 2002, IMMUNITY, V16, P595, DOI 10.1016/S1074-7613(02)00299-6; Salgado FJ, 2003, J BIOL CHEM, V278, P24849, DOI 10.1074/jbc.M212978200; Sambrook J., MOL CLONING LAB MANU; Samstag Y, 2003, J LEUKOCYTE BIOL, V73, P30, DOI 10.1189/jlb.0602272; Schwartz JCD, 2002, NAT IMMUNOL, V3, P427, DOI 10.1038/ni0502-427; Sciandra F, 2001, EUR J BIOCHEM, V268, P4590, DOI 10.1046/j.1432-1327.2001.02386.x; Shaw AS, 2001, NAT IMMUNOL, V2, P575, DOI 10.1038/89712; Tseng SY, 2002, CURR OPIN CELL BIOL, V14, P575, DOI 10.1016/S0955-0674(02)00370-8; WALLACE BG, 1989, J NEUROSCI, V9, P1294; Wang DH, 2004, MOL CELL BIOL, V24, P164, DOI 10.1128/MCB.24.1.164-171.2003; Wetzel SA, 2002, J IMMUNOL, V169, P6092, DOI 10.4049/jimmunol.169.11.6092; Wulfing C, 2002, NAT IMMUNOL, V3, P42, DOI 10.1038/ni741	49	31	35	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					50	58		10.1096/fj.04-3303com	http://dx.doi.org/10.1096/fj.04-3303com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16394267				2022-12-28	WOS:000235996000044
J	Hill, M; Pereira, V; Chauveau, C; Zagani, R; Remy, S; Tesson, L; Mazal, D; Ubillos, L; Brion, R; Ashgar, K; Mashreghi, MF; Kotsch, K; Moffett, J; Doebis, C; Seifert, M; Boczkowski, J; Osinaga, E; Anegon, I				Hill, M; Pereira, V; Chauveau, C; Zagani, R; Remy, S; Tesson, L; Mazal, D; Ubillos, L; Brion, R; Ashgar, K; Mashreghi, MF; Kotsch, K; Moffett, J; Doebis, C; Seifert, M; Boczkowski, J; Osinaga, E; Anegon, I			Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2,3-dioxygenase	FASEB JOURNAL			English	Article						HO-1; IDO; breast cancer; apoptosis; proliferation	NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE CELLS; DENDRITIC CELLS; TRYPTOPHAN DEGRADATION; EPITHELIAL-CELLS; GENE-TRANSFER; SOLID TUMOR; T-CELLS; EXPRESSION; APOPTOSIS	Heme oxygenase-1 (HO-1) is the rate limiting enzyme of heme catabolism whereas indoleamine 2,3 dioxygenase (IDO) catabolizes tryptophan through the kynurenine pathway. We analyzed the expression and biological effects of these enzymes in rat and human breast cancer cell lines. We show that rat (NMU and 13762) but not human cells (MCF-7 and T47D) express HO-1. When overexpressed, we found this enzyme to have anti-proliferative and proapoptotic effects by antioxidant mechanisms in these four cell lines. We show that IDO is expressed by rat and human breast cancer cells. IDO inhibition with 1-MT and siRNA leads to diminished proliferation in rat cells. In contrast, HO-1 negative human cell lines increase proliferation upon IDO inhibition. Since we also demonstrate that IDO inhibits the anti-proliferative HO-1, we propose that IDO has opposite effects on proliferation depending on the coexpression or not of HO-1. We also describe that HO-1 inhibits IDO at the post-translational level through heme starvation. In vivo, we show that rat normal breast expresses HO-1 and IDO. In contrast, N-nitrosomethylurea-induced breast adenocarcinomas only express IDO. In conclusion, we show that HO-1/IDO cross-regulation modulates apoptosis and proliferation in rat and human breast cancer cells.	INSERM, U643, ITERT, F-44093 Nantes 1, France; Fac Med, Dept Bioquim, Lab Oncol Basica & Biol Mol, Montevideo, Uruguay; Charite Hosp, Inst Med Immunol, Berlin, Germany; Uniformed Serv Univ Hlth Sci, Dept Anat, Bethesda, MD 20814 USA; INSERM, U408, Fac Med Xavier Bichat, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universidad de la Republica, Uruguay; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Uniformed Services University of the Health Sciences - USA; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Anegon, I (corresponding author), INSERM, U643, ITERT, 30 Bv Jean Monnet, F-44093 Nantes 1, France.	ianegon@nantes.inserm.fr	Anegon, Ignacio/I-7760-2018; Kotsch, Katja/AAG-2597-2021; Boczkowski, Jorge/S-7474-2018; Mashreghi, Mir-Farzin/S-2911-2019	Boczkowski, Jorge/0000-0001-6619-5785; Mashreghi, Mir-Farzin/0000-0002-8015-6907; Hill, Marcelo/0000-0002-1589-0320				BLOXAM DL, 1974, ANAL BIOCHEM, V60, P621, DOI 10.1016/0003-2697(74)90275-9; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Brown NS, 2001, BREAST CANCER RES, V3, P323, DOI 10.1186/bcr315; Burdick AD, 2003, CANCER RES, V63, P7825; CADY SG, 1991, ARCH BIOCHEM BIOPHYS, V291, P326, DOI 10.1016/0003-9861(91)90142-6; Chauveau C, 2002, AM J TRANSPLANT, V2, P581, DOI 10.1034/j.1600-6143.2002.20702.x; Chen GG, 2004, J CELL BIOCHEM, V92, P1246, DOI 10.1002/jcb.20157; CHOI SY, 1996, J PARODONTOL IMPLANT, V15, P19; COHEN LA, 1982, IN VITRO CELL DEV B, V18, P565; DRUMMOND GS, 1981, P NATL ACAD SCI-BIOL, V78, P6466, DOI 10.1073/pnas.78.10.6466; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fallarino F, 2002, INT IMMUNOL, V14, P65, DOI 10.1093/intimm/14.1.65; Fang J, 2003, CANCER RES, V63, P3567; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Haider A, 2002, J PHARMACOL EXP THER, V300, P188, DOI 10.1124/jpet.300.1.188; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hill M, 2004, BREAST CANCER RES TR, V84, P107, DOI 10.1023/B:BREA.0000018407.47909.78; Hwu P, 2000, J IMMUNOL, V164, P3596, DOI 10.4049/jimmunol.164.7.3596; Kampa M, 2004, BREAST CANCER RES, V6, pR63, DOI 10.1186/bcr752; Kaufmann SH, 2003, ONCOGENE, V22, P7414, DOI 10.1038/sj.onc.1206945; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Kudo Y, 2004, HUM REPROD, V19, P1222, DOI 10.1093/humrep/deh218; Lala PK, 2001, LANCET ONCOL, V2, P149, DOI 10.1016/S1470-2045(00)00256-4; Liu XM, 2002, CIRCULATION, V105, P79, DOI 10.1161/hc0102.101369; Liu ZM, 2004, ONCOGENE, V23, P503, DOI 10.1038/sj.onc.1207173; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Mayerhofer M, 2004, CANCER RES, V64, P3148, DOI 10.1158/0008-5472.CAN-03-1200; McDaid J, 2005, FASEB J, V19, P458, DOI 10.1096/fj.04-2217fje; MOFFETT JR, 1993, BRAIN RES, V623, P337, DOI 10.1016/0006-8993(93)91450-7; Munn DH, 2005, IMMUNITY, V22, P633, DOI 10.1016/j.immuni.2005.03.013; Munn DH, 2004, J CLIN INVEST, V114, P280, DOI 10.1172/JCI200421583; Oh GS, 2004, BIOCHEM BIOPH RES CO, V320, P1156, DOI 10.1016/j.bbrc.2004.06.061; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Ozawa N, 2002, J CLIN INVEST, V109, P457, DOI [10.1172/JCI0213190, 10.1172/JCI200213190]; Policastro L, 2004, MOL CARCINOGEN, V39, P103, DOI 10.1002/mc.20001; Pozo-Guisado E, 2002, BIOCHEM PHARMACOL, V64, P1375, DOI 10.1016/S0006-2952(02)01296-0; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Shilkaitis A, 2000, CARCINOGENESIS, V21, P227, DOI 10.1093/carcin/21.2.227; SHIMIZU S, 1988, BIOCHIM BIOPHYS ACTA, V967, P255, DOI 10.1016/0304-4165(88)90017-7; SHIMIZU T, 1978, J BIOL CHEM, V253, P4700; SONG R, 2004, J BIOL CHEM, V279, P4423; SONO M, 1980, J BIOL CHEM, V255, P1339; Sunamura Makoto, 2003, Angiogenesis, V6, P15, DOI 10.1023/A:1025803600840; Taille C, 2004, J BIOL CHEM, V279, P28681, DOI 10.1074/jbc.M310661200; Taille C, 2003, J BIOL CHEM, V278, P27160, DOI 10.1074/jbc.M300364200; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; Tanaka S, 2003, BRIT J CANCER, V88, P902, DOI 10.1038/sj.bjc.6600830; Thomas SR, 2001, J IMMUNOL, V166, P6332, DOI 10.4049/jimmunol.166.10.6332; Turcanu V, 1998, RES IMMUNOL, V149, P741, DOI 10.1016/S0923-2494(99)80050-9; Turcanu V, 1998, TRANSPL P, V30, P4184, DOI 10.1016/S0041-1345(98)01385-2; Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934; WERNERFELMAYER G, 1989, BIOCHIM BIOPHYS ACTA, V1012, P140, DOI 10.1016/0167-4889(89)90087-6; Xiao BG, 2004, STEROIDS, V69, P653, DOI 10.1016/j.steroids.2004.05.019; Yanagawa T, 2004, ORAL ONCOL, V40, P21, DOI 10.1016/S1368-8375(03)00128-3; YOSHINAGA T, 1982, J BIOL CHEM, V257, P7778; Zhang M, 2002, CELL RES, V12, P123, DOI 10.1038/sj.cr.7290118	57	136	141	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2005	19	14					1957	1968		10.1096/fj.05-3875com	http://dx.doi.org/10.1096/fj.05-3875com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16319139				2022-12-28	WOS:000234405500006
J	Thon, L; Mohlig, H; Mathieu, S; Lange, A; Bulanova, E; Winoto-Morbach, S; Schutze, S; Bulfone-Paus, S; Adam, D				Thon, L; Mohlig, H; Mathieu, S; Lange, A; Bulanova, E; Winoto-Morbach, S; Schutze, S; Bulfone-Paus, S; Adam, D			Ceramide mediates caspase-independent programmed cell death	FASEB JOURNAL			English	Article						tumor necrosis factor; RIP1; mitochondria	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; INDUCED APOPTOSIS; T-LYMPHOCYTES; INHIBITION; FAS; SPHINGOMYELINASE; CYTOTOXICITY; ACTIVATION; MITOCHONDRIA	Although numerous studies have implicated the sphingolipid ceramide in the induction of cell death, a causative function of ceramide in caspase-dependent apoptosis remains a highly debated issue. Here, we show that ceramide is a key mediator of a distinct route to programmed cell death (PCD), i.e., caspase-independent PCD. Under conditions where apoptosis is either not initiated or actively inhibited, TNF induces caspase-independent PCD in L929 fibrosarcoma cells, NIH3T3 fibroblasts, human leukemic Jurkat T cells, and lung fibroblasts by increasing intracellular ceramide levels prior to the onset of cell death. Survival is significantly enhanced when ceramide accumulation is prevented, as demonstrated in fibroblasts genetically deficient for acid sphingomyelinase, in L929 cells overexpressing acid ceramidase, by pharmacological intervention, or by RNA interference. Jurkat cells deficient for receptor-interacting protein 1 (RIP1) do not accumulate ceramide and therefore are fully resistant to caspase-independent PCD whereas Jurkat cells overexpressing the mitochondrial protein Bcl-2 are partially protected, implicating RIP1 and mitochondria as components of the ceramide death pathway. Our data point to a role of caspases (but not cathepsins) in suppressing the ceramide death pathway under physiological conditions. Moreover, clonogenic survival of tumor cells is clearly reduced by induction of the ceramide death pathway, promising additional options for the development of novel tumor therapies.	Univ Klinikum Schleswig Holstein, Inst Immunol, Kiel, Germany; Forschungszentrum Borstel, Abt Immunol & Zellbiol, Borstel, Germany	University of Kiel; Schleswig Holstein University Hospital; Forschungszentrum Borstel	Adam, D (corresponding author), Univ Klinikum Schleswig Holstein, Inst Immunol, Campus Kiel, Kiel, Germany.	dadam@email.uni-kiel.de	Adam, Dieter/E-9763-2010; Schütze, Stefan/C-8596-2011	Adam, Dieter/0000-0002-5668-5032; 				Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Cauwels A, 2003, NAT IMMUNOL, V4, P387, DOI 10.1038/ni914; Dbaibo GS, 2001, FEBS LETT, V503, P7, DOI 10.1016/S0014-5793(01)02625-4; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; Denecker G, 2001, CELL DEATH DIFFER, V8, P829, DOI 10.1038/sj.cdd.4400883; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Grassme H, 2000, SCIENCE, V290, P527, DOI 10.1126/science.290.5491.527; HENNET T, 1993, CANCER RES, V53, P1456; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P374, DOI 10.1016/S0968-0004(98)01289-4; Holland GN, 2000, OCUL IMMUNOL INFLAMM, V8, P1, DOI 10.1076/0927-3948(200003)8:1;1-S;FT001; HURWITZ R, 1994, BIOL CHEM H-S, V375, P447, DOI 10.1515/bchm3.1994.375.7.447; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Jensen JM, 1999, J CLIN INVEST, V104, P1761, DOI 10.1172/JCI5307; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jones BE, 1999, HEPATOLOGY, V30, P215, DOI 10.1002/hep.510300146; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Koonin EV, 2002, CELL DEATH DIFFER, V9, P394, DOI 10.1038/sj.cdd.4400991; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Luschen S, 2000, J BIOL CHEM, V275, P24670, DOI 10.1074/jbc.M003280200; Maurer BJ, 2000, JNCI-J NATL CANCER I, V92, P1897, DOI 10.1093/jnci/92.23.1897; Mengubas K, 1999, EXP CELL RES, V249, P116, DOI 10.1006/excr.1999.4474; Metkar SS, 2000, EXP CELL RES, V255, P18, DOI 10.1006/excr.1999.4773; Perry DK, 1999, TRENDS BIOCHEM SCI, V24, P226, DOI 10.1016/S0968-0004(99)01407-3; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Pirianov G, 2001, MOL CELL ENDOCRINOL, V172, P69, DOI 10.1016/S0303-7207(00)00380-4; Ramos B, 2003, MOL PHARMACOL, V64, P502, DOI 10.1124/mol.64.2.502; Reynolds CP, 2004, CANCER LETT, V206, P169, DOI 10.1016/j.canlet.2003.08.034; Sanchenkov A, 2001, JNCI-J NATL CANCER I, V93, P347, DOI 10.1093/jnci/93.5.347; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SCHUERMANN M, 1990, NUCLEIC ACIDS RES, V18, P4945, DOI 10.1093/nar/18.16.4945; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Strelow A, 2000, J EXP MED, V192, P601, DOI 10.1084/jem.192.5.601; Tanaka M, 1997, J AM CHEM SOC, V119, P7871, DOI 10.1021/ja9713385; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Vanden Berghe T, 2004, J BIOL CHEM, V279, P7925, DOI 10.1074/jbc.M307807200; Vanden Berghe T, 2003, J BIOL CHEM, V278, P5622, DOI 10.1074/jbc.M208925200; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; WANG E, 1991, J BIOL CHEM, V266, P14486; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Zhao S, 2004, J CELL PHYSIOL, V199, P47, DOI 10.1002/jcp.10453	47	107	113	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2005	19	14					1945	1956		10.1096/fj.05-3726com	http://dx.doi.org/10.1096/fj.05-3726com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16319138				2022-12-28	WOS:000234405500005
J	Tomas-Zapico, C; Caballero, B; Sierra, V; Vega-Naredo, I; Alvarez-Garcia, O; Tolivia, D; Rodriguez-Colunga, MJ; Coto-Montes, A				Tomas-Zapico, C; Caballero, B; Sierra, V; Vega-Naredo, I; Alvarez-Garcia, O; Tolivia, D; Rodriguez-Colunga, MJ; Coto-Montes, A			Survival mechanisms in a physiological oxidative stress model	FASEB JOURNAL			English	Article						autophagy; Syrian hamster; Harderian gland; cathepsins; cytokeratins; apoptosis; invasive process; metastasis	LYSOSOMAL CYSTEINE PROTEASES; DELTA-AMINOLEVULINIC-ACID; HAMSTER HARDERIAN-GLAND; PROGRAMMED CELL-DEATH; CATHEPSIN-H; TROPHOBLASTIC INVASION; PERIPHERAL-BLOOD; GENE-EXPRESSION; APOPTOSIS; PORPHYRINS	The Syrian hamster Harderian gland has as the remarkable feature of an extraordinary rate of porphyrin production, even higher than the liver. The low activity of the last enzyme of the route gives rise to the accumulation of the uncomplex porphyrins in the female glands. Moreover, due to the localization of the Harderian gland, porphyrins exposed to light produce reactive oxygen species and, thus, the gland presents a physiological oxidative stress, with a great number of sings of degeneration, but without compromising the gland integrity. The appearance of abnormal features in this gland was largely described in the past, but the significance is interpreted for the first time in this study. We have found that autophagic processes are the first result of an elevated porphyrin metabolism, as it is observed in both sexes. This mechanism is considered, in this case, as a constant renovation system that allows the normal gland activity to be sustained. Furthermore, there is a second procedure, invasive processes toward connective tissue, which even occasionally reach blood vessels with intravasation of damaged gland components into the bloodstream. This effect is a consequence of a strong oxidative stress environment that is mainly observed in the female gland, resembling to tumoral progression. Both mechanisms, autophagy and invasive processes, have to be implied in the maintenance of the gland integrity.	Univ Oviedo, Dept Morfol & Biol Celular, Fac Med, Oviedo 33006, Spain	University of Oviedo	Coto-Montes, A (corresponding author), Univ Oviedo, Dept Morfol & Biol Celular, Fac Med, C Julian Claveria S-N, Oviedo 33006, Spain.	acoto@uniovi.es	coto-montes, ana/D-2544-2016; Tomas-Zapico, Cristina/M-5399-2019; Sierra, 3479/J-9274-2012; Caballero-Garcia, Beatriz/AAC-2636-2020; Vega-Naredo, Ignacio/A-4245-2009	coto-montes, ana/0000-0002-6609-6258; Tomas-Zapico, Cristina/0000-0001-7823-0410; Caballero-Garcia, Beatriz/0000-0003-0242-9620; Sierra, Veronica/0000-0002-7491-3588; Vega-Naredo, Ignacio/0000-0003-1993-6725				Alberts B., 2002, MOL BIOL CELL, P1313; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Alvero AB, 2004, LAB INVEST, V84, P658, DOI 10.1038/labinvest.3700086; Antolin I, 1996, FASEB J, V10, P882, DOI 10.1096/fasebj.10.8.8666165; Antolin I, 1996, J STRUCT BIOL, V116, P377, DOI 10.1006/jsbi.1996.0055; ANTOLIN I, 1994, ANAT REC, V239, P349, DOI 10.1002/ar.1092390402; Asanuma K, 2003, FASEB J, V17, P1165, DOI 10.1096/fj.02-0580fje; Badminton MN, 2002, INT J CLIN PRACT, V56, P272; BARRETT AJ, 1980, BIOCHEM J, V187, P909, DOI 10.1042/bj1870909; BEAULATON J, 1982, INT REV CYTOL, V79, P215, DOI 10.1016/S0074-7696(08)61675-7; BLANKENSHIP TN, 1993, CELL TISSUE RES, V272, P227, DOI 10.1007/BF00302728; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broker LE, 2004, CANCER RES, V64, P27, DOI 10.1158/0008-5472.CAN-03-3060; BUCANA CD, 1972, Z ZELLFORSCH MIK ANA, V129, P178, DOI 10.1007/BF00306934; BUETTNER GR, 1979, FEBS LETT, V98, P18, DOI 10.1016/0014-5793(79)80141-6; Bursch W, 2000, J CELL SCI, V113, P1189; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Coto-Montes A, 2001, FREE RADICAL BIO MED, V30, P785, DOI 10.1016/S0891-5849(01)00468-3; Coto-Montes A, 2001, CHEM-BIOL INTERACT, V134, P135, DOI 10.1016/S0009-2797(00)00320-3; COTOMONTES A, 1994, CELL TISSUE RES, V278, P483; del Re EC, 2000, BRIT J CANCER, V82, P1317; DHerde K, 1996, REPROD NUTR DEV, V36, P175, DOI 10.1051/rnd:19960203; Ding SJ, 2004, MOL CELL PROTEOMICS, V3, P73, DOI 10.1074/mcp.M300094-MCP200; EMILIANI C, 1983, PHOTOCHEM PHOTOBIOL, V37, P487, DOI 10.1111/j.1751-1097.1983.tb04505.x; ENDERS AC, 1991, AM J ANAT, V192, P329, DOI 10.1002/aja.1001920403; Friedrich B, 1999, EUR J CANCER, V35, P138, DOI 10.1016/S0959-8049(98)00273-1; Fujita J, 2004, RESP MED, V98, P294, DOI 10.1016/j.rmed.2003.10.010; GABRIJELCIC D, 1992, EUR J CLIN CHEM CLIN, V30, P69; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Gradilone A, 2003, ONCOL REP, V10, P217; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; HARDELAND R, 1995, CELLULAR RHYTHMS IND, P145; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HOFFMAN RA, 1971, AM J ANAT, V132, P463, DOI 10.1002/aja.1001320405; Isahara K, 1999, NEUROSCIENCE, V91, P233, DOI 10.1016/S0306-4522(98)00566-1; Ishisaka R, 2001, J BIOCHEM-TOKYO, V129, P35, DOI 10.1093/oxfordjournals.jbchem.a002833; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kos J, 1997, CLIN CANCER RES, V3, P1815; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Levy-Strumpf N, 1998, ONCOGENE, V17, P3331, DOI 10.1038/sj.onc.1202588; Libbrecht L, 2003, J PATHOL, V199, P191, DOI 10.1002/path.1257; MOAN J, 1984, PHOTOCHEM PHOTOBIOL, V39, P445; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NICOLSON GL, 2001, CURR OPIN ONCOL, V3, P75; Ohsawa Y, 1998, ARCH HISTOL CYTOL, V61, P395, DOI 10.1679/aohc.61.395; Ollinger K, 2000, ARCH BIOCHEM BIOPHYS, V373, P346, DOI 10.1006/abbi.1999.1567; PAYNE AP, 1977, J ENDOCRINOL, V75, P73, DOI 10.1677/joe.0.0750073; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Raul U, 2004, INT J CANCER, V111, P662, DOI 10.1002/ijc.20349; RIMINGTON C, 1967, Q J MED, V36, P29; Roberg K, 2002, AM J PATHOL, V161, P89, DOI 10.1016/S0002-9440(10)64160-0; Roberg K, 1999, FREE RADICAL BIO MED, V27, P1228, DOI 10.1016/S0891-5849(99)00146-X; RODRIGUEZCOLUNGA MJ, 1993, CELL TISSUE RES, V274, P189, DOI 10.1007/BF00328000; SCHREURS FJG, 1995, POULTRY SCI, V74, P523, DOI 10.3382/ps.0740523; Sivaparvathi M, 1996, CANCER LETT, V104, P121, DOI 10.1016/0304-3835(96)04242-5; SPIKES JD, 1975, ANN NY ACAD SCI, V244, P496, DOI 10.1111/j.1749-6632.1975.tb41550.x; Stefan C, 1997, CHEM RES TOXICOL, V10, P636, DOI 10.1021/tx970006a; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STRUM JM, 1982, TISSUE CELL, V14, P149, DOI 10.1016/0040-8166(82)90014-3; TAKAHASHI T, 1981, PROTEOLITIC ENZYME C, P567; Tolivia D, 1996, MICROSC RES TECHNIQ, V34, P55, DOI 10.1002/(SICI)1097-0029(19960501)34:1<55::AID-JEMT8>3.3.CO;2-T; Tomas-Zapico C, 2002, FREE RADICAL BIO MED, V32, P1197, DOI 10.1016/S0891-5849(02)00812-2; Tomas-Zapico C, 2002, INT J BIOCHEM CELL B, V34, P544, DOI 10.1016/S1357-2725(01)00149-2; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Uchiyama Y, 2001, ARCH HISTOL CYTOL, V64, P233, DOI 10.1679/aohc.64.233; Uenishi T, 2003, CANCER SCI, V94, P851, DOI 10.1111/j.1349-7006.2003.tb01366.x; URIA H, 1994, CELL BIOL PROBLEMS C, P89; VERMA V, 1983, GYNECOL OBSTET INVES, V15, P193, DOI 10.1159/000299412; Waghray A, 2002, J BIOL CHEM, V277, P11533, DOI 10.1074/jbc.M109557200; Waghray A, 2001, CANCER RES, V61, P4283; Werman H A, 1989, Emerg Med Clin North Am, V7, P927; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780	73	26	26	1	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					2066	+		10.1096/fj.04-3595fje	http://dx.doi.org/10.1096/fj.04-3595fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16186173				2022-12-28	WOS:000232315700004
J	Bach, FH				Bach, FH			Heme oxygenase-1: a therapeutic amplification funnel	FASEB JOURNAL			English	Editorial Material							CARBON-MONOXIDE; MICROSATELLITE POLYMORPHISM; BILIVERDIN REDUCTASE; INDUCTION; PROTECTS; RAPAMYCIN; PROMOTER; GENE; SUSCEPTIBILITY; EXPRESSION		Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Bach, FH (corresponding author), 99 Brookline Ave, Boston, MA 02215 USA.	fritz_bach@hms.harvard.edu						Berberat PO, 2003, FASEB J, V17, P1724, DOI 10.1096/fj.03-0229fje; Bussolati B, 2004, BLOOD, V103, P761, DOI 10.1182/blood-2003-06-1974; Chen YH, 2002, HUM GENET, V111, P1, DOI 10.1007/s00439-002-0769-4; Deng YM, 2004, CIRCULATION, V110, P1855, DOI 10.1161/01.CIR.0000142610.10530.25; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Exner M, 2004, FREE RADICAL BIO MED, V37, P1097, DOI 10.1016/j.freeradbiomed.2004.07.008; Grosser N, 2003, BIOCHEM BIOPH RES CO, V308, P956, DOI 10.1016/S0006-291X(03)01504-3; KOIZUMI T, 1992, PROSTAGLANDINS, V43, P121, DOI 10.1016/0090-6980(92)90081-4; Kravets A, 2004, J BIOL CHEM, V279, P19916, DOI 10.1074/jbc.M314251200; Lavitrano M, 2004, FASEB J, V18, P1093, DOI 10.1096/fj.03-0996fje; Lee TS, 2004, CIRCULATION, V110, P1296, DOI 10.1161/01.CIR.0000140694.67251.9C; Lee TS, 2003, J BIOL CHEM, V278, P19325, DOI 10.1074/jbc.M300498200; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Maines MD, 2004, ANTIOXID REDOX SIGN, V6, P797, DOI 10.1089/1523086041798105; MOORE BA, 2004, EFFECTS CARBON MONOX; Nakao A, 2004, GASTROENTEROLOGY, V127, P595, DOI 10.1053/j.gastro.2004.05.059; Nakao A, 2003, AM J PATHOL, V163, P1587, DOI 10.1016/S0002-9440(10)63515-8; Novotny L, 2003, EXP BIOL MED, V228, P568, DOI 10.1177/15353702-0322805-29; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; OTTERBEIN LE, 2003, NAT MED, V29, P183; Poon M, 1996, J CLIN INVEST, V98, P2277, DOI 10.1172/JCI119038; Redaelli CA, 2002, HEPATOLOGY, V35, P1082, DOI 10.1053/jhep.2002.33067; Ryter SW, 2004, BIOESSAYS, V26, P270, DOI 10.1002/bies.20005; Sarady JK, 2004, FASEB J, V18, P854, DOI 10.1096/fj.03-0643fje; Schillinger M, 2004, J AM COLL CARDIOL, V43, P950, DOI 10.1016/j.jacc.2003.09.058; Sedlak TW, 2004, PEDIATRICS, V113, P1776, DOI 10.1542/peds.113.6.1776; SEHGAL SN, 1993, ANN NY ACAD SCI, V685, P58, DOI 10.1111/j.1749-6632.1993.tb35852.x; Soares MP, 2004, J IMMUNOL, V172, P3553, DOI 10.4049/jimmunol.172.6.3553; Soares MP, 2004, BLOOD, V103, P751, DOI 10.1182/blood-2003-11-3879; Visner GA, 2003, CIRCULATION, V107, P911, DOI 10.1161/01.CIR.0000048191.75585.60; Yamada N, 2000, AM J HUM GENET, V66, P187, DOI 10.1086/302729; Zhuang H, 2003, ANN NY ACAD SCI, V993, P276, DOI 10.1111/j.1749-6632.2003.tb07534.x; Zuckerbraun BS, 2003, J EXP MED, V198, P1707, DOI 10.1084/jem.20031003	34	94	96	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1216	1219		10.1096/fj.04-3485cmt	http://dx.doi.org/10.1096/fj.04-3485cmt			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16051687				2022-12-28	WOS:000231843700027
J	Tschope, C; Walther, T; Escher, F; Spillmann, F; Du, J; Altmann, C; Schimke, I; Bader, M; Sanchez-Ferrer, CF; Schultheiss, HP; Noutsias, M				Tschope, C; Walther, T; Escher, F; Spillmann, F; Du, J; Altmann, C; Schimke, I; Bader, M; Sanchez-Ferrer, CF; Schultheiss, HP; Noutsias, M			Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction, and oxidative stress in experimental diabetic cardiomyopathy	FASEB JOURNAL			English	Article						adhesion molecules; immune system; thiobarbituric acid reactive substances; transgenic animal	ADHESION MOLECULES; DILATED CARDIOMYOPATHY; HEART-FAILURE; BRADYKININ; EXPRESSION; RATS; RECEPTOR; HYPERGLYCEMIA; ANGIOTENSIN; METABOLISM	The mechanisms contributing to diabetic cardiomyopathy, as well as the protective pathways of the kallikrein-kinin-system (KKS), are incompletely understood. In a kallikrein-overexpressing rat model of streptozotocin (STZ)-induced diabetic cardiomyopathy, we investigated the involvement of inflammatory pathways, endothelial dysfunction, and oxidative stress. Six weeks after STZ injection, impairment of left ventricular (LV) function parameters measured by a Millar-tip catheter (peak LV systolic pressure; dP/dt(max); dP/dt(min)) was accompanied by a significant increment of ICAM-1 and VCAM-1 (CAMs) expression, as well as of beta(2)-leukocyteintegrins(+) (CD18(+), CD11a(+), CD11b(+)) and cytokine (TNF-alpha and IL-1 beta)-expressing infiltrates in male Sprague-Dawley (SD-STZ) rats compared with normoglycemic littermates. Furthermore, SD-STZ rats demonstrated a significant impairment of endothelium-dependent relaxation evoked by acetylcholine and significantly increased plasma TBARS (plasma thiobarbituric acid reactive substances) levels as a measure of oxidative stress. These diabetic cardiomyopathy-associated alterations were significantly attenuated (P<0.05) in diabetic transgenic rats expressing the human kallikrein 1 (hKLK1) gene with STZ-induced diabetes. CAMs expression, beta(2)-leukocyte-integrins(+), and cytokine-expressing infiltrates correlated significantly with all evaluated LV function parameters. The multiple protective effects of the KKS in experimental diabetic cardiomyopathy comprise the inhibition of intramyocardial inflammation (CAMs expression, beta(2)-leukocyte-integrins(+) infiltration and cytokine expression), an improvement of endothelium-dependent relaxation and the attenuation of oxidative stress. These insights might have therapeutic implications also for human diabetic cardiomyopathy.	Univ Med Berlin, Charite, Benjamin Franklin Dept Cardiol & Pneumonol, D-12220 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Univ Autonoma Madrid, Fac Med, Dept Pharmacol & Therapeut, Madrid, Spain	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Autonomous University of Madrid	Tschope, C (corresponding author), Univ Med Berlin, Charite, Benjamin Franklin Dept Cardiol & Pneumonol, Hindenburgdamm 30, D-12220 Berlin, Germany.	cstchoepe@yahoo.com	Noutsias, Michel/AAM-4006-2021; Bader, Michael/K-2124-2013	Tschope, Carsten/0000-0001-5243-8985; Bader, Michael/0000-0003-4780-4164; Escher, Felicitas/0000-0003-0678-5681; Spillmann, Frank/0000-0003-0002-5745; Noutsias, Michel/0000-0002-9066-5262				Adamopoulos Stamatis, 2002, Eur J Intern Med, V13, P233, DOI 10.1016/S0953-6205(02)00033-X; Bauters C, 2003, CARDIOVASC DIABETOL, V2, DOI 10.1186/1475-2840-2-1; Cai L, 2001, Cardiovasc Toxicol, V1, P181, DOI 10.1385/CT:1:3:181; Chavakis T, 2001, FASEB J, V15, P2365, DOI 10.1096/fj.01-0201com; Emanueli C, 2002, CIRCULATION, V106, P993, DOI 10.1161/01.CIR.0000027104.33206.C8; Emanueli C, 1999, CIRCULATION, V100, P2359, DOI 10.1161/01.CIR.100.23.2359; Esposito K, 2002, CIRCULATION, V106, P2067, DOI 10.1161/01.CIR.0000034509.14906.AE; Fiordaliso F, 2000, LAB INVEST, V80, P513, DOI 10.1038/labinvest.3780057; Gohlke P, 1997, ADV EXP MED BIOL, V432, P159; KANNEL WB, 1974, AM J CARDIOL, V34, P29, DOI 10.1016/0002-9149(74)90089-7; Marfella R, 2000, CIRCULATION, V101, P2247, DOI 10.1161/01.CIR.101.19.2247; Mikrut K, 2001, DIABETES RES CLIN PR, V51, P79, DOI 10.1016/S0168-8227(00)00222-9; MODRAK J, 1980, DIABETES, V29, P547, DOI 10.2337/diabetes.29.7.547; Monkemann H, 2002, AMINO ACIDS, V23, P331, DOI 10.1007/s00726-001-0146-y; MULVANY MJ, 1977, CIRC RES, V41, P19, DOI 10.1161/01.RES.41.1.19; Noutsias M, 1999, CIRCULATION, V99, P2124, DOI 10.1161/01.CIR.99.16.2124; Noutsias M, 2002, EUR HEART J SUPPL, V4, pI54, DOI 10.1016/S1520-765X(02)90112-4; Noutsias M, 2003, EUR J HEART FAIL, V5, P469, DOI 10.1016/S1388-9842(03)00037-0; Noutsias M, 2001, CIRCULATION, V104, P275; Noutsias M, 2002, MED SCI MONITOR, V8, pMT59; Pinto YM, 2000, FASEB J, V14, P1861; Rett K, 1997, AM J CARDIOL, V80, pA143, DOI 10.1016/S0002-9149(97)00470-0; Richardson P, 1996, CIRCULATION, V93, P841, DOI 10.1161/01.CIR.93.5.841; Rodriguez-Manas L, 2003, DIABETOLOGIA, V46, P556, DOI 10.1007/s00125-003-1056-1; Rodriguez-Manas L, 1998, BRIT J PHARMACOL, V123, P1495, DOI 10.1038/sj.bjp.0701749; ROSEN P, 1983, H-S Z PHYSIOL CHEM, V364, P1431, DOI 10.1515/bchm2.1983.364.2.1431; Scholz D, 1996, CELL TISSUE RES, V284, P415, DOI 10.1007/s004410050602; Shiuchi T, 2002, HYPERTENSION, V40, P329, DOI 10.1161/01.HYP.0000028979.98877.0C; Silva JA, 2000, FASEB J, V14, P1858; Spillmann F, 2002, INT IMMUNOPHARMACOL, V2, P1823, DOI 10.1016/S1567-5769(02)00174-1; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Sun Y, 2002, AM J PATHOL, V161, P1773, DOI 10.1016/S0002-9440(10)64454-9; TAKEDA K, 1984, CRIT CARE MED, V12, P957, DOI 10.1097/00003246-198411000-00007; Tschope C, 1999, AM J PHYSIOL-HEART C, V277, pH2333, DOI 10.1152/ajpheart.1999.277.6.H2333; Tschope C, 2002, J CARDIOVASC PHARM, V39, P478, DOI 10.1097/00005344-200204000-00003; Tschope C, 2004, FASEB J, V18, P1967, DOI 10.1096/fj.04-1614fje; Tschope C, 2004, FASEB J, V18, P828, DOI 10.1096/fj.03-0736com; Tschope C, 2004, CARDIOVASC RES, V61, P559, DOI 10.1016/j.cardiores.2003.10.018; Tschope C, 1999, IMMUNOPHARMACOLOGY, V44, P35, DOI 10.1016/S0162-3109(99)00109-5; Vallbracht KB, 2002, J AM COLL CARDIOL, V40, P515, DOI 10.1016/S0735-1097(02)01990-3; ZARICH SW, 1989, AM HEART J, V118, P1000, DOI 10.1016/0002-8703(89)90236-6; Zhang LF, 2003, CIRCULATION, V108, P472, DOI 10.1161/01.CIR.0000080378.96063.23	42	96	102	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					2057	+		10.1096/fj.05-4095fje	http://dx.doi.org/10.1096/fj.05-4095fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16129698				2022-12-28	WOS:000231843700003
J	Kobayashi, H; Kromminga, A; Dunlop, TW; Tychsen, B; Conrad, F; Suzuki, N; Memezawa, A; Bettermann, A; Aiba, S; Carlberg, C; Paus, R				Kobayashi, H; Kromminga, A; Dunlop, TW; Tychsen, B; Conrad, F; Suzuki, N; Memezawa, A; Bettermann, A; Aiba, S; Carlberg, C; Paus, R			A role of melatonin in neuroectodermal-mesodermal interactions: the hair follicle synthesizes melatonin and expresses functional melatonin receptors	FASEB JOURNAL			English	Review						melatonin; hair follicles; MT2; ROR alpha; estrogen receptors; C57BL/6 mice; apoptosis	HUMAN-BREAST-CANCER; NITRIC-OXIDE SYNTHASE; UV-INDUCED ERYTHEMA; WINTER FUR GROWTH; PINEAL-GLAND; NUCLEAR RECEPTOR; SEROTONINERGIC SYSTEM; N-ACETYLTRANSFERASE; TOPICAL TREATMENT; GENE-EXPRESSION	Since mammalian skin expresses the enzymatic apparatus for melatonin synthesis, it may be an extrapineal site of melatonin synthesis. However, evidence is still lacking that this is really the case in situ. Here, we demonstrate melatonin-like immunoreactivity (IR) in the outer root sheath (ORS) of mouse and human hair follicles (HFs), which corresponds to melatonin, as shown by radioimmunoassay and liquid chromatography/tandem mass spectrometry (LC/MS/MS). The melatonin concentration in organ-cultured mouse skin, mouse vibrissae follicles, and human scalp HFs far exceeds the respective melatonin serum level and is significantly increased ex vivo by stimulation with norepinephrine ( NE), the key stimulus for pineal melatonin synthesis. By real-time PCR, transcripts for the melatonin membrane receptor MT2 and for the nuclear mediator of melatonin signaling, retinoid orphan receptor alpha(ROR)alpha, are detectable in murine back skin. Transcript levels for these receptors fluctuate in a hair cycle-dependent manner, and are maximal during apoptosis-driven HF regression (catagen). Melatonin may play a role in hair cycle regulation, since its receptors (MT2 and ROR alpha) are expressed in murine skin in a hair cycle-dependent manner, and because it inhibits keratinocyte apoptosis and down-regulates ER alpha expression. Therefore, the HF is both, a prominent extrapineal melatonin source, and an important peripheral melatonin target tissue. Regulated intrafollicular melatonin synthesis and signaling may play a previously unrecognized role in the endogenous controls of hair growth, for example, by modulating keratinocyte apoptosis during catagen and by desensitizing the HF to estrogen signaling. As a prototypic neuroectodermal-mesodermal interaction model, the HF can be exploited for dissecting the obscure role of melatonin in such interactions in peripheral tissues.	Med Univ Lubeck, Univ Hosp Schleswig Holstein, Dept Dermatol, D-23538 Lubeck, Germany; Tohoku Univ Hosp, Dept Pharmaceut Sci, Sendai, Miyagi, Japan; Univ Kuopio, Dept Biochem, FIN-70211 Kuopio, Finland; Inst Immunol Clin Pathol & Mol Med, Hamburg, Germany; Tohoku Univ, Sch Med, Dept Dermatol, Sendai, Miyagi 980, Japan; Univ Hamburg, Hosp Eppendorf, Dept Dermatol, D-20246 Hamburg, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Lubeck; Tohoku University; Finland National Institute for Health & Welfare; University of Eastern Finland; Tohoku University; University of Hamburg	Paus, R (corresponding author), Med Univ Lubeck, Univ Hosp Schleswig Holstein, Dept Dermatol, D-23538 Lubeck, Germany.	paus@uke.uni-hamburg.de	Carlberg, Carsten/C-9075-2011; Paus, Ralf/F-6243-2011	Carlberg, Carsten/0000-0003-2633-0684; 				Acuna-Castroviejo D, 2001, J PINEAL RES, V30, P65, DOI 10.1034/j.1600-079X.2001.300201.x; Bangha E, 1996, ARCH DERMATOL RES, V288, P522, DOI 10.1007/s004030050096; Bangha E, 1997, DERMATOLOGY, V195, P248, DOI 10.1159/000245953; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; Botchkarev VA, 2004, PROG BRAIN RES, V146, P493; Botchkarev VA, 1998, AM J PATHOL, V153, P785, DOI 10.1016/S0002-9440(10)65621-0; Brzezinski Amnon, 1997, New England Journal of Medicine, V336, P186; Bubenik GA, 2002, DIGEST DIS SCI, V47, P2336, DOI 10.1023/A:1020107915919; Carlberg C, 2000, ANN NY ACAD SCI, V917, P387; Carrillo-Vico A, 2004, FASEB J, V18, P537, DOI 10.1096/fj.03-0694fje; Chanda S, 2000, AM J PHYSIOL-ENDOC M, V278, pE202, DOI 10.1152/ajpendo.2000.278.2.E202; CONRAD F, 2005, IN PRESS J INVESTIG; Conti A, 2000, J PINEAL RES, V28, P193, DOI 10.1034/j.1600-079X.2000.280401.x; COTSARELIS G, 2003, DISORDERS HAIR GROWT; Dai J, 2002, J PINEAL RES, V32, P112, DOI 10.1034/j.1600-079x.2002.1844.x; Dreher F, 1998, BRIT J DERMATOL, V139, P332, DOI 10.1046/j.1365-2133.1998.02447.x; Drijfhout WJ, 1996, NEUROSCI LETT, V202, P185, DOI 10.1016/0304-3940(95)12245-1; FINOCCHIARO LME, 1991, BIOCHEM J, V280, P727, DOI 10.1042/bj2800727; Fischer TW, 2001, J PINEAL RES, V31, P39, DOI 10.1034/j.1600-079X.2001.310106.x; Foitzik K, 2000, FASEB J, V14, P752, DOI 10.1096/fasebj.14.5.752; FOLES A, 1992, ADV PINEAL RES, V6, P235; GAUDET SJ, 1993, J INVEST DERMATOL, V101, P660, DOI 10.1111/1523-1747.ep12371672; Gonzalez R, 1991, Melanoma Res, V1, P237, DOI 10.1097/00008390-199111000-00003; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IBRAHEEM M, 1994, J ANAT, V185, P135; Ito N, 2005, FASEB J, V19, P1332, DOI 10.1096/fj.04-1968fje; Ito N, 2004, J INVEST DERMATOL, V122, P235, DOI 10.1046/j.1523-1747.2003.22145.x; Itoh MT, 1997, MOL CELL ENDOCRINOL, V136, P7, DOI 10.1016/S0303-7207(97)00206-2; Jin XW, 2003, MOL CELL BIOL, V23, P1054, DOI 10.1128/MCB.23.3.1054-1060.2003; Johnston B, 1999, J EXP ZOOL, V284, P437, DOI 10.1002/(SICI)1097-010X(19990901)284:4&lt;437::AID-JEZ10&gt;3.0.CO;2-X; Jou MJ, 2004, J PINEAL RES, V37, P55, DOI 10.1111/j.1600-079X.2004.00140.x; Kiefer T, 2002, BREAST CANCER RES TR, V71, P37, DOI 10.1023/A:1013301408464; Kobayashi H, 2005, EXP DERMATOL, V14, P157, DOI 10.1111/j.0906-6705.2005.0266p.x; Kobayashi H, 2004, J INVEST DERMATOL, V123; Kobayashi Y, 2003, J PINEAL RES, V35, P71, DOI 10.1034/j.1600-079X.2003.00053.x; Kvetnoy IM, 1999, HISTOCHEM J, V31, P1, DOI 10.1023/A:1003431122334; Lee P. P. N., 1993, Biological Signals, V2, P181; Leon J, 2004, LIFE SCI, V75, P765, DOI 10.1016/j.lfs.2004.03.003; Leon J, 2000, MOL PHARMACOL, V58, P967, DOI 10.1124/mol.58.5.967; LERNER AB, 1958, J AM CHEM SOC, V80, P2587, DOI 10.1021/ja01543a060; Lindner G, 1997, AM J PATHOL, V151, P1601; Liu C, 1997, NEURON, V19, P91, DOI 10.1016/S0896-6273(00)80350-5; LOGAN A, 1980, J INVEST DERMATOL, V74, P47, DOI 10.1111/1523-1747.ep12514608; Magerl M, 2001, J INVEST DERMATOL, V116, P947, DOI 10.1046/j.0022-202x.2001.01368.x; Maronde E, 1997, BIOL CELL, V89, P505, DOI 10.1016/S0248-4900(98)80006-3; MCCLOGHRY E, 1992, J PINEAL RES, V13, P139, DOI 10.1111/j.1600-079X.1992.tb00068.x; MCELHINNEY DB, 1994, J INVEST DERMATOL, V102, P258, DOI 10.1111/1523-1747.ep12371773; MENNENGA K, 1991, J PINEAL RES, V10, P159, DOI 10.1111/j.1600-079X.1991.tb00834.x; MOLIS TM, 1994, MOL ENDOCRINOL, V8, P1681, DOI 10.1210/me.8.12.1681; Muller-Rover S, 2001, J INVEST DERMATOL, V117, P3, DOI 10.1046/j.0022-202x.2001.01377.x; Naji L, 2004, LIFE SCI, V74, P2227, DOI 10.1016/j.lfs.2003.08.046; Nickel A, 2000, ARCH DERMATOL RES, V292, P366, DOI 10.1007/s004030000141; NIXON AJ, 1995, J EXP ZOOL, V272, P435, DOI 10.1002/jez.1402720605; NIXON AJ, 1993, J EXP ZOOL, V267, P47, DOI 10.1002/jez.1402670108; Oh HS, 1996, P NATL ACAD SCI USA, V93, P12525, DOI 10.1073/pnas.93.22.12525; Ohnemus U, 2005, ENDOCRINOLOGY, V146, P1214, DOI 10.1210/en.2004-1219; Paus R, 2004, DIFFERENTIATION, V72, P489, DOI 10.1111/j.1432-0436.2004.07209004.x; PAUS R, 1991, BRIT J DERMATOL, V124, P415, DOI 10.1111/j.1365-2133.1991.tb00618.x; PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365-2133.1990.tb06266.x; Paus R, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P61, DOI 10.1038/jidsymp.1997.13; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; Philpott M P, 1994, J Dermatol Sci, V7 Suppl, pS55, DOI 10.1016/0923-1811(94)90036-1; POEGGELER B, 1994, ANN NY ACAD SCI, V738, P419, DOI 10.1111/j.1749-6632.1994.tb21831.x; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; Poirel VJ, 2003, NEUROENDOCRINOL LETT, V24, P33; Pozo D, 1997, J CELL BIOCHEM, V65, P430, DOI 10.1002/(SICI)1097-4644(19970601)65:3<430::AID-JCB12>3.0.CO;2-J; Provinciali M, 1996, MECH AGEING DEV, V90, P1, DOI 10.1016/0047-6374(96)01746-0; Reiter RJ, 1998, ANN NY ACAD SCI, V854, P410, DOI 10.1111/j.1749-6632.1998.tb09920.x; Reiter RJ, 2003, BEST PRACT RES CL EN, V17, P273, DOI 10.1016/S1521-690X(03)00016-2; REITER RJ, 1991, MOL CELL ENDOCRINOL, V79, pC153, DOI 10.1016/0303-7207(91)90087-9; REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x; Rose J, 1998, COMP BIOCHEM PHYS A, V121, P263, DOI 10.1016/S1095-6433(98)10127-7; ROSE J, 1987, GEN COMP ENDOCR, V65, P212, DOI 10.1016/0016-6480(87)90168-7; Roseboom PH, 1998, MOL BRAIN RES, V63, P189, DOI 10.1016/S0169-328X(98)00273-3; Sainz RM, 2003, CELL MOL LIFE SCI, V60, P1407, DOI 10.1007/s00018-003-2319-1; Sainz RM, 1999, FASEB J, V13, P1547, DOI 10.1096/fasebj.13.12.1547; Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337; Semak I, 2004, ARCH BIOCHEM BIOPHYS, V421, P61, DOI 10.1016/j.abb.2003.08.036; Slominski A, 1994, Exp Dermatol, V3, P45, DOI 10.1111/j.1600-0625.1994.tb00265.x; Slominski A, 2002, FASEB J, V16, P896, DOI 10.1096/fj.01-0952fje; Slominski A, 1996, J BIOL CHEM, V271, P12281, DOI 10.1074/jbc.271.21.12281; Slominski A, 2005, FASEB J, V19, P176, DOI 10.1096/fj.04-2079rev; Slominski A, 2004, BBA-GENE STRUCT EXPR, V1680, P67, DOI 10.1016/j.bbaexp.2004.09.002; Slominski A, 2003, EUR J BIOCHEM, V270, P3335, DOI 10.1046/j.1432-1033.2003.03708.x; Slominski A, 2003, J CELL PHYSIOL, V196, P144, DOI 10.1002/jcp.10287; Slominski A, 2002, J INVEST DERMATOL, V119, P934, DOI 10.1046/j.1523-1747.2002.00156.x; SLOMINSKI A, 1993, EXP CELL RES, V206, P189, DOI 10.1006/excr.1993.1137; Slominski A, 2004, ENDOCRINOLOGY, V145, P941, DOI 10.1210/en.2003-0851; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; Steinmayr M, 1998, P NATL ACAD SCI USA, V95, P3960, DOI 10.1073/pnas.95.7.3960; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Thornton MJ, 2003, EXP DERMATOL, V12, P181, DOI 10.1034/j.1600-0625.2003.120209.x; TILLET Y, 1989, CELL TISSUE RES, V257, P23; Tosini G, 1998, BRAIN RES, V789, P221, DOI 10.1016/S0006-8993(97)01446-7; Vijayalaxmi, 2002, J CLIN ONCOL, V20, P2575, DOI 10.1200/JCO.2002.11.004; VIVIENROELS B, 1981, CELL TISSUE RES, V217, P105, DOI 10.1007/bf00233830; von Gall C, 2002, CELL TISSUE RES, V309, P151, DOI 10.1007/s00441-002-0581-4; von Gall C, 2000, EUR J NEUROSCI, V12, P964, DOI 10.1046/j.1460-9568.2000.00990.x; Warner M, 2003, METHOD ENZYMOL, V364, P448; WIESENBERG I, 1995, NUCLEIC ACIDS RES, V23, P327, DOI 10.1093/nar/23.3.327; WILLIAMS D, 1994, BRIT J DERMATOL, V130, P290, DOI 10.1111/j.1365-2133.1994.tb02923.x; Witt-Enderby PA, 2003, LIFE SCI, V72, P2183, DOI 10.1016/S0024-3205(03)00098-5; Yang SM, 2002, J PHARMACEUT BIOMED, V30, P781, DOI 10.1016/S0731-7085(02)00387-4; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509	107	97	109	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1710	+		10.1096/fj.04-2293fje	http://dx.doi.org/10.1096/fj.04-2293fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16030176				2022-12-28	WOS:000230923000017
J	Clarkson, AN; Liu, HZ; Rahman, R; Jackson, DM; Appleton, I; Kerr, DS				Clarkson, AN; Liu, HZ; Rahman, R; Jackson, DM; Appleton, I; Kerr, DS			Clomethiazole: mechanisms underlying lasting neuroprotection after hypoxia-ischemia	FASEB JOURNAL			English	Article						hippocampus; NOS; diaschisis; electrophysiology; arginase	NITRIC-OXIDE SYNTHASE; ORNITHINE-DECARBOXYLASE ACTIVITY; GAMMA-AMINOBUTYRIC-ACID; FOCAL CEREBRAL-ISCHEMIA; BRAIN-DAMAGE; TRANSHEMISPHERIC DIASCHISIS; MESSENGER-RNA; C-FOS; POLYAMINE LEVELS; NEURONAL DEATH	Damage after hypoxia-ischemia (HI) is observed in both cortical and subcortical regions. In this study. we employed a "Levine" rat model of HI (left carotid ligation + 1 h global hypoxia on PND-26) and used histological and electrophysiological paradigms to assess the long-term neuroprotective properties of clomethiazole (CMZ; a GABA(A) receptor modulator). Key enzymes involved in inflammation, namely nitric oxide synthase (NOS) and arginase, were also examined to assess potential CMZ mechanisms not involving GABA-R activation. Assessments were carried out 3 and 90 days post-HI. Extensive CNS lesions were evident after HI ipsilaterally at both short- and long-term intervals. CMZ significantly decreased the lesion size at 3 and 90 days (P < 0.01; P < 0.05). Evoked field potential analysis were used to assess hippocampal CA1 neuronal acitivity ex vivo. Electrophysiological measurements contralateral to the occlusion revealed impaired neuronal function after HI relative to short- long-term controls (P < 0.01, 3 and 14 days; P < 0.01, 90 days), with CMZ treatment providing near complete protection (P < 0.001 at 3 and 14 days; P < 0.01 at 90 days). Both NOS and arginase activities were significantly increased at 3 days (P < 0.01), with arginase remaining elevated at 90 days post-HI (P < 0.05) ipsilaterally. CMZ suppressed the HI-induced increase in iNOS and arginase activities (P 0.001; P < 0.05). These data provide evidence of long-term functional neuroprotection by CMZ in a model of HI. We further conclude that under conditions of HI, functional deficits are not restricted to the ipsilateral hemisphere and are due, at least in part, to changes in the activity of NOS and arginase.	Univ Otago, Sch Med Sci, Dept Pharmacol & Toxicol, Dunedin, New Zealand	University of Otago	Kerr, DS (corresponding author), Univ Otago, Sch Med Sci, Dept Pharmacol & Toxicol, POB, Dunedin, New Zealand.	steve.kerr@stonebow.otago.ac.nz		Clarkson, Andrew/0000-0003-3804-3834				ANDREWS RJ, 1991, STROKE, V22, P943, DOI 10.1161/01.STR.22.7.943; Baskaya MK, 1997, BRAIN RES, V744, P302; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHAN A, 1990, J NEUROSCI, V10, P311; BuchkremerRatzmann I, 1997, EUR J PHARMACOL, V320, P103, DOI 10.1016/S0014-2999(96)00891-6; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Butefisch CM, 2003, BRAIN, V126, P470, DOI 10.1093/brain/awg044; Chaulk D, 2003, EXP NEUROL, V182, P476, DOI 10.1016/S0014-4886(03)00121-3; Clarkson AN, 2004, FASEB J, V18, P1114, DOI 10.1096/fj.03-1203fje; Congar P, 2000, J NEUROPHYSIOL, V83, P2040, DOI 10.1152/jn.2000.83.4.2040; CORBETT D, 1990, BRAIN RES, V514, P300, DOI 10.1016/0006-8993(90)91424-F; CROSS AJ, 1989, BRIT J PHARMACOL, V98, P284, DOI 10.1111/j.1476-5381.1989.tb16893.x; CROSS AJ, 1995, BRIT J PHARMACOL, V114, P1625, DOI 10.1111/j.1476-5381.1995.tb14949.x; CROSS AJ, 1991, BRIT J PHARMACOL, V104, P406, DOI 10.1111/j.1476-5381.1991.tb12443.x; DOBKIN JA, 1989, ARCH NEUROL-CHICAGO, V46, P1333, DOI 10.1001/archneur.1989.00520480077023; Dogan A, 1999, J NEUROCHEM, V72, P765, DOI 10.1046/j.1471-4159.1999.0720765.x; DOMANN R, 1993, NEUROSCI LETT, V155, P69, DOI 10.1016/0304-3940(93)90675-B; Empson RM, 2000, BRAIN RES, V884, P31, DOI 10.1016/S0006-8993(00)02875-4; Escott KJ, 1998, J CEREBR BLOOD F MET, V18, P281, DOI 10.1097/00004647-199803000-00006; Fedele E, 1999, PROG NEUROBIOL, V58, P89, DOI 10.1016/S0301-0082(98)00077-X; Ferriero DM, 1996, NEUROBIOL DIS, V3, P64, DOI 10.1006/nbdi.1996.0006; Forman LJ, 1998, NEUROCHEM RES, V23, P141, DOI 10.1023/A:1022468522564; Galvin KA, 1998, PEDIATR RES, V44, P740, DOI 10.1203/00006450-199811000-00017; Gilby KL, 1997, MOL BRAIN RES, V48, P87, DOI 10.1016/S0169-328X(97)00085-5; Green AR, 2000, NEUROPHARMACOLOGY, V39, P1483, DOI 10.1016/S0028-3908(99)00233-6; Green AR, 1998, PHARMACOL THERAPEUT, V80, P123, DOI 10.1016/S0163-7258(98)00024-2; Green AR, 1996, NEUROPHARMACOLOGY, V35, P1243, DOI 10.1016/S0028-3908(96)00060-3; GUBITS RM, 1993, MOL BRAIN RES, V18, P228, DOI 10.1016/0169-328X(93)90194-T; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; Ha HC, 1998, P NATL ACAD SCI USA, V95, P11140, DOI 10.1073/pnas.95.19.11140; Hagberg H, 1996, PEDIATR RES, V40, P603, DOI 10.1203/00006450-199610000-00015; HALES TG, 1992, EUR J PHARMACOL, V210, P239, DOI 10.1016/0014-2999(92)90410-6; HALLMAYER J, 1985, ACTA NEUROPATHOL, V68, P27, DOI 10.1007/BF00688952; Harmon D, 2003, ANESTH ANALG, V97, P13, DOI 10.1213/01.ANE.0000063821; HEISS WD, 1993, STROKE, V24, P1784, DOI 10.1161/01.STR.24.12.1784; Henley CM, 1997, J NEUROCHEM, V69, P259; Hodges H, 1996, NEUROSCIENCE, V72, P959, DOI 10.1016/0306-4522(96)00004-8; HU JG, 1994, NEUROSCI LETT, V175, P41, DOI 10.1016/0304-3940(94)91073-1; HUANG Z, 1996, J CEREB BLOOD FLOW M, V15, P378; Iadecola C, 1997, J NEUROSCI, V17, P9157; Jensen FE, 1998, J NEUROPHYSIOL, V79, P73, DOI 10.1152/jn.1998.79.1.73; JOHANSEN FF, 1993, ACTA NEUROL SCAND, V88, P1; JOHANSEN FF, 1983, ACTA NEUROPATHOL, V61, P135, DOI 10.1007/BF00697393; Jude EB, 1999, DIABETOLOGIA, V42, P748, DOI 10.1007/s001250051224; KAMIYA H, 1994, NATURE, V371, P603, DOI 10.1038/371603a0; Kapoor M, 2004, AM J PATHOL, V165, P299, DOI 10.1016/S0002-9440(10)63297-X; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; KIRINO T, 1986, STROKE, V17, P455, DOI 10.1161/01.STR.17.3.455; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KLEIHUES P, 1975, BRAIN RES, V95, P61, DOI 10.1016/0006-8993(75)90207-3; KLEMPT ND, 1992, MOL BRAIN RES, V13, P93, DOI 10.1016/0169-328X(92)90048-G; LAGREZE HL, 1987, STROKE, V18, P882, DOI 10.1161/01.STR.18.5.882; LEVINE S, 1960, AM J PATHOL, V36, P1; Liu P, 2003, NEUROSCIENCE, V117, P965, DOI 10.1016/S0306-4522(02)00878-3; Marshall JWB, 2000, BRAIN RES BULL, V52, P21, DOI 10.1016/S0361-9230(99)00275-0; MOODY EJ, 1989, EUR J PHARMACOL, V164, P153, DOI 10.1016/0014-2999(89)90242-2; MUNELL F, 1994, DEV BRAIN RES, V77, P111, DOI 10.1016/0165-3806(94)90218-6; NATHAN T, 1991, J NEUROPHYSIOL, V66, P1704, DOI 10.1152/jn.1991.66.5.1704; NATHAN T, 1990, BRAIN RES, V531, P55, DOI 10.1016/0006-8993(90)90757-3; Nelson RM, 2000, BRIT J PHARMACOL, V130, P1124, DOI 10.1038/sj.bjp.0703398; Nelson RM, 2002, EUR J PHARMACOL, V452, P255, DOI 10.1016/S0014-2999(02)02233-1; NITSCH C, 1989, NEUROSCI LETT, V105, P263, DOI 10.1016/0304-3940(89)90631-9; Nurse S, 1996, J CEREBR BLOOD F MET, V16, P474, DOI 10.1097/00004647-199605000-00014; Palmer GC, 2001, CURR DRUG TARGETS, V2, P241, DOI 10.2174/1389450013348335; PASCHEN W, 1991, J CEREB BLOOD FLO S2, V11, P59; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; Pepicelli O, 2004, NEUROPHARMACOLOGY, V46, P480, DOI 10.1016/j.neuropharm.2003.10.010; Piantadosi CA, 1996, STROKE, V27, P327, DOI 10.1161/01.STR.27.2.327; PULSINELLI WA, 1982, ANN NEUROL, V11, P725; Que M, 1999, NEUROSCIENCE, V93, P1233, DOI 10.1016/S0306-4522(99)00197-9; Rao AM, 2000, J NEUROCHEM, V74, P1106; RAO AM, 1995, J NEUROCHEM, V65, P2639; Rao VLR, 1998, BRAIN RES, V783, P163, DOI 10.1016/S0006-8993(97)01301-2; Reinecke S, 1999, NEUROSCI LETT, V261, P85, DOI 10.1016/S0304-3940(99)00014-2; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Robello M, 1996, NEUROSCIENCE, V74, P99, DOI 10.1016/0306-4522(96)00110-8; Sari P, 2001, EPILEPSY RES, V47, P65, DOI 10.1016/S0920-1211(01)00295-9; SILVERSTEIN FS, 1986, J NEUROCHEM, V47, P1614, DOI 10.1111/j.1471-4159.1986.tb00803.x; Simi A, 2000, J CEREBR BLOOD F MET, V20, P1077, DOI 10.1097/00004647-200007000-00007; Simi A, 2002, J NEUROCHEM, V83, P727, DOI 10.1046/j.1471-4159.2002.01178.x; Sutherland BA, 2004, FASEB J, V18, P258, DOI 10.1096/fj.04-2806fje; Sydserff SG, 2000, BRAIN RES, V862, P59, DOI 10.1016/S0006-8993(00)02071-0; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TADOLINI B, 1988, BIOCHEM J, V249, P33, DOI 10.1042/bj2490033; TOWFIGHI J, 1994, BIOL NEONATE, V65, P108; TOWFIGHI J, 1995, ACTA NEUROPATHOL, V90, P375, DOI 10.1007/BF00315011; van den Tweel ERW, 2002, DEV NEUROSCI-BASEL, V24, P389, DOI 10.1159/000069044; Vannucci RC, 2001, PEDIATR RES, V49, P799, DOI 10.1203/00006450-200106000-00015; Wall MJ, 2003, EUR J NEUROSCI, V18, P869, DOI 10.1046/j.1460-9568.2003.02822.x; WATANABE H, 1990, FREE RADICAL BIO MED, V8, P507, DOI 10.1016/0891-5849(90)90150-H; WISE R, 1986, STROKE, V17, P853, DOI 10.1161/01.STR.17.5.853; Zheng YW, 2003, HIPPOCAMPUS, V13, P873, DOI 10.1002/hipo.10174; Ziemann U, 1996, ANN NEUROL, V40, P367, DOI 10.1002/ana.410400306	93	36	40	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1036	+		10.1096/fj.04-3367fje	http://dx.doi.org/10.1096/fj.04-3367fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15809357				2022-12-28	WOS:000228865300030
J	Desbois-Mouthon, C; Wendum, D; Cadoret, A; Rey, C; Leneuve, P; Blaise, A; Housset, C; Tronche, F; Le Bouc, Y; Holzenberger, M				Desbois-Mouthon, Christele; Wendum, Dominique; Cadoret, Axelle; Rey, Colette; Leneuve, Patricia; Blaise, Annick; Housset, Chantal; Tronche, Francois; Le Bouc, Yves; Holzenberger, Martin			Hepatocyte proliferation during liver regeneration is impaired in mice with liver-specific IGF-1R knockout	FASEB JOURNAL			English	Article						cyclin; insulin-like growth factor type 1 receptor; insulin receptor substrate; partial hepatectomy	GROWTH-FACTOR-I; INSULIN-RECEPTOR SUBSTRATE-1; RAT-BRAIN; EXPRESSION; BINDING; GENE; PHYSIOLOGY; IRS-1; PHOSPHORYLATION; DEGRADATION	Recent evidence indicates that growth hormone (GH) is involved in liver regeneration. To test whether insulin-like growth factor I (IGF-I) mediates this effect, we studied liver regeneration induced by partial hepatectomy in liver-specific IGF type 1 receptor knockout (LIGFREKO) mice. The absence of IGF-1R caused a significant decrease in hepatocyte proliferation in males (-52%), but not in females, as assessed by Ki67 immunohistochemistry. Cyclin D1 and cyclin A protein levels in the livers of LIGFREKO males were only half those in controls, indicating that cyclin induction during liver regeneration is dependent on IGF-1R signaling. Analyzing the signaling cascade initiated by IGF-1R, we observed a lack of IRS-1 induction in LIGFREKO livers. In contrast, the induction of IRS-2 synthesis was similar in LIGFREKO and control groups, suggesting the existence of differential regulation of IRS synthesis during liver regeneration. Regenerating livers from LIGFREKO animals also showed significantly less activated ERKs than controls. Our findings demonstrate that IGF-1R makes a significant contribution to liver regeneration. Using the LIGFREKO model, we provide new evidence that IGF-1R/IRS-1/ERK signaling may be the intracellular pathway controlling the cell cycle via cyclin D1 and cyclin A in the regenerating liver.	Hop St Antoine, INSERM, U515, F-75571 Paris 12, France; Hop St Antoine, INSERM, U680, F-75571 Paris 12, France; Univ Paris 06, Fac Med St Antoine, F-75012 Paris, France; Hop St Antoine, Serv Anatomopathol, F-75571 Paris, France; Coll France, CNRS, UMR 7148, F-75231 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France	Holzenberger, M (corresponding author), Hop St Antoine, INSERM, U515, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.	holzenberger@st-antoine.inserm.fr	TRONCHE, François/F-3895-2011; Holzenberger, Martin/N-9732-2018; Cadoret, Axelle/L-2529-2017; Desbois-Mouthon, Christele/M-7076-2017	Cadoret, Axelle/0000-0002-4283-6864; Desbois-Mouthon, Christele/0000-0002-0772-1711; Housset, Chantal/0000-0001-6469-0651; Holzenberger, Martin/0000-0003-4869-725X				Borowiak M, 2004, P NATL ACAD SCI USA, V101, P10608, DOI 10.1073/pnas.0403412101; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; Cadoret A, 2005, INT J CANCER, V114, P668, DOI 10.1002/ijc.20805; CARO JF, 1988, J CLIN INVEST, V81, P976, DOI 10.1172/JCI113451; Carrillo MC, 2001, LIFE SCI, V68, P1417, DOI 10.1016/S0024-3205(01)00936-5; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Dupont J, 2001, HORM RES, V55, P22, DOI 10.1159/000063469; Dupont JL, 2003, J BIOL CHEM, V278, P37256, DOI 10.1074/jbc.M302355200; Escribano O, 2003, HEPATOLOGY, V37, P1461, DOI 10.1053/jhep.2003.50245; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Giannone PJ, 2004, BBA-GEN SUBJECTS, V1672, P112, DOI 10.1016/j.bbagen.2004.03.003; Hallak H, 2002, HEPATOLOGY, V36, P1509, DOI 10.1053/jhep.2002.37138; Hamelers IHL, 2002, J BIOL CHEM, V277, P47645, DOI 10.1074/jbc.M208727200; Harada H, 2001, J APPL PHYSIOL, V91, P2816, DOI 10.1152/jappl.2001.91.6.2816; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Holzenberger M, 2000, ENDOCRINOLOGY, V141, P2557, DOI 10.1210/en.141.7.2557; Holzenberger M, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.21.e92; Kellendonk C, 2000, GENESIS, V26, P151, DOI 10.1002/(SICI)1526-968X(200002)26:2<151::AID-GENE17>3.0.CO;2-E; Kuemmerle JF, 2004, AM J PHYSIOL-GASTR L, V286, pG412, DOI 10.1152/ajpgi.00403.2003; LEE JY, 1994, HEPATOLOGY, V19, P656, DOI 10.1002/hep.1840190317; Leneuve P, 2001, BIOTECHNIQUES, V31, P1156, DOI 10.2144/01315rr05; Leu JI, 2003, MOL CELL BIOL, V23, P1251, DOI 10.1128/MCB.23.4.1251-1259.2003; Leu JI, 2003, J CLIN INVEST, V111, P129, DOI 10.1172/JCI200316712; Li W, 2002, J BIOL CHEM, V277, P28411, DOI 10.1074/jbc.M202807200; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; LORUP C, 1977, CELL TISSUE KINET, V10, P477, DOI 10.1111/j.1365-2184.1977.tb00866.x; Mangnall D, 2003, LIVER INT, V23, P124, DOI 10.1034/j.1600-0676.2003.00812.x; Mao XH, 1999, P NATL ACAD SCI USA, V96, P5037, DOI 10.1073/pnas.96.9.5037; MCELDUFF A, 1988, ENDOCRINOLOGY, V122, P1933, DOI 10.1210/endo-122-5-1933; Moghaddam AP, 1998, TOXICOLOGY, V130, P95, DOI 10.1016/S0300-483X(98)00095-X; MOHN KL, 1991, MOL CELL BIOL, V11, P1393, DOI 10.1128/MCB.11.3.1393; Paulsen J E, 1990, In Vivo, V4, P235; Pennisi PA, 2004, ENDOCRINOLOGY, V145, P4748, DOI 10.1210/en.2004-0655; Price JA, 2002, HEPATOLOGY, V36, P1089, DOI 10.1053/jhep.2002.36158; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; SANTOS A, 1994, MOL CELL ENDOCRINOL, V101, P85, DOI 10.1016/0303-7207(94)90222-4; SASAKI Y, 1993, J BIOL CHEM, V268, P3805; Sjogren K, 1999, P NATL ACAD SCI USA, V96, P7088, DOI 10.1073/pnas.96.12.7088; Smith LK, 1996, MOL CELL ENDOCRINOL, V122, P81, DOI 10.1016/0303-7207(96)03875-0; Taub R, 2004, NAT REV MOL CELL BIO, V5, P836, DOI 10.1038/nrm1489; von Wichert T, 2005, ONCOGENE, V24, P1284, DOI 10.1038/sj.onc.1208264; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324; Yamada Y, 1998, HEPATOLOGY, V28, P959, DOI 10.1002/hep.510280410; Zhang H, 2000, J BIOL CHEM, V275, P22558, DOI 10.1074/jbc.M000412200	45	88	94	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					773	+		10.1096/fj.05-4704fje	http://dx.doi.org/10.1096/fj.05-4704fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16484330	Green Submitted			2022-12-28	WOS:000237698700016
J	Noyan-Ashraf, MH; Wu, LY; Wang, R; Juurlink, BHJ				Noyan-Ashraf, Mohammad Hossein; Wu, Lingyun; Wang, Rui; Juurlink, Bernhard H. J.			Dietary approaches to positively influence fetal determinants of adult health	FASEB JOURNAL			English	Article									[Noyan-Ashraf, Mohammad Hossein; Juurlink, Bernhard H. J.] Univ Saskatchewan, Coll Med, Dept Anat & Cell Biol, Saskatoon, SK S7N 5E5, Canada; [Wu, Lingyun] Univ Saskatchewan, Coll Med, Dept Pharmacol, Saskatoon, SK S7N 5E5, Canada; [Wang, Rui] Univ Saskatchewan, Coll Med, Dept Physiol, Saskatoon, SK S7N 5E5, Canada	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan	Juurlink, BHJ (corresponding author), Univ Saskatchewan, Coll Med, Dept Anat & Cell Biol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	juurlink@duke.usask.ca	Wang, Rui/C-7824-2012	Wang, Rui/0000-0003-3825-3620					0	42	42	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					371	373		10.1096/fj.05-4889fje	http://dx.doi.org/10.1096/fj.05-4889fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16354723				2022-12-28	WOS:000207915000025
J	Sexton, A; Drake, PM; Mahmood, N; Harman, SJ; Shattock, RJ; Ma, JKC				Sexton, Amy; Drake, Pascal M.; Mahmood, Naheed; Harman, Sarah J.; Shattock, Robin J.; Ma, Julian K-C.			Transgenic plant production of Cyanovirin-N, an HIV microbicide	FASEB JOURNAL			English	Article									[Sexton, Amy; Drake, Pascal M.; Mahmood, Naheed; Harman, Sarah J.; Shattock, Robin J.; Ma, Julian K-C.] St Georges Univ London, Dept Cellular & Mol Med, Ctr Infect, London SW17 0RE, England	St Georges University London	Sexton, A (corresponding author), St Georges Univ London, Dept Cellular & Mol Med, Ctr Infect, London SW17 0RE, England.	a.sexton@sgul.ac.uk		Drake, Pascal/0000-0002-6181-0600; Harman, Sarah/0000-0001-6443-0614; Ma, Julian/0000-0003-0767-0042					0	64	71	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					356	358		10.1096/fj.05-4742fje	http://dx.doi.org/10.1096/fj.05-4742fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16354721				2022-12-28	WOS:000207915000020
J	Knight, KR; Uda, Y; Findlay, MW; Brown, DL; Cronin, KJ; Jamieson, E; Tai, T; Keramidaris, E; Penington, AJ; Rophael, J; Harrison, LC; Morrison, WA				Knight, KR; Uda, Y; Findlay, MW; Brown, DL; Cronin, KJ; Jamieson, E; Tai, T; Keramidaris, E; Penington, AJ; Rophael, J; Harrison, LC; Morrison, WA			RETRACTED: Vascularized tissue-engineered chambers promote survival and function of transplanted islets and improve glycemic control (Retracted Article. See vol 22, pg 3747, 2008)	FASEB JOURNAL			English	Article; Retracted Publication						streptozotocin; diabetes; islet transplantation; vascularized chambers; renal capsule	TYPE-1 DIABETES-MELLITUS; EXTRACELLULAR-MATRIX; GRAFT-SURVIVAL; MOUSE; ALGINATE; GROWTH; MODEL; MICROENCAPSULATION; GENERATION; MEMBRANE	We have developed a chamber model of islet engraftment that optimizes islet survival by rapidly restoring islet-extracellular matrix relationships and vascularization. Our aim was to assess the ability of syngeneic adult islets seeded into blood vessel-containing chambers to correct streptozotocin-induced diabetes in mice. Approximately 350 syngeneic islets suspended in Matrigel (R) extracellular matrix were inserted into chambers based on either the splenic or groin (epigastric) vascular beds, or, in the standard approach, injected under the renal capsule. Blood glucose was monitored weekly for 7 weeks, and an intraperitoneal glucose tolerance test performed at 6 weeks in the presence of the islet grafts. Relative to untreated diabetic animals, glycemic control significantly improved in all islet transplant groups, strongly correlating with islet counts in the graft (P < 0.01), and with best results in the splenic chamber group. Glycemic control deteriorated after chambers were surgically removed at week 8. Immunohistochemistry revealed islets with abundant insulin content in grafts from all groups, but with significantly more islets in splenic chamber grafts than the other treatment groups (P < 0.05). It is concluded that hyperglycemia in experimental type 1 diabetes can be effectively treated by islets seeded into a vascularized chamber functioning as a "pancreatic organoid".	Univ Melbourne, Dept Surg, Fitzroy, Vic 3065, Australia; Univ Michigan, Div Plast Surg, Ann Arbor, MI 48109 USA; Mater Misericordiae Univ Hosp, Dept Plast & Reconstruct Surg, Dublin 7, Ireland; St Vincents Inst, Fitzroy, Vic, Australia; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Autoimmun & Transplantat Div, Melbourne, Vic, Australia	University of Melbourne; University of Michigan System; University of Michigan; Mater Misericordiae University Hospital; University College Dublin; St. Vincent's Institute of Medical Research; Royal Melbourne Hospital; Walter & Eliza Hall Institute	Knight, KR (corresponding author), OBrien Inst Microsurg, 42 Fitzroy St, Fitzroy, Vic 3065, Australia.	Kenneth.Knight@svhm.org.au		Brown, David/0000-0002-5889-9886				Bhargava R, 2004, DIABETES, V53, P1311, DOI 10.2337/diabetes.53.5.1311; Bottino R, 2004, DIABETES, V53, P2559, DOI 10.2337/diabetes.53.10.2559; BROWN DL, 2005, IN PRESS CELL T 0928; Cassell OCS, 2001, ANN NY ACAD SCI, V944, P429; Cronin KJ, 2004, PLAST RECONSTR SURG, V113, P260, DOI 10.1097/01.PRS.0000095942.71618.9D; CUTHBERTSON RA, 1986, AUST J EXP BIOL MED, V64, P175, DOI 10.1038/icb.1986.19; DeVos P, 1997, DIABETOLOGIA, V40, P262; Dickson BC, 2003, TRANSPLANTATION, V75, P599, DOI 10.1097/01.TP.0000048226.28357.0D; Duvivier-Kali VF, 2001, DIABETES, V50, P1698, DOI 10.2337/diabetes.50.8.1698; FOLKMAN J, 1973, J EXP MED, V138, P745, DOI 10.1084/jem.138.4.745; Gray DWR, 2001, WORLD J SURG, V25, P497, DOI 10.1007/s002680020343; HILLER WFA, 1991, DIABETES, V40, P134, DOI 10.2337/diabetes.40.1.134; Hirshberg B, 2002, J CLIN ENDOCR METAB, V87, P5424, DOI 10.1210/jc.2002-020684; Hofer SOP, 2005, BRIT J PLAST SURG, V58, P1104, DOI 10.1016/j.bjps.2005.04.033; Jiang FX, 1999, DIABETES, V48, P722, DOI 10.2337/diabetes.48.4.722; Juang JH, 2000, TRANSPLANT P, V32, P1076, DOI 10.1016/S0041-1345(00)01131-3; Kawaguchi N, 1998, P NATL ACAD SCI USA, V95, P1062, DOI 10.1073/pnas.95.3.1062; Kin T, 2003, AM J TRANSPLANT, V3, P281, DOI 10.1034/j.1600-6143.2003.00049.x; Li XY, 2004, J BIOL CHEM, V279, P765, DOI 10.1074/jbc.M307907200; Matarazzo M, 2002, CELL TRANSPLANT, V11, P103; MELLGREN A, 1986, DIABETOLOGIA, V29, P670, DOI 10.1007/BF00869269; Messina A, 2005, FASEB J, V19, P1570, DOI 10.1096/fj.04-3241fje; Mian RW, 2000, TISSUE ENG, V6, P595, DOI 10.1089/10763270050199541; Nagata N, 2001, CELL TRANSPLANT, V10, P447; Niklason LE, 2001, JAMA-J AM MED ASSOC, V285, P573, DOI 10.1001/jama.285.5.573; Rother KI, 2004, J CLIN INVEST, V114, P877, DOI 10.1172/JC1200423235; Ryan EA, 2002, DIABETES, V51, P2148, DOI 10.2337/diabetes.51.7.2148; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Tanaka Y, 2000, BRIT J PLAST SURG, V53, P51, DOI 10.1054/bjps.1999.3186; Thomas HE, 1999, J IMMUNOL, V163, P1562	30	25	25	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					565	+		10.1096/fj.05-4879fje	http://dx.doi.org/10.1096/fj.05-4879fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16436466	Green Published			2022-12-28	WOS:000235996000005
J	Mei, FC; Young, TW; Liu, JS; Cheng, XD				Mei, FC; Young, TW; Liu, JS; Cheng, XD			RAS-mediated epigenetic inactivation of OPCML in oncogenic transformation of human ovarian surface epithelial cells	FASEB JOURNAL			English	Article						ovarian cancer; oncogene; DNA methylation	SIGNALING PATHWAY; DNA METHYLATION; GENE-MUTATIONS; CANCER; METHYLTRANSFERASE; EXPRESSION; PROTEIN; TUMORS; MODEL; PROTOONCOGENE	Opioid binding protein/cell adhesion molecule-like gene (OPCML), a recently identified tumor-suppressor, is frequently inactivated by allele loss and CpG island promoter methylation in epithelial ovarian cancer. Since elevated activation of the RAS signaling pathway, including overexpression of HER-2/neu and mutations of RAS and BRAF, is common in human ovarian carcinoma, we examined the cellular effect of oncogenic RAS on the expression status of OPCML in a genetically defined human ovarian cancer model. Our study revealed that RAS(V12)-mediated oncogenic transformation was accompanied by a concomitant loss of OPCML expression. Methylation-sensitive PCR analysis showed that the OPCML promoter was hypermethylated in RAS-transformed human ovarian epithelial cells (T29H) and that treatment with the DNA methyltransferase inhibitor 5'-aza-2'-deoxycytidine promoted demethylation of the OPCML promoter and restored OPCML expression in T29H cells. Furthermore, suppression of oncogenic RAS activity by stable siRNA specific for HRAS(V12) led to the demethylation and re-expression of OPCML in T29H cells, demonstrating that oncogenic RAS activity is directly responsible for the observed OPCML promoter hypermethylation and epigenetic gene silencing of OPCML. Taken together, our study suggests that elevation of the RAS signaling pathway may play an important role in epigenetic inactivation of OPCML in human epithelial ovarian cancer.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Sealy Ctr Canc Cell Biol,Sch Med, Galveston, TX 77555 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; UTMD Anderson Cancer Center	Cheng, XD (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Sealy Ctr Canc Cell Biol,Sch Med, 301 Univ Blvd, Galveston, TX 77555 USA.	xcheng@utmb.edu			NIGMS NIH HHS [GM060170] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060170] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alcock RA, 2002, ONCOGENE, V21, P7883, DOI 10.1038/sj.onc.1205948; Baylin Stephen B., 2000, P293; BOS JL, 1989, CANCER RES, V49, P4682; Contente S, 1999, MOL CELL BIOCHEM, V194, P79, DOI 10.1023/A:1006913122261; Deng C, 1998, BIOL CHEM, V379, P1113, DOI 10.1515/bchm.1998.379.8-9.1113; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Gemignani ML, 2003, GYNECOL ONCOL, V90, P378, DOI 10.1016/S0090-8258(03)00264-6; Guan RJ, 1999, GASTROENTEROLOGY, V116, P1063, DOI 10.1016/S0016-5085(99)70009-0; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; ICHIKAWA Y, 1994, CANCER RES, V54, P33; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MOK SCH, 1993, CANCER RES, V53, P1489; Ordway JM, 2004, ONCOGENE, V23, P3737, DOI 10.1038/sj.onc.1207483; Patton SE, 1998, CANCER RES, V58, P2253; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; PRUITT K, 2005, J BIOL CHEM; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; SCHOFIELD PR, 1989, EMBO J, V8, P489, DOI 10.1002/j.1460-2075.1989.tb03402.x; Sellar GC, 2003, NAT GENET, V34, P337, DOI 10.1038/ng1183; Shields JM, 2002, MOL CELL BIOL, V22, P2304, DOI 10.1128/MCB.22.7.2304-2317.2002; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Soejima K, 2003, ONCOGENE, V22, P4723, DOI 10.1038/sj.onc.1206510; Varras MN, 1999, ONCOLOGY-BASEL, V56, P89, DOI 10.1159/000011946; Yang G, 2003, ONCOGENE, V22, P5694, DOI 10.1038/sj.onc.1206858; Young T, 2005, ONCOGENE, V24, P6174, DOI 10.1038/sj.onc.1208753; Young TW, 2004, CANCER RES, V64, P4577, DOI 10.1158/0008-5472.CAN-04-0222	30	32	35	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2005	19	14					497	+		10.1096/fj.05-4586fje	http://dx.doi.org/10.1096/fj.05-4586fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16384911				2022-12-28	WOS:000234405500016
J	Krishnan, M; Park, JM; Cao, F; Wang, DX; Paulmurugan, R; Tseng, JR; Gonzalgo, ML; Gambhir, SS; Wu, JC				Krishnan, M; Park, JM; Cao, F; Wang, DX; Paulmurugan, R; Tseng, JR; Gonzalgo, ML; Gambhir, SS; Wu, JC			Effects of epigenetic modulation on reporter gene expression: implications for stem cell imaging	FASEB JOURNAL			English	Article						gene silencing; molecular imaging; stem cell transplant	POSITRON-EMISSION-TOMOGRAPHY; MYOBLAST TRANSFER THERAPY; TRANSGENE EXPRESSION; DNA METHYLATION; LIVING MICE; IN-VITRO; CANCER; TRANSPLANTATION; REACTIVATION; VECTOR	Tracking stem cell localization, survival, differentiation, and proliferation after transplantation in living subjects is essential for understanding stem cell biology and physiology. In this study, we investigated the long-term stability of reporter gene expression in an embryonic rat cardiomyoblast cell line and the role of epigenetic modulation on reversing reporter gene silencing. Cells were stably transfected with plasmids carrying cytomegalovirus promoter driving firefly luciferase reporter gene (CMV-Fluc) and passaged repeatedly for 3-8 months. Within the highest expressor clone, the firefly luciferase activity decreased progressively from passage 1 ( 843 +/- 28) to passage 20 ( 250 +/- 10) to passage 40 ( 44 +/- 3) to passage 60 ( 3 +/- 1 RLU/mu g; P < 0.05 vs. passage 1). Firefly luciferase activity was maximally rescued by treatment with 5-azacytidine ( DNA methyltransferase inhibitor) compared with trichostatin A ( histone deacetylase inhibitor) and retinoic acid ( transcriptional activator; P < 0.05). Increasing dosages of 5-azacytidine treatment led to higher levels of firefly luciferase mRNA ( RT-PCR) and protein ( Western blots) and inversely lower levels of methylation in the CMV promoter ( DNA nucleotide sequence). These in vitro results were extended to in vivo bioluminescence imaging (BLI) of cell transplant in living animals. Cells treated with 5-azacytidine were monitored for 2 wk compared with 1 wk for untreated cells ( P < 0.05). These findings should have important implications for reporter gene-based imaging of stem cell transplantation.	Stanford Univ, Mol Imaging Program Stanford, Dept Radiol, Palo Alto, CA 94304 USA; Stanford Univ, BioX Program, Palo Alto, CA 94304 USA; Johns Hopkins Med Inst, James Buchanan Brady Urol Inst, Baltimore, MD 21205 USA; Stanford Univ, Dept Bioengn, Palo Alto, CA 94304 USA; Stanford Univ, Dept Med, Div Cardiol, Palo Alto, CA 94304 USA	Stanford University; Stanford University; Johns Hopkins University; Johns Hopkins Medicine; Stanford University; Stanford University	Wu, JC (corresponding author), Stanford Univ, Sch Med, Edwards Bldg,R354, Stanford, CA 94305 USA.	joewu@stanford.edu	; Wu, Joseph/H-1067-2013	Paulmurugan, Ramasamy/0000-0001-7155-4738; Park, MD, PhD, FACR, Jinha M./0000-0002-0849-3482; Wu, Joseph/0000-0002-6068-8041	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL074883] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL074883] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JY, 2002, NAT MED, V8, P891, DOI 10.1038/nm743; Adonai N, 2002, P NATL ACAD SCI USA, V99, P3030, DOI 10.1073/pnas.052709599; Aicher A, 2003, CIRCULATION, V107, P2134, DOI 10.1161/01.CIR.0000062649.63838.C9; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Blasberg RG, 2003, J CLIN INVEST, V111, P1620, DOI 10.1172/JCI200318855; Bulte JWM, 2001, NAT BIOTECHNOL, V19, P1141, DOI 10.1038/nbt1201-1141; Bulte JWM, 2004, NMR BIOMED, V17, P484, DOI 10.1002/nbm.924; Cao YA, 2004, P NATL ACAD SCI USA, V101, P221, DOI 10.1073/pnas.2637010100; Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399; Cheng JC, 2004, CANCER CELL, V6, P151, DOI 10.1016/j.ccr.2004.06.023; Fan Y, 1996, MUSCLE NERVE, V19, P853, DOI 10.1002/(SICI)1097-4598(199607)19:7<853::AID-MUS7>3.0.CO;2-8; Fazzari MJ, 2004, NAT REV GENET, V5, P446, DOI 10.1038/nrg1349; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Gaetano C, 2000, GENE THER, V7, P1624, DOI 10.1038/sj.gt.3301296; Jacobs A, 2001, LANCET, V358, P727, DOI 10.1016/S0140-6736(01)05904-9; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kim YH, 2005, J NUCL MED, V46, P305; KIMES BW, 1976, EXP CELL RES, V98, P367, DOI 10.1016/0014-4827(76)90447-X; Kohyama J, 2001, DIFFERENTIATION, V68, P235, DOI 10.1046/j.1432-0436.2001.680411.x; Lee-Pullen TF, 2004, TRANSPLANTATION, V78, P1172, DOI 10.1097/01.TP.0000137936.75203.B4; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Lippincott-Schwartz J, 2003, SCIENCE, V300, P87, DOI 10.1126/science.1082520; Loser P, 1998, J VIROL, V72, P180; Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298; Marsee DK, 2004, CANCER GENE THER, V11, P121, DOI 10.1038/sj.cgt.7700661; Massoud TF, 2003, GENE DEV, V17, P545, DOI 10.1101/gad.1047403; Meier JL, 2001, J VIROL, V75, P1581, DOI 10.1128/JVI.75.4.1581-1593.2001; Muller-Ehmsen J, 2002, CIRCULATION, V105, P1720, DOI 10.1161/01.CIR.0000013782.76324.92; Penuelas I, 2005, GASTROENTEROLOGY, V128, P1787, DOI 10.1053/j.gastro.2005.03.024; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Rasmussen Theodore P, 2003, Reprod Biol Endocrinol, V1, P100, DOI 10.1186/1477-7827-1-100; Reinecke H, 2002, J MOL CELL CARDIOL, V34, P251, DOI 10.1006/jmcc.2001.1494; Rosenqvist N, 2002, J GENE MED, V4, P248, DOI 10.1002/jgm.268; Skuk D, 2003, J NEUROPATH EXP NEUR, V62, P951, DOI 10.1093/jnen/62.9.951; Smythe GM, 2001, J CELL MOL MED, V5, P33, DOI 10.1111/j.1582-4934.2001.tb00136.x; SORM F, 1964, EXPERIENTIA, V20, P202, DOI 10.1007/BF02135399; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Weissleder Ralph, 2000, Nature Medicine, V6, P351, DOI 10.1038/73219; Wu JC, 2004, J NUCL CARDIOL, V11, P491, DOI 10.1016/j.nuclcard.2004.04.004; Wu JC, 2002, CIRCULATION, V106, P180, DOI 10.1161/01.CIR.0000023620.59633.53; Wu JC, 2001, MOL THER, V4, P297, DOI 10.1006/mthe.2001.0460; Yamazaki S, 2003, J HEPATOL, V38, P107, DOI 10.1016/S0168-8278(03)80630-X	43	104	110	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					106	+		10.1096/fj.05-4551fje	http://dx.doi.org/10.1096/fj.05-4551fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16246867	Green Accepted			2022-12-28	WOS:000232991100011
J	Park, CS				Park, CS			Role of compensatory mammary growth in epigenetic control of gene expression	FASEB JOURNAL			English	Article						compensatory growth; mammary development; lactation potential; metabolic imprinting; epigenetics	MILK PROTEIN GENE; CELL-PROLIFERATION; DAIRY HEIFERS; LACTATION; RATS; GLAND; MECHANISMS; NUTRITION; DIFFERENTIATION; RESTRICTION	To better understand the role of nutrition in regulating mammary gland development and lactation, we designed a novel stair-step compensatory nutrition regimen that is a unique combination of dietary energy restriction and realimentation (refeeding) phases; the basic concept of this regimen is to exploit the biological nature of the compensatory growth phenomenon in concert with one or more hormone-sensitive allometric phases of mammary development (i. e., peripuberty through gestation). Nutritionally induced compensatory growth during different developmental stages before first parturition positively affects mammary development and life-long lactation performance. This permanent enhancement of mammary gland growth and lactation potential strongly suggests a possible mechanistic link between nutritionally induced compensatory growth, epigenetic control of mammary gene expression, and metabolic imprinting. We hypothesize that compensatory-directed metabolic imprinting once set during late pregnancy prior to the first parturition persistently maintains and exerts its adaptive response on mammogenesis and galactopoiesis (i. e., maintenance and/or enhancement of milk secretion). The ability to influence heritable genes regulating milk synthesis may be used to improve the quality and quantity of milk ( e. g., infant health, the secretion of certain immunoglobulins or growth factors) as well as the longevity of lactation.	N Dakota State Univ, Dept Anim & Range Sci, Fargo, ND 58105 USA	North Dakota State University Fargo	Park, CS (corresponding author), N Dakota State Univ, Dept Anim & Range Sci, Hultz Hall, Fargo, ND 58105 USA.	c.park@ndsu.edu						ASHWORTH A, 1986, NUTR REV, V44, P157, DOI 10.1111/j.1753-4887.1986.tb07613.x; Choi YJ, 1998, J NUTR BIOCHEM, V9, P380, DOI 10.1016/S0955-2863(98)00027-8; Choi YJ, 1997, J DAIRY SCI, V80, P519, DOI 10.3168/jds.S0022-0302(97)75965-4; CRENSHAW J D, 1989, Journal of Animal Science, V67, P107; Dijkstra J, 1997, J DAIRY SCI, V80, P2340, DOI 10.3168/jds.S0022-0302(97)76185-X; ENCINIAS AM, 2001, J ANIM S1, V79, P296; FILHO JDC, 2000, RES COMMUN MOL PATH, V108, P213; Ford JA, 2001, J DAIRY SCI, V84, P1669, DOI 10.3168/jds.S0022-0302(01)74602-4; Forsyth IA, 1996, J DAIRY SCI, V79, P1085, DOI 10.3168/jds.S0022-0302(96)76462-7; Ginger MR, 2001, MOL ENDOCRINOL, V15, P1993, DOI 10.1210/me.15.11.1993; Hales CN, 2003, DIABETOLOGIA, V46, P1013, DOI 10.1007/s00125-003-1131-7; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Kim HH, 2004, J NUTR, V134, P756, DOI 10.1093/jn/134.4.756; Kim SH, 1998, BRIT J NUTR, V79, P177, DOI 10.1079/BJN19980029; Kleinberg DL, 2000, J MAMMARY GLAND BIOL, V5, P7, DOI 10.1023/A:1009507030633; Laubach M. S., 2003, Journal of Dairy Science, V86, P166; Lin CH, 1998, J NUTR, V128, P1636, DOI 10.1093/jn/128.10.1636; Lucas A, 1996, BRIT J NUTR, V76, P605, DOI 10.1079/BJN19960066; Moon YS, 2002, ASIAN AUSTRAL J ANIM, V15, P1364, DOI 10.5713/ajas.2002.1364; Moon YS, 1999, J NUTR, V129, P1156, DOI 10.1093/jn/129.6.1156; NEWSHOLME EA, 1980, NEW ENGL J MED, V302, P400, DOI 10.1056/NEJM198002143020711; Park CS, 1998, J DAIRY SCI, V81, P243, DOI 10.3168/jds.S0022-0302(98)75572-9; PARK CS, 1989, GROWTH DEVELOP AGING, V53, P159; PARK CS, 1987, J ANIM SCI, V64, P1751, DOI 10.2527/jas1987.6461751x; PARK CS, 1988, FASEB J, V2, P2619, DOI 10.1096/fasebj.2.10.2454864; PARK CS, 2002, RECENT DEV RUMINANT, V4, P581; PERI I, 1993, J DAIRY SCI, V76, P742, DOI 10.3168/jds.S0022-0302(93)77398-1; Razin Aharon, 1999, Results and Problems in Cell Differentiation, V25, P189; REEVES PG, 1993, J NUTR, V123, P1936; Riggs A. D., 1996, TORRENTS SPRING, P1; RUSSELL DH, 1972, BIOCHEM J, V130, P71, DOI 10.1042/bj1300071; Sivaraman L, 1998, CARCINOGENESIS, V19, P1573, DOI 10.1093/carcin/19.9.1573; Thordarson G., 1987, The mammary gland. Development, regulation, and function., P459; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; Waterland RA, 1999, AM J CLIN NUTR, V69, P179; WILSON PN, 1960, BIOL REV, V35, P324, DOI 10.1111/j.1469-185X.1960.tb01327.x	38	31	31	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					1586	1591		10.1096/fj.05-3816hyp	http://dx.doi.org/10.1096/fj.05-3816hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16195367				2022-12-28	WOS:000232991100036
J	Funasaka, T; Yanagawa, T; Hogan, V; Raz, A				Funasaka, T; Yanagawa, T; Hogan, V; Raz, A			Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia	FASEB JOURNAL			English	Article						hypoxia-inducible factor-1; phosphoglucose isomerase; VEGF	NUCLEAR-LOCALIZATION SEQUENCE; FIBROBLAST GROWTH-FACTOR; TUMOR-CELLS; INDUCIBLE FACTOR-1; GLYCOLYTIC-ENZYMES; HEMOLYTIC-ANEMIA; CANCER-CELLS; ISOMERASE; NEUROLEUKIN; SECRETION	Phosphoglucose isomerase (PGI; EC 5.3.1.9) is a housekeeping cytosolic enzyme of the sugar metabolism pathways that plays a key role in glycolysis and gluconeogenesis. PGI is a multifunctional dimeric protein that extracellularly acts as a cytokine with properties that include autocrine motility factor (AMF) eliciting mitogenic, motogenic, differentiation functions and has been implicated in tumor progression and metastasis. Since metastasis is regulated in part by hypoxia, which induces the transcription of metastasis-associated genes and anaerobic glycolic metabolism, we questioned whether hypoxia also regulates the expression level of tumor cells' PGI/AMF. We establish here that in the human breast carcinoma BT-549 cells hypoxia enhanced expression of the transcription factor hypoxia-inducible factor (HIF)-1, which in turn led to the up-regulation of PGI/AMF expression and was specifically inhibited by inhibitors of the phosphatidylinositol 3'-kinase signaling pathway. In addition, the hypoxia induction of PGI/AMF expression was suppressed by inhibitors of vascular endothelial growth factor ( VEGF) or VEGF receptors, suggesting that hypoxia-inducible VEGF regulates the PGI/AMF expression. Hypoxia also enhanced cancer cell motility, and these effects were strongly inhibited by the PGI/AMF, VEGF, or VEGF receptor inhibitors. The results presented here suggest that under hypoxic conditions the expression of PGI/AMF is regulated in part by the HIF pathway, which in turn increases the flow of the glycolytic cascade leading to an increased anaerobic energy generation; thus, inhibition of PGI/AMF expression and activities may provide a new therapeutic modality for treatment of hypoxic tumors.	Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Tumor Progress & Metastasis Program, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Raz, A (corresponding author), Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Tumor Progress & Metastasis Program, 110 E Warren Ave, Detroit, MI 48201 USA.	raza@karmanos.org			NCI NIH HHS [CA 51714] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051714] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; BAUMANN M, 1990, CANCER INVEST, V8, P351, DOI 10.3109/07357909009012053; Beutler E, 1997, BLOOD CELL MOL DIS, V23, P402, DOI 10.1006/bcmd.1997.0157; Blancher C, 2001, CANCER RES, V61, P7349; Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Cao MJ, 2000, BIOCHEM BIOPH RES CO, V272, P485, DOI 10.1006/bbrc.2000.2803; Daly EB, 2004, BBA-MOL CELL RES, V1691, P17, DOI 10.1016/j.bbamcr.2003.11.004; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FAIK P, 1988, NATURE, V332, P455, DOI 10.1038/332455a0; FILELLA X, 1991, TUMOR BIOL, V12, P360, DOI 10.1159/000217737; Funasaka T, 2002, INT J CANCER, V101, P217, DOI 10.1002/ijc.10617; Galle J, 1999, BRIT J PHARMACOL, V127, P195, DOI 10.1038/sj.bjp.0702495; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; GOMM SA, 1988, BRIT J CANCER, V58, P797, DOI 10.1038/bjc.1988.312; GURNEY ME, 1986, SCIENCE, V234, P574, DOI 10.1126/science.3020690; Haga A, 2000, BBA-PROTEIN STRUCT M, V1480, P235, DOI 10.1016/S0167-4838(00)00075-3; JANS DA, 1994, FASEB J, V8, P841, DOI 10.1096/fasebj.8.11.8070633; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kim JW, 2005, TRENDS BIOCHEM SCI, V30, P142, DOI 10.1016/j.tibs.2005.01.005; KO FN, 1994, BLOOD, V84, P4226, DOI 10.1182/blood.V84.12.4226.bloodjournal84124226; Komi A, 2003, EXP CELL RES, V283, P91, DOI 10.1016/S0014-4827(02)00029-0; Krishnamachary B, 2003, CANCER RES, V63, P1138; Lin YZ, 1996, J BIOL CHEM, V271, P5305, DOI 10.1074/jbc.271.10.5305; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; Matsumoto I, 1999, SCIENCE, V286, P1732, DOI 10.1126/science.286.5445.1732; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; Niinaka Y, 1998, CANCER RES, V58, P2667; Niizeki H, 2002, BRIT J CANCER, V86, P1914, DOI 10.1038/sj.bjc.6600331; Pawson T, 2002, EUR J CANCER, V38, pS3, DOI 10.1016/S0959-8049(02)80597-4; RUBARTELLI A, 1991, BIOCHEM SOC T, V19, P255, DOI 10.1042/bst0190255; SCHROTER W, 1985, EUR J PEDIATR, V144, P301, DOI 10.1007/BF00441768; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SHWEIKI D, 1992, NATURE, V359, P845; SIVITZ WI, 1992, AM J PHYSIOL, V263, pE562, DOI 10.1152/ajpendo.1992.263.3.E562; Tsutsumi S, 2003, CANCER RES, V63, P242; Visconti RP, 2002, P NATL ACAD SCI USA, V99, P8219, DOI 10.1073/pnas.122109599; Watanabe H, 1996, CANCER RES, V56, P2960; Xu W, 1996, BLOOD, V87, P4502, DOI 10.1182/blood.V87.11.4502.bloodjournal87114502; Yakirevich E, 2000, BIOL REPROD, V62, P1016, DOI 10.1095/biolreprod62.4.1016; Yanagawa T, 2004, LAB INVEST, V84, P513, DOI 10.1038/labinvest.3700057; Yeo EJ, 2003, J NATL CANCER I, V95, P516, DOI 10.1093/jnci/95.7.516; Yoon DY, 2001, BIOCHEM BIOPH RES CO, V288, P882, DOI 10.1006/bbrc.2001.5867	46	79	85	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2005	19	11					1422	1430		10.1096/fj.05-3699com	http://dx.doi.org/10.1096/fj.05-3699com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16126909				2022-12-28	WOS:000232315700035
J	Nikolova, T; Czyz, J; Rolletschek, A; Blyszczuk, P; Fuchs, J; Jovtchev, G; Schuderer, J; Kuster, N; Wobus, AM				Nikolova, T; Czyz, J; Rolletschek, A; Blyszczuk, P; Fuchs, J; Jovtchev, G; Schuderer, J; Kuster, N; Wobus, AM			Electromagnetic fields affect transcript levels of apoptosis-related genes in embryonic stem cell-derived neural progenitor cells	FASEB JOURNAL			English	Article						mouse embryonic stem cells; neuronal differentiation; GADD45; bcl-2; bax	CENTRAL-NERVOUS-SYSTEM; DNA STRAND BREAKS; MAGNETIC-FIELD; HUMAN-LYMPHOCYTES; TYROSINE KINASES; TRANSGENIC MICE; MHZ MICROWAVES; MESSENGER-RNA; BRAIN-CELLS; EXPOSURE	Mouse embryonic stem (ES) cells were used as an experimental model to study the effects of electromagnetic fields (EMF). ES-derived nestin-positive neural progenitor cells were exposed to extremely low frequency EMF simulating power line magnetic fields at 50 Hz (ELF-EMF) and to radiofrequency EMF simulating the Global System for Mobile Communication (GSM) signals at 1.71 GHz (RF-EMF). Following EMF exposure, cells were analyzed for transcript levels of cell cycle regulatory, apoptosis-related, and neural-specific genes and proteins; changes in proliferation; apoptosis; and cytogenetic effects. Quantitative RT-PCR analysis revealed that ELF-EMF exposure to ES-derived neural cells significantly affected transcript levels of the apoptosis-related bcl-2, bax, and cell cycle regulatory "growth arrest DNA damage inducible" GADD45 genes, whereas mRNA levels of neural-specific genes were not affected. RF-EMF exposure of neural progenitor cells resulted in down-regulation of neural-specific Nurr1 and in up-regulation of bax and GADD45 mRNA levels. Short-term RF-EMF exposure for 6 h, but not for 48 h, resulted in a low and transient increase of DNA double-strand breaks. No effects of ELF- and RF-EMF on mitochondrial function, nuclear apoptosis, cell proliferation, and chromosomal alterations were observed. We may conclude that EMF exposure of ES-derived neural progenitor cells transiently affects the transcript level of genes related to apoptosis and cell cycle control. However, these responses are not associated with detectable changes of cell physiology, suggesting compensatory mechanisms at the translational and posttranslational level.	Inst Plant Genet & Crop Plant Res, In Vitro Differentiat Grp, D-06466 Gatersleben, Germany; Fdn Res Informat Technol Soc, CH-8004 Zurich, Switzerland	Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung	Wobus, AM (corresponding author), Inst Plant Genet & Crop Plant Res, In Vitro Differentiat Grp, Corrensstr 3, D-06466 Gatersleben, Germany.	wobusam@ipk-gatersleben.de	Blyszczuk, Przemyslaw/J-2153-2019; Kuster, Niels/B-9706-2008	Blyszczuk, Przemyslaw/0000-0003-2521-3232; Czyz, Jaroslaw/0000-0001-6779-7630; Kuster, Niels/0000-0002-5827-3728; Jovtchev, Gabriele/0000-0002-0170-4718; Fuchs, Joerg/0000-0003-4171-5371				Adey WR, 2000, CANCER RES, V60, P1857; ANDERSON D, 1994, MUTAT RES, V307, P261, DOI 10.1016/0027-5107(94)90300-X; *APPL BIOS FCU, 2003, US B APPL BIOS FCU, V2; Auvinen A, 2002, EPIDEMIOLOGY, V13, P356, DOI 10.1097/00001648-200205000-00018; Bethwaite P, 2001, CANCER CAUSE CONTROL, V12, P683, DOI 10.1023/A:1011297803849; Chan WY, 2002, ANAT RECORD, V267, P261, DOI 10.1002/ar.10100; Chung HK, 2003, J BIOL CHEM, V278, P28079, DOI 10.1074/jbc.M212835200; Czyz J, 2004, BIOELECTROMAGNETICS, V25, P296, DOI 10.1002/bem.10199; Czyz J, 2003, BIOL CHEM, V384, P1391, DOI 10.1515/BC.2003.155; Debiak M, 2004, DNA REPAIR, V3, P359, DOI 10.1016/j.dnarep.2003.11.013; Di Carlo A, 2002, J CELL BIOCHEM, V84, P447, DOI 10.1002/jcb.10036.abs; Dibirdik I, 1998, J BIOL CHEM, V273, P4035, DOI 10.1074/jbc.273.7.4035; Fassler R, 1996, J CELL SCI, V109, P2989; Feychting M, 1997, EPIDEMIOLOGY, V8, P384, DOI 10.1097/00001648-199707000-00006; Grassi C, 2004, CELL CALCIUM, V35, P307, DOI 10.1016/j.ceca.2003.09.001; Harry GJ, 2000, RADIAT RES, V153, P642; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; *IEC, 1995, EL COMP EMC; Ivancsits S, 2002, MUTAT RES-GEN TOX EN, V519, P1, DOI 10.1016/S1383-5718(02)00109-2; Jin M, 2000, J CELL BIOCHEM, V78, P371, DOI 10.1002/1097-4644(20000901)78:3<371::AID-JCB3>3.0.CO;2-M; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kim JY, 2003, J NEUROCHEM, V85, P1443, DOI 10.1046/j.1471-4159.2003.01780.x; Kuster N, 2000, BIOELECTROMAGNETICS, V21, P508, DOI 10.1002/1521-186X(200010)21:7<508::AID-BEM4>3.0.CO;2-F; KUSTER NN, 1997, MOBILE COMMUNICATION; Lagroye I, 2004, INT J RADIAT BIOL, V80, P11, DOI 10.1080/09553000310001642911; Lai H, 2004, ENVIRON HEALTH PERSP, V112, P687, DOI 10.1289/ehp.6355; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Leszczynski D, 2002, DIFFERENTIATION, V70, P120, DOI 10.1046/j.1432-0436.2002.700207.x; Li Yi, 2002, Space Med Med Eng (Beijing), V15, P374; LIBURDY RP, 1992, FEBS LETT, V301, P53, DOI 10.1016/0014-5793(92)80209-Y; Lidsky TI, 2003, BRAIN, V126, P5, DOI 10.1093/brain/awg014; Liu Yun, 2003, Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, V21, P339; Lonn S, 2004, INT J CANCER, V108, P450, DOI 10.1002/ijc.11578; Maeda T, 2002, J INVEST DERMATOL, V119, P22, DOI 10.1046/j.1523-1747.2002.01781.x; McFarlane EH, 2000, BIOELECTROCHEMISTRY, V52, P23, DOI 10.1016/S0302-4598(00)00078-7; Mostafapour SP, 2002, J NEUROSCI, V22, P4670, DOI 10.1523/JNEUROSCI.22-11-04670.2002; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Narita K, 1997, IN VIVO, V11, P329; Oldenburg O, 2004, AM J PHYSIOL-HEART C, V286, pH468, DOI 10.1152/ajpheart.00360.2003; Pacini S, 1999, NEUROSCI LETT, V267, P185, DOI 10.1016/S0304-3940(99)00362-6; PERRY P, 1974, NATURE, V251, P156, DOI 10.1038/251156a0; Pipkin JL, 1999, BIOELECTROMAGNETICS, V20, P347, DOI 10.1002/(SICI)1521-186X(199909)20:6<347::AID-BEM3>3.0.CO;2-I; Poot M, 1996, J HISTOCHEM CYTOCHEM, V44, P1363, DOI 10.1177/44.12.8985128; Ratajczak MZ, 2004, LEUKEMIA, V18, P29, DOI 10.1038/sj.leu.2403184; Repacholi MH, 1997, RADIAT RES, V147, P631, DOI 10.2307/3579630; Rohwedel J, 2001, TOXICOL IN VITRO, V15, P741, DOI 10.1016/S0887-2333(01)00074-1; Rolletschek A, 2004, TOXICOL LETT, V149, P361, DOI 10.1016/j.toxlet.2003.12.064; Rolletschek A, 2001, MECH DEVELOP, V105, P93, DOI 10.1016/S0925-4773(01)00385-9; Roos W, 2004, ONCOGENE, V23, P359, DOI 10.1038/sj.onc.1207080; Salford LG, 2003, ENVIRON HEALTH PERSP, V111, P881, DOI 10.1289/ehp.6039; Sarkar SA, 2002, CELL STRUCT FUNCT, V27, P99, DOI 10.1247/csf.27.99; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; Saunders RD, 2002, HEALTH PHYS, V83, P366, DOI 10.1097/00004032-200209000-00006; Schonborn F, 2000, BIOELECTROMAGNETICS, V21, P372, DOI 10.1002/1521-186X(200007)21:5<372::AID-BEM6>3.0.CO;2-S; Schuderer J, 2004, BIOELECTROMAGNETICS, V25, P582, DOI 10.1002/bem.20037; SINGH NP, 1991, MUTAT RES, V252, P289, DOI 10.1016/0165-1161(91)90008-V; SISKEN BF, 1995, J NEUROSCI RES, V42, P692, DOI 10.1002/jnr.490420512; Sommer AM, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-77; Stang A, 2001, EPIDEMIOLOGY, V12, P7, DOI 10.1097/00001648-200101000-00003; Suliman Y, 2001, CANCER RES, V61, P6467; SZMIGIELSKI S, 1982, BIOELECTROMAGNETICS, V3, P179, DOI 10.1002/bem.2250030202; TENFORDE TS, 1992, ANNU REV PUBL HEALTH, V13, P173, DOI 10.1146/annurev.publhealth.13.1.173; Utteridge TD, 2002, RADIAT RES, V158, P357, DOI 10.1667/0033-7587(2002)158[0357:LTEOEP]2.0.CO;2; Ventura C, 2004, FASEB J, V18, P155, DOI 10.1096/fj.04-2695fje; Wallace OB, 1999, ADV AMIN AC MIM PEPT, V2, P1, DOI 10.1016/S1874-5113(99)80003-3; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wetzel B J, 2001, Biomed Sci Instrum, V37, P203; Wilkinson BL, 2002, MOL BRAIN RES, V99, P67, DOI 10.1016/S0169-328X(02)00113-4; Winter C, 2002, MOL BRAIN RES, V104, P194, DOI 10.1016/S0169-328X(02)00378-9; Wobus A M, 2002, Methods Mol Biol, V185, P127; Wobus AM, 2005, PHYSIOL REV, V85, P635, DOI 10.1152/physrev.00054.2003; Woods M, 2000, FASEB J, V14, P2284, DOI 10.1096/fj.00-0164com; WU RY, 1994, BIOELECTROMAGNETICS, V15, P531, DOI 10.1002/bem.2250150606; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989	75	131	145	0	41	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1686	+		10.1096/fj.04-3549fje	http://dx.doi.org/10.1096/fj.04-3549fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16116041				2022-12-28	WOS:000231843700009
J	Aguado, T; Monory, K; Palazuelos, J; Stella, N; Cravatt, B; Lutz, B; Marsicano, G; Kokaia, Z; Guzman, M; Galve-Roperh, I				Aguado, T; Monory, K; Palazuelos, J; Stella, N; Cravatt, B; Lutz, B; Marsicano, G; Kokaia, Z; Guzman, M; Galve-Roperh, I			The endocannabinoid system drives neural progenitor proliferation	FASEB JOURNAL			English	Article						cannabinoid; CB1 receptor; NP	CANNABINOID RECEPTORS; ANANDAMIDE; BRAIN; NEUROGENESIS; INVOLVEMENT; ASTROCYTES; BLOCKADE; INJURY; CELLS; BINDS	The discovery of multipotent neural progenitor (NP) cells has provided strong support for the existence of neurogenesis in the adult brain. However, the signals controlling NP proliferation remain elusive. Endocannabinoids, the endogenous counterparts of marijuana-derived cannabinoids, act as neuromodulators via presynaptic CB1 receptors and also control neural cell death and survival. Here we show that progenitor cells express a functional endocannabinoid system that actively regulates cell proliferation both in vitro and in vivo. Specifically, NPs produce endocannabinoids and express the CB1 receptor and the endocannabinoid-inactivating enzyme fatty acid amide hydrolase ( FAAH). CB1 receptor activation promotes cell proliferation and neurosphere generation, an action that is abrogated in CB1-deficient NPs. Accordingly, proliferation of hippocampal NPs is increased in FAAH-deficient mice. Our results demonstrate that endocannabinoids constitute a new group of signaling cues that regulate NP proliferation and thus open novel therapeutic avenues for manipulation of NP cell fate in the adult brain.	Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain; Max Planck Inst Psychiat, D-80804 Munich, Germany; Univ Washington, Seattle, WA 98195 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Univ Lund Hosp, Lund Strateg Res Ctr Stem Cell Biol & Cell Therap, Lab Neurol Stem Cell Biol, SE-22184 Lund, Sweden	Complutense University of Madrid; Max Planck Society; University of Washington; University of Washington Seattle; Scripps Research Institute; Scripps Research Institute; Lund University; Skane University Hospital	Galve-Roperh, I (corresponding author), Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain.	igr@quim.ucm.es	Galve-Roperh, Ismael/AAG-2369-2020; PALAZUELOS, JAVIER/AAD-7313-2020; Lutz, Beat/AFK-6229-2022; Aguado, Tania/AAE-3972-2019; Marsicano, Giovanni/I-9603-2016; Kokaia, Zaal/AAL-6009-2020; PALAZUELOS, JAVIER/D-1211-2013; Lutz, Beat/AAG-4538-2022; AGUADO SANCHEZ, TANIA/ABD-6975-2021	PALAZUELOS, JAVIER/0000-0002-0409-1398; Kokaia, Zaal/0000-0003-2296-2449; AGUADO SANCHEZ, TANIA/0000-0003-4339-0443; Guzman, Manuel/0000-0001-7475-118X; Marsicano, Giovanni/0000-0003-3804-1951				Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Cernak I, 2004, J CEREBR BLOOD F MET, V24, P564, DOI 10.1097/00004647-200405000-00011; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; del Pulgar TG, 2002, J BIOL CHEM, V277, P36527, DOI 10.1074/jbc.M205797200; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Fernandez-Ruiz J, 2000, TRENDS NEUROSCI, V23, P14, DOI 10.1016/S0166-2236(99)01491-5; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188; Hart S, 2004, CANCER RES, V64, P1943, DOI 10.1158/0008-5472.CAN-03-3720; Howlett AC, 2004, NEUROPHARMACOLOGY, V47, P345, DOI 10.1016/j.neuropharm.2004.07.030; Jin KL, 2004, MOL PHARMACOL, V66, P204, DOI 10.1124/mol.66.2.204; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; Lie DC, 2004, ANNU REV PHARMACOL, V44, P399, DOI 10.1146/annurev.pharmtox.44.101802.121631; Maccarrone M, 2003, CELL DEATH DIFFER, V10, P946, DOI 10.1038/sj.cdd.4401284; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; Marsicano G, 2002, NATURE, V418, P530, DOI 10.1038/nature00839; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mechoulam R, 2002, Sci STKE, V2002, pre5, DOI 10.1126/stke.2002.129.re5; Mignone JL, 2004, J COMP NEUROL, V469, P311, DOI 10.1002/cne.10964; Molina-Holgado E, 2002, J NEUROSCI, V22, P9742, DOI 10.1523/jneurosci.22-22-09742.2002; Muthian S, 2004, NEUROSCIENCE, V129, P743, DOI 10.1016/j.neuroscience.2004.08.044; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Parmentier-Batteur S, 2002, J NEUROSCI, V22, P9771, DOI 10.1523/jneurosci.22-22-09771.2002; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Rueda D, 2002, J BIOL CHEM, V277, P46645, DOI 10.1074/jbc.M206590200; Schmidt-Hieber C, 2004, NATURE, V429, P184, DOI 10.1038/nature02553; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Walter L, 2002, J BIOL CHEM, V277, P20869, DOI 10.1074/jbc.M110813200; Williams EJ, 2003, J CELL BIOL, V160, P481, DOI 10.1083/jcb.200210164	33	243	254	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1704	+		10.1096/fj.05-3995fje	http://dx.doi.org/10.1096/fj.05-3995fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16037095				2022-12-28	WOS:000230923000013
J	Arimon, M; Diez-Perez, I; Kogan, MJ; Durany, N; Giralt, E; Sanz, F; Fernandez-Busquets, X				Arimon, M; Diez-Perez, I; Kogan, MJ; Durany, N; Giralt, E; Sanz, F; Fernandez-Busquets, X			Fine structure study of A beta(1-42) fibrillogenesis with atomic force microscopy	FASEB JOURNAL			English	Article						amyloid-beta peptide; Alzheimer; amyloid-beta fibrils; amyloid-beta protofibrils	AMYLOID-BETA-PROTEIN; POLYACRYLAMIDE-GEL-ELECTROPHORESIS; RAPID CELLULAR DEGENERATION; NUCLEAR-MAGNETIC-RESONANCE; IN-VITRO GROWTH; ALZHEIMERS-DISEASE; ELECTRON-MICROSCOPY; FIBRIL FORMATION; PEPTIDE; TOXICITY	One of the hallmarks of Alzheimer's disease is the self-aggregation of the amyloid beta peptide (A beta) in extracellular amyloid fibrils. Among the different forms of A beta, the 42-residue fragment (A beta(1-42)) readily self-associates and forms nucleation centers from where fibrils can quickly grow. The strong tendency of A beta(1-42) to aggregate is one of the reasons for the scarcity of data on its fibril formation process. We have used atomic force microscopy (AFM) to visualize in liquid environment the fibrillogenesis of synthetic A beta(1-42) on hydrophilic and hydrophobic surfaces. The results presented provide nanometric resolution of the main structures characteristic of the several steps from monomeric A beta(1-42) to mature fibrils in vitro. Oligomeric globular aggregates of A beta(1-42) precede the appearance of protofibrils, the first fibrillar species,although we have not obtained direct evidence of oligomer-protofibril interconversion. The protofibril dimensions deduced from our AFM images are consistent with a model that postulates the stacking of the peptide in a hairpin conformation perpendicular to the long axis of the protofibril, forming single-sheets ribbon-shaped. The most abundant form of A beta(1-42) fibril exhibits a nodular structure with a similar to 100-nm periodicity. This length is very similar 1) to the length of protofibril bundles that are the dominant feature at earlier stages in the aggregation process,2) to the period of helical structures that have been observed in the core of fibrils, and 3) to the distance between regularly spaced, structurally weak fibril points. Taken together, these data are consistent with the existence of a similar to 100-nm long basic protofibril unit that is a key fibril building block.	Univ Barcelona, Lab Recerca Nanobioengn, Barcelona, Spain; Univ Barcelona, Dept Quim Fis, E-08028 Barcelona, Spain; Inst Recerca Biomed Barcelona, Barcelona, Spain; Univ Int Catalunya, Fac Ciencies Salut, Barcelona, Spain; Univ Barcelona, Dept Quim Organ, Barcelona, Spain	University of Barcelona; University of Barcelona; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Universitat Internacional de Catalunya (UIC); University of Barcelona	Fernandez-Busquets, X (corresponding author), Res Ctr Bioelect & Nanobiosci, Barcelona Sci Pk,Josep Samitier 1-5, E-08028 Barcelona, Spain.	xfemandez_busquets@ub.edu	Díez-Pérez, Ismael/F-6402-2014; giralt, ernest/N-1669-2014; Fernàndez-Busquets, Xavier/K-1323-2014; kogan, Marcelo/I-2868-2013; Arimon, Muriel/I-4054-2015	Díez-Pérez, Ismael/0000-0003-0513-8888; giralt, ernest/0000-0001-8381-1797; Fernàndez-Busquets, Xavier/0000-0002-4622-9631; Arimon, Muriel/0000-0002-0894-3324				Antzutkin ON, 2004, MAGN RESON CHEM, V42, P231, DOI 10.1002/mrc.1341; Antzutkin ON, 2002, BIOCHEMISTRY-US, V41, P15436, DOI 10.1021/bi0204185; Benzinger TLS, 2000, BIOCHEMISTRY-US, V39, P3491, DOI 10.1021/bi991527v; Bhatia R, 2000, FASEB J, V14, P1233, DOI 10.1096/fasebj.14.9.1233; Biere AL, 1996, J BIOL CHEM, V271, P32916, DOI 10.1074/jbc.271.51.32916; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Brown CL, 2002, J AM CHEM SOC, V124, P6846, DOI 10.1021/ja0261271; Chamberlain AK, 2000, BIOPHYS J, V79, P3282, DOI 10.1016/S0006-3495(00)76560-X; Chaney MO, 1998, PROTEIN ENG, V11, P761, DOI 10.1093/protein/11.9.761; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; Esler WP, 1996, BIOCHEMISTRY-US, V35, P749, DOI 10.1021/bi951685w; Foguel D, 2003, P NATL ACAD SCI USA, V100, P9831, DOI 10.1073/pnas.1734009100; Goldsbury CS, 2000, J STRUCT BIOL, V130, P217, DOI 10.1006/jsbi.2000.4259; Gomez E, 1995, J ELECTROCHEM SOC, V142, P4091, DOI 10.1149/1.2048469; Guo JT, 2004, PROTEINS, V57, P357, DOI 10.1002/prot.20222; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Hu JG, 1998, BRAIN RES, V785, P195, DOI 10.1016/S0006-8993(97)01318-8; Kawahara M, 2000, BRAIN RES BULL, V53, P389, DOI 10.1016/S0361-9230(00)00370-1; Kawooya JK, 2003, ANAL BIOCHEM, V323, P103, DOI 10.1016/j.ab.2003.08.027; KELLER D, 1991, SURF SCI, V253, P353, DOI 10.1016/0039-6028(91)90606-S; Khurana R, 2003, BIOPHYS J, V85, P1135, DOI 10.1016/S0006-3495(03)74550-0; Klein WL, 2002, NEUROCHEM INT, V41, P345, DOI 10.1016/S0197-0186(02)00050-5; Koudinov AR, 1996, BIOCHEM BIOPH RES CO, V223, P592, DOI 10.1006/bbrc.1996.0940; Kowalewski T, 1999, P NATL ACAD SCI USA, V96, P3688, DOI 10.1073/pnas.96.7.3688; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li LP, 1999, BIOPHYS J, V76, P2871, DOI 10.1016/S0006-3495(99)77442-4; Lin H, 2001, FASEB J, V15, P2433, DOI 10.1096/fj.01-0377com; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; Malinchik SB, 1998, BIOPHYS J, V74, P537, DOI 10.1016/S0006-3495(98)77812-9; Parbhu A, 2002, PEPTIDES, V23, P1265, DOI 10.1016/S0196-9781(02)00061-X; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; POLLARD HB, 1993, ANN NY ACAD SCI, V695, P165, DOI 10.1111/j.1749-6632.1993.tb23046.x; Roher AE, 2000, BBA-MOL BASIS DIS, V1502, P31, DOI 10.1016/S0925-4439(00)00030-2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Serpell LC, 2000, BIOCHEMISTRY-US, V39, P13269, DOI 10.1021/bi000637v; Serpell LC, 2000, J MOL BIOL, V300, P1033, DOI 10.1006/jmbi.2000.3908; Serpell LC, 2000, BBA-MOL BASIS DIS, V1502, P16, DOI 10.1016/S0925-4439(00)00029-6; Stine WB, 1996, J PROTEIN CHEM, V15, P193, DOI 10.1007/BF01887400; Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; VESENKA J, 1992, ULTRAMICROSCOPY, V42, P1243, DOI 10.1016/0304-3991(92)90430-R; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Wang ZG, 2003, ULTRAMICROSCOPY, V97, P73, DOI 10.1016/S0304-3991(03)00031-7; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Yip CM, 2002, J MOL BIOL, V318, P97, DOI 10.1016/S0022-2836(02)00028-1; Zagorski MG, 1999, METHOD ENZYMOL, V309, P189; Zhu YJ, 2000, FASEB J, V14, P1244, DOI 10.1096/fasebj.14.9.1244	52	135	137	1	52	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1344	+		10.1096/fj.04-3137fje	http://dx.doi.org/10.1096/fj.04-3137fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15919759				2022-12-28	WOS:000229602600009
J	McGill, A; Frank, A; Emmett, N; Leech, SN; Turnbull, DM; Birch-Machin, MA; Reynolds, NJ				McGill, A; Frank, A; Emmett, N; Leech, SN; Turnbull, DM; Birch-Machin, MA; Reynolds, NJ			The antipsoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria	FASEB JOURNAL			English	Article						rho zero cells; psoriasis; ubiquinone pool; cytochrome c	CYTOCHROME-C RELEASE; ANTIPROLIFERATIVE ACTIVITY; ULTRASTRUCTURAL CHANGES; PSORIATIC EPIDERMIS; CYCLOSPORINE-A; HUMAN-CELLS; DITHRANOL; SKIN; INHIBITION; CHAIN	Anthralin is a potent topical drug, inducing clearance of psoriatic plaques. Anthralin disrupts mitochondrial function and structure, but its mechanism of action remains undefined. This study aimed to determine whether anthralin induced keratinocyte apoptosis as well as to investigate molecular mechanisms and the role of mitochondria. We studied human keratinocytes and human 143B rho(0) cells, which lack mitochondrial DNA and a functional respiratory chain. We show that anthralin disrupts mitochondrial membrane potential (Delta Psi(m)) and causes endogenous cytochrome c release, resulting in the activation of caspase-3 and characteristic morphological changes of apoptosis. Disruption of Delta Psi(m) and cytochrome c release were independent of mitochondrial permeability transition or caspase activation. Human 143B rho(0) cells were resistant to anthralin-induced cell death, disruption of Delta Psi(m), and cytochrome c release compared with the isogenic 143B rho(+) cell line. Using the intrinsic fluorescence of anthralin, rapid accumulation within mitochondria was observed independent of Delta Psi(m). Using assays that measure individual respiratory chain complexes, we show that anthralin specifically interacts with ubiquinone pool. These data indicate that anthralin induces apoptosis through a novel mitochondrial pathway dependent on oxidative respiration and involving electron transfer with the ubiquinone pool. These studies identify keratinocyte apoptosis as a potentially important mechanism involved in the clearance of psoriasis.	Univ Newcastle Upon Tyne, Sch Clin & Lab Sci, Skin & Environm Interact Res Grp, Newcastle Upon Tyne, Tyne & Wear, England; Univ Newcastle Upon Tyne, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Reynolds, NJ (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Framington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	N.J.Reynolds@ncl.ac.uk		Reynolds, Nick/0000-0002-6484-825X	Wellcome Trust [061178] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Al-Daraji WI, 2002, J INVEST DERMATOL, V118, P779, DOI 10.1046/j.1523-1747.2002.01709.x; Albayrak T, 2003, MOL BIOL CELL, V14, P3082, DOI 10.1091/mbc.e02-10-0631; BAXTER DL, 1970, J INVEST DERMATOL, V54, P410, DOI 10.1111/1523-1747.ep12259209; Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4; Birch-Machin Mark A., 1993, V2, P324; BIRCHMACHIN MA, 1994, BIOCHEM MED METAB B, V51, P35, DOI 10.1006/bmmb.1994.1004; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Cossarizza A, 1996, EXP CELL RES, V222, P84, DOI 10.1006/excr.1996.0011; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; Dedov VN, 2001, MICRON, V32, P653, DOI 10.1016/S0968-4328(00)00065-2; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Dominguez I, 2000, DEVELOPMENT, V127, P861; Duan S, 2003, J BIOL CHEM, V278, P1346, DOI 10.1074/jbc.M209269200; Fantin VR, 2002, CANCER CELL, V2, P29, DOI 10.1016/S1535-6108(02)00082-X; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Frey TG, 2000, TRENDS BIOCHEM SCI, V25, P319, DOI 10.1016/S0968-0004(00)01609-1; FUCHS J, 1990, J INVEST DERMATOL, V94, P71, DOI 10.1111/1523-1747.ep12873369; Gao WH, 2001, J CELL SCI, V114, P2855; GILLBERG BO, 1967, NATURE, V214, P415, DOI 10.1038/214415a0; GOTTLIEB AB, 1992, J INVEST DERMATOL, V98, P680, DOI 10.1111/1523-1747.ep12499901; Hail N, 2002, JNCI-J NATL CANCER I, V94, P1281, DOI 10.1093/jnci/94.17.1281; Hajek P, 2001, J BIOL CHEM, V276, P606, DOI 10.1074/jbc.M007871200; HAYDEN PJ, 1994, MOL PHARMACOL, V46, P186; Higuchi M, 1998, ONCOGENE, V17, P2515, DOI 10.1038/sj.onc.1202485; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KAMMERAU B, 1975, J INVEST DERMATOL, V64, P145, DOI 10.1111/1523-1747.ep12533307; KANERVA L, 1990, J CUTAN PATHOL, V17, P37, DOI 10.1111/j.1600-0560.1990.tb01676.x; KANERVA L, 1990, AM J DERMATOPATH, V12, P51, DOI 10.1097/00000372-199002000-00008; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KLUG H, 1987, J CUTAN PATHOL, V14, P212, DOI 10.1111/j.1600-0560.1987.tb01335.x; KOHEN E, 1986, CELL BIOCHEM FUNCT, V4, P157, DOI 10.1002/cbf.290040302; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lew W, 2004, TRENDS IMMUNOL, V25, P295, DOI 10.1016/j.it.2004.03.006; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Marchetti P, 1996, CANCER RES, V56, P2033; MARSDEN JR, 1983, BRIT J DERMATOL, V109, P209, DOI 10.1111/j.1365-2133.1983.tb07083.x; Muller K, 1997, J MED CHEM, V40, P3773, DOI 10.1021/jm970292n; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Pelicano H, 2003, J BIOL CHEM, V278, P37832, DOI 10.1074/jbc.M301546200; REICHERT U, 1985, J INVEST DERMATOL, V84, P130, DOI 10.1111/1523-1747.ep12275369; Rivas MV, 1997, J INVEST DERMATOL, V108, P188, DOI 10.1111/1523-1747.ep12334217; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Salvioli S, 2000, FEBS LETT, V469, P186, DOI 10.1016/S0014-5793(00)01266-7; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SMETS LA, 1994, BLOOD, V84, P1613; SWANBECK G, 1972, ACTA DERM-VENEREOL, V52, P94; TAYLOR RW, 1993, BIOCHIM BIOPHYS ACTA, V1181, P261, DOI 10.1016/0925-4439(93)90030-5; Todd C, 1998, AM J PATHOL, V153, P39, DOI 10.1016/S0002-9440(10)65543-5; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; WILBORN WH, 1974, J CUTAN PATHOL, V1, P132, DOI 10.1111/j.1600-0560.1974.tb00205.x; Yamada K, 2003, BIOCHEM PHARMACOL, V65, P339, DOI 10.1016/S0006-2952(02)01518-6	52	73	77	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2005	19	3					1012	+		10.1096/fj.04-2664fje	http://dx.doi.org/10.1096/fj.04-2664fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15802490				2022-12-28	WOS:000227901300043
J	Shaw, RW; Kim, SK; Kim, KM; Cottenoir, M; Sims, CL; Peng, J; Fisher, AJ				Shaw, RW; Kim, SK; Kim, KM; Cottenoir, M; Sims, CL; Peng, J; Fisher, AJ			Novel DNA and RNA inhibitors of metallo-beta-lactamase	FASEB JOURNAL			English	Meeting Abstract	Experimental Biology 2006 Meeting	APR 01-05, 2006	San Francisco, CA	Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut					Texas Tech Univ, Lubbock, TX 79409 USA; Univ Calif Davis, Davis, CA 95616 USA	Texas Tech University System; Texas Tech University; University of California System; University of California Davis									0	41	45	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR 7	2006	20	5	2				A898	A898		10.1096/fj.05-4055fje	http://dx.doi.org/10.1096/fj.05-4055fje			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	026GA	16293708				2022-12-28	WOS:000236326200376
J	Ali, FY; Davidson, SJ; Moraes, LA; Traves, SL; Paul-Clark, M; Bishop-Bailey, D; Warner, TD; Mitchell, JA				Ali, Ferhana Y.; Davidson, Simon J.; Moraes, Leonardo A.; Traves, Suzanne L.; Paul-Clark, Mark; Bishop-Bailey, David; Warner, Timothy D.; Mitchell, Jane A.			Role of nuclear receptor signaling in platelets: antithrombotic effects of PPAR beta	FASEB JOURNAL			English	Article									[Moraes, Leonardo A.; Warner, Timothy D.] Queen Marys Sch Med, William Harvey Res Inst, London, England; [Ali, Ferhana Y.; Davidson, Simon J.; Traves, Suzanne L.; Paul-Clark, Mark; Bishop-Bailey, David; Mitchell, Jane A.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Unit Crit Care Med, London, England	University of London; Queen Mary University London; Imperial College London	Mitchell, JA (corresponding author), Imperial Coll Sch Med, Unit Crit Care Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	j.a.mitchell@ic.ac.uk	Warner, Timothy D/A-1980-2009; Davidson, Simon/AGX-8916-2022; Mitchell, Jane A/A-1991-2009	Warner, Timothy D/0000-0003-3988-4408; Bishop-Bailey, David/0000-0003-2455-596X					0	97	97	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					326	328		10.1096/fj.05-4395fje	http://dx.doi.org/10.1096/fj.05-4395fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16368717				2022-12-28	WOS:000207915000009
J	Freeman, MW				Freeman, Mason W.			Statins, cholesterol, and the prevention of coronary heart disease	FASEB JOURNAL			English	Article							PLACEBO-CONTROLLED TRIAL; SIMVASTATIN; PRAVASTATIN; PROTECTION; EVENTS; MEN		Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Freeman, MW (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, 55 Fruit St, Boston, MA 02114 USA.	freeman@frodo.mgh.haarvard.edu						BROWN MS, 1984, SCI AM, V251, P58, DOI 10.1038/scientificamerican1184-58; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Collins R, 2003, LANCET, V361, P2005; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Grundy Scott M, 2004, J Am Coll Cardiol, V44, P720, DOI 10.1016/j.jacc.2004.07.001; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Navab M, 2005, ARTERIOSCL THROM VAS, V25, P1932, DOI 10.1161/01.ATV.0000174589.70190.e2; PEDERSEN TR, 1994, LANCET, V344, P1383; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Tonkin A, 1998, NEW ENGL J MED, V339, P1349	13	7	8	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					200	201		10.1096/fj.06-0202ufm	http://dx.doi.org/10.1096/fj.06-0202ufm			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449790				2022-12-28	WOS:000237698700003
J	Kartikasari, AER; Georgiou, NA; Visseren, FLJ; van Kats-Renaud, H; van Asbeck, BS; Marx, JJM				Kartikasari, Apriliana E. R.; Georgiou, Niki A.; Visseren, Frank L. J.; van Kats-Renaud, Henny; van Asbeck, B. Sweder; Marx, Joannes J. M.			Endothelial activation and induction of monocyte adhesion by nontransferrin-bound iron present in human sera	FASEB JOURNAL			English	Article									[Kartikasari, Apriliana E. R.; Georgiou, Niki A.; Visseren, Frank L. J.; van Kats-Renaud, Henny; van Asbeck, B. Sweder; Marx, Joannes J. M.] Univ Med Ctr Utrecht, Eijkman Winkler Ctr Med Microbiol Infect Dis & In, NL-3584 CX Utrecht, Netherlands; [Kartikasari, Apriliana E. R.; Georgiou, Niki A.; Visseren, Frank L. J.; van Kats-Renaud, Henny; van Asbeck, B. Sweder; Marx, Joannes J. M.] Univ Med Ctr Utrecht, Eijkman Grad Sch Immunol & Infect Dis, NL-3584 CX Utrecht, Netherlands; [Visseren, Frank L. J.] Univ Med Ctr Utrecht, Dept Vasc Med, NL-3584 CX Utrecht, Netherlands; [van Asbeck, B. Sweder] Univ Med Ctr Utrecht, Dept Internal Med, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Marx, JJM (corresponding author), Univ Med Ctr Utrecht, Eijkman Winkler Ctr Med Microbiol Infect Dis & In, 100 Heidelberglaan,G04-614, NL-3584 CX Utrecht, Netherlands.	jmarx@azu.nl	Marx, Joannes/AAS-9268-2020; Kartikasari, Apriliana E. R./AAN-4594-2020; Visseren, Frank LJ/I-4855-2013	kartikasari, april/0000-0002-8115-4866; Visseren, Frank/0000-0003-3951-5223					0	56	59	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					353	355		10.1096/fj.05-4700fje	http://dx.doi.org/10.1096/fj.05-4700fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16368718				2022-12-28	WOS:000207915000019
J	Shuto, T; Furuta, T; Oba, M; Xu, HD; Li, JD; Cheung, J; Gruenert, DC; Uehara, A; Suico, MA; Okiyoneda, T; Kai, H				Shuto, Tsuyoshi; Furuta, Takashi; Oba, Mariko; Xu, Haidong; Li, Jian-Dong; Cheung, Judy; Gruenert, Dieter C.; Uehara, Akiko; Suico, Mary Ann; Okiyoneda, Tsukasa; Kai, Hirofumi			Promoter hypomethylation of Toll-like receptor-2 gene is associated with increased proinflammatory response toward bacterial peptidoglycan in cystic fibrosis bronchial epithelial cells	FASEB JOURNAL			English	Article						DNA methylation; chronic inflammation	NF-KAPPA-B; NONTYPABLE HAEMOPHILUS-INFLUENZAE; PSEUDOMONAS-AERUGINOSA; MAP KINASE; EXPRESSION; TRANSCRIPTION; RECOGNITION; ACTIVATION; REGULATOR; PATHOGENS	Cystic fibrosis (CF) is the most common lethal inherited disorder caused by mutation in the gene encoding CF transmembrane regulator (CFTR). The clinical course of CF is characterized by recurrent pulmonary infections and chronic inflammation. Here, we show that toll-like receptor-2 (TLR2) expression and response were strongly enhanced in the human CF bronchial epithelial cell line, CFBE41o-. Treatment of the cells with 5-azacytidine decreased the promoter methylation within TLR2 proximal promoter and increased endogenous expression of TLR2 in non-CF 16HBE14o- cells, suggesting that TLR2 expression is epigenetically regulated by CpG methylation. Moreover, bisulfite sequence analysis revealed that TLR2 promoters were highly demethylated in CFBE41o- cells, implying that decreased methylation of the TLR2 promoter is responsible for CF-related up-regulation of TLR2. Finally, stable expression of WT-CFTR in CFBE41o- cells (CFBE41o-/WT-CFTR cells) reduced TLR2 expression and the response to its ligand peptidoglycan (PGN), implying a causal relationship between CFTR dysfunction and TLR2 up-regulation. Consistent with reduced expression of TLR2 in CFBE41o-/WT-CFTR cells, CpG methylation was increased in CFBE41o-/WT-CFTR cells. Taken together, our results demonstrate that TLR2 expression is epigenetically up-regulated in CF bronchial epithelial cells and suggest that TLR2 overexpression or prolonged activation of TLR2 signaling might be critical in CF pathogenesis.	Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Mol Med, Kumamoto 8620973, Japan; Univ So Calif, House Ear Inst, Gonda Dept Cell & Mol Biol, Los Angeles, CA USA; Calif Pacific Med Ctr, Inst Res, San Francisco, CA 94115 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Vermont, Dept Med, Burlington, VT USA; Tohoku Univ, Grad Sch Dent, Dept Microbiol & Immunol, Sendai, Miyagi, Japan	Kumamoto University; House Research Institute; University of Southern California; California Pacific Medical Center; California Pacific Medical Center Research Institute; University of California System; University of California San Francisco; University of Vermont; Tohoku University	Kai, H (corresponding author), Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Mol Med, Kumamoto 8620973, Japan.	hirokai@gpo.kumamoto-u.ac.jp		Okiyoneda, Tsukasa/0000-0002-5175-2224; Li, Jian-Dong/0000-0002-5593-050X				Bihl F, 2003, J IMMUNOL, V170, P6141, DOI 10.4049/jimmunol.170.12.6141; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Claus R, 2003, ONCOGENE, V22, P6489, DOI 10.1038/sj.onc.1206814; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; Detich N, 2002, J BIOL CHEM, V277, P35791, DOI 10.1074/jbc.C200408200; Firoved AM, 2004, INFECT IMMUN, V72, P5012, DOI 10.1128/IAI.72.9.5012-5018.2004; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Haehnel V, 2002, J IMMUNOL, V168, P5629, DOI 10.4049/jimmunol.168.11.5629; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1; Hornef MW, 2005, J ENDOTOXIN RES, V11, P124, DOI 10.1179/096805105X35224; Kirschning CJ, 2002, CURR TOP MICROBIOL, V270, P121; KITAURA Y, 1982, J MED CHEM, V25, P335, DOI 10.1021/jm00346a001; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; Lei DC, 1996, GENE THER, V3, P427; Li JD, 2003, J PHARMACOL SCI, V91, P1, DOI 10.1254/jphs.91.1; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Muir A, 2004, AM J RESP CELL MOL, V30, P777, DOI 10.1165/rcmb.2003-0329OC; Okiyoneda T, 2002, FEBS LETT, V526, P87, DOI 10.1016/S0014-5793(02)03134-4; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; Pier GB, 2002, CURR OPIN MICROBIOL, V5, P81, DOI 10.1016/S1369-5274(02)00290-4; Ratjen F, 2003, LANCET, V361, P681, DOI 10.1016/S0140-6736(03)12567-6; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; Seki Y, 2002, CANCER RES, V62, P6579; Shuto T, 2002, J BIOL CHEM, V277, P17263, DOI 10.1074/jbc.M112190200; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248; Uehara A, 2005, CELL MICROBIOL, V7, P53, DOI 10.1111/j.1462-5822.2004.00433.x; Wald D, 2003, NAT IMMUNOL, V4, P920, DOI 10.1038/ni968; Wang TY, 2001, J IMMUNOL, V167, P6924, DOI 10.4049/jimmunol.167.12.6924	33	88	93	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					782	+		10.1096/fj.05-4934fje	http://dx.doi.org/10.1096/fj.05-4934fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16478769				2022-12-28	WOS:000237698700020
J	D'Argenio, G; Valenti, M; Scaglione, G; Cosenza, V; Sorrentini, I; Di Marzo, V				D'Argenio, G; Valenti, M; Scaglione, G; Cosenza, V; Sorrentini, I; Di Marzo, V			Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation	FASEB JOURNAL			English	Article						cannabinoid; endocannabinoid; regulation; inflammatory bowel diseases	ENDOCANNABINOID SYSTEM; VANILLOID RECEPTOR; INDUCED COLITIS; CANNABINOIDS; VR1; INHIBITORS; PROTECTS; LIGAND; BINDS; MODEL	Direct stimulation of cannabinoid CB1 receptors exerts a protective function in animal models of inflammatory bowel diseases (IBDs). However, it is not known whether endocannabinoids are up-regulated during IBDs in animals or humans, nor whether pharmacological elevation of endocannabinoid levels can be exploited therapeutically in these disorders. In this study we addressed these questions. Colon inflammation was induced in mice and rats with 2,4-dinitrobenzene- and 2,4,6-trinitrobenzene sulfonic acids (DNBS and TNBS), respectively. DNBS-treated mice were treated chronically (for 3 or 7 days) with inhibitors of anandamide enzymatic hydrolysis (N-arachidonoyl-serotonin, AA-5-HT) or reuptake (VDM11), 10 or 5 mg/kg, s.c., or with 5-amino-salicilic acid (5-ASA, 1.4 mg/kg, i.r.). Endocannabinoids (anandamide and 2-arachidonoylglycerol, 2-AG) were quantified in mouse colon, or in rat colon mucosa and submucosa, and in bioptic samples from the colon of patients with untreated ulcerative colitis, by liquid chromatography-mass spectrometry. A strong elevation of anandamide, but not 2-AG, levels was found in the colon of DNBS-treated mice, in the colon submucosa of TNBS-treated rats, and in the biopsies of patients with ulcerative colitis. VDM-11 significantly elevated anandamide levels in the colon of DNBS-treated mice and concomitantly abolished inflammation, whereas AA-5-HT did not affect endocannabinoid levels and was significantly less efficacious at attenuating colitis. 5-ASA also increased anandamide levels and abolished colitis. Thus, anandamide is elevated in the inflamed colon of patients with ulcerative colitis, as well as in animal models of IBDs, to control inflammation, and elevation of its levels with inhibitors of its cellular reuptake might be used in the treatment of IBDs.	CNR, Ist Chim Biomol, Endocannabinoid Res Grp, I-80078 Pozzuoli, NA, Italy; Univ Naples Federico II, Naples, Italy; AO Rummo, Benevento, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR); University of Naples Federico II	Di Marzo, V (corresponding author), CNR, Ist Chim Biomol, Endocannabinoid Res Grp, Via Campi Flegrei 34, I-80078 Pozzuoli, NA, Italy.	vdimarzo@icmib.na.cnr.it	Di Marzo, Vincenzo/AAD-7742-2019	Di Marzo, Vincenzo/0000-0002-1490-3070				Anavi-Goffer S, 2003, EUR J PHARMACOL, V458, P61, DOI 10.1016/S0014-2999(02)02653-5; Bisogno T, 1998, BIOCHEM BIOPH RES CO, V248, P515, DOI 10.1006/bbrc.1998.8874; Capasso R, 2005, GASTROENTEROLOGY, V129, P941, DOI 10.1053/j.gastro.2005.06.018; Coutts AA, 2004, CURR OPIN PHARMACOL, V4, P572, DOI 10.1016/j.coph.2004.05.007; Cravatt BF, 2004, P NATL ACAD SCI USA, V101, P10821, DOI 10.1073/pnas.0401292101; De Petrocellis L, 2000, FEBS LETT, V483, P52, DOI 10.1016/S0014-5793(00)02082-2; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Di Marzo V, 2002, PROSTAG LEUKOTR ESS, V66, P377, DOI 10.1054/plef.2001.0349; Di Marzo V, 1998, BBA-LIPID LIPID MET, V1392, P153, DOI 10.1016/S0005-2760(98)00042-3; Fegley D, 2005, J PHARMACOL EXP THER, V313, P352, DOI 10.1124/jpet.104.078980; GOSO C, 1993, EUR J PHARMACOL, V249, P185, DOI 10.1016/0014-2999(93)90431-G; GUAGNINI F, IN PRESS GUT; Hanauer SB, 2004, GASTROENTEROLOGY, V126, P1582, DOI 10.1053/j.gastro.2004.02.071; Izzo AA, 2003, GASTROENTEROLOGY, V125, P765, DOI 10.1016/S0016-5085(03)00892-8; Izzo AA, 2001, BRIT J PHARMACOL, V134, P563, DOI 10.1038/sj.bjp.0704293; Kankuri E, 2001, INFLAMMATION, V25, P301, DOI 10.1023/A:1012860509440; Kihara N, 2003, GUT, V52, P713, DOI 10.1136/gut.52.5.713; Kozak KR, 2002, PROSTAG LEUKOTR ESS, V66, P211, DOI 10.1054/plef.2001.0359; KRAWISZ JE, 1984, GASTROENTEROLOGY, V87, P1344; Kunos G, 2004, NAT MED, V10, P678, DOI 10.1038/nm0704-678; Ligresti A, 2003, GASTROENTEROLOGY, V125, P677, DOI 10.1016/S0016-5085(03)00881-3; Mascolo N, 2002, FASEB J, V16, P1973, DOI 10.1096/fj.02-0338fje; Massa F, 2004, J CLIN INVEST, V113, P1202, DOI 10.1172/JCI200419465; Mathison R, 2004, BRIT J PHARMACOL, V142, P1247, DOI 10.1038/sj.bjp.0705889; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; MORRIS GP, 1989, GASTROENTEROLOGY, V96, P795, DOI 10.1016/0016-5085(89)90904-9; Pinto L, 2002, GASTROENTEROLOGY, V123, P227, DOI 10.1053/gast.2002.34242; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P1008, DOI 10.1056/NEJM199110033251406; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P928, DOI 10.1056/NEJM199109263251306; Sands BE, 2000, GASTROENTEROLOGY, V118, pS68, DOI 10.1016/S0016-5085(00)70007-2; SARTOR RB, 1991, INFLAMM BOWEL DIS, P337; Shanahan F, 2001, GASTROENTEROLOGY, V120, P622, DOI 10.1053/gast.2001.22122; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; VALENTI M, 2005, 2005 S CANN BURL VER, P158; Vigna SR, 2003, GASTROENTEROLOGY, V125, P973, DOI 10.1016/S0016-5085(03)01134-X; Ward SM, 2003, J COMP NEUROL, V465, P121, DOI 10.1002/cne.10801; Wright K, 2005, GASTROENTEROLOGY, V129, P437, DOI 10.1053/j.gastro.2005.05.026	39	184	186	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					568	+		10.1096/fj.05-4943fje	http://dx.doi.org/10.1096/fj.05-4943fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16403786				2022-12-28	WOS:000235996000027
J	Gerard, M; Debyser, Z; Desender, L; Kahle, PJ; Baert, J; Baekelandt, V; Engelborghs, Y				Gerard, M; Debyser, Z; Desender, L; Kahle, PJ; Baert, J; Baekelandt, V; Engelborghs, Y			The aggregation of alpha-synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy	FASEB JOURNAL			English	Article						Parkinson's disease; peptidyl-prolyl cis-trans isomerase; immunophilin; amyloid fibrils	FAMILIAL PARKINSONS-DISEASE; IN-VITRO; LEWY BODIES; IMMUNOSUPPRESSANT FK506; RYANODINE RECEPTOR; UNFOLDED PROTEINS; PROLYL ISOMERASE; FIBRIL FORMATION; AMYLOID FIBRILS; IMMUNOPHILINS	Aggregation of alpha-synuclein (alpha-SYN) plays a key role in Parkinson's disease (PD). We have used fluorescence correlation spectroscopy (FCS) to study alpha-SYN aggregation in vitro and discovered that this process is clearly accelerated by addition of FK506 binding proteins (FKBPs). This effect was observed both with E. coli SlyD FKBP and with human FKBP12 and was counteracted by FK506, a specific inhibitor of FKBP. The alpha-SYN aggregates formed in the presence of FKBP12 showed fibrillar morphology. The rotamase activity of FKBP apparently accelerates the folding and subsequent aggregation of alpha-SYN. Since FK506 and other nonimmunosuppressive FKBP inhibitors are known to display neuroregenerative and neuroprotective properties in disease models, the observed inhibition of rotamase activity and alpha-SYN aggregation, may explain their mode of action. Our results open perspectives for the treatment of PD with immunophilin ligands that inhibit a specific member of the FKBP family.	Katholieke Univ Leuven, Lab Neurobiol & Gene Therapy, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Lab Mol Virol & Gene Therapy, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Interdisciplinary Res Ctr, B-8500 Kortrijk, Belgium; Katholieke Univ Leuven, Lab Biomol Dynam, B-3001 Heverlee, Belgium; Univ Munich, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany; Katholieke Univ Leuven, Histol Lab, Interdisciplinary Res Ctr, B-8500 Kortrijk, Belgium	KU Leuven; KU Leuven; KU Leuven; KU Leuven; University of Munich; KU Leuven	Baekelandt, V (corresponding author), Katholieke Univ Leuven, Lab Neurobiol & Gene Therapy, Kapucijnenvoer 33, B-3000 Louvain, Belgium.	Veerle.baekelandt@med.kuleuven.be	Gerard, Melanie/B-6898-2019	Gerard, Melanie/0000-0003-0585-6978				Antony T, 2003, J BIOL CHEM, V278, P3235, DOI 10.1074/jbc.M208249200; Avramut M, 2003, CURR TOP MED CHEM, V3, P1376, DOI 10.2174/1568026033451871; Avramut M, 2002, PHYSIOL BEHAV, V77, P463, DOI 10.1016/S0031-9384(02)00934-4; Avramut M, 2001, DEV BRAIN RES, V132, P151, DOI 10.1016/S0165-3806(01)00307-8; Baskakov I, 1998, J BIOL CHEM, V273, P4831, DOI 10.1074/jbc.273.9.4831; Brecht S, 2003, NEUROSCIENCE, V120, P1037, DOI 10.1016/S0306-4522(03)00404-4; Bultynck G, 2001, J BIOL CHEM, V276, P47715, DOI 10.1074/jbc.M106573200; Bultynck G, 2001, BIOCHEM J, V354, P413, DOI 10.1042/0264-6021:3540413; Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1; Cohlberg JA, 2002, BIOCHEMISTRY-US, V41, P1502, DOI 10.1021/bi011711s; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Dolinski K, 1997, MOL BIOL CELL, V8, P2267, DOI 10.1091/mbc.8.11.2267; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Galat A, 2003, CURR TOP MED CHEM, V3, P1315, DOI 10.2174/1568026033451862; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Gold BG, 1997, EXP NEUROL, V147, P269, DOI 10.1006/exnr.1997.6630; Gold BG, 1999, J PHARMACOL EXP THER, V289, P1202; Guo X, 2001, EUR J NEUROSCI, V13, P1683, DOI 10.1046/j.0953-816x.2001.01542.x; HAN HY, 1995, CHEM BIOL, V2, P163, DOI 10.1016/1074-5521(95)90071-3; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; Hoyer W, 2004, BIOCHEMISTRY-US, V43, P16233, DOI 10.1021/bi048453u; Ibanez P, 2004, LANCET, V364, P1169, DOI 10.1016/S0140-6736(04)17104-3; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; Lakso M, 2003, J NEUROCHEM, V86, P165, DOI 10.1046/j.1471-4159.2003.01809.x; Lauwers E, 2003, BRAIN PATHOL, V13, P364; Li J, 2001, BIOCHEMISTRY-US, V40, P11604, DOI 10.1021/bi010616g; Lo BC, 2002, P NATL ACAD SCI USA, V99, P10813; Lu PJ, 1999, NATURE, V399, P784; Maertens G, 2005, FASEB J, V19, P1039, DOI 10.1096/fj.04-3373fje; Magde D, 1977, Mol Biol Biochem Biophys, V24, P43; MAGDE D, 1974, BIOPOLYMERS, V13, P29, DOI 10.1002/bip.1974.360130103; OHAMA E, 1976, ACTA NEUROPATHOL, V34, P311, DOI 10.1007/BF00696560; PARK ST, 1992, J BIOL CHEM, V267, P3316; PARSONS WH, 1993, ANN NY ACAD SCI, V685, P22, DOI 10.1111/j.1749-6632.1993.tb35847.x; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; ROSEN MK, 1990, SCIENCE, V248, P863, DOI 10.1126/science.1693013; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Steiner JP, 1997, P NATL ACAD SCI USA, V94, P2019, DOI 10.1073/pnas.94.5.2019; Tradler T, 1997, FEBS LETT, V407, P184, DOI 10.1016/S0014-5793(97)00345-1; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2001, J BIOL CHEM, V276, P43495, DOI 10.1074/jbc.C100551200; Uversky VN, 2001, FEBS LETT, V509, P31, DOI 10.1016/S0014-5793(01)03121-0; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Vercammen J, 2002, J BIOL CHEM, V277, P38045, DOI 10.1074/jbc.M205842200; Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; XIN HB, 1995, BIOCHEM BIOPH RES CO, V214, P263, DOI 10.1006/bbrc.1995.2283; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	49	48	52	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					524	+		10.1096/fj.05-5126fje	http://dx.doi.org/10.1096/fj.05-5126fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16410343				2022-12-28	WOS:000235996000020
J	Kunzelmann, K; Scheidt, K; Scharf, B; Ousingsawat, J; Schreiber, R; Wainwright, B; McMorran, B				Kunzelmann, K; Scheidt, K; Scharf, B; Ousingsawat, J; Schreiber, R; Wainwright, B; McMorran, B			Flagellin of Pseudomonas aeruginosa inhibits Na+ transport in airway epithelia	FASEB JOURNAL			English	Article						EnaC; flagella; cystic fibrosis; infection	TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS PATIENTS; SODIUM-CHANNEL ENAC; MOUSE TRACHEA; ION-TRANSPORT; CELLS; ATP; RELEASE; CFTR; LUNG	Pseudomonas aeruginosa causes severe life-threatening airway infections that are a frequent cause for hospitalization of cystic fibrosis (CF) patients. These Gram-negative pathogens possess flagella that contain the protein flagellin as a major structural component. Flagellin binds to the host cell glycolipid asialoGM1 (ASGM1), which appears enriched in luminal membranes of respiratory epithelial cells. We demonstrate that in mouse airways, luminal exposure to flagellin leads to inhibition of Na+ absorption by the epithelial Na+ channel ENaC, but does not directly induce a secretory response. Inhibition of ENaC was observed in tracheas of wild-type mice and was attenuated in mice homozygous for the frequent cystic fibrosis conductance regulator (CFTR) mutation G551D. Similar to flagellin, anti-ASGM1 antibody also inhibited ENaC. The inhibitory effects of flagellin on ENaC were attenuated by blockers of the purinergic signaling pathway, although an increase in the intracellular Ca2+ concentration by recombinant or purified flagellin or whole flagella was not observed. Because an inhibitor of the mitogen-activated protein kinase (MAPK) pathway also attenuated the effects of flagellin on Na+ absorption, we conclude that flagellin exclusively inhibits ENaC, probably due to release of ATP and activation of purinergic receptors of the P2Y subtype. Stimulation of these receptors activates the MAPK pathway, thereby leading to inhibition of ENaC. Thus, P. aeruginosa reduces Na+ absorption, which could enhance local mucociliary clearance, a mechanism that seem to be attenuated in CF.	Univ Regensburg, Inst Physiol, D-93053 Regensburg, Germany; Univ Regensburg, Inst Genet, D-93053 Regensburg, Germany; Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4067, Australia	University of Regensburg; University of Regensburg; University of Queensland	Kunzelmann, K (corresponding author), Univ Regensburg, Inst Physiol, Univ Str 31, D-93053 Regensburg, Germany.	uqkkunze@mailbox.uq.edu.au	Schreiber, Robert/Q-7550-2019	Kunzelmann, Karl/0000-0002-4583-7037; Wainwright, Brandon/0000-0003-0406-2092				Adamo R, 2004, AM J RESP CELL MOL, V30, P627, DOI 10.1165/rcmb.2003-0260OC; Bryan R, 1998, AM J RESP CELL MOL, V19, P269, DOI 10.1165/ajrcmb.19.2.2889; Castrop H, 2004, J CLIN INVEST, V114, P634, DOI 10.1172/JCI200421851; Crane JK, 2002, AM J PHYSIOL-GASTR L, V283, pG74, DOI 10.1152/ajpgi.00484.2001; Dagenais A, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-2; deBentzmann S, 1996, EUR RESPIR J, V9, P2145, DOI 10.1183/09031936.96.09102145; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Delaney SJ, 1996, EMBO J, V15, P955, DOI 10.1002/j.1460-2075.1996.tb00432.x; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; Eaves-Pyles TD, 2001, J IMMUNOL, V167, P7009, DOI 10.4049/jimmunol.167.12.7009; Evans DJ, 1998, AM J PHYSIOL-CELL PH, V275, pC1284, DOI 10.1152/ajpcell.1998.275.5.C1284; Falin R, 2005, AM J PHYSIOL-CELL PH, V288, pC1003, DOI 10.1152/ajpcell.00213.2004; Feldman M, 1998, INFECT IMMUN, V66, P43, DOI 10.1128/IAI.66.1.43-51.1998; FUKUDA H, 1994, NEUROCHEM INT, V25, P567, DOI 10.1016/0197-0186(94)90155-4; Gibson RL, 2003, AM J RESP CRIT CARE, V168, P918, DOI 10.1164/rccm.200304-505SO; GRAHAM A, 1993, EXP LUNG RES, V19, P77, DOI 10.3109/01902149309071082; Grassme H, 2000, SCIENCE, V290, P527, DOI 10.1126/science.290.5491.527; Gulbins E, 2004, J MOL MED, V82, P357, DOI 10.1007/s00109-004-0539-y; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; Jacob T, 2002, INFECT IMMUN, V70, P6399, DOI 10.1128/IAI.70.11.6399-6408.2002; Konig J, 2002, BBA-BIOMEMBRANES, V1565, P17, DOI 10.1016/S0005-2736(02)00502-3; KOSLOWSKY T, 1994, PFLUG ARCH EUR J PHY, V428, P597, DOI 10.1007/BF00374583; KRIVAN HC, 1988, P NATL ACAD SCI USA, V85, P6157, DOI 10.1073/pnas.85.16.6157; Kunzelmann K, 2004, FASEB J, V18, P142, DOI 10.1096/fj.04-2314fje; Kunzelmann K, 2004, J BIOL CHEM, V279, P48760, DOI 10.1074/jbc.M409747200; Kunzelmann K, 2002, PFLUG ARCH EUR J PHY, V444, P220, DOI 10.1007/s00424-002-0796-y; Kunzelmann Karl, 2003, Am J Respir Med, V2, P299; Lazarowski ER, 2004, J BIOL CHEM, V279, P36855, DOI 10.1074/jbc.M405367200; Lazarowski ER, 2003, MOL PHARMACOL, V64, P785, DOI 10.1124/mol.64.4.785; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; Ma HP, 2002, J BIOL CHEM, V277, P7641, DOI 10.1074/jbc.C100737200; McMorran BJ, 2001, AM J PHYSIOL-LUNG C, V281, pL740, DOI 10.1152/ajplung.2001.281.3.L740; McNamara N, 2001, P NATL ACAD SCI USA, V98, P9086, DOI 10.1073/pnas.161290898; Melmed G, 2003, J IMMUNOL, V170, P1406, DOI 10.4049/jimmunol.170.3.1406; Muir A, 2004, AM J RESP CELL MOL, V30, P777, DOI 10.1165/rcmb.2003-0329OC; Oceandy D, 2002, HUM MOL GENET, V11, P1059, DOI 10.1093/hmg/11.9.1059; Pier GB, 1996, SCIENCE, V271, P64, DOI 10.1126/science.271.5245.64; Pittet JF, 1996, AM J PHYSIOL-LUNG C, V270, pL232, DOI 10.1152/ajplung.1996.270.2.L232; Ralevic V, 1998, PHARMACOL REV, V50, P413; Ramos HC, 2004, TRENDS MICROBIOL, V12, P509, DOI 10.1016/j.tim.2004.09.002; RAMPHAL R, 1989, INFECT IMMUN, V57, P3066, DOI 10.1128/IAI.57.10.3066-3071.1989; Ratner AJ, 2001, J BIOL CHEM, V276, P19267, DOI 10.1074/jbc.M007703200; Reddy MM, 1996, SCIENCE, V271, P1876, DOI 10.1126/science.271.5257.1876; Ribeiro CMP, 2005, J BIOL CHEM, V280, P10202, DOI 10.1074/jbc.M410317200; Rochelle LG, 2000, AM J PHYSIOL-LUNG C, V279, pL14, DOI 10.1152/ajplung.2000.279.1.L14; Sabirov RZ, 2001, J GEN PHYSIOL, V118, P251, DOI 10.1085/jgp.118.3.251; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Schreiber R, 2005, CELL PHYSIOL BIOCHEM, V16, P99, DOI 10.1159/000087736; Schwiebert EM, 2003, BBA-BIOMEMBRANES, V1615, P7, DOI 10.1016/S0005-2736(03)00210-4; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Soong G, 2004, J CLIN INVEST, V113, P1482, DOI 10.1172/JCI200420773; STUTTS MJ, 1986, AM REV RESPIR DIS, V134, P17; Ullrich S, 2003, PFLUG ARCH EUR J PHY, V447, P23, DOI 10.1007/s00424-003-1136-6; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Wolfgang MC, 2004, P NATL ACAD SCI USA, V101, P6664, DOI 10.1073/pnas.0307553101; Yue G, 2002, J BIOL CHEM, V277, P11965, DOI 10.1074/jbc.M108951200; Zeng H, 2003, J IMMUNOL, V171, P3668, DOI 10.4049/jimmunol.171.7.3668	59	27	27	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					545	+		10.1096/fj.05-4454fje	http://dx.doi.org/10.1096/fj.05-4454fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16410345				2022-12-28	WOS:000235996000018
J	Miyazaki, I; Asanuma, M; Diaz-Corrales, FJ; Fukuda, M; Kitaichi, K; Miyoshi, K; Ogawa, N				Miyazaki, I; Asanuma, M; Diaz-Corrales, FJ; Fukuda, M; Kitaichi, K; Miyoshi, K; Ogawa, N			Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone formation-related molecules	FASEB JOURNAL			English	Article						dopamine quinone; quinone reductase; tyrosinase	PARKINSONS-DISEASE; RAT-BRAIN; OXIDATIVE STRESS; TYROSINE-HYDROXYLASE; SUBSTANTIA-NIGRA; CYTOTOXICITY; CELLS; METHYLAMPHETAMINE; CATECHOLAMINES; VULNERABILITY	Recently, the neurotoxicity of dopamine (DA) quinone formation by auto-oxidation of DA has focused on dopaminergic neuron-specific oxidative stress. In the present study, we examined DA quinone formation in methamphetamine (METH)-induced dopaminergic neuronal cell death using METH-treated dopaminergic cultured CATH. a cells and METH-injected mouse brain. In CATH. a cells, METH treatment dose-dependently increased the levels of quinoprotein (protein-bound quinone) and the expression of quinone reductase in parallel with neurotoxicity. A similar increase in quinoprotein levels was seen in the striatum of METH (4 mg/kg X4, i.p., 2 h interval)-injected BALB/c mice, coinciding with reduction of DA transporters. Furthermore, pretreatment of CATH. a cells with quinone reductase inducer, butylated hydroxyanisole, significantly and dose-dependently blocked METH-induced elevation of quinoprotein, and ameliorated METH-induced cell death. We also showed the protective effect of tyrosinase, which rapidly oxidizes DA and DA quinone to form stable melanin, against METH-induced dopaminergic neurotoxicity in vitro and in vivo using tyrosinase null mice. Our results indicate that DA quinone formation plays an important role, as a dopaminergic neuron-specific neurotoxic factor, in METH-induced neurotoxicity, which is regulated by quinone formation-related molecules.	Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Brain Sci, Okayama, Japan; Nagoya Univ, Grad Sch Med, Dept Med Technol, Nagoya, Aichi, Japan	Okayama University; Nagoya University	Asanuma, M (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Brain Sci, Okayama, Japan.	asachan@cc.okayama-u.ac.jp	soler, martha maricel m gomez/L-6025-2014; Diaz-Corrales, Francisco/L-7559-2014	soler, martha maricel m gomez/0000-0002-4412-8108; Diaz-Corrales, Francisco/0000-0002-5752-0205				ASANUMA M, 1995, MOL BRAIN RES, V33, P29, DOI 10.1016/0169-328X(95)00102-X; Asanuma M, 2004, ACTA MED OKAYAMA, V58, P221; Asanuma M, 2003, NEUROSCI LETT, V352, P13, DOI 10.1016/j.neulet.2003.08.015; Asanuma M, 2003, NEUROTOX RES, V5, P165, DOI 10.1007/BF03033137; AXT KJ, 1990, BRAIN RES, V515, P269, DOI 10.1016/0006-8993(90)90606-C; Cadet JL, 1998, NEUROCHEM INT, V32, P117, DOI 10.1016/S0197-0186(97)00031-4; Cavelier G, 2001, PROTEINS, V43, P420, DOI 10.1002/prot.1055.abs; Choi HJ, 2005, NEUROCHEM INT, V46, P329, DOI 10.1016/j.neuint.2004.10.009; Choi HJ, 2003, J NEUROCHEM, V86, P143, DOI 10.1046/j.1471-4159.2003.01808.x; Clement MW, 2002, J NEUROCHEM, V81, P414, DOI 10.1046/j.1471-4159.2002.00802.x; CUBELLS JF, 1994, J NEUROSCI, V14, P2260, DOI 10.1523/jneurosci.14-04-02260.1994; FORNSTEDT B, 1986, NEUROPHARMACOLOGY, V25, P451, DOI 10.1016/0028-3908(86)90242-X; Fumagalli F, 1999, J NEUROSCI, V19, P2424; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; Haque ME, 2003, NEUROSCI RES, V47, P31, DOI 10.1016/S0168-0102(03)00166-4; HEARING VJ, 1976, BIOCHEM J, V157, P549, DOI 10.1042/bj1570549; Higashi Y, 2000, J NEUROCHEM, V75, P1771, DOI 10.1046/j.1471-4159.2000.0751771.x; HOTCHKISS AJ, 1980, J PHARMACOL EXP THER, V214, P257; Joseph P, 2000, BIOCHEM PHARMACOL, V60, P207, DOI 10.1016/S0006-2952(00)00321-X; Kita T, 2003, J PHARMACOL SCI, V92, P178; Kitaichi K, 2003, EUR J PHARMACOL, V464, P39, DOI 10.1016/S0014-2999(03)01321-9; Kuhn DM, 1999, J NEUROCHEM, V73, P1309, DOI 10.1046/j.1471-4159.1999.0731309.x; Lai CT, 1997, BIOCHEM PHARMACOL, V53, P363, DOI 10.1016/S0006-2952(96)00731-9; LaVoie MJ, 1999, J NEUROCHEM, V73, P2546, DOI 10.1046/j.1471-4159.1999.0732546.x; LaVoie MJ, 1999, J NEUROSCI, V19, P1484, DOI 10.1523/jneurosci.19-04-01484.1999; Liu YJ, 1997, ANNU REV NEUROSCI, V20, P125; MAREK GJ, 1990, BRAIN RES, V513, P274, DOI 10.1016/0006-8993(90)90467-P; MIRANDA M, 1984, GEN PHARMACOL-VASC S, V15, P541, DOI 10.1016/0306-3623(84)90212-X; MIRANDA M, 1983, GEN PHARMACOL, V14, P231, DOI 10.1016/0306-3623(83)90002-2; Miyazaki I, 1999, NEUROCHEM RES, V24, P857, DOI 10.1023/A:1020953913490; Miyazaki I, 2005, CLIN NEUROPHARMACOL, V28, P155, DOI 10.1097/01.wnf.0000175523.33334.24; Munday R, 1998, CHEM-BIOL INTERACT, V108, P155, DOI 10.1016/S0009-2797(97)00105-1; Offen D, 1996, EXP NEUROL, V141, P32, DOI 10.1006/exnr.1996.0136; PAZ MA, 1991, J BIOL CHEM, V266, P689; RICAURTE GA, 1980, BRAIN RES, V193, P153, DOI 10.1016/0006-8993(80)90952-X; SCHMIDT CJ, 1985, J PHARMACOL EXP THER, V233, P539; SEIDEN LS, 1984, PHARMACOL BIOCHEM BE, V21, P29, DOI 10.1016/0091-3057(84)90125-4; Tief K, 1997, PIGM CELL RES, V10, P153; Tief K, 1996, EUR J BIOCHEM, V241, P12, DOI 10.1111/j.1432-1033.1996.0012t.x; Tief K, 1996, DEV DYNAM, V205, P445, DOI 10.1002/(SICI)1097-0177(199604)205:4<445::AID-AJA8>3.0.CO;2-I; Tief K, 1998, MOL BRAIN RES, V53, P307, DOI 10.1016/S0169-328X(97)00301-X; TSE DCS, 1976, J MED CHEM, V19, P37, DOI 10.1021/jm00223a008; Uhl GR, 1998, ANN NEUROL, V43, P555, DOI 10.1002/ana.410430503; WAGNER GC, 1980, BRAIN RES, V181, P151, DOI 10.1016/0006-8993(80)91265-2; WAGNER GC, 1983, BRAIN RES, V270, P285, DOI 10.1016/0006-8993(83)90602-9; Whitehead RE, 2001, J NEUROCHEM, V76, P1242, DOI 10.1046/j.1471-4159.2001.00125.x; Wrona M Z, 1997, NIDA Res Monogr, V173, P146; Yuan J, 2001, J NEUROCHEM, V77, P1338, DOI 10.1046/j.1471-4159.2001.00339.x	48	95	97	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					571	+		10.1096/fj.05-4996fje	http://dx.doi.org/10.1096/fj.05-4996fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16403784	Green Submitted			2022-12-28	WOS:000235996000028
J	Rolls, A; Cahalon, L; Bakalash, S; Avidan, H; Lider, O; Schwartz, M				Rolls, A; Cahalon, L; Bakalash, S; Avidan, H; Lider, O; Schwartz, M			A sulfated disaccharide derived from chondroitin sulfate proteoglycan protects against inflammation-associated neurodegeneration	FASEB JOURNAL			English	Article						encephalomyelitis; experimental autoimmune uveitis; immunosuppression	CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; HIGH-DOSE METHYLPREDNISOLONE; NF-KAPPA-B; MULTIPLE-SCLEROSIS; T-CELLS; TNF-ALPHA; THERAPEUTIC VACCINATION	Chondroitin sulfate proteoglycan (CSPG), a matrix protein that occurs naturally in the central nervous system (CNS), is considered to be a major inhibitor of axonal regeneration and is known to participate in activation of the inflammatory response. The degradation of CSPG by a specific enzyme, chondroitinase ABC, promotes repair. We postulated that a disaccharidic degradation product of this glycoprotein (CSPG-DS), generated following such degradation, participates in the modulation of the inflammatory responses and can, therefore, promote recovery in immune-induced neuropathologies of the CNS, such as experimental autoimmune encephalomyelitis (EAE) and experimental autoimmune uveitis (EAU). In these pathologies, the dramatic increase in T cells infiltrating the CNS is far in excess of the numbers needed for regular maintenance. Here, we show that CSPG-DS markedly alleviated the clinical symptoms of EAE and protected against the neuronal loss in EAU. The last effect was associated with a reduction in the numbers of infiltrating T cells and marked microglia activation. This is further supported by our in vitro results indicating that CSPG-DS attenuated T cell motility and decreased secretion of the cytokines interferon-gamma and tumor necrosis factor-alpha. Mechanistically, these effects are associated with an increase in SOCS-3 levels and a decrease in NF-kappa B. Our results point to a potential therapeutic modality, in which a compound derived from an endogenous CNS-resident molecule, known for its destructive role in CNS recovery, might be helpful in overcoming inflammation-induced neurodegenerative conditions.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	michal.schwartz@weizmann.ac.il		Rolls, Asya/0000-0001-5862-4287				ABDELBASSET E, 1995, J NEUROSCI RES, V41, P222, DOI 10.1002/jnr.490410210; Ariel A, 1998, J IMMUNOL, V161, P2465; Asher R A, 2001, Prog Brain Res, V132, P611; Bakalash S, 2003, INVEST OPHTH VIS SCI, V44, P3374, DOI 10.1167/iovs.03-0080; Benveniste EN, 1997, J MOL MED-JMM, V75, P165, DOI 10.1007/s001090050101; Bjartmar C, 2003, J NEUROL SCI, V206, P165, DOI 10.1016/S0022-510X(02)00069-2; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Butovsky O, 2005, MOL CELL NEUROSCI, V29, P381, DOI 10.1016/j.mcn.2005.03.005; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Chau CH, 2004, FASEB J, V18, P194, DOI 10.1096/fj.03-0196fje; Chavarria A, 2004, AUTOIMMUN REV, V3, P251, DOI 10.1016/j.autrev.2003.09.006; Chitnis T, 2003, IMMUNOL RES, V28, P223, DOI 10.1385/IR:28:3:223; Combs CK, 2001, J NEUROSCI, V21, P1179; Cooney RN, 2002, SHOCK, V17, P83, DOI 10.1097/00024382-200202000-00001; DeWitt DA, 1996, EXP NEUROL, V142, P103, DOI 10.1006/exnr.1996.0182; Dick AD, 2004, PROG RETIN EYE RES, V23, P617, DOI 10.1016/j.preteyeres.2004.06.005; Diem R, 2003, J NEUROSCI, V23, P6993, DOI 10.1523/JNEUROSCI.23-18-06993.2003; DSOUZA R, 2004, COMP CHONDROITINASE; Eng LF, 1996, NEUROCHEM RES, V21, P511, DOI 10.1007/BF02527717; Fang IM, 2004, EXP EYE RES, V78, P1043, DOI 10.1016/j.exer.2004.02.006; Fitch MT, 1997, EXP NEUROL, V148, P587, DOI 10.1006/exnr.1997.6701; Fujimoto T, 2001, INT IMMUNOL, V13, P359, DOI 10.1093/intimm/13.3.359; Fukuda T, 1997, J COMP NEUROL, V382, P141; Furlan R, 2001, J IMMUNOL, V167, P1821, DOI 10.4049/jimmunol.167.3.1821; Furlan Roberto, 2004, Methods Mol Med, V98, P171; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Grimpe B, 2002, PROG BRAIN RES, V137, P333; Haghighi SS, 2000, SPINAL CORD, V38, P733, DOI 10.1038/sj.sc.3101074; Hall GL, 1999, J NEUROIMMUNOL, V98, P105, DOI 10.1016/S0165-5728(99)00069-7; HASCALL VC, 1970, J BIOL CHEM, V245, P4920; Hauben E, 2001, J CLIN INVEST, V108, P591, DOI 10.1172/JCI200112837; Hausler KG, 2002, EUR J NEUROSCI, V16, P2113, DOI 10.1046/j.1460-9568.2002.02287.x; Hemmer B, 1996, J NEUROSCI RES, V45, P852; Inoue S, 2001, INT REV CYTOL, V210, P121; Kantele JM, 2000, J IMMUNOL, V164, P5035, DOI 10.4049/jimmunol.164.10.5035; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; Knepper PA, 1996, INVEST OPHTH VIS SCI, V37, P1360; Kotter MR, 2001, GLIA, V35, P204, DOI 10.1002/glia.1085; Laakko T, 2003, J BIOL CHEM, V278, P31621, DOI 10.1074/jbc.M304700200; Lemons ML, 1999, EXP NEUROL, V160, P51, DOI 10.1006/exnr.1999.7184; Leussink VI, 2001, ARCH NEUROL-CHICAGO, V58, P91, DOI 10.1001/archneur.58.1.91; Link J, 1994, Acta Neurol Scand Suppl, V158, P1; LUBLIN FD, 1985, SPRINGER SEMIN IMMUN, V8, P197; Madri JA, 1996, BIOCHEM CELL BIOL, V74, P749, DOI 10.1139/o96-082; Makarov SS, 2000, MOL MED TODAY, V6, P441, DOI 10.1016/S1357-4310(00)01814-1; Matsui Fumiko, 2004, Congenital Anomalies, V44, P181, DOI 10.1111/j.1741-4520.2004.00038.x; McKeon RJ, 1999, J NEUROSCI, V19, P10778, DOI 10.1523/JNEUROSCI.19-24-10778.1999; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Moser B, 1998, Int Rev Immunol, V16, P323, DOI 10.3109/08830189809043000; Nussenblatt RB, 1996, J AUTOIMMUN, V9, P575, DOI 10.1006/jaut.1996.0077; OLSSON T, 1995, IMMUNOL REV, V144, P245, DOI 10.1111/j.1600-065X.1995.tb00072.x; Pashenkov M, 2003, J NEUROIMMUNOL, V135, P154, DOI 10.1016/S0165-5728(02)00441-1; Peled A, 2000, BLOOD, V95, P3289, DOI 10.1182/blood.V95.11.3289.011k33_3289_3296; Pelletier AJ, 2000, BLOOD, V96, P2682; Pender MP, 2002, INTERN MED J, V32, P554, DOI 10.1046/j.1445-5994.2002.00269.x; POWRIE F, 1993, EUR J IMMUNOL, V23, P3043, DOI 10.1002/eji.1830231147; Prat A, 2005, CURR OPIN NEUROL, V18, P225, DOI 10.1097/01.wco.0000169737.99040.31; Properzi F, 2003, BIOCHEM SOC T, V31, P335, DOI 10.1042/BST0310335; Qian T, 2000, MED HYPOTHESES, V55, P452, DOI 10.1054/mehy.2000.1165; Raivich G, 2004, BRAIN RES REV, V46, P261, DOI 10.1016/j.brainresrev.2004.06.006; Rohowsky-Kochan C, 2000, MULT SCLER, V6, P69, DOI 10.1177/135245850000600203; Rolls A, 2004, EUR J NEUROSCI, V20, P1973, DOI 10.1111/j.1460-9568.2004.03676.x; Schaefer L, 2005, J CLIN INVEST, V115, P2223, DOI 10.1172/JCI23755; Schmidt J, 2000, BRAIN, V123, P1431, DOI 10.1093/brain/123.7.1431; Schwartz M, 2005, ACTA NEUROCHIR SUPPL, V93, P147; Segal BA, 2003, CURR ALLERGY ASTHM R, V3, P86, DOI 10.1007/s11882-003-0017-6; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sobel RA, 2001, J NEUROPATH EXP NEUR, V60, P1198, DOI 10.1093/jnen/60.12.1198; Soriano SF, 2002, J EXP MED, V196, P311, DOI 10.1084/jem.20012041; Steinsapir KD, 2000, RESTOR NEUROL NEUROS, V17, P157; Tanihara H, 2002, CORNEA, V21, pS62, DOI 10.1097/01.ico.0000263121.45898.d2; Thurau SR, 2003, AUTOIMMUN REV, V2, P171, DOI 10.1016/S1568-9972(03)00011-9; Wildbaum G, 2003, IMMUNITY, V19, P679, DOI 10.1016/S1074-7613(03)00291-7; WILLIAMS KC, 1994, CLIN NEUROSCI, V2, P229; Yang PZ, 2000, CHINESE MED J-PEKING, V113, P643; Yoles E, 1998, EXP NEUROL, V153, P1, DOI 10.1006/exnr.1998.6811; Zanin-Zhorov A, 2005, J IMMUNOL, V174, P3227, DOI 10.4049/jimmunol.174.6.3227	78	69	77	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					547	+		10.1096/fj.05-4540fje	http://dx.doi.org/10.1096/fj.05-4540fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16396993				2022-12-28	WOS:000235996000035
J	Warskulat, U; Borsch, E; Reinehr, R; Heller-Stilb, B; Monnighoff, I; Buchczyk, D; Donner, M; Flogel, U; Kappert, G; Soboll, S; Beer, S; Pfeffer, K; Marschall, HU; Gabrielsen, M; Amiry-Moghaddam, M; Ottersen, OP; Dienes, HP; Haussinger, DH				Warskulat, U; Borsch, E; Reinehr, R; Heller-Stilb, B; Monnighoff, I; Buchczyk, D; Donner, M; Flogel, U; Kappert, G; Soboll, S; Beer, S; Pfeffer, K; Marschall, HU; Gabrielsen, M; Amiry-Moghaddam, M; Ottersen, OP; Dienes, HP; Haussinger, DH			Chronic liver disease is triggered by taurine transporter knockout in the mouse	FASEB JOURNAL			English	Article						apoptosis; bile acids; compatible organic osmolytes; inflammation; fibrosis	GROWTH-FACTOR RECEPTOR; OXIDATIVE STRESS; ORGANIC OSMOLYTE; PROGENITOR CELLS; FATTY LIVER; RAT; ACTIVATION; RELEASE; CD95; MICE	Taurine is an abundant organic osmolyte with antioxidant and immunomodulatory properties. Its role in the pathogenesis of chronic liver disease is unknown. The liver phenotype was studied in taurine transporter knockout (taut-/-) mice. Hepatic taurine levels were similar to 21, 15 and 6 mu mol/ g liver wet weight in adult wild-type, heterozygous (taut+/-) and homozygous (taut-/-) mice, respectively. Immunoelectronmicroscopy revealed an almost complete depletion of taurine in Kupffer and sinusoidal endothelial cells, but not in parenchymal cells of (taut-/-) mice. Compared with wild- type mice, (taut-/-) and (taut+/-) mice developed moderate unspecific hepatitis and liver fibrosis with increased frequency of neoplastic lesions beyond 1 year of age. Liver disease in (taut-/-) mice was characterized by hepatocyte apoptosis, activation of the CD95 system, elevated plasma TNF-alpha levels, hepatic stellate cell and oval cell proliferation, and severe mitochondrial abnormalities in liver parenchymal cells. Mitochondrial dysfunction was suggested by a significantly lower respiratory control ratio in isolated mitochondria from (taut-/-) mice. Taut knockout had no effect on taurine-conjugated bile acids in bile; however, the relative amount of cholate-conjugates acid was decreased at the expense of 7-keto-cholate-conjugates. In conclusion, taurine deficiency due to defective taurine transport triggers chronic liver disease, which may involve mitochondrial dysfunction.	Univ Dusseldorf, Clin Gastroenterol Hepatol & Infectiol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Dept Physiol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Cent Inst Clin Chem & Lab Med, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Dept Biochem & Mol Biol 1, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Dept Med Microbiol, D-40225 Dusseldorf, Germany; Karolinska Univ Hosp Huddinge, Stockholm, Sweden; Univ Oslo, Ctr Mol Biol & Neurosci, N-0316 Oslo, Norway; Univ Cologne, Dept Pathol, D-5000 Cologne 41, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Karolinska Institutet; Karolinska University Hospital; University of Oslo; University of Cologne	Haussinger, DH (corresponding author), Univ Dusseldorf, Clin Gastroenterol Hepatol & Infectiol, Moorenstr 5, D-40225 Dusseldorf, Germany.	haeussin@uni-duesseldorf.de	Marschall, Hanns-Ulrich/K-8842-2017; Beer-Hammer, Sandra/C-7442-2014; Reinehr, Roland/G-6118-2016	Marschall, Hanns-Ulrich/0000-0001-7347-3085; Pfeffer, Klaus/0000-0002-5652-6330; Amiry-Moghaddam, Mahmood/0000-0003-1071-1247				ADAMSON GM, 1992, ARCH BIOCHEM BIOPHYS, V294, P223, DOI 10.1016/0003-9861(92)90161-O; ALME B, 1977, J LIPID RES, V18, P339; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P13615, DOI 10.1073/pnas.2336064100; AMIRYMOGHADDAM M, 1994, KIDNEY INT, V45, P10, DOI 10.1038/ki.1994.2; BANNASCH P, 1994, PATHOLOGY NEOPLASIA; Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034; BUCHE A, 1993, J BIOMOL STRUCT DYN, V11, P95, DOI 10.1080/07391102.1993.10508712; Cantz T, 2000, AM J PHYSIOL-GASTR L, V278, pG522, DOI 10.1152/ajpgi.2000.278.4.G522; Carson EJ, 1996, ALCOHOL CLIN EXP RES, V20, P132, DOI 10.1111/j.1530-0277.1996.tb01055.x; Chen Yue-Xiang, 2004, Hepatobiliary Pancreat Dis Int, V3, P106; Chesney RW, 1998, ADV EXP MED BIOL, V442, P463; *DAT SNP SING NUCL, 2005, NAT CTR BIOT INF NCB; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; El Idrissi A, 1999, J NEUROSCI, V19, P9459; ENGELHARDT NV, 1993, DIFFERENTIATION, V55, P19, DOI 10.1111/j.1432-0436.1993.tb00029.x; Flogel U, 1999, J MOL CELL CARDIOL, V31, P827, DOI 10.1006/jmcc.1998.0921; GREEN TR, 1991, BIOCHIM BIOPHYS ACTA, V1073, P91, DOI 10.1016/0304-4165(91)90187-L; GRISHAM MB, 1984, J BIOL CHEM, V259, P404; Heller-Stilb B, 2001, FASEB J, V15, P231, DOI 10.1096/fj.01-0691fje; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; KLINGENBERG M, 1959, BIOCHEM Z, V331, P486; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lang F, 1998, PFLUG ARCH EUR J PHY, V436, P377, DOI 10.1007/s004240050646; Lang F, 2000, PFLUG ARCH EUR J PHY, V440, P93, DOI 10.1007/s004240000247; Lang KS, 2002, PFLUG ARCH EUR J PHY, V443, P798, DOI 10.1007/s00424-001-0768-7; Libbrecht L, 2002, SEMIN CELL DEV BIOL, V13, P389, DOI 10.1016/S1084952102001258; Lima L, 2001, NUTR NEUROSCI, V4, P439, DOI 10.1080/1028415X.2001.11747379; Marschall HU, 2001, J LIPID RES, V42, P735; MCCUSKEY RS, 1990, J ELECTRON MICR TECH, V14, P237, DOI 10.1002/jemt.1060140305; McIntosh LM, 1998, ANAT RECORD, V252, P311, DOI 10.1002/(SICI)1097-0185(199810)252:2<311::AID-AR17>3.0.CO;2-Q; Medan D, 2005, J CELL PHYSIOL, V203, P78, DOI 10.1002/jcp.20201; Obinata K, 1996, ADV EXP MED BIOL, V403, P607; Oh SH, 2002, SEMIN CELL DEV BIOL, V13, P405, DOI 10.1016/S1084952102001271; Park E, 1998, ADV EXP MED BIOL, V442, P177; Peters-Regehr T, 1999, HEPATOLOGY, V29, P173, DOI 10.1002/hep.510290111; Reinehr R, 2003, FASEB J, V17, P731, DOI 10.1096/fj.02-0915fje; Reinehr R, 2004, J BIOL CHEM, V279, P23977, DOI 10.1074/jbc.M401519200; Reinehr R, 2004, J BIOL CHEM, V279, P10364, DOI 10.1074/jbc.M311997200; Reinehr R, 2003, GASTROENTEROLOGY, V125, P839, DOI 10.1016/S0016-5085(03)01055-2; Roskams T, 2003, AM J PATHOL, V163, P1301, DOI 10.1016/S0002-9440(10)63489-X; Roskams TA, 2003, SEMIN LIVER DIS, V23, P385; Schuller-Levis GB, 2004, NEUROCHEM RES, V29, P117, DOI 10.1023/B:NERE.0000010440.37629.17; Sergeeva OA, 2003, J PHYSIOL-LONDON, V550, P911, DOI 10.1113/jphysiol.2003.045864; Suzuki T, 2002, EMBO J, V21, P6581, DOI 10.1093/emboj/cdf656; TIMBRELL JA, 1995, GEN PHARMACOL-VASC S, V26, P453, DOI 10.1016/0306-3623(94)00203-Y; Warskulat U, 2004, FASEB J, V18, P577, DOI 10.1096/fj.03-0496fje; Warskulat U, 1997, J HEPATOL, V26, P1340, DOI 10.1016/S0168-8278(97)80470-9; Weik C, 1998, HEPATOLOGY, V27, P569, DOI 10.1002/hep.510270235; Welch WJ, 1996, CELL STRESS CHAPERON, V1, P109, DOI 10.1379/1466-1268(1996)001<0109:IOMACC>2.3.CO;2; Wettstein M, 1997, HEPATOLOGY, V26, P1560; Yamamoto S, 1996, ADV EXP MED BIOL, V403, P597; Zhang F, 1996, FEBS LETT, V391, P293, DOI 10.1016/0014-5793(96)00754-5	53	87	88	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					574	+		10.1096/fj.05-5016fje	http://dx.doi.org/10.1096/fj.05-5016fje			35	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16421246				2022-12-28	WOS:000235996000013
J	Albini, A; Dell'Eva, R; Vene, R; Ferrari, N; Buhler, DR; Noonan, DM; Fassina, G				Albini, A; Dell'Eva, R; Vene, R; Ferrari, N; Buhler, DR; Noonan, DM; Fassina, G			Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-kappa B and Akt as targets	FASEB JOURNAL			English	Article						angioprevention; chemoprevention; endothelial cells; NF-kappa B; Akt	HUMULUS-LUPULUS; PRENYLATED FLAVONOIDS; UP-REGULATION; TUMOR-GROWTH; IN-VIVO; ANGIOGENESIS; INHIBITION; ACTIVATION; CELLS; PRENYLFLAVONOIDS	Xanthohumol (XN), the principal flavonoid of the hop plant (Humulus lupulus L.) and a constituent of beer, has been suggested to have potential cancer chemopreventive activities. We have observed that most cancer chemopreventive agents show antiangiogenic properties in vitro and in vivo, a concept we termed "angioprevention." Here we show for the first time that XN can inhibit growth of a vascular tumor in vivo. Histopathology and in vivo angiogenesis assays indicated that tumor angiogenesis inhibition was involved. Further, we show the mechanisms for its inhibition of angiogenesis in vivo and related endothelial cell activities in vitro. XN repressed both the NF-kappa B and Akt pathways in endothelial cells, indicating that components of these pathways are major targets in the molecular mechanism of XN. Moreover, using in vitro analyses, we show that XN interferes with several points in the angiogenic process, including inhibition of endothelial cell invasion and migration, growth, and formation of a network of tubular-like structures. Our results suggest that XN can be added to the expanding list of antiangiogenic chemopreventive drugs whose potential in cancer prevention and therapy should be evaluated.	Univ Insubria, Dipartimento Sci Clin & Biol, Fac Med & Chirurg, I-21100 Varese, Italy; Ist Nazl Ric Canc, Mol Oncol Lab, I-16132 Genoa, Italy; Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA; Ist Nazl Ric Canc, Tumor Progress Unit, I-16132 Genoa, Italy; CNR, Sez Genova, Ist Bioimmagini & Fisiol Mol, Genoa, Italy	University of Insubria; University of Genoa; IRCCS AOU San Martino IST; Oregon State University; University of Genoa; IRCCS AOU San Martino IST; Consiglio Nazionale delle Ricerche (CNR); Istituto di Bioimmagini e Fisiologia Molecolare (IBFM-CNR)	Noonan, DM (corresponding author), Univ Insubria, Dipartimento Sci Clin & Biol, Fac Med & Chirurg, Via Ottorino Rossi 9, I-21100 Varese, Italy.	douglas.noonan@uninsubria.it	Albini, Adriana/J-3701-2018; Ferrari, Nicoletta/AAG-6049-2019; Noonan, Douglas/A-8620-2010	Ferrari, Nicoletta/0000-0002-6027-1035; Albini, Adriana/0000-0002-9624-5103; Noonan, Douglas/0000-0001-8058-0719	NIEHS NIH HHS [ES000210] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Albini A, 1997, AIDS, V11, P713, DOI 10.1097/00002030-199706000-00003; Albini A, 2001, CANCER RES, V61, P8171; ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004; ALBINI A, 1987, CANCER RES, V47, P3239; ANTO RJ, 1995, CANCER LETT, V97, P33, DOI 10.1016/0304-3835(95)03945-S; Barcelos LS, 2005, J LEUKOCYTE BIOL, V78, P352, DOI 10.1189/jlb.1104682; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bjorndahl M, 2005, P NATL ACAD SCI USA, V102, P15593, DOI 10.1073/pnas.0507865102; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Brown JR, 2005, J CLIN ONCOL, V23, P2840, DOI 10.1200/JCO.2005.09.051; Cai T, 1999, LAB INVEST, V79, P1151; Cao YH, 1999, NATURE, V398, P381, DOI 10.1038/18793; Chilov D, 1997, J BIOL CHEM, V272, P25176, DOI 10.1074/jbc.272.40.25176; DEVINCENZO R, 1995, ANTI-CANCER DRUG DES, V10, P481; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Farina AR, 1999, CELL GROWTH DIFFER, V10, P353; Fassina G, 2004, CLIN CANCER RES, V10, P4865, DOI 10.1158/1078-0432.CCR-03-0672; Ferrari N, 2005, CLIN CANCER RES, V11, P4610, DOI 10.1158/1078-0432.CCR-04-2210; Ferrari N, 2003, CLIN CANCER RES, V9, P6020; Garbisa S, 1999, NAT MED, V5, P1216, DOI 10.1038/15145; Garbisa S, 2001, CANCER-AM CANCER SOC, V91, P822, DOI 10.1002/1097-0142(20010215)91:4<822::AID-CNCR1070>3.0.CO;2-G; Gerhauser C, 2005, EUR J CANCER, V41, P1941, DOI 10.1016/j.ejca.2005.04.012; Gerhauser C, 2002, MOL CANCER THER, V1, P959; Goto K, 2005, CANCER LETT, V219, P215, DOI 10.1016/j.canlet.2004.07.034; Granata R, 2004, FASEB J, V18, P1456, DOI 10.1096/fj.04-1618fje; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Henderson MC, 2000, XENOBIOTICA, V30, P235, DOI 10.1080/004982500237631; Lambert JD, 2005, AM J CLIN NUTR, V81, p284S, DOI 10.1093/ajcn/81.1.284S; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Miranda CL, 2000, DRUG METAB DISPOS, V28, P1297; Miranda CL, 1999, FOOD CHEM TOXICOL, V37, P271, DOI 10.1016/S0278-6915(99)00019-8; Miranda CL, 2000, CANCER LETT, V149, P21, DOI 10.1016/S0304-3835(99)00328-6; NOVAK U, 1991, NUCLEIC ACIDS RES, V19, P3389, DOI 10.1093/nar/19.12.3389; Pan L, 2005, MOL NUTR FOOD RES, V49, P837, DOI 10.1002/mnfr.200500065; Scalbert A, 2005, AM J CLIN NUTR, V81, p215S, DOI 10.1093/ajcn/81.1.215S; Stevens JF, 1999, J CHROMATOGR A, V832, P97, DOI 10.1016/S0021-9673(98)01001-2; Stevens JF, 1997, PHYTOCHEMISTRY, V44, P1575, DOI 10.1016/S0031-9422(96)00744-3; Tosetti F, 2003, MOL PHARMACOL, V63, P565, DOI 10.1124/mol.63.3.565; Tosetti F, 2002, FASEB J, V16, P2, DOI 10.1096/fj.01-0300rev; Vanhoecke B, 2005, INT J CANCER, V117, P889, DOI 10.1002/ijc.21249; Zhao F, 2003, BIOL PHARM BULL, V26, P61, DOI 10.1248/bpb.26.61	42	156	172	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2005	19	14					527	+		10.1096/fj.05-5128fje	http://dx.doi.org/10.1096/fj.05-5128fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16403733				2022-12-28	WOS:000234405500014
J	Wedhas, N; Klamut, HJ; Dogra, C; Srivastava, AK; Mohan, S; Kumar, A				Wedhas, N; Klamut, HJ; Dogra, C; Srivastava, AK; Mohan, S; Kumar, A			Inhibition of mechanosensitive cation channels inhibits myogenic differentiation by suppressing the expression of myogenic regulatory factors and caspase-3 activity	FASEB JOURNAL			English	Article						mechanosensitive cation channels; gadolinium; myogenesis; C2C12; caspase-3; apoptosis	ACTIVATED PROTEIN-KINASE; SERUM RESPONSE FACTOR; SKELETAL-MUSCLE; ION CHANNELS; GROWTH-FACTOR; MECHANICAL STRETCH; INTRACELLULAR CA2+; BINDING PROTEIN; APOPTOSIS; CALCIUM	Mechanosensitive cation channels (MSC) are ubiquitous in eukaryotic cell types. However, the physiological functions of MSC in several tissues remain in question. In this study we have investigated the role of MSC in skeletal myogenesis. Treatment of C2C12 myoblasts with gadolinium ions ( MSC blocker) inhibited myotube formation and the myogenic index in differentiation medium (DM). The enzymatic activity of creatine kinase (CK) and the expression of myosin heavy chain-fast twitch (MyHCf) in C2C12 cultures were also blocked in response to gadolinium. Treatment of C2C12 myoblasts with gadolinium ions did not affect the expression of either cyclin A or cyclin D1 in DM. Other inhibitors of MSC such as streptomycin and GsTMx-4 also suppressed the expression of CK and MyHCf in C2C12 cultures. The inhibitory effect of gadolinium ions on myogenic differentiation was reversible and independent of myogenic cell type. Real-time-polymerase chain reaction analysis revealed that inhibition of MSC decreases the expression of myogenic transcription factors MyoD, myogenin, and Myf-5. Furthermore, the activity of skeletal alpha-actin promoter was suppressed on MSC blockade. Treatment of C2C12 myoblasts with gadolinium ions prevented differentiation-associated cell death and inhibited the cleavage of poly (ADP-ribose) polymerase and activation of caspase-3. On the other hand, delivery of active caspase-3 protein to C2C12 myoblasts reversed the inhibitory effect of gadolinium ions on myogenesis. Our data suggest that inhibition of MSC suppresses myogenic differentiation by inhibiting the caspase-3 activity and the expression of myogenic regulatory factors.	Jerry L Pettis Mem Vet Adm Med Ctr, Div Mol Genet, Musculoskeletal Dis Ctr, Loma Linda, CA 92354 USA; Loma Linda Univ, Dept Med, Loma Linda, CA 92350 USA; Loma Linda Univ, Dept Biochem, Loma Linda, CA 92350 USA	Loma Linda University; Loma Linda University	Kumar, A (corresponding author), Jerry L Pettis Mem Vet Adm Med Ctr, Div Mol Genet, Musculoskeletal Dis Ctr, 11201 Benton St,151, Loma Linda, CA 92354 USA.	Ashok.Kumar2@med.va.gov		Kumar, Ashok/0000-0001-8571-2848				Amthor H, 1998, CURR BIOL, V8, P642, DOI 10.1016/S0960-9822(98)70251-9; Amthor H, 1999, DEVELOPMENT, V126, P1041; Caldwell RA, 1998, AM J PHYSIOL-CELL PH, V275, pC619, DOI 10.1152/ajpcell.1998.275.2.C619; CAMPBELL JS, 1995, P NATL ACAD SCI USA, V92, P870, DOI 10.1073/pnas.92.3.870; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Chen AE, 2005, NATURE, V433, P317, DOI 10.1038/nature03126; Corey DP, 2003, NEURON, V39, P585, DOI 10.1016/S0896-6273(03)00505-1; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Formigli L, 2005, J CELL SCI, V118, P1161, DOI 10.1242/jcs.01695; FRANCO A, 1990, J PHYSIOL-LONDON, V427, P361, DOI 10.1113/jphysiol.1990.sp018176; Franco-Obregon A, 2002, J PHYSIOL-LONDON, V539, P391, DOI 10.1113/jphysiol.2001.013043; FRANCOOBREGON A, 1994, J PHYSIOL-LONDON, V481, P299, DOI 10.1113/jphysiol.1994.sp020440; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; Gonzalez I, 2004, MOL CELL BIOL, V24, P3607, DOI 10.1128/MCB.24.9.3607-3622.2004; Gottlieb PA, 2004, CNS NEUROL DISORD-DR, V3, P287, DOI 10.2174/1568007043337283; GUHARAY F, 1985, J PHYSIOL-LONDON, V363, P119, DOI 10.1113/jphysiol.1985.sp015699; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Hamill OP, 1996, PHARMACOL REV, V48, P231; Inoh H, 2002, FASEB J, V16, P405, DOI 10.1096/fj.01-0354fje; Juin P, 1998, J BIOL CHEM, V273, P17559, DOI 10.1074/jbc.273.28.17559; Kamradt MC, 2002, J BIOL CHEM, V277, P38731, DOI 10.1074/jbc.M201770200; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kumar A, 2004, FASEB J, V18, P1524, DOI 10.1096/fj.04-2414com; Kumar A, 2004, FASEB J, V18, P102, DOI 10.1096/fj.03-0453com; Kumar A, 2003, FASEB J, V17, P386, DOI 10.1096/fj.02-0542com; Kumar A, 2003, J BIOL CHEM, V278, P18868, DOI 10.1074/jbc.M212777200; Kumar A, 2002, J BIOL CHEM, V277, P46493, DOI 10.1074/jbc.M203654200; Langen RCJ, 2004, FASEB J, V18, P227, DOI 10.1096/fj.03-0251com; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; LANSMAN JB, 1990, J GEN PHYSIOL, V95, P679, DOI 10.1085/jgp.95.4.679; Li YP, 2003, AM J PHYSIOL-CELL PH, V285, pC370, DOI 10.1152/ajpcell.00453.2002; Lluis F, 2005, EMBO J, V24, P974, DOI 10.1038/sj.emboj.7600528; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; Martinac B, 2004, J CELL SCI, V117, P2449, DOI 10.1242/jcs.01232; Miller AL, 1998, J PHYSIOL-LONDON, V508, P793, DOI 10.1111/j.1469-7793.1998.793bp.x; Miyakoshi N, 2001, J CLIN INVEST, V107, P73, DOI 10.1172/JCI10459; Oswald RE, 2002, J BIOL CHEM, V277, P34443, DOI 10.1074/jbc.M202715200; Park JY, 2002, BIOCHEM BIOPH RES CO, V290, P1176, DOI 10.1006/bbrc.2001.6323; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; Schulz RA, 2004, DEV BIOL, V266, P1, DOI 10.1016/j.ydbio.2003.10.008; Seale P, 2000, DEV BIOL, V218, P115, DOI 10.1006/dbio.1999.9565; Shin KS, 1997, J BIOL CHEM, V272, P21227, DOI 10.1074/jbc.272.34.21227; Shin KS, 1996, DEV BIOL, V175, P14, DOI 10.1006/dbio.1996.0091; Sitcheran R, 2003, GENE DEV, V17, P2368, DOI 10.1101/gad.1114503; SMITH TH, 1993, DEVELOPMENT, V117, P1125; Soderling TR, 2001, CHEM REV, V101, P2341, DOI 10.1021/cr0002386; Stull JT, 2001, J BIOL CHEM, V276, P2311, DOI 10.1074/jbc.R000030200; Suchyna TM, 2004, NATURE, V430, P235, DOI 10.1038/nature02743; Suchyna TM, 2000, J GEN PHYSIOL, V115, P583, DOI 10.1085/jgp.115.5.583; Temm-Grove CJ, 1999, EXP CELL RES, V247, P293, DOI 10.1006/excr.1998.4362; Tureckova J, 2001, J BIOL CHEM, V276, P39264, DOI 10.1074/jbc.M104991200; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang J, 1997, CANCER RES, V57, P351; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; Wilson EM, 2004, MOL BIOL CELL, V15, P497, DOI 10.1091/mbc.E03-05-0351; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Yamazaki T, 1998, CIRC RES, V82, P430, DOI 10.1161/01.RES.82.4.430; Yang SH, 1999, MOL CELL BIOL, V19, P4028; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3	62	30	31	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2005	19	14					1986	1997		10.1096/fj.05-4198com	http://dx.doi.org/10.1096/fj.05-4198com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16319142				2022-12-28	WOS:000234405500009
J	Cumming, RC; Schubert, D				Cumming, RC; Schubert, D			Amyloid-beta induces disulfide bonding and aggregation of GAPDH in Alzheimer's disease	FASEB JOURNAL			English	Article						protein oxidation; apoptosis; neurodegeneration; protein insolubility	GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE-ACTIVITY; PROTEIN A-BETA; OXIDATIVE STRESS; NUCLEAR TRANSLOCATION; HUNTINGTONS-DISEASE; CELL-DEATH; RAT-BRAIN; APOPTOSIS; FILAMENTS; NERVE	GAPDH is a redox-sensitive glycolytic enzyme that also promotes apoptosis when translocated to the nucleus and associates with aggregate- prone proteins involved in neurodegenerative disorders. Recent evidence indicates that polymorphic variation within GAPDH genes is associated with an elevated risk of developing Alzheimer's disease ( AD). We previously demonstrated that GAPDH readily undergoes disulfide bonding following oxidant exposure, although the consequence of disulfide bonding on GAPDH activity or function is unknown. Here we show that increased GAPDH disulfide bonding is observed in detergent-insoluble extracts from AD patient and transgenic AD mouse brain tissue compared with age-matched controls. Exposure of primary rat cortical neurons to the pro-oxidant amyloid beta peptide promotes nuclear accumulation of a disulfide-linked form of GAPDH, which becomes detergent-insoluble. Disulfide bonding leads to a reduction in GAPDH enzymatic activity and correlates with the appearance of punctate aggregate- like GAPDH staining within the cytoplasm of both oxidant-treated HT22 cells and amyloid beta-treated primary cortical neurons. Our findings suggest that disulfide bonding of GAPDH and subsequent protein aggregate formation may have relevance to the pathophysiology of AD.	Salk Inst Biol Studies, Cellular Neurobiol Lab, La Jolla, CA 92037 USA	Salk Institute	Schubert, D (corresponding author), Salk Inst Biol Studies, Cellular Neurobiol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	schubert@salk.edu	Cumming, Robert/G-2185-2010					BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Bhattacharya K, 2001, BIOCHEM BIOPH RES CO, V285, P20, DOI 10.1006/bbrc.2001.5116; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; BRODIE AE, 1990, ARCH BIOCHEM BIOPHYS, V276, P212, DOI 10.1016/0003-9861(90)90028-W; BURKE JR, 1996, NAT MED, V347, P350; Butterfield DA, 2004, BRAIN PATHOL, V14, P426; Carlile GW, 2000, MOL PHARMACOL, V57, P2; CHUANG DM, 2004, ANN REV PHARM TOXICO; Cumming RC, 2004, J BIOL CHEM, V279, P21749, DOI 10.1074/jbc.M312267200; Dastoor Z, 2001, J CELL SCI, V114, P1643; DAVIS JB, 1994, BRAIN RES, V652, P169, DOI 10.1016/0006-8993(94)90334-4; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Forman HJ, 2004, AM J PHYSIOL-CELL PH, V287, pC246, DOI 10.1152/ajpcell.00516.2003; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; Giasson BI, 2002, FREE RADICAL BIO MED, V32, P1264, DOI 10.1016/S0891-5849(02)00804-3; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Koshy B, 1996, HUM MOL GENET, V5, P1311, DOI 10.1093/hmg/5.9.1311; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; Lee S, 2003, NAT STRUCT BIOL, V10, P725, DOI 10.1038/nsb961; Li Y, 2004, P NATL ACAD SCI USA, V101, P15688, DOI 10.1073/pnas.0403535101; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; Lind C, 1998, BIOCHEM BIOPH RES CO, V247, P481, DOI 10.1006/bbrc.1998.8695; Lindersson E, 2004, J BIOL CHEM, V279, P12924, DOI 10.1074/jbc.M306390200; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Mazzola JL, 2003, J NEUROSCI RES, V71, P279, DOI 10.1002/jnr.10484; Mazzola JL, 2001, J NEUROCHEM, V76, P442, DOI 10.1046/j.1471-4159.2001.00033.x; Mohr S, 1999, J BIOL CHEM, V274, P9427, DOI 10.1074/jbc.274.14.9427; Oyama R, 2000, BBA-PROTEIN STRUCT M, V1479, P91, DOI 10.1016/S0167-4838(00)00057-1; Ramsby ML, 1999, METH MOL B, V112, P53; Rhee S G, 2000, Sci STKE, V2000, ppe1; RYZLAK MT, 1988, BIOCHIM BIOPHYS ACTA, V954, P309, DOI 10.1016/0167-4838(88)90086-6; SABRI MI, 1971, J NEUROCHEM, V18, P1509, DOI 10.1111/j.1471-4159.1971.tb00013.x; Sawa A, 1997, P NATL ACAD SCI USA, V94, P11669, DOI 10.1073/pnas.94.21.11669; SCHULZE H, 1993, J NEUROCHEM, V60, P1915, DOI 10.1111/j.1471-4159.1993.tb13420.x; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; Senatorov VV, 2003, MOL CELL NEUROSCI, V22, P285, DOI 10.1016/S1044-7431(02)00013-1; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; SITIA R, 2004, SCI STKE, pPE27; Soucek T, 2003, NEURON, V39, P43, DOI 10.1016/S0896-6273(03)00367-2; SUNAGA K, 1995, NEUROSCI LETT, V200, P133, DOI 10.1016/0304-3940(95)12098-O; Tamaoka A, 1996, NEUROBIOL AGING, V17, P405, DOI 10.1016/0197-4580(96)00031-0; Tatton NA, 2000, EXP NEUROL, V166, P29, DOI 10.1006/exnr.2000.7489; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Tsuchiya K, 2005, EUR J NEUROSCI, V21, P317, DOI 10.1111/j.1460-9568.2005.03870.x; Tsuchiya K, 2004, LIFE SCI, V74, P3245, DOI 10.1016/j.lfs.2003.11.029; Wang Q, 2005, FASEB J, V19, P869, DOI 10.1096/fj.04-3210fje; Weber H, 2004, MOL MICROBIOL, V52, P133, DOI 10.1111/j.1365-2958.2004.03971.x; Welker E, 2001, P NATL ACAD SCI USA, V98, P4334, DOI 10.1073/pnas.071066598; Worthington V., 1993, WORTHINGTON ENZYME M	51	117	121	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					2060	+		10.1096/fj.05-4195fje	http://dx.doi.org/10.1096/fj.05-4195fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16186172				2022-12-28	WOS:000232315700006
J	Fischer, DF; van Dijk, R; Sluijs, JA; Nair, SM; Racchi, M; Levelt, CN; van Leeuwen, FW; Hol, EM				Fischer, DF; van Dijk, R; Sluijs, JA; Nair, SM; Racchi, M; Levelt, CN; van Leeuwen, FW; Hol, EM			Activation of the Notch pathway in Down syndrome: cross-talk of Notch and APP	FASEB JOURNAL			English	Article						Alzheimer disease; gamma-secretase complex; beta APP; Notch intracellular domain	AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE; INTRACELLULAR DOMAIN; ALZHEIMERS-DISEASE; GENE-EXPRESSION; FE65; PRESENILIN; CLEAVAGE; RELEASE; CELLS	Down syndrome (DS) patients suffer from mental retardation, but also display enhanced beta-APP production and develop cortical amyloid plaques at an early age. As beta-APP and Notch are both processed by beta-secretase, we analyzed expression of the Notch signaling pathway in the adult DS brain and in a model system for DS, human trisomy 21 fibroblasts by quantitative PCR. In adult DS cortex we found that Notch1, Dll1 and Hes1 expression is up-regulated. Moreover, DS fibroblasts and Alzheimer disease cortex also show overexpression of Notch1 and Dll1, indicating that enhanced beta-APP processing found in both DS and AD could be instrumental in these changes. Using pull-down studies we could demonstrate interaction of APP with Notch1, suggesting that these transmembrane proteins form heterodimers, but independent of beta-secretase. We could demonstrate binding of the intracellular domain of Notch1 to the APP adaptor protein Fe65. Furthermore, activated Notch1 can trans-activate an APP target gene, Kai1, and vice versa, activated APP can trans-activate the classical Notch target gene Hes1. These data suggest that Notch expression is activated in Down syndrome, possibly through cross-talk with APP signaling. This interaction might affect brain development, since the Notch pathway plays a pivotal role in neuron-glia differentiation.	Vrije Univ Amsterdam, CNCR, Dept Funct Genom, NL-1081 HV Amsterdam, Netherlands; Netherlands Inst Brain Res, Amsterdam, Netherlands; Univ Pavia, Dept Expt & Appl Pharmacol, I-27100 Pavia, Italy; Netherlands Ophthalm Res Inst, NL-1100 AC Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); University of Pavia; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	Fischer, DF (corresponding author), Vrije Univ Amsterdam, CNCR, Dept Funct Genom, Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands.	david@cncr.vu.nl	Racchi, Marco/G-6104-2018; Hol, Elly M/F-1891-2013; Hol, Elly/J-2025-2019	Racchi, Marco/0000-0002-7185-7808; Hol, Elly M/0000-0001-5604-2603; Hol, Elly/0000-0001-5604-2603; Fischer, David/0000-0002-6690-0197				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Berezovska O, 2001, J BIOL CHEM, V276, P30018, DOI 10.1074/jbc.M008268200; Blokzijl A, 2003, J CELL BIOL, V163, P723, DOI 10.1083/jcb.200305112; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; CHENG SV, 1988, P NATL ACAD SCI USA, V85, P6032, DOI 10.1073/pnas.85.16.6032; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Delatour B, 2001, AM J PATHOL, V158, P1585, DOI 10.1016/S0002-9440(10)64113-2; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; HILBICH C, 1993, J BIOL CHEM, V268, P26571; Ho A, 2004, P NATL ACAD SCI USA, V101, P2548, DOI 10.1073/pnas.0308655100; Hope AD, 2003, J NEUROCHEM, V86, P394, DOI 10.1046/j.1471-4159.2003.01844.x; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimberly WT, 2003, BIOCHEMISTRY-US, V42, P137, DOI 10.1021/bi026888g; Lleo A, 2003, J BIOL CHEM, V278, P47370, DOI 10.1074/jbc.M308480200; MANN DMA, 1989, J NEUROL SCI, V89, P169, DOI 10.1016/0022-510X(89)90019-1; Mao R, 2003, GENOMICS, V81, P457, DOI 10.1016/S0888-7543(03)00035-1; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; MONNING U, 1992, J BIOL CHEM, V267, P23950; Nishimura M, 1998, GENOMICS, V49, P69, DOI 10.1006/geno.1998.5213; NYE JS, 1994, DEVELOPMENT, V120, P2421; OH S, 2004, ANN M SOC NEUR; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Racchi M, 1999, BIOCHEM J, V338, P777, DOI 10.1042/0264-6021:3380777; Redmond L, 2000, NAT NEUROSCI, V3, P30, DOI 10.1038/71104; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Scheuermann S, 2001, J BIOL CHEM, V276, P33923, DOI 10.1074/jbc.M105410200; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Tanigaki K, 2001, NEURON, V29, P45, DOI 10.1016/S0896-6273(01)00179-9; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; van Dijk R, 2004, J NEUROCHEM, V90, P712, DOI 10.1111/j.1471-4159.2004.02528.x; WISNIEWSKI KE, 1990, AM J MED GENET, P274	46	81	85	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1451	1458		10.1096/fj.04-3395.com	http://dx.doi.org/10.1096/fj.04-3395.com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16126912				2022-12-28	WOS:000232315700038
J	Masaki, T; Chiba, S; Tatsukawa, H; Noguchi, H; Kakuma, T; Endo, M; Seike, M; Watanabe, T; Yoshimatsu, H				Masaki, T; Chiba, S; Tatsukawa, H; Noguchi, H; Kakuma, T; Endo, M; Seike, M; Watanabe, T; Yoshimatsu, H			The role of histamine H-1 receptor and H-2 receptor in LPS-induced liver injury	FASEB JOURNAL			English	Article						lipopolysaccharide; histamine receptor; tumor necrosis factor-a; IL-10	TUMOR-NECROSIS-FACTOR; GALACTOSAMINE-TREATED MICE; FULMINANT HEPATIC-FAILURE; BLOOD MONONUCLEAR-CELLS; H2 RECEPTORS; FACTOR-ALPHA; T-CELL; INTERFERON-GAMMA; IL-10 PRODUCTION; GENE-EXPRESSION	To examine the role of histamine H-1 and H-2 receptors in the regulation of lipopolysaccharide ( LPS)- induced liver injury, a combination of D- galactosamine and LPS ( GalN/ LPS) was administered to histamine H-1 receptor knockout ( H-1- R KO) and H-2 receptor knockout ( H-2- R KO) mice. The numbers of necrotic and apoptotic hepatocytes in the liver, as well as the levels of serum aspartate transaminase ( AST) and alanine transaminase ( ALT), were increased significantly by GalN/ LPS treatment compared to the appropriate controls. Pretreatment with histamine ameliorated the GalN/ LPS- induced necrotic and apoptotic changes in the hepatocytes and inhibited the elevation of serum AST and ALT levels. Histamine attenuated the GalN/ LPS- induced increases in the levels of TNF- alpha, but augmented those of IL- 10 both in the liver and serum. Histamine inhibited the GalN/ LPS- induced caspase- 3 activity in the liver. Furthermore, these effects of histamine were completely or partially attenuated in H-2- R KO mice, but not in H-1- R KO mice. Peritoneal macrophages from H-2- R KO mice exhibited blunted changes in the effects of histamine on LPS- induced TNF- alpha and IL- 10 production in vitro compared to the wild- type ( WT) controls. In summary, the present findings suggest that the histamine H-2- R- TNF- alpha and - IL- 10 pathways play protective roles in endotoxin- induced hepatic injury.	Oita Univ, Sch Med, Dept Internal Med, Hasama, Oita 8795593, Japan; RIKEN, Res Ctr Allergy & Immunol, Lab Immune Surveillance, Yokohama, Kanagawa, Japan	Oita University; RIKEN	Yoshimatsu, H (corresponding author), Oita Univ, Sch Med, Dept Internal Med, Hasama, Oita 8795593, Japan.	MASAKI@med.oita-u.ac.jp	Tatsukawa, Hideki/AAE-8377-2020	Masaki, Takayuki/0000-0002-2378-849X				BEER DJ, 1984, ADV IMMUNOL, V35, P209, DOI 10.1016/S0065-2776(08)60577-5; Deaciuc IV, 2000, ALCOHOL CLIN EXP RES, V24, P1557, DOI 10.1111/j.1530-0277.2000.tb04575.x; DELAMATA M, 1990, CLIN EXP IMMUNOL, V82, P479; DELVALLE J, 1992, AM J PHYSIOL, V263, pG967; Elenkov IJ, 1998, J IMMUNOL, V161, P2586; FIEDLER VB, 1992, J LAB CLIN MED, V120, P574; FREUDENBERG MA, 1991, INFECT IMMUN, V59, P2110, DOI 10.1128/IAI.59.6.2110-2115.1991; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; GANTNER F, 1995, GASTROENTEROLOGY, V109, P166, DOI 10.1016/0016-5085(95)90282-1; GROENEVELD PHP, 1988, IMMUNOLOGY, V63, P521; Gummuluru S, 1996, VIROLOGY, V225, P21, DOI 10.1006/viro.1996.0571; Hornyak SC, 2003, INFLAMMATION, V27, P317, DOI 10.1023/A:1026032611643; Horvath BV, 1999, IMMUNOL LETT, V70, P95, DOI 10.1016/S0165-2478(99)00126-1; IIMURO Y, 1994, J LEUKOCYTE BIOL, V55, P723, DOI 10.1002/jlb.55.6.723; Inoue I, 1996, P NATL ACAD SCI USA, V93, P13316, DOI 10.1073/pnas.93.23.13316; INOUE Y, 1994, SURGERY, V116, P356; Jirillo E, 2002, J ENDOTOXIN RES, V8, P319, DOI 10.1179/096805102125000641; Jutel M, 2002, CURR OPIN IMMUNOL, V14, P735, DOI 10.1016/S0952-7915(02)00395-3; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; KAMIJO R, 1993, J EXP MED, V178, P1435, DOI 10.1084/jem.178.4.1435; Kobayashi T, 2000, J CLIN INVEST, V105, P1741, DOI 10.1172/JCI9441; Kohka H, 2000, J IMMUNOL, V164, P6640, DOI 10.4049/jimmunol.164.12.6640; Kraly FS, 1996, PHARMACOL BIOCHEM BE, V53, P347, DOI 10.1016/0091-3057(95)02033-0; LEHMANN V, 1987, J EXP MED, V165, P657, DOI 10.1084/jem.165.3.657; LEIST M, 1994, J IMMUNOL, V153, P1778; LEIST M, 1995, AM J PATHOL, V146, P1220; LEVI RC, 1988, J PHARMACOL EXP THER, V246, P377; Masaki T, 2004, DIABETES, V53, P2250, DOI 10.2337/diabetes.53.9.2250; Masaki T, 2003, ENDOCRINOLOGY, V144, P2741, DOI 10.1210/en.2003-0031; Masaki T, 2004, HEPATOLOGY, V40, P177, DOI 10.1002/hep.20282; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI13930; McIntyre RC, 1997, SHOCK, V7, P36, DOI 10.1097/00024382-199701000-00004; MOVAT HZ, 1987, CAN J PHYSIOL PHARM, V65, P451, DOI 10.1139/y87-077; Nakama T, 2001, HEPATOLOGY, V33, P1441, DOI 10.1053/jhep.2001.24561; Nakamura T, 1997, EUR J PHARMACOL, V322, P83, DOI 10.1016/S0014-2999(96)00987-9; Okuyama H, 2003, HEPATOLOGY, V37, P1015, DOI 10.1053/jhep.2003.50203; Ostapowicz G, 2000, J GASTROEN HEPATOL, V15, P480, DOI 10.1046/j.1440-1746.2000.02074.x; Pajkrt D, 1997, J IMMUNOL, V158, P3971; Rizzardini M, 1998, HEPATOLOGY, V27, P703, DOI 10.1002/hep.510270311; Sass G, 2002, CYTOKINE, V19, P115, DOI 10.1006/cyto.2002.1948; Sirois J, 2000, J IMMUNOL, V164, P2964, DOI 10.4049/jimmunol.164.6.2964; Takahasi HK, 2003, CLIN IMMUNOL, V108, P274, DOI 10.1016/S1521-6616(03)00140-2; Tanaka M, 1996, J Clin Lab Immunol, V48, P17; Togias Alkis, 2003, Journal of Allergy and Clinical Immunology, V112, pS60, DOI 10.1016/S0091-6749(03)01878-5; VANNIER E, 1991, J EXP MED, V174, P281, DOI 10.1084/jem.174.1.281; Williams R, 1996, SEMIN LIVER DIS, V16, P343, DOI 10.1055/s-2007-1007247; Yamaguchi M, 2001, CLIN DIAGN LAB IMMUN, V8, P1234, DOI 10.1128/CDLI.8.6.1234-1239.2001	47	29	30	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1245	1252		10.1096/fj.04-3195com	http://dx.doi.org/10.1096/fj.04-3195com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16051691				2022-12-28	WOS:000231843700031
J	Poole, KES; van Bezooijen, RL; Loveridge, N; Hamersma, H; Papapoulos, SE; Lowik, CW; Reeve, J				Poole, KES; van Bezooijen, RL; Loveridge, N; Hamersma, H; Papapoulos, SE; Lowik, CW; Reeve, J			Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation	FASEB JOURNAL			English	Article						bone remodeling; immunohistochemistry; sclerosteosis	INTRACAPSULAR HIP FRACTURE; BMP ANTAGONIST; LINING CELLS; FEMORAL-NECK; PROTEIN; OSTEOCLASTS; APOPTOSIS; ESTROGEN; HORMONE; DENSITY	Osteocytes are the most abundant cells in bone and are ideally located to influence bone turnover through their syncytial relationship with surface bone cells. Osteocyte-derived signals have remained largely enigmatic, but it was recently reported that human osteocytes secrete sclerostin, an inhibitor of bone formation. Absent sclerostin protein results in the high bone mass clinical disorder sclerosteosis. Here we report that within adult iliac bone, newly embedded osteocytes were negative for sclerostin staining but became positive at or after primary mineralization. The majority of mature osteocytes in mineralized cortical and cancellous bone was positive for sclerostin with diffuse staining along dendrites in the osteocyte canaliculi. These findings provide for the first time in vivo evidence to support the concept that osteocytes secrete sclerostin after they become embedded in a mineralized matrix to limit further bone formation by osteoblasts. Sclerostin did not appear to influence the formation of osteocytes. We propose that sclerostin production by osteocytes may regulate the linear extent of formation and the induction or maintenance of a lining cell phenotype on bone surfaces. In doing so, sclerostin may act as a key inhibitory signal governing skeletal microarchitecture.	Univ Cambridge, Addenbrookes Hosp, Bone Res Grp, Dept Med, Cambridge CB2 2QQ, England; Leiden Univ, Ctr Med, Dept Endocrinol & Metab Dis, Leiden, Netherlands; Leiden Univ, Ctr Med, Dept Mol Cell Biol, Leiden, Netherlands	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC	Poole, KES (corresponding author), Univ Cambridge, Dept Med, MRC Clin Res Training Fellow Bone Res Grp, Box 157,Level 5, Cambridge CB2 2QQ, England.	kesp2@cam.ac.uk	Reeve, Jonathan/C-7551-2012	Reeve, Jonathan/0000-0002-4364-2682; Loveridge, Nigel/0000-0002-5550-7584				Allen MR, 2004, BONE, V35, P1003, DOI 10.1016/j.bone.2004.07.014; Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537; BEIGHTON P, 1976, ANN INTERN MED, V84, P393, DOI 10.7326/0003-4819-84-4-393; BEIGHTON P, 1977, CLIN GENET, V11, P1; BEIGHTON P, 1979, S AFR MED J, V55, P783; Bell KL, 1997, J BONE MINER RES, V12, P1231, DOI 10.1359/jbmr.1997.12.8.1231; Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811; Chow JWM, 1998, J BONE MINER RES, V13, P1760, DOI 10.1359/jbmr.1998.13.11.1760; DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632; Gross TS, 2005, J BONE MINER RES, V20, P250, DOI 10.1359/JBMR.041004; Gross TS, 2001, J APPL PHYSIOL, V90, P2514, DOI 10.1152/jappl.2001.90.6.2514; Hamersma H, 2003, CLIN GENET, V63, P192, DOI 10.1034/j.1399-0004.2003.00036.x; Kaptoge S, 2003, OSTEOPOROSIS INT, V14, P941, DOI 10.1007/s00198-003-1484-2; Kusu N, 2003, J BIOL CHEM, V278, P24113, DOI 10.1074/jbc.M301716200; Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200; Loveridge N, 2002, BONE, V30, P866, DOI 10.1016/S8756-3282(02)00732-9; Marotti G, 1996, Ital J Anat Embryol, V101, P25; MAROTTI G, 1992, BONE, V13, P363, DOI 10.1016/8756-3282(92)90452-3; Martin RB, 2000, BONE, V26, P1, DOI 10.1016/S8756-3282(99)00241-0; Martin RB, 2000, BONE, V26, P71, DOI 10.1016/S8756-3282(99)00242-2; Metz LN, 2003, BONE, V33, P753, DOI 10.1016/S8756-3282(03)00245-X; Noble BS, 2003, AM J PHYSIOL-CELL PH, V284, pC934, DOI 10.1152/ajpcell.00234.2002; Parfitt AM., 1983, BONE HISTOMORPHOMETR, V1983, P143; Power J, 2003, OSTEOPOROSIS INT, V14, P141, DOI 10.1007/s00198-002-1333-8; STEIN SA, 1983, NEUROLOGY, V33, P267, DOI 10.1212/WNL.33.3.267; Sutherland MK, 2004, BONE, V35, P828, DOI 10.1016/j.bone.2004.05.023; Tate MLK, 2004, INT J BIOCHEM CELL B, V36, P1, DOI 10.1016/S1357-2725(03)00241-3; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Tomkinson A, 1997, J CLIN ENDOCR METAB, V82, P3128, DOI 10.1210/jc.82.9.3128; van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454; Verborgt O, 2000, J BONE MINER RES, V15, P60, DOI 10.1359/jbmr.2000.15.1.60; WARMINGTON K, 2004, J BACK MUSCULOSKE S1, V19, P56; Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599	33	657	710	0	38	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1842	+		10.1096/fj.05-4221fje	http://dx.doi.org/10.1096/fj.05-4221fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16123173				2022-12-28	WOS:000231843700007
J	Weaver, A; da Silva, AG; Nuttall, RK; Edwards, DR; Shapiro, SD; Rivest, S; Yong, VW				Weaver, A; da Silva, AG; Nuttall, RK; Edwards, DR; Shapiro, SD; Rivest, S; Yong, VW			An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarization	FASEB JOURNAL			English	Article						autoimmunity; EAE/MS; cytokines; proteases; neuroimmunology	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; MESSENGER-RNA EXPRESSION; UP-REGULATION; GELATINASE B; INHIBITOR; MICE; MATRIX-METALLOPROTEINASE-9; CELLS; PROTEINS	Inflammation in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis ( EAE), is manifested by changes in matrix metalloproteinase ( MMP) expression and in the ratio of T helper ( Th) 1 and 2 effector cytokines. Here, we provide a comprehensive documentation of MMPs in EAE and report that of all the MMPs that could be measured at peak disease in spinal cord tissue, MMP- 12 was the most highly up- regulated. In contrast to previously published findings of MMPs in EAE, this increase in MMP- 12 expression was associated with protection, as MMP- 12 null mice had significantly worse maximum severity and EAE disease burden compared with wild- type ( WT) controls. When spleen and lymph node cells were removed from EAE- afflicted WT and MMP- 12 null mice at the same disease score before divergence of disease and restimulated in vitro, the MMP- 12 null cells had significantly higher Th1 to Th2 cytokine ratio. Measurements of the transcriptional regulators of T cell polarization revealed that MMP- 12 null cells had increased T- bet and reduced GATA- 3 expression, a condition that favors a Th1 bias. These results emphasize that specific MMPs can have beneficial roles in inflammation, and they implicate MMPs in T effector polarization for the first time.	Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 4N1, Canada; Univ E Anglia, Norwich NR4 7TJ, Norfolk, England; Harvard Univ, Sch Med, Boston, MA USA; Univ Laval, Quebec City, PQ, Canada	University of Calgary; University of Calgary; University of East Anglia; Harvard University; Harvard Medical School; Laval University	Yong, VW (corresponding author), Univ Calgary, Dept Oncol, 3330 Hosp Dr Calgary, Calgary, AB T2N 4N1, Canada.	vyong@ucalgary.ca	Edwards, Dylan R/B-4734-2009	Edwards, Dylan R/0000-0002-3292-2064; Rivest, Serge/0000-0002-6082-770X; Yong, V. Wee/0000-0002-2600-3563				Anthony DC, 1997, NEUROPATH APPL NEURO, V23, P406, DOI 10.1111/j.1365-2990.1997.tb01315.x; Anthony DC, 1998, J NEUROIMMUNOL, V87, P62, DOI 10.1016/S0165-5728(98)00046-0; Bar-Or A, 2003, BRAIN, V126, P2738, DOI 10.1093/brain/awg285; Brundula V, 2002, BRAIN, V125, P1297, DOI 10.1093/brain/awf133; Clements JM, 1997, J NEUROIMMUNOL, V74, P85, DOI 10.1016/S0165-5728(96)00210-X; Dubois B, 1999, J CLIN INVEST, V104, P1507, DOI 10.1172/JCI6886; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Esparza J, 2004, FASEB J, V18, P1682, DOI 10.1096/fj.04-2445com; GIJBELS K, 1994, J CLIN INVEST, V94, P2177, DOI 10.1172/JCI117578; Hartung HP, 2000, J NEUROIMMUNOL, V107, P140, DOI 10.1016/S0165-5728(00)00225-3; Hatton RD, 2003, SCIENCE, V302, P993, DOI 10.1126/science.1092040; HEWSON AK, 1995, INFLAMM RES, V44, P345, DOI 10.1007/BF01796266; ISSAZADEH S, 1995, J NEUROSCI RES, V40, P579, DOI 10.1002/jnr.490400503; Ito A, 1996, J BIOL CHEM, V271, P14657, DOI 10.1074/jbc.271.25.14657; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; KENNEDY MK, 1992, J IMMUNOL, V149, P2496; Kieseier BC, 1998, BRAIN, V121, P159, DOI 10.1093/brain/121.1.159; Larsen PH, 2004, J NEUROSCI, V24, P7597, DOI 10.1523/JNEUROSCI.2092-04.2004; Larsen PH, 2003, J NEUROSCI, V23, P11127, DOI 10.1523/jneurosci.23-35-11127.2003; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Leppert D, 1998, BRAIN, V121, P2327, DOI 10.1093/brain/121.12.2327; McQuibban GA, 2002, BLOOD, V100, P1160, DOI 10.1182/blood.V100.4.1160.h81602001160_1160_1167; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; Nuttall RK, 2003, MOL CANCER RES, V1, P333; Nygardas PT, 2002, CLIN EXP IMMUNOL, V128, P245, DOI 10.1046/j.1365-2249.2002.01855.x; O'Shea JJ, 2002, NAT REV IMMUNOL, V2, P37, DOI 10.1038/nri702; Pagenstecher A, 1998, AM J PATHOL, V152, P729; Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418; Sheu BC, 2001, CANCER RES, V61, P237; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; Steinman L, 2002, ANNU REV NEUROSCI, V25, P491, DOI 10.1146/annurev.neuro.25.112701.142913; Stuve O, 1996, ANN NEUROL, V40, P853, DOI 10.1002/ana.410400607; Toft-Hansen H, 2004, J IMMUNOL, V173, P5209, DOI 10.4049/jimmunol.173.8.5209; Tsutsui S, 2004, J NEUROSCI, V24, P1521, DOI 10.1523/JNEUROSCI.4271-03.2004; Vos CMP, 2003, J NEUROIMMUNOL, V138, P106, DOI 10.1016/S0165-5728(03)00036-5; Wells JEA, 2003, J NEUROSCI, V23, P10107, DOI 10.1523/jneurosci.23-31-10107.2003; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	40	114	128	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1668	+		10.1096/fj.04-2030fje	http://dx.doi.org/10.1096/fj.04-2030fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16081501				2022-12-28	WOS:000231843700022
J	Maier, TJ; Janssen, A; Schmidt, R; Geisslinger, G; Grosch, S				Maier, TJ; Janssen, A; Schmidt, R; Geisslinger, G; Grosch, S			Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells	FASEB JOURNAL			English	Article						colon cancer; nonsteroidal anti-inflammatory drugs; apoptosis	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GLYCOGEN-SYNTHASE KINASE-3; ADENOMATOUS POLYPOSIS; INHIBITOR CELECOXIB; COLORECTAL-CANCER; CYCLE ARREST; APOPTOSIS; ACTIVATION; PROTEIN; EXPRESSION	CCelecoxib, a cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drug, is a new anticarcinogenic agent. Its antitumor effects depend on the one hand on its COX-2-inhibiting potency, but on the other hand on COX-2-independent mechanisms, which until now have not been fully understood. Here, we investigated whether celecoxib has an impact on the APC/beta-catenin pathway, which has been shown to play a pivotal role in the development of various cancers, especially of the colon. After only 2 h of treatment of human Caco-2 colon carcinoma cells with 100 mu M celecoxib, we observed a rapid translocation of beta-catenin from its predominant membrane localization to the cytoplasm. Inhibition of the glycogen-synthase-kinase-3 beta (GSK-3 beta) by LiCl prevented this celecoxib-induced translocation, suggesting that phosphorylation of beta-catenin by the GSK-3 beta kinase was essential for this release. Furthermore, the cytosolic accumulation was accompanied by a rapid increase of beta-catenin in the nuclei, starting already 30 min after celecoxib treatment. The DNA binding activity of beta-catenin time dependently decreased 2 h after celecoxib treatment. After this cellular reorganization, we observed a caspase- and proteasome-dependent degradation of beta-catenin after 8 h of drug incubation. Celecoxib-induced beta-catenin degradation was also observed in various other tumor cell lines (HCT-116, MCF-7, and LNCAP) but was not seen after treatment of Caco-2 cells with either the anticarcinogenic nonsteroidal anti-inflammatory drug R-flurbiprofen or the highly COX-2-selective inhibitor rofecoxib. These findings indicate that the anticarcinogenic effects of celecoxib can be explained, at least partly, by an extensive degradation of beta-catenin in human colon carcinoma cells.	Univ Frankfurt Klinikum, Inst Klin Pharmakol, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Grosch, S (corresponding author), Univ Frankfurt Klinikum, Inst Klin Pharmakol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	groesch@em.uni-frankfurt.de	Groesch, Sabine/H-4251-2018	Groesch, Sabine/0000-0002-7262-6307				Abou-Issa Hussein, 2004, Expert Rev Anticancer Ther, V4, P725, DOI 10.1586/14737140.4.5.725; Arico S, 2002, J BIOL CHEM, V277, P27613, DOI 10.1074/jbc.M201119200; Basu GD, 2004, MOL CANCER RES, V2, P632; Boon EMJ, 2004, BRIT J CANCER, V90, P224, DOI 10.1038/sj.bjc.6601505; Brautigam L, 2001, J CHROMATOGR B, V761, P203, DOI 10.1016/S0378-4347(01)00333-4; Brown WA, 2001, DIGEST DIS SCI, V46, P2314, DOI 10.1023/A:1012326525692; Brozovic A, 2004, INT J CANCER, V112, P974, DOI 10.1002/ijc.20522; Chen TA, 2003, CANCER RES, V63, P4368; Cong F, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-10; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Dihlmann S, 2003, MOL CANCER THER, V2, P509; Easwaran V, 2003, CANCER RES, V63, P3145; Gardner SH, 2004, BRIT J CANCER, V91, P153, DOI 10.1038/sj.bjc.6601901; Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje; Grosch S, 2003, FASEB J, V17, P1316, DOI 10.1096/fj.02-0919fje; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heinen CD, 2002, GASTROENTEROLOGY, V123, P751, DOI 10.1053/gast.2002.35382; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Hugh TJ, 1999, BRIT J CANCER, V80, P1046, DOI 10.1038/sj.bjc.6690461; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Johnson AJ, 2002, BIOCHEM J, V366, P831, DOI 10.1042/BJ20020279; Kikuchi A, 2000, BIOCHEM BIOPH RES CO, V268, P243, DOI 10.1006/bbrc.1999.1860; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Kolligs FT, 2002, DIGESTION, V66, P131, DOI 10.1159/000066755; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Maier TJ, 2004, BIOCHEM PHARMACOL, V67, P1469, DOI 10.1016/j.bcp.2003.12.014; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Maruyama K, 2000, ONCOLOGY-BASEL, V59, P302, DOI 10.1159/000012187; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Niederberger E, 2001, FASEB J, V15, P1622, DOI 10.1096/fj.00-0716fje; Ougolkov AV, 2002, GASTROENTEROLOGY, V122, P60, DOI 10.1053/gast.2002.30306; Papkoff J, 1998, BIOCHEM BIOPH RES CO, V247, P851, DOI 10.1006/bbrc.1998.8888; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Rask K, 2003, BRIT J CANCER, V89, P1298, DOI 10.1038/sj.bjc.6601265; Rice PL, 2003, MOL CANCER THER, V2, P885; Roh H, 2001, CANCER RES, V61, P6563; Sadot E, 2002, J CELL SCI, V115, P2771; Sanz-Ortega J, 1999, PATHOL RES PRACT, V195, P677; SILENI VC, 1992, CANCER CHEMOTH PHARM, V30, P221, DOI 10.1007/BF00686317; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Steinhusen U, 2000, J BIOL CHEM, V275, P16345, DOI 10.1074/jbc.M001458200; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Trifan OC, 2003, J CELL MOL MED, V7, P207, DOI 10.1111/j.1582-4934.2003.tb00222.x; Virmani AK, 2001, CLIN CANCER RES, V7, P1998; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0; Yamada Y, 2001, JPN J CANCER RES, V92, P617, DOI 10.1111/j.1349-7006.2001.tb01139.x; Yang HM, 2004, CIRCULATION, V110, P301, DOI 10.1161/01.CIR.0000135467.43430.16; Zhang ZC, 2004, HEPATOLOGY, V39, P1028, DOI 10.1002/hep.20143; Zhu JX, 2004, CANCER RES, V64, P4309, DOI 10.1158/0008-5472.CAN-03-4063	56	115	121	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1353	+		10.1096/fj.04-3274fje	http://dx.doi.org/10.1096/fj.04-3274fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15946992				2022-12-28	WOS:000230207800024
J	Peter, JC; Tugler, J; Eftekhari, P; Maurice, D; Hoebeke, J; Roegel, JC				Peter, JC; Tugler, J; Eftekhari, P; Maurice, D; Hoebeke, J; Roegel, JC			Effects on heart rate of an anti-M2 acetylcholine receptor immune response in mice	FASEB JOURNAL			English	Article						electrocardiography; heart rate; acetylcholine; receptors; antibodies	IDIOPATHIC DILATED CARDIOMYOPATHY; CARDIAC MUSCARINIC RECEPTORS; HUMAN CHAGASIC IGG; MONOCLONAL-ANTIBODY; ANTAGONIST BINDING; K+ CHANNEL; AUTOANTIBODIES; AGONIST; DISEASE; AUTOIMMUNITY	Autoantibodies in vitro modulating the M2 acetylcholine receptor (M2ACh-R) were observed in patients with idiopathic dilated cardiomyopathy (IDC) or Chagas' cardiomyopathy (ChC). We investigated the in vivo consequences on heart rate of such antibodies in mice immunized with a peptide derived from the second extracellular loop of the M2ACh-R compared with mice immunized with an irrelevant peptide. Sera of mice immunized with the M2ACh-R- derived peptide recognized the M2ACh-R on immunoblots and enhanced agonist activity of carbachol toward the M2ACh-R transfected in CHO cells. In vivo, no difference could be shown in heart rate or heart rate variability between the two groups of mice. The decrease in heart rate induced by carbachol was more pronounced, however, in the M2ACh-R immunized mice. The increase in heart rate induced by atropine, gallamine, and isoproterenol was significantly attenuated in the M2ACh-R immunized mice. Analysis of heart rate variability further argued for an increased parasympathetic response to different drugs in the M2ACh-R immunized mice. Antibodies raised against the M2ACh-R can behave as positive M2AChR allosteric modulators in vivo. They might be protective in boosting the activity of the parasympathetic drive to the heart, especially in patients with a high sympathetic tone.	Sch Med, Inst Pharmacol, F-68250 Rouffach, France; CNRS, Inst Biol Mol & Cellulaire, Lab Immunol & Therapeut Chem, UPR 9021, F-67084 Strasbourg, France	Universite de Franche-Comte; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Roegel, JC (corresponding author), Sch Med, Inst Pharmacol, 27 Rue 4eme RSM, F-68250 Rouffach, France.	jcroegel@free.fr	Maurice, Donald/AAE-9332-2019					Brown F, 1999, VACCINE, V18, P50, DOI 10.1016/S0264-410X(99)00169-3; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; Chaves AA, 2003, LIFE SCI, V72, P2401, DOI 10.1016/S0024-3205(03)00137-1; Chiale PA, 2001, AUTOIMMUNITY, V34, P205, DOI 10.3109/08916930109007386; Chiale PA, 2001, CIRCULATION, V103, P1765, DOI 10.1161/01.CIR.103.13.1765; del Corsso C, 2004, AM J PHYSIOL-HEART C, V287, pH1928, DOI 10.1152/ajpheart.00044.2004; Elies R, 1996, J IMMUNOL, V157, P4203; Elies R, 1998, EUR J BIOCHEM, V251, P659, DOI 10.1046/j.1432-1327.1998.2510659.x; Fisher JT, 2004, FASEB J, V18, P711, DOI 10.1096/fj.03-0648fje; FU LX, 1993, J CLIN INVEST, V91, P1964, DOI 10.1172/JCI116416; Goin JC, 1997, FASEB J, V11, P77, DOI 10.1096/fasebj.11.1.9034169; Goin Juan Carlos, 1994, Neuroimmunomodulation, V1, P284; Hernandez CCQ, 2003, CARDIOVASC RES, V58, P55, DOI 10.1016/S0008-6363(02)00811-8; Jahns R, 2004, J CLIN INVEST, V113, P1419, DOI 10.1172/JCI200420149; Leiros CP, 1997, J BIOL CHEM, V272, P12989, DOI 10.1074/jbc.272.20.12989; LEPPIK RA, 1994, MOL PHARMACOL, V45, P983; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LUETJE CW, 1988, J BIOL CHEM, V263, P13357; MAGNUSSON Y, 1994, CIRCULATION, V89, P2760, DOI 10.1161/01.CIR.89.6.2760; Matsui S, 1999, J Card Fail, V5, P246, DOI 10.1016/S1071-9164(99)90009-X; Matsui S, 2001, J CARDIOVASC PHARM, V38, pS43, DOI 10.1097/00005344-200110001-00010; Mijares A, 1996, MOL CELL BIOCHEM, V164, P107, DOI 10.1007/BF00408646; Nascimento JHM, 2001, AM J PHYSIOL-CELL PH, V281, pC1251, DOI 10.1152/ajpcell.2001.281.4.C1251; NEIMARK J, 1993, PEPTIDE RES, V6, P219; Nevo U, 2004, J THEOR BIOL, V227, P583, DOI 10.1016/j.jtbi.2003.11.031; Peter JC, 2003, J BIOL CHEM, V278, P36740, DOI 10.1074/jbc.M306877200; Sowell MO, 1997, P NATL ACAD SCI USA, V94, P7921, DOI 10.1073/pnas.94.15.7921; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Wallukat G, 1999, LIFE SCI, V64, P465, DOI 10.1016/S0024-3205(98)00589-X; Wallukat G, 2002, NEW ENGL J MED, V347, P1806, DOI 10.1056/NEJM200211283472220; Yamada M, 1998, PHARMACOL REV, V50, P723; Zhang L, 2002, CHINESE MED J-PEKING, V115, P1127	32	16	16	4	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					943	949		10.1096/fj.04-3042com	http://dx.doi.org/10.1096/fj.04-3042com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15923404				2022-12-28	WOS:000230207800041
J	Zhang, R; Dzhura, I; Grueter, CE; Thiel, W; Colbran, RJ; Anderson, ME				Zhang, R; Dzhura, I; Grueter, CE; Thiel, W; Colbran, RJ; Anderson, ME			RETRACTED: A dynamic alpha-beta inter-subunit agonist signaling complex is a novel feedback mechanism for regulating L-type Ca2+ channel opening (Retracted article. See vol. 29, pg. 1125, 2015)	FASEB JOURNAL			English	Article; Retracted Publication						beta subunit; calcium channel; calmodulin	RABBIT VENTRICULAR MYOCYTES; CALMODULIN-BINDING; CALCIUM-CHANNELS; CA2+-DEPENDENT INACTIVATION; FACILITATION; KINASE; CONDUCTANCE; MODULATION; TERMINUS; DOMAINS	L-type Ca2+ channels are macromolecular protein complexes in neurons and myocytes that open in response to cell membrane depolarization to supply Ca2+ for regulating gene transcription and vesicle secretion and triggering cell contraction. L- type Ca2+ channels include a pore- forming a and an auxiliary beta subunit, and a subunit openings are regulated by cellular Ca2+ through a mechanism involving the Ca2+- sensing protein calmodulin ( CaM) and CaM binding motifs in the a subunit cytoplasmic C terminus. Here we show that these CaM binding motifs are " autoagonists" that increase a subunit openings by binding the beta subunit. The CaM binding domains are necessary and sufficient for the a subunit C terminus to bind the beta subunit in vitro, and excess CaM blocks this interaction. Addition of CaM binding domains to native cardiac L- type Ca2+ channels in excised cell membrane patches increases openings, and this agonist effect is prevented by excess CaM. Recombinant LTCC openings are also increased by exogenous CaM binding domains by a mechanism requiring the beta subunit, and excess CaM blocks this effect. Thus, the bifunctional ability of the alpha subunit CaM binding motifs to competitively associate with the beta subunit or CaM provides a novel paradigm for feedback control of cellular Ca2+ entry.	Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37240 USA; Vanderbilt Univ, Med Ctr, Dept Physiol & Mol Biophys, Nashville, TN USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Zhang, R (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, 383 Preston Res Bldg, Nashville, TN 37240 USA.	mark.anderson@vanderbilt.edu; roger.colbran@vanderbilt.edu	Colbran, Roger/AAU-7708-2021	Colbran, Roger/0000-0001-7401-8244; Grueter, Chad/0000-0001-8950-742X				BERS DM, 1994, METHOD CELL BIOL, V40, P3; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; CAMPBELL V, 1995, J PHYSIOL-LONDON, V485, P365, DOI 10.1113/jphysiol.1995.sp020735; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Dzhura I, 2003, J PHYSIOL-LONDON, V550, P731, DOI 10.1113/jphysiol.2003.043778; Dzhura I, 2000, NAT CELL BIOL, V2, P173, DOI 10.1038/35004052; Gamper N, 2003, J GEN PHYSIOL, V122, P17, DOI 10.1085/jgp.200208783; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Kepplinger KJF, 2000, FEBS LETT, V477, P161, DOI 10.1016/S0014-5793(00)01791-9; Kobrinsky E, 2003, J BIOL CHEM, V278, P5021, DOI 10.1074/jbc.M211254200; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Maltez JM, 2005, NAT STRUCT MOL BIOL, V12, P372, DOI 10.1038/nsmb909; McGee AW, 2004, NEURON, V42, P89, DOI 10.1016/S0896-6273(04)00149-7; Pate P, 2000, J BIOL CHEM, V275, P39786, DOI 10.1074/jbc.M007158200; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; Takahashi SX, 2004, P NATL ACAD SCI USA, V101, P7193, DOI 10.1073/pnas.0306665101; Tan HL, 2002, NATURE, V415, P442, DOI 10.1038/415442a; Van Petegem F, 2004, NATURE, V429, P671, DOI 10.1038/nature02588; VanDongen AMJ, 1996, BIOPHYS J, V70, P1303, DOI 10.1016/S0006-3495(96)79687-X; Wu YJ, 2001, J PHYSIOL-LONDON, V535, P679, DOI 10.1111/j.1469-7793.2001.t01-1-00679.x; Yasuda T, 2004, EUR J NEUROSCI, V20, P1, DOI 10.1111/j.1460-9568.2004.03434.x; YUE DT, 1990, P NATL ACAD SCI USA, V87, P753, DOI 10.1073/pnas.87.2.753; Zuhlke RD, 2000, J BIOL CHEM, V275, P21121, DOI 10.1074/jbc.M002986200; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	29	22	22	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1153	+		10.1096/fj.04-3283fje	http://dx.doi.org/10.1096/fj.04-3283fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15994413				2022-12-28	WOS:000230207800001
J	Funderburgh, ML; Du, YQ; Mann, MM; SundarRaj, N; Funderburgh, JL				Funderburgh, ML; Du, YQ; Mann, MM; SundarRaj, N; Funderburgh, JL			PAX6 expression identifies progenitor cells for corneal keratocytes	FASEB JOURNAL			English	Article						cornea; keratan sulfate; stem cell	MESENCHYMAL STEM-CELLS; BOVINE KERATOCYTES; IN-VITRO; PROTEOGLYCAN EXPRESSION; SKELETAL-MUSCLE; BONE-MARROW; PHENOTYPE; DIFFERENTIATION; FIBROBLASTS; SULFATE	Keratocytes of the corneal stroma produce a transparent extracellular matrix required for vision. During wound-healing and in vitro,keratocytes proliferate, becoming fibroblastic, and lose biosynthesis of unique corneal matrix components. This study sought identification of cells in the corneal stroma capable of assuming a keratocyte phenotype after extensive proliferation. About 3% of freshly isolated bovine stromal cells exhibited clonal growth. In low-mitogen media, selected clonal cultures displayed dendritic morphology and expressed high levels of keratan sulfate, aldehyde dehydrogenase 3A1, and keratocan, molecular markers of keratocyte phenotype. In protein-free media, both primary keratocytes and selected clonal cells aggregated to form attachment-independent spheroids expressing elevated levels of those marker molecules. The selected clonal cells exhibited normal karyotype and underwent replicative senescence after 65-70 population doublings;however, they continued expression of keratocyte phenotypic markers throughout their replicative life span. The progenitor cells expressed elevated mRNA for several genes characteristic of stem cells and also for genes expressed during ocular development PAX6, Six2, and Six3. PAX6 protein was detected in the cultured progenitor cells and a small number of stromal cells in intact tissue but was absent in cultured keratocytes and fibroblasts. Cytometry demonstrated PAX6 protein in 4% of freshly isolated stromal cells. These results demonstrate the presence of a previously unrecognized population of PAX6-positive cells in adult corneal stroma that maintain the potential to assume a keratocyte phenotype even after extensive replication. The presence of such progenitor cells has implications for corneal biology and for cell-based therapies targeting corneal scarring.	Univ Pittsburgh, Dept Ophthalmol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Funderburgh, JL (corresponding author), Eye & Ear Inst Pittsburgh, Rm 1009,203 Lothrop St, Pittsburgh, PA 15213 USA.	jlfunder@pitt.edu	DU, YIQIN/AAO-1566-2020; Du, Yiqin/A-7727-2018	DU, YIQIN/0000-0002-4330-0957; 	NEI NIH HHS [R01 EY016415, P30 EY008098-179003, EY09368, P30 EY008098, R03 EY013806, EY013806, R01 EY016415-01A1, R01 EY009368, 30-EY08098, R01 EY003263, EY003263] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY016415, R01EY003263, R01EY009368, P30EY008098, R03EY013806] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alsalameh S, 2004, ARTHRITIS RHEUM-US, V50, P1522, DOI 10.1002/art.20269; Arsenijevic Y, 2001, EXP NEUROL, V170, P48, DOI 10.1006/exnr.2001.7691; Baroffio A, 1996, DIFFERENTIATION, V60, P47, DOI 10.1046/j.1432-0436.1996.6010047.x; BAYANI J, 2004, CURRENT PROTOCOLS CE; Beales MP, 1999, INVEST OPHTH VIS SCI, V40, P1658; Beauchamp JR, 1999, J CELL BIOL, V144, P1113, DOI 10.1083/jcb.144.6.1113; Berryhill BL, 2002, INVEST OPHTH VIS SCI, V43, P3416; Bez A, 2003, BRAIN RES, V993, P18, DOI 10.1016/j.brainres.2003.08.061; Bourges JL, 2003, OPHTHALMOLOGY, V110, P1920, DOI 10.1016/S0161-6420(03)00617-1; Carlson EC, 2003, MOL VIS, V9, P615; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Chun MH, 2000, CRIT REV ONCOL HEMAT, V36, P89, DOI 10.1016/S1040-8428(00)00079-2; Collinson JM, 2003, DEV BIOL, V255, P303, DOI 10.1016/S0012-1606(02)00095-7; Connon CJ, 2003, OPHTHALMIC RES, V35, P177, DOI 10.1159/000071168; CONRAD AH, 1995, CELL MOTIL CYTOSKEL, V31, P93, DOI 10.1002/cm.970310203; CONRAD GW, 1974, EXP EYE RES, V18, P421, DOI 10.1016/0014-4835(74)90079-7; De Bari C, 2003, J CELL BIOL, V160, P909, DOI 10.1083/jcb.200212064; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Espana EM, 2003, INVEST OPHTH VIS SCI, V44, P5136, DOI 10.1167/iovs.03-0484; Funderburgh JL, 1996, J BIOL CHEM, V271, P31431, DOI 10.1074/jbc.271.49.31431; Funderburgh JL, 2003, J BIOL CHEM, V278, P45629, DOI 10.1074/jbc.M303292200; Funderburgh JL, 2001, J BIOL CHEM, V276, P44173, DOI 10.1074/jbc.M107596200; Gao R, 2003, DIABETES, V52, P2007, DOI 10.2337/diabetes.52.8.2007; GARANA RMR, 1992, INVEST OPHTH VIS SCI, V33, P3271; Ghanbari H, 2001, MECH DEVELOP, V101, P271, DOI 10.1016/S0925-4773(00)00572-4; Jiang YH, 2003, P NATL ACAD SCI USA, V100, P11854, DOI 10.1073/pnas.1834196100; Jiang YH, 2002, EXP HEMATOL, V30, P896, DOI 10.1016/S0301-472X(02)00869-X; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Lanza RP, 2000, SCIENCE, V288, P665, DOI 10.1126/science.288.5466.665; Lee RH, 2004, CELL PHYSIOL BIOCHEM, V14, P311, DOI 10.1159/000080341; Leppert G S, 1999, Ophthalmic Genet, V20, P7, DOI 10.1076/opge.20.1.7.2298; Liu CY, 2003, J BIOL CHEM, V278, P21672, DOI 10.1074/jbc.M301169200; Liu HW, 1997, J BONE MINER RES, V12, P1691, DOI 10.1359/jbmr.1997.12.10.1691; Long CJ, 2000, J BIOL CHEM, V275, P13918, DOI 10.1074/jbc.275.18.13918; Mabey DCW, 2003, LANCET, V362, P223, DOI 10.1016/S0140-6736(03)13914-1; Majumdar MK, 2000, J HEMATOTH STEM CELL, V9, P841, DOI 10.1089/152581600750062264; Marcon AS, 2003, CORNEA, V22, P19, DOI 10.1097/00003226-200301000-00005; Moller-Pedersen T, 1998, INVEST OPHTH VIS SCI, V39, P487; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; MULLER LJ, 1995, INVEST OPHTH VIS SCI, V36, P2557; Neurath AR, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-6; Park IK, 2004, J CLIN INVEST, V113, P175, DOI 10.1172/JCI200420800; Qi HL, 2003, P NATL ACAD SCI USA, V100, P3305, DOI 10.1073/pnas.0532693100; Ramaesh T, 2003, INVEST OPHTH VIS SCI, V44, P1871, DOI 10.1167/iovs.02-0576; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Schwartz M F, 1985, Cornea, V4, P58; Sell S, 2003, INT J BIOCHEM CELL B, V35, P267, DOI 10.1016/S1357-2725(02)00182-6; Shimano K, 2003, AM J PATHOL, V163, P3, DOI 10.1016/S0002-9440(10)63624-3; SUNDARRAJ N, 1985, CURR EYE RES, V4, P49; Tallheden T, 2003, J BONE JOINT SURG AM, V85A, P93, DOI 10.2106/00004623-200300002-00012; Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778; Tuli R, 2003, STEM CELLS, V21, P681, DOI 10.1634/stemcells.21-6-681; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Verfaillie CM, 2002, TRENDS CELL BIOL, V12, P502, DOI 10.1016/S0962-8924(02)02386-3; Vourc'h P, 2004, BIOCHEM BIOPH RES CO, V317, P893, DOI 10.1016/j.bbrc.2004.03.121; Yamamoto S, 2001, J NEUROSCI, V21, P9814, DOI 10.1523/JNEUROSCI.21-24-09814.2001; Yin L, 2002, HEPATOLOGY, V35, P315, DOI 10.1053/jhep.2002.31355; Yoon YD, 1998, CORNEA, V17, P180, DOI 10.1097/00003226-199803000-00011; Zhang Y, 2004, EXP HEMATOL, V32, P657, DOI 10.1016/j.exphem.2004.04.001; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	60	87	90	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1371	+		10.1096/fj.04-2770fje	http://dx.doi.org/10.1096/fj.04-2770fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15901670	Green Accepted			2022-12-28	WOS:000229602600010
J	Merx, MW; Godecke, A; Flogel, U; Schrader, J				Merx, MW; Godecke, A; Flogel, U; Schrader, J			Oxygen supply and nitric oxide scavenging by myoglobin contribute to exercise endurance and cardiac function	FASEB JOURNAL			English	Article						genetically altered mice; contractile function; echocardiography; cardiac pathophysiology	IN-VIVO; SYNTHASE; HEART; MICE; DIFFUSION; TRANSPORT; MODELS	Recent studies of myoglobin (Mb) knockout (myo(-/-)) mice have extended our understanding of Mb's diverse functions and have demonstrated a complex array of compensatory mechanisms. The present study was aimed at detailed analysis of cardiac function and exercise endurance in myo(-/-) mice and at providing evidence for Mb's functional relevance. Myo(-/-) isolated working hearts display decreased contractility (dP/dtmax 3883 +/- 351 vs. 4618 +/- 268 mmHg/sec, myo(-/-) vs. WT, P < 0.005). Due to a shift in sympathetic/parasympathetic tone, heart rate is reduced in conscious myo mice(-/-) (615 +/- 33 vs. 645 +/- 27 bpm, myo(-/-) vs. WT, P < 0.001). Oxygen consumption (VO2) under resting conditions (3082 +/- 413 vs. 4452 +/- 552 ml*kg(-1)*h(-1), myo(-/-) vs. WT, P < 0.001) and exercise endurance, as determined by spiroergometry, are decreased (466 +/- 113 vs. 585 +/- 153 m, myo(-/-) vs. WT, P < 0.01). Conscious myo(-/-) mice evaluated by echocardiography display lowered cardiac output (0.64 +/- 0.06 vs. 0.75 +/- 0.09 ml*min(-1)*g(-1), myo(-/-) vs. WT, P < 0.001), impaired systolic shortening (60 +/- 3.5 vs. 65 +/- 4%, myo(-/-) vs. WT, P < 0.001) and fail to respond to beta(1)-stimulation. Strikingly, the latter cardiac effects of Mb deficiency can be partially attenuated by NOS inhibition. Loss of Mb results in a distinct phenotype, even under resting conditions, and the importance of oxygen supply and nitric oxide scavenging by Mb is clearly demonstrated at the conscious animal level.	Rhein Westfal TH Aachen, Med Klin 1, Aachen, Germany; Univ Dusseldorf, Inst Herz & Kreislaufphysiol, D-4000 Dusseldorf, Germany	RWTH Aachen University; Heinrich Heine University Dusseldorf	Merx, MW (corresponding author), Univ Klinikum Aachen, Med Klin 1, Pauwelsstr 30, D-52057 Aachen, Germany.	mmerx@oukaachen.de						Brown GC, 2001, BBA-BIOENERGETICS, V1504, P46, DOI 10.1016/S0005-2728(00)00238-3; Desai KH, 1997, AM J PHYSIOL-HEART C, V272, pH1053, DOI 10.1152/ajpheart.1997.272.2.H1053; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Flogel U, 2004, FASEB J, V18, P1156, DOI 10.1096/fj.03-1382fje; Garry DJ, 1998, NATURE, V395, P905, DOI 10.1038/27681; Godecke A, 1999, P NATL ACAD SCI USA, V96, P10495, DOI 10.1073/pnas.96.18.10495; Godecke A, 2003, J BIOL CHEM, V278, P21761, DOI 10.1074/jbc.M302573200; Haywood GA, 1996, CIRCULATION, V93, P1087, DOI 10.1161/01.CIR.93.6.1087; Heger J, 2002, CIRC RES, V90, P93, DOI 10.1161/hh0102.102757; Lewis NP, 1996, CIRCULATION, V93, P720, DOI 10.1161/01.CIR.93.4.720; Meeson AP, 2001, CIRC RES, V88, P713, DOI 10.1161/hh0701.089753; Merx Marc W., 2001, FASEB Journal, V15, P1077; Merx MW, 2004, CIRCULATION, V109, P2560, DOI 10.1161/01.CIR.0000129774.09737.5B; Millikan GA, 1937, PROC R SOC SER B-BIO, V123, P218, DOI 10.1098/rspb.1937.0052; OBRIEN PJ, 1992, J MOL CELL CARDIOL, V24, P721, DOI 10.1016/0022-2828(92)93386-X; Papadopoulos S, 2001, P NATL ACAD SCI USA, V98, P5904, DOI 10.1073/pnas.101109798; Paulus WJ, 1997, CIRCULATION, V96, P3436; Rohrer DK, 1998, AM J PHYSIOL-HEART C, V274, pH1184, DOI 10.1152/ajpheart.1998.274.4.H1184; Schenkman KA, 1999, APPL SPECTROSC, V53, P332, DOI 10.1366/0003702991946541; Takahashi E, 2000, BIOPHYS J, V78, P3252, DOI 10.1016/S0006-3495(00)76861-5; Takahashi E, 1998, AM J PHYSIOL-HEART C, V275, pH225, DOI 10.1152/ajpheart.1998.275.1.H225; WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857; WITTENBERG JB, 1959, BIOL BULL, V117, P402; WITTENBERG JB, 1970, PHYSIOL REV, V50, P559, DOI 10.1152/physrev.1970.50.4.559; Wunderlich C, 2003, CIRC RES, V92, P1352, DOI 10.1161/01.RES.0000079026.70629.E5	25	36	36	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1015	+		10.1096/fj.04-2886fje	http://dx.doi.org/10.1096/fj.04-2886fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15817640				2022-12-28	WOS:000228865300023
J	Rim, JS; Mynatt, RL; Gawronska-Kozak, B				Rim, JS; Mynatt, RL; Gawronska-Kozak, B			Mesenchymal stem cells from the outer ear: a novel adult stem cell model system for the study of adipogenesis	FASEB JOURNAL			English	Article						clone; adipocyte differentiation; chondrogenesis; osteogenesis	HUMAN ADIPOSE-TISSUE; ADIPOCYTE DIFFERENTIATION; GENE-EXPRESSION; STROMAL CELLS; PPAR-GAMMA; WHITE FAT; ALPHA; PROLIFERATION; MACROSIALIN; METABOLISM	Adipocytes arise from multipotent stem cells of mesodermal origin, which also give rise to the muscle, bone, and cartilage lineages. However, signals and early molecular events that commit multipotent stem cells into the adipocyte lineage are not well established mainly due to lack of an adequate model system. We have identified a novel source of adult stem cells from the external murine ears referred to here as an ear mesenchymal stem cells (EMSC). EMSC have been isolated from several standard and mutant strains of mice. They are self-renewing, clonogenic, and multipotent, since they give rise to osteocytes, chondrocytes, and adipocytes. The in vitro characterization of EMSC indicates very facile adipogenic differentiation. Morphological, histochemical, and molecular analysis after the induction of differentiation showed that EMSC maintain adipogenic potentials up to fifth passage. A comparison of EMSC to the stromal-vascular (S-V) fraction of fat depots, under identical culture conditions (isobutyl-methylxanthine, dexamethasone, and insulin), revealed much more robust and consistent adipogenesis in EMSC than in the S-V fraction. In summary, we show that EMSC can provide a novel, easily obtainable, primary culture model for the study of adipogenesis.	Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Gawronska-Kozak, B (corresponding author), Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	kozakB@pbrc.edu	Mynatt, Randall L/N-1980-2017; Gawronska-Kozak, Barbara/A-2980-2017	Mynatt, Randall L/0000-0003-4399-0019; Gawronska-Kozak, Barbara/0000-0002-2006-8534	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072476] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK072476] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900; Banfi A, 2000, EXP HEMATOL, V28, P707, DOI 10.1016/S0301-472X(00)00160-0; Bennett CN, 2003, BIOCHEM BIOPH RES CO, V302, P12, DOI 10.1016/S0006-291X(03)00092-5; Boone C, 2000, J ANIM SCI, V78, P885; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Caserta F, 2001, AM J PHYSIOL-ENDOC M, V280, pE238, DOI 10.1152/ajpendo.2001.280.2.E238; Castro-Munozledo F, 2003, EXP CELL RES, V284, P163, DOI 10.1016/S0014-4827(02)00036-8; Cho YC, 2004, J CELL BIOCHEM, V91, P336, DOI 10.1002/jcb.10743; Danforth E, 2000, NAT GENET, V26, P13, DOI 10.1038/79111; Dani C, 1997, J CELL SCI, V110, P1279; Dani C, 1999, CELLS TISSUES ORGANS, V165, P173, DOI 10.1159/000016697; Davis KE, 2004, J BIOL CHEM, V279, P42453, DOI 10.1074/jbc.M402197200; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; FROST SC, 1985, J BIOL CHEM, V260, P2646; Gavrilova O, 2000, J CLIN INVEST, V105, P271, DOI 10.1172/JCI7901; Gawronska-Kozak B, 2004, TISSUE ENG, V10, P1251, DOI 10.1089/ten.2004.10.1251; Gimble JM, 1998, CRIT REV EUKAR GENE, V8, P141, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.30; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Gregoire FM, 2001, EXP BIOL MED, V226, P997, DOI 10.1177/153537020122601106; Halvorsen YDC, 2001, TISSUE ENG, V7, P729, DOI 10.1089/107632701753337681; HOLNESS CL, 1993, J BIOL CHEM, V268, P9661; Kelly KA, 1998, ENDOCRINOLOGY, V139, P2622, DOI 10.1210/en.139.5.2622; Koza RA, 2000, J BIOL CHEM, V275, P34486, DOI 10.1074/jbc.M002136200; Lee CH, 2003, ENDOCRINOLOGY, V144, P2201, DOI 10.1210/en.2003-0288; Li AC, 1998, J BIOL CHEM, V273, P5389, DOI 10.1074/jbc.273.9.5389; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MacDougald OA, 2002, TRENDS ENDOCRIN MET, V13, P5, DOI 10.1016/S1043-2760(01)00517-3; Mackay AM, 1998, TISSUE ENG, V4, P415, DOI 10.1089/ten.1998.4.415; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Moldes M, 2003, BIOCHEM J, V376, P607, DOI 10.1042/BJ20030426; Muraglia A, 2000, J CELL SCI, V113, P1161; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 2002, NAT BIOTECHNOL, V20, P791, DOI 10.1038/nbt0802-791; Rangwala SM, 2000, ANNU REV NUTR, V20, P535, DOI 10.1146/annurev.nutr.20.1.535; Reyes M, 2001, ANN NY ACAD SCI, V938, P231; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Ryden M, 2003, BIOCHEM BIOPH RES CO, V311, P391, DOI 10.1016/j.bbrc.2003.10.010; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; Sen A, 2001, J CELL BIOCHEM, V81, P312, DOI 10.1002/1097-4644(20010501)81:2<312::AID-JCB1046>3.0.CO;2-Q; Sewter CP, 2002, DIABETES, V51, P718, DOI 10.2337/diabetes.51.3.718; Shimba S, 2004, J BIOL CHEM, V279, P40946, DOI 10.1074/jbc.M400840200; Smith SR, 2003, DIABETES, V52, P2914, DOI 10.2337/diabetes.52.12.2914; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; Soukas A, 2001, J BIOL CHEM, V276, P34167, DOI 10.1074/jbc.M104421200; Tchoukalova YD, 2004, AM J PHYSIOL-REG I, V287, pR1132, DOI 10.1152/ajpregu.00337.2004; Tchoukalova YD, 2000, OBES RES, V8, P664, DOI 10.1038/oby.2000.85; van Harmelen V, 2004, METABOLISM, V53, P632, DOI 10.1016/j.metabol.2003.11.012; Weyer C, 2000, DIABETOLOGIA, V43, P1498, DOI 10.1007/s001250051560; Wolfrum C, 2003, J CLIN INVEST, V112, P345, DOI 10.1172/JCI18698; Yajima Y, 2003, ENDOCRINOLOGY, V144, P2559, DOI 10.1210/en.2002-220894; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Young HE, 2001, ANAT RECORD, V263, P350, DOI 10.1002/ar.1112; Young HE, 2001, ANAT RECORD, V264, P51, DOI 10.1002/ar.1128; Zehentner BK, 2000, DNA CELL BIOL, V19, P275, DOI 10.1089/10445490050021186; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859	56	57	65	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1205	+		10.1096/fj.04-3204fje	http://dx.doi.org/10.1096/fj.04-3204fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15857881				2022-12-28	WOS:000228865300004
J	Lee, KS; Lee, HK; Hayflick, JS; Lee, YC; Puri, KD				Lee, Kyung S.; Lee, Ho K.; Hayflick, Joel S.; Lee, Yong C.; Puri, Kamal D.			Inhibition of phosphoinositide 3-kinase delta attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model	FASEB JOURNAL			English	Article						allergy; inflammation; cell activation; lung cytokines; signal transduction	MAST-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; NEUTROPHIL TRAFFICKING; ADHESION MOLECULES; TRANSGENIC MICE; PROTEIN-KINASE; IN-VITRO; T-CELLS; B-CELLS; EXPRESSION	P110 delta phosphoinositide 3-kinase (PI3K) plays a pivotal role in the recruitment and activation of certain inflammatory cells. Recent findings revealed that the activity of p110 delta also contributes to allergen-IgE- induced mast cell activation and vascular permeability. We investigated the role of p110 delta in allergic airway inflammation and hyperresponsiveness using IC87114, a selective p110 delta inhibitor, in a mouse asthma model. BALB/c mice were sensitized with OVA and, upon OVA aerosol challenge, developed airway eosinophilia, mucus hypersecretion, elevation in cytokine and chemokine levels, up-regulation of ICAM-1 and VCAM-1 expression, and airway hyperresponsiveness. Intratracheal administration of IC87114 significantly (P < 0.05) attenuated OVA-induced influx into lungs of total leukocytes, eosinophils, neutrophils, and lymphocytes, as well as levels of IL-4, IL-5, IL-13, and RANTES in a dose-dependent manner. IC87114 also significantly (P < 0.05) reduced the serum levels of total IgE and OVA-specific IgE and LTC4 release into the airspace. Histological studies show that IC87114 inhibited OVA-induced lung tissue eosinophilia, airway mucus production, and inflammation score. In addition, IC87114 significantly (P < 0.05) suppressed OVA-induced airway hyperresponsiveness to inhaled methacholine. Western blot analyses of whole lung tissue lysates shows that IC87114 markedly attenuated the OVA-induced increase in expression of IL-4, IL-5, IL-13, ICAM-1, VCAM-1, RANTES, and eotaxin. Furthermore, IC87114 treatment markedly attenuated OVA-induced serine phosphorylation of Akt, a downstream effector of PI3K signaling. Taken together, our findings implicate that inhibition of p110 delta signaling pathway may have therapeutic potential for the treatment of allergic airway inflammation.	ICOS Corp, Bothell, WA 98021 USA; Chonbuk Natl Univ, Sch Med, Dept Internal Med, Res Ctr Allerg Immune Dis, Jeonju 561712, South Korea	Icos Corporation; Jeonbuk National University	Puri, KD (corresponding author), ICOS Corp, 22021 20th Ave SE, Bothell, WA 98021 USA.	leeyc@chonbuk.ac.kr; kpuri@icos.com						Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Clayton E, 2002, J EXP MED, V196, P753, DOI 10.1084/jem.20020805; COCKS BG, 1993, INT IMMUNOL, V5, P657, DOI 10.1093/intimm/5.6.657; Dabbagh K, 1999, J IMMUNOL, V162, P6233; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Elias JA, 2003, J CLIN INVEST, V111, P291, DOI 10.1172/JCI200317748; Emson CL, 1998, J EXP MED, V188, P399, DOI 10.1084/jem.188.2.399; Eum SY, 2003, AM J RESP CELL MOL, V28, P25, DOI 10.1165/rcmb.4532; Ezeamuzie CI, 2001, AM J RESP CRIT CARE, V164, P1633, DOI 10.1164/ajrccm.164.9.2101104; Fernandes DJ, 2003, J APPL PHYSIOL, V95, P844, DOI 10.1152/japplphysiol.00192.2003; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Fruman DA, 2002, SEMIN IMMUNOL, V14, P7, DOI 10.1006/smim.2001.0337; Fukao T, 2002, NAT IMMUNOL, V3, P295, DOI 10.1038/ni768; Fukao T, 2002, NAT IMMUNOL, V3, P875, DOI 10.1038/ni825; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Inami M, 2004, J BIOL CHEM, V279, P23123, DOI 10.1074/jbc.M401248200; Jia GQ, 1999, INT IMMUNOL, V11, P1, DOI 10.1093/intimm/11.1.1; Justice JP, 2002, AM J PHYSIOL-LUNG C, V282, pL1066, DOI 10.1152/ajplung.00195.2001; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kobayashi T, 2000, J IMMUNOL, V164, P3855, DOI 10.4049/jimmunol.164.7.3855; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; Koyasu S, 2003, NAT IMMUNOL, V4, P313, DOI 10.1038/ni0403-313; Kwak YG, 2003, J CLIN INVEST, V111, P1083, DOI 10.1172/JCI200316440; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Li L, 1999, J IMMUNOL, V162, P2477; Lorentz A, 2003, J ALLERGY CLIN IMMUN, V111, P1062, DOI 10.1067/mai.2003.1342; Lukacs NW, 2001, NAT REV IMMUNOL, V1, P108, DOI 10.1038/35100503; MacLean JA, 2000, J IMMUNOL, V165, P6568, DOI 10.4049/jimmunol.165.11.6568; MONTEFORT S, 1991, RESP MED, V85, P91, DOI 10.1016/S0954-6111(06)80284-2; MOSER R, 1992, J IMMUNOL, V149, P1432; Myou S, 2003, J EXP MED, V198, P1573, DOI 10.1084/jem.20030298; Nadler M J, 2000, Adv Immunol, V76, P325; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Okkenhaug K, 2002, SCIENCE, V297, P1031; Palframan RT, 1998, J EXP MED, V188, P1621, DOI 10.1084/jem.188.9.1621; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; Puri KD, 2005, BLOOD, V106, P150, DOI 10.1182/blood-2005-01-0023; Puri KD, 2004, BLOOD, V103, P3448, DOI 10.1182/blood-2003-05-1667; Sadhu C, 2003, BIOCHEM BIOPH RES CO, V308, P764, DOI 10.1016/S0006-291X(03)01480-3; Sadhu C, 2003, J IMMUNOL, V170, P2647, DOI 10.4049/jimmunol.170.5.2647; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Taube C, 2002, J IMMUNOL, V169, P6482, DOI 10.4049/jimmunol.169.11.6482; Tigani B, 2001, EUR J PHARMACOL, V433, P217, DOI 10.1016/S0014-2999(01)01515-1; Trifilieff A, 2000, AM J PHYSIOL-LUNG C, V279, pL1120, DOI 10.1152/ajplung.2000.279.6.L1120; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Vargaftig BB, 2003, AM J RESP CELL MOL, V28, P410, DOI 10.1165/rcmb.2002-0032OC; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zhu XD, 2000, J IMMUNOL METHODS, V240, P157, DOI 10.1016/S0022-1759(00)00192-7	53	208	236	2	44	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2006	20	3					455	465		10.1096/fj.05-5045com	http://dx.doi.org/10.1096/fj.05-5045com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	074LY	16507763				2022-12-28	WOS:000239815100009
J	Linden, D; William-Olsson, L; Ahnmark, A; Ekroos, K; Hallberg, C; Sjogren, HP; Becker, B; Svensson, L; Clapham, JC; Oscarsson, J; Schreyer, S				Linden, Daniel; William-Olsson, Lena; Ahnmark, Andrea; Ekroos, Kim; Hallberg, Carina; Sjogren, Helena P.; Becker, Bruno; Svensson, Lennart; Clapham, John C.; Oscarsson, Jan; Schreyer, Sandra			Liver-directed overexpression of mitochondrial glycerol-3-phosphate acyltransferase results in hepatic steatosis, increased triacylglycerol secretion and reduced fatty acid oxidation	FASEB JOURNAL			English	Article						GPAT; stearoyl-CoA desaturase; ADRP; adenovirus; fatty liver	GLYCEROL PHOSPHATE ACYLTRANSFERASE; LOW-DENSITY-LIPOPROTEIN; SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; RAT HEPATOCYTES; GENERAL-POPULATION; INSULIN-RESISTANCE; DEFICIENT MICE; EXPRESSION; PREVALENCE; ENZYMES	Glycerol-3-phosphate acyltransferase (GPAT) catalyzes the first committed step in triacylglycerol (TAG) and phospholipid biosynthesis. GPAT activity has been identified in both ER and mitochondrial subcellular fractions. The ER activity dominates in most tissues except in liver, where the mitochondrial isoform (mtGPAT) can constitute up to 50% of the total activity. To study the in vivo effects of hepatic mtGPAT overexpression, mice were transduced with adenoviruses expressing either murine mtGPAT or a catalytically inactive variant of the enzyme. Overexpressing mtGPAT resulted in massive 12- and 7-fold accumulation of liver TAG and diacylglycerol, respectively but had no effect on phospholipid or cholesterol ester content. Histological analysis showed extensive lipid accumulation in hepatocytes. Furthermore, mtGPAT transduction markedly increased adipocyte differentiation-related protein and stearoyl-CoA desaturase-1 (SCD-1) in the liver. In line with increased SCD-1 expression, 18:1 and 16:1 in the hepatic TAG fraction increased. In addition, mtGPAT overexpression decreased ex vivo fatty acid oxidation, increased liver TAG secretion rate 2-fold, and increased plasma TAG and cholesterol levels. These results support the hypothesis that increased hepatic mtGPAT activity associated with obesity and insulin resistance contributes to increased TAG biosynthesis and inhibition of fatty acid oxidation, responses that would promote hepatic steatosis and dyslipidemia.	AstraZeneca R&D, Dept Integrat Pharmacol, S-43183 Molndal, Sweden; Gothenburg Univ, Wallenberg Lab Cardiovasc Res, S-41124 Gothenburg, Sweden	AstraZeneca; University of Gothenburg	Linden, D (corresponding author), AstraZeneca R&D, Dept Integrat Pharmacol, S-43183 Molndal, Sweden.	daniel.linden@astrazeneca.com	Clapham, John/AAK-4715-2020					Alemany R, 2000, J GEN VIROL, V81, P2605, DOI 10.1099/0022-1317-81-11-2605; Ameen C, 2004, AM J PHYSIOL-ENDOC M, V287, pE1039, DOI 10.1152/ajpendo.00059.2004; Bedoucha M, 2001, J HEPATOL, V35, P17, DOI 10.1016/S0168-8278(01)00066-6; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; Bellentani S, 2000, ANN INTERN MED, V132, P112, DOI 10.7326/0003-4819-132-2-200001180-00004; BREMER J, 1976, MOL CELL BIOCHEM, V12, P113, DOI 10.1007/BF01731557; Coleman RA, 2004, PROG LIPID RES, V43, P134, DOI 10.1016/S0163-7827(03)00051-1; Dircks LK, 1997, BBA-LIPID LIPID MET, V1348, P17, DOI 10.1016/S0005-2760(97)00106-9; Edvardsson U, 1999, J LIPID RES, V40, P1177; Ekroos K, 2003, J LIPID RES, V44, P2181, DOI 10.1194/jlr.D300020-JLR200; Ekroos K, 2002, ANAL CHEM, V74, P941, DOI 10.1021/ac015655c; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; FOLCH J, 1957, J BIOL CHEM, V226, P497; GIBBONS GF, 1992, BIOCHEM J, V287, P749, DOI 10.1042/bj2870749; Gonzalez-Baro MR, 2001, J BIOL CHEM, V276, P43182, DOI 10.1074/jbc.M107885200; HALDAR D, 1979, J BIOL CHEM, V254, P4502; Hammond LE, 2005, J BIOL CHEM, V280, P25629, DOI 10.1074/jbc.M503181200; Hammond LE, 2002, MOL CELL BIOL, V22, P8204, DOI 10.1128/MCB.22.23.8204-8214.2002; Heath RJ, 1998, J BACTERIOL, V180, P1425, DOI 10.1128/JB.180.6.1425-1430.1998; Homan R, 1998, J CHROMATOGR B, V708, P21, DOI 10.1016/S0378-4347(97)00651-8; Igal RA, 2001, J BIOL CHEM, V276, P42205, DOI 10.1074/jbc.M103386200; JERKINS AA, 1995, J BIOL CHEM, V270, P1416, DOI 10.1074/jbc.270.38.22135; Lankester DL, 1998, J LIPID RES, V39, P1889; Lewin TM, 2005, AM J PHYSIOL-ENDOC M, V288, pE835, DOI 10.1152/ajpendo.00300.2004; Lewin TM, 2004, J BIOL CHEM, V279, P13488, DOI 10.1074/jbc.M314032200; Lewin TM, 2001, ARCH BIOCHEM BIOPHYS, V396, P119, DOI 10.1006/abbi.2001.2604; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; Li XH, 1996, J LIPID RES, V37, P210; Linden D, 2004, J LIPID RES, V45, P1279, DOI 10.1194/jlr.M400010-JLR200; Linden D, 2001, J LIPID RES, V42, P1831; Luyckx FH, 1998, INT J OBESITY, V22, P222, DOI 10.1038/sj.ijo.0800571; Marchesini G, 1999, AM J MED, V107, P450, DOI 10.1016/S0002-9343(99)00271-5; Marchesini G, 2001, DIABETES, V50, P1844, DOI 10.2337/diabetes.50.8.1844; MONROY G, 1972, J BIOL CHEM, V247, P6884; Muoio DM, 1999, BIOCHEM J, V338, P783, DOI 10.1042/0264-6021:3380783; Nemoto Y, 2000, J CLIN INVEST, V105, P1819, DOI 10.1172/JCI9575; Neschen S, 2005, CELL METAB, V2, P55, DOI 10.1016/j.cmet.2005.06.006; Neuschwander-Tetri BA, 2003, HEPATOLOGY, V37, P1202, DOI 10.1053/jhep.2003.50193; NOMURA H, 1988, JPN J MED, V27, P142, DOI 10.2169/internalmedicine1962.27.142; Ntambi JM, 1999, J LIPID RES, V40, P1549; SAGGERSON ED, 1980, BIOCHEM J, V190, P183, DOI 10.1042/bj1900183; Schadinger SE, 2005, AM J PHYSIOL-ENDOC M, V288, pE1195, DOI 10.1152/ajpendo.00513.2004; Seppala-Lindroos A, 2002, J CLIN ENDOCR METAB, V87, P3023, DOI 10.1210/jc.87.7.3023; SHIN DH, 1991, J BIOL CHEM, V266, P23834; Spady DK, 2000, J BIOL CHEM, V275, P27005; Steiner S, 1996, BIOCHEM BIOPH RES CO, V218, P777, DOI 10.1006/bbrc.1996.0138; Szczepaniak LS, 2005, AM J PHYSIOL-ENDOC M, V288, pE462, DOI 10.1152/ajpendo.00064.2004; van der Leij FR, 1999, BIOCHEM J, V341, P777, DOI 10.1042/0264-6021:3410777; WIGGINS D, 1992, BIOCHEM J, V284, P457, DOI 10.1042/bj2840457; YET SF, 1995, BIOCHEMISTRY-US, V34, P7303, DOI 10.1021/bi00022a003; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200; ZHANG WW, 1995, BIOTECHNIQUES, V18, P444	52	91	108	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2006	20	3					434	443		10.1096/fj.05-4568com	http://dx.doi.org/10.1096/fj.05-4568com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	074LY	16507761				2022-12-28	WOS:000239815100007
J	Aricha, R; Feferman, T; Souroujon, MC; Fuchs, S				Aricha, Revital; Feferman, Tali; Souroujon, Miriam C.; Fuchs, Sara			Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor	FASEB JOURNAL			English	Article									[Aricha, Revital; Feferman, Tali; Souroujon, Miriam C.; Fuchs, Sara] Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; [Souroujon, Miriam C.] Open Univ Israel, Raanana, Israel	Weizmann Institute of Science; Open University Israel	Fuchs, S (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.	sara.fuchs@weizmann.ac.il	, Tali/AAC-9642-2020	, Tali/0000-0002-4072-341X					0	36	37	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					374	376		10.1096/fj.05-4909fje	http://dx.doi.org/10.1096/fj.05-4909fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16365386				2022-12-28	WOS:000207915000026
J	Dickey, CA; Dunmore, J; Lu, BW; Wang, JW; Lee, WC; Kamal, A; Burrows, F; Eckman, C; Hutton, M; Petrucelli, L				Dickey, Chad A.; Dunmore, Judith; Lu, Bingwei; Wang, Ji-Wu; Lee, Wing C.; Kamal, Adeela; Burrows, Francis; Eckman, Christopher; Hutton, Michael; Petrucelli, Leonard			HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites	FASEB JOURNAL			English	Article						neurofibrillary tangles; Alzheimer's disease; proteasome	CELL-SURVIVAL; PROTEIN; DEMENTIA; CHIP; TOXICITY; MISSENSE; MUTATION; GENE	Neurofibrillary tangles (NFTs) are a characteristic neuropathological feature of Alzheimer's disease (AD), and molecular chaperones appear to be involved in the removal of disease-associated hyperphosphorylated tau, a primary component of NFTs. Here, novel HSP90 inhibitors were used to examine the impact of chaperone elevation on clearance of different tau species in transfected cells using a unique quantitative assay. The HSP90 inhibitors reduced levels of tau phosphorylated at proline-directed Ser/Thr sites (pS202/T205, pS396/S404) and conformationally altered ( MC-1) tau species, an epitope that is immeasurable by standard Western blot techniques. The selective clearance of these phospho-tau species and MC-1 tau was mediated via the proteasome, while lysosomal-mediated tau degradation seems to lack specificity for certain tau species, suggesting a more general role in total tau removal. Interestingly, tau phosphorylated at S262/S356 within the tau microtubule binding domain was minimally affected by chaperone induction. Overall, our data show that chaperone induction results in the selective clearance of specific phospho-tau and conformationally altered tau species mediated by the proteasome; however, the apparent stability of pS262/S356 tau may also explain why MARK is able to regulate normal tau function yet still be linked to the initiation of pathogenic tau hyperphosphorylation in AD.	Mayo Clin Jacksonville, Coll Med, Jacksonville, FL 32224 USA; Stanford Univ, Stanford, CA 94305 USA; Conforma Therapeut Corp, San Diego, CA USA	Mayo Clinic; Stanford University	Hutton, M (corresponding author), Mayo Clin Jacksonville, Coll Med, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	hutton.Michael@mayo.edu	Dickey, Chad A/H-4441-2011	Lee, Chris/0000-0001-9068-5274; Wang, Jiwu/0000-0002-9516-3384; Lu, Bingwei/0000-0002-5807-7014	NIA NIH HHS [P01 AG17216] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG017216] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bagatell R, 2004, MOL CANCER THER, V3, P1021; Biernat J, 2002, MOL BIOL CELL, V13, P4013, DOI 10.1091/mbc.02-03-0046; Dai Q, 2003, EMBO J, V22, P5446, DOI 10.1093/emboj/cdg529; Dickey Chad A., 2005, Current Alzheimer Research, V2, P231, DOI 10.2174/1567205053585927; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Dumanchin C, 1998, HUM MOL GENET, V7, P1825, DOI 10.1093/hmg/7.11.1825; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; HYMAN BT, 1988, ANN NEUROL, V23, P371, DOI 10.1002/ana.410230410; McDonough H, 2003, CELL STRESS CHAPERON, V8, P303, DOI 10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO;2; Nishimura I, 2004, CELL, V116, P671, DOI 10.1016/S0092-8674(04)00170-9; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; SHEN HY, 2005, J BIOL CHEM; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Shimura H, 2004, J BIOL CHEM, V279, P17957, DOI 10.1074/jbc.M400351200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Sun L, 2003, NEUROSCIENCE, V118, P1175, DOI 10.1016/S0306-4522(02)00697-8; TRINCZEK B, 1995, MOL BIOL CELL, V6, P1887, DOI 10.1091/mbc.6.12.1887; Waza M, 2005, NAT MED, V11, P1088, DOI 10.1038/nm1298; Weaver CL, 2000, NEUROBIOL AGING, V21, P719, DOI 10.1016/S0197-4580(00)00157-3	21	133	139	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					753	+		10.1096/fj.05-5343fje	http://dx.doi.org/10.1096/fj.05-5343fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16464956				2022-12-28	WOS:000237698700036
J	Fecchi, K; Volonte, D; Hezel, MP; Schmeck, K; Galbiati, F				Fecchi, Katia; Volonte, Daniela; Hezel, Michael P.; Schmeck, Kevin; Galbiati, Ferruccio			Spatial and temporal regulation of GLUT4 translocation by flotillin-1 and caveolin-3 in skeletal muscle cells	FASEB JOURNAL			English	Article						caveolae; glucose transporter; insulin signaling; detergent-resistant microdomains	MUSCULAR-DYSTROPHY LGMD-1C; NUCLEOTIDE EXCHANGE FACTOR; RICH MEMBRANE DOMAINS; GLUCOSE-TRANSPORTER; PROTEIN-KINASE; PLASMA-MEMBRANE; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE; HETEROOLIGOMERIC COMPLEX; INSULIN-RESISTANCE	Skeletal muscle tissue is one of the main sites where glucose uptake occurs in response to insulin. The glucose transporter type-4 (GLUT4) is primarily responsible for the insulin-stimulated increase in glucose uptake. Upon insulin stimulation, GLUT4 is recruited from intracellular reserves to the plasma membrane. The molecular mechanisms that regulate the translocation of GLUT4 to the sarcolemma remain to be fully identified. Here, we demonstrate that GLUT4 is localized to perinuclear stores that contain flotillin-1, a marker of lipid rafts, in skeletal muscle cells. Stimulation with insulin for 10 min results in the translocation of flotillin1/GLUT4-containing domains to the plasma membrane in a PI3K- and PKC zeta-dependent manner. We also demonstrate that caveolin-3, a marker of caveolae, is required for the insulin receptor-mediated activation of the PI3K- dependent pathway, which occurs 2 min after insulin stimulation. In fact, we demonstrate that lack of caveolin-3 significantly reduces insulin-stimulated glucose uptake in caveolin-3 null myotubes by inhibiting both PI3K and Akt, as well as the movement of GLUT4 to the plasma membrane. Interestingly, caveolin-3 moves away from the plasma membrane toward the cytoplasm 5 min after insulin stimulation and temporarily interacts with flotillin-1/GLUT4-containing domains before they reach the sarcolemma, with the consequent movement of the insulin receptor from caveolin-3-containing domains to flotillin-1-containing domains. Such translocation temporally matches the insulin-stimulated movement of Cbl and CrkII in flotillin-1/GLUT4-containing domains, as well as the activation of the GDP-GTP exchange factor C3G. Disruption of flotillin-1-based domains prevents the activation of C3G, movement of GLUT4 to the sarcolemma, and glucose uptake in response to insulin. Thus, the activation of the Cbl/C3G/TC10-dependent pathway, which occurs before flotillin-1/GLUT4-containing domains reach the plasma membrane, is flotillin-1 mediated and follows the activation of the PI3K- mediated signaling. Taken together, these results indicate that flotillin- 1 and caveolin-3 may regulate muscle energy metabolism through the spatial and temporal segregation of key components of the insulin signaling.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Galbiati, F (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA.	feg5@pitt.edu	Galbiati, Ferruccio/AAF-3527-2020; Fecchi, Katia/N-1380-2017	Fecchi, Katia/0000-0003-4397-5783	NATIONAL INSTITUTE ON AGING [R01AG022548] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG022548] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahmed Z, 1999, BIOCHEM J, V341, P665, DOI 10.1042/0264-6021:3410665; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; Capozza F, 2005, AM J PHYSIOL-CELL PH, V288, pC1317, DOI 10.1152/ajpcell.00489.2004; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; CZECH MP, 1993, J BIOL CHEM, V268, P9187; de Jong R, 1998, ONCOGENE, V17, P2805, DOI 10.1038/sj.onc.1202207; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; EHLER E, 1995, CIRCULATION, V92, P3289, DOI 10.1161/01.CIR.92.11.3289; Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FRA AM, 1994, J BIOL CHEM, V269, P30745; Galbiati F, 2000, P NATL ACAD SCI USA, V97, P9689, DOI 10.1073/pnas.160249097; Galbiati F, 2000, J BIOL CHEM, V275, P37702, DOI 10.1074/jbc.M006657200; Galbiati F, 1999, J BIOL CHEM, V274, P5843, DOI 10.1074/jbc.274.9.5843; Galbiati F, 2001, MOL BIOL CELL, V12, P2229, DOI 10.1091/mbc.12.8.2229; Galbiati F, 2001, J BIOL CHEM, V276, P21425, DOI 10.1074/jbc.M100828200; Galbiati F, 1999, J BIOL CHEM, V274, P25632, DOI 10.1074/jbc.274.36.25632; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Gustavsson J, 1996, MOL MED, V2, P367, DOI 10.1007/BF03401634; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Ling L, 2003, J BIOL CHEM, V278, P27301, DOI 10.1074/jbc.M302516200; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Liu J, 2005, J BIOL CHEM, V280, P1432, DOI 10.1074/jbc.M409740200; Malide D, 2000, J CELL SCI, V113, P4203; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; MOLDOVAN NI, 1995, EXP CELL RES, V219, P309, DOI 10.1006/excr.1995.1233; Moller DE, 2005, ANNU REV MED, V56, P45, DOI 10.1146/annurev.med.56.082103.104751; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; NOBLE M, 1995, TRANSGENIC RES, V4, P215, DOI 10.1007/BF01969114; OKADA T, 1994, J BIOL CHEM, V269, P3568; Oshikawa J, 2004, P NATL ACAD SCI USA, V101, P12670, DOI 10.1073/pnas.0402053101; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; Salzer U, 2001, BLOOD, V97, P1141, DOI 10.1182/blood.V97.4.1141; SARGIACOMO M, 1994, ONCOGENE, V9, P2589; SATOH S, 1993, J BIOL CHEM, V268, P17820; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schlegel A, 2001, BIOCHEM J, V359, P203, DOI 10.1042/0264-6021:3590203; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Shivakrupa R, 2003, J BIOL CHEM, V278, P52188, DOI 10.1074/jbc.M310656200; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; Somwar R, 2000, DIABETES, V49, P1794, DOI 10.2337/diabetes.49.11.1794; Somwar R, 2001, BIOCHEM J, V359, P639, DOI 10.1042/0264-6021:3590639; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song KS, 1997, CELL MOL BIOL, V43, P293; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; VOLDSTEDLUND M, 1993, J MEMBRANE BIOL, V136, P63; Volonte D, 2004, FASEB J, V18, P237, DOI 10.1096/fj.04-2215fje; Volonte D, 1999, J BIOL CHEM, V274, P12702, DOI 10.1074/jbc.274.18.12702; Volonte D, 2003, MOL BIOL CELL, V14, P4075, DOI 10.1091/mbc.E03-03-0161; Volonte D, 2002, MOL BIOL CELL, V13, P2502, DOI 10.1091/mbc.01-11-0529; Wang WC, 1996, J CELL BIOL, V135, P415, DOI 10.1083/jcb.135.2.415; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962	77	89	92	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					705	+		10.1096/fj.05-4661fje	http://dx.doi.org/10.1096/fj.05-4661fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16455755	Green Accepted			2022-12-28	WOS:000237698700043
J	Zhang, SX; Wang, JJ; Gao, GQ; Shao, CK; Mott, R; Ma, JX				Zhang, Sarah X.; Wang, Joshua J.; Gao, Guoquan; Shao, Chunkui; Mott, Robert; Ma, Jian-xing			Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor	FASEB JOURNAL			English	Article									[Zhang, Sarah X.; Wang, Joshua J.; Mott, Robert; Ma, Jian-xing] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Dept Med Endocrinol, Oklahoma City, OK USA; [Gao, Guoquan; Shao, Chunkui] Zhongshan Univ, Dept Biochem, Guangzhou, Guangdong, Peoples R China	University of Oklahoma System; University of Oklahoma Health Sciences Center; Sun Yat Sen University	Ma, JX (corresponding author), 941 Stanton L Young Blvd,BSEB 328B, Oklahoma City, OK 73104 USA.	jian-xing-ma@ouhsc.edu			NATIONAL EYE INSTITUTE [R01EY012231, R33EY015650, R21EY015650] Funding Source: NIH RePORTER; NEI NIH HHS [EY015650, EY12231] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))			0	246	270	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					323	325		10.1096/fj.05-4313fje	http://dx.doi.org/10.1096/fj.05-4313fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16368716				2022-12-28	WOS:000207915000008
J	Garbuzova-Davis, S; Gografe, SJ; Sanberg, CD; Willing, AE; Saporta, S; Cameron, DF; Desjarlais, T; Daily, J; Kuzmin-Nichols, N; Chamizo, W; Klasko, SK; Sanberg, PR				Garbuzova-Davis, S; Gografe, SJ; Sanberg, CD; Willing, AE; Saporta, S; Cameron, DF; Desjarlais, T; Daily, J; Kuzmin-Nichols, N; Chamizo, W; Klasko, SK; Sanberg, PR			Maternal transplantation of human umbilical cord blood cells provides prenatal therapy in Sanfilippo type B mouse model	FASEB JOURNAL			English	Article						transmigration; Naglu enzyme; CD34 and CD117 antigens	BONE-MARROW; FETAL CELLS; DIAGNOSIS; DISEASE; TROPHOBLAST; IMMUNOLOGY; PLACENTA; MURINE; FETUS	Numerous data support passage of maternal cells into the fetus during pregnancy in both human and animal models. However, functional benefits of maternal microchimerism in utero are unknown. The current study attempted to take advantage of this route for prenatal delivery of alpha-N-acetylglucosaminidase (Naglu) enzyme into the enzyme-deficient mouse model of Sanfilippo syndrome type B (MPS III B). Enzymatically sufficient mononuclear cells from human umbilical cord blood (MNC hUCB) were intravenously administered into heterozygote females modeling MPS III B on the 5th day of pregnancy during blastocyst implantation. The major findings were 1) administered MNC hUCB cells transmigrated and diffused into the embryos (E12.5); 2) some transmigrated cells expressed CD34 and CD117 antigens; 3) transmigrated cells were found in both the maternal and embryonic parts of placentas; 4) transmigrated cells corrected Naglu enzyme activity in all embryos; 5) administered MNC hUCB cells were extensively distributed in the organs and the blood of heterozygote mothers at one week after transplantation. Results indicate that prenatal delivery of Naglu enzyme by MNC hUCB cell administration into mothers of enzyme-deficient embryos is possible and may present a significant opportunity for new biotechnologies to treat many inherited disorders.	Univ S Florida, Dept Neurosurg, Coll Med, Ctr Excellence Aging & Brain Repair, Tampa, FL 33612 USA; Univ S Florida, Dept Physiol & Biophys, Coll Med, Tampa, FL 33612 USA; Univ S Florida, Dept Anat, Coll Med, Tampa, FL 33612 USA; Univ S Florida, Dept Pharmacol & Therapeut, Coll Med, Tampa, FL 33612 USA; Univ S Florida, Dept Psychiat, Coll Med, Tampa, FL 33612 USA; Univ S Florida, Dept Pathol, Coll Med, Tampa, FL 33612 USA; Univ S Florida, Div Comparat Med, Coll Med, Tampa, FL 33612 USA; Univ Technol Ctr II, Saneron CCEL Therapeut Inc, Tampa, FL USA; All Childrens Hosp, St Petersburg, Russia	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Garbuzova-Davis, S (corresponding author), Univ S Florida, Dept Neurosurg, Coll Med, Ctr Excellence Aging & Brain Repair, 12901 Bruce B Downs Blvd MDC 78, Tampa, FL 33612 USA.	sgarbuzo@hsc.usf.edu	Garbuzova-Davis, Svitlana/Q-3687-2019; Willing, Alison/AAP-7759-2021; Willing, Alison/I-4946-2012					Adamson SL, 2002, DEV BIOL, V250, P358, DOI 10.1006/dbio.2002.0773; Ando T, 2003, J CLIN ENDOCR METAB, V88, P2965, DOI 10.1210/jc.2002-021903; Bianchi DW, 1996, P NATL ACAD SCI USA, V93, P705, DOI 10.1073/pnas.93.2.705; BROXMEYER HE, 1989, P NATL ACAD SCI USA, V86, P3828, DOI 10.1073/pnas.86.10.3828; BULMER JN, 1988, PLACENTA, V9, P237, DOI 10.1016/0143-4004(88)90031-8; BURTON GJ, 1987, SCANNING MICROSCOPY, V1, P1811; CEUTERICK C, 1980, NEUROPADIATRIE, V11, P176, DOI 10.1055/s-2008-1071387; COPP AJ, 1995, TRENDS GENET, V11, P87, DOI 10.1016/S0168-9525(00)89008-3; Garbuzova-Davis S, 2005, STEM CELLS DEV, V14, P384, DOI 10.1089/scd.2005.14.384; Garbuzova-Davis S, 2003, J HEMATOTH STEM CELL, V12, P255, DOI 10.1089/152581603322022990; Georgiades P, 2002, PLACENTA, V23, P3, DOI 10.1053/plac.2001.0738; Gluckman E, 2005, SEMIN HEMATOL, V42, P85, DOI 10.1053/j.seminhematol.2005.01.006; Gografe SI, 2003, COMPARATIVE MED, V53, P622; HALL JM, 1995, BLOOD, V86, P2829; HE W, 1994, PRENATAL DIAG, V14, P17, DOI 10.1002/pd.1970140104; Hoogerbrugge P M, 1991, Bone Marrow Transplant, V7 Suppl 2, P71; Hopwood JJ, 2005, PRENATAL DIAG, V25, P148, DOI 10.1002/pd.1094; Johnson KL, 2001, ARTHRITIS RHEUM-US, V44, P1848, DOI 10.1002/1529-0131(200108)44:8<1848::AID-ART323>3.0.CO;2-L; JONES CJP, 1990, PLACENTA, V11, P395, DOI 10.1016/S0143-4004(05)80215-2; Kaufman M. H., 2001, ATLAS MOUSE DEV; Keep M, 2001, BRAIN RES, V894, P327, DOI 10.1016/S0006-8993(01)02012-1; Khosrotehrani K, 2004, JAMA-J AM MED ASSOC, V292, P75, DOI 10.1001/jama.292.1.75; Kleijer WJ, 1996, PRENATAL DIAG, V16, P829, DOI 10.1002/(SICI)1097-0223(199609)16:9<829::AID-PD953>3.0.CO;2-H; Li HH, 1999, P NATL ACAD SCI USA, V96, P14505, DOI 10.1073/pnas.96.25.14505; Lo YMD, 1996, BLOOD, V88, P4390; Lo YMD, 1998, BRIT J HAEMATOL, V100, P605; Marleau AM, 2003, LAB INVEST, V83, P673, DOI 10.1097/01.LAB.0000067500.85003.32; MARSH J, 1985, CLIN GENET, V27, P258; Mellor AL, 2000, ANNU REV IMMUNOL, V18, P367, DOI 10.1146/annurev.immunol.18.1.367; Mikami Tetsuya, 2002, Medical Electron Microscopy, V35, P96, DOI 10.1007/s007950200012; MUNTENER M, 1977, ACTA ANAT, V98, P241; Nayar B, 2002, INT J GYNECOL OBSTET, V79, P31, DOI 10.1016/S0020-7292(02)00187-X; NEUFELD EF, 1995, METABOLIC MOL BASES, V2, P2465; NOWAKOWSKI RW, 1989, PEDIATR RES, V26, P462, DOI 10.1203/00006450-198911000-00020; OBRIEN JS, 1972, P NATL ACAD SCI USA, V69, P1720, DOI 10.1073/pnas.69.7.1720; Peters C, 1998, BLOOD, V91, P2601, DOI 10.1182/blood.V91.7.2601.2601_2601_2608; Petit T, 1997, BRIT J HAEMATOL, V98, P767, DOI 10.1046/j.1365-2141.1997.2603076.x; PIJNENBORG R, 1981, PLACENTA, V2, P71, DOI 10.1016/S0143-4004(81)80042-2; SHAPIRO EG, 1995, J INHERIT METAB DIS, V18, P413, DOI 10.1007/BF00710053; SIMPSON JL, 1993, JAMA-J AM MED ASSOC, V270, P2357, DOI 10.1001/jama.270.19.2357; Staba SL, 2004, NEW ENGL J MED, V350, P1960, DOI 10.1056/NEJMoa032613; Thomson BG, 2000, BLOOD, V96, P2703; Todaro AM, 2000, BLOOD PURIFICAT, V18, P144, DOI 10.1159/000014438; Trundley A, 2004, TISSUE ANTIGENS, V63, P1, DOI 10.1111/j.1399-0039.2004.00170.x; van Nieuwenhoven ALV, 2003, HUM REPROD UPDATE, V9, P347, DOI 10.1093/humupd/dmg026; Wan WH, 2002, IMMUNOLOGY, V107, P261, DOI 10.1046/j.1365-2567.2002.01499.x; Ward JM, 2000, PATHOLOGY OF GENETICALLY ENGINEERED MICE, P103; Weber B, 1996, HUM MOL GENET, V5, P771, DOI 10.1093/hmg/5.6.771; Yu GL, 2004, BRAIN RES, V1018, P32, DOI 10.1016/j.brainres.2004.05.056; Zhao HG, 1996, P NATL ACAD SCI USA, V93, P6101, DOI 10.1073/pnas.93.12.6101; ZILLIACUS R, 1975, SCAND J HAEMATOL, V15, P333	51	15	17	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					485	+		10.1096/fj.05-4684fje	http://dx.doi.org/10.1096/fj.05-4684fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16401642				2022-12-28	WOS:000235996000031
J	Gonzalez-Herrera, IG; Prado-Lourenco, L; Pileur, F; Conte, C; Morin, A; Cabon, F; Prats, H; Vagner, S; Bayard, F; Audigier, S; Prats, AC				Gonzalez-Herrera, IG; Prado-Lourenco, L; Pileur, F; Conte, C; Morin, A; Cabon, F; Prats, H; Vagner, S; Bayard, F; Audigier, S; Prats, AC			Testosterone regulates FGF-2 expression during testis maturation by an IRES-dependent translational mechanism	FASEB JOURNAL			English	Article						translation control; transgenic mouse; growth factor; hormone; spermatogenesis	FIBROBLAST-GROWTH-FACTOR; RIBOSOME ENTRY SITE; FIBROBLAST-GROWTH-FACTOR-2 MESSENGER-RNA; HEPARAN-SULFATE PROTEOGLYCANS; CELL-CELL INTERACTIONS; ALTERNATIVE TRANSLATION; SERTOLI-CELLS; TRANSGENIC MICE; 3'-UNTRANSLATED REGION; GENE-EXPRESSION	Spermatogenesis is a complex process involving cell proliferation, differentiation, and apoptosis. Fibroblast growth factor 2 (FGF-2) is involved in testicular function, but its role in spermatogenesis has not been fully documented. The control of FGF-2 expression particularly occurs at the translational level, by an internal ribosome entry site (IRES)-dependent mechanism driving the use of alternative initiation codons. To study IRES activity regulation in vivo, we have developed transgenic mice expressing a bicistronic construct coding for two luciferase genes. Here, we show that the FGF-2 IRES is age-dependently activated in mouse testis, whereas EMCV and c-myc IRESs are not. Real-time PCR confirms that this regulation is translational. By using immunohistological techniques, we demonstrate that FGF-2 IRES stimulation occurs in adult, but not in immature, type-A spermatogonias. This is correlated with activation of endogenous FGF-2 expression in spermatogonia; whereas FGF-2 mRNA transcription is known to decrease in adult testis. Interestingly, the FGF-2 IRES activation is triggered by testosterone and is partially inhibited by siRNA directed against the androgen receptor. Two-dimensional analysis of proteins bound to the FGF-2 mRNA 5'UTR after UV cross-linking reveals that testosterone treatment correlates with the binding of several proteins. These data suggest a paracrine loop where IRES- dependent FGF-2 expression, stimulated by Sertoli cells in response to testosterone produced by Leydig cells, would in turn activate Leydig function and testosterone production. In addition, nuclear FGF-2 isoforms could be involved in an intracrine function of FGF-2 in the start of spermatogenesis, mitosis, or meiosis initiation. This report demonstrates that mRNA translation regulation by an IRES- dependent mechanism participates in a physiological process.	Hop Rangueil, Inst Louis Bugnard, INSERM U589, IFR31, F-31432 Toulouse 4, France; Univ Toulouse 3, F-31062 Toulouse, France; MilleGen, Prologue Biotech, Labege, France; Lab Oncogenese Differenciat & Transduct Signal, Villejuif, France; Ctr Hosp Univ Rangueil, Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse	Prats, AC (corresponding author), Hop Rangueil, Inst Louis Bugnard, INSERM U589, IFR31, Bat L3,Ave Jean Poulhes,BP 84225, F-31432 Toulouse 4, France.	pratsac@toulouse.inserm.fr	Vagner, Stephan/G-3664-2013; Cabon, Florence/B-3284-2013; Prats, Anne-Catherine/E-5051-2016	Cabon, Florence/0000-0002-6149-082X; Prats, Anne-Catherine/0000-0002-5282-3776; vagner, stephan/0000-0003-1452-7164; Prats, Herve/0000-0002-4861-2167				Arnaud E, 1999, MOL CELL BIOL, V19, P505; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Bonnal S, 2005, J BIOL CHEM, V280, P4144, DOI 10.1074/jbc.M411492200; Bonnal S, 2003, J BIOL CHEM, V278, P39330, DOI 10.1074/jbc.M305580200; Brucato S, 2002, EUR J BIOCHEM, V269, P502, DOI 10.1046/j.0014-2956.2001.02672.x; Chang CS, 2004, P NATL ACAD SCI USA, V101, P6876, DOI 10.1073/pnas.0307306101; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; Creancier L, 2001, MOL CELL BIOL, V21, P1833, DOI 10.1128/MCB.21.5.1833-1840.2001; Dyer JR, 2003, NAT NEUROSCI, V6, P219, DOI 10.1038/nn1018; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; Galy B, 2001, ONCOGENE, V20, P4613, DOI 10.1038/sj.onc.1204630; Galy B, 2001, ONCOGENE, V20, P1669, DOI 10.1038/sj.onc.1204271; Grootegoed JA, 2000, BEST PRACT RES CL EN, V14, P331, DOI 10.1053/beem.2000.0083; HALL SH, 1991, ENDOCRINOLOGY, V129, P1243, DOI 10.1210/endo-129-3-1243; HAN IS, 1993, MOL ENDOCRINOL, V7, P889, DOI 10.1210/me.7.7.889; Hofmann MC, 2005, STEM CELLS, V23, P200, DOI 10.1634/stemcells.2003-0036; KAMMA H, 1995, EXP CELL RES, V221, P187, DOI 10.1006/excr.1995.1366; KOIKE S, 1994, GROWTH REGULAT, V4, P77; LAHR G, 1992, FEBS LETT, V302, P43, DOI 10.1016/0014-5793(92)80280-T; Laslett AL, 1997, J STEROID BIOCHEM, V60, P171, DOI 10.1016/S0960-0760(96)00180-X; LASLETT AL, 1995, J STEROID BIOCHEM, V54, P245, DOI 10.1016/0960-0760(95)00138-P; Loir M, 1999, MOL REPROD DEV, V53, P434, DOI 10.1002/(SICI)1098-2795(199908)53:4&lt;434::AID-MRD9&gt;3.0.CO;2-L; Mainwaring WIP, 1979, BIOCHEM SOC T, V7, P556, DOI 10.1042/bst0070556; MAYERHOFER A, 1991, ENDOCRINOLOGY, V129, P921, DOI 10.1210/endo-129-2-921; McLachlan RI, 2000, BEST PRACT RES CL EN, V14, P345, DOI 10.1053/beem.2000.0084; Miura P, 2005, J BIOL CHEM, V280, P32997, DOI 10.1074/jbc.M503994200; Monesi V., 1978, Current Topics in Developmental Biology, V12, P11, DOI 10.1016/S0070-2153(08)60592-X; MULLANEY BP, 1991, BAILLIERE CLIN ENDOC, V5, P771, DOI 10.1016/S0950-351X(10)80014-X; Nugent MA, 2000, INT J BIOCHEM CELL B, V32, P115, DOI 10.1016/S1357-2725(99)00123-5; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; Prats AC, 2002, PROG NUCLEIC ACID RE, V72, P367, DOI 10.1016/S0079-6603(02)72075-8; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Pyronnet S, 2001, GENE DEV, V15, P2083, DOI 10.1101/gad.889201; Qin XL, 2004, J BIOL CHEM, V279, P13721, DOI 10.1074/jbc.M312854200; Roser JF, 2001, ANIM REPROD SCI, V68, P139, DOI 10.1016/S0378-4320(01)00151-8; SKINNER MK, 1991, ENDOCR REV, V12, P45, DOI 10.1210/edrv-12-1-45; SORDOILLET C, 1992, MOL CELL ENDOCRINOL, V89, P163, DOI 10.1016/0303-7207(92)90222-R; Steger K, 1998, HISTOCHEM CELL BIOL, V110, P57, DOI 10.1007/s004180050265; STEINBERGER A, 1979, IN VITRO CELL DEV B, V15, P23; SUZUKI K, 1991, P SOC EXP BIOL MED, V198, P728; Suzuki M, 1996, GENES CELLS, V1, P1077, DOI 10.1046/j.1365-2443.1996.d01-228.x; Teshima-Kondo S, 2004, FASEB J, V18, P1583, DOI 10.1096/fj.03-1118fje; Touriol C, 1999, J BIOL CHEM, V274, P21402, DOI 10.1074/jbc.274.30.21402; Touriol C, 2000, J BIOL CHEM, V275, P19361, DOI 10.1074/jbc.M908431199; UETANI N, 1994, CELL BIOL INT, V18, P85, DOI 10.1006/cbir.1994.1046; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, J BIOL CHEM, V270, P20376, DOI 10.1074/jbc.270.35.20376; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Van den Berghe L, 2000, MOL ENDOCRINOL, V14, P1709, DOI 10.1210/me.14.11.1709; Van Eden ME, 2004, RNA, V10, P720, DOI 10.1261/rna.5225204; vanDisselEmiliani FMF, 1996, ENDOCRINOLOGY, V137, P647, DOI 10.1210/en.137.2.647; Wagener A, 2000, ANIM REPROD SCI, V64, P65, DOI 10.1016/S0378-4320(00)00191-3	53	37	40	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					476	+		10.1096/fj.04-3314fje	http://dx.doi.org/10.1096/fj.04-3314fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16423876	Green Submitted			2022-12-28	WOS:000235996000008
J	Monraats, PS; Pireso, NMM; Schepers, A; Agema, WRP; Boesten, LSM; de Vries, MR; Zwinderman, AH; de Maat, MPM; Doevendans, PAFM; de Winter, RJ; Tio, RA; Waltenberger, J; 't Hart, LM; Frants, RR; Quax, PHA; van Vlijmen, BJM; Havekes, LM; van der Laarse, A; van der Wall, EE; Jukema, JW				Monraats, PS; Pireso, NMM; Schepers, A; Agema, WRP; Boesten, LSM; de Vries, MR; Zwinderman, AH; de Maat, MPM; Doevendans, PAFM; de Winter, RJ; Tio, RA; Waltenberger, J; 't Hart, LM; Frants, RR; Quax, PHA; van Vlijmen, BJM; Havekes, LM; van der Laarse, A; van der Wall, EE; Jukema, JW			Tumor necrosis factor-alpha plays an important role in restenosis development	FASEB JOURNAL			English	Article						TNF alpha; inflammation; transgenic mice; haplotype	TNF-ALPHA; TRANSGENIC MICE; CORONARY ANGIOPLASTY; MULTIPLE-SCLEROSIS; STENT ERA; GENE; POLYMORPHISMS; ARTERY; PROGRESSION; DISEASE	Genetic factors appear to be important in the restenotic process after percutaneous coronary intervention (PCI), as well as in inflammation, a pivotal factor in restenosis. TNF alpha, a key regulator of inflammatory responses, may exert critical influence on the development of restenosis after PCI. The GENetic DEterminants of Restenosis (GENDER) project included 3104 patients who underwent a successful PCI. Systematic genotyping for six polymorphisms in the TNF alpha gene was performed. The role of TNF alpha in restenosis was also assessed in ApoE*3-Leiden mice, TNF alpha knockout mice, and by local delivery of a TNF alpha biosynthesis inhibitor, thalidomide. The -238G-1031T haplotype of the TNF alpha gene increased clinical and angiographic risk of restenosis (P = 0.02 and P = 0.002, respectively). In a mouse model of reactive stenosis, arterial TNF alpha mRNA was significantly time-dependently up-regulated. Mice lacking TNF alpha or treated locally with thalidomide showed a reduction in reactive stenosis (P = 0.01 and P = 0.005, respectively). Clinical and preclinical data indicate that TNF alpha plays an important role in restenosis. Therefore, TNF alpha genotype may be used as a risk marker for restenosis and may contribute to individual patient screening prior to PCI in clinical practice. Inhibition of TNF alpha may be an anti-restenotic target strategy.	Leiden Univ, Med Ctr, Dept Cardiol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Surg, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Human Genet, Ctr Human & Clin Genet, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Gen Internal Med, NL-2300 RC Leiden, Netherlands; Interuniv Cardiol Inst Netherlands, Utrecht, Netherlands; TNO Qual Life, Gaubius Lab, Leiden, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Med Stat, NL-1105 AZ Amsterdam, Netherlands; Erasmus Univ, Med Ctr, Dept Hematol, NL-3000 DR Rotterdam, Netherlands; Univ Utrecht, Med Ctr, Dept Cardiol, NL-3508 TC Utrecht, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands; Acad Hosp, Dept Cardiol, Groningen, Netherlands; Univ Limburg, Acad Hosp Maastricht, Dept Cardiol, Maastricht, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Interuniversity Cardiology Institute of the Netherlands; Utrecht University; Netherlands Organization Applied Science Research; University of Amsterdam; Academic Medical Center Amsterdam; Erasmus University Rotterdam; Erasmus MC; Utrecht University; University of Amsterdam; Academic Medical Center Amsterdam; University of Groningen; Hasselt University; Maastricht University; Maastricht University Medical Centre (MUMC)	Jukema, JW (corresponding author), Leiden Univ, Med Ctr, Dept Cardiol, 5-P,POB 9600, NL-2300 RC Leiden, Netherlands.	j.w.jukema@lumc.nl	't Hart, Leen/ABG-3185-2021; Jukema, J. Wouter/ABD-6503-2021; Quax, Paul/ABD-5294-2020; Tio, Rene/ABG-2820-2020; Quax, Paul/W-8520-2019; Waltenberger, Johannes/I-1813-2013	't Hart, Leen/0000-0003-4401-2938; Jukema, J. Wouter/0000-0002-3246-8359; Quax, Paul/0000-0002-6853-5760; Pires, Nuno/0000-0001-5244-8550; Schepers, Abbey/0000-0003-0504-3491; Waltenberger, Johannes/0000-0002-2417-9880				Agema WRP, 2004, EUR HEART J, V25, P1163, DOI 10.1016/j.ehj.2004.05.006; Barcellos LF, 2004, ANN NEUROL, V55, P793, DOI 10.1002/ana.20092; Boesten LSM, 2005, CARDIOVASC RES, V66, P179, DOI 10.1016/j.cardiores.2005.01.001; Cheng S, 1999, GENOME RES, V9, P936, DOI 10.1101/gr.9.10.936; FONG CLW, 1994, NUCLEIC ACIDS RES, V22, P1108, DOI 10.1093/nar/22.6.1108; Hojo Y, 2001, ATHEROSCLEROSIS, V156, P165, DOI 10.1016/S0021-9150(00)00611-0; Huizinga TWJ, 1997, J NEUROIMMUNOL, V72, P149, DOI 10.1016/S0165-5728(96)00182-8; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; Kaluza W, 2000, J INVEST DERMATOL, V114, P1180, DOI 10.1046/j.1523-1747.2000.00001.x; Koch W, 2003, CYTOKINE, V24, P161, DOI 10.1016/j.cyto.2003.08.004; Lardenoye JHP, 2000, CIRC RES, V87, P248, DOI 10.1161/01.RES.87.3.248; Li WT, 2001, GENET EPIDEMIOL, V21, pS272, DOI 10.1002/gepi.2001.21.s1.s272; LIBBY P, 1992, CIRCULATION, V86, P47; Livak KJ, 1999, GENET ANAL-BIOMOL E, V14, P143, DOI 10.1016/S1050-3862(98)00019-9; Mehilli J, 2003, EUR HEART J, V24, P1523, DOI 10.1016/S0195-668X(03)00320-8; Park SJ, 2004, ARTERIOSCL THROM VAS, V24, P885, DOI 10.1161/01.ATV.0000124924.21961.c3; Pires NMM, 2005, BIOMATERIALS, V26, P5386, DOI 10.1016/j.biomaterials.2005.01.063; Saia F, 2003, CIRCULATION, V108, P1927, DOI 10.1161/01.CIR.0000096053.87580.CD; Schomig A, 1997, CIRCULATION, V96, P3880; Serrano CV, 1997, J AM COLL CARDIOL, V29, P1276, DOI 10.1016/S0735-1097(97)00070-3; Simmonds MJ, 2004, GENES IMMUN, V5, P267, DOI 10.1038/sj.gene.6364066; Skoog T, 1999, HUM MOL GENET, V8, P1443, DOI 10.1093/hmg/8.8.1443; Tanck MWT, 2003, ANN HUM GENET, V67, P175, DOI 10.1046/j.1469-1809.2003.00021.x; VANDENMAAGDENBERG AMJM, 1993, J BIOL CHEM, V268, P10540; Waldron-Lynch F, 2001, GENES IMMUN, V2, P82, DOI 10.1038/sj.gene.6363738; Welt FGP, 2002, ARTERIOSCL THROM VAS, V22, P1769, DOI 10.1161/01.ATV.0000037100.44766.5B; Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195	27	70	75	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2005	19	14					1998	2004		10.1096/fj.05-4634com	http://dx.doi.org/10.1096/fj.05-4634com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16319143				2022-12-28	WOS:000234405500010
J	Mulder, WJM; Strijkers, GJ; Habets, JW; Bleeker, EJW; van der Schaft, DWJ; Storm, G; Koning, GA; Griffioen, AW; Nicolay, K				Mulder, WJM; Strijkers, GJ; Habets, JW; Bleeker, EJW; van der Schaft, DWJ; Storm, G; Koning, GA; Griffioen, AW; Nicolay, K			MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle	FASEB JOURNAL			English	Article						paramagnetic liposomes; RGD peptide; alpha v beta 3-integrin; angiogenesis; tumor bearing mice	RGD-MODIFIED PROTEINS; ALPHA(V)BETA(3) INTEGRIN; 1.5 TESLA; IN-VIVO; ANGIOGENESIS; LIPOSOMES; CANCER; PEPTIDE; EXPRESSION; VASCULATURE	In oncological research, there is a great need for imaging techniques that specifically identify angiogenic blood vessels in tumors on the basis of differences in the expression level of biomolecular markers. In the angiogenic cascade, different cell surface receptors, including the alpha v beta 3-integrin, are strongly expressed on activated endothelial cells. In the present study, we aimed to image angiogenesis by detecting the expression of alpha v beta 3 in tumor bearing mice with a combination of magnetic resonance imaging (MRI) and fluorescence microscopy. To that end, we prepared MR-detectable and fluorescent liposomes, which carry similar to 700 alpha v beta 3-specific RGD peptides per liposome. RGD competition experiments and RAD-conjugated liposomes were used as controls for specificity. In vivo, both RAD liposomes and RGD liposomes gave rise to signal increase on T-1-weighted MR images. It was established by the use of ex vivo fluorescence microscopy that RGD liposomes and RAD liposomes accumulated in the tumor by different mechanisms. RGD liposomes were specifically associated with activated tumor endothelium, while RAD liposomes were located in the extravascular compartment. This study demonstrates that MR molecular imaging of angiogenesis is feasible by using a targeted contrast agent specific for the alpha v beta 3-integrin, and that the multimodality imaging approach gave insight into the exact mechanism of accumulation in the tumor.	Eindhoven Univ Technol, Dept Biomed Engn, Biomed NMR, NL-5600 MB Eindhoven, Netherlands; Maastricht Univ, Angiogenesis Lab, Res Inst Growth & Dev, Dept Pathol Internal Med, NL-6202 AZ Maastricht, Netherlands; Univ Hosp Maastricht, NL-6202 AZ Maastricht, Netherlands; UIPS, Dept Pharmaceut, NL-3508 TB Utrecht, Netherlands; Delft Univ Technol, Dept Radiat Radioisotopes & Reactors, Fac Sci Appl, NL-2629 JB Delft, Netherlands	Eindhoven University of Technology; Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC); Utrecht University; Delft University of Technology	Mulder, WJM (corresponding author), Eindhoven Univ Technol, Dept Biomed Engn, Biomed NMR, POB 513, NL-5600 MB Eindhoven, Netherlands.	w.j.m.mulder@tue.nl	Storm, Gerrit/O-8696-2016; Mulder, Willem J.M./B-7232-2009; Nicolay, Klaas/F-4192-2010; Koning, Gerben A/K-2326-2012; Strijkers, Gustav J/H-3158-2011	Mulder, Willem J.M./0000-0001-8665-3878; Koning, Gerben A/0000-0003-3090-2403; Strijkers, Gustav/0000-0001-6700-5058; Nicolay, Klaas/0000-0002-4179-616X				Allen TM, 1997, DRUGS, V54, P8, DOI 10.2165/00003495-199700544-00004; ALLEN TM, 1994, TRENDS PHARMACOL SCI, V15, P215, DOI 10.1016/0165-6147(94)90314-X; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen XY, 2004, MOL IMAGING, V3, P96, DOI 10.1162/1535350041464892; Chen XY, 2004, BIOCONJUGATE CHEM, V15, P41, DOI 10.1021/bc0300403; Colangelo S, 1998, ARTERIOSCL THROM VAS, V18, P52, DOI 10.1161/01.ATV.18.1.52; Dafni H, 2002, CANCER RES, V62, P6731; Dardzinski BJ, 2001, MAGN RESON IMAGING, V19, P1209, DOI 10.1016/S0730-725X(01)00448-9; de Lussanet QG, 2004, EUR J CANCER, V40, P1262, DOI 10.1016/j.ejca.2004.01.020; Dijkhuizen RM, 2002, STROKE, V33, P2100, DOI 10.1161/01.STR.0000023534.37670.F7; Doubrovin M, 2004, BIOCONJUGATE CHEM, V15, P1376, DOI 10.1021/bc0498572; Drummond DC, 1999, PHARMACOL REV, V51, P691; Dubey PK, 2004, J DRUG TARGET, V12, P257, DOI 10.1080/10611860410001728040; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gillies RJ, 2002, J MAGN RESON IMAGING, V16, P430, DOI 10.1002/jmri.10181; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Haubner R, 1997, ANGEW CHEM INT EDIT, V36, P1375; Haubner R, 2001, CANCER RES, V61, P1781; Haubner R, 1996, J AM CHEM SOC, V118, P7461, DOI 10.1021/ja9603721; Holig P, 2004, PROTEIN ENG DES SEL, V17, P433, DOI 10.1093/protein/gzh055; Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200; Huber MM, 1998, BIOCONJUGATE CHEM, V9, P242, DOI 10.1021/bc970153k; Israely T, 2004, MAGN RESON MED, V52, P741, DOI 10.1002/mrm.20203; Janssen APCA, 2003, INT J PHARMACEUT, V254, P55, DOI 10.1016/S0378-5173(02)00682-8; Janssen ML, 2002, CANCER RES, V62, P6146; Kok RJ, 2002, BIOCONJUGATE CHEM, V13, P128, DOI 10.1021/bc015561+; Koning GA, 2004, APPL RADIAT ISOTOPES, V61, P963, DOI 10.1016/j.apradiso.2004.05.020; Li KCP, 2004, BIOMED MICRODEVICES, V6, P113, DOI 10.1023/B:BMMD.0000031747.05317.81; Li KCP, 2002, J CELL BIOCHEM, P65, DOI 10.1002/jcb.10401; McDonald DM, 2003, NAT MED, V9, P713, DOI 10.1038/nm0603-713; Morawski AM, 2004, MAGN RESON MED, V51, P480, DOI 10.1002/mrm.20010; Moseley M, 2004, STROKE, V35, P2632, DOI 10.1161/01.STR.0000143214.22567.cb; MULDER WJ, 2005, P 13 ISMRM M MIAM FL; MULDER WJ, 2004, P 2U ESMRMB M COP DE; Mulder WJM, 2004, BIOCONJUGATE CHEM, V15, P799, DOI 10.1021/bc049949r; Padhani AR, 2002, J MAGN RESON IMAGING, V16, P407, DOI 10.1002/jmri.10176; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; Schiffelers RM, 2003, J CONTROL RELEASE, V91, P115, DOI 10.1016/S0168-3659(03)00240-2; Schraa AJ, 2002, INT J CANCER, V102, P469, DOI 10.1002/ijc.10727; Sipkins DA, 1998, NAT MED, V4, P623, DOI 10.1038/nm0598-623; Storm G, 1997, HYBRIDOMA, V16, P119, DOI 10.1089/hyb.1997.16.119; Thumshirn G, 2003, CHEM-EUR J, V9, P2717, DOI 10.1002/chem.200204304; Weissleder R, 2002, NAT REV CANCER, V2, P11, DOI 10.1038/nrc701; Weissleder R, 2001, RADIOLOGY, V219, P316, DOI 10.1148/radiology.219.2.r01ma19316; Winter PM, 2003, CANCER RES, V63, P5838; Zitzmann S, 2002, CANCER RES, V62, P5139	49	232	252	2	46	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2008	+		10.1096/fj.05-4145fje	http://dx.doi.org/10.1096/fj.05-4145fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16204353				2022-12-28	WOS:000232991100028
J	Brantley-Sieders, DM; Fang, WB; Hicks, DJ; Zhuang, GL; Yu, S; Chen, J				Brantley-Sieders, DM; Fang, WB; Hicks, DJ; Zhuang, GL; Yu, S; Chen, J			Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression	FASEB JOURNAL			English	Article						mouse model; adenocarcinoma; metastasis; receptor tyrosine kinases	RECEPTOR TYROSINE KINASE; BREAST-CANCER; SIGNALING PATHWAYS; CELL INTERACTIONS; EPH RECEPTORS; KIT RECEPTOR; GROWTH; CARCINOGENESIS; TUMORIGENESIS; NEOVASCULARIZATION	EphA2 belongs to a unique family of receptor tyrosine kinases that play critical roles in development and disease. Since EphA2 is required for ephrin-A1 ligand-induced vascular remodeling and is overexpressed in a variety of vascularized human adenocarcinomas, we assessed tumor angiogenesis and metastatic progression in EphA2-deficient host animals. 4T1 metastatic mammary adenocarcinoma cells transplanted subcutaneously and orthotopically into EphA2-deficient female mice displayed decreased tumor volume, tumor cell survival, microvascular density, and lung metastasis relative to tumor-bearing littermate controls. To determine if the phenotype in EphA2-deficient mice was endothelial cell intrinsic, we also analyzed endothelial cells isolated from EphA2-deficient animals for their ability to incorporate into tumor vessels in vivo, as well as to migrate in response to tumor-derived signals in vitro. EphA2-deficient endothelial cells displayed impaired survival and failed to incorporate into tumor microvessels in vivo, and displayed impaired tumor-mediated migration in vitro relative to controls. These data suggest that host EphA2 receptor tyrosine kinase function is required in the tumor microenvironment for tumor angiogenesis and metastatic progression.	Vanderbilt Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Chen, J (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, A-4323 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	jin.chen@vanderbilt.edu	Zhuang, Guanglei/K-6097-2013	Chen, Jin/0000-0002-5557-2079; Zhuang, Guanglei/0000-0001-8141-5096	NCI NIH HHS [CA95004] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095004] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollahi A, 2004, MOL CELL, V13, P649, DOI 10.1016/S1097-2765(04)00102-9; Adams RH, 2002, SEMIN CELL DEV BIOL, V13, P55, DOI 10.1006/scdb.2001.0289; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bicknell R, 2004, ANNU REV PHARMACOL, V44, P219, DOI 10.1146/annurev.pharmtox.44.101802.121650; Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Brantley-Sieders Dana M., 2004, Angiogenesis, V7, P17, DOI 10.1023/B:AGEN.0000037340.33788.87; Brantley-Sieders DM, 2004, J CELL SCI, V117, P2037, DOI 10.1242/jcs.01061; Carles-Kinch K, 2002, CANCER RES, V62, P2840; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Cheng N, 2002, MOL CANCER RES, V1, P2; Cheng N, 2003, NEOPLASIA, V5, P445, DOI 10.1016/S1476-5586(03)80047-7; Cheng N, 2002, CYTOKINE GROWTH F R, V13, P75, DOI 10.1016/S1359-6101(01)00031-4; Dobrzanski P, 2004, CANCER RES, V64, P910, DOI 10.1158/0008-5472.CAN-3430-2; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; Duxbury MS, 2004, ONCOGENE, V23, P1448, DOI 10.1038/sj.onc.1207247; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Haslam SZ, 2003, BREAST CANCER RES, V5, P208, DOI 10.1186/bcr615; Hristov M, 2003, ARTERIOSCL THROM VAS, V23, P1185, DOI 10.1161/01.ATV.0000073832.49290.B5; Leek RD, 2001, ANTICANCER RES, V21, P4325; Liu W, 2004, BRIT J CANCER, V90, P1620, DOI 10.1038/sj.bjc.6601723; Martiny-Baron G, 2004, NEOPLASIA, V6, P248, DOI 10.1593/neo.03457; Murai KK, 2003, J CELL SCI, V116, P2823, DOI 10.1242/jcs.00625; Nakamoto M, 2002, MICROSC RES TECHNIQ, V59, P58, DOI 10.1002/jemt.10177; Noren NK, 2004, P NATL ACAD SCI USA, V101, P5583, DOI 10.1073/pnas.0401381101; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; Patan S, 2004, CANC TREAT, V117, P3; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; REITH AD, 1993, ONCOGENE, V8, P45; Rossant J, 2002, ANNU REV CELL DEV BI, V18, P541, DOI 10.1146/annurev.cellbio.18.012502.105825; Schedin P, 2004, BREAST CANCER RES, V6, P93, DOI 10.1186/bcr772; Shin D, 2001, DEV BIOL, V230, P139, DOI 10.1006/dbio.2000.9957; Tsutsui Shinichi, 2003, Breast Cancer, V10, P312, DOI 10.1007/BF02967651; Uzzan B, 2004, CANCER RES, V64, P2941, DOI 10.1158/0008-5472.CAN-03-1957; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zantek ND, 2001, CLIN CANCER RES, V7, P3640; Zelinski DP, 2001, CANCER RES, V61, P2301	40	103	124	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2005	19	11					1884	+		10.1096/fj.05-4038fje	http://dx.doi.org/10.1096/fj.05-4038fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16166198				2022-12-28	WOS:000232315700012
J	Stenina, OI; Ustinov, V; Krukovets, I; Marinic, T; Topol, EJ; Plow, EF				Stenina, OI; Ustinov, V; Krukovets, I; Marinic, T; Topol, EJ; Plow, EF			Polymorphisms A387P in thrombospondin-4 and N700S in thrombospondin-1 perturb calcium binding sites	FASEB JOURNAL			English	Article						coronary artery disease; single nucleotide polymorphism; Ca2+ binding; TSP	OLIGOMERIC MATRIX PROTEIN; CORONARY-ARTERY-DISEASE; MULTIPLE EPIPHYSEAL DYSPLASIA; ION LUMINESCENCE PROBES; GROWTH-FACTOR; CA2+ BINDING; CATION-BINDING; MYOCARDIAL-INFARCTION; LIGAND-BINDING; DISULFIDE BOND	Recent genetic studies have associated members of the thrombospondin (TSP) gene family with premature cardiovascular disease. The disease-associated polymorphisms lead to single amino acid changes in TSP-4 (A387P) and TSP-1 (N700S). These substitutions reside in adjacent domains of these highly homologous proteins. Secondary structural predictive programs and the homology of the domains harboring these amino acid substitutions to those in other proteins pointed to potential alterations of putative Ca2+ binding sites that reside in close proximity to the polymorphic amino acids. Since Ca2+ binding is critical for the structure and function of TSP family members, direct evidence for differences in Ca2+ binding by the polymorphic forms was sought. Using synthetic peptides and purified recombinant variant fragments bearing the amino acid substitutions, we measured differences in Tb3+ luminescence as an index of Ca2+ binding. The Tb3+ binding constants placed the TSP-1 region affected by N700S polymorphism among other high-affinity Ca2+ binding sites. The affinity of Ca2+ binding was lower for peptides (3.5-fold) and recombinant fragments (10-fold) containing the S700 vs. the N700 form. In TSP-4, the P387 form acquired an additional Ca2+ binding site absent in the A387 form. The results of our study suggest that both substitutions (A387P in TSP-4 and N700S in TSP-1) alter Ca2+ binding properties. Since these substitutions exert the opposite effects on Ca2+ binding, a decrease in TSP-1 and an increase in TSP-4, the two TSP variants are likely to influence cardiovascular functions in distinct but yet pathogenic ways.	Cleveland Clin Fdn, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Stenina, OI (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, NB50,9500 Euclid Ave, Cleveland, OH 44195 USA.	stenino@ccf.org	Ustinov, Valentin/J-6301-2018	, Olga/0000-0002-1256-0545; Topol, Eric/0000-0002-1478-4729	NHLBI NIH HHS [P50HL077107-01] Funding Source: Medline; NIDDK NIH HHS [K01DK62128] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL077107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK062128] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASTERMARK J, 1991, J BIOL CHEM, V266, P2430; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BJORNHOLM B, 1993, BIOCHEMISTRY-US, V32, P2954; Boeke JD, 2002, MOBILE DNA, P24; BORIN G, 1989, BIOPOLYMERS, V28, P353, DOI 10.1002/bip.360280134; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; BRITTAIN HG, 1976, J AM CHEM SOC, V98, P8255, DOI 10.1021/ja00441a060; BURROUGHS SE, 1992, BIOPHYS CHEM, V42, P249; Chen H, 2000, J BIOL CHEM, V275, P26538, DOI 10.1074/jbc.M909780199; Chou JJ, 2001, NAT STRUCT BIOL, V8, P990, DOI 10.1038/nsb1101-990; Cierniewska-Cieslak A, 2002, J BIOL CHEM, V277, P11126, DOI 10.1074/jbc.M112388200; CIERNIEWSKI CS, 1994, BIOCHEMISTRY-US, V33, P12238, DOI 10.1021/bi00206a029; DERIAN CK, 1989, J BIOL CHEM, V264, P6615; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; Dukhanina EA, 1997, BIOCHEMISTRY-MOSCOW+, V62, P530; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; Haas TA, 1996, J BIOL CHEM, V271, P6017, DOI 10.1074/jbc.271.11.6017; Hannah BLA, 2004, J BIOL CHEM, V279, P51915, DOI 10.1074/jbc.M409632200; Hanney Stephen R., 2003, HEALTH RES POLICY SY, V1, P1, DOI DOI 10.1186/1478-4505-1-2; Hecht JT, 1998, MATRIX BIOL, V17, P269, DOI 10.1016/S0945-053X(98)90080-4; HIGHSMITH SR, 1983, J BIOL CHEM, V258, P6858; Hogg PJ, 1997, BIOCHEM J, V326, P709, DOI 10.1042/bj3260709; Horrocks W.D. Jr., 1983, PROG INORG CHEM, V31, P1; HORROCKS WD, 1981, ACCOUNTS CHEM RES, V14, P384, DOI 10.1021/ar00072a004; Hou J, 2000, CELL CALCIUM, V27, P309, DOI 10.1054/ceca.2000.0125; HUANG LH, 1989, BIOCHEM BIOPH RES CO, V160, P133, DOI 10.1016/0006-291X(89)91631-8; Kato T, 2003, CIRCULATION, V108, P712; Kettle S, 1999, J MOL BIOL, V285, P1277, DOI 10.1006/jmbi.1998.2368; KUZMIC P, 1992, ANAL BIOCHEM, V205, P65, DOI 10.1016/0003-2697(92)90579-V; Kvansakul M, 2004, EMBO J, V23, P1223, DOI 10.1038/sj.emboj.7600166; KWOK F, 1994, ARCH BIOCHEM BIOPHYS, V313, P274, DOI 10.1006/abbi.1994.1388; LAWLER J, 1982, J BIOL CHEM, V257, P2257; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LENKINSKI RE, 1978, BIOINORG CHEM, V8, P363, DOI 10.1016/S0006-3061(00)80169-6; Li MX, 1997, BIOCHEMISTRY-US, V36, P12519, DOI 10.1021/bi971222l; Manoharan HT, 1997, GENE, V193, P229, DOI 10.1016/S0378-1119(97)00126-1; MAUNE JF, 1992, BIOCHEMISTRY-US, V31, P7779, DOI 10.1021/bi00149a006; MISENHEIMER TM, 1995, J BIOL CHEM, V270, P1729, DOI 10.1074/jbc.270.4.1729; MORGELIN M, 1992, J BIOL CHEM, V267, P6137; Narizhneva NV, 2004, J BIOL CHEM, V279, P21651, DOI 10.1074/jbc.M311090200; Narouz-Ott L, 2000, J BIOL CHEM, V275, P37110, DOI 10.1074/jbc.M007223200; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; Peyvandi F, 2003, BLOOD, V102, p314A; REUKEN J, 1977, CALCIUM BINDING PROT; SNYDER AP, 1981, BIOCHEMISTRY-US, V20, P3334, DOI 10.1021/bi00515a003; SPEZIALE MV, 1991, ARCH BIOCHEM BIOPHYS, V286, P546, DOI 10.1016/0003-9861(91)90077-V; Stenberg Y, 1997, J BIOL CHEM, V272, P23255, DOI 10.1074/jbc.272.37.23255; STENFLO J, 1991, BLOOD, V78, P1637; Stenflo J, 1999, CRIT REV EUKAR GENE, V9, P59, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.50; Stenflo J, 2000, BBA-PROTEIN STRUCT M, V1477, P51, DOI 10.1016/S0167-4838(99)00262-9; Stenina OI, 2004, INT J BIOCHEM CELL B, V36, P1013, DOI 10.1016/j.biocel.2004.01.005; Stenina OI, 2003, CIRCULATION, V108, P1514, DOI 10.1161/01.CIR.0000089085.76320.4E; Tan KM, 2002, J CELL BIOL, V159, P373, DOI 10.1083/jcb.200206062; Thur J, 2001, J BIOL CHEM, V276, P6083, DOI 10.1074/jbc.M009512200; Topol EJ, 2001, CIRCULATION, V104, P2641, DOI 10.1161/hc4701.100910; TURK JL, 1986, ARCH BIOCHEM BIOPHYS, V245, P446, DOI 10.1016/0003-9861(86)90236-5; VANSCHARRENBURG GJM, 1985, BIOCHEMISTRY-US, V24, P334, DOI 10.1021/bi00323a015; WALTERSSON Y, 1993, BIOCHEMISTRY-US, V32, P7866, DOI 10.1021/bi00082a005; Walton B, 2003, CIRCULATION, V108, P771; WARD LD, 1985, METHOD ENZYMOL, V117, P400; Wessel J, 2003, CIRCULATION, V108, P767; Wessel J, 2004, AM HEART J, V147, P905, DOI 10.1016/j.ahj.2003.12.013; Wu XC, 1997, BIOCHEMISTRY-US, V36, P8649, DOI 10.1021/bi970278c; Yamada Y, 2002, NEW ENGL J MED, V347, P1916, DOI 10.1056/NEJMoa021445	65	33	34	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1893	+		10.1096/fj.05-3712fje	http://dx.doi.org/10.1096/fj.05-3712fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16148025				2022-12-28	WOS:000232315700025
J	Froy, O; Chapnik, N; Miskin, R				Froy, O; Chapnik, N; Miskin, R			Mouse intestinal cryptdins exhibit circadian oscillation	FASEB JOURNAL			English	Article						circadian rhythms, biological clock; defensins; FVB/N; C57BL/6	SUPRACHIASMATIC NUCLEUS; INNATE IMMUNITY; HELICOBACTER-FELIS; TRANSGENIC MICE; ALPHA-DEFENSINS; CROHNS-DISEASE; PANETH CELLS; CLOCK; GENE; EXPRESSION	The innate immunity utilizes a plethora of antibacterial polypeptides, known as defensins, to combat ingested bacteria. Mouse enteric defensins (cryptdins) are produced and secreted constitutively but are overexpressed in instances of infection and/or inflammation. Our objective was to determine whether the biological clock plays a role in cryptdin expression under healthy conditions. Analysis of cryptdin 1 and cryptdin 4 expression in the ileum and jejunum of the small intestine of FVB/N mice around the circadian cycle revealed oscillation that peaked at the end of the dark phase. To eliminate the possibility that cryptdin oscillation stems from food intake, we analyzed cryptdin expression under fasting conditions and found oscillation but with a 3 h phase-shift. Comparison of cryptdin expression in two mouse strains (C57BL/6 vs. FVB/N) revealed higher levels in C57BL/6, a mouse strain that is highly susceptible to enteric infection, due, most likely, to impaired cryptdin maturation. The results of this study indicate the involvement of the biological clock in regulating cryptdin expression in the small intestine and reinforce the capacity of food to act as a zeitgeber (synchronizer). With the assumption of similar control in humans, our results may imply that defensin expression peaks during the day.	Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual, Inst Biochem Food Sci & Nutr, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem; Weizmann Institute of Science	Froy, O (corresponding author), Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual, Inst Biochem Food Sci & Nutr, POB 12, IL-76100 Rehovot, Israel.	froy@agri.huji.ac.il	Froy, Oren/C-3550-2009					Aarbiou J, 2002, ANN MED, V34, P96, DOI 10.1080/07853890252953482; Akhtar RA, 2002, CURR BIOL, V12, P540, DOI 10.1016/S0960-9822(02)00759-5; Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Boivin DB, 2003, BLOOD, V102, P4143, DOI 10.1182/blood-2003-03-0779; Cassone VM, 2002, NUTRITION, V18, P814, DOI 10.1016/S0899-9007(02)00937-1; Challet E, 2003, BIOL CHEM, V384, P711, DOI 10.1515/BC.2003.079; Cohen O, 2002, MOL PSYCHIATR, V7, P874, DOI 10.1038/sj.mp.4001103; Cunliffe RN, 2001, GUT, V48, P176, DOI 10.1136/gut.48.2.176; Cunliffe RN, 2003, MOL IMMUNOL, V40, P463, DOI 10.1016/S0161-5890(03)00157-3; Fellermann K, 2003, EUR J GASTROEN HEPAT, V15, P627, DOI 10.1097/00042737-200306000-00008; Fox JG, 1996, GASTROENTEROLOGY, V110, P155, DOI 10.1053/gast.1996.v110.pm8536852; Froy O, 2005, IUBMB LIFE, V57, P41, DOI 10.1080/15216540500088912; Froy O, 2003, TRENDS GENET, V19, P684, DOI 10.1016/j.tig.2003.10.010; Froy O, 2002, CURR BIOL, V12, P147, DOI 10.1016/S0960-9822(01)00656-X; Froy O, 2003, SCIENCE, V300, P1303, DOI 10.1126/science.1084874; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Hastings M H, 1999, J Neurosci, V19, pRC11; Herzog ED, 1998, NAT NEUROSCI, V1, P708, DOI 10.1038/3708; Lawrance IC, 2001, HUM MOL GENET, V10, P445, DOI 10.1093/hmg/10.5.445; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lehrer RI, 2002, CURR OPIN IMMUNOL, V14, P96, DOI 10.1016/S0952-7915(01)00303-X; Lin PW, 2004, J BIOL CHEM, V279, P19902, DOI 10.1074/jbc.M311821200; Liu C, 1997, CELL, V91, P855, DOI 10.1016/S0092-8674(00)80473-0; Lucas RJ, 2001, BEHAV BRAIN RES, V125, P97, DOI 10.1016/S0166-4328(01)00274-1; McDonald MJ, 2001, CELL, V107, P567, DOI 10.1016/S0092-8674(01)00545-1; Mitchell GF, 1998, AM J PHYSIOL-HEART C, V274, pH747, DOI 10.1152/ajpheart.1998.274.3.H747; Mohammadi M, 1996, INFECT IMMUN, V64, P238, DOI 10.1128/IAI.64.1.238-245.1996; OUELLETTE AJ, 1994, INFECT IMMUN, V62, P5040, DOI 10.1128/IAI.62.11.5040-5047.1994; Ouellette AJ, 2004, BEST PRACT RES CL GA, V18, P405, DOI 10.1016/j.bpg.2003.10.010; PLANT J, 1974, NATURE, V248, P345, DOI 10.1038/248345a0; Pugh PL, 2004, BEHAV BRAIN RES, V155, P283, DOI 10.1016/j.bbr.2004.04.021; Raj PA, 2002, FEMS MICROBIOL LETT, V206, P9, DOI 10.1111/j.1574-6968.2002.tb10979.x; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Reppert SM, 1997, CELL, V89, P487, DOI 10.1016/S0092-8674(00)80229-9; ROBSON HG, 1972, J INFECT DIS, V126, P378, DOI 10.1093/infdis/126.4.378; Sakagami T, 1996, GUT, V39, P639, DOI 10.1136/gut.39.5.639; Salzman NH, 2003, NATURE, V422, P522, DOI 10.1038/nature01520; Shirafuji Y, 2003, J BIOL CHEM, V278, P7910, DOI 10.1074/jbc.M210600200; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; Yang D, 2002, TRENDS IMMUNOL, V23, P291, DOI 10.1016/S1471-4906(02)02246-9; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	45	30	30	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1920	+		10.1096/fj.05-4216fje	http://dx.doi.org/10.1096/fj.05-4216fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16129697				2022-12-28	WOS:000231843700002
J	von Bohlen und Halbach, O; Minichiello, L; Unsicker, K				von Bohlen und Halbach, O; Minichiello, L; Unsicker, K			Haploinsufficiency for trkB and trkC receptors induces cell loss and accumulation of alpha-synuclein in the substantia nigra	FASEB JOURNAL			English	Article						dopamine; mice; neurotrophins; striatum	NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; PARKINSONS-DISEASE; TYROSINE-HYDROXYLASE; DOPAMINE NEURONS; MESSENGER-RNA; RAT MODEL; BDNF; ASSOCIATION; EXPRESSION	The neurotrophins brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) have been shown to promote survival and differentiation of midbrain dopaminergic (DAergic) neurons in vitro and in vivo. This is consistent with their expression and that of their cognate receptors, trkB and trkC, in the nigrostriatal system. Degeneration of DAergic neurons of the substantia nigra and alpha-synuclein-positive aggregates in the remaining substantia nigra (SN) neurons are hallmarks of Parkinson's disease (PD). Reduced expression of BDNF has been reported in the SN from PD patients. Moreover, mutations in the BDNF gene have been found to play a role in the development of familial PD. We show now that haploinsufficiencies of the neurotrophin receptors trkB and/or trkC cause a reduction in numbers of SN neurons in aged (21-23 month old) mice, which is accompanied by a reduced density in striatal tyrosine hydroxylase immunoreactive (TH-ir) fibers. These aged mutant mice, in contrast to wild-type littermates, display an accumulation of alpha-synuclein in the remaining TH-positive neurons of the SN. We conclude that impairment in trkB and/or trkC signaling induces a phenotype in the aged SN, which includes two hallmarks of PD, losses of TH-positive neurons and axons along with massive neuronal deposits of alpha-synuclein.	Heidelberg Univ, Dept Neuroanat, Interdisciplinary Ctr Neurosci, D-69120 Heidelberg, Germany; European Mol Biol Lab, I-00016 Monterotondo, Italy	Ruprecht Karls University Heidelberg; European Molecular Biology Laboratory (EMBL)	von Bohlen und Halbach, O (corresponding author), Heidelberg Univ, Dept Neuroanat, Interdisciplinary Ctr Neurosci, Neuenheimer Feld 307, D-69120 Heidelberg, Germany.	O.von_Bohlen@web.de	von Bohlen und Halbach, Oliver/R-3464-2019; Minichiello, Liliana/AAA-7190-2022; von Bohlen und Halbach, Oliver/A-1060-2008	von Bohlen und Halbach, Oliver/0000-0002-6265-9156; von Bohlen und Halbach, Oliver/0000-0002-2613-2517				ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; ALTAR CA, 1994, EUR J NEUROSCI, V6, P1389, DOI 10.1111/j.1460-9568.1994.tb01001.x; Braak H, 2002, J NEUROL, V249, DOI [1007/s00415-002-1301-4, 10.1007/s00415-002-1301-4, DOI 10.1007/S00415-002-1301-4]; Ciechanover A, 2001, NAT MED, V7, P1108, DOI 10.1038/nm1001-1108; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dunnett SB, 1999, NATURE, V399, pA32, DOI 10.1038/399a032; Eilam R, 1998, P NATL ACAD SCI USA, V95, P12653, DOI 10.1073/pnas.95.21.12653; Emborg ME, 1998, J COMP NEUROL, V401, P253; Galpern WR, 1996, CELL TRANSPLANT, V5, P225, DOI 10.1016/0963-6897(95)02030-6; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; GOZLAN H, 1990, NEUROBIOL AGING, V11, P437, DOI 10.1016/0197-4580(90)90011-N; Hagg T, 1998, EXP NEUROL, V149, P183, DOI 10.1006/exnr.1997.6684; Hirsch EC, 2003, J NEURAL TRANSM-SUPP, P89, DOI 10.1007/978-3-7091-0643-3_6; Howells DW, 2000, EXP NEUROL, V166, P127, DOI 10.1006/exnr.2000.7483; Katoh-Semba R, 1998, NEUROSCI RES, V31, P227, DOI 10.1016/S0168-0102(98)00040-6; Kirik D, 2002, J NEUROSCI, V22, P2780, DOI 10.1523/JNEUROSCI.22-07-02780.2002; Klein RL, 1999, BRAIN RES, V847, P314, DOI 10.1016/S0006-8993(99)02116-2; Kohno R, 2004, BIOCHEM BIOPH RES CO, V318, P113, DOI 10.1016/j.bbrc.2004.04.012; Lee HJ, 2002, J BIOL CHEM, V277, P5411, DOI 10.1074/jbc.M105326200; Lee HJ, 2002, J BIOL CHEM, V277, P48976, DOI 10.1074/jbc.M208192200; Levivier M, 1995, J NEUROSCI, V15, P7810, DOI 10.1523/jneurosci.15-12-07810.1995; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; Markham A, 2004, EUR J NEUROSCI, V20, P1189, DOI 10.1111/j.1460-9568.2004.03578.x; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; MASUOKA DT, 1979, BRAIN RES, V169, P335, DOI 10.1016/0006-8993(79)91034-5; Miguez JM, 1999, J NEURAL TRANSM, V106, P1089, DOI 10.1007/s007020050225; Minichiello L, 1996, GENE DEV, V10, P2849, DOI 10.1101/gad.10.22.2849; Mogi M, 1999, NEUROSCI LETT, V270, P45, DOI 10.1016/S0304-3940(99)00463-2; Naoi M, 1999, MECH AGEING DEV, V111, P175, DOI 10.1016/S0047-6374(99)00064-0; Nishio T, 1998, NEUROREPORT, V9, P2847, DOI 10.1097/00001756-199808240-00030; Parain K, 1999, NEUROREPORT, V10, P557, DOI 10.1097/00001756-199902250-00021; Parsian A, 2004, PARKINSONISM RELAT D, V10, P213, DOI 10.1016/j.parkreldis.2003.12.003; TATTON WG, 1991, NEUROBIOL AGING, V12, P543, DOI 10.1016/0197-4580(91)90086-Y; Tompkins MM, 1997, BRAIN RES, V775, P24, DOI 10.1016/S0006-8993(97)00874-3; von Bohlen und Halbach O, 2004, PROG NEUROBIOL, V73, P151, DOI 10.1016/j.pneurobio.2004.05.002; von Bohlen und Halbach O, 2003, CELL TISSUE RES, V311, P139, DOI 10.1007/s00441-002-0662-4; Wakabayashi K, 1998, ACTA NEUROPATHOL, V96, P445, DOI 10.1007/s004010050918; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411	38	67	68	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1740	+		10.1096/fj.05-3845fje	http://dx.doi.org/10.1096/fj.05-3845fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16037097	Green Published			2022-12-28	WOS:000230923000012
J	Curley, JP; Pinnock, SB; Dickson, SL; Thresher, R; Miyoshi, N; Surani, MA; Keverne, EB				Curley, JP; Pinnock, SB; Dickson, SL; Thresher, R; Miyoshi, N; Surani, MA; Keverne, EB			Increased body fat in mice with a targeted mutation of the paternally expressed imprinted gene Peg3	FASEB JOURNAL			English	Article						Pw1; phenotype	PROTEIN; EVOLUTION; MEDIATOR; OBESITY; GROWTH; LOCUS; BAX	Peg3 encodes a C2H2 type zinc finger protein that is implicated in a novel physiological pathway regulating core body temperature, feeding behavior, and obesity in mice. Peg3(+/-) mutant mice develop an excess of abdominal, subcutaneous, and intra-scapular fat, despite a lifetime of lower food intake than wild-type animals. However, they start life with reduced fat reserves and are slower to enter puberty. These mice maintain a lower core body temperature, fail to respond to a cold challenge, and have lower metabolic activity as measured by oxygen consumption. Plasma leptin levels are significantly higher than in wild types, and Peg3(+/-) mice appear to have developed leptin resistance. Administration of exogenous leptin resulted in a significant reduction in food intake in wild-type mice that was not observed in Peg(3+/)- mutants. This mutation, which is strongly expressed in hypothalamic tissue during development, has the capacity to regulate multiple events relating to energy homeostasis.	Univ Cambridge, Subdept Anim Behav, Cambridge CB3 8AA, England; Univ Cambridge, Dept Physiol, Cambridge CB2 3EG, England; Dept Physiol, SE-40530 Gothenburg, Sweden; Univ Cambridge, Wellcome Trust Canc Res UK, Cambridge CB2 1QR, England	University of Cambridge; University of Cambridge; Cancer Research UK; University of Cambridge	Curley, JP (corresponding author), Univ Cambridge, Subdept Anim Behav, Cambridge CB3 8AA, England.	jpc38@cam.ac.uk	Dickson, Suzanne L/U-4628-2019	Dickson, Suzanne/0000-0002-3822-5294; Surani, Azim/0000-0002-8640-4318; Curley, James/0000-0001-5546-007X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barker DJP, 1998, MOTHERS BABIES HLTH; Barsh GS, 2000, NATURE, V404, P644, DOI 10.1038/35007519; Bateson P, 2004, NATURE, V430, P419, DOI 10.1038/nature02725; Blum W F, 1994, Growth Regul, V4 Suppl 1, P11; Charalambous M, 2003, P NATL ACAD SCI USA, V100, P8292, DOI 10.1073/pnas.1532175100; Charlier C, 2001, NAT GENET, V27, P367, DOI 10.1038/86856; Curley JP, 2004, P ROY SOC B-BIOL SCI, V271, P1303, DOI 10.1098/rspb.2004.2725; de Koning DJ, 2000, P NATL ACAD SCI USA, V97, P7947, DOI 10.1073/pnas.140216397; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Freking BA, 2002, GENOME RES, V12, P1496, DOI 10.1101/gr.571002; GALLOU C, 2004, GEN IMPR WORKSH MONT; Haig D, 2004, ANNU REV GENET, V38, P553, DOI 10.1146/annurev.genet.37.110801.142741; Hara J, 2001, NEURON, V30, P345, DOI 10.1016/S0896-6273(01)00293-8; Hattersley AT, 1998, NAT GENET, V19, P268, DOI 10.1038/953; Hiby SE, 2001, HUM MOL GENET, V10, P1093, DOI 10.1093/hmg/10.10.1093; Johnson MD, 2002, J BIOL CHEM, V277, P23000, DOI 10.1074/jbc.M201907200; Keverne EB, 1997, CURR OPIN NEUROBIOL, V7, P463, DOI 10.1016/S0959-4388(97)80023-2; Kim J, 2004, GENOMICS, V84, P47, DOI 10.1016/j.ygeno.2004.02.007; KIM YR, 1997, LAB HEMATOL, V3, P19; Kohda T, 2001, GENES CELLS, V6, P237, DOI 10.1046/j.1365-2443.2001.00412.x; Kuroiwa Y, 1996, NAT GENET, V12, P186, DOI 10.1038/ng0296-186; Li LL, 1999, SCIENCE, V284, P330, DOI 10.1126/science.284.5412.330; Lummaa V, 2002, TRENDS ECOL EVOL, V17, P141, DOI 10.1016/S0169-5347(01)02414-4; Ma D, 2004, J CLIN INVEST, V114, P339, DOI 10.1172/jci200419876; Moon YS, 2002, MOL CELL BIOL, V22, P5585, DOI 10.1128/MCB.22.15.5585-5592.2002; Morison IM, 1998, HUM MOL GENET, V7, P1599, DOI 10.1093/hmg/7.10.1599; Murphy SK, 2003, BIOESSAYS, V25, P577, DOI 10.1002/bies.10277; Murphy SK, 2001, GENOMICS, V71, P110, DOI 10.1006/geno.2000.6419; Nicholls RD, 2001, ANNU REV GENOM HUM G, V2, P153, DOI 10.1146/annurev.genom.2.1.153; Paulsen M, 2001, GENOME RES, V11, P2085, DOI 10.1101/gr.206901; Pinnock SB, 2001, EUR J NEUROSCI, V13, P576, DOI 10.1046/j.0953-816x.2000.01406.x; Plagge A, 2004, NAT GENET, V36, P818, DOI 10.1038/ng1397; Prentice AM, 2001, BRIT MED BULL, V60, P51, DOI 10.1093/bmb/60.1.51; Relaix F, 1996, DEV BIOL, V177, P383, DOI 10.1006/dbio.1996.0172; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; Relaix F, 2000, P NATL ACAD SCI USA, V97, P2105, DOI 10.1073/pnas.040378897; Schneider JE, 2000, HORM BEHAV, V37, P306, DOI 10.1006/hbeh.2000.1590; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; SMITH F, 2004, GEN IMPR WORKSH MONT; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Temple IK, 2002, J MED GENET, V39, P872, DOI 10.1136/jmg.39.12.872; TRIVERS R, 1999, GENOMIC IMPRINTING I, P1; Tycko B, 2002, J CELL PHYSIOL, V192, P245, DOI 10.1002/jcp.10129; Waterland RA, 2004, NUTRITION, V20, P63, DOI 10.1016/j.nut.2003.09.011; Welberg LAM, 2001, J NEUROENDOCRINOL, V13, P113, DOI 10.1046/j.1365-2826.2001.00601.x; Yamaguchi A, 2002, J BIOL CHEM, V277, P623, DOI 10.1074/jbc.M107435200; Yu SH, 2000, J CLIN INVEST, V105, P615, DOI 10.1172/JCI8437	48	87	90	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1302	+		10.1096/fj.04-3216fje	http://dx.doi.org/10.1096/fj.04-3216fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15928196				2022-12-28	WOS:000229602600004
J	Schildknecht, S; Bachschmid, M; Ullrich, V				Schildknecht, S; Bachschmid, M; Ullrich, V			Peroxynitrite provides the peroxide tone for PGHS-2-dependent prostacyclin synthesis in vascular smooth muscle cells	FASEB JOURNAL			English	Article						cyclooxygenase; prostanoid pathways	PROSTAGLANDIN-H SYNTHASE-1; NITRIC-OXIDE SYNTHASE; BOVINE CORONARY-ARTERIES; ENDOTHELIAL-CELLS; CYCLOOXYGENASE ACTIVITIES; HYDROPEROXIDE REDUCTION; SIMULTANEOUS GENERATION; TYROSINE NITRATION; REACTION-KINETICS; VESICULAR GLAND	Endotoxin-treated vascular smooth muscle cells (VSMCs) were recently shown to release high amounts of prostacyclin (PGI(2)) dependent on the induction of prostaglandin endoperoxide synthase-2 (PGHS-2). In contrast to endothelial PGI(2)-synthase, for which nitration and inhibition by peroxynitrite was reported, addition of SIN-I as a peroxynitrite-generating system did not cause inhibition but rather doubled PGI(2) release by VSMC. The hypothesis of peroxynitrite supplementing an unsaturated peroxide tone for PGHS-2 was supported by H2O2 exerting the same effect. Studies performed with purified PGHS-2 revealed maximal elevation of enzyme activity in the presence of equimolar concentrations of (NO)-N-center dot and O-center dot(2)-, which together form peroxynitrite, while excessive production of either one radical was inhibitory. Most importantly, 6-keto-PGF(1 alpha) formation by intact VSMC depended on a nearly equimolar generation of (NO)-N-center dot and center dot O-2(-) for providing the endogenous peroxide tone. These findings, together with the observation that an excess of exogenously added (NO)-N-center dot, as well as uric acid as a scavenger of peroxynitrite potently reduced PGI(2) release, underlined the role of peroxynitrite as the dominating and rate-limiting intracellular mediator of peroxide tone in VSMC. The results allow us to postulate a new cross-talk between the (NO)-N-center dot and the prostanoid pathways with a crucial role for peroxynitrite in providing the peroxide tone for a continuous activation of PGHS-2.	Univ Konstanz, Fak Biol, Dept Biol, D-78457 Constance, Germany	University of Konstanz	Ullrich, V (corresponding author), Univ Konstanz, Fak Biol, Dept Biol, Fach X910 Sonnenbuhl, D-78457 Constance, Germany.	volker.ullrich@uni-konstanz.de		Bachschmid, Markus Michael/0000-0002-0748-5528				Bachschmid M, 2003, FASEB J, V17, P914, DOI 10.1096/fj.02-0530fje; Boulanger CM, 1998, CIRC RES, V83, P1271, DOI 10.1161/01.RES.83.12.1271; Brophy CM, 2000, AM J PHYSIOL-HEART C, V278, pH991, DOI 10.1152/ajpheart.2000.278.3.H991; CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; Chen W, 1999, J BIOL CHEM, V274, P20301, DOI 10.1074/jbc.274.29.20301; Daiber A, 2002, J BIOL CHEM, V277, P11882, DOI 10.1074/jbc.M111988200; DAVIDGE ST, 1995, CIRC RES, V77, P274, DOI 10.1161/01.RES.77.2.274; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; DONI MG, 1988, EUR J PHARMACOL, V151, P19; EGAN RW, 1976, J BIOL CHEM, V251, P7329; FU JY, 1990, J BIOL CHEM, V265, P16737; Goldstein S, 2000, J BIOL CHEM, V275, P3031, DOI 10.1074/jbc.275.5.3031; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Gunther MR, 1997, J BIOL CHEM, V272, P17086, DOI 10.1074/jbc.272.27.17086; HALUSHKA PV, 1985, CRIT CARE MED, V13, P451, DOI 10.1097/00003246-198506000-00001; HEMLER M, 1976, J BIOL CHEM, V251, P5575; Jourd'heuil D, 2001, J BIOL CHEM, V276, P28799, DOI 10.1074/jbc.M102341200; KULMACZ RJ, 1994, J BIOL CHEM, V269, P5527; Kulmacz RJ, 1998, FEBS LETT, V430, P154, DOI 10.1016/S0014-5793(98)00657-7; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Landino LM, 1997, J BIOL CHEM, V272, P21565, DOI 10.1074/jbc.272.34.21565; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; Liou JY, 2001, J BIOL CHEM, V276, P34975, DOI 10.1074/jbc.M105946200; Lu GQ, 1999, J BIOL CHEM, V274, P16162, DOI 10.1074/jbc.274.23.16162; Margalit A, 1998, AM J PHYSIOL-REG I, V274, pR294, DOI 10.1152/ajpregu.1998.274.2.R294; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; MATTHEWS JS, 1995, BBA-MOL CELL RES, V1269, P237, DOI 10.1016/0167-4889(95)00125-X; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MONCADA S, 1976, PROSTAGLANDINS, V12, P715, DOI 10.1016/0090-6980(76)90048-4; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; OBANION MK, 1991, J BIOL CHEM, V266, P23261; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; RIMARACHIN JA, 1994, ARTERIOSCLER THROMB, V14, P1021, DOI 10.1161/01.ATV.14.7.1021; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; Sato Y, 2004, J BIOL CHEM, V279, P8827, DOI 10.1074/jbc.M310327200; Schildknecht S, 2005, BIOCHEM BIOPH RES CO, V327, P43, DOI 10.1016/j.bbrc.2004.11.132; Schildknecht S, 2004, FASEB J, V18, P757, DOI 10.1096/fj.03-0609fje; Schmidt P, 2003, J BIOL CHEM, V278, P12813, DOI 10.1074/jbc.M208080200; Schwarz PM, 1999, ARTERIOSCL THROM VAS, V19, P2584, DOI 10.1161/01.ATV.19.11.2584; Sies H, 1997, J BIOL CHEM, V272, P27812, DOI 10.1074/jbc.272.44.27812; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Song I, 2001, BIOCHEM BIOPH RES CO, V289, P869, DOI 10.1006/bbrc.2001.6071; Spisni E, 2001, EXP CELL RES, V266, P31, DOI 10.1006/excr.2001.5198; Tsai AL, 2000, PROSTAG OTH LIPID M, V62, P231, DOI 10.1016/S0090-6980(00)00083-6; TSAI AL, 1994, ARCH BIOCHEM BIOPHYS, V313, P367, DOI 10.1006/abbi.1994.1400; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; Tsai AL, 1999, J BIOL CHEM, V274, P21695, DOI 10.1074/jbc.274.31.21695; Upmacis RK, 1999, BIOCHEMISTRY-US, V38, P12505, DOI 10.1021/bi983049e; van der Donk WA, 2002, BIOCHEMISTRY-US, V41, P15451, DOI 10.1021/bi026938h; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Weaver JA, 2001, FREE RADICAL BIO MED, V30, P299, DOI 10.1016/S0891-5849(00)00466-4; Wu G, 1999, J BIOL CHEM, V274, P9231, DOI 10.1074/jbc.274.14.9231; ZEHETGRUBER M, 1993, LIFE SCI, V52, P1397, DOI 10.1016/0024-3205(93)90063-9; Zou MH, 1999, BRIT J PHARMACOL, V126, P1283, DOI 10.1038/sj.bjp.0702434; Zou MH, 1999, AM J PATHOL, V154, P1359, DOI 10.1016/S0002-9440(10)65390-4; Zou MH, 1998, BIOCHEM J, V336, P507, DOI 10.1042/bj3360507; Zou MH, 1996, FEBS LETT, V382, P101, DOI 10.1016/0014-5793(96)00160-3; Zou MH, 1997, BIOL CHEM, V378, P707, DOI 10.1515/bchm.1997.378.7.707	62	40	42	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2005	19	7					1169	+		10.1096/fj.04-3465fje	http://dx.doi.org/10.1096/fj.04-3465fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15878931				2022-12-28	WOS:000229602600018
J	Sun, XL; Wang, YX; Qing, H; Christensen, MA; Liu, YQ; Zhou, WH; Tong, YG; Xiao, CY; Huang, Y; Zhang, SZ; Liu, XH; Song, WH				Sun, XL; Wang, YX; Qing, H; Christensen, MA; Liu, YQ; Zhou, WH; Tong, YG; Xiao, CY; Huang, Y; Zhang, SZ; Liu, XH; Song, WH			Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes	FASEB JOURNAL			English	Article						secretase; amyloid beta; transcription; promoter; Alzheimer's disease	AMYLOID PRECURSOR PROTEIN; ALZHEIMERS BETA-SECRETASE; FACTOR-BINDING SITES; ASPARTYL PROTEASE; CORTICAL-NEURONS; ALPHA-SECRETASE; KNOCKOUT MICE; DOWN-SYNDROME; HUMAN BRAIN; IN-VITRO	Amyloid beta protein (A beta) is the principal component of neuritic plaques in Alzheiirner's disease (AD). A beta is derived from beta amyloid precursor protein (APP) by beta- and gamma-secretases. Beta-site APP cleaving enzyme 1 (BACE1) has been identified as the major beta-secretase. BACE2 is the homolog of BACE1. The BACE2 gene is on chromosome 21 and has been implicated in the pathogenesis of AD. However, the function of BACE2 in A beta generation is controversial. Some studies have shown that BACE2 cleaved APP at the beta-site whereas other studies showed it cleaved around the alpha-secretase site. To elucidate the involvement of BACE2 in AD pathogenesis, we compared BACE2 and BACE1 gene regulation and their functions in A beta generation. We cloned and functionally characterized the human BACE2 promoter. The BACE2 gene is controlled by a TATA-less promoter. Though Sp1 can regulate both BACE1 and BACE2 genes, comparative sequence analysis and transcription factor prediction showed little similarity between the two promoters. BACE1 increased APP cleavage at the beta-site and A beta production whereas BACE2 did not. Overexpression of BACE2 significantly increased sAPP levels in conditioned media but markedly reduced A beta production. Knockdown of BACE2 resulted in increased APP C83. Our data indicate that despite being homologous in amino acid sequence, BACE2 and BACE1 have distinct functions and transcriptional regulation. BACE2 is not a beta-secretase, but processes APP within the A beta domain at a site downstream of the alpha-secretase cleavage site. Our data argue against BACE2 being involved in the formation of neuritic plaques in AD.	Univ British Columbia, Dept Psychiat, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Grad Program Neurosci, Vancouver, BC V6T 1Z3, Canada; Sichuan Univ, W China Hosp, Dept Psychiat, Chengdu, Sichuan, Peoples R China; Sichuan Univ, W China Hosp, Dept Med Genet, Chengdu, Sichuan, Peoples R China; Sichuan Univ, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China	University of British Columbia; University of British Columbia; Sichuan University; Sichuan University; Sichuan University	Song, WH (corresponding author), Univ British Columbia, Dept Psychiat, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada.	weihong@interchange.ubc.ca	Song, Weihong/O-7623-2017	Song, Weihong/0000-0001-9928-889X; Tong, Yigang/0000-0002-8503-8045				Acquati F, 2000, FEBS LETT, V468, P59, DOI 10.1016/S0014-5793(00)01192-3; Andrau D, 2003, J BIOL CHEM, V278, P25859, DOI 10.1074/jbc.M302622200; Barath P, 2004, EUR J BIOCHEM, V271, P1781, DOI 10.1111/j.1432-1033.2004.04090.x; Basi G, 2003, J BIOL CHEM, V278, P31512, DOI 10.1074/jbc.M300169200; Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200; Busciglio J, 2002, NEURON, V33, P677, DOI 10.1016/S0896-6273(02)00604-9; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Charlwood J, 2001, J BIOL CHEM, V276, P16739, DOI 10.1074/jbc.M009361200; Christensen MA, 2004, MOL CELL BIOL, V24, P865, DOI 10.1128/MCB.24.2.865-874.2004; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DHooge R, 1996, NEUROREPORT, V7, P2807, DOI 10.1097/00001756-199611040-00080; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; Fluhrer R, 2002, J NEUROCHEM, V81, P1011, DOI 10.1046/j.1471-4159.2002.00908.x; Freiman RN, 2002, SCIENCE, V296, P2149, DOI 10.1126/science.1073845; Garcia-Martinez J, 2004, MOL CELL, V15, P303, DOI 10.1016/j.molcel.2004.06.004; Ge YW, 2004, FASEB J, V18, P1037, DOI 10.1096/fj.03-1379fje; Hussain I, 2000, MOL CELL NEUROSCI, V16, P609, DOI 10.1006/mcne.2000.0884; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kao SC, 2004, J BIOL CHEM, V279, P1942, DOI 10.1074/jbc.M309219200; Koistinaho M, 2001, P NATL ACAD SCI USA, V98, P14675, DOI 10.1073/pnas.261562998; Kosak ST, 2004, GENE DEV, V18, P1371, DOI 10.1101/gad.1209304; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; Li SH, 2002, MOL CELL BIOL, V22, P1277, DOI 10.1128/MCB.22.5.1277-1287.2002; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Loots GG, 2002, GENOME RES, V12, P832, DOI 10.1101/gr.225502; Loots GG, 2004, NUCLEIC ACIDS RES, V32, pW217, DOI 10.1093/nar/gkh383; Lott IT, 2001, MENT RETARD DEV D R, V7, P172, DOI 10.1002/mrdd.1025; Luo Y, 2003, NEUROBIOL DIS, V14, P81, DOI 10.1016/S0969-9961(03)00104-9; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Marcinkiewicz M, 2000, J NEUROCHEM, V75, P2133, DOI 10.1046/j.1471-4159.2000.0752133.x; Motonaga K, 2002, NEUROSCI LETT, V326, P64, DOI 10.1016/S0304-3940(02)00287-2; Murphy T, 2001, NEUROREPORT, V12, P631, DOI 10.1097/00001756-200103050-00040; Nowotny P, 2001, NEUROREPORT, V12, P1799, DOI 10.1097/00001756-200107030-00008; Ohno M, 2004, NEURON, V41, P27, DOI 10.1016/S0896-6273(03)00810-9; Osada S, 1997, J BIOCHEM, V121, P355; Ovcharenko I, 2004, GENOME RES, V14, P472, DOI 10.1101/gr.2129504; Parks CL, 1996, J BIOL CHEM, V271, P4417; Pham NL, 2004, ARTERIOSCL THROM VAS, V24, P982, DOI 10.1161/01.ATV.0000126679.70877.d0; PODLISNY MB, 1987, SCIENCE, V238, P669, DOI 10.1126/science.2960019; Przyborski SA, 2003, STEM CELLS, V21, P459; Qing H, 2004, FASEB J, V18, P1571, DOI 10.1096/fj.04-1994fje; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Ryu H, 2003, J NEUROSCI, V23, P3597; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Solans A, 2000, CYTOGENET CELL GENET, V89, P177, DOI 10.1159/000015608; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Sullivan AA, 2003, MOL ENDOCRINOL, V17, P2125, DOI 10.1210/me.2002-0430; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang GX, 2004, MOL GENET GENOMICS, V271, P468, DOI 10.1007/s00438-004-0998-4; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	56	107	115	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					739	749		10.1096/fj.04-3426com	http://dx.doi.org/10.1096/fj.04-3426com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15857888				2022-12-28	WOS:000229602600030
J	Hasturk, H; Kantarci, A; Ohira, T; Arita, M; Ebrahimi, N; Chiang, N; Petasis, NA; Levy, BD; Serhan, CN; Van Dyke, TE				Hasturk, H.; Kantarci, A.; Ohira, T.; Arita, M.; Ebrahimi, N.; Chiang, N.; Petasis, N. A.; Levy, B. D.; Serhan, C. N.; Van Dyke, T. E.			RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis	FASEB JOURNAL			English	Article									[Ohira, T.; Arita, M.; Chiang, N.; Levy, B. D.; Serhan, C. N.] Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; [Ohira, T.; Arita, M.; Chiang, N.; Levy, B. D.; Serhan, C. N.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Hasturk, H.; Kantarci, A.; Ebrahimi, N.; Van Dyke, T. E.] Boston Univ, Goldman Sch Dent Med, Dept Periodontol & Oral Biol, Boston, MA 02215 USA; [Petasis, N. A.] Univ So Calif, Dept Chem, Los Angeles, CA 90089 USA; [Levy, B. D.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Boston University; University of Southern California; Harvard University; Brigham & Women's Hospital	Serhan, CN (corresponding author), Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St, Boston, MA 02115 USA.	cnserhan@zeus.bwh.harvard.edu; tvandyke@bu.edu	Petasis, Nicos/B-3162-2009; Chiang, Nan/ABA-4924-2021	Petasis, Nicos/0000-0002-8864-4446; Chiang, Nan/0000-0003-1963-1585; Arita, Makoto/0000-0001-9902-0463	NCRR NIH HHS [RR-00533] Funding Source: Medline; NIDCR NIH HHS [DE-016191] Funding Source: Medline; NIGMS NIH HHS [GM-38765] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE016191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038765, R01GM038765, R37GM038765] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))			0	297	319	2	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					401	403		10.1096/fj.05-4724fje	http://dx.doi.org/10.1096/fj.05-4724fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16373400				2022-12-28	WOS:000207915000035
J	Yamashita, K; Ollinger, R; McDaid, J; Sakahama, H; Wang, HJ; Tyagi, S; Csizmadia, E; Smith, NR; Soares, MP; Bach, FH				Yamashita, Kenichiro; Oellinger, Robert; McDaid, James; Sakahama, Hideyasu; Wang, Hongjun; Tyagi, Shivraj; Csizmadia, Eva; Smith, Neal R.; Soares, Miguel P.; Bach, Fritz H.			Heme oxygenase-1 is essential for and promotes tolerance to transplanted organs	FASEB JOURNAL			English	Article						T regulatory cells (Tregs); co-stimulation	REGULATORY T-CELLS; CARBON-MONOXIDE; GRAFT-REJECTION; PROTECTIVE GENE; SUPPRESSES; OVEREXPRESSION; PREVENTS; DEATH; FAS; ARTERIOSCLEROSIS	This investigation focused on obtaining a further understanding of the role of heme oxygenase-1 (HO-1) in tolerance induction. Hearts from C57BL/6 (H-2(b)) mice survived long-term when transplanted into BALB/c (H-2(d)) recipients treated with the tolerance-inducing regimen of anti-CD40L antibody (MR-1) plus donor-specific transfusion (DST). Grafts did not, however, survive long-term in (HO-1(-/-)) recipients given the same treatment. Similarly, long-term survival induced by DST was ablated when HO-1 activity was blocked by zinc protoporphyrin IX (ZnPPIX). We further asked whether modulation of HO-1 expression/activity could be used to promote the induction of graft tolerance. DST alone (day 0) failed to promote any prolongation of survival of DBA/2 (H-2(d)) hearts transplanted into B6AF1 (H-2(b,k/d)) recipients. However, long-term survival and (dominant peripheral) tolerance were readily induced when DST was combined with induction of HO-1 expression by cobalt protoporphyrin IX (CoPPIX). HO-1 induction plus DST led to a significant up-regulation of Foxp3, TGF-beta, IL-10, and CTLA4, which suggests a prominent role for CD4+CD25+ regulatory T cells (Tregs). In fact, the tolerogenic effect of HO-1 plus DST was dependent on CD4+CD25+ Tregs as suggested by adoptively transferring these cells into irradiated recipients under various regimens. Taken together, these findings show that expression of HO-1 in a graft recipient can be essential for long-term graft survival and for induction of tolerance and that modulation of HO-1 expression/activity can be used therapeutically to synergize in the generation of graft tolerance.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Immunobiol Res Ctr,Dept Surg, Boston, MA 02215 USA; Univ Innsbruck, Dept Surg, Innsbruck, Austria; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA USA; Inst Culbenkian Ciencia, P-2781901 Oeiras, Portugal	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Innsbruck; Harvard University; Harvard Medical School; Massachusetts General Hospital	Bach, FH (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Immunobiol Res Ctr,Dept Surg, 99 Brookline Ave, Boston, MA 02215 USA.	fritz_bach@hms.harvard.edu	Öllinger, Robert/D-1538-2009; Soares, Miguel P/G-4188-2011; Wang, Hongjun/AAA-1319-2021	Soares, Miguel/0000-0002-9314-4833; Ollinger, Robert/0000-0002-4499-1673	NHLBI NIH HHS [HL67040, HL58688] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067040, R01HL058688] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Araujo JA, 2003, J IMMUNOL, V171, P1572, DOI 10.4049/jimmunol.171.3.1572; Baan C, 2004, AM J TRANSPLANT, V4, P811, DOI 10.1111/j.1600-6143.2004.00420.x; Bach FH, 1997, NAT MED, V3, P944, DOI 10.1038/nm0997-944; BACH FH, IN PRESS FASEB J; Bachas C, 1997, GAUGE THEORIES, APPLIED SUPERSYMMETRY AND QUANTUM GRAVITY II, P3; Bouchet D, 2002, TRANSPL IMMUNOL, V9, P235, DOI 10.1016/S0966-3274(02)00037-0; Braudeau C, 2004, GENE THER, V11, P701, DOI 10.1038/sj.gt.3302208; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Bushell A, 2005, J IMMUNOL, V174, P3290, DOI 10.4049/jimmunol.174.6.3290; Camara NOS, 2005, FREE RADICAL BIO MED, V38, P426, DOI 10.1016/j.freeradbiomed.2004.11.019; Chauveau C, 2002, AM J TRANSPLANT, V2, P581, DOI 10.1034/j.1600-6143.2002.20702.x; CHAUVEAU C, 2005, BLOOD; Choi BM, 2004, FREE RADICAL BIO MED, V36, P858, DOI 10.1016/j.freeradbiomed.2004.01.004; Exner M, 2004, TRANSPLANTATION, V77, P538, DOI 10.1097/01.TP.0000113467.36269.F8; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Graca L, 2005, TRENDS IMMUNOL, V26, P130, DOI 10.1016/j.it.2004.12.007; Green DR, 2003, IMMUNOL REV, V193, P70, DOI 10.1034/j.1600-065X.2003.00051.x; Hancock WW, 1998, NAT MED, V4, P1392, DOI 10.1038/3982; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Katori M, 2002, TRANSPLANTATION, V74, P905, DOI 10.1097/00007890-200210150-00001; Kingsley CI, 2002, J IMMUNOL, V168, P1080, DOI 10.4049/jimmunol.168.3.1080; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Lechler RI, 2005, NAT MED, V11, P605, DOI 10.1038/nm1251; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; McDaid J, 2005, FASEB J, V19, P458, DOI 10.1096/fj.04-2217fje; Nikolic B, 1996, J HEART LUNG TRANSPL, V15, P1171; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; Pae HO, 2004, J IMMUNOL, V172, P4744, DOI 10.4049/jimmunol.172.8.4744; Pae HO, 2004, MOL PHARMACOL, V66, P122, DOI 10.1124/mol.66.1.122; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; Roelen D, 2004, TRANSPLANTATION, V77, pS26, DOI 10.1097/01.TP.0000106469.12073.01; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; Soares MP, 1999, IMMUNOL TODAY, V20, P434, DOI 10.1016/S0167-5699(99)01530-3; Soares MP, 2001, IMMUNOL REV, V184, P275, DOI 10.1034/j.1600-065x.2001.1840124.x; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; VanParijs L, 1996, IMMUNITY, V4, P321, DOI 10.1016/S1074-7613(00)80440-9; Yamashita K, 2004, FASEB J, V18, P765, DOI 10.1096/fj.03-0839fje; Yet SF, 1999, J CLIN INVEST, V103, pR23, DOI 10.1172/JCI6163	43	92	101	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					776	+		10.1096/fj.05-4791fje	http://dx.doi.org/10.1096/fj.05-4791fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16473885				2022-12-28	WOS:000237698700023
J	Niculescu, MD; Craciunescu, CN; Zeisel, SH				Niculescu, MD; Craciunescu, CN; Zeisel, SH			Dietary choline deficiency alters global and gene-specific DNA methylation in the developing hippocampus of mouse fetal brains	FASEB JOURNAL			English	Article						Cdkn3; Kap; Cdkn2b; p15(INK4b); Calb2; calretinin; fetal brain; DNA methylation; choline deficiency; hippocampus	DEPENDENT KINASE INHIBITORS; SPATIAL MEMORY; AVAILABILITY ALTERS; RAT-BRAIN; SUPPLEMENTATION; LOCALIZATION; EXPRESSION; APOPTOSIS; CELLS; INACTIVATION	The availability of choline during critical periods of fetal development alters hippocampal development and affects memory function throughout life. Choline deficiency during fetal development reduces proliferation and migration of neuronal precursor cells in the mouse fetal hippocampus and these changes are associated with modifications in the protein levels of some cell cycle regulators and early differentiation markers. We fed C57 BL/6 mouse dams diets deficient or normal in choline content from days 12 to 17 of pregnancy, and then collected fetal brains on embryonic day 17. Using laser-capture micro-dissection we harvested cells from the ventricular and subventricular zones of Ammon's horn and from the prime germinal zone of the dentate gyrus (hippocampus). In the ventricular and subventricular zones from the choline-deficient group, we observed increased protein levels for kinase-associated phosphatase (Kap) and for p15(INK4b) (two cell cycle inhibitors). In the dentate gyrus, we observed increased levels of calretinin (an early marker of neuronal differentiation). In fetal brain from mothers fed a choline-deficient diet, DNA global methylation was decreased in the ventricular and subventricular zones of Ammon's horn. We also observed decreased gene-specific DNA methylation of the gene (Cdkn3) that encodes for Kap, correlating with increased expression of this protein. This was not the case for p15INK4b or calretinin (Cdkn2b and Calb2, respectively). These data suggest that choline deficiency-induced changes in gene methylation could mediate the expression of a cell cycle regulator and thereby alter brain development.	Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Zeisel, SH (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA.	steven_zeisel@unc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055865, P30DK056350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126, R21ES012997] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER; NIA NIH HHS [AG09525, P01 AG009525] Funding Source: Medline; NIDDK NIH HHS [P30 DK056350, DK56350, R01 DK055865, DK55865] Funding Source: Medline; NIEHS NIH HHS [ES10126, R21 ES012997, P30 ES010126, ES012997] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Albright CD, 1999, DEV BRAIN RES, V115, P123, DOI 10.1016/S0165-3806(99)00057-7; Albright CD, 2003, NUTR NEUROSCI, V6, P129, DOI 10.1080/1028415031000084418; Albright CD, 1998, NEUROCHEM RES, V23, P751, DOI 10.1023/A:1022411510636; Albright CD, 2001, DEV NEUROSCI-BASEL, V23, P100, DOI 10.1159/000048701; Albright CD, 1999, DEV BRAIN RES, V113, P13, DOI 10.1016/S0165-3806(98)00183-7; ALTMAN J, 1990, J COMP NEUROL, V301, P365, DOI 10.1002/cne.903010304; Brandner C, 2002, BRAIN RES, V928, P85, DOI 10.1016/S0006-8993(01)03363-7; Brandt MD, 2003, MOL CELL NEUROSCI, V24, P603, DOI 10.1016/S1044-7431(03)00207-0; Cooney CA, 2002, J NUTR, V132, p2393S; Craciunescu CN, 2003, J NUTR, V133, P3614, DOI 10.1093/jn/133.11.3614; Davies TG, 2002, PHARMACOL THERAPEUT, V93, P125, DOI 10.1016/S0163-7258(02)00182-1; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Finkelstein JD, 2000, SEMIN THROMB HEMOST, V26, P219, DOI 10.1055/s-2000-8466; Hamilton DW, 2005, CANCER LETT, V227, P75, DOI 10.1016/j.canlet.2004.11.044; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; Holmes GL, 2002, EPILEPSY RES, V48, P3, DOI 10.1016/S0920-1211(01)00321-7; Institute of Medicine, 1998, DIET REF INT THIAM R, P390, DOI [DOI 10.17226/6015, 10.17226/6015]; Jacobowitz D, 1997, CHEMOARCHITECTONIC A; Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; Meck WH, 1997, NEUROREPORT, V8, P3053, DOI 10.1097/00001756-199709290-00010; Meck WH, 2003, NEUROSCI BIOBEHAV R, V27, P385, DOI 10.1016/S0149-7634(03)00069-1; Niculescu MD, 2005, MOL BRAIN RES, V134, P309, DOI 10.1016/j.molbrainres.2004.11.001; Niculescu MD, 2004, J NEUROCHEM, V89, P1252, DOI 10.1111/j.1471-4159.2004.02414.x; REZNIKOV KY, 1991, ADV ANAT EMBRYOL CEL, V122, P1; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; RODIER PM, 1980, DEV MED CHILD NEUROL, V22, P525; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Xu XL, 2001, CANCER RES, V61, P7943; Yang XY, 2000, BIOSCIENCE REP, V20, P1, DOI 10.1023/A:1005556715479; Yen CLE, 2002, J NUTR, V132, P1840, DOI 10.1093/jn/132.7.1840; Yen CLE, 2001, FASEB J, V15, P1704, DOI 10.1096/fj.00-0800com; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413	36	232	244	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					43	49		10.1096/fj.05-4707com	http://dx.doi.org/10.1096/fj.05-4707com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16394266	Green Accepted, Green Submitted			2022-12-28	WOS:000235996000043
J	Baufreton, J; Zhu, ZT; Garret, M; Bioulac, B; Johnson, SW; Taupignon, AI				Baufreton, J; Zhu, ZT; Garret, M; Bioulac, B; Johnson, SW; Taupignon, AI			Dopamine receptors set the pattern of activity generated in subthalamic neurons	FASEB JOURNAL			English	Article						subthalamic nucleus; slow-wave sleep; burst-firing; basal ganglia	ACTION-POTENTIAL GENERATION; IN-VITRO; PARKINSONS-DISEASE; NUCLEUS NEURONS; BASAL GANGLIA; FUNCTIONAL-ANATOMY; CYTOPLASMIC TAIL; GLOBUS-PALLIDUS; FIRING RATES; C-FOS	Information processing in the brain requires adequate background neuronal activity. As Parkinson's disease progresses, patients typically become akinetic; the death of dopaminergic neurons leads to a dopamine-depleted state, which disrupts information processing related to movement in a brain area called the basal ganglia. Using agonists of dopamine receptors in the D1 and D2 families on rat brain slices, we show that dopamine receptors in these two families govern the firing pattern of neurons in the subthalamic nucleus, a crucial part of the basal ganglia. We propose a conceptual frame, based on specific properties of dopamine receptors, to account for the dominance of different background firing patterns in normal and dopamine-depleted states.	Univ Victor Segalen, UMR 5543, F-33076 Bordeaux, France; Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL 60611 USA; Oregon Hlth Sci Univ, Dept Physiol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Pharmacol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA	UDICE-French Research Universities; Universite de Bordeaux; Northwestern University; Feinberg School of Medicine; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Taupignon, AI (corresponding author), Univ Victor Segalen, UMR 5543, 146 Rue Saignat, F-33076 Bordeaux, France.	anne.taupignon@umr5543.u-bordeaux2.fr		Taupignon, Anne/0000-0002-4662-7971; Baufreton, Jerome/0000-0002-2623-6375	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038715] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38715] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; Awad H, 2000, J NEUROSCI, V20, P7871; Baufreton J, 2001, J NEUROPHYSIOL, V86, P75, DOI 10.1152/jn.2001.86.1.75; Baufreton J, 2003, J NEUROSCI, V23, P816; Benedetti F, 2004, NAT NEUROSCI, V7, P587, DOI 10.1038/nn1250; BERGMAN H, 1994, J NEUROPHYSIOL, V72, P507, DOI 10.1152/jn.1994.72.2.507; Beurrier C, 1999, J NEUROSCI, V19, P599, DOI 10.1523/jneurosci.19-02-00599.1999; Bevan MD, 2002, J NEUROPHYSIOL, V87, P1348, DOI 10.1152/jn.00582.2001; Bevan MD, 2000, J NEUROPHYSIOL, V83, P3169, DOI 10.1152/jn.2000.83.5.3169; Bezard E, 2001, J NEUROSCI, V21, P6853, DOI 10.1523/JNEUROSCI.21-17-06853.2001; BROWN LL, 1979, SCIENCE, V206, P1416, DOI 10.1126/science.505015; Cragg SJ, 2004, EUR J NEUROSCI, V20, P1788, DOI 10.1111/j.1460-9568.2004.03629.x; CROSSMAN AR, 1990, MOVEMENT DISORD, V5, P100, DOI 10.1002/mds.870050203; Demchyshyn LL, 2000, J BIOL CHEM, V275, P23446, DOI 10.1074/jbc.M000157200; Do MTH, 2003, NEURON, V39, P109, DOI 10.1016/S0896-6273(03)00360-X; Eggermont JJ, 1998, NEUROSCI BIOBEHAV R, V22, P355, DOI 10.1016/S0149-7634(97)00021-3; Feger J, 1997, ADV NEUROL, V74, P31; Francois C, 2000, J COMP NEUROL, V425, P121, DOI 10.1002/1096-9861(20000911)425:1<121::AID-CNE10>3.0.CO;2-G; Hallworth NE, 2003, J NEUROSCI, V23, P7525; Hartings JA, 2003, J NEUROSCI, V23, P5264; Hassani OK, 1999, NEUROSCIENCE, V92, P533, DOI 10.1016/S0306-4522(98)00765-9; Hassani OK, 1997, BRAIN RES, V749, P88, DOI 10.1016/S0006-8993(96)01167-5; Hassani OK, 1996, NEUROSCIENCE, V72, P105, DOI 10.1016/0306-4522(95)00535-8; HOLLERMAN JR, 1992, BRAIN RES, V590, P291, DOI 10.1016/0006-8993(92)91108-Q; Hutchison WD, 2004, J NEUROSCI, V24, P9240, DOI 10.1523/JNEUROSCI.3366-04.2004; Jackson A, 2000, FEBS LETT, V470, P183, DOI 10.1016/S0014-5793(00)01315-6; Krack P, 1999, BRAIN, V122, P1133, DOI 10.1093/brain/122.6.1133; Krahe R, 2004, NAT REV NEUROSCI, V5, P13, DOI 10.1038/nrn1296; Kreiss DS, 1996, NEUROSCIENCE, V72, P863, DOI 10.1016/0306-4522(95)00583-8; Kreiss DS, 1997, J NEUROSCI, V17, P6807; Levy R, 2002, J NEUROSCI, V22, P2855, DOI 10.1523/JNEUROSCI.22-07-02855.2002; Lisman JE, 1997, TRENDS NEUROSCI, V20, P38, DOI 10.1016/S0166-2236(96)10070-9; Magill PJ, 2001, NEUROSCIENCE, V106, P313, DOI 10.1016/S0306-4522(01)00281-0; Marino MJ, 2002, NEUROPHARMACOLOGY, V43, P147, DOI 10.1016/S0028-3908(02)00097-7; McCormick DA, 2001, ANNU REV PHYSIOL, V63, P815, DOI 10.1146/annurev.physiol.63.1.815; Mehta A, 2000, SYNAPSE, V37, P298, DOI 10.1002/1098-2396(20000915)37:4<298::AID-SYN7>3.0.CO;2-A; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; NAKANISHI H, 1987, BRAIN RES, V437, P35, DOI 10.1016/0006-8993(87)91524-1; Ni ZG, 2001, BRAIN RES, V899, P142, DOI 10.1016/S0006-8993(01)02219-3; Nutt JG, 2001, NEUROLOGY, V57, P1835, DOI 10.1212/WNL.57.10.1835; Otsuka T, 2001, J NEUROPHYSIOL, V86, P1816, DOI 10.1152/jn.2001.86.4.1816; OVERTON PG, 1995, J NEURAL TRANSM-PARK, V10, P41, DOI 10.1007/BF02256628; PARENT A, 1995, BRAIN RES REV, V20, P128, DOI 10.1016/0165-0173(94)00008-D; Sherman SM, 2001, TRENDS NEUROSCI, V24, P122, DOI 10.1016/S0166-2236(00)01714-8; Song WJ, 2000, J NEUROPHYSIOL, V84, P2630, DOI 10.1152/jn.2000.84.5.2630; Steriade M, 2000, NEUROSCIENCE, V101, P243, DOI 10.1016/S0306-4522(00)00353-5; Steriade M, 2001, NAT NEUROSCI, V4, P671, DOI 10.1038/89434; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; Svenningsson P, 2002, EUR J NEUROSCI, V15, P133, DOI 10.1046/j.0953-816x.2001.01840.x; TIBERI M, 1994, J BIOL CHEM, V269, P27925; Tumova K, 2003, J BIOL CHEM, V278, P8146, DOI 10.1074/jbc.M208059200; Urbain N, 2002, J NEUROSCI, V22, P8665; Urbain N, 2004, EUR J NEUROSCI, V20, P392, DOI 10.1111/j.1460-9568.2004.03488.x; Wichmann T, 2003, ANN NY ACAD SCI, V991, P199, DOI 10.1111/j.1749-6632.2003.tb07477.x; Zhu ZT, 2002, NEUROPHARMACOLOGY, V42, P772, DOI 10.1016/S0028-3908(02)00035-7; Zhu ZT, 2004, EUR J NEUROSCI, V19, P1296, DOI 10.1111/j.1460-9568.2004.03240.x	56	47	47	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					1771	1777		10.1096/fj.04-3401hyp	http://dx.doi.org/10.1096/fj.04-3401hyp			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16260646				2022-12-28	WOS:000234053100028
J	Kitamura, S; Yamasaki, Y; Kinomura, M; Sugaya, T; Sugiyama, H; Maeshima, Y; Makino, H				Kitamura, S; Yamasaki, Y; Kinomura, M; Sugaya, T; Sugiyama, H; Maeshima, Y; Makino, H			Establishment and characterization of renal progenitor like cells from S3 segment of nephron in rat adult kidney	FASEB JOURNAL			English	Article						S3 segment of proximal tubules; renal tubular epithelial cells; renal progenitor-like cell	HEMATOPOIETIC STEM-CELLS; BONE-MARROW CELLS; REGENERATION; EXPRESSION; PROLIFERATION; DIFFERENTIATE; CONTRIBUTE; ISCHEMIA; MARKERS	Kidney is thought to be a regenerative organ in terms of repair from acute tubular injury. It is unknown whether cell population contributes to repair disordered kidney. We attempted to identify and isolate highly proliferative cells from a single cell. We dissected a single nephron from adult rat kidney. Isolated nephrons were separated into segments and cultured. Outgrowing cells were replated after limiting dilution so that each well contained a single cell. One of cell line which was the most potent to grow was designated as rKS56. rKS56 cells showed cobblestone appearance and expressed immature cell markers relating to kidney development and mature tubular cell markers. rKS56 cells grew exponentially and could be maintained for 300 days without transformation. In different culture conditions, rKS56 cells differentiated into mature tubular cells defined by aquaporin-1, 2 expression, and responsiveness to parathyroid hormone or vasopressin. Engrafted to kidney in rat ischemic reperfusion model, rKS56 cells replaced in injured tubules in part after implantation and improved renal function. These results suggest rKS56 cells possess character such as self-renewal, multi-plasticity and capability of tissue repair. rKS56 may possibly contribute to the future development of cell therapy for renal regeneration.	Okayama Univ, Grad Sch Med, Dept Med & Clin Sci, Okayama 7008558, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 305, Japan; Tokyo Dent Coll, Corneal Transplant Ctr, Chiba, Japan	Okayama University; University of Tsukuba; Tokyo Dental College	Makino, H (corresponding author), Okayama Univ, Grad Sch Med, Dept Med & Clin Sci, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	makino@md.okayama-u.ac.jp	Sugiyama, Hitoshi/B-2252-2011	Sugiyama, Hitoshi/0000-0002-4127-6471				Al-Awqati Q, 2002, KIDNEY INT, V61, P387, DOI 10.1046/j.1523-1755.2002.00164.x; Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Cha JH, 2001, J AM SOC NEPHROL, V12, P1410, DOI 10.1681/ASN.V1271410; Clarke RB, 2003, CELL PROLIFERAT, V36, P1, DOI 10.1046/j.1365-2184.36.s.1.1.x; Cornacchia F, 2001, J CLIN INVEST, V108, P1649; Dekel B, 2003, NAT MED, V9, P53, DOI 10.1038/nm812; Disashi T, 1997, HYPERTENSION, V30, P1591, DOI 10.1161/01.HYP.30.6.1591; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Fuchs E, 2000, CELL, V100, P143, DOI 10.1016/S0092-8674(00)81691-8; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Imgrund M, 1999, KIDNEY INT, V56, P1423, DOI 10.1046/j.1523-1755.1999.00663.x; Ito T, 2001, J AM SOC NEPHROL, V12, P2625, DOI 10.1681/ASN.V12122625; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kale S, 2003, J CLIN INVEST, V112, P42, DOI 10.1172/JCI200317856; Kayahara T, 2003, FEBS LETT, V535, P131, DOI 10.1016/S0014-5793(02)03896-6; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Lavker RM, 2000, P NATL ACAD SCI USA, V97, P13473, DOI 10.1073/pnas.250380097; Lin FM, 2003, J AM SOC NEPHROL, V14, P1188, DOI 10.1097/01.ASN.0000061595.28546.A0; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Maeshima Y, 1998, J CLIN INVEST, V101, P2589, DOI 10.1172/JCI429; Makino H, 1996, DIABETES, V45, P488, DOI 10.2337/diabetes.45.4.488; NAKAMURA M, 1994, NEURON, V13, P67, DOI 10.1016/0896-6273(94)90460-X; Nakauchi Hiromitsu, 2004, Cornea, V23, pS2, DOI 10.1097/01.ico.0000136664.18129.4f; NATH KA, 1992, AM J KIDNEY DIS, V20, P1; Okamoto R, 2002, NAT MED, V8, P1011, DOI 10.1038/nm755; Oliver JA, 2002, AM J PHYSIOL-RENAL, V283, pF799, DOI 10.1152/ajprenal.00375.2001; Oliver JA, 2004, J CLIN INVEST, V114, P795, DOI 10.1172/JCI200420921; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Potten CS, 2003, DIFFERENTIATION, V71, P28, DOI 10.1046/j.1432-0436.2003.700603.x; Poulsom R, 2001, J PATHOL, V195, P229, DOI 10.1002/path.976; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; Rietze RL, 2001, NATURE, V412, P736, DOI 10.1038/35089085; Schwartz RE, 2002, J CLIN INVEST, V109, P1291, DOI 10.1172/JCI200215182; Sherley James L, 2002, ScientificWorldJournal, V2, P1906; Taniguchi H, 1996, NAT MED, V2, P198, DOI 10.1038/nm0296-198; Tateishi-Yuyama E, 2002, LANCET, V360, P427, DOI 10.1016/S0140-6736(02)09670-8; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Valerius MT, 2002, P NATL ACAD SCI USA, V99, P8090, DOI 10.1073/pnas.122229199; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X	41	145	165	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					1789	1797		10.1096/fj.05-3942com	http://dx.doi.org/10.1096/fj.05-3942com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16260649				2022-12-28	WOS:000234053100031
J	Tanneur, V; Duranton, C; Brand, VB; Sandu, CD; Akkaya, C; Kasinathan, RS; Gachet, C; Sluyter, R; Barden, JA; Wiley, JS; Lang, F; Huber, SM				Tanneur, V; Duranton, C; Brand, VB; Sandu, CD; Akkaya, C; Kasinathan, RS; Gachet, C; Sluyter, R; Barden, JA; Wiley, JS; Lang, F; Huber, SM			Purinoceptors are involved in the induction of an osmolyte permeability in malaria-infected and oxidized human erythrocytes	FASEB JOURNAL			English	Article						purinergic receptors; ATP release; oxidative stress; new permeability pathways; red blood cells	RED-BLOOD-CELLS; ANION CHANNEL; P2Y(1) RECEPTORS; ATP RELEASE; PLASMODIUM; PATHWAYS; PARASITE; MEMBRANE; MECHANISM; DEFORMATION	In human erythrocytes, infection by the malaria parasite Plasmodium falciparum or oxidative stress induces a new organic osmolyte and anion permeability. To examine a role for autocrine purinoceptor signaling during this induction process, erythrocytic purinoceptor expression, and ATP release were determined. Furthermore, using pharmacological and genetic approaches the dependence on purinoceptor signaling of osmolyte permeability and Plasmodium development, both in vitro and in vivo, were assessed. Extracellular ATP did not induce an osmolyte permeability in non-infected or non-oxidized erythrocytes. ATP and other purinoceptor agonists increased the induction of osmolyte permeability during infection or oxidation as measured by isosmotic hemolysis and patch-clamp recording. Purinoceptor antagonists and apyrase decreased the induced permeability. The observed pharmacology suggested the involvement of P2Y purinoceptors. Accordingly, human erythrocytes expressed P2Y(1) protein. Moreover, P2Y(1)-deficient mouse erythrocytes exhibited a delayed appearance of the osmolyte permeability during P. berghei infection-or oxidation compared with wild-type erythrocytes. Furthermore, the nonspecific purinoceptor antagonist suramin decreased in vitro growth and DNA/RNA amplification of P. falciparum in human erythrocytes and decreased in vivo growth of P. berghei. P. berghei developed slower in P2Y(1)-deficient mice in vivo compared with wild-type animals. In conclusion, induction of the osmolyte permeability in Plasmodium-infected erythrocytes involves autocrine purinoceptor signaling.	Univ Tubingen, Dept Physiol 1, D-72076 Tubingen, Germany; INSERM, U 311, Strasbourg, France; Univ Sydney, Nepean Hosp, Dept Med, Penrith, NSW, Australia; Univ Sydney, Dept Anat & Histol, Sydney, NSW 2006, Australia	Eberhard Karls University of Tubingen; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Nepean Hospital; University of Sydney; University of Sydney	Huber, SM (corresponding author), Univ Tubingen, Dept Physiol 1, Gmelinstr 5, D-72076 Tubingen, Germany.	stephan.huber@uni-tuebingen.de	Kasinathan, Ravi/B-7657-2013; DURANTON, CHRISTOPHE/E-9582-2019; Gachet, Christian/H-9156-2016; Sluyter, Ronald/B-5798-2009	DURANTON, CHRISTOPHE/0000-0003-1127-2346; Sluyter, Ronald/0000-0003-4909-686X; Wiley, James/0000-0001-9421-4154; Huber, Stephan/0000-0002-9430-8334				Alkhalil A, 2004, BLOOD, V104, P4279, DOI 10.1182/blood-2004-05-2047; Baumeister S, 2003, MOL BIOCHEM PARASIT, V132, P35, DOI 10.1016/j.molbiopara.2003.08.003; BERGFELD GR, 1992, CARDIOVASC RES, V26, P40, DOI 10.1093/cvr/26.1.40; Boyer JL, 1998, BRIT J PHARMACOL, V124, P1, DOI 10.1038/sj.bjp.0701837; Braunstein GM, 2001, J BIOL CHEM, V276, P6621, DOI 10.1074/jbc.M005893200; BREUER WV, 1987, J CELL PHYSIOL, V133, P55, DOI 10.1002/jcp.1041330107; Brugnara C, 1997, Curr Opin Hematol, V4, P122; Desai SA, 2000, NATURE, V406, P1001, DOI 10.1038/35023000; Desai SA, 2005, J BIOL CHEM, V280, P16861, DOI 10.1074/jbc.M414629200; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Duranton C, 2004, J GEN PHYSIOL, V123, P417, DOI 10.1085/jgp.200308919; Duranton C, 2003, CELL PHYSIOL BIOCHEM, V13, P189, DOI 10.1159/000072421; Egee S, 2002, J PHYSIOL-LONDON, V542, P795, DOI 10.1113/jphysiol.2002.022970; Fleck SL, 2003, J BIOL CHEM, V278, P47670, DOI 10.1074/jbc.M306603200; Fong AY, 2002, NEUROSCIENCE, V113, P809, DOI 10.1016/S0306-4522(02)00237-3; Ginsburg H, 2004, J MEMBRANE BIOL, V197, P113, DOI 10.1007/s00232-003-0646-7; GINSBURG H, 1983, MOL BIOCHEM PARASIT, V8, P177, DOI 10.1016/0166-6851(83)90008-7; GINSBURG H, 1994, PARASITE, V1, P5, DOI 10.1051/parasite/1994011005; Hoffman JF, 2004, P NATL ACAD SCI USA, V101, P12370, DOI 10.1073/pnas.0404228101; Huber SM, 2005, INT REV CYTOL, V246, P59, DOI 10.1016/S0074-7696(05)46003-9; Huber SM, 2004, J BIOL CHEM, V279, P41444, DOI 10.1074/jbc.M407618200; Huber SM, 2002, EMBO J, V21, P22, DOI 10.1093/emboj/21.1.22; Kirk K, 2001, PHYSIOL REV, V81, P495, DOI 10.1152/physrev.2001.81.2.495; KIRK K, 1995, J BIOL CHEM, V270, P24270, DOI 10.1074/jbc.270.41.24270; Kisilevsky R, 2002, ANTIMICROB AGENTS CH, V46, P2619, DOI 10.1128/AAC.46.8.2619-2626.2002; Knofler R, 1997, AM J HEMATOL, V56, P259, DOI 10.1002/(SICI)1096-8652(199712)56:4<259::AID-AJH11>3.0.CO;2-4; Lambert IH, 2004, NEUROCHEM RES, V29, P27, DOI 10.1023/B:NERE.0000010433.08577.96; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Leon C, 1999, J CLIN INVEST, V104, P1731, DOI 10.1172/JCI8399; Light DB, 2001, J MEMBRANE BIOL, V182, P193, DOI 10.1007/s0023201-0043-z; Mitchell CH, 1998, P NATL ACAD SCI USA, V95, P7174, DOI 10.1073/pnas.95.12.7174; Olearczyk J J, 2001, Med Sci Monit, V7, P669; Palmer RK, 1998, MOL PHARMACOL, V54, P1118, DOI 10.1124/mol.54.6.1118; Pedersen S, 1999, BBA-BIOMEMBRANES, V1416, P271, DOI 10.1016/S0005-2736(98)00228-4; Pitt SJ, 2005, MOL PHARMACOL, V67, P1705, DOI 10.1124/mol.104.009902; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rubino A, 1999, EUR J PHARMACOL, V370, P139, DOI 10.1016/S0014-2999(99)00150-8; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Sherman IW, 2004, CELL MOL BIOL, V50, P159; Sluyter R, 2004, J BIOL CHEM, V279, P44749, DOI 10.1074/jbc.M405631200; Sprague RS, 2001, AM J PHYSIOL-CELL PH, V281, pC1158, DOI 10.1152/ajpcell.2001.281.4.C1158; Sprague RS, 1998, AM J PHYSIOL-HEART C, V275, pH1726, DOI 10.1152/ajpheart.1998.275.5.H1726; Staines HM, 2003, J PHYSIOL-LONDON, V552, P177, DOI 10.1113/jphysiol.2003.051169; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; TRAMS EG, 1980, J THEOR BIOL, V87, P609, DOI 10.1016/0022-5193(80)90239-8; UHLEMANN AC, 2000, MACS MORE, V4, P7; von Kugelgen I, 2000, N-S ARCH PHARMACOL, V362, P310, DOI 10.1007/s002100000310; Zhang YL, 1998, J BIOL CHEM, V273, P12281, DOI 10.1074/jbc.273.20.12281	48	62	63	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					133	+		10.1096/fj.04-3371fje	http://dx.doi.org/10.1096/fj.04-3371fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16267125				2022-12-28	WOS:000234053100019
J	Dluzniewska, J; Sarnowska, A; Beresewicz, M; Johnson, I; Srai, SKS; Ramesh, B; Goldspink, G; Gorecki, DC; Zablocka, B				Dluzniewska, J; Sarnowska, A; Beresewicz, M; Johnson, I; Srai, SKS; Ramesh, B; Goldspink, G; Gorecki, DC; Zablocka, B			A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia	FASEB JOURNAL			English	Article						hippocampus; stroke; insulin-like growth factor 1; mechano-growth factor	GROWTH-FACTOR-I; CEREBRAL-ARTERY OCCLUSION; SKELETAL-MUSCLE; SPLICE VARIANTS; NEURONAL DEATH; GERBIL HIPPOCAMPUS; FOREBRAIN ISCHEMIA; HYPOXIA-ISCHEMIA; CELL-DEATH; EXPRESSION	The ischemic stroke is the third leading cause of death in developed countries. The C-terminal peptide of mechano-growth factor (MGF), an alternatively spliced variant of insulin-like growth factor 1 (IGF-1), was found to function independently from the rest of the molecule and showed a neuroprotective effect in vivo and in vitro. In vivo, in a gerbil model of transient brain ischemia, treatment with the synthetic MGF C-terminal peptide provided very significant protection to the vulnerable neurons. In the same model, ischemia evoked increased expression of endogenous MGF in the ischemia-resistant hippocampal neurons, suggesting that the endogenous MGF might have an important neuroprotective function. In an in vitro organotypic hippocampal culture model of neurodegeneration, the synthetic peptide was as potent as the full-length IGF-1 while its effect lasted significantly longer than that of recombinant IGF-1. While two peptides showed an additive effect, the neuroprotective action of the C-terminal MGF was independent from the IGF-1 receptor, indicating a new mode of action for this molecule. Although MGF is known for its regenerative capability in skeletal muscle, our findings demonstrate for the first time a neuroprotective role against ischemia for this specific IGF-1 isoform. Therefore, the C-terminal MGF peptide has a potential to be developed into a therapeutic modality for the prevention of neuronal damage.	Univ Portsmouth, Sch Pharm & Biomed Sci, Inst Biomed & Biomol Sci, Portsmouth PO1 2DT, Hants, England; Polish Acad Sci, Med Res Ctr, Mol Biol Unit, PL-02106 Warsaw, Poland; Polish Acad Sci, Med Res Ctr, Dept Neurorepair, PL-02106 Warsaw, Poland; UCL Royal Free & Univ Coll Med Sch, Dept Anat, London, England; UCL Royal Free & Univ Coll Med Sch, Dept Biochem & Mol Biol, London, England; UCL Royal Free & Univ Coll Med Sch, Dept Surg, Mol Tissue Repair Unit, London, England	University of Portsmouth; Polish Academy of Sciences; Polish Academy of Sciences; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School	Gorecki, DC (corresponding author), Univ Portsmouth, Sch Pharm & Biomed Sci, Inst Biomed & Biomol Sci, St Michaels Bldg,White Swan Rd, Portsmouth PO1 2DT, Hants, England.	darek.gorecki@port.ac.uk; zablocka@cmdik.pan.pl	Srai, Surjit K/C-5575-2009; Beresewicz Haller, Malgorzata/AAG-2147-2020; Srai, Kaila/AAE-7039-2021	Beresewicz Haller, Malgorzata/0000-0002-2204-5184; Johnson, Ian/0000-0001-5951-6990; Zablocka, Barbara/0000-0003-3116-7295	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aperghis M, 2004, BRAIN RES, V1009, P213, DOI 10.1016/j.brainres.2004.02.049; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Cheng CM, 2003, J NEUROSCI RES, V73, P1, DOI 10.1002/jnr.10634; DELBARRE G, 1991, J OCUL PHARMACOL, V7, P147, DOI 10.1089/jop.1991.7.147; DErcole AJ, 1996, MOL NEUROBIOL, V13, P227, DOI 10.1007/BF02740625; Dews M, 2000, ENDOCRINOLOGY, V141, P1289, DOI 10.1210/en.141.4.1289; Domanska-Janik K, 2004, MOL BRAIN RES, V121, P50, DOI 10.1016/j.molbrainres.2003.11.006; Fukudome Y, 2003, EUR J NEUROSCI, V17, P2006, DOI 10.1046/j.1460-9568.2003.02640.x; Garnier P, 2004, EUR J NEUROSCI, V20, P937, DOI 10.1111/j.1460-9568.2004.03551.x; Gleichmann M, 2000, NEUROSCI LETT, V282, P69, DOI 10.1016/S0304-3940(00)00857-0; Gorecki DC, 1999, MOL CELL NEUROSCI, V13, P218, DOI 10.1006/mcne.1999.0740; Guan J, 2000, J CEREBR BLOOD F MET, V20, P513, DOI 10.1097/00004647-200003000-00010; Guan J, 2001, NEUROSCIENCE, V105, P299, DOI 10.1016/S0306-4522(01)00145-2; Hameed M, 2003, J PHYSIOL-LONDON, V547, P247, DOI 10.1113/jphysiol.2002.032136; Hill M, 2003, J PHYSIOL-LONDON, V549, P409, DOI 10.1113/jphysiol.2002.035832; Hwang IK, 2004, NEUROCHEM INT, V45, P149, DOI 10.1016/j.neuint.2003.10.006; Ito Y, 2003, BRAIN RES, V985, P98, DOI 10.1016/S0006-8993(03)03173-1; Kaspar BK, 2003, SCIENCE, V301, P839, DOI 10.1126/science.1086137; Kawano T, 2001, J CEREBR BLOOD F MET, V21, P1268, DOI 10.1097/00004647-200111000-00003; Kroll RA, 1998, NEUROSURGERY, V42, P1083, DOI 10.1097/00006123-199805000-00082; LIPTON P, 1995, J NEUROSCI METH, V59, P151, DOI 10.1016/0165-0270(94)00205-U; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Liu XF, 2001, NEUROSCI LETT, V308, P91, DOI 10.1016/S0304-3940(01)01982-6; McKoy G, 1999, J PHYSIOL-LONDON, V516, P583, DOI 10.1111/j.1469-7793.1999.0583v.x; Owino V, 2001, FEBS LETT, V505, P259, DOI 10.1016/S0014-5793(01)02825-3; PAHLMARK K, 1993, STROKE, V24, P731, DOI 10.1161/01.STR.24.5.731; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Rytter A, 2003, J CEREBR BLOOD F MET, V23, P23, DOI 10.1097/01.WCB.0000034361.37277.1B; Sarnowska A, 2002, FOLIA NEUROPATHOL, V40, P101; Schabitz WR, 2001, STROKE, V32, P1226, DOI 10.1161/01.STR.32.5.1226; Schilling L, 1999, ADV EXP MED BIOL, V474, P123; SIEGFRIED JM, 1992, P NATL ACAD SCI USA, V89, P8107, DOI 10.1073/pnas.89.17.8107; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Tremblay R, 1999, J NEUROCHEM, V72, P102, DOI 10.1046/j.1471-4159.1999.0720102.x; Vicario-Abejon C, 2003, J NEUROSCI, V23, P895; Vincent AM, 2004, NEUROBIOL DIS, V16, P407, DOI 10.1016/j.nbd.2004.03.001; Wang JM, 2000, BRAIN RES, V859, P381, DOI 10.1016/S0006-8993(00)02008-4; Winn N, 2002, COLD SPRING HARB SYM, V67, P507, DOI 10.1101/sqb.2002.67.507; Yang HY, 2001, J MATER SCI TECHNOL, V17, P495; Yang SY, 2002, FEBS LETT, V522, P156, DOI 10.1016/S0014-5793(02)02918-6; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	41	105	129	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1896	+		10.1096/fj.05-3786fje	http://dx.doi.org/10.1096/fj.05-3786fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16144956				2022-12-28	WOS:000232315700029
J	Paintlia, AS; Paintlia, MK; Khan, M; Vollmer, T; Singh, AK; Singh, I				Paintlia, AS; Paintlia, MK; Khan, M; Vollmer, T; Singh, AK; Singh, I			HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis	FASEB JOURNAL			English	Article						lovastatin; oligodendrocyte progenitors; spinal cord; encephalomyelitis; multiple sclerosis; remyelination	CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; DEMYELINATING DISEASES; CNS REMYELINATION; NITRIC-OXIDE; GLIAL-CELLS; RHO; ACTIVATION; EXPRESSION; LOVASTATIN	Impaired remyelination due to degeneration of both postmitotic oligodendrocytes and oligodendrocyte progenitors (OPs) is the major hallmark of inflammatory demyelination in multiple sclerosis (MS) lesions and experimental autoimmune encephalomyelitis (EAE). Here, we have demonstrated the potential of lovastatin, a HMG-CoA reductase inhibitor, for the restoration of impaired remyelination mediated through enhanced survival and differentiation of OPs in the spinal cord of treated EAE animals. Lovastatin treatment significantly increased the level of myelin lipids in the spinal cord of treated EAE animals, coinciding with the attenuation of disease severity and inflammatory demyelination as compared with untreated EAE animals. The increased expression of myelin proteins and transcription factors associated with differentiating oligodendrocytes along with the increase in number of NG2(+)/BrdU(-) and NG2(+)/BrdU(+) cells, and the expression of proliferating OP-specific proteins, demonstrated the restoration of remyelination in the spinal cord of lovastatin-treated EAE animals. Corresponding to this, in vitro studies further corroborated the increased survival and differentiation of OPs in lovastatin-treated activated mixed glial cells suggesting that lovastatin protects against the degeneration of OPs and enhances their differentiation through induction of a pro-remyelinating environment in the spinal cord of treated EAE animals. Together, these data demonstrate that lovastatin has the potential to augment remyelination in MS lesions and other neuroinflammatory diseases.	Med Univ S Carolina, Children Res Inst, Dept Pediat, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA; Barrow Neurol Inst, Phoenix, AZ 85013 USA	Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Barrow Neurological Institute	Singh, I (corresponding author), Med Univ S Carolina, Children Res Inst, Dept Pediat, 173 Ashley Ave,509 CRI,POB 250515, Charleston, SC 29425 USA.	singhi@musc.edu	Singh, Ashok/HGF-2506-2022	Paintlia, Ajaib/0000-0003-4525-5333	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037766, R01NS034741, R01NS040144, R01NS022576, R37NS022576] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-40144, NS-22576, NS-37766, NS-34741] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Althaus HH, 2004, PROG BRAIN RES, V146, P415; Asakura K, 1998, J NEUROSCI, V18, P7700; Back SA, 2001, J NEUROSCI, V21, P1302; Baron W, 2002, EMBO J, V21, P1957, DOI 10.1093/emboj/21.8.1957; Bolot G, 2003, BIOCHIMIE, V85, P409, DOI 10.1016/S0300-9084(03)00044-0; Bruck W, 2003, J NEUROL SCI, V206, P181, DOI 10.1016/s0022-510x(02)00191-0; Brundin L, 2003, BRAIN PATHOL, V13, P322; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; CARSON MJ, 1993, NEURON, V10, P729, DOI 10.1016/0896-6273(93)90173-O; Cimini A, 2003, GLIA, V41, P3, DOI 10.1002/glia.10143; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; Dyer CA, 2000, J NEUROSCI RES, V60, P412, DOI 10.1002/(SICI)1097-4547(20000501)60:3<412::AID-JNR16>3.3.CO;2-5; Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371; GANSER AL, 1988, DEV NEUROSCI-BASEL, V10, P99, DOI 10.1159/000111961; Gensert JM, 1997, NEURON, V19, P197, DOI 10.1016/S0896-6273(00)80359-1; Giovannoni G, 1998, MULT SCLER J, V4, P212, DOI 10.1177/135245859800400323; Johnson-Anuna LN, 2005, J PHARMACOL EXP THER, V312, P786, DOI 10.1124/jpet.104.075028; Jurevics H, 2001, J NEUROCHEM, V77, P1067, DOI 10.1046/j.1471-4159.2001.00310.x; Khan M, 2000, J ENDOTOXIN RES, V6, P41, DOI 10.1177/09680519000060010601; Khan M, 1998, J NEUROCHEM, V71, P78; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Lassmann H, 2001, CURR OPIN NEUROL, V14, P253, DOI 10.1097/00019052-200106000-00001; Laufs U, 2000, TRENDS CARDIOVAS MED, V10, P143, DOI 10.1016/S1050-1738(00)00044-X; Liang XQ, 2004, J NEUROSCI, V24, P7140, DOI 10.1523/JNEUROSCI.5319-03.2004; Liberto CM, 2004, J NEUROCHEM, V89, P1092, DOI 10.1111/j.1471-4159.2004.02420.x; Linker RA, 2002, NAT MED, V8, P620, DOI 10.1038/nm0602-620; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; Marcus J, 2002, BBA-GEN SUBJECTS, V1573, P406, DOI 10.1016/S0304-4165(02)00410-5; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Mews I, 1998, MULT SCLER, V4, P55, DOI 10.1191/135245898678919582; Nath N, 2004, J IMMUNOL, V172, P1273, DOI 10.4049/jimmunol.172.2.1273; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Paintlia AS, 2004, J NEUROSCI RES, V77, P63, DOI 10.1002/jnr.20130; Paintlia AS, 2003, NEUROBIOL DIS, V14, P425, DOI 10.1016/j.nbd.2003.08.013; Paintlia MK, 2004, J NEUROSCI RES, V78, P347, DOI 10.1002/jnr.20261; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PITKANEN ASL, 1986, J NEUROL SCI, V74, P45, DOI 10.1016/0022-510X(86)90190-5; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; PRINEAS JW, 1993, ANN NEUROL, V33, P137, DOI 10.1002/ana.410330203; Ruffini F, 2001, GENE THER, V8, P1207, DOI 10.1038/sj.gt.3301523; Saluja I, 2001, GLIA, V33, P191, DOI 10.1002/1098-1136(200103)33:3<191::AID-GLIA1018>3.0.CO;2-M; Sim FJ, 2002, J NEUROSCI, V22, P2451, DOI 10.1523/JNEUROSCI.22-07-02451.2002; Sorensen PS, 2003, J NEUROL SCI, V206, P123, DOI 10.1016/S0022-510X(02)00343-X; Stanislaus R, 2001, J NEUROSCI RES, V66, P155, DOI 10.1002/jnr.1207; Tang Y, 1999, MOL CELL BIOL, V19, P1881; TSUJI S, 1985, J NEUROL SCI, V68, P175, DOI 10.1016/0022-510X(85)90098-X; Vollmer T, 2004, LANCET, V363, P1607, DOI 10.1016/S0140-6736(04)16205-3; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	48	81	88	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2005	19	11					1407	1421		10.1096/fj.05-3861com	http://dx.doi.org/10.1096/fj.05-3861com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16126908				2022-12-28	WOS:000232315700034
J	Cuzzocrea, S; Ayroldi, E; Di Paola, R; Agostini, M; Mazzon, E; Bruscoli, S; Genovese, T; Ronchetti, S; Caputi, AP; Riccardi, C				Cuzzocrea, S; Ayroldi, E; Di Paola, R; Agostini, M; Mazzon, E; Bruscoli, S; Genovese, T; Ronchetti, S; Caputi, AP; Riccardi, C			Role of glucocorticoid-induced TNF receptor family gene (GITR) in collagen-induced arthritis	FASEB JOURNAL			English	Article						rheumatoid arthritis; T lymphocyte activity; chemokines	IMMUNOREGULATORY T-CELLS; RHEUMATOID-ARTHRITIS; II COLLAGEN; AUTOIMMUNE ARTHRITIS; NITRIC-OXIDE; ENHANCED PRODUCTION; INTERFERON-GAMMA; MICE; LIGAND; ACTIVATION	In rheumatoid arthritis (RA), a widespread autoimmune/ inflammatory joint disease, early activation of effector CD4+ T lymphocytes, and cytokine production is followed by recruitment of other inflammatory cells, production of a range of inflammation mediators, tissue damage, and disease. GITR (glucocorticoid- induced TNFR family- related gene), a costimulatory molecule for T lymphocytes, increases CD4+ CD25- effector T cell activation while inhibiting suppressor activity of CD4+ CD25- T regulatory (Treg) cells. We analyzed the role of GITR in type II collagen (CII) - induced arthritis (CIA) using GITR -/- and GITR+/+ mice. Results indicate significantly less CIA induction in GITR+/+ mice than in GITR+/+ mice, with marked differences in erythema, edema, neutrophil infiltration, joint injury, and bone erosion. Production of IFN gamma, IL-6, TNF alpha, MIP-1 alpha, and MIP-2, inducible NOS (iNOS), COX-2, and nitrotyrosine poly-ADP-ribose (PAR) were also less in CII-treated GITR+/+ mice. Although CD4+ CD25+ Treg cells from GITR-/- and GITR-/- CII- challenged mice exerted similar suppressor activity in vitro, GITR triggering abrogated GITR+/+ Treg suppressor activity and costimulated CD4+ CD25- GITR+/+ effector cells. Furthermore, Treg cells from GITR-/- protected more than Treg cells from GITR+/+ mice against CIA when cotransferred with Treg-depleted splenocytes from arthritic GITR+/+ animals into severe combined immunodeficient (SCID) mice. In conclusion, GITR plays a critical role in the immunological response against CII and in the development of CIA.	Policlin Univ, Dipartimento Clin & Sperimentale Med & Farmacol, I-98123 Messina, Italy; Univ Perugia, Dipartimento Med Clin & Sperimentale, Sez Farmacol Tossicol & Chemioterapia, I-06100 Perugia, Italy	AOU Policlinico Gaetano Martino; University of Messina; University of Perugia	Riccardi, C (corresponding author), Policlin Univ, Dipartimento Clin & Sperimentale Med & Farmacol, I-98123 Messina, Italy.	salvator@unime.it; riccardi@unipg.it	Riccardi, Carlo/N-4610-2014; Agostini, Massimiliano/AAE-7971-2019; Ronchetti, Simona/L-2325-2013; di paola, rosanna/U-4356-2019; Agostini, Massimiliano/G-9579-2014; Mazzon, Emanuela/AAL-4334-2020	Riccardi, Carlo/0000-0001-9257-3997; Agostini, Massimiliano/0000-0003-3124-2072; Ronchetti, Simona/0000-0002-5639-4243; di paola, rosanna/0000-0001-6725-8581; Agostini, Massimiliano/0000-0003-3124-2072; GENOVESE, Tiziana/0000-0002-3335-7327; bruscoli, stefano/0000-0003-0313-1615; mazzon, emanuela/0000-0002-5073-717X; Ayroldi, Emira/0000-0002-9073-7297				Alonzi T, 1998, J EXP MED, V187, P461, DOI 10.1084/jem.187.4.461; Bardos T, 2003, ARTHRITIS RES THER, V5, pR106, DOI 10.1186/ar624; Bauerova K, 1999, GEN PHYSIOL BIOPHYS, V18, P15; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beutler B, 1998, BLOOD CELL MOL DIS, V24, P216, DOI 10.1006/bcmd.1998.0187; BOISSIER MC, 1995, EUR J IMMUNOL, V25, P1184, DOI 10.1002/eji.1830250508; Cannon GW, 1996, ARTHRITIS RHEUM-US, V39, P1677, DOI 10.1002/art.1780391010; Cuzzocrea S, 2003, ARTHRITIS RHEUM-US, V48, P3544, DOI 10.1002/art.11351; Cuzzocrea S, 2001, EUR CYTOKINE NETW, V12, P568; Cuzzocrea S, 2000, AM J PATHOL, V157, P2065, DOI 10.1016/S0002-9440(10)64845-6; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Gerli R, 2001, TRENDS IMMUNOL, V22, P72, DOI 10.1016/S1471-4906(00)01829-9; HARRIS ED, 1990, NEW ENGL J MED, V323, P996; HOLMDAHL R, 1990, IMMUNOL REV, V118, P193, DOI 10.1111/j.1600-065X.1990.tb00817.x; HOLMDAHL R, 1989, CLIN EXP RHEUMATOL, V7, pS51; Jung HW, 2004, EXP MOL MED, V36, P13, DOI 10.1038/emm.2004.2; KADOWAKI KM, 1994, CLIN EXP IMMUNOL, V97, P212; KAKIMOTO K, 1988, J IMMUNOL, V140, P78; KOCH AE, 1994, J CLIN INVEST, V93, P921, DOI 10.1172/JCI117097; KOCH AE, 1992, J CLIN INVEST, V90, P772, DOI 10.1172/JCI115950; Kohm AP, 2004, J IMMUNOL, V172, P4686, DOI 10.4049/jimmunol.172.8.4686; Lamhamedi-Cherradi SE, 2003, NAT IMMUNOL, V4, P255, DOI 10.1038/ni894; Liu ZG, 2003, J CLIN INVEST, V112, P1332, DOI 10.1172/JCI200319209; Luross JA, 2002, ARTHRITIS RHEUM, V46, P1671, DOI 10.1002/art.10328; Mackay F, 2002, CURR OPIN IMMUNOL, V14, P783, DOI 10.1016/S0952-7915(02)00407-7; Mauri C, 1996, EUR J IMMUNOL, V26, P1511, DOI 10.1002/eji.1830260716; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; MIESEL R, 1995, INFLAMMATION, V19, P379, DOI 10.1007/BF01534394; Morgan ME, 2003, ARTHRITIS RHEUM, V48, P1452, DOI 10.1002/art.11063; Myers LK, 2000, ARTHRITIS RHEUM-US, V43, P2687, DOI 10.1002/1529-0131(200012)43:12<2687::AID-ANR8>3.0.CO;2-9; Nocentini G, 1997, P NATL ACAD SCI USA, V94, P6216, DOI 10.1073/pnas.94.12.6216; Nurieva RI, 2003, J CLIN INVEST, V111, P701, DOI 10.1172/JCI200317321; OCHI T, 2003, BIOCHEM PHARMACOL, V66, P1555; PIGUET PF, 1992, IMMUNOLOGY, V77, P510; Ronchetti S, 2002, BLOOD, V100, P350, DOI 10.1182/blood-2001-12-0276; Ronchetti S, 2004, EUR J IMMUNOL, V34, P613, DOI 10.1002/eji.200324804; Rothstein DM, 2003, IMMUNOL REV, V196, P85, DOI 10.1046/j.1600-065X.2003.00088.x; Rudolphi U, 1997, ARTHRITIS RHEUM, V40, P1409, DOI 10.1002/art.1780400808; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Sigidin YA, 2001, SCAND J RHEUMATOL, V30, P203; Spinicelli S, 2002, CELL DEATH DIFFER, V9, P1382, DOI 10.1038/sj.cdd.4401140; Stasiuk LM, 1996, CELL IMMUNOL, V173, P269, DOI 10.1006/cimm.1996.0277; Stephens GL, 2004, J IMMUNOL, V173, P5008, DOI 10.4049/jimmunol.173.8.5008; Szabo C, 1997, J EXP MED, V186, P1041, DOI 10.1084/jem.186.7.1041; Szabo C, 1998, P NATL ACAD SCI USA, V95, P3867, DOI 10.1073/pnas.95.7.3867; Tada Y, 1999, J IMMUNOL, V162, P203; Tak PP, 1996, CLIN IMMUNOL IMMUNOP, V80, P129, DOI 10.1006/clin.1996.0106; TAKAI Y, 1989, ARTHRITIS RHEUM, V32, P594, DOI 10.1002/anr.1780320513; THORBECKE GJ, 1992, P NATL ACAD SCI USA, V89, P7375, DOI 10.1073/pnas.89.16.7375; Thornton S, 1999, ARTHRITIS RHEUM, V42, P1109, DOI 10.1002/1529-0131(199906)42:6<1109::AID-ANR7>3.0.CO;2-7; Tone M, 2003, P NATL ACAD SCI USA, V100, P15059, DOI 10.1073/pnas.2334901100; Uraushihara K, 2003, J IMMUNOL, V171, P708, DOI 10.4049/jimmunol.171.2.708; WATSON WC, 1990, J EXP MED, V172, P1331, DOI 10.1084/jem.172.5.1331; Yamanishi Y, 2002, AM J PATHOL, V160, P123, DOI 10.1016/S0002-9440(10)64356-8; Yoshioka T, 2000, EUR J IMMUNOL, V30, P2815, DOI 10.1002/1521-4141(200010)30:10<2815::AID-IMMU2815>3.0.CO;2-#	55	87	100	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1253	1265		10.1096/fj.04-3556com	http://dx.doi.org/10.1096/fj.04-3556com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16051692				2022-12-28	WOS:000231843700032
J	Mahn, K; Borras, C; Knock, GA; Taylor, P; Khan, IY; Sugden, D; Poston, L; Ward, JP; Sharpe, RM; Vina, J; Aaronson, PI; Mann, GE				Mahn, K; Borras, C; Knock, GA; Taylor, P; Khan, IY; Sugden, D; Poston, L; Ward, JP; Sharpe, RM; Vina, J; Aaronson, PI; Mann, GE			Dietary soy isoflavone-induced increases in antioxidant and eNOS gene expression lead to improved endothelial function and reduced blood pressure in vivo	FASEB JOURNAL			English	Article						soy protein; phytoestrogens; oxidative stress	CORONARY-HEART-DISEASE; ESTROGEN-RECEPTOR; POSTMENOPAUSAL WOMEN; ENZYME EXPRESSION; OXIDATIVE STRESS; GENISTEIN; PHYTOESTROGENS; CHANNELS; MODULATION; RELAXATION	Epidemiological evidence suggests that populations consuming large amounts of soy protein have a reduced incidence of coronary heart disease (1-5). The cardiovascular risks associated with conventional hormone replacement therapy in postmenopausal women (5-7) have precipitated a search for alternative estrogen receptor modulators. Here we report that long-term feeding of rats with a soy protein-rich (SP) diet during gestation and adult life results in decreased oxidative stress, improved endothelial function, and reduced blood pressure in vivo measured by radiotelemetry in aged male offspring. Improved vascular reactivity in animals fed an SP diet was paralleled by increased mitochondrial glutathione and mRNA levels for endothelial nitric oxide synthase (eNOS) and the antioxidant enzymes manganese superoxide dismutase and cytochrome c oxidase. Reduced eNOS and antioxidant gene expression, impaired endothelial function, and elevated blood pressure in animals fed a soy-deficient diet was reversed after refeeding them an SP diet for 6 months. Our findings suggest that an SP diet increases eNOS and antioxidant gene expression in the vasculature and other tissues, resulting in reduced oxidative stress and increased NO bioavailability. The improvement in endothelial function, increased gene expression, and reduced blood pressure by soy isoflavones have implications for alternative therapy for postmenopausal women and patients at risk of coronary heart disease.	Kings Coll London, Sch Biomed & Hlth Sci, Cardiovasc Div, London SE1 1UL, England; Kings Coll London, Sch Biomed & Hlth Sci, Reprod Hlth Endocrinol & Dev Div, London SE1 1UL, England; Kings Coll London, Sch Biomed & Hlth Sci, Asthma Allergy & Lung Biol Div, London SE1 1UL, England; Kings Coll London, Sch Med, London SE1 1UL, England; Univ Valencia, Fac Med, Dept Fisiol, Valencia, Spain; Ctr Reprod Biol, Human Reprod Sci Unit, Med Res Council, Edinburgh EH3 9ET, Midlothian, Scotland	University of London; King's College London; University of London; King's College London; University of London; King's College London; University of London; King's College London; University of Valencia; UK Research & Innovation (UKRI); Medical Research Council UK (MRC)	Mann, GE (corresponding author), Kings Coll London, Sch Biomed & Hlth Sci, Cardiovasc Div, Guys Campus, London SE1 1UL, England.	giovanni.mann@kcl.ac.uk	Vina, Jose/AAB-3069-2021; borras, consuelo/Y-3407-2019; Sharpe, Richard M/D-2725-2013	Vina, Jose/0000-0001-9709-0089; borras, consuelo/0000-0003-4606-1792; Sharpe, Richard M/0000-0003-1686-8085; Mann, Giovanni/0000-0001-7311-2044; Taylor, Paul David/0000-0002-4740-4307; Aaronson, Philip Irving/0000-0003-1086-1202	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADLERCREUTZ H, 1993, LANCET, V342, P1209, DOI 10.1016/0140-6736(93)92188-Y; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; ANDERSON JW, 1995, NEW ENGL J MED, V333, P276, DOI 10.1056/NEJM199508033330502; Armitage JA, 2004, J PHYSIOL-LONDON, V561, P355, DOI 10.1113/jphysiol.2004.072009; Atanassova N, 2000, ENDOCRINOLOGY, V141, P3898, DOI 10.1210/en.141.10.3898; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Borras C, 2005, AGING CELL, V4, P113, DOI 10.1111/j.1474-9726.2005.00151.x; Borras C, 2003, FREE RADICAL BIO MED, V34, P546, DOI 10.1016/S0891-5849(02)01356-4; Chambliss KL, 2002, ENDOCR REV, V23, P665, DOI 10.1210/er.2001-0045; Clark JT, 2004, ENDOCRINE, V25, P173, DOI 10.1385/ENDO:25:2:173; DAS KC, 1995, AM J PHYSIOL-LUNG C, V269, pL588, DOI 10.1152/ajplung.1995.269.5.L588; Dick GM, 2001, J BIOL CHEM, V276, P34594, DOI 10.1074/jbc.M104689200; Doerge DR, 2000, RAPID COMMUN MASS SP, V14, P673, DOI 10.1002/(SICI)1097-0231(20000430)14:8<673::AID-RCM935>3.3.CO;2-6; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Farhat MY, 1996, FASEB J, V10, P615, DOI 10.1096/fasebj.10.5.8621060; Figtree GA, 2000, J AM COLL CARDIOL, V35, P1977, DOI 10.1016/S0735-1097(00)00645-8; Gluckman PD, 2004, SCIENCE, V305, P1733, DOI 10.1126/science.1095292; Griendling KK, 2003, CIRCULATION, V108, P1912, DOI 10.1161/01.CIR.0000093660.86242.BB; Hodgson JM, 1999, AM J HYPERTENS, V12, P47, DOI 10.1016/S0895-7061(98)00216-7; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; JOY S, 2003, J PHYSL P, V547, pC137; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; Khan LY, 2003, HYPERTENSION, V41, P168, DOI 10.1161/01.HYP.0000047511.97879.FC; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lee SY, 2003, FASEB J, V17, P947, DOI 10.1096/fj.02-0807fje; Lissin LW, 2000, J AM COLL CARDIOL, V35, P1403; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Mishra SK, 2000, CARDIOVASC RES, V46, P539, DOI 10.1016/S0008-6363(00)00049-3; Montano MM, 2004, ONCOGENE, V23, P2442, DOI 10.1038/sj.onc.1207358; Nestel P, 2003, CURR OPIN LIPIDOL, V14, P3, DOI 10.1097/00041433-200302000-00002; Ritchie MR, 2004, BRIT J NUTR, V91, P447, DOI 10.1079/BJN20031062; Rivas M, 2002, J NUTR, V132, P1900, DOI 10.1093/jn/132.7.1900; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Ruehlmann DO, 1998, FASEB J, V12, P613, DOI 10.1096/fasebj.12.7.613; Setchell KDR, 1999, J NUTR, V129, p758S, DOI 10.1093/jn/129.3.758S; SIMONS LA, 2000, AM J CARDIOL, V3, P47; Squadrito F, 2003, AM J MED, V114, P470, DOI 10.1016/S0002-9343(03)00059-7; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; Strehlow K, 2003, CIRC RES, V93, P170, DOI 10.1161/01.RES.0000082334.17947.11; Suzuki K, 2002, INT J CANCER, V99, P846, DOI 10.1002/ijc.10428; Teede HJ, 2003, ARTERIOSCL THROM VAS, V23, P1066, DOI 10.1161/01.ATV.0000072967.97296.4A; Tschugguel W, 2001, J CLIN ENDOCR METAB, V86, P3833, DOI 10.1210/jc.86.8.3833; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; Valverde Miguel A., 2002, Trends in Biochemical Sciences, V27, P172, DOI 10.1016/S0968-0004(02)02075-3; Walker HA, 2001, CIRCULATION, V103, P258, DOI 10.1161/01.CIR.103.2.258; Zhou LZH, 2001, FREE RADICAL BIO MED, V31, P1405, DOI 10.1016/S0891-5849(01)00719-5; Zhu Y, 2002, SCIENCE, V295, P505, DOI 10.1126/science.1065250	50	141	146	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1755	+		10.1096/fj.05-4008fje	http://dx.doi.org/10.1096/fj.05-4008fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16107535				2022-12-28	WOS:000231843700011
J	Jorgensen, SB; Wojtaszewski, JFP; Viollet, B; Andreelli, F; Birk, JB; Hellsten, Y; Schjerling, P; Vaulont, S; Neufer, PD; Richter, EA; Pilegaard, H				Jorgensen, SB; Wojtaszewski, JFP; Viollet, B; Andreelli, F; Birk, JB; Hellsten, Y; Schjerling, P; Vaulont, S; Neufer, PD; Richter, EA; Pilegaard, H			Effects of alpha-AMPK knockout on exercise-induced gene activation in mouse skeletal muscle	FASEB JOURNAL			English	Article						gene transcription; mRNA; AICAR; PGC-1 alpha; PDK4; adenosine nucleotides; inosine monophosphate	5'-AMP-ACTIVATED PROTEIN-KINASE; GLYCOGEN-SYNTHASE KINASE; ACETYL-COA CARBOXYLASE; GLUCOSE-TRANSPORT; FIBER-TYPE; TRANSCRIPTIONAL ACTIVATION; MITOCHONDRIAL BIOGENESIS; SUBSTRATE-SPECIFICITY; ENERGY DEPRIVATION; PHYSICAL-ACTIVITY	We tested the hypothesis that 5'AMP-activated protein kinase (AMPK) plays an important role in regulating the acute, exercise-induced activation of metabolic genes in skeletal muscle, which were dissected from whole-body alpha 2- and alpha 1-AMPK knockout (KO) and wild-type (WT) mice at rest, after treadmill running (90 min), and in recovery. Running increased alpha 1-AMPK kinase activity, phosphorylation (P) of AMPK, and acetyl-CoA carboxylase (ACC)beta in alpha 2-WT and alpha 2-KO muscles and increased alpha 2-AMPK kinase activity in alpha 2-WT. In alpha 2-KO muscles, AMPK-P and ACC beta-P were markedly lower compared with alpha 2-WT. However, in alpha 1-WT and alpha 1-KO muscles, AMPK-P and ACC beta-P levels were identical at rest and increased similarly during exercise in the two genotypes. The alpha 2-KO decreased peroxisome-proliferator-activated receptor 7 coactivator (PGC)-1 alpha, uncoupling protein-3 (UCP3), and hexokinase II (HKII) transcription at rest but did not affect exercise-induced transcription. Exercise increased the mRNA content of PGC-1 alpha, Forkhead box class O (FOXO)1, HKII, and pyruvate dehydrogenase kinase 4 (PDK4) similarly in alpha 2-WT and alpha 2-KO mice, whereas glucose transporter GLUT 4, carnitine palmitoyltransferase I (CPTI), lipoprotein lipase, and UCP3 mRNA were unchanged by exercise in both genotypes. CPTI mRNA was lower in alpha 2-KO muscles than in alpha 2-WT muscles at all time-points. In alpha 1-WT and alpha 1-KO muscles, running increased the mRNA content of PGC-1 alpha and FOXO1 similarly. The alpha 2-KO was associated with lower muscle adenosine 5'-triphosphate content, and the inosine monophosphate content increased substantially at the end of exercise only in alpha 2-KO muscles. In addition, subcutaneous injection of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) increased the mRNA content of PGC-1 alpha, HKII, FOXO1, PDK4, and UCP3, and alpha 2-KO abolished the AICAR-induced increases in PGC-1 alpha and HKII mRNA. In conclusion, KO of the alpha 2- but not the alpha 1-AMPK isoform markedly diminished AMPK activation during running. Nevertheless, exercise-induced activation of the investigated genes in mouse skeletal muscle was not impaired in alpha- or alpha 2-AMPK KO muscles. Although it cannot be ruled out that activation of the remaining alpha-isoform is sufficient to increase gene activation during exercise, the present data do not support an essential role of AMPK in regulating exercise-induced gene activation in skeletal muscle.	Univ Copenhagen, Inst Exercise & Sport Sci, Dept Human Physiol, Copenhagen Muscle Res Ctr, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Inst Mol Biol & Physiol, Copenhagen, Denmark; Rigshosp, Dept Mol Muscle Biol, DK-2100 Copenhagen, Denmark; Univ Paris 05, Dept Genet Dev & Mol Pathol, CNRS, INSERM,Inst Cochin, Paris, France; Yale Univ, John B Pierce Lab, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA	University of Copenhagen; University of Copenhagen; Rigshospitalet; University of Copenhagen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Yale University; The John B Pierce Laboratory, Inc	Jorgensen, SB (corresponding author), Univ Copenhagen, Inst Exercise & Sport Sci, Dept Human Physiol, Copenhagen Muscle Res Ctr, 13 Univ Pk, DK-2100 Copenhagen, Denmark.	SBJorgensen@ifi.ku.dk	Vaulont, Sophie/O-6732-2017; Birk, Jesper B/D-3523-2015; Schjerling, Peter/F-6194-2011; Viollet, Benoit/O-6927-2017; Pilegaard, Henriette/M-2315-2014; Wojtaszewski, Jørgen FP/P-6583-2014; Richter, Erik A./Y-8131-2019; Viollet, Benoit/N-2397-2019; Hellsten, Ylva/B-3420-2015	Birk, Jesper B/0000-0001-9775-4789; Schjerling, Peter/0000-0001-7138-3211; Viollet, Benoit/0000-0002-0121-0224; Pilegaard, Henriette/0000-0002-1071-0327; Wojtaszewski, Jørgen FP/0000-0001-9785-6830; Richter, Erik A./0000-0002-6850-3056; Viollet, Benoit/0000-0002-0121-0224; Hellsten, Ylva/0000-0002-2435-9558; wojtaszewski, jorgen/0000-0001-8185-3408				Ai H, 2002, AM J PHYSIOL-ENDOC M, V282, pE1291, DOI 10.1152/ajpendo.00167.2001; Aronson D, 1997, J CLIN INVEST, V99, P1251, DOI 10.1172/JCI119282; Aschenbach WG, 2004, SPORTS MED, V34, P91, DOI 10.2165/00007256-200434020-00003; Baldwin KM, 2002, AM J PHYS MED REHAB, V81, pS40, DOI 10.1097/00002060-200211001-00006; Bergeron R, 2001, AM J PHYSIOL-ENDOC M, V281, pE1340, DOI 10.1152/ajpendo.2001.281.6.E1340; Buhl ES, 2001, DIABETES, V50, P12, DOI 10.2337/diabetes.50.1.12; CARLING D, 1989, BIOCHIM BIOPHYS ACTA, V1012, P81, DOI 10.1016/0167-4889(89)90014-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; Derave W, 2000, DIABETES, V49, P1281, DOI 10.2337/diabetes.49.8.1281; Figueroa A, 2003, MOL CELL BIOL, V23, P4991, DOI 10.1128/MCB.23.14.4991-5004.2003; Fluck M, 2000, J APPL PHYSIOL, V88, P352, DOI 10.1152/jappl.2000.88.1.352; Fujii N, 2000, BIOCHEM BIOPH RES CO, V273, P1150, DOI 10.1006/bbrc.2000.3073; Furuyama T, 2003, BIOCHEM J, V375, P365, DOI 10.1042/BJ20030022; Hildebrandt AL, 2000, AM J PHYSIOL-ENDOC M, V278, pE1078, DOI 10.1152/ajpendo.2000.278.6.E1078; Holmes BF, 1999, J APPL PHYSIOL, V87, P1990, DOI 10.1152/jappl.1999.87.5.1990; Holmes BF, 2004, AM J PHYSIOL-ENDOC M, V287, pE739, DOI 10.1152/ajpendo.00080.2004; Jones TE, 2003, AM J PHYSIOL-ENDOC M, V284, pE96, DOI 10.1152/ajpendo.00316.2002; Jorgensen SB, 2004, J BIOL CHEM, V279, P1070, DOI 10.1074/jbc.M306205200; Jorgensen SB, 2004, DIABETES, V53, P3074, DOI 10.2337/diabetes.53.12.3074; Kamei Y, 2003, FEBS LETT, V536, P232, DOI 10.1016/S0014-5793(03)00062-0; Kiens B, 2004, J APPL PHYSIOL, V97, P1209, DOI 10.1152/japplphysiol.01278.2003; Lo WS, 2001, SCIENCE, V293, P1142, DOI 10.1126/science.1062322; Longnus SL, 2003, AM J PHYSIOL-REG I, V284, pR936, DOI 10.1152/ajpregu.00319.2002; MacLean PS, 2002, BIOCHEM BIOPH RES CO, V292, P409, DOI 10.1006/bbrc.2002.6654; McGee SL, 2004, DIABETES, V53, P1208, DOI 10.2337/diabetes.53.5.1208; McGee SL, 2003, DIABETES, V52, P926, DOI 10.2337/diabetes.52.4.926; Neufer PD, 1996, AM J PHYSIOL-CELL PH, V271, pC1828; NEUFER PD, 1993, AM J PHYSIOL, V265, pC1597; ODOHERTY RM, 1994, AM J PHYSIOL, V266, pE171; Ojuka EO, 2000, J APPL PHYSIOL, V88, P1072, DOI 10.1152/jappl.2000.88.3.1072; Ojuka EO, 2002, AM J PHYSIOL-ENDOC M, V282, pE1008, DOI 10.1152/ajpendo.00512.2001; PASSONNEAU JV, 1967, ANAL BIOCHEM, V19, P315, DOI 10.1016/0003-2697(67)90167-4; Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850; Pilegaard H, 2002, J PHYSIOL-LONDON, V541, P261, DOI 10.1113/jphysiol.2002.016832; Pilegaard H, 2000, AM J PHYSIOL-ENDOC M, V279, pE806; Rose AJ, 2003, J PHYSIOL-LONDON, V553, P303, DOI 10.1113/jphysiol.2003.054171; Salt I, 1998, BIOCHEM J, V334, P177, DOI 10.1042/bj3340177; Seip RL, 1997, AM J PHYSIOL-ENDOC M, V272, pE255; Shang J, 2004, J BIOL CHEM, V279, P12076, DOI 10.1074/jbc.M400431200; Stoppani J, 2002, AM J PHYSIOL-ENDOC M, V283, pE1239, DOI 10.1152/ajpendo.00278.2002; Suwa M, 2003, J APPL PHYSIOL, V95, P960, DOI 10.1152/japplphysiol.00349.2003; Tullson P C, 1991, Exerc Sport Sci Rev, V19, P507; TULLSON PC, 1990, AM J PHYSIOL, V258, pC258, DOI 10.1152/ajpcell.1990.258.2.C258; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567; Wang W, 2002, MOL CELL BIOL, V22, P3425, DOI 10.1128/MCB.22.10.3425-3436.2002; Wang WG, 2003, J BIOL CHEM, V278, P27016, DOI 10.1074/jbc.M300318200; Winder WW, 2000, J APPL PHYSIOL, V88, P2219, DOI 10.1152/jappl.2000.88.6.2219; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; Wojtaszewski JFP, 2003, BIOCHEM SOC T, V31, P1290; Wojtaszewski JFP, 2000, J PHYSIOL-LONDON, V528, P221, DOI 10.1111/j.1469-7793.2000.t01-1-00221.x; WOODGETT JR, 1983, EUR J BIOCHEM, V136, P481, DOI 10.1111/j.1432-1033.1983.tb07766.x; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4; Wright DC, 2004, DIABETES, V53, P330, DOI 10.2337/diabetes.53.2.330; Zhou M, 2000, AM J PHYSIOL-ENDOC M, V279, pE622, DOI 10.1152/ajpendo.2000.279.3.E622; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	57	223	234	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2005	19	7					1146	+		10.1096/fj.04-3144fje	http://dx.doi.org/10.1096/fj.04-3144fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15878932				2022-12-28	WOS:000229602600017
J	Marneros, AG; Olsen, BR				Marneros, AG; Olsen, BR			Physiological role of collagen XVIII and endostatin	FASEB JOURNAL			English	Review						basement membrane; retinal pigment epithelium; age-related macular degeneration; hydrocephalus; heparan sulfate proteoglycan	BASAL LAMINAR DEPOSIT; ANGIOGENESIS INHIBITOR ENDOSTATIN; EPITHELIUM-DERIVED FACTOR; FAMILIAL EXUDATIVE VITREORETINOPATHY; TISSUE-SPECIFIC DIFFERENCES; BASEMENT-MEMBRANE ZONES; HIGH-FAT DIET; KNOBLOCH-SYNDROME; MACULAR DEGENERATION; PIGMENT-EPITHELIUM	Collagen XVIII is a component of basement membranes (BMs) with the structural properties of both a collagen and a proteoglycan. Proteolytic cleavage within its C-terminal domain releases a fragment, endostatin, which has been reported to have anti-angiogenesis effects. Molecular studies demonstrated binding of the endostatin domain to heparan sulfate and to BM components like laminin and perlecan, but the functional role of these interactions in vivo remains unknown. Insights into the physiological function of collagen XVIII/endostatin have recently been obtained through the identification of inactivating mutations in the human collagen XVIII/endostatin gene (COL18A1) in patients with Knobloch syndrome, characterized by age-dependent vitreoretinal degeneration and occipital encephalocele. That collagen XVIII/endostatin has an essential role in ocular development and the maintenance of visual function is further demonstrated by the ocular abnormalities seen in mice lacking collagen XVIII/endostatin. Age-dependent loss of vision in these mutant mice is associated with pathological accumulation of deposits under the retinal pigment epithelium, as seen in early stages of age-related macular degeneration in humans. In addition, recent evidence suggests that lack of collagen XVIII/ endostatin predisposes to hydrocephalus formation. These recent findings demonstrate an important role for collagen XVIII/endostatin in cell-matrix interactions in certain tissues that may be compensated for in other tissues expressing this collagen.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Marneros, AG (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	Alexander_Marneros@hms.harvard.edu; Bjorn_Olsen@hms.harvard.edu		Marneros, Alexander/0000-0003-3866-020X				Abdollahi A, 2004, MOL CELL, V13, P649, DOI 10.1016/S1097-2765(04)00102-9; Ackley BD, 2001, J CELL BIOL, V152, P1219, DOI 10.1083/jcb.152.6.1219; AHMAD NN, 1991, P NATL ACAD SCI USA, V88, P6624, DOI 10.1073/pnas.88.15.6624; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Annunen S, 1999, AM J HUM GENET, V65, P974, DOI 10.1086/302585; Auricchio A, 2002, MOL THER, V6, P490, DOI 10.1006/mthe.2002.0702; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; Bix G, 2004, J CELL BIOL, V166, P97, DOI 10.1083/jcb.200401150; Cousins SW, 2003, INVEST OPHTH VIS SCI, V44, P1221, DOI 10.1167/iovs.02-0285; Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047; Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643; Dixelius J, 2002, CANCER RES, V62, P1944; Dixelius J, 2003, CANCER LETT, V196, P1, DOI 10.1016/S0304-3835(03)00267-2; Doll JA, 2003, NAT MED, V9, P774, DOI 10.1038/nm870; Dong SC, 2003, J BIOL CHEM, V278, P1700, DOI 10.1074/jbc.M209276200; Dorrell MI, 2002, INVEST OPHTH VIS SCI, V43, P3500; EKLUND L, 2001, THESIS U OULU OULU; Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910; Fukai N, 2002, EMBO J, V21, P1535, DOI 10.1093/emboj/21.7.1535; Gehlbach P, 2003, GENE THER, V10, P637, DOI 10.1038/sj.gt.3301931; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; GOTTSCH JD, 1993, ARCH OPHTHALMOL-CHIC, V111, P126, DOI 10.1001/archopht.1993.01090010130039; Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267; Hanai J, 2002, J CELL BIOL, V158, P529, DOI 10.1083/jcb.200203064; Hanai J, 2002, J BIOL CHEM, V277, P16464, DOI 10.1074/jbc.M112274200; Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289; Hohenester E, 1998, EMBO J, V17, P1656, DOI 10.1093/emboj/17.6.1656; Ito M, 1999, ANAT EMBRYOL, V200, P403, DOI 10.1007/s004290050289; JAVAHERIAN K, 2002, IN PRESS J BIOL CHEM; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Kliemann SE, 2003, AM J MED GENET A, V119A, P15, DOI 10.1002/ajmg.a.20070; Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415; KNOBLOCH WH, 1972, AM J OPHTHALMOL, V73, P517, DOI 10.1016/0002-9394(72)90003-7; Koganei J., 1885, ARCH MIKROSK ANAT, V25, P1, DOI [10.1007/BF02966370, DOI 10.1007/BF02966370]; Kuo CJ, 2001, J CELL BIOL, V152, P1233, DOI 10.1083/jcb.152.6.1233; LANG R, 1994, DEVELOPMENT, V120, P3395; LANG RA, 1993, CELL, V74, P453, DOI 10.1016/0092-8674(93)80047-I; Li Q, 2004, AM J PATHOL, V165, P415, DOI 10.1016/S0002-9440(10)63307-X; Marneros AG, 2004, EMBO J, V23, P89, DOI 10.1038/sj.emboj.7600014; Marneros AG, 2003, INVEST OPHTH VIS SCI, V44, P2367, DOI 10.1167/iovs.02-1180; Marneros AG, 2001, MATRIX BIOL, V20, P337, DOI 10.1016/S0945-053X(01)00151-2; MARNEROS AG, 2004, THESIS U OSLO UNIPUB; Menzel O, 2004, HUM MUTAT, V23, P77, DOI 10.1002/humu.10284; Miosge N, 2003, J HISTOCHEM CYTOCHEM, V51, P285, DOI 10.1177/002215540305100303; Mongiat M, 2003, J BIOL CHEM, V278, P4238, DOI 10.1074/jbc.M210445200; Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5; Moulton KS, 2004, CIRCULATION, V110, P1330, DOI 10.1161/01.CIR.0000140720.79015.3C; MURAGAKI Y, 1995, P NATL ACAD SCI USA, V92, P8763, DOI 10.1073/pnas.92.19.8763; Nakamoto T, 2002, PLANT PROD SCI, V5, P175, DOI 10.1626/pps.5.175; OH SP, 1994, GENOMICS, V19, P494, DOI 10.1006/geno.1994.1098; Ohlmann AV, 2004, INVEST OPHTH VIS SCI, V45, P2384, DOI 10.1167/iovs.03-1214; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PASSOSBUENO MR, 1994, AM J MED GENET, V52, P170, DOI 10.1002/ajmg.1320520209; Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6; Ramirez F, 1996, CURR OPIN GENET DEV, V6, P309, DOI 10.1016/S0959-437X(96)80007-4; REHN M, 1994, J BIOL CHEM, V269, P13929; REHN M, 1995, J BIOL CHEM, V270, P4705, DOI 10.1074/jbc.270.9.4705; REHN M, 1994, P NATL ACAD SCI USA, V91, P4234, DOI 10.1073/pnas.91.10.4234; Ricard-Blum S, 2004, J BIOL CHEM, V279, P2927, DOI 10.1074/jbc.M309868200; Richards AJ, 1996, HUM MOL GENET, V5, P1339, DOI 10.1093/hmg/5.9.1339; Richter M, 1998, INVEST OPHTH VIS SCI, V39, P2450; Robitaille J, 2002, NAT GENET, V32, P326, DOI 10.1038/ng957; Saarela J, 1998, MATRIX BIOL, V16, P319, DOI 10.1016/S0945-053X(98)90003-8; Saarela J, 1998, AM J PATHOL, V153, P611, DOI 10.1016/S0002-9440(10)65603-9; Sasaki T, 1998, EMBO J, V17, P4249, DOI 10.1093/emboj/17.15.4249; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348; SEAVER LH, 1993, AM J MED GENET, V46, P203, DOI 10.1002/ajmg.1320460221; Sertie AL, 1996, HUM MOL GENET, V5, P843, DOI 10.1093/hmg/5.6.843; Sertie AL, 2000, HUM MOL GENET, V9, P2051, DOI 10.1093/hmg/9.13.2051; Shichiri M, 2001, FASEB J, V15, P1044, DOI 10.1096/fj.99-1083com; Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722; Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; Suzuki OT, 2002, AM J HUM GENET, V71, P1320, DOI 10.1086/344695; Takahashi K, 2003, FASEB J, V17, P896, DOI 10.1096/fj.02-0824fje; Thumann G, 2001, SURV OPHTHALMOL, V45, P345, DOI 10.1016/S0039-6257(00)00195-8; Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130; Toomes C, 2004, AM J HUM GENET, V74, P721, DOI 10.1086/383202; Utriainen A, 2004, HUM MOL GENET, V13, P2089, DOI 10.1093/hmg/ddh213; VANDERSCHAFT TL, 1994, GRAEF ARCH CLIN EXP, V232, P40, DOI 10.1007/BF00176436; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; Wickstrom SA, 2001, CANCER RES, V61, P6511; WOBMANN PR, 1972, AM J OPHTHALMOL, V73, P90, DOI 10.1016/0002-9394(72)90311-X; Xu Q, 2004, CELL, V116, P883, DOI 10.1016/S0092-8674(04)00216-8; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Ylikarppa R, 2003, FASEB J, V17, P2257, DOI 10.1096/fj.02-1001fje; Yurchenco PD, 2004, MATRIX BIOL, V22, P521, DOI 10.1016/j.matbio.2003.10.006; Zorick TS, 2001, EUR J HUM GENET, V9, P811, DOI 10.1038/sj.ejhg.5200721	93	163	173	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2005	19	7					716	728		10.1096/fj.04-2134rev	http://dx.doi.org/10.1096/fj.04-2134rev			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15857886				2022-12-28	WOS:000229602600028
J	Rosmarakis, ES; Soteriades, ES; Vergidis, PI; Kasiakou, SK; Falagas, ME				Rosmarakis, ES; Soteriades, ES; Vergidis, PI; Kasiakou, SK; Falagas, ME			From conference abstract to full paper: differences between data presented in conferences and journals	FASEB JOURNAL			English	Article						abstract; conference; paper; article; impact factor	RESPIRATORY-TRACT INFECTIONS; IN-VIVO ACTIVITIES; ACUTE OTITIS-MEDIA; STREPTOCOCCUS-PNEUMONIAE; VITRO; CEPHALOSPORIN; CARBAPENEM; RESISTANCE; ACCURACY; PUBLICATION	Background: We studied the type and frequency of differences between data presented in conference abstracts and subsequent published papers in the fields of infectious diseases and microbiology. Methods: We reviewed all abstracts from the first session of 7 of 15 major research categories presented in the 1999 and 2000 Interscience Conference on Antimicrobial Agents and Chemotherapy. For each selected pair of abstract and related published paper, two independent investigators performed a detailed data comparison. Results: From 190 abstracts reviewed, 68 (36%) were subsequently published as full papers by March 2004. Fifty-two pairs referred to the same study population and period. Differences were found in 30 of 51 pairs, which were further analyzed (point estimate=59%, 95% C.I.: 45-73%). The identified differences were related to both the aims and conclusions of the study (3/30), the study conclusions only (2/30), numbers and/or rates of the studied patients (10/30), numbers or rates of microbiological isolates (9/30), MIC values or K, values (5/30), other pharmacological properties of antibiotics (2/30), odds ratio (1/30), and duration of observation (1/30). Some differences were considered major. In bivariable associations, time to publication (from presentation in the conference to publication of the full paper) was associated with identifiable differences between the conference abstract and the full paper (OR=1.76, 95% CI 0.95-3.24/year of delay, P=0.07). Conclusions: It is reassuring that although we identified several reportable differences, only a very small proportion of studies exhibited differences in their aims and/or conclusions. Researchers may benefit from the above findings in improving the accuracy of presented data.	Alfa Inst Biomed Sci, Maroussi 15123, Greece; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	Alfa Institute Of Biomedical Sciences; Harvard University; Harvard T.H. Chan School of Public Health; Tufts University	Falagas, ME (corresponding author), Alfa Inst Biomed Sci, 9 Neapoleos St, Maroussi 15123, Greece.	matthew.falagas@tufts.edu						[Anonymous], 2004, ANN INTERN MED, V140, P480, DOI 10.7326/0003-4819-140-6-200403160-00015; Aracil B, 2001, J ANTIMICROB CHEMOTH, V48, P592, DOI 10.1093/jac/48.4.592; ARACIL B, 2000, 40 ICAAC TOR CAN CAT, V145, P66; Bert F, 2000, CLIN INFECT DIS, V31, P1295, DOI 10.1086/317469; BERT F, 1999, 39 ICAAC SAN FRANC C, V513, P591; Block SL, 2002, PEDIATR INFECT DIS J, V21, P859, DOI 10.1097/00006454-200209000-00015; BLOCK SL, 1999, 39 ICAAC SAN FRANC C, V53, P141; Bruinsma N, 2003, J ANTIMICROB CHEMOTH, V51, P385, DOI 10.1093/jac/dkg072; BRUINSMA N, 2000, 40 ICAAC TOR CAN CAT, V101, P403; Burke T, 1999, CLIN THER, V21, P1664, DOI 10.1016/S0149-2918(99)80046-0; BURKE T, 1999, 39 ICAAC SAN FRANC C, V170, P709; Bydder Sean A, 2004, Australas Radiol, V48, P25, DOI 10.1111/j.1440-1673.2004.01243.x; Castillo J, 2002, EUR J ANAESTH, V19, P888, DOI 10.1017/S0265021502001424; Clark J, 2002, ANTIMICROB AGENTS CH, V46, P1108, DOI 10.1128/AAC.46.4.1108-1111.2002; Daluiski A, 1998, J ORTHOPAED RES, V16, P645, DOI 10.1002/jor.1100160603; Damrikarnlert L, 2000, J CHEMOTHERAPY, V12, P79; DAMRIKARNLERT L, 1999, 39 ICAAC SAN FRANC C, V165, P707; FABRY J, 1999, 39 ICAAC SAN FRANC C, V85, P408; FERNANDEZMAZARR.C, 2000, 40 ICAAC TOR CAN CAT, V142, P66; Fung-Tomc JC, 2002, ANTIMICROB AGENTS CH, V46, P971, DOI 10.1128/AAC.46.4.971-976.2002; FUNGTOMC J, 2000, 40 ICAAC TOR CAN CAT, V1063, P193; Glinka T, 2003, BIOORGAN MED CHEM, V11, P591, DOI 10.1016/S0968-0896(02)00431-5; GLINKA T, 2000, 40 ICAAC TOR CAN CAT, V1071, P195; GOODMAN SN, 1994, ANN INTERN MED, V121, P11, DOI 10.7326/0003-4819-121-1-199407010-00003; GROUNDSTROEM KW, 1999, 39 ICAAC SAN FRANC C, V305, P656; Harbarth S, 2002, CLIN INFECT DIS, V35, pE120, DOI 10.1086/344468; Harris AD, 2001, CLIN INFECT DIS, V32, P1055, DOI 10.1086/319600; HARRIS AD, 2000, 40 ICAAC TOR CAN CAT, V82, P399; HARRIS AD, 2000, 40 ICAAC TOR CAN CAT, V83, P399; Harris AHS, 2002, J PSYCHOL, V136, P141, DOI 10.1080/00223980209604145; Hikida M, 1999, ANTIMICROB AGENTS CH, V43, P2010, DOI 10.1128/AAC.43.8.2010; HIKIDA M, 1999, 39 ICAAC SAN FRANC C, V387, P294; Hjaltested EKR, 2003, SCAND J INFECT DIS, V35, P21, DOI 10.1080/0036554021000026996; HUCZCO E, 2000, 40 ICAAC TOR CAN CAT, V1064, P194; IZUMI K, 1999, 39 ICAAC SAN FRANC C, V386, P294; Jasko JJ, 2003, CLIN ORTHOP RELAT R, P98, DOI 10.1097/01.blo.0000093902.12372.76; King MD, 2002, CLIN INFECT DIS, V34, P641, DOI 10.1086/338637; KING MD, 2000, 40 ICAAC TOR CAN CAT, V68, P255; KRISTINSSON KG, 1999, 39 ICAAC SAN FRANC C, V57, P142; Larian B, 2001, OTOLARYNG HEAD NECK, V125, P166, DOI 10.1067/mhn.2001.117870; Leblebicioglu H, 2002, J CHEMOTHERAPY, V14, P181, DOI 10.1179/joc.2002.14.2.181; LEBLEBICIOGLU H, 2000, 40 ICAAC TOR CAN CAT, V131, P508; LIM CC, 2000, 40 ICAAC TOR CAN CAT, V70, P256; Lim CCT, 2002, RADIOLOGY, V222, P219, DOI 10.1148/radiol.2221010499; Lumio JT, 2004, AM J MED, V116, P78, DOI 10.1016/j.amjmed.2003.08.031; Marx WF, 1999, AM J NEURORADIOL, V20, P1173; Mikamo H, 2000, J ANTIMICROB CHEMOTH, V46, P471, DOI 10.1093/jac/46.3.471; Mylotte JM, 2001, AM J INFECT CONTROL, V29, P139, DOI 10.1067/mic.2001.114225; MYLOTTE JM, 2000, 40 ICAAC TOR CAN CAT, V97, P402; Nagano R, 1999, ANTIMICROB AGENTS CH, V43, P2497, DOI 10.1128/AAC.43.10.2497; NAGANO R, 1999, 39 ICAAC SAN FRANC C, V402, P299; Nambiar S, 2002, ARCH PEDIAT ADOL MED, V156, P621, DOI 10.1001/archpedi.156.6.621; NAMBIAR S, 1999, 39 ICAAC SAN FRANC C, V186, P735; Namyslowski G, 2002, J CHEMOTHERAPY, V14, P508, DOI 10.1179/joc.2002.14.5.508; NAMYSLOWSKI G, 1999, 39 ICAAC SAN FRANC C, V172, P710; NARINE L, 1994, CAN MED ASSOC J, V144, P449; Perez-Trallero E, 2001, ANTIMICROB AGENTS CH, V45, P3334, DOI 10.1128/AAC.45.12.3334-3340.2001; Pitkin RM, 1998, JAMA-J AM MED ASSOC, V280, P267, DOI 10.1001/jama.280.3.267; Pitkin RM, 1999, JAMA-J AM MED ASSOC, V281, P1110, DOI 10.1001/jama.281.12.1110; Pradat P, 2001, EUR J EPIDEMIOL, V17, P47, DOI 10.1023/A:1010902614443; Prazuck T, 2002, SEX TRANSM DIS, V29, P624, DOI 10.1097/00007435-200211000-00002; PRAZUCK T, 2000, 40 ICAAC TOR CAN CAT, V129, P507; Sader H S, 2000, Braz J Infect Dis, V4, P245; SADER HS, 1999, 39 ICAAC SAN FRANC C, V58, P142; SAMORE M, 2000, 40 ICAAC TOR CAN, P123; Stolk P, 2002, PHARMACOEPIDEM DR S, V11, P105, DOI 10.1002/pds.687; Swenson JM, 2002, J ANTIMICROB CHEMOTH, V49, P845, DOI 10.1093/jac/dkf020; SWENSON JM, 1999, 39 ICAAC SAN FRANC C, V394, P297; SYROGIANNOPOULO.GA, 2000, 40 ICAAC TOR CAN CAT, V139, P65; Syrogiannopoulos GA, 2001, ANTIMICROB AGENTS CH, V45, P342, DOI 10.1128/AAC.45.1.342-344.2001; Walby A, 2001, Emerg Med (Fremantle), V13, P460, DOI 10.1046/j.1035-6851.2001.00262.x; Yu VL, 2002, J INFECT DIS, V186, P127, DOI 10.1086/341087; YU VL, 2000, 40 INT C ANT AG CHEM, V593, P441	73	69	67	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					673	680		10.1096/fj.04-3140lfe	http://dx.doi.org/10.1096/fj.04-3140lfe			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15857882				2022-12-28	WOS:000229602600024
J	[Anonymous]				[Anonymous]			Thrombolytic (fibrinolytic) drugs and progress in treating cardiovascular disease	FASEB JOURNAL			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; THERAPY											Albers GW, 2004, CHEST, V126, p483S, DOI 10.1378/chest.126.3_suppl.483S; FLETCHER AP, 1958, T ASSOC AM PHYSICIAN, V71, P287; Lenfant C, 2003, NEW ENGL J MED, V349, P868, DOI 10.1056/NEJMsa035507; Menon V, 2004, CHEST, V126, p549S, DOI 10.1378/chest.126.3_suppl.549S; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905	5	1	1	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2005	19	6					671	671		10.1096/fj.05-3896bkt	http://dx.doi.org/10.1096/fj.05-3896bkt			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15791008				2022-12-28	WOS:000228865300042
J	Oshima, Y; Oshima, S; Nambu, H; Kachi, S; Takahashi, K; Umeda, N; Shen, J; Dong, A; Apte, RS; Duh, E; Hackett, SF; Okaye, G; Ishibashi, K; Handa, J; Melia, M; Weigand, S; Yancopoulos, G; Zack, DJ; Campochiaro, PA				Oshima, Y; Oshima, S; Nambu, H; Kachi, S; Takahashi, K; Umeda, N; Shen, J; Dong, A; Apte, RS; Duh, E; Hackett, SF; Okaye, G; Ishibashi, K; Handa, J; Melia, M; Weigand, S; Yancopoulos, G; Zack, DJ; Campochiaro, PA			Different effects of angiopoietin-2 in different vascular beds in the eye: new vessels are most sensitive	FASEB JOURNAL			English	Article						angiogenesis; neovascularization; Tie2; vascular endothelial growth factor	ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; INCREASED EXPRESSION; RETINAL NEOVASCULARIZATION; OCULAR NEOVASCULARIZATION; GENE-EXPRESSION; TIE2 RECEPTOR; ANGIOGENESIS; MICE; MODEL	In this study, we used double transgenic mice with inducible expression of angiopoietin-2 (Ang2) to investigate the role of Ang2 in the retinal and choroidal circulations and in three models of ocular neovascularization (NV). Mice with induced expression of Ang2 ubiquitously, or specifically in the retina, survived and appeared grossly normal. They also had normal-appearing retinal and choroidal circulations, demonstrating that high levels of Ang2 did not induce regression of mature retinal or choroidal vessels. When Ang2 expression was induced soon after birth, there was increased density of the deep capillary bed on postnatal day (P) 11 that returned to normal by P18, the time that retinal vascular development is usually completed. In mice with ischemic retinopathy, induction of Ang2 during the ischemic period resulted in a significant increase in retinal NV, but induction of Ang2 at a later time point when ischemia (and vascular endothelial growth factor [VEGF]) was less, hastened regression of NV. In triple transgenic mice that coexpressed VEGF and Ang2, the increased expression of Ang2 inhibited VEGF-induced NV in the retina. Increased expression of Ang2 also resulted in regression of choroidal neovascularization. These data suggest that ocular neovascularization, but not mature retinal or choroidal vessels, is sensitive to Ang2; a high Ang2/VEGF ratio promotes regression, while high Ang2 in the setting of hypoxia and/or concomitantly high Ang2 and VEGF stimulate neovascularization.	Johns Hopkins Univ, Sch Med, Dept Ophthalmol & Neurosci, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21287 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	Johns Hopkins University; Johns Hopkins University; Regeneron	Campochiaro, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Ophthalmol & Neurosci, Maumenee 719,600 N Wolfe St, Baltimore, MD 21287 USA.	pcampo@jhmi.edu		Zack, Don/0000-0002-7966-1973; Umeda, Naoyasu/0000-0001-5814-8356	NEI NIH HHS [EY05951, P30EY1765, EY12609] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY001765, R01EY012609] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; Beck H, 2000, AM J PATHOL, V157, P1473, DOI 10.1016/S0002-9440(10)64786-4; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chang MA, 2000, INVEST OPHTH VIS SCI, V41, P4281; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4; Hackett SF, 2000, J CELL PHYSIOL, V184, P275, DOI 10.1002/1097-4652(200009)184:3<275::AID-JCP1>3.3.CO;2-Z; Hackett SF, 2002, J CELL PHYSIOL, V192, P182, DOI 10.1002/jcp.10128; Hazzard TM, 2000, MOL HUM REPROD, V6, P993, DOI 10.1093/molehr/6.11.993; Kim I, 2000, ONCOGENE, V19, P4549, DOI 10.1038/sj.onc.1203800; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Miquerol L, 2000, DEVELOPMENT, V127, P3941; Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428; Nambu H, 2004, GENE THER, V11, P865, DOI 10.1038/sj.gt.3302230; Nambu H, 2003, INVEST OPHTH VIS SCI, V44, P3650, DOI 10.1167/iovs.02-0985; Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2; Okamoto N, 1997, AM J PATHOL, V151, P281; Okoye G, 2003, J NEUROSCI, V23, P4164; Ozaki H, 1998, AM J PATHOL, V153, P757, DOI 10.1016/S0002-9440(10)65619-2; Pichiule P, 2002, J APPL PHYSIOL, V93, P1131, DOI 10.1152/japplphysiol.00318.2002; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Shih SC, 2002, AM J PATHOL, V161, P35, DOI 10.1016/S0002-9440(10)64154-5; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Teichert-Kuliszewska K, 2001, CARDIOVASC RES, V49, P659, DOI 10.1016/S0008-6363(00)00231-5; Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7; Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180; Visconti RP, 2002, P NATL ACAD SCI USA, V99, P8219, DOI 10.1073/pnas.122109599; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; YI X, 1997, LAB INVEST, V235, P313	36	86	91	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					963	+		10.1096/fj.04-2209fje	http://dx.doi.org/10.1096/fj.04-2209fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15802489				2022-12-28	WOS:000227901300040
J	Laezza, C; Notarnicola, M; Caruso, MG; Messa, C; Macchia, M; Bertini, S; Minutolo, F; Portella, G; Fiorentino, L; Stingo, S; Bifulco, M				Laezza, Chiara; Notarnicola, Maria; Caruso, Maria Gabriella; Messa, Caterina; Macchia, Marco; Bertini, Simone; Minutolo, Filippo; Portella, Giuseppe; Fiorentino, Laura; Stingo, Stefania; Bifulco, Maurizio			N6-isopentenyladenosine arrests tumor cell proliferation by inhibiting farnesyl diphosphate synthase and protein prenylation	FASEB JOURNAL			English	Article						cell growth; isoprenoid pathway	THYROID EPITHELIAL-CELLS; PLANT CYTOKININ ANALOGS; HUMAN COLORECTAL-CANCER; FLUORESCENT-PROBES; LEUKEMIA-CELLS; BINDING; GROWTH; THYROTROPIN; APOPTOSIS; ADENOSINE	The physiological effects of a variety of N6-substituted adenine and adenosine derivatives called cytokinins have been documented in plants, but information on their occurrence and function in other biological system is limited. Here we investigated the anti-proliferative effect of N6-isopentenyladenosine (i(6)A), an adenosine and isoprenoid derivative, in a thyroid cell system, FRTL-5 wild-type, and K-ras transformed KiMol cells. Addition of i(6)A to FRTL-5 cells caused a dose-dependent arrest of the G(0)-G(1) cell phase transition associated with a reduction of cells in the S phase that was much more evident in KiMol cells. I(6)A arrested tumor cell proliferation by inhibiting farnesyl diphosphate synthase (FPPS) and protein prenylation. Indeed the addition of farnesol reversed these effects and i(6)A affected protein prenylation, in particular lamin B processing. I(6)A effect was not mediated by the adenosine receptor but was due to a direct modulation of FPPS enzyme activity as a result of its uptake inside the cells. I(6)A inhibited FPPS activity more efficaciously in KiMol cells than in normal FRTL-5. Moreover, the i(6)A anti-proliferative effect was evaluated in vivo in a nude mouse xenograft model, where KiMol cells were implanted subcutaneously. Mice treated with i(6)A showed a drastic reduction in tumor volume. Our findings indicate that this isoprenoid end product might be used for antineoplastic therapy, an application emulating that of the lovastatin and/or farnesyltransferase inhibitors.	Univ Salerno, Dipartimento Sci Farmaceut, I-84084 Fisciano, Salerno, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, Naples, Italy; Univ Pisa, Dipartimento Sci Farmaceut, I-56100 Pisa, Italy; IRCCS S Bellis Castellana G Bari, Biochim Lab, Bari, Italy; CNR, IEOS, I-00185 Rome, Italy	University of Salerno; University of Naples Federico II; University of Pisa; IRCCS Saverio de Bellis; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR)	Laezza, C (corresponding author), Univ Salerno, Dipartimento Sci Farmaceut, Ponte Melillo, I-84084 Fisciano, Salerno, Italy.	maubiful@unina.it	Portella, Giuseppe/AFU-6826-2022; Minutolo, Filippo/A-7480-2011; laez, chi/AAW-4437-2020	Minutolo, Filippo/0000-0002-3312-104X; MACCHIA, MARCO/0000-0002-5565-2044; PORTELLA, Giuseppe/0000-0001-8276-9769; Bifulco, Maurizio/0000-0002-1771-4531; BERTINI, SIMONE/0000-0001-8832-8075				AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; Aronov AM, 1998, J MED CHEM, V41, P4790, DOI 10.1021/jm9802620; BIFULCO M, 1990, J BIOL CHEM, V265, P19336; Boturyn D, 1997, TETRAHEDRON, V53, P5485, DOI 10.1016/S0040-4020(97)00235-4; BURNS DM, 1976, CANCER BIOCHEM BIOPH, V1, P269; Caruso MG, 2003, SCAND J GASTROENTERO, V38, P80, DOI 10.1080/00365520310000483; CHANG Y, 1982, J PHARM SCI, V71, P328, DOI 10.1002/jps.2600710317; FAUST JR, 1991, J BIOL CHEM, V266, P9961; FUSCO A, 1981, INT J CANCER, V28, P655, DOI 10.1002/ijc.2910280519; FUSCO A, 1982, CANCER RES, V42, P618; GALLO RC, 1969, SCIENCE, V165, P400, DOI 10.1126/science.165.3891.400; Graaf MR, 2004, CANCER TREAT REV, V30, P609, DOI 10.1016/j.ctrv.2004.06.010; Griffey RH, 1996, J MED CHEM, V39, P5100, DOI 10.1021/jm950937o; Gupta SD, 1999, J LIPID RES, V40, P1572; HACKER B, 1983, J PHARM SCI, V72, P902, DOI 10.1002/jps.2600720815; HARGROVE JL, 1982, J CELL PHYSIOL, V111, P232, DOI 10.1002/jcp.1041110303; Ishii Y, 2002, CELL GROWTH DIFFER, V13, P19; KERSTEN H, 1984, PROG NUCLEIC ACID RE, V31, P59, DOI 10.1016/S0079-6603(08)60375-X; KRISANS SK, 1994, J BIOL CHEM, V269, P14165; Laezza C, 1998, P NATL ACAD SCI USA, V95, P13646, DOI 10.1073/pnas.95.23.13646; Laezza C, 1997, EXP CELL RES, V234, P178, DOI 10.1006/excr.1997.3610; Laezza C, 1997, FEBS LETT, V413, P260, DOI 10.1016/S0014-5793(97)00924-1; LATEN HM, 1985, P NATL ACAD SCI USA, V82, P1113, DOI 10.1073/pnas.82.4.1113; Macchia M, 1998, BIOORG MED CHEM LETT, V8, P3223, DOI 10.1016/S0960-894X(98)00582-4; Meisel H, 1998, FEBS LETT, V433, P265, DOI 10.1016/S0014-5793(98)00927-2; MITTELMAN A, 1975, ANN NY ACAD SCI, V255, P225, DOI 10.1111/j.1749-6632.1975.tb29228.x; Notarnicola M, 2004, ANTICANCER RES, V24, P3837; Notarnicola M, 2004, ONCOLOGY-BASEL, V67, P351, DOI 10.1159/000082918; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; Portella G, 2003, FASEB J, V17, P1771, DOI 10.1096/fj.02-1129fje; SANTISTEBAN P, 1987, J BIOL CHEM, V262, P4048; Sinensky M, 2000, BBA-MOL CELL BIOL L, V1484, P93, DOI 10.1016/S1388-1981(00)00009-3; VANDERPLOEG I, 1992, J NEUROCHEM, V58, P1221; Vermeulen K, 2002, LEUKEMIA, V16, P299, DOI 10.1038/sj.leu.2402378; Vermeulen K, 2002, EXP HEMATOL, V30, P1107, DOI 10.1016/S0301-472X(02)00894-9; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1099, DOI 10.1210/endo-114-4-1099; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	37	50	50	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2006	20	3					412	418		10.1096/fj.05-4044lsf	http://dx.doi.org/10.1096/fj.05-4044lsf			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	074LY	16507758				2022-12-28	WOS:000239815100004
J	Liu, XL; Pachori, AS; Ward, CA; Davis, JP; Gnecchi, M; Kong, DL; Zhang, LN; Murduck, J; Yet, SF; Perrella, MA; Pratt, RE; Dzau, VJ; Melo, LG				Liu, Xiaoli; Pachori, Alok S.; Ward, Christopher A.; Davis, J. Paul; Gnecchi, Massimiliano; Kong, Deling; Zhang, Lunan; Murduck, Jared; Yet, Shaw-Fang; Perrella, Mark A.; Pratt, Richard E.; Dzau, Victor J.; Melo, Luis G.			Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function	FASEB JOURNAL			English	Article						echocardiography; gene therapy; ischemia; myocardial infarction; reperfusion; viruses	MYOCARDIAL-INFARCTION; TARGETED DELETION; GENE-EXPRESSION; REPERFUSION; PROLIFERATION; ANTIOXIDANT; BILIRUBIN; PROTECTS; DELIVERY; RUPTURE	We reported previously that predelivery of the anti-oxidant gene heme oxygenase-1 (HO-1) to the heart by adeno associated virus (AAV) markedly reduces injury after acute myocardial infarction (MI). However, the effect of HO-1 gene delivery on postinfarction recovery has not been investigated. In the current study, we assessed the effect of HO-1 gene delivery on post-MI left ventricle (LV) remodeling and function using echocardiographic imaging and histomorphometric approaches. Two groups of Sprague-Dawley rats were injected with 4 x 10(11) particles of AAV-LacZ (control) or AAV-hHO-1 in the LV wall. Eight wk after gene transfer, the animals were subjected to 30 min of ischemia by ligation of left anterior descending artery (LAD) followed by reperfusion. Echocardiographic measurements were obtained in a blinded fashion prior and at 1.5 and 3 months after I/R. Ejection fraction (EF) was reduced by 13% and 40% in the HO-1 and LacZ groups, respectively at 1.5 months after MI. Three months after MI, EF recovered fully in the HO-1, but only partially in the LacZ-treated animals. Post-MI LV dimensions were markedly increased and the anterior wall was markedly thinned in the LacZ-treated animals compared with the HO-1-treated animals. Significant myocardial scarring and fibrosis were observed in the LacZ-group in association with elevated levels of interstitial collagen I and III and MMP-2 activity. Post-MI myofibroblast accumulation was reduced in the HO-1-treated animals, and retroviral overexpression of HO-1 reduced proliferation of isolated cardiac fibroblasts. Our data indicate that rAAV-HO-1 gene transfer markedly reduces fibrosis and ventricular remodeling and restores LV function and chamber dimensions after myocardial infarction.	Queens Univ, Dept Physiol, Kingston, ON K7L 3N6, Canada; Brigham & Womens Hosp, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Duke Univ, Med Ctr, Dept Med, Durham, NC USA; Univ Saskatchewan, Coll Med, Dept Physiol, Saskatoon, SK S7N 0W0, Canada	Queens University - Canada; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Duke University; University of Saskatchewan	Melo, LG (corresponding author), Queens Univ, Dept Physiol, 18 Stuart St, Kingston, ON K7L 3N6, Canada.	melol@post.queensu.ca	Yet, Shaw-Fang/B-1067-2010; Gnecchi, Massimiliano/J-8609-2018; Liu, Xiaoli/HGE-7614-2022; Yet, Shaw-Fang/O-8583-2019; Gnecchi, Massimiliano/X-7095-2019	Gnecchi, Massimiliano/0000-0001-7435-4328; Gnecchi, Massimiliano/0000-0001-7435-4328; Liu, Xiaoli/0000-0003-2904-4413; Yet, Shaw-Fang/0000-0001-9097-3962	NHLBI NIH HHS [HL 072010, HL 35610, HL 05316, HL 073219] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035610, R37HL035610, R01HL073219, R01HL072010] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agrawal RS, 2004, GENE THER, V11, P962, DOI 10.1038/sj.gt.3302250; BALLA G, 1992, J BIOL CHEM, V267, P18148; Clark JE, 2000, AM J PHYSIOL-HEART C, V278, pH643, DOI 10.1152/ajpheart.2000.278.2.H643; CLEUTJENS JPM, 1995, AM J PATHOL, V147, P325; Creemers EEJM, 2001, CIRC RES, V89, P201, DOI 10.1161/hh1501.094396; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; Guo YR, 2004, AM J PHYSIOL-HEART C, V286, pH1649, DOI 10.1152/ajpheart.00971.2003; Hawkes SP, 2000, METH MOL B, V151, P399, DOI 10.1385/1-59259-046-2:399; Hayashidani S, 2003, AM J PHYSIOL-HEART C, V285, pH1229, DOI 10.1152/ajpheart.00207.2003; Holmes DR, 2003, AM J CARDIOL, V91, p50A; ITO H, 1993, CIRCULATION, V87, P355, DOI 10.1161/01.CIR.87.2.355; JUDGUTT BI, 1996, CIRCULATION, V94, P94; Jugdutt BI, 2003, CIRCULATION, V108, P1395, DOI 10.1161/01.CIR.0000085658.98621.49; Li PF, 1999, FEBS LETT, V448, P206, DOI 10.1016/S0014-5793(99)00370-1; Manabe I, 2002, CIRC RES, V91, P1103, DOI 10.1161/01.RES.0000046452.67724.B8; Matsumura S, 2005, J CLIN INVEST, V115, P599, DOI 10.1172/JCI200522304; Maulik N, 1996, J MOL CELL CARDIOL, V28, P1261, DOI 10.1006/jmcc.1996.0116; Melo LG, 2002, CIRCULATION, V105, P602, DOI 10.1161/hc0502.103363; Nian M, 2004, CIRC RES, V94, P1543, DOI 10.1161/01.RES.0000130526.20854.fa; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; PACHORI AS, 2004, AAV HO 1 GENE THERAP; Siwik DA, 2001, AM J PHYSIOL-CELL PH, V280, pC53, DOI 10.1152/ajpcell.2001.280.1.C53; Snyder R, 1996, CURRENT PROTOCOLS HU; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Virag JI, 2003, AM J PATHOL, V163, P2433, DOI 10.1016/S0002-9440(10)63598-5; Volti GL, 2002, BIOCHEM BIOPH RES CO, V296, P1077, DOI 10.1016/S0006-291X(02)02054-5; Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5; Yet SF, 1999, J CLIN INVEST, V103, pR23, DOI 10.1172/JCI6163	29	89	123	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					207	216		10.1096/fj.05-4435com	http://dx.doi.org/10.1096/fj.05-4435com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449792				2022-12-28	WOS:000237698700005
J	Mason, AJ; Martinez, A; Glaubitz, C; Danos, O; Kichler, A; Bechinger, B				Mason, A. James; Martinez, Amelie; Glaubitz, Clemens; Danos, Olivier; Kichler, Antoine; Bechinger, Burkhard			The antibiotic and DNA-transfecting peptide LAH4 selectively associates with, and disorders, anionic lipids in mixed membranes	FASEB JOURNAL			English	Article						(31)P MAS and (2)H solid-state NMR; phosphatidylserine asymmetry; gene transfer	PHOSPHOLIPID-BILAYER MEMBRANES; LACTOFERRIN-DERIVED PEPTIDES; STATE NMR-SPECTROSCOPY; ANTIMICROBIAL PEPTIDE; MAGNETIC-RESONANCE; LYTIC PEPTIDES; BETA-PEPTIDE; GRAMICIDIN-S; TUMOR-CELLS; PHOSPHATIDYLSERINE	The histidine-rich amphipathic peptide LAH4 has antibiotic and DNA delivery capabilities. The peptide has a strong affinity for anionic lipids found in the outer membrane of bacterial membranes. A role for anionic lipids in release of cationic plasmid-containing complexes has been proposed previously, and disruption of membrane asymmetry and presentation of phosphatidylserine (PS) in the membrane outer leaflet is a general feature observed in diseased mammalian cells. Therefore, to understand the peptide-lipid interactions in more detail, solidstate NMR experiments on model membranes have been performed. (31)P MAS NMR on mixed phosphatidylcholine (PC)/PS and PC/phosphatidylglycerol (PG) membranes has been used to demonstrate a strong interaction between LAH4 and anionic lipids. By using deuterated lipids and wide-line (2)H NMR when probing lipid chain order, it is demonstrated that LAH4 preferentially interacts with PS over PC and effectively disorders the anionic PS lipid fatty acyl chains. In addition, we demonstrate that the efficiency of gene transfer in vitro to different cell lines is closely related to the degree of disruption of PS acyl chains for four isomers of LAH4. This work suggests a mechanism of selective destabilization by LAH4 of anionic lipids in the membranes of cells during transfection with implications for nucleic acid delivery in vivo.	[Mason, A. James; Bechinger, Burkhard] Univ Strasbourg 1, Inst Bel, Fac Chim, CNRS UMR717 LC3, Strasbourg, France; [Martinez, Amelie; Glaubitz, Clemens; Danos, Olivier; Kichler, Antoine] Genethon CNRS UMR8115, Evry, France; [Mason, A. James] Goethe Univ Frankfurt, Ctr Biomol Magnet Resonance, Frankfurt, Germany; [Mason, A. James] Goethe Univ Frankfurt, Inst Biophys Chem, Frankfurt, Germany	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Goethe University Frankfurt; Goethe University Frankfurt	Mason, AJ (corresponding author), Inst Isis, 8 Rue Gaspard Monge, F-67000 Strasbourg, France.	jmason@chimie.u-strasbg.fr	Glaubitz, Clemens/D-5714-2011; Mason, James/J-2273-2012	Glaubitz, Clemens/0000-0002-3554-6586; Mason, James/0000-0003-0411-602X; Kichler, Antoine/0000-0003-0593-2424				Andersen JF, 2004, BIOCHEMISTRY-US, V43, P6987, DOI 10.1021/bi049655t; Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D; Bechinger B, 1996, J MOL BIOL, V263, P768, DOI 10.1006/jmbi.1996.0614; Bechinger B, 1999, BBA-BIOMEMBRANES, V1462, P157, DOI 10.1016/S0005-2736(99)00205-9; Bechinger B, 2005, BBA-BIOMEMBRANES, V1712, P101, DOI 10.1016/j.bbamem.2005.03.003; Bechinger B, 2004, CRIT REV PLANT SCI, V23, P271, DOI 10.1080/07352680490452825; Bechinger B, 1997, J MEMBRANE BIOL, V156, P197, DOI 10.1007/s002329900201; Blazyk J, 2001, J BIOL CHEM, V276, P27899, DOI 10.1074/jbc.M102865200; Bonev B, 2001, PHYS CHEM CHEM PHYS, V3, P2904, DOI 10.1039/b103352m; Buffy JJ, 2004, BIOCHEMISTRY-US, V43, P9800, DOI 10.1021/bi036243w; Callahan MK, 2003, J IMMUNOL, V170, P4840, DOI 10.4049/jimmunol.170.9.4840; Chen HM, 1997, BBA-GEN SUBJECTS, V1336, P171, DOI 10.1016/S0304-4165(97)00024-X; CRUCIANI RA, 1991, P NATL ACAD SCI USA, V88, P3792, DOI 10.1073/pnas.88.9.3792; DAVIS JH, 1983, BIOCHIM BIOPHYS ACTA, V737, P117, DOI 10.1016/0304-4157(83)90015-1; Epand RF, 2003, EUR J BIOCHEM, V270, P1240, DOI 10.1046/j.1432-1033.2003.03484.x; Gidalevitz D, 2003, P NATL ACAD SCI USA, V100, P6302, DOI 10.1073/pnas.0934731100; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; Kichler A, 2003, M S-MED SCI, V19, P1046, DOI 10.1051/medsci/200319111046; Kichler A, 2003, P NATL ACAD SCI USA, V100, P1564, DOI 10.1073/pnas.0337677100; Kol MA, 2003, BIOCHEMISTRY-US, V42, P231, DOI 10.1021/bi0268403; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Lewis RNAH, 2003, BIOCHEMISTRY-US, V42, P440, DOI 10.1021/bi026707a; Ludtke SJ, 1996, BIOCHEMISTRY-US, V35, P13723, DOI 10.1021/bi9620621; Mason AJ, 2005, BBA-BIOMEMBRANES, V1714, P1, DOI 10.1016/j.bbamem.2005.06.003; Nieh MP, 2004, LANGMUIR, V20, P7893, DOI 10.1021/la048641l; Nieh MP, 2002, BIOPHYS J, V82, P2487, DOI 10.1016/S0006-3495(02)75591-4; Prenner EJ, 2001, BBA-BIOMEMBRANES, V1510, P83, DOI 10.1016/S0005-2736(00)00337-0; Ran S, 2002, CANCER RES, V62, P6132; Rinaldi AC, 2002, BIOCHEM J, V368, P91, DOI 10.1042/BJ20020806; SCHAFER H, 1995, J MAGN RESON SER A, V116, P145, DOI 10.1006/jmra.1995.0002; SEELIG A, 1974, BIOCHEMISTRY-US, V13, P4839, DOI 10.1021/bi00720a024; SEELIG J, 1978, BIOCHIM BIOPHYS ACTA, V515, P105, DOI 10.1016/0304-4157(78)90001-1; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Shin SY, 2001, J PEPT RES, V58, P504, DOI 10.1034/j.1399-3011.2001.00934.x; STERNIN E, 1983, J MAGN RESON, V55, P274, DOI 10.1016/0022-2364(83)90239-1; TURNER GL, 1986, J MAGN RESON, V70, P408, DOI 10.1016/0022-2364(86)90129-0; UTSUGI T, 1991, CANCER RES, V51, P3062; Vogt TCB, 1999, J BIOL CHEM, V274, P29115, DOI 10.1074/jbc.274.41.29115; Wieprecht T, 1997, BIOCHEMISTRY-US, V36, P12869, DOI 10.1021/bi971398n; Yang N, 2004, J PEPT SCI, V10, P37, DOI 10.1002/psc.470; Yang N, 2002, J PEPT RES, V60, P187, DOI 10.1034/j.1399-3011.2002.21008.x; Zelphati O, 1996, P NATL ACAD SCI USA, V93, P11493, DOI 10.1073/pnas.93.21.11493	43	79	79	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					320	322		10.1096/fj.05-4293fje	http://dx.doi.org/10.1096/fj.05-4293fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16352649				2022-12-28	WOS:000207915000007
J	Goffinet, C; Keppler, OT				Goffinet, C; Keppler, OT			Efficient nonviral gene delivery into primary lymphocytes from rats and mice	FASEB JOURNAL			English	Article						T cells; B cells; NK cells; nucleofection; rodents	IMMUNODEFICIENCY-VIRUS TYPE-1; NATURAL-KILLER-CELLS; T-CELL; B-LYMPHOCYTES; IN-VIVO; TRANSIENT TRANSFECTION; HIV-1 INFECTION; PLASMID DNA; THERAPY; CD4	A rapid method for efficient gene delivery into primary rodent lymphocytes would greatly facilitate the study of signaling and metabolic pathways in untransformed hematopoietic cells as well as the validation of gene expression and targeting strategies before the generation of knockout or knock-down animals. Here, we report that species-adapted nucleofection procedures combined with optimized cultivation conditions render proliferating primary T cells, B cells, and natural killer cells from widely used rat and mouse strains susceptible to high-level gene delivery. As a result, transgene expression levels were enhanced similar to 10- to 370-fold over established protocols. The effectiveness of the nucleofection approach for functional analyses was demonstrated by specific down-regulation of CD4 cell surface molecules by either transient expression of the endocytosis-inducing Nef protein from human immunodeficiency virus or by specific gene silencing mediated by small interfering RNA. In conclusion, this species-adapted procedure for nonviral gene delivery renders primary rodent lymphocytes accessible to rapid functional ex vivo studies, which until now have not been feasible. Furthermore, nucleofection may aid the advancement of therapeutic nonviral gene delivery approaches.	Univ Heidelberg, Dept Virol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Keppler, OT (corresponding author), Univ Heidelberg, Dept Virol, Neuenheimer Feld 324, D-69120 Heidelberg, Germany.	oliver_keppler@med.uni-heidelberg.de	Goffinet, Christine/L-4878-2019; Wilson, Matthew H/K-3193-2013	Goffinet, Christine/0000-0002-3959-004X; 	NIMH NIH HHS [R01-MH64396] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH064396] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abbott A, 2004, NATURE, V428, P464, DOI 10.1038/428464a; Aihara H, 1998, NAT BIOTECHNOL, V16, P867, DOI 10.1038/nbt0998-867; Boulaiz H, 2005, CELL MOL BIOL, V51, P3, DOI 10.1170/T594; BUSCHLE M, 1990, J IMMUNOL METHODS, V133, P77, DOI 10.1016/0022-1759(90)90321-L; Butticaz C, 2003, ANTIVIR THER, V8, P373; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Cron RQ, 1997, J IMMUNOL METHODS, V205, P145, DOI 10.1016/S0022-1759(97)00065-3; Doms RW, 2000, GENE DEV, V14, P2677, DOI 10.1101/gad.833300; Ebert O, 1997, GENE THER, V4, P296, DOI 10.1038/sj.gt.3300394; Fernandez-Llebrez P, 2004, J NEUROPATH EXP NEUR, V63, P574, DOI 10.1093/jnen/63.6.574; Friedmann T, 1997, ANN MED, V29, P575, DOI 10.3109/07853899709007485; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; Gaspar HB, 2005, EXPERT OPIN BIOL TH, V5, P1175, DOI 10.1517/14712598.5.9.1175; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hallett WHD, 2004, CELL MOL IMMUNOL, V1, P12; Hanazono Y, 2000, J HEMATOTH STEM CELL, V9, P611, DOI 10.1089/15258160050196641; Hozumi K, 2000, IMMUNOL LETT, V71, P61, DOI 10.1016/S0165-2478(99)00167-4; Huang H, 1998, J IMMUNOL METHODS, V215, P173, DOI 10.1016/S0022-1759(98)00088-X; Keppler OT, 1999, GLYCOBIOLOGY, V9, P557, DOI 10.1093/glycob/9.6.557; Keppler OT, 2005, J VIROL, V79, P1655, DOI 10.1128/JVI.79.3.1655-1665.2005; Keppler OT, 2002, J EXP MED, V195, P719, DOI 10.1084/jem.20011549; Lai W, 2003, J IMMUNOL METHODS, V282, P93, DOI 10.1016/j.jim.2003.07.015; Lechardeur D, 2005, ADV DRUG DELIVER REV, V57, P755, DOI 10.1016/j.addr.2004.12.008; Li LH, 2001, FASEB J, V15, P586, DOI 10.1096/fj.00-0447fje; McManus MT, 2002, J IMMUNOL, V169, P5754, DOI 10.4049/jimmunol.169.10.5754; Michel N, 2005, CURR BIOL, V15, P714, DOI 10.1016/j.cub.2005.02.058; MINCHIN SA, 1990, J IMMUNOL, V145, P2427; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; Muller JR, 1998, J IMMUNOL, V161, P1354; Murata K, 1996, INT J CANCER, V68, P102, DOI 10.1002/(SICI)1097-0215(19960927)68:1<102::AID-IJC18>3.0.CO;2-D; Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725; Paul Stephane, 2002, Current Gene Therapy, V2, P91, DOI 10.2174/1566523023348101; Peng SL, 2001, IMMUNITY, V14, P13, DOI 10.1016/S1074-7613(01)00085-1; Rajagopalan S, 2000, METH MOL B, V121, P265; Rols MP, 1998, NAT BIOTECHNOL, V16, P168, DOI 10.1038/nbt0298-168; Rossi GR, 2003, HUM GENE THER, V14, P385, DOI 10.1089/104303403321208989; Schakowski Frank, 2004, Genet Vaccines Ther, V2, P1, DOI 10.1186/1479-0556-2-1; Suzuki T, 1998, FEBS LETT, V425, P436, DOI 10.1016/S0014-5793(98)00284-1; Tarner IH, 2003, ANN NY ACAD SCI, V998, P512, DOI 10.1196/annals.1254.067; Tarner IH, 2002, CLIN IMMUNOL, V105, P304, DOI 10.1006/clim.2002.5299; TITOMIROV AV, 1991, BIOCHIM BIOPHYS ACTA, V1088, P131, DOI 10.1016/0167-4781(91)90162-F; Trompeter HI, 2003, J IMMUNOL METHODS, V274, P245, DOI 10.1016/S0022-1759(02)00431-3; Tsai G, 2004, P NATL ACAD SCI USA, V101, P8485, DOI 10.1073/pnas.0402662101; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; Volpers C, 2004, J GENE MED, V6, pS164, DOI 10.1002/jgm.496; Wang JJ, 2004, MOL THER, V9, P577, DOI 10.1016/j.ymthe.2003.12.011; Youinou P, 2005, ANN NY ACAD SCI, V1050, P19, DOI 10.1196/annals.1313.003; Zhou N, 2004, GENE THER, V11, P1703, DOI 10.1038/sj.gt.3302339	49	53	54	2	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					500	+		10.1096/fj.05-4651fje	http://dx.doi.org/10.1096/fj.05-4651fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16401643				2022-12-28	WOS:000235996000030
J	Pullar, CE; Grahn, JC; Liu, W; Isseroff, RR				Pullar, CE; Grahn, JC; Liu, W; Isseroff, RR			beta 2-Adrenergic receptor activation delays wound healing	FASEB JOURNAL			English	Article						wound re-epithelialization; ERK activation; keratinocyte migration; focal adhesions	HUMAN EPIDERMAL-KERATINOCYTES; BETA-ADRENERGIC STIMULATION; PROTEIN PHOSPHATASE 2A; CELL-MIGRATION; BETA(2)-ADRENERGIC RECEPTOR; HUMAN SKIN; EXTRACELLULAR-MATRIX; KINASE ACTIVATION; FOCAL ADHESIONS; GROWTH	Keratinocytes migrate directionally into the wound bed to initiate re-epithelialization, necessary for wound closure and restoration of barrier function. They solely express the beta 2-adrenergic receptor (beta 2-AR) subtype of beta-ARs and can also synthesize beta-AR agonists generating a hormonal mediator network in the skin. Emerging studies from our laboratory demonstrate that beta-AR agonists decrease keratinocyte migration via a protein phosphatase (PP) 2A-dependent mechanism. Here we have extended our investigations to observe the effects of beta 2-AR activation on keratinocyte polarization, migration, and ERK phosphorylation at the wound edge, cytoskeletal organization, phospho-ERK intracellular localization, proliferation, human skin wound re-epithelialization, wound-induced ERK phosphorylation, and murine skin wound healing. We demonstrate that in keratinocytes, beta 2-AR activation is antimotogenic and anti-mitogenic with both mechanisms being PP2A dependent. beta 2-AR activation dramatically alters the organization of the actin cytoskeleton and prevents localization of phospho-ERK to the lamellipodial edge and its colocalization with vinculin. Finally, we demonstrate a beta 2-AR-mediated delay in re-epithelialization and decrease in wound-induced epidermal ERK phosphorylation in human skin wounds and a delay in re-epithelialization in murine tail-clip wounds. Our work uncovers novel keratinocyte biology and a previously unrecognized role for the adrenergic hormonal mediator network in the wound repair process. Pullar, C. E., Grahn, J. C., Liu, W., Isseroff, R. R. beta 2-Adrenergic receptor activation delays wound healing.	Univ Calif Davis, Dept Dermatol, Davis, CA 95616 USA	University of California System; University of California Davis	Pullar, CE (corresponding author), Univ Calif Davis, Dept Dermatol, TB 192,1 Shields Ave, Davis, CA 95616 USA.	cepullar@ucdavis.edu	Isseroff, Roslyn Rivkah/AAD-8478-2021	Isseroff, Roslyn Rivkah/0000-0001-7813-0858	NIAMS NIH HHS [AR 44518, AR 48827] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044518, K01AR048827] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahmed N, 2002, ONCOGENE, V21, P1370, DOI 10.1038/sj.onc.1205286; Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Arbabi S, 2004, J TRAUMA, V56, P265, DOI 10.1097/01.TA.0000109859.91202.C8; Ashcroft GS, 2003, J CLIN INVEST, V111, P1309, DOI 10.1172/KCO200316288; Beningo KA, 2001, J CELL BIOL, V153, P881, DOI 10.1083/jcb.153.4.881; Bogoyevitch MA, 1996, BIOCHEM J, V314, P115, DOI 10.1042/bj3140115; BURRIDGE K, 1989, BIOESSAYS, V10, P104, DOI 10.1002/bies.950100403; Chen J, 2002, J INVEST DERMATOL, V119, P1261, DOI 10.1046/j.1523-1747.2002.19611.x; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Cupp Craig L, 2002, Facial Plast Surg, V18, P53, DOI 10.1055/s-2002-19827; D'Souza SJA, 2002, J BIOL CHEM, V277, P10626, DOI 10.1074/jbc.M111956200; Denda M, 2003, J INVEST DERMATOL, V121, P142, DOI 10.1046/j.1523-1747.2003.12310.x; Denda M, 2000, AM J PHYSIOL-REG I, V278, pR367, DOI 10.1152/ajpregu.2000.278.2.R367; Detillion CE, 2004, PSYCHONEUROENDOCRINO, V29, P1004, DOI 10.1016/j.psyneuen.2003.10.003; DONALDSON DJ, 1984, COMP BIOCHEM PHYS C, V78, P267, DOI 10.1016/0742-8413(84)90081-1; EEDY DJ, 1990, BRIT J DERMATOL, V122, P477, DOI 10.1111/j.1365-2133.1990.tb14724.x; Frank DE, 2004, J CELL SCI, V117, P1351, DOI 10.1242/jcs.01003; GABBIANI G, 1978, J CELL BIOL, V76, P561, DOI 10.1083/jcb.76.3.561; Gillbro JM, 2004, J INVEST DERMATOL, V123, P346, DOI 10.1111/j.0022-202X.2004.23210.x; Gilmore AP, 1996, STRUCTURE, V4, P647, DOI 10.1016/S0969-2126(96)00069-X; HAAS AF, 1990, J INVEST DERMATOL, V94, P822, DOI 10.1111/1523-1747.ep12874679; Haruta Y, 1997, Eur J Ophthalmol, V7, P334; ISSEROFF RR, 1987, J LIPID RES, V28, P1342; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Kawada M, 1999, BBA-MOL CELL RES, V1452, P209, DOI 10.1016/S0167-4889(99)00126-3; Kiely PA, 2005, J BIOL CHEM, V280, P7624, DOI 10.1074/jbc.M412889200; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kratz G, 1998, MICROSC RES TECHNIQ, V42, P345, DOI 10.1002/(SICI)1097-0029(19980901)42:5<345::AID-JEMT5>3.0.CO;2-O; KUBLER MD, 1993, J INVEST DERMATOL, V100, P785, DOI 10.1111/1523-1747.ep12476492; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; LIU GS, 1990, J OCUL PHARMACOL, V6, P101, DOI 10.1089/jop.1990.6.101; Liu ZX, 2002, J BIOL CHEM, V277, P10452, DOI 10.1074/jbc.M107551200; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Matsubayashi Y, 2004, CURR BIOL, V14, P731, DOI 10.1016/j.cub.2004.03.060; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; MCSWIGAN JD, 1981, P NATL ACAD SCI-BIOL, V78, P7670, DOI 10.1073/pnas.78.12.7670; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Mulrooney J, 2000, EXP CELL RES, V258, P332, DOI 10.1006/excr.2000.4964; Nankova BB, 1999, ACTA PHYSIOL SCAND, V167, P1; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Providence KM, 2004, J CELL PHYSIOL, V200, P297, DOI 10.1002/jcp.20016; Pullar CE, 2003, J BIOL CHEM, V278, P22555, DOI 10.1074/jbc.M300205200; REIDY JJ, 1994, BRIT J OPHTHALMOL, V78, P377, DOI 10.1136/bjo.78.5.377; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; SCHALLREUTER KU, 1993, ARCH DERMATOL RES, V285, P216, DOI 10.1007/BF00372012; SCHALLREUTER KU, 1995, J INVEST DERMATOL, V104, P953, DOI 10.1111/1523-1747.ep12606218; Schallreuter KU, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P37, DOI 10.1038/jidsymp.1997.9; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Sharma GD, 2003, J BIOL CHEM, V278, P21989, DOI 10.1074/jbc.M302650200; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Stahle M, 2003, J CELL SCI, V116, P3835, DOI 10.1242/jcs.00679; STEINKRAUS V, 1992, J INVEST DERMATOL, V98, P475, DOI 10.1111/1523-1747.ep12499860; Steinkraus V, 1996, ARCH DERMATOL RES, V288, P549, DOI 10.1007/BF02505253; Tseraidis G S, 1972, Vestn Dermatol Venerol, V46, P40; Turchi L, 2002, J INVEST DERMATOL, V119, P56, DOI 10.1046/j.1523-1747.2002.01805.x; Ugi S, 2004, MOL CELL BIOL, V24, P8778, DOI 10.1128/MCB.24.19.8778-8789.2004; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271; Zou YZ, 2001, CIRCULATION, V104, P102, DOI 10.1161/hc2601.090987	60	81	86	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					76	86		10.1096/fj.05-4188com	http://dx.doi.org/10.1096/fj.05-4188com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16394270				2022-12-28	WOS:000235996000047
J	Razzaque, MS; Sitara, D; Taguchi, T; St-Arnaud, R; Lanske, B				Razzaque, MS; Sitara, D; Taguchi, T; St-Arnaud, R; Lanske, B			Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process	FASEB JOURNAL			English	Article						rescue; klotho; phosphate	FAMILIAL TUMORAL CALCINOSIS; OXIDATIVE STRESS; HUMAN EPIDERMIS; MUTATION; APOPTOSIS; HYPERPHOSPHATEMIA; EXPRESSION; DEFICIENT; PHOSPHATE; ABLATION	Fibroblast growth factor 23 null mice (Fgf-23(-/-)) have a short lifespan and show numerous biochemical and morphological features consistent with premature aging-like phenotypes, including kyphosis, severe muscle wasting, hypogonadism, osteopenia, emphysema, uncoordinated movement, T cell dysregulation, and atrophy of the intestinal villi, skin, thymus, and spleen. Furthermore, increased vitamin D activities in homozygous mutants are associated with severe atherosclerosis and widespread soft tissue calcifications; ablation of vitamin D activity from Fgf-23(-/-) mice, by genetically deleting the 1 alpha(OH)ase gene, eliminates atherosclerosis and ectopic calcifications and significantly rescues premature aging-like features of Fgf-23(-/-) mice, resulting in prolonged survival of Fgf-23(-/-)/ 1 alpha(OH)ase(-/-) double mutants. Our results indicate a novel role of Fgf-23 in developing premature aging-like features through regulating vitamin D homeostasis. Finally, our data support a new model of interactions among Fgf-23, vitamin D, and klotho, a gene described as being associated with premature aging process.	Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA; Nagasaki Univ, Grad Sch Biomed Sci, Dept Pathol, Nagasaki 852, Japan; Shriners Hosp Children, Genet Unit, Montreal, PQ, Canada	Harvard University; Harvard School of Dental Medicine; Nagasaki University; McGill University	Lanske, B (corresponding author), Harvard Univ, Sch Dent Med, Dept Dev Biol, Res & Educ Bldg,Room 303,188 Longwood Ave, Boston, MA 02115 USA.	beate_lanske@hsdm.harvard.edu	Razzaque, Mohammed S./K-4282-2019; RAZZAQUE, MOHAMMED/M-6017-2019	SITARA, DESPINA/0000-0002-4836-5039; Lanske, Beate/0000-0003-4638-804X	NIDDK NIH HHS [R01 DK073944-01A2, R01 DK073944] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073944] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai XY, 2004, ENDOCRINOLOGY, V145, P5269, DOI 10.1210/en.2004-0233; Benet-Pages A, 2005, HUM MOL GENET, V14, P385, DOI 10.1093/hmg/ddi034; Dardenne O, 2001, ENDOCRINOLOGY, V142, P3135, DOI 10.1210/en.142.7.3135; de Boer J, 2002, SCIENCE, V296, P1276, DOI 10.1126/science.1070174; Delmas D, 2005, MOL NUTR FOOD RES, V49, P377, DOI 10.1002/mnfr.200400098; Dolle MET, 1997, NAT GENET, V17, P431, DOI 10.1038/ng1297-431; Edwards MG, 2003, PHYSIOL GENOMICS, V13, P119, DOI 10.1152/physiolgenomics.00172.2002; EVERS BM, 1994, SURG CLIN N AM, V74, P23; Gilhar A, 2004, BRIT J DERMATOL, V150, P56, DOI 10.1111/j.1365-2133.2004.05715.x; Gilhar A, 2004, J GERONTOL A-BIOL, V59, P411; Ichikawa S, 2005, J CLIN ENDOCR METAB, V90, P2420, DOI 10.1210/jc.2004-2302; Johnson FB, 1999, CELL, V96, P291, DOI 10.1016/S0092-8674(00)80567-X; Judge S, 2005, FASEB J, V19, P419, DOI 10.1096/fj.04-2622fje; Kawai T, 2000, J IMMUNOL, V164, P2102, DOI 10.4049/jimmunol.164.4.2102; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Lakatta EG, 2003, CIRCULATION, V107, P139, DOI 10.1161/01.CIR.0000048892.83521.58; Larsson T, 2005, J CLIN ENDOCR METAB, V90, P2424, DOI 10.1210/jc.2004-2238; MARTIN CJ, 1977, AM REV RESPIR DIS, V115, P981; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; QUARLESLD, 2003, AM J PHYSL ENDOCRINO, V285, pE1; Radak Z, 2004, FASEB J, V18, P749, DOI 10.1096/fj.03-0509fje; Rauser CL, 2003, EXP GERONTOL, V38, P27, DOI 10.1016/S0531-5565(02)00148-1; Razzaque MS, 2005, NEPHROL DIAL TRANSPL, V20, P2032, DOI 10.1093/ndt/gfh991; Razzaque MS, 1997, J PATHOL, V183, P24; Razzaque MS, 2003, INVEST OPHTH VIS SCI, V44, P1616, DOI 10.1167/iovs.02-0644; Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081; Sitara D, 2004, MATRIX BIOL, V23, P421, DOI 10.1016/j.matbio.2004.09.007; Taub DD, 2005, IMMUNOL REV, V205, P72, DOI 10.1111/j.0105-2896.2005.00275.x; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Tsujikawa H, 2003, MOL ENDOCRINOL, V17, P2393, DOI 10.1210/me.2003-0048; Yamamoto K, 2002, EUR HEART J, V23, P277; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696	35	264	274	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					720	+		10.1096/fj.05-5432fje	http://dx.doi.org/10.1096/fj.05-5432fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16436465	Green Accepted			2022-12-28	WOS:000235996000007
J	Bell, RM; Cave, AC; Johar, S; Hearse, DJ; Shah, AM; Shattock, MJ				Bell, RM; Cave, AC; Johar, S; Hearse, DJ; Shah, AM; Shattock, MJ			Pivotal role of NOX-2-containing NADPH oxidase in early ischemic preconditioning	FASEB JOURNAL			English	Article						reperfusion; gp91(phox); reactive oxygen species (ROS); adenosine; PKC	PROTEIN-KINASE-C; ANGIOTENSIN-II; NITRIC-OXIDE; CARDIAC-HYPERTROPHY; FREE-RADICALS; ACTIVATION; ADENOSINE; P47(PHOX); EPSILON; PHOSPHORYLATION	Reactive oxygen species (ROS)-mediated signaling is implicated in early ischemic preconditioning ( PC). A NOX-2-containing NADPH oxidase is a recognized major source of ROS in cardiac myocytes, whose activity is augmented by preconditioning mimetics, such as angiotensin II. We hypothesized that this oxidase is an essential source of ROS in PC. Hearts from wild-type ( WT) and NOX-2 knockout ( KO) mice were Langendorff perfused and subjected to 35 min ischemia/reperfusion with or without preceding PC or drug treatment. Infarct size was measured by triphenyl tetrazolium chloride staining, and NADPH oxidase activity by lucigenin chemiluminescence. PC significantly attenuated infarct size in WT ( 26 +/- 2% vs. control, 38 +/- 2%, P < 0.05) yet was ineffective in KO hearts ( 33 +/- 3% vs. control, 34 +/- 3%). Concomitantly, PC significantly increased NADPH oxidase activity in WT (+ 41 +/- 13%; P < 0.05), but not in KO ( - 5 +/- 18%, P = NS). The ROS scavenger MPG (N-2-mercaptopropionyl glycine, 300 mu mol/ L) abrogated PC in WT ( 39 +/- 2% vs. control, 33 +/- 1%). CCPA ( 2-chloro N6 cyclopentyl adenosine, 200 nmol/L), a putative ROS-independent PC trigger, significantly attenuated infarct size in WT, MPG-treated WT and KO hearts ( 24 +/- 2, 23 +/- 1, and 20 +/- 3%, respectively, P < 0.05). Furthermore, CCPA did not augment NADPH oxidase activity over control (+ 22 +/- 11%, P = NS). Inhibition of protein kinase C (PKC) with chelerythrine (CHE, 2 mu mol/ L) completely abrogated both PC ( 38 +/- 2% vs. CHE alone, 35 +/- 2%) and associated increases in oxidase activity (+ 3 +/- 10%, P = NS). PKC-dependent activation of a NOX-2-containing NADPH oxidase is pivotally involved in early ischemic PC. However, adenosine receptor activation can trigger a ROS and NOX-2 independent PC pathway.	Kings Coll London, St Thomas Hosp, Rayne Inst, Div Cardiovasc, London SE1 7EH, England; Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Cardiol, Div Cardiovasc, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; King's College London	Shattock, MJ (corresponding author), Kings Coll London, St Thomas Hosp, Rayne Inst, Div Cardiovasc, London SE1 7EH, England.	michael.shattock@kcl.ac.uk	Johar, Sofian/AAX-7450-2021	Johar, Sofian/0000-0002-5962-6492; Shattock, Michael/0000-0001-6242-7585; Shah, Ajay/0000-0002-6547-0631				Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Baines CP, 1997, J MOL CELL CARDIOL, V29, P207, DOI 10.1006/jmcc.1996.0265; Bell RM, 2001, CARDIOVASC RES, V52, P274, DOI 10.1016/S0008-6363(01)00394-7; Bendall JK, 2002, CIRCULATION, V105, P293, DOI 10.1161/hc0302.103712; Broussas M, 1999, J LEUKOCYTE BIOL, V66, P495, DOI 10.1002/jlb.66.3.495; Byrne JA, 2003, CIRC RES, V93, P802, DOI 10.1161/01.RES.0000099504.30207.F5; CLARK KJ, 1995, J BIOL CHEM, V270, P7097, DOI 10.1074/jbc.270.13.7097; Cohen MV, 2001, CIRC RES, V89, P273, DOI 10.1161/hh1501.094266; Das DK, 1999, MOL CELL BIOCHEM, V196, P59, DOI 10.1023/A:1006966128795; Di-Capua N, 2003, J NEUROCHEM, V84, P409, DOI 10.1046/j.1471-4159.2003.01563.x; Diaz RJ, 1997, J MOL CELL CARDIOL, V29, P129, DOI 10.1006/jmcc.1996.0258; Dikalov S, 1996, ARCH BIOCHEM BIOPHYS, V326, P207, DOI 10.1006/abbi.1996.0067; Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Iliodromitis EK, 1998, J MOL CELL CARDIOL, V30, P2201, DOI 10.1006/jmcc.1998.0780; Kawamura S, 1998, AM J PHYSIOL-HEART C, V275, pH2266; Krause KH, 2004, JPN J INFECT DIS, V57, pS28; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lebuffe G, 2003, AM J PHYSIOL-HEART C, V284, pH299, DOI 10.1152/ajpheart.00706.2002; Li JM, 2002, HYPERTENSION, V40, P477, DOI 10.1161/01.HYP.0000032031.30374.32; Li JM, 2002, CIRC RES, V90, P143, DOI 10.1161/hh0202.103615; Liu HP, 2001, AM J PHYSIOL-HEART C, V281, pH191; LIU YG, 1995, J MOL CELL CARDIOL, V27, P883, DOI 10.1016/0022-2828(95)90038-1; MARTYN KD, 2005, CELL SIGNAL      MAY; Miyamae M, 1998, P NATL ACAD SCI USA, V95, P8262, DOI 10.1073/pnas.95.14.8262; Miyawaki H, 1997, CIRC RES, V80, P790, DOI 10.1161/01.res.80.6.790; Mocanu MM, 2002, J MOL CELL CARDIOL, V34, P661, DOI 10.1006/jmcc.2002.2006; Nakano A, 1997, CORONARY ARTERY DIS, V8, P343, DOI 10.1097/00019501-199706000-00003; Paul K, 1997, CIRC RES, V81, P643; Ping PP, 1999, CIRC RES, V84, P587, DOI 10.1161/01.RES.84.5.587; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; REIMER KA, 1986, AM J PHYSIOL, V251, pH1306, DOI 10.1152/ajpheart.1986.251.6.H1306; Seshiah PN, 2002, CIRC RES, V91, P406, DOI 10.1161/01.RES.0000033523.08033.16; Tani M, 2001, CARDIOVASC RES, V49, P56, DOI 10.1016/S0008-6363(00)00240-6; Yamamori T, 2004, BIOCHEM BIOPH RES CO, V316, P720, DOI 10.1016/j.bbrc.2004.02.108; YAMAZAKI T, 1995, CIRC RES, V77, P258, DOI 10.1161/01.RES.77.2.258; Yao ZH, 1999, AM J PHYSIOL-HEART C, V277, pH2504; Yue Y, 2002, CARDIOVASC RES, V55, P681, DOI 10.1016/S0008-6363(02)00452-2; Zimmerman MC, 2004, CIRC RES, V95, P532, DOI 10.1161/01.RES.0000139957.22530.b9; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001	40	77	79	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2037	+		10.1096/fj.04-2774fje	http://dx.doi.org/10.1096/fj.04-2774fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16236999				2022-12-28	WOS:000232991100012
J	Asmis, R; Wang, YM; Xu, L; Kisgati, M; Begley, JG; Mieyal, JJ				Asmis, R; Wang, YM; Xu, L; Kisgati, M; Begley, JG; Mieyal, JJ			A novel thiol oxidation-based mechanism for adriamycin-induced cell injury in human macrophages	FASEB JOURNAL			English	Article						cell death; oxidative stress; glutathione; glutathione reductase; glutaredoxin	MONOCYTE-DERIVED MACROPHAGES; LOW-DENSITY-LIPOPROTEIN; GLUTATHIONE-REDUCTASE; S-GLUTATHIONYLATION; ANTICANCER AGENTS; CARDIAC TOXICITY; REDOX; INHIBITION; MOUSE; ACID	Adriamycin is a widely used antitumor antibiotic, but its use has been limited by its cytotoxicity in both cardiomyocytes and non-cardiac tissues. While adriamycin's ability to redox cycle via one-electron transfer reactions and generate ROS is thought to promote cardiotoxicity, the mechanisms involved in non-cardiac tissue injury are not clear. Here we show that prolonged exposure ( 48 h) of human monocyte-derived macrophages to adriamycin at concentrations as low as 1 mu M promotes caspase-independent cell death. Treatment of cells with scavengers of superoxide and peroxyl radicals blocked adriamycin-induced oxidation of dichlorodihydrofluorescein ( DCFH) but did not prevent macrophage injury. Macrophages treated with either adriamycin or the thiol oxidant diamide showed elevated levels of glutathione disulfide and increased protein-S-glutathionylation prior to cell injury, indicating that thiol oxidation is involved in adriamycin-induced macrophage death. Furthermore, inhibition of glutathione reductase (GR) with 1,3-bis[2-chloroethyl]-1-nitrosourea or transfection of macrophages with small inhibitory RNA ( siRNA) directed against GR or glutaredoxin (Grx) potentiated adriamycin-induced macrophage injury. Thus, both GR and Grx appear to play a crucial role in protecting macrophages from adriamycin-induced cell injury. These findings suggest a new mechanism for adriamycin-induced tissue injury whereby thiol oxidation, rather than one-electron redox cycling and ROS generation, mediates adriamycin-induced cell damage.	Univ Kentucky, Div Cardiovasc Med, Lexington, KY 40506 USA; Univ Kentucky, Grad Ctr Nutr Sci, Lexington, KY 40506 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA	University of Kentucky; University of Kentucky; Case Western Reserve University	Asmis, R (corresponding author), Univ Texas, Hlth Sci Ctr, Div Nephrol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	asmis@uthscsa.edu			NHLBI NIH HHS [HL-70963] Funding Source: Medline; NIA NIH HHS [2 PO1 AG-15885, 1 R01 AG-024413] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG015885, R01AG024413] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Asmis R, 1998, EUR J BIOCHEM, V255, P147, DOI 10.1046/j.1432-1327.1998.2550147.x; Asmis R, 2003, CIRC RES, V92, pE20, DOI 10.1161/01.RES.0000051886.43510.90; Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; BEELEN RHJ, 1989, HUMAN MONOCYTES, P7; Birtle AJ, 2000, CLIN ONCOL-UK, V12, P146, DOI 10.1053/clon.2000.9141; BLAND KI, 1984, ANN SURG, V199, P782, DOI 10.1097/00000658-198406000-00017; BRUNMARK A, 1989, FREE RADICAL BIO MED, V7, P435, DOI 10.1016/0891-5849(89)90126-3; Chaudiere J, 1999, FOOD CHEM TOXICOL, V37, P949, DOI 10.1016/S0278-6915(99)00090-3; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; CROMACK DT, 1990, J TRAUMA, V30, pS129; DENEKE SM, 1989, AM J PHYSIOL, V257, P163; DEVEREUX DF, 1979, CANCER, V43, P932, DOI 10.1002/1097-0142(197903)43:3<932::AID-CNCR2820430322>3.0.CO;2-A; DiPietro LA, 1998, J CLIN INVEST, V101, P1693, DOI 10.1172/JCI1020; DIPIETRO LA, 1995, SHOCK, V4, P233, DOI 10.1097/00024382-199510000-00001; DOROSHOW JH, 1981, J CLIN INVEST, V68, P1053, DOI 10.1172/JCI110328; EHRKE MJ, 1989, SEMIN ONCOL, V16, P230; Fernberg JO, 2001, MED ONCOL, V18, P231, DOI 10.1385/mo:18:3:231; FINLEY KT, 1974, CHEM QUINOID COMPO 2, P878; GANT TW, 1988, CHEM-BIOL INTERACT, V65, P157, DOI 10.1016/0009-2797(88)90052-X; Garner AP, 1999, CANCER RES, V59, P1929; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Giustarini D, 2004, J CELL MOL MED, V8, P201, DOI 10.1111/j.1582-4934.2004.tb00275.x; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Groves R W, 2000, Adv Skin Wound Care, V13, P107; HARRISON LE, 1995, J SURG RES, V58, P646; Horenstein MS, 2000, MOL GENET METAB, V71, P436, DOI 10.1006/mgme.2000.3043; Jung K, 2001, ADV DRUG DELIVER REV, V49, P87, DOI 10.1016/S0169-409X(01)00128-4; Kang YJ, 2002, CHEM RES TOXICOL, V15, P1, DOI 10.1021/tx015532n; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Lothstein L, 2001, DRUG RESIST UPDATE, V4, P169, DOI 10.1054/drup.2001.0201; Low QEH, 2001, AM J PATHOL, V159, P457, DOI 10.1016/S0002-9440(10)61717-8; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; Miura T, 2000, BIOCHEM PHARMACOL, V60, P95, DOI 10.1016/S0006-2952(00)00303-8; Morrissette Naomi, 1999, Trends in Cell Biology, V9, P199, DOI 10.1016/S0962-8924(99)01540-8; PARONI R, 1995, CLIN CHEM, V41, P448; POWELL SR, 1995, FREE RADICAL BIO MED, V18, P159, DOI 10.1016/0891-5849(94)00109-W; REID VC, 1993, ATHEROSCLEROSIS, V98, P17, DOI 10.1016/0021-9150(93)90219-K; Reszka KJ, 2001, BIOCHEMISTRY-US, V40, P15349, DOI 10.1021/bi011869c; Savvides SN, 2002, J BIOL CHEM, V277, P2779, DOI 10.1074/jbc.M108190200; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Shelton MD, 2005, ANTIOXID REDOX SIGN, V7, P348, DOI 10.1089/ars.2005.7.348; Starke DW, 1997, FREE RADICAL BIO MED, V23, P373, DOI 10.1016/S0891-5849(97)00009-9; Ueda-Kawamitsu H, 2002, BIOCHEM PHARMACOL, V63, P1209, DOI 10.1016/S0006-2952(02)00878-X; UNTUCHTGRAU R, 1981, EUR J BIOCHEM, V120, P407, DOI 10.1111/j.1432-1033.1981.tb05718.x; VILE G, 1990, BIOCHEM PHARMACOL, V39, P769, DOI 10.1016/0006-2952(90)90157-G; WELLS WW, 1995, FREE RADICAL BIO MED, V18, P699, DOI 10.1016/0891-5849(94)00188-P; Wintergerst ES, 1998, HISTOCHEM CELL BIOL, V110, P231, DOI 10.1007/s004180050285; Wu LC, 1997, J SURG RES, V72, P162, DOI 10.1006/jsre.1997.5178; Yen HC, 1996, J CLIN INVEST, V98, P1253, DOI 10.1172/JCI118909; Yin XH, 1998, BIOCHEM PHARMACOL, V56, P87, DOI 10.1016/S0006-2952(98)00099-9	50	31	32	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2005	19	11					1866	+		10.1096/fj.04-2991fje	http://dx.doi.org/10.1096/fj.04-2991fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16160061				2022-12-28	WOS:000232315700015
J	Lanone, S; Bloc, S; Foresti, R; Almolki, A; Taille, C; Callebert, J; Conti, M; Goven, D; Aubier, M; Dureuil, B; El-Benna, J; Motterlini, R; Boczkowski, J				Lanone, S; Bloc, S; Foresti, R; Almolki, A; Taille, C; Callebert, J; Conti, M; Goven, D; Aubier, M; Dureuil, B; El-Benna, J; Motterlini, R; Boczkowski, J			Bilirubin decreases NOS2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats	FASEB JOURNAL			English	Article						oxygen free radicals; nitric oxide	HEME OXYGENASE-1; SERUM BILIRUBIN; SYNTHASE EXPRESSION; OXIDATIVE STRESS; IN-VIVO; ANTIOXIDANT; SUPEROXIDE; BILIVERDIN; ACTIVATION; INDUCTION	We investigated a possible beneficial role for bilirubin, one of the products of heme degradation by the cytoprotective enzyme heme oxygenase-1 in counteracting Escherichia coli endotoxin-mediated toxicity. Homozygous jaundice Gunn rats, which display high plasma bilirubin levels due to deficiency of glucuronyl transferase activity, and Sprague-Dawley rats subjected to sustained exogenous bilirubin administration were more resistant to endotoxin (LPS)-induced hypotension and death compared with nonhyperbilirubinemic rats. LPS-stimulated production of nitric oxide ( NO) was significantly decreased in hyperbilirubinemic rats compared with normal animals; this effect was associated with reduction of inducible NO synthase (NOS2) expression in renal, myocardial, and aortic tissues. Furthermore, NOS2 protein expression and activity were reduced in murine macrophages stimulated with LPS and preincubated with bilirubin at concentrations similar to that found in the serum of hyperbilirubinemic animals. This effect was secondary to inhibition of NAD(P)H oxidase since 1) inhibition of NAD(P) H oxidase attenuated NOS2 induction by LPS, 2) bilirubin decreased NAD(P) H oxidase activity in vivo and in vitro, and 3) down-regulation of NOS2 by bilirubin was reversed by addition of NAD(P) H. These findings indicate that bilirubin can act as an effective agent to reduce mortality and counteract hypotension elicited by endotoxin through mechanisms involving a decreased NOS2 induction secondary to inhibition of NAD(P)H oxidase.	INSERM, U700, Fac 10, F-75870 Paris, France; Univ Paris 07, Fac Med Xavier Bichat, U683, Paris, France; Northwick Pk Inst Med Res, Dept Surg Res, Vasc Biol Unit, Harrow, Middx, England; Univ Paris 07, Hop Lariboisiere, Serv Biochim, Paris, France; Univ Paris 11, Hop Kremlin Bicetre, Serv Biochim, Paris, France; Hop Charles Nicole, Dept Anesthesie Reanimat, Rouen, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Imperial College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; CHU de Rouen	Boczkowski, J (corresponding author), INSERM, U700, Fac 10, Bichat BP416, F-75870 Paris, France.	jbb2@bichat.inserm.fr	Motterlini, Roberto/G-2489-2013; Boczkowski, Jorge/S-7474-2018; Motterlini, Roberto/Q-1890-2019; Lanone, Sophie/I-4042-2016; Taille, Camille/J-3751-2017; callebert, jacques/L-4569-2017	Motterlini, Roberto/0000-0003-2684-2612; Boczkowski, Jorge/0000-0001-6619-5785; Motterlini, Roberto/0000-0003-2684-2612; Lanone, Sophie/0000-0003-2509-8799; foresti, roberta/0000-0002-0836-7937				Adin CA, 2005, AM J PHYSIOL-RENAL, V288, pF778, DOI 10.1152/ajprenal.00215.2004; Babior BM, 2002, ARCH BIOCHEM BIOPHYS, V397, P342, DOI 10.1006/abbi.2001.2642; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; BENARON DA, 1991, LANCET, V338, P78, DOI 10.1016/0140-6736(91)90074-Y; Boczkowski J, 1996, J CLIN INVEST, V98, P1550, DOI 10.1172/JCI118948; Carreras MC, 2004, HEPATOLOGY, V40, P157, DOI 10.1002/hep.20255; Chen CC, 1999, MOL PHARMACOL, V55, P481; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Clark JE, 2000, AM J PHYSIOL-HEART C, V278, pH643, DOI 10.1152/ajpheart.2000.278.2.H643; CONTI M, 1991, CLIN CHEM, V37, P1273; DENNERY PA, 1995, FREE RADICAL BIO MED, V19, P395, DOI 10.1016/0891-5849(95)00032-S; Dore S, 1999, ANN NY ACAD SCI, V890, P167, DOI 10.1111/j.1749-6632.1999.tb07991.x; Elzi DJ, 2001, AM J PHYSIOL-CELL PH, V281, pC350; Foresti R, 1999, BIOCHEM J, V339, P729, DOI 10.1042/0264-6021:3390729; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; Giovannoni G, 1997, ANN CLIN BIOCHEM, V34, P193, DOI 10.1177/000456329703400212; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Hansen TWR, 1996, PEDIATR RES, V39, P1072, DOI 10.1203/00006450-199606000-00023; Hopkins PN, 1996, ARTERIOSCL THROM VAS, V16, P250, DOI 10.1161/01.ATV.16.2.250; JULOUSCHAEFFER G, 1990, AM J PHYSIOL, V259, pH1038, DOI 10.1152/ajpheart.1990.259.4.H1038; Kato Y, 2003, HEPATOLOGY, V38, P364, DOI 10.1053/jhep.2003.50300; Kaur H, 2003, FEBS LETT, V543, P113, DOI 10.1016/S0014-5793(03)00420-4; Knowles RG, 1998, METH MOL B, V100, P67; Kranc KR, 2000, EUR J BIOCHEM, V267, P7094, DOI 10.1046/j.1432-1327.2000.01812.x; KWAK JY, 1991, BIOCHIM BIOPHYS ACTA, V1076, P369, DOI 10.1016/0167-4838(91)90478-I; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Macarthur H, 2000, P NATL ACAD SCI USA, V97, P9753, DOI 10.1073/pnas.97.17.9753; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Nakao A, 2004, GASTROENTEROLOGY, V127, P595, DOI 10.1053/j.gastro.2004.05.059; O'Brien A, 2001, AM J RESP CRIT CARE, V164, P365, DOI 10.1164/ajrccm.164.3.2002052; O'Dowd Y, 2004, BIOCHEM PHARMACOL, V68, P2003, DOI 10.1016/j.bcp.2004.06.023; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Piao YJ, 2005, FREE RADICAL BIO MED, V38, P989, DOI 10.1016/j.freeradbiomed.2004.11.011; Polytarchou C, 2004, FREE RADICAL RES, V38, P501, DOI 10.1080/10715760410001684621; Ritter C, 2004, CRIT CARE MED, V32, P342, DOI 10.1097/01.CCM.0000109454.13145.CA; Samb A, 2002, AM J PHYSIOL-LUNG C, V283, pL596, DOI 10.1152/ajplung.00446.2001; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Taille C, 2005, J BIOL CHEM, V280, P25350, DOI 10.1074/jbc.M503512200; Taille C, 2004, J BIOL CHEM, V279, P28681, DOI 10.1074/jbc.M310661200; TANAKA Y, 1992, NEUROSURGERY, V30, P195, DOI 10.1227/00006123-199202000-00008; Temme EHM, 2001, CANCER CAUSE CONTROL, V12, P887, DOI 10.1023/A:1013794407325; Wang WZW, 2004, HEPATOLOGY, V40, P424, DOI 10.1002/hep.20334; YAMAGUCHI T, 1995, BIOCHEM BIOPH RES CO, V214, P11, DOI 10.1006/bbrc.1995.2250; Zhou J, 1999, PHARMACOL RES, V39, P363, DOI 10.1006/phrs.1998.0450	44	206	211	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1890	+		10.1096/fj.04-2368fje	http://dx.doi.org/10.1096/fj.04-2368fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16129699				2022-12-28	WOS:000231843700004
J	Gombart, AF; Borregaard, N; Koeffler, HP				Gombart, AF; Borregaard, N; Koeffler, HP			Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D-3	FASEB JOURNAL			English	Article						sepsis; wound healing; monocytes; VDRE	C/EBP-EPSILON; ANTIBACTERIAL PEPTIDES; HUMAN KERATINOCYTES; GRANULE DEFICIENCY; SEMINAL PLASMA; GENOME BROWSER; CUTTING EDGE; HOST-DEFENSE; HUMAN CAP18; EXPRESSION	The innate immune system of mammals provides a rapid response to repel assaults from numerous infectious agents including bacteria, viruses, fungi, and parasites. A major component of this system is a diverse combination of cationic antimicrobial peptides that include the alpha- and beta-defensins and cathelicidins. In this study, we show that 1,25-dihydroxyvitamin D-3 and three of its analogs induced expression of the human cathelicidin antimicrobial peptide (CAMP) gene. This induction was observed in acute myeloid leukemia (AML), immortalized keratinocyte, and colon cancer cell lines, as well as normal human bone marrow (BM)-derived macrophages and fresh BM cells from two normal individuals and one AML patient. The induction occurred via a consensus vitamin D response element (VDRE) in the CAMP promoter that was bound by the vitamin D receptor (VDR). Induction of CAMP in murine cells was not observed and expression of CAMP mRNA in murine VDR-deficient bone marrow was similar to wild-type levels. Comparison of mammalian genomes revealed evolutionary conservation of the VDRE in a short interspersed nuclear element or SINE in the CAMP promoter of primates that was absent in the mouse, rat, and canine genomes. Our findings reveal a novel activity of 1,25-dihydroxyvitamin D3 and the VDR in regulation of primate innate immunity.	Univ Calif Los Angeles, Div Hematol Oncol, David Geffen Sch Med, Dept Med,Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; Univ Copenhagen, Rigshosp, Dept Hematol, DK-2100 Copenhagen, Denmark	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Rigshospitalet; University of Copenhagen	Gombart, AF (corresponding author), Univ Calif Los Angeles, Div Hematol Oncol, David Geffen Sch Med, Dept Med,Cedars Sinai Med Ctr, Davis Bldg 5019,8700 Beverly Blvd, Los Angeles, CA 90048 USA.	gombarta@csmc.edu	Gombart, Adrian/AAV-4738-2020	Gombart, Adrian/0000-0001-7830-0693	NATIONAL CANCER INSTITUTE [R01CA026038] Funding Source: NIH RePORTER; NCI NIH HHS [CA26038-20] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agerberth B, 2000, BLOOD, V96, P3086, DOI 10.1182/blood.V96.9.3086.h8003086_3086_3093; Anderson E, 2002, HUM REPROD, V17, P2529, DOI 10.1093/humrep/17.10.2529; Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D; Armogida SA, 2004, ALLERGY ASTHMA PROC, V25, P297; Bals R, 1999, J CLIN INVEST, V103, P1113, DOI 10.1172/JCI6570; Bals R, 1998, P NATL ACAD SCI USA, V95, P9541, DOI 10.1073/pnas.95.16.9541; Bals R, 1999, INFECT IMMUN, V67, P6084, DOI 10.1128/IAI.67.11.6084-6089.1999; Boman HG, 2003, J INTERN MED, V254, P197, DOI 10.1046/j.1365-2796.2003.01228.x; Carlberg C, 1998, CRIT REV EUKAR GENE, V8, P19, DOI 10.1615/CritRevEukarGeneExpr.v8.i1.20; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; Di Nardo A, 2003, J IMMUNOL, V170, P2274, DOI 10.4049/jimmunol.170.5.2274; Dorschner RA, 2001, J INVEST DERMATOL, V117, P91, DOI 10.1046/j.1523-1747.2001.01340.x; Erdag G, 2002, ANN SURG, V235, P113, DOI 10.1097/00000658-200201000-00015; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Frohm M, 1996, EUR J BIOCHEM, V237, P86, DOI 10.1111/j.1432-1033.1996.0086n.x; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Gombart AF, 2002, CURR OPIN HEMATOL, V9, P36, DOI 10.1097/00062752-200201000-00007; Gombart AF, 2001, BLOOD, V97, P2561, DOI 10.1182/blood.V97.9.2561; Hammami-Hamza S, 2001, MOL HUM REPROD, V7, P625, DOI 10.1093/molehr/7.7.625; Hancock R. E. W., 2002, Current Drug Targets - Infectious Disorders, V2, P79, DOI 10.2174/1568005024605855; Hancock REW, 2000, P NATL ACAD SCI USA, V97, P8856, DOI 10.1073/pnas.97.16.8856; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; Hancock REW, 2000, TRENDS MICROBIOL, V8, P402, DOI 10.1016/S0966-842X(00)01823-0; Hase K, 2003, GASTROENTEROLOGY, V125, P1613, DOI 10.1053/j.gastro.2003.08.028; Hase K, 2002, INFECT IMMUN, V70, P953, DOI 10.1128/IAI.70.2.953-963.2002; Hayes CE, 2003, CELL MOL BIOL, V49, P277; Islam D, 2001, NAT MED, V7, P180, DOI 10.1038/84627; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; KHANNAGUPTA A, 1994, BLOOD, V84, P294; Kirikae T, 1998, INFECT IMMUN, V66, P1861, DOI 10.1128/IAI.66.5.1861-1868.1998; KOEFFLER HP, 1983, BLOOD, V62, P709; Larrick JW, 1996, FEBS LETT, V398, P74, DOI 10.1016/S0014-5793(96)01199-4; LARRICK JW, 1995, INFECT IMMUN, V63, P1291, DOI 10.1128/IAI.63.4.1291-1297.1995; Lehrer RI, 2002, CURR OPIN HEMATOL, V9, P18, DOI 10.1097/00062752-200201000-00004; Lehrer RI, 1999, CURR OPIN IMMUNOL, V11, P23, DOI 10.1016/S0952-7915(99)80005-3; Malm J, 2000, INFECT IMMUN, V68, P4297, DOI 10.1128/IAI.68.7.4297-4302.2000; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Murakami M, 2005, PEDIATR RES, V57, P10, DOI 10.1203/01.PDR.0000148068.32201.50; Murakami M, 2002, J DENT RES, V81, P845, DOI 10.1177/154405910208101210; Murakami M, 2002, J INVEST DERMATOL, V119, P1090, DOI 10.1046/j.1523-1747.2002.19507.x; Nilsson MF, 1999, INFECT IMMUN, V67, P2561, DOI 10.1128/IAI.67.5.2561-2566.1999; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; PERL TM, 1995, JAMA-J AM MED ASSOC, V274, P338, DOI 10.1001/jama.274.4.338; Putsep K, 2002, LANCET, V360, P1144, DOI 10.1016/S0140-6736(02)11201-3; Quartin AA, 1997, JAMA-J AM MED ASSOC, V277, P1058, DOI 10.1001/jama.277.13.1058; Schauber J, 2003, GUT, V52, P735, DOI 10.1136/gut.52.5.735; Scott MG, 2002, J IMMUNOL, V169, P3883, DOI 10.4049/jimmunol.169.7.3883; Seow WK, 2003, AUST DENT J, V48, P156, DOI 10.1111/j.1834-7819.2003.tb00026.x; Sorensen O, 1997, BLOOD, V90, P2796; Sorensen O, 1997, J IMMUNOL METHODS, V206, P53, DOI 10.1016/S0022-1759(97)00084-7; Sorensen OE, 2003, J IMMUNOL, V170, P5583, DOI 10.4049/jimmunol.170.11.5583; Tavor S, 2002, BLOOD, V99, P1794, DOI 10.1182/blood.V99.5.1794; Toell A, 2000, BIOCHEM J, V352, P301, DOI 10.1042/0264-6021:3520301; Tsukasaki K, 2004, INT J CANCER, V109, P875, DOI 10.1002/ijc.20028; Turner J, 1998, ANTIMICROB AGENTS CH, V42, P2206, DOI 10.1128/AAC.42.9.2206; VANDERMEER TJ, 1995, SURGERY, V117, P656, DOI 10.1016/S0039-6060(95)80009-3; Verbeek W, 1999, BLOOD, V94, P3141, DOI 10.1182/blood.V94.9.3141.421k41_3141_3150; Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909; White JH, 2004, J STEROID BIOCHEM, V89-90, P239, DOI 10.1016/j.jsbmb.2004.03.074; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391; Zasloff M, 2002, LANCET, V360, P1116, DOI 10.1016/S0140-6736(02)11239-6; Zasloff M, 2002, NEW ENGL J MED, V347, P1199, DOI 10.1056/NEJMe020106	65	779	812	2	51	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1067	1077		10.1096/fj.04-3284com	http://dx.doi.org/10.1096/fj.04-3284com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	15985530				2022-12-28	WOS:000230923000035
J	Lee, J; Hever, A; Willhite, D; Zlotnik, A; Hevezi, P				Lee, J; Hever, A; Willhite, D; Zlotnik, A; Hevezi, P			Effects of RNA degradation on gene expression analysis of human postmortem tissues	FASEB JOURNAL			English	Article						thymus; RNA quality; GPCR	MESSENGER-RNA; DENDRITIC CELLS; RECEPTOR; PROFILE; STABILITY; CHEMOKINE; QUALITY; BRAIN; ASPM; RAT	The Affymetrix GeneChip platform was used to build a gene expression database of the normal human body. Postmortem human tissues represent a valuable source of biological materials for this type of study, but their use entails some delays before harvesting such tissues. We first evaluated the RNA quality obtained from tissues obtained 3-5 h postmortem and found variations that were both tissue and donor-dependent. RNAs extracted from brain regions were of higher quality than those obtained from the gut, while the cause of death was a significant factor in donor-dependent differences. To avoid these variables, we used rat duodenum to determine the effects of RNA degradation on the analysis of gene expression. Surprisingly, even samples exhibiting significant RNA degradation yielded robust gene expression results, comparable to those obtained using intact samples at a certain signal intensity cutoff. We extended these findings to our human expression database and obtained similar results, indicating that the Affymetrix platform, which is biased to the 3' end of transcripts for detection, can tolerate significant RNA degradation, while still yielding high quality expression data. Our resulting body index expression database is a valuable research tool. As examples of potential uses, we report novel expression sites for four potential therapeutic targets-CCL27, GPR22, GPR113 and GPR128-and as well as a set of thymus-specific genes, including three not previously associated with the thymus.	Neurocrine Biosci Inc, Dept Mol Med, San Diego, CA 92130 USA	Neurocrine Biosciences	Hevezi, P (corresponding author), Neurocrine Biosci Inc, Dept Mol Med, 12790 El Camino Real, San Diego, CA 92130 USA.	phevezi@neurocrine.com	Zlotnik, Albert/C-3791-2011					Auer H, 2003, NAT GENET, V35, P292, DOI 10.1038/ng1203-292; Bahn S, 2001, J CHEM NEUROANAT, V22, P79, DOI 10.1016/S0891-0618(01)00099-0; Bond J, 2003, AM J HUM GENET, V73, P1170, DOI 10.1086/379085; Bond J, 2002, NAT GENET, V32, P316, DOI 10.1038/ng995; Fredriksson R, 2003, FEBS LETT, V554, P381, DOI 10.1016/S0014-5793(03)01196-7; Gonzalez-Maeso J, 2002, NEUROPSYCHOPHARMACOL, V26, P468, DOI 10.1016/S0893-133X(01)00342-6; Granucci F, 2001, EUR J IMMUNOL, V31, P2539, DOI 10.1002/1521-4141(200109)31:9<2539::AID-IMMU2539>3.0.CO;2-9; Greenberg SA, 2002, NEUROLOGY, V59, P1170, DOI 10.1212/WNL.59.8.1170; Homey B, 2002, NAT MED, V8, P157, DOI 10.1038/nm0202-157; Hsiao LL, 2001, PHYSIOL GENOMICS, V7, P97, DOI 10.1152/physiolgenomics.00040.2001; Huang Shuguang, 2003, Am J Pharmacogenomics, V3, P279, DOI 10.2165/00129785-200303040-00005; HUMPHREYS-BEHER M G, 1986, Biotechnology and Applied Biochemistry, V8, P392; Inoue H, 2002, FORENSIC SCI INT, V130, P127, DOI 10.1016/S0379-0738(02)00352-3; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Iwamoto K, 2004, MOL PSYCHIATR, V9, P406, DOI 10.1038/sj.mp.4001437; Jewell SD, 2002, AM J CLIN PATHOL, V118, P733; JOHNSON SA, 1986, J NEUROSCI RES, V16, P267, DOI 10.1002/jnr.490160123; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Malboeuf CM, 2001, BIOTECHNIQUES, V30, P1074, DOI 10.2144/01305rr06; Malnic B, 2004, P NATL ACAD SCI USA, V101, P2584, DOI 10.1073/pnas.0307882100; Mimmack ML, 2004, BIOL PSYCHIAT, V55, P337, DOI 10.1016/j.biopsych.2003.09.007; Norment AM, 2000, J IMMUNOL, V164, P639, DOI 10.4049/jimmunol.164.2.639; ODowd BF, 1997, GENE, V187, P75, DOI 10.1016/S0378-1119(96)00722-6; PAPSIDERO LD, 1981, J NATL CANCER I, V66, P37; Preece P, 2003, MOL BRAIN RES, V116, P7, DOI 10.1016/S0169-328X(03)00208-0; Ryan CA, 2004, TOXICOL LETT, V150, P301, DOI 10.1016/j.toxlet.2004.02.002; Sanoudou D, 2004, PHYSIOL GENOMICS, V16, P222, DOI 10.1152/physiolgenomics.00137.2003; Schmidt W. M., 2003, International Journal of Clinical Pharmacology and Therapeutics, V41, P624; Schmidt WM, 2004, INT J CANCER, V112, P200, DOI 10.1002/ijc.20401; Schoor O, 2003, BIOTECHNIQUES, V35, P1192, DOI 10.2144/03356rr01; Selinger DW, 2003, GENOME RES, V13, P216, DOI 10.1101/gr.912603; Serralta A, 2003, TOXICOL IN VITRO, V17, P769, DOI 10.1016/S0887-2333(03)00122-X; Shippy R, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-61; Tebo J, 2003, J BIOL CHEM, V278, P12085, DOI 10.1074/jbc.M212992200; Tomita H, 2004, BIOL PSYCHIAT, V55, P346, DOI 10.1016/j.biopsych.2003.10.013; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vicari AP, 1997, IMMUNITY, V7, P291, DOI 10.1016/S1074-7613(00)80531-2; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Yang E, 2003, GENOME RES, V13, P1863, DOI 10.1101/gr.1272403	40	85	87	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1356	+		10.1096/fj.04-3552fje	http://dx.doi.org/10.1096/fj.04-3552fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15955843				2022-12-28	WOS:000230207800017
J	Muhlhauser, U; Zolk, O; Rau, T; Munzel, F; Wieland, T; Eschenhagen, T				Muelhaeuser, Ulrike; Zolk, Oliver; Rau, Thomas; Muenzel, Felix; Wieland, Thomas; Eschenhagen, Thomas			Atorvastatin desensitizes beta-adrenergic signaling in cardiac myocytes via reduced isoprenylation of G-protein gamma-subunits	FASEB JOURNAL			English	Article						statins; receptor pharmacology; cardiac contractile function	HETEROTRIMERIC G-PROTEINS; HMG-COA REDUCTASE; IN-VITRO; RECEPTOR; EXPRESSION; TISSUE; CELLS; LOCALIZATION; ASSOCIATION; PRENYLATION	Statins exert pleiotropic, cholesterol-independent effects by reducing isoprenylation of monomeric GTPases. Here we examined whether statins also reduce isoprenylation of gamma-subunits of heterotrimeric G-proteins and thereby affect beta-adrenergic signaling and regulation of force in cardiac myocytes. Neonatal rat cardiac myocytes (NRCM) were treated with atorvastatin (0.1- 10 mu mol/l; 12-48 h) and examined for adenylyl cyclase regulating G-protein alpha- (G alpha), beta- (G beta), and gamma- (G gamma) subunits and cAMP accumulation. Engineered heart tissue (EHT) from NRCM was used to evaluate contractile consequences. In atorvastatin-treated NRCM, a second band of G gamma 3 with a lower apparent molecular weight appeared in cytosol and particulate fractions that was absent in vehicle-treated NRCM, but also seen after GGTI-298, a geranylgeranyl transferase inhibitor. In parallel, G beta accumulated in the cytosol and total cellular content of Gas was reduced. In atorvastatin-treated NRCM, the cAMP-increasing effect of isoprenaline was reduced. Likewise, the positive inotropic effect of isoprenaline was desensitized and reduced after treatment with atorvastatin. The effects of atorvastatin were abolished by mevalonate and/or geranylgeranyl pyrophosphate, but not by farnesyl pyrophosphate or squalene. Taken together, the results of this study show that atorvastatin desensitizes NRCM to beta-adrenergic stimulation by a mechanism that involves reduced isoprenylation of G gamma and subsequent reductions in the cellular content of G alpha s.	Univ Hamburg, Med Ctr, Inst Expt & Clin Pharmacol, D-20246 Hamburg, Germany; Univ Erlangen Nurnberg, Inst Clin Pharmacol, Erlangen, Germany; Heidelberg Univ, Inst Pharmacol & Toxicol Mannheim, D-6800 Mannheim, Germany	University of Hamburg; University of Erlangen Nuremberg; Ruprecht Karls University Heidelberg	Eschenhagen, T (corresponding author), Univ Hamburg, Med Ctr, Inst Expt & Clin Pharmacol, Martinistr 52, D-20246 Hamburg, Germany.	t.eschenhagen@uke.uni-hamburg.de	Wieland, Thomas/Q-1506-2019; Wieland, Thomas/G-1772-2012	Wieland, Thomas/0000-0001-8262-8261; Wieland, Thomas/0000-0001-8262-8261; Zolk, Oliver/0000-0002-8220-3834				Bohm M, 2005, Z KARDIOL, V94, P223, DOI 10.1007/s00392-005-0210-9; Bountioukos M, 2003, AM J CARDIOL, V92, P613, DOI 10.1016/S0002-9149(03)00737-9; Chen CA, 2001, ONCOGENE, V20, P1643, DOI 10.1038/sj.onc.1204185; CHILOECHES A, 1995, FEBS LETT, V361, P46, DOI 10.1016/0014-5793(95)00139-Z; Cicha I, 2004, ARTERIOSCL THROM VAS, V24, P2046, DOI 10.1161/01.ATV.0000145943.19099.a3; Cilla DD, 1996, CLIN PHARMACOL THER, V60, P687, DOI 10.1016/S0009-9236(96)90218-0; El-Armouche A, 2003, CARDIOVASC RES, V60, P478, DOI 10.1016/j.cardiores.2003.09.014; El-Armouche A, 2003, FASEB J, V17, P437, DOI 10.1096/fj.02-0057fje; ESCHENHAGEN T, 1993, CELL BIOL INT, V17, P723, DOI 10.1006/cbir.1993.1135; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; Fishburn CS, 1999, J BIOL CHEM, V274, P18793, DOI 10.1074/jbc.274.26.18793; Fu HW, 1999, RECENT PROG HORM RES, V54, P315; GADBUT AP, 1994, J BIOL CHEM, V269, P30707; HANSEN CA, 1995, J MOL CELL CARDIOL, V27, P471, DOI 10.1016/S0022-2828(08)80043-0; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Lee YI, 2003, FEBS LETT, V555, P329, DOI 10.1016/S0014-5793(03)01267-5; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; MCLEISH KR, 1993, BIOCHEM BIOPH RES CO, V197, P763, DOI 10.1006/bbrc.1993.2544; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; Murga C, 1997, FEBS LETT, V409, P24, DOI 10.1016/S0014-5793(97)00476-6; Node K, 2003, CIRCULATION, V108, P839, DOI 10.1161/01.CIR.0000084539.58092.DE; Nusse O, 1996, J CELL SCI, V109, P221; Park HJ, 2002, CIRC RES, V91, P143, DOI 10.1161/01.RES.0000028149.15986.4C; Pomerantz KB, 1997, BIOCHEMISTRY-US, V36, P9523, DOI 10.1021/bi963069l; PRONIN AN, 1993, FEBS LETT, V328, P89, DOI 10.1016/0014-5793(93)80971-V; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; Qian YM, 1998, BIOORGAN MED CHEM, V6, P293, DOI 10.1016/S0968-0896(97)10040-2; Sari R, 2001, EUR J PHARMACOL, V432, P91, DOI 10.1016/S0014-2999(01)01454-6; Schnabel P, 1996, CELL SIGNAL, V8, P413, DOI 10.1016/S0898-6568(96)00087-3; Schwindinger WF, 2004, MOL CELL BIOL, V24, P7758, DOI 10.1128/MCB.24.17.7758-7768.2004; Schwindinger WF, 2003, J BIOL CHEM, V278, P6575, DOI 10.1074/jbc.M211132200; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; Steinberg SF, 1999, CIRC RES, V85, P1101; Stern RH, 2000, J CLIN PHARMACOL, V40, P616, DOI 10.1177/00912700022009396; Wedegaertner PB, 1998, BIOL SIGNAL RECEPT, V7, P125; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zimmermann WH, 2002, CIRC RES, V90, P223, DOI 10.1161/hh0202.103644; Zolk O, 2004, AM J PHYSIOL-HEART C, V286, pH1248, DOI 10.1152/ajpheart.00599.2003; Zolk O, 2000, CAN J PHYSIOL PHARM, V78, P187, DOI 10.1139/cjpp-78-3-187	41	55	57	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					785	+		10.1096/fj.05-5067fje	http://dx.doi.org/10.1096/fj.05-5067fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16467371				2022-12-28	WOS:000237698700030
J	Haase, H; Alvarez, J; Petzhold, D; Doller, A; Behlke, J; Erdmann, J; Hetzer, R; Regitz-Zagrosek, V; Vassort, G; Morano, I				Haase, H; Alvarez, J; Petzhold, D; Doller, A; Behlke, J; Erdmann, J; Hetzer, R; Regitz-Zagrosek, V; Vassort, G; Morano, I			Ahnak is critical for cardiac Ca(v)1.2 calcium channel function and its beta-adrenergic regulation	FASEB JOURNAL			English	Article							CA2+ CHANNEL; PROTEIN-KINASE; RAT-HEART; SUBUNIT; PHOSPHORYLATION; MEMBRANE; MODULATION; GENE; PKA; IDENTIFICATION	Defective L-type Ca2+ channel (I-CaL) regulation is one major cause for contractile dysfunction in the heart. The I-CaL is enhanced by sympathetic nervous stimulation: via the activation of beta-adrenergic receptors, PKA phosphorylates the alpha 1C(Ca(V)1.2)- and beta 2-channel subunits and ahnak, an associated 5643-amino acid (aa) protein. In this study, we examined the role of a naturally occurring, genetic variant Ile5236Thr-ahnak on I-CaL. Binding experiments with ahnak fragments (wild-type, Ile5236Thr mutated) and patch clamp recordings revealed that Ile5236Thr-ahnak critically affected both beta 2 subunit interaction and I-CaL regulation. Binding affinity between ahnak-C1 (aa 4646-5288) and beta 2 subunit decreased by approximate to 50% after PKA phosphorylation or in the presence of Ile5236Thr-ahnak peptide. On native cardiomyocytes, intracellular application of this mutated ahnak peptide mimicked the PKA-effects on I-CaL increasing the amplitude by approximate to 60% and slowing its inactivation together with a leftward shift of its voltage dependency. Both mutated Ile5236Thr-peptide and Ile5236Thr-fragment (aa 5215-5288) prevented specifically the further up-regulation of I-CaL by isoprenaline. Hence, we suggest the ahnak-C1 domain serves as physiological brake on I-CaL. Relief from this inhibition is proposed as common pathway used by sympathetic signaling and Ile5236Thr- ahnak fragments to increase I-CaL. This genetic ahnak variant might cause individual differences in I-CaL regulation upon physiological challenges or therapeutic interventions.	Max Delbruck Ctr Mol Med, MDC, D-13092 Berlin, Germany; Inst Cardiol, Havana, Cuba; Univ Med, Charite, Cardiovasc Res Ctr, Berlin, Germany; Deutsch Herzzentrum Berlin, Berlin, Germany; INSERM, U637, Montpellier 5, France; Univ Med, Charite, Johannes Muller Inst Physiol, Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; German Heart Center Berlin; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Haase, H (corresponding author), Robert Rossle Str 10, D-13092 Berlin, Germany.	haase@mdc-berlin.de	Erdmann, Jeanette/P-7513-2014; Erdmann, Jeanette/A-4417-2009	Erdmann, Jeanette/0000-0002-4486-6231; Regitz-Zagrosek, Vera/0000-0002-3566-3467				Aimond F, 1999, CARDIOVASC RES, V42, P402, DOI 10.1016/S0008-6363(99)00070-X; Alvarez J, 2004, J BIOL CHEM, V279, P12456, DOI 10.1074/jbc.M312177200; Behlke J, 1997, BIOCHEMISTRY-US, V36, P5149, DOI 10.1021/bi962755h; Benaud C, 2004, J CELL BIOL, V164, P133, DOI 10.1083/jcb.200307098; Bunemann M, 1999, J BIOL CHEM, V274, P33851, DOI 10.1074/jbc.274.48.33851; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Charnet P, 1995, BIOCHIMIE, V77, P957, DOI 10.1016/0300-9084(95)80008-5; Colecraft HM, 2002, J PHYSIOL-LONDON, V541, P435, DOI 10.1113/jphysiol.2002.018515; Erdmann J, 2001, J AM COLL CARDIOL, V38, P322, DOI 10.1016/S0735-1097(01)01387-0; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gentil BJ, 2003, J HISTOCHEM CYTOCHEM, V51, P339, DOI 10.1177/002215540305100309; Gerhardstein BL, 1999, BIOCHEMISTRY-US, V38, P10361, DOI 10.1021/bi990896o; Haase H, 2004, FASEB J, V18, P839, DOI 10.1096/fj.03-0446fje; HAASE H, 1993, FEBS LETT, V335, P217, DOI 10.1016/0014-5793(93)80733-B; Haase H, 1999, FASEB J, V13, P2161, DOI 10.1096/fasebj.13.15.2161; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HASHIMOTO T, 1995, EXP CELL RES, V217, P258, DOI 10.1006/excr.1995.1085; HESCHELER J, 1986, PFLUG ARCH EUR J PHY, V407, P182, DOI 10.1007/BF00580674; Hohaus A, 2002, FASEB J, V16, DOI 10.1096/fj.01-0855com; Hohaus A, 2000, BIOCHEM J, V348, P657, DOI 10.1042/0264-6021:3480657; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Hulme JT, 2003, P NATL ACAD SCI USA, V100, P13093, DOI 10.1073/pnas.2135335100; Kamp TJ, 1996, J PHYSIOL-LONDON, V492, P89, DOI 10.1113/jphysiol.1996.sp021291; Kobrinsky E, 2004, BIOPHYS J, V87, P844, DOI 10.1529/biophysj.104.041152; Komuro A, 2004, P NATL ACAD SCI USA, V101, P4053, DOI 10.1073/pnas.0308619101; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Muth JN, 1999, J BIOL CHEM, V274, P21503, DOI 10.1074/jbc.274.31.21503; Restituito S, 2000, J NEUROSCI, V20, P9046; Schroder F, 1998, CIRCULATION, V98, P969, DOI 10.1161/01.CIR.98.10.969; Sekiya F, 1999, J BIOL CHEM, V274, P13900, DOI 10.1074/jbc.274.20.13900; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; SHISTIK E, 1995, J PHYSIOL-LONDON, V489, P55, DOI 10.1113/jphysiol.1995.sp021029; SHTIVELMAN E, 1993, J CELL BIOL, V120, P625, DOI 10.1083/jcb.120.3.625; SHTIVELMAN E, 1992, P NATL ACAD SCI USA, V89, P5472, DOI 10.1073/pnas.89.12.5472; Splawski I, 2004, CELL, V119, P19, DOI 10.1016/j.cell.2004.09.011; Straub BK, 2003, J CELL SCI, V116, P4985, DOI 10.1242/jcs.00815; Sussman J, 2001, J CELL BIOL, V154, P1019, DOI 10.1083/jcb.200105121; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; Van Wagoner DR, 2000, J MOL CELL CARDIOL, V32, P1101, DOI 10.1006/jmcc.2000.1147; WEI XY, 1994, J BIOL CHEM, V269, P1635	41	60	61	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2005	19	14					1969	1977		10.1096/fj.05-3997com	http://dx.doi.org/10.1096/fj.05-3997com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16319140				2022-12-28	WOS:000234405500007
J	Zwerina, J; Tzima, S; Hayer, S; Redlich, K; Hoffmann, O; Hanslik-Schnabel, B; Smolen, JS; Kollias, G; Schett, G				Zwerina, J; Tzima, S; Hayer, S; Redlich, K; Hoffmann, O; Hanslik-Schnabel, B; Smolen, JS; Kollias, G; Schett, G			Heme oxygenase 1 (HO-1) regulates osteoclastogenesis and bone resorption	FASEB JOURNAL			English	Article						osteoclasts; tumor necrosis factor; inflammatory bone loss	TUMOR-NECROSIS-FACTOR; MEDIATED JOINT DESTRUCTION; RHEUMATOID-ARTHRITIS; GENE-EXPRESSION; DIFFERENTIATION FACTOR; OXIDATIVE STRESS; MINERAL DENSITY; TRANSGENIC MICE; UP-REGULATION; FACTOR-ALPHA	Heme oxygenase 1 (HO-1) plays an important role in vascular disease, transplantation, and inflammation. In animal models of acute and chronic inflammation, induction of HO-1 has antiinflammatory and cytoprotective properties. Since inflammation is an important trigger of osteoclastogenesis, we hypothesized that HO-1 might influence osteoclastogenesis. We investigated the effects of induction of HO-1 on osteoclast formation in vitro and in vivo. Furthermore, we addressed the role of HO-1 in inflammatory bone loss in humans. When HO-1 was induced by hemin in vitro, a significant dose-dependent inhibition of osteoclastogenesis was observed. Up-regulation of HO-1 was mediated by activation of MAPK and primarily prevented differentiation of osteoclast precursors to osteoclasts,whereas it did not affect mature osteoclasts. Anti-osteoclastogenic properties of hemin were based on a down-regulation of c-fms, RANK, TRAF-6, and c-fos. In addition, induction of HO-1 inhibited TNF-triggered osteoclast differentiation in vitro as well as LPS-driven inflammatory bone loss in vivo. Furthermore, HO-1 induction suppressed osteoclastogenesis and bone destruction in a TNF-mediated arthritis. In line, assessment of synovial tissue from rheumatoid arthritis patients revealed that osteoclasts are usually HO-1 negative. Moreover, serum levels of bilirubin, a metabolite of HO-1, were elevated in rheumatoid arthritis patients without bone damage, suggesting HO-1 affects bone loss in humans. In summary, these data indicate that HO-1 negatively regulates osteoclastogenesis, leading to a positive net balance of bone.	Med Univ Vienna, Div Rheumatol, Dept Internal Med 3, A-1090 Vienna, Austria; Alexander Fleming Biomed Sci Res Ctr, Vari, Greece; Univ Vienna, Inst Pharmacol & Toxicol, Vienna, Austria; Med Univ Vienna, Dept Orthoped & Orthoped Surg, A-1090 Vienna, Austria	Medical University of Vienna; Alexander Fleming Biomedical Sciences Research Center; University of Vienna; Medical University of Vienna	Schett, G (corresponding author), Med Univ Vienna, Div Rheumatol, Dept Internal Med 3, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	georg.schett@meduniwien.ac.at	Kollias, George/A-7079-2012	Kollias, George/0000-0003-1867-3150				Alvarez-Maqueda M, 2004, J BIOL CHEM, V279, P21929, DOI 10.1074/jbc.M400492200; Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; CAMHI SL, 1995, AM J RESP CELL MOL, V13, P387, DOI 10.1165/ajrcmb.13.4.7546768; Chen GG, 2004, J CELL BIOCHEM, V92, P1246, DOI 10.1002/jcb.20157; CONTE D, 1989, AM J GASTROENTEROL, V84, P1231; Datta PK, 1999, J AM SOC NEPHROL, V10, P2540; David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082; Devesa I, 2005, LAB INVEST, V85, P34, DOI 10.1038/labinvest.3700205; Djousse L, 2001, AM J CARDIOL, V87, P1196, DOI 10.1016/S0002-9149(01)01494-1; El Maghraoui A, 1999, J RHEUMATOL, V26, P2205; Endler G, 2004, THROMB HAEMOSTASIS, V91, P155, DOI 10.1160/TH03-05-0291; Fondevila C, 2004, HEPATOLOGY, V40, P1333, DOI 10.1002/hep.20480; Goldring SR, 2002, J RHEUMATOL, V29, P44; Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P; Harpavat M, 2004, J CLIN GASTROENTEROL, V38, P218, DOI 10.1097/00004836-200403000-00005; Haugeberg G, 2000, ARTHRITIS RHEUM, V43, P522, DOI 10.1002/1529-0131(200003)43:3<522::AID-ANR7>3.0.CO;2-Y; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Kitaura H, 2004, J IMMUNOL, V173, P4838, DOI 10.4049/jimmunol.173.8.4838; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Lin HY, 2003, BIOCHEM PHARMACOL, V66, P1821, DOI 10.1016/S0006-2952(03)00422-2; Liu ZM, 2004, ONCOGENE, V23, P503, DOI 10.1038/sj.onc.1207173; Ohta K, 2003, EXP EYE RES, V77, P665, DOI 10.1016/j.exer.2003.08.014; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002-9440(10)63016-7; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Redlich K, 2004, AM J PATHOL, V164, P543, DOI 10.1016/S0002-9440(10)63144-6; Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582; Redlich K, 2002, ARTHRITIS RHEUM, V46, P785, DOI 10.1002/art.10097; Schett G, 2003, ARTHRITIS RHEUM, V48, P2042, DOI 10.1002/art.11150; SEITZ M, 1994, BRIT J RHEUMATOL, V33, P613; Shigeyama Y, 2000, ARTHRITIS RHEUM, V43, P2523, DOI 10.1002/1529-0131(200011)43:11<2523::AID-ANR20>3.0.CO;2-Z; Siffledeen JS, 2004, INFLAMM BOWEL DIS, V10, P220, DOI 10.1097/00054725-200405000-00007; Soares MP, 2004, J IMMUNOL, V172, P3553, DOI 10.4049/jimmunol.172.6.3553; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; Takeda Y, 2004, CLIN EXP IMMUNOL, V138, P237, DOI 10.1111/j.1365-2249.2004.02594.x; Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Vicente AM, 2003, J PHARMACOL EXP THER, V307, P1030, DOI 10.1124/jpet.103.057992; Wiesel P, 2000, CIRCULATION, V102, P3015, DOI 10.1161/01.cir.102.24.3015; Wu WT, 2004, BIOCHEM J, V379, P587, DOI 10.1042/BJ20031579; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Zwerina J, 2004, ARTHRITIS RHEUM, V50, P277, DOI 10.1002/art.11487	45	108	113	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2011	+		10.1096/fj.05-4278fje	http://dx.doi.org/10.1096/fj.05-4278fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16234431				2022-12-28	WOS:000232991100013
J	O'Malley, D; Irving, AJ; Harvey, J				O'Malley, D; Irving, AJ; Harvey, J			Leptin-induced dynamic changes in the actin cytoskeleton mediate the activation and synaptic clustering of BK channels	FASEB JOURNAL			English	Article						PI 3-kinase; actin cytoskeleton; PtdIns(3,4,5)P-3	CA2+-ACTIVATED K+ CHANNELS; RAT HIPPOCAMPAL-NEURONS; LARGE-CONDUCTANCE; PHOSPHOINOSITIDE 3-KINASE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; POTASSIUM CHANNEL; CALCIUM-CHANNEL; RHO-GTPASES; EXCITOTOXICITY; REPOLARIZATION	Phosphoinositide 3-kinase (PI3-kinase) has been shown to link leptin receptor activation to stimulation of large conductance Ca2+-activated K+ (BK) channels and subsequent inhibition of hippocampal epileptiform-like activity. However, the downstream targets of PI3-kinase in this action of leptin are unknown. Here we show that BK channel activation by leptin is dependent on the actin cytoskeleton, as it is prevented by actin filament stabilization and mimicked by actin disruption. Fluorescent labeling of polymerized actin filaments revealed that leptin promotes the rapid rearrangement of actin filaments via activation of PI 3-kinase; an action paralleled by discrete increases in PtdIns( 3,4,5) P-3 immunoreactivity in close proximity to BK channels. After leptin exposure, there was also an actin-dependent increase in the association of BK channel immunoreactivity with synaptic markers. These data are consistent with the notion that leptin activates BK channels via PI 3-kinase-dependent reorganization of actin filaments and subsequent clustering of BK channels at synapses.	Univ Dundee, Ninewells Hosp & Med Sch, Inst Neurosci, Div Pathol & Neurosci, Dundee DD1 9SY, Scotland	University of Dundee	Harvey, J (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Inst Neurosci, Div Pathol & Neurosci, Dundee DD1 9SY, Scotland.	j.z.harvey@dundee.ac.uk		Harvey, Jenni/0000-0002-9858-001X; O'Malley, Dervla/0000-0002-7031-4879	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABELE AE, 1990, NEURON, V4, P413, DOI 10.1016/0896-6273(90)90053-I; Allison DW, 1998, J NEUROSCI, V18, P2423; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Cantiello HF, 1996, EXP PHYSIOL, V81, P505, DOI 10.1113/expphysiol.1996.sp003953; Cantrell DA, 2001, J CELL SCI, V114, P1439; Chen RY, 2002, J HISTOCHEM CYTOCHEM, V50, P697, DOI 10.1177/002215540205000511; Cheng HL, 2000, J BIOL CHEM, V275, P27197; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Coussen F, 2002, J NEUROSCI, V22, P6426, DOI 10.1523/jneurosci.22-15-06426.2002; Endres M, 1999, J CLIN INVEST, V103, P347, DOI 10.1172/JCI4953; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; FURUKAWA K, 1995, EXP NEUROL, V133, P153, DOI 10.1006/exnr.1995.1018; Furukawa K, 1997, J NEUROSCI, V17, P8178, DOI 10.1523/jneurosci.17-21-08178.1997; Golding NL, 1999, J NEUROSCI, V19, P8789, DOI 10.1523/JNEUROSCI.19-20-08789.1999; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamm-Alvarez SF, 1998, PHYSIOL REV, V78, P1109, DOI 10.1152/physrev.1998.78.4.1109; Harvey J, 2000, J BIOL CHEM, V275, P4660, DOI 10.1074/jbc.275.7.4660; Harvey J, 2000, J PHYSIOL-LONDON, V527, P95, DOI 10.1111/j.1469-7793.2000.00095.x; Hilpela P, 2004, CURR TOP MICROBIOL, V282, P117; Hu H, 2001, J NEUROSCI, V21, P9585, DOI 10.1523/JNEUROSCI.21-24-09585.2001; Huang H, 2002, NEUROSCI LETT, V332, P141, DOI 10.1016/S0304-3940(02)00836-4; Kraft R, 2000, J MEMBRANE BIOL, V175, P25, DOI 10.1007/s002320001052; Lesage F, 2004, P NATL ACAD SCI USA, V101, P671, DOI 10.1073/pnas.0307681100; Maguire G, 1998, NEUROREPORT, V9, P665, DOI 10.1097/00001756-199803090-00019; Meyer G, 2002, J NEUROCHEM, V83, P490, DOI 10.1046/j.1471-4159.2002.01185.x; Niswender KD, 2003, J HISTOCHEM CYTOCHEM, V51, P275, DOI 10.1177/002215540305100302; Oheim M, 2000, EUR BIOPHYS J BIOPHY, V29, P67, DOI 10.1007/s002490050253; Petrecca K, 2000, J NEUROSCI, V20, P8736; Piao L, 2003, PFLUG ARCH EUR J PHY, V446, P523, DOI 10.1007/s00424-003-1079-y; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; Sakisaka T, 1997, MOL CELL BIOL, V17, P3841, DOI 10.1128/MCB.17.7.3841; Shanley LJ, 2002, J PHYSIOL-LONDON, V545, P933, DOI 10.1113/jphysiol.2002.029488; Shanley LJ, 2002, NAT NEUROSCI, V5, P299, DOI 10.1038/nn824; Shanley LJ, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-24-j0001.2001; Shao LR, 1999, J PHYSIOL-LONDON, V521, P135, DOI 10.1111/j.1469-7793.1999.00135.x; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; STORM JF, 1987, J PHYSIOL-LONDON, V385, P733, DOI 10.1113/jphysiol.1987.sp016517; Terzic A, 1996, J PHYSIOL-LONDON, V492, P395, DOI 10.1113/jphysiol.1996.sp021316; Toro L, 1998, NEWS PHYSIOL SCI, V13, P112; Unno T, 1999, BRIT J PHARMACOL, V127, P1703, DOI 10.1038/sj.bjp.0702711; Valgeirsdottir S, 1998, J CELL SCI, V111, P1973; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Wang ZR, 2004, AM J PHYSIOL-HEART C, V286, pH749, DOI 10.1152/ajpheart.00398.2003; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517; Zhou Q, 2001, P NATL ACAD SCI USA, V98, P1261, DOI 10.1073/pnas.031573798	49	50	52	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1917	+		10.1096/fj.05-4166fje	http://dx.doi.org/10.1096/fj.05-4166fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16166199				2022-12-28	WOS:000232315700013
J	Rui, T; Kvietys, PR				Rui, T; Kvietys, PR			NF-kappa B and AP-1 differentially contribute to the induction of Mn-SOD and eNOS during the development of oxidant tolerance	FASEB JOURNAL			English	Article						anoxia/reoxygenation; oxidant stress; PMN transendothelial migration	MANGANESE SUPEROXIDE-DISMUTASE; NECROSIS-FACTOR-ALPHA; NITRIC-OXIDE; MYOCARDIAL-ISCHEMIA; MONOCLONAL-ANTIBODY; TRANSCRIPTIONAL INDUCTION; REPERFUSION INJURY; ENDOTHELIAL-CELLS; CARDIAC MYOCYTES; P-SELECTIN	Exposure of cardiac myocytes to anoxia/reoxygenation (A/R) increases myocyte oxidant stress and converts the myocytes to a proinflammatory phenotype. These oxidant-induced effects are prevented by pretreatment of the myocytes with an oxidant stress (A/R or H2O2) 24 h earlier ( oxidant tolerance). Although NF-kappa B and AP-1 ( nuclear signaling) and Mn-SOD and eNOS ( effector enzymes) have been implicated in the development oxidant tolerance, the precise relationship between the nuclear transcription factors and the effector enzymes in the development of oxidant tolerance has not been defined. Herein, we show that an initial A/R challenge results in nuclear accumulation of both NF-kappa B and AP-1 ( EMSA). In addition, blockade of nuclear translocation of NF-kappa B (SN50) or AP-1 ( decoy oligonucleotide) prevents the development of oxidant tolerance, i.e., the second A/R challenge produces the same quantitative effects as the initial A/R challenge. In this model, nuclear translocation of both NF-kappa B and AP-1 is required for induction of Mn-SOD, while nuclear translocation of AP-1, but not NF-kappa B, is a prerequisite for induction of eNOS. Collectively, our findings indicate that NF-kappa B and AP-1 work in concert to ensure the induction eNOS and Mn-SOD, which in turn are important for the development of oxidant tolerance.	Univ Western Ontario, Vasc Cell Biol Lab, Ctr Crit Illness Res, Lawson Hlth Res Inst, London, ON N6A 4G5, Canada; Univ Western Ontario, Dept Med Biophys, London, England	Western University (University of Western Ontario); Western University (University of Western Ontario)	Kvietys, PR (corresponding author), Univ Western Ontario, Vasc Cell Biol Lab, Ctr Crit Illness Res, Lawson Hlth Res Inst, 800 Commissioners Rd,VRL 6th FL, London, ON N6A 4G5, Canada.	pkvietys@uwo.ca	Rui, Tao/H-7044-2016					Bell RM, 2002, CARDIOVASC RES, V53, P405, DOI 10.1016/S0008-6363(01)00472-2; Borrello S, 1997, ARCH BIOCHEM BIOPHYS, V348, P289, DOI 10.1006/abbi.1997.0355; Carden DL, 2000, J PATHOL, V190, P255, DOI 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6; Cepinskas G, 1999, CIRC RES, V84, P103; Cepinskas G, 2001, ACTA PHYSIOL SCAND, V173, P23, DOI 10.1046/j.1365-201X.2001.00881.x; Coronella-Wood J, 2004, J BIOL CHEM, V279, P33567, DOI 10.1074/jbc.M404013200; Dana A, 2000, CIRCULATION, V101, P2841, DOI 10.1161/01.CIR.101.24.2841; Darville MI, 2000, ENDOCRINOLOGY, V141, P153, DOI 10.1210/en.141.1.153; Davis ME, 2004, J BIOL CHEM, V279, P163, DOI 10.1074/jbc.M307528200; ENTMAN ML, 1991, FASEB J, V5, P2529, DOI 10.1096/fasebj.5.11.1868978; Faraci FM, 2004, ARTERIOSCL THROM VAS, V24, P1367, DOI 10.1161/01.ATV.0000133604.20182.cf; Fisslthaler B, 2003, NITRIC OXIDE-BIOL CH, V8, P253, DOI 10.1016/S1089-8603(03)00042-9; GRANGER DN, 1994, J LEUKOCYTE BIOL, V55, P662, DOI 10.1002/jlb.55.5.662; Guo Y, 1999, P NATL ACAD SCI USA, V96, P11507, DOI 10.1073/pnas.96.20.11507; Guo Z, 2003, J BIOL CHEM, V278, P23570, DOI 10.1074/jbc.M303431200; HARTMAN JC, 1995, CARDIOVASC RES, V30, P47, DOI 10.1016/0008-6363(95)00015-1; Hoffmann A, 2001, J CELL PHYSIOL, V188, P33, DOI 10.1002/jcp.1092; Jordan JE, 1999, CARDIOVASC RES, V43, P860, DOI 10.1016/S0008-6363(99)00187-X; Kaneko M, 2004, BIOL PHARM BULL, V27, P1202, DOI 10.1248/bpb.27.1202; Kim HP, 1999, J BIOL CHEM, V274, P37455, DOI 10.1074/jbc.274.52.37455; Lacza Z, 2004, J NEUROCHEM, V90, P942, DOI 10.1111/j.1471-4159.2004.02553.x; Lacza Z, 2003, FREE RADICAL BIO MED, V35, P1217, DOI 10.1016/S0891-5849(03)00510-0; Lacza Z, 2001, FREE RADICAL BIO MED, V31, P1609, DOI 10.1016/S0891-5849(01)00754-7; LEFER DJ, 1993, CIRCULATION, V88, P1779, DOI 10.1161/01.CIR.88.4.1779; LEPIC E, 2001, CAN J CARDIOL, V17, P388; Lesnefsky EJ, 2001, J MOL CELL CARDIOL, V33, P1065, DOI 10.1006/jmcc.2001.1378; MA XL, 1992, CIRCULATION, V86, P937, DOI 10.1161/01.CIR.86.3.937; Maehara K, 2000, J CELL BIOCHEM, V77, P474, DOI 10.1002/(SICI)1097-4644(20000601)77:3<474::AID-JCB12>3.0.CO;2-H; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Navarro-Antolin J, 2000, J BIOL CHEM, V275, P3075, DOI 10.1074/jbc.275.5.3075; Palazzo AJ, 1998, AM J PHYSIOL-HEART C, V275, pH1865, DOI 10.1152/ajpheart.1998.275.5.H1865; Palazzo AJ, 1998, AM J PHYSIOL-HEART C, V275, pH2300, DOI 10.1152/ajpheart.1998.275.6.H2300; Peakman MC, 2003, BRAIN RES, V970, P73, DOI 10.1016/S0006-8993(03)02230-3; Peng TQ, 2003, J BIOL CHEM, V278, P8099, DOI 10.1074/jbc.M207288200; Rui T, 2005, CARDIOVASC RES, V65, P719, DOI 10.1016/j.cardiores.2004.11.019; Rui T, 2003, CARDIOVASC RES, V59, P901, DOI 10.1016/S0008-6363(03)00502-9; Rui T, 2001, AM J PHYSIOL-HEART C, V281, pH440, DOI 10.1152/ajpheart.2001.281.1.H440; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIMPSON PJ, 1988, J CLIN INVEST, V81, P624, DOI 10.1172/JCI113364; SMITH EF, 1988, AM J PHYSIOL, V255, pH1060, DOI 10.1152/ajpheart.1988.255.5.H1060; Song W, 2000, CARDIOVASC RES, V45, P595, DOI 10.1016/S0008-6363(99)00395-8; Tai SC, 2004, ARTERIOSCL THROM VAS, V24, P405, DOI 10.1161/01.ATV.0000109171.50229.33; Tay YMS, 2004, FREE RADICAL RES, V38, P591, DOI 10.1080/10715760410001694008; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Vulin AI, 2004, J BIOL CHEM, V279, P25172, DOI 10.1074/jbc.M403184200; Wang D, 1999, AM J HYPERTENS, V12, P174, DOI 10.1016/S0895-7061(98)00235-0; WEYRICH AS, 1993, J CLIN INVEST, V91, P2620, DOI 10.1172/JCI116501; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wilson SH, 2000, ATHEROSCLEROSIS, V148, P23, DOI 10.1016/S0021-9150(99)00211-7; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Xuan YT, 1999, CIRC RES, V84, P1095, DOI 10.1161/01.RES.84.9.1095; YAMASHITA N, 1994, J CLIN INVEST, V94, P2193, DOI 10.1172/JCI117580; Yeh CH, 2005, J SURG RES, V125, P109, DOI 10.1016/j.jss.2004.11.009; Yellon DM, 1998, CARDIOVASC RES, V37, P21, DOI 10.1016/S0008-6363(97)00214-9	54	24	28	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1908	+		10.1096/fj.05-4028fje	http://dx.doi.org/10.1096/fj.05-4028fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16157693				2022-12-28	WOS:000232315700019
J	Tscharntke, M; Pofahl, R; Krieg, T; Haase, I				Tscharntke, M; Pofahl, R; Krieg, T; Haase, I			Ras-induced spreading and wound closure in human epidermal keratinocytes	FASEB JOURNAL			English	Article						wound epithelialization; cell spreading; Rac1; epidermis; wound healing	GROWTH-FACTOR; ACTIVATION; MIGRATION; MICE; DIFFERENTIATION; PROLIFERATION; EXPRESSION; SAFE	Although it is known that growth factor signaling cascades are active during epithelial wound healing, signals that regulate reepithelialization after wounding are not very well characterized. The small GTP binding protein Ras is a molecular switch involved in the regulation of signals originating from different growth factor receptors. We have investigated consequences of its activation in primary human keratinocytes. We provide evidence that activation of Ras can lead to shape changes of keratinocytes caused by rearrangements of the actin cytoskeleton that result in membrane protrusion and ruffling. Similar shape changes were found in the migrating tip of newly formed epithelium in mouse wounds. These cytoskeletal changes occur independently of keratinocyte terminal differentiation, and they can determine the speed of wound epithelialization in vitro. Using various mutant constructs and specific pharmacological inhibitors, we found that the effects of activated Ras on the cytoskeleton of keratinocytes are mediated by a phosphatidylinositol 3 kinase-independent activation of Rac. Our results suggest that growth factor-induced, Ras-mediated changes of keratinocyte shape may be an important mechanism that determines the speed of wound epithelialization.	Univ Cologne, Dept Dermatol, D-50924 Cologne, Germany; Univ Cologne, CMMC, Ctr Mol Med, D-50924 Cologne, Germany	University of Cologne; University of Cologne	Haase, I (corresponding author), Univ Cologne, Dept Dermatol, Joseph Stelzmann Str 9, D-50924 Cologne, Germany.	Ingo.Haase@uni-koeln.de						ANDO Y, 1993, J INVEST DERMATOL, V100, P633, DOI 10.1111/1523-1747.ep12472297; Barbieri JT, 2002, ANNU REV CELL DEV BI, V18, P315, DOI 10.1146/annurev.cellbio.18.012502.134748; BROWN GL, 1989, NEW ENGL J MED, V321, P76, DOI 10.1056/NEJM198907133210203; Chaturvedi V, 2003, AM J PATHOL, V162, P161, DOI 10.1016/S0002-9440(10)63807-2; Dajee M, 2002, ONCOGENE, V21, P1527, DOI 10.1038/sj.onc.1205287; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Eckes B, 2000, J CELL SCI, V113, P2455; Haase I, 2001, J CLIN INVEST, V108, P527, DOI 10.1172/JCI200112153; Haase I, 2003, J CELL SCI, V116, P3227, DOI 10.1242/jcs.00610; Haase I, 2002, J INVEST DERMATOL, V118, P891, DOI 10.1046/j.1523-1747.2002.17631.x; Hobbs RM, 2004, J INVEST DERMATOL, V123, P503, DOI 10.1111/j.0022-202X.2004.23225.x; Jenzora A, 2005, FEBS LETT, V579, P455, DOI 10.1016/j.febslet.2004.10.110; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; Nanney LB, 1996, MOL CELLULAR BIOL WO, P171; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Schoff CK, 2004, JCT COATINGSTECH, V1, P64; TSUBOI R, 1993, J INVEST DERMATOL, V101, P49, DOI 10.1111/1523-1747.ep12358892; Watt FM, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 1, P113; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Zhu AJ, 1996, J CELL SCI, V109, P3013	25	15	16	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1836	+		10.1096/fj.04-3327fje	http://dx.doi.org/10.1096/fj.04-3327fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16170018				2022-12-28	WOS:000232315700011
J	Vihanto, MM; Plock, J; Erni, D; Frey, BM; Frey, FJ; Huynh-Do, U				Vihanto, MM; Plock, J; Erni, D; Frey, BM; Frey, FJ; Huynh-Do, U			Hypoxia up-regulates expression of Eph receptors and ephrins in mouse skin	FASEB JOURNAL			English	Article						angiogenesis; gene regulation; hypoxia; RNA interference	INDUCIBLE FACTOR-1; VASCULAR MORPHOGENESIS; TYROSINE KINASES; CELL-MIGRATION; GROWTH-FACTOR; TUMOR-GROWTH; RAT-BRAIN; IN-VIVO; ANGIOGENESIS; ACTIVATION	Eph receptor tyrosine kinases and their ligands ( ephrins) are key players during the development of the embryonic vasculature; however, their role and regulation in adult angiogenesis remain to be defined. Both receptors and ligands have been shown to be up- regulated in a variety of tumors. To address the hypothesis that hypoxia is an important regulator of Ephs/ ephrins expression, we developed a mouse skin flap model of hypoxia. We demonstrate that our model truly represents segmental skin hypoxia by applying four independent methods: continuous measurement of partial cutaneous oxygen tension, monitoring of tissue lactate/ pyruvate ratio, time course of hypoxia- inducible factor- 1 alpha ( HIF- 1 alpha) induction, and localization of stabilized HIF- 1a by immunofluorescence in the hypoxic skin flap. Our experiments indicate that hypoxia up- regulates not only HIF- 1 alpha and vascular endothelial growth factor ( VEGF) expression, but also Ephs and ephrins of both A and B subclasses in the skin. In addition, we show that in Hep3B and PC- 3 cells, the hypoxia- induced up- regulation of Ephs and ephrins is abrogated by small interfering RNA- mediated down- regulation of HIF- 1 alpha. These novel findings shed light on the role of this versatile receptor/ ligand family in adult angiogenesis. Furthermore, our model offers considerable potential for analyzing distinct mechanisms of neovascularization in gene- targeted mice.	Univ Bern, Dept Hypertens & Nephrol, Inselspital, CH-3010 Bern, Switzerland; Univ Bern, Dept Clin Res, Inselspital, CH-3010 Bern, Switzerland; Univ Bern, Dept Plast Surg, Inselspital, CH-3010 Bern, Switzerland	University of Bern; University of Bern; University of Bern	Huynh-Do, U (corresponding author), Univ Bern, Dept Hypertens & Nephrol, Inselspital, CH-3010 Bern, Switzerland.	uyen.huynh-do@insel.ch	Plock, Jan A./I-2451-2017; Plock, Jan/ABE-9876-2020	Plock, Jan A./0000-0002-9495-6198; 				Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; ANDRES AC, 1994, ONCOGENE, V9, P1461; Bergeron M, 1999, EUR J NEUROSCI, V11, P4159, DOI 10.1046/j.1460-9568.1999.00845.x; Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Dobrzanski P, 2004, CANCER RES, V64, P910, DOI 10.1158/0008-5472.CAN-3430-2; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; GERDES J, 1984, J IMMUNOL, V133, P1710; Han DC, 2002, J BIOL CHEM, V277, P45655, DOI 10.1074/jbc.M203165200; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; Jin KL, 2000, NEUROSCIENCE, V99, P577, DOI 10.1016/S0306-4522(00)00207-4; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Mao WG, 2004, CANCER RES, V64, P781, DOI 10.1158/0008-5472.CAN-03-1047; Martiny-Baron G, 2004, NEOPLASIA, V6, P248, DOI 10.1593/neo.03457; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Minh TC, 2002, J RECONSTR MICROSURG, V18, P115, DOI 10.1055/s-2002-19892; Moritz W, 2002, FASEB J, V16, P745, DOI 10.1096/fj.01-0403fje; Nakada M, 2004, CANCER RES, V64, P3179, DOI 10.1158/0008-5472.CAN-03-3667; Nawrocki AR, 2002, J BIOL CHEM, V277, P14647, DOI 10.1074/jbc.M111549200; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rosenberger C, 2003, KIDNEY INT, V64, P874, DOI 10.1046/j.1523-1755.2003.00159.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; Straume O, 2002, AM J PATHOL, V160, P1009, DOI 10.1016/S0002-9440(10)64922-X; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Suenobu S, 2002, BIOCHEM BIOPH RES CO, V293, P1124, DOI 10.1016/S0006-291X(02)00330-3; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Uyen HD, 2002, J CELL SCI, V115, P3073; Vindis C, 2004, J BIOL CHEM, V279, P27965, DOI 10.1074/jbc.M401295200; Vindis C, 2003, J CELL BIOL, V162, P661, DOI 10.1083/jcb.200302073; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1997, KIDNEY INT, V51, P560, DOI 10.1038/ki.1997.79; Zelinski DP, 2001, CANCER RES, V61, P2301	36	107	111	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1689	+		10.1096/fj.04-3647fje	http://dx.doi.org/10.1096/fj.04-3647fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16081502				2022-12-28	WOS:000231843700023
J	Adlam, VJ; Harrison, JC; Porteous, CM; James, AM; Smith, RAJ; Murphy, MP; Sammut, IA				Adlam, VJ; Harrison, JC; Porteous, CM; James, AM; Smith, RAJ; Murphy, MP; Sammut, IA			Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury	FASEB JOURNAL			English	Article						TPP; oxidative damage; MitoQ	COMPLEX-I ACTIVITY; PERMEABILITY TRANSITION; OXIDATIVE DAMAGE; CYTOCHROME-C; HEART; ISCHEMIA/REPERFUSION; FIBROBLASTS; DYSFUNCTION; ACTIVATION; DELIVERY	Mitochondrial oxidative damage contributes to a wide range of pathologies, including cardiovascular disorders and neurodegenerative diseases. Therefore, protecting mitochondria from oxidative damage should be an effective therapeutic strategy. However, conventional antioxidants have limited efficacy due to the difficulty of delivering them to mitochondria in situ. To overcome this problem, we developed mitochondria-targeted antioxidants, typified by MitoQ, which comprises a lipophilic triphenylphosphonium (TPP) cation covalently attached to a ubiquinol antioxidant. Driven by the large mitochondrial membrane potential, the TPP cation concentrates MitoQ several hundred-fold within mitochondria, selectively preventing mitochondrial oxidative damage. To test whether MitoQ was active in vivo, we chose a clinically relevant form of mitochondrial oxidative damage: cardiac ischemia-reperfusion injury. Feeding MitoQ to rats significantly decreased heart dysfunction, cell death, and mitochondrial damage after ischemia-reperfusion. This protection was due to the antioxidant activity of MitoQ within mitochondria, as an untargeted antioxidant was ineffective and accumulation of the TPP cation alone gave no protection. Therefore, targeting antioxidants to mitochondria in vivo is a promising new therapeutic strategy in the wide range of human diseases such as Parkinson's disease, diabetes, and Friedreich's ataxia where mitochondrial oxidative damage underlies the pathology.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; Univ Otago, Dept Chem, Dunedin, New Zealand; Univ Otago, Dept Pharmacol & Toxicol, Dunedin, New Zealand; Univ Otago, Dept Biochem, Dunedin, New Zealand	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of Otago; University of Otago; University of Otago	Murphy, MP (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	mpm@mrc-dunn.cam.ac.uk	Murphy, Michael P/C-2120-2009; James, Andrew M/A-2639-2015	Murphy, Michael P/0000-0003-1115-9618; James, Andrew M/0000-0002-0515-9649; Harrison, Joanne/0000-0002-2431-4480; Sammut, Ivan/0000-0002-9217-9452				Aliev MK, 2002, CARDIOVASC RES, V53, P48, DOI 10.1016/S0008-6363(01)00474-6; Asimakis GK, 2002, CIRCULATION, V105, P981, DOI 10.1161/hc0802.104502; Asin-Cayuela J, 2004, FEBS LETT, V571, P9, DOI 10.1016/j.febslet.2004.06.045; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bergmeyer HU., 1974, METHODS ENZYMATIC AN, P574, DOI [10.1016/B978-0-12-091302-2.50010-4, DOI 10.1016/B978-0-12-091302-2.50010-4]; Berkich DA, 2003, ARCH BIOCHEM BIOPHYS, V420, P279, DOI 10.1016/j.abb.2003.09.021; Borutaite V, 2001, BBA-MOL BASIS DIS, V1537, P101, DOI 10.1016/S0925-4439(01)00062-X; Chen ZY, 1998, J MOL CELL CARDIOL, V30, P2281, DOI 10.1006/jmcc.1998.0789; Clarkson AN, 2004, FASEB J, V18, P1114, DOI 10.1096/fj.03-1203fje; Dhanasekaran A, 2004, J BIOL CHEM, V279, P37575, DOI 10.1074/jbc.M404003200; GRINIUS LL, 1970, BIOCHIM BIOPHYS ACTA, V216, P1, DOI 10.1016/0005-2728(70)90153-2; HARDY L, 1991, BIOCHEM J, V274, P133, DOI 10.1042/bj2740133; James AM, 1996, BIOCHEM J, V318, P401, DOI 10.1042/bj3180401; Jauslin ML, 2003, FASEB J, V17, P1972, DOI 10.1096/fj.03-0240fje; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Kelso GF, 2002, ANN NY ACAD SCI, V959, P263, DOI 10.1111/j.1749-6632.2002.tb02098.x; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Lesnefsky EJ, 2003, ARCH BIOCHEM BIOPHYS, V420, P287, DOI 10.1016/j.abb.2003.09.046; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marczin N, 2003, ARCH BIOCHEM BIOPHYS, V420, P222, DOI 10.1016/j.abb.2003.08.037; Murphy MP, 2000, ADV DRUG DELIVER REV, V41, P235, DOI 10.1016/S0169-409X(99)00069-1; Murphy MP, 1997, TRENDS BIOTECHNOL, V15, P326, DOI 10.1016/S0167-7799(97)01068-8; Murphy MP, 2001, BBA-BIOENERGETICS, V1504, P1, DOI 10.1016/S0005-2728(00)00234-6; OKAMOTO K, 1985, CHEM PHARM BULL, V33, P3745; Paradies G, 2004, CIRC RES, V94, P53, DOI 10.1161/01.RES.0000109416.56608.64; Ragan MT, 1987, MITOCHONDRIA PRACTIC, P79; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Sadek HA, 2003, ARCH BIOCHEM BIOPHYS, V420, P201, DOI 10.1016/j.abb.2003.09.029; Sammut IA, 2001, AM J PATHOL, V158, P1821, DOI 10.1016/S0002-9440(10)64138-7; Smith RAJ, 2003, P NATL ACAD SCI USA, V100, P5407, DOI 10.1073/pnas.0931245100; Suzuki K, 2002, CIRCULATION, V106, pI270, DOI 10.1161/01.cir.0000032880.55215.92; Vasquez-Vivar J, 2000, J BIOL CHEM, V275, P14064, DOI 10.1074/jbc.275.19.14064; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Weiss JN, 2003, CIRC RES, V93, P292, DOI 10.1161/01.RES.0000087542.26971.D4; Wright AF, 2004, NAT GENET, V36, P1153, DOI 10.1038/ng1448; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404	37	502	533	1	64	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1088	1095		10.1096/fj.05-3718com	http://dx.doi.org/10.1096/fj.05-3718com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	15985532				2022-12-28	WOS:000230923000037
J	Bolon, ML; Ouellette, Y; Li, FY; Tyml, K				Bolon, ML; Ouellette, Y; Li, FY; Tyml, K			Abrupt reoxygenation following hypoxia reduces electrical coupling between endothelial cells of wild-type but not connexin40 null mice in oxidant- and PKA-dependent manner	FASEB JOURNAL			English	Article						vascular resistance; Bessel function model; cremaster muscle	GAP-JUNCTION CHANNELS; ANTI-HYPOXIA/REOXYGENATION AGENTS; TYROSINE KINASE ACTIVATION; IN-VITRO; INTERCELLULAR COMMUNICATION; FEED ARTERIES; PATHWAY; VASODILATION; INJURY; REPERFUSION	Although electrical coupling along the arteriolar endothelium is central in arteriolar conducted response and in control of vascular resistance, little is known about the pathophysiological effect of hypoxia and reoxygenation (H/R) on this coupling. We examined this effect in a monolayer of cultured microvascular endothelial cells (ECs) derived from wild-type (WT) or connexin (Cx)40(-/-) mice (Cx40 is a key gap junction protein in ECs). To assess electrical coupling, we used a current injection technique and Bessel function model to compute the monolayer intercellular resistance. Hypoxia (0.1% O-2, 1 h) followed by abrupt reoxygenation (5-90 min) reduced coupling (i.e., increased resistance) in WT but not in Cx40(-/-) monolayer. H/R increased superoxide production and reduced protein kinase A (PKA) activity in both monolayers. Activation of PKA by 8-bromo-cAMP prevented the reduction in coupling. Preloading of the WT monolayer with the antioxidant ascorbate prevented reductions in both PKA activity and cell coupling. Inhibition of PKA with 6-22 amide during normoxia mimicked the reduction in coupling. Finally, hypoxia followed by slow reoxygenation caused no change in superoxide level, PKA activity, or coupling. Using intravital microscopy, we assessed the physiological relevance of these findings in terms of KCl-induced conducted vasoconstriction in arterioles of WT mouse cremaster muscle in vivo. Ischemia ( 1 h) followed by abrupt reperfusion (15-30 min) reduced conduction. 8-bromo-cAMP prevented this reduction, while 6-22 amide mimicked this reduction in control nonischemic arterioles. We propose that abrupt reoxygenation reduces interendothelial electrical coupling via oxidant- and PKA-dependent signaling that targets Cx40. We suggest that this mechanism contributes to compromised arteriolar function after H/R.	Lawson Hlth Res Inst, Ctr Crit Illness Res, Victoria Res Lab, London, ON N6C 2V5, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada; Mayo Clin & Mayo Fdn, Coll Med, Dept Pediat, Rochester, MN 55905 USA; Univ Western Ontario, Dept Med Biophys, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Mayo Clinic; Western University (University of Western Ontario)	Tyml, K (corresponding author), Lawson Hlth Res Inst, Ctr Crit Illness Res, Victoria Res Lab, 6th Floor,800 Commissioners Rd, London, ON N6C 2V5, Canada.	ktyml@lhsc.on.ca						Burt JM, 2003, CELL COMMUN ADHES, V10, P287, DOI 10.1080/714040441; de Wit C, 2000, CIRC RES, V86, P649, DOI 10.1161/01.RES.86.6.649; Dimon-Gadal S, 1998, J BIOL CHEM, V273, P22833, DOI 10.1074/jbc.273.35.22833; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; El Jamali A, 2004, FASEB J, V18, P1096, DOI 10.1096/fj.03-1054fje; Emerson GG, 2001, AM J PHYSIOL-HEART C, V280, pH160; Figueroa XF, 2003, CIRC RES, V92, P793, DOI 10.1161/01.RES.0000065918.90271.9A; Gustafsson F, 1999, ACTA PHYSIOL SCAND, V167, P11; Haefliger JA, 2004, CARDIOVASC RES, V62, P345, DOI 10.1016/j.cardiores.2003.11.015; HASHIMOTO Y, 1994, J SURG RES, V57, P693, DOI 10.1006/jsre.1994.1203; Hastie LE, 1997, J CELL PHYSIOL, V172, P373, DOI 10.1002/(SICI)1097-4652(199709)172:3<373::AID-JCP11>3.0.CO;2-7; Lee YN, 2002, TOXICOLOGY, V179, P51, DOI 10.1016/S0300-483X(02)00289-5; Li JM, 2004, AM J PHYSIOL-REG I, V287, pR1014, DOI 10.1152/ajpregu.00124.2004; Lidington D, 2000, J CELL PHYSIOL, V185, P117, DOI 10.1002/1097-4652(200010)185:1<117::AID-JCP11>3.0.CO;2-7; Lidington D, 2003, J VASC RES, V40, P149, DOI 10.1159/000070712; Lidington D, 2002, J CELL PHYSIOL, V193, P373, DOI 10.1002/jcp.10179; Martinez AD, 2000, BRAIN RES REV, V32, P250, DOI 10.1016/S0165-0173(99)00086-7; Meneshian A, 2002, MICROCIRCULATION, V9, P161, DOI 10.1038/sj.mn.7800136; Mottet D, 2003, J BIOL CHEM, V278, P31277, DOI 10.1074/jbc.M300763200; Musa H, 2004, J PHYSIOL-LONDON, V557, P863, DOI 10.1113/jphysiol.2003.059386; Musa H, 2003, BIOPHYS J, V84, P205, DOI 10.1016/S0006-3495(03)74843-7; Nishida M, 2000, ENDOTHELIUM-NEW YORK, V7, P279, DOI 10.3109/10623320009072214; Rose K, 2005, J CELL PHYSIOL, V204, P131, DOI 10.1002/jcp.20283; Sandow SL, 2003, CARDIOVASC RES, V60, P643, DOI 10.1016/j.cardiores.2003.09.017; Seko Y, 1996, BIOCHEM BIOPH RES CO, V226, P530, DOI 10.1006/bbrc.1996.1389; Simon AM, 1998, CURR BIOL, V8, P295, DOI 10.1016/S0960-9822(98)70113-7; TRAUB O, 1994, EUR J CELL BIOL, V64, P101; Tyml K, 2001, AM J PHYSIOL-HEART C, V281, pH1397; van Rijen HVM, 2000, CARDIOVASC RES, V45, P941, DOI 10.1016/S0008-6363(99)00373-9; Wu F, 2002, FEBS LETT, V520, P122, DOI 10.1016/S0014-5793(02)02804-1; Yamakoshi Y, 2003, J AM CHEM SOC, V125, P12803, DOI 10.1021/ja0355574; Yamamoto Y, 2001, J PHYSIOL-LONDON, V535, P181, DOI 10.1111/j.1469-7793.2001.00181.x; Zhang YW, 2000, PLANTA MED, V66, P119, DOI 10.1055/s-2000-11126; Zhang YW, 2000, PLANTA MED, V66, P114, DOI 10.1055/s-2000-11128; Zhang YW, 2002, PROSTAG LEUKOTR ESS, V67, P253, DOI 10.1054/plef.2002.0427; Zhang YW, 1999, PROSTAG LEUKOTR ESS, V61, P33, DOI 10.1054/plef.1999.0070; Zhou L, 1999, J CELL BIOL, V144, P1033, DOI 10.1083/jcb.144.5.1033	37	28	29	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1725	+		10.1096/fj.04-3446fje	http://dx.doi.org/10.1096/fj.04-3446fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16037099				2022-12-28	WOS:000230923000011
J	Chan, SW; Egan, PA				Chan, SW; Egan, PA			Hepatitis C virus envelope proteins regulate CHOP via induction of the unfolded protein response	FASEB JOURNAL			English	Article						ER-associated degradation; UPR	ENDOPLASMIC-RETICULUM STRESS; ER STRESS; TRANSCRIPTION FACTOR; MESSENGER-RNA; CELL-DEATH; GLYCOPROTEIN COMPLEXES; TRANSLATIONAL CONTROL; POSSIBLE INVOLVEMENT; MEDIATED APOPTOSIS; MAMMALIAN-CELLS	Unfolded protein response (UPR) is a cellular adaptive response that functions to reduce stress caused by malfolded proteins in the endoplasmic reticulum ( ER). UPR can be induced under physiological or pathological conditions and is responsible for the pathogenesis of many human diseases. Hepatitis C virus (HCV) is a single-stranded, positive-sense RNA virus causing chronic diseases. Its genome encodes two envelope proteins E1 and E2, which mature in the ER to form a noncovalently bound, native complex and disulfide aggregates and have previously been shown to induce expression of the molecular chaperone immunoglobulin heavy chain binding protein. In this study, we show that HCV envelope protein expression regulates another stress indicator CCAAT/enhancer-binding protein-homologous protein (CHOP). The ER-stress element and the activating transcription factor 4 element in the CHOP promoter were activated to a similar extent by HCV envelope protein expression. Using mouse embryonic fibroblasts deficient in the ER stress kinase RNA-activated protein kinase-like ER-resident kinase (PERK), we showed that PERK was necessary and sufficient for activating the CHOP promoter. Expression of HCV E1 and/or E2 also induced splicing of X-box binding protein 1 and transactivation of the unfolded protein response element, leading to the speculation that HCV E1 and E2 not only regulate the UPR but also ER-associated degradation.	UMIST, Fac Life Sci, Manchester M60 1QD, Lancs, England; Manchester Royal Infirm, Manchester M13 9WL, Lancs, England	University of Manchester; University of Manchester	Chan, SW (corresponding author), UMIST, Fac Life Sci, Jacksons Mill,POB 88,Sackerville St, Manchester M60 1QD, Lancs, England.	wan.chan@manchester.ac.uk		Chan, Shiu-Wan/0000-0002-4018-9309	Medical Research Council [G0000092] Funding Source: Medline; MRC [G0000092] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bitko V, 2001, J CELL BIOCHEM, V80, P441, DOI 10.1002/1097-4644(20010301)80:3<441::AID-JCB170>3.0.CO;2-C; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; Bruhat A, 2000, MOL CELL BIOL, V20, P7192, DOI 10.1128/MCB.20.19.7192-7204.2000; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; Choukhi A, 1998, J VIROL, V72, P3851, DOI 10.1128/JVI.72.5.3851-3858.1998; Ciccaglione AR, 2004, VIRUS RES, V104, P1, DOI 10.1016/j.virusres.2004.02.002; Deleersnyder V, 1997, J VIROL, V71, P697, DOI 10.1128/JVI.71.1.697-704.1997; Dimcheff DE, 2004, J BIOL CHEM, V279, P33782, DOI 10.1074/jbc.M403304200; Dubuisson J, 1996, J VIROL, V70, P778, DOI 10.1128/JVI.70.2.778-786.1996; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; Fernandez PM, 2000, BREAST CANCER RES TR, V59, P15, DOI 10.1023/A:1006332011207; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; HARADA S, 1995, J GEN VIROL, V76, P1223, DOI 10.1099/0022-1317-76-5-1223; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Iwawaki T, 2001, NAT CELL BIOL, V3, P158, DOI 10.1038/35055065; Jordan R, 2002, J VIROL, V76, P9588, DOI 10.1128/JVI.76.19.9588-9599.2002; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kishimoto T, 1998, CELL GROWTH DIFFER, V9, P337; Liberman E, 1999, J VIROL, V73, P3718, DOI 10.1128/JVI.73.5.3718-3722.1999; Liu N, 2004, J NEUROVIROL, V10, P189, DOI 10.1080/13550280490448043; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; MATSUURA Y, 1992, J VIROL, V66, P1425, DOI 10.1128/JVI.66.3.1425-1431.1992; Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Merola M, 2001, J VIROL, V75, P11205, DOI 10.1128/JVI.75.22.11205-11217.2001; Michalak JP, 1997, J GEN VIROL, V78, P2299, DOI 10.1099/0022-1317-78-9-2299; Moradpour D, 2002, TRENDS MOL MED, V8, P476, DOI 10.1016/S1471-4914(02)02395-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Reimold AM, 2000, GENE DEV, V14, P152; Roderick HL, 1997, FEBS LETT, V405, P181, DOI 10.1016/S0014-5793(97)00183-X; Sansonno D, 2004, J VIRAL HEPATITIS, V11, P27, DOI 10.1046/j.1365-2893.2003.00474.x; Schroder M, 2003, MOL MICROBIOL, V49, P591, DOI 10.1046/j.1365-2958.2003.03585.x; Selby M, 1999, J IMMUNOL, V162, P669; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shuda M, 2003, J HEPATOL, V38, P605, DOI 10.1016/S0168-8278(03)00029-1; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Sood R, 2000, GENETICS, V154, P787; Su HL, 2002, J VIROL, V76, P4162, DOI 10.1128/JVI.76.9.4162-4171.2002; Tardif KD, 2002, J VIROL, V76, P7453, DOI 10.1128/JVI.76.15.7453-7459.2002; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wang Y, 2000, J BIOL CHEM, V275, P27013; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Xu ZC, 1997, J VIROL, V71, P7387, DOI 10.1128/JVI.71.10.7387-7392.1997; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhou X J, 1993, Zhonghua Bing Li Xue Za Zhi, V22, P157; Zhu LX, 2004, WORLD J GASTROENTERO, V10, P2972; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	58	117	120	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1510	+		10.1096/fj.04-3455fje	http://dx.doi.org/10.1096/fj.04-3455fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16006626				2022-12-28	WOS:000230923000030
J	Hasaneen, NA; Zucker, S; Cao, J; Chiarelli, C; Panettieri, RA; Foda, HD				Hasaneen, NA; Zucker, S; Cao, J; Chiarelli, C; Panettieri, RA; Foda, HD			Cyclic mechanical strain-induced proliferation and migration of human airway smooth muscle cells: role of EMMPRIN and MMPs	FASEB JOURNAL			English	Article						matrix metalloproteinase; asthma	MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; EPIDERMAL-GROWTH-FACTOR; TENASCIN-C; TYROSINE PHOSPHORYLATION; EPITHELIAL-CELLS; GENE-EXPRESSION; LUNG INJURY; ACTIVATION; INHIBITOR; INDUCTION	Airway smooth muscle (ASM) proliferation and migration are major components of airway remodeling in asthma. Asthmatic airways are exposed to mechanical strain, which contributes to their remodeling. Matrix metalloproteinase (MMP) plays an important role in remodeling. In the present study, we examined if the mechanical strain of human ASM (HASM) cells contributes to their proliferation and migration and the role of MMPs in this process. HASM were exposed to mechanical strain using the FlexCell system. HASM cell proliferation, migration and MMP release, activation, and expression were assessed. Our results show that cyclic strain increased the proliferation and migration of HASM; cyclic strain increased release and activation of MMP-1, -2, and -3 and membrane type 1-MMP; MMP release was preceded by an increase in extracellular MMP inducer; Prinomastat [ a MMP inhibitor ( MMPI)] significantly decreased cyclic strain-induced proliferation and migration of HASM; and the strain-induced increase in the release of MMPs was accompanied by an increase in tenascin-C release. In conclusion, cyclic mechanical strain plays an important role in HASM cell proliferation and migration. This increase in proliferation and migration is through an increase in MMP release and activation. Pharmacological MMPIs should be considered in the pursuit of therapeutic options for airway remodeling in asthma.	SUNY Stony Brook, Hlth Sci Ctr, Stony Brook, NY 11794 USA; Vet Adm Med Ctr, Dept Med & Res, Northport, NY 11768 USA; Univ Penn, Med Ctr, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania	Foda, HD (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Stony Brook, NY 11794 USA.	Hussein.Foda@med.va.gov	panettieri, reynold/AAG-9485-2019		NATIONAL CANCER INSTITUTE [R01CA079866] Funding Source: NIH RePORTER; NCI NIH HHS [CA79866, R01 CA079866] Funding Source: Medline; NHLBI NIH HHS [R01 HL064634, HL-646340] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Belien ATJ, 1999, J CELL BIOL, V144, P373, DOI 10.1083/jcb.144.2.373; Black JL, 2003, RESP PHYSIOL NEUROBI, V137, P339, DOI 10.1016/S1569-9048(03)00157-5; Black JL, 2001, AM J RESP CRIT CARE, V164, pS63, DOI 10.1164/ajrccm.164.supplement_2.2106059; Buckley S, 2001, AM J PHYSIOL-LUNG C, V281, pL427; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; Chess PR, 2000, AM J PHYSIOL-LUNG C, V279, pL43; Cleek RL, 1997, J BIOMED MATER RES, V35, P525, DOI 10.1002/(SICI)1097-4636(19970615)35:4<525::AID-JBM12>3.0.CO;2-A; Corbel M, 2001, EUR J PHARMACOL, V426, P113, DOI 10.1016/S0014-2999(01)01209-2; Cowan KN, 2000, J CLIN INVEST, V105, P21, DOI 10.1172/JCI6539; Cowan KN, 1999, CIRC RES, V84, P1223, DOI 10.1161/01.RES.84.10.1223; CROWAN K, 1997, CIRCULATION S1, V96, P243; DeCastro R, 1996, J INVEST DERMATOL, V106, P1260, DOI 10.1111/1523-1747.ep12348959; Deryugina EI, 2003, INT J CANCER, V104, P533, DOI 10.1002/ijc.10977; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; DEZELASNY ETS, 1993, AM J RESP CELL MOL B, V9, P645; Elias JA, 2000, AM J RESP CRIT CARE, V161, pS168, DOI 10.1164/ajrccm.161.supplement_2.a1q4-4; Foda HD, 1996, LAB INVEST, V74, P538; Foda HD, 1999, AM J PHYSIOL-LUNG C, V277, pL174, DOI 10.1152/ajplung.1999.277.1.L174; Foda HD, 2001, AM J RESP CELL MOL, V25, P717, DOI 10.1165/ajrcmb.25.6.4558f; Fowlkes JL, 1999, ANN NY ACAD SCI, V878, P696, DOI 10.1111/j.1749-6632.1999.tb07765.x; Fowlkes JL, 2002, CYTOKINE GROWTH F R, V13, P277, DOI 10.1016/S1359-6101(02)00005-9; Gabison EE, 2005, AM J PATHOL, V166, P209, DOI 10.1016/S0002-9440(10)62245-6; Galvez BG, 2001, J BIOL CHEM, V276, P37491, DOI 10.1074/jbc.M104094200; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664, DOI 10.1165/ajrcmb.16.6.9191468; Guo HM, 2000, CANCER RES, V60, P888; Haseneen NA, 2003, AM J PHYSIOL-LUNG C, V284, pL541, DOI 10.1152/ajplung.00290.2002; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; HEDIN U, 1991, AM J PATHOL, V139, P649; Hirst SJ, 2000, AM J RESP CELL MOL, V23, P335, DOI 10.1165/ajrcmb.23.3.3990; HIRST SJ, 1992, AM J RESP CELL MOL, V7, P574, DOI 10.1165/ajrcmb/7.6.574; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; Johnson S, 1999, AM J PHYSIOL-LUNG C, V277, pL1109, DOI 10.1152/ajplung.1999.277.6.L1109; Jones PL, 1996, CIRC RES, V79, P1131, DOI 10.1161/01.RES.79.6.1131; Jones PL, 1999, J CELL SCI, V112, P435; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; JONES PL, 1995, J CELL SCI, V108, P519; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Latijnhouwers MA, 1996, J PATHOL, V178, P30, DOI 10.1002/(SICI)1096-9896(199601)178:1<30::AID-PATH442>3.0.CO;2-7; Li, 2000, Arterioscler Thromb Vasc Biol, V20, pE1; Li CH, 2003, FASEB J, V17, P2106, DOI 10.1096/fj.03-0150fje; Lim M, 1998, FEBS LETT, V441, P88, DOI 10.1016/S0014-5793(98)01474-4; LIU M, 1992, AM J PHYSIOL, V263, pL376; MIYAUCHI T, 1990, J BIOCHEM-TOKYO, V107, P316, DOI 10.1093/oxfordjournals.jbchem.a123045; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; NOVERAL JP, 1994, AM J PHYSIOL-LUNG C, V267, pL761, DOI 10.1152/ajplung.1994.267.6.L761; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; Oudin S, 2002, AM J RESP CELL MOL, V27, P107, DOI 10.1165/ajrcmb.27.1.4766; PANETTIERI RA, 1995, AM J RESP CELL MOL, V13, P205, DOI 10.1165/ajrcmb.13.2.7626288; PANETTIERI RA, 1990, AM J PHYSIOL, V259, pL365, DOI 10.1152/ajplung.1990.259.6.L365; Pavlaki M, 2002, J BIOL CHEM, V277, P2740, DOI 10.1074/jbc.M108987200; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Rajah R, 1996, AM J PHYSIOL-LUNG C, V271, pL1014, DOI 10.1152/ajplung.1996.271.6.L1014; Rajah R, 1999, AM J RESP CELL MOL, V20, P199, DOI 10.1165/ajrcmb.20.2.3148; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Sameshima T, 2000, CANCER LETT, V157, P177, DOI 10.1016/S0304-3835(00)00485-7; Schwartz SM, 1997, J CLIN INVEST, V100, pS87; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Seiki M, 2003, CANCER METAST REV, V22, P129, DOI 10.1023/A:1023087113214; Shalinsky DR, 1999, ANN NY ACAD SCI, V878, P236, DOI 10.1111/j.1749-6632.1999.tb07689.x; Smith PG, 2003, AM J RESP CELL MOL, V28, P436, DOI 10.1165/rcmb.4754; SMITH PG, 1994, AM J RESP CELL MOL, V10, P85, DOI 10.1165/ajrcmb.10.1.8292386; Spinale FG, 2000, CARDIOVASC RES, V46, P225, DOI 10.1016/S0008-6363(99)00431-9; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STEWART AG, 1994, CLIN EXP PHARMACOL P, V21, P277, DOI 10.1111/j.1440-1681.1994.tb02513.x; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Tschumperlin DJ, 2001, AM J RESP CRIT CARE, V164, pS90, DOI 10.1164/ajrccm.164.supplement_2.2106060; Uzui H, 2000, ATHEROSCLEROSIS, V149, P51, DOI 10.1016/S0021-9150(99)00295-6; Vaalamo M, 1996, BRIT J DERMATOL, V135, P52; Yamamoto K, 1999, J BIOL CHEM, V274, P21840, DOI 10.1074/jbc.274.31.21840; Zucker S, 2001, AM J PATHOL, V158, P1921, DOI 10.1016/S0002-9440(10)64660-3	72	71	76	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1507	+		10.1096/fj.04-3350fje	http://dx.doi.org/10.1096/fj.04-3350fje			33	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16014803				2022-12-28	WOS:000230923000020
J	Ito, N; Ito, T; Kromminga, A; Bettermann, A; Takigawa, M; Kees, F; Straub, RH; Paus, R				Ito, N; Ito, T; Kromminga, A; Bettermann, A; Takigawa, M; Kees, F; Straub, RH; Paus, R			Human hair follicles display a functional equivalent of the hypothalamic-pituitary-adrenal (HPA) axis and synthesize cortisol	FASEB JOURNAL			English	Article						CRH; ACTH; alpha-MSH; proopiomelanocortin; stress	CORTICOTROPIN-RELEASING HORMONE; MELANOCYTE-STIMULATING HORMONE; CYCLE-DEPENDENT EXPRESSION; HUMAN SKIN; MELANOCORTIN-1 RECEPTOR; MESSENGER-RNA; FACTOR CRF; PROOPIOMELANOCORTIN; STRESS; POMC	The skin and its major appendages are prominent target organs and potent sources of key players along the classical hypothalamic-pituitary axis, such as corticotropin releasing hormone (CRH), adrenocorticotropic hormone ( ACTH), and a melanocyte stimulating hormone (alpha-MSH), and even express key steroidogenic enzymes. Therefore, it may have established local stress response systems that resemble the hypothalamic-pituitary-adrenal (HPA) axis. However, functional evidence that this is indeed the case in normal human skin in situ has still been missing. We show that microdissected, organ-cultured human scalp hair follicles respond to CRH stimulation by up-regulating proopiomelanocortin ( POMC) transcription and immunoreactivity (IR) for ACTH and alpha-MSH, which must have been processed from POMC. CRH, alpha-MSH, and ACTH also modulate expression of their cognate receptors (CRH-R1, MC1-R, MC2-R). In addition, the strongest stimulus for adrenal cortisol production, ACTH, also up-regulates cortisol-IR in the hair follicles. Isolated human hair follicles secrete substantial levels of cortisol into the culture medium, and this activity is further up-regulated by CRH. CRH also modulates important functional hair growth parameters in vitro (hair shaft elongation, catagen induction, hair keratinocyte proliferation, melanin production). Finally, human hair follicles display HPA axis-like regulatory feedback systems, since the glucocorticoid receptor agonist hydrocortisone down-regulates follicular CRH expression. Thus, even in the absence of endocrine, neural, or vascular systemic connections, normal human scalp hair follicles directly respond to CRH stimulation in a strikingly similar manner to what is seen in the classical HPA axis, including synthesis and secretion of cortisol and activation of prototypic neuroendocrine feedback loops.	Univ Hamburg, Dept Dermatol, Univ Hosp Hamburg Eppendorf, D-20246 Hamburg, Germany; Hamamatsu Univ Sch Med, Dept Dermatol, Hamamatsu, Shizuoka 43131, Japan; Inst Immunol, Clin Pathol & Mol Med, Hamburg, Germany; Univ Regensburg, Dept Pharmacol, Regensburg, Germany; Univ Med Ctr Regensburg, Dept Internal Med 1, Regensburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; Hamamatsu University School of Medicine; University of Regensburg; University of Regensburg	Paus, R (corresponding author), Univ Hamburg, Dept Dermatol, Univ Hosp Hamburg Eppendorf, Martinistr 52, D-20246 Hamburg, Germany.	paus@uke.uni-hamburg.de	Paus, Ralf/F-6243-2011	Straub, Rainer H/0000-0003-1165-4555				AGREN UM, 1995, J CELL PHYSIOL, V164, P240, DOI 10.1002/jcp.1041640204; Aoki E, 2003, EXP DERMATOL, V12, P371, DOI 10.1034/j.1600-0625.2002.120403.x; Arck PC, 2001, FASEB J, V15, P2536, DOI 10.1096/fj.00-0699fje; AUBER L., 1952, TRANS ROY SOC EDINBURGH, V62, P191; Bohm M, 2002, J INVEST DERMATOL, V118, P533, DOI 10.1046/j.0022-202x.2001.01704.x; Bohm M, 2000, HORM RES, V54, P287, DOI 10.1159/000053273; Botchkarev VA, 2000, FASEB J, V14, P1931, DOI 10.1096/fj.99-0930com; Botchkarev VA, 2003, AM J PATHOL, V162, P709, DOI 10.1016/S0002-9440(10)63866-7; Botchkarev VA, 1999, ANN NY ACAD SCI, V885, P433; Burton PJ, 1998, ENDOCRINOLOGY, V139, P376, DOI 10.1210/en.139.1.376; Chakraborty AK, 1996, BBA-MOL CELL RES, V1313, P130, DOI 10.1016/0167-4889(96)00063-8; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; Deplewski D, 2000, ENDOCR REV, V21, P363, DOI 10.1210/er.21.4.363; Dodds HM, 1997, ANAL BIOCHEM, V247, P342, DOI 10.1006/abio.1997.2074; Elliott RJ, 2004, J INVEST DERMATOL, V122, P1010, DOI 10.1111/j.0022-202X.2004.22404.x; Ermak G, 1997, J INVEST DERMATOL, V108, P160, DOI 10.1111/1523-1747.ep12332925; Flint MS, 2003, STRESS, V6, P59, DOI 10.1080/1025389031000088426; Foitzik K, 2003, AM J PATHOL, V162, P1611, DOI 10.1016/S0002-9440(10)64295-2; Fritsch M, 2001, J INVEST DERMATOL, V116, P793, DOI 10.1046/j.1523-1747.2001.01312.x; GOODYER CG, 1981, CIBA F SYMP, V86, P89; Greenspan F. S., 2004, BASIC CLIN ENDOCRINO; Harbuz MS, 2003, ANN NY ACAD SCI, V992, P99, DOI 10.1111/j.1749-6632.2003.tb03141.x; Hoffman R, 2001, EUR J DERMATOL, V11, P296; Ito N, 2004, J INVEST DERMATOL, V122, P235, DOI 10.1046/j.1523-1747.2003.22145.x; Ito T, 2005, BRIT J DERMATOL, V152, P623, DOI 10.1111/j.1365-2133.2005.06453.x; Ito T, 2004, AM J PATHOL, V164, P623, DOI 10.1016/S0002-9440(10)63151-3; Kaneko K, 2003, EXP DERMATOL, V12, P47, DOI 10.1034/j.1600-0625.2003.120106.x; Kauser S, 2004, J INVEST DERMATOL, V123, P184, DOI 10.1111/j.0022-202X.2004.22724.x; Kono M, 2001, FASEB J, V15, P2297, DOI 10.1096/fj.01-0254fje; Lechner O, 2000, EUR J IMMUNOL, V30, P337; Lindner G, 1997, AM J PATHOL, V151, P1601; Luger TA, 1998, ANN NY ACAD SCI, V840, P381, DOI 10.1111/j.1749-6632.1998.tb09577.x; Maurer M, 1997, LAB INVEST, V77, P319; Mazurkiewicz JE, 1999, ANN NY ACAD SCI, V885, P427; Miller DB, 2002, METABOLISM, V51, P5, DOI 10.1053/meta.2002.33184; Moustafa M, 2002, J INVEST DERMATOL, V119, P1244, DOI 10.1046/j.1523-1747.2002.19602.x; Muller-Rover S, 2001, J INVEST DERMATOL, V117, P3, DOI 10.1046/j.0022-202x.2001.01377.x; Paus R, 1999, ANN NY ACAD SCI, V885, P350; Paus R, 2005, TRENDS IMMUNOL, V26, P32, DOI 10.1016/j.it.2004.09.014; Paus R, 2003, J INVEST DERM SYMP P, V8, P188, DOI 10.1046/j.1087-0024.2003.00807.x; PAUS R, 1994, J INVEST DERMATOL, V103, P143, DOI 10.1111/1523-1747.ep12392542; PAUS R, 1994, DEV BIOL, V163, P230, DOI 10.1006/dbio.1994.1139; Paus R, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P61, DOI 10.1038/jidsymp.1997.13; Paus R, 1999, J INVEST DERM SYMP P, V4, P226, DOI 10.1038/sj.jidsp.5640217; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; PAUS R, 2003, DERMATOLOGY, V68, P1007; PETRAGLIA F, 1987, NATURE, V328, P717, DOI 10.1038/328717a0; Petraglia F, 1998, J REPROD IMMUNOL, V39, P221, DOI 10.1016/S0165-0378(98)00024-2; PHILPOTT MP, 1994, J DERMATOL SCI, V7, P55; Quevedo ME, 2001, IN VITRO CELL DEV-AN, V37, P50; QUIRK SJ, 1990, J STEROID BIOCHEM, V35, P623, DOI 10.1016/0022-4731(90)90208-A; Rogoff D, 2001, J STEROID BIOCHEM, V78, P77, DOI 10.1016/S0960-0760(01)00076-0; Roloff B, 1998, FASEB J, V12, P287, DOI 10.1096/fasebj.12.3.287; Roth KA, 1999, J HISTOCHEM CYTOCHEM, V47, P1644; Serres M, 1996, ARCH DERMATOL RES, V288, P140, DOI 10.1007/BF02505823; Sinclair R, 1999, HDB DIS HAIR SCALP, P3; Slominski A, 2000, ENDOCR REV, V21, P457, DOI 10.1210/er.21.5.457; SLOMINSKI A, 1992, EXPERIENTIA, V48, P50, DOI 10.1007/BF01923606; Slominski A, 2005, AM J PHYSIOL-ENDOC M, V288, pE701, DOI 10.1152/ajpendo.00519.2004; SLOMINSKI A, 1993, MOL CELL ENDOCRINOL, V93, pC1, DOI 10.1016/0303-7207(93)90131-3; Slominski A, 1996, INT J DERMATOL, V35, P849, DOI 10.1111/j.1365-4362.1996.tb05049.x; SLOMINSKI A, 1993, J LAB CLIN MED, V122, P658; SLOMINSKI A, 1995, FEBS LETT, V374, P113, DOI 10.1016/0014-5793(95)01090-2; Slominski A, 1996, J CLIN ENDOCR METAB, V81, P2746, DOI 10.1210/jc.81.7.2746; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Slominski A, 2004, ENDOCRINOLOGY, V145, P941, DOI 10.1210/en.2003-0851; Slominski A, 1996, FEBS LETT, V399, P175, DOI 10.1016/S0014-5793(96)01315-4; SLOMINSKI A, 1998, BIOCHIM BIOPHYS ACTA, V19, P147; SLOMINSKI A, 1996, BIOCHIM BIOPHYS ACTA, V15, P247; SLOMINSKI A, 2003, REGULATION PERIPHERA, P149; Slominski AT, 1999, ANN NY ACAD SCI, V885, P287; Stander S, 2002, EXP DERMATOL, V11, P42, DOI 10.1034/j.1600-0625.2002.110105.x; STENN KS, 1993, SKIN PHARMACOL, V6, P125; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; STEWART PM, 2003, WILLIAMS TXB ENDOCRI, P493; Straub RH, 2003, ARTHRITIS RHEUM, V48, P1504, DOI 10.1002/art.11036; Thiboutot D, 2003, J INVEST DERMATOL, V120, P905, DOI 10.1046/j.1523-1747.2003.12244.x; Tobin DJ, 2001, EXP GERONTOL, V36, P29, DOI 10.1016/S0531-5565(00)00210-2; Toda Y, 1999, PATHOL INT, V49, P479, DOI 10.1046/j.1440-1827.1999.00875.x; Wang GM, 2002, ENDOCRINOLOGY, V143, P621, DOI 10.1210/en.143.2.621; WEIHUA Z, 2001, P NATL ACAD SCI USA, V22, P6330; Whiting DA, 2004, STRUCTURE HUMAN HAIR; WHITING DA, 1996, COLOR ATLAS DIFFEREN, P4; Yong PYK, 2000, J CLIN ENDOCR METAB, V85, P4728, DOI 10.1210/jc.85.12.4728; Yu L, 2002, MOL CELL ENDOCRINOL, V190, P9, DOI 10.1016/S0303-7207(02)00041-2; Zbytek B, 2004, J ENDOCRINOL, V181, pR1, DOI 10.1677/joe.0.181R001; Zouboulis CC, 2002, P NATL ACAD SCI USA, V99, P7148, DOI 10.1073/pnas.102180999; Zouboulis CC, 2000, HORM RES, V54, P230, DOI 10.1159/000053265	88	375	389	4	57	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1332	+		10.1096/fj.04-1968fje	http://dx.doi.org/10.1096/fj.04-1968fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15946990				2022-12-28	WOS:000230207800022
J	Kwidzinski, E; Bunse, J; Aktas, O; Richter, D; Mutlu, L; Zipp, F; Nitsch, R; Bechmann, I				Kwidzinski, E; Bunse, J; Aktas, O; Richter, D; Mutlu, L; Zipp, F; Nitsch, R; Bechmann, I			Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation	FASEB JOURNAL			English	Article						IDO; EAE; tryptophan; microglia	QUINOLINIC ACID CONCENTRATIONS; CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; IFN-GAMMA; IMMUNE PRIVILEGE; INTERFERON-GAMMA; FAS LIGAND; RELAPSING PARALYSIS; MICROGLIAL CELLS; HUMAN BRAIN	The tryptophan (trp)-catabolizing enzyme indolamine 2,3-dioxygenase (IDO) is induced by the T helper 1 ( Th 1) cytokine IFN-gamma during infections in various tissues including the brain. Recent studies demonstrated an immune modulatory function of this enzyme, since IDO-mediated depletion of trp hinders T cell proliferation, while its inhibition by 1-methyl-tryptophan (1-Mt) induces breakdown of immune tolerance in the placenta, leading to rejection of allogeneic concepti. Here, we tested IDO expression and function during experimental autoimmune encephalomyelitis (EAE) actively induced in adult SJL mice by immunization with PLP139-151. IDO activity ( determined by HPLC analysis of the kynurenine/tryptophan ratio) was increased in the spleen during the preclinical phase, and within the brain and spinal cord at the onset of symptoms. Immunocytochemistry revealed macrophages/activated microglia expressing IDO during EAE and in vitro experiments confirmed IDO induction in microglia upon IFN-gamma. treatment with synergistic effects of TNF-alpha. Inhibition of IDO by systemic administration of 1-Mt at clinical onset significantly exacerbated disease scores. From these data, it is tempting to speculate that IFN-alpha. from encephalitogenic Th 1 cells induces local IDO expression, thereby initiating a negative feedback loop which may underlie the self-limitation of autoimmune inflammation during EAE and multiple sclerosis.	Charite, Inst Cell Biol & Neurobiol, Ctr Anat, Berlin, Germany; Charite, Inst Neuroimmunol Clin & Expt Neuroimmunol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Kwidzinski, E (corresponding author), Charite, Inst Cell Biol & Neurobiol, Ctr Anat, Berlin, Germany.	kwidzinski@charite.de	Aktas, Orhan/B-7623-2009; Nitsch, Robert/AAI-9129-2021; Zipp, Frauke/C-9968-2015	Aktas, Orhan/0000-0002-2020-9210; Zipp, Frauke/0000-0002-1231-1928				Aktas O, 2003, J EXP MED, V197, P725, DOI 10.1084/jem.20021425; AlberatiGiani D, 1996, J NEUROCHEM, V66, P996; AlberatiGiani D, 1997, J IMMUNOL, V159, P419; Bechmann I, 2000, GLIA, V32, P25, DOI 10.1002/1098-1136(200010)32:1<25::AID-GLIA30>3.0.CO;2-Y; Bechmann I, 1999, GLIA, V27, P62, DOI 10.1002/(SICI)1098-1136(199907)27:1<62::AID-GLIA7>3.0.CO;2-S; Bechmann I, 2002, J NEUROIMMUNOL, V132, P60, DOI 10.1016/S0165-5728(02)00311-9; Bechmann I, 2001, EUR J NEUROSCI, V14, P1651, DOI 10.1046/j.0953-816x.2001.01793.x; BECHMANN I, 2005, FASEB J; BROCKE S, 1993, NATURE, V365, P642, DOI 10.1038/365642a0; Burudi EME, 2002, J VIROL, V76, P12233, DOI 10.1128/JVI.76.23.12233-12241.2002; CARLIN JM, 1989, J LEUKOCYTE BIOL, V45, P29, DOI 10.1002/jlb.45.1.29; Choi C, 1999, J IMMUNOL, V162, P1889; Currier AR, 2000, J INTERF CYTOK RES, V20, P369, DOI 10.1089/107999000312306; Daubener W, 1999, ADV EXP MED BIOL, V467, P517; Depboylu C, 2004, EUR J NEUROSCI, V19, P2997, DOI 10.1111/j.0953-816X.2004.03404.x; Diem R, 2003, J NEUROSCI, V23, P6993, DOI 10.1523/JNEUROSCI.23-18-06993.2003; Diestel A, 2003, J EXP MED, V198, P1729, DOI 10.1084/jem.20030975; Dorr J, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-04-j0001.2002; Fallarino I, 2002, CELL DEATH DIFFER, V9, P1069, DOI 10.1038/sj.cdd.4401073; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Guillemin GJ, 2005, GLIA, V49, P15, DOI 10.1002/glia.20090; Hayashi T, 2004, J CLIN INVEST, V114, P270, DOI 10.1172/JCI200421275; HEYES MP, 1989, ANN NEUROL, V26, P275; HEYES MP, 1990, BRAIN RES, V531, P148, DOI 10.1016/0006-8993(90)90768-7; Heyes MP, 1998, FASEB J, V12, P881, DOI 10.1096/fasebj.12.10.881; Hobom M, 2004, BRAIN PATHOL, V14, P148, DOI 10.1111/j.1750-3639.2004.tb00047.x; Kamradt T, 2001, NEW ENGL J MED, V344, P655, DOI 10.1056/NEJM200103013440907; Kassiotis G, 2001, J EXP MED, V193, P427, DOI 10.1084/jem.193.4.427; Krakowski M, 1996, EUR J IMMUNOL, V26, P1641, DOI 10.1002/eji.1830260735; Kwidzinski E, 2003, J NEURAL TRANSM-SUPP, P29, DOI 10.1007/978-3-7091-0643-3_2; Laich A, 2002, CLIN CHEM, V48, P579; Lee GK, 2002, IMMUNOLOGY, V107, P452, DOI 10.1046/j.1365-2567.2002.01526.x; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Munn DH, 1999, J EXP MED, V189, P1363, DOI 10.1084/jem.189.9.1363; Nettelnbreker E, 1998, J MED MICROBIOL, V47, P141, DOI 10.1099/00222615-47-2-141; OHMORI K, 1992, LAB INVEST, V66, P54; PFEFFERKORN ER, 1984, P NATL ACAD SCI-BIOL, V81, P908, DOI 10.1073/pnas.81.3.908; Phillips TA, 1999, J IMMUNOL, V162, P6053; Priller J, 2001, NAT MED, V7, P1356, DOI 10.1038/nm1201-1356; Robinson CM, 2003, J INTERF CYTOK RES, V23, P413, DOI 10.1089/107999003322277829; Sakurai K, 2002, J NEUROIMMUNOL, V129, P186, DOI 10.1016/S0165-5728(02)00176-5; SANDYK R, 1988, INT J NEUROSCI, V43, P207, DOI 10.3109/00207458808986171; SARDAR AM, 1995, NEUROSCI LETT, V187, P9, DOI 10.1016/0304-3940(95)11324-P; SCHWARCZ R, 1983, SCIENCE, V219, P316, DOI 10.1126/science.6849138; STREILEIN JW, 1993, CURR OPIN IMMUNOL, V5, P428, DOI 10.1016/0952-7915(93)90064-Y; Ullrich O, 2001, FASEB J, V15, P1460, DOI 10.1096/fj.00-0540fje; Widner B, 1997, CLIN CHEM, V43, P2424; Willenborg DO, 1996, J IMMUNOL, V157, P3223	48	232	243	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1347	+		10.1096/fj.04-3228fje	http://dx.doi.org/10.1096/fj.04-3228fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15939737				2022-12-28	WOS:000230207800033
J	Manoli, I; Le, H; Alesci, S; McFann, KK; Su, YA; Kino, T; Chrousos, GP; Blackman, MR				Manoli, I; Le, H; Alesci, S; McFann, KK; Su, YA; Kino, T; Chrousos, GP; Blackman, MR			Monoamine oxidase-A is a major target gene for glucocorticoids in human skeletal muscle cells	FASEB JOURNAL			English	Article						dexamethasone; myopathy; mitochondria; catecholamine; hydrogen peroxide	MAO-A; MITOCHONDRIAL DYSFUNCTION; EXPRESSION; DEXAMETHASONE; STRESS; ACTIVATION; PROTEASOME; APOPTOSIS; PROMOTER; PATHWAY	Skeletal myopathy is a common complication of endogenous and exogenous glucocorticoid excess, yet its pathogenetic mechanisms remain unclear. There is accumulating evidence that mitochondrial dysfunction and oxidative stress are involved in this process. To explore the glucocorticoid-induced transcriptional adaptations that may affect mitochondrial function in skeletal muscle, we studied gene expression profiles in dexamethasone-treated primary human skeletal myocytes using a cDNA microarray, which contains 501 mitochondria-related genes. We found that monoamine oxidase A (MAO-A) was the most significantly up-regulated gene. MAO-A is the primary enzyme metabolizing catecholamines and dietary amines, and its role in skeletal muscle remains largely unexplored. Dexamethasone induced dose- and time- dependent increases of MAO-A gene and protein expression, while its effects on MAO-B were minimal. Both the glucocorticoid receptor ( GR) and the Sp1 transcription factor were required for dexamethasone-induced MAO-A mRNA expression, as blockade of the GR with RU 486 or ablation of Sp1 binding with mithramycin abrogated MAO-A mRNA induction. The observed dexamethasone effect was biologically functional, as this steroid significantly increased MAO-mediated hydrogen peroxide production. We suggest that MAO-A-mediated oxidative stress can lead to cell damage, representing a novel pathogenetic mechanism for glucocorticoid-induced myopathy and a potential target for therapeutic intervention.	Natl Ctr Complementary & Alternat Med, Endocrine Sect, Clin Invest Lab, NIH, Bethesda, MD 20892 USA; UOA, Dept Pediat 1, GR-11527 Athens, Greece; NIMH, Clin Neuroendocrinol Branch, NIH, Bethesda, MD 20892 USA; NCCAM, Off Clin & Regulat Affairs, NIH, Bethesda, MD 20892 USA; LUMC, Dept Pathol, Maywood, IL 60153 USA; NICHD, Reprod Biol & Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Manoli, I (corresponding author), Natl Ctr Complementary & Alternat Med, Endocrine Sect, Clin Invest Lab, NIH, 9 Mem Dr,Bldg 9,Room 1N105, Bethesda, MD 20892 USA.	manolii@mail.nih.gov	Blackman, Marc/AAT-5771-2021	Manoli, Irini/0000-0003-1543-2941	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000618, ZIAHD008732, ZIAHD000615] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000615, Z01HD000618, Z01HD008732] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [Z01AT000009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002659, ZIAMH002659] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alesci S, 2004, 17TH IEEE SYMPOSIUM ON COMPUTER-BASED MEDICAL SYSTEMS, PROCEEDINGS, P329, DOI 10.1109/CBMS.2004.1311736; ARORA RC, 1977, EXP NEUROL, V55, P318, DOI 10.1016/0014-4886(77)90003-6; Auclair D, 1997, AM J PHYSIOL-CELL PH, V272, pC1007; BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; Bianchi P, 2003, J AM SOC NEPHROL, V14, P855, DOI 10.1097/01.ASN.0000058909.00567.5C; BLACKMAN MR, 1995, ENDOCRINOLOGY, P2702; Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004; Burke WJ, 2004, NEUROTOXICOLOGY, V25, P101, DOI 10.1016/S0161-813X(03)00090-1; Carlo P, 1996, BRAIN RES, V711, P175, DOI 10.1016/0006-8993(95)01353-9; Chrousos GP, 2000, INT J OBESITY, V24, pS50, DOI 10.1038/sj.ijo.0801278; Chrousos GP, 2004, AM J MED, V117, P204, DOI 10.1016/j.amjmed.2004.05.006; Cohen G, 1997, P NATL ACAD SCI USA, V94, P4890, DOI 10.1073/pnas.94.10.4890; Combaret L, 2004, BIOCHEM J, V378, P239, DOI 10.1042/BJ20031660; Conejo R, 2001, J CELL PHYSIOL, V187, P96, DOI 10.1002/1097-4652(2001)9999:9999<::AID-JCP1058>3.0.CO;2-V; CVIJIC G, 1995, FUNCT NEUROL, V10, P175; DENNEY RM, 1994, J NEUROCHEM, V63, P843; Denney RM, 1995, PROG BRAIN RES, V106, P57; Duclos M, 2004, AM J PHYSIOL-ENDOC M, V286, pE159, DOI 10.1152/ajpendo.00281.2003; EDELSTEIN SB, 1986, CELL MOL NEUROBIOL, V6, P121, DOI 10.1007/BF00711066; Frost RA, 1997, ENDOCRINOLOGY, V138, P4153, DOI 10.1210/en.138.10.4153; Furlong RA, 1999, AM J MED GENET, V88, P398, DOI 10.1002/(SICI)1096-8628(19990820)88:4<398::AID-AJMG18>3.3.CO;2-P; Gold PW, 2002, MOL PSYCHIATR, V7, P254, DOI 10.1038/sj.mp.4001032; Gomes-Marcondes MCC, 2002, CANCER LETT, V180, P69, DOI 10.1016/S0304-3835(02)00006-X; GRIMSBY J, 1991, P NATL ACAD SCI USA, V88, P3637, DOI 10.1073/pnas.88.9.3637; Hasselgren P O, 1999, Curr Opin Clin Nutr Metab Care, V2, P201, DOI 10.1097/00075197-199905000-00002; Hauptmann N, 1996, ARCH BIOCHEM BIOPHYS, V335, P295, DOI 10.1006/abbi.1996.0510; Haynes LE, 2004, BRAIN RES, V1026, P157, DOI 10.1016/j.brainres.2004.05.117; Isaeva EV, 2003, J PHYSIOL-LONDON, V547, P453, DOI 10.1113/jphysiol.2002.036129; Iuchi T, 2003, CIRC RES, V92, P81, DOI 10.1161/01.RES.0000050588.35034.3C; Jenkins BD, 2001, TRENDS ENDOCRIN MET, V12, P122, DOI 10.1016/S1043-2760(00)00357-X; Kennedy BP, 2003, J NEURAL TRANSM, V110, P789, DOI 10.1007/s00702-003-0828-6; KHALEELI AA, 1983, CLIN ENDOCRINOL, V18, P155, DOI 10.1111/j.1365-2265.1983.tb03198.x; Kopin IJ, 1998, AM J PHYSIOL-REG I, V275, pR165, DOI 10.1152/ajpregu.1998.275.1.R165; Kunduzova OR, 2002, FASEB J, V16, P1129, DOI 10.1096/fj.01-1008fje; LaFramboise WA, 2003, J MOL CELL CARDIOL, V35, P1307, DOI 10.1016/S0022-2828(03)00245-1; Li SW, 2001, MOL BRAIN RES, V93, P1, DOI 10.1016/S0169-328X(01)00120-6; Li YP, 2003, AM J PHYSIOL-CELL PH, V285, pC806, DOI 10.1152/ajpcell.00129.2003; Malorni W, 1998, FEBS LETT, V426, P155, DOI 10.1016/S0014-5793(98)00315-9; Marinovic AC, 2002, J BIOL CHEM, V277, P16673, DOI 10.1074/jbc.M200501200; MAROLDA M, 1991, ITAL J NEUROL SCI, V12, P409; MARONE JR, 1994, J APPL PHYSIOL, V77, P1685; Maurel A, 2003, AM J PHYSIOL-HEART C, V284, pH1460, DOI 10.1152/ajpheart.00700.2002; Mitsui T, 2002, J NEUROL, V249, P1004, DOI 10.1007/s00415-002-0774-5; Navegantes LCC, 2004, AM J PHYSIOL-ENDOC M, V286, pE642, DOI 10.1152/ajpendo.00371.2003; Orzechowski A, 2002, REPROD NUTR DEV, V42, P197, DOI 10.1051/rnd:2002018; Orzechowski A, 2003, J MUSCLE RES CELL M, V24, P33, DOI 10.1023/A:1024887431768; Oshima Y, 2004, MUSCLE NERVE, V30, P49, DOI 10.1002/mus.20036; Ponchel F, 2003, BMC BIOTECHNOL, V3, DOI 10.1186/1472-6750-3-18; Qu Z, 2000, GENE THER, V7, P428, DOI 10.1038/sj.gt.3301103; Ruest LB, 2002, J BIOL CHEM, V277, P5418, DOI 10.1074/jbc.M110685200; Seymour CB, 2003, BRIT J CANCER, V89, P1979, DOI 10.1038/sj.bjc.6601361; Shih JC, 1995, PROG BRAIN RES, V106, P49; Shih JC, 2004, CURR MED CHEM, V11, P1995, DOI 10.2174/0929867043364757; SHIH JC, 1990, J NEUR TR S, P41; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; Slotkin TA, 1998, BRAIN RES BULL, V47, P345, DOI 10.1016/S0361-9230(98)00111-7; Stangel M, 1996, J NEUROPATH EXP NEUR, V55, P36, DOI 10.1097/00005072-199601000-00004; Thompson MG, 1999, J CELL PHYSIOL, V181, P455, DOI 10.1002/(SICI)1097-4652(199912)181:3<455::AID-JCP9>3.0.CO;2-K; Tokunaga N, 2003, NEUROCHEM INT, V43, P573, DOI 10.1016/S0197-0186(03)00064-0; Vgontzas AN, 2003, J CLIN ENDOCR METAB, V88, P2087, DOI 10.1210/jc.2002-021176; YOUDIM MBH, 1972, NATURE, V236, P225, DOI 10.1038/236225b0; YOUDIM MBH, 1989, FASEB J, V3, P1753, DOI 10.1096/fasebj.3.6.2495232; ZHU QS, 1994, J NEUROSCI, V14, P7393	64	58	60	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1359	+		10.1096/fj.04-3660fje	http://dx.doi.org/10.1096/fj.04-3660fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15946989				2022-12-28	WOS:000230207800021
J	Huang, DR; Wujek, J; Kidd, G; He, TT; Cardona, A; Sasse, ME; Stein, EJ; Kish, J; Tani, M; Charo, IF; Proudfoot, AE; Rollins, BJ; Handel, T; Ransohoff, RM				Huang, DR; Wujek, J; Kidd, G; He, TT; Cardona, A; Sasse, ME; Stein, EJ; Kish, J; Tani, M; Charo, IF; Proudfoot, AE; Rollins, BJ; Handel, T; Ransohoff, RM			Chronic expression of monocyte chemoattractant protein-1 in the central nervous system causes delayed encephalopathy and impaired microglial function in mice	FASEB JOURNAL			English	Article						chemokines; chemokine receptors; transgenic mice; macrophages	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; AMYOTROPHIC-LATERAL-SCLEROSIS; MULTIPLE-SCLEROSIS; CHEMOKINE RECEPTORS; CELL-ACTIVATION; TRANSGENIC MICE; MCP-1; INDUCTION; RESIDENT; RECRUITMENT	Increased central nervous system (CNS) levels of monocyte chemoattractant protein 1 [CC chemokine ligand 2 (CCL2) in the systematic nomenclature] have been reported in chronic neurological diseases such as human immunodeficiency virus type 1-associated dementia, amyotrophic lateral sclerosis, and multiple sclerosis. However, a pathogenic role for CCL2 has not been confirmed, and there is no established model for the effects of chronic CCL2 expression on resident and recruited CNS cells. We report that aged (>6 months) transgenic (tg) mice expressing CCL2 under the control of the human glial fibrillary acidic protein promoter (huGFAP-CCL2(hi) tg(+) mice) manifested encephalopathy with mild perivascular leukocyte infiltration, impaired blood brain barrier function, and increased CD45-immunoreactive microglia, which had morphologic features of activation. huGFAP-CCL2(hi) tg(+) mice lacking CC chemokine receptor 2 (CCR2) were normal, showing that chemokine action via CCR2 was required. Studies of cortical slice preparations using video confocal microscopy showed that microglia in the CNS of huGFAP-CCL2(hi) tg(+) mice were defective in expressing amoeboid morphology. Treatment with mutant CCL2 peptides, a receptor antagonist and an obligate monomer, also suppressed morphological transformation in this assay, indicating a critical role for CCL2 in microglial activation and suggesting that chronic CCL2 exposure desensitized CCR2 on microglia, which in the CNS of huGFAP-CCL2(hi) tg(+) mice, did not up-regulate cell-surface expression of major histocompatibility complex class II, CD11b, CD11c, or CD40, in contrast to recruited perivascular macrophages that expressed enhanced levels of these markers. These results indicate that huGFAP-CCL2(hi) tg(+) mice provide a useful model to study how chronic CNS expression of CCL2 alters microglial function and CNS physiology.	Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA; Gladstone Inst Cardiovasc Dis, San Francisco, CA USA; Serono Pharmaceut Res Inst, Geneva, Switzerland; Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med, Dana Farber Canc Inst,Dept Med Oncol, Boston, MA 02115 USA; Univ Calif Berkeley, Berkeley, CA 94720 USA	Cleveland Clinic Foundation; University of California System; University of California San Francisco; The J David Gladstone Institutes; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; University of California System; University of California Berkeley	Ransohoff, RM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci NC3, 9500 Euclid Ave, Cleveland, OH 44195 USA.	ransohr@ccf.org	Cardona, Astrid E/K-4749-2013	Cardona, Astrid E/0000-0002-5093-8078; Kidd, Grahame/0000-0003-3956-2206	NINDS NIH HHS [3R01 NS32151-09] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032151] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Archelos JJ, 2000, ANN NEUROL, V47, P694, DOI 10.1002/1531-8249(200006)47:6<694::AID-ANA2>3.0.CO;2-W; Banisadr G, 2002, J NEUROCHEM, V81, P257, DOI 10.1046/j.1471-4159.2002.00809.x; Berman JW, 1996, J IMMUNOL, V156, P3017; Boddeke EWGM, 1999, J NEUROIMMUNOL, V98, P176, DOI 10.1016/S0165-5728(99)00096-X; Bornemann KD, 2001, AM J PATHOL, V158, P63, DOI 10.1016/S0002-9440(10)63945-4; BRENNER M, 1994, J NEUROSCI, V14, P1030, DOI 10.1523/JNEUROSCI.14-03-01030.1994; Conant K, 1998, P NATL ACAD SCI USA, V95, P3117, DOI 10.1073/pnas.95.6.3117; Dailey ME, 1999, METHODS, V18, P222, DOI 10.1006/meth.1999.0775; Fife BT, 2000, J EXP MED, V192, P899, DOI 10.1084/jem.192.6.899; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Gonzalez E, 2002, P NATL ACAD SCI USA, V99, P13795, DOI 10.1073/pnas.202357499; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Grewal IS, 1997, J IMMUNOL, V159, P401; Grewal IS, 1996, SCIENCE, V273, P1864, DOI 10.1126/science.273.5283.1864; Gu L, 2000, NATURE, V404, P407, DOI 10.1038/35006097; Gu L, 1997, J LEUKOCYTE BIOL, V62, P577, DOI 10.1002/jlb.62.5.577; Gunn MD, 1997, J IMMUNOL, V158, P376; Henkel JS, 2004, ANN NEUROL, V55, P221, DOI 10.1002/ana.10805; Huang DR, 2000, IMMUNOL REV, V177, P52, DOI 10.1034/j.1600-065X.2000.17709.x; Huang DR, 2002, J NEUROSCI, V22, P10633; Huang DR, 2001, J EXP MED, V193, P713, DOI 10.1084/jem.193.6.713; HULKOWER K, 1993, J IMMUNOL, V150, P2525; Ichikawa M, 1999, CELL IMMUNOL, V191, P97, DOI 10.1006/cimm.1998.1414; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Izikson L, 2000, J EXP MED, V192, P1075, DOI 10.1084/jem.192.7.1075; Juedes AE, 2001, J IMMUNOL, V166, P5168, DOI 10.4049/jimmunol.166.8.5168; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kajihara N, 2003, CIRCULATION, V108, P213, DOI 10.1161/01.cir.0000087426.18858.3a; Karpus WJ, 1998, J EXP MED, V187, P733, DOI 10.1084/jem.187.5.733; Katz-Levy Y, 1999, J CLIN INVEST, V104, P599, DOI 10.1172/JCI7292; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Mahad DJ, 2003, SEMIN IMMUNOL, V15, P23, DOI 10.1016/S1044-5323(02)00125-2; Marrs GS, 2001, NAT NEUROSCI, V4, P1006, DOI 10.1038/nn717; McManus C, 1998, J NEUROIMMUNOL, V86, P20, DOI 10.1016/S0165-5728(98)00002-2; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; Minagar A, 2002, J NEUROL SCI, V202, P13, DOI 10.1016/S0022-510X(02)00207-1; Palframan RT, 2001, J EXP MED, V194, P1361, DOI 10.1084/jem.194.9.1361; Penninger JM, 2001, NAT IMMUNOL, V2, P389, DOI 10.1038/87687; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; RANSOHOFF RM, 1993, FASEB J, V7, P592, DOI 10.1096/fasebj.7.6.8472896; Rezaie P, 2001, BRAIN RES REV, V35, P55, DOI 10.1016/S0165-0173(01)00042-X; ROLLINS BJ, 1991, CANCER CELL-MON REV, V3, P517; RUTLEDGE BJ, 1995, J IMMUNOL, V155, P4838; Sanders VJ, 1998, AIDS, V12, P1021, DOI 10.1097/00002030-199809000-00008; Santambrogio L, 2001, P NATL ACAD SCI USA, V98, P6295, DOI 10.1073/pnas.111152498; Schmidtmayerova H, 1996, P NATL ACAD SCI USA, V93, P700, DOI 10.1073/pnas.93.2.700; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Sedgwick JD, 1998, J IMMUNOL, V160, P5320; Simpson J, 2000, J NEUROIMMUNOL, V108, P192, DOI 10.1016/S0165-5728(00)00274-5; Simpson JE, 1998, J NEUROIMMUNOL, V84, P238, DOI 10.1016/S0165-5728(97)00208-7; Siveke JT, 1998, J IMMUNOL, V160, P550; Sriram S, 1997, NEUROLOGY, V48, P464, DOI 10.1212/WNL.48.2.464; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.3.CO;2-A; Tan J, 1999, SCIENCE, V286, P2352, DOI 10.1126/science.286.5448.2352; TAUB DD, 1995, J CLIN INVEST, V95, P1370, DOI 10.1172/JCI117788; TRAUGOTT U, 1983, SCIENCE, V219, P308, DOI 10.1126/science.6217550; TUOHY VK, 1989, J IMMUNOL, V142, P1523; VAN DV, 1999, AM J PATHOL, V154, P45; Wilms H, 2003, J NEUROIMMUNOL, V144, P139, DOI 10.1016/j.jneuroim.2003.08.042; Wujek JR, 2002, J NEUROPATH EXP NEUR, V61, P23, DOI 10.1093/jnen/61.1.23; Yacubova E, 2002, NATURE, V415, P77, DOI 10.1038/415077a; YAMAMOTO M, 2005, IN PRESS AM J PATHOL	63	38	40	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					761	772		10.1096/fj.04-3104com	http://dx.doi.org/10.1096/fj.04-3104com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15857890				2022-12-28	WOS:000229602600032
J	Meredith, EJ; Holder, MJ; Chamba, A; Challa, A; Lee, AD; Bunce, CM; Drayson, MT; Pilkington, G; Blakely, RD; Dyer, MJS; Barnes, NM; Gordon, J				Meredith, EJ; Holder, MJ; Chamba, A; Challa, A; Lee, AD; Bunce, CM; Drayson, MT; Pilkington, G; Blakely, RD; Dyer, MJS; Barnes, NM; Gordon, J			The serotonin transporter (SLC6A4) is present in B-cell clones of diverse malignant origin: probing a potential antitumor target for psychotropics	FASEB JOURNAL			English	Article						5-hydroxytryptamine; Burkitt's lymphoma; B cell lymphoma	3,4-METHYLENEDIOXYMETHAMPHETAMINE ECSTASY; LYMPHOMA CELLS; D-FENFLURAMINE; APOPTOSIS; DRUGS; BRAIN; LYMPHOCYTES; MDMA; METHYLENEDIOXYMETHAMPHETAMINE; PHARMACOKINETICS	Following our previous description of the serotonin transporter (SERT) acting as a conduit to 5-hydroxytryptamine (5-HT)-mediated apoptosis, specifically in Burkitt's lymphoma, we now detail its expression among a broad spectrum of B cell malignancy, while exploring additional SERT substrates for potential therapeutic activity. SERT was readily detected in derived B cell lines with origins as diverse as B cell precursor acute lymphoblastic leukemia, mantle cell lymphoma, diffuse large B cell lymphoma, and multiple myeloma. Concentration and timecourse kinetics for the antiproliferative and proapoptotic activities of the amphetamine derivatives fenfluramine (an appetite suppressant) and 3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy") revealed them as being similar to the endogenous indoleamine. A tricyclic antidepressant, clomipramine, instead mirrored the behavior of the selective serotonin reuptake inhibitor fluoxetine, both being effective in the low micromolar range. A majority of neoplastic clones were sensitive to one or more of the serotonergic compounds. Dysregulated bcl-2 expression, either by t(14; 18)(q32;q21) translocation or its introduction as a constitutively active transgene, provided protection from proapoptotic but not antiproliferative outcomes. These data indicate a potential for SERT as a novel anti-tumor target for amphetamine analogs, while evidence is presented that the seemingly more promising antidepressants are likely impacting malignant B cells independently of the transporter itself.	Univ Birmingham, Sch Med, Div Immun & Infect, MRC Ctr Immune Regulat,Inst Biomed Res, Birmingham B15 2TT, W Midlands, England; ENT Dept Univ Hosp, Birmingham, W Midlands, England; Univ Birmingham, Div Biosci, Birmingham, W Midlands, England; Univ Portsmouth, Sch Pharm & Biomed Sci, Portsmouth, Hants, England; Vanderbilt Univ, Med Ctr, Ctr Mol Neurosci, Dept Pharmacol, Nashville, TN USA; Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England; Univ Birmingham, Sch Med, Div Neurosci, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham; University of Portsmouth; Vanderbilt University; University of Leicester; University of Birmingham	Gordon, J (corresponding author), Univ Birmingham, Sch Med, Div Immun & Infect, MRC Ctr Immune Regulat,Inst Biomed Res, Vincent Dr, Birmingham B15 2TT, W Midlands, England.	j.gordon@bham.ac.uk	Barnes, Nicholas/ABE-6312-2020; Gordon, John/F-6443-2011; Dyer, Martin/F-2691-2014	Dyer, Martin/0000-0002-5033-2236; Drayson, Mark/0000-0002-1528-7564; Bunce, Chris/0000-0003-4084-8973	NIDA NIH HHS [DA-07390] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007390] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Anthony IC, 2003, BRAIN, V126, P1058, DOI 10.1093/brain/awg118; BALDESSARINI, 2001, GOODMAN GILLMANS PHA, P399; Batara JF, 2003, CURR OPIN NEUROL, V16, P671, DOI 10.1097/00019052-200312000-00005; Bauman AL, 2000, J NEUROSCI, V20, P7571; Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8; Belous A R, 2001, Neurosci Behav Physiol, V31, P185, DOI 10.1023/A:1005268425375; Bengel D, 1998, NEUROREPORT, V9, P2989, DOI 10.1097/00001756-199809140-00013; BLAKELY RD, 1994, J EXP BIOL, V196, P263; BOELSTERLI UA, 1987, CELL BIOL TOXICOL, V3, P231, DOI 10.1007/BF00117862; Bolo NR, 2000, NEUROPSYCHOPHARMACOL, V23, P428, DOI 10.1016/S0893-133X(00)00116-0; Bowyer JF, 2003, NEUROTOXICOLOGY, V24, P379, DOI 10.1016/S0161-813X(03)00030-5; Chanan-Khan Asher, 2004, Curr Treat Options Oncol, V5, P261, DOI 10.1007/s11864-004-0017-3; Coiffier B, 1998, BLOOD, V92, P1927; Connor TJ, 2004, IMMUNOLOGY, V111, P357, DOI 10.1111/j.0019-2805.2004.01847.x; Daley E, 2005, BIOCHEM BIOPH RES CO, V328, P623, DOI 10.1016/j.bbrc.2005.01.028; De Letter EA, 2004, FORENSIC SCI INT, V141, P85, DOI 10.1016/j.forsciint.2003.12.015; Fanburg BL, 1997, AM J PHYSIOL-LUNG C, V272, pL795, DOI 10.1152/ajplung.1997.272.5.L795; Fenton SL, 2003, LEUKEMIA, V17, P568, DOI 10.1038/sj.leu.2402843; Gagro A, 2003, EUR J IMMUNOL, V33, P1889, DOI 10.1002/eji.200323357; Garcia-Repetto R, 2003, FORENSIC SCI INT, V135, P110, DOI 10.1016/S0379-0738(03)00179-8; Glatz K, 2003, J NEUROCHEM, V86, P1072, DOI 10.1046/j.1471-4159.2003.01944.x; Gordon J, 2003, TRENDS IMMUNOL, V24, P438, DOI 10.1016/S1471-4906(03)00176-5; Gordon J, 1996, ADV EXP MED BIOL, V406, P139; Hiemke C, 2000, PHARMACOL THERAPEUT, V85, P11, DOI 10.1016/S0163-7258(99)00048-0; Jimenez A, 2004, TOXICOL APPL PHARM, V196, P223, DOI 10.1016/j.taap.2003.12.017; Ketabi-Kiyanvash N, 2003, ADDICT BIOL, V8, P413, DOI 10.1080/13556210310001646475; Lee SL, 2001, FASEB J, V15, P1324, DOI 10.1096/fj.00-0431fje; McCloskey N, 1999, EUR J IMMUNOL, V29, P3236, DOI 10.1002/(SICI)1521-4141(199910)29:10<3236::AID-IMMU3236>3.0.CO;2-T; Montiel-Duarte C, 2002, BBA-MOL BASIS DIS, V1588, P26, DOI 10.1016/S0925-4439(02)00112-6; Montiel-Duarte C, 2004, BIOCHEM PHARMACOL, V67, P1025, DOI 10.1016/j.bcp.2003.10.020; Mossner R, 2000, NEUROCHEM INT, V36, P197, DOI 10.1016/S0197-0186(99)00122-9; Mossner R, 2001, LIFE SCI, V68, P873, DOI 10.1016/S0024-3205(00)00992-9; NISSBRANDT H, 1991, N-S ARCH PHARMACOL, V344, P16; Pellegrin P, 1997, FEBS LETT, V418, P101, DOI 10.1016/S0014-5793(97)01339-2; Pellegrino TC, 2001, INT IMMUNOPHARMACOL, V1, P665, DOI 10.1016/S1567-5769(00)00051-5; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; Racke K, 1996, BEHAV BRAIN RES, V73, P83; Ramamoorthy S, 1998, METHOD ENZYMOL, V296, P347; Reeve HL, 1999, AM J PHYSIOL-LUNG C, V277, pL662, DOI 10.1152/ajplung.1999.277.3.L662; Rooprai HK, 2003, ACTA NEUROCHIR, V145, P683, DOI 10.1007/s00701-003-0073-7; Rothman RB, 2002, PHARMACOL THERAPEUT, V95, P73, DOI 10.1016/S0163-7258(02)00234-6; SEELIG A, 1994, P NATL ACAD SCI USA, V91, P68, DOI 10.1073/pnas.91.1.68; Serafeim A, 2003, BLOOD, V101, P3212, DOI 10.1182/blood-2002-07-2044; Serafeim A, 2002, BLOOD, V99, P2545, DOI 10.1182/blood.V99.7.2545; Serafeim Adamantios, 2001, Current Opinion in Pharmacology, V1, P398, DOI 10.1016/S1471-4892(01)00069-8; TATE CG, 1994, J BIOL CHEM, V269, P26303; Vivero L E, 1998, J Emerg Med, V16, P197, DOI 10.1016/S0736-4679(97)00289-8; Walther DJ, 2003, CELL, V115, P851, DOI 10.1016/S0092-8674(03)01014-6; WEISS J, 2003, J PHARM EXP THER; WILLIAMS CKO, 1983, EUR J CANCER CLIN ON, V19, P741, DOI 10.1016/0277-5379(83)90007-X; Xia ZL, 2000, PROG NEUROBIOL, V60, P501, DOI 10.1016/S0301-0082(99)00036-2; Yang GB, 2004, J NEUROIMMUNOL, V146, P46, DOI 10.1016/j.jneuroim.2003.10.044; Zhu CB, 2004, MOL PHARMACOL, V65, P1462, DOI 10.1124/mol.65.6.1462	53	67	69	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1187	+		10.1096/fj.04-3477fje	http://dx.doi.org/10.1096/fj.04-3477fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15870169				2022-12-28	WOS:000229602600021
J	Greco, A; Calle, A; Morfin, F; Thouvenot, D; Cayre, M; Kindbeiter, K; Martin, L; Levillain, O; Diaz, JJ				Greco, A; Calle, A; Morfin, F; Thouvenot, D; Cayre, M; Kindbeiter, K; Martin, L; Levillain, O; Diaz, JJ			S-adenosyl methionine decarboxylase activity is required for the outcome of herpes simplex virus type 1 infection and represents a new potential therapeutic target	FASEB JOURNAL			English	Article						HSV-1; SAMDC	RIBOSOMAL-PROTEIN SYNTHESIS; MESSENGER-RNA; POLYAMINE METABOLISM; TRANSLATIONAL CONTROL; THYMIDINE KINASE; ANTIVIRAL DRUGS; HELA-CELLS; ACCUMULATION; REPLICATION; ACYCLOVIR	All the available antiherpetic drugs are directed against viral proteins. Their extensive clinical use has led to the emergence of resistant viral strains. There is a need for the treatment of herpes infections due to resistant strains, especially for immunocompromised patients. To design new kinds of drugs, we have developed a strategy to identify cellular targets. Herpes simplex virus type I (HSV-1) infection is concomitant to a repression of most host protein synthesis. However, some cellular proteins continue to be efficiently synthesized. We speculated that some of them could determine the outcome of infection. Since two polyamines, spermidine and spermine, are components of the HSV-1 virions, we investigated whether enzymes involved in their synthesis could be required for viral infection. We show that inhibition of S-adenosyl methionine decarboxylase, a key enzyme of the polyamine metabolic pathway, prevents HSV-1 infection. Inhibition of polyamine synthesis prevents infection of culture cells with HSV-1 laboratory strains as well as clinical isolates that are resistant to the conventional antiviral drugs acyclovir and foscarnet. Our data provide the opportunity to develop molecules with a novel mechanism of action for the treatment of herpes infection.	UCBL, CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, F-69622 Villeurbanne, France; Fac Med Laennec, INSERM, U369, F-69372 Lyon, France; Hospices Civils Lyon, Virol Lab, F-69373 Lyon, France; Lab NMDA, UMR 6156, F-13288 Marseille, France; CEI Lyon 1, Idealp Pharma, F-69603 Villeurbanne, France; Fac Med Laennec, INSERM, U499, F-69372 Lyon, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm)	Greco, A (corresponding author), UCBL, CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, 43 Blvd 11 Novembre 1918, F-69622 Villeurbanne, France.	greco@cgmc.univ-lyon1.fr	DIAZ, Jean-Jacques/H-3018-2014; MORFIN, Florence/M-7176-2014; DIAZ, Jean-Jacques/AAT-3846-2021; Morfin, Florence/ABG-5220-2020; Cayre, Myriam/AAG-4614-2021	DIAZ, Jean-Jacques/0000-0002-7914-4319; DIAZ, Jean-Jacques/0000-0002-7914-4319; 				Ashley RL, 1999, CLIN MICROBIOL REV, V12, P1; BESSON MT, 1986, COMP BIOCHEM PHYS B, V83, P589, DOI 10.1016/0305-0491(86)90300-7; BIRNBAUM MJ, 1988, INSECT BIOCHEM, V18, P853, DOI 10.1016/0020-1790(88)90110-2; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; Crute JJ, 2002, NAT MED, V8, P386, DOI 10.1038/nm0402-386; Danve C, 2002, J VIROL METHODS, V105, P207, DOI 10.1016/S0166-0934(02)00103-9; DIAZ JJ, 1993, J GEN VIROL, V74, P397, DOI 10.1099/0022-1317-74-3-397; Diaz JJ, 1996, NATURE, V379, P273, DOI 10.1038/379273a0; EFSTATHIOU S, 1989, J GEN VIROL, V70, P869, DOI 10.1099/0022-1317-70-4-869; ESTRIDGE JK, 1989, VIROLOGY, V168, P67, DOI 10.1016/0042-6822(89)90404-2; EVERETT RD, 1985, EMBO J, V4, P1973, DOI 10.1002/j.1460-2075.1985.tb03880.x; Everly DN, 2002, J VIROL, V76, P8560, DOI 10.1128/JVI.76.17.8560-8571.2002; FRANCKE B, 1978, BIOCHEMISTRY-US, V17, P5494, DOI 10.1021/bi00618a026; GIBSON W, 1971, P NATL ACAD SCI USA, V68, P2818, DOI 10.1073/pnas.68.11.2818; GOLDIN AL, 1981, J VIROL, V38, P50, DOI 10.1128/JVI.38.1.50-58.1981; Greco A, 1997, MOL GEN GENET, V256, P320, DOI 10.1007/s004380050575; Greco A, 2000, ELECTROPHORESIS, V21, P2522, DOI 10.1002/1522-2683(20000701)21:12<2522::AID-ELPS2522>3.3.CO;2-1; HARDWICKE MA, 1994, J VIROL, V68, P4797, DOI 10.1128/JVI.68.8.4797-4810.1994; HILL TJ, 1975, J GEN VIROL, V28, P341, DOI 10.1099/0022-1317-28-3-341; Hossain A, 1997, J GEN VIROL, V78, P3341, DOI 10.1099/0022-1317-78-12-3341; KEMP LM, 1988, VIROLOGY, V166, P258, DOI 10.1016/0042-6822(88)90170-5; KHAN NA, 1991, CELL BIOL INT REP, V15, P9, DOI 10.1016/0309-1651(91)90078-W; Khodarev NN, 1999, P NATL ACAD SCI USA, V96, P12062, DOI 10.1073/pnas.96.21.12062; LANGLOIS M, 1986, J BIOL STAND, V14, P201, DOI 10.1016/0092-1157(86)90004-1; LARDER BA, 1985, VIROLOGY, V146, P262, DOI 10.1016/0042-6822(85)90009-1; Laurent AM, 1998, J GEN VIROL, V79, P2765, DOI 10.1099/0022-1317-79-11-2765; MAYMAN BA, 1985, J VIROL, V53, P1; MCCORMICK FP, 1975, J GEN VIROL, V27, P25, DOI 10.1099/0022-1317-27-1-25; Morfin F, 1999, ANTIMICROB AGENTS CH, V43, P2412, DOI 10.1128/AAC.43.10.2412; Morfin F, 2003, J CLIN VIROL, V26, P29, DOI 10.1016/S1386-6532(02)00263-9; MOSCA JD, 1992, J VIROL, V66, P3811, DOI 10.1128/JVI.66.6.3811-3822.1992; Oredsson SM, 2003, BIOCHEM SOC T, V31, P366, DOI 10.1042/BST0310366; PAJUNEN A, 1988, J BIOL CHEM, V263, P17040; PELECH SL, 1986, P NATL ACAD SCI USA, V83, P5968, DOI 10.1073/pnas.83.16.5968; POHJANPELTO P, 1988, LIFE SCI, V42, P2011, DOI 10.1016/0024-3205(88)90501-2; RAINA A, 1981, MED BIOL, V59, P428; Roizman Bernard, 1993, P11; Schang LM, 2002, J VIROL, V76, P7874, DOI 10.1128/JVI.76.15.7874-7882.2002; Schang LM, 1998, J VIROL, V72, P5626, DOI 10.1128/JVI.72.7.5626-5637.1998; SCHENCK P, 1988, J GEN VIROL, V69, P99, DOI 10.1099/0022-1317-69-1-99; Seiler N, 1970, Methods Biochem Anal, V18, P259, DOI 10.1002/9780470110362.ch5; Simonin D, 1997, J GEN VIROL, V78, P435, DOI 10.1099/0022-1317-78-2-435; SINCLAIR MC, 1994, J GEN VIROL, V75, P1083, DOI 10.1099/0022-1317-75-5-1083; STRAMBI C, 1993, ARCH INSECT BIOCHEM, V24, P203, DOI 10.1002/arch.940240404; STROM T, 1987, J VIROL, V61, P2198, DOI 10.1128/JVI.61.7.2198-2207.1987; TABOR CW, 1976, ANNU REV BIOCHEM, V45, P285, DOI 10.1146/annurev.bi.45.070176.001441; TYMS AS, 1979, BIOCHEM BIOPH RES CO, V86, P312, DOI 10.1016/0006-291X(79)90867-2; Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327; WARRELL RP, 1983, J CLIN ONCOL, V1, P52, DOI 10.1200/JCO.1983.1.1.52	49	15	21	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2005	19	6					1128	+		10.1096/fj.04-2108fje	http://dx.doi.org/10.1096/fj.04-2108fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15863396				2022-12-28	WOS:000228865300002
J	Ott, I; Keller, U; Knoedler, M; Gotze, KS; Doss, K; Fischer, P; Urlbauer, K; Debus, G; von Bubnoff, N; Rudelius, M; Schomig, A; Peschel, C; Oostendorp, RAJ				Ott, I; Keller, U; Knoedler, M; Gotze, KS; Doss, K; Fischer, P; Urlbauer, K; Debus, G; von Bubnoff, N; Rudelius, M; Schomig, A; Peschel, C; Oostendorp, RAJ			Endothelial-like cells expanded from CD34(+) blood cells improve left ventricular function after experimental myocardial infarction	FASEB JOURNAL			English	Article						endothelial progenitor cells; cord blood; umbilical vein endothelial cells	PROGENITOR CELLS; STEM-CELLS; TRANSPLANTATION; MOBILIZATION; HEART; NEOVASCULARIZATION; VASCULOGENESIS; REGENERATION; RECRUITMENT; EXPRESSION	Mobilization and recruitment of endothelial progenitor cells (EPC) contributes to vasculogenesis in vivo. So far, applications for cell therapy are limited by the number of available cells. Expansion of EPC or their progeny may, therefore, facilitate its therapeutic use in ischemic disease. The aim of this study was to expand CD34+ EPC-derived progeny from different sources, characterize them, and investigate their potential for use in therapeutic vasculogenesis. CD34+ cells from G-CSF-mobilized peripheral blood (PB) and cord blood (CB) were isolated using immunomagnetic beads and cultured in endothelial cell medium. Cells were expanded up to 16 (PB) and up to 46 (CB) population doublings, respectively. Immunophenotypic and mRNA expression analyses showed a high degree of similarity between the cultured cells and human umbilical vein endothelial cells (HUVEC). By day 14 after transplantation, transplanted human CD31-positive EPC-derived cells were detected. These cells expressed the proliferation marker Ki67 and formed vessel-like structures in ischemic myocardium. Most strikingly, transplantation of EPC-derived cells improved left ventricular function after experimental ischemia, as shown by echocardiography. In conclusion, cells cultured from CD34+ EPC can be expanded in vitro to clinically relevant numbers. In vivo, these cells proliferate, form vascular structures, and improve left ventricular function after experimental myocardial infarction. Therefore, in vitro expanded EPC-derived endothelial cells may be beneficial in the treatment of ischemic disease.	Tech Univ Munich, Med Klin & Poliklin 3, Dept Med 1, D-81675 Munich, Germany; Tech Univ Munich, Dept Med 3, D-81675 Munich, Germany; Krankenhaus Neuperlach, Dept Obstet & Gynecol, Munich, Germany; Tech Univ Munich, Dept Pathol, D-81675 Munich, Germany	Technical University of Munich; Technical University of Munich; Technical University of Munich	Oostendorp, RAJ (corresponding author), Tech Univ Munich, Med Klin & Poliklin 3, Dept Med 1, Ismaninger Str 22, D-81675 Munich, Germany.	oostendorp@lrz.tum.de	von Bubnoff, Nikolas/F-2351-2017; Oostendorp, Robert A. J./K-9841-2018; von Bubnoff, Nikolas/AAG-1845-2021	von Bubnoff, Nikolas/0000-0001-9593-8947; Oostendorp, Robert A. J./0000-0002-4947-0412; 				Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Gehling UM, 2000, BLOOD, V95, P3106; Gill M, 2001, CIRC RES, V88, P167; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Heeschen C, 2003, BLOOD, V102, P1340, DOI 10.1182/blood-2003-01-0223; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Herder C, 2003, ARTERIOSCL THROM VAS, V23, P2266, DOI 10.1161/01.ATV.0000100403.78731.9F; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JEREMY RW, 1987, J AM COLL CARDIOL, V9, P989, DOI 10.1016/S0735-1097(87)80298-X; Kawamoto A, 2003, CIRCULATION, V107, P461, DOI 10.1161/01.CIR.0000046450.89986.50; Kawamoto A, 2001, CIRCULATION, V103, P634; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Moore MAS, 2001, ANN NY ACAD SCI, V938, P36; Muller-Ehmsen J, 2002, CIRCULATION, V105, P1720, DOI 10.1161/01.CIR.0000013782.76324.92; Murohara T, 2001, TRENDS CARDIOVAS MED, V11, P303, DOI 10.1016/S1050-1738(01)00128-1; Nieda M, 1997, BRIT J HAEMATOL, V98, P775, DOI 10.1046/j.1365-2141.1997.2583074.x; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; ORLIC D, 2003, CIRC RES, V92, P6; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; RAFII S, 2003, NAT MED, V8, P841; Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0; Schmeisser A, 2003, ADV EXP MED BIOL, V522, P59; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Shintani S, 2001, CIRCULATION, V103, P2776, DOI 10.1161/hc2301.092122; Solovey A, 1997, NEW ENGL J MED, V337, P1584, DOI 10.1056/NEJM199711273372203; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442; Tran N, 2002, TRANSPLANT P, V34, P3262, DOI 10.1016/S0041-1345(02)03589-3; Vasa M, 2001, CIRCULATION, V103, P2885, DOI 10.1161/hc2401.092816; Yau TM, 2003, ANN THORAC SURG, V75, P169, DOI 10.1016/S0003-4975(02)04290-X	36	101	116	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					992	+		10.1096/fj.04-3219fje	http://dx.doi.org/10.1096/fj.04-3219fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15814609				2022-12-28	WOS:000228865300025
J	Zhang, HY; Sawashita, J; Fu, XY; Korenaga, T; Yan, JM; Mori, M; Higuchi, K				Zhang, Huanyu; Sawashita, Jinko; Fu, Xiaoying; Korenaga, Tatsumi; Yan, Jingmin; Mori, Masayuki; Higuchi, Keiichi			Transmissibility of mouse AApoAII amyloid fibrils: inactivation by physical and chemical methods	FASEB JOURNAL			English	Article						amyloidosis; disruption; organic compounds	PRION PROTEIN; CONFORMATIONAL TRANSITIONS; NORDIHYDROGUAIARETIC ACID; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; BETA PROTEIN; IN-VITRO; APOLIPOPROTEIN; TETRACYCLINES; AGGREGATION	AApoAII amyloid fibrils have exhibited prion-like transmissibility in mouse senile amyloidosis. We have demonstrated that AApoAII is extremely active and can induce amyloidosis following doses less than 1 pg. We tested physical and chemical methods to disrupt AApoAII fibrils in vitro as determined by thioflavin T binding and electron microscopy (EM) as well as inactivating the transmissibility of AApoAII fibrils in vivo. Complete disruption of AApoAII fibrils was achieved by treatment with formic acid, 6 M guanidine hydrochloride, and autoclaving in an alkaline solution. Injection of these disrupted AApoAII fibrils did not induce amyloidosis in mice. Disaggregation with 6 M urea, autoclaving, and alkaline solution was incomplete, and injection of these AApoAII fibrils induced mild amyloidosis. Treatment with formalin, delipidation, freeze-thaw, and RNase did not have any major effect. A distinct correlation was obtained between the amounts of amyloid fibrils and the transmissibility of amyloid fibrils, thereby indicating the essential role of fibril conformation for transmission of amyloidosis. We also studied the inactivation of AApoAII fibrils by several organic compounds in vitro and in vivo. AApoAII amyloidosis provides a valuable system for studying factors that may prevent transmission of amyloid disease as well as potential novel therapies.	Shinshu Univ, Grad Sch Med, Dept Aging Biol, Inst Aging & Adaptat, Matsumoto, Nagano 3908621, Japan	Shinshu University	Higuchi, K (corresponding author), Shinshu Univ, Grad Sch Med, Dept Aging Biol, Inst Aging & Adaptat, Asahi 3-1-1, Matsumoto, Nagano 3908621, Japan.	khiguchi@sch.md.shinshu-u.ac.jp		Sawashita, Jinko/0000-0001-8016-6649				BAKER HF, 1994, MOL NEUROBIOL, V8, P25, DOI 10.1007/BF02778005; Ban T, 2003, J BIOL CHEM, V278, P16462, DOI 10.1074/jbc.C300049200; Benson MD, 2001, GENOMICS, V72, P272, DOI 10.1006/geno.2000.6499; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Bitan G, 2005, AMYLOID, V12, P88, DOI 10.1080/13506120500106958; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Botelho MG, 2003, J BIOL CHEM, V278, P34259, DOI 10.1074/jbc.M303189200; BROWN P, 1982, J INFECT DIS, V145, P683, DOI 10.1093/infdis/145.2.683; BROWN P, 1984, NEW ENGL J MED, V310, P727; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Cardoso I, 2003, FASEB J, V17, P803, DOI 10.1096/fj.02-0764com; Caughey B, 2000, NAT MED, V6, P751, DOI 10.1038/77476; Chesebro B, 1998, SCIENCE, V279, P42, DOI 10.1126/science.279.5347.42; Chiba T, 1999, AM J PATHOL, V155, P1319, DOI 10.1016/S0002-9440(10)65234-0; Cui D, 2002, PATHOL INT, V52, P40, DOI 10.1046/j.1440-1827.2002.01309.x; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Eriksen JL, 2003, J CLIN INVEST, V112, P440, DOI 10.1172/JCI200318162; Fichet G, 2004, LANCET, V364, P521, DOI 10.1016/S0140-6736(04)16810-4; Fischer MB, 2000, NATURE, V408, P479, DOI 10.1038/35044100; Forloni G, 2002, P NATL ACAD SCI USA, V99, P10849, DOI 10.1073/pnas.162195499; Forloni G, 2001, FEBS LETT, V487, P404, DOI 10.1016/S0014-5793(00)02380-2; Fu XY, 2004, FEBS LETT, V563, P179, DOI 10.1016/S0014-5793(04)00295-9; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; HIGUCHI K, 1993, FEBS LETT, V317, P207, DOI 10.1016/0014-5793(93)81277-7; HIGUCHI K, 1995, LAB INVEST, V72, P75; Higuchi K, 1998, LAB INVEST, V78, P1535; HIGUCHI K, 1986, J BIOL CHEM, V261, P2834; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KLUNK WE, 1990, J NEUROCHEM, V54, P2050, DOI 10.1111/j.1471-4159.1990.tb04910.x; Lundmark K, 2002, P NATL ACAD SCI USA, V99, P6979, DOI 10.1073/pnas.092205999; May BCH, 2003, P NATL ACAD SCI USA, V100, P3416, DOI 10.1073/pnas.2627988100; McDonnell G, 2003, CLIN INFECT DIS, V36, P1152, DOI 10.1086/374668; MERLINI G, 1995, P NATL ACAD SCI USA, V92, P2959, DOI 10.1073/pnas.92.7.2959; Moss MA, 2004, MOL PHARMACOL, V66, P592; Naiki H, 1998, BIOCHEMISTRY-US, V37, P17882, DOI 10.1021/bi980550y; Ono K, 2003, J NEUROCHEM, V87, P172, DOI 10.1046/j.1471-4159.2003.01976.x; Ono K, 2002, J NEUROCHEM, V81, P434, DOI 10.1046/j.1471-4159.2002.00904.x; PRAS M, 1969, J EXP MED, V130, P777, DOI 10.1084/jem.130.4.777; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; SAFAR J, 1993, J BIOL CHEM, V268, P20276; Sigurdsson EM, 2002, TRENDS MOL MED, V8, P411, DOI 10.1016/S1471-4914(02)02403-6; Silveira JR, 2005, NATURE, V437, P257, DOI 10.1038/nature03989; Southwick PC, 1996, J NEUROCHEM, V66, P259; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Tomiyama T, 1996, J BIOL CHEM, V271, P6839, DOI 10.1074/jbc.271.12.6839; Vanderstichele H, 2000, AMYLOID, V7, P245, DOI 10.3109/13506120009146438; Westermark P, 2002, AMYLOID, V9, P197; Westermark P, 1998, AM J PATHOL, V152, P1125; Wickner RB, 1999, J BIOL CHEM, V274, P555, DOI 10.1074/jbc.274.2.555; Xing YM, 2002, J BIOL CHEM, V277, P33164, DOI 10.1074/jbc.M111570200; Xing YM, 2001, LAB INVEST, V81, P493, DOI 10.1038/labinvest.3780257; YONEZU T, 1986, FEBS LETT, V203, P149, DOI 10.1016/0014-5793(86)80732-3; Zerovnik E, 2002, EUR J BIOCHEM, V269, P3362, DOI 10.1046/j.1432-1033.2002.03024.x; Zobeley E, 1999, MOL MED, V5, P240, DOI 10.1007/BF03402121	55	22	22	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					1012	+		10.1096/fj.05-4890fje	http://dx.doi.org/10.1096/fj.05-4890fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16549653				2022-12-28	WOS:000240157700039
J	Dickstein, DL; Biron, KE; Ujiie, M; Pfeifer, CG; Jeffries, AR; Jefferies, WA				Dickstein, Dara L.; Biron, Kaan E.; Ujiie, Maki; Pfeifer, Cheryl G.; Jeffries, Andrew R.; Jefferies, Wilfred A.			A beta peptide immunization restores blood-brain barrier integrity in Alzheimer disease	FASEB JOURNAL			English	Article						brain; microcirculation; vaccination; plaques	CENTRAL-NERVOUS-SYSTEM; VASCULAR ENDOTHELIAL-CELLS; AMYLOID-BETA; MOUSE MODEL; CEREBROSPINAL-FLUID; MEMORY DEFICITS; MICE; DEMENTIA; INFLAMMATION; ACTIVATION	Immunization with amyloid beta (A beta) peptides or passive immunization with antibodies against A beta has been reported to reduce plaque burden, neuritic dystrophy, early Tau pathology, microgliosis as well as reversing learning and memory deficits. This has created a central paradox: how does vaccination in peripheral tissues reduce plaque burden in the brain? No single explanation for these phenomena has yet been presented. To reconcile these observations, we demonstrate that the integrity of the blood-brain barrier (BBB), a structural barrier between the brain and the blood, is compromised in Tg2576 Alzheimer disease (AD) model mice. We immunized Tg2576 mice with A beta before and after the onset of AD-type neuropathology and observed that BBB permeability, amyloid burden, and microgliosis are decreased in immunized mice. It is concluded that the integrity of the BBB is disrupted in AD mice, and after A beta immunization the immune system clears A beta from sources in the brain as it would in peripheral organs lacking barriers. Once A beta is removed, the integrity of the BBB is restored. The data therefore provide an intellectual framework for understanding how the immune system can clear amyloid deposits from AD brains and suggest new strategies for limiting disease progression in amyloidopathies.	Univ British Columbia, Michael Smith Labs, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z4, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Jefferies, WA (corresponding author), Univ British Columbia, Michael Smith Labs, 2185 E Mall, Vancouver, BC V6T 1Z4, Canada.	wilf@brc.ubc.ca	Dickstein, Dara/AAH-6603-2020; Dickstein, Dara/F-3036-2013	Pfeifer, Cheryl/0000-0001-8584-228X				Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Blanc EM, 1997, J NEUROCHEM, V68, P1870; Das P, 2003, J NEUROSCI, V23, P8532; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; DeMattos RB, 2002, SCIENCE, V295, P2264, DOI 10.1126/science.1067568; Dickson DW, 2004, J CLIN INVEST, V114, P23, DOI 10.1172/JC1200422317; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; Ferrer I, 2004, BRAIN PATHOL, V14, P11, DOI 10.1111/j.1750-3639.2004.tb00493.x; Giri R, 2000, AM J PHYSIOL-CELL PH, V279, pC1772, DOI 10.1152/ajpcell.2000.279.6.C1772; Grammas P, 2001, NEUROBIOL AGING, V22, P837, DOI 10.1016/S0197-4580(01)00276-7; Guo JT, 2002, J NEUROSCI, V22, P5900; HAMPEL H, 1995, DEMENTIA, V6, P348, DOI 10.1159/000106969; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kalaria RN, 1998, MOL BRAIN RES, V62, P101, DOI 10.1016/S0169-328X(98)00190-9; KAWAI M, 1990, AM J PATHOL, V137, P1435; Lemere CA, 2003, NEUROBIOL DIS, V14, P10, DOI 10.1016/S0969-9961(03)00044-5; Lemere CA, 2003, NEUROCHEM RES, V28, P1017, DOI 10.1023/A:1023203122036; LEONARDI A, 1985, J NEUROL SCI, V67, P253, DOI 10.1016/0022-510X(85)90121-2; Methia N, 2001, MOL MED, V7, P810, DOI 10.1007/BF03401973; MIYAKAWA T, 1982, VIRCHOWS ARCH B, V40, P121, DOI 10.1007/BF02932857; Mohajeri MH, 2004, FEBS LETT, V562, P16, DOI 10.1016/S0014-5793(04)00169-3; Mohajeri MH, 2002, J BIOL CHEM, V277, P33012, DOI 10.1074/jbc.M203193200; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Mruthinti S, 2004, NEUROBIOL AGING, V25, P1023, DOI 10.1016/j.neurobiolaging.2003.11.001; Nelson PT, 2002, ANN MED, V34, P491, DOI 10.1080/078538902321117698; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Oddo S, 2004, NEURON, V43, P321, DOI 10.1016/j.neuron.2004.07.003; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Paris D, 2000, NEUROBIOL AGING, V21, P183, DOI 10.1016/S0197-4580(99)00111-6; Pogue AI, 2004, NEUROREPORT, V15, P1507, DOI 10.1097/01.wnr.0000130539.39937.1d; Racke MM, 2005, J NEUROSCI, V25, P629, DOI 10.1523/JNEUROSCI.4337-04.2005; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Suhara T, 2003, NEUROBIOL AGING, V24, P437, DOI 10.1016/S0197-4580(02)00135-5; Tarkowski E, 2002, NEUROBIOL AGING, V23, P237, DOI 10.1016/S0197-4580(01)00285-8; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; Uchikado H, 2004, ACTA NEUROPATHOL, V107, P341, DOI 10.1007/s00401-003-0815-x; Ueno M, 2004, HISTOCHEM CELL BIOL, V122, P131, DOI 10.1007/s00418-004-0684-y; Ujiie M, 2003, MICROCIRCULATION, V10, P463, DOI 10.1038/sj.mn.7800212; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; Vagnucci AH, 2003, LANCET, V361, P605, DOI 10.1016/S0140-6736(03)12521-4; Wardlaw JM, 2003, STROKE, V34, P806, DOI 10.1161/01.STR.0000058480.77236.B3; Wong ML, 1996, NAT MED, V2, P581, DOI 10.1038/nm0596-581; Xu J, 2001, J CEREBR BLOOD F MET, V21, P702, DOI 10.1097/00004647-200106000-00008; Yin KJ, 2002, J NEUROSCI, V22, P9764	50	101	108	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2006	20	3					426	433		10.1096/fj.05-3956com	http://dx.doi.org/10.1096/fj.05-3956com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	074LY	16507760				2022-12-28	WOS:000239815100006
J	Abbott, GW; Butler, MH; Goldstein, SAN				Abbott, Geoffrey W.; Butler, Margaret H.; Goldstein, Steve A. N.			Phosphorylation and protonation of neighboring MiRP2 sites: function and pathophysiology of MiRP2-Kv3.4 potassium channels in periodic paralysis	FASEB JOURNAL			English	Article						KCNE3; periodic paralysis; MiRP2; Kv3.4	LONG-QT SYNDROME; MINK-RELATED PEPTIDES; TO-WORK TRANSITION; CARDIAC-ARRHYTHMIA; SKELETAL-MUSCLE; ENHANCED INACTIVATION; MOLECULAR-BASIS; NERVOUS-SYSTEM; MUTATIONS; EXERCISE	MinK-related peptide 2 (MiRP2) and Kv3.4 subunits assemble in skeletal muscle to create subthreshold, voltage-gated potassium channels. MiRP2 acts on Kv3.4 to shift the voltage dependence of activation, speed recovery from inactivation, suppress cumulative inactivation and increase unitary conductance. We previously found an R83H missense mutation in MiRP2 that segregated with periodic paralysis in two families and diminished the effects of MiRP2 on Kv3.4. Here we show that MiRP2 has a single, functional PKC phosphorylation site at serine 82 and that normal MiRP2- Kv3.4 function requires phosphorylation of the site. The R83H variant does not prevent PKC phosphorylation of neighboring S82; rather, the change shifts the voltage dependence of activation and endows MiRP2- Kv3.4 channels with sensitivity to changes in intracellular pH across the physiological range. Thus, current passed by single R83H channels decreases as internal pH is lowered (pK(a) similar to 7.3, consistent with histidine protonation) whereas wild-type channels are largely insensitive. These findings identify a key regulatory domain in MiRP2 and suggest a mechanistic link between acidosis and episodes of periodic paralysis.	Univ Chicago, Pritzker Sch Med, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago, Pritzker Sch Med, Inst Mol Pediat Sci, Chicago, IL 60637 USA; Cornell Univ, Weill Med Coll, Dept Med, Greenberg Div Cardiol, New York, NY USA; Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY USA	University of Chicago; University of Chicago; Cornell University; Cornell University	Goldstein, SAN (corresponding author), Univ Chicago, Pritzker Sch Med, Dept Pediat, 5721 S Maryland Ave,MC8000, Chicago, IL 60637 USA.	sangoldstein@uchicago.edu	; Goldstein, Steven A./E-9817-2015	Abbott, Geoffrey/0000-0003-4552-496X; Goldstein, Steven A./0000-0001-5207-5061	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079275] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL079275] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott GW, 1998, Q REV BIOPHYS, V31, P357, DOI 10.1017/S0033583599003467; Abbott GW, 2002, FASEB J, V16, DOI 10.1096/fj.01-0520hyp; Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Abbott GW, 2001, CELL, V104, P217, DOI 10.1016/S0092-8674(01)00207-0; ADAMS GR, 1990, J APPL PHYSIOL, V69, P968, DOI 10.1152/jappl.1990.69.3.968; Antz C, 1999, NAT STRUCT BIOL, V6, P146; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; BARSTOW TJ, 1994, J APPL PHYSIOL, V77, P1742, DOI 10.1152/jappl.1994.77.4.1742; Bulman DE, 1999, NEUROLOGY, V53, P1932, DOI 10.1212/WNL.53.9.1932; Chuang ML, 1999, J APPL PHYSIOL, V87, P1048, DOI 10.1152/jappl.1999.87.3.1048; CONNETT RJ, 1987, J APPL PHYSIOL, V63, P2360, DOI 10.1152/jappl.1987.63.6.2360; CONNETT RJ, 1987, J APPL PHYSIOL, V63, P2366, DOI 10.1152/jappl.1987.63.6.2366; COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; FONTAINE B, 1994, NAT GENET, V6, P267, DOI 10.1038/ng0394-267; Gamper G, 1998, ACTA MED AUST, V25, P106; GEORGE AL, 1993, NAT GENET, V3, P305, DOI 10.1038/ng0493-305; Gutmann L, 2000, NEUROL CLIN, V18, P195, DOI 10.1016/S0733-8619(05)70185-7; Ikeda K, 2002, INTERNAL MED, V41, P743, DOI 10.2169/internalmedicine.41.743; Isbrandt D, 2002, J MOL MED-JMM, V80, P524, DOI 10.1007/s00109-002-0364-0; Jurkat-Rott K, 2004, NEUROLOGY, V62, P1012, DOI 10.1212/01.WNL.0000119392.29624.88; Jurkat-Rott K, 2000, P NATL ACAD SCI USA, V97, P9549, DOI 10.1073/pnas.97.17.9549; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; Kowalchuk JM, 2000, J APPL PHYSIOL, V89, P200, DOI 10.1152/jappl.2000.89.1.200; Kuzmenkin A, 2002, BRAIN, V125, P835, DOI 10.1093/brain/awf071; LANDAU EM, 1981, J GEN PHYSIOL, V77, P647, DOI 10.1085/jgp.77.6.647; Lopes CMB, 2001, J BIOL CHEM, V276, P24449, DOI 10.1074/jbc.C100184200; McCracken VJ, 2001, CELL MICROBIOL, V3, P1, DOI 10.1046/j.1462-5822.2001.00090.x; McCrossan ZA, 2004, NEUROPHARMACOLOGY, V47, P787, DOI 10.1016/j.neuropharm.2004.06.018; Park KH, 2003, FASEB J, V17, DOI 10.1096/fj.03-0577fje; PLANT LD, 2005, IN PRESS J CLIN INVE; Plaster NM, 2001, CELL, V105, P511, DOI 10.1016/S0092-8674(01)00342-7; Ptacek L, 1998, AM J MED, V105, P58, DOI 10.1016/S0002-9343(98)00123-5; PTACEK LJ, 1991, AM J HUM GENET, V49, P851; Ptacek LJ, 1999, SEMIN NEUROL, V19, P363, DOI 10.1055/s-2008-1040851; Ptacek LJ, 1999, DIGEST DIS SCI, V44, p94S; PTACEK LJ, 1994, CELL, V77, P863; PTACEK LJ, 1991, AM J HUM GENET, V49, P378; ROJAS CV, 1991, NATURE, V354, P387, DOI 10.1038/354387a0; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SCHROTER KH, 1991, FEBS LETT, V278, P211, DOI 10.1016/0014-5793(91)80119-N; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Sesti F, 1998, J GEN PHYSIOL, V112, P651, DOI 10.1085/jgp.112.6.651; Splawski I, 2002, SCIENCE, V297, P1333, DOI 10.1126/science.1073569; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Splawski I, 1997, NEW ENGL J MED, V336, P1562, DOI 10.1056/NEJM199705293362204; STEPHENS GJ, 1995, J PHYSIOL-LONDON, V484, P1; STRINGER W, 1994, J APPL PHYSIOL, V76, P1462, DOI 10.1152/jappl.1994.76.4.1462; Tawil R, 2000, ANN NEUROL, V47, P46, DOI 10.1002/1531-8249(200001)47:1<46::AID-ANA9>3.3.CO;2-8; Tengan C H, 1994, Arq Neuropsiquiatr, V52, P501; Tyson J, 1997, HUM MOL GENET, V6, P2179, DOI 10.1093/hmg/6.12.2179; Walter G, 1999, J PHYSIOL-LONDON, V519, P901, DOI 10.1111/j.1469-7793.1999.0901n.x; Wasserman K, 1997, J APPL PHYSIOL, V83, P631, DOI 10.1152/jappl.1997.83.2.631	52	33	35	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					293	301		10.1096/fj.05-5070com	http://dx.doi.org/10.1096/fj.05-5070com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449802	Green Submitted			2022-12-28	WOS:000237698700015
J	Cardoso, I; Saraiva, MJ				Cardoso, I.; Saraiva, M. J.			Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model	FASEB JOURNAL			English	Article						metalloproteinase-9; serum amyloid P component; amyloid neuropathy; treatment	P-COMPONENT; POLYNEUROPATHY; MATRIX-METALLOPROTEINASE-9; DEPOSITION; FIBRILS; DISEASE; FIBRILLOGENESIS; TETRACYCLINES; AGGREGATION; PROTEOLYSIS	Familial amyloidotic polyneuropathy is an autosomal dominant disorder mainly characterized by the extracellular deposition of transthyretin, with special involvement of the peripheral nerve. Several animal models have been generated, including transgenic mice carrying the most prevalent TTR mutation (TTR Val30Met). TTR-Val30Met mice without endogenous TTR (TTR-Val30Met X TTR-KO) were previously analyzed in our laboratory and similar to 60% of the animals over 1 year of age were found to have deposition as amyloid, i.e., with Congo red (CR) -positive material, constituting a good tool to investigate the effect of drugs on TTR deposition and fibrillogenesis. We recently showed that the drug doxycycline acts in vitro as a TTR fibril disrupter. In the present work we assessed the activity of this drug in vivo in the TTR-Met30Val X TTR-KO mice. Doxycycline was administrated in the drinking water to 23- to 28-month-old mice over a period of 3 months. Immunohistochemistry analyses revealed no differences in nonfibrillar TTR deposition between treated (n = 11) and untreated mice (n = 11). However, CR-positive material was observed only in the control group (untreated) whereas none of the animals treated with doxycycline was CR-positive. Immunohistochemistry for several markers associated with amyloid, such as matrix metalloproteinase-9 (MMP-9) and serum amyloid P component (SAP), was performed. MMP-9 was altered with significantly lower levels in treated animals compared with the control group. Mouse SAP was absent in treated animals, being observed only in untreated animals presenting TTR congophilic deposits. These results indicate that doxycycline is capable of disrupting TTR CR-positive amyloid deposits and decreases standard markers associated with fibrillar deposition, being a potential drug in the treatment of amyloidosis.	IBMC, Mol Neurobiol Unit, P-4150180 Oporto, Portugal; Univ Porto, Inst Biomed Sci Abel Salazar, P-4100 Oporto, Portugal	Universidade do Porto; Universidade do Porto	Saraiva, MJ (corresponding author), IBMC, Mol Neurobiol Unit, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.	mjsaraiv@ibmc.up.pt	Saraiva, Maria João/K-3907-2013; Cardoso, Isabel/K-3903-2013; Lima, Marta T/C-7042-2009	Saraiva, Maria João/0000-0002-3360-6899; Cardoso, Isabel/0000-0003-2472-7055; 				ANDRADE C, 1952, BRAIN, V75, P408, DOI 10.1093/brain/75.3.408; BALTZ ML, 1986, CLIN EXP IMMUNOL, V66, P691; Bendeck MP, 2002, AM J PATHOL, V160, P1089, DOI 10.1016/S0002-9440(10)64929-2; Botto M, 1997, NAT MED, V3, P855, DOI 10.1038/nm0897-855; CAMPISTOL JM, 1992, KIDNEY INT, V42, P915, DOI 10.1038/ki.1992.368; Cardoso I, 2003, FASEB J, V17, P803, DOI 10.1096/fj.02-0764com; Cardoso I, 2002, J MOL BIOL, V317, P683, DOI 10.1006/jmbi.2002.5441; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; COIMBRA A, 1971, BRAIN, V94, P199, DOI 10.1093/brain/94.2.199; De Felice FG, 2001, FASEB J, V15, P1297, DOI 10.1096/fj.00-0676fje; Duivenvoorden WCM, 1997, INVAS METAST, V17, P312; Fernandez FG, 2005, AM J TRANSPLANT, V5, P671, DOI 10.1111/j.1600-6143.2005.00751.x; Forloni G, 2001, FEBS LETT, V487, P404, DOI 10.1016/S0014-5793(00)02380-2; Gillmore JD, 2000, NUCL MED COMMUN, V21, P735, DOI 10.1097/00006231-200008000-00006; Helbecque N, 2003, NEUROSCI LETT, V350, P181, DOI 10.1016/S0304-3940(03)00905-4; Hughes PM, 2002, NEUROSCIENCE, V113, P273, DOI 10.1016/S0306-4522(02)00183-5; Inoue S, 1998, J STRUCT BIOL, V124, P1, DOI 10.1006/jsbi.1998.4052; Koistinaho M, 2005, J CEREBR BLOOD F MET, V25, P460, DOI 10.1038/sj.jcbfm.9600040; Lee CZ, 2004, STROKE, V35, P1715, DOI 10.1161/01.STR.0000129334.05181.b6; Lee LK, 2003, MED SCI MONITOR, V9, pBR54; Maeda S, 2003, AMYLOID, V10, P17; Pepys MB, 1996, CIBA F SYMP, V199, P73; PEPYS MB, 1979, CLIN EXP IMMUNOL, V38, P284; Pepys MB, 2002, NATURE, V417, P254, DOI 10.1038/417254a; Pepys MB, 2001, PHILOS T R SOC B, V356, P203, DOI 10.1098/rstb.2000.0766; PUCHTLER H, 1965, J HISTOCHEM CYTOCHEM, V13, P693, DOI 10.1177/13.8.693; Saraiva MJ, 2004, J MOL NEUROSCI, V23, P35, DOI 10.1385/JMN:23:1-2:035; Sousa MM, 2001, AM J PATHOL, V159, P1993; Sousa MM, 2002, AM J PATHOL, V161, P1935, DOI 10.1016/S0002-9440(10)64469-0; Sousa MM, 2004, FASEB J, V18, P124, DOI 10.1096/fj.04-2022fje; Sousa MM, 2001, J NEUROSCI, V21, P7576, DOI 10.1523/JNEUROSCI.21-19-07576.2001; Stix B, 2001, AM J PATHOL, V159, P561, DOI 10.1016/S0002-9440(10)61727-0; Tagliavini F, 2000, J MOL BIOL, V300, P1309, DOI 10.1006/jmbi.2000.3840; TENNENT GA, 1995, P NATL ACAD SCI USA, V92, P4299, DOI 10.1073/pnas.92.10.4299; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	35	117	128	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					234	239		10.1096/fj.05-4509com	http://dx.doi.org/10.1096/fj.05-4509com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449795				2022-12-28	WOS:000237698700008
J	Rivera-Milla, E; Oidtmann, B; Panagiotidis, CH; Baier, M; Sklaviadis, T; Hoffmann, R; Zhou, Y; Solis, GP; Stuermer, CAO; Malaga-Trillo, E				Rivera-Milla, Eric; Oidtmann, Birgit; Panagiotidis, Cynthia H.; Baier, Michael; Sklaviadis, Theodoros; Hoffmann, Rudolf; Zhou, Yi; Solis, Gonzalo P.; Stuermer, Claudia A. O.; Malaga-Trillo, Edward			Disparate evolution of prion protein domains and the distinct origin of Doppel- and prion-related loci revealed by fish-to-mammal comparisons	FASEB JOURNAL			English	Article									[Rivera-Milla, Eric; Solis, Gonzalo P.; Stuermer, Claudia A. O.; Malaga-Trillo, Edward] Univ Konstanz, Dept Biol, D-78457 Constance, Germany; [Oidtmann, Birgit; Hoffmann, Rudolf] Univ Munich, Inst Zool Fish Biol & Fish Dis, Munich, Germany; [Panagiotidis, Cynthia H.; Sklaviadis, Theodoros] Aristotle Univ Thessaloniki, Sch Pharmaceut Sci, GR-54006 Thessaloniki, Greece; [Panagiotidis, Cynthia H.; Sklaviadis, Theodoros] INA CERTH, Thessaloniki, Greece; [Baier, Michael] Robert Koch Inst, Project Neurodegenerat Dis, D-1000 Berlin, Germany; [Zhou, Yi] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA; [Zhou, Yi] Dana Farber Canc Inst, Boston, MA 02115 USA	University of Konstanz; University of Munich; Aristotle University of Thessaloniki; Robert Koch Institute; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute	Malaga-Trillo, E (corresponding author), Univ Konstanz, Dept Biol, D-78457 Constance, Germany.	edward.malaga@uni-konstanz.de	Dafou, Dimitra/N-6094-2015; Sklaviadis, Theoodoros/AGK-6763-2022	Dafou, Dimitra/0000-0003-4170-0612; Solis, Gonzalo P./0000-0002-2359-3780; Sklaviadis, Theodoros/0000-0002-0246-3100					0	73	77	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					317	319		10.1096/fj.05-4279fje	http://dx.doi.org/10.1096/fj.05-4279fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16352647	Green Submitted			2022-12-28	WOS:000207915000006
J	McColl, SR; St-Onge, M; Dussault, AA; Laflamme, C; Bouchard, L; Boulanger, J; Pouliot, M				McColl, SR; St-Onge, M; Dussault, AA; Laflamme, C; Bouchard, L; Boulanger, J; Pouliot, M			Immunomodulatory impact of the A(2A) adenosine receptor on the profile of chemokines produced by neutrophils	FASEB JOURNAL			English	Article						polymorphonuclear leukocytes; experimental animal models; resolution of inflammation	MACROPHAGE INFLAMMATORY PROTEIN-1; NECROSIS-FACTOR-ALPHA; POLYMORPHONUCLEAR LEUKOCYTES; DOWN-REGULATION; EXPRESSION; MECHANISM; CYCLOOXYGENASE-2; RECRUITMENT; RELEASE; SITES	In LPS-stimulated human neutrophils, engagement of the adenosine A(2A) receptor selectively prevented the expression and release of TNF-alpha, MIP-1 alpha/CCL3, MIP-1 beta/CCL4, MIP-2 alpha/CXCL2, and MIP-3 alpha/CCL20. In mice lacking the A(2A) receptor, granulocytes that migrated into the air pouch 4 h after LPS injection expressed higher mRNA levels of TNF-alpha, MIP-1 alpha, and MIP-1 beta than PMNs from wild-type mice. In mononuclear cells present in the air pouch 72 h after LPS injection, expression of IL-1 beta, TNF-alpha, IL- 6, and MCP-2/CCL6 was higher in A(2A)R knockout mice. In addition to highlighting neutrophils as an early and pivotal target for mediating adenosine anti-inflammatory activities, these results identify TNF-alpha and the MIP chemokine family as gene products whose expression is pivotally affected by activation of A(2A)R in LPS-activated PMNs. Modulation by A(2A)R in the production of inflammatory signals by PMNs may thus influence the evolution of an inflammatory response by reducing the activation status of inflammatory cells.	CHUL, Ctr Rech Rhumatol & Immunol, CHUQ, Ste Foy, PQ G1V 4G2, Canada; Univ Laval, Dept Anat Physiol, Fac Med, Quebec City, PQ G1K 7P4, Canada; Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA, Australia	Laval University; Laval University; University of Adelaide	Pouliot, M (corresponding author), CHUL, Ctr Rech Rhumatol & Immunol, CHUQ, 2705 Laurier Blvd,Off T1-49, Ste Foy, PQ G1V 4G2, Canada.	Marc.Pouliot@crchul.ulaval.ca	Pouliot, Marc/G-4103-2016	Pouliot, Marc/0000-0002-2466-5424	Canadian Institutes of Health Research [64315, 72200] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Boyum A, 1968, Scand J Clin Lab Invest Suppl, V97, P77; Cadieux JS, 2005, J CELL SCI, V118, P1437, DOI 10.1242/jcs.01737; Cassatella MA, 1999, ADV IMMUNOL, V73, P369, DOI 10.1016/S0065-2776(08)60791-9; CRONSTEIN BN, 1993, J CLIN INVEST, V92, P2675, DOI 10.1172/JCI116884; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5, DOI 10.1152/jappl.1994.76.1.5; Edwards S.L., 1994, BIOCH PHYSL NEUTROPH; FANTONE JC, 1985, HUM PATHOL, V16, P973, DOI 10.1016/S0046-8177(85)80273-2; FANTONE JC, 1981, PROSTAG LEUKOTR ESS, V7, P195, DOI 10.1016/0161-4630(81)90062-8; Flamand N, 2000, AM J RESP CRIT CARE, V161, pS88, DOI 10.1164/ajrccm.161.supplement_1.ltta-18; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Garcia-Ramallo E, 2002, J IMMUNOL, V169, P6467, DOI 10.4049/jimmunol.169.11.6467; Gillitzer R, 2001, J LEUKOCYTE BIOL, V69, P513; HACHICHA M, 1995, J EXP MED, V182, P2019, DOI 10.1084/jem.182.6.2019; Hachicha M, 1998, J IMMUNOL, V160, P449; Kuraishi Y, 2001, Nihon Yakurigaku Zasshi, V117, P248; Ledent C, 1997, NATURE, V388, P674, DOI 10.1038/41771; Maurer M, 2004, INT J BIOCHEM CELL B, V36, P1882, DOI 10.1016/j.biocel.2003.10.019; MCCOLL SR, 1992, J EXP MED, V176, P593, DOI 10.1084/jem.176.2.593; Montesinos MC, 1997, J EXP MED, V186, P1615, DOI 10.1084/jem.186.9.1615; OFLAHERTY JT, 1979, PROSTAGLANDINS, V17, P201, DOI 10.1016/0090-6980(79)90039-X; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Parker LC, 2005, J LEUKOCYTE BIOL, V77, P886, DOI 10.1189/jlb.1104636; PILLINGER MH, 1995, RHEUM DIS CLIN N AM, V21, P691; Pouliot M, 2002, J IMMUNOL, V169, P5279, DOI 10.4049/jimmunol.169.9.5279; Sawyer D W, 1989, Rev Infect Dis, V11 Suppl 7, pS1532; Scapini P, 2001, EUR J IMMUNOL, V31, P1981, DOI 10.1002/1521-4141(200107)31:7<1981::AID-IMMU1981>3.0.CO;2-X; Scapini P, 2000, IMMUNOL REV, V177, P195, DOI 10.1034/j.1600-065X.2000.17706.x; Thiel M, 2003, MICROBES INFECT, V5, P515, DOI 10.1016/S1286-4579(03)00068-6; THIEL M, 1995, J LAB CLIN MED, V126, P275	29	79	83	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					187	+		10.1096/fj.05-4804fje	http://dx.doi.org/10.1096/fj.05-4804fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16280366	Green Accepted			2022-12-28	WOS:000234053100015
J	Caspersen, C; Wang, N; Yao, J; Sosunov, A; Chen, X; Lustbader, JW; Xu, HW; Stern, D; McKhann, G; Yan, SD				Caspersen, C; Wang, N; Yao, J; Sosunov, A; Chen, X; Lustbader, JW; Xu, HW; Stern, D; McKhann, G; Yan, SD			Mitochondrial A beta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease	FASEB JOURNAL			English	Article						oxidative stress; transgenic mouse model of Alzheimer's disease; respiratory chain enzyme; intracellular A beta; energy metabolism	AMYLOID PRECURSOR PROTEIN; INTRANEURONAL A-BETA-42 ACCUMULATION; CYTOCHROME-C-OXIDASE; OXIDATIVE STRESS; TRANSGENIC MICE; ENDOPLASMIC-RETICULUM; PLAQUE-FORMATION; CELL-DEATH; HIPPOCAMPAL-NEURONS; DOWN-SYNDROME	Although amyloid-beta peptide (A beta) is the neurotoxic species implicated in the pathogenesis of Alzheimer's disease ( AD), mechanisms through which intracellular A beta impairs cellular properties, resulting in neuronal dysfunction, remain to be clarified. Here we demonstrate that intracellular A beta is present in mitochondria from brains of transgenic mice with targeted neuronal overexpression of mutant human amyloid precursor protein and AD patients. A beta progressively accumulates in mitochondria and is associated with diminished enzymatic activity of respiratory chain complexes (III and IV) and a reduction in the rate of oxygen consumption. Importantly, mitochondria-associated A beta, principally A beta 42, was detected as early as 4 months, before extensive extracellular A beta deposits. Our studies delineate a new means through which A beta potentially impairs neuronal energetics, contributing to cellular dysfunction in AD.	Columbia Univ Coll Phys & Surg, Dept Surg, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Obstet & Gynecol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA; Univ Cincinnati, Coll Med, Deans Off, Cincinnati, OH 45229 USA; Fujian Med Univ, Dept Neurol, Affiliated Hosp 1, Fuzhou, Peoples R China	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; University System of Ohio; University of Cincinnati; Fujian Medical University	Yan, SD (corresponding author), Columbia Univ Coll Phys & Surg, Dept Surg, 650 W 168th St,Black Bldg,Room 17-07, New York, NY 10032 USA.	sdy1@columbia.edu			NIA NIH HHS [P50 AG08702, AG16736, P01 AG17490] Funding Source: Medline; NINDS NIH HHS [NS 042855] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG017490, P50AG008702, R01AG016736] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030; ARISPE N, 1994, ANN NY ACAD SCI, V747, P256; Bahr BA, 1998, J COMP NEUROL, V397, P139; Bosetti F, 2002, NEUROBIOL AGING, V23, P371, DOI 10.1016/S0197-4580(01)00314-1; Brizio C, 2000, EUR J BIOCHEM, V267, P4346, DOI 10.1046/j.1432-1327.2000.01464.x; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cardoso SM, 2001, FASEB J, V15, P1439, DOI 10.1096/fj.00-0561fje; Casley CS, 2002, J NEUROCHEM, V80, P91, DOI 10.1046/j.0022-3042.2001.00681.x; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; Du Y, 2001, NEUROLOGY, V57, P801, DOI 10.1212/WNL.57.5.801; Eckert A, 2001, J NEUROSCI RES, V64, P183, DOI 10.1002/jnr.1064; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Glabe C, 2001, J MOL NEUROSCI, V17, P137, DOI 10.1385/JMN:17:2:137; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; Gyure KA, 2001, ARCH PATHOL LAB MED, V125, P489; Hartmann T, 1999, EUR ARCH PSY CLIN N, V249, P291, DOI 10.1007/s004060050102; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; He XY, 2001, EUR J BIOCHEM, V268, P4899, DOI 10.1046/j.0014-2956.2001.02421.2421.x; Hoffman JM, 2000, J NUCL MED, V41, P1920; Hoshi M, 1997, J BIOL CHEM, V272, P2038, DOI 10.1074/jbc.272.4.2038; HSUAN F, 2005, BIOCHEM BIOPH RES CO, V328, P1; Kienlen-Campard P, 2002, J BIOL CHEM, V277, P15666, DOI 10.1074/jbc.M200887200; Kim HS, 2002, NEUROREPORT, V13, P1989, DOI 10.1097/00001756-200210280-00032; KISH SJ, 1992, J NEUROCHEM, V59, P776, DOI 10.1111/j.1471-4159.1992.tb09439.x; Kobayashi A, 1996, J BIOCHEM-TOKYO, V119, P775, DOI 10.1093/oxfordjournals.jbchem.a021307; KOO EH, 1994, J BIOL CHEM, V269, P17386; KUDO T, 2003, ALZHEIMERS DIS RELAT, P415; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; Lai J C, 1979, Methods Enzymol, V55, P51; Lesnefsky EJ, 2001, AM J PHYSIOL-HEART C, V280, pH2770; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230; Magrane J, 2004, J NEUROSCI, V24, P1700, DOI 10.1523/JNEUROSCI.4330-03.2004; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Marques CA, 2003, J BIOL CHEM, V278, P28294, DOI 10.1074/jbc.M212265200; MARTIN BL, 1995, J BIOL CHEM, V270, P26727, DOI 10.1074/jbc.270.45.26727; Mattson MP, 2002, J NEUROVIROL, V8, P539, DOI 10.1080/13550280290100978; Mattson MP, 1998, BRAIN RES, V807, P167, DOI 10.1016/S0006-8993(98)00763-X; Maurer I, 2000, NEUROBIOL AGING, V21, P455, DOI 10.1016/S0197-4580(00)00112-3; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; Mori C, 2002, AMYLOID, V9, P88, DOI 10.3109/13506120208995241; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Muller WE, 2001, BIOCHEM SOC T, V29, P617, DOI 10.1042/BST0290617; MUTISYA EM, 1994, J NEUROCHEM, V63, P2179; Nishimura I, 1998, J NEUROSCI, V18, P2387, DOI 10.1523/jneurosci.18-07-02387.1998; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Pappolla MA, 1998, AM J PATHOL, V152, P871; PARKER WD, 1994, NEUROLOGY, V44, P1090, DOI 10.1212/WNL.44.6.1090; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Perry George, 1998, J Alzheimers Dis, V1, P45; Pillot T, 1996, J BIOL CHEM, V271, P28757, DOI 10.1074/jbc.271.46.28757; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Silverman Daniel H.S., 1999, Clin Positron Imaging, V2, P119, DOI 10.1016/S1095-0397(99)00020-5; Silverman Daniel H S, 2002, Mol Imaging Biol, V4, P283, DOI 10.1016/S1536-1632(02)00016-1; Tabner BJ, 2002, FREE RADICAL BIO MED, V32, P1076, DOI 10.1016/S0891-5849(02)00801-8; Takahashi RH, 2002, AM J PATHOL, V161, P1869, DOI 10.1016/S0002-9440(10)64463-X; Takahashi RH, 2004, J NEUROSCI, V24, P3592, DOI 10.1523/JNEUROSCI.5167-03.2004; Tamagno E, 2003, FREE RADICAL BIO MED, V35, P45, DOI 10.1016/S0891-5849(03)00244-2; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Tieu K, 2003, J CLIN INVEST, V112, P892, DOI 10.1172/JCI200318797; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wilson CA, 1999, J NEUROPATH EXP NEUR, V58, P787, DOI 10.1097/00005072-199908000-00001; Wirths O, 2001, NEUROSCI LETT, V306, P116, DOI 10.1016/S0304-3940(01)01876-6; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003; Wood SJ, 1996, J BIOL CHEM, V271, P4086; Yan SD, 1997, NATURE, V389, P689; Yang AJ, 1998, J NEUROSCI RES, V52, P691, DOI 10.1002/(SICI)1097-4547(19980615)52:6<691::AID-JNR8>3.0.CO;2-3; Zhang Y, 2002, J CELL BIOL, V156, P519, DOI 10.1083/jcb.200110119	75	574	590	2	47	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2040	+		10.1096/fj.05-3735fje	http://dx.doi.org/10.1096/fj.05-3735fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16210396				2022-12-28	WOS:000232991100026
J	Kato, H; Ishida, J; Imagawa, S; Saito, T; Suzuki, N; Matsuoka, T; Sugaya, T; Tanimoto, K; Yokoo, T; Ohneda, O; Sugiyama, F; Yagami, K; Fujita, T; Yamamoto, M; Nangaku, M; Fukamizu, A				Kato, H; Ishida, J; Imagawa, S; Saito, T; Suzuki, N; Matsuoka, T; Sugaya, T; Tanimoto, K; Yokoo, T; Ohneda, O; Sugiyama, F; Yagami, K; Fujita, T; Yamamoto, M; Nangaku, M; Fukamizu, A			Enhanced erythropoiesis mediated by activation of the renin-angiotensin system via angiotensin II type 1a receptor	FASEB JOURNAL			English	Article						RAS; ANG II; erythropoietin	TISSUE-SPECIFIC REGULATION; RENAL-ARTERY STENOSIS; DEFICIENT MICE; ERYTHROID PROGENITORS; CELL TUMOR; EXPRESSION; ANEMIA; GENE; RATS; ERYTHROCYTOSIS	Although clinical and experimental studies have long suggested a role for the renin-angiotensin system (RAS) in the regulation of erythropoiesis, the molecular basis of this role has not been well understood. We report here that transgenic mice carrying both the human renin and human angiotensinogen genes displayed persistent erythrocytosis as well as hypertension. To identify the receptor molecule responsible for this phenotype, we introduced both transgenes into the AT1a receptor null background and found that the hematocrit level in the compound mice was restored to the normal level. Angiotensin II has been shown to influence erythropoiesis by two means, up-regulation of erythropoietin levels and direct stimulation of erythroid progenitor cells. Thus, we conducted bone marrow transplantation experiments and clarified that AT1a receptors on bone marrow-derived cells were dispensable for RAS-dependent erythrocytosis. Plasma erythropoietin levels and kidney erythropoietin mRNA expression in the double transgenic mice were significantly increased compared with those of the wild-type control, while the elevated plasma erythropoietin levels were significantly attenuated in the compound mice. These results provide clear genetic evidence that activated RAS enhances erythropoiesis through the AT1a receptor of kidney cells and that this effect is mediated by the elevation of plasma erythropoietin levels in vivo.	Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Div Hematol, Inst Clin Med, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Lab Anim Resource Ctr, Tsukuba, Ibaraki 3058577, Japan; Univ Tokyo, Sch Med, Div Nephrol & Endocrinol, Bunkyo Ku, Tokyo 1138655, Japan; Jikei Univ, Dept Internal Med, Sch Med, Div Nephrol & Hypertens,Minato Ku, Tokyo, Japan	University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Tokyo; Jikei University	Fukamizu, A (corresponding author), Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan.	akif@tara.tsukuba.ac.jp	Tanimoto, Keiji/B-2600-2014; Suzuki, Norio/F-3456-2010; Suzuki, Norio/AAZ-9458-2021	Suzuki, Norio/0000-0001-6100-3350; Tanimoto, Keiji/0000-0003-1971-6546				Albiston AL, 2001, J BIOL CHEM, V276, P48623, DOI 10.1074/jbc.C100512200; ANAGNOSTOU A, 1976, J LAB CLIN MED, V88, P707; Benohr P, 2004, NEPHRON EXP NEPHROL, V98, pE124, DOI 10.1159/000081556; Chikuma M, 2000, AM J PHYSIOL-ENDOC M, V279, pE1242, DOI 10.1152/ajpendo.2000.279.6.E1242; Coulthard MG, 2002, ARCH DIS CHILD, V86, P307, DOI 10.1136/adc.86.4.307; Crowley SD, 2004, ACTA PHYSIOL SCAND, V181, P561, DOI 10.1111/j.1365-201X.2004.01331.x; de la Grange PB, 2002, STEM CELLS, V20, P269, DOI 10.1634/stemcells.20-3-269; Ebert BL, 1999, BLOOD, V94, P1864; Fandrey J, 2004, AM J PHYSIOL-REG I, V286, pR977, DOI 10.1152/ajpregu.00577.2003; FISHER JW, 1967, J PHARMACOL EXP THER, V157, P618; Freudenthaler SM, 1999, EUR J CLIN INVEST, V29, P816; FRIED W, 1982, J LAB CLIN MED, V99, P520; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; Gossmann J, 2001, KIDNEY INT, V60, P83, DOI 10.1046/j.1523-1755.2001.00773.x; GOULD AB, 1973, LAB INVEST, V28, P719; GOULD AB, 1980, J LAB CLIN MED, V96, P523; Hartley C, 2003, BRIT J HAEMATOL, V122, P623, DOI 10.1046/j.1365-2141.2003.04467.x; Hisada Y, 2001, LAB INVEST, V81, P1243, DOI 10.1038/labinvest.3780338; HUDGSON P, 1967, BMJ-BRIT MED J, V1, P18, DOI 10.1136/bmj.1.5531.18; Lambert JF, 2000, J NEUROSCI METH, V95, P127, DOI 10.1016/S0165-0270(99)00157-0; Mrug M, 2004, SEMIN NEPHROL, V24, P120, DOI 10.1016/j.semnephrol.2003.11.006; Mrug M, 1997, J CLIN INVEST, V100, P2310, DOI 10.1172/JCI119769; Naeshiro I, 1998, EUR J PHARMACOL, V354, P179, DOI 10.1016/S0014-2999(98)00451-8; Nakano Y, 2004, BLOOD, V104, P4300, DOI 10.1182/blood-2004-04-1631; NAKAO K, 1967, BLOOD-J HEMATOL, V29, P754, DOI 10.1182/blood.V29.5.754.754; Nunia V, 2004, J RADIAT RES, V45, P11, DOI 10.1269/jrr.45.11; PESCHLE C, 1973, ENDOCRINOLOGY, V92, P358; REMYNSE LC, 1989, J UROLOGY, V142, P1560, DOI 10.1016/S0022-5347(17)39165-6; Rodgers KE, 2000, STEM CELLS, V18, P287, DOI 10.1634/stemcells.18-4-287; Santos RAS, 2003, P NATL ACAD SCI USA, V100, P8258, DOI 10.1073/pnas.1432869100; Stephen MR, 1998, J CLIN PATHOL, V51, P75, DOI 10.1136/jcp.51.1.75; SUGAYA T, 1995, J BIOL CHEM, V270, P18719, DOI 10.1074/jbc.270.32.18719; TAKASE K, 1995, ARZNEIMITTEL-FORSCH, V45-1, P15; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; VLAHAKOS DV, 1995, CLIN NEPHROL, V43, P53; Vlahakos DV, 2003, KIDNEY INT, V63, P1187, DOI 10.1046/j.1523-1755.2003.00850.x; Yanai K, 2000, J BIOL CHEM, V275, P5, DOI 10.1074/jbc.275.1.5; Yasuda Y, 1998, J BIOL CHEM, V273, P25381, DOI 10.1074/jbc.273.39.25381	39	89	99	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2023	+		10.1096/fj.05-3820fje	http://dx.doi.org/10.1096/fj.05-3820fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16223784				2022-12-28	WOS:000232991100021
J	Amiry-Moghaddam, M; Lindland, H; Zelenin, S; Roberg, BA; Gundersen, BB; Petersen, P; Rinvik, E; Torgner, IA; Ottersen, OP				Amiry-Moghaddam, M; Lindland, H; Zelenin, S; Roberg, BA; Gundersen, BB; Petersen, P; Rinvik, E; Torgner, IA; Ottersen, OP			Brain mitochondria contain aquaporin water channels: evidence for the expression of a short AQP9 isoform in the inner mitochondrial membrane	FASEB JOURNAL			English	Article						water channels; mitochondria; Parkinson's disease; astrocytes; substantia nigra	PHOSPHATE-ACTIVATED GLUTAMINASE; NEUTRAL SOLUTE CHANNEL; RAT-BRAIN; ISCHEMIC BRAIN; MOLECULAR CHARACTERIZATION; ASTROCYTE MITOCHONDRIA; GLYCEROL FACILITATOR; ENERGY-METABOLISM; ESCHERICHIA-COLI; HYPOXIA-ISCHEMIA	Aquaporins are a family of water channels found in animals, plants, and microorganisms. A subfamily of aquaporins, the aquaglyceroporins, are permeable for water as well as certain solutes such as glycerol, lactate, and urea. Here we show that the brain contains two isoforms of AQP9 - an aquaglyceroporin with a particularly broad substrate specificity - and that the more prevalent of these isoforms is expressed in brain mitochondria. The mitochondrial AQP9 isoform is detected as an similar to 25 kDa band in immunoblots. This isoform is likely to correspond to a new AQP9 mRNA that is obtained by alternative splicing and has a shorter ORF than the liver isoform. Subfractionation experiments and high-resolution immunogold analyses revealed that this novel AQP9 isoform is enriched in mitochondrial inner membranes. AQP9 immunopositive mitochondria occurred in astrocytes throughout the brain and in a subpopulation of neurons in the substantia nigra, ventral tegmental area, and arcuate nucleus. In the latter structures, the AQP9 immunopositive mitochondria were located in neurons that were also immunopositive for tyrosine hydroxylase, as demonstrated by double labeling immunogold electron microscopy. Our findings suggest that mitochondrial AQP9 is a hallmark of astrocytes and midbrain dopaminergic neurons. In physiological conditions, the flux of lactate and other metabolites through AQP9 may confer an advantage by allowing the mitochondria to adjust to the metabolic status of the extramitochondrial cytoplasm. We hypothesize that the complement of mitochondrial AQP9 in dopaminergic neurons may relate to the vulnerability of these neurons in Parkinson's disease.	Univ Oslo, Ctr Mol Biol & Neurosci, N-0317 Oslo, Norway; Univ Oslo, Nord Ctr Water Imbalance Related Disorders, N-0317 Oslo, Norway; Univ Oslo, Inst Basic Med Sci, Dept Biochem, N-0317 Oslo, Norway; Karolinska Inst, Dept Woman & Child Hlth, Stockholm, Sweden	University of Oslo; University of Oslo; University of Oslo; Karolinska Institutet	Amiry-Moghaddam, M (corresponding author), Univ Oslo, Ctr Mol Biol & Neurosci, POB 1105 Blindern, N-0317 Oslo, Norway.	mahmo@medisin.uio.no	, PeturHenry/H-1506-2011; Roberg, Bjørg/B-4589-2013	Amiry-Moghaddam, Mahmood/0000-0003-1071-1247; Gundersen, Brigitta/0000-0002-7801-9348				Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Amiry-Moghaddam M, 2003, NAT REV NEUROSCI, V4, P991, DOI 10.1038/nrn1252; Amiry-Moghaddam M, 2004, FASEB J, V18, P542, DOI 10.1096/fj.03-0869fje; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Badaut J, 2004, NEUROSCIENCE, V128, P27, DOI 10.1016/j.neuroscience.2004.05.042; Badaut J, 2001, J CEREBR BLOOD F MET, V21, P477, DOI 10.1097/00004647-200105000-00001; BRANDT RB, 1987, ARCH BIOCHEM BIOPHYS, V259, P412, DOI 10.1016/0003-9861(87)90507-8; Cancherini DV, 2003, AM J PHYSIOL-RENAL, V285, pF1291, DOI 10.1152/ajprenal.00103.2003; Carbrey JM, 2003, P NATL ACAD SCI USA, V100, P2945, DOI 10.1073/pnas.0437994100; Cater HL, 2003, J NEUROCHEM, V87, P1381, DOI 10.1046/j.1471-4159.2003.02100.x; Da Cruz S, 2003, J BIOL CHEM, V278, P41566, DOI 10.1074/jbc.M304940200; Dardzinski BJ, 2000, PEDIATR RES, V48, P248, DOI 10.1203/00006450-200008000-00021; Dijkhuizen RM, 1998, STROKE, V29, P695, DOI 10.1161/01.STR.29.3.695; Dugan LL, 2004, J BIOENERG BIOMEMBR, V36, P317, DOI 10.1023/B:JOBB.0000041761.61554.44; Elkjaer ML, 2000, BIOCHEM BIOPH RES CO, V276, P1118, DOI 10.1006/bbrc.2000.3505; Fiskum G, 2004, J BIOENERG BIOMEMBR, V36, P347, DOI 10.1023/B:JOBB.0000041766.71376.81; GO KG, 1988, METAB BRAIN DIS, V3, P257, DOI 10.1007/BF00999535; Gorell JM, 1999, NEUROTOXICOLOGY, V20, P239; Jensen MO, 2002, P NATL ACAD SCI USA, V99, P6731, DOI 10.1073/pnas.102649299; Kitano T, 2002, LIFE SCI, V72, P557, DOI 10.1016/S0024-3205(02)02251-8; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; Laake JH, 1999, NEUROSCIENCE, V88, P1137, DOI 10.1016/S0306-4522(98)00298-X; Lee WK, 2005, AM J PHYSIOL-RENAL, V288, pF27, DOI 10.1152/ajprenal.00224.2004; Liu ZH, 2002, J ENHANC HEAT TRANSF, V9, P99, DOI 10.1080/10655130214158; MAUREL C, 1994, J BIOL CHEM, V269, P11869; Miwa S, 2003, BIOCHEM SOC T, V31, P1300; Nicchia GP, 2001, J HISTOCHEM CYTOCHEM, V49, P1547, DOI 10.1177/002215540104901208; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; Nielsen S, 1997, J NEUROSCI, V17, P171; Nihei K, 2001, ARCH HISTOL CYTOL, V64, P81, DOI 10.1679/aohc.64.81; Oshio K, 2003, ACT NEUR S, V86, P525; Phillis JW, 1999, NEUROSCI LETT, V272, P195, DOI 10.1016/S0304-3940(99)00584-4; Roberg B, 2000, AM J PHYSIOL-CELL PH, V279, pC648, DOI 10.1152/ajpcell.2000.279.3.C648; Roberg B, 1999, NEUROCHEM RES, V24, P383, DOI 10.1023/A:1020985600422; ROBERG B, 1995, NEUROCHEM INT, V27, P367, DOI 10.1016/0197-0186(95)00018-4; Schipper HM, 1998, EXP NEUROL, V152, P188, DOI 10.1006/exnr.1998.6854; Schurr A, 2002, INT J MOL MED, V10, P131, DOI 10.3892/ijmm.10.2.131; Sheline CT, 2004, ANN NEUROL, V55, P645, DOI 10.1002/ana.20047; Starkov AA, 1997, BIOSCIENCE REP, V17, P273, DOI 10.1023/A:1027380527769; SWEET G, 1990, J BACTERIOL, V172, P424, DOI 10.1128/JB.172.1.424-430.1990; Takumi Y, 1999, NAT NEUROSCI, V2, P618, DOI 10.1038/10172; Tsukaguchi H, 1998, J BIOL CHEM, V273, P24737, DOI 10.1074/jbc.273.38.24737; Tsukaguchi H, 1999, AM J PHYSIOL-RENAL, V277, pF685, DOI 10.1152/ajprenal.1999.277.5.F685; Veech RL, 2001, IUBMB LIFE, V51, P241; VONZGLINICKI T, 1987, J THEOR BIOL, V127, P127, DOI 10.1016/S0022-5193(87)80123-6; Zardoya R, 2001, J MOL EVOL, V52, P391, DOI 10.1007/s002390010169; Zelenina M, 2004, J BIOL CHEM, V279, P51939, DOI 10.1074/jbc.M407645200	47	103	109	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1459	1467		10.1096/fj.04-3515com	http://dx.doi.org/10.1096/fj.04-3515com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16126913				2022-12-28	WOS:000232315700039
J	Madeira, A; Pommet, JM; Prochiantz, A; Allinquant, B				Madeira, A; Pommet, JM; Prochiantz, A; Allinquant, B			SET protein (TAF1 beta, I2PP2A) is involved in neuronal apoptosis induced by an amyloid precursor protein cytoplasmic subdomain	FASEB JOURNAL			English	Article						Alzheimer's disease; cell death; antisense strategy; subcellular localization	CASPASE-CLEAVAGE; GAMMA-SECRETASE; NEUROFIBRILLARY TANGLES; ALZHEIMERS-DISEASE; TERMINAL FRAGMENT; IN-VITRO; TAU; APP; DOMAIN; SUPPRESSOR	When overexpressed, a short cytoplasmic domain of the amyloid precursor protein (APP), normally unmasked in the brain of Alzheimer's disease patients, activates caspase-3 and induces neuronal death. Death induction by this "Jcasp" domain is lost when tyrosine 653 is changed into an aspartate, suggesting specific interactions with unknown partners. To identify these putative partners and start to elucidate the mechanisms involved in Jcasp-induced cell death, we internalized a biotinylated version of the peptide into primary neurons and analyzed intracellular interacting proteins by pull-down and mass spectrometry. We find that SET protein, also called template-activating factor (TAF1 beta) or phosphatase 2A inhibitor 2 (I-2(PP2A)), specifically binds Jcasp early after internalization and that SET and Jcasp interact directly in vitro. Downregulation of SET reduces Jcasp-induced cell death, confirming a role of this protein in Jcasp-induced apoptosis. Conversely, SET gain of function increases cell death, which suggests that SET level is crucial for neuronal survival/ death. Taken together, these results suggest that SET is part of a neuronal apoptotic pathway related to Alzheimer's disease and provides a new entry in the analysis of this pathology.	Ctr Paul Broca, INSERM, U573, F-75014 Paris, France; ENS, CNRS, UMR 8542, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Allinquant, B (corresponding author), Ctr Paul Broca, INSERM, U573, 2 Ter Rue Alesia, F-75014 Paris, France.	Bernadette.Allinquant@broca.inserm.fr						ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919; Bertrand E, 2001, MOL CELL NEUROSCI, V18, P503, DOI 10.1006/mcne.2001.1030; Blalock EM, 2004, P NATL ACAD SCI USA, V101, P2173, DOI 10.1073/pnas.0308512100; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Canela N, 2003, J BIOL CHEM, V278, P1158, DOI 10.1074/jbc.M207497200; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; Compagnone NA, 2000, MOL ENDOCRINOL, V14, P875, DOI 10.1210/me.14.6.875; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Dumanchin-Njock C, 2001, J NEUROCHEM, V78, P1153, DOI 10.1046/j.1471-4159.2001.00513.x; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Galvan V, 2002, J NEUROCHEM, V82, P283, DOI 10.1046/j.1471-4159.2002.00970.x; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Gong CX, 2000, J BIOL CHEM, V275, P5535, DOI 10.1074/jbc.275.8.5535; GONG CX, 1995, J NEUROCHEM, V65, P732, DOI 10.1046/j.1471-4159.1995.65020732.x; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Guo HS, 2004, AM J PATHOL, V165, P523, DOI 10.1016/S0002-9440(10)63317-2; Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189; Kim HS, 2003, FASEB J, V17, P1951, DOI 10.1096/fj.03-0106fje; Kroenke CD, 1997, BIOCHEMISTRY-US, V36, P8145, DOI 10.1021/bi9705669; LAFONT F, 1992, DEVELOPMENT, V114, P17; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Li SP, 2004, J PINEAL RES, V36, P186, DOI 10.1111/j.1600-079X.2004.00116.x; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Lu DC, 2003, ANN NEUROL, V54, P781, DOI 10.1002/ana.10761; Mbebi C, 2002, J BIOL CHEM, V277, P20979, DOI 10.1074/jbc.M107948200; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; Qu DB, 2002, J BIOL CHEM, V277, P7324, DOI 10.1074/jbc.M107270200; Rissman RA, 2004, J CLIN INVEST, V114, P121, DOI 10.1172/JCI200420640; Rohn TT, 2000, J NEUROCHEM, V74, P2331, DOI 10.1046/j.1471-4159.2000.0742331.x; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Soriano S, 2001, J BIOL CHEM, V276, P29045, DOI 10.1074/jbc.M102456200; Su JH, 2001, BRAIN RES, V898, P350, DOI 10.1016/S0006-8993(01)02018-2; Sudo H, 2000, MOL CELL NEUROSCI, V16, P708, DOI 10.1006/mcne.2000.0910; Telese F, 2005, EMBO REP, V6, P77, DOI 10.1038/sj.embor.7400309; VON LM, 1992, MOL CELL BIOL, V12, P3346; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Wen CH, 2000, P NATL ACAD SCI USA, V97, P14524, DOI 10.1073/pnas.011446498; Yang FS, 1998, AM J PATHOL, V152, P379; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Zhao M, 2003, NEUROBIOL DIS, V14, P391, DOI 10.1016/j.nbd.2003.07.006; Zheng PZ, 1998, P NATL ACAD SCI USA, V95, P14745, DOI 10.1073/pnas.95.25.14745	51	95	102	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1905	+		10.1096/fj.05-3839fje	http://dx.doi.org/10.1096/fj.05-3839fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16162853				2022-12-28	WOS:000232315700014
J	Zhang, JS; Krassilnikova, S; Gharaei, AA; Fassaei, HR; Esmailzadeh, L; Asadi, A; Edwards, DS; Harris, TD; Azure, M; Tellides, G; Sinusas, AJ; Zaret, BL; Bender, JR; Sadeghi, MM				Zhang, JS; Krassilnikova, S; Gharaei, AA; Fassaei, HR; Esmailzadeh, L; Asadi, A; Edwards, DS; Harris, TD; Azure, M; Tellides, G; Sinusas, AJ; Zaret, BL; Bender, JR; Sadeghi, MM			alpha v beta 3-Targeted detection of arteriopathy in transplanted human coronary arteries: an autoradiographic study	FASEB JOURNAL			English	Article						vitronectin receptor; imaging; transplant vasculopathy	VITRONECTIN RECEPTOR; HEART-TRANSPLANTATION; ENDOTHELIAL-CELLS; ALPHA(V)BETA(3); VASCULOPATHY; REJECTION; INJURY; ARTERIOSCLEROSIS; TRANSDUCTION; PATHOGENESIS	Graft arteriopathy (GA), characterized by diffuse concentric narrowing of coronary arteries, is the major cause of late graft failure in cardiac transplantation. alpha v beta 3 Integrin is up-regulated in proliferating vascular cells and may constitute an appropriate target for imaging GA. We used a human/mouse chimeric model of GA, in which segments of human coronary artery were transplanted to severe combined immunodeficiency mice, followed by reconstitution with allogeneic human peripheral blood mononuclear cells (PBMC). This led to vascular remodeling characterized by neointima formation over a period of 4 wk. alpha v beta 3 expression in the graft was minimal in animals without PBMC, considerably increased by 2 wk, and decreased toward baseline by 4 wk after PBMC reconstitution. Cell proliferation was maximal at 2 wk, correlating with peak alpha v beta 3 expression. RP748, an In-111-labeled alpha v beta 3 ( active conformation)- targeted radiotracer was injected into groups of 5 recipients at 0, 2, and 4 wk after PBMC reconstitution. Relative uptakes, defined as autoradiographic intensity in the graft/native aortas closely tracked the proliferative process. Specificity of uptake was demonstrated using excess nonlabeled tracer. In conclusion, alpha v beta 3 integrin is transiently up-regulated ( and activated) in GA and may be targeted by RP748 for detection of the proliferative process in early GA.	VA Connecticut Healthcare Syst, West Haven, CT 06516 USA; Yale Univ, Sch Med, Raymond & Beverly Sackler Cardiovasc Mol Imaging, Sect Cardiovasc Med, New Haven, CT USA; Yale Univ, Sch Med, Sect Cardiothorac Surg, New Haven, CT USA; Yale Univ, Sch Med, Interdepartmental Program Vasc Biol & Transplanta, New Haven, CT USA; Bristol Myers Squibb Med Imaging, N Billerica, MA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; Yale University; Yale University; Bristol-Myers Squibb	Sadeghi, MM (corresponding author), VA Connecticut Healthcare Syst, 950 Campbell Ave,111B, West Haven, CT 06516 USA.	mehran.sadeghi@yale.edu	Sinusas, Albert J/A-7235-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070295] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL-70295] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bishop GG, 2001, CIRCULATION, V103, P1906, DOI 10.1161/01.cir.103.14.1906; Di Filippo S, 2003, J HEART LUNG TRANSPL, V22, P876, DOI 10.1016/S1053-2498(02)00664-2; Elhendy A, 2002, AM J CARDIOL, V89, P964, DOI 10.1016/S0002-9149(02)02247-6; EVERETT JP, 1992, J HEART LUNG TRANS S, V11, P133; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; Harris TD, 2003, CANCER BIOTHER RADIO, V18, P627, DOI 10.1089/108497803322287727; Haubner R, 1999, J NUCL MED, V40, P1061; Horton MA, 1997, INT J BIOCHEM CELL B, V29, P721, DOI 10.1016/S1357-2725(96)00155-0; Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9; Kapadia SR, 1999, CURR OPIN CARDIOL, V14, P140, DOI 10.1097/00001573-199903000-00011; Koh KP, 2004, J CLIN INVEST, V114, P846, DOI 10.1172/JCI200421767; Lenihan DJ, 1999, AM HEART J, V137, P942, DOI 10.1016/S0002-8703(99)70420-5; Libby P, 2001, IMMUNITY, V14, P387, DOI 10.1016/S1074-7613(01)00119-4; Lorber MI, 1999, TRANSPLANTATION, V67, P897, DOI 10.1097/00007890-199903270-00018; Meoli DF, 2004, J CLIN INVEST, V113, P1684, DOI 10.1172/JCI200420352; Mitchell RN, 2004, CARDIOVASC PATHOL, V13, P33, DOI 10.1016/S1054-8807(03)00108-X; Moiseeva EP, 2001, CARDIOVASC RES, V52, P372, DOI 10.1016/S0008-6363(01)00399-6; Pober JS, 2002, AM J TRANSPLANT, V2, P201, DOI 10.1034/j.1600-6143.2002.20302.x; RICKENBACHER PR, 1995, CIRCULATION, V92, P3445, DOI 10.1161/01.CIR.92.12.3445; Sadeghi MM, 2004, CIRCULATION, V110, P84, DOI 10.1161/01.CIR.0000133319.84326.70; SALOMON RN, 1991, AM J PATHOL, V138, P791; SHATTIL SJ, 1995, THROMB HAEMOSTASIS, V74, P149; Slepian MJ, 1998, CIRCULATION, V97, P1818, DOI 10.1161/01.CIR.97.18.1818; SMART FW, 1991, AM J CARDIOL, V67, P243, DOI 10.1016/0002-9149(91)90553-W; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Tellides G, 2000, NATURE, V403, P207, DOI 10.1038/35003221; Tilney NL, 1997, TRANSPLANTATION, V64, P945, DOI 10.1097/00007890-199710150-00001; Wang YN, 2004, FASEB J, V18, P606, DOI 10.1096/fj.03-0840fje; Yamani MH, 2002, J AM COLL CARDIOL, V39, P804, DOI 10.1016/S0735-1097(01)01823-X; Yamani MH, 2002, CIRCULATION, V105, P1955, DOI 10.1161/01.CIR.0000014971.09169.BC	31	15	16	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2005	19	11					1857	+		10.1096/fj.05-4130fje	http://dx.doi.org/10.1096/fj.05-4130fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16150802				2022-12-28	WOS:000232315700020
J	McColl, G; Vantipalli, MC; Lithgow, GJ				McColl, G; Vantipalli, MC; Lithgow, GJ			C-elegans ortholog of mammalian Ku70 interacts with insulin-like signaling to modulate stress resistance and life span	FASEB JOURNAL			English	Article						cku-70; cku-80; daf-2; daf-16; aging; stress response; DNA repair	HEAT-SHOCK FACTOR; CAENORHABDITIS-ELEGANS; INDUCIBLE HEAT-SHOCK-PROTEIN-70; OXIDATIVE STRESS; LONGEVITY; DAF-2; GENE; LONG; DNA; EXPRESSION	The mammalian Ku heterodimer has important roles in DNA double strand break repair, telomere maintenance, cell cycle checkpoint-arrest, tumor suppression, and cellular stress resistance. To investigate the evolutionarily conserved functions of Ku, we knocked down expression by RNA interference (RNAi) of Ku genes in C. elegans. We found that C. elegans Ku70 (CKU-70) is required for resistance to genotoxic stress, regulates cytotoxic stress responses, and influences aging. The latter effects are dependent on an IGF-1/insulin-like signaling pathway previously shown to affect life span. Reduction of CKU-70 activity amplifies the aging phenotype of long-lived insulin receptor daf-2 mutations in a daf-16-dependent manner. These observations support the view that organismal stress resistance determines life span and Ku70 modulates these effects.	Buck Inst Age Res, Novato, CA 94945 USA	Buck Institute for Research on Aging	McColl, G (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	gmccoll@buckinstitute.org	McColl, Gawain/Y-8959-2018	McColl, Gawain/0000-0002-6347-6722	NATIONAL INSTITUTE ON AGING [R01AG029631, R01AG021069] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG029631, R01AG21069, R01 AG021069] Funding Source: Medline; PHS HHS [R0-122868] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Barsyte D, 2001, FASEB J, V15, P627, DOI 10.1096/fj.99-0966com; BEANAN MJ, 1992, DEVELOPMENT, V116, P755; Boulton SJ, 2002, SCIENCE, V295, P127, DOI 10.1126/science.1065986; Calini V, 2003, TOXICOL IN VITRO, V17, P561, DOI 10.1016/S0887-2333(03)00116-4; Campisi J, 2003, NAT REV CANCER, V3, P339, DOI 10.1038/nrc1073; Gems D, 1998, GENETICS, V150, P129; Glaab WE, 1999, MUTAT RES-FUND MOL M, V427, P67, DOI 10.1016/S0027-5107(99)00091-3; Gu YS, 2000, P NATL ACAD SCI USA, V97, P2668, DOI 10.1073/pnas.97.6.2668; HARTMAN PS, 1982, GENETICS, V102, P159; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; Jeong YS, 2003, DNA REPAIR, V2, P1309, DOI 10.1016/j.dnarep.2003.07.003; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kenny MK, 2001, J BIOL CHEM, V276, P9532, DOI 10.1074/jbc.M009297200; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LARSEN PL, 1995, GENETICS, V139, P1567; Lee SJ, 2001, CELL STRESS CHAPERON, V6, P273, DOI 10.1379/1466-1268(2001)006<0273:ROIHSP>2.0.CO;2; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; LITHGOW GJ, 1994, J GERONTOL, V49, pB270, DOI 10.1093/geronj/49.6.B270; Lithgow GJ, 1996, BIOESSAYS, V18, P809, DOI 10.1002/bies.950181007; McElwee J, 2003, AGING CELL, V2, P111, DOI 10.1046/j.1474-9728.2003.00043.x; McElwee JJ, 2004, J BIOL CHEM, V279, P44533, DOI 10.1074/jbc.M406207200; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Morley JF, 2004, MOL BIOL CELL, V15, P657, DOI 10.1091/mbc.E03-07-0532; Murakami S, 1996, GENETICS, V143, P1207; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Park SH, 2000, RADIAT RES, V153, P318, DOI 10.1667/0033-7587(2000)153[0318:IHSPII]2.0.CO;2; SIERRARIVERA E, 1993, RADIAT RES, V135, P40, DOI 10.2307/3578394; Sijen T, 2001, CELL, V107, P465, DOI 10.1016/S0092-8674(01)00576-1; STERNAGLE T, 1999, C ELEGANS PRACTICAL, P51; Tang D, 2001, BIOCHEM BIOPH RES CO, V280, P280, DOI 10.1006/bbrc.2000.4118; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Walker DW, 2000, NATURE, V405, P296, DOI 10.1038/35012693; Walker GA, 2003, AGING CELL, V2, P131, DOI 10.1046/j.1474-9728.2003.00045.x; Walker GA, 2003, FASEB J, V17, P1960, DOI 10.1096/fj.03-0164fje; Walker GA, 2001, J GERONTOL A-BIOL, V56, pB281, DOI 10.1093/gerona/56.7.B281; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Yang SH, 1996, MOL CELL BIOL, V16, P3799, DOI 10.1128/mcb.16.7.3799; Yang SH, 1996, RADIAT RES, V146, P603, DOI 10.2307/3579375; Yokoyama K, 2002, FEBS LETT, V516, P53, DOI 10.1016/S0014-5793(02)02470-5; Yu H, 2001, J MOL BIOL, V314, P1017, DOI 10.1006/jmbi.2000.5210	49	16	21	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1716	+		10.1096/fj.04-2447fje	http://dx.doi.org/10.1096/fj.04-2447fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16099946	Green Accepted			2022-12-28	WOS:000231843700016
J	Kupatt, C; Horstkotte, J; Vlastos, GA; Pfosser, A; Lebherz, C; Semisch, M; Thalgott, M; Buttner, K; Browarzyk, C; Mages, J; Hoffmann, R; Deten, A; Lamparter, M; Muller, F; Beck, H; Buning, H; Boekstegers, P; Hatzopoulos, AK				Kupatt, C; Horstkotte, J; Vlastos, GA; Pfosser, A; Lebherz, C; Semisch, M; Thalgott, M; Buttner, K; Browarzyk, C; Mages, J; Hoffmann, R; Deten, A; Lamparter, M; Muller, F; Beck, H; Buning, H; Boekstegers, P; Hatzopoulos, AK			Embryonic endothelial progenitor cells expressing a broad range of proangiogenic and remodeling factors enhance vascularization and tissue recovery in acute and chronic ischemia	FASEB JOURNAL			English	Article						myocardial infarction; angiogenesis; endothelium-derived factors	MARROW-DERIVED CELLS; STEM-CELLS; MYOCARDIAL-INFARCTION; IN-VITRO; GROWTH; VIVO; ANGIOGENESIS; NEOVASCULARIZATION; RETROINFUSION; RECRUITMENT	Clonal embryonic endothelial progenitor cells (eEPCs) isolated from embryonic day 7.5 mice home specifically to hypoxic areas in mouse tumor metastases but spare normal organs and do not form carcinomas. Based on these results, we assessed the potential of eEPCs to enhance vascularization and limit organ dysfunction after ischemia in syngenic and xenotypic organisms. The angiogenic potential of eEPCs was evaluated in chronic ischemic rabbit hindlimbs after regional application by retroinfusion. eEPC treatment improved limb perfusion, paralleled by an increase in capillary density and collateral blood vessel number. Systemic eEPC infusion into mice after ischemic cardiac insult increased postischemic heart output measured by a marked improvement in left ventricle developed pressure and both systolic and diastolic functions. In vitro, eEPCs strongly induced vascular outgrowths from aortic rings. To address the molecular basis of this intrinsic angiogenic potential, we investigated the eEPC transcriptome. Genome-wide Affymetrix GeneChip analysis revealed that the eEPCs express a wealth of secreted factors known to induce angiogenesis, tissue remodeling, and organogenesis that may contribute to the eEPC-mediated beneficial effects. Our findings show that eEPCs induce blood vessel growth and cardioprotection in severe ischemic conditions providing a readily available source to study the mechanisms of neovascularization and tissue recovery.	Vanderbilt Univ, Dept Med, Div Cardiovasc Med, Nashville, TN 37232 USA; GSF Munich, Res Ctr Environm & Hlth, Inst Clin Mol Biol & Tumor Genet, D-81377 Munich, Germany; Klinikum Grosshadern, D-81377 Munich, Germany; Tech Univ Munich, Inst Med Microbiol, D-81675 Munich, Germany; Max Von Pettenkofer Inst, Dept Bacteriol, D-80336 Munich, Germany; Univ Leipzig, Inst Physiol, D-04103 Leipzig, Germany; Univ Munich, Gene Ctr, D-81377 Munich, Germany	Vanderbilt University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Technical University of Munich; University of Munich; Leipzig University; University of Munich	Hatzopoulos, AK (corresponding author), Vanderbilt Univ, Dept Med, Div Cardiovasc Med, 2220 Pierce Ave, Nashville, TN 37232 USA.	antonis.hatzopoulos@vanderbilt.edu	Hatzopoulos, Antonis/X-2043-2019; Hoffmann, Reinhard/I-8748-2018; Hatzopoulos, Antonis/D-2049-2010; Buening, Hildegard/AAJ-2352-2020; Buening, Hildegard/AAV-9928-2021	Hatzopoulos, Antonis/0000-0001-5610-0017; Hoffmann, Reinhard/0000-0003-1514-1183; Buening, Hildegard/0000-0002-3365-6933; Kupatt, Christian/0000-0002-3611-1218				Aicher A, 2003, CIRCULATION, V107, P2134, DOI 10.1161/01.CIR.0000062649.63838.C9; Amin MA, 2003, CIRC RES, V93, P321, DOI 10.1161/01.RES.0000087641.56024.DA; Barandon L, 2003, CIRCULATION, V108, P2282, DOI 10.1161/01.CIR.0000093186.22847.4C; Beck H, 2003, J CEREBR BLOOD F MET, V23, P709, DOI 10.1097/01.WCB.0000065940.18332.8D; Beckner ME, 2002, MICROVASC RES, V63, P259, DOI 10.1006/mvre.2001.2384; Bock-Marquette I, 2004, NATURE, V432, P466, DOI 10.1038/nature03000; Britten MB, 2003, CIRCULATION, V108, P2212, DOI 10.1161/01.CIR.0000095788.78169.AF; Byrd N, 2002, DEVELOPMENT, V129, P361; Corbel SY, 2003, NAT MED, V9, P1528, DOI 10.1038/nm959; Eisenberg LM, 2004, STEM CELLS DEV, V13, P614, DOI 10.1089/scd.2004.13.614; Hatzopoulos AK, 1998, DEVELOPMENT, V125, P1457; Heil M, 2004, CIRC RES, V94, P573, DOI 10.1161/01.RES.0000124603.46777.EB; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Kamihata H, 2001, CIRCULATION, V104, P1046, DOI 10.1161/hc3501.093817; Kawamoto A, 2001, CIRCULATION, V103, P634; Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Kryczek I, 2005, CANCER RES, V65, P465; Kupatt C, 2003, FASEB J, V17, P705, DOI 10.1096/fj.02-0673fje; Kupatt C, 2002, GENE THER, V9, P518, DOI 10.1038/sj.gt.3301673; Kupatt C, 2002, J LEUKOCYTE BIOL, V72, P455; Lebherz C, 2003, ENDOTHELIUM-J ENDOTH, V10, P257, DOI 10.1080/713715242; Masuda H, 2003, CARDIOVASC RES, V58, P390, DOI 10.1016/S0008-6363(02)00785-X; Sato N, 2003, DEV BIOL, V260, P404, DOI 10.1016/S0012-1606(03)00256-2; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Shintani S, 2001, CIRCULATION, V103, P897, DOI 10.1161/01.CIR.103.6.897; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Vajkoczy P, 2003, J EXP MED, V197, P1755, DOI 10.1084/jem.20021659; von Degenfeld G, 2003, J AM COLL CARDIOL, V42, P1120, DOI 10.1016/S0735-1097(03)00915-X; Wei JW, 2004, CANCER CELL, V5, P477, DOI 10.1016/S1535-6108(04)00116-3; Witzenbichler B, 1998, AM J PATHOL, V153, P381, DOI 10.1016/S0002-9440(10)65582-4; Wollert KC, 2004, LANCET, V364, P141, DOI 10.1016/S0140-6736(04)16626-9; Ziegelhoeffer T, 2004, CIRC RES, V94, P230, DOI 10.1161/01.RES.0000110419.50982.1C	34	96	101	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1576	+		10.1096/fj.04-3282fje	http://dx.doi.org/10.1096/fj.04-3282fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16009705				2022-12-28	WOS:000230923000026
J	Tonello, C; Vindigni, V; Zavan, B; Abatangelo, S; Abatangelo, G; Brun, P; Cortivo, R				Tonello, C; Vindigni, V; Zavan, B; Abatangelo, S; Abatangelo, G; Brun, P; Cortivo, R			In vitro reconstruction of an endothelialized skin substitute provided with a microcapillary network using biopolymer scaffolds	FASEB JOURNAL			English	Article						endothelial cells; skin substitute; angiogenesis; hyaluronic acid; tissue engineering	HYALURONIC-ACID; CELLS; KERATINOCYTES; EQUIVALENT; REPLACEMENT; DERMIS; ULCERS; WOUNDS	SSuccessful in vitro reconstruction of skin requires the inclusion of several cell types that give rise in coculture to the specific elements present in native skin, and the appropriate scaffolding structure to house and support these cells. In addition to the two main structural components, epidermis and dermis, one critical apparatus of the skin is a capillary network that guarantees adequate perfusion of nutrients and oxygen. The aim of the present study was to develop an in vitro coculture system that assumed the human dermal-epidermal architecture and included a microcapillary network in a three-dimensional biomaterial that guaranteed ease of handling in a clinical setting. Endothelialized skin (ES) was prepared by coculturing three human cell types: keratinocytes, fibroblasts, and endothelial cells, obtained from human full-thickness skin samples, in scaffolds produced from modified hyaluronic acid. Results were evaluated by histological and immunohistochemical analyses at different time points. In vitro, engineered skin obtained with this composite culture developed into a well-differentiated upper layer of stratified keratinocytes lining a dermal-like structure, in which fibroblasts, extracellular matrix and a microvascular network were present. Furthermore, the biodegradable fabric produced from hyaluronic acid and used as the scaffolding support for this in vitro constructed skin graft greatly facilitated handling in the perioperative period.	Univ Padua, Dept Histol Microbiol & Med Biotechnol, I-35100 Padua, Italy	University of Padua	Abatangelo, G (corresponding author), Univ Padua, Dept Histol Microbiol & Med Biotechnol, Via G Colombo 3, I-35100 Padua, Italy.	g.abatangelo@unipd.it	Vindigni, Vincenzo/K-5059-2016; Brun, Paola/K-5729-2016	Vindigni, Vincenzo/0000-0001-6638-9010; Brun, Paola/0000-0002-4204-3549				Balasubramani M, 2001, BURNS, V27, P534, DOI 10.1016/S0305-4179(01)00018-3; Black AF, 1999, CELL BIOL TOXICOL, V15, P81, DOI 10.1023/A:1007541713398; Black AF, 1998, FASEB J, V12, P1331, DOI 10.1096/fasebj.12.13.1331; BRIGGAMAN RA, 1968, J INVEST DERMATOL, V514, P54; Brun P, 2000, Ostomy Wound Manage, V46, P44; Caravaggi C, 2003, DIABETES CARE, V26, P2853, DOI 10.2337/diacare.26.10.2853; CUONO CB, 1987, PLAST RECONSTR SURG, V80, P626, DOI 10.1097/00006534-198710000-00029; EADY RAJ, 1994, J INVEST DERMATOL, V103, pS13, DOI 10.1111/1523-1747.ep12398895; Galassi G, 2000, BIOMATERIALS, V21, P2183, DOI 10.1016/S0142-9612(00)00147-2; GALLICO GG, 1984, NEW ENGL J MED, V311, P448, DOI 10.1056/NEJM198408163110706; GALLICO GG, 1989, PLAST RECONSTR SURG, V84, P1; Giuggioli D, 2003, RHEUMATOLOGY, V42, P694, DOI 10.1093/rheumatology/keg106; GREEN H, 1979, P NATL ACAD SCI USA, V76, P5665, DOI 10.1073/pnas.76.11.5665; Griffiths M, 2004, TISSUE ENG, V10, P1180, DOI 10.1089/ten.2004.10.1180; Grigolo B, 2003, Chir Organi Mov, V88, P351; Guerret S, 2003, WOUND REPAIR REGEN, V11, P35, DOI 10.1046/j.1524-475X.2003.11107.x; Halbleib M, 2003, BIOMATERIALS, V24, P3125, DOI 10.1016/S0142-9612(03)00156-X; HANSBROUGH JF, 1994, SURGERY, V115, P633; Hudon V, 2003, BRIT J DERMATOL, V148, P1094, DOI 10.1046/j.1365-2133.2003.05298.x; Jones I, 2002, BRIT J PLAST SURG, V55, P185, DOI 10.1054/bjps.2002.3800; Lam PK, 1999, J TRAUMA, V47, P918, DOI 10.1097/00005373-199911000-00017; Lisignoli G, 2003, Chir Organi Mov, V88, P363; Lobmann R, 2003, J DIABETES COMPLICAT, V17, P199, DOI 10.1016/S1056-8727(02)00218-0; MURPHY JF, 2005, FASEB J ONLINE  0107; Pavesio Alessandra, 2003, Novartis Found Symp, V249, P203; Remuzzi A, 2004, TISSUE ENG, V10, P699, DOI 10.1089/1076327041348347; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; SCALA C, 1992, J HISTOCHEM CYTOCHEM, V40, P1799, DOI 10.1177/40.11.1431065; Schechner JS, 2003, FASEB J, V17, P2250, DOI 10.1096/fj.03-0257com; Supp DM, 2002, FASEB J, V16, DOI 10.1096/fj.01-0868com; Tonello C, 2003, BIOMATERIALS, V24, P1205, DOI 10.1016/S0142-9612(02)00450-7; Trompezinski S, 2004, EXP DERMATOL, V13, P98, DOI 10.1111/j.0906-6705.2004.00137.x; Turner NJ, 2004, BIOMATERIALS, V25, P5955, DOI 10.1016/j.biomaterials.2004.02.002; Weber E, 2004, LYMPHOLOGY, V37, P15; Zacchi V, 1998, J BIOMED MATER RES, V40, P187, DOI 10.1002/(SICI)1097-4636(199805)40:2<187::AID-JBM3>3.0.CO;2-H	36	52	54	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1546	+		10.1096/fj.05-3804fje	http://dx.doi.org/10.1096/fj.05-3804fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15972294				2022-12-28	WOS:000230207800010
J	Kraman, M; McCright, B				Kraman, M; McCright, B			Functional conservation of Notch1 and Notch2 intracellular domains	FASEB JOURNAL			English	Article						ICD; PEST; CSL	ANKYRIN REPEATS; CELL FATE; SEL-10; MICE; MUTATION; PROTEOLYSIS; RECEPTORS; PATHWAYS; DEFECTS; PROTEIN	The Notch receptor is a key component of a highly conserved signaling pathway that regulates cell fate determination during development. In Drosophila, where Notch signaling was first identified and studied, there is only one Notch receptor. In contrast, mammals have four Notch receptor genes, Notch1-4. Notch1 and Notch2 are both required for embryo viability, are widely expressed in mammals, and are structurally conserved. It is presently unknown if these two receptors are functionally redundant or if they have unique capabilities related to differences in their amino acid sequences. In contrast to the rest of the molecule, the amino acid sequences of a large region of the Notch intracellular domain are not highly conserved and thus may be able to interact with distinct transcription factors and mediate the expression of different sets of genes. To determine if the function of this region is conserved, the last 426 amino acids of the Notch2 receptor have been replaced with the corresponding region of Notch1 in mice by using gene targeting. We have determined that even though the amino acid sequences of this region are only 37% identical (137/426), the C-terminal region of the Notch1 intracellular domain can functionally replace that of Notch2 in vivo.	US FDA, Div Cellular & Gene Therapies, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA)	McCright, B (corresponding author), US FDA, Div Cellular & Gene Therapies, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA.	mccright@cber.fda.gov		Kraman, Matthew/0000-0002-5040-0067				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; Beatus P, 2001, MECH DEVELOP, V104, P3, DOI 10.1016/S0925-4773(01)00373-2; Bigas A, 1998, MOL CELL BIOL, V18, P2324, DOI 10.1128/MCB.18.4.2324; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Espinosa L, 2003, J BIOL CHEM, V278, P32227, DOI 10.1074/jbc.M304001200; Foltz DR, 2001, BIOCHEM BIOPH RES CO, V286, P484, DOI 10.1006/bbrc.2001.5421; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hamada Y, 1999, DEVELOPMENT, V126, P3415; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; Kile BT, 2003, MAMM GENOME, V14, P81, DOI 10.1007/s00335-002-2160-0; Krebs LT, 2003, GENESIS, V37, P139, DOI 10.1002/gene.10241; Krebs LT, 2000, GENE DEV, V14, P1343; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; Lai EC, 2004, DEVELOPMENT, V131, P965, DOI 10.1242/dev.01074; Lubman OY, 2004, MOL CELL, V13, P619, DOI 10.1016/S1097-2765(04)00120-0; McCright B, 2001, DEVELOPMENT, V128, P491; McCright B, 2002, DEVELOPMENT, V129, P1075; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Ramain P, 2001, CURR BIOL, V11, P1729, DOI 10.1016/S0960-9822(01)00562-0; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Saxena MT, 2001, J BIOL CHEM, V276, P40268, DOI 10.1074/jbc.M107234200; Shimizu K, 2002, BIOCHEM BIOPH RES CO, V291, P775, DOI 10.1006/bbrc.2002.6528; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Uyttendaele H, 2001, P NATL ACAD SCI USA, V98, P5643, DOI 10.1073/pnas.091584598; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644	32	22	22	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2005	19	7					1311	+		10.1096/fj.04-3407fje	http://dx.doi.org/10.1096/fj.04-3407fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15897231				2022-12-28	WOS:000229602600012
J	Pandey, M; Loskutoff, DJ; Samad, F				Pandey, M; Loskutoff, DJ; Samad, F			Molecular mechanisms of tumor necrosis factor-alpha-mediated plasminogen activator inhibitor-1 expression in adipocytes	FASEB JOURNAL			English	Article						obesity; insulin resistance; insulin; transforming growth factor-beta; PKC; P44/42; NF-kappa B	PROTEIN-KINASE-C; GROWTH-FACTOR-BETA; PAI-1 GENE-EXPRESSION; ADIPOSE-TISSUE; MESSENGER-RNA; TNF-ALPHA; UP-REGULATION; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; PHORBOL ESTERS	Increased expression of plasminogen activator inhibitor - 1 (PAI-1) in adipose tissues is thought to contribute to both the cardiovascular and metabolic complications associated with obesity. Tumor necrosis factor alpha (TNF-alpha) is chronically elevated in adipose tissues of obese rodents and humans and has been directly implicated to induce PAI-1 in adipocytes. In this study, we used 3T3-L1 adipocytes to examine the mechanism by which TNF-alpha up-regulates PAI-1 in the adipocyte. Acute ( 3 h) and chronic ( 24 h) exposure of 3T3-L1 adipocytes to TNF-alpha induces PAI-1 mRNA by increasing the rate of transcription of the PAI-1 gene, and de novo protein synthesis is not required for this process. Although the p44/42 and PKC signaling pathways appear to be significant in the induction of PAI-1 mRNA in response to acute treatment with TNF-alpha, the more dramatic induction of PAI-1 mRNA observed in response to chronic exposure of adipocytes to TNF-alpha was mediated by these and additional signaling molecules, including p38, PI3-kinase, tyrosine kinases, and the transcription factor NF-kappa B. Moreover, the dramatic increase in PAI-1 observed after chronic exposure of adipocytes to TNF-alpha was accompanied by increased metabolic insulin resistance. Finally, we demonstrate that the PKC pathway is also central for PAI-1 induction in response to insulin and transforming growth factor-beta (TGF-beta), two additional molecules which are elevated in obesity and shown to directly induce PAI-1 in the adipocyte. The understanding of the mechanism of regulating PAI-1 expression in the adipocytes at the molecular level provides new insight to help identify novel targets in fighting the pathological complications of obesity.	La Jolla Inst Mol Med, Div Vasc Biol, San Diego, CA 92121 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	Scripps Research Institute; University of California System; University of California San Diego	Samad, F (corresponding author), La Jolla Inst Mol Med, Div Vasc Biol, 4570 Execut Dr,Suite 100, San Diego, CA 92121 USA.	fsamad@ljimm.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071146] Funding Source: NIH RePORTER; NHLBI NIH HHS [1R01HLO71146-01A2] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5; Alexander JP, 2001, INVEST OPHTH VIS SCI, V42, P2831; Arts J, 1999, ARTERIOSCL THROM VAS, V19, P39, DOI 10.1161/01.ATV.19.1.39; Bazzoni F, 1995, J INFLAMM, V45, P221; Bigda Jacek, 1997, Archivum Immunologiae et Therapiae Experimentalis, V45, P263; CHRISTENSEN RL, 1987, INT J BIOCHEM, V19, P259; Cigolini M, 1999, ATHEROSCLEROSIS, V143, P81, DOI 10.1016/S0021-9150(98)00281-0; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; Claycombe KJ, 2002, J BIOL CHEM, V277, P30784, DOI 10.1074/jbc.M204463200; FEARNS C, 1995, VASCULAR CONTROL HEM, P207; Fluckey JD, 2004, AM J PHYSIOL-ENDOC M, V286, pE753, DOI 10.1152/ajpendo.00155.2003; FOTSIS T, 1993, P NATL ACAD SCI USA, V90, P2690, DOI 10.1073/pnas.90.7.2690; GEORG B, 1989, MOL CELL ENDOCRINOL, V61, P87, DOI 10.1016/0303-7207(89)90192-5; Goeddel DV, 1999, CHEST, V116, p69S, DOI 10.1378/chest.116.suppl_1.69S; Gottschling-Zeller H, 2000, METABOLISM, V49, P666, DOI 10.1016/S0026-0495(00)80046-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Hamaguchi E, 2003, J PHARMACOL EXP THER, V307, P987, DOI 10.1124/jpet.103.054346; Harp JB, 2004, CURR OPIN LIPIDOL, V15, P303, DOI 10.1097/00041433-200406000-00010; HAUSS P, 1993, CELL IMMUNOL, V150, P439, DOI 10.1006/cimm.1993.1211; HEATON JH, 1992, MOL ENDOCRINOL, V6, P53, DOI 10.1210/me.6.1.53; Hershko DD, 2004, J CELL BIOCHEM, V91, P951, DOI 10.1002/jcb.20014; Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857; Hostamisligil GS, 1999, EXP CLIN ENDOCR DIAB, V107, P119, DOI 10.1055/s-0029-1212086; Hotamisligil Gokhan S., 1996, P554; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Hou BD, 2004, J BIOL CHEM, V279, P18127, DOI 10.1074/jbc.M310438200; IMAKI T, 1995, J CLIN INVEST, V96, P231, DOI 10.1172/JCI118026; Ishizuka T, 2004, ENDOCR RES, V30, P287, DOI 10.1081/ERC-120039580; Jain RG, 1999, J CELL PHYSIOL, V179, P58, DOI 10.1002/(SICI)1097-4652(199904)179:1<58::AID-JCP8>3.0.CO;2-1; Juhan-Vague I, 2003, J THROMB HAEMOST, V1, P1575, DOI 10.1046/j.1538-7836.2003.00279.x; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; Kim JK, 2004, J CLIN INVEST, V114, P823, DOI 10.1172/JCI200422230; Kumakura S, 2003, LEUKEMIA LYMPHOMA, V44, P497, DOI 10.1080/1042819021000047010; Kye KC, 2004, J INVEST DERMATOL, V122, P1365, DOI 10.1111/j.0022-202X.2004.22615.x; Lee JY, 2000, J BIOL CHEM, V275, P29290, DOI 10.1074/jbc.M000170200; LeMagueresseBattistoni B, 1996, ENDOCRINOLOGY, V137, P4243, DOI 10.1210/en.137.10.4243; LEVIN EG, 1988, FIBRINOLYSIS S, V2, P19; Lopez S, 1999, THROMB HAEMOSTASIS, V81, P415, DOI 10.1055/s-0037-1614488; Loskutoff DJ, 1998, ARTERIOSCL THROM VAS, V18, P1, DOI 10.1161/01.ATV.18.1.1; LOSKUTOFF DJ, 2000, NEW FRONTIER VASCULA, P151; LOSKUTOFF DJ, 2000, EXCERPTA MED INT C S; Lundgren CH, 1996, CIRCULATION, V93, P106, DOI 10.1161/01.CIR.93.1.106; MAYER M, 1988, J BIOL CHEM, V263, P15688; MEULDERS Q, 1992, KIDNEY INT, V42, P327, DOI 10.1038/ki.1992.293; MOHAMED F, 1995, ARTERIOSCL THROM VAS, V15, P52, DOI 10.1161/01.ATV.15.1.52; Morange PE, 2000, ARTERIOSCL THROM VAS, V20, P1150, DOI 10.1161/01.ATV.20.4.1150; Motojima M, 1999, BBA-MOL CELL RES, V1449, P217, DOI 10.1016/S0167-4889(99)00014-2; Naaz A, 2003, ENDOCRINOLOGY, V144, P3315, DOI 10.1210/en.2003-0076; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Okada H, 1998, CIRCULATION, V97, P2175, DOI 10.1161/01.CIR.97.21.2175; Pandey M, 2003, AM J PATHOL, V162, P933, DOI 10.1016/S0002-9440(10)63888-6; Penhoat A, 1996, MOL CELL ENDOCRINOL, V121, P57, DOI 10.1016/0303-7207(96)03851-8; PERALDI MN, 1992, BIOCHIM BIOPHYS ACTA, V1134, P189, DOI 10.1016/0167-4889(92)90175-B; PERSHADSINGH HA, 1987, BIOCHEM BIOPH RES CO, V145, P1384, DOI 10.1016/0006-291X(87)91591-9; Samad F, 1999, THROMB HAEMOSTASIS, V82, P742, DOI 10.1055/s-0037-1615906; Samad F, 1997, MOL MED, V3, P37, DOI 10.1007/BF03401666; Samad F, 1999, P NATL ACAD SCI USA, V96, P6902, DOI 10.1073/pnas.96.12.6902; Samad F, 1996, J CLIN INVEST, V97, P37, DOI 10.1172/JCI118404; Samad F, 2000, MOL MED, V6, P680, DOI 10.1007/BF03402048; SAMAD F, 1997, FIBRINOLYSIS PROTEOL, V11, P17; Sartipy P, 2003, P NATL ACAD SCI USA, V100, P7265, DOI 10.1073/pnas.1133870100; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; Schafer K, 2001, FASEB J, V15, P1840, DOI 10.1096/fj.00-0750fje; SCHNEIDER DJ, 1992, DIABETES, V41, P890, DOI 10.2337/diabetes.41.7.890; Seidell JC, 2000, BRIT J NUTR, V83, pS5, DOI 10.1017/S000711450000088X; Sharma AM, 2002, INT J OBESITY, V26, pS5, DOI 10.1038/sj.ijo.0802210; Treichel JA, 1998, J NEUROCHEM, V71, P1944; Uno S, 1998, J BIOCHEM, V123, P806; Valverde AM, 1996, ENDOCRINOLOGY, V137, P3832, DOI 10.1210/en.137.9.3832; VAN OX, 1993, NATURE, V361, P266; VANHINSBERGH VWM, 1994, BLOOD, V84, P2984; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092	73	66	67	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1317	+		10.1096/fj.04-3459fje	http://dx.doi.org/10.1096/fj.04-3459fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15928193				2022-12-28	WOS:000229602600001
J	Keller, P; Penkowa, M; Keller, C; Steensberg, A; Fischer, CP; Giralt, M; Hidalgo, J; Pedersen, BK				Keller, P; Penkowa, M; Keller, C; Steensberg, A; Fischer, CP; Giralt, M; Hidalgo, J; Pedersen, BK			RETRACTED: Interleukin-6 receptor expression in contracting human skeletal muscle: regulating role of IL-6 (Retracted article. See vol. 28, pg. 1526, 2014)	FASEB JOURNAL			English	Article; Retracted Publication						gp130; exercise; rhIL-6 infusion; mouse; IL-6 KO	MESSENGER-RNA EXPRESSION; NECROSIS-FACTOR-ALPHA; SIGNAL TRANSDUCER; AUTOCRINE REGULATION; GENE-EXPRESSION; SOLUBLE IL-6; HALF-LIFE; PLASMA; ASSOCIATION; ACTIVATION	Contracting muscle fibers produce and release IL-6, and plasma levels of this cytokine are markedly elevated in response to physical exercise. We recently showed autocrine regulation of IL-6 in human skeletal muscle in vivo and hypothesized that this may involve up-regulation of the IL-6 receptor. Therefore, we investigated IL-6 receptor regulation in response to exercise and IL-6 infusion in humans. Furthermore, using IL-6-deficient mice, we investigated the role of IL-6 in the IL-6 receptor response to exercise. Human skeletal muscle biopsies were obtained in relation to: 3 h of bicycle exercise and rest (n=6+5), or recombinant human IL-6 infusion (rhIL-6) or saline infusion (n=6+6). We further obtained skeletal muscle samples from IL-6 knockout (KO) mice and wild-type C57/BL-6 mice in response to a I-h bout of exercise. In exercising human skeletal muscle, IL-6 receptor mRNA increased sixfold with a peak at 6 h postexercise. Detection of the IL-6 receptor protein by immunohistochemistry revealed a pronounced staining following exercise that was primarily located at the cell membrane of the muscle fibers, whereas muscle gp130 expression and plasma levels of soluble IL-6 receptor were unaffected. Infusion of rhIL-6 to humans had no effect on the mRNA level of the IL-6 receptor, whereas there was an increase at the protein level. IL-6 receptor mRNA increased similarly in muscle of both IL-6 KO mice and wild-type mice in response to exercise. In conclusion, exercise increases IL-6 receptor production in human skeletal muscle. This effect is most prominent 6 h after the end of the exercise bout, suggesting a postexercise-sensitizing mechanism to IL-6 when plasma IL-6 is concomitantly low. Exercise-induced increases in IL-6 receptor mRNA most likely occurs via an IL-6 independent mechanism as shown in IL-6 KO mice and the human rhIL-6 infusion study, whereas IL-6 receptor protein levels are responsive to elevated plasma IL-6 levels.	Univ Copenhagen Hosp, Dept Infect Dis, Ctr Inflammat & Metab, Copenhagen, Denmark; Univ Copenhagen Hosp, Copenhagen Muscle Res Ctr, Copenhagen, Denmark; Univ Copenhagen, Panum Inst, Dept Med Anat, DK-2200 Copenhagen, Denmark; Autonomous Univ Barcelona, Fac Sci, Anim Physiol Unit, E-08193 Barcelona, Spain	University of Copenhagen; University of Copenhagen; University of Copenhagen; Autonomous University of Barcelona	Keller, P (corresponding author), Univ Hosp, Rigshosp, Dept Infect Dis, Tagensvej 20, DK-2200 Copenhagen, Denmark.	pernillekeller@yahoo.com	Pedersen, Bente Klarlund/AGR-3217-2022; Hidalgo, Juan/C-9082-2011; Giralt, Mercedes/K-1626-2014	Pedersen, Bente Klarlund/0000-0001-6508-6288; Hidalgo, Juan/0000-0003-0921-1122; Giralt, Mercedes/0000-0002-1806-1528; Fischer, Christian/0000-0002-0657-9143				BAUER J, 1989, J EXP MED, V170, P1537, DOI 10.1084/jem.170.5.1537; Bruunsgaard H, 2004, EXP GERONTOL, V39, P255, DOI 10.1016/j.exger.2003.10.012; CASTELL JV, 1988, EUR J BIOCHEM, V177, P357, DOI 10.1111/j.1432-1033.1988.tb14384.x; Fasshauer M, 2003, HORM METAB RES, V35, P147, DOI 10.1055/s-2003-39075; Febbraio MA, 2003, J PHYSIOL-LONDON, V549, P607, DOI 10.1113/jphysiol.2003.042374; Franchimont N, 1997, J CLIN INVEST, V100, P1797, DOI 10.1172/JCI119707; Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847; GEISTERFER M, 1995, CYTOKINE, V7, P503, DOI 10.1006/cyto.1995.0068; GERHARTZ C, 1994, EUR J BIOCHEM, V223, P265, DOI 10.1111/j.1432-1033.1994.tb18991.x; Hiscock N, 2004, FASEB J, V18, P992, DOI 10.1096/fj.03-1259fje; Keller P, 2004, J APPL PHYSIOL, V97, P1309, DOI 10.1152/japplphysiol.00284.2004; Keller P, 2003, BIOCHEM BIOPH RES CO, V310, P550, DOI 10.1016/j.bbrc.2003.09.048; Klouche M, 1999, J IMMUNOL, V163, P4583; Kubaszek A, 2003, DIABETES, V52, P558, DOI 10.2337/diabetes.52.2.558; Lu H, 2001, FASEB J, V15, pA6; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; MullerNewen G, 1996, EUR J BIOCHEM, V236, P837, DOI 10.1111/j.1432-1033.1996.00837.x; Ostrowski K, 1998, J PHYSIOL-LONDON, V513, P889, DOI 10.1111/j.1469-7793.1998.889ba.x; Path G, 2001, J CLIN ENDOCR METAB, V86, P2281, DOI 10.1210/jc.86.5.2281; Penkowa M, 2003, FASEB J, V17, DOI 10.1096/fj.03-0311fje; Peters M, 1996, J EXP MED, V183, P1399, DOI 10.1084/jem.183.4.1399; Peters M, 1997, J EXP MED, V185, P755, DOI 10.1084/jem.185.4.755; Pilegaard H, 2000, AM J PHYSIOL-ENDOC M, V279, pE806; SAITO M, 1992, J IMMUNOL, V148, P4066; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Steensberg A, 2000, J PHYSIOL-LONDON, V529, P237, DOI 10.1111/j.1469-7793.2000.00237.x; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; Takizawa H, 1996, AM J PHYSIOL-LUNG C, V270, pL346, DOI 10.1152/ajplung.1996.270.3.L346; Terry CF, 2000, J BIOL CHEM, V275, P18138, DOI 10.1074/jbc.M000379200; Thabard W, 2001, CYTOKINE, V14, P352, DOI 10.1006/cyto.2001.0911; van Hall G, 2003, J CLIN ENDOCR METAB, V88, P3005, DOI 10.1210/jc.2002-021687; Van Wagoner NJ, 1999, J NEUROSCI, V19, P5236; Vionnet N, 2000, AM J HUM GENET, V67, P1470, DOI 10.1086/316887; Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102-75; Wolford JK, 2003, MOL GENET METAB, V80, P338, DOI 10.1016/j.ymgme.2003.07.003; Zhang Y, 2000, AM J PHYSIOL-ENDOC M, V279, pE196, DOI 10.1152/ajpendo.2000.279.1.E196; ZOHLNHOFER D, 1992, FEBS LETT, V306, P219, DOI 10.1016/0014-5793(92)81004-6	39	59	62	2	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1181	+		10.1096/fj.04-3278fje	http://dx.doi.org/10.1096/fj.04-3278fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15837717				2022-12-28	WOS:000228865300013
J	Tong, H; Bernstein, D; Murphy, E; Steenbergen, C				Tong, H; Bernstein, D; Murphy, E; Steenbergen, C			The role of beta-adrenergic receptor signaling in cardioprotection	FASEB JOURNAL			English	Article						Gs protein; PKA; ischemic preconditioning	PROTEIN-KINASE-A; BETA(2)-ADRENERGIC RECEPTOR; G(I) PROTEINS; HEART; PHOSPHORYLATION; REPERFUSION; INHIBITION; ISCHEMIA; SYSTEM; INJURY	This study examines the role of the Beta2-adrenergic receptor (Beta2-AR) in cardioprotection. The Beta2-AR couples to Gs and Gi proteins. Gs activates PKA, which phosphorylates the receptor and switches Beta2-AR coupling from Gs to Gi. Prior to 20 min of global ischemia, mouse hearts were either perfused for 30 min without treatment (control), treated with 10 nmol/L of isoproterenol (ISO) for 5 min followed by 5 min washout, or preconditioned with 4 cycles of 5 min ischemia and 5 min reflow (PC). Recovery of left ventricular developed pressure (LVDP) and infarct size were measured. Intermittent ISO treatment improved post-ischemic recovery of LVDP (58.5+/-4.8% vs. 22.0+/-6.3% in control) and reduced infarct size (31.0+/-2.4% vs. 53.0+/-4.6% in control). The Gi inhibitor pertussis toxin blocked the ISO-induced improvement in postischemic LVDP and infarct size. To test the role of Beta2-AR in PC, we studied mice lacking Beta2-AR (Beta2-AR-/-) and found that PC had no effect on postischemic LVDP or infarct size in Beta2-AR-/-. To test whether PKA is required for the PC and ISO-induced protection, hearts were treated with the PKA inhibitors PKI and H-89. We found that PKI and H-89 blocked the PC- and ISO-induced improvement in postischemic LVDP and infarct size. These data show an important role for Beta2-AR in cardioprotection and support the novel hypothesis that preconditioning involves switching of Beta2-AR coupling from Gs to Gi.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Stanford Univ, Dept Pediat, Stanford, CA USA; NIEHS, Lab Signal Transduct, Res Triangle Pk, NC USA	Duke University; Stanford University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Steenbergen, C (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.	steen001@mc.duke.edu		Bernstein, Daniel/0000-0001-7761-5853	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039752, R29HL039752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES010004] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-51535, R01 HL039752, HL-39752] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAXTER GF, 1994, CIRCULATION, V90, P2993, DOI 10.1161/01.CIR.90.6.2993; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Chruscinski AJ, 1999, J BIOL CHEM, V274, P16694, DOI 10.1074/jbc.274.24.16694; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Diaz RJ, 1997, J MOL CELL CARDIOL, V29, P129, DOI 10.1006/jmcc.1996.0258; Frances C, 2003, J CARDIOVASC PHARM, V41, P396, DOI 10.1097/00005344-200303000-00008; Gabel SA, 2001, AM J PHYSIOL-HEART C, V280, pH1963, DOI 10.1152/ajpheart.2001.280.5.H1963; Gauthier C, 2000, TRENDS PHARMACOL SCI, V21, P426, DOI 10.1016/S0165-6147(00)01562-5; Harris TE, 1997, BIOCHEM BIOPH RES CO, V232, P648, DOI 10.1006/bbrc.1997.6344; Lochner A, 1999, CIRCULATION, V100, P958, DOI 10.1161/01.CIR.100.9.958; Lohse MJ, 2003, CIRC RES, V93, P896, DOI 10.1161/01.RES.0000102042.83024.CA; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nomura Y, 2003, MOL CELL BIOCHEM, V248, P179, DOI 10.1023/A:1024100722413; Oldenburg O, 2002, CARDIOVASC RES, V55, P544, DOI 10.1016/S0008-6363(02)00332-2; Schultz JEJ, 1996, CIRC RES, V78, P1100, DOI 10.1161/01.RES.78.6.1100; Sichelschmidt OJ, 2003, CARDIOVASC RES, V58, P602, DOI 10.1016/S0008-6363(03)00261-X; Tong HY, 2004, CIRC RES, V94, P1133, DOI 10.1161/01.RES.0000126048.32383.6B; Xiao RP, 2000, CIRC RES, V87, P635, DOI 10.1161/01.RES.87.8.635; XIAO RP, 2001, BETA ADRENERGIC SIGN; Zamah AM, 2002, J BIOL CHEM, V277, P31249, DOI 10.1074/jbc.M202753200; Zheng M, 2000, J BIOL CHEM, V275, P40635, DOI 10.1074/jbc.M006325200	22	60	65	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					983	+		10.1096/fj.04-3067fje	http://dx.doi.org/10.1096/fj.04-3067fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15802488				2022-12-28	WOS:000227901300041
J	Wolinetz, C				Wolinetz, Carrie			FASEB opposes using science classes to teach intelligent design, creationism, and other non-scientific beliefs	FASEB JOURNAL			English	Editorial Material									FASEB Off Publ Affairs, Bethesda, MD 20814 USA		Wolinetz, C (corresponding author), FASEB Off Publ Affairs, 9650 Rockville Pike, Bethesda, MD 20814 USA.	cwolinetz@faseb.org							0	0	0	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2006	20	3					408	409		10.1096/fj.06-0302ufm	http://dx.doi.org/10.1096/fj.06-0302ufm			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	074LY	16507756				2022-12-28	WOS:000239815100002
J	Ogasawara, J; Sanpei, M; Rahman, N; Sakurai, T; Kizaki, T; Hitomi, Y; Ohno, H; Izawa, T				Ogasawara, Junetsu; Sanpei, Minori; Rahman, Nazibur; Sakurai, Tomonobu; Kizaki, Takako; Hitomi, Yoshiaki; Ohno, Hideki; Izawa, Tetsuya			beta-Adrenergic receptor trafficking by exercise in rat adipocytes: roles of G-protein-coupled receptor kinase-2, beta-arrestin-2, and the ubiquitin-proteasome pathway	FASEB JOURNAL			English	Article									[Ogasawara, Junetsu; Sanpei, Minori; Rahman, Nazibur; Sakurai, Tomonobu; Izawa, Tetsuya] Tokyo Metropolitan Univ, Grad Sch Sci, Dept Kinesiol, Tokyo 1920397, Japan; [Kizaki, Takako; Hitomi, Yoshiaki; Ohno, Hideki] Kyorin Univ, Sch Med, Dept Mol Predict Med & Sport Sci, Tokyo, Japan	Tokyo Metropolitan University; Kyorin University	Izawa, T (corresponding author), Tokyo Metropolitan Univ, Grad Sch Sci, Dept Kinesiol, 1-1 Minami Ohsawa, Tokyo 1920397, Japan.	izawa@comp.metro-u.ac.jp		Izawa, Tetsuya/0000-0001-5197-9085					0	10	10	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					350	352		10.1096/fj.05-4688fje	http://dx.doi.org/10.1096/fj.05-4688fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16368719				2022-12-28	WOS:000207915000018
J	Billington, RA; Bellomo, EA; Floriddia, EM; Erriquez, J; Distasi, C; Genazzani, AA				Billington, RA; Bellomo, EA; Floriddia, EM; Erriquez, J; Distasi, C; Genazzani, AA			A transport mechanism for NAADP in a rat basophilic cell line	FASEB JOURNAL			English	Article						pyridine nucleotides; calcium; RBL-2H3 cell line; cADPR	ADENINE-DINUCLEOTIDE PHOSPHATE; CYCLIC ADP-RIBOSE; SEA-URCHIN EGGS; PANCREATIC-ACINAR-CELLS; CA2+ RELEASE; INOSITOL TRISPHOSPHATE; RYANODINE RECEPTOR; MOBILIZES CA2+; BETA-CELLS; CALCIUM	NAADP is a second messenger that releases Ca2+ from intracellular stores. Surprisingly, it has been recently shown that extracellular application of NAADP is capable of inducing intracellular Ca2+ release. This is particularly important since the only mammalian enzymes known to catalyze the synthesis of this second messenger are located extracellularly. In the present manuscript, we have investigated whether mammalian cells possess a transport system capable of transporting this highly charged molecule into cells. Indeed, in RBL-2H3 cells, a rat basophilic cell line, and in SK-N-BE cells, a neuroblastoma cell line, [P-32]NAADP is efficiently transported inside cells. NAADP transport is Na+ and Ca2+ dependent, is partially blocked by dipyridamole, but is unaffected by nitrobenzylthioinosine. RBL-2H3 cells also transport [P-32] cADPR, but the differences in the pharmacological profile suggest that NAADP transport proceeds by a novel mechanism. Lastly, extracellular application of NAADP, but not NADP, induced a raise in intracellular Ca2+. This is the first demonstration that NAADP is transported into cells and highlights the possibility that, alongside a second messenger, NAADP might also act as an autocrine/paracrine signal.	DiSCAFF, I-28100 Novara, Italy; Univ Piemonte Orientale, DFB Ctr, I-28100 Novara, Italy	University of Eastern Piedmont Amedeo Avogadro	Billington, RA (corresponding author), DiSCAFF, Via Bovio 6, I-28100 Novara, Italy.	billington@pharm.unipmn.it	Billington, Richard/HGB-1970-2022; Genazzani, Armando/AAI-8280-2020; Distasi, Carla/AAE-1839-2021	Distasi, Carla/0000-0001-8815-3252; Floriddia, Elisa/0000-0003-2304-8114; Billington, Richard/0000-0001-7288-8916; Genazzani, Armando/0000-0003-1923-7430; erriquez, jessica/0000-0002-7152-0930; Bellomo, Elisa/0000-0003-4823-2209				Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; Adebanjo OA, 1999, NAT CELL BIOL, V1, P409, DOI 10.1038/15640; Albrieux M, 1998, J BIOL CHEM, V273, P14566, DOI 10.1074/jbc.273.23.14566; Bak J, 2001, CURR BIOL, V11, P987, DOI 10.1016/S0960-9822(01)00269-X; Billington RA, 2000, BIOCHEM BIOPH RES CO, V276, P112, DOI 10.1006/bbrc.2000.3444; Billington RA, 2002, J PHYSIOL-LONDON, V544, P107, DOI 10.1113/jphysiol.2002.030098; Cancela JM, 2002, EMBO J, V21, P909, DOI 10.1093/emboj/21.5.909; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; CHINI EN, 1995, J BIOL CHEM, V270, P3216, DOI 10.1074/jbc.270.7.3216; Churamani D, 2004, BIOCHEM J, V380, P449, DOI 10.1042/BJ20031754; Churchill GC, 2003, CURR BIOL, V13, P125, DOI 10.1016/S0960-9822(03)00002-2; Churchill GC, 2002, CELL, V111, P703, DOI 10.1016/S0092-8674(02)01082-6; De Flora A, 1997, INT J BIOCHEM CELL B, V29, P1149, DOI 10.1016/S1357-2725(97)00062-9; Franco L, 2001, J BIOL CHEM, V276, P21642, DOI 10.1074/jbc.M010536200; Galione A, 2005, MOL INTERV, V5, P73, DOI 10.1124/mi.5.2.4; Genazzani AA, 2002, CURR BIOL, V12, pR432, DOI 10.1016/S0960-9822(02)00918-1; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; Gerasimenko JV, 2003, J CELL BIOL, V163, P271, DOI 10.1083/jcb.200306134; Guida L, 2004, J BIOL CHEM, V279, P22066, DOI 10.1074/jbc.M314137200; Guida L, 2002, J BIOL CHEM, V277, P47097, DOI 10.1074/jbc.M207793200; Guse Andreas H., 2002, Current Molecular Medicine (Hilversum), V2, P273, DOI 10.2174/1566524024605707; Heidemann AC, 2005, J BIOL CHEM, V280, P35630, DOI 10.1074/jbc.M507338200; Hohenegger M, 1999, BRIT J PHARMACOL, V128, P1235, DOI 10.1038/sj.bjp.0702935; Lee HC, 2004, CURR MOL MED, V4, P227, DOI 10.2174/1566524043360753; Lee HC, 1998, BBA-GEN SUBJECTS, V1425, P263, DOI 10.1016/S0304-4165(98)00079-8; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; Mitchell KJ, 2003, J BIOL CHEM, V278, P11057, DOI 10.1074/jbc.M210257200; Patel S, 2000, J BIOL CHEM, V275, P36495, DOI 10.1074/jbc.C000458200; Santella L, 2000, J BIOL CHEM, V275, P8301, DOI 10.1074/jbc.275.12.8301; Schuber F, 2004, CURR MOL MED, V4, P249, DOI 10.2174/1566524043360708; Thomas JM, 2001, BIOCHEM J, V359, P451, DOI 10.1042/0264-6021:3590451; Thorn JA, 1996, GEN PHARMACOL, V27, P613, DOI 10.1016/0306-3623(95)02053-5; Yamasaki M, 2005, CURR BIOL, V15, P874, DOI 10.1016/j.cub.2005.04.033; Yamasaki M, 2004, J BIOL CHEM, V279, P7234, DOI 10.1074/jbc.M311088200	36	41	41	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					521	+		10.1096/fj.05-5058fje	http://dx.doi.org/10.1096/fj.05-5058fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16403787				2022-12-28	WOS:000235996000029
J	Ledda-Columbano, GM; Molotzu, F; Pibiri, M; Cossu, C; Perra, A; Columbano, A				Ledda-Columbano, GM; Molotzu, F; Pibiri, M; Cossu, C; Perra, A; Columbano, A			Thyroid hormone induces cyclin D1 nuclear translocation and DNA synthesis in adult rat cardiomyocytes	FASEB JOURNAL			English	Article						T3; BrdU; cyclins	HEPATOCYTE PROLIFERATION; CELL-PROLIFERATION; IN-VIVO; RETINOBLASTOMA PROTEIN; EXPRESSION; HYPERTROPHY; HEART; PHOSPHORYLATION; RECEPTOR; GENES	Although mammalian cardiomyocytes lose their proliferative capacity after birth, there is evidence that postmitotic cardiomyocytes can proliferate provided that cyclin D1 accumulates in the nucleus. Here we show by Northern blot, Western analysis, and immunohistochemistry that 3,5,3'-triiodothyronine (T3) treatment of adult rats caused an increase of cyclin D1 mRNA and protein levels. The increased cyclin D1 protein content was associated with its translocation into the nucleus of cardiomyocytes. These changes were accompanied by the re-entry of cardiomyocytes into the cell cycle, as demonstrated by increased levels of cyclin A, PCNA, and incorporation of bromodeoxyuridine into DNA (labeling index was 30.2% in T3-treated rats vs. 2.2% in controls). Entry into the S phase was associated with an increased mitotic activity as demonstrated by positivity of cardiomyocyte nuclei to antibodies anti-phosphohistone-3, a specific marker of the mitotic phase (mitotic index was 3.01/1000 cardiomyocte nuclei in hyperthyroid rats vs. 0.04 in controls). No biochemical or histological signs of tissue damage were observed in the heart of T3-treated rats. These results demonstrated that T3 treatment is associated with a re-entry of cardiomyocytes into the cell cycle and so may be important for the development of future therapeutic strategies aimed at inducing proliferation of cardiomyocytes.-Ledda-Columbano, G. M., Molotzu, F., Pibiri, M., Cossu, C., Perra, A., Columbano, A. Thyroid hormone induces cyclin D1 nuclear translocation and DNA synthesis in adult rat cardiomyocytes.	Univ Cagliari, Dept Toxicol, Oncol & Mol Pathol Unit, Sez Oncol & Patol Mol, I-09124 Cagliari, Italy	University of Cagliari	Ledda-Columbano, GM (corresponding author), Univ Cagliari, Dept Toxicol, Oncol & Mol Pathol Unit, Sez Oncol & Patol Mol, Via Porcell 4, I-09124 Cagliari, Italy.	gmledda@unica.it	Columbano, Amedeo/C-7463-2011	Columbano, Amedeo/0000-0002-6956-9030; PIBIRI, MONICA/0000-0002-9660-9616				Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; Antos CL, 2003, J BIOL CHEM, V278, P28930, DOI 10.1074/jbc.M303113200; ASTORRI E, 1977, J MOL CELL CARDIOL, V9, P763, DOI 10.1016/S0022-2828(77)80021-7; Barrera-Hernandez G, 1999, ENDOCRINOLOGY, V140, P5267, DOI 10.1210/en.140.11.5267; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Busk PK, 2002, CARDIOVASC RES, V56, P64, DOI 10.1016/S0008-6363(02)00510-2; Chaudhry HW, 2004, J BIOL CHEM, V279, P35858, DOI 10.1074/jbc.M404975200; De K, 2004, J ENDOCRINOL, V182, P303, DOI 10.1677/joe.0.1820303; DILLMANN WH, 1990, AM J MED, V88, P626, DOI 10.1016/0002-9343(90)90530-Q; Flink IL, 1998, J MOL CELL CARDIOL, V30, P563, DOI 10.1006/jmcc.1997.0620; FRANCAVILLA A, 1994, HEPATOLOGY, V20, P1237, DOI 10.1002/hep.1840200521; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Garcia-Silva S, 2004, MOL CELL BIOL, V24, P7514, DOI 10.1128/MCB.24.17.7514-7523.2004; Gonzalez-Sancho JM, 2002, MOL CARCINOGEN, V34, P25, DOI 10.1002/mc.10046; Hasmall S, 2001, ARCH TOXICOL, V75, P357, DOI 10.1007/s002040100246; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; JACKSON T, 1991, MOL CELL BIOCHEM, V104, P15; Kajstura J, 1998, P NATL ACAD SCI USA, V95, P8801, DOI 10.1073/pnas.95.15.8801; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; Klein I, 2001, NEW ENGL J MED, V344, P501, DOI 10.1056/NEJM200102153440707; KLEIN I, 1986, J CLIN INVEST, V77, P1694, DOI 10.1172/JCI112488; KLEIN I, 1988, ENDOCRINOLOGY, V123, P203, DOI 10.1210/endo-123-1-203; Ledda-Columbano GM, 2005, J ENDOCRINOL, V185, P393, DOI 10.1677/joe.1.06110; Ledda-Columbano GM, 1998, ONCOGENE, V17, P1039, DOI 10.1038/sj.onc.1202018; Liao HS, 2001, CIRC RES, V88, P443; Lin HM, 2002, J BIOL CHEM, V277, P28733, DOI 10.1074/jbc.M203380200; LINZBACH AJ, 1960, AM J CARDIOL, V5, P370, DOI 10.1016/0002-9149(60)90084-9; LORTET S, 1989, J CARDIOVASC PHARM, V14, P707, DOI 10.1097/00005344-198911000-00006; MORKIN E, 1993, CIRCULATION, V87, P1451, DOI 10.1161/01.CIR.87.5.1451; Natsume H, 2003, BIOCHEM BIOPH RES CO, V309, P408, DOI 10.1016/j.bbrc.2003.08.019; Ohmura T, 1996, LIFE SCI, V58, pPL211, DOI 10.1016/0024-3205(96)00039-2; Ojamaa K, 2000, ENDOCRINOLOGY, V141, P2139, DOI 10.1210/en.141.6.2139; OJAMAA K, 1992, AM J PHYSIOL, V263, pE534, DOI 10.1152/ajpendo.1992.263.3.E534; Pasumarthi KBS, 2005, CIRC RES, V96, P110, DOI 10.1161/01.RES.0000152326.91223.4F; Pibiri M, 2001, FASEB J, V15, P1006, DOI 10.1096/fj.00-0416com; Poolman RA, 1999, CIRC RES, V85, P117, DOI 10.1161/01.RES.85.2.117; Sadoshima J, 1997, CIRC RES, V80, P228, DOI 10.1161/01.RES.80.2.228; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Soonpaa MH, 1997, J CLIN INVEST, V99, P2644, DOI 10.1172/JCI119453; Soonpaa MH, 1998, CIRC RES, V83, P15, DOI 10.1161/01.RES.83.1.15; TAMALE-SALI E G, 1992, Journal of Obstetrics and Gynaecology (Abingdon), V12, P19, DOI 10.3109/01443619209029911; Tamamori M, 1998, AM J PHYSIOL-HEART C, V275, pH2036, DOI 10.1152/ajpheart.1998.275.6.H2036; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; von Harsdorf R, 2004, LANCET, V363, P1306, DOI 10.1016/S0140-6736(04)16006-6; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	47	34	37	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					87	94		10.1096/fj.05-4202com	http://dx.doi.org/10.1096/fj.05-4202com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16394271				2022-12-28	WOS:000235996000048
J	Coffey, VG; Zhong, ZH; Shield, A; Canny, BJ; Chibalin, AV; Zierath, JR; Hawley, JA				Coffey, VG; Zhong, ZH; Shield, A; Canny, BJ; Chibalin, AV; Zierath, JR; Hawley, JA			Early signaling responses to divergent exercise stimuli in skeletal muscle from well-trained humans	FASEB JOURNAL			English	Article						adaptation; endurance; hypertrophy; plasticity	ACTIVATED PROTEIN-KINASE; GLYCOGEN-SYNTHASE KINASE-3; MAMMALIAN TARGET; RESISTANCE EXERCISE; BIOCHEMICAL ADAPTATIONS; MYOTUBE HYPERTROPHY; GENE-EXPRESSION; MESSENGER-RNA; FIBER-TYPE; INSULIN	Skeletal muscle from strength- and endurance-trained individuals represents diverse adaptive states. In this regard, AMPK-PGC-1 alpha signaling mediates several adaptations to endurance training, while up-regulation of the Akt-TSC2-mTOR pathway may underlie increased protein synthesis after resistance exercise. We determined the effect of prior training history on signaling responses in seven strength- trained and six endurance-trained males who undertook 1 h cycling at 70% VO2peak or eight sets of five maximal repetitions of isokinetic leg extensions. Muscle biopsies were taken at rest, immediately and 3 h postexercise. AMPK phosphorylation increased after cycling in strength- trained (54%; P<0.05) but not endurance-trained subjects. Conversely, AMPK was elevated after resistance exercise in endurance-(114%; P<0.05), but not strength-trained subjects. Akt phosphorylation increased in endurance- (50%; P<0.05), but not strength-trained subjects after cycling but was unchanged in either group after resistance exercise. TSC2 phosphorylation was decreased (47%; P<0.05) in endurance- trained subjects following resistance exercise, but cycling had little effect on the phosphorylation state of this protein in either group. p70S6K phosphorylation increased in endurance- (118%; P<0.05), but not strength- trained subjects after resistance exercise, but was similar to rest in both groups after cycling. Similarly, phosphorylation of S6 protein, a substrate for p70 S6K, was increased immediately following resistance exercise in endurance- (129%; P<0.05), but not strength- trained subjects. In conclusion, a degree of "response plasticity" is conserved at opposite ends of the endurance-hypertrophic adaptation continuum. Moreover, prior training attenuates the exercise specific signaling responses involved in single mode adaptations to training.	RMIT Univ, Sch Med Sci, Bundoora, Vic 3083, Australia; Karolinska Inst, Dept Surg Sci, Stockholm, Sweden; Monash Univ, Dept Physiol, Clayton, Vic 3168, Australia	Royal Melbourne Institute of Technology (RMIT); Karolinska Institutet; Monash University	Hawley, JA (corresponding author), RMIT Univ, Sch Med Sci, POB 71, Bundoora, Vic 3083, Australia.	john.hawley@rmit.edu.au	Hawley, John A/U-3814-2018	Hawley, John A/0000-0002-0886-9881; Zierath, Juleen/0000-0001-6891-7497; Chibalin, Alexander/0000-0002-6339-6271; Shield, Anthony/0000-0002-0393-2466				ALLEN TE, 1976, RES QUART, V47, P299, DOI 10.1080/10671315.1976.10615376; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Aschenbach WG, 2004, SPORTS MED, V34, P91, DOI 10.2165/00007256-200434020-00003; ATHERTON PJ, 2005, FASEB J; Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com; Baar K, 1999, Exerc Sport Sci Rev, V27, P333; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; BOOTH FW, 1991, PHYSIOL REV, V71, P541, DOI 10.1152/physrev.1991.71.2.541; Creer A, 2005, J APPL PHYSIOL, V99, P950, DOI 10.1152/japplphysiol.00110.2005; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; EVANS WJ, 1982, MED SCI SPORT EXER, V14, P101; Glass DJ, 2003, NAT CELL BIOL, V5, P87, DOI 10.1038/ncb0203-87; Hawley JA, 2002, CLIN EXP PHARMACOL P, V29, P218, DOI 10.1046/j.1440-1681.2002.03623.x; HICKSON RC, 1980, EUR J APPL PHYSIOL O, V45, P255, DOI 10.1007/BF00421333; Higginson J, 2002, PFLUG ARCH EUR J PHY, V445, P437, DOI 10.1007/s00424-002-0939-1; Holloszy J O, 1977, Ann N Y Acad Sci, V301, P440, DOI 10.1111/j.1749-6632.1977.tb38220.x; HOLLOSZY JO, 1967, J BIOL CHEM, V242, P2278; Hudson ER, 2003, CURR BIOL, V13, P861, DOI 10.1016/S0960-9822(03)00249-5; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; JORGENSEN SB, 2005, FASEB J; Karlsson HKR, 2004, AM J PHYSIOL-ENDOC M, V287, pE1, DOI 10.1152/ajpendo.00430.2003; Kubica N, 2005, J BIOL CHEM, V280, P7570, DOI 10.1074/jbc.M413732200; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Murgia M, 2000, NAT CELL BIOL, V2, P142, DOI 10.1038/35004013; Nader GA, 2001, J APPL PHYSIOL, V90, P1936, DOI 10.1152/jappl.2001.90.5.1936; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Nielsen JN, 2003, BIOCHEM BIOPH RES CO, V312, P1147, DOI 10.1016/j.bbrc.2003.11.041; Rennie MJ, 2004, ANNU REV PHYSIOL, V66, P799, DOI 10.1146/annurev.physiol.66.052102.134444; Rennie MJ, 2000, ANNU REV NUTR, V20, P457, DOI 10.1146/annurev.nutr.20.1.457; Reynolds TH, 2002, J BIOL CHEM, V277, P17657, DOI 10.1074/jbc.M201142200; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Sakamoto K, 2004, BIOCHEM BIOPH RES CO, V319, P419, DOI 10.1016/j.bbrc.2004.05.020; Sakamoto K, 2002, J APPL PHYSIOL, V93, P369, DOI 10.1152/japplphysiol.00167.2002; Saltin B, 1969, Mal Cardiovasc, V10, P393; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Terada S, 2002, BIOCHEM BIOPH RES CO, V296, P350, DOI 10.1016/S0006-291X(02)00881-1; Thompson HS, 2003, ACTA PHYSIOL SCAND, V178, P61, DOI 10.1046/j.1365-201X.2003.01112.x; Thorell A, 1999, AM J PHYSIOL-ENDOC M, V277, pE733, DOI 10.1152/ajpendo.1999.277.4.E733; Vyas DR, 2002, AM J PHYSIOL-CELL PH, V283, pC545, DOI 10.1152/ajpcell.00049.2002; Wadley GD, 2001, J APPL PHYSIOL, V90, P436, DOI 10.1152/jappl.2001.90.2.436; Widegren U, 1998, FASEB J, V12, P1379, DOI 10.1096/fasebj.12.13.1379; Widegren U, 2001, ACTA PHYSIOL SCAND, V172, P227, DOI 10.1046/j.1365-201x.2001.00855.x; Williamson DL, 2001, J APPL PHYSIOL, V91, P1955, DOI 10.1152/jappl.2001.91.5.1955; Wojtaszewski JFP, 2003, AM J PHYSIOL-ENDOC M, V284, pE813, DOI 10.1152/ajpendo.00436.2002; Wretman C, 2001, J PHYSIOL-LONDON, V535, P155, DOI 10.1111/j.1469-7793.2001.00155.x; Yang YF, 2005, J APPL PHYSIOL, V98, P1745, DOI 10.1152/japplphysiol.01185.2004; Yu M, 2003, J PHYSIOL-LONDON, V546, P327, DOI 10.1113/jphysiol.2002.034223; Zierath JR, 2004, PLOS BIOL, V2, P1523, DOI 10.1371/journal.pbio.0020348	48	243	250	2	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					190	+		10.1096/fj.05-4809fje	http://dx.doi.org/10.1096/fj.05-4809fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16267123				2022-12-28	WOS:000234053100020
J	Fontana, L; Chen, Y; Prijateli, P; Sakai, T; Fassler, R; Sakai, LY; Rifkin, DB				Fontana, L; Chen, Y; Prijateli, P; Sakai, T; Fassler, R; Sakai, LY; Rifkin, DB			Fibronectin is required for integrin alpha v beta 6-mediated activation of latent TGF-beta complexes containing LTBP-1	FASEB JOURNAL			English	Article						LTBP; TGF-beta; fibronectin null cells	GROWTH-FACTOR-BETA; EXTRACELLULAR-MATRIX; BINDING-PROTEIN; TRANSFORMING GROWTH-FACTOR-BETA-1; ALPHA-5-BETA-1 INTEGRIN; CULTURED FIBROBLASTS; IN-VITRO; CELLS; EXPRESSION; TGF-BETA-1	Transforming growth factor-beta s (TGF-beta) are secreted as latent complexes consisting of the TGF-beta dimer, the TGF-beta propeptide dimer, and the latent TGF-beta binding protein ( LTBP). Although the bonds between TGF-beta and its propeptide are cleaved intracellulary, the propeptide associates with TGF-beta by electrostatic interactions, thereby conferring latency to the complex. We reported that a specific sequence of LTBP-1 is required for latent TGF-beta activation by the integrin alpha v beta 6. Here we describe a 24 amino acid sequence from the hinge domain required for activation. The LTBP-1 polypeptide rL1N, which includes the hinge, associates with fibronectin in binding assays. We present evidence that fibronectin null cells minimally activate latent TGF-beta and poorly incorporate the active hinge sequence into their matrix. In addition, cells missing the fibronectin receptor alpha 5 beta 1 exhibit defective activation of latent TGF-beta by alpha v beta 6 and decreased matrix incorporation. The results indicate specificity for integrin-mediated latent TGF-beta activation that include unique sequences in LTBP-1 and an appropriate matrix molecule.	NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA; Oregon Hlth & Sci Univ, Shriners Hosp Children, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Dept Mol Med, Martinsried, Germany	New York University; New York University; Oregon Health & Science University; Oregon Health & Science University; Max Planck Society	Rifkin, DB (corresponding author), NYU, Sch Med, Dept Cell Biol, 550 1st Ave, New York, NY 10016 USA.	rifkid01@med.nyu.edu			NATIONAL CANCER INSTITUTE [R01CA078422, R01CA034282] Funding Source: NIH RePORTER; NCI NIH HHS [CA78422, CA34282] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Annes JP, 2004, J CELL BIOL, V165, P723, DOI 10.1083/jcb.200312172; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; BALZA E, 1988, FEBS LETT, V228, P42, DOI 10.1016/0014-5793(88)80580-5; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Brownh PD, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037500; Cai T, 2000, BIOCHEM BIOPH RES CO, V274, P519, DOI 10.1006/bbrc.2000.3177; Collo G, 1999, J CELL SCI, V112, P569; Dallas SL, 2005, J BIOL CHEM, V280, P18871, DOI 10.1074/jbc.M410762200; Dallas SL, 2000, J BONE MINER RES, V15, P68, DOI 10.1359/jbmr.2000.15.1.68; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; FFRENCHCONSTANT C, 1995, EXP CELL RES, V221, P261, DOI 10.1006/excr.1995.1374; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Gohongi T, 1999, NAT MED, V5, P1203, DOI 10.1038/13524; Huang XZ, 1998, J CELL SCI, V111, P2189; Huang XZ, 1996, J CELL BIOL, V133, P921, DOI 10.1083/jcb.133.4.921; HYNES RO, 1982, J CELL BIOL, V95, P369, DOI 10.1083/jcb.95.2.369; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Isogai Z, 2003, J BIOL CHEM, V278, P2750, DOI 10.1074/jbc.M209256200; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; Koli K, 2001, MICROSC RES TECHNIQ, V52, P354, DOI 10.1002/1097-0029(20010215)52:4<354::AID-JEMT1020>3.0.CO;2-G; KORNBLIHTT AR, 1984, EMBO J, V3, P221, DOI 10.1002/j.1460-2075.1984.tb01787.x; LYON M, 1994, J BIOL CHEM, V269, P11216; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Mazzieri R, 2000, METH MOL B, V142, P13; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; Mu DZ, 2002, J CELL BIOL, V157, P493, DOI 10.1083/jcb.200109100; MULLER G, 1987, P NATL ACAD SCI USA, V84, P5600, DOI 10.1073/pnas.84.16.5600; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Munger JS, 1998, MOL BIOL CELL, V9, P2627, DOI 10.1091/mbc.9.9.2627; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; Nunes I, 1997, J CELL BIOL, V136, P1151, DOI 10.1083/jcb.136.5.1151; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PARTENHEIMER A, 1995, J IMMUNOL, V155, P5557; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Saharinen J, 2000, MOL BIOL CELL, V11, P2691, DOI 10.1091/mbc.11.8.2691; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; Taipale J, 1996, J HISTOCHEM CYTOCHEM, V44, P875, DOI 10.1177/44.8.8756760; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; Unsold C, 2001, J CELL SCI, V114, P187; Verderio E, 1999, J HISTOCHEM CYTOCHEM, V47, P1417, DOI 10.1177/002215549904701108; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WRANN M, 1987, EMBO J, V6, P1633, DOI 10.1002/j.1460-2075.1987.tb02411.x; WU CY, 1993, J BIOL CHEM, V268, P21883; Yu Q, 2000, GENE DEV, V14, P163	57	132	137	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					1798	1808		10.1096/fj.05-4134com	http://dx.doi.org/10.1096/fj.05-4134com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16260650				2022-12-28	WOS:000234053100032
J	Sonawane, ND; Hu, J; Muanprasat, C; Verkman, AS				Sonawane, ND; Hu, J; Muanprasat, C; Verkman, AS			Luminally active, nonabsorbable CFTR inhibitors as potential therapy to reduce intestinal fluid loss in cholera	FASEB JOURNAL			English	Article						diarrhea; cystic fibrosis; chloride channel; drug discovery	ORAL REHYDRATION SOLUTION; BLIND CLINICAL-TRIAL; CHLORIDE SECRETION; DIARRHEAL DISEASE; CELL-LINE; EFFICACY; TOXIN; MECHANISM; CHANNEL; PORE	Enterotoxin-mediated secretory diarrheas such as cholera involve chloride secretion by enterocytes into the intestinal lumen by the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. We previously identified glycine hydrazide CFTR blockers that by electrophysiological studies appeared to block the CFTR anion pore at its lumen-facing surface. Here, we synthesize highly water-soluble, nonabsorbable malondihydrazides by coupling 2,4-disulfobenzaldehyde, 4-sulfophenylisothiocyante, and polyethylene glycol (PEG) moieties to 2-naphthalenylamino-[(3,5- dibromo-2,4-dihydroxyphenyl) methylene] propanedioic acid dihydrazide, and aminoacethydrazides by coupling PEG to [(N-2-naphthalenyl)-2-(2hydroxyethyl)]-glycine- 2-[(3,5-dibromo-2,4-dihydroxyphenyl) methylene] hydrazide. Compounds rapidly, fully and reversibly blocked CFTR-mediated chloride current with K-i of 2-8 mu M when added to the apical surface of epithelial cell monolayers. Compounds did not pass across Caco-2 monolayers, and were absorbed by < 2%/hr in mouse intestine. Luminally added compounds blocked by > 90% cholera toxin-induced fluid secretion in mouse intestinal loops, without inhibiting intestinal fluid absorption. These orally administered, nonabsorbable, nontoxic CFTR inhibitors may reduce intestinal fluid losses in cholera.	Univ Calif San Francisco, Dept Med, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Dept Med, Cardiovasc Res Inst, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu			NEI NIH HHS [EY-13574] Funding Source: Medline; NHLBI NIH HHS [HL-73854] Funding Source: Medline; NIAID NIH HHS [AI-062530] Funding Source: Medline; NIBIB NIH HHS [EB-00415] Funding Source: Medline; NIDDK NIH HHS [DK-43840, DK35124, DK-72517] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043840, R37DK035124, P30DK072517, R01DK035124] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alam NH, 2003, GUT, V52, P1419, DOI 10.1136/gut.52.10.1419; Alam NH, 2001, PEDIATRICS, V107, P613, DOI 10.1542/peds.107.4.613; Barrett KE, 2000, ANNU REV PHYSIOL, V62, P535, DOI 10.1146/annurev.physiol.62.1.535; BERN C, 1992, B WORLD HEALTH ORGAN, V70, P705; Boedeker EC, 2005, CURR OPIN GASTROEN, V21, P15; CHAO AC, 1994, EMBO J, V13, P1065, DOI 10.1002/j.1460-2075.1994.tb06355.x; Currid A, 2004, J PHYSIOL-LONDON, V555, P241, DOI 10.1113/jphysiol.2003.059295; Dawson David C., 1999, Physiological Reviews, V79, pS47; GABRIEL SE, 1994, SCIENCE, V266, P107, DOI 10.1126/science.7524148; Guerrant RL, 2003, CLIN INFECT DIS, V37, P398, DOI 10.1086/376619; Guiraldes E, 1995, J DIARRHOEAL DIS RES, V13, P207; Khan WA, 2002, LANCET, V360, P1722, DOI 10.1016/S0140-6736(02)11680-1; Kosek M, 2003, B WORLD HEALTH ORGAN, V81, P197; Kunzelmann K, 1999, Rev Physiol Biochem Pharmacol, V137, P1; Kunzelmann K, 2002, PHYSIOL REV, V82, P245, DOI 10.1152/physrev.00026.2001; Ma TH, 2002, J CLIN INVEST, V110, P1651, DOI 10.1172/JCI200216112; McCarty NA, 2000, J EXP BIOL, V203, P1947; Muanprasat C, 2004, J GEN PHYSIOL, V124, P125, DOI 10.1085/jgp.200409059; Pickens JC, 2004, CHEM BIOL, V11, P1205, DOI 10.1016/j.chembiol.2004.06.008; Santosham M, 1996, J PEDIATR-US, V128, P45, DOI 10.1016/S0022-3476(96)70426-2; Sears CL, 1996, MICROBIOL REV, V60, P167, DOI 10.1128/MMBR.60.1.167-215.1996; Sheppard DN, 1997, J PHYSIOL-LONDON, V503, P333, DOI 10.1111/j.1469-7793.1997.333bh.x; Sonawane ND, 2005, J PHARM SCI-US, V94, P134, DOI 10.1002/jps.20228; Svennerholm AM, 2004, BEST PRACT RES CL GA, V18, P421, DOI 10.1016/j.bpg.2003.11.004; Taddei A, 2004, FEBS LETT, V558, P52, DOI 10.1016/S0014-5793(04)00011-0; Thiagarajah JR, 2005, TRENDS PHARMACOL SCI, V26, P172, DOI 10.1016/j.tips.2005.02.003; Thiagarajah JR, 2004, GASTROENTEROLOGY, V126, P511, DOI 10.1053/j.gastro.2003.11.005; THIAGARAJAH JR, 2002, J PHYSL, V536, P541; Zhou Z, 2002, J GEN PHYSIOL, V120, P647, DOI 10.1085/jgp.20028685	29	45	56	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					130	+		10.1096/fj.05-4818fje	http://dx.doi.org/10.1096/fj.05-4818fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16317066				2022-12-28	WOS:000234053100004
J	Fieger, CB; Huang, MC; Van Brocklyn, JR; Goetzl, EJ				Fieger, CB; Huang, MC; Van Brocklyn, JR; Goetzl, EJ			Type 1 sphingosine 1-phosphate G protein-coupled receptor signaling of lymphocyte functions requires sulfation of its extracellular amino-terminal tyrosines	FASEB JOURNAL			English	Article						T cell receptors; lipid mediators; chemotaxis; cytokines	TYROSYLPROTEIN SULFOTRANSFERASE; EXPRESSION	The type 1 sphingosine 1-phosphate (S1P) G protein-coupled receptor (S1P1) transduces signals from S1P that mediate thymocyte emigration, T cell transmigration of lymph nodes, and T cell chemotaxis in tissues. Alterations in expression of functional S1P1 receptors by lymphocytes are the major mechanisms controlling their responses to S1P and were thought to be solely a consequence of the balance between surface down-regulation and insertion. However, results now show that lack of sulfation of tyrosines 19 and 22 of the extracellular N terminus of S1P1 diminishes high-affinity S1P binding and decreases S1P signaling of T cell migration and other functions. Non-sulfatable mutant (Y19,22F) S1P1 endows T cells with lower-affinity binding of [P-32]S1P than wild-type S1P1 and transduces lesser effects of S1P on chemotaxis, chemokine-elicited chemotaxis, and T cell receptor-mediated proliferation and cytokine generation. Inhibition of S1P1 tyrosine sulfation or sulfatase removal of S1P1 sulfate in mouse CD4 T cells suppresses immune functional effects of S1P. Tyrosine sulfation of S1P1 may be a major controller of S1P effects on T cell traffic.	Univ Calif San Francisco, Dept Med Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University System of Ohio; Ohio State University	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Dept Med Microbiol & Immunol, Room UB8B,UC Box 0711,533 Parnassus & 4th Ave, San Francisco, CA 94143 USA.	egoetzl@itsa.ucsf.edu	Van Brocklyn, Jim/A-9733-2010		NHLBI NIH HHS [R01-HL-31809, R01 HL031809, R01 HL031809-22A2, P0-HL68738, P01 HL068738] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068738, R01HL031809] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bannert N, 2001, J EXP MED, V194, P1661, DOI 10.1084/jem.194.11.1661; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Costagliola S, 2002, EMBO J, V21, P504, DOI 10.1093/emboj/21.4.504; Dorsam G, 2003, J IMMUNOL, V171, P3500, DOI 10.4049/jimmunol.171.7.3500; Farzan M, 2002, J BIOL CHEM, V277, P29484, DOI 10.1074/jbc.M203361200; Goetzl EJ, 2004, J CLIN INVEST, V114, P1531, DOI 10.1172/JCI200423704; Graeler M, 2002, FASEB J, V16, P1874, DOI 10.1096/fj.02-0548com; Graeler M, 2002, J IMMUNOL, V169, P4084, DOI 10.4049/jimmunol.169.8.4084; Graeler MH, 2003, J BIOL CHEM, V278, P27737, DOI 10.1074/jbc.C300147200; Grahler MH, 2005, J IMMUNOL, V174, P1997; LEE RWH, 1985, P NATL ACAD SCI USA, V82, P6143, DOI 10.1073/pnas.82.18.6143; LEE RWH, 1983, J BIOL CHEM, V258, P1326; Lo CG, 2005, J EXP MED, V201, P291, DOI 10.1084/jem.20041509; Moore BCJ, 2003, OTOL NEUROTOL, V24, P243, DOI 10.1097/00129492-200303000-00019; Ouyang YB, 1998, P NATL ACAD SCI USA, V95, P2896, DOI 10.1073/pnas.95.6.2896; Sardar VM, 2002, BBA-MOL CELL BIOL L, V1582, P309, DOI 10.1016/S1388-1981(02)00185-3; Tigyi G, 2002, BBA-MOL CELL BIOL L, V1582, pVII, DOI 10.1016/S1388-1981(02)00130-0; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229	18	17	25	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1926	+		10.1096/fj.05-4476fje	http://dx.doi.org/10.1096/fj.05-4476fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16148028	Green Accepted			2022-12-28	WOS:000232315700024
J	Segarra, M; Vilardell, C; Matsumoto, K; Esparza, J; Lozano, E; Serra-Pages, C; Urbano-Marquez, A; Yamada, KM; Cid, MC				Segarra, M; Vilardell, C; Matsumoto, K; Esparza, J; Lozano, E; Serra-Pages, C; Urbano-Marquez, A; Yamada, KM; Cid, MC			Dual function of focal adhesion kinase in regulating integrin-induced MMP-2 and MMP-9 release by human T lymphoid cells	FASEB JOURNAL			English	Article						matrix metalloproteinases; lymphocytes; fibronectin	PROTEIN-TYROSINE KINASE; GTPASE-ACTIVATING PROTEIN; GELATINASE-A MMP-2; N-TERMINAL KINASE; MATRIX METALLOPROTEINASES; B MMP-9; V-SRC; EXPRESSION; FAK; MOTILITY	Integrin engagement induces matrix metalloproteinase (MMP) production by lymphocytes, allowing their progression into tissues. Focal adhesion kinase (FAK) is a key component of integrin-mediated signaling pathways regulating cell migration. We explored the role of FAK in integrin-induced gelatinase production by Jurkat T cells. Elevation of FAK expression by transient transfection increased cell invasiveness and gelatinase production and release driven by fibronectin. FAK point mutants revealed that gelatinase release was not dependent on FAK kinase activity but did require Y397, a binding site for Src-type tyrosine kinases. Requirement of Src kinases was further demonstrated by transfection with Src kinase-deficient mutants and treatment with a Src inhibitor. Transfection of truncated forms demonstrated dual functional elements in the FAK molecule. The FRNK fragment decreased gelatinase release, whereas the FAT subfragment enhanced it. FRNK inhibitory signals were transduced through Src-dependent pCAS phosphorylation and subsequent ERK1/2 activation. In contrast, FAT stimulated gelatinase secretion, which was also dependent on Src-kinase activity, was associated with a decreased ERK1/2 phosphorylation. This dual function of FAK in gelatinase secretion is then associated with changes in ERK1/2 activation status, a pathway coordinating cycles of adhesion/ release required for cell migration and defines a novel regulatory step in the complex control of MMP function.	Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Dept Internal Med, E-08036 Barcelona, Spain; Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Dept Immunol, E-08036 Barcelona, Spain; Natl Inst Dent & Craniofacial Res, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD USA	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Cid, MC (corresponding author), Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Dept Internal Med, Villarroel 170, E-08036 Barcelona, Spain.	mccid@clinic.ub.es	Cid, Maria C./J-4553-2016; Segarra, Marta/ABE-2312-2020; Lozano, Ester/H-2215-2014	Cid, Maria C./0000-0002-4730-0938; Lozano, Ester/0000-0002-6307-9807; Yamada, Kenneth/0000-0003-1512-6805	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000524] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Akagi T, 2002, MOL CELL BIOL, V22, P7015, DOI 10.1128/MCB.22.20.7015-7023.2002; Alexandropoulos K, 2003, IMMUNOL REV, V192, P181, DOI 10.1034/j.1600-065X.2003.00021.x; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cawson T, 1998, MOL MED TODAY, V4, P130, DOI 10.1016/S1357-4310(97)01192-1; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Esparza J, 1999, BLOOD, V94, P2754, DOI 10.1182/blood.V94.8.2754.420k09_2754_2766; Faveeuw C, 2001, BLOOD, V98, P688, DOI 10.1182/blood.V98.3.688; Fiore E, 2002, ONCOGENE, V21, P5213, DOI 10.1038/sj.onc.1205684; Fonseca PM, 2004, CELL SIGNAL, V16, P621, DOI 10.1016/j.cellsig.2003.10.004; Fukata M, 1999, J CELL SCI, V112, P4491; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; ILLC D, 1995, NATURE, V377, P539; Itoh T, 2002, J IMMUNOL, V169, P2643, DOI 10.4049/jimmunol.169.5.2643; Johnatty RN, 1997, J IMMUNOL, V158, P2327; Judson PL, 1999, CANCER, V86, P1551, DOI 10.1002/(SICI)1097-0142(19991015)86:6<1551::AID-CNCR23>3.0.CO;2-P; Katz BZ, 2003, J BIOL CHEM, V278, P29115, DOI 10.1074/jbc.M212396200; Kim MH, 2001, ANTICANCER RES, V21, P45; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; LEPPERT D, 1995, FASEB J, V9, P1473, DOI 10.1096/fasebj.9.14.7589989; Liu GH, 2002, MOL CELL BIOL, V22, P2751, DOI 10.1128/MCB.22.8.2751-2760.2002; Liu SC, 2000, J CELL SCI, V113, P3563; Madri JA, 1996, BIOCHEM CELL BIOL, V74, P749, DOI 10.1139/o96-082; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; McQuibban GA, 2002, BLOOD, V100, P1160, DOI 10.1182/blood.V100.4.1160.h81602001160_1160_1167; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; NOJIMA Y, 1995, CELL IMMUNOL, V161, P8, DOI 10.1006/cimm.1995.1002; Oktay MH, 2003, HUM PATHOL, V34, P240, DOI 10.1053/hupa.2003.40; Opdenakker G, 2001, J LEUKOCYTE BIOL, V69, P851; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Owen JL, 2003, J IMMUNOL, V171, P4340, DOI 10.4049/jimmunol.171.8.4340; OWENS LV, 1995, CANCER RES, V55, P2752; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Ren XD, 2000, J CELL SCI, V113, P3673; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; ROMANIC AM, 1994, J CELL BIOL, V125, P1165, DOI 10.1083/jcb.125.5.1165; Ruest PJ, 2001, MOL CELL BIOL, V21, P7641, DOI 10.1128/MCB.21.22.7641-7652.2001; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Schnaeker EM, 2004, CANCER RES, V64, P8924, DOI 10.1158/0008-5472.CAN-04-0324; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Taylor JM, 1998, J BIOL CHEM, V273, P8063, DOI 10.1074/jbc.273.14.8063; Tran H, 2002, J CELL SCI, V115, P2031; Trocme C, 1998, J BIOL CHEM, V273, P20677, DOI 10.1074/jbc.273.32.20677; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wahlgren J, 2001, J PATHOL, V194, P217, DOI 10.1002/path.854; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Xia MH, 1996, J IMMUNOL, V156, P160; Yakubenko VP, 2000, EXP CELL RES, V260, P73, DOI 10.1006/excr.2000.5002	71	52	56	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1875	+		10.1096/fj.04-3574fje	http://dx.doi.org/10.1096/fj.04-3574fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16260653				2022-12-28	WOS:000232315700009
J	Joshi, MB; Philippova, M; Ivanov, D; Allenspach, R; Erne, P; Resink, TSJ				Joshi, MB; Philippova, M; Ivanov, D; Allenspach, R; Erne, P; Resink, TSJ			T-cadherin protects endothelial cells from oxidative stress-induced apoptosis	FASEB JOURNAL			English	Article						serum-withdrawal; survival; signaling	SMOOTH-MUSCLE; DOWN-REGULATION; N-CADHERIN; EXPRESSION; ADHESION; SURVIVAL; GROWTH; DEATH; ACTIVATION; SIGNAL	In vascular tissue, T-cadherin (T-cad) is up-regulated in vivo under disease conditions associated with oxidative stress and concomitant cell migration, proliferation and apoptosis/ survival. Using cultures of human umbilical vein endothelial cells (HUVEC), we examined whether there is a functional relationship between oxidative stress, T-cad expression, and cell survival status. Culture of HUVEC under conditions of oxidative stress (e. g., serum deprivation, inclusion of H2O2) resulted in increased T-cad expression. Oxidative stress-induced increases in T-cad were inhibited by the free radical-scavenging antioxidant, N-acetylcysteine, and the flavin-containing oxidase inhibitor, diphenyleneiodonium. Thus reactive oxygen species (ROS) contribute to stress-induced elevation of T-cad in HUVEC. Compared with control cells, HUVEC overexpressing T-cad (T-cad+-HUVEC) had higher phosphorylation levels for phosphatidylinositol 3-kinase (PI3K) target Akt and mTOR target p70(S6K) (survival pathway regulators), but lower levels for p38MAPK (death pathway regulator). T-cad+-HUVEC exposed to stress (serum-deprivation, TNF-alpha, actinomycin D, staurosporine) exhibited reduced caspase activation together with increased cell survival. Protection against stress-induced apoptosis in T-cad+-HUVEC was abrogated by either PI3K-inhibitor wortmannin or mTOR-inhibitor rapamycin. We conclude that T-cad overexpression in HUVEC protects against stress-induced apoptosis through activation of the PI3K/Akt/mTOR survival signal pathway and concomitant suppression of the p38 MAPK proapoptotic pathway. ROS-induced changes in T-cad expression may play an important role in controlling tissue cellularity during vascular remodeling.	Univ Basel Hosp, Cardiovasc Labs, Dept Res, CH-4031 Basel, Switzerland; Luzern Kantonsspital, Div Cardiol, Luzern, Switzerland	University of Basel; Lucerne Cantonal Hospital	Resink, TSJ (corresponding author), Univ Basel Hosp, Cardiovasc Labs, Dept Res, Hebelstr 20, CH-4031 Basel, Switzerland.	Therese-J.Resink@unibas.ch	Joshi, Manjunath B/G-2052-2012; Filippova, Maria/GXH-7313-2022	Joshi, Manjunath/0000-0002-1310-5480; Filippova, Maria/0000-0003-3124-3155				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Beohar N, 2004, CIRCULATION, V109, P108, DOI 10.1161/01.CIR.0000105724.30980.CD; Bezzi M, 2003, J BIOL CHEM, V278, P43603, DOI 10.1074/jbc.M308114200; Blanc A, 2003, INT J MOL MED, V11, P229; Bochkov VN, 1996, BIOCHEM J, V317, P297, DOI 10.1042/bj3170297; Cantara S, 2004, J VASC RES, V41, P202, DOI 10.1159/000077408; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Chan S, 2004, BRIT J CANCER, V91, P1420, DOI 10.1038/sj.bjc.6602162; Choy JC, 2001, J MOL CELL CARDIOL, V33, P1673, DOI 10.1006/jmcc.2001.1419; Corda S, 2001, AM J RESP CELL MOL, V24, P762, DOI 10.1165/ajrcmb.24.6.4228; Das DK, 2004, BIOCHEMISTRY-MOSCOW+, V69, P10, DOI 10.1023/B:BIRY.0000016345.19027.54; de Nigris F, 2003, TRENDS MOL MED, V9, P351, DOI 10.1016/S1471-4914(03)00139-4; Fredette BJ, 1996, DEVELOPMENT, V122, P3163; Geng YH, 2002, ARTERIOSCL THROM VAS, V22, P1370, DOI 10.1161/01.ATV.0000031341.84618.A4; Gil J, 2003, FREE RADICAL BIO MED, V35, P1500, DOI 10.1016/j.freeradbiomed.2003.08.022; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; Hao JH, 2004, CANCER RES, V64, P3607, DOI 10.1158/0008-5472.CAN-03-3648; Harfouche R, 2003, FASEB J, V17, P1523, DOI 10.1096/fj.02-0698fje; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Iurlaro M, 2004, AM J PATHOL, V165, P181, DOI 10.1016/S0002-9440(10)63287-7; Ivanov D, 2004, CARDIOVASC RES, V64, P132, DOI 10.1016/j.cardiores.2004.06.010; Ivanov D, 2004, EXP CELL RES, V293, P207, DOI 10.1016/j.yexcr.2003.09.030; Ivanov D, 2001, HISTOCHEM CELL BIOL, V115, P231; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; King AR, 2003, LAB INVEST, V83, P1497, DOI 10.1097/01.LAB.0000093096.62765.85; Koller E, 1996, J BIOL CHEM, V271, P30061, DOI 10.1074/jbc.271.47.30061; Kudrjashova E, 2002, HISTOCHEM CELL BIOL, V118, P281, DOI 10.1007/s00418-002-0463-6; Kuzmenko YS, 1998, FEBS LETT, V434, P183, DOI 10.1016/S0014-5793(98)00977-6; Laprise P, 2004, J CELL PHYSIOL, V199, P32, DOI 10.1002/jcp.10432; Li AE, 1999, CIRC RES, V85, P304, DOI 10.1161/01.RES.85.4.304; Ling SH, 2002, ENDOCRINOLOGY, V143, P1119, DOI 10.1210/en.143.3.1119; Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mattiussi S, 2004, CARDIOVASC RES, V61, P693, DOI 10.1016/j.cardiores.2003.12.008; Papadakis CM, 2000, EUR PHYS J E, V1, P275, DOI 10.1007/s101890050029; Philippova M, 2005, FASEB J, V19, P588, DOI 10.1096/fj.04-2430fje; Philippova M, 2003, HISTOCHEM CELL BIOL, V120, P353, DOI 10.1007/s00418-003-0584-6; Philippova MP, 1998, FEBS LETT, V429, P207, DOI 10.1016/S0014-5793(98)00598-5; Recchioni R, 2002, METABOLISM, V51, P1384, DOI 10.1053/meta.2002.35579; Resink TJ, 1999, FEBS LETT, V463, P29, DOI 10.1016/S0014-5793(99)01594-X; Shen XD, 2004, AM J PATHOL, V165, P1315, DOI 10.1016/S0002-9440(10)63390-1; Sorenson CM, 2004, BBA-MOL CELL RES, V1644, P169, DOI 10.1016/j.bbamcr.2003.08.010; Tran NL, 2002, J BIOL CHEM, V277, P32905, DOI 10.1074/jbc.M200300200; Tsuruga M, 2003, MOL CELL BIOCHEM, V250, P131, DOI 10.1023/A:1024912806686; VESTAL DJ, 1992, J CELL BIOL, V119, P451, DOI 10.1083/jcb.119.2.451; Wang ZS, 2001, CANCER RES, V61, P7171; Wyder L, 2000, CANCER RES, V60, P4682; Yilmaz A, 2003, BIOCHEM BIOPH RES CO, V306, P730, DOI 10.1016/S0006-291X(03)01064-7; Zafarullah M, 2003, CELL MOL LIFE SCI, V60, P6, DOI 10.1007/s000180300001; Zajchowski LD, 2002, EUR J BIOCHEM, V269, P737, DOI 10.1046/j.0014-2956.2001.02715.x	51	72	80	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1737	+		10.1096/fj.05-3834fje	http://dx.doi.org/10.1096/fj.05-3834fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16099944				2022-12-28	WOS:000231843700017
J	Siatskas, C; Underwood, J; Ramezani, A; Hawley, RG; Medin, JA				Siatskas, C; Underwood, J; Ramezani, A; Hawley, RG; Medin, JA			Specific pharmacological dimerization of KDR in lentivirally transduced human hematopoietic cells activates antiapoptotic and proliferative mechanisms	FASEB JOURNAL			English	Article						heat shock proteins; selective growth advantage; gene therapy; microarray analysis; AP20187	ENDOTHELIAL GROWTH-FACTOR; HEAT-SHOCK-PROTEIN; IN-VIVO SELECTION; SIGNAL-TRANSDUCTION; MOLECULAR CHAPERONES; GENE-EXPRESSION; C-KIT; RECEPTOR; SURVIVAL; APOPTOSIS	Selective and regulatable expansion of transduced cells could augment gene therapy for many disorders. The activation of modified growth factor receptors via synthetic chemical inducers of dimerization allows for the coordinated growth of transduced cells. This system can also provide information on specific receptor- mediated signaling without interference from other family members. Although several receptor subunits have been investigated in this context, little is known about the precise molecular events associated with dimerizer- initiated signaling. We have constructed and expressed an AP20187- regulated KDR chimeric receptor in human TF1 cells and analyzed activation of this gene switch using functional, biochemical, and microarray analyses. When deprived of natural ligands, GM- CSF, interleukin- 3, or erythropoietin, AP20187 prevented apoptosis of transduced TF1 cells, induced dose- dependent proliferation, and supported long- term growth. In addition, AP20187 stimulation activated the signaling molecules associated with mitogen- activated protein kinase and phosphatidyl- inositol 3- kinase/ Akt pathways. Microarray analysis determined that a number of transcripts involved in a variety of cellular processes were differentially expressed. Notably, mRNAs affiliated with heat stress, including Hsp70 and Hsp105, were up- regulated. Functional assays showed that Hsp70 and Hsp105 protected transduced TF1 cells from apoptosis and premature senescence, in part through regulation of Akt. These observations delineate specific roles for kinase insert domain- containing receptor, or KDR, signaling and suggest strategies to endow genetically modified cells with a survival advantage enabling the generation of adequate cell numbers for therapeutic outcomes.	Univ Hlth Network, Ontario Canc Inst, Div Stem Cell & Dev Biol, Toronto, ON M5G 2M1, Canada; George Washington Univ, Med Ctr, Dept Anat & Cell Biol, Washington, DC 20037 USA; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; George Washington University; University of Toronto; University of Toronto	Medin, JA (corresponding author), Univ Hlth Network, Ontario Canc Inst, Div Stem Cell & Dev Biol, 67 Coll St,Room 406, Toronto, ON M5G 2M1, Canada.	jmedin@uhnres.utoronto.ca		Hawley, Robert/0000-0003-3512-5818	NHLBI NIH HHS [HL70569] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe Mayumi, 2001, Angiogenesis, V4, P289, DOI 10.1023/A:1016018617152; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Birkenkamp KU, 2003, J IMMUNOL, V171, P1623, DOI 10.4049/jimmunol.171.4.1623; Blau CA, 1997, P NATL ACAD SCI USA, V94, P3076, DOI 10.1073/pnas.94.7.3076; Bornfeldt KE, 2000, CIRC RES, V86, P1101, DOI 10.1161/01.RES.86.11.1101; Clackson T, 1997, CURR OPIN CHEM BIOL, V1, P210, DOI 10.1016/S1367-5931(97)80012-9; Cortes F, 1999, MECH DEVELOP, V83, P161, DOI 10.1016/S0925-4773(99)00030-1; Coulombe P, 2003, MOL CELL BIOL, V23, P4542, DOI 10.1128/MCB.23.13.4542-4558.2003; Damjanovich S, 1997, P NATL ACAD SCI USA, V94, P13134, DOI 10.1073/pnas.94.24.13134; Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978; Dias S, 2002, BLOOD, V99, P2532, DOI 10.1182/blood.V99.7.2532; Dorsam ST, 2004, BLOOD, V103, P1676, DOI 10.1182/blood-2003-07-2202; Follenzi A, 2002, METHOD ENZYMOL, V346, P454; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GUO CM, 1995, J BIOL CHEM, V270, P27562, DOI 10.1074/jbc.270.46.27562; Halene S, 2000, HUM GENE THER, V11, P1259, DOI 10.1089/10430340050032366; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Helmbrecht K, 2000, CELL PROLIFERAT, V33, P341, DOI 10.1046/j.1365-2184.2000.00189.x; Huang HM, 1999, BLOOD, V93, P2569, DOI 10.1182/blood.V93.8.2569.408k08_2569_2577; Iuliucci JD, 2001, J CLIN PHARMACOL, V41, P870, DOI 10.1177/00912700122010771; Jin LQ, 1998, P NATL ACAD SCI USA, V95, P8093, DOI 10.1073/pnas.95.14.8093; Jin LQ, 2000, NAT GENET, V26, P64, DOI 10.1038/79194; Jin LQ, 1998, BLOOD, V91, P890, DOI 10.1182/blood.V91.3.890.890_890_897; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kabrun N, 1997, DEVELOPMENT, V124, P2039; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Knight EL, 2000, ONCOGENE, V19, P5398, DOI 10.1038/sj.onc.1203915; Koishi M, 2001, CLIN CANCER RES, V7, P215; Kwak HJ, 1998, CELL IMMUNOL, V187, P1, DOI 10.1006/cimm.1998.1309; KWARTA MM, 1992, BIOCHIM BIOPHYS ACTA, V1134, P178; Larrivee B, 2003, J BIOL CHEM, V278, P22006, DOI 10.1074/jbc.M212158200; Li B, 2000, J BIOL CHEM, V275, P29823, DOI 10.1074/jbc.M002015200; Li ZY, 2002, MOL THER, V5, P420, DOI 10.1006/mthe.2002.0565; MAVILIO F, 1994, BLOOD, V83, P1988; MCCLOSKEY P, 1994, CELL GROWTH DIFFER, V5, P1105; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Neff T, 2002, BLOOD, V100, P2026, DOI 10.1182/blood-2002-03-0792; Neff T, 2001, BLOOD, V97, P2535, DOI 10.1182/blood.V97.9.2535; Nollen EAA, 2002, J CELL SCI, V115, P2809; Otto KG, 2001, BLOOD, V97, P3662, DOI 10.1182/blood.V97.11.3662; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; Ramezani A, 2000, MOL THER, V2, P458, DOI 10.1006/mthe.2000.0190; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Rosas M, 2005, FEBS LETT, V579, P191, DOI 10.1016/j.febslet.2004.11.074; Santos SCR, 2004, BLOOD, V103, P3883, DOI 10.1182/BLOOD-2003-05-1634; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Temple R, 2001, AM J RESP CELL MOL, V25, P425, DOI 10.1165/ajrcmb.25.4.4456; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Whitney ML, 2001, J BIOL CHEM, V276, P41191, DOI 10.1074/jbc.M103191200; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Yang SY, 2002, ARTERIOSCL THROM VAS, V22, P1797, DOI 10.1161/01.ATV.0000038995.31179.24; Yao Q, 2003, CLIN CANCER RES, V9, P4483; Yokota S, 2000, CANCER RES, V60, P2942; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6; Zhang H T, 1999, Angiogenesis, V3, P211, DOI 10.1023/A:1009085422384; Zhao SM, 2004, MOL THER, V10, P456, DOI 10.1016/j.ymthe.2004.05.014; Zhao SM, 2002, EMBO J, V21, P2159, DOI 10.1093/emboj/21.9.2159; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553; Zippo A, 2004, BLOOD, V103, P4536, DOI 10.1182/blood-2003-11-3827	68	10	12	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1752	+		10.1096/fj.05-4006fje	http://dx.doi.org/10.1096/fj.05-4006fje			31	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16076962				2022-12-28	WOS:000231843700024
J	Yatsiv, I; Grigoriadis, N; Simeonidou, C; Stahel, PF; Schmidt, OI; Alexandrovich, AG; Tsenter, J; Shohami, E				Yatsiv, I; Grigoriadis, N; Simeonidou, C; Stahel, PF; Schmidt, OI; Alexandrovich, AG; Tsenter, J; Shohami, E			Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury	FASEB JOURNAL			English	Article						apoptosis; traumatic brain injury; cytokines; therapy	TRAUMATIC BRAIN-INJURY; RECOMBINANT-HUMAN-ERYTHROPOIETIN; PERMANENT CEREBRAL-ISCHEMIA; COGNITIVE FUNCTION; DIALYSIS PATIENTS; NERVOUS-SYSTEM; MOUSE-BRAIN; MICE; RECEPTOR; RATS	Traumatic brain injury (TBI) is a leading cause of morbidity and mortality in young people in industrialized countries. Although various anti-inflammatory and antiapoptotic modalities have shown neuroprotective effects in experimental models of TBI, to date, no specific pharmacological agent aimed at blocking the progression of secondary brain damage has been approved for clinical use. Erythropoietin (Epo) belongs to the cytokine superfamily and has traditionally been viewed as a hematopoiesis-regulating hormone. The newly discovered neuroprotective properties of Epo lead us to investigate its effect in TBI in a mouse model of closed head injury. Recombinant human erythropoietin (rhEpo) was injected at 1 and 24 h after TBI, and the effect on recovery of motor and cognitive functions, tissue inflammation, axonal degeneration, and apoptosis was evaluated up to 14 days. Motor deficits were lower, cognitive function was restored faster, and less apoptotic neurons and caspase-3 expression were found in rhEpo-treated as compared with vehicle-treated animals (P<0.05). Axons at the trauma area in rhEpo-treated mice were relatively well preserved compared with controls (shown by their density; P<0.01). Immunohistochemical analysis revealed a reduced activation of glial cells by staining for GFAP and complement receptor type 3 (CD11b/CD18) in the injured hemisphere of Epo- vs. vehicle-treated animals. We propose that further studies on Epo in TBI should be conducted in order to consider it as a novel therapy for TBI.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Rehabil Med, Jerusalem, Israel; AHEPA Univ Hosp, Dept Neurol, Thessaloniki, Greece; Aritotle Univ, Fac Med, Dept Physiol, Thessaloniki, Greece; Chairte Univ Med Sch, Dept Trauma & Reconstruct Surg, Berlin, Germany	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hadassah University Medical Center; Aristotle University of Thessaloniki; Ahepa University Hospital	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il						Adembri C, 2004, J NEUROTRAUM, V21, P1103, DOI 10.1089/0897715041651079; Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Bernaudin M, 2000, GLIA, V30, P271, DOI 10.1002/(SICI)1098-1136(200005)30:3<271::AID-GLIA6>3.3.CO;2-8; Bernaudin M, 2002, J CEREBR BLOOD F MET, V22, P393, DOI 10.1097/00004647-200204000-00003; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Buemi M, 2002, CLIN SCI, V103, P275, DOI 10.1042/cs1030275; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Catania MA, 2002, EUR J PHARMACOL, V437, P147, DOI 10.1016/S0014-2999(02)01292-X; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Coleman T, 2004, CRIT CARE, V8, P337, DOI 10.1186/cc2897; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Ehrenreich H, 2004, METAB BRAIN DIS, V19, P195, DOI 10.1023/B:MEBR.0000043969.96895.3c; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Erbayraktar Serhat, 2003, Curr Hematol Rep, V2, P465; Genc S, 2004, BRAIN RES, V1000, P19, DOI 10.1016/j.brainres.2003.12.037; Genc S, 2001, NEUROSCI LETT, V298, P139, DOI 10.1016/S0304-3940(00)01716-X; Ghezzi P, 2004, CELL DEATH DIFFER, V11, pS37, DOI 10.1038/sj.cdd.4401450; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Juul SE, 1999, PEDIATR RES, V46, P543, DOI 10.1203/00006450-199911000-00009; Juul SE, 1998, PEDIATR RES, V43, P40, DOI 10.1203/00006450-199801000-00007; Juul SE, 2000, CLIN PERINATOL, V27, P527, DOI 10.1016/S0095-5108(05)70037-3; Kumral A, 2004, BEHAV BRAIN RES, V153, P77, DOI 10.1016/j.bbr.2003.11.002; Kumral A, 2003, BIOL NEONATE, V83, P224, DOI 10.1159/000068926; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Litchfield S, 2001, ACTA NEUROPATHOL, V101, P17; Macdougall Iain C, 2003, Curr Hematol Rep, V2, P459; MARSH JT, 1991, KIDNEY INT, V39, P155, DOI 10.1038/ki.1991.20; MASUDA S, 1994, J BIOL CHEM, V269, P19488; Matsushita H, 2003, NEUROREPORT, V14, P1757, DOI 10.1097/00001756-200309150-00020; Mogensen J, 2004, PHARMACOL BIOCHEM BE, V77, P381, DOI 10.1016/j.pbb.2003.11.017; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; *NAT CTR INJ PREV, 2001, INJ FACT BOOK 2001 2, P1; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Pickett JL, 1999, AM J KIDNEY DIS, V33, P1122, DOI 10.1016/S0272-6386(99)70150-2; Prass K, 2003, STROKE, V34, P1981, DOI 10.1161/01.STR.0000080381.76409.B2; Ribatti D, 1999, BLOOD, V93, P2627, DOI 10.1182/blood.V93.8.2627.408k21_2627_2636; Schmidt O., 2004, EUR J TRAUMA, V30, P135, DOI DOI 10.1007/S00068-004-1394-9; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Smith KJ, 2003, CARDIOVASC RES, V59, P538, DOI 10.1016/S0008-6363(03)00468-1; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; TEMPLE RM, 1995, NEPHROL DIAL TRANSPL, V10, P1733; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Wagner KU, 2000, DEVELOPMENT, V127, P4949; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Yu XB, 2002, DEVELOPMENT, V129, P505; 2004, PHARMOS ANNOUNCES RE	60	192	220	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1701	+		10.1096/fj.05-3907fje	http://dx.doi.org/10.1096/fj.05-3907fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16099948				2022-12-28	WOS:000231843700015
J	Bruewer, M; Utech, M; Ivanov, AI; Hopkins, AM; Parkos, CA; Nusrat, A				Bruewer, M; Utech, M; Ivanov, AI; Hopkins, AM; Parkos, CA; Nusrat, A			Interferon-gamma induces internalization of epithelial tight junction proteins via a macropinocytosis-like process	FASEB JOURNAL			English	Article						cytokines; inflammation; mucosa	INFLAMMATORY-BOWEL-DISEASE; NECROSIS-FACTOR-ALPHA; BARRIER FUNCTION; IFN-GAMMA; GROWTH-FACTOR; INTESTINAL EPITHELIUM; DISTINCT ROLES; CLASS-I; ENDOCYTOSIS; CELLS	IIncreased epithelial permeability is observed in inflammatory states. However, the mechanism by which inflammatory mediators such as IFN-gamma increase epithelial permeability is unknown. We recently observed that IFN-gamma induces disassembly of tight junctions (TJ); in this study we asked whether such TJ disassembly is mediated by endocytosis of junctional proteins. The role of three major internalization pathways in disruption of TJ in IFN-gamma-treated intestinal epithelial cells was analyzed using selective inhibitors and markers of the pathways. No role for the clathrin-and caveolar-mediated endocytosis in the IFN-gamma-induced internalization of TJ proteins was observed. However, inhibitors of macropinocytosis blocked internalization of TJ proteins and junctional proteins colocalized with macropinocytosis markers, dextran and phosphatidylinositol-3,4,5-trisphosphate. Internalized TJ proteins were identified in early and recycling endosomes but not in late endosomes/lysosomes. These results for the first time suggest that IFN-gamma produces a leaky epithelial barrier by inducing macropinoytosis of TJ proteins.	Emory Univ, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, Atlanta, GA 30322 USA; Univ Munster, Dept Gen Surg, D-4400 Munster, Germany	Emory University; University of Munster	Nusrat, A (corresponding author), Emory Univ, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, Whitehead Res Bldg,Room 105E,615 Michael St, Atlanta, GA 30322 USA.	anusrat@emory.edu	Parkos, Charles a/B-3896-2009; Nusrat, Asma/B-3887-2009; Hopkins, Ann/C-3400-2012	Hopkins, Ann/0000-0003-2836-6584	NIDDK NIH HHS [DK 61379, DK 59888, DK 55679] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK055679, R01DK055679, R01DK061379, R01DK059888] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS RB, 1993, J IMMUNOL, V150, P2356; Ahdieh M, 2001, AM J PHYSIOL-CELL PH, V281, pC2029, DOI 10.1152/ajpcell.2001.281.6.C2029; Amyere M, 2002, INT J MED MICROBIOL, V291, P487; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Basuroy S, 2003, J BIOL CHEM, V278, P11916, DOI 10.1074/jbc.M211710200; Bossuyt J, 2002, FEBS LETT, V511, P113, DOI 10.1016/S0014-5793(01)03323-3; Brossart P, 1997, BLOOD, V90, P1594, DOI 10.1182/blood.V90.4.1594.1594_1594_1599; Bruewer M, 2003, J IMMUNOL, V171, P6164, DOI 10.4049/jimmunol.171.11.6164; Bush J, 1996, MOL BIOL CELL, V7, P1623, DOI 10.1091/mbc.7.10.1623; CALDWELL RB, 1984, EXP CELL RES, V150, P104, DOI 10.1016/0014-4827(84)90706-7; Clayburgh DR, 2004, LAB INVEST, V84, P282, DOI 10.1038/labinvest.3700050; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8; Grisendi S, 1998, J CELL PHYSIOL, V176, P465, DOI 10.1002/(SICI)1097-4652(199809)176:3<465::AID-JCP3>3.0.CO;2-M; Hamasaki M, 2004, ANAT REC PART A, V277A, P298, DOI 10.1002/ar.a.20027; Han XN, 2003, SHOCK, V19, P229, DOI 10.1097/00024382-200303000-00006; Harhaj NS, 2002, J CELL PHYSIOL, V193, P349, DOI 10.1002/jcp.10183; Harris E, 2001, J CELL SCI, V114, P3035; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Hoekstra D, 2004, J CELL SCI, V117, P2183, DOI 10.1242/jcs.01217; Hopkins AM, 2003, J CELL SCI, V116, P725, DOI 10.1242/jcs.00300; ILLINGER D, 1990, BIOCHIM BIOPHYS ACTA, V1030, P82, DOI 10.1016/0005-2736(90)90241-F; Ivanov AI, 2004, MOL BIOL CELL, V15, P2639, DOI 10.1091/mbc.E04-02-0163; Ivanov AI, 2004, MOL BIOL CELL, V15, P176, DOI 10.1091/mbc.E03-05-0319; IVANOV AI, 2004, INFLAMM BOWEL DIS, P115; KATZ KD, 1989, GASTROENTEROLOGY, V97, P927, DOI 10.1016/0016-5085(89)91499-6; Kauppi M, 2002, J CELL SCI, V115, P899; Kim S, 2002, MICROB PATHOGENESIS, V33, P225, DOI 10.1006/mpat.2002.0531; Kohler K, 2004, J CELL BIOL, V165, P175, DOI 10.1083/jcb.200312118; Liu Y, 2000, J CELL SCI, V113, P2363; MADARA JL, 1992, J CLIN INVEST, V89, P1938, DOI 10.1172/JCI115800; MADARA JL, 1987, GASTROENTEROLOGY, V92, P1133, DOI 10.1016/S0016-5085(87)91069-9; MADARA JL, 1990, J MEMBRANE BIOL, V116, P177, DOI 10.1007/BF01868675; MADARA JL, 1989, J CLIN INVEST, V83, P724, DOI 10.1172/JCI113938; Mankertz J, 2000, J CELL SCI, V113, P2085; Marano CW, 1998, J MEMBRANE BIOL, V161, P263, DOI 10.1007/s002329900333; Matsuda M, 2004, J CELL SCI, V117, P1247, DOI 10.1242/jcs.00972; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; McKay DM, 1997, J IMMUNOL, V159, P2382; Meier O, 2002, J CELL BIOL, V158, P1119, DOI 10.1083/jcb.200112067; Mesa R, 2001, J CELL SCI, V114, P4041; Mohrmann K, 1999, MOL MEMBR BIOL, V16, P81, DOI 10.1080/096876899294797; Montaner LJ, 1999, J IMMUNOL, V162, P4606; MOSS AL, 1991, J CELL PHYSIOL, V149, P319, DOI 10.1002/jcp.1041490220; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; NIESSNER M, 1995, CLIN EXP IMMUNOL, V101, P428; Nusrat A, 2001, INFECT IMMUN, V69, P1329, DOI 10.1128/IAI.69.3.1329-1336.2001; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; O'Neil D, 1999, J IMMUNOL, V162, P791; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P10315, DOI 10.1021/bi025943i; PITELKA DR, 1983, J CELL BIOL, V96, P613, DOI 10.1083/jcb.96.3.613; POLAKCHARCON S, 1979, J CELL SCI, V35, P393; POLAKCHARCON S, 1980, J NATL CANCER I, V65, P53; Razani B, 2001, EXP CELL RES, V271, P36, DOI 10.1006/excr.2001.5372; RISINGER MA, 1981, TISSUE CELL, V13, P413, DOI 10.1016/0040-8166(81)90015-X; SANDLE GI, 1990, GASTROENTEROLOGY, V99, P97, DOI 10.1016/0016-5085(90)91235-X; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; Sato M, 2003, NAT CELL BIOL, V5, P1016, DOI 10.1038/ncb1054; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Shigematsu S, 2003, J BIOL CHEM, V278, P10683, DOI 10.1074/jbc.M208563200; Shurety W, 1996, J CELL SCI, V109, P2927; So ALP, 2000, DIGEST DIS SCI, V45, P1130, DOI 10.1023/A:1005593717644; STAEHELIN LA, 1973, J CELL SCI, V13, P763; Stallmach Andreas, 2004, Int J Colorectal Dis, V19, P308, DOI 10.1007/s00384-003-0554-4; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Van Dyke RW, 2000, HEPATOLOGY, V32, P1357, DOI 10.1053/jhep.2000.19790; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; WEST MA, 1989, J CELL BIOL, V109, P2731, DOI 10.1083/jcb.109.6.2731; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Yamamoto Y, 2003, BIOCHEM BIOPH RES CO, V308, P270, DOI 10.1016/S0006-291X(03)01358-5; Youakim A, 1999, AM J PHYSIOL-GASTR L, V276, pG1279, DOI 10.1152/ajpgi.1999.276.5.G1279; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	74	278	286	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					923	933		10.1096/fj.04-3260com	http://dx.doi.org/10.1096/fj.04-3260com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15923402				2022-12-28	WOS:000230207800039
J	Louis, NA; Hamilton, KE; Kong, TQ; Colgan, SP				Louis, NA; Hamilton, KE; Kong, TQ; Colgan, SP			HIF-dependent induction of apical CD55 coordinates epithelial clearance of neutrophils	FASEB JOURNAL			English	Article						inflammation; adhesion; mucosa; leukocyte; resolution	DECAY-ACCELERATING FACTOR; HYPOXIA-INDUCIBLE FACTOR; VASCULAR ENDOTHELIAL-CELLS; INTERCELLULAR-ADHESION MOLECULE-1; INFLAMMATORY-BOWEL-DISEASE; NECROSIS-FACTOR-ALPHA; TRANSEPITHELIAL MIGRATION; INTESTINAL EPITHELIA; NITRIC-OXIDE; FACTOR-I	Sites of inflammation are associated with dramatic shifts in tissue metabolism. Inflammation can result in significant tissue hypoxia, with resultant induction of hypoxia-responsive genes. Given this association, we hypothesized that neutrophil (PMN) ligands expressed on epithelial cells may be regulated by hypoxia. Initial studies confirmed earlier results that epithelial hypoxia enhances PMN transepithelial migration and promotes apical clearance of PMN from the epithelial surface. A screen of known PMN ligands revealed a surprisingly stable expression pattern in hypoxia. However, this screen identified one gene, CD55, as a highly hypoxia-inducible molecule expressed on the apical membrane of mucosal epithelia. Subsequent studies verified the induction of CD55 mRNA and protein expression by hypoxia. Overexpression of CD55 by transfection in nonhypoxic epithelia resulted in a similar pattern of apical PMN clearance, and peptide mimetics corresponding to the PMN binding site on DAF blocked such apical clearance of PMN. Studies directed at understanding molecular pathways of hypoxia inducibility revealed that a similar to 200 bp region of the CD55 gene conferred hypoxia inducibility for CD55. These studies identified a functional binding site for the transcriptional regulator hypoxia-inducible factor (HIF). Taken together, these results identify HIF-dependent induction of epithelial CD55 in the resolution of ongoing inflammation through clearance of apical PMN.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Neonatol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Colgan, SP (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Neonatol, Thorn Bldg 704,20 Shattuck St, Boston, MA 02115 USA.	colgan@zeus.bwh.harvard.edu	Louis, Nancy/G-5163-2011; Hamilton, Kathryn/AAA-9643-2022; Colgan, Sean P./B-4573-2009	Louis, Nancy/0000-0001-7092-8136; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050189, R01DK050189, R29DK050189] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE161191] Funding Source: Medline; NIDDK NIH HHS [DK50189, DK62007] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad SR, 2003, IMMUNOLOGY, V110, P258, DOI 10.1046/j.1365-2567.2003.01733.x; Berstad AE, 1998, GUT, V42, P522, DOI 10.1136/gut.42.4.522; Colgan SP, 1996, J EXP MED, V184, P1003, DOI 10.1084/jem.184.3.1003; Collard CD, 1999, AM J PHYSIOL-CELL PH, V276, pC450, DOI 10.1152/ajpcell.1999.276.2.C450; Collard CD, 1997, CIRCULATION, V96, P326; Comerford KM, 2002, CANCER RES, V62, P3387; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; DHARMSATHAPHORN K, 1990, METHOD ENZYMOL, V192, P354; Eltzschig HK, 2003, J EXP MED, V198, P783, DOI 10.1084/jem.20030891; Friedman GB, 1998, J CELL PHYSIOL, V176, P76, DOI 10.1002/(SICI)1097-4652(199807)176:1<76::AID-JCP9>3.0.CO;2-5; Furuta GT, 2001, J EXP MED, V193, P1027, DOI 10.1084/jem.193.9.1027; Haddad JJ, 2003, CRIT CARE, V7, P47, DOI 10.1186/cc1840; Hatoum OA, 2003, GASTROENTEROLOGY, V125, P58, DOI 10.1016/S0016-5085(03)00699-1; HAUSER CJ, 1988, J LAB CLIN MED, V112, P68; Huber D, 2000, J BIOL CHEM, V275, P5773, DOI 10.1074/jbc.275.8.5773; Inaba T, 1998, CLIN EXP IMMUNOL, V112, P237; Jaye DL, 2000, ANN NY ACAD SCI, V915, P151; Karhausen J, 2005, CELL CYCLE, V4, P256; Karhausen J, 2004, J CLIN INVEST, V114, P1098, DOI 10.1172/JCI200421086; KING PD, 1990, EUR J IMMUNOL, V20, P363, DOI 10.1002/eji.1830200220; Kokura S, 2002, FREE RADICAL BIO MED, V33, P427, DOI 10.1016/S0891-5849(02)00852-3; Kong TQ, 2004, P NATL ACAD SCI USA, V101, P10440, DOI 10.1073/pnas.0401339101; KORETZ K, 1992, BRIT J CANCER, V66, P810, DOI 10.1038/bjc.1992.365; Kruschewski M, 2001, DIGEST DIS SCI, V46, P2336, DOI 10.1023/A:1012334727509; Lawrence DW, 2003, J EXP MED, V198, P999, DOI 10.1084/jem.20030380; Lewis JS, 1999, J LEUKOCYTE BIOL, V66, P889, DOI 10.1002/jlb.66.6.889; Lin F, 2004, J IMMUNOL, V172, P3836, DOI 10.4049/jimmunol.172.6.3836; Liu Y, 2002, J BIOL CHEM, V277, P10028, DOI 10.1074/jbc.M109720200; Liu Y, 2001, J BIOL CHEM, V276, P40156, DOI 10.1074/jbc.M104138200; Mason JC, 1999, BLOOD, V94, P1673, DOI 10.1182/blood.V94.5.1673.417a05_1673_1682; Mason JC, 2002, AM J PHYSIOL-CELL PH, V282, pC578, DOI 10.1152/ajpcell.00339.2001; MEDOF ME, 1987, P NATL ACAD SCI USA, V84, P2007, DOI 10.1073/pnas.84.7.2007; Oshima T, 2000, J IMMUNOL, V164, P1078, DOI 10.4049/jimmunol.164.2.1078; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; PARKOS CA, 1991, J CLIN INVEST, V88, P1605, DOI 10.1172/JCI115473; Parkos CA, 1996, MOL MED, V2, P489, DOI 10.1007/BF03401908; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Roth U, 2004, BIOL CHEM, V385, P239, DOI 10.1515/BC.2004.018; Saadi S, 2002, FASEB J, V16, DOI 10.1096/fj.01-0690hyp; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Shafren DR, 2000, J GEN VIROL, V81, P889, DOI 10.1099/0022-1317-81-4-889; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Song WC, 2004, CURR DIRECT AUTOIMMU, V7, P181; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Taylor CT, 2000, P NATL ACAD SCI USA, V97, P12091, DOI 10.1073/pnas.220211797; Taylor CT, 1998, GASTROENTEROLOGY, V114, P657, DOI 10.1016/S0016-5085(98)70579-7; THOMAS DJ, 1993, J IMMUNOL, V150, P151; Wartenberg M, 2003, FASEB J, V17, P503, DOI 10.1096/fj.02-0358fje; Yamada K, 2004, J IMMUNOL, V172, P3869, DOI 10.4049/jimmunol.172.6.3869; Yokoyama K, 2001, HEPATO-GASTROENTEROL, V48, P401; Zampetaki A, 2004, FASEB J, V18, P1090, DOI 10.1096/fj.03-0991fje; Zen K, 2004, MOL BIOL CELL, V15, P3926, DOI 10.1091/mbc.E04-04-0317	53	60	62	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2005	19	8					950	959		10.1096/fj.04-3251com	http://dx.doi.org/10.1096/fj.04-3251com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15923405				2022-12-28	WOS:000230207800042
J	Prinzen, C; Muller, U; Endres, K; Fahrenholz, F; Postina, R				Prinzen, C; Muller, U; Endres, K; Fahrenholz, F; Postina, R			Genomic structure and functional characterization of the human ADAM10 promoter	FASEB JOURNAL			English	Article						Alzheimer disease; amyloid precursor protein; alpha-secretase; luciferase promoter assay; retinoic acid	AMYLOID PRECURSOR PROTEIN; TRANSCRIPTION FACTOR; ALZHEIMERS-DISEASE; BETA-PROTEIN; MEMBRANE-PROTEINS; POU DOMAIN; DISINTEGRIN; ALPHA; GENE; SEQUENCE	The ADAM10 gene encodes a membrane-bound disintegrin-metalloproteinase, which, after overexpression in an Alzheimer disease ( AD) mouse model, prevents amyloid pathology and improves long-term potentiation and memory. Because enhancing ADAM10 expression appears to be a reasonable approach for treatment of AD, we functionally analyzed the ADAM10 gene. Both human and mouse ADAM10 genes comprise similar to 160 kbp, are composed of 16 exons, and are evolutionarily highly conserved within 500 bp upstream of either translation initiation site. By using luciferase reporter assays, we demonstrate that nucleotides - 2179 to - 1 upstream of the human ADAM10 translation initiation site represent a functional TATA-less promoter. Within this region we identified and examined several single nucleotide polymorphisms, but did not detect significant differences in their appearance between AD and nondemented control subjects. By deletion analysis, site-directed mutagenesis, transcription factor overexpression and electrophoretic mobility shift assays, we identified nucleotides - 508 to - 300 as the core promoter and found Sp1, USF, and retinoic acid-responsive elements to modulate its activity. Finally, we identified vitamin A acid (RA) as an inducer of human ADAM10 promoter activity. This finding suggests that pharmacologic targeting of RA receptors may increase the expression of the alpha-secretase ADAM10 with beneficial effects on AD pathology.	Johannes Gutenberg Univ Mainz, Inst Biochem, D-55128 Mainz, Germany; Univ Giessen, Inst Human Genet, Giessen, Germany	Johannes Gutenberg University of Mainz; Justus Liebig University Giessen	Postina, R (corresponding author), Johannes Gutenberg Univ Mainz, Inst Biochem, Becherweg 30, D-55128 Mainz, Germany.	bio.chemie@uni-mainz.de	Endres, Kristina/K-4960-2015					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Anders A, 2001, FASEB J, V15, P1837, DOI 10.1096/fj.01-0007fje; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Chiang MY, 1998, NEURON, V21, P1353, DOI 10.1016/S0896-6273(00)80654-6; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; Goodman AB, 2003, P NATL ACAD SCI USA, V100, P2901, DOI 10.1073/pnas.0437937100; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Howard L, 1996, BIOCHEM J, V317, P45, DOI 10.1042/bj3170045; Ishida A, 1997, NEUROREPORT, V8, P2133, DOI 10.1097/00001756-199707070-00009; IZUMI R, 1992, GENE, V112, P189, DOI 10.1016/0378-1119(92)90375-Y; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KOVACS DM, 1995, HUM MOL GENET, V4, P1527, DOI 10.1093/hmg/4.9.1527; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LANNFELT L, 1995, NAT MED, V1, P829, DOI 10.1038/nm0895-829; LANS MS, 1994, J BIOL CHEM, V269, P14170; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; Loots GG, 2002, GENOME RES, V12, P832, DOI 10.1101/gr.225502; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Misner DL, 2001, P NATL ACAD SCI USA, V98, P11714, DOI 10.1073/pnas.191369798; Mitsuda N, 1997, J BIOL CHEM, V272, P23489, DOI 10.1074/jbc.272.38.23489; Muller U, 1996, NEUROLOGY, V47, P1575, DOI 10.1212/WNL.47.6.1575; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Penn I, 1998, Pediatr Transplant, V2, P56; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rietveld I, 2003, EUR J EPIDEMIOL, V18, P191; Rinaldi P, 2003, NEUROBIOL AGING, V24, P915, DOI 10.1016/S0197-4580(03)00031-9; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Salbaum J M, 1989, Prog Clin Biol Res, V317, P277; Santamarina-Fojo S, 2000, P NATL ACAD SCI USA, V97, P7987, DOI 10.1073/pnas.97.14.7987; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; Schwartz S, 2003, NUCLEIC ACIDS RES, V31, P3518, DOI 10.1093/nar/gkg579; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sennvik K, 2000, NEUROSCI LETT, V278, P169, DOI 10.1016/S0304-3940(99)00929-5; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Suske G, 2000, Methods Mol Biol, V130, P175; Takahashi J, 1999, J NEUROBIOL, V38, P65, DOI 10.1002/(SICI)1097-4695(199901)38:1<65::AID-NEU5>3.3.CO;2-H; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; Weis L, 1997, MOL CELL BIOL, V17, P2973, DOI 10.1128/MCB.17.6.2973; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; YAMASHITA K, 1997, NEW CERAMICS, V10, P15; Yamazaki K, 1997, GENOMICS, V46, P528, DOI 10.1006/geno.1997.5043; Yavari R, 1998, HUM MOL GENET, V7, P1161, DOI 10.1093/hmg/7.7.1161; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	56	106	110	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1522	+		10.1096/fj.04-3619fje	http://dx.doi.org/10.1096/fj.04-3619fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15972296				2022-12-28	WOS:000230207800011
J	Grotendorst, GR; Duncan, MR				Grotendorst, GR; Duncan, MR			Individual domains of connective tissue growth factor regulate fibroblast proliferation and myofibroblast differentiation	FASEB JOURNAL			English	Article						fibrosis; cytokine; cell proliferation	IMMEDIATE-EARLY GENE; TGF-BETA; NRK FIBROBLASTS; CELL-GROWTH; CCN FAMILY; EXPRESSION; CYR61; CANCER; IDENTIFICATION; OVEREXPRESSION	All members of the Ctgf, Cyr61, and Nov (CCN) family share a high degree of sequence homology and conservation of structural motifs and domains. Here, we present data about a structure function analysis of connective tissue growth factor (CTGF), a prototypic member of the CCN family, which has been shown to be a downstream mediator of transforming growth factor-beta activities on fibroblasts. Our findings demonstrate the two domains of CTGF function to mediate two distinct biological effects. The N-terminal domain of CTGF mediates myofibroblast differentiation and collagen synthesis. The C-terminal domain of CTGF mediates fibroblast proliferation. These data provide a molecular basis for the divergence of CTGF actions on connective tissue cell types and suggest a model for functional analysis of all of the CCN family gene products.	Lovelace Resp Res Inst, Albuquerque, NM 87108 USA	Lovelace Respiratory Research Institute	Grotendorst, GR (corresponding author), Lovelace Resp Res Inst, 2425 Ridgecrest Dr SE, Albuquerque, NM 87108 USA.	ggrotend@lrri.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065603] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 65603] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; ANZANO MA, 1983, P NATL ACAD SCI-BIOL, V80, P6264, DOI 10.1073/pnas.80.20.6264; Ayer-Lelievre C., 2001, Molecular Pathology, V54, P105, DOI 10.1136/mp.54.2.105; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Fan WH, 2000, EUR J CELL BIOL, V79, P915, DOI 10.1078/0171-9335-00122; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Grotendorst GR, 2004, FASEB J, V18, P469, DOI 10.1096/fj.03-0699com; Gupta N, 2001, J CLIN PATHOL-MOL PA, V54, P293, DOI 10.1136/mp.54.5.293; Hirasaki S, 2001, HEPATOL RES, V19, P294, DOI 10.1016/S1386-6346(00)00101-7; Hishikawa K, 1999, CIRCULATION, V100, P2108, DOI 10.1161/01.CIR.100.20.2108; Hogan BLM, 1999, CELL, V96, P225, DOI 10.1016/S0092-8674(00)80562-0; HOLTEN J, 1990, NINA NOTAT, V4, P1; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; Kothapalli D, 2000, J CELL PHYSIOL, V182, P119, DOI 10.1002/(SICI)1097-4652(200001)182:1<119::AID-JCP13>3.0.CO;2-4; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; Manara MC, 2002, AM J PATHOL, V160, P849, DOI 10.1016/S0002-9440(10)64908-5; McCartney-Francis N L, 1998, Int Rev Immunol, V16, P553, DOI 10.3109/08830189809043009; MURRAY GT, 1993, MATER ENGN, V2, P1; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Roberts AB, 2002, CYTOKINE GROWTH F R, V13, P3, DOI 10.1016/S1359-6101(01)00027-2; Robertson G, 2001, UASGCP REP, V2001, P43; Roestenberg P, 2004, DIABETES CARE, V27, P1164, DOI 10.2337/diacare.27.5.1164; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SOMA Y, 1989, J CELL PHYSIOL, V140, P246, DOI 10.1002/jcp.1041400209; Tong XJ, 2001, J BIOL CHEM, V276, P47709, DOI 10.1074/jbc.M107878200; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; Yang DH, 1998, J CLIN ENDOCR METAB, V83, P2593, DOI 10.1210/jc.83.7.2593; Zhang R, 1998, MOL CELL BIOL, V18, P6131, DOI 10.1128/MCB.18.10.6131	44	163	192	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					729	738		10.1096/fj.04-3217com	http://dx.doi.org/10.1096/fj.04-3217com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15857887				2022-12-28	WOS:000229602600029
J	Roche, E; Sepulcre, P; Reig, JA; Santana, A; Soria, B				Roche, E; Sepulcre, P; Reig, JA; Santana, A; Soria, B			Ectodermal commitment of insulin-producing cells derived from mouse embryonic stem cells	FASEB JOURNAL			English	Article						neuroectoderm; pancreatic beta-cells; diabetes	SECRETING CELLS; TRANSCRIPTION FACTORS; ENDOCRINE PANCREAS; PLASMA-ALBUMIN; DIFFERENTIATION; EXPRESSION; GENES; PRECURSORS; PROGENITOR; LIVER	Embryonic stem cells possess the ability to differentiate in vitro into a variety of cell lineages, including insulin-producing cells. Pancreatic beta-cells derive from foregut endoderm during embryonic development. However, previous reports using transgenic mice strongly indicate that insulin-positive cells may be generated also through the neuroectoderm pathway. To analyze this point, a culture system was performed in which only ectoderm committed cells were present. Based on published work, we achieved this by maintaining transfected clonal R1 mouse embryonic stem cells in monolayer in the absence of LIF. Contrary to differentiation protocols via embryoid body formation, monolayer cultured cells displayed ectodermal fates according to the marker gene expression pattern. Under these particular conditions, neomycin was added in order to select insulin-expressing cells. The cell lineage obtained expressed Pdx1, Pax6, Isl1, AChE, MBP, TH, and GS genes, confirming ectodermal commitment, even though some of these factors are also expressed in endoderm. In addition these cells displayed excitatory properties similar to astrocytes. Co-expression of insulin II and nestin was observed in monolayer culture and in the presence of specific conditioned media. No expression of early endodermal markers was detected along monolayer cultures. Altogether, these observations suggest that cells with ectoderm fates could participate in vitro in the derivation of insulin-producing cells. These results have implications for insulin gene regulation and hormone secretion in order to generate insulin-producing cells for replacement protocols in the treatment of diabetes.	Univ Miguel Hernandez, Inst Bioingn, Alicante 03550, Spain; Natl Univ Singapore, Dept Surg, Singapore 117548, Singapore	Universidad Miguel Hernandez de Elche; National University of Singapore	Soria, B (corresponding author), Univ Miguel Hernandez, Inst Bioingn, Alicante 03550, Spain.	bemat.soria@umh.es	RODRIGUEZ, ALFREDO SANTANA/AAE-2934-2019; , Bernat/AAL-6470-2021; Roche, Enrique/V-5738-2017	RODRIGUEZ, ALFREDO SANTANA/0000-0002-1075-9948; Roche, Enrique/0000-0001-5128-1672; REIG MACIA, JUAN ANTONIO/0000-0002-5947-7183; Soria, Bernat/0000-0002-2356-0380				ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; Anisimov SV, 2002, GENOMICS, V79, P169, DOI 10.1006/geno.2002.6687; Atouf F, 1995, J NEUROENDOCRINOL, V7, P957, DOI 10.1111/j.1365-2826.1995.tb00741.x; Blyszczuk P, 2003, P NATL ACAD SCI USA, V100, P998, DOI 10.1073/pnas.0237371100; Brogiolo W, 2001, CURR BIOL, V11, P213, DOI 10.1016/S0960-9822(01)00068-9; Chakrabarti SK, 2003, TRENDS ENDOCRIN MET, V14, P78, DOI 10.1016/S1043-2760(02)00039-5; Chu K, 2001, RECENT PROG HORM RES, V56, P23, DOI 10.1210/rp.56.1.23; de la Rosa EJ, 2000, TRENDS NEUROSCI, V23, P454, DOI 10.1016/S0166-2236(00)01628-3; DELTOUR L, 1993, P NATL ACAD SCI USA, V90, P527, DOI 10.1073/pnas.90.2.527; Dunn-Meynell AA, 1998, BRAIN RES, V814, P41, DOI 10.1016/S0006-8993(98)00956-1; Ferber S, 2000, NAT MED, V6, P568, DOI 10.1038/75050; Gerber SH, 2002, DIABETES, V51, pS3, DOI 10.2337/diabetes.51.2007.S3; HAKELIEN AM, 2004, BIOCH BIOPHYS RES CO; Hamazaki T, 2001, FEBS LETT, V497, P15, DOI 10.1016/S0014-5793(01)02423-1; Hernandez-Sanchez C, 2003, EMBO J, V22, P5582, DOI 10.1093/emboj/cdg515; Hernandez-Sanchez C, 2002, DIABETES, V51, P770, DOI 10.2337/diabetes.51.3.770; Herrera PL, 2000, DEVELOPMENT, V127, P2317; Hori Y, 2002, P NATL ACAD SCI USA, V99, P16105, DOI 10.1073/pnas.252618999; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Jiang YH, 2003, P NATL ACAD SCI USA, V100, P11854, DOI 10.1073/pnas.1834196100; Kahan BW, 2003, DIABETES, V52, P2016, DOI 10.2337/diabetes.52.8.2016; Kim SK, 2001, GENE DEV, V15, P111, DOI 10.1101/gad.859401; Kojima H, 2004, P NATL ACAD SCI USA, V101, P2458, DOI 10.1073/pnas.0308690100; Kojima H, 2002, DIABETES, V51, P1398, DOI 10.2337/diabetes.51.5.1398; Kojima H, 2003, NAT MED, V9, P596, DOI 10.1038/nm867; Ku HT, 2004, STEM CELLS, V22, P1205, DOI 10.1634/stemcells.2004-0027; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; Lemke Greg, 1993, Current Opinion in Neurobiology, V3, P703, DOI 10.1016/0959-4388(93)90141-K; Leon-Quinto T, 2004, DIABETOLOGIA, V47, P1442, DOI 10.1007/s00125-004-1458-8; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; Lumelsky N, 2001, SCIENCE, V292, P1389, DOI 10.1126/science.1058866; Maestre I, 2003, ENDOCRINOLOGY, V144, P335, DOI 10.1210/en.2001-211282; MARTIN F, 1995, DIABETOLOGIA, V38, P860, DOI 10.1007/s001250050364; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; NADAL A, 1995, P NATL ACAD SCI USA, V92, P1426, DOI 10.1073/pnas.92.5.1426; Nadal A, 1997, GLIA, V19, P343, DOI 10.1002/(SICI)1098-1136(199704)19:4<343::AID-GLIA7>3.0.CO;2-Y; Odorico JS, 2001, STEM CELLS, V19, P193, DOI 10.1634/stemcells.19-3-193; Pachernik J, 2002, REPROD NUTR DEV, V42, P317, DOI 10.1051/rnd:2002028; Paparella M, 2002, TOXICOL IN VITRO, V16, P589, DOI 10.1016/S0887-2333(02)00052-8; Pattyn A, 2003, DEVELOPMENT, V130, P4149, DOI 10.1242/dev.00641; Perez-Villamil B, 1999, ENDOCRINOLOGY, V140, P3857, DOI 10.1210/en.140.8.3857; PEREZVILLAMIL B, 1994, ENDOCRINOLOGY, V135, P2342, DOI 10.1210/en.135.6.2342; PERLER F, 1980, CELL, V20, P555, DOI 10.1016/0092-8674(80)90641-8; Piper K, 2002, DIABETOLOGIA, V45, P1045, DOI 10.1007/s00125-002-0864-z; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Roche E, 2003, MED BIOL ENG COMPUT, V41, P384, DOI 10.1007/BF02348079; Roche E, 2003, CYTOTECHNOLOGY, V41, P145, DOI 10.1023/A:1024878807264; Rorsman P, 2003, DIABETOLOGIA, V46, P1029, DOI 10.1007/s00125-003-1153-1; Schuit FC, 2001, DIABETES, V50, P1, DOI 10.2337/diabetes.50.1.1; Schuldiner M, 2000, P NATL ACAD SCI USA, V97, P11307, DOI 10.1073/pnas.97.21.11307; Sipione S, 2004, DIABETOLOGIA, V47, P499, DOI 10.1007/s00125-004-1349-z; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; Sommer L, 1996, MOL CELL NEUROSCI, V8, P221, DOI 10.1006/mcne.1996.0060; Soria B, 2001, DIFFERENTIATION, V68, P205, DOI 10.1046/j.1432-0436.2001.680408.x; Soria B, 2000, DIABETES, V49, P157, DOI 10.2337/diabetes.49.2.157; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Tropepe V, 2001, NEURON, V30, P65, DOI 10.1016/S0896-6273(01)00263-X; Vicario-Abejon C, 2003, J NEUROSCI, V23, P895; Wagner J, 1999, NAT BIOTECHNOL, V17, P653, DOI 10.1038/10862; Wells JM, 2003, DIABETES-METAB RES, V19, P191, DOI 10.1002/dmrr.364; Wilson ME, 2003, MECH DEVELOP, V120, P65, DOI 10.1016/S0925-4773(02)00333-7; Wolkow CA, 2000, SCIENCE, V290, P147, DOI 10.1126/science.290.5489.147; Yamada T, 2002, STEM CELLS, V20, P41, DOI 10.1634/stemcells.20-1-41; Yang XJ, 1999, DIABETES, V48, P1763, DOI 10.2337/diabetes.48.9.1763; Yin Y, 2002, STEM CELLS, V20, P338, DOI 10.1634/stemcells.20-4-338; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; Zalzman M, 2003, P NATL ACAD SCI USA, V100, P7253, DOI 10.1073/pnas.1136854100	67	29	72	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1341	+		10.1096/fj.04-3024fje	http://dx.doi.org/10.1096/fj.04-3024fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15928194	Green Published			2022-12-28	WOS:000229602600002
J	Kropf, P; Fuentes, JM; Fahnrich, E; Arpa, L; Herath, S; Weber, V; Soler, G; Celada, A; Modolell, M; Muller, I				Kropf, P; Fuentes, JM; Fahnrich, E; Arpa, L; Herath, S; Weber, V; Soler, G; Celada, A; Modolell, M; Muller, I			Arginase and polyamine synthesis are key factors in the regulation of experimental leishmaniasis in vivo	FASEB JOURNAL			English	Article						L-arginine metabolism; Leishmania major; infection; macrophages	NITRIC-OXIDE SYNTHASE; HUMAN MONONUCLEAR-CELLS; L-ARGININE; MURINE MACROPHAGES; ALTERNATIVE ACTIVATION; MAJOR INFECTION; T-CELLS; EXPRESSION; AVAILABILITY; CYTOKINES	Arginase 1, an enzyme induced by Th2 cytokines, is a hallmark of alternatively activated macrophages and is responsible for the hydrolysis of L-arginine into ornithine, the building block for the production of polyamines. Upregulation of arginase 2 has been observed in a variety of diseases, but the mechanisms by which arginase contributes to pathology are not well understood. We reveal here a unique role for arginase 1 in the pathogenesis of nonhealing leishmaniasis, a prototype Th2 disease, and demonstrate that the activity of this enzyme promotes pathology and uncontrolled growth of Leishmania parasites in vivo. Inhibition of arginase activity during the course of infection has a clear therapeutic effect, as evidenced by markedly reduced pathology and efficient control of parasite replication. Despite the clear amelioration of the disease, this treatment does not alter the Th2 response. To address the underlying mechanisms, the arginase-induced L-arginine catabolism was investigated and the results demonstrate that arginase regulates parasite growth directly by affecting the polyamine synthesis in macrophages.	Univ London Imperial Coll Sci Technol & Med, Dept Immunol, Fac Med, London W2 1PG, England; Univ Extremadura, EU Enfermeria & TO, Dept Bioquim & Biol Mol, Caceres, Spain; Max Planck Inst Immunobiol, D-7800 Freiburg, Germany; Univ Barcelona, Grp Macrophage Biol, E-08007 Barcelona, Spain; Univ Extremadura, Fac Vet, Dept Bioquim & Biol Mol, Caceres, Spain	Imperial College London; Universidad de Extremadura; Max Planck Society; University of Barcelona; Universidad de Extremadura	Muller, I (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Immunol, Fac Med, Norfolk Pl, London W2 1PG, England.	i.muller@imperial.ac.uk	Celada, Antonio/I-1714-2016; Fuentes, Jose M/H-9490-2014; Fuentes, Jose M./AAV-5164-2021	Fuentes, Jose M/0000-0001-6910-2089; Fuentes, Jose M./0000-0001-6910-2089; SOLER, GERMAN/0000-0002-5859-1371; Celada, Antonio/0000-0003-3883-2171				Bansal V, 2003, CURR OPIN CLIN NUTR, V6, P223, DOI 10.1097/00075197-200303000-00012; Berkowitz DE, 2003, CIRCULATION, V108, P2000, DOI 10.1161/01.CIR.0000092948.04444.C7; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Boucher JL, 1999, CELL MOL LIFE SCI, V55, P1015, DOI 10.1007/s000180050352; Bronte V, 2003, J IMMUNOL, V170, P270, DOI 10.4049/jimmunol.170.1.270; Bruch-Gerharz D, 2003, AM J PATHOL, V162, P203, DOI 10.1016/S0002-9440(10)63811-4; CAMARGO EP, 1978, EXP PARASITOL, V46, P141, DOI 10.1016/0014-4894(78)90125-X; Cederbaum SD, 2004, MOL GENET METAB, V81, pS38, DOI 10.1016/j.ymgme.2003.10.012; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; Custot J, 1997, J AM CHEM SOC, V119, P4086, DOI 10.1021/ja970285o; DIEZ A, 1994, BIOL CHEM H-S, V375, P537, DOI 10.1515/bchm3.1994.375.8.537; DING AH, 1988, J IMMUNOL, V141, P2407; Duleu S, 2004, J IMMUNOL, V172, P6298, DOI 10.4049/jimmunol.172.10.6298; El-Gayar S, 2003, J IMMUNOL, V171, P4561, DOI 10.4049/jimmunol.171.9.4561; Etges R, 1998, J MOL MED, V76, P372, DOI 10.1007/s001090050230; Fligger J, 1999, IMMUNOBIOLOGY, V200, P169, DOI 10.1016/S0171-2985(99)80068-0; Fuentes JM, 2000, ANAL BIOCHEM, V285, P276, DOI 10.1006/abio.2000.4784; Gobert AP, 2000, INFECT IMMUN, V68, P4653, DOI 10.1128/IAI.68.8.4653-4657.2000; Goerdt S, 1999, IMMUNITY, V10, P137, DOI 10.1016/S1074-7613(00)80014-X; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Hasko G, 2000, SHOCK, V14, P144, DOI 10.1097/00024382-200014020-00012; Hesse M, 2001, J IMMUNOL, V167, P6533, DOI 10.4049/jimmunol.167.11.6533; HOFMANN F, 1978, Biochemical Society Transactions, V6, P990; Iniesta V, 2002, PARASITE IMMUNOL, V24, P113, DOI 10.1046/j.1365-3024.2002.00444.x; Iniesta V, 2001, J EXP MED, V193, P777, DOI 10.1084/jem.193.6.777; Jenkinson CP, 1996, COMP BIOCHEM PHYS B, V114, P107, DOI 10.1016/0305-0491(95)02138-8; Jost MM, 2003, FASEB J, V17, P2281, DOI 10.1096/fj.03-0071fje; Kepka-Lenhart D, 2000, AM J PHYSIOL-REG I, V279, pR2237; Kropf P, 2004, INFECT IMMUN, V72, P1920, DOI 10.1128/IAI.72.4.1920-1928.2004; Kropf P, 2004, J LEUKOCYTE BIOL, V76, P48, DOI 10.1189/jlb.1003484; Kropf P, 2003, PARASITE IMMUNOL, V25, P439, DOI 10.1111/j.1365-3024.2003.00655.x; KROPF P, 1958, METHOD MICROBIOL, P419; Kusmartsev S, 2004, J IMMUNOL, V172, P989, DOI 10.4049/jimmunol.172.2.989; Loke P, 2000, EUR J IMMUNOL, V30, P2669, DOI 10.1002/1521-4141(200009)30:9&lt;2669::AID-IMMU2669&gt;3.0.CO;2-1; Louis CA, 1999, AM J PHYSIOL-REG I, V276, pR237, DOI 10.1152/ajpregu.1999.276.1.R237; Marques L, 2004, J IMMUNOL, V173, P1103, DOI 10.4049/jimmunol.173.2.1103; MAUEL J, 1991, J LEUKOCYTE BIOL, V49, P73, DOI 10.1002/jlb.49.1.73; Meurs H, 2002, BRIT J PHARMACOL, V136, P391, DOI 10.1038/sj.bjp.0704725; Moali C, 1998, BIOCHEMISTRY-US, V37, P10453, DOI 10.1021/bi980742t; MODOLELL M, 1995, EUR J IMMUNOL, V25, P1101, DOI 10.1002/eji.1830250436; MORGAN DML, 1994, BIOCHEM SOC T, V22, P879, DOI 10.1042/bst0220879; Morris CR, 2004, AM J RESP CRIT CARE, V170, P148, DOI 10.1164/rccm.200309-1304OC; Muller S, 2001, TRENDS PARASITOL, V17, P242, DOI 10.1016/S1471-4922(01)01908-0; Munder M, 1999, J IMMUNOL, V163, P3771; Munder M, 2005, BLOOD, V105, P2549, DOI 10.1182/blood-2004-07-2521; Munder M, 1998, J IMMUNOL, V160, P5347; MUNDER PG, 1971, FEBS LETT, V15, P191, DOI 10.1016/0014-5793(71)80309-5; Noel W, 2004, TRENDS PARASITOL, V20, P126, DOI 10.1016/j.pt.2004.01.004; Ochoa JB, 2001, ANN SURG, V233, P393, DOI 10.1097/00000658-200103000-00014; Perez-Cano FJ, 2003, CELL IMMUNOL, V226, P86, DOI 10.1016/j.cellimm.2003.09.009; Rangel MD, 2002, CLIN EXP MED, V2, P53; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055; Roberts SC, 2004, J BIOL CHEM, V279, P23668, DOI 10.1074/jbc.M402042200; Rodriguez PC, 2002, J BIOL CHEM, V277, P21123, DOI 10.1074/jbc.M110675200; Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933; Sacks D, 2002, NAT IMMUNOL, V3, P1041, DOI 10.1038/ni1102-1041; Stempin C, 2002, J LEUKOCYTE BIOL, V72, P727; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Tenu JP, 1999, NITRIC OXIDE-BIOL CH, V3, P427, DOI 10.1006/niox.1999.0255; TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x; Vincendeau P, 2003, TRENDS PARASITOL, V19, P9, DOI 10.1016/S1471-4922(02)00010-7; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; Xu LY, 2003, IMMUNOLOGY, V110, P141, DOI 10.1046/j.1365-2567.2003.01713.x; Zea AH, 1998, INFECT IMMUN, V66, P499, DOI 10.1128/IAI.66.2.499-504.1998; Zhang MH, 1997, J EXP MED, V185, P1759, DOI 10.1084/jem.185.10.1759; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	67	220	225	1	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1000	+		10.1096/fj.04-3416fje	http://dx.doi.org/10.1096/fj.04-3416fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15811879				2022-12-28	WOS:000228865300028
J	Lee, I; Hong, WJ				Lee, Ian; Hong, Wanjin			Diverse membrane-associated proteins contain a novel SMP domain	FASEB JOURNAL			English	Article						PROBE; chaperones; signaling; eukaryotic; complexes	MITOCHONDRIAL-MEMBRANES; HOMOLOGY DOMAINS; COMPLEXES; DATABASE; FOLD	We have analyzed the sequence of a mitochondrial integral membrane protein, Mdm12, and found that it forms the prototype for a novel domain, designated the SMP domain, that is common to an extended family of membrane-associated proteins. Comprehensive sequence searches using protein alignment models of SMP proteins were cross-validated by statistical resampling; providing strong support for these relationships. No consensus of 3-dimensional structure was reached upon threading sequences through known folds. SMP proteins are widespread amongst eukaryotic species with a particular enrichment in plants and features suggestive of species-specific functional variations. Members of 2 SMP families, the mitochore and tricalbin proteins, are essential components of protein complexes involved in mitochondrial inheritance and receptor endocytosis while a third SMP protein family, HT008, is associated with the Rvs161-Rvs167 complex, a known regulator of sphingolipid metabolism. In addition, HT008 and PDZK8 SMP proteins possess additional protein-protein interaction domains in domain architectures that are typical of protein scaffolds and adaptors. We therefore predict that the SMP domain is an important link between these distinct membrane-associated proteins and a key regulatory hub for unidentified global regulators.	Inst Mol & Cell Biol, Computat Mol Biol Programme, Singapore 138673, Singapore; Inst Mol & Cell Biol, Membrane Biol Lab, Singapore 138673, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Lee, I (corresponding author), Inst Mol & Cell Biol, Computat Mol Biol Programme, 61 Biopolis Dr, Singapore 138673, Singapore.	leehh@imcb.a-star.edu.sg	HONG, Wanjin/E-9927-2010					Aravind L, 1999, J MOL BIOL, V287, P1023, DOI 10.1006/jmbi.1999.2653; Blomberg N, 1999, TRENDS BIOCHEM SCI, V24, P441, DOI 10.1016/S0968-0004(99)01472-3; Boldogh IR, 2003, MOL BIOL CELL, V14, P4618, DOI 10.1091/mbc.E03-04-0225; Creutz CE, 2004, CELL MOL LIFE SCI, V61, P1208, DOI 10.1007/s00018-004-4029-8; Germann M, 2005, J BIOL CHEM, V280, P4270, DOI 10.1074/jbc.M412454200; Goodstadt L, 2001, BIOINFORMATICS, V17, P845, DOI 10.1093/bioinformatics/17.9.845; Hurley JH, 1997, PROTEIN SCI, V6, P477; JONES DT, 1995, PROTEINS, V23, P387, DOI 10.1002/prot.340230312; Kondo-Okamoto N, 2003, J BIOL CHEM, V278, P48997, DOI 10.1074/jbc.M308436200; Landgraf C, 2004, PLOS BIOL, V2, P94, DOI 10.1371/journal.pbio.0020014; Lee SY, 2003, P NATL ACAD SCI USA, V100, P2651, DOI 10.1073/pnas.0437972100; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Neuwald AF, 1999, GENOME RES, V9, P27; Neuwald AF, 1997, NUCLEIC ACIDS RES, V25, P1665, DOI 10.1093/nar/25.9.1665; RANGANATHAN R, 1997, CURR BIOL, V7, P770; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Schulz TA, 2004, BIOCHEMISTRY-US, V43, P3987, DOI 10.1021/bi036082w; Soti C, 2005, CURR OPIN CELL BIOL, V17, P210, DOI 10.1016/j.ceb.2005.02.012	20	66	67	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					202	206		10.1096/fj.05-4581hyp	http://dx.doi.org/10.1096/fj.05-4581hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449791				2022-12-28	WOS:000237698700004
J	Petrosillo, G; Di Venosa, N; Pistolese, M; Casanova, G; Tiravanti, E; Colantuono, G; Federici, A; Paradies, G; Ruggiero, FM				Petrosillo, G.; Di Venosa, N.; Pistolese, M.; Casanova, G.; Tiravanti, E.; Colantuono, G.; Federici, A.; Paradies, G.; Ruggiero, F. M.			Protective effect of melatonin against mitochondrial dysfunction associated with cardiac ischemia-reperfusion: role of cardiolipin	FASEB JOURNAL			English	Article						ROS; mitochondria; MPT	CYTOCHROME-C-OXIDASE; OXYGEN RADICAL GENERATION; RAT-HEART MITOCHONDRIA; PERMEABILITY TRANSITION; MYOCARDIAL REPERFUSION; LIVER-MITOCHONDRIA; RESPIRATORY-CHAIN; COMPLEX-I; HYDROGEN-PEROXIDE; OXIDATIVE STRESS	Reactive oxygen species (ROS) are considered an important factor in ischemia/reperfusion injury to cardiac myocytes. Mitochondrial respiration, mainly at the level of complex I and III, is an important source of ROS generation and hence a potential contributor of cardiac reperfusion injury. Appropriate antioxidant strategies could be particularly useful to limit this ROS generation and associated mitochondrial dysfunction. Melatonin has been shown to effectively protect against ischemic-reperfusion myocardial damage. The mechanism by which melatonin exerts this cardioprotective effect is not well established. In the present study we examined the effects of melatonin on various parameters of mitochondrial bioenergetics in a Langerdoff isolated perfused rat heart model. After isolation of mitochondria from control, ischemic-reperfused and melatonin-treated ischemic-reperfused rat heart, various bioenergetic parameters were evaluated such as rates of mitochondrial oxygen consumption, complex I and complex III activity, H2O2 production as well as the degree of lipid peroxidation, cardiolipin content, and cardiolipin oxidation. We found that reperfusion significantly altered all these mitochondrial parameters, while melatonin treatment had strong protective effect attenuating these alterations. This effect appears to be due, at least in part, to the preservation, by ROS attack, of the content and integrity of cardiolipin molecules which play a pivotal role in mitochondrial bioenergetics. Protection of mitochondrial dysfunction was associated with an improvement of post-ischemic hemodynamic function of the heart. Melatonin had also strong protective effect against oxidative alterations to complex I and III as well as to cardiolipin in isolated mitochondria.	Univ Bari, Dept Biochem & Mol Biol, Bari, Italy; Univ Bari, CNR, Inst Biomembranes & Bioenerget, Bari, Italy; Univ Bari, Dept Emergency & Transplantat, Bari, Italy; Univ Bari, Dept Pharmacol & Human Physiol, Bari, Italy	Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle Ricerche (CNR); Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Paradies, G (corresponding author), Univ Bari, Dept Biochem & Mol Biol, Bari, Italy.	g.paradies@biologia.uniba.it		PETROSILLO, GIUSEPPE/0000-0001-8035-8368; federici, antonio/0000-0001-5102-9995				Adlam VJ, 2005, FASEB J, V19, P1088, DOI 10.1096/fj.05-3718com; Allegra M, 2003, J PINEAL RES, V34, P1, DOI 10.1034/j.1600-079X.2003.02112.x; AMBROSIO G, 1991, J MOL CELL CARDIOL, V23, P1359, DOI 10.1016/0022-2828(91)90183-M; Andrabi SA, 2004, FASEB J, V18, P869, DOI 10.1096/fj.03-1031fje; Becker LB, 2004, CARDIOVASC RES, V61, P461, DOI 10.1016/j.cardiores.2003.10.025; BLACK MJ, 1974, ANAL BIOCHEM, V58, P246, DOI 10.1016/0003-2697(74)90464-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; Buege J A, 1978, Methods Enzymol, V52, P302; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Das DK, 1994, ANN NY ACAD SCI, V723, P116; Dobsak P, 2003, Pathophysiology, V9, P179, DOI 10.1016/S0928-4680(02)00080-9; Drose S, 2002, BBA-BIOENERGETICS, V1556, P65, DOI 10.1016/S0005-2728(02)00307-9; FRY M, 1981, J BIOL CHEM, V256, P1874; Halestrap AP, 2004, CARDIOVASC RES, V61, P372, DOI 10.1016/S0008-6363(03)00533-9; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; Hatch GM, 1996, MOL CELL BIOCHEM, V159, P139, DOI 10.1007/BF00420916; HESS ML, 1984, J MOL CELL CARDIOL, V16, P969, DOI 10.1016/S0022-2828(84)80011-5; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; Kaneko S, 2000, LIFE SCI, V67, P101, DOI 10.1016/S0024-3205(00)00607-X; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Lagneux C, 2000, LIFE SCI, V66, P503, DOI 10.1016/S0024-3205(99)00620-7; Lange C, 2001, EMBO J, V20, P6591, DOI 10.1093/emboj/20.23.6591; Leon J, 2004, LIFE SCI, V75, P765, DOI 10.1016/j.lfs.2004.03.003; Leon J, 2005, J PINEAL RES, V38, P1, DOI 10.1111/j.1600-079X.2004.00181.x; Lesnefsky EJ, 2004, J BIOL CHEM, V279, P47961, DOI 10.1074/jbc.M409720200; Lesnefsky EJ, 2001, J MOL CELL CARDIOL, V33, P1065, DOI 10.1006/jmcc.2001.1378; Lopez-Torres M, 2002, FREE RADICAL BIO MED, V32, P882, DOI 10.1016/S0891-5849(02)00773-6; Martin M, 2000, FASEB J, V14, P1677; MCCORD JM, 1988, FREE RADICAL BIO MED, V4, P9, DOI 10.1016/0891-5849(88)90005-6; McMillin JB, 2002, BBA-MOL CELL BIOL L, V1585, P97, DOI 10.1016/S1388-1981(02)00329-3; Okatani Y, 2003, EUR J PHARMACOL, V469, P145, DOI 10.1016/S0014-2999(03)01643-1; Paradies G, 2002, GENE, V286, P135, DOI 10.1016/S0378-1119(01)00814-9; Paradies G, 2001, MITOCHONDRION, V1, P151, DOI 10.1016/S1567-7249(01)00011-3; Paradies G, 1999, FREE RADICAL BIO MED, V27, P42, DOI 10.1016/S0891-5849(99)00032-5; Paradies G, 2004, CIRC RES, V94, P53, DOI 10.1161/01.RES.0000109416.56608.64; Paradies G, 1997, FEBS LETT, V406, P136, DOI 10.1016/S0014-5793(97)00264-0; Paradies G, 1998, FEBS LETT, V424, P155, DOI 10.1016/S0014-5793(98)00161-6; Paradies G, 1997, BBA-BIOENERGETICS, V1319, P5, DOI 10.1016/S0005-2728(97)00012-1; PARINANDI NL, 1988, CHEM PHYS LIPIDS, V49, P215, DOI 10.1016/0009-3084(88)90009-6; Petrosillo G, 2004, J BIOL CHEM, V279, P53103, DOI 10.1074/jbc.M407500200; PETROSILLO G, 2003, FASEB J, V17, P714, DOI DOI 10.1096/fj.02-0729fje; Reiter RJ, 2003, CARDIOVASC RES, V58, P10, DOI 10.1016/S0008-6363(02)00827-1; ROBINSON NC, 1993, J BIOENERG BIOMEMBR, V25, P153, DOI 10.1007/BF00762857; RUGGIERO FM, 1984, LIPIDS, V19, P171, DOI 10.1007/BF02534794; Salie R, 2001, J MOL CELL CARDIOL, V33, P343, DOI 10.1006/jmcc.2000.1306; Schlame M, 1997, BBA-LIPID LIPID MET, V1348, P207, DOI 10.1016/S0005-2760(97)00119-7; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; SHANDELYA SML, 1993, CIRCULATION, V87, P536, DOI 10.1161/01.CIR.87.2.536; Tan DX, 1998, J PINEAL RES, V25, P184, DOI 10.1111/j.1600-079X.1998.tb00558.x; THOMPSONGORMAN SL, 1990, J BIOL CHEM, V265, P6656; VandenHoek TL, 1996, AM J PHYSIOL-HEART C, V270, pH1334, DOI 10.1152/ajpheart.1996.270.4.H1334; XIA Y, 1995, J BIOL CHEM, V270, P18797, DOI 10.1074/jbc.270.32.18797; Zhang M, 2002, J BIOL CHEM, V277, P43553, DOI 10.1074/jbc.C200551200; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404	57	101	122	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					269	276		10.1096/fj.05-4692com	http://dx.doi.org/10.1096/fj.05-4692com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449799				2022-12-28	WOS:000237698700012
J	Stephens, FB; Constantin-Teodosiu, D; Laithwaite, D; Simpson, EJ; Greenhaff, PL				Stephens, Francis B.; Constantin-Teodosiu, Dumitru; Laithwaite, David; Simpson, Elizabeth J.; Greenhaff, Paul L.			Insulin stimulates L-carnitine accumulation in human skeletal muscle	FASEB JOURNAL			English	Article									[Stephens, Francis B.; Constantin-Teodosiu, Dumitru; Laithwaite, David; Simpson, Elizabeth J.; Greenhaff, Paul L.] Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Ctr Integrated Syst Biol & Med, Nottingham NG7 2UH, England	University of Nottingham	Stephens, FB (corresponding author), Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Sch Med, Nottingham NG7 2UH, England.	mbxfbs@nottingham.ac.uk	, Liz/M-7432-2019	, Liz/0000-0001-9353-6258; Constantin-Teodosiu, Dumitru/0000-0002-8448-5564; Greenhaff, Paul/0000-0003-4403-0490; Stephens, Francis/0000-0001-6312-5351					0	73	75	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					377	379		10.1096/fj.05-4985fje	http://dx.doi.org/10.1096/fj.05-4985fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16368715				2022-12-28	WOS:000207915000027
J	Garrison, HH; Stith, AL; Gerbi, SA				Garrison, HH; Stith, AL; Gerbi, SA			Foreign postdocs: the changing face of biomedical science in the US	FASEB JOURNAL			English	Editorial Material									Federat Amer Soc Expt Biol, Bethesda, MD USA; Howard Hughes Med Inst, Chevy Chase, MD USA; Brown Univ, Div Biol & Med, Providence, RI 02912 USA	Howard Hughes Medical Institute; Brown University	Garrison, HH (corresponding author), Federat Amer Soc Expt Biol, Bethesda, MD USA.	hgarrison@faseb.org		Garrison, Howard/0000-0001-9455-3527				BROWN HA, FINDINGS 2005 CGS IN; *COMM LARG SCAL SC, 2003, LARG SCAL BIOM SCI E; DILLON S, 2004, NY TIMES        1221; Finn Michael G., 2003, STAY RATES FOREIGN D; Freeman R, 2001, SCIENCE, V294, P2293, DOI 10.1126/science.1067477; Freeman R. B., 2005, NBER WORKING PAPER; Garrison HH, 2003, FASEB J, V17, P2169, DOI 10.1096/fj.03-0836life; Gerbi SA, 2001, SCIENCE, V292, P1489, DOI 10.1126/science.1059268; LIU M, 2003, ANAL BREIF 2; *NAT AC SCI COMM S, 2002, ENH POSTD EXP SCI EN; *NAT SCI FDN, 1994, SEL DAT SCI ENG DOCT; National Research Council, 2005, BRIDG IND FOST IND N; National Research Council, 2005, POL IMPL INT GRAD ST; National Research Council, 1998, TRENDS EARL CAR LIF; National Science Board, 2004, SCI ENG IND 2004, V2; SAHADI J, 2005, BIG JOBS PAY BADLY; Yamagata H, 2002, TRENDS FACULTY ATTRI	17	14	14	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2005	19	14					1938	1942		10.1096/fj.05-1203ufm	http://dx.doi.org/10.1096/fj.05-1203ufm			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16319136				2022-12-28	WOS:000234405500003
J	Li, ZH; Zhao, RJ; Wu, XH; Sun, Y; Yao, M; Li, JJ; Xu, YH; Gu, JR				Li, ZH; Zhao, RJ; Wu, XH; Sun, Y; Yao, M; Li, JJ; Xu, YH; Gu, JR			Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics	FASEB JOURNAL			English	Article						EGFR; peptide synthesis; peptide ligand	EFFICIENT GENE-TRANSFER; IN-VITRO; FORMULATIONS; LIPIDS	Epidermal growth factor receptor (ErbB1, EGFR) is overexpressed in a variety of human cancer cells. It has been considered as a rational target for drug delivery. To identify novel ligands with specific binding capabilities to EGFR, we screened a phage display peptide library and found an enriched phage clone encoding the amino acid sequence YHWYGYT-PQNVI (designated as GE11). Competitive binding assay and Scatchard analysis revealed that GE11 peptide bound specifically and efficiently to EGFR with a dissociation constant of similar to 22 nM, but with much lower mitogenic activity than with EGF. We showed that the peptides were internalized preferentially into EGFR highly expressing cells, and they accumulated in EGFR overexpressing tumor xenografts after i.v. delivery in vivo. In gene delivery studies, GE11-conjugated polyethylenimine (PEI) vectors were less mitogenic, but still quite efficient at transfecting genes into EGFR highly expressing cells and tumor xenografts. Taken together, GE11 is a potentially safe and efficient targeting moiety for selective drug delivery systems mediated through EGFR.	Shanghai Jiao Tong Univ, Natl Lab Oncogenes & Related Genes, Coll Med, Shanghai Canc Inst, Shanghai 200032, Peoples R China; Shanghai Jiao Tong Univ, Sch Pharm, Shanghai 200032, Peoples R China; Fudan Univ, Coll Med, Shanghai 200433, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Fudan University	Xu, YH (corresponding author), Shanghai Jiao Tong Univ, Natl Lab Oncogenes & Related Genes, Coll Med, Shanghai Canc Inst, 25-2200,Xietu Rd, Shanghai 200032, Peoples R China.	yhxu@sjtu.edu.cn	Xu, Yuhong/E-4247-2012	Li, Zonghai/0000-0003-2448-3636				Balasubramaniam RP, 1996, GENE THER, V3, P163; Binetruy-Tournaire R, 2000, EMBO J, V19, P1525, DOI 10.1093/emboj/19.7.1525; Blessing T, 2001, BIOCONJUGATE CHEM, V12, P529, DOI 10.1021/bc0001488; Chiu SH, 2004, J CONTROL RELEASE, V97, P357, DOI 10.1016/j.jconrel.2004.03.019; Gorman CM, 1997, GENE THER, V4, P983, DOI 10.1038/sj.gt.3300473; Gosselin MA, 2001, BIOCONJUGATE CHEM, V12, P989, DOI 10.1021/bc0100455; Gosselin MA, 2002, BIOCONJUGATE CHEM, V13, P1044, DOI 10.1021/bc025512c; Halin C, 2003, CANCER RES, V63, P3202; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Jong M, 2003, EUR J NUCL MED MOL I, V30, P463, DOI 10.1007/s00259-002-1107-8; Kunath K, 2003, J GENE MED, V5, P588, DOI 10.1002/jgm.382; Kursa M, 2003, BIOCONJUGATE CHEM, V14, P222, DOI 10.1021/bc0256087; Langer M., 2001, Current Medicinal Chemistry - Anti-Cancer Agents, V1, P71, DOI 10.2174/1568011013354877; Lee ER, 1996, HUM GENE THER, V7, P1701, DOI 10.1089/hum.1996.7.14-1701; Li S, 2000, AM J PHYSIOL-LUNG C, V278, pL504, DOI 10.1152/ajplung.2000.278.3.L504; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; Mamot C, 2003, CANCER RES, V63, P3154; MICHAEL SI, 1995, GENE THER, V2, P660; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; Rajotte D, 1999, J BIOL CHEM, V274, P11593, DOI 10.1074/jbc.274.17.11593; SafiejkoMroczka B, 1996, J HISTOCHEM CYTOCHEM, V44, P641, DOI 10.1177/44.6.8666749; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SOLODIN I, 1995, BIOCHEMISTRY-US, V34, P13537, DOI 10.1021/bi00041a033; White SJ, 2001, HYPERTENSION, V37, P449, DOI 10.1161/01.HYP.37.2.449; Wolschek MF, 2002, HEPATOLOGY, V36, P1106, DOI 10.1053/jhep.2002.36372; Woodburn JR, 1999, PHARMACOL THERAPEUT, V82, P241, DOI 10.1016/S0163-7258(98)00045-X; Zou YY, 2000, CANCER GENE THER, V7, P683, DOI 10.1038/sj.cgt.7700156	28	309	340	6	121	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2005	19	14					1978	1985		10.1096/fj.05-4058com	http://dx.doi.org/10.1096/fj.05-4058com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16319141				2022-12-28	WOS:000234405500008
J	Taha, TA; Kitatani, K; El-Alwani, M; Bielawski, J; Hannun, YA; Obeid, LM				Taha, TA; Kitatani, K; El-Alwani, M; Bielawski, J; Hannun, YA; Obeid, LM			Loss of sphingosine kinase-1 activates the intrinsic pathway of programmed cell death: modulation of sphingolipid levels and the induction of apoptosis	FASEB JOURNAL			English	Article						ceramide; Bax; mitochondria	CANCER-THERAPY; SPHINGOSINE-1-PHOSPHATE PHOSPHOHYDROLASE; SIGNAL-TRANSDUCTION; INHIBITS APOPTOSIS; MOLECULAR-CLONING; CYTOCHROME-C; CA2+ SIGNALS; CERAMIDE; MEMBRANE; GROWTH	Activation of sphingosine kinase-1 (SK1) by overexpression or agonist stimulation promotes cell proliferation, survival, and anti-apoptosis. Studies on the function of endogenous SK1 are lacking. Endogenous SK1 has been shown to be down-regulated under stress, and knockdown of the enzyme reduces the percentage of viable MCF-7 breast cancer cells (Taha, T. A. et al. 2004. J. Biol. Chem. 279, 20546- 20554). In this study, we examined the mechanisms by which SK1 loss affects the growth of cells. Knockdown of the enzyme by small interfering RNA caused cell cycle arrest and induced apoptosis. Cell death involved effector caspase activation, cytochrome c release and Bax oligomerization in the mitochondrial membrane, thus placing SK1 knockdown upstream of the mitochondrial pathway of apoptosis. SK1 knockdown also induced significant increases in ceramide levels in whole cells and in mitochondria enriched fractions of cells. Inhibition of de novo sphingolipid biosynthesis with myriocin significantly attenuated Bax oligomerization and downstream caspase activation after SK1 loss. These studies for the first time implicate endogenous SK1 as an important survival enzyme in MCF-7 cells and link the biological consequences of knocking down the enzyme to its biochemical role as a regulator of sphingolipid metabolism.	Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Ralph H Johnson Vet Adm Hosp, Div Gen Internal Med, Charleston, SC 29401 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Obeid, LM (corresponding author), Med Univ S Carolina, Dept Med, 114 Doughty St,POB 250779, Charleston, SC 29425 USA.	obeidl@musc.edu	Kitatani, Kazuyuki/H-7100-2019	Kitatani, Kazuyuki/0000-0002-8516-6135; obeid, lina/0000-0002-0734-0847	NATIONAL CANCER INSTITUTE [P01CA097132] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016583] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA097132] Funding Source: Medline; NIA NIH HHS [AG16583] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bektas M, 2005, ONCOGENE, V24, P178, DOI 10.1038/sj.onc.1208019; Belaud-Rotureau MA, 2000, APOPTOSIS, V5, P551, DOI 10.1023/A:1009693630664; Birbes H, 2005, BIOCHEM J, V386, P445, DOI 10.1042/BJ20041627; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brindley DN, 2002, BBA-MOL CELL BIOL L, V1582, P33, DOI 10.1016/S1388-1981(02)00135-X; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0; Cuvillier O, 2001, BLOOD, V98, P2828, DOI 10.1182/blood.V98.9.2828; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; Edsall LC, 2001, J NEUROCHEM, V76, P1573, DOI 10.1046/j.1471-4159.2001.00164.x; El-Assaad W, 1998, BIOCHEM J, V336, P735, DOI 10.1042/bj3360735; ENDO K, 1991, CANCER RES, V51, P1613; Eto M, 2003, PROSTATE, V57, P66, DOI 10.1002/pros.10275; French KJ, 2003, CANCER RES, V63, P5962; Furuya S, 1998, J NEUROCHEM, V71, P366; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Granata R, 2004, FASEB J, V18, P1456, DOI 10.1096/fj.04-1618fje; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; Hannun YA, 1997, ADV EXP MED BIOL, V400, P305; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hong GY, 1999, FEBS LETT, V460, P513, DOI 10.1016/S0014-5793(99)01400-3; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Ibrahim FBM, 2004, J BIOL CHEM, V279, P44802, DOI 10.1074/jbc.M403977200; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Johnson KR, 2003, J BIOL CHEM, V278, P34541, DOI 10.1074/jbc.M301741200; Jung EM, 1998, J INVEST DERMATOL, V110, P318, DOI 10.1046/j.1523-1747.1998.00137.x; Kashkar H, 2005, J BIOL CHEM, V280, P20804, DOI 10.1074/jbc.M410869200; KHAN WA, 1990, BIOCHEM BIOPH RES CO, V172, P683, DOI 10.1016/0006-291X(90)90728-6; Kleuser B, 1998, CANCER RES, V58, P1817; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kroesen BJ, 2003, J BIOL CHEM, V278, P14723, DOI 10.1074/jbc.M210756200; Kurinna SM, 2004, CANCER RES, V64, P7852, DOI 10.1158/0008-5472.CAN-04-1552; Kwon YG, 2001, J BIOL CHEM, V276, P10627, DOI 10.1074/jbc.M011449200; Le Stunff H, 2002, J CELL BIOL, V158, P1039, DOI 10.1083/jcb.200203123; Lee TK, 1998, TAIWAN J MATH, V2, P457, DOI 10.11650/twjm/1500407017; LIMAYE VS, 2005, BLOOD; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Luberto C, 2002, J BIOL CHEM, V277, P41128, DOI 10.1074/jbc.M206747200; Mandala SM, 2000, P NATL ACAD SCI USA, V97, P7859, DOI 10.1073/pnas.120146897; Melendez AJ, 2004, J IMMUNOL, V173, P1596, DOI 10.4049/jimmunol.173.3.1596; Melendez AJ, 2002, J BIOL CHEM, V277, P17255, DOI 10.1074/jbc.M110944200; Nava VE, 2000, CANCER RES, V60, P4468; Nava VE, 2002, EXP CELL RES, V281, P115, DOI 10.1006/excr.2002.5658; Novgorodov SA, 2005, J BIOL CHEM, V280, P16096, DOI 10.1074/jbc.M411707200; Ogawa C, 2003, J BIOL CHEM, V278, P1268, DOI 10.1074/jbc.M209514200; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; OKOSHI H, 1991, CANCER RES, V51, P6019; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Olivera A, 2003, J BIOL CHEM, V278, P46452, DOI 10.1074/jbc.M308749200; Osawa Y, 2001, J IMMUNOL, V167, P173, DOI 10.4049/jimmunol.167.1.173; PARK YS, 1994, CANCER RES, V54, P2213; Pettus BJ, 2003, FASEB J, V17, P1411, DOI 10.1096/fj.02-1038com; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Pitson SM, 2002, J BIOL CHEM, V277, P49545, DOI 10.1074/jbc.M206687200; Reiss U, 2004, J BIOL CHEM, V279, P1281, DOI 10.1074/jbc.M309646200; Siskind LJ, 2002, J BIOL CHEM, V277, P26796, DOI 10.1074/jbc.M200754200; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Tafani M, 2002, J BIOL CHEM, V277, P49569, DOI 10.1074/jbc.M208915200; Taha TA, 2005, J BIOL CHEM, V280, P17196, DOI 10.1074/jbc.M413744200; Taha TA, 2004, J BIOL CHEM, V279, P20546, DOI 10.1074/jbc.M401259200; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Uchida Y, 2003, J INVEST DERMATOL, V120, P662, DOI 10.1046/j.1523-1747.2003.12098.x; vanEchtenDeckert G, 1997, J BIOL CHEM, V272, P15825, DOI 10.1074/jbc.272.25.15825; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Young KW, 2000, EUR J PHARMACOL, V402, P55, DOI 10.1016/S0014-2999(00)00509-4; Zhu XF, 2003, CANCER LETT, V193, P149, DOI 10.1016/S0304-3835(03)00050-8	75	121	133	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2005	19	14					482	+		10.1096/fj.05-4412fje	http://dx.doi.org/10.1096/fj.05-4412fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16507765				2022-12-28	WOS:000234405500015
J	Mazzola, S; Forni, M; Albertini, M; Bacci, ML; Zannoni, A; Gentilini, F; Lavitrano, M; Bach, FH; Otterbein, LE; Clement, MG				Mazzola, S; Forni, M; Albertini, M; Bacci, ML; Zannoni, A; Gentilini, F; Lavitrano, M; Bach, FH; Otterbein, LE; Clement, MG			Carbon monoxide pretreatment prevents respiratory derangement and ameliorates hyperacute endotoxic shock in pigs	FASEB JOURNAL			English	Article						LPS; CO; heme oxygenase	GMP-RELATED MESSENGER; HEME OXYGENASE-1; NITRIC-OXIDE; CYCLIC-GMP; LUNG INJURY; IN-VIVO; INHALATION; PULMONARY; INFLAMMATION; EXPRESSION	Endotoxic shock, one of the most prominent causes of mortality in intensive care units, is characterized by pulmonary hypertension, systemic hypotension, heart failure, widespread endothelial activation/ injury, and clotting culminating in disseminated intravascular coagulation and multi-organ system failure. In the last few years, studies in rodents have shown that administration of low concentrations of carbon monoxide ( CO) exerts potent therapeutic effects in a variety of diseases/disorders. In this study, we have administered CO ( one our pretreatment at 250 ppm) in a clinically relevant, well-characterized model of LPS-induced acute lung injury in pigs. Pretreatment only with inhaled CO significantly ameliorated several of the acute pathological changes induced by endotoxic shock. In terms of lung physiology, CO pretreatment corrected the LPS-induced changes in resistance and compliance and improved the derangement in pulmonary gas exchange. In terms of coagulation and inflammation, CO reduced the development of disseminated intravascular coagulation and completely suppressed serum levels of the proinflammatory IL-1 beta in response to LPS, while augmenting the anti-inflammatory cytokine IL-10. Moreover, the effects of CO blunted the deterioration of kidney and liver function, suggesting a beneficial effect in terms of end organ damage associated with endotoxic shock. Lastly, CO pretreatment prevents LPS-induced ICAM expression on lung endothelium and inhibits leukocyte marginalization on lung parenchyma.	Univ Milan, Dipartimento Patol Anim Igiene & Sanita Pubbl Vet, Sez Biochim & Fisiol Vet, Milan, Italy; Univ Bologna, Dipartimento Morfofisiol Vet & Prod Anim, Bologna, Italy; Univ Milan Bicocca, Dipartimento Sci Chirurg & Terapia Intens, Milan, Italy; Univ Bologna, Dipartimento Clin Vet, Bologna, Italy; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Immunobiol Res Ctr, Boston, MA 02115 USA	University of Milan; University of Bologna; University of Milano-Bicocca; University of Bologna; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Mazzola, S (corresponding author), Via Celoria 10, I-20133 Milan, Italy.	silvia.mazzola@unimi.it	Albertini, Mariangela/I-5989-2017; Bacci, Maria Laura/B-8494-2013; Lavitrano, Marialuisa/H-3417-2012; Mazzola, Silvia Michela/J-8137-2012	Albertini, Mariangela/0000-0002-6969-7809; Mazzola, Silvia Michela/0000-0001-8131-4340; Forni, Monica/0000-0003-1310-6202; Bacci, Maria Laura/0000-0001-6702-5868				Akamatsu Y, 2004, FASEB J, V18, P771, DOI 10.1096/fj.03-0921fje; Albertini M, 2000, J CRIT CARE, V15, P73, DOI 10.1053/jcrc.2000.7903; Ameredes BT, 2003, AM J PHYSIOL-LUNG C, V285, pL1270, DOI 10.1152/ajplung.00145.2003; Aukrust Pal, 2004, Am J Cardiovasc Drugs, V4, P169, DOI 10.2165/00129784-200404030-00004; Bouchet D, 2002, TRANSPL IMMUNOL, V9, P235, DOI 10.1016/S0966-3274(02)00037-0; BRIAN JE, 1994, STROKE, V25, P639, DOI 10.1161/01.STR.25.3.639; Cardell LO, 1998, BRIT J PHARMACOL, V124, P1065, DOI 10.1038/sj.bjp.0701878; Cardell LO, 1998, PULM PHARMACOL THER, V11, P309, DOI 10.1006/pupt.1998.0152; Choi AMK, 2002, ANTIOXID REDOX SIGN, V4, P227, DOI 10.1089/152308602753666271; DANGELO E, 1991, J APPL PHYSIOL, V70, P2602, DOI 10.1152/jappl.1991.70.6.2602; Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503; FURCHGOTT RF, 1991, BLOOD VESSELS, V28, P52; HYRICH KL, 2004, ANN RHEUM DIS; Ishikawa K, 2003, CURR PHARM DESIGN, V9, P2489, DOI 10.2174/1381612033453767; KOCHI T, 1988, J APPL PHYSIOL, V64, P441; Kourembanas S, 2002, ANTIOXID REDOX SIGN, V4, P291, DOI 10.1089/152308602753666343; Lavitrano M, 2004, FASEB J, V18, P1093, DOI 10.1096/fj.03-0996fje; Macdougall IC, 2004, NEPHROL DIAL TRANSPL, V19, P73, DOI 10.1093/ndt/gfh1060; Mayr FB, 2005, AM J RESP CRIT CARE, V171, P354, DOI 10.1164/rccm.200404-446OC; Middelveld RJM, 2003, ACTA PHYSIOL SCAND, V179, P203, DOI 10.1046/j.1365-201X.2003.01141.x; Middelveld RJM, 2002, ACTA PHYSIOL SCAND, V176, P71, DOI 10.1046/j.1365-201X.2002.01007.x; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; Nakao A, 2003, AM J PATHOL, V163, P1587, DOI 10.1016/S0002-9440(10)63515-8; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; Otterbein LE, 2002, ANTIOXID REDOX SIGN, V4, P309, DOI 10.1089/152308602753666361; Rutgeerts P, 2004, GASTROENTEROLOGY, V126, P1593, DOI 10.1053/j.gastro.2004.02.070; Ryter SW, 2004, BIOESSAYS, V26, P270, DOI 10.1002/bies.20005; Sarady JK, 2002, AM J RESP CELL MOL, V27, P739, DOI 10.1165/rcmb.4816; Sass G, 2003, HEPATOLOGY, V38, P909, DOI 10.1053/jhep.2003.50386; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; Wang R, 1997, BRIT J PHARMACOL, V121, P927, DOI 10.1038/sj.bjp.0701222; Yet SF, 1997, J BIOL CHEM, V272, P4295, DOI 10.1074/jbc.272.7.4295; Zampetaki A, 2003, EXP BIOL MED, V228, P442, DOI 10.1177/15353702-0322805-02; Zuckerbraun BS, 2003, J EXP MED, V198, P1707, DOI 10.1084/jem.20031003	36	76	84	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2045	+		10.1096/fj.05-3782fje	http://dx.doi.org/10.1096/fj.05-3782fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16223783				2022-12-28	WOS:000232991100020
J	Corti, S; Locatelli, F; Papadimitriou, D; Donadoni, C; Del Bo, R; Fortunato, F; Strazzer, S; Salani, S; Bresolin, N; Comi, GP				Corti, S; Locatelli, F; Papadimitriou, D; Donadoni, C; Del Bo, R; Fortunato, F; Strazzer, S; Salani, S; Bresolin, N; Comi, GP			Multipotentiality, homing properties, and pyramidal neurogenesis of CNS-derived LeX(ssea-1)(+)/CXCR4(+) stem cells	FASEB JOURNAL			English	Article						neural stem cells; transplantation; neurodegenerative diseases	NEURAL STEM; PROGENITOR CELLS; HEMATOPOIETIC STEM; INTRAVENOUS TRANSPLANTATION; CHOLINERGIC NEURONS; DIRECTED MIGRATION; ADULT RATS; MOUSE; MUSCLE; DIFFERENTIATION	Achieving efficient distribution of neural stem cells throughout the central nervous system (CNS) and robust generation of specific neurons is a major challenge for the development of cell-mediated therapy for neurodegenerative diseases. We isolated a primitive neural stem cell subset, double positive for LeX(Le) and CXCR4(CX) antigens that possesses CNS homing potential and extensive neuronal repopulating capacity. Le(+)CX(+) cells are multipotential and can generate neurons as well as myogenic and endothelial cells. In vivo Le(+)CX(+) cells displayed widespread incorporation and differentiated into cortical and hippocampal pyramidal neurons. Since intravenous delivery could be a less invasive route of transplantation, we investigated whether Le(+)CX(+) cells could migrate across endothelial monolayers. Intracerebral coadministration of SDF enabled migration of intravenously injected Le(+) CX+ cells into the CNS and a small, yet significant, number of donor cells differentiated into neurons. The isolation of a specific neural stem cell population could offer major advantages to neuronal replacement strategies.	Univ Milan, IRCCS Fdn Osped Maggiore Policlin Mangiagalli & R, Dept Neurol Sci, Dino Ferrari Ctr, I-20122 Milan, Italy; Univ Milan, Ctr Excellence Neurodegenerat Dis, Milan, Italy; IRCCS Eugenio Medea, Lecce, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Milan; IRCCS Eugenio Medea	Comi, GP (corresponding author), Univ Milan, IRCCS Fdn Osped Maggiore Policlin Mangiagalli & R, Dept Neurol Sci, Dino Ferrari Ctr, Padiglione Ponti,Via Francesco Sforza 35, I-20122 Milan, Italy.	giacomo.comi@unimi.it	Comi, Giacomo P/K-5702-2016; FEDERICA, LOCATELLI/AAA-5601-2020; Corti, Stefania/K-6034-2016; strazzer, sandra/AAH-5712-2019	Comi, Giacomo P/0000-0002-1383-5248; FEDERICA, LOCATELLI/0000-0002-8243-5483; Corti, Stefania/0000-0001-5425-969X; strazzer, sandra/0000-0001-8414-6565; Bresolin, Nereo/0000-0001-6694-3595				Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385; Capela A, 2002, NEURON, V35, P865, DOI 10.1016/S0896-6273(02)00835-8; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chu K, 2004, NEUROSCI RES, V50, P459, DOI 10.1016/j.neures.2004.08.015; Chu K, 2003, NEUROSCI LETT, V343, P129, DOI 10.1016/S0304-3940(03)00174-5; Corti S, 2004, BRAIN, V127, P2518, DOI 10.1093/brain/awh273; Corti S, 2002, EXP CELL RES, V277, P74, DOI 10.1006/excr.2002.5543; Corti S, 2001, EXP CELL RES, V268, P36, DOI 10.1006/excr.2001.5267; Donadoni C, 2004, J HISTOCHEM CYTOCHEM, V52, P1333, DOI 10.1369/jhc.4A6320.2004; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Galli R, 2000, NAT NEUROSCI, V3, P986, DOI 10.1038/79924; Gao J, 2005, NEUROSCIENCE, V131, P257, DOI 10.1016/j.neuroscience.2004.10.033; Gocht A, 1996, HISTOL HISTOPATHOL, V11, P1007; Guillery RW, 1997, J COMP NEUROL, V386, P2, DOI 10.1002/(SICI)1096-9861(19970915)386:1<2::AID-CNE2>3.0.CO;2-6; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Jang YY, 2004, NAT CELL BIOL, V6, P532, DOI 10.1038/ncb1132; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Jin KL, 2005, NEUROBIOL DIS, V18, P366, DOI 10.1016/j.nbd.2004.10.010; Kim M, 2003, J NEUROSCI, V23, P10703; Lee ST, 2005, NEUROSCI RES, V52, P243, DOI 10.1016/j.neures.2005.03.016; Lee Y, 2002, BLOOD, V99, P4307, DOI 10.1182/blood.V99.12.4307; Moore MAS, 2001, ANN NY ACAD SCI, V938, P36; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; Petropoulos H, 2002, J BIOL CHEM, V277, P15393, DOI 10.1074/jbc.M112141200; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092-8674(03)00437-9; Rajan P, 2003, J CELL BIOL, V161, P911, DOI 10.1083/jcb.200211021; Rietze RL, 2001, NATURE, V412, P736, DOI 10.1038/35089085; Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100; Sun LX, 2004, J CLIN INVEST, V113, P1364, DOI 10.1172/JCI200420001; Szabo PE, 2002, MECH DEVELOP, V115, P157, DOI 10.1016/S0925-4773(02)00087-4; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; Wernig M, 2004, J NEUROSCI, V24, P5258, DOI 10.1523/JNEUROSCI.0428-04.200; Winkler C, 1998, MOL CELL NEUROSCI, V11, P99, DOI 10.1006/mcne.1998.0674; Wu P, 2002, NAT NEUROSCI, V5, P1271, DOI 10.1038/nn974; Wurmser AE, 2004, NATURE, V430, P350, DOI 10.1038/nature02604; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129; Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200	39	57	65	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2005	19	11					1860	+		10.1096/fj.05-4170fje	http://dx.doi.org/10.1096/fj.05-4170fje			34	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16150803				2022-12-28	WOS:000232315700022
J	Woltjer, RL; Cimino, PJ; Boutte, AM; Schantz, AM; Montine, KS; Larson, EB; Bird, T; Quinn, JF; Zhang, J; Montine, TJ				Woltjer, RL; Cimino, PJ; Boutte, AM; Schantz, AM; Montine, KS; Larson, EB; Bird, T; Quinn, JF; Zhang, J; Montine, TJ			Proteomic determination of widespread detergent insolubility, including A beta but not tau, early in the pathogenesis of Alzheimer's disease	FASEB JOURNAL			English	Article						prodromal; dementia; sarkosyl; presenilin	MILD COGNITIVE IMPAIRMENT; AMYLOID PLAQUES; NEUROFIBRILLARY TANGLES; GENETIC-VARIATION; APOLIPOPROTEIN-D; ALPHA-SYNUCLEIN; FATAL ATTRACTIONS; TRANSGENIC MICE; PROTEINS; BRAIN	Biochemical characterization of the major detergent-insoluble proteins that comprise hallmark histopathologic lesions initiated the molecular era of Alzheimer's disease (AD) research. Here, we reinvestigated detergent-insoluble proteins in AD using modern proteomic techniques. Using liquid chromatography (LC)-mass spectrometry (MS)-MS-based proteomics, we robustly identified 125 proteins in the detergent-insoluble fraction of late-onset AD (LOAD) temporal cortex that included several proteins critical to A beta production, components of synaptic scaffolding, and products of genes linked to an increased risk of LOAD; we verified 15 of 15 of these proteins by Western blot. Following multiple analyses, we estimated that these represent similar to 80% of detergent-insoluble proteins in LOAD detectable by our method. A beta, tau, and 7 of 8 other newly identified detergent-insoluble proteins were disproportionately increased in temporal cortex from patients with LOAD and AD derived from mutations in PSEN1 and PSEN2; all of these except tau were elevated in individuals with prodromal dementia, while none except A beta were elevated in aged APPswe mice. These results are consistent with the amyloid hypothesis of AD and extend it to include widespread protein insolubility, not exclusively A beta insolubility, early in AD pathogenesis even before the onset of clinical dementia.	Univ Washington, Harborview Med Ctr, Dept Pathol, Seattle, WA 98104 USA; Univ Washington, Div Neuropathol, Dept Pathol, Seattle, WA 98104 USA; Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR USA	Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Oregon Health & Science University	Montine, TJ (corresponding author), Univ Washington, Harborview Med Ctr, Dept Pathol, Box 359791, Seattle, WA 98104 USA.	tmontine@u.washington.edu		Montine, Kathleen/0000-0003-2110-8363; Cimino, P.J./0000-0003-0441-4502	NIA NIH HHS [AG24011, AG22040, AG23801, AG05136, AG06781] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K01AG022040, R01AG024011, U01AG006781, P50AG005136, R01AG023801] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bennett DA, 2005, NEUROLOGY, V64, P834, DOI 10.1212/01.WNL.0000152982.47274.9E; Bertram L, 2005, NEW ENGL J MED, V352, P884, DOI 10.1056/NEJMoa042765; Boyd-Kimball D, 2005, NEUROSCIENCE, V132, P313, DOI 10.1016/j.neuroscience.2004.12.022; Busciglio J, 1997, J NEUROSCI, V17, P5101, DOI 10.1523/jneurosci.17-13-05101.1997; CARLIER MF, 1984, BIOCHIMIE, V66, P305, DOI 10.1016/0300-9084(84)90007-5; Carr S, 2004, MOL CELL PROTEOMICS, V3, P531, DOI 10.1074/mcp.T400006-MCP200; David S, 1998, MOL BRAIN RES, V54, P276, DOI 10.1016/S0169-328X(97)00343-4; Deguchi M, 2000, J BIOL CHEM, V275, P29875, DOI 10.1074/jbc.M005384200; deLeon MJ, 1997, NEUROBIOL AGING, V18, P1, DOI 10.1016/S0197-4580(96)00213-8; DeMattos RB, 2004, NEURON, V41, P193, DOI 10.1016/S0896-6273(03)00850-X; Desai PP, 2003, AM J MED GENET B, V116B, P98, DOI 10.1002/ajmg.b.10798; Donahue JE, 1999, P NATL ACAD SCI USA, V96, P6468, DOI 10.1073/pnas.96.11.6468; Fonte V, 2002, P NATL ACAD SCI USA, V99, P9439, DOI 10.1073/pnas.152313999; Gan L, 2004, J BIOL CHEM, V279, P5565, DOI 10.1074/jbc.M306183200; GEARING M, 1995, NEUROLOGY, V45, P461, DOI 10.1212/WNL.45.3.461; Ghoshal N, 2002, EXP NEUROL, V177, P475, DOI 10.1006/exnr.2002.8014; Ginsberg SD, 2000, ANN NEUROL, V48, P77, DOI 10.1002/1531-8249(200007)48:1<77::AID-ANA12>3.3.CO;2-1; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hasegawa M, 2002, J BIOL CHEM, V277, P49071, DOI 10.1074/jbc.M208046200; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; He WX, 2004, NAT MED, V10, P959, DOI 10.1038/nm1088; Helisalmi S, 2004, J NEUROL, V251, P951, DOI 10.1007/s00415-004-0470-8; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Huynh DP, 1997, J NEUROPATH EXP NEUR, V56, P1009, DOI 10.1097/00005072-199709000-00006; Jing Z, 2005, NEUROBIOL AGING, V26, P207, DOI 10.1016/j.neurobiolaging.2004.03.012; Kahle PJ, 2001, AM J PATHOL, V159, P2215, DOI 10.1016/S0002-9440(10)63072-6; Kalback W, 2002, BIOCHEMISTRY-US, V41, P922, DOI 10.1021/bi015685+; Keller JN, 2005, NEUROLOGY, V64, P1152, DOI 10.1212/01.WNL.0000156156.13641.BA; KOWALL NW, 1991, ANN NEUROL, V29, P162, DOI 10.1002/ana.410290208; Kukull WA, 2002, ARCH NEUROL-CHICAGO, V59, P1737, DOI 10.1001/archneur.59.11.1737; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Larson EB, 2004, ANN INTERN MED, V140, P501, DOI 10.7326/0003-4819-140-7-200404060-00008; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Lee VMY, 1999, METHOD ENZYMOL, V309, P81; Levi O, 2003, NEUROBIOL DIS, V13, P273, DOI 10.1016/S0969-9961(03)00045-7; Li Y, 2004, P NATL ACAD SCI USA, V101, P15688, DOI 10.1073/pnas.0403535101; MACCIONI RB, 1995, PHYSIOL REV, V75, P835, DOI 10.1152/physrev.1995.75.4.835; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; Minamide LS, 2000, NAT CELL BIOL, V2, P628, DOI 10.1038/35023579; Mitchell TW, 2002, ANN NEUROL, V51, P182, DOI 10.1002/ana.10086; Morris JC, 2001, ARCH NEUROL-CHICAGO, V58, P397, DOI 10.1001/archneur.58.3.397; Morris JC, 2001, J MOL NEUROSCI, V17, P101, DOI 10.1385/JMN:17:2:101; Nagy JI, 1996, BRAIN RES, V717, P173, DOI 10.1016/0006-8993(95)01526-4; Navarro A, 2003, EXP NEUROL, V184, P697, DOI 10.1016/S0014-4886(03)00315-7; Ntais C, 2004, AM J EPIDEMIOL, V159, P527, DOI 10.1093/aje/kwh069; Parkin ET, 1999, J NEUROCHEM, V72, P1534, DOI 10.1046/j.1471-4159.1999.721534.x; Petrovitch H, 2005, ANN NEUROL, V57, P98, DOI 10.1002/ana.20318; Riley KP, 2002, ANN NEUROL, V51, P567, DOI 10.1002/ana.10161; Roses AD, 1996, ANN NY ACAD SCI, V777, P146, DOI 10.1111/j.1749-6632.1996.tb34413.x; Shiozaki A, 2004, J ALZHEIMERS DIS, V6, P257; Smillie KJ, 2005, BIOCHEM SOC SYMP, V72, P87, DOI 10.1042/bss0720087; Soderberg L, 2005, J BIOL CHEM, V280, P1007, DOI 10.1074/jbc.M403628200; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; Stoltzner SE, 2000, AM J PATHOL, V156, P489, DOI 10.1016/S0002-9440(10)64753-0; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; Trojanowski JQ, 2001, J ALZHEIMERS DIS, V3, P117, DOI 10.3233/JAD-2001-3116; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; Trojanowski JQ, 2000, ANN NY ACAD SCI, V924, P62; Tsuang DW, 2002, MED CLIN N AM, V86, P591, DOI 10.1016/S0025-7125(02)00003-2; Umahara T, 2004, ACTA NEUROPATHOL, V108, P279, DOI 10.1007/s00401-004-0885-4; Wang Q, 2005, FASEB J, V19, P869, DOI 10.1096/fj.04-3210fje; WHALLEY L, 2002, DEMENTIA; White L, 2002, ANN NY ACAD SCI, V977, P9, DOI 10.1111/j.1749-6632.2002.tb04794.x; WONG CW, 1985, P NATL ACAD SCI USA, V82, P8729, DOI 10.1073/pnas.82.24.8729; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YAMADA T, 1990, NEUROSCI LETT, V120, P163, DOI 10.1016/0304-3940(90)90028-8; Yao PJ, 2004, TRENDS NEUROSCI, V27, P24, DOI 10.1016/j.tins.2003.10.012; Zhou Y, 2004, J BIOL CHEM, V279, P39155, DOI 10.1074/jbc.M405456200	71	47	47	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1923	+		10.1096/fj.05-4263fje	http://dx.doi.org/10.1096/fj.05-4263fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16129700				2022-12-28	WOS:000231843700001
J	Dominguez, F; Yanez-Mo, M; Sanchez-Madrid, F; Simon, C				Dominguez, F; Yanez-Mo, M; Sanchez-Madrid, F; Simon, C			Embryonic implantation and leukocyte transendothelial migration: different processes with similar players?	FASEB JOURNAL			English	Article						implantation; leukocyte trafficking; integrins; chemokines; L-selectin	ENDOMETRIAL EPITHELIAL-CELLS; ADHESION MOLECULES; GENE-EXPRESSION; MUCIN MUC1; INTEGRINS; SELECTIN; CYTOSKELETON; BLASTOCYST; CHEMOKINES; APOPTOSIS	A clear parallelism between the different steps in human embryo-endometrial apposition/adhesion/invasion and leukocyte-endothelium rolling/adhesion/extravasation can be established. During human implantation and leukocyte trafficking, a first wave of soluble mediators regulates the expression and functional activity of adhesion molecules such as L-selectin and integrins, which mediate both processes. Apical surfaces of human endometrial epithelium and endothelium are key elements for the initiation of molecular interactions to capture the blastocyst or leukocyte, respectively. Subsequently, the blastocyst and the leukocyte migrate through the epithelium and endothelium toward their final destination, the endometrial stroma, to initiate placentation or the inflammatory foci as part of the immune response. Similarities between the intermediate molecular mechanisms of these two physiologically unrelated processes are discussed.	Univ Valencia, FIVI, Valencia 46015, Spain; Univ Valencia, Sch Med, Dept Pediat Obstet & Gynecol, Valencia, Spain; Univ Autonoma Madrid, Hosp Princesa, Serv Inmunol, Madrid, Spain	University of Valencia; University of Valencia; Autonomous University of Madrid; Hospital de La Princesa	Simon, C (corresponding author), Univ Valencia, FIVI, C Guadassuar 1, Valencia 46015, Spain.	csimon@ivi.es	Dominguez, Francisco/AAA-7260-2020; Sanchez-Madrid, Francisco/M-7889-2016; Yáñez-Mó, María/K-8577-2014; Simon, Carlos/G-2186-2014; YÃÃez-MÃ, Maria/AAI-4544-2020	Dominguez, Francisco/0000-0002-7620-8081; Sanchez-Madrid, Francisco/0000-0001-5303-0762; Yáñez-Mó, María/0000-0001-7484-2866; Simon, Carlos/0000-0003-0902-9531; YÃÃez-MÃ, Maria/0000-0001-7484-2866				Barreiro O, 2004, FRONT BIOSCI-LANDMRK, V9, P1849, DOI 10.2741/1285; Barreiro O, 2002, J CELL BIOL, V157, P1233, DOI 10.1083/jcb.200112126; BARREIRO O, IN PRESS BLOOD; Bentin-Ley U, 2000, HUM REPROD, V15, P67; Berditchevski F, 2001, J CELL SCI, V114, P4143; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; Bischof P, 2002, J REPROD IMMUNOL, V55, P3, DOI 10.1016/S0165-0378(01)00142-5; Borthwick JM, 2003, MOL HUM REPROD, V9, P19, DOI 10.1093/molehr/gag004; Caballero-Campo P, 2002, MOL HUM REPROD, V8, P375, DOI 10.1093/molehr/8.4.375; Carson DD, 2002, MOL HUM REPROD, V8, P871, DOI 10.1093/molehr/8.9.871; Dominguez F, 2003, MOL HUM REPROD, V9, P189, DOI 10.1093/molehr/gag024; Galan A, 2000, HUM REPROD, V15, P74; Genbacev OD, 2003, SCIENCE, V299, P405, DOI 10.1126/science.1079546; Geng JG, 1997, J CELL BIOL, V137, P743, DOI 10.1083/jcb.137.3.743; Goldman-Wohl D, 2002, MOL CELL ENDOCRINOL, V187, P233, DOI 10.1016/S0303-7207(01)00687-6; Gonzalez-Amaro R, 1999, CRIT REV IMMUNOL, V19, P389; HEY NA, 1994, J CLIN ENDOCR METAB, V78, P337, DOI 10.1210/jc.78.2.337; Imhof BA, 2004, NAT REV IMMUNOL, V4, P432, DOI 10.1038/nri1375; IRVING JA, 1995, EXP CELL RES, V217, P419, DOI 10.1006/excr.1995.1105; Kamijo T, 1998, MOL HUM REPROD, V4, P990, DOI 10.1093/molehr/4.10.990; Kao LC, 2002, ENDOCRINOLOGY, V143, P2119, DOI 10.1210/en.143.6.2119; Kayisli UA, 2002, AM J REPROD IMMUNOL, V47, P213, DOI 10.1034/j.1600-0897.2002.01075.x; Le Naour F, 2000, SCIENCE, V287, P319, DOI 10.1126/science.287.5451.319; LESSEY BA, 1992, J CLIN INVEST, V90, P188, DOI 10.1172/JCI115835; Lessey BA, 2002, J REPROD IMMUNOL, V55, P101, DOI 10.1016/S0165-0378(01)00139-5; Ley K, 2004, NAT REV IMMUNOL, V4, P325, DOI 10.1038/nri1351; Luscinskas FW, 2002, IMMUNOL REV, V186, P57, DOI 10.1034/j.1600-065X.2002.18606.x; Martin JC, 2000, BIOL REPROD, V63, P1370, DOI 10.1095/biolreprod63.5.1370; Matsumoto H, 2004, BIOL REPROD, V70, P729, DOI 10.1095/biolreprod.103.022764; Meseguer M, 2001, BIOL REPROD, V64, P590, DOI 10.1095/biolreprod64.2.590; Milstone DS, 2000, DEV DYNAM, V219, P63, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1035>3.0.CO;2-D; Miyado K, 2000, SCIENCE, V287, P321, DOI 10.1126/science.287.5451.321; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Nagaoka K, 2003, J BIOL CHEM, V278, P29048, DOI 10.1074/jbc.M300470200; Nardo LG, 2003, J REPROD MED, V48, P355; Paria BC, 2002, SCIENCE, V296, P2185, DOI 10.1126/science.1071601; Park KR, 2000, MOL HUM REPROD, V6, P252, DOI 10.1093/molehr/6.3.252; Riesewijk A, 2003, MOL HUM REPROD, V9, P253, DOI 10.1093/molehr/gag037; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Shufaro Y, 2001, FERTIL STERIL, V75, P1217, DOI 10.1016/S0015-0282(01)01795-2; Simon C, 1997, J CLIN ENDOCR METAB, V82, P2607, DOI 10.1210/jc.82.8.2607; STEPHENS LE, 1995, GENE DEV, V9, P1883, DOI 10.1101/gad.9.15.1883; TORTOSA CG, 1993, VIRCHOWS ARCH A, V423, P287, DOI 10.1007/BF01606892; Urzainqui A, 2002, IMMUNITY, V17, P401, DOI 10.1016/S1074-7613(02)00420-X; Vestweber D, 2002, CURR OPIN CELL BIOL, V14, P587, DOI 10.1016/S0955-0674(02)00372-1; Vicente-Manzanares M, 2004, NAT REV IMMUNOL, V4, P110, DOI 10.1038/nri1268; Vicente-Manzanares M, 2002, INT REV CYTOL, V216, P233; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; ZHOU Y, 1993, J CLIN INVEST, V91, P950, DOI 10.1172/JCI116316	49	74	81	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1056	1060		10.1096/fj.05-3781hyp	http://dx.doi.org/10.1096/fj.05-3781hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	15985528				2022-12-28	WOS:000230923000033
J	Bernardini, G; Kim, JY; Gismondi, A; Butcher, EC; Santoni, A				Bernardini, G; Kim, JY; Gismondi, A; Butcher, EC; Santoni, A			Chemoattractant induces LFA-1 associated PI3K activity and cell migration that are dependent on Fyn signaling	FASEB JOURNAL			English	Article						Src; leukocytes; fMLP-stimulation	PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; INTEGRIN ACTIVATION; PHOSPHATIDYLINOSITOL 3-KINASE; LEUKOCYTE TRANSMIGRATION; T-LYMPHOCYTES; KINASE; NEUTROPHIL; PROTEIN; CHEMOKINES	The activation state of integrins on leukocytes is tightly controlled by the association of intracellular molecules to the cytoplasmic domain of the integrin. To identify signaling intermediates involved in chemoattractant receptor-induced integrin activation, we analyzed the ability of LFA-1 integrin to associate with members of Src tyrosine kinase and phosphatidylinositol 3Kinase (PI 3K) families following fMLP stimulation of a lymphoid T cell line stably expressing the fMLP receptor (fPR). fMLP- induced cell activation resulted in a rapid increase of integrin-associated PI 3Kinase activity in G protein and Src kinase dependent manner. We show, upon fMLP- stimulation, a rapid and transient association of the Src tyrosine kinase Fyn with LFA-1. Also, by transiently expressing mutant forms of this kinase, we demonstrated that Fyn is required for the integrin associated PI 3K activity. Furthermore, overexpression of the mutant form of Fyn resulted in a significant impairment of fMLP- induced cell migration through ICAM-1-coated filters, while ICAM-1 independent migration was not affected. Our observations indicate that chemoattractant receptor engagement induces Fyn-dependent PI 3K activation in association with LFA-1 and suggests that Fyn is necessary to initiate and/or to regulate chemoattractant-mediated LFA-1 activation to promote directional migration.	Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy; Univ Roma La Sapienza, Ist Pasteur, Fondaz Cenci Bolognetti, Rome, Italy; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA USA; Vet Affair Hlth Care Syst, Ctr Mol Biol & Med, Palo Alto, CA USA	Sapienza University Rome; Fondazione Cenci Bolognetti; Sapienza University Rome; Stanford University	Bernardini, G (corresponding author), Univ Roma La Sapienza, Dept Expt Med & Pathol, Via Regina Elena 324, I-00161 Rome, Italy.	giovanni.bernardini@uniroma1.it	santoni, angela/K-8997-2016; BERNARDINI, Giovanni/AAA-8160-2019	santoni, angela/0000-0003-1206-7731; BERNARDINI, Giovanni/0000-0002-3705-2598				Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Bowman EP, 1998, J BIOL CHEM, V273, P28040, DOI 10.1074/jbc.273.43.28040; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; Caveggion E, 2003, J CELL PHYSIOL, V195, P276, DOI 10.1002/jcp.10236; Cerboni C, 1998, EUR J IMMUNOL, V28, P1005, DOI 10.1002/(SICI)1521-4141(199803)28:03<1005::AID-IMMU1005>3.0.CO;2-O; Chernock RD, 2001, BLOOD, V97, P608, DOI 10.1182/blood.V97.3.608; Chodniewicz D, 2003, BLOOD, V102, P2251, DOI 10.1182/blood-2002-09-2936; Chung CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; Dustin ML, 2004, NAT IMMUNOL, V5, P363, DOI 10.1038/ni1057; Giagulli C, 2004, IMMUNITY, V20, P25, DOI 10.1016/S1074-7613(03)00350-9; Griffiths EK, 2002, CURR OPIN IMMUNOL, V14, P317, DOI 10.1016/S0952-7915(02)00334-5; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Laudanna C, 2002, IMMUNOL REV, V186, P37, DOI 10.1034/j.1600-065X.2002.18604.x; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011; Liu Y, 2004, J IMMUNOL, V172, P7, DOI 10.4049/jimmunol.172.1.7; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; Miura Y, 2000, BLOOD, V96, P1733, DOI 10.1182/blood.V96.5.1733.h8001733_1733_1739; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; Pribila JT, 2004, ANNU REV IMMUNOL, V22, P157, DOI 10.1146/annurev.immunol.22.012703.104649; Ptasznik A, 1996, J BIOL CHEM, V271, P25204, DOI 10.1074/jbc.271.41.25204; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; Reif K, 2004, J IMMUNOL, V173, P2236, DOI 10.4049/jimmunol.173.4.2236; Rose DM, 2001, J IMMUNOL, V167, P2824, DOI 10.4049/jimmunol.167.5.2824; Sadhu C, 2003, BIOCHEM BIOPH RES CO, V308, P764, DOI 10.1016/S0006-291X(03)01480-3; Sadhu C, 2003, J IMMUNOL, V170, P2647, DOI 10.4049/jimmunol.170.5.2647; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Sotsios Y, 2000, IMMUNOL REV, V177, P217, DOI 10.1034/j.1600-065X.2000.17712.x; TAKATA M, 1995, FEBS LETT, V374, P407, DOI 10.1016/0014-5793(95)01160-G; TURNER L, 1995, J IMMUNOL, V155, P2437; Uhlemann AC, 1997, BIOCHEM BIOPH RES CO, V239, P68, DOI 10.1006/bbrc.1997.7429; Weber KSC, 2001, MOL BIOL CELL, V12, P3074, DOI 10.1091/mbc.12.10.3074; Zabel BA, 1999, J EXP MED, V190, P1241, DOI 10.1084/jem.190.9.1241	40	10	11	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2005	19	8					1305	+		10.1096/fj.04-3352fje	http://dx.doi.org/10.1096/fj.04-3352fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15955842				2022-12-28	WOS:000230207800015
J	Ayash-Rashkovsky, M; Bentwich, Z; Arditti, F; Friedman, S; Reisner, Y; Borkow, G				Ayash-Rashkovsky, M; Bentwich, Z; Arditti, F; Friedman, S; Reisner, Y; Borkow, G			A novel small animal model for HIV-1 infection	FASEB JOURNAL			English	Article						Trimera; humoral and cellular responses; PBMC	PERIPHERAL-BLOOD LYMPHOCYTES; CYTOTOXIC T-LYMPHOCYTES; HUMAN IMMUNE-SYSTEM; ENGRAFTED HUMAN T; B-CELL LYMPHOMAS; TRIMERA MOUSE; RADIATION CHIMERA; PRIMATE MODELS; MICE; AIDS	Lethally irradiated normal BALB/c mice, reconstituted with murine SCID bone marrow and engrafted with human PBMC (Trimera mice), were used to establish a novel murine model for HIV-1 infection. The Trimera mice were successfully infected with different clades and primary isolates of T- and M-tropic HIV-1, with the infection persisting in the animals for 4-6 wk. Rapid loss of the human CD4+ T cells, decrease in CD4/CD8 ratio, and increased T cell activation accompanied the viral infection. All HIV-1 infected animals were able to generate both primary and secondary immune responses, including HIV specific human Immoral and cellular responses. In addition to testing the efficacy of new antiviral compounds, this new murine HIV-1 model may be used for studying host-virus interactions and, most importantly, for screening and developing potential HIV-1 protective vaccines and adjuvants (Ayash-Rashkovsky et al., http://www.fasebi.org/cgi/doi/10.1096/fj.04-3185fje; doi:10.1096/fi.04-3185fie.).	Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91010 Jerusalem, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem; Weizmann Institute of Science	Bentwich, Z (corresponding author), Hebrew Univ Jerusalem, Fac Agr, IL-76701 Rehovot, Israel.	zbentwich@rosettagenomics.com; borkow@agri.huji.ac.il	Borkow, Gadi/W-4294-2019; Reisner, Yair/AAA-4772-2019	Reisner, Yair/0000-0002-3354-6945				Ayash-Rashkovsky M, 2002, VACCINE, V20, P2684, DOI 10.1016/S0264-410X(02)00202-5; Ayash-Rashkovsky M, 2001, BIOCHEM BIOPH RES CO, V282, P1169, DOI 10.1006/bbrc.2001.4698; Ben-Yedidia T, 1999, INT IMMUNOL, V11, P1043, DOI 10.1093/intimm/11.7.1043; Bocher WO, 2001, EUR J IMMUNOL, V31, P2071, DOI 10.1002/1521-4141(200107)31:7<2071::AID-IMMU2071>3.0.CO;2-D; Bonyhadi ML, 1997, MOL MED TODAY, V3, P246, DOI 10.1016/S1357-4310(97)01046-0; Browning J, 1997, P NATL ACAD SCI USA, V94, P14637, DOI 10.1073/pnas.94.26.14637; Burakova T, 1997, TRANSPLANTATION, V63, P1166, DOI 10.1097/00007890-199704270-00018; GALUN E, 1995, J INFECT DIS, V172, P25, DOI 10.1093/infdis/172.1.25; Garcia S, 1997, BLOOD, V89, P329, DOI 10.1182/blood.V89.1.329.329_329_336; Haigwood NL, 1999, J MED PRIMATOL, V28, P154, DOI 10.1111/j.1600-0684.1999.tb00264.x; Ilan E, 1999, HEPATOLOGY, V29, P553, DOI 10.1002/hep.510290228; Joag SV, 2000, MICROBES INFECT, V2, P223, DOI 10.1016/S1286-4579(00)00266-5; Jolicoeur P, 1999, LEUKEMIA, V13, pS78, DOI 10.1038/sj.leu.2401293; Kumar A, 2001, VIROLOGY, V285, P1, DOI 10.1006/viro.2001.0942; Leng QB, 2001, J ACQ IMMUN DEF SYND, V27, P389, DOI 10.1097/00126334-200108010-00010; Locher CP, 2001, IMMUNOL REV, V183, P127, DOI 10.1034/j.1600-065x.2001.1830111.x; LUBIN I, 1991, SCIENCE, V252, P427, DOI 10.1126/science.1826797; LUBIN I, 1994, BLOOD, V83, P2368; MARCUS H, 1995, BLOOD, V86, P398, DOI 10.1182/blood.V86.1.398.bloodjournal861398; Mosier D E, 1996, Semin Immunol, V8, P255, DOI 10.1006/smim.1996.0032; Mosier DE, 1996, HOSP PRACT, V31, P41, DOI 10.1080/21548331.1996.11443344; MOSIER DE, 1992, AIDS RES HUM RETROV, V8, P735; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; MOSIER DE, 1991, SCIENCE, V251, P791, DOI 10.1126/science.1990441; MOSIER DE, 1990, CURR TOP MICROBIOL, V166, P317; MOSIER DE, 1996, HOSP PRACT OF ED, V31, P53; MOSIER DE, 1996, HOSP PRACT OF ED, V31, P59; Nath BM, 2000, TRENDS MICROBIOL, V8, P426, DOI 10.1016/S0966-842X(00)01816-3; NISHINO Y, 1994, VACCINE, V12, P485, DOI 10.1016/0264-410X(94)90304-2; Reid W, 2001, P NATL ACAD SCI USA, V98, P9271, DOI 10.1073/pnas.161290298; Reisner Y, 1998, TRENDS BIOTECHNOL, V16, P242, DOI 10.1016/S0167-7799(98)01203-7; Sawada S, 1998, J EXP MED, V187, P1439, DOI 10.1084/jem.187.9.1439; SAXON A, 1991, J CLIN INVEST, V87, P658, DOI 10.1172/JCI115043; Segall H, 1996, BLOOD, V88, P721, DOI 10.1182/blood.V88.2.721.bloodjournal882721; ShapiraNahor O, 1997, J VIROL, V71, P4495, DOI 10.1128/JVI.71.6.4495-4501.1997; TARYLEHMANN M, 1992, J EXP MED, V175, P503, DOI 10.1084/jem.175.2.503; TARYLEHMANN M, 1995, IMMUNOL TODAY, V16, P529, DOI 10.1016/0167-5699(95)80046-8; TARYLEHMANN M, 1994, J EXP MED, V180, P1817, DOI 10.1084/jem.180.5.1817; Zussman A, 2003, AIDS, V17, P653, DOI 10.1097/00002030-200303280-00002	39	8	8	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1149	+		10.1096/fj.04-3184fje	http://dx.doi.org/10.1096/fj.04-3184fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15833767				2022-12-28	WOS:000228865300016
J	Bloquel, C; Bejjani, R; Bigey, P; Bedioui, F; Doat, M; BenEzra, D; Scherman, D; Behar-Cohen, F				Bloquel, C.; Bejjani, R.; Bigey, P.; Bedioui, F.; Doat, M.; BenEzra, D.; Scherman, D.; Behar-Cohen, F.			Plasmid electrotransfer of eye ciliary muscle: principles and therapeutic efficacy using hTNF-alpha soluble receptor in uveitis	FASEB JOURNAL			English	Article									[Bloquel, C.; Bigey, P.; Bedioui, F.; Scherman, D.] Univ Paris 05, INSERM,Ecole Normale Super Chem Paris, CNRS,Fac Sci Pharmaceut & Biol,U640, Chem & Genet Pharmacol Lab,UMR8151, F-75270 Paris, France; [Bejjani, R.; Doat, M.; BenEzra, D.; Behar-Cohen, F.] Univ Paris 05, INSERM, U598, F-75270 Paris, France; [BenEzra, D.] Hadassah Hebrew Univ Hosp, Jerusalem, Israel; [Behar-Cohen, F.] Rothschild Fdn, Lab Innovat Therapeut, Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Hebrew University of Jerusalem; Hadassah University Medical Center	Scherman, D (corresponding author), Univ Paris 05, INSERM,Ecole Normale Super Chem Paris, CNRS,Fac Sci Pharmaceut & Biol,U640, Chem & Genet Pharmacol Lab,UMR8151, 4 Ave Observ, F-75270 Paris, France.	daniel.scherman@univ-paris5.fr	Bedioui, Fethi/N-3507-2014	Bedioui, Fethi/0000-0002-0063-4412; Scherman, Daniel/0000-0003-1207-1298; bigey, pascal/0000-0002-6795-8569					0	45	52	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					389	391		10.1096/fj.05-4737fje	http://dx.doi.org/10.1096/fj.05-4737fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16352651				2022-12-28	WOS:000207915000031
J	Santucci, L; Mencarelli, A; Renga, B; Pasut, G; Veronese, F; Zacheo, A; Germani, A; Fiorucci, S				Santucci, Luca; Mencarelli, Andrea; Renga, Barbara; Pasut, Gianfranco; Veronese, Francesco; Zacheo, Antonella; Germani, Antonia; Fiorucci, Stefano			Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO-pegylated epirubicin	FASEB JOURNAL			English	Article						anthracycline-induced miocardiopathy; cell apoptosis; HUVEC; mitochondrial membrane depolarization; colon cancer cells	DOXORUBICIN INDUCES APOPTOSIS; CANCER CELLS; MITOCHONDRIAL DYSFUNCTION; ANTIINFLAMMATORY DRUGS; ENDOTHELIAL-CELLS; GROWTH-INHIBITION; CARDIOTOXICITY; SURVIVIN; GENE; CARDIOMYOCYTE	The use of the anthracycline epirubicin (EPI) is limited by the risk of a dilatory congestive heart failure that develops as a consequence of induction of a mitochondrial-dependent cardiomyocyte and endothelial cell apoptosis. Nitric oxide ( NO) increases the antitumoral activity of several chemotherapics, while it provides protection against apoptosis induced by oxidative stress both in endothelial cells and cardiomyocytes. The aim of the present study was to investigate whether the addition of an NO-releasing moiety to a pegylated derivative of EPI (p-EPI-NO) confers to the drug a different cytotoxic profile against tumoral and normal cells. The cytotoxic profile of the drugs was investigated in Caco-2 cell line, in embryonic rat heart-derived myoblasts (H9c2), in adult cardiomyocytes, and in endothelial cells (HUVEC). p-EPI-NO was more efficient than EPI in inducing Caco-2 cell apoptosis, while it spared HUVEC, H9c2 cells and adult cardiomyocytes from EPI-induced toxicity. Exposure of cells to p-EPI-NO resulted in a NO-mediated inhibition of cellular respiration followed by mitochondrial membrane depolarization and cell death in Caco-2 cells but not in HUVEC and H9c2 cells in which mitochondrial membrane polarization was maintained at the expense of glycolytically generated ATP. These findings indicate that addition of an NO-releasing moiety to p-EPI increases the anti-neoplastic activity of the drug, while it reduces its cytotoxicity against nonneoplastic cells.	Univ Perugia, Dept Clin & Expt Med, Clin Gastroenterol & Epatol, I-06122 Perugia, Italy; Univ Padua, Dept Pharmaceut Sci, Padua, Italy; Ist Ricovero & Cura Carattere Sci, Lab Patol Vasc, Ist Dermopat Immacolata, Rome, Italy; Ist Ricovero & Cura Carattere Sci, Lab Biol Vasc & Terapia Gen, Ctr Cardiol Fdn Monzino, Rome, Italy	University of Perugia; University of Padua; IRCCS Istituto Dermopatico dell'Immacolata (IDI)	Santucci, L (corresponding author), Univ Perugia, Dept Clin & Expt Med, Clin Gastroenterol & Epatol, Via Enrico Pozzo, I-06122 Perugia, Italy.	lsant@unipg.it	Pasut, Gianfranco/I-5944-2012; Zacheo, Antonella/AAI-1422-2020; Fiorucci, Stefano/I-1251-2012	Pasut, Gianfranco/0000-0002-8754-0899; 				Adams DJ, 2001, LEUKEMIA, V15, P1852, DOI 10.1038/sj.leu.2402291; Almeida A, 2001, P NATL ACAD SCI USA, V98, P15294, DOI 10.1073/pnas.261560998; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Arola OJ, 2000, CANCER RES, V60, P1789; Bellarosa D, 2001, J PHARMACOL EXP THER, V296, P276; Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602; Chan EM, 1996, CAN J PHYSIOL PHARM, V74, P904, DOI 10.1139/cjpp-74-8-904; Chang J, 1996, AM J PHYSIOL-LUNG C, V270, pL931, DOI 10.1152/ajplung.1996.270.6.L931; Chang Q, 2004, WORLD J GASTROENTERO, V10, P415; Chao JI, 2004, J BIOL CHEM, V279, P20267, DOI 10.1074/jbc.M312381200; Childs AC, 2002, CANCER RES, V62, P4592; Chung P, 2003, NITRIC OXIDE-BIOL CH, V8, P119, DOI 10.1016/S1089-8603(02)00147-7; Cook JA, 1997, BRIT J CANCER, V76, P325, DOI 10.1038/bjc.1997.386; Cook T, 2004, CANCER RES, V64, P8015, DOI 10.1158/0008-5472.CAN-04-2212; Delikouras A, 2001, TRANSPLANTATION, V71, P599, DOI 10.1097/00007890-200103150-00004; Evig CB, 2004, NITRIC OXIDE-BIOL CH, V10, P119, DOI 10.1016/j.niox.2004.03.006; Fiorucci S, 2004, J IMMUNOL, V173, P874, DOI 10.4049/jimmunol.173.2.874; Garber K, 2004, J NATL CANCER I, V96, P1805, DOI 10.1093/jnci/96.24.1805; Gupta S, 1998, CANCER RES, V58, P1785; Huguenin S, 2004, PROSTATE, V61, P132, DOI 10.1002/pros.20081; Huigsloot M, 2002, J BIOL CHEM, V277, P35869, DOI 10.1074/jbc.M200378200; Jensen BV, 2002, ANN ONCOL, V13, P699, DOI 10.1093/annonc/mdf132; Kelso EJ, 1997, J MOL CELL CARDIOL, V29, P3385, DOI 10.1006/jmcc.1997.0563; Kluza J, 2004, ONCOGENE, V23, P7018, DOI 10.1038/sj.onc.1207936; Lavagna C, 2003, CURR CANCER DRUG TAR, V3, P407, DOI 10.2174/1568009033481750; Leri A, 1999, CIRC RES, V84, P752; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; LLESUY SF, 1990, FREE RADICAL BIO MED, V8, P259, DOI 10.1016/0891-5849(90)90071-P; Lorenzo E, 2002, J BIOL CHEM, V277, P10883, DOI 10.1074/jbc.M107442200; Maejima Y, 2005, J MOL CELL CARDIOL, V38, P163, DOI 10.1016/j.yjmcc.2004.10.012; Mitchell JB, 1996, BRIT J CANCER, V74, pS181; Monastyrskaya E, 2002, NITRIC OXIDE-BIOL CH, V7, P127, DOI 10.1016/S1089-8603(02)00107-6; Morpurgo Margherita, 2004, Methods Mol Biol, V283, P45; NIELSEN D, 1990, J CLIN ONCOL, V8, P1806, DOI 10.1200/JCO.1990.8.11.1806; Pai VB, 2000, DRUG SAFETY, V22, P263, DOI 10.2165/00002018-200022040-00002; Perl A, 2004, TRENDS IMMUNOL, V25, P360, DOI 10.1016/j.it.2004.05.001; RHODEN W, 1993, BRIT HEART J, V70, P499; Riganti C, 2005, CANCER RES, V65, P516; Ryberg M, 1998, J CLIN ONCOL, V16, P3502, DOI 10.1200/JCO.1998.16.11.3502; Sacco G, 2003, BRIT J PHARMACOL, V139, P641, DOI 10.1038/sj.bjp.0705270; Santucci L, 2005, GASTROENTEROLOGY, V128, P1243, DOI 10.1053/j.gastro.2005.01.051; SEYMOUR LW, 1994, BRIT J CANCER, V70, P636, DOI 10.1038/bjc.1994.363; Spallarossa P, 2004, J MOL CELL CARDIOL, V37, P837, DOI 10.1016/j.yjmcc.2004.05.024; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; Suschek CV, 1999, J BIOL CHEM, V274, P6130, DOI 10.1074/jbc.274.10.6130; Swain SM, 2003, CANCER, V97, P2869, DOI 10.1002/cncr.11407; Tsang WP, 2003, LIFE SCI, V73, P2047, DOI 10.1016/S0024-3205(03)00566-6; Walford G, 2003, J THROMB HAEMOST, V1, P2112, DOI 10.1046/j.1538-7836.2003.00345.x; Wallace KB, 2003, PHARMACOL TOXICOL, V93, P105, DOI 10.1034/j.1600-0773.2003.930301.x; Wang SW, 2004, J BIOL CHEM, V279, P25535, DOI 10.1074/jbc.M400944200; Wang ZX, 2004, ONCOGENE, V23, P8146, DOI 10.1038/sj.onc.1207992; Wink DA, 1997, NITRIC OXIDE-BIOL CH, V1, P88, DOI 10.1006/niox.1996.0108; Working PK, 1999, J PHARMACOL EXP THER, V289, P1128; Wu S, 2002, J MOL CELL CARDIOL, V34, P1595, DOI 10.1006/jmcc.2002.2110; Yeh RK, 2004, BIOCHEM PHARMACOL, V67, P2197, DOI 10.1016/j.bcp.2004.02.027; Zhou YY, 2000, AM J PHYSIOL-HEART C, V279, pH429	56	39	39	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					765	+		10.1096/fj.05-4452fje	http://dx.doi.org/10.1096/fj.05-4452fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16455756				2022-12-28	WOS:000237698700042
J	Pleskova, M; Beck, KF; Behrens, MH; Huwiler, A; Fichtlscherer, B; Wingerter, O; Brandes, RP; Mulsch, A; Pfeilschifter, J				Pleskova, M; Beck, KF; Behrens, MH; Huwiler, A; Fichtlscherer, B; Wingerter, O; Brandes, RP; Mulsch, A; Pfeilschifter, J			Nitric oxide down-regulates the expression of the catalytic NADPH oxidase subunit Nox1 in rat renal mesangial cells	FASEB JOURNAL			English	Article						kidney; siRNA; promoter; reactive oxygen species	SOLUBLE GUANYLYL CYCLASE; SUPEROXIDE-DISMUTASE; MESSENGER-RNA; SYNTHASE EXPRESSION; GENE-EXPRESSION; REACTIVE OXYGEN; IDENTIFICATION; ACTIVATION; COMPONENTS; AMPLIFICATION	Glomerular mesangial cells can produce high amounts of nitric oxide ( NO) and reactive oxygen species (ROS). Here we analyzed the impact of NO on the ROS-generating system, particularly on the NADPH oxidase Nox1. Nox1 mRNA and protein levels were markedly decreased by treatment of mesangial cells with the NO-releasing compound DETA-NO in a concentration- and time-dependent fashion. By altering the cGMP signaling system with different inhibitors or activators, we revealed that the effect of NO on Nox1 expression is at least in part mediated by cGMP. Analysis of a reporter construct comprising the 2547 bp of the nox1 promoter region revealed that a stimulatory effect of IL-1 beta on nox1 transcription is counteracted by an inhibitory effect of IL-1 beta-evoked endogenous NO formation. Moreover, pretreatment of mesangial cells with DETA-NO attenuated platelet-derived growth factor ( PDGF)-BB or serum stimulated production of superoxide as assessed by real-time EPR spectroscopy and dichlorofluorescein formation. Transfection of mesangial cells with siRNAs directed against Nox1 and Nox4 revealed that inhibition of Nox1, but not Nox4 expression, is responsible for the reduced ROS formation by NO. Obviously, there exists a fine-tuned crosstalk between NO and ROS generating systems in the course of inflammatory diseases.	Univ Frankfurt Klinikum, Pharmazentrum Frankfurt, D-60590 Frankfurt, Germany; Goethe Univ Frankfurt, Inst Kardiovask Physiol, D-6000 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Pfeilschifter, J (corresponding author), Univ Frankfurt Klinikum, Pharmazentrum Frankfurt, Theodor Stern Kai,7, D-60590 Frankfurt, Germany.	pfeilschifter@em.uni-frankfurt.de	Brandes, Ralf P/L-3058-2017	Brandes, Ralf P/0000-0002-8035-0048				Akool ES, 2003, MOL CELL BIOL, V23, P4901, DOI 10.1128/MCB.23.14.4901-4916.2003; Ambasta RK, 2004, J BIOL CHEM, V279, P45935, DOI 10.1074/jbc.M406486200; Babior B M, 1995, Curr Opin Hematol, V2, P55; BAUD L, 1993, BRIT MED BULL, V49, P621, DOI 10.1093/oxfordjournals.bmb.a072635; Beck KF, 1998, FEBS LETT, V435, P35, DOI 10.1016/S0014-5793(98)01035-7; Beck KF, 1999, J EXP BIOL, V202, P645; Bellamy TC, 2002, J BIOL CHEM, V277, P31801, DOI 10.1074/jbc.M205936200; Bogdan C, 2000, CURR OPIN IMMUNOL, V12, P64, DOI 10.1016/S0952-7915(99)00052-7; Bogdan C, 2001, TRENDS CELL BIOL, V11, P66, DOI 10.1016/S0962-8924(00)01900-0; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Cattell V, 2002, KIDNEY INT, V61, P816, DOI 10.1046/j.1523-1755.2002.00226.x; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; DARLEYUSMAR V, 1995, FEBS LETT, V369, P131, DOI 10.1016/0014-5793(95)00764-Z; Eberhardt W, 2000, J IMMUNOL, V165, P5788, DOI 10.4049/jimmunol.165.10.5788; Eberhardt W, 1998, J IMMUNOL, V160, P4961; Frank S, 1999, FASEB J, V13, P869, DOI 10.1096/fasebj.13.8.869; Fujii H, 1997, J BIOL CHEM, V272, P32773, DOI 10.1074/jbc.272.52.32773; Fukai T, 2000, J CLIN INVEST, V105, P1631, DOI 10.1172/JCI9551; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Gorin Y, 2003, AM J PHYSIOL-RENAL, V285, pF219, DOI 10.1152/ajprenal.00414.2002; Hruby Z, 1997, CLIN EXP IMMUNOL, V107, P76, DOI 10.1046/j.1365-2249.1997.d01-906.x; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; JONES SA, 1995, J AM SOC NEPHROL, V5, P1483; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; Keller T, 2003, NITRIC OXIDE-BIOL CH, V9, P183, DOI 10.1016/j.niox.2004.01.003; Kloss S, 2003, J BIOL CHEM, V278, P2377, DOI 10.1074/jbc.M206453200; KUNZ D, 1994, P NATL ACAD SCI USA, V91, P5387, DOI 10.1073/pnas.91.12.5387; Kuzkaya N, 2003, J BIOL CHEM, V278, P22546, DOI 10.1074/jbc.M302227200; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; MARTYN KD, 2005, CELL SIGNAL; MUHL H, 1995, J CLIN INVEST, V95, P1941, DOI 10.1172/JCI117876; Muhl H, 1996, EUR J PHARMACOL, V317, P137, DOI 10.1016/S0014-2999(96)00701-7; Mulsch A, 1997, BRIT J PHARMACOL, V120, P681, DOI 10.1038/sj.bjp.0700982; PFEILSCHIFTER J, 1994, NEWS PHYSIOL SCI, V9, P271, DOI 10.1152/physiologyonline.1994.9.6.271; PFEILSCHIFTER J, 1991, BIOCHEM BIOPH RES CO, V175, P372, DOI 10.1016/0006-291X(91)91574-V; PFEILSCHIFTER J, 1990, FEBS LETT, V273, P185, DOI 10.1016/0014-5793(90)81080-8; Pfeilschifter J, 2002, KIDNEY INT, V61, P809, DOI 10.1046/j.1523-1755.2002.00225.x; Pfeilschifter J, 2001, PFLUG ARCH EUR J PHY, V442, P479, DOI 10.1007/s004240100586; RADEKE HH, 1990, KIDNEY INT, V37, P767, DOI 10.1038/ki.1990.44; RADEKE HH, 1991, J BIOL CHEM, V266, P21025; Rupprecht HD, 2000, KIDNEY INT, V57, P70, DOI 10.1046/j.1523-1755.2000.00828.x; Sandau K, 1997, J IMMUNOL, V158, P4938; Sano H, 1997, IMMUNOLOGY, V92, P118, DOI 10.1046/j.1365-2567.1997.00322.x; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHULTZ PJ, 1991, AM J PHYSIOL, V261, pF600, DOI 10.1152/ajprenal.1991.261.4.F600; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Wingler M, 2001, FREE RADICAL BIO MED, V31, P1456, DOI 10.1016/S0891-5849(01)00727-4	49	54	55	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					139	+		10.1096/fj.05-3791fje	http://dx.doi.org/10.1096/fj.05-3791fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16254042				2022-12-28	WOS:000232991100002
J	Southgate, RJ; Bruce, CR; Carey, AL; Steinberg, GR; Walder, K; Monks, R; Watt, MJ; Hawley, JA; Birnbaum, MJ; Febbraio, MA				Southgate, RJ; Bruce, CR; Carey, AL; Steinberg, GR; Walder, K; Monks, R; Watt, MJ; Hawley, JA; Birnbaum, MJ; Febbraio, MA			PGC-1 alpha gene expression is down-regulated by Akt-mediated phosphorylation and nuclear exclusion of FoxO1 in insulin-stimulated skeletal muscle	FASEB JOURNAL			English	Article						peroxisome proliferator activator receptor gamma coactivator-1 alpha	COACTIVATOR 1-ALPHA PGC-1-ALPHA; TRANSCRIPTIONAL COACTIVATOR; ADIPOSE-TISSUE; KINASE; RESISTANCE; FKHR; ASSOCIATION; METABOLISM; ACTIVATION; MEF2	There are multiple binding domains on the promoter region of the peroxisome proliferator activator receptor. coactivator-1 a (PGC-1 alpha) gene, including a trio of insulin responsive elements that are activated by the forkhead box class-O (FoxO1) winged helix transcription factor, which is known to be regulated by acute transforming retrovirus thymoma (Akt). Here we show that in skeletal muscle biopsy specimens from healthy humans and cultured human skeletal myotubes, insulin phosphorylates Akt (Ser(473)) and FoxO1 (Thr(24), Ser(256)), leading to reduced nuclear abundance of FoxO1 total protein. This is associated with an insulin-mediated repression of the mRNA expression PGC-1 alpha and downstream genes associated with oxidative phosphorylation. In contrast, in muscle taken from insulin resistant humans or in palmitate-treated insulin resistant myotubes, neither Akt nor FoxO1 was phosphorylated by insulin, resulting in a failure for nuclear exclusion of FoxO1 total protein, and an inability for insulin to repress the mRNA expression of PGC-1 alpha and down- stream genes. To determine whether the regulation of FoxO1 was Akt dependent, we next treated Akt2 -/- and wild-type mice with or without insulin. Insulin phosphorylated Akt and FoxO1 (Thr(24), Ser(256)) resulting in a reduced nuclear expression of FoxO1 total protein in wild-type but not Akt2 -/- skeletal muscle. We conclude that insulin decreases the expression of genes involved in oxidative metabolism in healthy but not insulin resistant muscle, due to a decrease in FoxO1 phosphorylation and nuclear exclusion secondary to reduced Akt activity.	RMIT Univ, Cellular & Mol Metab Lab, Bundoora, Vic 3083, Australia; RMIT Univ, Exercise Metab Grp, Bundoora, Vic 3083, Australia; Univ Melbourne, Dept Med, Fitzroy, Vic 3065, Australia; Univ Melbourne, St Vincents Inst, Fitzroy, Vic 3065, Australia; Deakin Univ, Metab Res Unit, Sch Hlth Sci, Waurn Ponds 3217, Australia; Univ Penn, Sch Med, Howard Hughes Med Inst, Cox Inst,Dept Med, Philadelphia, PA 19104 USA	Royal Melbourne Institute of Technology (RMIT); Royal Melbourne Institute of Technology (RMIT); University of Melbourne; St. Vincent's Institute of Medical Research; University of Melbourne; Deakin University; Howard Hughes Medical Institute; University of Pennsylvania	Febbraio, MA (corresponding author), RMIT Univ, Cellular & Mol Metab Lab, POB 71, Bundoora, Vic 3083, Australia.	mark.febbraio@rmit.edu.au	Hawley, John A/U-3814-2018; Febbraio, Mark/AAE-9632-2019	Hawley, John A/0000-0002-0886-9881; Bruce, Clinton/0000-0002-0515-3343; Steinberg, Gregory/0000-0001-5425-8275; Birnbaum, Morris/0000-0001-9972-8680; Febbraio, Mark/0000-0002-9296-4418; Carey, Andrew/0000-0003-3452-1501				Attie AD, 2003, NAT GENET, V34, P244, DOI 10.1038/ng0703-244; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Chan MHS, 2004, FASEB J, V18, P1785, DOI 10.1096/fj.03-1039fje; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRUNKHORN S, 2004, P KEYST S DIAB MELL, V137, P84; Czubryt MP, 2003, P NATL ACAD SCI USA, V100, P1711, DOI 10.1073/pnas.0337639100; Daitoku H, 2003, DIABETES, V52, P642, DOI 10.2337/diabetes.52.3.642; Febbraio MA, 2000, J APPL PHYSIOL, V89, P1055, DOI 10.1152/jappl.2000.89.3.1055; GORDON JW, 2003, J APPL PHYSIOL, V90, P389; Hammarstedt A, 2003, BIOCHEM BIOPH RES CO, V301, P578, DOI 10.1016/S0006-291X(03)00014-7; Huang X, 1999, DIABETES, V48, P1508, DOI 10.2337/diabetes.48.8.1508; Ichida M, 2002, J BIOL CHEM, V277, P50991, DOI 10.1074/jbc.M210262200; Imae M, 2003, J MOL ENDOCRINOL, V30, P253, DOI 10.1677/jme.0.0300253; Kamei Y, 2004, J BIOL CHEM, V279, P41114, DOI 10.1074/jbc.M400674200; Kelley DE, 1999, AM J PHYSIOL-ENDOC M, V277, pE1130; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Ling C, 2004, J CLIN INVEST, V114, P1518, DOI 10.1172/JCI200421889; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Schulz RA, 2004, DEV BIOL, V266, P1, DOI 10.1016/j.ydbio.2003.10.008; Semple RK, 2004, INT J OBESITY, V28, P176, DOI 10.1038/sj.ijo.0802482; Short KR, 2003, DIABETES, V52, P1888, DOI 10.2337/diabetes.52.8.1888; Stump CS, 2003, P NATL ACAD SCI USA, V100, P7996, DOI 10.1073/pnas.1332551100; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; ZIERATH JR, 1994, DIABETOLOGIA, V37, P270, DOI 10.1007/BF00398054	34	56	57	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2072	+		10.1096/fj.05-3993fje	http://dx.doi.org/10.1096/fj.05-3993fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16203862				2022-12-28	WOS:000232991100032
J	Bewick, GA; Gardiner, JV; Dhillo, WS; Kent, AS; White, NE; Webster, Z; Ghatei, MA; Bloom, SR				Bewick, GA; Gardiner, JV; Dhillo, WS; Kent, AS; White, NE; Webster, Z; Ghatei, MA; Bloom, SR			Postembryonic ablation of AgRP neurons in mice leads to a lean, hypophagic phenotype	FASEB JOURNAL			English	Article						neuropeptide Y; hypothalamic arcuate nucleus; food intake regulation; neuroendocrinology; gut hormone	AGOUTI-RELATED-PROTEIN; AMPHETAMINE-REGULATED TRANSCRIPT; DISEASE GENE-PRODUCT; INHIBITS FOOD-INTAKE; IN-VIVO; NEUROPEPTIDE-Y; HYPOTHALAMIC NEURONS; ENERGY HOMEOSTASIS; MESSENGER-RNA; MALE RATS	Agouti-related protein ( AgRP) and neuropeptide Y ( NPY) are colocalized in arcuate nucleus ( arcuate) neurons implicated in the regulation of energy balance. Both AgRP and NPY stimulate food intake when administered into the third ventricle and are up- regulated in states of negative energy balance. However, mice with targeted deletion of either NPY or AgRP or both do not have major alterations in energy homeostasis. Using bacterial artificial chromosome ( BAC) transgenesis we have targeted expression of a neurotoxic CAG expanded form of ataxin- 3 to AgRP- expressing neurons in the arcuate. This resulted in a 47% loss of AgRP neurons by 16 weeks of age, a significantly reduced body weight, ( wild- type mice ( WT) 34.7 +/- 0.7 g vs. transgenic mice ( Tg) 28.6 +/- 0.6 g, P < 0.001), and reduced food intake ( WT 5.0 +/- 0.2 vs. Tg 3.6 +/- 0.1 g per day, P < 0.001). Transgenic mice had significantly reduced total body fat, plasma insulin, and increased brown adipose tissue UCP1 expression. Transgenic mice failed to respond to peripherally administered ghrelin but retained sensitivity to PYY 3- 36. These data suggest that postembryonic partial loss of AgRP/ NPY neurons leads to a lean, hypophagic phenotype.	Hammersmith Hosp, Ctr Clin Sci, MRC, Core Transgen Facil, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Metab Med, London SW7 2AZ, England	Imperial College London; Imperial College London	Bloom, SR (corresponding author), Hammersmith Hosp, Dept Metab Med, Fac Med, Imperial Coll London, 6th Floor,Commonwealth Bldg,Du Cane Rd, London W12 0NN, England.	s.bloom@imperial.ac.uk		Gardiner, James/0000-0001-9357-1387; Bewick, Gavin/0000-0002-4335-8403; Dhillo, Waljit/0000-0001-5950-4316	National Institute for Health Research [03/DHCS/03/G121/48] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		ADRIAN TE, 1983, NATURE, V306, P584, DOI 10.1038/306584a0; Batterham RL, 2002, NATURE, V418, P650, DOI 10.1038/nature00887; Bouret SG, 2004, SCIENCE, V304, P108, DOI 10.1126/science.1095004; BRADY LS, 1990, NEUROENDOCRINOLOGY, V52, P441, DOI 10.1159/000125626; Challis BG, 2004, P NATL ACAD SCI USA, V101, P4695, DOI 10.1073/pnas.0306931101; Challis BG, 2003, BIOCHEM BIOPH RES CO, V311, P915, DOI 10.1016/j.bbrc.2003.10.089; Chen HY, 2004, ENDOCRINOLOGY, V145, P2607, DOI 10.1210/en.2003-1596; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; Clarke DC, 2004, PHYSIOL GENOMICS, V17, P31, DOI 10.1152/physiolgenomics.00190.2003; Cowley MA, 2003, NEURON, V37, P649, DOI 10.1016/S0896-6273(03)00063-1; EGAWA M, 1991, AM J PHYSIOL, V260, P328; Elias CF, 1998, J COMP NEUROL, V402, P442, DOI 10.1002/(SICI)1096-9861(19981228)402:4<442::AID-CNE2>3.0.CO;2-R; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Hahn TM, 1998, NAT NEUROSCI, V1, P271, DOI 10.1038/1082; Halatchev IG, 2004, ENDOCRINOLOGY, V145, P2585, DOI 10.1210/en.2003-1754; Hara J, 2001, NEURON, V30, P345, DOI 10.1016/S0896-6273(01)00293-8; Hewson AK, 2000, J NEUROENDOCRINOL, V12, P1047, DOI 10.1046/j.1365-2826.2000.00584.x; JONES PM, 1989, ENDOCRINOLOGY, V125, P334, DOI 10.1210/endo-125-1-334; Kaelin CB, 2004, ENDOCRINOLOGY, V145, P5798, DOI 10.1210/en.2004-0956; Kong WM, 2003, FASEB J, V17, P1688, DOI 10.1096/fj.02-0805fje; Magin-Lachmann C, 2003, BMC BIOTECHNOL, V3, DOI 10.1186/1472-6750-3-2; Makimura H, 2002, BMC NEUROSCI, V3, DOI 10.1186/1471-2202-3-18; Mejia JE, 2000, GENOMICS, V70, P165, DOI 10.1006/geno.2000.6372; Mizuno TM, 1999, ENDOCRINOLOGY, V140, P814, DOI 10.1210/en.140.2.814; Murphy KG, 2000, J ENDOCRINOL, V166, P659, DOI 10.1677/joe.0.1660659; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; Perreault M, 2004, INT J OBESITY, V28, P879, DOI 10.1038/sj.ijo.0802640; Qian S, 2002, MOL CELL BIOL, V22, P5027, DOI 10.1128/MCB.22.14.5027-5035.2002; Rossi M, 1998, ENDOCRINOLOGY, V139, P4428, DOI 10.1210/en.139.10.4428; SALMON DMW, 1985, INT J OBESITY, V9, P443; Shah Eliza Mountcastle, 1993, Current Opinion in Neurobiology, V3, P738, DOI 10.1016/0959-4388(93)90146-P; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; Stanley SA, 2004, AM J PHYSIOL-ENDOC M, V287, pE583, DOI 10.1152/ajpendo.00576.2003; Stanley SA, 1999, ENDOCRINOLOGY, V140, P5459, DOI 10.1210/en.140.11.5459; Stanley SA, 2001, BRAIN RES, V893, P186, DOI 10.1016/S0006-8993(00)03312-6; Taheri S, 2001, NEUROREPORT, V12, P459, DOI 10.1097/00001756-200103050-00008; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Wren AM, 2001, J CLIN ENDOCR METAB, V86, P5992, DOI 10.1210/jc.86.12.5992; Wren AM, 2001, DIABETES, V50, P2540, DOI 10.2337/diabetes.50.11.2540; Yasuda T, 2004, EXP BIOL MED, V229, P235, DOI 10.1177/153537020422900303; Yoshizawa T, 2001, BRAIN RES BULL, V56, P349, DOI 10.1016/S0361-9230(01)00578-0; Zhang YM, 1998, NAT GENET, V20, P123, DOI 10.1038/2417	44	180	183	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1680	+		10.1096/fj.04-3434fje	http://dx.doi.org/10.1096/fj.04-3434fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16099943				2022-12-28	WOS:000231843700019
J	Korn, T; Magnus, T; Jung, S				Korn, T; Magnus, T; Jung, S			Autoantigen specific T cells inhibit glutamate uptake in astrocytes by decreasing expression of astrocytic glutamate transporter GLAST: a mechanism mediated by tumor necrosis factor-alpha	FASEB JOURNAL			English	Article						central nervous system; TNF-alpha; myelin basic protein	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS; RAT-BRAIN; DIFFERENTIAL EXPRESSION; ASPARTATE TRANSPORTER; SURFACE EXPRESSION; ARACHIDONIC-ACID; NMDA RECEPTOR; AXONAL DAMAGE; UP-REGULATION	Glutamate excitotoxicity is increasingly being recognized as a pathogenic mechanism in autoimmune inflammatory disorders of the central nervous system (CNS). Astrocytes are the predominant players in clearing the extracellular space from glutamate and normally have extensive spare capacities in terms of glutamate uptake. We asked what might be the basis of glutamate accumulation in T cell triggered autoimmune inflammation. In vitro, coculture of primary rat astrocytes with activated myelin basic protein (MBP)-specific T cells resulted in a decrease of astrocytic glutamate uptake rates (V-max). In parallel, the amount of the Na+-dependent glutamate transporter GLAST was reduced within 48-60 h. Significant decreases of GLAST protein were observed in astrocytes harvested after incubation with T cells activated by MBP during coculture or after incubation with T cell blasts preactivated in the presence of splenocytes beforehand. Since exposure of astrocytes to cell-free supernatant of MBP-activated T cells also resulted in reduced expression of GLAST, a humoral factor appeared to be the driving agent. In blocking experiments using neutralizing antibodies and by incubation of astrocytes with recombinant cytokines, tumor necrosis factor-alpha (TNF-alpha) was identified as being responsible for the down-modulation of GLAST. GLAST was also down-regulated in the CNS of autoimmune encephalomyelitic rats but not in animals suffering from systemic inflammation. Since the loss of GLAST was not confined to inflammatory infiltrates, here too, a humoral factor seemed to be causative. In conclusion, T cell derived TNF-alpha impairs glutamate clearance capacity of astrocytes in vitro and probably also in vivo providing a pathogenic link to glutamate excitotoxicity that may contribute to early axonal dysfunction remote from active autoimmune inflammatory demyelination.	Univ Saarland, Dept Neurol, Homburg, Germany	Saarland University	Korn, T (corresponding author), Harvard Univ, Brigham & Womens Hosp, Inst Med, Ctr Neurol Dis, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	tkorn@rics.bwh.harvard.edu	Korn, Thomas/AAE-6960-2019	Korn, Thomas/0000-0002-3633-0955				BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; Barnett MH, 2004, ANN NEUROL, V55, P458, DOI 10.1002/ana.20016; BEAL MF, 1992, FASEB J, V6, P3338, DOI 10.1096/fasebj.6.15.1464368; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bielekova B, 2000, NAT MED, V6, P1167, DOI 10.1038/80516; Bozzali M, 2002, AM J NEURORADIOL, V23, P985; CENDES F, 1995, ANN NEUROL, V37, P123, DOI 10.1002/ana.410370125; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CLARK MA, 1988, BIOCHEM J, V250, P125, DOI 10.1042/bj2500125; Conradt M, 1997, J NEUROCHEM, V68, P1244, DOI 10.1046/j.1471-4159.1997.68031244.x; DAVIE CA, 1994, BRAIN, V117, P49, DOI 10.1093/brain/117.1.49; Davis KE, 1998, J NEUROSCI, V18, P2475; De Stefano N, 2001, ARCH NEUROL-CHICAGO, V58, P65, DOI 10.1001/archneur.58.1.65; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dowd LA, 1996, J NEUROCHEM, V67, P508, DOI 10.1046/j.1471-4159.1996.67020508.x; Duan SM, 1999, J NEUROSCI, V19, P10193; ERECINSKA M, 1990, PROG NEUROBIOL, V35, P245, DOI 10.1016/0301-0082(90)90013-7; Figiel M, 2003, EXP NEUROL, V183, P124, DOI 10.1016/S0014-4886(03)00134-1; Fine SM, 1996, J BIOL CHEM, V271, P15303, DOI 10.1074/jbc.271.26.15303; Flugel A, 2001, IMMUNITY, V14, P547, DOI 10.1016/s1074-7613(01)00143-1; Fu L, 1998, BRAIN, V121, P103, DOI 10.1093/brain/121.1.103; Gegelashvili G, 1996, NEUROREPORT, V8, P261, DOI 10.1097/00001756-199612200-00052; Gold R, 1996, BRAIN, V119, P651, DOI 10.1093/brain/119.2.651; HARTUNG HP, 1995, NEUROLOGY, V45, pS22, DOI 10.1212/WNL.45.6_Suppl_6.S22; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Hynd MR, 2004, NEUROCHEM INT, V45, P583, DOI 10.1016/j.neuint.2004.03.007; Ikonomidou C, 1995, CURR OPIN NEUROL, V8, P487, DOI 10.1097/00019052-199512000-00017; JUNG S, 1991, J NEUROIMMUNOL, V35, P1, DOI 10.1016/0165-5728(91)90156-2; JUNG S, 1995, EUR J IMMUNOL, V25, P1391, DOI 10.1002/eji.1830250538; Kanai Y, 2004, PFLUG ARCH EUR J PHY, V447, P469, DOI 10.1007/s00424-003-1146-4; Kanai Y, 1997, CURR OPIN CELL BIOL, V9, P565, DOI 10.1016/S0955-0674(97)80035-X; Kassiotis G, 1999, EUR J IMMUNOL, V29, P774, DOI 10.1002/(SICI)1521-4141(199903)29:03<774::AID-IMMU774>3.0.CO;2-T; Kassiotis G, 2001, J EXP MED, V193, P427, DOI 10.1084/jem.193.4.427; Kim SY, 2003, J NEUROCHEM, V87, P1485, DOI 10.1046/j.1471-4159.2003.02128.x; KLOCKNER U, 1993, J BIOL CHEM, V268, P14594; Korn T, 2005, GLIA, V49, P73, DOI 10.1002/glia.20101; Korner H, 1996, IMMUNOL CELL BIOL, V74, P465, DOI 10.1038/icb.1996.77; Ledeboer A, 2002, EUR J NEUROSCI, V16, P1175, DOI 10.1046/j.1460-9568.2002.02200.x; LEHRE KP, 1995, J NEUROSCI, V15, P1835; Lehre KP, 1998, J NEUROSCI, V18, P8751, DOI 10.1523/jneurosci.18-21-08751.1998; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; Lopez-Bayghen E, 2004, J NEUROCHEM, V91, P200, DOI 10.1111/j.1471-4159.2004.02706.x; Lucchinetti CF, 1996, BRAIN PATHOL, V6, P259, DOI 10.1111/j.1750-3639.1996.tb00854.x; Magnus T, 2002, J NEUROPATH EXP NEUR, V61, P760, DOI 10.1093/jnen/61.9.760; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; MARTIN R, 1992, J IMMUNOL, V148, P1359; Matsuura S, 2002, GLIA, V37, P178, DOI 10.1002/glia.10020; Matute C, 2002, EUR J PHARMACOL, V447, P239, DOI 10.1016/S0014-2999(02)01847-2; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; Muraro PA, 1997, J CLIN INVEST, V100, P339, DOI 10.1172/JCI119539; NOKTA MA, 1995, VIROLOGY, V208, P590, DOI 10.1006/viro.1995.1190; Ohgoh M, 2002, J NEUROIMMUNOL, V125, P170, DOI 10.1016/S0165-5728(02)00029-2; Otis TS, 1996, J NEUROSCI, V16, P1634, DOI 10.1523/jneurosci.16-05-01634.1996; Pahan K, 2000, J NEUROCHEM, V75, P576, DOI 10.1046/j.1471-4159.2000.0750576.x; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Pitt D, 2003, NEUROLOGY, V61, P1113, DOI 10.1212/01.WNL.0000090564.88719.37; Pitt D, 2000, NAT MED, V6, P67, DOI 10.1038/71555; Poitry-Yamate CL, 2002, J NEUROCHEM, V82, P987, DOI 10.1046/j.1471-4159.2002.01075.x; Probert L, 2000, BRAIN, V123, P2005, DOI 10.1093/brain/123.10.2005; RAINE CS, 1991, NEUROPATH APPL NEURO, V17, P265, DOI 10.1111/j.1365-2990.1991.tb00724.x; RAMACHANDRAN B, 1993, J BIOL CHEM, V268, P23891; ROTHMAN SM, 1995, TRENDS NEUROSCI, V18, P57; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Rothstein JD, 1996, CLIN NEUROSCI, V3, P348; RUDDLE NH, 1990, J EXP MED, V172, P1193, DOI 10.1084/jem.172.4.1193; Schmitt A, 1997, J NEUROSCI, V17, P1, DOI 10.1523/jneurosci.17-01-00001.1997; Sibson NR, 1998, P NATL ACAD SCI USA, V95, P316, DOI 10.1073/pnas.95.1.316; Smith T, 2000, NAT MED, V6, P62, DOI 10.1038/71548; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Susarla BTS, 2004, J NEUROCHEM, V91, P1151, DOI 10.1111/j.1471-4159.2004.02791.x; Suzuki K, 2001, J CELL SCI, V114, P3717; Swanson RA, 1997, J NEUROSCI, V17, P932; Szymocha R, 2000, J VIROL, V74, P6433, DOI 10.1128/JVI.74.14.6433-6441.2000; Takahashi JL, 2003, ANN NEUROL, V53, P588, DOI 10.1002/ana.10519; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Taupin VR, 1997, EUR J IMMUNOL, V27, P905, DOI 10.1002/eji.1830270416; URENJAK J, 1993, J NEUROSCI, V13, P981, DOI 10.1523/jneurosci.13-03-00981.1993; Wang GW, 2003, EDUC ASIA-PACIFIC, V2, P1; Watase K, 1998, EUR J NEUROSCI, V10, P976, DOI 10.1046/j.1460-9568.1998.00108.x; Weishaupt A, 2000, J IMMUNOL, V165, P7157, DOI 10.4049/jimmunol.165.12.7157; Zelenaia OA, 2000, J NEUROCHEM, V75, P2252, DOI 10.1046/j.1471-4159.2000.0752252.x; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; ZIELASEK J, 1992, CELL IMMUNOL, V141, P111, DOI 10.1016/0008-8749(92)90131-8	88	99	103	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1878	+		10.1096/fj.05-3748fje	http://dx.doi.org/10.1096/fj.05-3748fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16123171				2022-12-28	WOS:000231843700006
J	Sudo, R; Mitaka, T; Ikeda, M; Tanishita, K				Sudo, R; Mitaka, T; Ikeda, M; Tanishita, K			Reconstruction of 3D stacked-up structures by rat small hepatocytes on microporous membranes	FASEB JOURNAL			English	Article						bile canaliculus; three-dimensional culture; tissue engineering	HEPATIC NONPARENCHYMAL CELLS; ORGANIC ANION TRANSPORTER; LIVER-CELLS; MULTICELLULAR SPHEROIDS; EXTRACELLULAR-MATRIX; BILE CANALICULI; DIFFERENTIATION; CULTURE; GROWTH; TISSUE	The three-dimensional (3D) culture of hepatocytes is essential for the reconstruction of functional hepatic tissues in vitro. In the present experiment, we developed a 3D-culture method in order to reconstruct hepatic cordlike structures by stacking up two-dimensional (2D) tissues composed of rat small hepatocytes (SHs), which are hepatic progenitor cells. Pairs of membranes were prepared and the cells were separately cultured on each membrane. After the SH colonies had developed, one membrane was inverted on top of the other to form an SH bilayer. Thereafter, we investigated whether the stacked cells were organized into differentiated tissues. In the 3D stacked-up structures, bile canaliculi (BC) started to form and gradually developed into anastomosing networks. Transmission electron microscopy revealed that the SHs of the upper and lower layers adhered to one another, and that BC formed between them. Bile canalicular proteins localized on the lumina of the tubular structures. Furthermore, the cells within the structures exhibited mRNA transcription of the hepatic-differentiation markers and maintained a relatively high level of albumin secretion. We conclude that highly differentiated 3D tissues, including functional BC, can be reconstructed by stacking up layers of SHs. This 3D stacked-up culture is useful for the reconstruction of tissue-engineered livers.	Keio Univ, Sch Fundamental Sci & Technol, Ctr Life Sci & Technol, Kohoku Ku, Yokohama, Kanagawa 2238522, Japan; Sapporo Med Univ, Sch Med, Canc Res Inst, Dept Pathophysiol, Sapporo, Hokkaido, Japan	Keio University; Sapporo Medical University	Sudo, R (corresponding author), Keio Univ, Sch Fundamental Sci & Technol, Ctr Life Sci & Technol, Kohoku Ku, 3-14-1 Hiyoshi, Yokohama, Kanagawa 2238522, Japan.	rsudo@2000.jukuin.keio.ac.jp	Mitaka, Toshihiro/K-9424-2013; Sudo, Ryo/D-2319-2010	Mitaka, Toshihiro/0000-0001-9467-4871; Sudo, Ryo/0000-0002-1053-9662				Abu-Absi SF, 2002, EXP CELL RES, V274, P56, DOI 10.1006/excr.2001.5467; BARTH CA, 1982, P NATL ACAD SCI-BIOL, V79, P4985, DOI 10.1073/pnas.79.16.4985; BENZEEV A, 1988, P NATL ACAD SCI USA, V85, P2161, DOI 10.1073/pnas.85.7.2161; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CLAYTON DF, 1985, MOL CELL BIOL, V5, P2623, DOI 10.1128/MCB.5.10.2623; Desmet VJ, 2001, LIVER BIOL PATHOBIOL, P3; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; GERLACH JC, 1995, HEPATOLOGY, V22, P546, DOI 10.1002/hep.1840220226; Gordon GJ, 2000, AM J PATHOL, V157, P771, DOI 10.1016/S0002-9440(10)64591-9; Griffith LG, 2002, SCIENCE, V295, P1009, DOI 10.1126/science.1069210; Harada K, 2003, J HEPATOL, V39, P716, DOI 10.1016/S0168-8278(03)00412-4; Jiang JL, 2002, CELL TRANSPLANT, V11, P403, DOI 10.3727/000000002783985648; KOIDE N, 1990, EXP CELL RES, V186, P227, DOI 10.1016/0014-4827(90)90300-Y; LANDRY J, 1985, J CELL BIOL, V101, P914, DOI 10.1083/jcb.101.3.914; MATSUSHITA T, 1991, APPL MICROBIOL BIOT, V36, P324; Mitaka T, 1999, HEPATOLOGY, V29, P111, DOI 10.1002/hep.510290103; MITAKA T, 1995, BIOCHEM BIOPH RES CO, V214, P310, DOI 10.1006/bbrc.1995.2289; MITAKA T, 1992, HEPATOLOGY, V16, P440, DOI 10.1002/hep.1840160224; Mitaka Toshihiro, 2002, J Hepatobiliary Pancreat Surg, V9, P697, DOI 10.1007/s005340200096; Mizuguchi T, 2000, ARTIF ORGANS, V24, P271, DOI 10.1046/j.1525-1594.2000.06506.x; MOONEY D, 1992, J CELL PHYSIOL, V151, P497, DOI 10.1002/jcp.1041510308; MOONEY DJ, 1995, J BIOMED MATER RES, V29, P959, DOI 10.1002/jbm.820290807; Ogawa K, 2004, TRANSPLANTATION, V77, P1783, DOI 10.1097/01.tp.0000131153.78169.24; OSHIO C, 1981, SCIENCE, V212, P1041, DOI 10.1126/science.7015506; Powers MJ, 2002, TISSUE ENG, V8, P499, DOI 10.1089/107632702760184745; Roelofsen H, 1998, J CELL SCI, V111, P1137; Sakai Y, 1996, INT J ARTIF ORGANS, V19, P294; SINGHVI R, 1994, SCIENCE, V264, P696, DOI 10.1126/science.8171320; Sudo R, 2005, ANN BIOMED ENG, V33, P696, DOI 10.1007/s10439-005-1690-5; Sudo R, 2004, J CELL PHYSIOL, V199, P252, DOI 10.1002/jcp.10407; Sugimoto S, 2002, J CELL BIOCHEM, V87, P16, DOI 10.1002/jcb.10274; Sundback CA, 2000, GASTROENTEROLOGY, V118, P438; Vos TA, 1998, HEPATOLOGY, V28, P1637, DOI 10.1002/hep.510280625; WATT FM, 1988, P NATL ACAD SCI USA, V85, P5576, DOI 10.1073/pnas.85.15.5576; Yamashita Y, 2003, CELL TRANSPLANT, V12, P101, DOI 10.3727/000000003108746687	35	42	47	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1695	+		10.1096/fj.04-3269fje	http://dx.doi.org/10.1096/fj.04-3269fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16107536				2022-12-28	WOS:000231843700010
J	Hilberg, T; Deigner, HP; Moller, E; Claus, RA; Ruryk, A; Glaser, D; Landre, JBP; Brunkhorst, FM; Reinhart, K; Gabriel, HHW; Russwurm, S				Hilberg, T; Deigner, HP; Moller, E; Claus, RA; Ruryk, A; Glaser, D; Landre, JBP; Brunkhorst, FM; Reinhart, K; Gabriel, HHW; Russwurm, S			Transcription in response to physical stress - clues to the molecular mechanisms of exercise-induced asthma	FASEB JOURNAL			English	Article						microarray; leukotriene; acute-phase response; gene expression	INDIVIDUAL ANAEROBIC THRESHOLD; INTERLEUKIN-6 PRODUCTION; CYTOKINE RESPONSE; SKELETAL-MUSCLE; IMMUNE-SYSTEM; MESSENGER-RNA; RECEPTOR; EXPRESSION; CELLS; IL-6	To clarify stress-induced immunological reactions and molecular events during exercise and the potential relevance to exercise-induced bronchoconstriction, transcriptional responses to standardized physical stress were determined. Six healthy, young volunteers underwent an endurance exercise of 90% of their individual anaerobic threshold for 90 min. Time-dependent alterations in the expression pattern of leukocytes from healthy, trained subjects were analyzed by DNA microarrays before and 2 h and 6 h after exercise. Starting out from a large collection of cDNA library clones comprising more than 70,000 human expressed sequence tags, we selected, designed, and immobilized oligonucleotide probes (60-70mers) for transcripts of 5000 stress and inflammation-relevant genes. Exercise-induced stress provoked changes in the expression of 433 gene activities 2 h and/or 6 h after exercise, which could be grouped into six clusters. The most prominent feature was an enhanced transcription of two genes, coding for 5-lipoxygenase (ALOX5) and ALOX5-activating protein. Moreover, enhanced levels of leukotriene B-4 (LTB4) and LTC4 (P < 0.05) were detected in plasma after exercise. Our data demonstrate that exercise alters the activities of a distinct number of genes. In particular, they possibly provide novel insights into the molecular mechanisms of exercise-induced bronchoconstriction and suggest that enhanced transcription of ALOX5 and its activating protein together with a present predisposition of the subject critically contribute to exercise-induced asthma.	Univ Jena, Sch Chem Sci, D-07749 Jena, Germany; Univ Jena, Dept Sports Med, Wollnitzerstr 42, D-07749 Jena, Germany; SIRS Lab GmbH, Jena, Germany; Univ Hosp Jena, Dept Anesthesiol & Intens Care Med, Jena, Germany	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena	Hilberg, T (corresponding author), Univ Jena, Sch Chem Sci, Wollnitzerstr 42, D-07749 Jena, Germany.	thomas.hilberg@uni-jena.de; h-p.deigner@uea.ac.uk	Claus, Ralf A./Q-4035-2016	Claus, Ralf A./0000-0001-7232-4088; Brunkhorst, Frank Martin/0000-0002-8132-8651				ARM JP, 1988, AM REV RESPIR DIS, V138, P47, DOI 10.1164/ajrccm/138.1.47; Ball CA, 2002, SCIENCE, V298, P539; Bethin KE, 2000, P NATL ACAD SCI USA, V97, P9317, DOI 10.1073/pnas.97.16.9317; Caillaud C, 2003, CAN J APPL PHYSIOL, V28, P793, DOI 10.1139/h03-059; Ericson SG, 1998, BLOOD, V91, P2099, DOI 10.1182/blood.V91.6.2099.2099_2099_2107; Febbraio MA, 2003, EXERC IMMUNOL REV, V9, P34; Fehrenbach E, 2003, EXERC IMMUNOL REV, V9, P58; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847; GABRIEL H, 1992, INT J SPORTS MED, V13, P359, DOI 10.1055/s-2007-1021281; Gadient RA, 1999, STEM CELLS, V17, P127, DOI 10.1002/stem.170127; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Helgadottir A, 2004, NAT GENET, V36, P233, DOI 10.1038/ng1311; Hilberg T, 2003, EUR J APPL PHYSIOL, V90, P639, DOI 10.1007/s00421-003-0907-2; Hoshino M, 1989, Arerugi, V38, P1302; Huber W, 2003, STAT APPL GENET MOL, P2; Keller C, 2001, FASEB J, V15, P2748, DOI 10.1096/fj.01-0507fje; KESTLER DP, 1995, BLOOD, V86, P4559, DOI 10.1182/blood.V86.12.4559.bloodjournal86124559; Kippelen P, 2004, INT J SPORTS MED, V25, P130; Lacy P, 1998, BLOOD, V91, P2508, DOI 10.1182/blood.V91.7.2508.2508_2508_2516; Lauter J, 1996, BIOMETRICS, V52, P964, DOI 10.2307/2533057; MELANI C, 1993, BLOOD, V81, P2744; Moldoveanu AI, 2001, SPORTS MED, V31, P115, DOI 10.2165/00007256-200131020-00004; MONTEROJULIAN FA, 1994, J IMMUNOL METHODS, V169, P111, DOI 10.1016/0022-1759(94)90130-9; Nieman DC, 2003, J APPL PHYSIOL, V94, P1917, DOI 10.1152/japplphysiol.01130.2002; Ostrowski K, 1998, J PHYSIOL-LONDON, V508, P949, DOI 10.1111/j.1469-7793.1998.949bp.x; Pedersen BK, 2000, PHYSIOL REV, V80, P1055, DOI 10.1152/physrev.2000.80.3.1055; Prucha M, 2004, SHOCK, V22, P29, DOI 10.1097/01.shk.0000129199.30965.02; Rao GN, 1996, J BIOL CHEM, V271, P27760, DOI 10.1074/jbc.271.44.27760; Rundell KW, 2002, SPORTS MED, V32, P583, DOI 10.2165/00007256-200232090-00004; SAD S, 1995, IMMUNITY, V2, P271, DOI 10.1016/1074-7613(95)90051-9; Sayers I, 2003, CLIN EXP ALLERGY, V33, P1103, DOI 10.1046/j.1365-2222.2003.01733.x; Shephard RJ, 2001, BRIT J SPORT MED, V35, P223, DOI 10.1136/bjsm.35.4.223; SIMON R, 2003, DESIGN ANAL DNA MICR; Starkie R, 2003, FASEB J, V17, P884, DOI 10.1096/fj.02-0670fje; Steensberg A, 2003, AM J PHYSIOL-ENDOC M, V285, pE433, DOI 10.1152/ajpendo.00074.2003; Steensberg A, 2003, EXERC IMMUNOL REV, V9, P40; STEGMANN H, 1981, INT J SPORTS MED, V2, P160, DOI 10.1055/s-2008-1034604; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Storms WW, 2003, MED SCI SPORT EXER, V35, P1464, DOI 10.1249/01.MSS.0000084533.75912.B4; STOUTHARD JML, 1995, AM J PHYSIOL-ENDOC M, V268, pE813, DOI 10.1152/ajpendo.1995.268.5.E813; van der Meijden M, 1998, CELL IMMUNOL, V190, P156, DOI 10.1006/cimm.1998.1387; Weinstock C, 1997, MED SCI SPORT EXER, V29, P345, DOI 10.1097/00005768-199703000-00009; XIN XN, 1995, ENDOCRINOLOGY, V136, P132, DOI 10.1210/en.136.1.132; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368; Zhao L, 2004, NAT MED, V10, P966, DOI 10.1038/nm1099	46	36	37	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1492	+		10.1096/fj.04-3063fje	http://dx.doi.org/10.1096/fj.04-3063fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16027142				2022-12-28	WOS:000230923000019
J	Dip, R; Naegeli, H				Dip, R; Naegeli, H			More than just strand breaks: the recognition of structural DNA discontinuities by DNA-dependent protein kinase catalytic subunit	FASEB JOURNAL			English	Review						genome; double strand break; DNA synthesis; eukaryote; DNA-PK	RNA-POLYMERASE-II; V(D)J RECOMBINATION; TELOMERE LENGTH; HOMOLOGOUS RECOMBINATION; CHROMOSOMAL STABILITY; LATENT POPULATION; BINDING PROTEIN; DOWN-REGULATION; POTENTIAL ROLE; PK	The DNA-dependent protein kinase (DNA-PK) is a trimeric factor originally identified as an enzyme that becomes activated upon incubation with DNA. Genetic defects in either the catalvtic subunit (DNA-PKCS) or the two Ku components of DNA-PK result in immunodeficiency, radiosensitivity, and premature aging. This combined phenotype is generally attributed to the requirement for DNA-PK in the repair of DNA double strand breaks during various biological processes. However, recent studies revealed that DNA-PKCS, a member of the growing family of phosphatidylinositol 3-kinases, participates in signal transduction cascades related to apoptotic cell death, telomere maintenance and other pathways of genome surveillance. These manifold functions of DNA-PKcs have been associated with an increasing number of protein interaction partners and phosphorylation targets. Here we review the DNA binding properties of DNA-PKcs and highlight its ability to interact with an astounding diversity of nucleic acid substrates. This survey indicates that the large catalytic subunit of DNA-PK functions as a sensor of not only broken DNA molecules, but of a wider spectrum of aberrant, unusual, or specialized structures that interrupt the standard double helical conformation of DNA.-Dip, R., Naegeli, H. More than just strand breaks: the recognition of structural DNA discontinuities by DNA-dependent protein kinase catalytic subunit.	Univ Zurich, Inst Vet Pharmacol & Toxicol, CH-8057 Zurich, Switzerland	University of Zurich	Naegeli, H (corresponding author), Univ Zurich, Inst Vet Pharmacol & Toxicol, Winterthurerstr 260, CH-8057 Zurich, Switzerland.	naegelih@vetpharm.unizh.ch						Achanta G, 2001, CANCER RES, V61, P8723; Ai R, 2004, MOL BIOL REP, V31, P91, DOI 10.1023/B:MOLE.0000031358.71141.78; Allen C, 2002, P NATL ACAD SCI USA, V99, P3758, DOI 10.1073/pnas.052545899; Bailey SM, 2004, DNA REPAIR, V3, P225, DOI 10.1016/j.dnarep.2003.10.013; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Block WD, 2004, NUCLEIC ACIDS RES, V32, P4351, DOI 10.1093/nar/gkh761; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; Boskovic J, 2003, EMBO J, V22, P5875, DOI 10.1093/emboj/cdg555; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; Burma S, 2004, DNA REPAIR, V3, P909, DOI 10.1016/j.dnarep.2004.03.021; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; CHEN GC, 2004, IN PRESS J CELL PHYS; Chibazakura T, 1997, EUR J BIOCHEM, V247, P1166, DOI 10.1111/j.1432-1033.1997.01166.x; Chiu CY, 1998, J MOL BIOL, V284, P1075, DOI 10.1006/jmbi.1998.2212; Chu WM, 2000, CELL, V103, P909, DOI 10.1016/S0092-8674(00)00194-X; Cox MM, 2002, MUTAT RES-FUND MOL M, V510, P107, DOI 10.1016/S0027-5107(02)00256-7; DeFazio LG, 2002, EMBO J, V21, P3192, DOI 10.1093/emboj/cdf299; Delacote F, 2002, NUCLEIC ACIDS RES, V30, P3454, DOI 10.1093/nar/gkf452; di Fagagna FD, 2001, CURR BIOL, V11, P1192, DOI 10.1016/S0960-9822(01)00328-1; Dip R, 2004, BIOCHEM J, V381, P165, DOI 10.1042/BJ20031666; Dore AS, 2004, DNA REPAIR, V3, P33, DOI 10.1016/j.dnarep.2003.09.003; Douglas P, 2001, J BIOL CHEM, V276, P18992, DOI 10.1074/jbc.M011703200; Downs JA, 2004, NAT REV MOL CELL BIO, V5, P367, DOI 10.1038/nrm1367; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Erdemir T, 2002, MOL MICROBIOL, V46, P947, DOI 10.1046/j.1365-2958.2002.03224.x; Espejel S, 2004, EMBO REP, V5, P503, DOI 10.1038/sj.embor.7400127; Espejel S, 2002, EMBO J, V21, P6275, DOI 10.1093/emboj/cdf593; Espejel S, 2002, EMBO J, V21, P2207, DOI 10.1093/emboj/21.9.2207; Fujimori A, 2000, IMMUNOGENETICS, V51, P965, DOI 10.1007/s002510000227; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Gilley D, 2001, P NATL ACAD SCI USA, V98, P15084, DOI 10.1073/pnas.261574698; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Goytisolo FA, 2001, MOL CELL BIOL, V21, P3642, DOI 10.1128/MCB.21.11.3642-3651.2001; Hammarsten O, 2000, J BIOL CHEM, V275, P1541, DOI 10.1074/jbc.275.3.1541; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Iwabuchi K, 2003, J BIOL CHEM, V278, P36487, DOI 10.1074/jbc.M304066200; Jack MT, 2004, J BIOL CHEM, V279, P15269, DOI 10.1074/jbc.M309917200; Jensen R, 2004, P NATL ACAD SCI USA, V101, P6134, DOI 10.1073/pnas.0400051101; Jhappan C, 2000, MOL CELL BIOL, V20, P4075, DOI 10.1128/MCB.20.11.4075-4083.2000; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; Jin SF, 1997, J BIOL CHEM, V272, P24763, DOI 10.1074/jbc.272.40.24763; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Koike M, 1999, J CELL SCI, V112, P4031; Kumar S, 1998, J BIOL CHEM, V273, P25654, DOI 10.1074/jbc.273.40.25654; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; Mauldin SK, 2002, NUCLEIC ACIDS RES, V30, P4075, DOI 10.1093/nar/gkf529; Meek K, 2001, J IMMUNOL, V167, P2142, DOI 10.4049/jimmunol.167.4.2142; Merkle D, 2002, BIOCHEMISTRY-US, V41, P12706, DOI 10.1021/bi0263558; Michaelidis TM, 2002, BIOL CHEM, V383, P1683, DOI 10.1515/BC.2002.189; Mondello C, 2001, CANCER RES, V61, P4520; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Nueda A, 1999, J BIOL CHEM, V274, P14988, DOI 10.1074/jbc.274.21.14988; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Park JS, 1999, J BIOL CHEM, V274, P32520, DOI 10.1074/jbc.274.45.32520; Rapp A, 2004, J CELL SCI, V117, P4935, DOI 10.1242/jcs.01355; REDDY YV, 2004, IN PRESS J BIOL CHEM; Rothbarth K, 1999, J CELL SCI, V112, P2223; Schild-Poulter C, 2003, CANCER RES, V63, P7197; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Sheppard HM, 2000, BBA-GENE STRUCT EXPR, V1493, P41, DOI 10.1016/S0167-4781(00)00155-X; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Smider V, 1998, MOL CELL BIOL, V18, P6853, DOI 10.1128/MCB.18.11.6853; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Soubeyrand S, 2003, CANCER RES, V63, P1198; Soubeyrand S, 2001, P NATL ACAD SCI USA, V98, P9605, DOI 10.1073/pnas.171211398; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; Tramontano F, 2005, J CELL BIOCHEM, V94, P58, DOI 10.1002/jcb.20295; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; van Heemst D, 2004, DNA REPAIR, V3, P43, DOI 10.1016/j.dnarep.2003.09.004; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang S, 2000, P NATL ACAD SCI USA, V97, P1584, DOI 10.1073/pnas.97.4.1584; Watanabe F, 2003, INT J BIOCHEM CELL B, V35, P432, DOI 10.1016/S1357-2725(02)00268-6; Wechsler T, 2004, P NATL ACAD SCI USA, V101, P1247, DOI 10.1073/pnas.0307765100; Weterings E, 2003, NUCLEIC ACIDS RES, V31, P7238, DOI 10.1093/nar/gkg889; WILER R, 1995, P NATL ACAD SCI USA, V92, P11485, DOI 10.1073/pnas.92.25.11485; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wu XT, 1997, MUTAT RES-DNA REPAIR, V385, P13, DOI 10.1016/S0921-8777(97)00035-9; Yamamura J, 2001, FEBS LETT, V489, P166, DOI 10.1016/S0014-5793(01)02098-1; Yavuzer U, 1998, GENE DEV, V12, P2188, DOI 10.1101/gad.12.14.2188; Yumoto Y, 1998, J BIOCHEM-TOKYO, V124, P519, DOI 10.1093/oxfordjournals.jbchem.a022143; Zhang SS, 2004, NUCLEIC ACIDS RES, V32, P1, DOI 10.1093/nar/gkg933	97	31	37	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					704	715		10.1096/fj.04-3041rev	http://dx.doi.org/10.1096/fj.04-3041rev			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15857885	Green Accepted			2022-12-28	WOS:000229602600027
J	Koti, RS; Tsui, JC; Lobos, E; Yang, WX; Seifalian, AM; Davidson, BR				Koti, RS; Tsui, JC; Lobos, E; Yang, WX; Seifalian, AM; Davidson, BR			Nitric oxide synthase distribution and expression with ischemic preconditioning of the rat liver	FASEB JOURNAL			English	Article						isoforms; endothelial; inducible; hepatoprotection; ischemia reperfusion injury	CORONARY-ARTERY-DISEASE; REPERFUSION INJURY; HEPATIC ISCHEMIA; L-ARGININE; TRANSPLANTATION; METABOLISM; MECHANISMS; GENERATION; MANAGEMENT; TOLERANCE	This study was undertaken to identify nitric oxide synthase (NOS) isoforms responsible for the generation of cytoprotective NO during liver ischemic preconditioning (IPC). Sprague-Dawley rats were subjected to 45 min lobar ischemia followed by 2 h reperfusion. L-arginine or NO)nitro-L-arginine methyl ester (L-NAME) was administered to stimulate or block NO synthesis. Study groups (n=6) had 1) sham laparotomy, 2) ischemia reperfusion (IR), 3) IPC with 5 min ischemia and 10 min reperfusion before IR, 4) L-arginine before IR, or 5) L-NAME + IPC before IR. Liver function tests, nitrite + nitrate (NOx) and plasma amino acids were analyzed. The endothelial cell and inducible isoforms of NOS (eNOS and iNOS) were identified using immunohistochemistry and Western blotting. Both IPC and L-arginine treatment increased NOx (P<0.05) and improved serum liver enzymes (P<0.05) when compared with IR. These effects were prevented by L-NAME. Hepatic vein NOx was significantly higher than circulating NOx. iNOS expression was absent within the groups. The preconditioned livers were associated with up-regulation of eNOS expression and also increased L-arginine levels. The effects of L-arginine administration were similar to those evident following IPC. Thus, cytoprotective NO generation during IPC of the liver was a result of increased eNOS expression and increased L-arginine substrate availability.	UCL, Acad Div Surg & Intervent Sci, London NW3 2PF, England; Royal Free Hampstead NHS Trust Hosp, Dept Surg & Liver, Transplantat Unit, London NW3 2QG, England; Univ Leipzig, Inst Anat, D-04103 Leipzig, Germany	University of London; University College London; University of London; University College London; Leipzig University	Seifalian, AM (corresponding author), UCL, Acad Div Surg & Intervent Sci, Rowland Hill St, London NW3 2PF, England.	A.Seifalian@MedSch.UCL.AC.UK	Seifalian, Alexander M/I-6028-2013; Tsui, Janice/T-7858-2019	Seifalian, Alexander M/0000-0002-1180-3322; seifalian, Alexander/0000-0002-8334-9376				Blum A, 2000, CIRCULATION, V101, P2160, DOI 10.1161/01.CIR.101.18.2160; Cottart CH, 1999, HEPATOLOGY, V29, P809, DOI 10.1002/hep.510290317; DELVA E, 1989, ANN SURG, V209, P211, DOI 10.1097/00000658-198902000-00012; Hingorani AD, 1999, CIRCULATION, V100, P1515, DOI 10.1161/01.CIR.100.14.1515; JAESCHKE H, 1991, AM J PHYSIOL, V260, pG355, DOI 10.1152/ajpgi.1991.260.3.G355; JAESCHKE H, 2003, AM J PHYSL LIVER PHY, V254, pG15; KNOWLES RG, 1990, BIOCHEM J, V270, P833, DOI 10.1042/bj2700833; KOO A, 1992, HEPATOLOGY, V15, P507, DOI 10.1002/hep.1840150325; Koti RS, 2003, DIGEST SURG, V20, P383, DOI 10.1159/000072064; Koti RS, 2002, LIVER TRANSPLANT, V8, P1182, DOI 10.1053/jlts.2002.36846; Koti RS, 2002, FASEB J, V16, P1654, DOI 10.1096/fj.01-1034fje; Langle F, 1997, TRANSPLANTATION, V63, P1225; Ling H, 1999, AM J PHYSIOL-RENAL, V277, pF383; Nagase S, 1997, BIOCHEM BIOPH RES CO, V233, P150, DOI 10.1006/bbrc.1997.6428; Napoli C, 2003, P NATL ACAD SCI USA, V100, P2112, DOI 10.1073/pnas.0336359100; Napoli C, 2001, NITRIC OXIDE-BIOL CH, V5, P88, DOI 10.1006/niox.2001.0337; Peralta C, 1999, HEPATOLOGY, V29, P126, DOI 10.1002/hep.510290104; Peralta C, 1996, BIOCHEM BIOPH RES CO, V229, P264, DOI 10.1006/bbrc.1996.1790; Peralta C, 2001, TRANSPLANTATION, V71, P529, DOI 10.1097/00007890-200102270-00008; Redondo J, 2000, CRYOBIOLOGY, V41, P292, DOI 10.1006/cryo.2000.2285; Serafin A, 2002, AM J PATHOL, V161, P587, DOI 10.1016/S0002-9440(10)64214-9; Serracino-Inglott Ferdinand, 2002, BMC Gastroenterol, V2, P22, DOI 10.1186/1471-230X-2-22; Sindram D, 2002, J HEPATOL, V36, P78, DOI 10.1016/S0168-8278(01)00229-X; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Szabo G, 1998, J CARDIOVASC PHARM, V31, P221, DOI 10.1097/00005344-199802000-00007; TSAO PS, 1990, AM J PHYSIOL, V259, pH1660, DOI 10.1152/ajpheart.1990.259.6.H1660; Wang QD, 1997, J CARDIOVASC PHARM, V29, P291, DOI 10.1097/00005344-199702000-00020; WINDMUELLER HG, 1981, AM J PHYSIOL, V241, pE473, DOI 10.1152/ajpendo.1981.241.6.E473; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Yagnik GP, 2002, HEPATOLOGY, V36, P573, DOI 10.1053/jhep.2002.35058; Yin DP, 1998, TRANSPLANTATION, V66, P152, DOI 10.1097/00007890-199807270-00002; ZEBALLOS GA, 1995, CIRCULATION, V91, P2982, DOI 10.1161/01.CIR.91.12.2982	33	46	53	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1155	+		10.1096/fj.04-3220fje	http://dx.doi.org/10.1096/fj.04-3220fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15870170				2022-12-28	WOS:000229602600022
J	Mauri, P; Scarpa, A; Nascimbeni, AC; Benazzi, L; Parmagnani, E; Mafficini, A; Della Peruta, M; Bassi, C; Miyazaki, K; Sorio, C				Mauri, P; Scarpa, A; Nascimbeni, AC; Benazzi, L; Parmagnani, E; Mafficini, A; Della Peruta, M; Bassi, C; Miyazaki, K; Sorio, C			Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers	FASEB JOURNAL			English	Article						secreted proteins; proteomics; MudPIT	UROKINASE PLASMINOGEN-ACTIVATOR; IN-VIVO; MOLECULAR CLASSIFICATION; EXTRACELLULAR-MATRIX; SHOTGUN PROTEOMICS; MASS-SPECTROMETRY; HEPARAN-SULFATE; TUMOR-GROWTH; EXPRESSION; CARCINOMA	The purpose of this study is to identify novel proteins released by cancer cells that are involved in extracellular matrix (ECM) remodeling using small-volume samples and automated technology. We applied multidimensional protein identification technology (MudPIT), which incorporates two-dimensional capillary chromatography coupled to tandem mass spectrometry to small quantities of serum-free supernatants of resting or phorbol ester-activated Suit-2 pancreatic cancer cells. Selected markers were validated in additional pancreatic cancer cell lines, primary cancers, and xenografted cancer cells. MudPIT analysis of 10 mu l of supernatants identified 46 proteins, 21 of which are classified as secreted, and 10 have never been associated with pancreatic cancer. These include CSPG2/versican, Mac25/angiomodulin, IGFBP-1, HSPG2/perlecan, syndecan 4, FAM3C, APLP2, cyclophilin B, beta 2 microglobulin, and ICA69. Evidence that cancer cells release these proteins in vivo was obtained for CSPG2/versican and Mac25/angiomodulin by immunohistochemistry on both primary pancreatic cancers and in a model consisting of Suit-2 cells embedded in an amorphous matrix and implanted in athymic mice. MudPIT allowed efficient and rapid identification of proteins released by cancer cells, including molecules previously undescribed in the type of cancer analyzed. Our finding that pancreatic cancer cells secrete a series of proteoglycans, including versican, perlecan, syndecan I and 4, challenges the common view that fibroblasts of tumor stroma are the sole source of these molecules.	Univ Verona, Dipartimento Patol, Sez Patol Gen, I-37134 Verona, Italy; CNR, Ist Tecnol Biomed, I-20133 Milan, Italy; Univ Verona, Dipartimento Sci Chirurg & Gastroenterol, I-37100 Verona, Italy; Yokohama City Univ, Kihara Inst Biol Res, Yokohama, Kanagawa 232, Japan	University of Verona; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Verona; Yokohama City University	Sorio, C (corresponding author), Univ Verona, Dipartimento Patol, Sez Patol Gen, Strada Grazie, I-37134 Verona, Italy.	claudio.sorio@univr.it	benazzi, louise/AAW-2684-2020; scarpa, aldo/K-6832-2016; Mauri, Pietro Luigi/AAC-3095-2019; della peruta, marco/H-8704-2016; Paulo, Joao A/C-7781-2011; Nascimbeni, Anna Chiara/AAG-4782-2021; Mafficini, Andrea/AAK-8158-2020; Sorio, Claudio/F-2764-2018	scarpa, aldo/0000-0003-1678-739X; Mauri, Pietro Luigi/0000-0003-4364-0393; Paulo, Joao A/0000-0002-4291-413X; Mafficini, Andrea/0000-0002-7471-3121; Sorio, Claudio/0000-0003-2739-4014; Della Peruta, Marco/0000-0002-5580-1847; SALVIA, Roberto/0000-0002-3514-8473				Adachi Y, 2001, INT J CANCER, V95, P216, DOI 10.1002/1097-0215(20010720)95:4<216::AID-IJC1037>3.0.CO;2-O; Akaogi K, 1996, P NATL ACAD SCI USA, V93, P8384, DOI 10.1073/pnas.93.16.8384; Albo D, 1998, J SURG RES, V76, P86, DOI 10.1006/jsre.1998.5299; Aspberg A, 1999, J BIOL CHEM, V274, P20444, DOI 10.1074/jbc.274.29.20444; BARNARD JA, 2003, GASTROINTESTINAL CAN, P33; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Bramhall SR, 1997, J PATHOL, V182, P347, DOI 10.1002/(SICI)1096-9896(199707)182:3<347::AID-PATH848>3.0.CO;2-J; Buchholz M, 2003, CANCER RES, V63, P4945; Cantero D, 1997, BRIT J CANCER, V75, P388, DOI 10.1038/bjc.1997.63; Carr S, 2004, MOL CELL PROTEOMICS, V3, P531, DOI 10.1074/mcp.T400006-MCP200; Cattaneo M, 2003, ONCOGENE, V22, P6359, DOI 10.1038/sj.onc.1206665; Cattaruzza S, 2002, J BIOL CHEM, V277, P47626, DOI 10.1074/jbc.M206521200; Conejo JR, 2000, INT J CANCER, V88, P12, DOI 10.1002/1097-0215(20001001)88:1<12::AID-IJC3>3.0.CO;2-T; Corthals GL, 2000, ELECTROPHORESIS, V21, P1104, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1104::AID-ELPS1104>3.3.CO;2-3; Cravatt BF, 2000, CURR OPIN CHEM BIOL, V4, P663, DOI 10.1016/S1367-5931(00)00147-2; Crnogorac-Jurcevic T, 2001, ONCOGENE, V20, P7437, DOI 10.1038/sj.onc.1204935; Diehn M, 2000, NAT GENET, V25, P58, DOI 10.1038/75603; Durr E, 2004, NAT BIOTECHNOL, V22, P985, DOI 10.1038/nbt993; Ellenrieder V, 2000, INT J CANCER, V85, P14, DOI 10.1002/(SICI)1097-0215(20000101)85:1<14::AID-IJC3>3.3.CO;2-F; Gao J, 2003, J PROTEOME RES, V2, P643, DOI 10.1021/pr034038x; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gordon J, 2003, INT J CANCER, V103, P316, DOI 10.1002/ijc.10828; Griffin TJ, 2001, J BIOL CHEM, V276, P45497, DOI 10.1074/jbc.R100014200; Gygi SP, 2000, P NATL ACAD SCI USA, V97, P9390, DOI 10.1073/pnas.160270797; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hansel DE, 2003, CANCER RES, V63, P7032; Hill AS, 2003, GENE CHROMOSOME CANC, V38, P260, DOI 10.1002/gcc.10277; HUANG CJ, 1994, ANAL CELL PATHOL, V6, P93; Isogai Z, 2002, J BIOL CHEM, V277, P4565, DOI 10.1074/jbc.M110583200; Kasper HU, 2001, VIRCHOWS ARCH, V438, P116; Kishibe J, 2000, J BIOL CHEM, V275, P15321, DOI 10.1074/jbc.275.20.15321; Kitamura N, 2001, CLIN EXP METASTAS, V18, P561, DOI 10.1023/A:1011900818419; Kratchmarova I, 2002, MOL CELL PROTEOMICS, V1, P213, DOI 10.1074/mcp.M200006-MCP200; Kunzli BM, 2002, CANCER-AM CANCER SOC, V94, P228, DOI 10.1002/cncr.10162; LIOTTA LA, 2002, CANC HDB, V1, P225; Liu HB, 2004, ANAL CHEM, V76, P4193, DOI 10.1021/ac0498563; Liu W, 1998, J BIOL CHEM, V273, P22825, DOI 10.1074/jbc.273.35.22825; Martin DB, 2004, CANCER RES, V64, P347, DOI 10.1158/0008-5472.CAN-03-2062; MAURI PL, 2003, 16 INT MASS SPECTR C; Moore PS, 2001, VIRCHOWS ARCH, V439, P798, DOI 10.1007/s004280100474; Mor-Vaknin N, 2003, NAT CELL BIOL, V5, P59, DOI 10.1038/ncb898; Nagakubo D, 2003, J IMMUNOL, V171, P553, DOI 10.4049/jimmunol.171.2.553; Pejler G, 2003, EUR J BIOCHEM, V270, P3971, DOI 10.1046/j.1432-1033.2003.03785.x; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pilon M, 2000, MOL BIOL CELL, V11, P3277, DOI 10.1091/mbc.11.10.3277; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Rustgi A. K., 2003, GASTROINTESTINAL CAN, P69; Sato J, 1999, J CELL BIOCHEM, V75, P187, DOI 10.1002/(SICI)1097-4644(19991101)75:2<187::AID-JCB1>3.0.CO;2-R; Schneider D, 2002, BBA-MOL BASIS DIS, V1588, P1, DOI 10.1016/S0925-4439(02)00052-2; Sharma B, 1998, J CLIN INVEST, V102, P1599, DOI 10.1172/JCI3793; Sorio C, 2001, VIRCHOWS ARCH, V438, P154, DOI 10.1007/s004280000343; Tamura M, 2001, JPN J CANCER RES, V92, P762, DOI 10.1111/j.1349-7006.2001.tb01159.x; Tinari N, 1997, BIOCHEM BIOPH RES CO, V232, P367, DOI 10.1006/bbrc.1997.6258; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wight TN, 1997, AM J PATHOL, V151, P963; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; Wu CC, 2003, NAT BIOTECHNOL, V21, P262, DOI 10.1038/nbt0303-262; Xie MJ, 2002, PANCREAS, V25, P234, DOI 10.1097/00006676-200210000-00004; Zhu Y, 2002, GENOMICS, V80, P144, DOI 10.1006/geno.2002.6816	59	98	110	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1125	+		10.1096/fj.04-3000fje	http://dx.doi.org/10.1096/fj.04-3000fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15985535				2022-12-28	WOS:000229602600020
J	Moreno, MC; Sande, P; Marcos, HA; de Zavalia, N; Sarmiento, MIK; Rosenstein, RE				Moreno, MC; Sande, P; Marcos, HA; de Zavalia, N; Sarmiento, MIK; Rosenstein, RE			Effect of glaucoma on the retinal glutamate/glutamine cycle activity	FASEB JOURNAL			English	Article						excitotoxicity; glutamatergic neurons; hyaluronic acid	OPTIC-NERVE TRANSECTION; NITRIC-OXIDE SYNTHASE; GLIAL MULLER CELLS; INTRAOCULAR-PRESSURE; GLUTAMATE TRANSPORTER; OCULAR HYPERTENSION; MEMANTINE TREATMENT; RATS; SYNTHETASE; RECEPTORS	Glutamate-induced excitotoxicity has been proposed to mediate the death of retinal ganglion cells in glaucoma. The metabolic dependence of glutamatergic neurons upon glia via the glutamate/glutamine cycle to provide the precursor for neurotransmitter glutamate is well established. Thus, the aim of the present work was to study the retinal glutamate/glutamine activity in eyes with hypertension induced by intracameral injections of hyaluronic acid (HA). For this purpose, weekly injections of HA were performed unilaterally in the rat anterior chamber, whereas the contralateral eye was injected with saline solution. At 3 or 10 weeks of treatment, glutamate and glutamine uptake and release were assessed using [H-3]-glutamate and [H-3]-glutamine as radioligands, respectively. In addition, glutamine synthetase activity was assessed by a spectrophotometric assay, whereas glutaminase activity was measured through the conversion of [H-3]-glutamine to [H-3]-glutamate. At 3 weeks of treatment with HA, a significant decrease (P<0.01) in glutamate uptake and glutamine synthetase activity was observed. Glutamine uptake and release, as well as glutaminase activity, were significantly increased (P<0.01) in eyes injected with HA for 3 weeks compared with vehicle-injected eyes, whereas [H-3]-glutamate release did not change in hypertensive eyes. Only the changes in glutamine synthetase activity persisted at 10 weeks of treatment with HA. These results indicate a significant alteration in the retinal glutamate/glutamine cycle activity in hypertensive eyes. Since these changes preceded both functional and histological alterations induced by ocular hypertension, these results support the involvement of glutamate in glaucomatous neuropathy.	Univ Buenos Aires, Fac Med, Dept Bioquim Humana,CONICET, Lab Neuroquim Retiniana & Oftalmol Expt, RA-1121 Buenos Aires, DF, Argentina; Univ Moron, Fac Med, Histol Lab, Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Rosenstein, RE (corresponding author), Univ Buenos Aires, Fac Med, Dept Bioquim Humana,CONICET, Lab Neuroquim Retiniana & Oftalmol Expt, Paraguya 2155,5 P, RA-1121 Buenos Aires, DF, Argentina.	ruthr@fmed.uba.ar						ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Benozzi J, 2002, INVEST OPHTH VIS SCI, V43, P2196; Brooks DE, 1997, AM J VET RES, V58, P864; Carter-Dawson L, 2002, INVEST OPHTH VIS SCI, V43, P2633; CULCASI M, 1994, J BIOL CHEM, V269, P12589; DAVID P, 1988, EXP EYE RES, V46, P657, DOI 10.1016/S0014-4835(88)80054-X; DEROUICHE A, 1995, J NEUROSCI RES, V42, P131, DOI 10.1002/jnr.490420115; Dkhissi O, 1999, INVEST OPHTH VIS SCI, V40, P990; Gegelashvili G, 1998, BRAIN RES BULL, V45, P233, DOI 10.1016/S0361-9230(97)00417-6; Hare WA, 2004, INVEST OPHTH VIS SCI, V45, P2625, DOI 10.1167/iovs.03-0566; Hare WA, 2004, INVEST OPHTH VIS SCI, V45, P2640, DOI 10.1167/iovs.03-0567; Honkanen RA, 2003, ARCH OPHTHALMOL-CHIC, V121, P183; KALLONIATIS M, 1994, VISUAL NEUROSCI, V11, P793, DOI 10.1017/S0952523800003096; Kaushik S, 2003, J Postgrad Med, V49, P90; KVAMME E, 1985, METHOD ENZYMOL, V113, P241; Lam TT, 2003, INVEST OPHTH VIS SCI, V44, P638, DOI 10.1167/iovs.02-0255; Levkovitch-Verbin H, 2002, J GLAUCOMA, V11, P396, DOI 10.1097/00061198-200210000-00005; LOUZADAJUNIOR P, 1992, J NEUROCHEM, V59, P358, DOI 10.1111/j.1471-4159.1992.tb08912.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Martin KRG, 2002, INVEST OPHTH VIS SCI, V43, P2236; Meister A., 1970, METHOD ENZYMOL, V17, P900, DOI 10.1016/0076-6879(71)17304-1; MOORE CG, 1995, CURR EYE RES, V14, P711, DOI 10.3109/02713689508998499; Moreno MC, 2004, FREE RADICAL BIO MED, V37, P803, DOI 10.1016/j.freeradbiomed.2004.06.001; MORENO MC, 2005, IN PRESS EXP EYE RES; MORENO MC, 2002, RETINAL DAMAGE CHRON; Morrison JC, 1997, EXP EYE RES, V64, P85, DOI 10.1006/exer.1996.0184; MOSINGER JL, 1991, EXP NEUROL, V113, P10, DOI 10.1016/0014-4886(91)90140-8; Naskar R, 2000, INVEST OPHTH VIS SCI, V41, P1940; Neufeld AH, 2004, BRAIN RES BULL, V62, P455, DOI 10.1016/j.brainresbull.2003.07.005; Otis TS, 1998, J NEUROSCI, V18, P7099; Poitry S, 2000, J NEUROSCI, V20, P1809; POW DV, 1994, NEUROSCIENCE, V60, P355, DOI 10.1016/0306-4522(94)90249-6; REITER RJ, 1995, FRONT NEUROENDOCRIN, V16, P383, DOI 10.1006/frne.1995.1014; RIEPE RE, 1977, NATURE, V268, P654, DOI 10.1038/268654a0; Ritch R, 2000, MED HYPOTHESES, V54, P221, DOI 10.1054/mehy.1999.0025; Saenz DA, 2004, FASEB J, V18, P1912, DOI 10.1096/fj.04-2062fje; Saenz DA, 2002, J PINEAL RES, V33, P31, DOI 10.1034/j.1600-079X.2002.01880.x; SARTHY PV, 1978, J CELL BIOL, V78, P675, DOI 10.1083/jcb.78.3.675; SHAREEF SR, 1995, EXP EYE RES, V61, P379, DOI 10.1016/S0014-4835(05)80131-9; Shen F, 2004, INVEST OPHTH VIS SCI, V45, P3107, DOI 10.1167/iovs.03-0948; Siu AW, 1999, J PINEAL RES, V27, P122, DOI 10.1111/j.1600-079X.1999.tb00606.x; Takahata K, 2003, INVEST OPHTH VIS SCI, V44, P1760, DOI 10.1167/iovs.02-0471; TAKATSUNA Y, 1994, CURR EYE RES, V13, P629, DOI 10.3109/02713689408999898; Tanaka K, 2000, NEUROSCI RES, V37, P15, DOI 10.1016/S0168-0102(00)00104-8; Thoreson WB, 1999, PROG RETIN EYE RES, V18, P765, DOI 10.1016/S1350-9462(98)00031-7; Ueda J, 1998, JPN J OPHTHALMOL, V42, P337, DOI 10.1016/S0021-5155(98)00026-4; Vorwerk CK, 2000, INVEST OPHTH VIS SCI, V41, P3615; Wamsley S, 2005, ARCH OPHTHALMOL-CHIC, V123, P64, DOI 10.1001/archopht.123.1.64; Wang X, 2000, EXP BRAIN RES, V132, P476, DOI 10.1007/s002210000360; Woldemussie E, 2004, GLIA, V47, P109, DOI 10.1002/glia.20000	50	68	71	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1161	+		10.1096/fj.04-3313fje	http://dx.doi.org/10.1096/fj.04-3313fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15870062				2022-12-28	WOS:000229602600023
J	Chelu, MG; Goonasekera, SA; Durham, WJ; Tang, W; Lueck, JD; Riehl, J; Pessah, IN; Zhang, PM; Bhattacharjee, MB; Dirksen, RT; Hamilton, SL				Chelu, Mihail G.; Goonasekera, Sanjeewa A.; Durham, William J.; Tang, Wei; Lueck, John D.; Riehl, Joyce; Pessah, Isaac N.; Zhang, Pumin; Bhattacharjee, Meenakshi B.; Dirksen, Robert T.; Hamilton, Susan L.			Heat- and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse	FASEB JOURNAL			English	Article									[Chelu, Mihail G.; Durham, William J.; Tang, Wei; Zhang, Pumin; Hamilton, Susan L.] Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; [Bhattacharjee, Meenakshi B.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Goonasekera, Sanjeewa A.; Lueck, John D.; Dirksen, Robert T.] Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; [Riehl, Joyce; Pessah, Isaac N.] Univ Calif Davis, Dept VM Mol Biosci, Davis, CA 95616 USA; [Riehl, Joyce; Pessah, Isaac N.] Univ Calif Davis, Ctr Childrens Environm Hlth & Dis Prevent, Davis, CA 95616 USA	Baylor College of Medicine; Baylor College of Medicine; University of Rochester; University of California System; University of California Davis; University of California System; University of California Davis	Hamilton, SL (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, 1 Baylor Plaza, Houston, TX 77030 USA.	susanh@bcm.tmc.edu	Pessah, Isaac N/K-7985-2017; Chelu, Mihail/AAM-7426-2020	Pessah, Isaac N/0000-0002-8149-588X; Chelu, Mihail/0000-0001-9688-1604; Hamilton, Susan/0000-0003-0241-9369; Lueck, John/0000-0002-1820-711X	NIAMS NIH HHS [AR44864, AR46513, AR41802, AR44657] Funding Source: Medline; NIEHS NIH HHS [ES11269] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR044657, R01AR044864, R01AR041802, R01AR046513, R01AR044657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011269] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))			0	129	132	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					329	330		10.1096/fj.05-4497fje	http://dx.doi.org/10.1096/fj.05-4497fje			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16284304				2022-12-28	WOS:000207915000010
J	Hsieh, CC; Papaconstantinou, J				Hsieh, Ching-Chyuan; Papaconstantinou, John			Thioredoxin-ASK1 complex levels regulate ROS-mediated p38 MAPK pathway activity in livers of aged and long-lived Snell dwarf mice	FASEB JOURNAL			English	Article						rotenone; MKK3 kinase; MKP-1 levels; MAPK signaling	OXIDATIVE STRESS-RESPONSE; LIFE-SPAN; POSTTRANSCRIPTIONAL REGULATION; SIGNALING PATHWAY; NUCLEAR EXPORT; KINASE; ACTIVATION; EXTENSION; APOPTOSIS; RESISTANCE	We have proposed that the age-associated increase of reactive oxygen species (ROS) by electron transport chain (ETC) dysfunction may cause the elevated basal level of p38 MAPK stress response pathway activity. However, the mechanism by which ROS activates this pathway is not clear. Here we propose that activation of the p38 MAPK pathway by complex I (CI) generated ROS, in response to rotenone (ROT) treatment, is based on the ability of reduced Trx to bind to and inhibit ASK 1 and its release from the complex upon oxidation. This balance of free vs. bound ASK1 regulates the level of p38 MAPK pathway activity. To support this mechanism we demonstrate that the production of ROS by ROT treated AML12 hepatocyte cells dissociates the Trx-ASK1 complex, thereby increasing p38 MAPK pathway activity. This mechanism is supported by the ability of N-acetyl cysteine (NAC) to prevent dissociation of Trx-ASK1 and activation of the p38 MAPK pathway. We also demonstrated that the ratio of ASK1/Trx-ASK1 increases in aged mouse livers and that this correlates with the increased basal activity of the p38 MAPK pathway. The longevity of Snell dwarf mice has been attributed to their resistance to oxidative stress. A comparison of the levels of Tx-ASK1 in young and aged dwarfs showed a higher abundance of the complex than in their age-matched controls. These results, which are indicative of a decreased level of oxidative stress, suggest that increased ROS production in aged liver may alter the ratio of ASK1 and Trx-ASK1, thereby increasing the age-associated basal level of p38 MAPK pathway activity.	Univ Texas, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Papaconstantinou, J (corresponding author), Univ Texas, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.	jpapacon@utmb.edu	Papaconstantinou, John/E-3312-2010		NATIONAL INSTITUTE ON AGING [P01AG021830, P30AG024832] Funding Source: NIH RePORTER; NIA NIH HHS [1P01 AG 021830-01, P30 AG024832, P01 AG021830] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALESSI DR, 1993, ONCOGENE, V8, P2015; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; An MR, 1996, MOL CELL BIOL, V16, P2295; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Bonilla E, 2002, EXP GERONTOL, V37, P629, DOI 10.1016/S0531-5565(01)00229-7; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FLEMING JE, 1992, MUTAT RES, V275, P267, DOI 10.1016/0921-8734(92)90031-J; Flurkey K, 2001, P NATL ACAD SCI USA, V98, P6736, DOI 10.1073/pnas.111158898; Golden TR, 2002, AGING CELL, V1, P117, DOI 10.1046/j.1474-9728.2002.00015.x; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Hauck SJ, 2002, HORM METAB RES, V34, P481, DOI 10.1055/s-2002-34787; Hsieh CC, 1998, MOL BIOL CELL, V9, P1479, DOI 10.1091/mbc.9.6.1479; Hsieh CC, 2004, MECH AGEING DEV, V125, P785, DOI 10.1016/j.mad.2004.07.008; Hsieh CC, 2003, MECH AGEING DEV, V124, P733, DOI 10.1016/S0047-6374(03)00083-6; Hsieh CC, 2002, MECH AGEING DEV, V123, P1423, DOI 10.1016/S0047-6374(02)00084-2; Hsieh CC, 2002, MECH AGEING DEV, V123, P1229, DOI 10.1016/S0047-6374(02)00036-2; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kotlyarov A, 2002, MOL CELL BIOL, V22, P4827, DOI 10.1128/MCB.22.13.4827-4835.2002; Kulisz A, 2002, AM J PHYSIOL-LUNG C, V282, pL1324, DOI 10.1152/ajplung.00326.2001; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Madsen MA, 2004, BIOCHEM BIOPH RES CO, V318, P998, DOI 10.1016/j.bbrc.2004.04.126; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Murakami S, 2003, FASEB J, V17, P1565, DOI 10.1096/fj.02-1092fje; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; PAPACONSTANTINOU J, 1994, ANN NY ACAD SCI, V719, P195, DOI 10.1111/j.1749-6632.1994.tb56829.x; Powis G, 2000, FREE RADICAL BIO MED, V29, P312, DOI 10.1016/S0891-5849(00)00313-0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Saito H, 2001, J BIOL CHEM, V276, P29307, DOI 10.1074/jbc.M103740200; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sampayo JN, 2003, AGING CELL, V2, P319, DOI 10.1046/j.1474-9728.2003.00063.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Suh YS, 2001, MECH AGEING DEV, V122, P1797, DOI 10.1016/S0047-6374(01)00301-3; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; Zhang R, 2004, CIRC RES, V94, P1483, DOI 10.1161/01.RES.0000130525.37646.a7	50	157	168	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					259	268		10.1096/fj.05-4376com	http://dx.doi.org/10.1096/fj.05-4376com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449798	Green Accepted			2022-12-28	WOS:000237698700011
J	Marques, C; Guo, WM; Pereira, P; Taylor, A; Patterson, C; Evans, PC; Shang, F				Marques, Carla; Guo, Weimin; Pereira, Paulo; Taylor, Allen; Patterson, Cam; Evans, Paul C.; Shang, Fu			The triage of damaged proteins: degradation by the ubiquitin-proteasome pathway or repair by molecular chaperones	FASEB JOURNAL			English	Article						CHIP; heat shock proteins; isopeptidase; luciferase	AMYOTROPHIC-LATERAL-SCLEROSIS; HEAT-SHOCK PROTEINS; TRANSMEMBRANE CONDUCTANCE REGULATOR; CU/ZN SUPEROXIDE-DISMUTASE; LENS EPITHELIAL-CELLS; ABNORMAL PROTEINS; QUALITY-CONTROL; DEPENDENT DEGRADATION; ACTIVATING ENZYME; OXIDATIVE STRESS	Accumulation of damaged proteins is causally related to many age-related diseases. The ubiquitin-proteasome pathway (UPP) plays a role in selective degradation of damaged proteins, whereas molecular chaperones, such as heat shock proteins, are involved in refolding denatured proteins. This work demonstrates for the first time that the UPP and molecular chaperones work in a competitive manner and that the fates of denatured proteins are determined by the relative activities of the UPP and molecular chaperones. Enhanced UPP activity suppresses the refolding of denatured proteins whereas elevated chaperone activity inhibits the degradation of denatured proteins. CHIP, a co-chaperone with E3 activity, plays a pivotal role in determining the fates of the damaged proteins. The delicate balance between UPP-mediated degradation and refolding of denatured proteins is governed by relative levels of CHIP and other molecular chaperones. Isopeptidases, the enzymes that reverse the actions of CHIP, also play an important role in determining the fate of denatured proteins.	Tufts Univ, USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Univ Coimbra, Fac Med, Ctr Ophthalmol, IBILI, Coimbra, Portugal; Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC USA; Imperial Coll London, BHF Cardiovasc Med, London, England	Tufts University; United States Department of Agriculture (USDA); Universidade de Coimbra; University of North Carolina; University of North Carolina Chapel Hill; Imperial College London	Shang, F (corresponding author), Tufts Univ, USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA.	fu.shang@tufts.edu	Pereira, Paulo/AAD-8375-2022; Guo, Weimin/B-3155-2009; Marques, Carla/AAC-9838-2019	Pereira, Paulo/0000-0002-9908-2290; Guo, Weimin/0000-0003-4318-7154; Marques, Carla/0000-0002-1817-4813; Evans, Paul/0000-0001-7975-681X	NATIONAL EYE INSTITUTE [P30EY013078, R29EY011717, R01EY011717, R01EY013250] Funding Source: NIH RePORTER; NEI NIH HHS [P30 EY013078, R01 EY011717-08, EY11717, R01 EY011717-07, R01 EY011717-06A1, R01 EY011717, EY13078, EY13250, R29 EY011717, R01 EY013250] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Benaroudj N, 2000, NAT CELL BIOL, V2, P833, DOI 10.1038/35041081; Benharouga M, 2001, J CELL BIOL, V153, P957, DOI 10.1083/jcb.153.5.957; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Bush KT, 1997, J BIOL CHEM, V272, P9086; Ciechanover A, 1995, COLD SPRING HARB SYM, V60, P491, DOI 10.1101/SQB.1995.060.01.053; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Cyr DM, 1997, J BIOENERG BIOMEMBR, V29, P29, DOI 10.1023/A:1022455621111; Doong H, 2003, J BIOL CHEM, V278, P28490, DOI 10.1074/jbc.M209682200; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; Evans PC, 2003, J BIOL CHEM, V278, P23180, DOI 10.1074/jbc.M301863200; Feldman DE, 2000, CURR OPIN STRUC BIOL, V10, P26, DOI 10.1016/S0959-440X(99)00044-5; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; Gaczynska M, 1996, J BIOL CHEM, V271, P17275, DOI 10.1074/jbc.271.29.17275; Gelman MS, 2002, J BIOL CHEM, V277, P11709, DOI 10.1074/jbc.M111958200; GOLDBERG AL, 1972, P NATL ACAD SCI USA, V69, P422, DOI 10.1073/pnas.69.2.422; HERSHKO A, 1982, J BIOL CHEM, V257, P3964; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; Hoffman EK, 1996, J NEUROL SCI, V139, P15, DOI 10.1016/S0022-510X(96)00031-7; Hungness ES, 2002, BIOCHEM BIOPH RES CO, V290, P469, DOI 10.1006/bbrc.2001.6168; Hyun DH, 2003, J NEUROCHEM, V86, P363, DOI 10.1046/j.1471-4159.2003.01841.x; JAHNGEN JH, 1986, J BIOL CHEM, V261, P3760; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; Kampinga HH, 2003, MOL CELL BIOL, V23, P4948, DOI 10.1128/MCB.23.14.4948-4958.2003; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee DH, 1998, MOL CELL BIOL, V18, P30, DOI 10.1128/MCB.18.1.30; Liu CW, 2002, J BIOL CHEM, V277, P26815, DOI 10.1074/jbc.M201782200; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Luders J, 1998, BIOL CHEM, V379, P1217, DOI 10.1515/bchm.1998.379.10.1217; Marques C, 2004, FASEB J, V18, P1424, DOI 10.1096/fj.04-1743fje; Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091; McClellan AJ, 2001, NAT CELL BIOL, V3, pE51, DOI 10.1038/35055162; McDonough H, 2003, CELL STRESS CHAPERON, V8, P303, DOI 10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO;2; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Minnnaugh EG, 2004, MOL CANCER THER, V3, P551; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; Rajapandi T, 2000, J BIOL CHEM, V275, P22597, DOI 10.1074/jbc.M002035200; Ross CA, 2004, TRENDS CELL BIOL, V14, P703, DOI 10.1016/j.tcb.2004.10.006; SADIS S, 1995, MOL CELL BIOL, V15, P4086; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297; Shang F, 2001, EXP EYE RES, V73, P229, DOI 10.1006/exer.2001.1029; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; Shang F, 2001, EXP EYE RES, V73, P827, DOI 10.1006/exer.2001.1091; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; Stathopulos PB, 2003, P NATL ACAD SCI USA, V100, P7021, DOI 10.1073/pnas.1237797100; Strickland E, 2000, J BIOL CHEM, V275, P5565, DOI 10.1074/jbc.275.8.5565; TAYLOR A, 1987, FREE RADICAL BIO MED, V3, P371, DOI 10.1016/0891-5849(87)90015-3; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wilkinson KD, 1999, J NUTR, V129, P1933, DOI 10.1093/jn/129.11.1933; WING SS, 1995, BIOCHEM J, V305, P125, DOI 10.1042/bj3050125; Yonehara M, 1996, J BIOL CHEM, V271, P2641, DOI 10.1074/jbc.271.5.2641; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492	60	85	90	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					741	+		10.1096/fj.05-5080fje	http://dx.doi.org/10.1096/fj.05-5080fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16469848	Green Submitted, Green Accepted			2022-12-28	WOS:000237698700027
J	Seo, J; Barhoumi, R; Johnson, AE; Lupton, JR; Chapkin, RS				Seo, Jeongmin; Barhoumi, Rola; Johnson, Arthur E.; Lupton, Joanne R.; Chapkin, Robert S.			Docosahexaenoic acid selectively inhibits plasma membrane targeting of lipidated proteins	FASEB JOURNAL			English	Article						intracellular trafficking; subcellular localization	POLYUNSATURATED FATTY-ACIDS; H-RAS; N-RAS; ACYL-CHAIN; K-RAS; PHOSPHOLIPID-BILAYERS; ENDOPLASMIC-RETICULUM; TYROSINE KINASES; EXOCYTIC PATHWAY; MOLECULAR ORDER	Membrane localization of lipidated cytosolic signaling proteins is mediated by interactions between specific lipid anchors and membranes, but little is known about the regulatory role of membrane composition in lipidated protein membrane targeting. Here, using green fluorescent protein (GFP) chimeras and quantitative fluorescence microscopy in living mouse colonocytes, we show that docosahexaenoic acid (DHA), a dietary polyunsaturated fatty acid (PUFA) with membrane lipid-modifying properties, selectively inhibits plasma membrane (PM) targeting and increases the endomembrane localization of lipidated proteins that are cytoplasmic cargo in the exocytic pathway, without affecting the exocytic pathway itself. DHA selectivity seems to be dictated by the protein trafficking route, independent of the functional state of proteins and the location and composition of membrane anchors. DHA enrichment in cell membranes was required to elicit the inhibitory effect. These data reveal that membrane lipid composition influences cell signaling by modulating intracellular trafficking and localization of membrane proteins, providing a potential molecular mechanism for the documented health benefits of DHA.	Texas A&M Univ, Fac Nutr, Dept Nutr & Food Sci, College Stn, TX 77843 USA; Texas A&M Univ, Dept Vet Integrat Biosci, College Stn, TX 77843 USA; Texas A&M Univ, Ctr Environm & Rural Hlth, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem Med, College Stn, TX 77843 USA; Texas A&M Univ, Dept Genet, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Chapkin, RS (corresponding author), Texas A&M Univ, Fac Nutr, Dept Nutr & Food Sci, TAMU 2253, College Stn, TX 77843 USA.	r-chapkin@tamu.edu	Johnson, Arthur E/G-3457-2012	Chapkin, Robert/0000-0002-6515-3898	NCI NIH HHS [R01 CA059034, CA-59034] Funding Source: Medline; NIEHS NIH HHS [P30ES09106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Arozarena I, 2004, MOL CELL BIOL, V24, P1516, DOI 10.1128/MCB.24.4.1516-1530.2004; Babia T, 1999, J CELL SCI, V112, P477; Bergmann JE, 1989, METHOD CELL BIOL, V32, P85; Bijlmakers MJJE, 1999, J CELL BIOL, V145, P457, DOI 10.1083/jcb.145.3.457; BOS JL, 1989, CANCER RES, V49, P4682; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Davidson LA, 1999, CARCINOGENESIS, V20, P785, DOI 10.1093/carcin/20.5.785; Dietrich LEP, 2004, EMBO J, V23, P45, DOI 10.1038/sj.emboj.7600015; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; EHRINGER W, 1990, CHEM PHYS LIPIDS, V54, P79, DOI 10.1016/0009-3084(90)90063-W; Gawrisch K, 2003, LIPIDS, V38, P445, DOI 10.1007/s11745-003-1082-0; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; HOLTE LL, 1995, BIOPHYS J, V68, P2396, DOI 10.1016/S0006-3495(95)80422-4; Huster D, 1997, BIOPHYS J, V73, P855, DOI 10.1016/S0006-3495(97)78118-9; Huster D, 1998, BIOCHEMISTRY-US, V37, P17299, DOI 10.1021/bi980078g; Janecki AJ, 2000, J HISTOCHEM CYTOCHEM, V48, P1479, DOI 10.1177/002215540004801105; Kamens J S, 2001, Curr Opin Investig Drugs, V2, P1213; Kim K, 1997, INT J CANCER, V71, P767, DOI 10.1002/(SICI)1097-0215(19970529)71:5<767::AID-IJC13>3.0.CO;2-5; Kloog Y, 2000, MOL MED TODAY, V6, P398, DOI 10.1016/S1357-4310(00)01789-5; Koenig BW, 1997, BIOPHYS J, V73, P1954, DOI 10.1016/S0006-3495(97)78226-2; KUISMANEN E, 1989, METHOD CELL BIOL, V32, P257; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; Linder ME, 2004, J CELL SCI, V117, P521, DOI 10.1242/jcs.00989; Lobo S, 2002, J BIOL CHEM, V277, P41268, DOI 10.1074/JBC.M206573200; Lowell CA, 2004, MOL IMMUNOL, V41, P631, DOI 10.1016/j.molimm.2004.04.010; Ma DWL, 2004, FASEB J, V18, P1040, DOI 10.1096/fj.03-1430fje; Matallanas D, 2003, J BIOL CHEM, V278, P4572, DOI 10.1074/jbc.M209807200; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Mitchell DC, 1998, BIOPHYS J, V74, P879, DOI 10.1016/S0006-3495(98)74011-1; Mitchell DC, 1998, BIOPHYS J, V75, P896, DOI 10.1016/S0006-3495(98)77578-2; Nakamura MT, 2004, ANNU REV NUTR, V24, P345, DOI 10.1146/annurev.nutr.24.121803.063211; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; Perez de Castro I, 2004, MOL CELL BIOL, V24, P3485, DOI 10.1128/MCB.24.8.3485-3496.2004; Perez de Castro I, 2003, CANCER RES, V63, P1615; Pinheiro J, 2001, MIXED EFFECTS MODELS; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; Rose DP, 1999, PHARMACOL THERAPEUT, V83, P217, DOI 10.1016/S0163-7258(99)00026-1; Rotblat B, 2004, MOL CELL BIOL, V24, P6799, DOI 10.1128/MCB.24.15.6799-6810.2004; Roth AF, 2002, J CELL BIOL, V159, P23, DOI 10.1083/jcb.200206120; Roux A, 2005, EMBO J, V24, P1537, DOI 10.1038/sj.emboj.7600631; Roy MO, 2000, BIOCHEMISTRY-US, V39, P8298, DOI 10.1021/bi000512q; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; Shaikh SR, 2004, BIOPHYS J, V87, P1752, DOI 10.1529/biophysj.104.044552; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Siddiqui AA, 1998, J BIOL CHEM, V273, P3712, DOI 10.1074/jbc.273.6.3712; Stillwell W, 2003, CHEM PHYS LIPIDS, V126, P1, DOI 10.1016/S0009-3084(03)00101-4; Stulnig TM, 2003, INT ARCH ALLERGY IMM, V132, P310, DOI 10.1159/000074898; Stulnig TM, 2001, J BIOL CHEM, V276, P37335, DOI 10.1074/jbc.M106193200; Talbot WA, 1997, BIOCHEMISTRY-US, V36, P5827, DOI 10.1021/bi962437i; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587; Wong WSF, 2004, BBA-PROTEINS PROTEOM, V1697, P53, DOI 10.1016/j.bbapap.2003.11.013; Yu Calvin C K, 2003, Curr Dir Autoimmun, V6, P61; Zimmerberg J, 1999, ADV DRUG DELIVER REV, V38, P197, DOI 10.1016/S0169-409X(99)00029-0	64	51	56	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					770	+		10.1096/fj.05-4683fje	http://dx.doi.org/10.1096/fj.05-4683fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16469846				2022-12-28	WOS:000237698700026
J	Tarsitano, M; De Falco, S; Colonna, V; McGhee, JD; Persico, MG				Tarsitano, Marina; De Falco, Sandro; Colonna, Vincenza; McGhee, James D.; Persico, M. Graziella			The C. elegans pvf-1 gene encodes a PDGF/VEGF-like factor able to bind mammalian VEGF receptors and to induce angiogenesis	FASEB JOURNAL			English	Article						growth factors; evolutionary conservation; Flt-1/KDR	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; TYROSINE-KINASE RECEPTORS; CAENORHABDITIS-ELEGANS; FACTOR DETERMINANTS; CELL-MIGRATION; EXPRESSION; IDENTIFICATION; GLYCOSYLATION; NEUROPILIN-1	Members of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family have been implicated in a variety of functions in vertebrates, especially angiogenesis. Here we identify and characterize a PDGF/VEGF-like factor (named PVF-1) from the nematode C. elegans. We show that PVF-1 has biochemical properties similar to vertebrate PDGF/VEGF growth factors. More important, PVF-1 binds to the human receptors VEGFR-1 (Flt-1) and VEGFR-2 (KDR) and is able to induce angiogenesis in two model systems derived from vertebrates. Our results highlight the widespread evolutionary conservation of this important class of growth factors and raise the possibility that C. elegans can provide a simple experimental system in which to investigate how these factors function.	CNR, Inst Genet & Biophys A Buzzati Traverso, I-80131 Naples, Italy; Univ Calgary, Dept Biochem & Mol Biol, Genes & Dev Res Grp, Calgary, AB T2N 4N1, Canada	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); University of Calgary	Persico, MG (corresponding author), CNR, Inst Genet & Biophys A Buzzati Traverso, Via Pietro Castellino 111, I-80131 Naples, Italy.	persico@igb.cnr.it	De Falco, Sandro/P-6724-2015; Colonna, Vincenza/H-2021-2014	De Falco, Sandro/0000-0002-6501-1697; Colonna, Vincenza/0000-0002-3966-0474; McGhee, James/0000-0001-7266-7275				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Cho NK, 2002, CELL, V108, P865, DOI 10.1016/S0092-8674(02)00676-1; Duchek P, 2001, CELL, V107, P17, DOI 10.1016/S0092-8674(01)00502-5; Errico M, 2004, J BIOL CHEM, V279, P43929, DOI 10.1074/jbc.M401418200; Fukushige T, 1996, DEV BIOL, V178, P276, DOI 10.1006/dbio.1996.0218; Heino TI, 2001, MECH DEVELOP, V109, P69, DOI 10.1016/S0925-4773(01)00510-X; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hoch RV, 2003, DEVELOPMENT, V130, P4769, DOI 10.1242/dev.00721; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Macias A, 2004, INT J DEV BIOL, V48, P1087, DOI 10.1387/ijdb.041859am; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; Mamluk R, 2002, J BIOL CHEM, V277, P24818, DOI 10.1074/jbc.M200730200; McKay SJ, 2003, COLD SPRING HARB SYM, V68, P159, DOI 10.1101/sqb.2003.68.159; MELLO C, 1996, METHODS CELL BIOL; Munier AI, 2002, EMBO REP, V3, P1195, DOI 10.1093/embo-reports/kvf242; Neufeld G, 2002, ADV EXP MED BIOL, V515, P81; Persico MG, 1999, CURR TOP MICROBIOL, V237, P31; Popovici C, 1999, GENOME RES, V9, P1026, DOI 10.1101/gr.9.11.1026; Popovici C, 2002, NEUROSCI LETT, V329, P116, DOI 10.1016/S0304-3940(02)00595-5; POTGENS AJG, 1994, J BIOL CHEM, V269, P32879; Rosin D, 2004, DEVELOPMENT, V131, P1939, DOI 10.1242/dev.01101; Ruhrberg C, 2003, BIOESSAYS, V25, P1052, DOI 10.1002/bies.10351; Schachter H, 2004, CURR OPIN STRUC BIOL, V14, P607, DOI 10.1016/j.sbi.2004.09.005; Storkebaum E, 2004, J CLIN INVEST, V113, P14, DOI 10.1172/JCI200420682; Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092; Uutela M, 2001, CIRCULATION, V103, P2242; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wood WB, 1988, NEMATODE CAENORHABDI; Ziche M, 1997, LAB INVEST, V76, P517	32	41	45	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					227	233		10.1096/fj.05-4147com	http://dx.doi.org/10.1096/fj.05-4147com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449794				2022-12-28	WOS:000237698700007
J	Kim, JH; Lee, JA; Song, YM; Park, CH; Hwang, SJ; Kim, YS; Kaang, BK; Son, H				Kim, JH; Lee, JA; Song, YM; Park, CH; Hwang, SJ; Kim, YS; Kaang, BK; Son, H			Overexpression of calbindin-D-28K in hippocampal progenitor cells increases neuronal differentiation and neurite outgrowth	FASEB JOURNAL			English	Article						hippocampus; CaMK; NeuroD	CALCIUM-BINDING PROTEINS; PYRAMIDAL NEURONS; GRANULE CELLS; PHENOTYPE; NEUROTROPHIN-3; INACTIVATION; FACILITATION; STIMULATION; CHANNELS; CURRENTS	Excitatory stimuli are known to be a potent regulator for induction of neuronal differentiation. Calbindin-D-28K buffers intracellular Ca2+ and modifies synaptic functions in neurons. However, the effects of calbindin-D-28K on the regulation of activity-induced neuronal differentiation and related biochemical modifications remain unsolved. In the present study, by a gain-of-function study with retroviral vector system and dicer-generated small interfering RNA (d-siRNA) to effectively knock down the expression of calbindin-D-28K, we demonstrated that calbindin-D-28K at a physiologically relevant level promoted neuronal differentiation and neurite outgrowth. Increase of neuronal differentiation by calbindin-D-28K overexpression was concurrent with the expression of basic helix-loop-helix ( bHLH) transcriptional factors, phosphorylation of calcium and calmodulin-dependent protein kinase II (CaMKII) and NeuroD at Ser(336). KN-62, a highly specific CaMKII inhibitor, blocked the up-regulation of proneural bHLH genes, p-CaMKII, and pSer(336)NeuroD. Calbindin-D-28K appeared to facilitate neuronal differentiation of both fetal and adult hippocampal progenitor cells. Together, these findings establish the novel calbindin-regulated function of CaMKII and NeuroD in control of neuronal differentiation and neurite outgrowth.	Hanyang Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 133791, South Korea; Hanyang Univ, Coll Med, Dept Microbiol, Seoul 133791, South Korea; Hanyang Univ, Coll Med, Dept Anat & Cell Biol, Seoul 133791, South Korea; Seoul Natl Univ, Natl Res Lab Neurobiol, Inst Mol Biol & Genet, Sch Biol Sci,Coll Nat Sci, Seoul 151742, South Korea; Seoul Natl Univ Hosp & Coll Med, Dept Neurol, Seoul 110799, South Korea	Hanyang University; Hanyang University; Hanyang University; Seoul National University (SNU); Seoul National University (SNU)	Son, H (corresponding author), Hanyang Univ, Coll Med, Dept Biochem & Mol Biol, 17 Haengdang Dong, Seoul 133791, South Korea.	hyeonson@hanyang.ac.kr						Alexianu ME, 1998, J NEUROSCI RES, V51, P58, DOI 10.1002/(SICI)1097-4547(19980101)51:1<58::AID-JNR6>3.0.CO;2-K; BAIMBRIDGE KG, 1992, TRENDS NEUROSCI, V15, P303, DOI 10.1016/0166-2236(92)90081-I; Blatow M, 2003, NEURON, V38, P79, DOI 10.1016/S0896-6273(03)00196-X; Boukhaddaoui H, 2000, EUR J NEUROSCI, V12, P2068, DOI 10.1046/j.1460-9568.2000.00105.x; Boukhaddaoui H, 2001, J NEUROSCI, V21, P8789, DOI 10.1523/JNEUROSCI.21-22-08789.2001; COLLAZO D, 1992, NEURON, V9, P643, DOI 10.1016/0896-6273(92)90028-C; DAILEY ME, 1994, J NEUROBIOL, V25, P243, DOI 10.1002/neu.480250305; Deisseroth K, 2004, NEURON, V42, P535, DOI 10.1016/S0896-6273(04)00266-1; Dumas TC, 2004, HIPPOCAMPUS, V14, P701, DOI 10.1002/hipo.10210; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Gaudilliere B, 2004, NEURON, V41, P229, DOI 10.1016/S0896-6273(03)00841-9; Kim JH, 2005, J NEUROCHEM, V94, P417, DOI 10.1111/j.1471-4159.2005.03208.x; Kim JS, 2004, J NEUROCHEM, V89, P324, DOI 10.1046/j.1471-4159.2004.02329.x; KOHR G, 1991, EXP BRAIN RES, V85, P543; Lee JA, 2001, LEARN MEMORY, V8, P220, DOI 10.1101/lm.40201; Marty S, 1996, NEURON, V16, P565, DOI 10.1016/S0896-6273(00)80075-6; MATTSON MP, 1991, NEURON, V6, P41, DOI 10.1016/0896-6273(91)90120-O; Miyata T, 1999, GENE DEV, V13, P1647, DOI 10.1101/gad.13.13.1647; Molinari S, 1996, P NATL ACAD SCI USA, V93, P8028, DOI 10.1073/pnas.93.15.8028; Myers JW, 2003, NAT BIOTECHNOL, V21, P324, DOI 10.1038/nbt792; Nagerl UV, 1998, J PHYSIOL-LONDON, V509, P39, DOI 10.1111/j.1469-7793.1998.039bo.x; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Shin MH, 2002, EXP MOL MED, V34, P401, DOI 10.1038/emm.2002.57; SUTHERLAND MK, 1992, MOL BRAIN RES, V13, P239; TANAKA O, 1995, MOL BRAIN RES, V30, P1, DOI 10.1016/0169-328X(94)00265-G; TILLOTSON D, 1979, P NATL ACAD SCI USA, V76, P1497, DOI 10.1073/pnas.76.3.1497; Vazquez G, 1997, BIOCHEM BIOPH RES CO, V239, P562, DOI 10.1006/bbrc.1997.7501; VICARIOABEJON C, 1995, NEURON, V15, P105, DOI 10.1016/0896-6273(95)90068-3; Wayman GA, 2004, J NEUROSCI, V24, P3786, DOI 10.1523/JNEUROSCI.3294-03.2004; Weissman TA, 2004, NEURON, V43, P647, DOI 10.1016/j.neuron.2004.08.015	30	26	26	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					109	+		10.1096/fj.05-4826fje	http://dx.doi.org/10.1096/fj.05-4826fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16278289				2022-12-28	WOS:000234053100018
J	Sugano, M; Tsuchida, K; Hata, T; Makino, N				Sugano, M; Tsuchida, K; Hata, T; Makino, N			RNA interference targeting SHP-1 attenuates myocardial infarction in rats	FASEB JOURNAL			English	Article						siRNA; apoptosis; gene therapy	PROTEIN-TYROSINE-PHOSPHATASE; GENE-EXPRESSION; MEDIATED APOPTOSIS; ISCHEMIA; MYOCYTES; ISCHEMIA/REPERFUSION; REPERFUSION; INHIBITION; ACTIVATION; DELIVERY	The Src homology domain 2 (SH2)-containing tyrosine phosphatase- 1 (SHP-1) plays a key role in apoptosis and decreases phosphorylation of Akt. Apoptosis of cardiomyocytes is thought to contribute to the increased area of acute myocardial infarction ( AMI), and Akt activation exerts a powerful cardioprotective effect after ischemia. Thus, a therapeutic strategy designed to inhibit expression of SHP-1 would be beneficial in AMI. Here we report that siRNA targeting SHP-1 reduced infarct size in a rat model of AMI. Upon injection into the ischemic left ventricular wall, the vector-based siRNA significantly suppressed the increase in the SHP-1 mRNA and the SHP-1 protein levels. The siRNA vector also significantly reduced the SHP-1 that bound to Fas-R. The SHP-1 siRNA vector increased phospho-Akt and reduced DNA fragmentation and caspase activity compared with the scramble siRNA vector. Finally, the area of myocardial infarction was significantly smaller with the SHP-1 siRNA vector than with the scramble siRNA vector at 2 days after LCA ligation. In conclusion, SHP-1 in the heart increased from the early stage of AMI, and this increase was thought to contribute to the increased area of myocardial infarction. Suppression of SHP-1 with the SHP-1 siRNA vector markedly reduced the infarct size in AMI.	Kyushu Univ, Dept Mol & Cellular Biol, Div Mol & Clin Gerontol, Med Inst Bioregulat, Beppu, Oita 8740838, Japan	Kyushu University	Sugano, M (corresponding author), Kyushu Univ, Dept Mol & Cellular Biol, Div Mol & Clin Gerontol, Med Inst Bioregulat, 4546 Tsurumihara, Beppu, Oita 8740838, Japan.	massy@tsurumi.beppu.kyushu-u.ac.jp						Black SC, 1998, J MOL CELL CARDIOL, V30, P733, DOI 10.1006/jmcc.1998.0660; Bousquet C, 1998, J BIOL CHEM, V273, P7099, DOI 10.1074/jbc.273.12.7099; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bryant D, 1998, CIRCULATION, V97, P1375, DOI 10.1161/01.CIR.97.14.1375; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; Cui TX, 2001, CARDIOVASC RES, V49, P863, DOI 10.1016/S0008-6363(00)00299-6; Daigle I, 2002, NAT MED, V8, P61, DOI 10.1038/nm0102-61; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Guo DQ, 2000, J BIOL CHEM, V275, P11216, DOI 10.1074/jbc.275.15.11216; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; Kajstura J, 1996, LAB INVEST, V74, P86; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Lee P, 2003, AM J PHYSIOL-HEART C, V284, pH456, DOI 10.1152/ajpheart.00777.2002; Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944; Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912; Matsui T, 2001, CIRCULATION, V104, P330; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Mizuno K, 2002, J IMMUNOL, V169, P778, DOI 10.4049/jimmunol.169.2.778; Nakagami H, 2002, ARTERIOSCL THROM VAS, V22, P238, DOI 10.1161/hq0202.104001; Song W, 2000, CARDIOVASC RES, V45, P595, DOI 10.1016/S0008-6363(99)00395-8; Stephanou A, 2001, J BIOL CHEM, V276, P28340, DOI 10.1074/jbc.M101177200; SU X, 1995, IMMUNITY, V2, P353, DOI 10.1016/1074-7613(95)90143-4; Sugano M, 2002, FASEB J, V16, P1421, DOI 10.1096/fj.01-0894fje; Takeshita S, 1996, LAB INVEST, V74, P1061; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; Thangaraju M, 1999, J BIOL CHEM, V274, P29549, DOI 10.1074/jbc.274.41.29549; Wishcamper CA, 2003, BRAIN RES, V974, P88, DOI 10.1016/S0006-8993(03)02564-2; Yamaoka M, 2000, J MOL CELL CARDIOL, V32, P881, DOI 10.1006/jmcc.2000.1132; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Yoshida H, 2000, HYPERTENSION, V35, P25, DOI 10.1161/01.HYP.35.1.25	34	32	35	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2054	+		10.1096/fj.05-4020fje	http://dx.doi.org/10.1096/fj.05-4020fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16223786				2022-12-28	WOS:000232991100018
J	Chau, JFL; Lee, MK; Law, JWS; Chung, SK; Chung, SSM				Chau, JFL; Lee, MK; Law, JWS; Chung, SK; Chung, SSM			Sodium/myo-inositol cotransporter-1 is essential for the development and function of the peripheral nerves	FASEB JOURNAL			English	Article						SMIT; neuropathy; respiration; neonatal lethality	DIABETIC NEUROPATHY; CONDUCTION-VELOCITY; SYNAPSE FORMATION; XENOPUS-OOCYTES; MYO-INOSITOL; MYOINOSITOL; EXPRESSION; GLUCOSE; CELLS; MICE	Sodium/myo- inositol cotransporter-1 (SMIT-1) is one of the transporters responsible for importing myo-inositol (MI) into the cells. MI is a precursor for a family of signal transduction molecules, phosphatidylinositol, and its derivatives that regulates many cellular functions. SMIT-1 null mice died soon after birth due to respiratory failure, but neonatal lethality was prevented by prenatal maternal MI supplement. Although the lung air sacs were closed, lung development was not significantly affected in the SMIT-1 null mice. The development of the peripheral nerves, including the brachial plexus, facial, vagus, and intercostal nerves, and the phrenic nerve that innervates the diaphragm was severely affected. All of these peripheral nerve abnormalities were corrected by prenatal MI supplement, indicating that MI is essential for the development of peripheral nerve and that neonatal lethality of the SMIT-1 knockout mice is most likely due to abnormal development of the nerves that control breathing. In the adult SMIT-1 deficient mice rescued by MI supplement, MI content in their brain, kidney, skeletal muscle, liver, and sciatic nerve was greatly reduced. The sciatic nerve, in particular, was most dependent on SMIT-1 for the accumulation of MI, and nerve conduction velocity and protein kinase C activity in this tissue were significantly reduced by SMIT-1 deficiency.	Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Chung, SSM (corresponding author), Univ Hong Kong, Inst Mol Biol, 8-F Kadoorie Biol Sci Bldg Pokfulam, Hong Kong, Hong Kong, Peoples R China.	skchung@hkucc.hku.hk; smchung@hkucc.hku.hk						BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Berry GT, 2003, J BIOL CHEM, V278, P18297, DOI 10.1074/jbc.M213176200; Berry GT, 1999, J PEDIATR-US, V135, P94, DOI 10.1016/S0022-3476(99)70334-3; Chauvin TR, 2004, BIOL REPROD, V70, P744, DOI 10.1095/biolreprod.103.022731; Coady MJ, 2002, J BIOL CHEM, V277, P35219, DOI 10.1074/jbc.M204321200; DYCK PJ, 1988, NEW ENGL J MED, V319, P542, DOI 10.1056/NEJM198809013190904; EAGLE H, 1957, J BIOL CHEM, V226, P191; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; GREENE DA, 1988, DIABETES, V37, P688, DOI 10.2337/diabetes.37.6.688; GREENE DA, 1975, J CLIN INVEST, V55, P1326, DOI 10.1172/JCI108052; Guo W, 1997, MOL BRAIN RES, V51, P91, DOI 10.1016/S0169-328X(97)00220-9; HAGER K, 1995, J MEMBRANE BIOL, V143, P103; Hamilton JW, 1944, J NUTR, V27, P213, DOI 10.1093/jn/27.3.213; Handler JS, 1996, KIDNEY INT, V49, P1682, DOI 10.1038/ki.1996.246; HITOMI K, 1994, BBA-BIOMEMBRANES, V1190, P469, DOI 10.1016/0005-2736(94)90110-4; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; KNIPPER M, 1993, NEUROREPORT, V4, P483, DOI 10.1097/00001756-199305000-00005; Lin WC, 2000, P NATL ACAD SCI USA, V97, P1299, DOI 10.1073/pnas.97.3.1299; Matskevitch J, 1998, PFLUG ARCH EUR J PHY, V436, P854, DOI 10.1007/s004240050714; Misgeld T, 2002, NEURON, V36, P635, DOI 10.1016/S0896-6273(02)01020-6; NOAKES PG, 1993, DEV BIOL, V155, P275, DOI 10.1006/dbio.1993.1025; Poppe R, 1997, J NEUROCHEM, V69, P84, DOI 10.1046/j.1471-4159.1997.69010084.x; PRPIC V, 1982, J BIOL CHEM, V257, P1315; Sima AAF, 1997, DIABETES, V46, P301, DOI 10.2337/diabetes.46.2.301; Song ZT, 2003, MOL CELL NEUROSCI, V23, P638, DOI 10.1016/S1044-7431(03)00096-4; Takei K, 1998, SCIENCE, V282, P1705, DOI 10.1126/science.282.5394.1705; Uldry M, 2001, EMBO J, V20, P4467, DOI 10.1093/emboj/20.16.4467; WILLIAMSON JR, 1985, AM J PHYSIOL, V248, pC203, DOI 10.1152/ajpcell.1985.248.3.C203; Wright EM, 2004, PFLUG ARCH EUR J PHY, V447, P510, DOI 10.1007/s00424-003-1063-6	30	49	50	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2005	19	11					1887	+		10.1096/fj.05-4192fje	http://dx.doi.org/10.1096/fj.05-4192fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16174787				2022-12-28	WOS:000232315700008
J	Song, JN; da Costa, KA; Fischer, LM; Kohlmeier, M; Kwock, L; Wang, SL; Zeisel, SH				Song, JN; da Costa, KA; Fischer, LM; Kohlmeier, M; Kwock, L; Wang, SL; Zeisel, SH			Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD)	FASEB JOURNAL			English	Article						choline; liver function; single nucleotide polymorphism (SNP); nonalcoholic fatty liver disease pregnancy; NTD; transfection; site-directed mutagenesis	PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; DENSITY LIPOPROTEIN SECRETION; CHOLINE DEFICIENCY; HEPATIC STEATOSIS; PLASMODIUM-FALCIPARUM; MALARIA PARASITE; PHOSPHATIDYLCHOLINE; RAT; BIOSYNTHESIS; HEPATOCYTES	Phosphatidylethanolamine N-methyltransferase (PEMT) catalyzes phosphatidylcholine synthesis. PEMT knockout mice have fatty livers, and it is possible that, in humans, nonalcoholic fatty liver disease (NAFLD) might be associated with PEMT gene polymorphisms. DNA samples from 59 humans without fatty liver and from 28 humans with NAFLD were genotyped for a single nucleotide polymorphism in exon 8 of PEMT, which leads to a V175M substitution. V175M is a loss of function mutation, as determined by transiently transfecting McArdle-RH7777 cells with constructs of wild-type PEMT open reading frame or the V175M mutant. Met/Met at residue 175 (loss of function SNP) occurred in 67.9% of the NAFLD subjects and in only 40.7% of control subjects (P < 0.03). For the first time we report that a polymorphism of the human PEMT gene (V175M) is associated with diminished activity and may confer susceptibility to NAFLD.	Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Radiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Zeisel, SH (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Nutr, CB 7461,McGavran Greenberg Bldg, Chapel Hill, NC 27599 USA.	zeisel@unc.edu			NIA NIH HHS [P01 AG009525, AG09525] Funding Source: Medline; NIDDK NIH HHS [P30 DK056350, DK56350, R01 DK055865, DK55865] Funding Source: Medline; NIEHS NIH HHS [P30 ES010126, ES10126] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055865, P30DK056350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AN IT MICR EXC, 2004, AN IT MICR EXC; Ancelin ML, 1998, BLOOD, V91, P1426, DOI 10.1182/blood.V91.4.1426; BJORNSTAD P, 1966, J LIPID RES, V7, P38; Bravo AA, 2001, NEW ENGL J MED, V344, P495, DOI 10.1056/NEJM200102153440706; BREMER J, 1961, BIOCHIM BIOPHYS ACTA, V46, P205, DOI 10.1016/0006-3002(61)90745-4; Browning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422; Brunt EM, 2001, SEMIN LIVER DIS, V21, P3, DOI 10.1055/s-2001-12925; BUCHMAN AL, 1995, HEPATOLOGY, V22, P1399, DOI 10.1002/hep.1840220510; DACOSTA KA, 1995, CARCINOGENESIS, V16, P327, DOI 10.1093/carcin/16.2.327; DIXON WT, 1984, RADIOLOGY, V153, P189, DOI 10.1148/radiology.153.1.6089263; DROUVA SV, 1986, ENDOCRINOLOGY, V119, P2611, DOI 10.1210/endo-119-6-2611; Falck-Ytter Y, 2001, SEMIN LIVER DIS, V21, P17, DOI 10.1055/s-2001-12926; Fishbein MH, 1997, MAGN RESON IMAGING, V15, P287, DOI 10.1016/S0730-725X(96)00224-X; Goldenberger D, 1997, J CLIN MICROBIOL, V35, P2733, DOI 10.1128/JCM.35.11.2733-2739.1997; KIRK K, 1991, BIOCHEM J, V278, P521, DOI 10.1042/bj2780521; LEE JKT, 1984, RADIOLOGY, V153, P195, DOI 10.1148/radiology.153.1.6089264; Lehane AM, 2004, BIOCHEM BIOPH RES CO, V320, P311, DOI 10.1016/j.bbrc.2004.05.164; LYMAN RL, 1971, CAN J BIOCHEM CELL B, V49, P71, DOI 10.1139/o71-011; Noga AA, 2002, J BIOL CHEM, V277, P42358, DOI 10.1074/jbc.M204542200; Reo NV, 2002, BBA-MOL CELL BIOL L, V1580, P171, DOI 10.1016/S1388-1981(01)00202-5; RIDGWAY ND, 1988, J BIOL CHEM, V263, P16864; RIDGWAY ND, 1988, J BIOL CHEM, V263, P16856; Saito S, 2001, J HUM GENET, V46, P529, DOI 10.1007/s100380170035; SAS Institute Inc, 1999, SAS STAT US GUID VER; Schwahn BC, 2003, FASEB J, V17, P512, DOI 10.1096/fj.02-0456fje; Shen L, 2003, WORLD J GASTROENTERO, V9, P1106; TESSITORE L, 1995, INT J EXP PATHOL, V76, P125; TING A, 1971, VOX SANG, V20, P561, DOI 10.1111/j.1423-0410.1971.tb00469.x; Vance DE, 1997, BBA-LIPID LIPID MET, V1348, P142, DOI 10.1016/S0005-2760(97)00108-2; Waite KA, 2002, J NUTR, V132, P68, DOI 10.1093/jn/132.1.68; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; Walkey CJ, 1997, P NATL ACAD SCI USA, V94, P12880, DOI 10.1073/pnas.94.24.12880; YAO Z, 1990, BIOCHEM CELL BIOL, V68, P552, DOI 10.1139/o90-079; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1989, J BIOL CHEM, V264, P11373; Yates Z, 2002, HAEMATOLOGICA, V87, P751; YOUNG DL, 1971, J LIPID RES, V12, P590; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413; Zeisel SH, 2003, J NUTR, V133, P1302; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061; Zhu XN, 2004, DEV BRAIN RES, V149, P121, DOI 10.1016/j.devbrainres.2004.01.004; Zhu XN, 2003, BIOCHEM J, V370, P987, DOI 10.1042/BJ20021523; [No title captured]	43	165	171	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1266	1271		10.1096/fj.04-3580com	http://dx.doi.org/10.1096/fj.04-3580com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16051693	Green Accepted			2022-12-28	WOS:000231843700033
J	Nikoshkov, A; Hurd, YL; Yakovleva, T; Bazov, I; Marinova, Z; Cebers, G; Pasikova, N; Gharibyan, A; Terenius, L; Bakalkin, G				Nikoshkov, A; Hurd, YL; Yakovleva, T; Bazov, I; Marinova, Z; Cebers, G; Pasikova, N; Gharibyan, A; Terenius, L; Bakalkin, G			Prodynorphin transcripts and proteins differentially expressed and regulated in the adult human brain	FASEB JOURNAL			English	Article						preprodynorphin; opioid peptides; kappa-opioid receptor; alternative transcripts	MESSENGER-RNA EXPRESSION; FUNCTIONAL POLYMORPHISM; OPIOID RECEPTOR; BINDING PROTEIN; LEU-ENKEPHALIN; UP-REGULATION; SPINAL-CORD; DYNORPHIN; GENE; RAT	Transcription from multiple promoters along with alternative mRNA splicing constitutes the basis for cell-specific gene expression and mRNA and protein diversity. The prodynorphin gene (PDYN) gives rise to prodynorphin (PDYN), precursor to dynorphin opioid peptides that regulate diverse physiological functions and are implicated in various neuropsychiatric disorders. Here, we characterized PDYN transcripts and proteins in the adult human brain and studied PDYN processing and intracellular localization in model cell lines. Seven PDYN mRNAs were identified in the human brain; two of the transcripts, FL1 and FL2, encode the full-length PDYN. The dominant, FL1 transcript shows high expression in limbic-related structures such as the nucleus accumbens and amygdala. The second, FL2 transcript is only expressed in few brain structures such as the claustrum and hypothalamus. FL-PDYN was identified for the first time in the brain as the dominant PDYN protein product. Three novel PDYNs expressed from spliced or truncated PDYN transcripts either lack a central segment but are still processed into dynorphins, or are translated into N-terminally truncated proteins. One truncated PDYN is located in the cell nucleus, suggesting a novel nonopioid function for this protein. The complexity of PDYN expression and diversity of its protein products may be relevant for diverse levels of plasticity in adaptive responses for the dynorphin system.	Karolinska Inst, Sect Psychiat, Dept Clin Neurosci, S-17176 Stockholm, Sweden; Karolinska Inst, Sect Alcohol & Drug Dependence Res, Dept Clin Neurosci, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Hurd, YL (corresponding author), Karolinska Hosp, Psychiat Sect, Dept Clin Neurosci R500, S-17176 Stockholm, Sweden.	Yasmin.hurd@cns.ki.se	Pasikova, Natalia/K-2056-2018; Gharibyan, Anna L./B-3401-2010	Gharibyan, Anna L./0000-0001-9070-6215; Bakalkin, Georgy/0000-0002-8074-9833; Bazov, Igor/0000-0003-4388-1656	NIDA NIH HHS [DA-313312] Funding Source: Medline	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BAKALKIN G, 1994, MOL BRAIN RES, V24, P301, DOI 10.1016/0169-328X(94)90143-0; BAKALKIN G, 1995, P NATL ACAD SCI USA, V92, P9024, DOI 10.1073/pnas.92.20.9024; Bakalkin G, 1997, BIOCHEM BIOPH RES CO, V231, P135, DOI 10.1006/bbrc.1997.6062; BAKALKIN GY, 1991, FEBS LETT, V282, P175, DOI 10.1016/0014-5793(91)80471-E; Bigey P, 2000, GENE, V242, P407, DOI 10.1016/S0378-1119(99)00501-6; BOTTGER A, 1995, J CELL BIOL, V130, P1251, DOI 10.1083/jcb.130.6.1251; Brown CH, 1998, J NEUROSCI, V18, P9480, DOI 10.1523/jneurosci.18-22-09480.1998; Campos D, 2003, MOL CELL NEUROSCI, V22, P135, DOI 10.1016/S1044-7431(03)00040-X; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Cenci MA, 1998, EUR J NEUROSCI, V10, P2694, DOI 10.1046/j.1460-9568.1998.t01-1-00285.x; Chen ACH, 2002, AM J MED GENET, V114, P429, DOI 10.1002/ajmg.10362; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTENSSONNYLANDER I, 1985, REGUL PEPTIDES, V11, P65, DOI 10.1016/0167-0115(85)90032-1; CLARK AJL, 1990, MOL ENDOCRINOL, V4, P1737, DOI 10.1210/mend-4-11-1737; De Vries TJ, 2002, J NEUROSCI, V22, P3321; Dores RM, 2000, NEUROENDOCRINOLOGY, V72, P224, DOI 10.1159/000054591; DOUGLASS J, 1994, MOL ENDOCRINOL, V8, P333, DOI 10.1210/me.8.3.333; Fagergren P, 2003, EUR J NEUROSCI, V17, P2212, DOI 10.1046/j.1460-9568.2003.02636.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRAMSCH C, 1982, BRAIN RES, V233, P65, DOI 10.1016/0006-8993(82)90930-1; HORIKAWA S, 1983, NATURE, V306, P611, DOI 10.1038/306611a0; Horvath GC, 2003, BBA-GENE STRUCT EXPR, V1625, P165, DOI 10.1016/S0167-4781(02)00604-8; Hurd YL, 2002, MOL PSYCHIATR, V7, P75, DOI 10.1038/sj/mp/4000930; HURD YL, 1993, SYNAPSE, V13, P357, DOI 10.1002/syn.890130408; Ji RR, 2002, J NEUROSCI, V22, P478, DOI 10.1523/JNEUROSCI.22-02-00478.2002; KHACHATURIAN H, 1993, HDB EXPT PHARM, P471; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kreek MJ, 2002, NAT REV DRUG DISCOV, V1, P710, DOI 10.1038/nrd897; Kuzmin A, 2000, J PHARMACOL EXP THER, V295, P1031; MANSOUR A, 1994, MOL CELL NEUROSCI, V5, P124, DOI 10.1006/mcne.1994.1015; McLaughlin JP, 2003, J NEUROSCI, V23, P5674, DOI 10.1523/jneurosci.23-13-05674.2003; Modrek B, 2003, NAT GENET, V34, P177, DOI 10.1038/ng1159; NARANJO JR, 1991, NEURON, V6, P607, DOI 10.1016/0896-6273(91)90063-6; Newton SS, 2002, J NEUROSCI, V22, P10883; NYBERG F, 1987, REGUL PEPTIDES, V17, P159, DOI 10.1016/0167-0115(87)90025-5; Palko L, 2004, J CELL SCI, V117, P465, DOI 10.1242/jcs.00870; Pattee P, 2003, J BIOL CHEM, V278, P53098, DOI 10.1074/jbc.M306724200; Sharifi N, 1999, NEUROPEPTIDES, V33, P236, DOI 10.1054/npep.1999.0023; Sheffler DJ, 2003, TRENDS PHARMACOL SCI, V24, P107, DOI 10.1016/S0165-6147(03)00027-0; Shirayama Y, 2004, J NEUROCHEM, V90, P1258, DOI 10.1111/j.1471-4159.2004.02589.x; Shuster SJ, 2000, NEUROSCIENCE, V96, P373, DOI 10.1016/S0306-4522(99)00472-8; Stogmann E, 2002, ANN NEUROL, V51, P260, DOI 10.1002/ana.10108; Tan-No K, 2005, PAIN, V113, P301, DOI 10.1016/j.pain.2004.11.004; Tanne-Gariepy J, 2002, J COMP NEUROL, V454, P140, DOI 10.1002/cne.10425; Telkov M, 1998, BRAIN RES, V804, P284, DOI 10.1016/S0006-8993(98)00706-9; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; Wang X, 2003, NEUROSCIENCE, V118, P681, DOI 10.1016/S0306-4522(03)00020-4; Wang ZJ, 2001, J NEUROSCI, V21, P1779, DOI 10.1523/JNEUROSCI.21-05-01779.2001; Xu M, 2004, J NEUROSCI, V24, P4576, DOI 10.1523/JNEUROSCI.5552-03.2004; Yuferov V, 2001, BRAIN RES BULL, V55, P65, DOI 10.1016/S0361-9230(01)00496-8; Zimmer A, 2001, J NEUROSCI, V21, P9499, DOI 10.1523/JNEUROSCI.21-23-09499.2001	51	35	35	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1543	+		10.1096/fj.05-3743fje	http://dx.doi.org/10.1096/fj.05-3743fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16014400				2022-12-28	WOS:000230923000023
J	Schwabe, RF; Sakurai, H				Schwabe, RF; Sakurai, H			IKK beta phosphorylates p65 at S468 in transactivaton domain 2	FASEB JOURNAL			English	Article						signal transduction; inflammation	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; TATA-BINDING PROTEIN; TRANSCRIPTIONAL ACTIVITY; LINKS INFLAMMATION; ACTIVATION; KINASE; SUBUNIT; SERINE-536; RELA/P65	The transcription factor nuclear factor-kappa B (NF-kappa B) subunit p65 is phosphorylated by I kappa B kinase (IKK) at S536 in transactivation domain (TAD) 1. In this study, we investigate the presence of IKK sites in TAD2 of p65. Recombinant IKK beta, but not IKK alpha, phosphorylated a GST-p65 substrate in which TAD1 was deleted. Mutational analysis revealed S468 as the only IKK site in TAD2. S468 phosphorylation occurred rapidly after TNF-alpha and IL-1 beta in T cell, B cell, cervix carcinoma, hepatoma, breast cancer, and astrocytoma lines and in primary hepatic stellate cells as well as peripheral blood mononuclear cells. S468-phosphorylated p65 coimmunoprecipitated with I kappa B alpha, indicating that p65 is phosphorylated while bound to I kappa B alpha. Dominant negative IKK beta or pharmacological IKK inhibition blocked S468 phosphorylation after TNF-a or IL-1 beta, whereas dominant negative IKK beta or inhibitors of MEK, p38, JNK, PI-3 kinase, or GSK-3 had no effect. p65S468A-reconstituted p65-/- mouse embryonic fibroblasts (MEFs) showed a small, but significant, elevation of NF-kappa B-driven luciferase activity and RANTES mRNA levels after TNF-alpha and IL-1 beta in comparison to wtp65-reconstituted MEFs. p65 nuclear translocation was not altered in p65S468A-expressing MEFs. In conclusion, our results indicate that 1) IKK beta phosphorylates multiple p65 sites, 2) IKK beta phosphorylates p65 in an I kappa B-p65 complex, and 3) S468 phosphorylation slightly reduces TNF-alpha- and IL-1 beta-induced NF-kappa B activation.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Toyama Med & Pharmaceut Univ, Dept Pathogen Biochem, Toyama, Japan	Columbia University; University of Toyama	Schwabe, RF (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.	rfs2102@columbia.edu	Schwabe, Robert/AAY-6506-2021; Sakurai, Hiroaki/AAE-4294-2019	Sakurai, Hiroaki/0000-0003-0657-9570				Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185; Bae JS, 2003, BIOCHEM BIOPH RES CO, V305, P1094, DOI 10.1016/S0006-291X(03)00869-6; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Buss H, 2004, J BIOL CHEM, V279, P49571, DOI 10.1074/jbc.C400442200; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336; Moriyoshi K, 1996, NEURON, V16, P255, DOI 10.1016/S0896-6273(00)80044-6; Okazaki T, 2003, BIOCHEM BIOPH RES CO, V300, P807, DOI 10.1016/S0006-291X(02)02932-7; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; Schmitz ML, 2004, CHEMBIOCHEM, V5, P1348, DOI 10.1002/cbic.200400144; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Schwabe RF, 2002, AM J PHYSIOL-GASTR L, V283, pG204, DOI 10.1152/ajpgi.00016.2002; Schwabe RF, 2001, J IMMUNOL, V166, P6812, DOI 10.4049/jimmunol.166.11.6812; Schwabe RF, 2001, HEPATOLOGY, V33, P81, DOI 10.1053/jhep.2001.20799; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Takada Y, 2004, J BIOL CHEM, V279, P15096, DOI 10.1074/jbc.M311192200; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Vermeulen L, 2002, BIOCHEM PHARMACOL, V64, P963, DOI 10.1016/S0006-2952(02)01161-9; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	33	63	68	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1758	+		10.1096/fj.05-3736fje	http://dx.doi.org/10.1096/fj.05-3736fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16046471				2022-12-28	WOS:000230923000008
J	Shilling, R; Federici, L; Walas, F; Venter, H; Velamakanni, S; Woebking, B; Balakrishnan, L; Luisi, B; van Veen, HW				Shilling, R; Federici, L; Walas, F; Venter, H; Velamakanni, S; Woebking, B; Balakrishnan, L; Luisi, B; van Veen, HW			A critical role of a carboxylate in proton conduction by the ATP-binding cassette multidrug transporter LmrA	FASEB JOURNAL			English	Article						molecular mechanism; multidrug resistance; protein structure	RESISTANCE P-GLYCOPROTEIN; RETRACTED ARTICLE. SEE; ABC TRANSPORTER; LACTOCOCCUS-LACTIS; ESCHERICHIA-COLI; MUTATIONAL ANALYSIS; CROSS-LINKING; PROTEIN; SUBSTRATE; DOMAIN	The ATP binding cassette (ABC) transporter LmrA from the bacterium Lactococcus lactis is a homolog of the human multidrug resistance P-glycoprotein (ABCB1), the activity of which impairs the efficacy of chemotherapy. In a previous study, LmrA was shown to mediate ethidium efflux by an ATP-dependent proton-ethidium symport reaction in which the carboxylate E314 is critical. The functional importance of this key residue for ABC proteins was suggested by its conservation in a wider family of related transporters; however, the structural basis of its role was not apparent. Here, we have used homology modeling to define the structural environment of E314. The residue is nested in a hydrophobic environment that probably elevates its pK(a), accounting for the pH dependency of drug efflux that we report in this work. Functional analyses of wild-type and mutant proteins in cells and proteoliposomes support our proposal for the mechanistic role of E314 in proton-coupled ethidium transport. As the carboxylate is known to participate in proton translocation by secondary-active transporters, our observations suggest that this substituent can play a similar role in the activity of ABC transporters.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1PD, England	University of Cambridge; University of Cambridge	van Veen, HW (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.	hwv20@cam.ac.uk	Venter, Rietie/E-4795-2013; van Veen, Hendrik W./A-4162-2008	Venter, Rietie/0000-0001-5569-7755; van Veen, Hendrik W./0000-0002-9658-8077	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Alqwai O, 2003, BIOCHEM BIOPH RES CO, V311, P696, DOI 10.1016/j.bbrc.2003.10.049; Balakrishnan L, 2004, J BIOL CHEM, V279, P11273, DOI 10.1074/jbc.M308494200; Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; Brown MH, 2001, J MOL MICROB BIOTECH, V3, P163; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Checover S, 2001, BIOCHEMISTRY-US, V40, P4281, DOI 10.1021/bi002574m; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; Dong JH, 2005, SCIENCE, V308, P1023, DOI 10.1126/science.1106592; Ecker GF, 2004, MOL PHARMACOL, V66, P1169, DOI 10.1124/mol.104.001420; Edgar R, 1999, EMBO J, V18, P822, DOI 10.1093/emboj/18.4.822; Hafkemeyer P, 1998, BIOCHEMISTRY-US, V37, P16400, DOI 10.1021/bi980871+; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Huda N, 2003, ANTIMICROB AGENTS CH, V47, P2413, DOI 10.1128/AAC.47.8.2413-2417.2003; Janvilisri T, 2005, BIOCHEM J, V385, P419, DOI 10.1042/BJ20040791; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; Kaiser RD, 1998, BIOCHEMISTRY-US, V37, P8180, DOI 10.1021/bi980064a; Kerr ID, 2002, BBA-BIOMEMBRANES, V1561, P47, DOI 10.1016/S0304-4157(01)00008-9; Kim SH, 2004, MICROBIOL-SGM, V150, P2493, DOI 10.1099/mic.0.27312-0; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2001, J BIOL CHEM, V276, P31800, DOI 10.1074/jbc.M103498200; Margolles A, 1999, BIOCHEMISTRY-US, V38, P16298, DOI 10.1021/bi990855s; Mehler EL, 2002, PROTEINS, V48, P283, DOI 10.1002/prot.10153; Morrill JA, 1999, J GEN PHYSIOL, V114, P71, DOI 10.1085/jgp.114.1.71; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Periole X, 2004, BIOCHEMISTRY-US, V43, P6858, DOI 10.1021/bi049949e; Pleban K, 2004, BIOORG MED CHEM LETT, V14, P5823, DOI 10.1016/j.bmcl.2004.09.040; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; Reuter G, 2003, J BIOL CHEM, V278, P35193, DOI 10.1074/jbc.M306226200; Reyes CL, 2005, SCIENCE, V308, P1028, DOI 10.1126/science.1107733; Sakaeda T, 2001, BIOL PHARM BULL, V24, P935, DOI 10.1248/bpb.24.935; Sakamoto K, 2001, J BACTERIOL, V183, P5371, DOI 10.1128/JB.183.18.5371-5375.2001; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Shilling RA, 2003, INT J ANTIMICROB AG, V22, P200, DOI 10.1016/S0924-8579(03)00212-7; Situ D, 2004, J BIOL CHEM, V279, P38871, DOI 10.1074/jbc.M403832200; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Steinfels E, 2004, BIOCHEMISTRY-US, V43, P7491, DOI 10.1021/bi0362018; Stenham DR, 2003, FASEB J, V17, P2287, DOI 10.1096/fj.03-0107fje; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; Tamura N, 2003, CURR OPIN CHEM BIOL, V7, P570, DOI 10.1016/j.cbpa.2003.08.014; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; van Veen HW, 1998, NATURE, V391, P291, DOI 10.1038/34669; VANVEEN HW, 1993, J BIOL CHEM, V268, P19377; VanVeen HW, 1996, P NATL ACAD SCI USA, V93, P10668, DOI 10.1073/pnas.93.20.10668; Vazquez-Laslop N, 1999, BIOCHEMISTRY-US, V38, P16925, DOI 10.1021/bi991988g; Venter H, 2003, NATURE, V426, P866, DOI 10.1038/nature02173; WOOD WB, 1981, BIOCH PROBLEMS APPR; Yerushalmi H, 2000, BIOCHEMISTRY-US, V39, P14711, DOI 10.1021/bi001892i; ZANI ML, 1993, J BIOL CHEM, V268, P3216; Zhang DW, 2003, J BIOL CHEM, V278, P46052, DOI 10.1074/jbc.M308403200; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441	57	26	26	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1698	+		10.1096/fj.04-3558fje	http://dx.doi.org/10.1096/fj.04-3558fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16040836				2022-12-28	WOS:000230923000009
J	Wang, WG; Graeler, MH; Goetzl, EJ				Wang, WG; Graeler, MH; Goetzl, EJ			Type 4 sphingosine 1-phosphate G protein-coupled receptor (S1P(4)) transduces S1P effects on T cell proliferation and cytokine secretion without signaling migration	FASEB JOURNAL			English	Article						lipid mediators; immunoregulation; chemotaxis; chemokines; proliferation	SPHINGOSINE-1-PHOSPHATE; SUPPRESSION; ACTIVATION; EXPRESSION; LIGAND	Sphingosine 1-phosphate (S1P) has diverse effects on T cells that are mediated by the predominant S1P(1) and S1P(4) G protein-coupled receptors (GPCRs). S1P(4) is expressed principally by leukocytes, but little is known of its T cell effects in immunity. Two approaches were used to investigate S1P(4) signals in T cells. First, S1P(4) was introduced into D10G4.1 mouse Th2 cells and EL4. IL-2 mouse T cells lacking endogenous S1P GPCRs. Second, mouse splenic CD4 T cells were treated with FTY720 to suppress S1P1 and leave S1P(4) GPCRs as the only functionally relevant S1P receptor. Unlike S1P(1), S1P(4) failed to transduce chemotactic responses of any of the S1P(4)- only T cells to S1P or the phyto-S1P ligand selective for S1P(4), or to suppress their chemotactic responses to chemokines. The S1P-S1P(4) axis significantly inhibited T cell proliferation in each of the S1P(4)- only T cells activated by anti-CD3 and anti-CD28 MoAbs. Secretion of IL-4 by S1P(4)-D10G4.1 cells, IL-2 by S1P(4)-EL4. IL-2, and IFN-gamma by FTY720-treated CD4 T cells were significantly inhibited by S1P. In contrast, S1P enhanced secretion of IL- 10 by stimulated S1P(4)- D10G4.1 T cells. Thus, S1P(4) mediates immunosuppressive effects of S1P by inhibiting proliferation and secretion of effector cytokines, while enhancing secretion of the suppressive cytokine IL-10.	Univ Calif San Francisco, Dept Med & Microbiol Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Dept Med & Microbiol Immunol, UB8B,Box 0711,533 Parnassus 4th Ave, San Francisco, CA 94143 USA.	egoetzl@itsa.ucsf.edu	Gräler, Markus/ABH-1905-2021	Gräler, Markus/0000-0001-6650-7849	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-31809] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200; Candelore MR, 2002, BIOCHEM BIOPH RES CO, V297, P600; DELPRETE G, 1993, J IMMUNOL, V150, P353; Dorsam G, 2003, J IMMUNOL, V171, P3500, DOI 10.4049/jimmunol.171.7.3500; Goetzl EJ, 2004, J CELL BIOCHEM, V92, P1104, DOI 10.1002/jcb.20053; Goetzl EJ, 1999, J IMMUNOL, V162, P2049; Graeler M, 2002, FASEB J, V16, P1874, DOI 10.1096/fj.02-0548com; Graeler M, 2002, J IMMUNOL, V169, P4084, DOI 10.4049/jimmunol.169.8.4084; Graeler MH, 2003, J BIOL CHEM, V278, P27737, DOI 10.1074/jbc.C300147200; Graler MH, 2004, FASEB J, V18, P551, DOI 10.1096/fj.03-0910fje; Graler MH, 2003, J CELL BIOCHEM, V89, P507, DOI 10.1002/jcb.10537; Huang MC, 2002, BBA-MOL CELL BIOL L, V1582, P161, DOI 10.1016/S1388-1981(02)00151-8; Jin YX, 2003, BLOOD, V101, P4909, DOI 10.1182/blood-2002-09-2962; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; MALABARBA MG, 1995, J BIOL CHEM, V270, P9630, DOI 10.1074/jbc.270.16.9630; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Thomson AW, 1998, CYTOKINE HDB; Van Brocklyn JR, 2000, BLOOD, V95, P2624; Wang WG, 2004, FASEB J, V18, P1043, DOI 10.1096/fj.04-1555fje	19	114	122	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1731	+		10.1096/fj.05-3730fje	http://dx.doi.org/10.1096/fj.05-3730fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16046470				2022-12-28	WOS:000230923000007
J	Hurskainen, M; Eklund, L; Hagg, PO; Fruttiger, M; Sormunen, R; Ilves, M; Pihlajaniemi, T				Hurskainen, M; Eklund, L; Hagg, PO; Fruttiger, M; Sormunen, R; Ilves, M; Pihlajaniemi, T			Abnormal maturation of the retinal vasculature in type XVIII collagen/endostatin deficient mice and changes in retinal glial cells due to lack of collagen types XV and XVIII	FASEB JOURNAL			English	Article						Col18a1(-/-) mice; VEGF	ENDOTHELIAL GROWTH-FACTOR; FACTOR VEGF; BILATERAL PSEUDOTUMOR; ENDOGENOUS INHIBITOR; NORRIES-DISEASE; ASTROCYTES; EXPRESSION; ANGIOGENESIS; HETEROGENEITY; RETINOPATHY	Type XVIII collagen is important in the early phase of retinal vascular development and for the regression of the primary vasculature in the vitreous body after birth. We show here that the retina in Col18a1(-/-) mice becomes densely vascularized by anomalous anastomoses from the persistent hyaloid vasculature by day 10 after birth. In situ hybridizations revealed normal VEGF mRNA expression, but the phenotype of collagen XVIII deficient mice closely resembled that of mice expressing VEGF(120) and VEGF(188) isoforms only, suggesting that type XVIII collagen may be involved in VEGF function. Type XVIII collagen was found to be indispensable for angiogenesis in the eye, as also oxygen-induced neovascularization was less intense than normal in the Col18a1(-/-) mice. We observed a marked increase in the amount of retinal astrocytes in the Col18a1(-/-) mice. Whereas the retinal vessels of wild-type mice are covered by astrocytes and the regressing, thin hyaloid vessels are devoid of astrocytes, the retinal vessels in the Col18a1(-/-) mice were similarly covered by astrocytes but not the persistent hyaloid vessels in the vitreous body. Interestingly, double null mice lacking type XVIII collagen and its homologue type XV collagen had the persistent hyaloid vessels covered by astrocytes, including the parts located in the vitreous body. We thus hypothesize that type XV collagen is a regulator of glial cell recruitment around vessels and that type XVIII collagen regulates their proliferation.	Univ Oulu, Collagen Res Unit, Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; Univ Oulu, Dept Ophthalmol, SF-90220 Oulu, Finland; UCL, Wolfson Inst Biomed Res, London, England; Univ Oulu, Dept Pathol, Oulu, Finland; Univ Oulu, Bioctr Oulu, Oulu, Finland; Univ Oulu, Dept Physiol, Oulu, Finland	University of Oulu; University of Oulu; University of Oulu; University of London; University College London; University of Oulu; University of Oulu; University of Oulu	Pihlajaniemi, T (corresponding author), Univ Oulu, Collagen Res Unit, Bioctr Oulu, POB 5000, FIN-90014 Oulu, Finland.	taina.pihlajaniemi@oulu.fi		Hurskainen, Merja/0000-0001-8270-8974; Fruttiger, Marcus/0000-0002-6962-5485; Pihlajaniemi, Taina/0000-0002-1664-9045				Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x; ANDERSEN SR, 1961, ARCH OPHTHALMOL-CHIC, V66, P614, DOI 10.1001/archopht.1961.00960010616003; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; Eklund L, 2001, P NATL ACAD SCI USA, V98, P1194, DOI 10.1073/pnas.031444798; Fruttiger M, 1996, NEURON, V17, P1117, DOI 10.1016/S0896-6273(00)80244-5; Fruttiger M, 2002, INVEST OPHTH VIS SCI, V43, P522; Fukai N, 2002, EMBO J, V21, P1535, DOI 10.1093/emboj/21.7.1535; Hackett SF, 2002, J CELL PHYSIOL, V192, P182, DOI 10.1002/jcp.10128; Haddad A, 2001, J NEUROSCI METH, V106, P131, DOI 10.1016/S0165-0270(01)00335-1; Halfter W, 1998, J BIOL CHEM, V273, P25404, DOI 10.1074/jbc.273.39.25404; KIVIRIKKO S, 1995, AM J PATHOL, V147, P1500; LEVINE RA, 1983, OPHTHALMOLOGY, V90, P1600; LING TL, 1989, J COMP NEUROL, V286, P345, DOI 10.1002/cne.902860305; Luo J, 1999, J NEUROSCI, V19, P10014, DOI 10.1523/jneurosci.19-22-10014.1999; Majalahti-Palviainen T, 2000, ENDOCRINOLOGY, V141, P731, DOI 10.1210/en.141.2.731; Marneros AG, 2003, INVEST OPHTH VIS SCI, V44, P2367, DOI 10.1167/iovs.02-1180; McKeller RN, 2002, P NATL ACAD SCI USA, V99, P3848, DOI 10.1073/pnas.052484199; Muona A, 2002, MATRIX BIOL, V21, P89, DOI 10.1016/S0945-053X(01)00187-1; MURAGAKI Y, 1995, P NATL ACAD SCI USA, V92, P8763, DOI 10.1073/pnas.92.19.8763; Myers JC, 1996, CELL TISSUE RES, V286, P493, DOI 10.1007/s004410050719; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Provis JM, 1997, EXP EYE RES, V65, P555, DOI 10.1006/exer.1997.0365; Ramchandran R, 1999, BIOCHEM BIOPH RES CO, V255, P735, DOI 10.1006/bbrc.1999.0248; REHN M, 1995, J BIOL CHEM, V270, P4705, DOI 10.1074/jbc.270.9.4705; Reichel MB, 1998, CELL DEATH DIFFER, V5, P156, DOI 10.1038/sj.cdd.4400326; Saarela J, 1998, AM J PATHOL, V153, P611, DOI 10.1016/S0002-9440(10)65603-9; SCHNITZER J, 1988, J NEUROCYTOL, V17, P433, DOI 10.1007/BF01189801; Sertie AL, 2000, HUM MOL GENET, V9, P2051, DOI 10.1093/hmg/9.13.2051; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362; Stone J, 1996, INVEST OPHTH VIS SCI, V37, P290; STONE J, 1987, J COMP NEUROL, V255, P35, DOI 10.1002/cne.902550104; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; Suzuki OT, 2002, AM J HUM GENET, V71, P1320, DOI 10.1086/344695; Walker E, 1942, ARCH NEURO PSYCHIATR, V48, P13, DOI 10.1001/archneurpsyc.1942.02290070023002; WARBURG M, 1963, ACTA OPHTHALMOL, V41, P134; WARBURG M, 1979, T OPHTHAL SOC UK, V99, P272; Yamada H, 2000, AM J PATHOL, V156, P477, DOI 10.1016/S0002-9440(10)64752-9; Ylikarppa R, 2003, FASEB J, V17, P2257, DOI 10.1096/fj.02-1001fje; Ylikarppa R, 2003, MATRIX BIOL, V22, P443, DOI 10.1016/S0945-053X(03)00074-X; Zhang Y, 1999, DEV BRAIN RES, V118, P135, DOI 10.1016/S0165-3806(99)00140-6; Zhang YF, 1997, INVEST OPHTH VIS SCI, V38, P1653; Zhuo L, 1997, DEV BIOL, V187, P36, DOI 10.1006/dbio.1997.8601	46	44	44	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1564	+		10.1096/fj.04-3101fje	http://dx.doi.org/10.1096/fj.04-3101fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15976268				2022-12-28	WOS:000230207800006
J	Oh, SW; Moon, JD; Lim, HJ; Park, SY; Kim, T; Park, J; Han, MH; Snyder, M; Choi, EY				Oh, SW; Moon, JD; Lim, HJ; Park, SY; Kim, T; Park, J; Han, MH; Snyder, M; Choi, EY			Calixarene derivative as a tool for highly sensitive detection and oriented immobilization of proteins in a microarray format through noncovalent molecular interaction	FASEB JOURNAL			English	Article						protein microarray; Calixcrown; antibody; orientation; diagnostic application	LINKED-IMMUNOSORBENT-ASSAY; RAT-LIVER; ACID; ANTIBODIES; COMPLEXES; FIBROSIS; BINDING	One important factor in fabricating protein microarray is to immobilize proteins without losing their activity on a solid phase. To keep them functional, it is necessary to immobilize proteins in a way that preserve their folded structural integrity. In a previous study, we developed novel Calixarene derivatives for the immobilization of proteins on the surface of a glass slide (1). In this study, we compared the sensitivity and the specificity of the linker molecules with those of five other protein attachment agents on glass slides using a prostate- specific antigen and its antibodies as a model system. The Calixcrown- coated protein chip showed a superior sensitivity and a much lower detection limit than those chips prepared by other methods. When we tested the capability of Calixcrown to immobilize antibody molecules, it appeared that Calixcrown makes arrangement of antibody be more regular with the vertical orientation than the covalent- bond agent. We also observed that the Calixcrown chip could be used for the diagnostic application with clinical samples from prostate cancer and HIV patients. Finally, we applied the Calixcrown chip using an antibody microarray to identify up- or down-regulated proteins in specific tissue and detected several up- or down-regulated proteins from a rat liver by administering toxin. Thus, the Calixcrown chip can be used as a powerful tool with a wide range of applications, including protein-protein interaction, protein-DNA interaction, and an enzyme activity assay.	Hallym Univ, Dept Genet Engn, Chunchon 200702, South Korea; BodiTech MedInc, Chunchon 200160, South Korea; Hallym Univ, Dept Chem, Chunchon 200702, South Korea; Protogen Inc, Chunchon 200160, South Korea; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Hallym University; Hallym University; Yale University	Choi, EY (corresponding author), Hallym Univ, Dept Genet Engn, Chunchon 200702, South Korea.	euichoi@hallym.ac.kr						Angenendt P, 2002, ANAL BIOCHEM, V309, P253, DOI 10.1016/S0003-2697(02)00257-9; Belov L, 2001, CANCER RES, V61, P4483; Benters R, 2001, CHEMBIOCHEM, V2, P686, DOI 10.1002/1439-7633(20010903)2:9<686::AID-CBIC686>3.0.CO;2-S; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER JE, 1992, J IMMUNOL METHODS, V150, P77, DOI 10.1016/0022-1759(92)90066-3; Cahill DJ, 2001, J IMMUNOL METHODS, V250, P81, DOI 10.1016/S0022-1759(01)00325-8; Casnati A, 2001, CALIXARENES 2001, P365; CHOI EY, 1995, J NEUROCHEM, V64, P371; Diamond D, 2001, ANAL CHEM, V73, p22A, DOI 10.1021/ac012376g; Emili AQ, 2000, NAT BIOTECHNOL, V18, P393, DOI 10.1038/74442; Galfre G, 1981, Methods Enzymol, V73, P3; GE H, 2000, NUCLEIC ACIDS RES, V28, P3; Gutsche C. D., 1998, MONOGRAPHS SUPRAMOLE; Haab BB, 2001, GENOME BIOL, V2; Hayami S, 1999, BIOCHEM PHARMACOL, V58, P1941, DOI 10.1016/S0006-2952(99)00295-6; HEYSEL S, 1995, PROTEIN SCI, V4, P2532, DOI 10.1002/pro.5560041210; Joos TO, 2000, ELECTROPHORESIS, V21, P2641, DOI 10.1002/1522-2683(20000701)21:13<2641::AID-ELPS2641>3.3.CO;2-X; Kudo M., 1996, NATURE, V382, P522; Lee Y, 2003, PROTEOMICS, V3, P2289, DOI 10.1002/pmic.200300541; Lin Q, 1998, BIOPOLYMERS, V47, P285, DOI 10.1002/(SICI)1097-0282(1998)47:4<285::AID-BIP4>3.3.CO;2-3; Lueking A, 1999, ANAL BIOCHEM, V270, P103, DOI 10.1006/abio.1999.4063; MacBeath G, 2000, SCIENCE, V289, P1760; Mandolini L., 2000, CALIXARENES ACTION; Martin BD, 1998, LANGMUIR, V14, P3971, DOI 10.1021/la9713311; Mendoza LG, 1999, BIOTECHNIQUES, V27, P778, DOI 10.2144/99274rr01; Nejjari M, 2001, J PATHOL, V195, P473, DOI 10.1002/path.964; Oshima T, 2002, BIOMACROMOLECULES, V3, P438, DOI 10.1021/bm010148q; PAN T, 1989, P NATL ACAD SCI USA, V86, P3145, DOI 10.1073/pnas.86.9.3145; Peluso P, 2003, ANAL BIOCHEM, V312, P113, DOI 10.1016/S0003-2697(02)00442-6; Ramirez J, 2000, J AM CHEM SOC, V122, P6884, DOI 10.1021/ja000717m; Sakaida I, 2003, LIFE SCI, V72, P943, DOI 10.1016/S0024-3205(02)02342-1; SHENG YJ, 2002, PHYS REV E, V66; Song D, 2000, J COLLOID INTERF SCI, V221, P25, DOI 10.1006/jcis.1999.6560; Sreekumar A, 2001, CANCER RES, V61, P7585; Stone MM, 2002, J AM SOC MASS SPECTR, V13, P964, DOI 10.1016/S1044-0305(02)00417-8; Tannapfel A, 2003, J PATHOL, V201, P238, DOI 10.1002/path.1420; Tsai MY, 2001, J BIOMED MATER RES, V55, P554, DOI 10.1002/1097-4636(20010615)55:4<554::AID-JBM1049>3.0.CO;2-V; Turkova J, 1999, J CHROMATOGR B, V722, P11, DOI 10.1016/S0378-4347(98)00434-4; Zhu H, 2003, CURR OPIN CHEM BIOL, V7, P55, DOI 10.1016/S1367-5931(02)00005-4; Zlatanova J, 2001, Methods Mol Biol, V170, P17	40	72	77	1	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1335	+		10.1096/fj.04-2098fje	http://dx.doi.org/10.1096/fj.04-2098fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15939735				2022-12-28	WOS:000230207800031
J	Pullamsetti, S; Kiss, L; Ghofrani, HA; Voswinckel, R; Haredza, P; Klepetko, W; Aigner, C; Fink, L; Muyal, JP; Weissmann, N; Grimminger, F; Seeger, W; Schermuly, RT				Pullamsetti, S; Kiss, L; Ghofrani, HA; Voswinckel, R; Haredza, P; Klepetko, W; Aigner, C; Fink, L; Muyal, JP; Weissmann, N; Grimminger, F; Seeger, W; Schermuly, RT			Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension	FASEB JOURNAL			English	Article						PAH; DDAH; SDMA	NITRIC-OXIDE SYNTHASE; L-ARGININE; ENDOTHELIAL DYSFUNCTION; PLASMA-LEVELS; EXPRESSION; IDENTIFICATION; DYSREGULATION; METABOLISM; INHIBITOR; PATHWAY	Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS) and has been implicated in endothelial dysfunction. ADMA is metabolized by the enzyme dimethylarginine dimethylaminohydrolase (DDAH), with DDAH2 representing the predominant endothelial DDAH isoform. Symmetric dimethylarginine (SDMA), also originating from arginine methylation by protein arginine methyltransferases, is an inhibitor of intracellular arginine uptake. In both chronic pulmonary hypertensive rats and patients suffering from idiopathic pulmonary arterial hypertension (IPAH; NYHA class III and IV), a marked increase in plasma ADMA and SDMA levels, as well as tissue levels of asymmetric and symmetric dimethylated proteins, was observed. Moreover, when comparing lung tissue from pulmonary hypertensive rats and IPAH patients to corresponding normal lung tissue, expression of DDAH2 was found to be reduced at both the mRNA and the protein level with no significant changes in DDAH1 expression. These findings were further supported by demonstrating a decrease in DDAH2 function in the experimental pulmonary hypertension model. Immunohistochemistry in human and rat control tissue demonstrated both isoforms of DDAH in the endothelial layer and in the alveolar epithelium. In contrast, in pulmonary hypertensive tissue, the immunoreactivity of DDAH2 in pulmonary endothelium was significantly decreased compared with DDAH1. Therefore, altogether we can conclude that enhanced dimethylarginine levels may contribute to vascular abnormalities in pulmonary arterial hypertension. Suppression of endothelial DDAH2 expression and function represents an important underlying mechanism.	Univ Giessen, Dept Internal Med, D-35392 Giessen, Germany; Univ Vienna, Dept Cardiothorac Surg, A-1090 Vienna, Austria; Univ Giessen, Dept Pathol, D-35392 Giessen, Germany	Justus Liebig University Giessen; University of Vienna; Justus Liebig University Giessen	Schermuly, RT (corresponding author), Med Klin, Klin Str 36, D-35392 Giessen, Germany.	ralph.schermuly@innere.med.uni-giessen.de	Ghofrani, Hossein Ardeschir/AAD-2856-2022; Ghofrani, Ardeschir/AAD-5293-2020; Aigner, Clemens/A-7284-2019	Ghofrani, Ardeschir/0000-0002-2029-4419; Aigner, Clemens/0000-0002-7787-991X; Schermuly, Ralph/0000-0002-5167-6970; Weissmann, Norbert/0000-0003-2675-3871; Pullamsetti, Soni Savai/0000-0003-0440-8831; Seeger, Werner/0000-0003-1946-0894; Grimminger, Friedrich/0000-0001-8725-6276				Abbasi F, 2001, AM J CARDIOL, V88, P1201, DOI 10.1016/S0002-9149(01)02063-X; Achan V, 2002, CIRC RES, V90, P764, DOI 10.1161/01.RES.0000014450.40853.2B; Alonso D, 2003, HEART FAIL REV, V8, P107, DOI 10.1023/A:1022155206928; Ameshima S, 2003, CIRC RES, V92, P1162, DOI 10.1161/01.RES.0000073585.50092.14; Arrigoni FI, 2003, CIRCULATION, V107, P1195, DOI 10.1161/01.CIR.0000051466.00227.13; Azuma H, 1999, Nihon Yakurigaku Zasshi, V114 Suppl 1, p33P; Boger RH, 1998, CIRCULATION, V98, P1842, DOI 10.1161/01.CIR.98.18.1842; Boger RH, 2000, CIRCULATION, V101, pE160; Boger RH, 2000, CIRC RES, V87, P99, DOI 10.1161/01.RES.87.2.99; Bowers R, 2004, AM J RESP CRIT CARE, V169, P764, DOI 10.1164/rccm.200301-147OC; Closs EI, 1997, NITRIC OXIDE-BIOL CH, V1, P65, DOI 10.1006/niox.1996.0106; Cooke JP, 2004, CIRCULATION, V109, P1813, DOI 10.1161/01.CIR.0000126823.07732.D5; Cracowski JL, 2001, AM J RESP CRIT CARE, V164, P1038, DOI 10.1164/ajrccm.164.6.2104033; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; DALONZO GE, 1991, ANN INTERN MED, V115, P343, DOI 10.7326/0003-4819-115-5-343; Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327; GHOSH SK, 1988, J BIOL CHEM, V263, P19024; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; Gorenflo M, 2001, J CARDIOVASC PHARM, V37, P489, DOI 10.1097/00005344-200104000-00016; Ito A, 1999, CIRCULATION, V99, P3092, DOI 10.1161/01.CIR.99.24.3092; ITO K, 1988, BRIT J PHARMACOL, V94, P1175, DOI 10.1111/j.1476-5381.1988.tb11636.x; Ito KM, 2000, AM J PHYSIOL-HEART C, V279, pH1786, DOI 10.1152/ajpheart.2000.279.4.H1786; Jones LC, 2003, BIOCHEM BIOPH RES CO, V310, P836, DOI 10.1016/j.bbrc.2003.09.097; Knipp M, 2000, ANAL BIOCHEM, V286, P257, DOI 10.1006/abio.2000.4805; Leiper JM, 1999, BIOCHEM J, V343, P209, DOI 10.1042/0264-6021:3430209; Lin KY, 2002, CIRCULATION, V106, P987, DOI 10.1161/01.CIR.0000027109.14149.67; Lu TM, 2004, AM J CARDIOL, V94, P157, DOI 10.1016/j.amjcard.2004.03.052; Luscher TF, 2000, CIRCULATION, V102, P2434, DOI 10.1161/01.CIR.102.19.2434; MEHTA S, 1995, CIRCULATION, V92, P1539, DOI 10.1161/01.CIR.92.6.1539; Millatt LJ, 2003, CIRCULATION, V108, P1493, DOI 10.1161/01.CIR.0000089087.25930.FF; MOLTENI A, 1984, P SOC EXP BIOL MED, V176, P88; Nagaya N, 2001, AM J RESP CRIT CARE, V163, P887, DOI 10.1164/ajrccm.163.4.2007116; Nakazawa H, 1999, BRIT J PHARMACOL, V128, P1098, DOI 10.1038/sj.bjp.0702878; OGAWA T, 1987, ARCH BIOCHEM BIOPHYS, V252, P526, DOI 10.1016/0003-9861(87)90060-9; Ohnishi M, 2002, CLIN SCI, V103, p241S, DOI 10.1042/CS103S241S; Piatti PM, 2003, CIRCULATION, V107, P429, DOI 10.1161/01.CIR.0000046489.24563.79; Schermuly RT, 2004, CIRC RES, V94, P1101, DOI 10.1161/01.RES.0000126050.41296.8E; Schermuly RT, 2004, AM J RESP CRIT CARE, V169, P39, DOI 10.1164/rccm.200302-282OC; Simonneau G, 2004, J AM COLL CARDIOL, V43, p5S, DOI 10.1016/j.jacc.2004.02.037; Stuhlinger MC, 2003, CIRCULATION, V108, P933, DOI 10.1161/01.CIR.0000085067.55901.89; Stuhlinger MC, 2002, JAMA-J AM MED ASSOC, V287, P1420, DOI 10.1001/jama.287.11.1420; Sydow K, 2003, ATHEROSCLEROSIS SUPP, V4, P41, DOI 10.1016/S1567-5688(03)00033-3; Teerlink T, 2002, ANAL BIOCHEM, V303, P131, DOI 10.1006/abio.2001.5575; Weis M, 2004, CIRCULATION, V109, P500, DOI 10.1161/01.CIR.0000109692.16004.AF	44	143	150	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1175	+		10.1096/fj.04-3223fje	http://dx.doi.org/10.1096/fj.04-3223fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15827267				2022-12-28	WOS:000228865300018
J	Langhorst, MF; Reuter, A; Luxenhofer, G; Boneberg, EM; Legler, DF; Plattner, H; Stuermer, CAO				Langhorst, Matthias F.; Reuter, Alexander; Luxenhofer, Georg; Boneberg, Eva-Maria; Legler, Daniel F.; Plattner, Helmut; Stuermer, Claudia A. O.			Preformed reggie/flotillin caps: stable priming platforms for macrodomain assembly in T cells	FASEB JOURNAL			English	Article						lipid rafts; signal transduction; T cell activation; actin cytoskeleton; raft clustering	ENRICHED MEMBRANE DOMAINS; LIPID RAFTS; ANCHORED PROTEINS; PLASMA-MEMBRANE; ANTIGEN RECEPTOR; IMMUNE SYNAPSE; RHO-FAMILY; VAV; LCK; REORGANIZATION	T cell activation after contact with an antigen-presenting cell depends on the regulated assembly of the T cell receptor signaling complex, which involves the polarized assembly of a stable, raft-like macrodomain surrounding engaged T cell receptors. Here we show that the preformed reggie/flotillin caps present in resting T cells act as priming platforms for macrodomain assembly. Preformed reggie-1/flotillin-2 caps are exceptionally stable, as shown by fluorescence recovery after photobleaching (FRAP). Upon T cell stimulation, signaling molecules are recruited to the stable reggie/flotillin caps. Importantly, a trans-negative reggie-1/flotillin-2 deletion mutant, which interferes with assembly of the preformed reggie/ flotillin cap, impairs raft polarization and macrodomain formation after T cell activation. Accordingly, expression of the trans-negative reggie-1 mutant leads to the incorrect positioning of the guanine nucleotide exchange factor Vav, resulting in defects in cytoskeletal reorganization. Thus, the preformed reggie/ flotillin caps are stable priming platforms for the assembly of multiprotein complexes controlling actin reorganization during T cell activation.	Univ Konstanz, Dev Neurobiol Grp, Dept Biol, D-7750 Constance, Germany; Univ Konstanz, Biotechnol Inst Thurgau, Tagerwilen, Switzerland	University of Konstanz	Langhorst, MF (corresponding author), Univ Str 10, D-78457 Constance, Germany.			Legler, Daniel F./0000-0001-8610-4764				Barda-Saad M, 2005, NAT IMMUNOL, V6, P80, DOI 10.1038/ni1143; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Bunnell SC, 2001, IMMUNITY, V14, P315, DOI 10.1016/S1074-7613(01)00112-1; Cao YJ, 2002, EMBO J, V21, P4809, DOI 10.1093/emboj/cdf499; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; Filipp D, 2004, J IMMUNOL, V172, P4266, DOI 10.4049/jimmunol.172.7.4266; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Fragoso R, 2003, J IMMUNOL, V170, P913, DOI 10.4049/jimmunol.170.2.913; Gaus K, 2005, J CELL BIOL, V171, P121, DOI 10.1083/jcb.200505047; Golub T, 2004, CURR OPIN NEUROBIOL, V14, P542, DOI 10.1016/j.conb.2004.08.003; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Gordy C, 2004, J IMMUNOL, V172, P2030, DOI 10.4049/jimmunol.172.4.2030; Haglund K, 2004, J CELL SCI, V117, P2557, DOI 10.1242/jcs.01148; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Hazarika P, 1999, J CELL BIOCHEM, V75, P147, DOI 10.1002/(SICI)1097-4644(19991001)75:1<147::AID-JCB15>3.0.CO;2-D; He HT, 2005, SEMIN IMMUNOL, V17, P23, DOI 10.1016/j.smim.2004.09.001; HERMAN A, 1990, J EXP MED, V172, P709, DOI 10.1084/jem.172.3.709; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Huang JY, 2000, P NATL ACAD SCI USA, V97, P10923, DOI 10.1073/pnas.97.20.10923; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; Klonis N, 2002, EUR BIOPHYS J BIOPHY, V31, P36, DOI 10.1007/s00249-001-0202-2; KWON G, 1994, CELL SIGNAL, V6, P663, DOI 10.1016/0898-6568(94)90049-3; Lang DM, 1998, J NEUROBIOL, V37, P502, DOI 10.1002/(SICI)1097-4695(199812)37:4<502::AID-NEU2>3.0.CO;2-S; Langhorst MF, 2005, CELL MOL LIFE SCI, V62, P2228, DOI 10.1007/s00018-005-5166-4; Langhorst MF, 2004, CELL SIGNAL, V16, P1283, DOI 10.1016/j.cellsig.2004.03.013; Liu J, 2005, J BIOL CHEM, V280, P1432, DOI 10.1074/jbc.M409740200; Mittelbrunn M, 2002, J IMMUNOL, V169, P6691, DOI 10.4049/jimmunol.169.12.6691; Morgan MM, 2001, J IMMUNOL, V167, P5708, DOI 10.4049/jimmunol.167.10.5708; Morrow IC, 2002, J BIOL CHEM, V277, P48834, DOI 10.1074/jbc.M209082200; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Neumann-Giesen C, 2004, BIOCHEM J, V378, P509, DOI 10.1042/BJ20031100; Petersson K, 2004, SCAND J IMMUNOL, V59, P345, DOI 10.1111/j.0300-9475.2004.01404.x; Rajendran L, 2003, P NATL ACAD SCI USA, V100, P8241, DOI 10.1073/pnas.1331629100; Rodgers W, 2005, TRENDS IMMUNOL, V26, P97, DOI 10.1016/j.it.2004.11.016; Rodgers W, 2001, EXP CELL RES, V267, P173, DOI 10.1006/excr.2001.5253; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; SCHROEDER WT, 1994, J BIOL CHEM, V269, P19983; Sharma P, 2004, CELL, V116, P577, DOI 10.1016/S0092-8674(04)00167-9; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Slaughter N, 2003, CLIN IMMUNOL, V108, P138, DOI 10.1016/S1521-6616(03)00097-4; Stuermer CAO, 2004, FASEB J, V18, P1731, DOI 10.1096/fj.04-2150fje; Stuermer CAO, 2001, MOL BIOL CELL, V12, P3031, DOI 10.1091/mbc.12.10.3031; Subczynski WK, 2003, BBA-BIOMEMBRANES, V1610, P231, DOI 10.1016/S0005-2736(03)00021-X; Tu XL, 2004, J PROTEOME RES, V3, P445, DOI 10.1021/pr0340779; Valensin S, 2002, EUR J IMMUNOL, V32, P435, DOI 10.1002/1521-4141(200202)32:2<435::AID-IMMU435>3.0.CO;2-H; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Weber I, 2003, METHOD ENZYMOL, V361, P34; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	56	47	52	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					711	+		10.1096/fj.05-4760fje	http://dx.doi.org/10.1096/fj.05-4760fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16452278	Green Published			2022-12-28	WOS:000237698700044
J	Moore, LR; Fujioka, H; Williams, PS; Chalmers, JJ; Grimberg, B; Zimmerman, PA; Zborowski, M				Moore, Lee R.; Fujioka, Hisashi; Williams, P. Stephen; Chalmers, Jeffrey J.; Grimberg, Brian; Zimmerman, Peter A.; Zborowski, Maciej			Hemoglobin degradation in malaria-infected erythrocytes determined from live cell magnetophoresis	FASEB JOURNAL			English	Article						erythrocyte magnetic susceptibility; Plasmodium falciparum; hemozoin; ferriheme; heme; toxicity	INTRAERYTHROCYTIC PLASMODIUM-FALCIPARUM; MAGNETIC-SUSCEPTIBILITY; BETA-HEMATIN; WHOLE-BLOOD; RED-CELLS; IN-VITRO; PARASITE; HEME; CHLOROQUINE; SEPARATION	During intra-erythrocytic development, malaria trophozoites digest hemoglobin, which leads to parasite growth and asexual replication while accumulating toxic heme. To avoid death, the parasite synthesizes insoluble hemozoin crystals in the digestive vacuole through polymerization of beta-hematin dimers. In the process, the heme is converted to a high-spin ferriheme whose magnetic properties were studied as early as 1936 by Pauling et al. Here, by magnetophoretic cell motion analysis, we provide evidence for a graduated increase of live cell magnetic susceptibility with developing blood-stage parasites, compatible with the increase in hemozoin content and the mechanism used by P. falciparum to avoid heme toxicity. The measured magnetophoretic mobility of the erythrocyte infected with a late-stage schizont form was m = 2.94 x 10(-6) mm(3) s/kg, corresponding to the net volume magnetic susceptibility ( relative to water) of Delta(X) = 1.80 x 10(-6), significantly higher than that of the oxygenated erythrocyte (-0.18 x 10(-6)) but lower than that of the fully deoxygenated erythrocyte (3.33 x 10(-6)). The corresponding fraction of hemoglobin converted to hemozoin, calculated based on the known magnetic susceptibilities of hemoglobin heme and hemozoin ferriheme, was 0.50, in agreement with the published biochemical and crystallography data. Magnetophoretic analysis of live erythrocytes could become significant for antimalarial drug susceptibility and resistance determination.	Cleveland Clin Fdn, Dept Biomed Engn, Lerner Res Inst, Cleveland, OH 44195 USA; Case Western Reserve Univ, Sch Med, Inst Pathol, Cleveland, OH 44106 USA; Ohio State Univ, Dept Chem & Biomol Engn, Columbus, OH 43210 USA; Case Western Reserve Univ, Ctr Global Hlth & Dis, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University; University System of Ohio; Ohio State University; Case Western Reserve University	Zborowski, M (corresponding author), Cleveland Clin Fdn, Dept Biomed Engn, Lerner Res Inst, 9500 Euclid Ave,ND20, Cleveland, OH 44195 USA.	zborowm@ccf.org	Grimberg, Brian/I-1251-2013; Williams, Philip/C-2774-2008	Grimberg, Brian/0000-0002-6015-4912; Williams, Philip/0000-0002-5951-2612	NCI NIH HHS [CA-062349, R01 CA062349] Funding Source: Medline; NIAID NIH HHS [R01 AI052312, AI-523213, R01 AI046919] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052312, R01AI046919] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099; Bartoszek M, 2001, PHYSICA B, V307, P217, DOI 10.1016/S0921-4526(01)00630-5; Bazylinski DA, 2004, NAT REV MICROBIOL, V2, P217, DOI 10.1038/nrmicro842; Becker K, 2004, INT J PARASITOL, V34, P163, DOI 10.1016/j.ijpara.2003.09.011; Becker R., 1982, ELECTROMAGNETIC FIEL; BENDRAT K, 1995, NATURE, V378, P138, DOI 10.1038/378138a0; Bohle DS, 1998, J AM CHEM SOC, V120, P8255, DOI 10.1021/ja980962u; Carpino F, 2005, J MAGN MAGN MATER, V293, P546, DOI 10.1016/j.jmmm.2005.01.071; Carter V, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-35; CERDONIO M, 1978, P NATL ACAD SCI USA, V75, P4916, DOI 10.1073/pnas.75.10.4916; CERDONIO M, 1985, P NATL ACAD SCI USA, V82, P102, DOI 10.1073/pnas.82.1.102; Coryell CD, 1937, J AM CHEM SOC, V59, P633, DOI 10.1021/ja01283a012; Cranmer SL, 1997, T ROY SOC TROP MED H, V91, P363, DOI 10.1016/S0035-9203(97)90110-3; Dunin-Borkowski RE, 1998, SCIENCE, V282, P1868, DOI 10.1126/science.282.5395.1868; Dzekunov SM, 2000, MOL BIOCHEM PARASIT, V110, P107, DOI 10.1016/S0166-6851(00)00261-9; Egan TJ, 2002, J INORG BIOCHEM, V91, P19, DOI 10.1016/S0162-0134(02)00372-0; Egan TJ, 2002, BIOCHEM J, V365, P343, DOI 10.1042/BJ20020793; FABRY ME, 1983, BIOCHEMISTRY-US, V22, P4119, DOI 10.1021/bi00286a020; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Ginsburg H, 1998, BIOCHEM PHARMACOL, V56, P1305, DOI 10.1016/S0006-2952(98)00184-1; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; Greenwood B, 2002, NATURE, V415, P670, DOI 10.1038/415670a; GUTIERREZ Y, 2000, DIAGNOSTIC PATHOLOGY, V2, P235; HEDELBERGER M, 1946, J IMMUNOL, V52, P325; KROGSTAD DF, 2001, ESSENTIALS TROPICAL, P341; Krugliak M, 2002, MOL BIOCHEM PARASIT, V119, P249, DOI 10.1016/S0166-6851(01)00427-3; Kumar S, 2005, TOXICOL LETT, V157, P175, DOI 10.1016/j.toxlet.2005.03.004; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Lelievre J, 2005, EXP PARASITOL, V109, P195, DOI 10.1016/j.exppara.2004.11.012; McCloskey KE, 2003, ANAL CHEM, V75, P6868, DOI 10.1021/ac034315j; MELVILLE D, 1975, NATURE, V255, P706, DOI 10.1038/255706a0; Miller JC., 1992, STAT ANAL CHEM; Moore LR, 2004, ANAL CHEM, V76, P3899, DOI 10.1021/ac049910f; Noland GS, 2003, MOL BIOCHEM PARASIT, V130, P91, DOI 10.1016/S0166-6851(03)00163-4; ORJIH AU, 1993, BIOCHIM BIOPHYS ACTA, V1157, P270, DOI 10.1016/0304-4165(93)90109-L; ORJIH AU, 1994, EXPERIENTIA, V50, P34, DOI 10.1007/BF01992046; Pagola S, 2000, NATURE, V404, P307, DOI 10.1038/35005132; PAUL F, 1981, LANCET, V2, P70; PAULING L, 1977, P NATL ACAD SCI USA, V74, P2612, DOI 10.1073/pnas.74.7.2612; Plyavin' Yu. A., 1983, Magnetohydrodynamics, V19, P349; Recktenwald D., 1998, CELL SEPARATION METH; Ridley RG, 2003, NATURE, V424, P887, DOI 10.1038/424887a; SAVICKI JP, 1984, P NATL ACAD SCI-BIOL, V81, P5417, DOI 10.1073/pnas.81.17.5417; Spees WM, 2001, MAGN RESON MED, V45, P533, DOI 10.1002/mrm.1072; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; TAYLOR TE, 2000, HUNTERS TROPICAL MED, P614; Tripathi AK, 2004, ANAL BIOCHEM, V325, P85, DOI 10.1016/j.ab.2003.10.016; UHLEMANN AC, 2000, MACS MORE, V4, P7; WEISSKOFF RM, 1992, MAGNET RESON MED, V24, P375, DOI 10.1002/mrm.1910240219; Zborowski M, 2003, BIOPHYS J, V84, P2638, DOI 10.1016/S0006-3495(03)75069-3; Zborowski Maciej, 2005, Methods Mol Biol, V295, P291; Zhang JM, 1999, MOL BIOCHEM PARASIT, V99, P129, DOI 10.1016/S0166-6851(99)00008-0	53	72	75	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					747	+		10.1096/fj.05-5122fje	http://dx.doi.org/10.1096/fj.05-5122fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16461330	Green Accepted			2022-12-28	WOS:000237698700038
J	Schulz, LL; Tyler, JK				Schulz, LL; Tyler, JK			The histone chaperone ASF1 localizes to active DNA replication forks to mediate efficient DNA replication	FASEB JOURNAL			English	Article						anti-silencing function 1; chromatin; knockdown; Drosophila	CHROMATIN ASSEMBLY FACTOR-1; TOUSLED-LIKE KINASES; S-PHASE; SACCHAROMYCES-CEREVISIAE; DAMAGE CHECKPOINT; IN-VIVO; DROSOPHILA; CELLS; YEAST; CAF-1	The packaging of the eukaryotic genome into chromatin is likely to regulate all processes that occur on the DNA template. The assembly and disassembly of chromatin structures from histone proteins and DNA are mediated by histone chaperones, including the histone H3/H4 chaperone anti-silencing function 1 (ASF1). To address the function of ASF1 in metazoan cells, we used RNA interference-mediated knockdown of Drosophila melanogaster ASF1 (dASF1). Cells lacking dASF1 accumulate in S phase of the cell cycle as determined by flow cytometry analysis of DNA content and quantitation of the proportion of cells with replication foci. In agreement, bromodeoxyuridine (BrdU) pulse-chase analysis demonstrates that the absence of ASF1 leads to delayed progression through S-phase. Furthermore, the absence of ASF1 leads to a reduced ability to incorporate the nucleoside analog BrdU, indicating that ASF1 is required for efficient DNA replication. We have also found that dASF1 colocalizes with DNA replication foci throughout S phase by immunofluorescence analysis and that these dASF1 foci are disrupted upon inhibition of DNA replication by treatment of cells with hydroxyurea. As such, these results demonstrate that dASF1 is present at active, but not stalled, replication forks. We propose that dASF1 has a direct role in modifying chromatin structure during DNA replication and that this function of dASF1 is important for the processivity of the replication machinery.	Univ Colorado, Hlth Sci Ctr Fitzsimons, Dept Biochem & Mol Genet, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus	Tyler, JK (corresponding author), Univ Colorado, Hlth Sci Ctr Fitzsimons, Dept Biochem & Mol Genet, Mail Stop 8101,POB 6511, Aurora, CO 80045 USA.	Jessica.tyler@uchsc.edu		Tyler, Jessica/0000-0001-9765-1659	NATIONAL CANCER INSTITUTE [R01CA095641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064475] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA095641, CA95641] Funding Source: Medline; NIGMS NIH HHS [R01 GM064475] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adkins MW, 2004, J BIOL CHEM, V279, P52069, DOI 10.1074/jbc.M406113200; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Carrera P, 2003, GENE DEV, V17, P2578, DOI 10.1101/gad.276703; Claycomb JM, 2002, J CELL BIOL, V159, P225, DOI 10.1083/jcb.200207046; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Franco AA, 2005, GENE DEV, V19, P1365, DOI 10.1101/gad.1305005; Gerbi SA, 2002, CURR OPIN GENET DEV, V12, P243, DOI 10.1016/S0959-437X(02)00292-7; Groth A, 2005, MOL CELL, V17, P301, DOI 10.1016/j.molcel.2004.12.018; Groth A, 2003, EMBO J, V22, P1676, DOI 10.1093/emboj/cdg151; Henderson DS, 2000, GENETICS, V154, P1721; Hoek M, 2003, P NATL ACAD SCI USA, V100, P12183, DOI 10.1073/pnas.1635158100; Klemm RD, 2001, P NATL ACAD SCI USA, V98, P8361, DOI 10.1073/pnas.131006898; KRUDE T, 1995, EXP CELL RES, V220, P304, DOI 10.1006/excr.1995.1320; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Lipford JR, 2001, MOL CELL, V7, P21, DOI 10.1016/S1097-2765(01)00151-4; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mello JA, 2002, EMBO REP, V3, P329, DOI 10.1093/embo-reports/kvf068; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Myung K, 2003, P NATL ACAD SCI USA, V100, P6640, DOI 10.1073/pnas.1232239100; Nabatiyan A, 2004, MOL CELL BIOL, V24, P2853, DOI 10.1128/MCB.24.7.2853-2862.2004; Prado F, 2004, EMBO REP, V5, P497, DOI 10.1038/sj.embor.7400128; Ramey CJ, 2004, MOL CELL BIOL, V24, P10313, DOI 10.1128/MCB.24.23.10313-10327.2004; Sillje HHW, 2001, CURR BIOL, V11, P1068, DOI 10.1016/S0960-9822(01)00298-6; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; Tyler JK, 2001, MOL CELL BIOL, V21, P6574, DOI 10.1128/MCB.21.19.6574-6584.2001; Vogelauer M, 2002, MOL CELL, V10, P1223, DOI 10.1016/S1097-2765(02)00702-5; Zabaronick SR, 2005, MOL CELL BIOL, V25, P652, DOI 10.1128/MCB.25.2.652-660.2005; Zhang ZG, 2000, NATURE, V408, P221, DOI 10.1038/35041601	30	61	63	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					488	+		10.1096/fj.05-5020fje	http://dx.doi.org/10.1096/fj.05-5020fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16396992				2022-12-28	WOS:000235996000036
J	Sotiriou, SN; Orlova, VV; Al-Fakhri, N; Ihanus, E; Economopoulou, M; Isermann, B; Bdeir, K; Nawroth, PP; Preissner, KT; Gahmberg, CG; Koschinsky, ML; Chavakis, T				Sotiriou, SN; Orlova, VV; Al-Fakhri, N; Ihanus, E; Economopoulou, M; Isermann, B; Bdeir, K; Nawroth, PP; Preissner, KT; Gahmberg, CG; Koschinsky, ML; Chavakis, T			Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin	FASEB JOURNAL			English	Article						plasminogen/angiostatin kringle 4; coronary arteries; prothrombotic tissue factor	NF-KAPPA-B; ANTIINFLAMMATORY FACTOR; TRANSCRIPTION FACTOR; TRANSGENIC MICE; LEUKOCYTE; APOLIPOPROTEIN(A); ATHEROGENESIS; MIGRATION; PATHWAY; BINDING	Lipoprotein(a) [Lp(a)], consisting of LDL and the unique constituent apolipoprotein(a) [apo(a)], which contains multiple repeats resembling plasminogen kringle 4, is considered a risk factor for the development of atherosclerotic disorders. However, the underlying mechanisms for the atherogenicity of Lp(a) are not completely understood. Here, we define a novel function of Lp(a) in promoting inflammatory cell recruitment that may contribute to its atherogenicity. Through its apo(a) moiety Lp(a) specifically interacts with the beta 2-integrin Mac-1, thereby promoting the adhesion of monocytes and their transendothelial migration in a Mac-1-dependent manner. Interestingly, the interaction between Mac-1 and Lp(a) was strengthened in the presence of proatherogenic homocysteine and was blocked by plasminogen/angiostatin kringle 4. Through its interaction with Mac-1, Lp(a) induced activation of the proinflammatory transcription factor NF kappa B, as well as the NF kappa B-related expression of prothrombotic tissue factor. In atherosclerotic coronary arteries Lp(a) was found to be localized in close proximity to Mac-1 on infiltrating mononuclear cells. Taken together, our data demonstrate that Lp(a), via its apo(a) moiety, is a ligand for the beta 2-integrin Mac-1, thereby facilitating inflammatory cell recruitment to atherosclerotic plaques. These observations suggest a novel mechanism for the atherogenic properties of Lp(a).	Natl Canc Inst, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; Heidelberg Univ, Dept Internal Med 1, Heidelberg, Germany; Univ Marburg, Dept Clin Chem & Mol Diagnost, Marburg, Germany; Univ Helsinki, Fac Biosci, Div Biochem, FIN-00014 Helsinki, Finland; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Giessen, Inst Biochem, Giessen, Germany; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ruprecht Karls University Heidelberg; Philipps University Marburg; University of Helsinki; University of Pennsylvania; Justus Liebig University Giessen; Queens University - Canada	Chavakis, T (corresponding author), Natl Canc Inst, Expt Immunol Branch, NIH, 10 Ctr Dr,Rm 4B17, Bethesda, MD 20892 USA.	chavakist@mail.nih.gov	Gahmberg, Carl/AAE-1876-2019; Chavakis, Triantafyllos/ABE-8845-2020; Orlova, Valeria V/C-6065-2014	Orlova, Valeria V/0000-0002-1169-2802; Koschinsky, Marlys/0000-0002-2643-2288; Gahmberg, Carl/0000-0001-9892-9296	NATIONAL CANCER INSTITUTE [Z01BC010664, ZIABC010664] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen S, 1998, FASEB J, V12, P1765, DOI 10.1096/fasebj.12.15.1765; Angles-Cano E, 2001, ANN NY ACAD SCI, V936, P261; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Becker L, 2004, BIOCHEMISTRY-US, V43, P9978, DOI 10.1021/bi049536d; Bierhaus A, 2001, DIABETES, V50, P2792, DOI 10.2337/diabetes.50.12.2792; BIERHAUS A, 1995, J BIOL CHEM, V270, P26419, DOI 10.1074/jbc.270.44.26419; Boisvert WA, 1998, J CLIN INVEST, V101, P353, DOI 10.1172/JCI1195; CALLOW MJ, 1995, J CLIN INVEST, V96, P1639, DOI 10.1172/JCI118203; Caplice NM, 2001, BLOOD, V98, P2980, DOI 10.1182/blood.V98.10.2980; Chavakis E, 2001, CIRCULATION, V103, P2102; Chavakis T, 2000, BLOOD, V96, P514; Chavakis T, 2005, BLOOD, V105, P1036, DOI 10.1182/blood-2004-01-0166; Chavakis T, 2004, J BIOL CHEM, V279, P55602, DOI 10.1074/jbc.M404676200; Chavakis T, 2003, J EXP MED, V198, P1507, DOI 10.1084/jem.20030800; Chavakis T, 2003, THROMB HAEMOSTASIS, V89, P13; Chavakis T, 2002, NAT MED, V8, P687, DOI 10.1038/nm728; Falco C, 1998, THROMB HAEMOSTASIS, V79, P818, DOI 10.1055/s-0037-1615071; FAN ST, 1993, J IMMUNOL, V150, P2972; FAN ST, 1991, J CLIN INVEST, V87, P50, DOI 10.1172/JCI115000; Foody JM, 2000, ARTERIOSCL THROM VAS, V20, P493, DOI 10.1161/01.ATV.20.2.493; Gabel BR, 1998, BIOCHEMISTRY-US, V37, P7892, DOI 10.1021/bi973186w; Gahmberg CG, 1997, CURR OPIN CELL BIOL, V9, P643, DOI 10.1016/S0955-0674(97)80117-2; GERRITY RG, 1981, AM J PATHOL, V103, P181; Glader CA, 2002, J INTERN MED, V252, P27, DOI 10.1046/j.1365-2796.2002.00997.x; HARPEL PC, 1992, P NATL ACAD SCI USA, V89, P10193, DOI 10.1073/pnas.89.21.10193; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Ingalls RR, 1997, J IMMUNOL, V159, P433; Kang C, 2002, ARTERIOSCL THROM VAS, V22, P1232, DOI 10.1161/01.ATV.0000021144.87870.C8; KEIPER T, 2006, IN PRESS FASEB J; Kim CH, 2004, J LEUKOCYTE BIOL, V75, P286, DOI 10.1189/jlb.0103038; Koschinsky ML, 2004, CURR OPIN LIPIDOL, V15, P167, DOI 10.1097/00041433-200404000-00009; Kronenberg F, 1999, CIRCULATION, V100, P1154, DOI 10.1161/01.CIR.100.11.1154; LACKNER C, 1993, HUM MOL GENET, V2, P933, DOI 10.1093/hmg/2.7.933; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; LI R, 1993, J BIOL CHEM, V268, P17513; LIBBY P, 1991, LAB INVEST, V64, P5; Lishko VK, 2004, BLOOD, V104, P719, DOI 10.1182/blood-2003-09-3016; MAHER VMG, 1995, JAMA-J AM MED ASSOC, V274, P1771, DOI 10.1001/jama.274.22.1771; Marcovina Santica M, 2002, Semin Vasc Med, V2, P335, DOI 10.1055/s-2002-35404; Marcovina SM, 1996, CLIN CHEM, V42, P436; Marcovina SM, 2003, CURR OPIN LIPIDOL, V14, P361, DOI 10.1097/00041433-200308000-00004; Moulton KS, 2003, P NATL ACAD SCI USA, V100, P4736, DOI 10.1073/pnas.0730843100; NAGEH MF, 1997, ARTERIOSCLER THROMB, V80, P810; OBRIEN KD, 1993, J CLIN INVEST, V92, P945, DOI 10.1172/JCI116670; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Pluskota E, 2004, J BIOL CHEM, V279, P18063, DOI 10.1074/jbc.M310462200; Rand ML, 1998, ARTERIOSCL THROM VAS, V18, P1393, DOI 10.1161/01.ATV.18.9.1393; Rezzonico R, 2001, BLOOD, V97, P2932, DOI 10.1182/blood.V97.10.2932; Rosenfeld ME, 2002, ARTERIOSCL THROM VAS, V22, P361, DOI 10.1161/hq0302.104847; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Santoso S, 2002, J EXP MED, V196, P679, DOI 10.1084/jem.20020267; Schmal H, 1998, J IMMUNOL, V161, P3685; Shi C, 2001, CIRC RES, V89, P859, DOI 10.1161/hh2201.099166; Spijkers PPEM, 2005, BLOOD, V105, P170, DOI 10.1182/blood-2004-02-0498; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512; von Depka M, 2000, BLOOD, V96, P3364; Weisel JW, 2001, BIOCHEMISTRY-US, V40, P10424, DOI 10.1021/bi010556e	58	85	105	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					559	+		10.1096/fj.05-4857fje	http://dx.doi.org/10.1096/fj.05-4857fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16403785				2022-12-28	WOS:000235996000026
J	Warner, TD; Vojnovic, I; Bishop-Bailey, D; Mitchell, JA				Warner, TD; Vojnovic, I; Bishop-Bailey, D; Mitchell, JA			Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and-2	FASEB JOURNAL			English	Article						coxibs; nonsteroid anti-inflammatory drugs; prostaglandins	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTAGLANDIN H-2 SYNTHASE; CYCLO-OXYGENASE-2; SELECTIVITY; MECHANISM; THERAPY; FLUID; SITE	It is widely believed that the potencies of nonsteroid anti-inflammatory drugs ( NSAIDs) as inhibitors of cyclooxygenase ( COX) are influenced by protein binding in the extracellular fluid, since NSAIDs are bound to circulating albumin by well over 95%. This is an important point because the protein concentrations in synovial fluid and the central nervous system, which are sites of NSAID action, are markedly different from those in plasma. Here we have used a modified whole-blood assay to compare the potencies of aspirin, celecoxib, diclofenac, indomethacin, lumiracoxib, meloxicam, naproxen, rofecoxib, sodium salicylate, and SC560 as inhibitors of COX-1 and COX-2 in the presence of differing concentrations of protein. The potencies of diclofenac, naproxen, rofecoxib, and salicylate, but not aspirin, celecoxib, indomethacin, lumiracoxib, meloxicam, or SC560, against COX-1 ( human platelets) increased as protein concentrations were reduced. Varying protein concentrations did not affect the potencies of any of the drugs against COX-2, with the exception of sodium salicylate (A549 cells). Clearly, our findings show that the selectivity of inhibitors for COX-1 and COX-2, which are taken to be linked to their efficacy and side effects, may change in different extracellular fluid conditions. In particular, selectivity in one body compartment does not demonstrate selectivity in another. Thus, whole-body safety or toxicity cannot be linked to one definitive measure of COX selectivity.	Univ London, Queen Marys Sch Med & Dent, Barts & London, William Harvey Res Inst, London EC1M 6BQ, England; Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Dept Cardiothorac Pharmacol, Unit Crit Care Med, London SW3 6LY, England	University of London; Queen Mary University London; Imperial College London; Royal Brompton Hospital	Warner, TD (corresponding author), Univ London, Queen Marys Sch Med & Dent, Barts & London, William Harvey Res Inst, Charterhouse Sq, London EC1M 6BQ, England.	t.d.warner@qmul.ac.uk	Mitchell, Jane A/A-1991-2009; Warner, Timothy D/A-1980-2009	Warner, Timothy D/0000-0003-3988-4408; Bishop-Bailey, David/0000-0003-2455-596X				FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; Gierse JK, 1999, BIOCHEM J, V339, P607, DOI 10.1042/0264-6021:3390607; Lanzo CA, 2000, BIOCHEMISTRY-US, V39, P6228, DOI 10.1021/bi992761o; LOLL PJ, 1995, NAT STRUCT BIOL, V2, P637, DOI 10.1038/nsb0895-637; Mitchell JA, 1997, MOL PHARMACOL, V51, P907, DOI 10.1124/mol.51.6.907; Mitchell JA, 1999, BRIT J PHARMACOL, V128, P1121, DOI 10.1038/sj.bjp.0702897; MITCHELL JA, 1994, BRIT J PHARMACOL, V113, P1008, DOI 10.1111/j.1476-5381.1994.tb17093.x; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Pouplana R, 2002, J COMPUT AID MOL DES, V16, P683, DOI 10.1023/A:1022488507391; ROTH GJ, 1983, BIOCHEMISTRY-US, V22, P4672, DOI 10.1021/bi00289a010; Rowlinson SW, 2003, J BIOL CHEM, V278, P45763, DOI 10.1074/jbc.M305481200; Selinsky BS, 2001, BIOCHEMISTRY-US, V40, P5172, DOI 10.1021/bi010045s; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Soliva R, 2003, J MED CHEM, V46, P1372, DOI 10.1021/jm0209376; Swan A, 2002, ANN RHEUM DIS, V61, P493, DOI 10.1136/ard.61.6.493; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Warner TD, 2004, FASEB J, V18, P790, DOI 10.1096/fj.03-0645rev; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Williams KM, 2001, J BIOCHEM BIOPH METH, V47, P197, DOI 10.1016/S0165-022X(00)00135-4	19	35	36	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					542	+		10.1096/fj.05-4434fje	http://dx.doi.org/10.1096/fj.05-4434fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16403783				2022-12-28	WOS:000235996000025
J	Chiarugi, A				Chiarugi, A			Simple but not simpler": toward a unified picture of energy requirements in cell death	FASEB JOURNAL			English	Review						necrosis; ATP; apoptosis	MITOCHONDRIAL PERMEABILITY TRANSITION; POLY(ADP-RIBOSE) POLYMERASE; CHROMATIN CONDENSATION; CYTOCHROME-C; SIGNAL-TRANSDUCTION; NEURONAL DEATH; ENDONUCLEASE-G; DNA-DAMAGE; APOPTOSIS; NECROSIS	In 1996, Wang and his group empirically disclosed a key role of (deoxy)-ATP in functioning of the apoptotic machinery. After almost a decade, and despite the emerged intricacy of the death pathways, ATP is still considered a key determinant of apoptosis with no apparent active roles in necrosis. Yet recent findings indicate that apoptosis proceeds even without energy and that necrosis can be regulated by ATP-dependent processes. This review strictly focuses on current knowledge on the role of energy in execution of different death programs. A thorough understanding of energy requirements in cell death can help to overcome obsolete dogmas in cell biology, paving the way to a more integrated, albeit not simpler, view of the molecular mechanisms contributing to cell dismantling.	Univ Florence, Dept Pharmacol, I-50139 Florence, Italy	University of Florence	Chiarugi, A (corresponding author), Univ Florence, Dept Pharmacol, Viale Pieraccini 6, I-50139 Florence, Italy.	alberto.chiarugi@unifi.it						Abraham MC, 2004, TRENDS CELL BIOL, V14, P184, DOI 10.1016/j.tcb.2004.03.002; Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; Barkla DH, 1999, PATHOLOGY, V31, P230, DOI 10.1080/003130299105043; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Cecconi F, 1999, CELL DEATH DIFFER, V6, P1087, DOI 10.1038/sj.cdd.4400602; Chautan M, 1999, CURR BIOL, V9, P967, DOI 10.1016/S0960-9822(99)80425-4; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chiarugi A, 2002, TRENDS PHARMACOL SCI, V23, P122, DOI 10.1016/S0165-6147(00)01902-7; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; Cipriani G, 2005, J BIOL CHEM, V280, P17227, DOI 10.1074/jbc.M414526200; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; Cuervo AM, 2004, MOL CELL BIOCHEM, V263, P55, DOI 10.1023/B:MCBI.0000041848.57020.57; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Eguchi Y, 1997, CANCER RES, V57, P1835; Eguchi Y, 1999, CANCER RES, V59, P2174; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Formigli L, 2000, J CELL PHYSIOL, V182, P41, DOI 10.1002/(SICI)1097-4652(200001)182:1<41::AID-JCP5>3.0.CO;2-7; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Holland GN, 2000, OCUL IMMUNOL INFLAMM, V8, P1, DOI 10.1076/0927-3948(200003)8:1;1-S;FT001; Hong SJ, 2004, TRENDS PHARMACOL SCI, V25, P259, DOI 10.1016/j.tips.2004.03.005; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Irvine RA, 2005, MOL CELL BIOL, V25, P294, DOI 10.1128/MCB.25.1.294-302.2005; JACOBSON MD, 1994, BIOCHEM SOC T, V22, P600, DOI 10.1042/bst0220600; James C, 1997, CURR BIOL, V7, P246, DOI 10.1016/S0960-9822(06)00120-5; Kanduc D, 2002, INT J ONCOL, V21, P165; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; Kass GEN, 1996, BIOCHEM J, V318, P749, DOI 10.1042/bj3180749; KATONA K, 2005, IN PRESS CANC LETT; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kerr JFR, 2002, TOXICOLOGY, V181, P471, DOI 10.1016/S0300-483X(02)00457-2; Kyriakis JM, 2001, NATURE, V414, P265, DOI 10.1038/35104735; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Leist M, 1999, EXP CELL RES, V249, P396, DOI 10.1006/excr.1999.4514; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lockshin RA, 2004, INT J BIOCHEM CELL B, V36, P2405, DOI 10.1016/j.biocel.2004.04.011; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; MAJNO G, 1995, AM J PATHOL, V146, P3; Moroni F, 2001, CELL DEATH DIFFER, V8, P921, DOI 10.1038/sj.cdd.4400884; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Nicotera P, 1998, TOXICOL LETT, V103, P139; Nicotera P, 2004, ONCOGENE, V23, P2757, DOI 10.1038/sj.onc.1207559; Nicotera P, 1999, BIOCHEM SOC SYMP, V66, P69, DOI 10.1042/bss0660069; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; Riedl SJ, 2005, NATURE, V434, P926, DOI 10.1038/nature03465; Saelens X, 2005, J CELL BIOL, V168, P545, DOI 10.1083/jcb.200407162; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; Scovassi AI, 2004, BIOCHEM PHARMACOL, V68, P1041, DOI 10.1016/j.bcp.2004.04.023; Scovassi AI, 1999, MOL CELL BIOCHEM, V199, P125; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shah A, 1999, AGING MENT HEALTH, V3, P153, DOI 10.1080/13607869956316; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Shimizu S, 1996, CANCER RES, V56, P2161; Shimizu S, 1996, ONCOGENE, V12, P2045; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SKOOG L, 1974, J BIOL CHEM, V249, P6434; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tsujimoto Y, 1997, CELL DEATH DIFFER, V4, P429, DOI 10.1038/sj.cdd.4400262; Van Cruchten S, 2002, ANAT HISTOL EMBRYOL, V31, P214, DOI 10.1046/j.1439-0264.2002.00398.x; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Wang BL, 2004, CHINESE J ORG CHEM, V24, P973; Yasuhara N, 1997, GENES CELLS, V2, P55, DOI 10.1046/j.1365-2443.1997.1010302.x; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	79	45	54	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					1783	1788		10.1096/fj.05-4200rev	http://dx.doi.org/10.1096/fj.05-4200rev			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16260648				2022-12-28	WOS:000234053100030
J	Ethier, MF; Madison, JM				Ethier, MF; Madison, JM			IL-4 inhibits calcium transients in bovine trachealis cells by a ryanodine receptor dependent mechanism	FASEB JOURNAL			English	Article						interleukin (IL)-13; airway smooth muscle; ionomycin; caffeine; carbachol; cyclic ADP-ribose	AIRWAY SMOOTH-MUSCLE; CYCLIC-ADP-RIBOSE; CYCLOPIAZONIC ACID; EOTAXIN RELEASE; CYTOSOLIC CA2+; INTERLEUKIN-4; CHANNEL; MODULATION; EXPRESSION; CYTOKINES	IL-4 and IL-13 have important roles in the pathogenesis of asthma. A novel finding was that brief exposure of airway smooth muscle cells to IL-4 inhibited carbachol-stimulated calcium transients. We hypothesized that IL-4 inhibits transients by decreasing calcium store content and tested this by measuring the effects of IL-4 on transients induced by a nonspecific ionophore. Bovine trachealis cells were loaded with fura 2-AM, and cytosolic calcium concentrations ([Ca2+]i) were measured in single cells by digital microscopy. Stimulation (S1) with carbachol (10 mu M) caused rapid, transient increases in [Ca2+](i) to 1299 +/- 355 nM (n= 5). After recovery of calcium stores, stimulation (S2) of the same cells with ionomycin (10 mu M), in the absence of extracellular calcium, also increased [Ca2+](i) to give S2/S1 ratio of 1.03 +/- 0.29. However, after 20 min of IL-4 (50 ng/ml), but not IL-13, ionomycin transients were decreased to 0.50 +/- 0.16 (S2/S1, P=0.02, n= 6). IL-4 did not inhibit transients with ryanodine receptor calcium release channels (RyR) blocked by ryanodine (200 mu M) (S2/S1= 1.01 +/- 0.11) but still did in the presence of 8-bromo cyclic ADP-ribose, an antagonist of cyclic ADP-ribose (cADPR) signaling at RyR (S2/S1= 0.48 +/- 0.13). Together, findings suggest that IL-4 decreases intracellular calcium stores by mechanisms dependent on RyR, but not on cADPR signaling.	Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Madison, JM (corresponding author), Univ Massachusetts, Sch Med, Dept Med, LRB 319,364 Plantat St, Worcester, MA 01605 USA.	Mark.Madison@umassmed.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054143] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL054143, R01 HL054143-10, R01 HL054143-06, HL-54143, R01 HL054143-07A1, R01 HL054143-09] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abramov AY, 2003, CELL CALCIUM, V33, P101, DOI 10.1016/S0143-4160(02)00203-8; BIZZARRI C, 1994, J BIOL CHEM, V269, P13817; Deshpande DA, 2005, AM J PHYSIOL-LUNG C, V288, pL773, DOI 10.1152/ajplung.00217.2004; Deshpande DA, 2003, FASEB J, V17, P452, DOI 10.1096/fj.02-0450fje; Ethier MF, 2005, J PHARMACOL EXP THER, V313, P127, DOI 10.1124/jpet.104.079343; Ethier MF, 2001, AM J PHYSIOL-LUNG C, V281, pL126, DOI 10.1152/ajplung.2001.281.1.L126; Faffe DS, 2005, J ALLERGY CLIN IMMUN, V115, P514, DOI 10.1016/j.jaci.2004.11.033; Faffe DS, 2003, AM J PHYSIOL-LUNG C, V285, pL907, DOI 10.1152/ajplung.00120.2003; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hawker KM, 1998, AM J PHYSIOL-LUNG C, V275, pL469, DOI 10.1152/ajplung.1998.275.3.L469; Hirst SJ, 2002, AM J RESP CRIT CARE, V165, P1161, DOI 10.1164/ajrccm.165.8.2107158; JANSSEN LJ, 1993, AM J PHYSIOL, V265, pC877, DOI 10.1152/ajpcell.1993.265.4.C877; Jiang H, 2000, J ALLERGY CLIN IMMUN, V105, P1063, DOI 10.1067/mai.2000.107604; John M, 1998, AM J RESP CELL MOL, V18, P84, DOI 10.1165/ajrcmb.18.1.2813; John M, 1997, J IMMUNOL, V158, P1841; KAJITA J, 1993, AM J PHYSIOL, V264, pL496, DOI 10.1152/ajplung.1993.264.5.L496; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laporte JC, 2001, AM J RESP CRIT CARE, V164, P141, DOI 10.1164/ajrccm.164.1.2008060; Laporte R, 2004, PHARMACOL REV, V56, P439, DOI 10.1124/pr.56.4.1; Liu M, 2003, J BIOL CHEM, V278, P5462, DOI 10.1074/jbc.M209111200; Liu XB, 1996, J PHARMACOL EXP THER, V277, P789; Madison JM, 2001, AM J RESP CELL MOL, V25, P239, DOI 10.1165/ajrcmb.25.2.4286; Madison JM, 1998, AM J PHYSIOL-LUNG C, V275, pL852, DOI 10.1152/ajplung.1998.275.5.L852; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Mitchell RW, 2000, AM J PHYSIOL-LUNG C, V278, pL1091, DOI 10.1152/ajplung.2000.278.5.L1091; Moore PE, 2002, AM J PHYSIOL-LUNG C, V282, pL847, DOI 10.1152/ajplung.00245.2001; MORGAN AJ, 1994, BIOCHEM J, V300, P665, DOI 10.1042/bj3000665; OCONNELL RJ, 2005, P AM THORACIC SOC, V2, pA238; Prakash YS, 1998, AM J PHYSIOL-CELL PH, V274, pC1653, DOI 10.1152/ajpcell.1998.274.6.C1653; Pype JL, 1999, AM J RESP CELL MOL, V21, P528, DOI 10.1165/ajrcmb.21.4.3660; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; Sethi JK, 1997, J BIOL CHEM, V272, P16358, DOI 10.1074/jbc.272.26.16358; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; White RA, 2003, FASEB J, V17, P482, DOI 10.1096/fj.02-0622fje; YAMAKURA T, 1995, LONG TERM ECOLOGICAL, V2, P2; ZIMANYI I, 1992, MOL PHARMACOL, V42, P1049	39	7	7	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					154	+		10.1096/fj.05-4031fje	http://dx.doi.org/10.1096/fj.05-4031fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16280365	Green Accepted			2022-12-28	WOS:000234053100014
J	Schreiner, B; Voss, J; Wischhusen, JR; Dombrowski, Y; Steinle, A; Lochmuller, H; Dalakas, M; Melms, A; Wiendl, H				Schreiner, B; Voss, J; Wischhusen, JR; Dombrowski, Y; Steinle, A; Lochmuller, H; Dalakas, M; Melms, A; Wiendl, H			Expression of toll-like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates IL-8 release, and up-regulation of NKG2D-ligands	FASEB JOURNAL			English	Article						immunobiology of muscle; TLR; myositis; myoblasts	DOUBLE-STRANDED-RNA; INCLUSION-BODY MYOSITIS; NF-KAPPA-B; MATRIX METALLOPROTEINASES; DIFFERENTIAL EXPRESSION; MONOCLONAL-ANTIBODY; CYTOKINE EXPRESSION; ADHESION MOLECULES; DUCHENNE DYSTROPHY; ENDOTHELIAL-CELLS	The particular microenvironment of the skeletal muscle can be the site of complex immune reactions. Toll-like receptors (TLRs) mediate inflammatory stimuli from pathogens and endogenous danger signals and link the innate and adaptive immune system. We investigated innate immune responses in human muscle. Analyzing TLR1-9 mRNA in cultured myoblasts and rhabdomyosarcoma cells, we found constitutive expression of TLR3. The TLR3 ligand Poly (I:C), a synthetic analog of dsRNA, and IFN-gamma increased TLR3 levels. TLR3 was mainly localized intracellularly and regulated at the protein level. Poly (I:C) challenge 1) activated nuclear factor-kappa B (NF-kappa B), 2) increased IL-8 release, and 3) up-regulated NKG2D ligands and NK-cell-mediated lysis of muscle cells. We examined muscle biopsy specimens of 6 HIV patients with inclusion body myositis/polymyositis (IBM/ PM), 7 cases of sporadic IBM and 9 nonmyopathic controls for TLR3 expression. TLR3 mRNA levels were elevated in biopsy specimens from patients with IBM and HIV-myopathies. Muscle fibers in inflammatory myopathies expressed TLR3 in close proximity of infiltrating mononuclear cells. Taken together, our study suggests an important role of TLR3 in the immunobiology of muscle, and has substantial implications for the understanding of the pathogenesis of inflammatory myopathies or therapeutic interventions like vaccinations or gene transfer.	Univ Tubingen, Dept Gen Neurol, Hertie Inst Clin Brain Res, Tubingen, Germany; NINDS, NIH, Bethesda, MD 20892 USA; Univ Tubingen, Dept Immunol, Inst Cell Biol, Tubingen, Germany; Univ Munich, Genzentrum, Friedrich Baur Inst, Munich, Germany; Univ Munich, Dept Neurol, Munich, Germany; Univ Wurzburg, Dept Neurol & Gynecol, Wurzburg, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Eberhard Karls University of Tubingen; University of Munich; University of Munich; University of Wurzburg	Wiendl, H (corresponding author), Julius Maximilians Univ Wurzburg, Clin Res Grp Multiple Sclerosis & Neuroimmunol, Dept Neurol, Josef Schneider Str 11, D-97080 Wurzburg, Germany.	heinz.wiendl@klinik.uni-wuerzburg.de	Dombrowski, Yvonne/N-7020-2019; Voss, Joachim/AAA-1277-2020; Steinle, Alexander/E-6131-2012; Wiendl, Heinz/AAX-6041-2021	Dombrowski, Yvonne/0000-0003-1732-6288; Steinle, Alexander/0000-0001-5081-8503; Wiendl, Heinz/0000-0003-4310-3432; Lochmuller, Hanns/0000-0003-2324-8001; Voss, Joachim/0000-0002-8072-6244	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [K22NR008672] Funding Source: NIH RePORTER; NINR NIH HHS [K22 NR008672] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; ARAHATA K, 1984, ANN NEUROL, V16, P193, DOI 10.1002/ana.410160206; Baggiolini M, 2000, IMMUNOL TODAY, V21, P418, DOI 10.1016/S0167-5699(00)01672-8; Banwell BL, 2000, NEUROLOGY, V54, P1033, DOI 10.1212/WNL.54.5.1033; Campbell JJ, 2000, CURR OPIN IMMUNOL, V12, P336, DOI 10.1016/S0952-7915(00)00096-0; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Choi YC, 2000, NEUROLOGY, V54, P65, DOI 10.1212/WNL.54.1.65; Cosman D, 2001, IMMUNITY, V14, P123, DOI 10.1016/S1074-7613(01)00095-4; Dalakas Marinos C., 2001, Current Opinion in Pharmacology, V1, P300, DOI 10.1016/S1471-4892(01)00053-4; Dalakas MC, 1998, ARCH NEUROL-CHICAGO, V55, P1509, DOI 10.1001/archneur.55.12.1509; Dalakas MC, 2003, LANCET, V362, P971, DOI 10.1016/S0140-6736(03)14368-1; DALAKAS MC, 1991, NEW ENGL J MED, V325, P1487, DOI 10.1056/NEJM199111213252107; De Bleecker JL, 2002, NEUROLOGY, V58, P1779, DOI 10.1212/WNL.58.12.1779; De Paepe B, 2004, NEUROMUSCULAR DISORD, V14, P265, DOI 10.1016/j.nmd.2004.01.001; DEBLEECKER JL, 1994, J NEUROPATH EXP NEUR, V53, P369, DOI 10.1097/00005072-199407000-00008; Dunn C, 2003, J EXP MED, V197, P1427, DOI 10.1084/jem.20022059; Farina C, 2005, J NEUROIMMUNOL, V159, P12, DOI 10.1016/j.jneuroim.2004.09.009; Friese MA, 2003, CANCER RES, V63, P8996; Funami K, 2004, INT IMMUNOL, V16, P1143, DOI 10.1093/intimm/dxh115; GOEBELS N, 1992, J IMMUNOL, V149, P661; Groh V, 2001, NAT IMMUNOL, V2, P255, DOI 10.1038/85321; HOHLFELD R, 1994, IMMUNOL TODAY, V15, P269, DOI 10.1016/0167-5699(94)90006-X; Hohlfeld Reinhard, 1997, Current Opinion in Rheumatology, V9, P520, DOI 10.1097/00002281-199711000-00007; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kaiser WJ, 2004, J IMMUNOL, V172, P1699, DOI 10.4049/jimmunol.172.3.1699; Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200; Kieseier BC, 2001, BRAIN, V124, P341, DOI 10.1093/brain/124.2.341; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lundberg I, 1995, J NEUROIMMUNOL, V63, P9, DOI 10.1016/0165-5728(95)00122-0; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Maaser C, 2004, J IMMUNOL, V172, P5056, DOI 10.4049/jimmunol.172.8.5056; Matsumoto M, 2002, BIOCHEM BIOPH RES CO, V293, P1364, DOI 10.1016/S0006-291X(02)00380-7; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; Matsumoto M, 2004, MICROBIOL IMMUNOL, V48, P147, DOI 10.1111/j.1348-0421.2004.tb03500.x; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Muzio M, 2000, J IMMUNOL, V164, P5998, DOI 10.4049/jimmunol.164.11.5998; Raju R, 2003, J NEUROIMMUNOL, V141, P125, DOI 10.1016/S0165-5728(03)00218-2; Raulet DH, 2003, NAT REV IMMUNOL, V3, P781, DOI 10.1038/nri1199; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Sabroe I, 2003, J IMMUNOL, V171, P1630, DOI 10.4049/jimmunol.171.4.1630; Schaefer TM, 2005, J IMMUNOL, V174, P992, DOI 10.4049/jimmunol.174.2.992; Schmidt KN, 2004, J IMMUNOL, V172, P138, DOI 10.4049/jimmunol.172.1.138; Sheehy ME, 2001, J IMMUNOL METHODS, V249, P99, DOI 10.1016/S0022-1759(00)00329-X; Steinle A, 2001, IMMUNOGENETICS, V53, P279, DOI 10.1007/s002510100325; Sugiura T, 2000, J IMMUNOL, V164, P6593, DOI 10.4049/jimmunol.164.12.6593; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tews DS, 1996, J NEUROPATH EXP NEUR, V55, P342, DOI 10.1097/00005072-199603000-00009; TEWS DS, 1995, J NEUROIMMUNOL, V59, P185, DOI 10.1016/0165-5728(95)00045-4; VALIANTE NM, 1992, CELL IMMUNOL, V145, P187, DOI 10.1016/0008-8749(92)90322-G; Welte SA, 2003, EUR J IMMUNOL, V33, P194, DOI 10.1002/immu.200390022; Wiendl H, 2000, ANN NEUROL, V48, P679, DOI 10.1002/1531-8249(200010)48:4<679::AID-ANA19>3.3.CO;2-M; Wiendl H, 2003, HUM IMMUNOL, V64, P1050, DOI 10.1016/j.humimm.2003.07.001; Wiendl H, 2003, FASEB J, V17, P1892, DOI 10.1096/fj.03-0039fje; Wiendl H, 2003, BRAIN, V126, P1026, DOI 10.1093/brain/awg114	57	70	76	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					118	+		10.1096/fj.05-4342fje	http://dx.doi.org/10.1096/fj.05-4342fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16293707				2022-12-28	WOS:000234053100009
J	Maul, B; Krause, W; Pankow, K; Becker, M; Gembardt, F; Alenina, N; Walther, T; Bader, M; Siems, WE				Maul, B; Krause, W; Pankow, K; Becker, M; Gembardt, F; Alenina, N; Walther, T; Bader, M; Siems, WE			Central angiotensin II controls alcohol consumption via its AT1 receptor	FASEB JOURNAL			English	Article						angiotensin; dopamine; alcohol; knockout mice; transgenic rats	BLOOD-PRESSURE; TRANSGENIC RATS; C57/BL10 MICE; BRAIN; GENE; PREFERENCE; ADDICTION; DOPAMINE; INJECTIONS; INHIBITORS	Pharmacological and genetic manipulations of the renin-angiotensin system (RAS) have been found to alter the voluntary consumption of alcohol. Here we characterize the role of central angiotensin II (Ang II) in alcohol intake first by using transgenic rats that express an antisense RNA against angiotensinogen and consequently have reduced Ang II levels exclusively in the central nervous system [TGR(ASrAOGEN)680]. These rats consumed markedly less alcohol in comparison to their wild-type controls. Second, Spirapril, an inhibitor of the angiotensin-converting enzyme ( ACE), which passes the blood-brain barrier, did not influence the alcohol consumption in the TGR(ASrAOGEN) 680, but it significantly reduced alcohol intake in wild-type rats. Studies in knockout mice indicated that the central effect of Ang II on alcohol consumption is mediated by the angiotensin receptor AT1 whereas the AT2 receptor and the bradykinin B2 receptor are not involved. Furthermore, the dopamine concentration in the ventral tegmental area (VTA) is markedly reduced in rats with low central Ang II, strengthening our hypothesis of a role of dopaminergic transmission in Ang II-controlled alcohol preference. Our results indicate that a distinct drug-mediated control of the central RAS could be a promising therapy for alcohol disease.	Inst Mol Pharmacol, Berlin, Germany; Erasmus MC, Dept Pharmacol, Rotterdam, Netherlands; Charite, Dept Cardiol, Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany	Erasmus University Rotterdam; Erasmus MC; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Siems, WE (corresponding author), FMP, Robert Rossle Str 10, D-13125 Berlin, Germany.	siems@fmp-berlin.de	Gembardt, Florian/H-2360-2011; Bader, Michael/K-2124-2013	Gembardt, Florian/0000-0003-2739-345X; Becker, Matthias/0000-0001-9965-6648; Bader, Michael/0000-0003-4780-4164				Baltatu O, 2004, ACTA PHYSIOL SCAND, V181, P579, DOI 10.1111/j.1365-201X.2004.01333.x; Baltatu O, 2000, HYPERTENSION, V35, P409, DOI 10.1161/01.HYP.35.1.409; BORKOWSKI JA, 1995, J BIOL CHEM, V270, P13706, DOI 10.1074/jbc.270.23.13706; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Crabbe JC, 1996, NAT GENET, V14, P98, DOI 10.1038/ng0996-98; FITTS DA, 1993, PHARMACOL BIOCHEM BE, V45, P35, DOI 10.1016/0091-3057(93)90082-5; GRUPP LA, 1988, PHARMACOL BIOCHEM BE, V29, P479, DOI 10.1016/0091-3057(88)90007-X; GRUPP LA, 1993, NIAAA RES MONOGRAPH, V23, P37; Herz A, 1997, PSYCHOPHARMACOLOGY, V129, P99, DOI 10.1007/s002130050169; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; ITO M, 1995, P NATL ACAD SCI USA, V92, P3521, DOI 10.1073/pnas.92.8.3521; Jenkins TA, 1996, ADV EXP MED BIOL, V396, P93; Kakinuma Y, 1997, NEUROSCI LETT, V232, P167, DOI 10.1016/S0304-3940(97)00605-8; KIMURA S, 1992, EMBO J, V11, P821, DOI 10.1002/j.1460-2075.1992.tb05119.x; Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0; Little HJ, 1999, PSYCHOPHARMACOLOGY, V147, P182, DOI 10.1007/s002130051159; Maul J, 2001, FASEB J, V15, P1640, DOI 10.1096/fj.00-097fje; MENDELSOHN FAO, 1993, BRAIN RES, V613, P221; Monti J, 2001, AM J PHYSIOL-REG I, V280, pR233, DOI 10.1152/ajpregu.2001.280.1.R233; O'Callaghan MJ, 2002, PSYCHOPHARMACOLOGY, V160, P206, DOI 10.1007/s00213-001-0968-z; O'Callaghan MJ, 2002, PHARMACOL BIOCHEM BE, V72, P475, DOI 10.1016/S0091-3057(02)00717-7; Ogier M, 2003, HYPERTENSION, V42, P978, DOI 10.1161/01.HYP.0000094982.97568.65; Phillips TJ, 1998, NAT NEUROSCI, V1, P610, DOI 10.1038/2843; POPOV N, 1973, ACTA BIOL MED GER, V31, P51; Roberts AJ, 2000, J PHARMACOL EXP THER, V293, P1002; ROBERTSON JM, 1993, PHARMACOL BIOCHEM BE, V46, P751, DOI 10.1016/0091-3057(93)90197-2; Schinke M, 1999, P NATL ACAD SCI USA, V96, P3975, DOI 10.1073/pnas.96.7.3975; Spanagel R, 2003, BEST PRACT RES CL GA, V17, P507, DOI 10.1016/S1521-6918(03)00031-3; Spanagel R, 1999, TRENDS NEUROSCI, V22, P521, DOI 10.1016/S0166-2236(99)01447-2; SYBERTZ E J, 1987, Journal of Cardiovascular Pharmacology, V10, pS105; Takai S, 1996, LIFE SCI, V59, pPL331, DOI 10.1016/0024-3205(96)00527-9; Thorsell A, 2002, NEUROPEPTIDES, V36, P182, DOI 10.1054/npep.2002.0897; Tom B, 2002, BRIT J PHARMACOL, V137, P276, DOI 10.1038/sj.bjp.0704862; Tracy HA, 1997, ALCOHOL, V14, P511, DOI 10.1016/S0741-8329(97)00041-4; Vervoort VS, 2002, SCIENCE, V296, P2401; von Bohlen und Halbach O, 2001, REGUL PEPTIDES, V99, P209, DOI 10.1016/S0167-0115(01)00258-0; Walther T, 1999, BEHAV BRAIN RES, V100, P1, DOI 10.1016/S0166-4328(98)00078-3; Weisinger RS, 1999, PHYSIOL BEHAV, V67, P369, DOI 10.1016/S0031-9384(99)00085-2; Winkler A, 1998, BBA-MOL BASIS DIS, V1406, P219, DOI 10.1016/S0925-4439(97)00041-0; Wyss JM, 2003, CLIN EXP HYPERTENS, V25, P455, DOI 10.1081/CEH-120024988	40	36	37	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1474	1481		10.1096/fj.05-3742com	http://dx.doi.org/10.1096/fj.05-3742com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16126915				2022-12-28	WOS:000232315700041
J	Weksler, BB; Subileau, EA; Perriere, N; Charneau, P; Holloway, K; Leveque, M; Tricoire-Leignel, H; Nicotra, A; Bourdoulous, S; Turowski, P; Male, DK; Roux, F; Greenwood, J; Romero, IA; Couraud, PO				Weksler, BB; Subileau, EA; Perriere, N; Charneau, P; Holloway, K; Leveque, M; Tricoire-Leignel, H; Nicotra, A; Bourdoulous, S; Turowski, P; Male, DK; Roux, F; Greenwood, J; Romero, IA; Couraud, PO			Blood-brain barrier-specific properties of a human adult brain endothelial cell line	FASEB JOURNAL			English	Article						drug permeability; cellular junctions; multidrug resistance; in vitro model	IN-VITRO MODEL; P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; TIGHT JUNCTIONS; T-LYMPHOCYTES; EXPRESSION; TRANSPORT; PROTEIN; PERMEABILITY; MONOLAYERS	Establishment of a human model of the blood-brain barrier has proven to be a difficult goal. To accomplish this, normal human brain endothelial cells were transduced by lentiviral vectors incorporating human telomerase or SV40 T antigen. Among the many stable immortalized clones obtained by sequential limiting dilution cloning of the transduced cells, one was selected for expression of normal endothelial markers, including CD31, VE cadherin, and von Willebrand factor. This cell line, termed hCMEC/D3, showed a stable normal karyotype, maintained contact-inhibited monolayers in tissue culture, exhibited robust proliferation in response to endothelial growth factors, and formed capillary tubes in matrix but no colonies in soft agar. hCMEC/D3 cells expressed telomerase and grew indefinitely without phenotypic dedifferentiation. These cells expressed chemokine receptors, up-regulated adhesion molecules in response to inflammatory cytokines, and demonstrated blood-brain barrier characteristics, including tight junctional proteins and the capacity to actively exclude drugs. hCMEC/D3 are excellent candidates for studies of blood-brain barrier function, the responses of brain endothelium to inflammatory and infectious stimuli, and the interaction of brain endothelium with lymphocytes or tumor cells. Thus, hCMEC/D3 represents the first stable, fully characterized, well-differentiated human brain endothelial cell line and should serve as a widely usable research tool.	Univ Paris 05, INSERM, Inst Cochin, CNRS,UMR 8104, Paris, France; Open Univ, Dept Biol Sci, Milton Keynes, Bucks, England; Hop Fernand Widal, INSERM, Paris, France; UCL, Inst Ophthalmol, Div Cellular Therapy, London, England; Inst Pasteur, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Open University - UK; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of London; University College London; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Weksler, BB (corresponding author), Cornell Univ, Weill Med Coll, New York, NY 10021 USA.	babette@mail.med.cornell.edu; couraud@cochin.inserm.fr	Romero, Ignacio/A-7381-2008; Tricoire-Leignel, Hélène/ABG-2320-2020; CHARNEAU, Pierre/M-1565-2017	Tricoire-Leignel, Hélène/0000-0002-2881-2962; CHARNEAU, Pierre/0000-0003-1184-5773; Male, David/0000-0002-1242-3137; Leveque, Mathilde/0000-0003-1253-3798; Greenwood, John/0000-0003-4496-2984; Holloway, Courtney Jean/0000-0003-3661-1957; Romero, Ignacio/0000-0002-0322-9180	Multiple Sclerosis Society [630, 675] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Multiple Sclerosis Society(National Multiple Sclerosis Society); Wellcome Trust(Wellcome TrustEuropean Commission)		Abbott NJ, 1995, NEW CONCEPTS OF A BLOOD-BRAIN BARRIER, P239; ABBOTT NJ, 1992, J CELL SCI, V103, P23; Allen JD, 2002, MOL CANCER THER, V1, P417; Andjelkovic AV, 2000, J NEUROCHEM, V75, P1898, DOI 10.1046/j.1471-4159.2000.0751898.x; Begley DJ, 2004, CURR PHARM DESIGN, V10, P1295, DOI 10.2174/1381612043384844; Berezowski V, 2004, BRAIN RES, V1018, P1, DOI 10.1016/j.brainres.2004.05.092; Berger O, 1999, MOL MED, V5, P795, DOI 10.1007/BF03401992; Bo L, 1996, J NEUROPATH EXP NEUR, V55, P1060, DOI 10.1097/00005072-199655100-00006; Callahan MK, 2004, J NEUROIMMUNOL, V153, P150, DOI 10.1016/j.jneuroim.2004.05.004; Cecchelli R, 1999, ADV DRUG DELIVER REV, V36, P165, DOI 10.1016/S0169-409X(98)00083-0; Cisternino S, 2004, PHARM RES-DORDR, V21, P1382, DOI 10.1023/B:PHAM.0000036911.49191.da; Cisternino S, 2003, PHARMACEUT RES, V20, P1607, DOI 10.1023/A:1026187301648; DEHOUCK MP, 1992, J NEUROCHEM, V58, P1790, DOI 10.1111/j.1471-4159.1992.tb10055.x; DOROVINIZIS K, 1991, LAB INVEST, V64, P425; Eisenblatter T, 2003, BRAIN RES, V971, P221, DOI 10.1016/S0006-8993(03)02401-6; Etienne-Manneville S, 2000, J IMMUNOL, V165, P3375, DOI 10.4049/jimmunol.165.6.3375; FELLER N, 1995, BRIT J CANCER, V72, P543, DOI 10.1038/bjc.1995.371; Flynn G, 2003, J NEUROIMMUNOL, V136, P84, DOI 10.1016/S0165-5728(03)00009-2; Golden PL, 1999, BRAIN RES, V819, P143, DOI 10.1016/S0006-8993(98)01305-5; Greenwood J, 1996, J NEUROIMMUNOL, V71, P51, DOI 10.1016/S0165-5728(96)00130-0; Gu XL, 2003, INVEST OPHTH VIS SCI, V44, P3219, DOI 10.1167/ivos.02-0852; Gutmann H, 1999, DRUG METAB DISPOS, V27, P937; Hoheisel D, 1998, BIOCHEM BIOPH RES CO, V244, P312, DOI 10.1006/bbrc.1997.8051; JOO F, 1993, NEUROCHEM INT, V23, P499, DOI 10.1016/0197-0186(93)90098-P; Mark KS, 1999, LIFE SCI, V64, P1941, DOI 10.1016/S0024-3205(99)00139-3; Mayer U, 1997, J CLIN INVEST, V100, P2430, DOI 10.1172/JCI119784; MURPHY PR, 1992, MOL ENDOCRINOL, V6, P877, DOI 10.1210/me.6.6.877; Muruganandam A, 1997, FASEB J, V11, P1187, DOI 10.1096/fasebj.11.13.9367354; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; Omari KM, 2003, J NEUROIMMUNOL, V134, P166, DOI 10.1016/S0165-5728(02)00423-X; Perriere N, 2005, J NEUROCHEM, V93, P279, DOI 10.1111/j.1471-4159.2004.03020.x; Prieto P, 2004, ATLA-ALTERN LAB ANIM, V32, P37, DOI 10.1177/026119290403200107; RAINE CS, 1994, ANN NEUROL, V36, pS61, DOI 10.1002/ana.410360716; Regina A, 1998, J NEUROCHEM, V71, P705; Rist RJ, 1997, BRAIN RES, V768, P10, DOI 10.1016/S0006-8993(97)00586-6; Robey RW, 2001, BBA-BIOMEMBRANES, V1512, P171, DOI 10.1016/S0005-2736(01)00308-X; Romero IA, 1997, BRAIN RES, V756, P133, DOI 10.1016/S0006-8993(97)00127-3; Romero IA, 2003, NEUROSCI LETT, V344, P112, DOI 10.1016/S0304-3940(03)00348-3; ROUX F, 1994, J CELL PHYSIOL, V159, P101, DOI 10.1002/jcp.1041590114; RUBIN LL, 1991, J CELL BIOL, V115, P1725, DOI 10.1083/jcb.115.6.1725; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; Schinkel AH, 1999, ADV DRUG DELIVER REV, V36, P179, DOI 10.1016/S0169-409X(98)00085-4; Seetharaman S, 1998, J NEUROCHEM, V70, P1151, DOI 10.1046/j.1471-4159.1998.70031151.x; Stins MF, 1997, J NEUROIMMUNOL, V76, P81, DOI 10.1016/S0165-5728(97)00036-2; VANBREE JBMM, 1988, J PHARMACOL EXP THER, V247, P1233; Wolburg H, 2002, VASC PHARMACOL, V38, P323, DOI 10.1016/S1537-1891(02)00200-8; Wong D, 1999, J NEUROPATH EXP NEUR, V58, P138, DOI 10.1097/00005072-199902000-00004; Yamazaki M, 2001, J PHARMACOL EXP THER, V296, P723; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Zennou V, 2001, NAT BIOTECHNOL, V19, P446, DOI 10.1038/88115; Zhang WD, 2003, FASEB J, V17, P2085, DOI 10.1096/fj.02-1131fje	52	963	1007	5	107	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1872	+		10.1096/fj.04-3458fje	http://dx.doi.org/10.1096/fj.04-3458fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16141364	Bronze			2022-12-28	WOS:000232315700043
J	Tauskela, JS; Brunette, E; O'Reilly, N; Mealing, G; Comas, T; Gendron, TF; Monette, R; Morley, P				Tauskela, JS; Brunette, E; O'Reilly, N; Mealing, G; Comas, T; Gendron, TF; Monette, R; Morley, P			An alternative Ca2+-dependent mechanism of neuroprotection by the metalloporphyrin class of superoxide dismutase mimetics	FASEB JOURNAL			English	Article						NMDA; ischemia; antioxidants; oxygen-glucose deprivation	CYTOCHROME-C RELEASE; PEROXYNITRITE DECOMPOSITION; CATALYTIC ANTIOXIDANTS; MITOCHONDRIAL DYSFUNCTION; OXIDATIVE STRESS; NITRIC-OXIDE; GLUTAMATE EXCITOTOXICITY; MANGANESE PORPHYRINS; HIPPOCAMPAL-NEURONS; IRON PORPHYRINS	This study challenges the conventional view that metalloporphyrins protect cultured cortical neurons in models of cerebral ischemia by acting as intracellular catalytic antioxidants [ superoxide dismutase ( SOD) mimetics]. High SOD- active Mn(III)porphyrins meso- substituted with N, N'- dimethylimidazolium or N- alkylpyridinium groups did not protect neurons against oxygen- glucose deprivation ( OGD), although lower SOD- active and - inactive para isomers protected against N- methyl- D- aspartate ( NMDA) exposure. Mn(III)meso- tetrakis( 4- benzoic acid) porphyrin ( Mn(III)TBAP), as well as SOD- inactive metalloTBAPs and other phenyl ring- or beta- substituted metalloporphyrins that contained redox- insensitive metals, protected cultures against OGD and NMDA neurotoxicity. Crucially, neuroprotective metalloporphyrins suppressed OGD- or NMDA- induced rises in intracellular Ca2+ concentration in the same general rank order as observed for neuroprotection. Results from paraquat toxicity, intracellular fluorescence quenching, electrophysiology, mitochondrial Ca2+, and spontaneous synaptic activity experiments suggest a model in which metalloporphyrins, acting at the plasma membrane, protect neurons against OGD by suppressing postsynaptic NMDA receptor- mediated Ca2+ rises, thereby indirectly preventing accumulation of neurotoxic mitochondrial Ca2+ levels. Though neuroprotective in a manner not originally intended, SOD- inactive metalloporphyrins may represent promising therapeutic agents in diseases such as cerebral ischemia, in which Ca2+ toxicity is implicated. Conventional syntheses aimed at improving the catalytic antioxidant capability and/ or intracellular access of metalloporphyrins may not yield improved efficacy in some disease models.	Natl Res Council Canada, Inst Biol Sci, Synapt Pathophysiol Grp, Ottawa, ON K1A 0R6, Canada	National Research Council Canada	Tauskela, JS (corresponding author), Natl Res Council Canada, Inst Biol Sci, Synapt Pathophysiol Grp, Montreal Rd Campus,Bldg M-54, Ottawa, ON K1A 0R6, Canada.	joe.tauskela@nrc-cnrc.gc.ca						Batainic-Haberle I, 2004, DALTON T, P1696, DOI 10.1039/b400818a; BATINCHABERLE I, 2005, INORG CHEM, V38, P4011; Batinic-Haberle I, 1998, J BIOL CHEM, V273, P24521, DOI 10.1074/jbc.273.38.24521; BatinicHaberle I, 1997, ARCH BIOCHEM BIOPHYS, V343, P225, DOI 10.1006/abbi.1997.0157; Bloodsworth A, 2000, FREE RADICAL BIO MED, V28, P1017, DOI 10.1016/S0891-5849(00)00194-5; Bossy-Wetzel E, 2004, NEURON, V41, P351, DOI 10.1016/S0896-6273(04)00015-7; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; Castilho RF, 1999, J NEUROCHEM, V72, P1394, DOI 10.1046/j.1471-4159.1999.721394.x; Crow JP, 2000, FREE RADICAL BIO MED, V28, P1487, DOI 10.1016/S0891-5849(00)00249-5; Crow JP, 1999, ARCH BIOCHEM BIOPHYS, V371, P41, DOI 10.1006/abbi.1999.1414; Day BJ, 2004, DRUG DISCOV TODAY, V9, P557, DOI 10.1016/S1359-6446(04)03139-3; Day BJ, 1995, J PHARMACOL EXP THER, V275, P1227; Day BJ, 1999, FREE RADICAL BIO MED, V26, P730, DOI 10.1016/S0891-5849(98)00261-5; Day BJ, 1997, ARCH BIOCHEM BIOPHYS, V347, P256, DOI 10.1006/abbi.1997.0341; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; Ferrer-Sueta G, 2003, J BIOL CHEM, V278, P27432, DOI 10.1074/jbc.M213302200; Galindo MF, 2003, BRIT J PHARMACOL, V139, P797, DOI 10.1038/sj.bjp.0705309; Gardner PR, 1996, ARCH BIOCHEM BIOPHYS, V325, P20, DOI 10.1006/abbi.1996.0003; Gauuan PJF, 2002, BIOORGAN MED CHEM, V10, P3013, DOI 10.1016/S0968-0896(02)00153-0; Grima G, 2001, EUR J NEUROSCI, V14, P1762, DOI 10.1046/j.0953-816x.2001.01799.x; Haghighi SS, 1996, NEUROL RES, V18, P509; Halliwell B, 1978, BIOCHEM SOC T, V6, P1342, DOI 10.1042/bst0061342; Hongpaisan J, 2004, J NEUROSCI, V24, P10878, DOI 10.1523/JNEUROSCI.3278-04.2004; Hurtado O, 2003, FASEB J, V17, P2082, DOI 10.1096/fj.02-1086fje; Ikeda J, 1996, J NEUROSCI RES, V43, P613; Jensen MP, 2002, INORG CHEM, V41, P4788, DOI 10.1021/ic011089s; Kachadourian R, 2004, BIOCHEM PHARMACOL, V67, P77, DOI 10.1016/j.bcp.2003.08.036; Kachadourian R, 2003, J INORG BIOCHEM, V95, P240, DOI 10.1016/S0162-0134(03)00135-1; Khodorov B, 2004, PROG BIOPHYS MOL BIO, V86, P279, DOI 10.1016/j.pbiomolbio.2003.10.002; Klann E, 1998, J NEUROPHYSIOL, V80, P452, DOI 10.1152/jn.1998.80.1.452; Konorev EA, 2002, FREE RADICAL BIO MED, V33, P988, DOI 10.1016/S0891-5849(02)00989-9; Li QY, 2001, J NEUROCHEM, V78, P746, DOI 10.1046/j.1471-4159.2001.00457.x; LIU DX, 1995, FREE RADICAL BIO MED, V18, P861, DOI 10.1016/0891-5849(94)00214-5; Luetjens CM, 2000, J NEUROSCI, V20, P5715; Mackensen GB, 2001, J NEUROSCI, V21, P4582, DOI 10.1523/JNEUROSCI.21-13-04582.2001; Mealing GAR, 2001, J PHARMACOL EXP THER, V297, P906; MURPHY TH, 1992, J NEUROSCI, V12, P4834; Muscoli C, 2003, BRIT J PHARMACOL, V140, P445, DOI 10.1038/sj.bjp.0705430; OGURA A, 1987, NEUROSCI LETT, V78, P69, DOI 10.1016/0304-3940(87)90563-5; Okado-Matsumoto A, 2004, FREE RADICAL BIO MED, V37, P401, DOI 10.1016/j.freeradbiomed.2004.04.040; Osakada F, 2004, J PHARMACOL EXP THER, V311, P51, DOI 10.1124/jpet.104.070334; PASTERNACK RF, 1981, J INORG BIOCHEM, V15, P261, DOI 10.1016/S0162-0134(00)80161-0; Patel M, 1996, NEURON, V16, P345, DOI 10.1016/S0896-6273(00)80052-5; Patel M, 1999, TRENDS PHARMACOL SCI, V20, P359, DOI 10.1016/S0165-6147(99)01336-X; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; Pfeiffer S, 1998, MOL PHARMACOL, V53, P795, DOI 10.1124/mol.53.4.795; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; RICCHELLI F, 1995, J PHOTOCH PHOTOBIO B, V29, P109, DOI 10.1016/1011-1344(95)07155-U; Ross AD, 2002, FREE RADICAL BIO MED, V33, P1657, DOI 10.1016/S0891-5849(02)01140-1; Sharma SS, 2004, J NEUROSURG, V101, P669, DOI 10.3171/jns.2004.101.4.0669; Sheng HX, 2002, DRUG NEWS PERSPECT, V15, P654, DOI 10.1358/dnp.2002.15.10.740236; Sheng HX, 2002, FREE RADICAL BIO MED, V33, P947, DOI 10.1016/S0891-5849(02)00979-6; Spasojevic I, 2003, J BIOL CHEM, V278, P6831, DOI 10.1074/jbc.M211346200; STRICKLAND JA, 1988, BIOCHEMISTRY-US, V27, P8870, DOI 10.1021/bi00424a027; Tauskela JS, 2003, AM J PHYSIOL-CELL PH, V285, pC899, DOI 10.1152/ajpcell.00110.2003; Thiyagarajan M, 2004, BRIT J PHARMACOL, V142, P899, DOI 10.1038/sj.bjp.0705811; Trackey JL, 2001, J NEUROCHEM, V79, P445, DOI 10.1046/j.1471-4159.2001.00584.x; Trostchansky A, 2003, FREE RADICAL BIO MED, V35, P1293, DOI 10.1016/j.freeradbiomed.2003.07.004; Trova MP, 2003, BIOORGAN MED CHEM, V11, P2695, DOI 10.1016/S0968-0896(03)00272-4; TSIEN RY, 1981, NATURE, V290, P527, DOI 10.1038/290527a0; Urushitani M, 2001, J NEUROSCI RES, V63, P377, DOI 10.1002/1097-4547(20010301)63:5<377::AID-JNR1032>3.0.CO;2-#; Vergun O, 2001, J PHYSIOL-LONDON, V531, P147, DOI 10.1111/j.1469-7793.2001.0147j.x; Vesce S, 2004, J NEUROCHEM, V90, P683, DOI 10.1111/j.1471-4159.2004.02516.x; Vornov JJ, 1998, EXP NEUROL, V149, P109, DOI 10.1006/exnr.1997.6673; Warner DS, 2004, J EXP BIOL, V207, P3221, DOI 10.1242/jeb.01022; Zhang YM, 2004, J NEUROSCI, V24, P10616, DOI 10.1523/JNEUROSCI.2469-04.2004	66	28	31	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1734	+		10.1096/fj.05-3795fje	http://dx.doi.org/10.1096/fj.05-3795fje			36	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16081500				2022-12-28	WOS:000231843700020
J	Tang, PCY; Yakimov, AO; Teesdale, MA; Coady, MA; Dardik, A; Elefteriades, JA; Tellides, G				Tang, PCY; Yakimov, AO; Teesdale, MA; Coady, MA; Dardik, A; Elefteriades, JA; Tellides, G			Transmural inflammation by interferon-gamma-producing T cells correlates with outward vascular remodeling and intimal expansion of ascending thoracic aortic aneurysms	FASEB JOURNAL			English	Article						aortic diseases; cytokines; leukocytes	IFN-GAMMA; ELASTIN DEGRADATION; LYMPHOID-TISSUE; ATHEROSCLEROSIS; DISEASE; LESIONS; ARTERIOSCLEROSIS; DETERMINANTS; LYMPHOCYTES; EXPRESSION	Arterial pathology manifests as aneurysmal or obstructive disease depending on changes in lumen size due to vascular remodeling ( change in vessel external diameter) and/or intimal expansion. Recent clinical and experimental observations in abdominal aortic aneurysms have led to the emerging dogma that Th2-dominant immune responses result in expansive vascular remodeling and luminal ectasia, whereas Th1 immune responses cause intimal hyperplasia and luminal stenosis. We tested this hypothesis by descriptive analyses of 31 non-aneurysmal and 29 aneurysmal ascending thoracic aortic specimens. Approximately half the aneurysms were distinguished by transmural inflammation. The remaining aneurysms and all the non-aneurysmal aortas had a similar leukocytic infiltrate that spared the inner media. Aneurysm tissue had increased expression of the prototypical Th1 cytokine, interferon (IFN)-gamma, and undetectable Th2 cytokines. Specimens with inner media infiltration displayed robust production of IFN-gamma, induction of the IFN-gamma- inducible chemokines IP-10 and Mig, and recruitment of lymphocytes bearing their cognate receptor CXCR3. Transmural inflammation and IFN-gamma production were associated with increased aortic external diameter, intimal thickening, preserved vascular smooth muscle cell density, and decreased matrix proteins. Th1, but not Th2, immune responses have a positive correlation with both outward vascular remodeling and intimal expansion of ascending thoracic aortic aneurysms.	Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA; Yale Univ, Sch Med, Interdept Program Vasc Biol & Transplantat, New Haven, CT 06510 USA	Yale University; Yale University	Tellides, G (corresponding author), Boyer Ctr Mol Med 454, 295 Congress Ave, New Haven, CT 06510 USA.	george.tellides@yale.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070295] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL70295-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Absi TS, 2003, J THORAC CARDIOV SUR, V126, P344, DOI 10.1016/S0022-5223(02)73576-9; Bobryshev YV, 2001, ATHEROSCLEROSIS, V154, P15, DOI 10.1016/S0021-9150(00)00441-X; BOBRYSHEV YV, 1995, CARDIOVASC RES, V29, P689, DOI 10.1016/0008-6363(96)88642-1; CENACCHI G, 1995, J SUBMICR CYTOL PATH, V27, P75; Dal Canto AJ, 2001, J CLIN INVEST, V107, pR15, DOI 10.1172/JCI11540; Davis VA, 2001, J SURG RES, V101, P152, DOI 10.1006/jsre.2001.6281; EMESON EE, 1988, AM J PATHOL, V130, P369; FREESTONE T, 1995, ARTERIOSCL THROM VAS, V15, P1145, DOI 10.1161/01.ATV.15.8.1145; Ghorpade A, 1996, ANN NY ACAD SCI, V800, P138, DOI 10.1111/j.1749-6632.1996.tb33305.x; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; HALLORAN BG, 1995, J SURG RES, V59, P17, DOI 10.1006/jsre.1995.1126; Hance KA, 2002, J VASC SURG, V35, P254, DOI 10.1067/mva.2002.120382; Juvonen J, 1997, ARTERIOSCL THROM VAS, V17, P2843, DOI 10.1161/01.ATV.17.11.2843; KATSUDA S, 1992, AM J PATHOL, V140, P907; KOCH AE, 1990, AM J PATHOL, V137, P1199; LopezCandales A, 1997, AM J PATHOL, V150, P993; Millonig G, 2002, ATHEROSCLEROSIS, V160, P441, DOI 10.1016/S0021-9150(01)00596-2; Nagano H, 1997, J CLIN INVEST, V100, P550, DOI 10.1172/JCI119564; Ocana E, 2003, ATHEROSCLEROSIS, V170, P39, DOI 10.1016/S0021-9150(03)00282-X; Ruddle NH, 1999, IMMUNOL RES, V19, P119, DOI 10.1007/BF02786481; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; Satta J, 1998, EUR J VASC ENDOVASC, V15, P313, DOI 10.1016/S1078-5884(98)80034-8; Schonbeck U, 2002, AM J PATHOL, V161, P499, DOI 10.1016/S0002-9440(10)64206-X; Shimizu K, 2004, J CLIN INVEST, V114, P300, DOI 10.1172/JCI200419855; SZEKANECZ Z, 1994, AGENTS ACTIONS, V42, P159, DOI 10.1007/BF01983484; Tellides G, 2000, NATURE, V403, P207, DOI 10.1038/35003221; Thompson RW, 2002, CARDIOVASC SURG, V10, P389, DOI 10.1016/S0967-2109(02)00042-X; Topouzis S, 1996, DEV BIOL, V178, P430, DOI 10.1006/dbio.1996.0229; VASAN RS, 1995, CIRCULATION, V91, P734, DOI 10.1161/01.CIR.91.3.734; Wang YN, 2004, FASEB J, V18, P606, DOI 10.1096/fj.03-0840fje; Ward MR, 2000, CIRCULATION, V102, P1186, DOI 10.1161/01.CIR.102.10.1186; Wick G, 1997, FASEB J, V11, P1199, DOI 10.1096/fasebj.11.13.9367355; WOLINSKY H, 1967, CIRC RES, V20, P409, DOI 10.1161/01.RES.20.4.409; Xiong WF, 2004, J IMMUNOL, V172, P2607, DOI 10.4049/jimmunol.172.4.2607; XU QB, 1990, CLIN IMMUNOL IMMUNOP, V56, P344, DOI 10.1016/0090-1229(90)90155-J	36	64	69	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1528	+		10.1096/fj.05-3671fje	http://dx.doi.org/10.1096/fj.05-3671fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16014397				2022-12-28	WOS:000230923000025
J	Bentzinger, CF; Barzaghi, P; Lin, S; Ruegg, MA				Bentzinger, CF; Barzaghi, P; Lin, S; Ruegg, MA			Overexpression of mini-agrin in skeletal muscle increases muscle integrity and regenerative capacity in laminin-alpha 2-deficient mice	FASEB JOURNAL			English	Article						muscular dystrophy; laminin-alpha 2 deficiency; muscle regeneration	CONGENITAL MUSCULAR-DYSTROPHY; MUTANT MICE; DYSTROGLYCAN BINDING; LAMININ ALPHA-1; LAMA2 GENE; G-DOMAIN; CHAIN; MOUSE; EXPRESSION; FORM	Mutations in the gene encoding the alpha 2 subunit of laminins cause the severe "merosin- deficient congenital muscular dystrophy" ( MDC1A). We have recently shown that overexpression of a miniaturized form of the molecule agrin (mini-agrin) counteracts the disease in dy(W)/dy(W) mice, a model for MDC1A. However, these mice express some residual truncated laminin- 2, suggesting that the observed amelioration might be due to mini-agrin's presenting the residual laminin-alpha 2 2 to its receptors. Here we show that the mini-agrin counteracts the disease in dy(3K)/ dy(3K) mice, which are null for laminin-alpha 2. As in dy(W)/ dy(W) mice, mini-agrin improves both the function and structure of muscle. We show that muscle regeneration after injury is severely impaired in dy3K/ dy3K mice but is restored in the mini-agrin-expressing littermates. In summary, our results 1) show that the direct linkage of muscle basal lamina with the sarcolemma is the basis of mini-agrin-mediated amelioration and 2) provide unprecedented evidence that this linkage is important for proper regeneration of muscle fibers after injury. Our findings thus suggest that treatment with mini-agrin might be beneficial over the entire spectrum of the MDC1A disease, whose severity inversely correlates with expression levels and the size of the truncation in laminin- alpha 2.	Univ Basel, Biozentrum, CH-4056 Basel, Switzerland	University of Basel	Ruegg, MA (corresponding author), Univ Basel, Biozentrum, Klingelbergstr 70, CH-4056 Basel, Switzerland.	markus-a.ruegg@unibas.ch	Ruegg, Markus/X-7256-2019; Bentzinger, C. Florian/A-1151-2015	Ruegg, Markus/0000-0002-4974-9384; Bentzinger, C. Florian/0000-0003-0422-9622; Lin, Shuo/0000-0003-2317-0339				AUFDERHEIDE E, 1987, J CELL BIOL, V105, P599, DOI 10.1083/jcb.105.1.599; Briguet A, 2004, NEUROMUSCULAR DISORD, V14, P675, DOI 10.1016/j.nmd.2004.06.008; Burkin DJ, 2001, J CELL BIOL, V152, P1207, DOI 10.1083/jcb.152.6.1207; Cohn RD, 2002, CELL, V110, P639, DOI 10.1016/S0092-8674(02)00907-8; Colognato H, 1999, CURR BIOL, V9, P1327, DOI 10.1016/S0960-9822(00)80056-1; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; COVAULT J, 1986, J CELL BIOL, V102, P731, DOI 10.1083/jcb.102.3.731; Gawlik K, 2004, HUM MOL GENET, V13, P1775, DOI 10.1093/hmg/ddh190; Gesemann M, 1998, J BIOL CHEM, V273, P600, DOI 10.1074/jbc.273.1.600; GESEMANN M, 1995, J CELL BIOL, V128, P625, DOI 10.1083/jcb.128.4.625; Guo LT, 2003, NEUROMUSCULAR DISORD, V13, P207, DOI 10.1016/s0960-8966(02)00266-3; HARRIS JB, 1990, ELECTRON MICROSC REV, V3, P183, DOI 10.1016/0892-0354(90)90001-9; HARRIS JB, 1978, CLIN EXP PHARMACOL P, V5, P587, DOI 10.1111/j.1440-1681.1978.tb00714.x; Jones G, 1999, J NEUROSCI, V19, P3376; Jones KJ, 2001, J MED GENET, V38, P649, DOI 10.1136/jmg.38.10.649; Kammerer RA, 1999, EMBO J, V18, P6762, DOI 10.1093/emboj/18.23.6762; Kuang W, 1998, J CLIN INVEST, V102, P844, DOI 10.1172/JCI3705; Kuang W, 1999, LAB INVEST, V79, P1601; Langenbach KJ, 2002, MUSCLE NERVE, V26, P644, DOI 10.1002/mus.10258; Li SH, 2003, DEV CELL, V4, P613, DOI 10.1016/S1534-5807(03)00128-X; Mayer U, 1997, NAT GENET, V17, P318, DOI 10.1038/ng1197-318; MEIER H, 1970, LIFE SCI 2-BIOCH GEN, V9, P137, DOI 10.1016/0024-3205(70)90306-1; MICHELSON AM, 1955, P NATL ACAD SCI USA, V41, P1079, DOI 10.1073/pnas.41.12.1079; Miyagoe Y, 1997, FEBS LETT, V415, P33, DOI 10.1016/S0014-5793(97)01007-7; Moll J, 2001, NATURE, V413, P302, DOI 10.1038/35095054; Moore C, 2001, P NATL ACAD SCI USA, V98, P14655, DOI 10.1073/pnas.251291598; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Ringelmann B, 1999, EXP CELL RES, V246, P165, DOI 10.1006/excr.1998.4244; RUEGG MA, 2005, IN PRESS MOL MECH MU; Schwander M, 2003, DEV CELL, V4, P673, DOI 10.1016/S1534-5807(03)00118-7; Spence HJ, 2004, EMBO REP, V5, P484, DOI 10.1038/sj.embor.7400140; Talts JF, 2000, J BIOL CHEM, V275, P35192, DOI 10.1074/jbc.M003261200; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; Yu H, 2003, BIOCHEM J, V371, P289, DOI 10.1042/BJ20021500	35	75	76	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2005	19	8					934	942		10.1096/fj.04-3376com	http://dx.doi.org/10.1096/fj.04-3376com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15923403				2022-12-28	WOS:000230207800040
J	Boyd, JG; Doucette, R; Kawaja, MD				Boyd, JG; Doucette, R; Kawaja, MD			Defining the role of olfactory ensheathing cells in facilitating axon remyelination following damage to the spinal cord	FASEB JOURNAL			English	Review						OECs; remyelination; axon regeneration; Schwann cell; olfactoryy axon	NERVE GROWTH-FACTOR; ROOT GANGLION NEURITES; SCHWANN-CELLS; ADULT-RAT; GLIA TRANSPLANTS; IN-VITRO; DELAYED TRANSPLANTATION; FUNCTIONAL RECOVERY; BASAL LAMINA; CORTICOSPINAL TRACT	Olfactory ensheathing cells (OECs) are unique cells that are responsible for the successful regeneration of olfactory axons throughout the life of adult mammals. More than a decade of research has shown that implantation of OECs may be a promising therapy for damage to the nervous system, including spinal cord injury. Based on this research, several clinical trials worldwide have been initiated that use autologous transplantation of olfactory tissue containing OECs into the damaged spinal cord of humans. However, research from several laboratories has challenged the widely held belief that OECs are directly responsible for myelinating axons and promoting axon regeneration. The purpose of this review is to provide a working hypothesis that integrates several current ideas regarding the mechanisms of the beneficial effects of OECs. Specifically, OECs promote axon regeneration and functional recovery indirectly by augmenting the endogenous capacity of host Schwann cells to invade the damaged spinal cord. Together with Schwann cells, OECs create a 3-dimensional matrix that provides a permissive microenvironment for successful axon regeneration in the adult mammalian central nervous system.	Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada; Univ Saskatchewan, Dept Anat & Cell Biol, Saskatoon, SK, Canada	Queens University - Canada; University of Saskatchewan	Boyd, JG (corresponding author), Queens Univ, Dept Anat & Cell Biol, Room 926,Botterell Hall, Kingston, ON K7L 3N6, Canada.	boydg@post.queensu.ca	Messier, Claude/A-2322-2008; Boyd, J. Gordon/L-3060-2019	Messier, Claude/0000-0002-4791-1763; 				Akiyama Y, 2004, NEURON GLIA BIOL, V1, P47, DOI 10.1017/s1740925x04000079; ANTON ES, 1994, P NATL ACAD SCI USA, V91, P2795, DOI 10.1073/pnas.91.7.2795; Au E, 2003, GLIA, V41, P224, DOI 10.1002/glia.10160; BARBER PC, 1982, NEUROSCIENCE, V7, P3077, DOI 10.1016/0306-4522(82)90231-7; Barnett SC, 2000, BRAIN, V123, P1581, DOI 10.1093/brain/123.8.1581; Barnett SC, 2004, TRENDS NEUROSCI, V27, P54, DOI 10.1016/j.tins.2003.10.011; Barnett SC, 2004, J NEUROTRAUM, V21, P375, DOI 10.1089/089771504323004520; Barnett SC, 2004, J ANAT, V204, P57, DOI 10.1111/j.1469-7580.2004.00257.x; BARNETT SC, 1993, DEV BIOL, V155, P337, DOI 10.1006/dbio.1993.1033; BLAKEMORE WF, 1975, J NEUROCYTOL, V4, P745, DOI 10.1007/BF01181634; Boyd J G, 2003, Anat Rec B New Anat, V271, P49, DOI 10.1002/ar.b.10011; Boyd JG, 2004, P NATL ACAD SCI USA, V101, P2162, DOI 10.1073/pnas.0303842101; Brook GA, 2000, EUR J NEUROSCI, V12, P3224, DOI 10.1046/j.1460-9568.2000.00228.x; Bunge MB, 2002, PROG BRAIN RES, V137, P275; BUNGE MB, 1994, EXP NEUROL, V127, P76, DOI 10.1006/exnr.1994.1082; David S, 2002, NEUROSCIENTIST, V8, P33, DOI 10.1177/107385840200800108; DEMELLO TR, 2003, 34932003 SOC NEUR; DEVON R, 1995, BRAIN RES, V688, P223, DOI 10.1016/0006-8993(95)00562-5; DEVON R, 1992, BRAIN RES, V589, P175; DOUCETTE JR, 1984, ANAT REC, V210, P385, DOI 10.1002/ar.1092100214; DOUCETTE R, 1995, HISTOL HISTOPATHOL, V10, P503; DOUCETTE R, 1991, J COMP NEUROL, V312, P451, DOI 10.1002/cne.903120311; DOUCETTE R, 1994, GLIA, V10, P296, DOI 10.1002/glia.440100408; ELDRIDGE CF, 1987, J CELL BIOL, V105, P1023, DOI 10.1083/jcb.105.2.1023; ELDRIDGE CF, 1989, J NEUROSCI, V9, P625; Feron F, 1998, ARCH OTOLARYNGOL, V124, P861, DOI 10.1001/archotol.124.8.861; Field PM, 2003, J NEUROCYTOL, V32, P317, DOI 10.1023/B:NEUR.0000010089.37032.48; FRAHER JP, 1982, J ANAT, V134, P149; Franceschini IA, 1996, DEV BIOL, V173, P327, DOI 10.1006/dbio.1996.0027; FRANKLIN RJM, 1993, INT J DEV NEUROSCI, V11, P641, DOI 10.1016/0736-5748(93)90052-F; Franklin RJM, 1996, GLIA, V17, P217, DOI 10.1002/(SICI)1098-1136(199607)17:3<217::AID-GLIA4>3.0.CO;2-Y; Franklin RJM, 2002, BRAIN RES BULL, V57, P827, DOI 10.1016/S0361-9230(01)00765-1; Franklin Robin J M, 2003, Anat Rec B New Anat, V271, P71, DOI 10.1002/ar.b.10013; Fu SY, 1997, MOL NEUROBIOL, V14, P67, DOI 10.1007/BF02740621; Garcia-Alias G, 2004, J NEUROSCI RES, V75, P632, DOI 10.1002/jnr.20029; Gomez VM, 2003, J NEUROCYTOL, V32, P53, DOI 10.1023/A:1027328331832; Hayes KC, 1997, J NEUROTRAUM, V14, P235, DOI 10.1089/neu.1997.14.235; Imaizumi T, 2000, BRAIN RES, V854, P70, DOI 10.1016/S0006-8993(99)02285-4; Imaizumi T, 1998, J NEUROSCI, V18, P6176; Imaizumi T, 2000, NAT BIOTECHNOL, V18, P949, DOI 10.1038/79432; JAHED A, 2003, 3585 SOC NEUR; Jasmin L, 2000, J NEUROSCI, V20, P9215; Kato T, 2000, GLIA, V30, P209, DOI 10.1002/(SICI)1098-1136(200005)30:3<209::AID-GLIA1>3.0.CO;2-8; Keyvan-Fouladi N, 2002, BRAIN RES REV, V40, P325, DOI 10.1016/S0165-0173(02)00215-1; Keyvan-Fouladi N, 2003, J NEUROSCI, V23, P9428; Kocsis JD, 2002, J REHABIL RES DEV, V39, P287; Lakatos A, 2000, GLIA, V32, P214, DOI 10.1002/1098-1136(200012)32:3<214::AID-GLIA20>3.0.CO;2-7; Lakatos A, 2003, BRAIN, V126, P598, DOI 10.1093/brain/awg055; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; Li Y, 2003, J NEUROSCI, V23, P7783; Li Y, 1998, J NEUROSCI, V18, P10514; Lipson AC, 2003, EXP NEUROL, V180, P167, DOI 10.1016/S0014-4886(02)00058-4; Lu J, 2002, BRAIN, V125, P14, DOI 10.1093/brain/awf014; Lu J, 2001, BRAIN RES, V889, P344, DOI 10.1016/S0006-8993(00)03235-2; Lu K, 2002, SPINE, V27, P887, DOI 10.1097/00007632-200204150-00021; MATTHEWS MA, 1979, NEUROPATH APPL NEURO, V5, P161, DOI 10.1111/j.1365-2990.1979.tb00617.x; MCNICHOLAS LF, 1980, EXP NEUROL, V69, P383, DOI 10.1016/0014-4886(80)90221-6; Nash HH, 2002, J NEUROSCI, V22, P7111; Navarro X, 1999, ANN NEUROL, V45, P207, DOI 10.1002/1531-8249(199902)45:2<207::AID-ANA11>3.0.CO;2-K; PIXLEY SK, 1992, GLIA, V5, P269, DOI 10.1002/glia.440050405; Pixley SK, 1996, INT J DEV NEUROSCI, V14, P823, DOI 10.1016/S0736-5748(96)00057-3; Plant GW, 2003, J NEUROTRAUM, V20, P1, DOI 10.1089/08977150360517146; Plant GW, 2002, J NEUROSCI, V22, P6083; Podratz JL, 1998, GLIA, V23, P383, DOI 10.1002/(SICI)1098-1136(199808)23:4<383::AID-GLIA10>3.0.CO;2-O; RAISMAN G, 1985, NEUROSCIENCE, V14, P237, DOI 10.1016/0306-4522(85)90176-9; Ramer LM, 2004, GLIA, V47, P189, DOI 10.1002/glia.20054; Ramer LM, 2004, J COMP NEUROL, V473, P1, DOI 10.1002/cne.20049; Ramon-Cueto A, 2000, NEURON, V25, P425, DOI 10.1016/S0896-6273(00)80905-8; Ramon-Cueto A, 1998, J NEUROSCI, V18, P3803; Ramon-Cueto A, 1998, BRAIN RES BULL, V46, P175, DOI 10.1016/S0361-9230(97)00463-2; RAMONCUETO A, 1995, GLIA, V14, P163, DOI 10.1002/glia.440140302; RAMONCUETO A, 1993, EUR J NEUROSCI, V5, P1172, DOI 10.1111/j.1460-9568.1993.tb00971.x; RAMONCUETO A, 1992, NEUROSCIENCE, V47, P213, DOI 10.1016/0306-4522(92)90134-N; RAMONCUETO A, 1994, EXP NEUROL, V127, P232, DOI 10.1006/exnr.1994.1099; Riddell JS, 2004, GLIA, V47, P150, DOI 10.1002/glia.20041; Santos-Benito Fernando F, 2003, Anat Rec B New Anat, V271, P77, DOI 10.1002/ar.b.10015; Santos-Silva A, 2001, NEUROSCI RES, V40, P189, DOI 10.1016/S0168-0102(01)00204-8; Sasaki M, 2004, J NEUROSCI, V24, P8485, DOI 10.1523/JNEUROSCI.1998-04.2004; SCHWOB JE, 1992, J NEUROSCI, V12, P3896; Sims TJ, 1998, J NEUROPATH EXP NEUR, V57, P866, DOI 10.1097/00005072-199809000-00008; Smith PM, 2001, GLIA, V36, P342, DOI 10.1002/glia.1121; Takami T, 2002, J NEUROSCI, V22, P6670; Tennent R, 1996, DEV BRAIN RES, V95, P135, DOI 10.1016/0165-3806(96)00091-0; Verdu E, 2003, GLIA, V42, P275, DOI 10.1002/glia.10217; Verdu E, 2001, NEUROREPORT, V12, P2303, DOI 10.1097/00001756-200108080-00005; Vincent AJ, 2003, GLIA, V41, P393, DOI 10.1002/glia.10171; von Euler M, 2002, J NEUROPATH EXP NEUR, V61, P64, DOI 10.1093/jnen/61.1.64; VOYVODIC JT, 1989, NATURE, V342, P430, DOI 10.1038/342430a0; WALLACE MC, 1987, SURG NEUROL, V27, P209, DOI 10.1016/0090-3019(87)90031-0; Wang ZH, 1996, ACTA NEUROPATHOL, V91, P180, DOI 10.1007/s004010050411; WEIS J, 1991, J CELL BIOL, V113, P1385, DOI 10.1083/jcb.113.6.1385; West NR, 2001, NEUROPATHOLOGY, V21, P188, DOI 10.1046/j.1440-1789.2001.00398.x; Wewetzer K, 2002, CELL TISSUE RES, V309, P337, DOI 10.1007/s00441-002-0607-y; Woodhall E, 2001, MOL BRAIN RES, V88, P203, DOI 10.1016/S0169-328X(01)00044-4	94	108	121	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					694	703		10.1096/fj.04-2833rev	http://dx.doi.org/10.1096/fj.04-2833rev			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15857884				2022-12-28	WOS:000229602600026
J	Sakao, S; Taraseviciene-Stewart, L; Lee, JD; Wood, K; Cool, CD; Voelkel, NF				Sakao, S; Taraseviciene-Stewart, L; Lee, JD; Wood, K; Cool, CD; Voelkel, NF			Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells	FASEB JOURNAL			English	Article						pulmonary hypertension; shear stress; VEGF; VEGF receptor blockade	PULMONARY-HYPERTENSION; GROWTH-FACTOR; EXPRESSION; SURVIVIN; RECEPTORS; INHIBITOR; HIERARCHY; PROTEIN; CANCER; GENE	We have demonstrated that VEGF receptor blockade in combination with chronic hypoxia causes in rats severe angioproliferative pulmonary hypertension (SAPH) associated with arterial occlusion by proliferating endothelial cells, and we postulate that the established, lumen-occluding lesions are the result of the emergence of apoptosis-resistant proliferating cells. To study the dependence of exuberant endothelial cell proliferation on initial apoptosis, we adapted the CELLMAX artificial capillary system to analyze the effects of a VEGF receptor antagonist (SU5416) on human pulmonary microvascular endothelial cells under pulsatile shear stress. Immunohistochemical staining for caspase-3 and PCNA and flow cytometry for Annexin-V and BrdU supported our concept, since SU5416 caused initial apoptosis (35.8% at 24 h after the SU5416 addition and 4.8% in control cells) whereas the surviving cells became hyperproliferative ( PCNA positive). Flow cytometry showed that apoptosis inhibition prevented the proliferation following the initial apoptosis. These lumen-filling endothelial cells were apoptosis resistant, grew without serum, and were phenotypically altered in that they express the tumor marker survivin. Hyperproliferative apoptosis-resistant cells were also generated by adding apoptosed cells instead of the VEGF receptor blocker to the CELLMAX system. In conclusion, endothelial cell death resulted in the selection of an apoptosis-resistant, proliferating phenotypically altered endothelial cell phenotype.	Univ Colorado, Hlth Sci Ctr, Pulm Hypertens Ctr, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Voelkel, NF (corresponding author), Div Pulm Sci & Crit Care Med, 4200 E 9th Ave,C272, Denver, CO 80262 USA.	norbert.voelkel@uchsc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066254] Funding Source: NIH RePORTER; NHLBI NIH HHS [5P01 HL66254-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ameshima S, 2003, CIRC RES, V92, P1162, DOI 10.1161/01.RES.0000073585.50092.14; Cool CD, 1999, AM J PATHOL, V155, P411, DOI 10.1016/S0002-9440(10)65137-1; Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI14122; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GOLPON H, 2004, FASEB J         0902; Hirose S, 2000, PATHOL INT, V50, P472, DOI 10.1046/j.1440-1827.2000.01068.x; Ingram DA, 2005, BLOOD, V105, P2783, DOI 10.1182/blood-2004-08-3057; Ingram DA, 2004, BLOOD, V104, P2752, DOI 10.1182/blood-2004-04-1396; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Kishi H, 2004, J UROLOGY, V171, P1855, DOI 10.1097/01.ju.0000120317.88372.03; Ma JF, 2002, J GASTROINTEST CANC, V32, P73, DOI 10.1385/IJGC:32:2-3:73; Mathew R, 2004, CIRCULATION, V110, P1499, DOI 10.1161/01.CIR.0000141576.39579.23; Mendel DB, 2000, ANTI-CANCER DRUG DES, V15, P29; Mikami T, 2003, AM J CLIN PATHOL, V119, P723, DOI 10.1309/YLX4L4H36K54X92H; Pi XC, 2004, CIRC RES, V94, P362, DOI 10.1161/01.RES.0000112406.27800.6F; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Rimensberger PC, 2001, CIRCULATION, V103, P544, DOI 10.1161/01.CIR.103.4.544; Sarela AI, 2002, BRIT J CANCER, V86, P886, DOI 10.1038/sj.bjc.6600133; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Sitbon O, 2002, J AM COLL CARDIOL, V40, P780, DOI 10.1016/S0735-1097(02)02012-0; Taraseviciene-Stewart L, 2001, FASEB J, V15, P427, DOI 10.1096/fj.00-0343com; TARASEVICIENEST.L, 2003, 4 INT C MECH CELL DE; TUDER RM, 1994, AM J PATHOL, V144, P275; Wang XC, 2003, SCIENCE, V302, P1563, DOI 10.1126/science.1087641	27	201	210	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1178	+		10.1096/fj.04-3261fje	http://dx.doi.org/10.1096/fj.04-3261fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15897232				2022-12-28	WOS:000229602600013
J	Akahoshi, T; Tanigawa, T; Sarfeh, IJ; Chiou, SK; Hashizume, M; Maehara, Y; Jones, MK				Akahoshi, T; Tanigawa, T; Sarfeh, IJ; Chiou, SK; Hashizume, M; Maehara, Y; Jones, MK			Selective cyclooxygenase (COX) inhibition causes damage to portal hypertensive gastric mucosa: roles of nitric oxide and NF-kappa B	FASEB JOURNAL			English	Article						celecoxib; indomethacin; NF-kappa B	INCREASED SUSCEPTIBILITY; SYNTHASE EXPRESSION; RAT; ACTIVATION; INJURY; GENE; KEY; LIPOPOLYSACCHARIDE; ERK2	Portal hypertension (PHT) is associated with increased susceptibility of the gastric mucosa to injury by a variety of factors, including nonsteroidal anti-inflammatory drugs (NSAIDs) that nonselectively inhibit both isoforms of cyclooxygenase (COX-1 and -2). PHT gastric mucosa also has excessive nitric oxide (NO) production that contributes to the general increased susceptibility to injury. Using a rat model of PHT, we studied whether selective COX inhibition, which does not damage normal (normotensive) gastric mucosa, is sufficient to cause PHT gastric damage and, if so, whether and how excessive NO is involved. Indomethacin, a nonselective NSAID, caused 2.4-fold more gastric injury to PHT vs. normotensive sham-operated (SO) control rats. Neither NS-398 nor celecoxib, selective COX-2 inhibitors, caused gastric damage in either SO or PHT rats. SC-560, a selective COX-1 inhibitor, did not cause gastric damage in SO rats but dose-dependently caused gastric damage in PHT rats. There was a compensatory increase in COX-2 expression and activity in SC-560-treated SO rats but not SC-560-treated PHT rats. Partial inhibition of NO production restored gastric COX-2 expression and activity levels in SC-560-treated PHT rats to those of SC-560-treated SO rats, by a mechanism consistent with induction of NF-kappa B, and significantly reduced gastric damage. These studies indicate that, in contrast to normotensive gastric mucosa, inhibition of COX-1 alone is sufficient to cause PHT gastric damage as a result of excessive NO that prevents the induction of NF-kappa B and the compensatory increase in COX-2.	Univ Calif Irvine, DVA Med Ctr, Long Beach, CA 90822 USA; Dept Vet Affairs Med Ctr, Dept Med, Long Beach, CA USA; Dept Vet Affairs Med Ctr, Dept Surg, Long Beach, CA USA; Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 812, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Disaster & Emergency Med, Fukuoka 812, Japan	University of California System; University of California Irvine; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; Kyushu University; Kyushu University	Jones, MK (corresponding author), Univ Calif Irvine, DVA Med Ctr, 5901 E 7th St, Long Beach, CA 90822 USA.	michael.jones4@med.va.gov	Maehara, Yoshihiko/A-4867-2010; Tanigawa, Tetsuya/J-6131-2019; Akahoshi, Tomohiko/AAU-4886-2021	Tanigawa, Tetsuya/0000-0002-9305-1637; 				Arai K, 2003, GUT, V52, P1242, DOI 10.1136/gut.52.9.1242; Blais V, 2001, J NEUROPATH EXP NEUR, V60, P893, DOI 10.1093/jnen/60.9.893; Boku K, 2001, GASTROENTEROLOGY, V120, P134, DOI 10.1053/gast.2001.20916; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clancy R, 2000, J IMMUNOL, V165, P1582, DOI 10.4049/jimmunol.165.3.1582; DAMICO G, 1990, GASTROENTEROLOGY, V99, P1558, DOI 10.1016/0016-5085(90)90458-D; Diaz-Cazorla M, 1999, J AM SOC NEPHROL, V10, P943; Gadano AC, 1999, J HEPATOL, V30, P896, DOI 10.1016/S0168-8278(99)80145-7; Habib A, 1997, J IMMUNOL, V158, P3845; Heller J, 1999, HEPATOLOGY, V30, P698, DOI 10.1002/hep.510300301; ICHIKAWA Y, 1994, GASTROENTEROLOGY, V106, P702, DOI 10.1016/0016-5085(94)90705-6; ISHIKAWA T, 1992, SURGERY, V112, P341; Jones MK, 1999, FASEB J, V13, P2186, DOI 10.1096/fasebj.13.15.2186; Kawanaka H, 2001, FASEB J, V15, P574; Liu SF, 1997, J IMMUNOL, V159, P3976; Liu SF, 1999, MOL PHARMACOL, V55, P658; Marshall HE, 2002, J BIOL CHEM, V277, P34223, DOI 10.1074/jbc.M201638200; Muller-Quade J, 2000, APPL ALGEBR ENG COMM, V11, P35, DOI 10.1007/s002000000024; Ohta M, 1998, HEPATOLOGY, V27, P906, DOI 10.1002/hep.510270403; Ohta M, 1997, GASTROENTEROLOGY, V112, P1920, DOI 10.1053/gast.1997.v112.pm9178684; Pausawasdi N, 2002, AM J PHYSIOL-GASTR L, V282, pG1069, DOI 10.1152/ajpgi.00164.2001; Pique JM, 1997, BAILLIERE CLIN GASTR, V11, P257, DOI 10.1016/S0950-3528(97)90039-7; Saeki T, 2004, AM J PHYSIOL-GASTR L, V286, pG68, DOI 10.1152/ajpgi.00538.2002; SARFEH IJ, 1991, J CLIN GASTROENTEROL, V13, pS18, DOI 10.1097/00004836-199112001-00003; SARFEH IJ, 1988, SURGERY, V104, P79; SARFEH IJ, 1989, DIGEST DIS SCI, V34, P225, DOI 10.1007/BF01536055; SARFEH IJ, 1982, SURG GYNECOL OBSTET, V155, P167; Takahashi S, 2001, AM J PHYSIOL-GASTR L, V280, pG1296, DOI 10.1152/ajpgi.2001.280.6.G1296; Tanaka A, 2002, ALIMENT PHARM THERAP, V16, P90, DOI 10.1046/j.1365-2036.16.s2.22.x; TARNAWSKI A, 1988, J CLIN GASTROENTEROL, V10, pS35, DOI 10.1097/00004836-198812001-00008; TARNAWSKI AS, 1988, HEPATOLOGY, V8, P1488, DOI 10.1002/hep.1840080604; Tomikawa M, 1999, ANN SURG, V230, P38, DOI 10.1097/00000658-199907000-00006; Tsugawa K, 2003, FASEB J, V17, P2316, DOI 10.1096/fj.02-1107fje; WALLACE JL, 1990, AM J PHYSIOL, V259, pG462, DOI 10.1152/ajpgi.1990.259.3.G462; WALLACE JL, 1992, GASTROENTEROL CLIN N, V21, P631; WALLACE JL, 1991, GASTROENTEROLOGY, V100, P878, DOI 10.1016/0016-5085(91)90259-N; Wallace JL, 2000, GASTROENTEROLOGY, V119, P706, DOI 10.1053/gast.2000.16510; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; WHITTLE BJR, 1980, NATURE, V284, P271, DOI 10.1038/284271a0	39	8	8	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1163	+		10.1096/fj.04-3325fje	http://dx.doi.org/10.1096/fj.04-3325fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15845610				2022-12-28	WOS:000228865300009
J	Belleudi, F; Leone, L; Aimati, L; Stirparo, MG; Cardinali, G; Marchese, C; Frati, L; Picardo, M; Torrisi, MR				Belleudi, Francesca; Leone, Laura; Aimati, Laura; Stirparo, Maria Giovanna; Cardinali, Giorgia; Marchese, Cinzia; Frati, Luigi; Picardo, Mauro; Torrisi, Maria Rosaria			Endocytic pathways and biological effects induced by UVB-dependent or ligand-dependent activation of the keratinocyte growth factor receptor	FASEB JOURNAL			English	Article									[Belleudi, Francesca; Leone, Laura; Stirparo, Maria Giovanna; Marchese, Cinzia; Frati, Luigi; Torrisi, Maria Rosaria] Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, Rome, Italy; [Aimati, Laura; Torrisi, Maria Rosaria] Azienda Osped St Andrea, Rome, Italy; [Cardinali, Giorgia; Picardo, Mauro] Ist Dermatol S Maria & S Gallicano, Rome, Italy; [Torrisi, Maria Rosaria] Ist Neurol Mediterraneo Neuromed, Pozzilli, Italy	Sapienza University Rome; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG); IRCCS Neuromed	Torrisi, MR (corresponding author), Dip Med Sperimentale & Patol, Viale Regina Elena 324, I-00161 Rome, Italy.	mara.torrisi@uniroma1.it	Picardo, Mauro/A-6978-2011; Marchese, Cinzia/J-1323-2018; Cardinali, Giorgia/H-1814-2016; Frati, Luigi/ABI-7437-2020	Picardo, Mauro/0000-0003-4899-6639; Cardinali, Giorgia/0000-0002-7527-9451; MARCHESE, CINZIA/0000-0002-9280-8917					0	31	33	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					395	397		10.1096/fj.05-3934fje	http://dx.doi.org/10.1096/fj.05-3934fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16354720				2022-12-28	WOS:000207915000033
J	Pintucci, G; Saunders, PC; Gulkarov, I; Sharony, R; Kadian-Dodov, DL; Bohmann, K; Baumann, FG; Galloway, AC; Mignatti, P				Pintucci, Giuseppe; Saunders, Paul C.; Gulkarov, Iosif; Sharony, Ram; Kadian-Dodov, Daniella L.; Bohmann, Katja; Baumann, F. Gregory; Galloway, Aubrey C.; Mignatti, Paolo			Anti-proliferative and anti-inflammatory effects of topical MAPK inhibition in arterialized vein grafts	FASEB JOURNAL			English	Article									[Pintucci, Giuseppe; Saunders, Paul C.; Gulkarov, Iosif; Sharony, Ram; Kadian-Dodov, Daniella L.; Bohmann, Katja; Baumann, F. Gregory; Galloway, Aubrey C.; Mignatti, Paolo] NYU, Sch Med, Dept Cardiothorac Surg, Seymour Cohn Cardiovasc Surg Res Lab, New York, NY 10016 USA; [Mignatti, Paolo] NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	New York University; New York University	Pintucci, G (corresponding author), NYU, Sch Med, Dept Cardiothorac Surg, Seymour Cohn Cardiovasc Surg Res Lab, 530 1st Ave,NB 15W16, New York, NY 10016 USA.	pintug01@med.nyu.edu		Mignatti, Paolo/0000-0002-8157-457X; Galoway, Aubrey/0000-0001-5461-3820	NHLBI NIH HHS [5 R01 HL70203-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070203] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))			0	19	27	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					398	400		10.1096/fj.05-4114fje	http://dx.doi.org/10.1096/fj.05-4114fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16303874				2022-12-28	WOS:000207915000034
J	Qin, ZY; Itoh, S; Jeney, V; Ushio-Fukai, M; Fukai, T				Qin, Zhenyu; Itoh, Shinichi; Jeney, Viktoria; Ushio-Fukai, Masuko; Fukai, Tohru			Essential role for the Menkes ATPase in activation of extracellular superoxide dismutase: implication for vascular oxidative stress	FASEB JOURNAL			English	Article									[Qin, Zhenyu; Itoh, Shinichi; Jeney, Viktoria; Ushio-Fukai, Masuko; Fukai, Tohru] Emory Univ, Sch Med, Div Cardiol, Dept Med, Atlanta, GA 30322 USA	Emory University	Fukai, T (corresponding author), Emory Univ, Sch Med, Div Cardiol, Dept Med, 101 Woodruff Circle,WMB 319, Atlanta, GA 30322 USA.	tfukai@emory.edu	Jeney, Viktória/AAF-5355-2019; Jeney, Viktoria/A-6779-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL058000, R01HL070187] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58000, R01 HL70187] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))			0	76	77	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					334	336		10.1096/fj.05-4564fje	http://dx.doi.org/10.1096/fj.05-4564fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16371425				2022-12-28	WOS:000207915000012
J	Rasmussen, BB; Fujita, S; Wolfe, RR; Mittendorfer, B; Roy, M; Rowe, VL; Volpi, E				Rasmussen, Blake B.; Fujita, Satoshi; Wolfe, Robert R.; Mittendorfer, Bettina; Roy, Mona; Rowe, Vincent L.; Volpi, Elena			Insulin resistance of muscle protein metabolism in aging	FASEB JOURNAL			English	Article						skeletal muscle; hyperinsulinemia; leg blood flow; phenylalanine	SKELETAL-MUSCLE; AMINO-ACIDS; NITRIC-OXIDE; WHOLE-BODY; PHYSIOLOGICAL HYPERINSULINEMIA; EUGLYCEMIC HYPERINSULINEMIA; SYSTEMIC HYPERINSULINEMIA; VASCULAR-TONE; BLOOD-FLOW; YOUNG	A reduced response of older skeletal muscle to anabolic stimuli may contribute to the development of sarcopenia. We hypothesized that muscle proteins are resistant to the anabolic action of insulin in the elderly. We examined the effects of hyperinsulinemia on muscle protein metabolism in young (25 +/- 2 year) and older (68 +/- 1 year) healthy subjects using stable isotope tracer techniques. Leg blood flow was higher in the young at baseline and increased during hyperinsulinemia, whereas it did not change in the elderly. Glucose concentrations and muscle uptake were not different between groups at baseline and during hyperinsulinemia. Leg phenylalanine net balance was not different at baseline and significantly increased in both groups with hyperinsulinemia (P < 0.05) but to a greater extent in the young (P < 0.05). Muscle protein synthesis increased only in the young during hyperinsulinemia. Muscle protein breakdown did not significantly change in either group, although it tended to decrease in the elderly. Changes in muscle protein synthesis were correlated with changes in leg amino acid delivery (R= 0.89; P= 0.0001) and blood flow (R= 0.90; P < 0.0001). In conclusion, skeletal muscle protein synthesis is resistant to the anabolic action of insulin in older subjects, which may be an important contributor to the development of sarcopenia.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ So Calif, Dept Kinesiol, Los Angeles, CA USA; Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA; Univ So Calif, Dept Med, Los Angeles, CA USA; Univ So Calif, Dept Surg, Los Angeles, CA USA	University of Texas System; University of Texas Medical Branch Galveston; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Volpi, E (corresponding author), Univ Texas, Med Branch, Dept Internal Med, Div Geriatr Med, 301 Univ Blvd, Galveston, TX 77555 USA.	evolpi@utmb.edu	Volpi, Elena/I-4459-2012	Rasmussen, Blake/0000-0001-7854-5375; Volpi, Elena/0000-0001-8776-0384	NCRR NIH HHS [M01 RR000043-450887, M01 RR00073, M01 RR000073-438733, M01 RR000043, S10 RR16650, M01 RR000073, S10 RR016650-01, M01 RR00043] Funding Source: Medline; NIA NIH HHS [R01 AG018311, P30 AG024832, R01 AG018311-05, R01 AG18311, P30 AG17231, P60 AG017231, P30 AG024832-039004] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000043, M01RR000073, S10RR016650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG024832, R01AG018311, P60AG017231] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		American Diabetes Association, 2004, Diabetes Care, V27 Suppl 1, pS5, DOI 10.2337/diacare.27.2007.S5; Anthony JC, 2001, J NUTR, V131, p856S, DOI 10.1093/jn/131.3.856S; Balagopal P, 1997, AM J PHYSIOL-ENDOC M, V273, pE790, DOI 10.1152/ajpendo.1997.273.4.E790; Baron AD, 2000, DIABETES, V49, P768, DOI 10.2337/diabetes.49.5.768; Bell JA, 2005, AM J PHYSIOL-ENDOC M, V289, pE999, DOI 10.1152/ajpendo.00170.2005; BENNET WM, 1989, CLIN SCI, V76, P447, DOI 10.1042/cs0760447; BENNET WM, 1990, AM J PHYSIOL, V259, pE185, DOI 10.1152/ajpendo.1990.259.2.E185; BIOLO G, 1995, AM J PHYSIOL-ENDOC M, V268, pE75, DOI 10.1152/ajpendo.1995.268.1.E75; BIOLO G, 1995, J CLIN INVEST, V95, P811, DOI 10.1172/JCI117731; BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477; CALDER AG, 1992, RAPID COMMUN MASS SP, V6, P421, DOI 10.1002/rcm.1290060704; Cardillo CM, 2000, HYPERTENSION, V35, P1237, DOI 10.1161/01.HYP.35.6.1237; Cuthbertson D, 2004, FASEB J, V18, P422, DOI 10.1096/fj.04-2640fje; Dardevet D, 2002, J NUTR, V132, P95, DOI 10.1093/jn/132.1.95; DEFEO P, 1993, DIABETES, V42, P995, DOI 10.2337/diabetes.42.7.995; DENNE SC, 1991, AM J PHYSIOL, V261, pE809, DOI 10.1152/ajpendo.1991.261.6.E809; DUTTA C, 1995, J GERONTOL A-BIOL, V50, P1, DOI 10.1093/gerona/50A.Special_Issue.1; EVANS WJ, 1995, J GERONTOL A-BIOL, V50, P5, DOI 10.1093/gerona/50A.Special_Issue.5; GELFAND RA, 1987, J CLIN INVEST, V80, P1, DOI 10.1172/JCI113033; Guillet C, 2004, FASEB J, V18, P1586, DOI 10.1096/fj.03-1341fje; Hasten DL, 2000, AM J PHYSIOL-ENDOC M, V278, pE620, DOI 10.1152/ajpendo.2000.278.4.E620; HESLIN MJ, 1992, AM J PHYSIOL, V262, pE911, DOI 10.1152/ajpendo.1992.262.6.E911; Hillier TA, 1998, AM J PHYSIOL-ENDOC M, V274, pE1067, DOI 10.1152/ajpendo.1998.274.6.E1067; JORFELDT L, 1978, METABOLISM, V27, P97, DOI 10.1016/0026-0495(78)90128-2; JORFELDT L, 1971, CLIN SCI, V41, P459, DOI 10.1042/cs0410459; Kimball SR, 1997, AM J PHYSIOL-CELL PH, V272, pC754, DOI 10.1152/ajpcell.1997.272.2.C754; Kimball SR, 1996, AM J PHYSIOL-CELL PH, V270, pC705, DOI 10.1152/ajpcell.1996.270.2.C705; Kimball SR, 1998, AM J PHYSIOL-CELL PH, V274, pC221, DOI 10.1152/ajpcell.1998.274.1.C221; LEXELL J, 1995, J GERONTOL A-BIOL, V50, P11; LOUARD RJ, 1992, J CLIN INVEST, V90, P2348, DOI 10.1172/JCI116124; Mather KJ, 2004, DIABETES, V53, P2060, DOI 10.2337/diabetes.53.8.2060; MENEILLY GS, 1995, J CLIN ENDOCR METAB, V80, P1899, DOI 10.1210/jc.80.6.1899; Miller AW, 2002, HYPERTENSION, V40, P78, DOI 10.1161/01.HYP.0000022806.87281.62; MOLLERLOSWICK AC, 1994, AM J PHYSIOL, V266, pE645, DOI 10.1152/ajpendo.1994.266.4.E645; MOSONI L, 1995, AM J PHYSIOL-ENDOC M, V268, pE328, DOI 10.1152/ajpendo.1995.268.2.E328; NEWMAN E, 1994, METABOLISM, V43, P70, DOI 10.1016/0026-0495(94)90159-7; Nygren J, 2003, DIABETES, V52, P1377, DOI 10.2337/diabetes.52.6.1377; Paddon-Jones D, 2004, AM J PHYSIOL-ENDOC M, V286, pE321, DOI 10.1152/ajpendo.00368.2003; Rasmussen B B, 2002, J Nutr Health Aging, V6, P358; Rasmussen BB, 2000, J APPL PHYSIOL, V88, P386, DOI 10.1152/jappl.2000.88.2.386; Roubenoff R, 2001, JAMA-J AM MED ASSOC, V286, P1230, DOI 10.1001/jama.286.10.1230; SCHERRER U, 1994, J CLIN INVEST, V94, P2511, DOI 10.1172/JCI117621; STEINBERG HO, 1994, J CLIN INVEST, V94, P1172, DOI 10.1172/JCI117433; TESSARI P, 1991, J CLIN INVEST, V88, P27, DOI 10.1172/JCI115287; Tinetti ME, 1997, NEW ENGL J MED, V337, P1279, DOI 10.1056/NEJM199710303371806; Volpi E, 2003, AM J CLIN NUTR, V78, P250, DOI 10.1093/ajcn/78.2.250; Volpi E, 1998, J CLIN INVEST, V101, P2000, DOI 10.1172/JCI939; Volpi E, 2001, JAMA-J AM MED ASSOC, V286, P1206, DOI 10.1001/jama.286.10.1206; Volpi E, 2000, J CLIN ENDOCR METAB, V85, P4481, DOI 10.1210/jc.85.12.4481; Volpi E, 1999, AM J PHYSIOL-ENDOC M, V277, pE513, DOI 10.1152/ajpendo.1999.277.3.E513; WELLE S, 1993, AM J PHYSIOL, V264, pE693, DOI 10.1152/ajpendo.1993.264.5.E693; WELLE S, 1995, AM J PHYSIOL-ENDOC M, V268, pE422, DOI 10.1152/ajpendo.1995.268.3.E422; WELLE S, 1990, AM J PHYSIOL, V258, pE990, DOI 10.1152/ajpendo.1990.258.6.E990; WOLF RF, 1992, SURGERY, V112, P284; Wolfe RR, 1992, RADIOACTIVE STABLE I; WOLFE RR, 1992, RADIOACTIVE STABLE I, P167; WOLFSON L, 1995, J GERONTOL A-BIOL, V50, P64; YARASHESKI KE, 1993, AM J PHYSIOL, V265, pE210, DOI 10.1152/ajpendo.1993.265.2.E210	58	246	249	2	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					768	+		10.1096/fj.05-4607fje	http://dx.doi.org/10.1096/fj.05-4607fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16464955	Green Accepted			2022-12-28	WOS:000237698700033
J	Shen, JB; Pappano, AJ; Liang, BT				Shen, Jian-Bing; Pappano, Achilles J.; Liang, Bruce T.			Extracellular ATP-stimulated current in wild-type and P2X(4) receptor transgenic mouse ventricular myocytes: implications for a cardiac physiologic role of P2X(4) receptors	FASEB JOURNAL			English	Article						ion channels; membrane current; mouse; heart	PHARMACOLOGICAL PROFILE; CALCIUM CURRENT; RAT; CHANNELS; COPPER; ZINC; OVEREXPRESSION; CONTRACTILITY; PURINOCEPTORS; ACTIVATION	P2X receptors, activated by extracellular ATP, may be important in regulating cardiac function. The objective of the present study was to characterize the electrophysiologic actions of P2X(4) receptors in cardiac myocytes and to determine whether they are involved in mediating the effect of extracellular ATP. Membrane currents under voltage clamp were determined in myocytes from both wild-type (WT) and P2X(4) receptor-overexpressing transgenic (TG) mice. The P2X agonist 2-meSATP induced an inward current at -100 mV that was greater in magnitude (2-fold) in TG than in WT ventricular cells. In the presence of the P2X(4) receptor-selective allosteric enhancer ivermectin (3 mu M), the 2-meSATP-stimulated current increased significantly in both WT and TG ventricular cells, consistent with an important role of P2X(4) receptors in mediating the ATP current not only in TG but also WT myocytes. That the current in both WT and TG cells showed similar voltage-dependence and reverse potential (similar to 0 mV) further suggests a role for this receptor in the normal electrophysiological action of ATP in WT murine cardiac myocytes. The P2X antagonist suramin was only able to block partially the 2-meSATP-stimulated current in WT cells, implying that both P2X(4) receptor and another yet-to-be-identified P2X receptor mediate this current.	Univ Connecticut, Ctr Hlth, Pat & Jim Calhoun Cardiol Ctr, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Pharmacol, Farmington, CT 06030 USA	University of Connecticut; University of Connecticut	Liang, BT (corresponding author), Univ Connecticut, Ctr Hlth, Pat & Jim Calhoun Cardiol Ctr, MC-3946,263 Farmington Ave, Farmington, CT 06030 USA.	bliang@uchc.edu	Shen, Jianbing/U-8796-2019	Shen, Jianbing/0000-0002-4109-8353	NHLBI NIH HHS [R01-HL48225] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048225] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acuna-Castillo C, 2000, J NEUROCHEM, V74, P1529, DOI 10.1046/j.1471-4159.2000.0741529.x; Bo XN, 2003, CELL TISSUE RES, V313, P159, DOI 10.1007/s00441-003-0758-5; BO XN, 1995, FEBS LETT, V375, P129, DOI 10.1016/0014-5793(95)01203-Q; Coddou C, 2003, EUR J PHARMACOL, V472, P49, DOI 10.1016/S0014-2999(03)01864-8; Heubach JF, 1999, CARDIOVASC RES, V42, P173, DOI 10.1016/S0008-6363(98)00262-4; Hille B., 2001, ION CHANNELS EXCITAB; Hu B, 2002, J BIOL CHEM, V277, P15752, DOI 10.1074/jbc.M112097200; Hu B, 2001, FASEB J, V15, P2739, DOI 10.1096/fj.01-0445fje; Jones CA, 2000, BRIT J PHARMACOL, V129, P388, DOI 10.1038/sj.bjp.0703059; Khakh BS, 1999, NAT NEUROSCI, V2, P322, DOI 10.1038/7233; Kunapuli SP, 1998, BIOCHEM J, V336, P513, DOI 10.1042/bj3360513; LEWIS CA, 1979, J PHYSIOL-LONDON, V286, P417, DOI 10.1113/jphysiol.1979.sp012629; Mei QB, 2001, AM J PHYSIOL-HEART C, V281, pH334, DOI 10.1152/ajpheart.2001.281.1.H334; Michel AD, 1997, MOL PHARMACOL, V51, P524; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; PARKER KE, 1995, AM J PHYSIOL-HEART C, V269, pH789, DOI 10.1152/ajpheart.1995.269.3.H789; Priel A, 2004, J GEN PHYSIOL, V123, P281, DOI 10.1085/jgp.200308986; Ralevic V, 1998, PHARMACOL REV, V50, P413; SCAMPS F, 1994, BRIT J PHARMACOL, V113, P982, DOI 10.1111/j.1476-5381.1994.tb17089.x; Shen JB, 2005, FASEB J, V19, pA517; Soto F, 1996, P NATL ACAD SCI USA, V93, P3684, DOI 10.1073/pnas.93.8.3684; Vassort G, 2001, PHYSIOL REV, V81, P767, DOI 10.1152/physrev.2001.81.2.767; Xiong KM, 1999, J NEUROPHYSIOL, V81, P2088, DOI 10.1152/jn.1999.81.5.2088; Yang A, 2004, AM J PHYSIOL-HEART C, V287, pH1096, DOI 10.1152/ajpheart.00079.2004	24	37	40	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					277	284		10.1096/fj.05-4749com	http://dx.doi.org/10.1096/fj.05-4749com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449800				2022-12-28	WOS:000237698700013
J	Thomas, DM; Francescutti-Verbeem, DM; Kuhn, DM				Thomas, DM; Francescutti-Verbeem, DM; Kuhn, DM			Gene expression profile of activated microglia under conditions associated with dopamine neuronal damage	FASEB JOURNAL			English	Article						microarray analysis; HIV TAT; lipopolysaccharide; neurodegeneration	HIV-ASSOCIATED DEMENTIA; PARKINSONS-DISEASE; INDUCED NEUROTOXICITY; MICROARRAY ANALYSIS; ALZHEIMERS-DISEASE; PROTEIN; METHAMPHETAMINE; BRAIN; INFLAMMATION; STRIATUM	Microglia are the resident antigen-presenting cells within the central nervous system (CNS), and they serve immune-like functions in protecting the brain against injury and invading pathogens. By contrast, activated microglia can secrete numerous reactants that damage neurons. The pathogenesis of various neurodegenerative diseases has been associated with microglial activation, but the signaling pathways that program a neuronally protective or destructive phenotype in microglia are not known. To increase the understanding of microglial activation, microarray analysis was used to profile the transcriptome of BV-2 microglial cells after activation. Microglia were activated by lipopolysaccharide, the HIV neurotoxic protein TAT, and dopamine quinone, each of which has been linked to dopamine neuronal damage. We identified 210 of 9882 genes whose expression was differentially regulated by all activators (116 increased and 94 decreased in expression). Gene ontology analysis assigned up-regulated genes to a number of specific biological processes and molecular functions, including immune response, inflammation, and cytokine/chemokine activity. Genes down-regulated in expression contribute to conditions that are permissive of microglial migration, lowered adhesion to matrix, lessened phagocytosis, and reduction in receptors that oppose chemotaxis and inflammation. These results elaborate a broad profile of microglial genes whose expression is altered by conditions associated with both neurodegenerative diseases and microglial activation.	John D Dingell VA Med Ctr, R&D Serv, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI 48202 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48202 USA	Wayne State University; Wayne State University	Kuhn, DM (corresponding author), John D Dingell VA Med Ctr, R&D Serv, 11R,4646 John R, Detroit, MI 48201 USA.	donald.kuhn@wayne.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA014692, R01DA017327, R01DA010756] Funding Source: NIH RePORTER; NIDA NIH HHS [DA10756, DA014692, DA17327] Funding Source: Medline; NIEHS NIH HHS [P30ES006639] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aksenov MY, 2003, BRAIN RES, V987, P1, DOI 10.1016/S0006-8993(03)03194-9; Albright AV, 2004, J NEUROIMMUNOL, V157, P27, DOI 10.1016/j.jneuroim.2004.09.007; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Baker CA, 2003, P NATL ACAD SCI USA, V100, P675, DOI 10.1073/pnas.0237313100; Blalock EM, 2004, P NATL ACAD SCI USA, V101, P2173, DOI 10.1073/pnas.0308512100; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; Chao CC, 1997, J PHARMACOL EXP THER, V281, P998; Chen ZG, 2005, J NEUROBIOL, V62, P207, DOI 10.1002/neu.20099; Dodds DC, 1997, J BIOL CHEM, V272, P21488, DOI 10.1074/jbc.272.34.21488; Duke DC, 2004, DEV NEUROSCI-BASEL, V26, P30, DOI 10.1159/000080709; Elward K, 2003, MOL IMMUNOL, V40, P85, DOI 10.1016/S0161-5890(03)00109-3; Gao HM, 2003, FASEB J, V17, P1957, DOI 10.1096/fj.03-0203fje; Gregoire S, 2005, MOL CELL BIOL, V25, P2273, DOI 10.1128/MCB.25.6.2273-2287.2005; Grunblatt E, 2004, J NEURAL TRANSM, V111, P1543, DOI 10.1007/s00702-004-0212-1; Grunblatt E, 2001, J NEUROCHEM, V78, P1, DOI 10.1046/j.1471-4159.2001.00397.x; Hediger MA, 2004, PFLUG ARCH EUR J PHY, V447, P465, DOI 10.1007/s00424-003-1192-y; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Kempermann G, 2003, SCIENCE, V302, P1689, DOI 10.1126/science.1092864; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Koutsilieri E, 2002, J NEURAL TRANSM, V109, P767, DOI 10.1007/s007020200063; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kuhn DM, 1999, J NEUROCHEM, V73, P1309, DOI 10.1046/j.1471-4159.1999.0731309.x; LaVoie MJ, 2004, EXP NEUROL, V187, P47, DOI 10.1016/j.expneurol.2004.01.010; LaVoie MJ, 1999, J NEUROSCI, V19, P1484, DOI 10.1523/jneurosci.19-04-01484.1999; Le WD, 2001, J NEUROSCI, V21, P8447, DOI 10.1523/JNEUROSCI.21-21-08447.2001; Lee MLT, 2000, P NATL ACAD SCI USA, V97, P9834, DOI 10.1073/pnas.97.18.9834; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; Lopez-Rivera E, 2005, P NATL ACAD SCI USA, V102, P3685, DOI 10.1073/pnas.0408217102; Maguire-Zeiss KA, 2005, MOL BRAIN RES, V134, P18, DOI 10.1016/j.molbrainres.2004.09.014; McGeer PL, 2004, PARKINSONISM RELAT D, V10, pS3, DOI 10.1016/j.parkreldis.2004.01.005; Moran LB, 2004, NEUROGENETICS, V5, P95, DOI 10.1007/s10048-004-0172-5; Morner A, 2003, AIDS, V17, P1451, DOI 10.1097/01.aids.0000076269.76134.c7; Nath A, 1996, J VIROL, V70, P1475, DOI 10.1128/JVI.70.3.1475-1480.1996; Ogata T, 2003, BRAIN RES, V981, P174, DOI 10.1016/S0006-8993(03)03028-2; Ouchi Y, 2005, ANN NEUROL, V57, P168, DOI 10.1002/ana.20338; PIANI D, 1994, J IMMUNOL, V152, P3578; Rowe DB, 1998, J NEUROSCI RES, V53, P551, DOI 10.1002/(SICI)1097-4547(19980901)53:5<551::AID-JNR5>3.3.CO;2-T; Speliotes EK, 1996, NEUROSCIENCE, V70, P67, DOI 10.1016/0306-4522(95)00301-X; Stokes AH, 1999, J NEUROSCI RES, V55, P659, DOI 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Streit WJ, 2004, J NEUROSCI RES, V77, P1, DOI 10.1002/jnr.20093; TERPE HJ, 1994, HISTOCHEMISTRY, V101, P41, DOI 10.1007/BF00315830; Thomas DM, 2004, J NEUROCHEM, V88, P380, DOI 10.1046/j.1471-4159.2003.02182.x; Thomas DM, 2004, J PHARMACOL EXP THER, V311, P1, DOI 10.1124/jpet.104.070961; Tsuda M, 2005, TRENDS NEUROSCI, V28, P101, DOI 10.1016/j.tins.2004.12.002; Wang GJ, 2004, BRAIN, V127, P2452, DOI 10.1093/brain/awh269; Wang TG, 2005, FASEB J, V19, P1134, DOI 10.1096/fj.04-2457fje; Webster SD, 2000, J LEUKOCYTE BIOL, V67, P109, DOI 10.1002/jlb.67.1.109; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8	51	52	56	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2005	19	14					515	+		10.1096/fj.05-4873fje	http://dx.doi.org/10.1096/fj.05-4873fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16384912				2022-12-28	WOS:000234405500017
J	Nahin, RL				Nahin, RL			Identifying and pursuing research priorities at the National Center for Complementary and Alternative Medicine	FASEB JOURNAL			English	Article						disease burden; NCCAM funding; public health	OBSTRUCTIVE PULMONARY-DISEASE; CHRONIC KIDNEY-DISEASE; UNITED-STATES; CARE EXPENDITURES; ECONOMIC BURDEN; ALZHEIMERS-DISEASE; PREVALENCE; COSTS; HEALTH; DISORDERS	As part of its planning process, the National Center for Complementary and Alternative Medicine ( NCCAM), a component of the National Institutes of Health, periodically evaluates how well it applies its criteria for setting research priorities. For its most recent evaluation, NCCAM compared funding levels in fiscal years 2000 and 2003 for 18 diseases with a substantial public health burden including Alzheimer's disease, arthritis, back pain, cancer, diabetes, coronary heart disease, HIV/ AIDS, migraine, and stroke, with 7 measures of disease burden: 1) prevalence, 2) mortality, 3) years of life lost ( YLL), 4) years lost to disability ( YLD), 5) disability- adjusted life years ( DALY's), 6) direct costs of illness ( COI), and 7) total COI. There is an increasing relationship between NCCAM research funding and disease burden over the 4- year study period that reflects funding of specific research initiatives. The strength of the individual correlations varied among measures, with the strongest correlations seen with total COI and the weakest seen with mortality. When applied with its other criteria, measures of disease burden aid identification and matching of NCCAM priorities with levels of support.	NIH, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine	Nahin, RL (corresponding author), NIH, Natl Ctr Complementary & Alternat Med, 9000 Rockville Pike,Bldg 31,Room 2B-11, Bethesda, MD 20892 USA.	nahinr@mail.nih.gov		Nahin, Richard/0000-0002-3682-4816				ADAMS PF, 1995, VITAL HLTH STAT, V10, P193; Adelmann PK, 2003, ADM POLICY MENT HLTH, V31, P111, DOI 10.1023/B:APIH.0000003017.78877.56; *AG HEALTHC RES QU, 2004, 1996 EXP COND; *AM HEART ASS, 2004, AM HEART ASS HEART D; [Anonymous], 2001, JAMA, V285, P1571; Barnes Patricia M, 2004, Adv Data, P1; Bedir E, 2002, J AGR FOOD CHEM, V50, P3150, DOI 10.1021/jf011682s; Berman JD, 2004, ANNU REV MED, V55, P239, DOI 10.1146/annurev.med.55.091902.103657; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; BOLEN J, 2001, MMWR-MORBID MORTAL W, V51, P948; Bozzette SA, 1998, NEW ENGL J MED, V339, P1897, DOI 10.1056/NEJM199812243392606; Bozzette SA, 2001, NEW ENGL J MED, V344, P817, DOI 10.1056/NEJM200103153441107; Brookmeyer R, 1998, AM J PUBLIC HEALTH, V88, P1337, DOI 10.2105/AJPH.88.9.1337; Brown ML, 2001, ANNU REV PUBL HEALTH, V22, P91, DOI 10.1146/annurev.publhealth.22.1.91; BROWN ML, 2002, MED CARE, V40, pIV17; Burton WN, 2002, J OCCUP ENVIRON MED, V44, P523, DOI 10.1097/00043764-200206000-00013; *CDC, 2000, HIV AIDS SURV REP 20, P12; *CDC PREV, 1999, HIV AIDS SURV SUPPL, P7; *CDC PREV, 2002, HIV AIDS SURV REP, P8; Chilcott LA, 1996, PHARMACOECONOMICS, V10, P1, DOI 10.2165/00019053-199600101-00003; CISTERNAN M, 2003, MMWR-MORBID MORTAL W, V52, P1124; Cohen JW, 2003, HEALTH AFFAIR, V22, P129, DOI 10.1377/hlthaff.22.2.129; Colice GL, 2004, CHEST, V125, P2140, DOI 10.1378/chest.125.6.2140; Coresh J, 2003, AM J KIDNEY DIS, V41, P1, DOI 10.1053/ajkd.2003.50007; Druss BG, 2002, HEALTH AFFAIR, V21, P105, DOI 10.1377/hlthaff.21.4.105; Druss BG, 2001, HEALTH AFFAIR, V20, P233, DOI 10.1377/hlthaff.20.6.233; Dunlop DD, 2003, ARTHRIT RHEUM-ARTHR, V49, P101, DOI 10.1002/art.10913; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; ERNST RL, 1994, AM J PUBLIC HEALTH, V84, P1261, DOI 10.2105/AJPH.84.8.1261; FRIED VM, 2003, CHARTBOOK TRENDS HLT; Greenberg PE, 2003, J CLIN PSYCHIAT, V64, P1465, DOI 10.4088/JCP.v64n1211; GREENBERG PE, 1993, J CLIN PSYCHIAT, V54, P405; Gross CP, 1999, NEW ENGL J MED, V340, P1881, DOI 10.1056/NEJM199906173402406; HARDY M, 2002, AHRQ PUBLICATION; Hellinger FJ, 2000, J ACQ IMMUN DEF SYND, V24, P182; Hodgson TA, 1999, PREV MED, V29, P173, DOI 10.1006/pmed.1999.0534; Hodgson TA, 1999, MED CARE, V37, P994, DOI 10.1097/00005650-199910000-00004; Hodgson TA, 2001, MED CARE, V39, P599, DOI 10.1097/00005650-200106000-00008; Hodgson TA, 1999, HEALTH CARE FINANC R, V21, P119; HOGAN P, 2002, DIABETES CARE, V26, P917; Hu XH, 1999, ARCH INTERN MED, V159, P813, DOI 10.1001/archinte.159.8.813; Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F; *I MED, 1998, SCI OPP PUBL NEEDS I; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Kleinman A., 2002, SCI PLACEBO INTERDIS, P1; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; Levey AS, 2003, ANN INTERN MED, V139, P137, DOI 10.7326/0003-4819-139-2-200307150-00013; Lin MC, 2001, CIRCULATION, V103, P2038; Lipton RB, 2001, HEADACHE, V41, P646, DOI 10.1046/j.1526-4610.2001.041007646.x; Luo XM, 2004, SPINE, V29, P79, DOI 10.1097/01.BRS.0000105527.13866.0F; MATHERS CD, 2002, 50 WORLD HLTH; Mathews WC, 2000, MED CARE, V38, P750, DOI 10.1097/00005650-200007000-00007; McNeil JM, 2001, JAMA-J AM MED ASSOC, V285, P1571; Michaud CM, 2001, JAMA-J AM MED ASSOC, V285, P535, DOI 10.1001/jama.285.5.535; Minino Arialdi M, 2002, Natl Vital Stat Rep, V50, P1; Nahin RL, 2001, BRIT MED J, V322, P161, DOI 10.1136/bmj.322.7279.161; Narrow WE, 2002, ARCH GEN PSYCHIAT, V59, P115, DOI 10.1001/archpsyc.59.2.115; *NAT CTR HLTH STAT, 1999, MMWR-MORBID MORTAL W, V48, P349; *NAT HEART LUNG BL, 2004, 2004 CHART BOOK CARD; Niederman MS, 1998, CLIN THER, V20, P820, DOI 10.1016/S0149-2918(98)80144-6; *NIH, 1997, PUBLICATION; *NIH, 2000, DIS SPEC EST DIR IND; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; PLEIS JR, 2003, NATL HLTH INTERVIEW, V10; PLEIS JR, 2003, VITAL HLTH STAT, V10; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Richmond J, 1996, JAMA-J AM MED ASSOC, V276, P313; Rizzo JA, 1998, MED CARE, V36, P1471, DOI 10.1097/00005650-199810000-00006; Rost K, 1998, AM J PSYCHIAT, V155, P883, DOI 10.1176/ajp.155.7.883; Russell MW, 1998, AM J CARDIOL, V81, P1110, DOI 10.1016/S0002-9149(98)00136-2; Sandler RS, 2002, GASTROENTEROLOGY, V122, P1500, DOI 10.1053/gast.2002.32978; Snedecor GW., 1968, STAT METHODS; Thom TJ, 1996, IN VIVO, V10, P255; Trupin L, 2003, EUR RESPIR J, V22, P462, DOI 10.1183/09031936.03.00094203; *US CENS BUR, 2004, STAT ABSTR US; Varmus H, 1999, NEW ENGL J MED, V340, P1914, DOI 10.1056/NEJM199906173402411; Walsh JK, 1999, SLEEP, V22, pS386; Ward MM, 2000, RESP MED, V94, P1123, DOI 10.1053/rmed.2000.0933; Watanabe CMH, 2001, P NATL ACAD SCI USA, V98, P6577, DOI 10.1073/pnas.111126298; *WHO, 2002, RED RISKS PROM HEALT, P228; *WHO, 2002, WORLD HLTH REPORT 20, P228; *WHO, 1997, MAJ FIND REC AD HOC; Wilson L, 2000, RESP MED, V94, P204, DOI 10.1053/rmed.1999.0720; Wilson T, 2004, MON LABOR REV, V127, P3; Yelin E, 2002, EUR RESPIR J, V19, P414, DOI 10.1183/09031936.02.00522001; YELIN E, 2003, DIRECT INDIRECT COST; 1997, MMWR MORB MORTAL WKL, V50, P334	89	9	9	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1209	1215		10.1096/fj.05-3727LFE	http://dx.doi.org/10.1096/fj.05-3727LFE			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16051686				2022-12-28	WOS:000231843700026
J	Nicchia, GP; Srinivas, M; Li, W; Brosnan, CF; Frigeri, A; Spray, DC				Nicchia, GP; Srinivas, M; Li, W; Brosnan, CF; Frigeri, A; Spray, DC			New possible roles for aquaporin-4 in astrocytes: cell cytoskeleton and functional relationship with connexin43	FASEB JOURNAL			English	Article						AQP4; Cx43; gap junctions; siRNA	FIBRILLARY ACIDIC PROTEIN; REACTIVE ASTROCYTES; WATER TRANSPORT; ASTROGLIAL MORPHOLOGY; NEURONAL REGULATION; ACTIN CYTOSKELETON; MESSENGER-RNA; BRAIN-INJURY; GLIAL-CELLS; EXPRESSION	Aquaporin-4 (AQP4), the main water channel in the brain, is expressed in the perivascular membranes of mouse, rat, and human astrocytes. In a previous study, we used small interfering RNA (siRNA) to specifically knock down AQP4 in rat astrocyte primary cultures and found that together with reduced osmotic permeability, AQP4 knockdown (KD) led to altered cell morphology. However, a recent report on primary cultured astrocytes from AQP4 null mice (KO) showed no morphological differences compared with wild types. In this study, we compared the effect of AQP4 KD in mouse, rat, and human astrocyte primary cultures and found that AQP4 KD in human astrocytes resulted in a morphological phenotype similar to that found in rat. In contrast, AQP4 KD in mouse astrocytes caused only very mild morphological changes. The actin cytoskeleton of untreated astrocytes exhibited strong species-specific differences, with F-actin being organized in cortical bands in mouse and in stress fibers in rat and human astrocytes. Surprisingly, as a consequence of AQP4 KD, F-actin cytoskeleton was depolymerized in rat and human whereas it was completely rearranged in mouse astrocytes. Although AQP4 KD induced alterations of the cell cytoskeleton, we found that the expression of dystrophin (DP71), beta-dystroglycan, and alpha-syntrophin was not altered. AQP4 KD in cultured mouse astrocytes produced strong down-regulation of connexin43 (Cx43) with a concomitant reduction in cell coupling while no major alterations in Cx43 expression were found in rat and human cells. Taken together, these results demonstrate that with regard to these properties, human astrocytes in culture are more similar to rat than to mouse astrocytes. Moreover, even though AQP4 KD in mouse astrocytes did not result in a dramatic morphological phenotype, it induced a remarkable rearrangement of F-actin, not related to disruption of the dystrophin complex, indicating a primary role of this water channel in the cytoskeleton changes observed. Finally, the strong down-regulation of Cx43 and cell coupling in AQP4 KD mouse astrocytes indicate that a functional relationship likely exists between water channels and gap junctions in brain astrocytes.	Univ Bari, Dipartimento Fisiol Gen & Ambientale, I-70126 Bari, Italy; Univ Bari, CEGBA, I-70126 Bari, Italy; Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10464 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10464 USA	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Nicchia, GP (corresponding author), Univ Bari, Dipartimento Fisiol Gen & Ambientale, Via Amendola 165-A, I-70126 Bari, Italy.	p.nicchia@biologia.uniba.it	frigeri, Antonio/AAC-6336-2022	Frigeri, Antonio/0000-0002-5284-2934; Spray, David/0000-0001-8368-5073; Li, Wei/0000-0002-7941-7022	NINDS NIH HHS [NS41282] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Al-Ghoul KJ, 2003, ANAT REC PART A, V273A, P714, DOI 10.1002/ar.a.10080; Allansson L, 2001, J NEUROCHEM, V76, P472, DOI 10.1046/j.1471-4159.2001.00097.x; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P13615, DOI 10.1073/pnas.2336064100; Badaut J, 2003, ACTA NEUROCHIR SUPPL, V86, P495; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; De Pina-Benabou MH, 2001, J NEUROSCI, V21, P6635; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; ENKVIST MOK, 1994, J NEUROCHEM, V62, P489; Frigeri A, 2002, FASEB J, V16, P1120, DOI 10.1096/fj.01-0797fje; FRIGERI A, 1995, J CELL SCI, V108, P2993; GOLDMAN JE, 1990, BRAIN RES, V528, P189, DOI 10.1016/0006-8993(90)91657-3; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; Hawrylak N, 1998, GLIA, V22, P260, DOI 10.1002/(SICI)1098-1136(199803)22:3<260::AID-GLIA5>3.0.CO;2-9; John GR, 2004, J NEUROSCI, V24, P2837, DOI 10.1523/JNEUROSCI.4789-03.2004; Kielian T, 2004, NEUROCHEM INT, V45, P429, DOI 10.1016/j.neuint.2003.09.010; LaDu MJ, 2001, NEUROCHEM INT, V39, P427, DOI 10.1016/S0197-0186(01)00050-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SHC, 1992, LAB INVEST, V67, P465; Leis JA, 2005, GLIA, V50, P407, DOI 10.1002/glia.20145; Liberto CM, 2004, J NEUROCHEM, V89, P1092, DOI 10.1111/j.1471-4159.2004.02420.x; Matsutani S, 1997, GLIA, V20, P1, DOI 10.1002/(SICI)1098-1136(199705)20:1<1::AID-GLIA1>3.0.CO;2-E; MCMILLIAN MK, 1994, TRENDS NEUROSCI, V17, P138, DOI 10.1016/0166-2236(94)90086-8; Moran J, 1996, AM J PHYSIOL-CELL PH, V271, pC1901, DOI 10.1152/ajpcell.1996.271.6.C1901; Nagelhus EA, 1999, GLIA, V26, P47, DOI 10.1002/(SICI)1098-1136(199903)26:1<47::AID-GLIA5>3.0.CO;2-5; Nicchia GP, 2003, FASEB J, V17, P1508, DOI 10.1096/fj.02-1183fje; Nicchia GP, 2000, GLIA, V31, P29, DOI 10.1002/(SICI)1098-1136(200007)31:1<29::AID-GLIA30>3.0.CO;2-3; Nielsen S, 1997, J NEUROSCI, V17, P171; Paul S, 1996, EUR J NEUROSCI, V8, P2361, DOI 10.1111/j.1460-9568.1996.tb01199.x; Pu PY, 2004, CLIN NEUROL NEUROSUR, V107, P49, DOI 10.1016/j.clineuro.2004.03.006; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Saadoun S, 2002, J NEUROL NEUROSUR PS, V72, P262, DOI 10.1136/jnnp.72.2.262; Scemes E, 1998, GLIA, V24, P65, DOI 10.1002/(SICI)1098-1136(199809)24:1<65::AID-GLIA7>3.0.CO;2-#; SHAO YP, 1994, GLIA, V11, P1, DOI 10.1002/glia.440110103; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; Soroceanu L, 2001, GLIA, V33, P107, DOI 10.1002/1098-1136(200102)33:2<107::AID-GLIA1010>3.0.CO;2-4; Spray DC, 1998, CIRC RES, V83, P679, DOI 10.1161/01.RES.83.6.679; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Tomimoto H, 1997, ACTA NEUROPATHOL, V94, P146, DOI 10.1007/s004010050686; TORANALLERAND CD, 1991, BRAIN RES, V558, P296; Vila M, 2001, CURR OPIN NEUROL, V14, P483, DOI 10.1097/00019052-200108000-00009; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; WARTH A, 2005, ACTA NEUROPATHOL; Wu VW, 1998, J NEUROSCI RES, V51, P675, DOI 10.1002/(SICI)1097-4547(19980315)51:6<675::AID-JNR2>3.3.CO;2-N; Yu XS, 2004, J CELL SCI, V117, P871, DOI 10.1242/jcs.00945; YU XS, 2005, J BIOL CHEM	47	131	140	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1674	+		10.1096/fj.04-3281fje	http://dx.doi.org/10.1096/fj.04-3281fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16103109				2022-12-28	WOS:000231843700012
J	Bhattacharya, R; Decker, NK; Hughes, DA; Mukherjee, P; Shah, V; McNiven, MA; Mukhopadhyay, D				Bhattacharya, R; Decker, NK; Hughes, DA; Mukherjee, P; Shah, V; McNiven, MA; Mukhopadhyay, D			Regulatory role of dynamin-2 in VEGFR-2/KDR-mediated endothelial signaling	FASEB JOURNAL			English	Article						VPF; endothelial cells; cell cycle; receptor endocytosis	VASCULAR-PERMEABILITY FACTOR; GROWTH-FACTOR RECEPTOR-2; TYROSINE KINASE; TUMOR-CELLS; VEGF; VASCULOGENESIS; ANGIOGENESIS; TRAFFICKING; ASSOCIATION; ENDOCYTOSIS	Vascular endothelial growth factor receptor-2 (VEGFR-2, also known as KDR) is a receptor tyrosine kinase (RTK) regulating mitogenic, chemotactic, permeability, and survival signals in vascular endothelial cells (EC) in response to its ligand, vascular permeability factor/VEGF (VPF/VEGF), arguably the most important angiogenic cytokine. However, the compartmentalization of KDR in EC and the mechanisms regulating this process have not been well defined. Here, we demonstrate that KDR is present on the plasma membrane, on endosomes, and in the perinuclear region of EC and colocalizes with early endosomal antigen (EEA1), caveolin-1, and dynamin-2, a signal transducing GTPase involved in receptor endocytosis. Furthermore, we also observed that dynamin-2 coimmunoprecipitates with KDR and is required for EC signaling/survival. Interestingly, EC overexpressing a mutant form of dynamin deficient in GTP binding ( K44A) caused a selective inhibition in KDR protein level and endosomal vesicle formation and induced cell cycle arrest by inducing p21. Taken together, our findings suggest that dynamin-2 regulates KDR expression and function and hence plays an important role in VPF/VEGF mediated angiogenesis.	Mayo Clin & Mayo Fdn, Ctr Canc, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med, GI Res Unit, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Mukhopadhyay, D (corresponding author), Mayo Clin & Mayo Fdn, Ctr Canc, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	mukhopadhyay.debabrata@mayo.edu			NCI NIH HHS [CA-78383] Funding Source: Medline; NHLBI NIH HHS [HL-072178, HL-70567] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078383, R01CA078383] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072178, R01HL070567] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Cao S, 2001, J BIOL CHEM, V276, P14249, DOI 10.1074/jbc.M006258200; Chatterjee S, 2003, J CELL SCI, V116, P3645, DOI 10.1242/jcs.00664; Chaturvedi K, 2001, J BIOL CHEM, V276, P12345, DOI 10.1074/jbc.M008054200; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Datta K, 2004, CANCER RES, V64, P456, DOI 10.1158/0008-5472.CAN-03-2706; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DVORAK HF, 1979, JNCI-J NATL CANCER I, V62, P1459; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Fish KN, 2000, J CELL BIOL, V150, P145, DOI 10.1083/jcb.150.1.145; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GUIDI AJ, 1995, J NATL CANCER I, V87, P1237, DOI 10.1093/jnci/87.16.1237; Henley JR, 1996, J CELL BIOL, V133, P761, DOI 10.1083/jcb.133.4.761; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; KOCH AE, 1994, J IMMUNOL, V152, P4149; Kreitzer G, 2000, NAT CELL BIOL, V2, P125, DOI 10.1038/35000081; Labrecque L, 2003, MOL BIOL CELL, V14, P334, DOI 10.1091/mbc.E02-07-0379; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li SW, 1996, J BIOL CHEM, V271, P3863; Maier O, 1996, BIOCHEM BIOPH RES CO, V223, P229, DOI 10.1006/bbrc.1996.0876; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Minshall RD, 2000, J CELL BIOL, V150, P1057, DOI 10.1083/jcb.150.5.1057; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Muro S, 2003, J CELL SCI, V116, P1599, DOI 10.1242/jcs.00367; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1986, CANCER RES, V46, P5629; Shajahan AN, 2004, J BIOL CHEM, V279, P20392, DOI 10.1074/jbc.M308710200; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Wheeler YRY, 2003, FASEB J, V17, P1733, DOI 10.1096/fj.02-0942fje; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; Zezula J, 1997, J BIOL CHEM, V272, P29967, DOI 10.1074/jbc.272.47.29967	42	67	69	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1692	+		10.1096/fj.05-3889fje	http://dx.doi.org/10.1096/fj.05-3889fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16049137				2022-12-28	WOS:000230923000004
J	Lanni, A; Moreno, M; Lombardi, A; de Lange, P; Silvestri, E; Ragni, M; Farina, P; Baccari, GC; Fallahi, P; Antonelli, A; Goglia, F				Lanni, A; Moreno, M; Lombardi, A; de Lange, P; Silvestri, E; Ragni, M; Farina, P; Baccari, GC; Fallahi, P; Antonelli, A; Goglia, F			3,5-Diiodo-L-thyronine powerfully reduces adiposity in rats by increasing the burning of fats	FASEB JOURNAL			English	Article						thyroid hormone; mitochondria; liver; energy metabolism	ACETYL-COA CARBOXYLASE; CARNITINE PALMITOYLTRANSFERASE-I; THYROID-HORMONE ACTION; RESTING METABOLIC-RATE; UNCOUPLING PROTEIN-3; MALONYL-COA; ENERGY-METABOLISM; OXYGEN-CONSUMPTION; RAPID STIMULATION; SKELETAL-MUSCLE	The effect of thyroid hormones on metabolism has long supported their potential as drugs to stimulate fat reduction, but the concomitant induction of a thyrotoxic state has greatly limited their use. Recent evidence suggests that 3,5-diiodo-L-thyronine (T-2), a naturally occurring iodothyronine, stimulates metabolic rate via mechanisms involving the mitochondrial apparatus. We examined whether this effect would result in reduced energy storage. Here, we show that T-2 administration to rats receiving a high-fat diet (HFD) reduces both adiposity and body weight gain without inducing thyrotoxicity. Rats receiving HFD + T-2 showed ( when compared with rats receiving HFD alone) a 13% lower body weight, a 42% higher liver fatty acid oxidation rate, similar to 50% less fat mass, a complete disappearance of fat from the liver, and significant reductions in the serum triglyceride and cholesterol levels (-52% and -18%, respectively). Thyroid hormones and thyroid-stimulating hormone (TSH) serum levels were not influenced by T-2 administration. The biochemical mechanism underlying the effects of T-2 on liver metabolism involves the carnitine palmitoyl-transferase system and mitochondrial uncoupling. If the results hold true for humans, pharmacological administration of T-2 might serve to counteract the problems associated with overweight, such as accumulation of lipids in liver and serum, without inducing thyrotoxicity. However, the results reported here do not exclude deleterious effects of T-2 on a longer time scale as well as do not show that T-2 acts in the same way in humans.	Univ Sannio, Dipartimento Sci Biol & Ambientali, I-82100 Benevento, Italy; Univ Naples 2, Dipartimento Sci Vita, I-81100 Caserta, Italy; Univ Naples Federico II, Dipartimento Sci Biol, Sez Igiene & Fisiol, I-80134 Naples, Italy; Univ Pisa, Dipartimento Med Interna, I-56126 Pisa, Italy	University of Sannio; Universita della Campania Vanvitelli; University of Naples Federico II; University of Pisa	Goglia, F (corresponding author), Univ Sannio, Dipartimento Sci Biol & Ambientali, Via Port Arsa 11, I-82100 Benevento, Italy.	goglia@unisannio.it	Ragni, Maurizio/AAB-1527-2020; de Lange, Pieter/GXA-3052-2022	Ragni, Maurizio/0000-0001-6548-741X; MORENO, Maria/0000-0002-6218-5501; Silvestri, Elena/0000-0002-0592-9033; GOGLIA, Fernando/0000-0003-0468-9645				Abu-Elheiga L, 2000, P NATL ACAD SCI USA, V97, P1444, DOI 10.1073/pnas.97.4.1444; Acin A, 1999, BIOCHEM BIOPH RES CO, V258, P278, DOI 10.1006/bbrc.1999.0530; ALEXSON SEH, 1988, J BIOL CHEM, V263, P13564; Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1038/nrdp.2015.80; Arnold S, 1998, EUR J BIOCHEM, V252, P325, DOI 10.1046/j.1432-1327.1998.2520325.x; Ball SG, 1997, J MOL ENDOCRINOL, V19, P137, DOI 10.1677/jme.0.0190137; BRAVERMAN LE, 2000, THYROID, P515; BROWN GC, 1985, BIOCHEM J, V225, P399, DOI 10.1042/bj2250399; Brown SB, 1997, J BIOL CHEM, V272, P2163, DOI 10.1074/jbc.272.4.2163; CASTELLANI LW, 1991, BIOCHIM BIOPHYS ACTA, V1086, P197, DOI 10.1016/0005-2760(91)90008-6; Cimmino M, 1996, J ENDOCRINOL, V149, P319, DOI 10.1677/joe.0.1490319; Davis PJ, 2002, J ENDOCRINOL INVEST, V25, P377, DOI 10.1007/BF03344022; de Lange P, 2003, FASEB J, V17, P350, DOI 10.1096/fj.03-0342fje; de Lange P, 2001, ENDOCRINOLOGY, V142, P3414, DOI 10.1210/en.142.8.3414; Fail PA, 1999, TOXICOL SCI, V52, P107, DOI 10.1093/toxsci/52.1.107; FREAKE HC, 1995, ANNU REV NUTR, V15, P263, DOI 10.1146/annurev.nu.15.070195.001403; Gilat T, 2003, HEPATOLOGY, V38, P436, DOI 10.1053/jhep.2003.50348; Goglia F, 1999, FEBS LETT, V452, P115, DOI 10.1016/S0014-5793(99)00642-0; GOGLIA F, 1994, FEBS LETT, V346, P295, DOI 10.1016/0014-5793(94)00476-5; Goglia F, 2005, BIOCHEMISTRY-MOSCOW+, V70, P164, DOI 10.1007/s10541-005-0097-0; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; HORST C, 1989, BIOCHEM J, V261, P945, DOI 10.1042/bj2610945; HORST C, 1995, J ENDOCRINOL, V145, P291, DOI 10.1677/joe.0.1450291; Hulbert AJ, 2000, BIOL REV, V75, P519, DOI 10.1017/S146479310000556X; Jansen MS, 2000, J BIOL CHEM, V275, P34989, DOI 10.1074/jbc.M001752200; Kadenbach B, 2000, FREE RADICAL BIO MED, V29, P211, DOI 10.1016/S0891-5849(00)00305-1; Kadenbach B, 2003, BBA-BIOENERGETICS, V1604, P77, DOI 10.1016/S0005-2728(03)00027-6; Kerner J, 2001, AM J PHYSIOL-ENDOC M, V281, pE1054; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; Krauss S, 2005, NAT REV MOL CELL BIO, V6, P248, DOI 10.1038/nrm1592; Lanni A, 2003, FEBS LETT, V543, P5, DOI 10.1016/S0014-5793(03)00320-X; Lanni A, 2001, J ENDOCRINOL INVEST, V24, P897, DOI 10.1007/BF03343949; LANNI A, 1992, MOL CELL ENDOCRINOL, V86, P143, DOI 10.1016/0303-7207(92)90138-V; Lanni A, 1999, FEBS LETT, V444, P250, DOI 10.1016/S0014-5793(99)00061-7; Lanni A, 1996, J PHYSIOL-LONDON, V494, P831, DOI 10.1113/jphysiol.1996.sp021536; LAZAR MA, 1990, J CLIN INVEST, V86, P1777, DOI 10.1172/JCI114906; Lazar MA, 2003, J CLIN INVEST, V112, P497, DOI 10.1172/JCI200319479; Lombardi A, 1998, BIOCHEM J, V330, P521, DOI 10.1042/bj3300521; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; Moreno M, 1997, J PHYSIOL-LONDON, V505, P529, DOI 10.1111/j.1469-7793.1997.529bb.x; Moreno M, 2002, ENDOCRINOLOGY, V143, P504, DOI 10.1210/en.143.2.504; MUNDAY MR, 1991, BIOCHEM J, V280, P733, DOI 10.1042/bj2800733; OH SS, 1994, P SOC EXP BIOL MED, V207, P260, DOI 10.3181/00379727-207-43814; OREILLY I, 1992, ACTA ENDOCRINOL-COP, V127, P542, DOI 10.1530/acta.0.1270542; Pearse AGE., 1980, HISTOCHEMISTRY THEOR; Pinna G, 1997, J CLIN ENDOCR METAB, V82, P1535, DOI 10.1210/jc.82.5.1535; PORTER RK, 1993, NATURE, V362, P628, DOI 10.1038/362628a0; Ramsey JJ, 2000, FREE RADICAL BIO MED, V29, P946, DOI 10.1016/S0891-5849(00)00417-2; Rousset S, 2004, DIABETES, V53, pS130, DOI 10.2337/diabetes.53.2007.S130; SADDIK M, 1993, J BIOL CHEM, V268, P25836; Shibusawa N, 2003, J CLIN INVEST, V112, P588, DOI 10.1172/JCI200318377; SOBOLL S, 1993, BIOCHIM BIOPHYS ACTA, V1144, P1, DOI 10.1016/0005-2728(93)90024-A; Tanabe T, 1981, Methods Enzymol, V71 Pt C, P5; Velasco G, 1998, J BIOL CHEM, V273, P21497, DOI 10.1074/jbc.273.34.21497; Velasco G, 1997, ARCH BIOCHEM BIOPHYS, V337, P169, DOI 10.1006/abbi.1996.9784; Young ME, 1996, FEBS LETT, V382, P43, DOI 10.1016/0014-5793(96)00129-9; Zammit VA, 1999, BIOCHEM J, V343, P505, DOI 10.1042/0264-6021:3430505; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	59	118	123	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9								10.1096/fj.05.3977fje	http://dx.doi.org/10.1096/fj.05.3977fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16014396				2022-12-28	WOS:000230923000024
J	Ellis, S; Mouihate, A; Pittman, QJ				Ellis, S; Mouihate, A; Pittman, QJ			Early life immune challenge alters innate immune responses to lipopolysaccharide: implications for host defense as adults	FASEB JOURNAL			English	Article						fever; cytokine; hypothalamic-pituitary-adrenal axis; neonate	PITUITARY-ADRENAL AXIS; FACTOR-KAPPA-B; MESSENGER-RNA; MATERNAL-CARE; LOCALIZED INFLAMMATION; FEVER; GLUCOCORTICOIDS; EXPRESSION; ENDOTOXIN; RECEPTOR	Fever is the most common manifestation of the innate immune response to invading pathogens. Animals prevented from developing fever have increased morbidity and mortality to infection. We now show that early life events can program this innate immune response, in that rats that have been challenged neonatally with the immune stimulant lipopolysaccharide (LPS) have both suppressed febrile responses to LPS as adults and significantly reduced nuclear factor (NF)-kappa B activation in peripheral immune organs. This was associated with reduced levels of proinflammatory cytokines tumor necrosis factor (TNF)-alpha, and interleukin-6 (IL- 6) in the plasma after adult LPS challenge, compared with animals that have received saline neonatally. In contrast, adult LPS challenge elicited higher corticosterone levels in the animals that had been treated neonatally with LPS. When this increased corticosterone response was negated by adrenalectomy or by administration of the glucocorticoid receptor antagonist RU-486, both the cytokine and febrile responses were normalized. This study indicates that the innate immune response can be programmed by a neonatal LPS challenge, whereby an amplified hypothalamic-pituitary-adrenal response causes reduced cytokine synthesis and an attenuated febrile response to an adult immune challenge. In light of the importance of fever in the host defense response, these alterations may have deleterious consequences on an individual's ability to combat disease later in life.	Univ Calgary, Fac Med, Hotchkiss Brain Inst, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada	University of Calgary	Pittman, QJ (corresponding author), Univ Calgary, Fac Med, Hotchkiss Brain Inst, Dept Physiol & Biophys, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	pittman@ucalgary.ca		Pittman, Quentin/0000-0003-0984-7665				Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Almawi WY, 2002, J MOL ENDOCRINOL, V28, P69, DOI 10.1677/jme.0.0280069; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BESEDOVSKY H, 1986, SCIENCE, V233, P652, DOI 10.1126/science.3014662; Bethin KE, 2000, P NATL ACAD SCI USA, V97, P9317, DOI 10.1073/pnas.97.16.9317; Blackwell TS, 1997, AM J RESP CELL MOL, V17, P3, DOI 10.1165/ajrcmb.17.1.f132; Blatteis CM, 2000, J PHYSIOL-LONDON, V526, P470; Blatteis CM, 1998, ANN NY ACAD SCI, V840, P608, DOI 10.1111/j.1749-6632.1998.tb09600.x; Boisse L, 2004, J NEUROSCI, V24, P4928, DOI 10.1523/JNEUROSCI.1077-04.2004; Bowie A, 2000, J LEUKOCYTE BIOL, V67, P508, DOI 10.1002/jlb.67.4.508; Caldji C, 2000, BIOL PSYCHIAT, V48, P1164, DOI 10.1016/S0006-3223(00)01084-2; Cartmell T, 2000, J PHYSIOL-LONDON, V526, P653, DOI 10.1111/j.1469-7793.2000.00653.x; Cartmell T, 2003, J PHYSIOL-LONDON, V549, P653, DOI 10.1113/jphysiol.2002.037291; Cartmell T, 2001, J PHYSIOL-LONDON, V531, P171, DOI 10.1111/j.1469-7793.2001.0171j.x; Chai Z, 1996, J EXP MED, V183, P311, DOI 10.1084/jem.183.1.311; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; COELHO MM, 1995, AM J PHYSIOL-REG I, V269, pR527, DOI 10.1152/ajpregu.1995.269.3.R527; De Bosscher K, 2000, J NEUROIMMUNOL, V109, P16, DOI 10.1016/S0165-5728(00)00297-6; Hawiger J, 2001, IMMUNOL RES, V23, P99, DOI 10.1385/IR:23:2-3:099; JACOBSON L, 1988, ENDOCRINOLOGY, V122, P1343, DOI 10.1210/endo-122-4-1343; Jiang QQ, 2000, INFECT IMMUN, V68, P1265, DOI 10.1128/IAI.68.3.1265-1270.2000; Kakizaki Y, 1999, ENDOCR J, V46, P487, DOI 10.1507/endocrj.46.487; Kapcala LP, 1995, ANN NY ACAD SCI, V771, P419, DOI 10.1111/j.1749-6632.1995.tb44699.x; Kluger MJ, 1998, ANN NY ACAD SCI, V856, P224, DOI 10.1111/j.1749-6632.1998.tb08329.x; Kozak W, 1998, ANN NY ACAD SCI, V856, P33, DOI 10.1111/j.1749-6632.1998.tb08310.x; Ledeboer A, 2002, AM J PHYSIOL-REG I, V282, pR1762, DOI 10.1152/ajpregu.00766.2001; Leon LR, 1998, AM J PHYSIOL-REG I, V275, pR269, DOI 10.1152/ajpregu.1998.275.1.R269; Li ZH, 2004, J ENDOTOXIN RES, V10, P39, DOI 10.1179/096805104225003825; Liu D, 1997, SCIENCE, V277, P1659, DOI 10.1126/science.277.5332.1659; Macri S, 2004, EUR J NEUROSCI, V20, P1017, DOI 10.1111/j.1460-9568.2004.03541.x; MASFERRER JL, 1994, J PHARMACOL EXP THER, V270, P1340; MATHISON JC, 1979, J IMMUNOL, V123, P2133; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; MEANEY MJ, 1985, DEV BRAIN RES, V22, P301, DOI 10.1016/0165-3806(85)90183-X; Meltzer JC, 2003, BRAIN BEHAV IMMUN, V17, P482, DOI 10.1016/S0889-1591(03)00084-9; Mouihate A, 2003, ENDOCRINOLOGY, V144, P2454, DOI 10.1210/en.2002-0093; Nadeau S, 2003, J NEUROSCI, V23, P5536, DOI 10.1523/jneurosci.23-13-05536.2003; NEWMAN SP, 1994, BIOCHEM BIOPH RES CO, V202, P931, DOI 10.1006/bbrc.1994.2019; Nilsson C, 2002, EUR J ENDOCRINOL, V146, P251, DOI 10.1530/eje.0.1460251; PLOTSKY PM, 1993, MOL BRAIN RES, V18, P195, DOI 10.1016/0169-328X(93)90189-V; Quan N, 2000, J NEUROSCI, V20, P6473, DOI 10.1523/JNEUROSCI.20-17-06473.2000; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RIVIER C, 1989, ENDOCRINOLOGY, V125, P2800, DOI 10.1210/endo-125-6-2800; ROTH J, 1993, AM J PHYSIOL, V265, pR653, DOI 10.1152/ajpregu.1993.265.3.R653; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Scotte M, 1996, CYTOKINE, V8, P115, DOI 10.1006/cyto.1996.0016; SHANKS N, 1995, J NEUROSCI, V15, P376, DOI 10.1523/jneurosci.15-01-00376.1995; Shanks N, 2000, P NATL ACAD SCI USA, V97, P5645, DOI 10.1073/pnas.090571897; Tatro JB, 2000, CLIN INFECT DIS, V31, pS190, DOI 10.1086/317519; Turnbull AV, 1995, BRAIN BEHAV IMMUN, V9, P253, DOI 10.1006/brbi.1995.1026; Turrin NP, 2001, BRAIN RES BULL, V54, P443, DOI 10.1016/S0361-9230(01)00445-2; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276	53	89	90	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1519	+		10.1096/fj.04-3569fje	http://dx.doi.org/10.1096/fj.04-3569fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15972802				2022-12-28	WOS:000230207800009
J	Liou, AKF; Zhou, ZG; Pei, W; Lim, TM; Yin, XM; Chen, J				Liou, AKF; Zhou, ZG; Pei, W; Lim, TM; Yin, XM; Chen, J			BimEL up-regulation potentiates AIF translocation and cell death in response to MPTP	FASEB JOURNAL			English	Article						mitochondria; calpain I; MPP plus treatment	APOPTOSIS-INDUCING FACTOR; SPINAL-CORD-INJURY; DOPAMINERGIC NEURONAL CELLS; CEREBELLAR GRANULE NEURONS; CYTOCHROME-C RELEASE; BH3-ONLY PROTEIN BIM; BCL-2 FAMILY MEMBER; PARKINSONS-DISEASE; OXIDATIVE STRESS; PC12 CELLS	This study attempted to elucidate the signaling mechanism underlying dopaminergic cell death in the MPP+ model for Parkinson's disease. In neuronal-differentiated PC12 cells, through the regulation by activated JNK and c-jun, BimEL expression was markedly increased in response to MPP+ treatment, which led to the cell degeneration. In lieu of Smac translocation as seen in other paradigms, up-regulation of BimEL effected an increase in calpain I activity that, in turn, mediated AIF release from the mitochondria. In support, we found that knocking down BimEL expression resulted in a decrease in calpain I activity, as well as AIF release from the mitochondria and cell death. Finally, inhibition of calpain activity mitigated AIF release from the mitochondria and cell death. Under cell-free conditions, activated purified calpain I could induce the release of AIF from isolated mitochondria without the participation of BimEL or activated JNK, suggesting that AIF release is a direct consequence of calpain I activity. In concert, the results suggest a novel signaling pathway for dopaminergic cell degeneration, in which MPP+ induces the up-regulation of BimEL, which in turn potentiates an elevation in calpain I activity that mediates AIF release and cell death in a caspase-independent manner.	Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Pittsburgh Inst Neurodegenerat Disorders, Pittsburgh, PA USA; Natl Univ Singapore, Dept Sci Biol, Singapore 117548, Singapore; Vet Affairs Pittsburgh Hlth Care Syst, Educ & Clin Ctr, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National University of Singapore; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System	Liou, AKF (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, S507 Biomed Sci Tower,3500 Terrace St, Pittsburgh, PA 15261 USA.	lioukf@upmc.edu		Chen, Jun/0000-0002-8077-3403	NINDS NIH HHS [NS45048, NS44178, NS43802] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043802, R01NS044178, R01NS045048] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bai J, 2002, NEUROSCI LETT, V321, P81, DOI 10.1016/S0304-3940(02)00058-7; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; Bizat N, 2003, J NEUROSCI, V23, P5020; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Cao GD, 2004, J NEUROSCI, V24, P6189, DOI 10.1523/JNEUROSCI.1426-04.2004; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chera B, 2002, ANN NY ACAD SCI, V965, P274; Choi WS, 1999, EXP NEUROL, V159, P274, DOI 10.1006/exnr.1999.7133; Choi WS, 1999, J NEUROSCI RES, V57, P86, DOI 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.0.CO;2-E; Choi WS, 2001, J NEUROCHEM, V77, P1531, DOI 10.1046/j.1471-4159.2001.00368.x; Crocker SJ, 2003, J NEUROSCI, V23, P4081; Crocker SJ, 2001, P NATL ACAD SCI USA, V98, P13385, DOI 10.1073/pnas.231177098; Du YS, 1997, J NEUROCHEM, V69, P1382; Eberhardt O, 2000, J NEUROSCI, V20, P9126; Fennell DA, 2001, BRIT J CANCER, V84, P1397, DOI 10.1054/bjoc.2001.1788; Fonfria E, 2002, EUR J NEUROSCI, V16, P2013, DOI 10.1046/j.1460-9568.2002.02269.x; Fribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004; Friedrich P, 2004, BIOCHEM BIOPH RES CO, V323, P1131, DOI 10.1016/j.bbrc.2004.08.194; Gelinas S, 2002, J NEUROSCI RES, V70, P90, DOI 10.1002/jnr.10315; Gomez C, 2001, J NEUROSCI RES, V63, P421, DOI 10.1002/1097-4547(20010301)63:5<421::AID-JNR1037>3.0.CO;2-4; Gonzalez-Polo RA, 2003, J NEUROCHEM, V84, P305, DOI 10.1046/j.1471-4159.2003.01520.x; Harris C, 2002, J NEUROCHEM, V83, P992, DOI 10.1046/j.1471-4159.2002.01219.x; Hildeman DA, 2002, CURR OPIN IMMUNOL, V14, P354, DOI 10.1016/S0952-7915(02)00335-7; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Jiang XJ, 2003, SCIENCE, V299, P223, DOI 10.1126/science.1076807; Jiang ZH, 2004, J NEUROCHEM, V89, P168, DOI 10.1111/j.1471-4159.2004.02319.x; Kaul S, 2003, EUR J NEUROSCI, V18, P1387, DOI 10.1046/j.1460-9568.2003.02864.x; Kim HE, 2001, BIOCHEM BIOPH RES CO, V286, P659, DOI 10.1006/bbrc.2001.5446; Kovacsovics M, 2002, CURR BIOL, V12, P838, DOI 10.1016/S0960-9822(02)00842-4; Kowaltowski AJ, 2004, FREE RADICAL BIO MED, V37, P1845, DOI 10.1016/j.freeradbiomed.2004.09.005; Krepela E, 2004, BIOL CHEM, V385, P153, DOI 10.1515/BC.2004.034; Kulich SM, 2003, J BIOSCIENCES, V28, P83, DOI 10.1007/BF02970136; Lee CS, 2003, NEUROCHEM INT, V43, P147, DOI 10.1016/S0197-0186(02)00214-0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Linseman DA, 2002, J NEUROSCI, V22, P9287; Liu XQ, 2003, IMMUNITY, V19, P341, DOI 10.1016/S1074-7613(03)00234-6; Marti A, 2001, MECH DEVELOP, V104, P89, DOI 10.1016/S0925-4773(01)00381-1; McMahon A, 1998, MOL BRAIN RES, V54, P56, DOI 10.1016/S0169-328X(97)00305-7; Napankangas U, 2003, MOL BRAIN RES, V120, P30, DOI 10.1016/j.molbrainres.2003.09.016; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Plenchette S, 2001, LEUKEMIA, V15, P1572, DOI 10.1038/sj.leu.2402231; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Ray SK, 2003, J CHEM NEUROANAT, V26, P119, DOI 10.1016/S0891-0618(03)00044-9; Ray SK, 2001, ANN NY ACAD SCI, V939, P436; Ray SK, 2000, BRAIN RES, V867, P80, DOI 10.1016/S0006-8993(00)02260-5; Ray SK, 2003, CNS NEUROL DISORD-DR, V2, P173, DOI 10.2174/1568007033482887; Sun DS, 2003, CELL BIOL INT, V27, P769, DOI 10.1016/S1065-6995(03)00165-3; Tretter L, 2004, NEUROCHEM RES, V29, P569, DOI 10.1023/B:NERE.0000014827.94562.4b; Villunger A, 2003, BLOOD, V101, P2393, DOI 10.1182/blood-2002-07-2132; Wang HM, 2003, ANN NY ACAD SCI, V991, P132; Wilson-Annan J, 2003, J CELL BIOL, V162, P877, DOI 10.1083/jcb.200302144; Yamaguchi H, 2002, J BIOL CHEM, V277, P41604, DOI 10.1074/jbc.M207516200; Yang LC, 1998, J NEUROSCI, V18, P8145; Yin KJ, 2002, J NEUROSCI, V22, P9764; Yokoyama T, 2002, IMMUNOL LETT, V81, P107, DOI 10.1016/S0165-2478(02)00003-2; Zhang J, 2000, J NEUROPATH EXP NEUR, V59, P53, DOI 10.1093/jnen/59.1.53; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	63	61	63	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2005	19	8					1350	+		10.1096/fj.04-3258fje	http://dx.doi.org/10.1096/fj.04-3258fje			30	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15941767				2022-12-28	WOS:000230207800029
J	Kawamori, T; Osta, W; Johnson, KR; Pettus, BJ; Bielawski, J; Tanaka, T; Wargovich, MJ; Reddy, BS; Hannun, YA; Obeid, LM; Zhou, DH				Kawamori, Toshihiko; Osta, Walid; Johnson, Korey R.; Pettus, Benjamin J.; Bielawski, Jacek; Tanaka, Takuji; Wargovich, Michael J.; Reddy, Bandaru S.; Hannun, Yusuf A.; Obeid, Lina M.; Zhou, Daohong			Sphingosine kinase 1 is up-regulated in colon carcinogenesis	FASEB JOURNAL			English	Article									[Kawamori, Toshihiko; Zhou, Daohong] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Osta, Walid] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA; [Johnson, Korey R.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; [Pettus, Benjamin J.; Bielawski, Jacek; Hannun, Yusuf A.; Obeid, Lina M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Tanaka, Takuji] Kanazawa Med Univ, Dept Pathol, Kanazawa, Ishikawa, Japan; [Wargovich, Michael J.] Univ S Carolina, Dept Pathol, S Carolina Canc Ctr, Columbia, SC 29208 USA; [Reddy, Bandaru S.] Inst Canc Prevent, Chemoprevent & Nutr Carcinogenesis Program, Valhalla, NY USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Kanazawa Medical University; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Kawamori, T (corresponding author), Med Univ S Carolina, Dept Pathol & Lab Med, 165 Ashley Ave,Suite 309, Charleston, SC 29425 USA.	kawamori@musc.edu; zhoud@musc.edu	Kawamori, Toshihiko/G-7636-2012; Tanaka, Takuji/G-5246-2010		NATIONAL CANCER INSTITUTE [P01CA097132, R01CA102558] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017677] Funding Source: NIH RePORTER; NCI NIH HHS [CA102558, CA86688, P01CA097132] Funding Source: Medline; NCRR NIH HHS [P20RR017677] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))			0	154	171	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					386	388		10.1096/fj.05-4331fje	http://dx.doi.org/10.1096/fj.05-4331fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16319132				2022-12-28	WOS:000207915000030
J	Myzak, MC; Dashwood, WM; Orner, GA; Ho, E; Dashwood, RH				Myzak, MC; Dashwood, WM; Orner, GA; Ho, E; Dashwood, RH			Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc(min) mice	FASEB JOURNAL			English	Article						chemoprevention; colorectal cancer; diet; gene regulation	CHAIN FATTY-ACIDS; INDUCE APOPTOSIS; COLON-CANCER; TRICHOSTATIN; EXPRESSION; P21(WAF1/CIP1); TRANSCRIPTION; ACETYLATION; BUTYRATE; ENZYMES	Sulforaphane (SFN) is an isothiocyanate from broccoli that induces phase 2 detoxification enzymes. We recently reported that SFN acts as a histone deacetylase ( HDAC) inhibitor in human colon cancer cells in vitro, and the present study sought to extend these findings in vivo. In mice treated with a single oral dose of 10 mu mol SFN, there was significant inhibition of HDAC activity in the colonic mucosa after 6 h, and immunoblots revealed a concomitant increase in acetylated histones H3 and H4, which returned to control levels by 48 h. Longer-term treatment with SFN in the diet resulted in levels of acetylated histones and p21(WAF1) in the ileum, colon, prostate, and peripheral blood mononuclear cells that were elevated compared with controls. Consistent with these findings, SFN suppressed tumor development in Apc(min) mice, and there was an increase in acetylated histones in the polyps, including acetylated histones specifically associated with the promoter region of the P21 and bax genes. These results provide the first evidence for HDAC inhibition by SFN in vivo and imply that such a mechanism might contribute to the cancer chemoprotective and therapeutic effects of SFN, alone or in combination with other HDAC inhibitors currently undergoing clinical trials.	Oregon State Univ, Linus Pauling Inst Sci & Med, Corvallis, OR 97331 USA; Oregon State Univ, Mol & Cellular Biol Program, Corvallis, OR 97331 USA; Oregon State Univ, Dept Nutr & Exercise Sci, Corvallis, OR 97331 USA; Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA	Oregon State University; Oregon State University; Oregon State University; Oregon State University	Dashwood, RH (corresponding author), Oregon State Univ, Linus Pauling Inst Sci & Med, Corvallis, OR 97331 USA.	Rod.Dashwood@oregonstate.edu	Orner, Gayle A./F-6876-2013; Dashwood, Roderick H/E-9090-2011; Dashwood, Roderick/AAF-2025-2020	Orner, Gayle A./0000-0002-4812-5297; 	NATIONAL CANCER INSTITUTE [P01CA090890, R29CA065525, R01CA080176, R01CA065525, R21CA100608, R01CA107693] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA090890-01A29001, P01 CA090890-05S1, CA-107693, R01 CA080176-04, R01 CA065525, CA-90890, CA-80176, CA-65525, P01 CA090890-01A20003, CA-100608, R01 CA065525-08, P01 CA090890-05, P01 CA090890, R01 CA065525-09, R01 CA080176-05, R01 CA080176] Funding Source: Medline; NIEHS NIH HHS [P30 ES00210] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Acquavella J, 1999, CANCER EPIDEM BIOMAR, V8, P947; ACQUAVELLA J, 1999, CANCER EPIDEM BIOMAR, V7, P647; Ben-Dor A, 2005, MOL CANCER THER, V4, P177; Chen ZX, 2002, CANCER LETT, V188, P127, DOI 10.1016/S0304-3835(02)00322-1; Chung FL, 2000, CARCINOGENESIS, V21, P2287, DOI 10.1093/carcin/21.12.2287; Dashwood RH, 2002, MUTAT RES-REV MUTAT, V511, P89, DOI 10.1016/S1383-5742(02)00005-4; Della Ragione F, 2001, FEBS LETT, V499, P199, DOI 10.1016/S0014-5793(01)02539-X; Druesne N, 2004, CARCINOGENESIS, V25, P1227, DOI 10.1093/carcin/bgh123; Eggler AL, 2005, P NATL ACAD SCI USA, V102, P10070, DOI 10.1073/pnas.0502402102; Eickhoff B, 2000, BIOL CHEM, V381, P107, DOI 10.1515/BC.2000.015; Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367; Fahey JW, 2002, P NATL ACAD SCI USA, V99, P7610, DOI 10.1073/pnas.112203099; Finzer P, 2001, ONCOGENE, V20, P4768, DOI 10.1038/sj.onc.1204652; Gottlicher M, 2004, ANN HEMATOL S1, V83, pS91; Hinnebusch BF, 2002, J NUTR, V132, P1012, DOI 10.1093/jn/132.5.1012; Kelly WK, 2003, CLIN CANCER RES, V9, P3578; Kobayashi H, 2004, INT J CANCER, V109, P207, DOI 10.1002/ijc.11697; Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315; Lavelle D, 2001, AM J HEMATOL, V68, P170, DOI 10.1002/ajh.1174; Lee JM, 2005, FASEB J, V19, P1061, DOI 10.1096/fj.04-2591hyp; Lipkin M, 1999, ANNU REV NUTR, V19, P545, DOI 10.1146/annurev.nutr.19.1.545; Mariadason JM, 2000, CANCER RES, V60, P4561; McBain JA, 1997, BIOCHEM PHARMACOL, V53, P1357, DOI 10.1016/S0006-2952(96)00904-5; Myzak MC, 2004, CANCER RES, V64, P5767, DOI 10.1158/0008-5472.CAN-04-1326; MYZAK MC, 2006, IN PRESS CURR DRUG T; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Reddy BS, 2000, CANCER EPIDEM BIOMAR, V9, P239; Remiszewski SW, 2002, J MED CHEM, V45, P753, DOI 10.1021/jm015568c; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Sandor V, 2002, CLIN CANCER RES, V8, P718; Seow A, 2002, CARCINOGENESIS, V23, P2055, DOI 10.1093/carcin/23.12.2055; Woo SH, 2002, J MED CHEM, V45, P2877, DOI 10.1021/jm020154k; Yang K, 2003, CARCINOGENESIS, V24, P605, DOI 10.1093/carcin/24.3.605; Yasui W, 2003, ANN NY ACAD SCI, V983, P220, DOI 10.1111/j.1749-6632.2003.tb05977.x; Yoxall V, 2005, INT J CANCER, V117, P356, DOI 10.1002/ijc.21191; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399; ZHANG YS, 1994, P NATL ACAD SCI USA, V91, P3147, DOI 10.1073/pnas.91.8.3147; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X; Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440	39	263	269	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					506	+		10.1096/fj.05-4785fje	http://dx.doi.org/10.1096/fj.05-4785fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16407454	Green Accepted			2022-12-28	WOS:000235996000022
J	Udagawa, T; Puder, M; Wood, M; Schaefer, BC; D'Amato, RJ				Udagawa, T; Puder, M; Wood, M; Schaefer, BC; D'Amato, RJ			Analysis of tumor-associated stromal cells using SCID GFP transgenic mice: contribution of local and bone marrow-derived host cells	FASEB JOURNAL			English	Article						tumor; stroma; cancer; Flk-1; VEGFR2; angiogenesis; endothelial cells; GFP	GENETIC-HETEROGENEITY; STEM-CELLS; IN-VIVO; ANGIOGENESIS; GROWTH; INDUCTION; ANGIOPOIETIN-2; MECHANISMS; PHENOTYPE; DORMANCY	The green fluorescence protein (GFP) from the UBI-GFP/BL6 transgenic line was bred into C57BL/6J-scid and C.B-17-scid mice for investigating host-tumor cell interactions. These mice express high levels of GFP under the control of the ubiquitin promoter in virtually all cells examined. In tumor tissue generated by implanting tumor cells in the GFP transgenic SCID mice, the tumor cells and tumor-associated murine host cells were clearly distinguished by GFP expression. A population of cells expressing the endothelial cell marker VEGFR-2/Flk-1, and the progenitor markers c-Kit and Sca-1, were incorporated into tumor tissue. The majority of the Flk-1-positive cells were hematopoietic-derived cells that coexpressed CD45. To investigate the contribution of bone marrow-derived cells to the formation of tumor vessels and stroma, tumor cells were implanted in nontransgenic SCID mice that received a bone marrow transplant from GFP-expressing SCID mice. Although GFP-positive cells were readily detected by histology in tumors taken from bone marrow transplanted animals, they were spatially isolated and lacked organization. In contrast, if tumors were implanted in nontransgenic SCID mice adjacent to a patch of transplanted GFP-expressing skin, these tumors recruited GFP-positive cells that organized into tumor vessels. The results demonstrate that hematopoietic-derived cells, including Flk-1(+)/CD45(+) cells, readily colonized the tumor stroma but were minimally incorporated in the tumor vasculature. The majority of the tumor vessels were instead recruited from tissue adjacent to the tumor. The expression of Flk-1 on nonendothelial, tumor-associated host cells raises the possibility that VEGF antagonists, such as Avastin, could inhibit tumor growth by a mechanism involving hematopoietic-derived CD45(+)/Flk-1(+) cells, in addition to direct suppression of endothelial cell function.-Udagawa, T., Puder, M., Wood, M., Schaefer, B. C., D'Amato, R. J. Analysis of tumor-associated stromal cells using SCID GFP transgenic mice: contribution of local and bone marrow-derived host cells.	Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA; Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Childrens Hosp, Dept Ophthalmol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Uniformed Services University of the Health Sciences - USA	Udagawa, T (corresponding author), Childrens Hosp, Vasc Biol Program, 1 Blackfan Cr, Boston, MA 02115 USA.	taturo.udagawa@childrens.harvard.edu		Schaefer, Brian C/0000-0001-8877-3507	NATIONAL CANCER INSTITUTE [K01CA087013] Funding Source: NIH RePORTER; NCI NIH HHS [KO1 CA087013-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Araki R, 1997, P NATL ACAD SCI USA, V94, P2438, DOI 10.1073/pnas.94.6.2438; Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; Bavik C, 1996, P NATL ACAD SCI USA, V93, P3110, DOI 10.1073/pnas.93.7.3110; BOERRIGTER METI, 1995, MECH AGEING DEV, V82, P31, DOI 10.1016/0047-6374(95)01603-W; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; Esposito I, 2004, J CLIN PATHOL, V57, P630, DOI 10.1136/jcp.2003.014498; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Hudson WA, 1998, LEUKEMIA, V12, P2029, DOI 10.1038/sj.leu.2401236; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Noonan FP, 2003, J INVEST DERMATOL, V121, P1175, DOI 10.1046/j.1523-1747.2003.12560.x; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Rajantie I, 2004, BLOOD, V104, P2084, DOI 10.1182/blood-2004-01-0336; Renz JF, 1996, J SURG RES, V65, P34, DOI 10.1006/jsre.1996.0340; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Risau W, 1992, GROWTH FACTORS, V7, P261, DOI 10.3109/08977199209046408; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871; Schaefer BC, 2001, CELL IMMUNOL, V214, P110, DOI 10.1006/cimm.2001.1895; Shaked Y, 2005, CANCER CELL, V7, P101, DOI 10.1016/j.ccr.2004.11.023; SURI C, 1996, CELL, V87, P1170; Udagawa T, 2002, FASEB J, V16, P1361, DOI 10.1096/fj.01-0813com; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yang M, 2003, P NATL ACAD SCI USA, V100, P14259, DOI 10.1073/pnas.2436101100; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553	32	62	62	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					95	102		10.1096/fj.04-3669com	http://dx.doi.org/10.1096/fj.04-3669com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16394272				2022-12-28	WOS:000235996000049
J	Zvara, A; Bencsik, P; Fodor, G; Csont, TS; Hackler, L; Dux, MR; Furst, S; Jancso, G; Puskas, LG; Ferdinandy, P				Zvara, A; Bencsik, P; Fodor, G; Csont, TS; Hackler, L; Dux, MR; Furst, S; Jancso, G; Puskas, LG; Ferdinandy, P			Capsaicin-sensitive sensory neurons regulate myocardial function and gene expression pattern of rat hearts: a DNA microarray study	FASEB JOURNAL			English	Article						transient receptor potential vanilloid receptor-1; matrix metalloproteinase-13; cytochrome P450; farnesyl-transferase; ApoB; GABA receptor	SYNTHASE-CONTAINING NEURONS; VANILLOID RECEPTOR TRPV1; NITRIC-OXIDE; SUBSTANCE-P; GUINEA-PIG; INDUCED DEPLETION; PEPTIDE; CHANNELS; NERVES; PEROXYNITRITE	We have previously shown that capsaicin-sensitive sensory nerves contribute to the regulation of normal cardiac function and to the development of cardiac adaptation to ischemic stress; however, the underlying molecular mechanisms remain unknown. Therefore, here we assessed cardiac functional alterations and relative gene expression changes by DNA microarray analysis of 6400 genes in rat hearts 7 days after the end of systemic capsaicin treatment protocol leading to selective sensory chemodenervation. Capsaicin pretreatment resulted in a cardiac dysfunction characterized by elevation of left ventricular end-diastolic pressure and led to altered expression of 80 genes of known function or homology to known sequences. Forty-seven genes exhibited significant up-regulation and 33 genes were down-regulated (changes ranged from -3.9 to +4.8fold). The expression changes of 10 selected genes were verified, and an additional 11 genes were examined by real-time quantitative PCR. This is the first demonstration that gene expression changes in the heart due to capsaicin pretreatment included vanilloid receptor-1 (capsaicin receptor), transient receptor potential protein, GABA receptor rho-3 subunit, 5-hydroxytryptamine 3 receptor B, neurokinin receptor 2, endothelial nitric oxide synthase, matrix metalloproteinase-13, cytochrome P450, farnesyl-transferase, ApoB, and leptin. None of the genes have been previously shown to be involved in the mechanism of the cardiac functional effects of sensory chemodenervation by capsaicin. We conclude that capsaicin-sensitive sensory nerves play a significant role in the regulation of a variety of neuronal and non-neuronal genes in the heart and possibly in other tissues as well.	Univ Szeged, Cardiovasc Res Grp, Dept Biochem, H-6720 Szeged, Hungary; Hungarian Acad Sci, Lab Funct Genom, Biol Res Ctr, Szeged, Hungary; Hungarian Acad Sci, Neuro Psychopharmacol Res Grp, Szeged, Hungary; Semmelweis Univ, Dept Pharmacol & Pharmacotherapy, Budapest, Hungary; Univ Szeged, Dept Physiol, Szeged, Hungary	Szeged University; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Academy of Sciences; Semmelweis University; Szeged University	Ferdinandy, P (corresponding author), Univ Szeged, Cardiovasc Res Grp, Dept Biochem, Dom Ter 9, H-6720 Szeged, Hungary.	peter@bioch.szote.u-szeged.hu	Ferdinandy, Péter/H-9181-2019	Bencsik, Peter/0000-0003-1936-6232				Benson CJ, 1999, CIRC RES, V84, P921; Clapham DE, 2003, PHARMACOL REV, V55, P591, DOI 10.1124/pr.55.4.6; Cook SA, 2002, J BIOL CHEM, V277, P22528, DOI 10.1074/jbc.M201462200; Cortright DN, 2004, EUR J BIOCHEM, V271, P1814, DOI 10.1111/j.1432-1033.2004.04082.x; Csonka C, 1999, CIRCULATION, V100, P2260, DOI 10.1161/01.CIR.100.22.2260; Csont T, 2003, EUR J PHARMACOL, V476, P107, DOI 10.1016/S0014-2999(03)02117-4; Csont T, 2002, AM J PHYSIOL-HEART C, V283, pH69, DOI 10.1152/ajpheart.00817.2001; Dvorakova M, 2001, HISTOCHEM CELL BIOL, V116, P223, DOI 10.1007/s004180100308; Ferdinandy P, 2000, CIRC RES, V87, P241, DOI 10.1161/01.RES.87.3.241; Ferdinandy P, 1997, N-S ARCH PHARMACOL, V356, P356, DOI 10.1007/PL00005062; Ferrer-Montiel A, 2004, EUR J BIOCHEM, V271, P1820, DOI 10.1111/j.1432-1033.2004.04083.x; FRANCOCERECEDA A, 1988, ACTA PHYSIOL SCAND, V133, P1; FRANCOCERECEDA A, 1987, PEPTIDES, V8, P399, DOI 10.1016/0196-9781(87)90117-3; Golech SA, 2004, MOL BRAIN RES, V132, P87, DOI 10.1016/j.molbrainres.2004.08.025; Hamashima H, 2001, NEUROSCI RES, V39, P133, DOI 10.1016/S0168-0102(00)00208-X; HOLZER P, 1991, PHARMACOL REV, V43, P143; Hoover DB, 2000, JPN J PHARMACOL, V84, P367, DOI 10.1254/jjp.84.367; JANCSO G, 1992, EXP PHYSIOL, V77, P405, DOI 10.1113/expphysiol.1992.sp003603; JANCSO G, 1987, ACTA PHYSIOL HUNG, V69, P295; JANCSO G, 1977, NATURE, V270, P741, DOI 10.1038/270741a0; JANCSO G, 1985, NEUROSCI LETT, V59, P209, DOI 10.1016/0304-3940(85)90201-0; JANCSO N, 1968, PHARM PAIN, P33; Kadowaki K, 2004, MOL BRAIN RES, V125, P105, DOI 10.1016/j.molbrainres.2004.03.021; Kallner G, 1998, J CARDIOVASC PHARM, V32, P500, DOI 10.1097/00005344-199809000-00023; Katona M, 2004, N-S ARCH PHARMACOL, V370, P436, DOI 10.1007/s00210-004-0985-7; KRUGER L, 1989, J COMP NEUROL, V280, P291, DOI 10.1002/cne.902800210; Labrakakis C, 2003, J PHYSIOL-LONDON, V549, P131, DOI 10.1113/jphysiol.2002.031963; Li YJ, 1996, EUR J PHARMACOL, V311, P163, DOI 10.1016/0014-2999(96)00426-8; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Loffler S, 2004, REGUL PEPTIDES, V122, P131, DOI 10.1016/j.regpep.2004.06.009; MAGGI CA, 1989, BRIT J PHARMACOL, V97, P103, DOI 10.1111/j.1476-5381.1989.tb11929.x; Morenilla-Palao C, 2004, J BIOL CHEM, V279, P25665, DOI 10.1074/jbc.M311515200; Nagy I, 2004, EUR J PHARMACOL, V500, P351, DOI 10.1016/j.ejphar.2004.07.037; Nilius B, 2003, ENDOTHELIUM-J ENDOTH, V10, P5, DOI 10.1080/10623320303356; Nishio H, 2002, JPN J PHARMACOL, V89, P242, DOI 10.1254/jjp.89.242; Onody A, 2003, FEBS LETT, V536, P35, DOI 10.1016/S0014-5793(03)00006-1; Palotas A, 2004, NEUROCHEM RES, V29, P1563, DOI 10.1023/B:NERE.0000029570.57903.74; PAPKA RE, 1984, NEUROSCIENCE, V12, P1277, DOI 10.1016/0306-4522(84)90021-6; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Puskas LG, 2002, BIOTECHNIQUES, V32, P1330, DOI 10.2144/02326mt04; Puskas LG, 2002, BIOTECHNIQUES, V33, P898, DOI 10.2144/02334mt03; RANKIN AJ, 1990, REGUL PEPTIDES, V30, P65, DOI 10.1016/0167-0115(90)90048-2; REN K, 1995, NEUROSCIENCE, V65, P505, DOI 10.1016/0306-4522(94)00510-C; RITTER S, 1992, J COMP NEUROL, V318, P103, DOI 10.1002/cne.903180108; Robbins J, 2001, PHARMACOL THERAPEUT, V90, P1, DOI 10.1016/S0163-7258(01)00116-4; Slavikova J, 1997, NEUROCHEM RES, V22, P1013, DOI 10.1023/A:1022431011019; Sosunov AA, 1996, CELL TISSUE RES, V284, P19, DOI 10.1007/s004410050563; Szallasi A, 1995, BRAIN RES, V703, P175, DOI 10.1016/0006-8993(95)01094-7; Szallasi A, 2004, J MED CHEM, V47, P2717, DOI 10.1021/jm030560j; Szallasi A, 2002, LANCET NEUROL, V1, P167, DOI 10.1016/S1474-4422(02)00072-8; Tokuoka H, 2003, NEURON, V38, P521, DOI 10.1016/S0896-6273(03)00290-3; van der Stelt M, 2004, EUR J BIOCHEM, V271, P1827, DOI 10.1111/j.1432-1033.2004.04081.x; Yamaguchi F, 2001, MOL BRAIN RES, V86, P189, DOI 10.1016/S0169-328X(00)00213-8; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zahner MR, 2003, J PHYSIOL-LONDON, V551, P515, DOI 10.1113/jphysiol.2003.048207	55	44	51	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					160	+		10.1096/fj.05-4060fje	http://dx.doi.org/10.1096/fj.05-4060fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16278290				2022-12-28	WOS:000234053100016
J	Enokido, Y; Suzuki, E; Iwasawa, K; Namekata, K; Okazawa, H; Kimura, H				Enokido, Y; Suzuki, E; Iwasawa, K; Namekata, K; Okazawa, H; Kimura, H			Cystathionine beta-synthase, a key enzyme for homocysteine metabolism, is preferentially expressed in the radial glia/astrocyte lineage of developing mouse CNS	FASEB JOURNAL			English	Article						homocystinuria; hippocampal dentate gyrus; glial cells; seizure; neural stem cells	ALPHA-B-CRYSTALLIN; FIBRILLARY ACIDIC PROTEIN; HEAT-SHOCK PROTEINS; GROWTH-FACTOR ALPHA; KAINIC ACID; REACTIVE ASTROCYTES; SEIZURE ACTIVITY; MICE DEFICIENT; DNA-DAMAGE; STEM-CELLS	Cystathionine beta-synthase (CBS; EC 4.2.1.22) is a key enzyme in the generation of cysteine from methionine. A deficiency of CBS leads to homocystinuria, an inherited human disease characterized by mental retardation, seizures, psychiatric disturbances, skeletal abnormalities, and vascular disorders; however, the underlying mechanisms remain largely unknown. Here, we show the regional and cellular distribution of CBS in the adult and developing mouse brain. In the adult mouse brain, CBS was expressed ubiquitously, but it is expressed most intensely in the cerebellar molecular layer and hippocampal dentate gyrus. Immunohistochemical analysis revealed that CBS is preferentially expressed in cerebellar Bergmann glia and in astrocytes throughout the brain. At early developmental stages, CBS was expressed in neuroepithelial cells in the ventricular zone, but its expression changed to radial glial cells and then to astrocytes during the late embryonic and neonatal periods. CBS was most highly expressed in juvenile brain, and a striking induction was observed in cultured astrocytes in response to EGF, TGF-alpha, cAMP, and dexamethasone. Moreover, CBS was significantly accumulated in reactive astrocytes in the hippocampus after kainic acid-induced seizures, and cerebellar morphological abnormalities were observed in CBS-deficient mice. Taken together, these results suggest that CBS plays a crucial role in the development and maintenance of the CNS and that radial glia/astrocyte dysfunction might be involved in the complex neuropathological features associated with abnormal homocysteine metabolism.	Tokyo Med & Dent Univ, Med Res Inst, Dept Neuropathol, Bunkyo Ku, Tokyo 1138510, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mol Genet, Tokyo, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neurochem, Tokyo, Japan; Tokyo Metropolitan Inst Neurosci, Dept Mol Neurobiol, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	Enokido, Y (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Neuropathol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	enokido.npat@mri.tmd.ac.jp	Kimura, Hideo/AGK-0606-2022	Kimura, Hideo/0000-0002-6069-0475; Enokido, Yasushi/0000-0003-3252-504X				Altman J, 1997, DEV CEREBELLAR SYSTE; Alvarez-Buylla A, 2001, NAT REV NEUROSCI, V2, P287, DOI 10.1038/35067582; BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; Brenner M, 2001, NAT GENET, V27, P117, DOI 10.1038/83679; CARSON NAJ, 1962, ARCH DIS CHILD, V37, P505, DOI 10.1136/adc.37.195.505; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Chen ZT, 2001, HUM MOL GENET, V10, P433, DOI 10.1093/hmg/10.5.433; Goffinet A., 2000, MOUSE BRAIN DEV; GOSS SJ, 1986, J CELL SCI, V82, P309; Ho PI, 2002, J NEUROSCI RES, V70, P694, DOI 10.1002/jnr.10416; Imura T, 1999, J NEUROSCI, V19, P9768; IWAKI T, 1992, AM J PATHOL, V140, P345; Jacobson M., 1991, DEV NEUROBIOLOGY; Kato K, 1999, J NEUROCHEM, V73, P229, DOI 10.1046/j.1471-4159.1999.0730229.x; Kruman II, 2004, J BIOL CHEM, V279, P43952, DOI 10.1074/jbc.M408025200; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Lino M, 2001, SCIENCE, V292, P926, DOI 10.1126/science.1058827; Lipton SA, 1997, P NATL ACAD SCI USA, V94, P5923, DOI 10.1073/pnas.94.11.5923; Lisovoski F, 1997, J NEUROPATH EXP NEUR, V56, P459, DOI 10.1097/00005072-199705000-00001; Maclean KN, 2004, J BIOL CHEM, V279, P8558, DOI 10.1074/jbc.M310211200; Maclean KN, 2002, J CELL PHYSIOL, V192, P81, DOI 10.1002/jcp.10118; Mattson MP, 2003, TRENDS NEUROSCI, V26, P137, DOI 10.1016/S0166-2236(03)00032-8; Maurel D, 2000, GLIA, V29, P212, DOI 10.1002/(SICI)1098-1136(20000201)29:3<212::AID-GLIA3>3.0.CO;2-6; Mudd S., 2001, METABOLIC MOL BASES, P2007; MUDD SH, 1964, SCIENCE, V143, P1443, DOI 10.1126/science.143.3613.1443; Namekata K, 2004, J BIOL CHEM, V279, P52961, DOI 10.1074/jbc.M406820200; Oikawa S, 2003, ONCOGENE, V22, P3530, DOI 10.1038/sj.onc.1206440; OMURA T, 1984, J BIOCHEM-TOKYO, V96, P1491, DOI 10.1093/oxfordjournals.jbchem.a134978; Plumier JCL, 1996, NEUROSCIENCE, V75, P849, DOI 10.1016/0306-4522(96)00317-X; Qian XM, 2000, NEURON, V28, P69, DOI 10.1016/S0896-6273(00)00086-6; Rabchevsky AG, 1998, J NEUROSCI, V18, P10541, DOI 10.1523/jneurosci.18-24-10541.1998; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; RAKIC P, 1988, PROG BRAIN RES, V73, P15; Ratnam S, 2002, J BIOL CHEM, V277, P42912, DOI 10.1074/jbc.M206588200; RENKAWEK K, 1992, ACTA NEUROPATHOL, V83, P324, DOI 10.1007/BF00296796; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Robert K, 2003, J HISTOCHEM CYTOCHEM, V51, P363, DOI 10.1177/002215540305100311; Rosenquist TH, 2001, P NUTR SOC, V60, P53; Rosenquist TH, 1996, P NATL ACAD SCI USA, V93, P15227, DOI 10.1073/pnas.93.26.15227; Sakai K, 2003, J NEUROSCI, V23, P550; Scott JM, 1999, P NUTR SOC, V58, P441, DOI 10.1017/S0029665199000580; SHINOHARA H, 1993, J NEUROL SCI, V119, P203, DOI 10.1016/0022-510X(93)90135-L; Surtees R, 1997, PEDIATR RES, V42, P577, DOI 10.1203/00006450-199711000-00004; Tanaka M, 2003, J NEUROSCI, V23, P2804, DOI 10.1523/jneurosci.23-07-02804.2003; Tanaka S, 1998, J NEUROSCI, V18, P6358; Volpe J., 1995, NEUROLOGY NEWBORN, P43; Wang H, 2003, BLOOD, V101, P3901, DOI 10.1182/blood-2002-08-2606; WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585; Yamasaki M, 2001, J NEUROSCI, V21, P7691, DOI 10.1523/JNEUROSCI.21-19-07691.2001; Yap S, 2001, J INHERIT METAB DIS, V24, P437, DOI 10.1023/A:1010525528842; Yun SJ, 2002, NEUROSCI LETT, V324, P45, DOI 10.1016/S0304-3940(02)00173-8	51	170	185	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1854	+		10.1096/fj.05-3724fje	http://dx.doi.org/10.1096/fj.05-3724fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16160063				2022-12-28	WOS:000232315700017
J	Zeng, LX; Xu, HS; Chew, TL; Eng, E; Sadeghi, MM; Adler, S; Kanwar, YS; Danesh, FR				Zeng, LX; Xu, HS; Chew, TL; Eng, E; Sadeghi, MM; Adler, S; Kanwar, YS; Danesh, FR			HMG CoA reductase inhibition modulates VEGF-induced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation	FASEB JOURNAL			English	Article						endothelial dysfunction; statin; vascular endothelial growth factor; diabetic nephropathy	GROWTH-FACTOR; SIGNALING PATHWAY; STATINS; TRANSDUCTION; SIMVASTATIN; EXPRESSION; GTPASES; KINASE	The beneficial effects of statins are usually assumed to stem from their ability to reduce cholesterol biosynthesis. However, because statins are potent inhibitors of the mevalonate, which governs diverse cell signaling pathways, inhibition of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase may also result in pleiotropic effects. The present study describes a novel pleiotropic effect of statins on vascular endothelial growth factor (VEGF)-induced glomerular endothelial cell (GEnC) hyperpermeability. Using live cell imaging with green fluorescent protein-tagged myosin regulatory light chain (MLC) and correlative biochemical analyses, we investigated 1) VEGF signaling pathway leading to GEnC hyperpermeability and 2) the modulatory effects of statins on VEGF signaling. Our findings indicate that VEGF stimulation elicits a robust increase in GEnC permeability. The signaling pathway that mediates VEGF-induced GEnC hyperpermeability involves RhoA activation leading to actin cytoskeletal remodeling, MLC diphosphorylation, and enhanced paracellular gap formation. Remarkably, cotreatment of endothelial cells with simvastatin, a hydrophobic statin, reversed VEGF-induced GEnC hyperpermeability by preventing MLC diphosphorylation, and cytoskeletal remodeling. In summary, this study identifies RhoA and MLC phosphorylation as key mediators of VEGF-induced endothelial cell hyperpermeability and demonstrates the modulatory effects of statins on VEGF signaling pathway.	Northwestern Univ, Feinberg Sch Med, Div Nephrol Hypertens, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Yale Sch Med, Div Cardiovasc Med, New Haven, CT USA; New York Med Coll, Dept Med, Valhalla, NY 10595 USA; Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Yale University; New York Medical College; Northwestern University	Danesh, FR (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Nephrol Hypertens, 303 E Chicago Ave,Searle Bldg 10-563, Chicago, IL 60611 USA.	f-rahimi@northwestern.edu		Danesh, Farhad/0000-0001-6849-5239	PHS HHS [67604, 64106] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADLER S, 1992, AM J PHYSIOL, V262, pF697; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Athyros VG, 2003, CURR MED RES OPIN, V19, P615, DOI 10.1185/030079903125002315; Carbajal JM, 2000, AM J PHYSIOL-CELL PH, V279, pC195; Carmeliet P, 2000, ANN NY ACAD SCI, V902, P249; Chen J, 2002, AM J PHYSIOL-CELL PH, V282, pC1053, DOI 10.1152/ajpcell.00292.2001; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Collins R, 2003, LANCET, V361, P2005; Cooper ME, 1999, DIABETES, V48, P2229, DOI 10.2337/diabetes.48.11.2229; Danesh FR, 2004, FASEB J, V18, P805, DOI 10.1096/fj.03-0839rev; Danesh FR, 2002, P NATL ACAD SCI USA, V99, P8301, DOI 10.1073/pnas.122228799; De Vriese A, 2001, J AM SOC NEPHROL, V12, P993, DOI 10.1681/ASN.V125993; Flyvbjerg A, 2002, DIABETES, V51, P3090, DOI 10.2337/diabetes.51.10.3090; GARCIA JGN, 1995, J INVEST MED, V43, P117; Garcia Joe G. N., 1996, Seminars in Thrombosis and Hemostasis, V22, P309, DOI 10.1055/s-2007-999025; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; Jacobson JR, 2004, AM J RESP CELL MOL, V30, P662, DOI 10.1165/rcmb.2003-0267OC; Kang DH, 2003, CURR OPIN NEPHROL HY, V12, P43, DOI 10.1097/00041552-200301000-00008; Kim SI, 2000, KIDNEY INT, V58, pS88, DOI 10.1046/j.1523-1755.2000.07714.x; Maron DJ, 2000, CIRCULATION, V101, P207, DOI 10.1161/01.CIR.101.2.207; McFarlane SI, 2002, J CLIN ENDOCR METAB, V87, P1451, DOI 10.1210/jc.87.4.1451; Pedram A, 2002, J BIOL CHEM, V277, P44385, DOI 10.1074/jbc.M202391200; Qin J, 2003, KIDNEY INT, V64, P565, DOI 10.1046/j.1523-1755.2003.00127.x; Sadeghi NM, 2000, J IMMUNOL, V165, P2712, DOI 10.4049/jimmunol.165.5.2712; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; SIMON M, 1995, AM J PHYSIOL-RENAL, V268, pF240, DOI 10.1152/ajprenal.1995.268.2.F240; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Sorensson J, 2002, J AM SOC NEPHROL, V13, P2639, DOI 10.1097/01.ASN.0000033277.32822.23; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797; VAN AL, 1997, GENE DEV, V11, P2295; Vasile E, 1999, J HISTOCHEM CYTOCHEM, V47, P159, DOI 10.1177/002215549904700205; Vaughan CJ, 2000, J AM COLL CARDIOL, V35, P1, DOI 10.1016/S0735-1097(99)00525-2; Wojciak-Stothard B, 2002, VASC PHARMACOL, V39, P187, DOI 10.1016/S1537-1891(03)00008-9; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Wolfrum S, 2003, ARTERIOSCL THROM VAS, V23, P729, DOI 10.1161/01.ATV.0000063385.12476.A7; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6; Zeng LX, 2004, J AM SOC NEPHROL, V15, P1711, DOI 10.1097/01.ASN.0000129839.91567.68	38	61	71	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1845	+		10.1096/fj.05-4240fje	http://dx.doi.org/10.1096/fj.05-4240fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16160062				2022-12-28	WOS:000232315700016
J	Zeller, A; Arras, M; Lazaris, A; Jurd, R; Rudolph, U				Zeller, A; Arras, M; Lazaris, A; Jurd, R; Rudolph, U			Distinct molecular targets for the central respiratory and cardiac actions of the general anesthetics etomidate and propofol	FASEB JOURNAL			English	Article						anesthesia; respiratory depression; animal model; GABA(A) receptor	A RECEPTOR; MICE; GABA(A); SITES	General anesthetics are among the most widely used and important therapeutic agents. The molecular targets mediating different endpoints of the anesthetic state in vivo are currently largely unknown. The analysis of mice carrying point mutations in neurotransmitter receptor subunits is a powerful tool to assess the contribution of the respective receptor subtype to the pharmacological actions of clinically used general anesthetics. We examined the involvement of beta 3-containing GABA(A) receptors in the respiratory, cardiovascular, hypothermic, and sedative actions of etomidate and propofol using beta 3(N265M) knock-in mice carrying etomidate- and propofol-insensitive beta 3-containing GABA(A) receptors. Although the respiratory depressant action of etomidate and propofol, as determined by blood gas analysis, was almost absent in beta 3(N265M) mice, the cardiac depressant and hypothermic effects, as determined by radiotelemetry, and the sedative effect, as determined by decrease of motor activity, were still present. Taken together with previous findings, our results show that both immobilization and respiratory depression are mediated by beta 3-containing GABA(A) receptors, hypnosis by both beta 3 and beta 2-containing GABA(A) receptors, while the hypothermic, cardiac depressant, and sedative actions are largely independent of beta 3-containing GABA(A) receptors.	Univ Zurich, Inst Pharmacol & Toxicol, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Lab Anim Sci, CH-8057 Zurich, Switzerland	University of Zurich; University of Zurich	Rudolph, U (corresponding author), Univ Zurich, Inst Pharmacol & Toxicol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	rudolph@pharma.unizh.ch		Arras, Margarete/0000-0003-3864-9879				Arras M, 2001, COMPARATIVE MED, V51, P443; Barnard EA, 1998, PHARMACOL REV, V50, P291; Belelli D, 1997, P NATL ACAD SCI USA, V94, P11031, DOI 10.1073/pnas.94.20.11031; Bergen Joseph M., 1997, Journal of Emergency Medicine, V15, P221, DOI 10.1016/S0736-4679(96)00350-2; Cirone J, 2004, ANESTHESIOLOGY, V100, P1438, DOI 10.1097/00000542-200406000-00016; ERHARDT W, 1984, RES EXP MED, V184, P159, DOI 10.1007/BF01852390; Franks NP, 2004, TRENDS PHARMACOL SCI, V25, P601, DOI 10.1016/j.tips.2004.09.003; Jurd R, 2002, FASEB J, V16, P250, DOI 10.1096/fj.02-0611fje; Keyl C, 2000, ANESTH ANALG, V91, P1188, DOI 10.1097/00000539-200011000-00027; Krasowski MD, 1999, CELL MOL LIFE SCI, V55, P1278, DOI 10.1007/s000180050371; Krasowski MD, 1998, MOL PHARMACOL, V53, P530, DOI 10.1124/mol.53.3.530; KRASSIOUKOV AV, 1993, CAN J ANAESTH, V40, P761, DOI 10.1007/BF03009773; Lichtenbelt BJ, 2004, CLIN PHARMACOKINET, V43, P577, DOI 10.2165/00003088-200443090-00002; Manzke T, 2003, SCIENCE, V301, P226, DOI 10.1126/science.1084674; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Paris A, 2003, ANESTHESIOLOGY, V99, P889, DOI 10.1097/00000542-200310000-00022; Reynolds DS, 2003, J NEUROSCI, V23, P8608; Richter DW, 2003, TRENDS MOL MED, V9, P542, DOI 10.1016/j.molmed.2003.10.010; Rudolph U, 2004, NAT REV NEUROSCI, V5, P709, DOI 10.1038/nrn1496; SELLGREN J, 1994, ANESTHESIOLOGY, V80, P534, DOI 10.1097/00000542-199403000-00009; Sessler DI, 1997, NEW ENGL J MED, V336, P1730, DOI 10.1056/NEJM199706123362407; Siegwart R, 2002, J NEUROCHEM, V80, P140, DOI 10.1046/j.0022-3042.2001.00682.x; Siegwart Roberta, 2003, BMC Pharmacol, V3, P13, DOI 10.1186/1471-2210-3-13; Spani D, 2003, LAB ANIM-UK, V37, P54, DOI 10.1258/002367703762226692; Zuperku EJ, 2002, RESP PHYSIOL NEUROBI, V131, P121, DOI 10.1016/S1569-9048(02)00042-3	25	48	56	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1677	+		10.1096/fj.04-3443fje	http://dx.doi.org/10.1096/fj.04-3443fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16046472				2022-12-28	WOS:000230923000005
J	Planaguma, A; Claria, J; Miquel, R; Lopez-Parra, M; Titos, E; Masferrer, JL; Arroyo, V; Rodes, J				Planaguma, A; Claria, J; Miquel, R; Lopez-Parra, M; Titos, E; Masferrer, JL; Arroyo, V; Rodes, J			The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPAR gamma activation	FASEB JOURNAL			English	Article						inflammation; liver injury; Kupffer cells; hepatic stellate cells; nuclear receptors	HEPATIC STELLATE CELLS; RECEPTOR-GAMMA; RAT-LIVER; PROSTAGLANDIN E-2; RENAL-FUNCTION; KUPFFER CELLS; IN-VITRO; EXPRESSION; DISEASE; CIRRHOSIS	The importance of inflammation in initiating the sequence of events that lead to liver fibrosis is increasingly recognized. In this study, we tested the effects of SC-236, a selective cyclooxygenase (COX)-2 inhibitor, in rats with carbon tetrachloride (CCl4)-induced liver fibrosis. Livers from CCl4-treated rats showed increased COX-2 expression and 15-deoxyprostaglandin (PG)J(2) (15d-PGJ(2)) formation, as well as decreased peroxisome proliferator-activated receptor (PPAR)gamma expression. In these animals, SC-236 reduced liver fibrosis as revealed by histological analysis and by a reduction in hepatic hydroxyproline levels, metalloproteinase-2 activity, and alpha-smooth muscle actin expression. Interestingly, SC-236 normalized 15d-PGJ(2) levels and restored PPAR gamma expression in the liver Of CCl4-treated rats. In isolated hepatic stellate cells (HSCs)-the major player in liver fibrogenesis-and Kupffer cells-the cell type primarily responsible for increased hepatic COX-2-SC-236 exhibited remarkable pro-apoptotic and growth inhibitory properties. Of interest, SC-236 decreased HSC viability to a similar extent than the PPAR gamma ligand rosiglitazone. Moreover, SC-236 significantly induced PPAR gamma expression in HSCs and acted as a potent PPAR gamma agonist in a luciferase-reporter trans-activation assay. These data indicate that, by mechanisms involving non-parenchymal cell apoptosis and PPAR gamma activation, the selective COX-2 inhibitor SC-236 might have therapeutic potential for prevention of liver fibrosis.	Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Hosp Clin, DNA Unit, E-08036 Barcelona, Spain; Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Hosp Clin, Pathol Lab, E-08036 Barcelona, Spain; Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Hosp Clin, Liver Unit, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Claria, J (corresponding author), Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Hosp Clin, DNA Unit, Villarroel 170, E-08036 Barcelona, Spain.	jclaria@clinic.ub.es	Titos, Esther/AAA-5394-2019; Claria, Joan/M-7772-2019; Arroyo, Vicente/F-9189-2015	Titos, Esther/0000-0002-2543-2243; Arroyo, Vicente/0000-0002-2728-1848; Claria, Joan/0000-0003-4333-7749				Badawi AF, 2004, CANCER RES, V64, P1181, DOI 10.1158/0008-5472.CAN-03-2556; Bataller R, 2001, HEPATOLOGY, V33, P956, DOI 10.1053/jhep.2001.23500; Bell-Parikh LC, 2003, J CLIN INVEST, V112, P945, DOI 10.1172/JCI200318012; Benyon RC, 2001, SEMIN LIVER DIS, V21, P373, DOI 10.1055/s-2001-17552; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bosch-Marce M, 1999, GASTROENTEROLOGY, V116, P1167, DOI 10.1016/S0016-5085(99)70020-X; Brenner DA, 2000, J HEPATOL, V32, P32, DOI 10.1016/S0168-8278(00)80413-4; Cheng JD, 2002, HEPATOL RES, V23, P185, DOI 10.1016/S1386-6346(01)00177-2; Claria J, 2003, PROSTAG OTH LIPID M, V72, P19, DOI 10.1016/S1098-8823(03)00075-3; Claria J, 2003, CURR PHARM DESIGN, V9, P2177, DOI 10.2174/1381612033454054; DECKER K, 1990, EUR J BIOCHEM, V192, P245, DOI 10.1111/j.1432-1033.1990.tb19222.x; Deulofeu R, 2000, CLIN SCI, V99, P315, DOI 10.1042/CS20000127; Duffield JS, 2005, J CLIN INVEST, V115, P56, DOI 10.1172/JCI200522675; Efsen E, 2001, HEPATOLOGY, V33, P713, DOI 10.1053/jhep.2001.22761; Endoh T, 1996, CARCINOGENESIS, V17, P467, DOI 10.1093/carcin/17.3.467; Enomoto N, 2000, AM J PHYSIOL-GASTR L, V279, pG100, DOI 10.1152/ajpgi.2000.279.1.G100; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Friedman SL, 2004, NAT CLIN PRACT GASTR, V1, P98, DOI 10.1038/ncpgasthep0055; Friedman SL, 2005, J CLIN INVEST, V115, P29, DOI 10.1172/JCI200523928; Frungieri MB, 2002, P NATL ACAD SCI USA, V99, P15072, DOI 10.1073/pnas.232422999; Galli A, 2002, GASTROENTEROLOGY, V122, P1924, DOI 10.1053/gast.2002.33666; Gallois C, 1998, J BIOL CHEM, V273, P23183, DOI 10.1074/jbc.273.36.23183; GEERTS A, 1988, J HEPATOL, V6, P50, DOI 10.1016/S0168-8278(88)80461-6; Hazra S, 2004, J BIOL CHEM, V279, P11392, DOI 10.1074/jbc.M310284200; Hui AY, 2004, J HEPATOL, V41, P251, DOI 10.1016/j.jhep.2004.04.033; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Jiang XH, 2002, ONCOGENE, V21, P6113, DOI 10.1038/sj.onc.1205778; KIKAWA Y, 1984, P NATL ACAD SCI-BIOL, V81, P1317, DOI 10.1073/pnas.81.5.1317; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; Leng J, 2003, HEPATOLOGY, V38, P756, DOI 10.1053/jhep.2003.50380; Lopez-Parra M, 2005, J HEPATOL, V42, P75, DOI 10.1016/j.jhep.2004.09.011; Lopez-Parra M, 2002, BRIT J PHARMACOL, V135, P891, DOI 10.1038/sj.bjp.0704528; Maddox JF, 2004, TOXICOL SCI, V77, P290, DOI 10.1093/toxsci/kfh028; Marra F, 2000, GASTROENTEROLOGY, V119, P466, DOI 10.1053/gast.2000.9365; Miyahara T, 2000, J BIOL CHEM, V275, P35715, DOI 10.1074/jbc.M006577200; Miyajima A, 2001, J UROLOGY, V166, P1124, DOI 10.1016/S0022-5347(05)65933-2; Mohammed NA, 2004, J CLIN PATHOL, V57, P350, DOI 10.1136/jcp.2003.012120; Nanji AA, 1997, GASTROENTEROLOGY, V112, P943, DOI 10.1053/gast.1997.v112.pm9041257; Nanji AA, 1997, HEPATOLOGY, V26, P1538, DOI 10.1002/hep.510260622; Negishi M, 2002, PROSTAG OTH LIPID M, V68-9, P611, DOI 10.1016/S0090-6980(02)00059-X; Nunez O, 2004, GUT, V53, P1665, DOI 10.1136/gut.2003.038364; Planaguma A, 2002, FASEB J, V16, P1937, DOI 10.1096/fj.02-0224fje; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Romano M, 2003, FASEB J, V17, P1986, DOI 10.1096/fj.03-0053rev; Souto EO, 2001, AM J PHYSIOL-GASTR L, V280, pG805, DOI 10.1152/ajpgi.2001.280.5.G805; Titos E, 2003, FASEB J, V17, P1745, DOI 10.1096/fj.02-1157fje; Tome S, 2004, ALIMENT PHARM THER, V19, P707, DOI 10.1111/j.1365-2036.2004.01881.x; Tsai CH, 2003, J ORAL PATHOL MED, V32, P146, DOI 10.1034/j.1600-0714.2003.00004.x; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Wong BCY, 2004, GASTROENTEROLOGY, V126, P136, DOI 10.1053/j.gastro.2003.10.063; Wright MC, 2001, GASTROENTEROLOGY, V121, P685, DOI 10.1053/gast.2001.27188; Yamamoto H, 2003, GASTROENTEROLOGY, V125, P556, DOI 10.1016/S0016-5085(03)00904-1	53	116	124	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1120	+		10.1096/fj.04-2753fje	http://dx.doi.org/10.1096/fj.04-2753fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15876570				2022-12-28	WOS:000229602600019
J	Gerber, D; Quintana, FJ; Bloch, I; Cohen, IR; Shai, Y				Gerber, D; Quintana, FJ; Bloch, I; Cohen, IR; Shai, Y			D-enantiomer peptide of the TCR alpha transmembrane domain inhibits T-cell activation in vitro and in vivo	FASEB JOURNAL			English	Article						transmembrane domain assembly; peptide inhibitor; immunosuppression; protein-protein interaction	HELIX-HELIX INTERACTIONS; ADJUVANT ARTHRITIS; POLAR; DIMERIZATION; LYMPHOCYTES; RECOGNITION; SPECIFICITY; INTERFACE; VACCINATE; MEMBRANES	T cell activation requires the cross-talk between the CD3-signaling complex and the T cell receptor (TCR). A synthetic peptide coding for the TCR alpha. transmembrane domain (CP) binds CD3 molecules, interferes with the CD3/TCR cross-talk, and inhibits T cell activation. Intermolecular interactions are sterically constrained; accordingly no sequence-specific interactions are thought to occur between D- and L-stereoisomers. This argument was recently challenged when applied to intra-membrane protein assembly. In this paper we studied the ability of a D-stereoisomer of CP (D-CP) to inhibit T cell activation. L-CP and D-CP co-localized with the TCR in the membrane and inhibited T cell activation in a sequence-specific manner. In vivo, both L-CP and D-CP inhibited adjuvant arthritis. In molecular terms, these results suggest the occurrence of structural reorientation that facilitates native-like interactions between D-CP and CD3 within the membrane. In clinical terms, our results demonstrate that D-stereoisomers retain the therapeutic properties of their L-stereoisomers, while they benefit from an increased resistance to degradation.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Yechiel.Shai@weizmann.ac.il	Quintana, Francisco Javier/AAB-6915-2020; Cohen, Irun R/B-3542-2009					ANDERTON SM, 1994, J IMMUNOL, V152, P3656; Arkin IT, 2002, BBA-BIOMEMBRANES, V1565, P347, DOI 10.1016/S0005-2736(02)00580-1; Call ME, 2002, CELL, V111, P967, DOI 10.1016/S0092-8674(02)01194-7; Chin CN, 2000, J MOL BIOL, V303, P1, DOI 10.1006/jmbi.2000.4122; Curran AR, 2003, CURR OPIN STRUC BIOL, V13, P412, DOI 10.1016/S0959-440X(03)00102-7; Fleming KG, 2001, P NATL ACAD SCI USA, V98, P14340, DOI 10.1073/pnas.251367498; Fruton J. S., 1972, MOL LIFE HIST ESSAYS; Gerber D, 2000, J BIOL CHEM, V275, P23602, DOI 10.1074/jbc.M002596200; Gerber D, 2002, J MOL BIOL, V322, P491, DOI 10.1016/S0022-2836(02)00807-0; Hermansson M, 2003, J MOL BIOL, V334, P803, DOI 10.1016/j.jmb.2003.10.019; HOLOSHITZ J, 1983, SCIENCE, V219, P56, DOI 10.1126/science.6336851; HOLOSHITZ J, 1984, J CLIN INVEST, V73, P211, DOI 10.1172/JCI111193; Kliger Y, 1997, J BIOL CHEM, V272, P13496, DOI 10.1074/jbc.272.21.13496; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; Li RH, 2004, J BIOL CHEM, V279, P26666, DOI 10.1074/jbc.M314168200; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Manolios N, 1997, NAT MED, V3, P84, DOI 10.1038/nm0197-84; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MANOLIOS N, 1994, EUR J IMMUNOL, V24, P84, DOI 10.1002/eji.1830240114; Melnyk RA, 2004, J BIOL CHEM, V279, P16591, DOI 10.1074/jbc.M313936200; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; MILTON RCD, 1992, SCIENCE, V256, P1445, DOI 10.1126/science.1604320; Quintana FJ, 2003, J IMMUNOL, V171, P3533, DOI 10.4049/jimmunol.171.7.3533; Quintana FJ, 2002, J IMMUNOL, V169, P3422, DOI 10.4049/jimmunol.169.6.3422; Ruan WM, 2004, J BIOL CHEM, V279, P3273, DOI 10.1074/jbc.M309311200; Ruan WM, 2004, PROTEIN SCI, V13, P555, DOI 10.1110/ps.03357404; Sal-Man N, 2004, J MOL BIOL, V344, P855, DOI 10.1016/j.jmb.2004.09.066; Sal-Man N, 2004, BIOCHEMISTRY-US, V43, P2309, DOI 10.1021/bi0356294; Senes A, 2004, CURR OPIN STRUC BIOL, V14, P465, DOI 10.1016/j.sbi.2004.07.007; VANEDEN W, 1985, P NATL ACAD SCI USA, V82, P5117; VANEDEN W, 1988, NATURE, V331, P171, DOI 10.1038/331171a0; Wang XM, 2002, CLIN IMMUNOL, V105, P199, DOI 10.1006/clim.2002.5270; Wang XM, 2002, CELL IMMUNOL, V215, P12, DOI 10.1016/S0008-8749(02)00002-3; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	36	31	37	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1190	+		10.1096/fj.04-3498fje	http://dx.doi.org/10.1096/fj.04-3498fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15837719				2022-12-28	WOS:000228865300012
J	Waters, D; Greene, CM; Fernandez, ML				Waters, D; Greene, CM; Fernandez, ML			Plasma responses to cholesterol, lutein and alpha-tocopherol from eggs in postmenopausal women are related	FASEB JOURNAL			English	Meeting Abstract	Experimental Biology 2006 Meeting	APR 01-05, 2006	San Francisco, CA	Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut					Univ Connecticut, Dept Nutr Sci, Storrs, CT 06269 USA	University of Connecticut				Pyne, Susan/0000-0002-6608-9584; Pyne, Nigel/0000-0002-5657-4578	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071152, R01HL079396, R01HL061469] Funding Source: NIH RePORTER; NCI NIH HHS [CA-92160] Funding Source: Medline; NHLBI NIH HHS [R01 HL-71152/, R01 HL-79396, HL-61469] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))			0	71	72	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR 7	2006	20	5	2				A1058	A1058						1	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	026GA	16319133				2022-12-28	WOS:000236326202087
J	Kempe, DS; Lang, PA; Duranton, C; Akel, A; Lang, KS; Huber, SM; Wieder, T; Lang, F				Kempe, Daniela S.; Lang, Philipp A.; Duranton, Christophe; Akel, Ahmad; Lang, Karl S.; Huber, Stephan M.; Wieder, Thomas; Lang, Florian			Enhanced programmed cell death of iron-deficient erythrocytes	FASEB JOURNAL			English	Article									[Lang, Florian] Univ Tubingen, Inst Physiol, Dept Physiol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Lang, F (corresponding author), Univ Tubingen, Inst Physiol, Dept Physiol, Gmelinstr 5, D-72076 Tubingen, Germany.	florian.lang@uni-tuebingen.de	Lang, Karl S/R-2505-2016; DURANTON, CHRISTOPHE/E-9582-2019	DURANTON, CHRISTOPHE/0000-0003-1127-2346; Huber, Stephan/0000-0002-9430-8334; Lang, Karl/0000-0001-9783-7605					0	211	214	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					368	370		10.1096/fj.05-4872fje	http://dx.doi.org/10.1096/fj.05-4872fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16371427				2022-12-28	WOS:000207915000024
J	Sakai, K; Arao, T; Shimoyama, T; Murofushi, K; Sekijima, M; Kaji, N; Tamura, T; Saijo, N; Nishio, K				Sakai, Kazuko; Arao, Tokuzo; Shimoyama, Tatsu; Murofushi, Kimiko; Sekijima, Masaru; Kaji, Naoko; Tamura, Tomohide; Saijo, Nagahiro; Nishio, Kazuto			Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor	FASEB JOURNAL			English	Article									[Nishio, Kazuto] Natl Canc Ctr, Shien Lab, Chuo Ku, Tokyo 1040045, Japan; [Nishio, Kazuto] Natl Canc Ctr, Res Inst, Div Pharmacol, Tokyo 104, Japan; [Sakai, Kazuko; Murofushi, Kimiko] Ochanomizu Univ, Fac Sci, Dept Biol, Tokyo 112, Japan; [Sekijima, Masaru; Kaji, Naoko] Mitsubishi Chem Safety Inst Ltd, Ibaraki, Japan	National Cancer Center - Japan; National Cancer Center - Japan; Ochanomizu University; Mitsubishi Chemical Holdings Corporation; Mitsubishi Chemical Safety Institute	Nishio, K (corresponding author), Natl Canc Ctr, Shien Lab, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan.	knishio@gan2.res.ncc.go.jp							0	37	39	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					311	313		10.1096/fj.05-4034fje	http://dx.doi.org/10.1096/fj.05-4034fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16373402				2022-12-28	WOS:000207915000004
J	Kojro, E; Postina, R; Buro, C; Meiringer, C; Gehrig-Burger, K; Fahrenholz, F				Kojro, E; Postina, R; Buro, C; Meiringer, C; Gehrig-Burger, K; Fahrenholz, F			The neuropeptide PACAP promotes alpha-secretase pathway for processing Alzheimer amyloid precursor protein	FASEB JOURNAL			English	Article						PAC(1) recepter; GPCR; ADAM 10	CYCLASE-ACTIVATING POLYPEPTIDE; SIGNAL-REGULATED KINASE; NECROSIS-FACTOR-ALPHA; ADENYLATE-CYCLASE; PHOSPHOLIPASE-C; NEURITE OUTGROWTH; COUPLED RECEPTORS; RAT-BRAIN; CONVERTING-ENZYME; TYROSINE KINASE	The neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) has neurotrophic as well as anti-apoptotic properties and is involved in learning and memory processes. Its specific G protein-coupled receptor PAC(1) is expressed in several central nervous system (CNS) regions, including the hippocampal formation. Here we examined the effect of PAC1 receptor activation on alpha-secretase cleavage of the amyloid precursor protein (APP) and the production of secreted APP (APPs alpha). Stimulation of endogenously expressed PAC1 receptors with PACAP in human neuroblastoma cells increased APPsa secretion, which was completely inhibited by the PAC1 receptor specific antagonist PACAP-(6-38). In HEK cells, stably overexpressing the functional PAC1 receptors PACAP- 27 and PACAP- 38 strongly stimulated alpha-secretase cleavage of APP. The PACAP-induced APPsa production was dose dependent and saturable. This increase of alpha-secretase activity was completely abolished by hydroxamate-based metalloproteinase inhibitors, including a preferential ADAM 10 inhibitor. By using several specific protein kinase inhibitors, we show that the MAP-kinase pathway [including extracellular-regulated kinase (ERK) 1 and ERK2] and phosphatidylinositol 3-kinase mediate the PACAP- induced alpha-secretase activation. Our findings provide evidence for a role of the neuropeptide PACAP in stimulation of the nonamyloidogenic pathway, which might be related to its neuroprotective properties.	Johannes Gutenberg Univ Mainz, Inst Biochem, D-55128 Mainz, Germany	Johannes Gutenberg University of Mainz	Kojro, E (corresponding author), Johannes Gutenberg Univ Mainz, Inst Biochem, D-55128 Mainz, Germany.	kojro@uni-mainz.de; bio.chemie@uni-mainz.de						Arimura A, 1998, JPN J PHYSIOL, V48, P301, DOI 10.2170/jjphysiol.48.301; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BASILLE M, 1995, J NEUROCHEM, V65, P1318; Bhave SV, 2004, J NEUROCHEM, V88, P359, DOI 10.1046/j.1471-4159.2003.02167.x; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Caille I, 2004, DEVELOPMENT, V131, P2173, DOI 10.1242/dev.01103; Canet-Aviles RM, 2002, MOL BRAIN RES, V102, P62, DOI 10.1016/S0169-328X(02)00184-5; Cappai R, 1999, FEBS LETT, V442, P95, DOI 10.1016/S0014-5793(98)01635-4; CAUVIN A, 1991, REGUL PEPTIDES, V35, P161, DOI 10.1016/0167-0115(91)90478-Y; Chatterjee TK, 1996, J BIOL CHEM, V271, P32226, DOI 10.1074/jbc.271.50.32226; Crespo Piero, 2004, Methods Mol Biol, V250, P203; Dogrukol-Ak D, 2004, CURR PHARM DESIGN, V10, P1325, DOI 10.2174/1381612043384934; Efthimiopoulos S, 1996, J NEUROCHEM, V67, P872; Eggenberger M, 1999, NEUROPEPTIDES, V33, P107, DOI 10.1054/npep.1999.0004; FEANY MB, 1995, SCIENCE, V268, P869, DOI 10.1126/science.7754370; Gimpl G, 2000, EUR J BIOCHEM, V267, P2483, DOI 10.1046/j.1432-1327.2000.01280.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUO Z, 1998, INORG CHIM ACTA, V1, P273; Gutwein P, 2002, FASEB J, V16, P292, DOI 10.1096/fj.02-0430fje; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hooper NM, 2002, CURR MED CHEM, V9, P1107, DOI 10.2174/0929867023370121; Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775; Joo KM, 2004, J COMP NEUROL, V476, P388, DOI 10.1002/cne.20231; Kojro E, 2005, SUB CELL BIOCHEM, V38, P105; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lazarovici P, 1998, MOL PHARMACOL, V54, P547, DOI 10.1124/mol.54.3.547; Lee RKK, 1997, J NEUROCHEM, V68, P1830; Little KD, 2004, MOL BIOL CELL, V15, P2375, DOI 10.1091/mbc.E03-12-0886; Ludwig A, 2005, COMB CHEM HIGH T SCR, V8, P161, DOI 10.2174/1386207053258488; MASUO Y, 1992, BRAIN RES, V575, P113, DOI 10.1016/0006-8993(92)90430-H; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Moroo I, 1998, BRAIN RES, V795, P191, DOI 10.1016/S0006-8993(98)00291-1; Mucke L, 1996, ANN NY ACAD SCI, V777, P82, DOI 10.1111/j.1749-6632.1996.tb34405.x; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Nielsen KM, 2004, MOL CELL NEUROSCI, V25, P629, DOI 10.1016/j.mcn.2003.12.004; Nitsch RM, 2000, ANN NEUROL, V48, P913, DOI 10.1002/1531-8249(200012)48:6<913::AID-ANA12>3.3.CO;2-J; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; Otto C, 2001, J NEUROSCI, V21, P5520, DOI 10.1523/JNEUROSCI.21-15-05520.2001; Pantaloni C, 1996, J BIOL CHEM, V271, P22146, DOI 10.1074/jbc.271.36.22146; Parkin ET, 2002, BIOCHEMISTRY-US, V41, P4972, DOI 10.1021/bi015936e; Parvathy S, 1999, BIOCHEMISTRY-US, V38, P9728, DOI 10.1021/bi9906827; Petanceska SS, 1999, J NEUROCHEM, V73, P2316, DOI 10.1046/j.1471-4159.1999.0732316.x; Pisegna JR, 1996, J BIOL CHEM, V271, P17267, DOI 10.1074/jbc.271.29.17267; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; Racchi M, 1999, J NEUROCHEM, V72, P2464, DOI 10.1046/j.1471-4159.1999.0722464.x; Reglodi D, 2000, ANN NY ACAD SCI, V921, P119; ROBBERECHT P, 1992, MOL PHARMACOL, V42, P347; Sacchetti B, 2001, NEUROBIOL LEARN MEM, V76, P1, DOI 10.1006/nlme.2001.4014; Sakai Y, 2004, MOL BRAIN RES, V123, P18, DOI 10.1016/j.molbrainres.2003.12.013; Sanderson MP, 2005, J BIOL CHEM, V280, P1826, DOI 10.1074/jbc.M408804200; Seternes OM, 1999, MOL ENDOCRINOL, V13, P1071, DOI 10.1210/me.13.7.1071; Sherwood NM, 2000, ENDOCR REV, V21, P619, DOI 10.1210/er.21.6.619; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; SUDA K, 1991, J CLIN ENDOCR METAB, V72, P958, DOI 10.1210/jcem-72-5-958; Uchida D, 1996, BRAIN RES, V736, P280, DOI 10.1016/0006-8993(96)00716-0; Vaudry D, 2000, PHARMACOL REV, V52, P269; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9; Xu HX, 1996, P NATL ACAD SCI USA, V93, P4081, DOI 10.1073/pnas.93.9.4081; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Yunta M, 2003, CELL SIGNAL, V15, P559, DOI 10.1016/S0898-6568(02)00147-X; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200; Zhou CJ, 2001, PEPTIDES, V22, P1111, DOI 10.1016/S0196-9781(01)00437-5; Zimmermann M, 2004, J NEUROCHEM, V90, P1489, DOI 10.1111/j.1471-4159.2004.02680.x	64	92	99	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					512	+		10.1096/fj.05-4812fje	http://dx.doi.org/10.1096/fj.05-4812fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16401644				2022-12-28	WOS:000235996000033
J	Shimizu, T; Sekine, H; Yang, J; Isoi, Y; Yamato, M; Kikuchi, A; Kobayashi, E; Okano, T				Shimizu, T; Sekine, H; Yang, J; Isoi, Y; Yamato, M; Kikuchi, A; Kobayashi, E; Okano, T			Polysurgery of cell sheet grafts overcomes diffusion limits to produce thick, vascularized myocardial tissues	FASEB JOURNAL			English	Article						poly(N-isopropylacrylamide); electrophysiology; microsurgery	RESPONSIVE CULTURE DISHES; STEM-CELLS; TRANSPLANTATION; CARTILAGE; SURFACES; HARVEST; SHAPE	Recently, the field of tissue engineering has progressed rapidly, but poor vascularization remains a major obstacle in bioengineering cell-dense tissues, limiting the viable size of constructs due to hypoxia, nutrient insufficiency, and waste accumulation. Therefore, new technologies for fabricating functional tissues with a well-organized vasculature are required. In the present study, neonatal rat cardiomyocytes were harvested as intact sheets from temperature-responsive culture dishes and stacked into cell-dense myocardial tissues. However, the thickness limit for layered cell sheets in subcutaneous tissue was similar to 80 mu m (3 layers). To overcome this limitation, repeated transplantation of triple-layer grafts was performed at 1, 2, or 3 day intervals. The two overlaid grafts completely synchronized and the whole tissues survived without necrosis in the 1 or 2 day interval cases. Multistep transplantation also created similar to 1 mm thick myocardium with a well-organized microvascular network. Furthermore, functional multilayer grafts fabricated over a surgically connectable artery and vein revealed complete graft perfusion via the vessels and ectopic transplantation of the grafts was successfully performed using direct vessel anastomoses. These cultured cell sheet integration methods overcome long-standing barriers to producing thick, vascularized tissues, revealing a possible solution for the clinical repair of various damaged organs, including the impaired myocardium.	Tokyo Womens Med Univ, Inst Adv Biomed Engn & Sci, Shinjuku Ku, Tokyo 1628666, Japan; Jichi Univ, Sch Med, Ctr Mol Med, Div Organ Replacement Res, Kawachi, Tochigi 3290498, Japan	Tokyo Women's Medical University; Jichi Medical University	Okano, T (corresponding author), Tokyo Womens Med Univ, Inst Adv Biomed Engn & Sci, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	tokano@abmes.twmu.ac.jp	Tatsuya, Shimizu/AAN-5675-2021; Okano, Teruo/J-4028-2012					BRITTBERG M, 1994, NEW ENGL J MED, V331, P889, DOI 10.1056/NEJM199410063311401; Cao YL, 1997, PLAST RECONSTR SURG, V100, P297, DOI 10.1097/00006534-199708000-00001; Harimoto M, 2002, J BIOMED MATER RES, V62, P464, DOI 10.1002/jbm.10228; Hirose M, 2000, BIOMACROMOLECULES, V1, P377, DOI 10.1021/bm0002961; Kaihara S, 2000, TISSUE ENG, V6, P105, DOI 10.1089/107632700320739; Kirsner RS, 1998, TRENDS BIOTECHNOL, V16, P246, DOI 10.1016/S0167-7799(98)01196-2; Koh CJ, 2004, J AM SOC NEPHROL, V15, P1113, DOI 10.1097/01.ASN.0000119683.59068.F0; Kulig KM, 2004, TRANSPL IMMUNOL, V12, P303, DOI 10.1016/j.trim.2003.12.005; Kushida A, 2000, J BIOMED MATER RES, V51, P216, DOI 10.1002/(SICI)1097-4636(200008)51:2<216::AID-JBM10>3.0.CO;2-K; Kushida A, 1999, J BIOMED MATER RES, V45, P355, DOI 10.1002/(SICI)1097-4636(19990615)45:4<355::AID-JBM10>3.0.CO;2-7; Kushida A, 2001, J BIOMED MATER RES, V54, P37, DOI 10.1002/1097-4636(200101)54:1<37::AID-JBM5>3.0.CO;2-7; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Leor J, 2000, CIRCULATION, V102, P56; Neumann T, 2003, MICROVASC RES, V66, P59, DOI 10.1016/S0026-2862(03)00040-2; Nishida K, 2004, TRANSPLANTATION, V77, P379, DOI 10.1097/01.TP.0000110320.45678.30; Nishida K, 2004, NEW ENGL J MED, V351, P1187, DOI 10.1056/NEJMoa040455; Nugent HM, 2003, CIRC RES, V92, P1068, DOI 10.1161/01.RES.0000073844.41372.38; OKANO T, 1993, J BIOMED MATER RES, V27, P1243, DOI 10.1002/jbm.820271005; Papadaki M, 2001, AM J PHYSIOL-HEART C, V280, pH168, DOI 10.1152/ajpheart.2001.280.1.H168; Sakai T, 2001, J THORAC CARDIOV SUR, V121, P932, DOI 10.1067/mtc.2001.113600; Shimizu T, 2002, CIRC RES, V90, pE40, DOI 10.1161/hh0302.105722; Shimizu T, 2003, BIOMATERIALS, V24, P2309, DOI 10.1016/S0142-9612(03)00110-8; Shimizu T, 2002, J BIOMED MATER RES, V60, P110, DOI 10.1002/jbm.1284; Shin H, 2003, BIOMATERIALS, V24, P4353, DOI 10.1016/S0142-9612(03)00339-9; Shin'oka T, 2001, NEW ENGL J MED, V344, P532, DOI 10.1056/NEJM200102153440717; Shiroyanagi Y, 2004, BJU INT, V93, P1069, DOI 10.1111/j.1464-410X.2004.04783.x; Xiu DR, 2001, MICROSURG, V21, P16, DOI 10.1002/1098-2752(2001)21:1<16::AID-MICR1003>3.0.CO;2-B; YAMADA N, 1990, MAKROMOL CHEM-RAPID, V11, P571; Yamato M, 2002, BIOMATERIALS, V23, P561, DOI 10.1016/S0142-9612(01)00138-7; Zandonella C, 2003, NATURE, V421, P884, DOI 10.1038/421884a; Zimmermann WH, 2002, CIRC RES, V90, P223, DOI 10.1161/hh0202.103644; Zimmermann WH, 2002, CIRCULATION, V106, pI151, DOI 10.1161/01.cir.0000032876.55215.10	32	347	366	7	66	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					708	+		10.1096/fj.05-4715fje	http://dx.doi.org/10.1096/fj.05-4715fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16439619				2022-12-28	WOS:000235996000003
J	Steelman, CA; Recknor, JC; Nettleton, D; Reecy, JM				Steelman, CA; Recknor, JC; Nettleton, D; Reecy, JM			Transcriptional profiling of myostatin-knockout mice implicates Wnt signaling in postnatal skeletal muscle growth and hypertrophy	FASEB JOURNAL			English	Article						microarray; Wnt4; satellite cells	SATELLITE CELL ACTIVATION; TGF-BETA; GENE-EXPRESSION; PROMOTES PROLIFERATION; FAMILY PROTEINS; DIFFERENTIATION; MYOGENESIS; PATHWAY; MYF5; MYOD	Myostatin is an inhibitor of skeletal muscle growth. Disruption of the Mstn gene in mice results in muscles that weigh two to three times those of controls, but precisely how myostatin signals to exert its effects on muscle is unclear. We used the Affymetrix GeneChip system to identify differences in gene expression between myostatin null and wild-type mice. The results indicated a switch in muscle fiber type, from slow to fast, in the absence of myostatin. They also indicated that myostatin may act upstream of Wnt pathway components. Notably, it repressed expression of Wnt4. Wnt4 was capable of stimulating satellite cell proliferation, while inhibition of Wnt signaling down-regulated satellite cell proliferation. This evidence points to a role for Wnt/calcium signaling in the growth and maintenance of postnatal skeletal muscle. This study offers new insight into potential downstream targets of myostatin, which will be beneficial for elucidation of the mechanism through which myostatin acts to inhibit muscle growth.	Iowa State Univ, Dept Anim Sci, Ames, IA 50011 USA; Iowa State Univ, Dept Stat, Ames, IA 50011 USA	Iowa State University; Iowa State University	Reecy, JM (corresponding author), Iowa State Univ, Dept Anim Sci, 2255 Kildee Hall, Ames, IA 50011 USA.	jreecy@iastate.edu		Nettleton, Dan/0000-0002-6045-1036; Reecy, James/0000-0003-4602-0990				Anakwe K, 2003, DEVELOPMENT, V130, P3503, DOI 10.1242/dev.00538; Armstrong DD, 2005, AM J PHYSIOL-CELL PH, V289, pC853, DOI 10.1152/ajpcell.00093.2005; Beauchamp JR, 2000, J CELL BIOL, V151, P1221, DOI 10.1083/jcb.151.6.1221; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284; Bouley J, 2005, PROTEOMICS, V5, P490, DOI 10.1002/pmic.200400925; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; Carlson CJ, 1999, AM J PHYSIOL-REG I, V277, pR601, DOI 10.1152/ajpregu.1999.277.2.R601; Carson JA, 2001, FASEB J, V15, P207, DOI 10.1096/fj.01-0544fje; Chakravarthy MV, 2000, J APPL PHYSIOL, V89, P1365, DOI 10.1152/jappl.2000.89.4.1365; Chakravarthy MV, 2001, CELL MOL LIFE SCI, V58, P1150, DOI 10.1007/PL00000929; Chen AE, 2005, NATURE, V433, P317, DOI 10.1038/nature03126; Cooper RN, 1999, J CELL SCI, V112, P2895; Csete M, 2001, J CELL PHYSIOL, V189, P189, DOI 10.1002/jcp.10016; CULLEY G, 1807, OBSERVATIONS LIVESTO; De Boer J, 2004, TISSUE ENG, V10, P393, DOI 10.1089/107632704323061753; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; DU SJ, 1995, MOL CELL BIOL, V15, P2625; Fan CM, 1997, DEV BIOL, V191, P160, DOI 10.1006/dbio.1997.8713; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Galli LM, 2004, DEV BIOL, V269, P489, DOI 10.1016/j.ydbio.2004.01.041; Girgenrath S, 2005, MUSCLE NERVE, V31, P34, DOI 10.1002/mus.20175; Grobet L, 1997, NAT GENET, V17, P71, DOI 10.1038/ng0997-71; Hanset R., 1986, Exploiting new technologies in animal breeding. Genetic developments., P71; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Ikeya M, 1998, DEVELOPMENT, V125, P4969; Kamanga-Sollo E, 2003, J CELL PHYSIOL, V197, P225, DOI 10.1002/jcp.10362; Kambadur R, 1997, GENOME RES, V7, P910, DOI 10.1101/gr.7.9.910; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Ladher RK, 2000, DEV BIOL, V218, P183, DOI 10.1006/dbio.1999.9586; Langley B, 2002, J BIOL CHEM, V277, P49831, DOI 10.1074/jbc.M204291200; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Lescher B, 1998, DEV DYNAM, V213, P440, DOI 10.1002/(SICI)1097-0177(199812)213:4<440::AID-AJA9>3.0.CO;2-6; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Martyn JK, 2004, ANAT REC PART A, V281A, P1363, DOI 10.1002/ar.a.20140; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; McCroskery S, 2003, J CELL BIOL, V162, P1135, DOI 10.1083/jcb.200207056; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; Ouko L, 2004, J BIOL CHEM, V279, P26707, DOI 10.1074/jbc.M402877200; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; Philip B, 2005, CELL SIGNAL, V17, P365, DOI 10.1016/j.cellsig.2004.08.003; Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092-8674(03)00437-9; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Rebbapragada A, 2003, MOL CELL BIOL, V23, P7230, DOI 10.1128/MCB.23.20.7230-7242.2003; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Renzoni EA, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-24; Rios R, 2002, AM J PHYSIOL-CELL PH, V282, pC993, DOI 10.1152/ajpcell.00372.2001; Rios R, 2001, BIOCHEM BIOPH RES CO, V280, P561, DOI 10.1006/bbrc.2000.4159; ROBERTSON TA, 1993, NEUROPATH APPL NEURO, V19, P350, DOI 10.1111/j.1365-2990.1993.tb00451.x; Rochat A, 2004, MOL BIOL CELL, V15, P4544, DOI 10.1091/mbc.E03-11-0816; Sakamoto K, 2004, BIOCHEM BIOPH RES CO, V319, P419, DOI 10.1016/j.bbrc.2004.05.020; Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933; SCHULTZ E, 1985, MUSCLE NERVE, V8, P217, DOI 10.1002/mus.880080307; Sherwood RI, 2004, CELL, V119, P543, DOI 10.1016/j.cell.2004.10.021; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; Tajbakhsh S, 1996, NATURE, V384, P266, DOI 10.1038/384266a0; TAJBAKHSH S, 1994, P NATL ACAD SCI USA, V91, P747, DOI 10.1073/pnas.91.2.747; Tajbakhsh S, 1998, DEVELOPMENT, V125, P4155; Taylor WE, 2001, AM J PHYSIOL-ENDOC M, V280, pE221, DOI 10.1152/ajpendo.2001.280.2.E221; Thomas M, 2000, J BIOL CHEM, V275, P40235, DOI 10.1074/jbc.M004356200; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wagner J, 2000, DEV BIOL, V228, P86, DOI 10.1006/dbio.2000.9921; Yoshino K, 2001, MECH DEVELOP, V102, P45, DOI 10.1016/S0925-4773(01)00282-9; Zhou SH, 2004, J BONE MINER RES, V19, P463, DOI 10.1359/JBMR.0301239; Zhu XY, 2004, CYTOKINE, V26, P262, DOI 10.1016/j.cyto.2004.03.007	73	98	107	2	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					580	+		10.1096/fj.05-5125fje	http://dx.doi.org/10.1096/fj.05-5125fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16423875				2022-12-28	WOS:000235996000012
J	Vandebrouck, A; Ducret, T; Basset, O; Sebille, S; Raymond, G; Ruegg, U; Gailly, P; Cognard, C; Constantin, B				Vandebrouck, A; Ducret, T; Basset, O; Sebille, S; Raymond, G; Ruegg, U; Gailly, P; Cognard, C; Constantin, B			Regulation of store-operated calcium entries and mitochondrial uptake by minidystrophin expression in cultured myotubes	FASEB JOURNAL			English	Article						mitochondria; skeletal muscle cells; Duchenne muscular dystrophy	SKELETAL-MUSCLE FIBERS; DYSTROPHIN GENE-TRANSFER; CONTRACTING IN-VITRO; MDX MYOTUBES; SARCOPLASMIC-RETICULUM; LEAK CHANNEL; CELLS; CA2+; INFLUX; LOCALIZATION	Defective expression of dystrophin in muscle cells is the primary feature of Duchenne muscular dystrophy (DMD), which is accompanied by fiber necrosis and intracellular calcium mishandling. These features led to the hypothesis that dystrophin could control calcium movements. Calcium mishandling in human DMD myotubes is dependent on contraction and/or calcium release activity, suggesting the involvement of channels being activated during these processes. Forced expression of minidystrophin at the plasma membrane of dystrophin-deficient Sol8 myotubes reactivates appropriate sarcolemmal expression of dystrophin-associated proteins and results in normal calcium homeostasis. In active dystrophic myotubes, store-operated calcium channels could be responsible for a sustained calcium influx in muscle cells. We show here that depletion of calcium stores ( sarcoplasmic reticulum) by repetitive activation of calcium release and blockade of SERCA leads to a calcium influx. In myotubes expressing recombinant minidystrophin, these store-dependent influxes were reduced to a level similar to that observed in myotubes expressing native dystrophin. High store-dependent calcium influxes in dystrophin-deficient myotubes were associated with sustained cytosolic calcium transients and high intramitochondrial entries, while lower store-dependent calcium influx in myotubes expressing minidystrophin resulted in shorter calcium transients and reduced calcium uptake into mitochondria. We propose that minidystrophin negatively regulates sarcolemmal store-dependent calcium channels, which reduces store-dependent calcium influx, as well as its mitochondrial uptake. Forced expression of minidystrophin in dystrophic cells might restore the regulation of sarcolemmal store-dependent channels, which could protect against calcium mishandling.	Univ Poitiers, CNRS, UMR 6187, Inst Physiol & Biol Cellulaires, F-86022 Poitiers, France; Univ Geneva, Pharmacol Lab, Geneva, Switzerland; Univ Catholique Louvain, Dept Physiol, B-1200 Brussels, Belgium	Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; University of Geneva; Universite Catholique Louvain	Constantin, B (corresponding author), Univ Poitiers, CNRS, UMR 6187, Inst Physiol & Biol Cellulaires, 40 Ave Recteur Pineau, F-86022 Poitiers, France.	bruno.constantin@univ-poitiers.fr	COGNARD, Christian/P-5305-2016; Sebille, Stéphane/P-7959-2016; Constantin, Bruno/AAH-6463-2021	Ducret, Thomas/0000-0002-5146-6869; RUEGG, Urs/0000-0001-6078-8280; Constantin, Bruno/0000-0003-1668-581X				Arnaudeau S, 2001, J BIOL CHEM, V276, P29430, DOI 10.1074/jbc.M103274200; BLINKS JR, 1978, J PHYSIOL-LONDON, V277, P291, DOI 10.1113/jphysiol.1978.sp012273; Challet C, 2001, J BIOL CHEM, V276, P3791, DOI 10.1074/jbc.M006209200; COGNARD C, 1993, CELL CALCIUM, V14, P333, DOI 10.1016/0143-4160(93)90054-A; CONSTANTIN B, 1993, CELL CALCIUM, V14, P135, DOI 10.1016/0143-4160(93)90083-I; DACOSTA AG, 1986, ARCH BIOCHEM BIOPHYS, V249, P199, DOI 10.1016/0003-9861(86)90575-8; Decrouy A, 1997, GENE THER, V4, P401, DOI 10.1038/sj.gt.3300407; Decrouy A, 1998, GENE THER, V5, P59, DOI 10.1038/sj.gt.3300553; ENGLAND SB, 1990, NATURE, V343, P180, DOI 10.1038/343180a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; Gilabert JA, 2000, EMBO J, V19, P6401, DOI 10.1093/emboj/19.23.6401; Gilabert JA, 2001, EMBO J, V20, P2672, DOI 10.1093/emboj/20.11.2672; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hopf FW, 1996, J BIOL CHEM, V271, P22358, DOI 10.1074/jbc.271.37.22358; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; IMBERT N, 1995, CELL CALCIUM, V18, P177, DOI 10.1016/0143-4160(95)90062-4; Imbert N, 1996, NEUROMUSCULAR DISORD, V6, P351, DOI 10.1016/0960-8966(96)00351-3; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; Kurebayashi N, 2001, J PHYSIOL-LONDON, V533, P185, DOI 10.1111/j.1469-7793.2001.0185b.x; Marchand E, 2004, EXP CELL RES, V297, P363, DOI 10.1016/j.yexcr.2004.02.032; Marchand E, 2001, CELL CALCIUM, V29, P85, DOI 10.1054/ceca.2000.0159; Maroto R, 2005, NAT CELL BIOL, V7, P179, DOI 10.1038/ncb1218; MASUDA T, 1992, J CELL BIOL, V119, P543, DOI 10.1083/jcb.119.3.543; McCarter GC, 1997, GENE THER, V4, P483, DOI 10.1038/sj.gt.3300405; MERRITT JE, 1987, J BIOL CHEM, V262, P17362; PORTER GA, 1992, J CELL BIOL, V117, P997, DOI 10.1083/jcb.117.5.997; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Robert V, 2001, J BIOL CHEM, V276, P4647, DOI 10.1074/jbc.M006337200; Rybakova IN, 2000, J CELL BIOL, V150, P1209, DOI 10.1083/jcb.150.5.1209; STRAUB V, 1992, J CELL BIOL, V119, P1183, DOI 10.1083/jcb.119.5.1183; TURNER PR, 1991, J CELL BIOL, V115, P1701, DOI 10.1083/jcb.115.6.1701; Tutdibi O, 1999, J PHYSIOL-LONDON, V515, P859, DOI 10.1111/j.1469-7793.1999.859ab.x; Vandebrouck C, 2002, J CELL BIOL, V158, P1089, DOI 10.1083/jcb.200203091; Vandebrouck C, 2001, NEUROMUSCULAR DISORD, V11, P72, DOI 10.1016/S0960-8966(00)00153-X; WAKAYAMA Y, 1993, ACTA NEUROPATHOL, V86, P567, DOI 10.1007/BF00294294; WILLIAMS JH, 1990, MUSCLE NERVE, V13, P1118, DOI 10.1002/mus.880131206	37	49	50	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					136	+		10.1096/fj.04-3633fje	http://dx.doi.org/10.1096/fj.04-3633fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16254044	Green Published			2022-12-28	WOS:000232991100004
J	Jung, JE; Lee, HG; Cho, IH; Chung, DH; Yoon, SH; Yang, YM; Lee, JW; Choi, S; Park, JW; Ye, SK; Chung, MH				Jung, JE; Lee, HG; Cho, IH; Chung, DH; Yoon, SH; Yang, YM; Lee, JW; Choi, S; Park, JW; Ye, SK; Chung, MH			STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells	FASEB JOURNAL			English	Article						vascular endothelial growth factor; hypoxia inducible factor 1; signal transducers and activators of transcription	HYPOXIA-INDUCIBLE FACTOR-1; CONSTITUTIVE ACTIVATION; NUCLEAR TRANSLOCATION; TRANSCRIPTION FACTOR; ANGIOGENESIS; MECHANISMS; CBP/P300; REQUIRES; BINDING; PROTEIN	Aberrantly enhanced vascular endothelial growth factor (VEGF) gene expression is associated with increased tumor growth and metastatic spread of solid malignancies, including human renal carcinomas. Persistent activation of STAT3 is linked to tumor-associated angiogenesis, but underlying mechanisms remain unclear. Therefore, we examined whether STAT3 modulates the stability and activity of hypoxia-inducible factor-1 alpha (HIF-1 alpha), and in turn enhances VEGF expression. We found that STAT3 was activated in ischemic rat kidneys and hypoxic human renal carcinoma cells. We also found that hypoxia-induced activation of STAT3 transactivated the VEGF promoter and increased the expression of VEGF transcripts. Consistent with these findings,STAT3 inhibition attenuated the hypoxic induction of VEGF. Interestingly,activated STAT3 increased HIF-1 alpha protein levels due to the HIF-1 alpha stability by blocking HIF-1 alpha degradation and accelerated its de novo synthesis. The novel interaction of STAT3 with HIF-1 alpha was identified in hypoxic renal carcinoma cells. Furthermore, hypoxia recruited STAT3,HIF-1 alpha, and p300 to the VEGF promoter and induced histone H3 acetylation. Therefore, these findings provide compelling evidence that a causal relationship exists between STAT3 activation and HIF-1-dependent angiogenesis and suggest that therapeutic modalities designed to disrupt STAT3 signaling hold considerable promise for the blocking tumor growth and enhancing apoptosis of cancer cells and tissues.	Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 151, South Korea; Seoul Natl Univ, Coll Dent, Dept Physiol, Seoul, South Korea; Seoul Natl Univ, Inst Dent Res, Seoul, South Korea; Konkuk Univ, Coll Med, Dept Premed Sci, Chungju, South Korea; Konkuk Univ, Biofood & Drug Res Ctr, Chungju, South Korea; Seoul Natl Univ, Coll Med, Dept Tumor Biol, Canc Res Inst, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Konkuk University; Konkuk University Medical Center; Konkuk University; Seoul National University (SNU)	Ye, SK (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol, 28 Yongon Dong, Seoul 110799, South Korea.	sangkyu@snu.ac.kr	Ye, Sang Kyu/J-2768-2012; Chung, Doo Hyun/J-2791-2012; Park, Jong-Wan/J-2758-2012; Lee, Jung Weon/F-9149-2012; Lee, Jung Weon/AAC-1146-2020	Lee, Jung Weon/0000-0003-2722-8200				Agani F, 1998, MOL PHARMACOL, V54, P749, DOI 10.1124/mol.54.5.749; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Chun YS, 2000, BIOCHEM BIOPH RES CO, V268, P652, DOI 10.1006/bbrc.2000.2180; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Desbaillets I, 1999, ONCOGENE, V18, P1447, DOI 10.1038/sj.onc.1202424; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harmey JH, 1998, ANN SURG ONCOL, V5, P271, DOI 10.1007/BF02303785; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Lal A, 2001, JNCI-J NATL CANCER I, V93, P1337, DOI 10.1093/jnci/93.17.1337; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; Liu K, 2005, J IMMUNOL, V174, P1630, DOI 10.4049/jimmunol.174.3.1630; Mol JC, 2002, GREEN CHEM, V4, P5, DOI 10.1039/b109896a; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; ROLAND H, 2002, FASEB J, V16, P1151; Schaefer LK, 2002, ONCOGENE, V21, P2058, DOI 10.1038/sj.onc.1205263; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Ye SK, 2001, IMMUNITY, V15, P813, DOI 10.1016/S1074-7613(01)00230-8	32	339	366	2	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1296	+		10.1096/fj.04-3099fje	http://dx.doi.org/10.1096/fj.04-3099fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15919761				2022-12-28	WOS:000229602600007
J	Ameln, H; Gustafsson, T; Sundberg, CJ; Okamoto, K; Jansson, E; Poellinger, L; Makino, Y				Ameln, H; Gustafsson, T; Sundberg, CJ; Okamoto, K; Jansson, E; Poellinger, L; Makino, Y			Physiological activation of hypoxia inducible factor-1 in human skeletal muscle	FASEB JOURNAL			English	Article						exercise; gene expression; gene regulation; ischemia; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; GENE-EXPRESSION; FACTOR 1-ALPHA; EXERCISE; ERYTHROPOIETIN; ANGIOGENESIS; ISCHEMIA; TRANSCRIPTION; DESATURATION; RESTRICTION	The human hypoxia inducible factor 1 (HIF-1) system is activated under various pathological conditions, yet less is known about its physiological regulation in healthy human tissue. We have studied the effect of exercise on the activation of HIF-1 in human skeletal muscle. Employing a model where oxygen consumption increases and oxygen tension can be manipulated, nine healthy male subjects performed 45 min of one-legged knee-extension exercise. Biopsies were taken before, directly after, and 30, 120, and 360 min after exercise. Exercise led to elevated HIF-1 alpha protein levels and a more prevalent nuclear staining of HIF-1 alpha. Interestingly, a concurrent decrease in von Hippel-Lindau tumor suppressor protein (VHL) levels was detected in some subjects. Moreover, exercise induced an increase in the DNA binding activity of HIF-1 alpha. Characterization of gene expression by real-time PCR demonstrated that the HIF-1 target genes VEGF and EPO were activated. VEGF mRNA was further increased when blood flow to the exercising leg was restricted. In conclusion, these data clearly demonstrate that physical activity induces the HIF-1-mediated signaling pathway in human skeletal muscle, providing the first evidence that human HIF-1 alpha can be activated during physiologically relevant conditions.	Karolinska Inst, Dept Physiol & Pharmacol, Sect Mol Exercise Physiol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Lab Med, S-17177 Stockholm, Sweden; Univ Tokyo, Inst Med Sci, Div Clin Immunol, Tokyo, Japan	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of Tokyo	Ameln, H (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, Sect Mol Exercise Physiol, S-17177 Stockholm, Sweden.	Helene.Ameln@fyfa.ki.se; Thomas.Gustafson@fyfa.ki.se	Sundberg, Carl Johan/B-9356-2013; Gustafsson, Thomas/AAH-1056-2019	Sundberg, Carl Johan/0000-0002-7000-466X; Rundqvist, Helene/0000-0002-5617-9076; Gustafsson, Thomas/0000-0002-1559-4206				BERGSTROM J, 1962, SCAND J CLIN LAB INV, V14, P1; BLOMQVIST CG, 1983, ANNU REV PHYSIOL, V45, P169, DOI 10.1146/annurev.ph.45.030183.001125; BORG G, 1982, INT J SPORTS MED, V3, P153, DOI 10.1055/s-2008-1026080; Brieger J, 1999, J MOL MED-JMM, V77, P505, DOI 10.1007/s001099900022; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESPLANCHES D, 1993, PFLUG ARCH EUR J PHY, V425, P263, DOI 10.1007/BF00374176; EIKEN O, 1985, EUR J APPL PHYSIOL O, V54, P451, DOI 10.1007/BF00422950; EIKEN O, 1987, ACTA PHYSIOL SCAND, V131, P339, DOI 10.1111/j.1748-1716.1987.tb08248.x; Gustafsson T, 1999, AM J PHYSIOL-HEART C, V276, pH679, DOI 10.1152/ajpheart.1999.276.2.H679; Gustafsson T, 2001, FRONT BIOSCI-LANDMRK, V6, pD75, DOI 10.2741/gustafss; HOGAN MC, 1983, J APPL PHYSIOL, V55, P1134, DOI 10.1152/jappl.1983.55.4.1134; HOHORST HJ, 1962, L PLUS LACTATBESTIMM, P266; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; HUDLICKA O, 1992, PHYSIOL REV, V72, P369, DOI 10.1152/physrev.1992.72.2.369; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Lee SH, 2000, NEW ENGL J MED, V342, P626, DOI 10.1056/NEJM200003023420904; Marti HH, 2004, J EXP BIOL, V207, P3233, DOI 10.1242/jeb.01049; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Pilegaard H, 2000, AM J PHYSIOL-ENDOC M, V279, pE806; RICHARDSON RS, 1995, J CLIN INVEST, V96, P1916, DOI 10.1172/JCI118237; Richardson RS, 2001, J APPL PHYSIOL, V91, P2679, DOI 10.1152/jappl.2001.91.6.2679; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Sundberg C J, 1994, Acta Physiol Scand Suppl, V615, P1; SUNDBERG CJ, 1992, ACTA PHYSIOL SCAND, V146, P1, DOI 10.1111/j.1748-1716.1992.tb09386.x; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; TERRADOS N, 1990, J APPL PHYSIOL, V68, P2369, DOI 10.1152/jappl.1990.68.6.2369; Vogt M, 2001, J APPL PHYSIOL, V91, P173, DOI 10.1152/jappl.2001.91.1.173; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Williams RS, 1996, HDB PHYSL EXERCISE R, P1124; Yasuda Y, 1998, J BIOL CHEM, V273, P25381, DOI 10.1074/jbc.273.39.25381; Yokomizo R, 2002, MOL HUM REPROD, V8, P441, DOI 10.1093/molehr/8.5.441; Zhong H, 1999, CANCER RES, V59, P5830	40	182	185	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1009	+		10.1096/fj.04-2304fje	http://dx.doi.org/10.1096/fj.04-2304fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15811877				2022-12-28	WOS:000228865300029
J	Russell, AP; Hesselink, MKC; Lo, SK; Schrauwen, P				Russell, AP; Hesselink, MKC; Lo, SK; Schrauwen, P			Regulation of metabolic transcriptional co-activators and transcription factors with acute exercise	FASEB JOURNAL			English	Article						PGC-1; PPAR-1 alpha; REBP-1c; FKHR; MCIP1	HUMAN SKELETAL-MUSCLE; CONTROLLING MITOCHONDRIAL BIOGENESIS; MESSENGER-RNA EXPRESSION; ACTIVATED RECEPTOR-ALPHA; LIPOPROTEIN-LIPASE GENE; FATTY-ACID OXIDATION; PPAR-GAMMA; NUCLEAR RECEPTORS; LIPID-METABOLISM; FACTOR FKHR	Endurance exercise improves insulin sensitivity and increases fat oxidation, which are partly facilitated by the induction of metabolic transcription factors. Next to exercise, increased levels of FFA's also increase the gene expression of transcription factors, hence making it difficult to discern the effects from contractile signals produced during exercise, from those produced by increased circulatory FFA's. We aimed to investigate, in human skeletal muscle, whether acute exercise affects gene expression of metabolic transcriptional co-activators and transcription factors, including PGC-1 alpha, PRC, PPAR alpha, beta/delta, and gamma and RXR, SREBP-1c and FKHR, and to discern the effect of exercise per se from those of elevated levels of FFA. Two hours of endurance exercise was performed either in the fasted state, or following carbohydrate ingestion prior to and during exercise, thereby blunting the fasting-induced increase in FA availability and oxidation. Of the genes measured, PGC-1 alpha and PRC mRNA increased immediately after, while PPAR beta/delta and FKHR mRNA increased 1-4 h after exercise, irrespective of the increases in FFA's. Our results suggest that the induction in vivo of metabolic transcription factors implicated in mitochondrial biogenesis are under the control of inherent signals, (PGC-1 alpha, PRC), while those implicated in substrate selection are under the control of associated signals (PPAR beta/delta, FKHR) stimulated from the contracting skeletal muscle that are independent of circulating FFA levels.	Clin Romande Readaptat SUVA Care, Sion, Switzerland; Maastricht Univ, Dept Movement Sci, Maastricht, Netherlands; Univ Sydney, Inst Int Hlth, Sydney, NSW 2006, Australia; Maastricht Univ, Dept Human Biol, Maastricht, Netherlands	Maastricht University; University of Sydney; Maastricht University	Russell, AP (corresponding author), Clin Romande Readaptat, Case Postale 352,Av Gd Champsec 90, CH-1951 Sion, Switzerland.	aaron.russell@crr-suva.ch		Russell, Aaron/0000-0002-7323-9501; schrauwen, patrick/0000-0002-0973-847X; LO, Sing Kai/0000-0001-8401-1759				Andersson U, 2001, MOL CELL BIOL, V21, P3738, DOI 10.1128/MCB.21.11.3738-3749.2001; Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268; Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com; Barthel A, 2002, ENDOCRINOLOGY, V143, P3183, DOI 10.1210/endo.143.8.8792; BERGSTROM J, 1975, SCAND J CLIN LAB INV, V35, P606, DOI 10.3109/00365517509095787; Bey L, 1998, GENE, V209, P31, DOI 10.1016/S0378-1119(98)00003-1; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coyle EF, 1997, AM J PHYSIOL-ENDOC M, V273, pE268, DOI 10.1152/ajpendo.1997.273.2.E268; DELA F, 1994, DIABETES, V43, P862, DOI 10.2337/diabetes.43.7.862; DELA F, 1992, AM J PHYSIOL, V263, pE1134; Delerive P, 2002, J BIOL CHEM, V277, P3913, DOI 10.1074/jbc.M109409200; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Furuyama T, 2003, BIOCHEM J, V375, P365, DOI 10.1042/BJ20030022; Goto M, 2000, BIOCHEM BIOPH RES CO, V274, P350, DOI 10.1006/bbrc.2000.3134; Herzig S, 2003, NATURE, V426, P190, DOI 10.1038/nature02110; HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831; Horowitz JF, 2000, AM J PHYSIOL-ENDOC M, V279, pE348, DOI 10.1152/ajpendo.2000.279.2.E348; Ikeda S, 2002, BIOCHEM BIOPH RES CO, V296, P395, DOI 10.1016/S0006-291X(02)00883-5; Jeukendrup AE, 1999, J PHYSIOL-LONDON, V515, P579, DOI 10.1111/j.1469-7793.1999.579ac.x; Kaestner KH, 2000, GENE DEV, V14, P142; Kamei Y, 2003, FEBS LETT, V536, P232, DOI 10.1016/S0014-5793(03)00062-0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kliewer SA, 1998, CURR OPIN GENET DEV, V8, P576, DOI 10.1016/S0959-437X(98)80014-2; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Knutti D, 2001, TRENDS ENDOCRIN MET, V12, P360, DOI 10.1016/S1043-2760(01)00457-X; Latasa MJ, 2000, P NATL ACAD SCI USA, V97, P10619, DOI 10.1073/pnas.180306597; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Matsuzaka T, 2002, J LIPID RES, V43, P107; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Muoio DM, 2002, J BIOL CHEM, V277, P26089, DOI 10.1074/jbc.M203997200; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; Norrbom J, 2004, J APPL PHYSIOL, V96, P189, DOI 10.1152/japplphysiol.00765.2003; Ojuka EO, 2003, FASEB J, V17, P675, DOI 10.1096/fj.02-0951com; Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Russell AP, 2003, DIABETES, V52, P2874, DOI 10.2337/diabetes.52.12.2874; Russell AP, 2003, PFLUG ARCH EUR J PHY, V445, P563, DOI 10.1007/s00424-002-0943-5; Scarpulla RC, 2002, GENE, V286, P81, DOI 10.1016/S0378-1119(01)00809-5; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Schrauwen P, 2002, DIABETES, V51, P2220, DOI 10.2337/diabetes.51.7.2220; Schrauwen P, 2002, AM J PHYSIOL-ENDOC M, V282, pE11, DOI 10.1152/ajpendo.2002.282.1.E11; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Schuur ER, 2001, J BIOL CHEM, V276, P33554, DOI 10.1074/jbc.M105555200; Short KR, 2003, DIABETES, V52, P1888, DOI 10.2337/diabetes.52.8.1888; Simoneau JA, 1999, FASEB J, V13, P2051, DOI 10.1096/fasebj.13.14.2051; Terada S, 2002, BIOCHEM BIOPH RES CO, V296, P350, DOI 10.1016/S0006-291X(02)00881-1; THARP GD, 1975, MED SCI SPORT EXER, V7, P6; Tunstall RJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE66, DOI 10.1152/ajpendo.00475.2001; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61	61	124	129	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					986	+		10.1096/fj.04-3168fje	http://dx.doi.org/10.1096/fj.04-3168fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15814608	Green Published			2022-12-28	WOS:000228865300024
J	Wang, TG; Pei, Z; Zhang, W; Liu, B; Langenbach, R; Lee, C; Wilson, B; Reece, JM; Miller, DS; Hong, JS				Wang, TG; Pei, Z; Zhang, W; Liu, B; Langenbach, R; Lee, C; Wilson, B; Reece, JM; Miller, DS; Hong, JS			MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration	FASEB JOURNAL			English	Article						cyclooxygenase-2; prostaglandin E-2; microglia; neuron; Parkinson's disease	LIPOPOLYSACCHARIDE-INDUCED NEUROTOXICITY; PARKINSONS-DISEASE; NITRIC-OXIDE; SUBSTANTIA-NIGRA; MICROGLIAL ACTIVATION; ALZHEIMERS-DISEASE; PROSTAGLANDIN E-2; MOUSE MODEL; MPTP MODEL; CYCLOOXYGENASE	The importance of cyclooxygenase-2 (COX-2) in mediating Parkinson's disease (PD) was suggested in reports, indicating that COX-2 selective inhibitors or genetic knockout reduce 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic (DA) neurotoxicity in a mouse model of PD. However, cell types and mechanisms underlying the activation of COX-2 have not been clearly elucidated in these animal studies. Using primary neuron-glia cultures, we aimed to determine 1) whether microglia participate in 1-methyl-4-phenylpryridinium (MPP)-induced COX-2 activation and 2) whether the activation of COX-2 contributes to subsequent neurotoxicity. MPP+, in a concentration-dependent manner, increased prostaglandin E-2 (PGE(2)) production in mixed neuron-microglia cultures but not in enriched neuron, microglia, or astroglia cultures nor in mixed neuron-astroglia cultures. MPP+-induced PGE2 increase was completely abolished by treatment with DuP697, a COX-2 selective inhibitor. DuP697 also significantly reduced MPP+-induced DA neurotoxicity as determined by DA uptake assay. Immunocytochemistry and confocal microscopy studies showed enhanced COX-2 expression in both microglia and neurons after MPP+ treatment. However, neuronal increase in COX-2 expression was not totally dependent on the production of PGE(2) from microglia, since microglia deficient in COX-2 only attenuated, but did not completely block, MPP+-increased PGE(2) production in mixed neuron-microglia cultures, suggesting that part of PGE(2) production was originated from neurons. Together, these results indicate that MPP+-induced COX-2 expression and subsequent PGE(2) production depend on interactions between neurons and microglia. Microgliosis may also be responsible for the COX-2 activation in neurons, leading to the enhanced DA neurotoxicity, which, in turn, reinforces microgliosis. Thus inhibition of microgliosis and COX-2 activity may stop this vicious circle and be valuable strategies in PD therapy.	NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA; Univ Florida, Coll Pharm, Gainesville, FL 32610 USA; NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Confocal Microscopy Ctr, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); State University System of Florida; University of Florida; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Hong, JS (corresponding author), NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	hong3@niehs.nih.gov	Hong, Jau-Shyong/F-1920-2019	Hong, Jau-Shyong/0000-0002-3056-8401	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES080048, Z01ES090082, Z01ES080048, ZIAES021179, ZIAES090082, Z01ES021179] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Banati RB, 1998, MOVEMENT DISORD, V13, P221, DOI 10.1002/mds.870130205; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; Bronstein DM, 1995, BRAIN RES, V704, P112, DOI 10.1016/0006-8993(95)01189-7; Chen HL, 2003, ARCH NEUROL-CHICAGO, V60, P1059, DOI 10.1001/archneur.60.8.1059; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Feng ZH, 2002, NEUROSCI LETT, V329, P354, DOI 10.1016/S0304-3940(02)00704-8; Gao HM, 2003, FASEB J, V17, DOI 10.1096/fj.03-0109fje; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Hoozemans JJM, 2002, BRAIN RES, V951, P218, DOI 10.1016/S0006-8993(02)03164-5; Langenbach R, 1999, BIOCHEM PHARMACOL, V58, P1237, DOI 10.1016/S0006-2952(99)00158-6; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LEE SH, 1992, J BIOL CHEM, V267, P25934; Liberatore GT, 1999, NAT MED, V5, P1403; Liu B, 2000, NEUROSCIENCE, V97, P749, DOI 10.1016/S0306-4522(00)00057-9; Liu B, 2002, ANN NY ACAD SCI, V962, P318, DOI 10.1111/j.1749-6632.2002.tb04077.x; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; MERRILL JE, 1992, J VIROL, V66, P2217, DOI 10.1128/JVI.66.4.2217-2225.1992; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Olanow CW, 2004, ANNU REV MED, V55, P41, DOI 10.1146/annurev.med.55.091902.104422; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Qin LY, 2002, J NEUROCHEM, V83, P973, DOI 10.1046/j.1471-4159.2002.01210.x; Sairam K, 2003, BRAIN RES, V966, P245, DOI 10.1016/S0006-8993(02)04174-4; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Teismann P, 2003, ANN NY ACAD SCI, V991, P272; Teismann P, 2001, SYNAPSE, V39, P167, DOI 10.1002/1098-2396(200102)39:2<167::AID-SYN8>3.0.CO;2-U; UHL GR, 1985, LANCET, V1, P956; Wang TG, 2004, J PHARMACOL EXP THER, V308, P975, DOI 10.1124/jpet.103.059683; Wang TG, 2004, J NEUROCHEM, V88, P939, DOI 10.1046/j.1471-4159.2003.02242.x; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002	31	82	106	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2005	19	6					1134	+		10.1096/fj.04-2457fje	http://dx.doi.org/10.1096/fj.04-2457fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15845609				2022-12-28	WOS:000228865300010
J	El-Agnaf, OMA; Salem, SA; Paleologou, KE; Curran, MD; Gibson, MJ; Court, JA; Schlossmacher, MG; Allsop, D				El-Agnaf, Omar M. A.; Salem, Sultan A.; Paleologou, Katerina E.; Curran, Martin D.; Gibson, Mark J.; Court, Jennifer A.; Schlossmacher, Michael G.; Allsop, David			Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease	FASEB JOURNAL			English	Article						CSF; PD; Lewy bodies; alpha-syn fibrils; oligomers	ALZHEIMERS-DISEASE; LOCUS TRIPLICATION; SOLUBLE OLIGOMERS; MOUSE MODEL; LEWY BODY; PATHOGENESIS; MUTATIONS; DEMENTIA; BRAIN; TOXICITY	To date there is no accepted clinical diagnostic test for Parkinson's disease (PD) based on biochemical analysis of blood or cerebrospinal fluid (CSF). alpha-Synuclein (alpha-syn) protein has been linked to the pathogenesis of PD with the discovery of mutations in the gene encoding alpha-syn in familial cases with early-onset PD. Lewy bodies and Lewy neurites, which constitute the main pathological features in the brains of patients with sporadic PD and dementia with Lewy bodies, are formed by the conversion of soluble monomers of alpha-syn into insoluble aggregates. We recently reported the presence of alpha-syn in normal human blood plasma and in postmortem CSF. Here, we investigated whether alpha-syn can be used as a biomarker for PD. We have developed a novel ELISA method that detects only oligomeric "soluble aggregates" of alpha-syn. Using this ELISA, we report the presence of significantly elevated (P = 0.002) levels of oligomeric forms of alpha-syn in plasma samples obtained from 34 PD patients compared with 27 controls; 52% (95% confidence intervals 0.353-0.687) of the PD patients displayed signals > 0.5 OD with our ELISA assay in comparison to only 14.8% ( 95% confidence intervals 0.014-0.281) for the control cases. An analysis of the test's diagnostic value revealed a specificity of 0.852 (95% confidence intervals 0.662-0.958), sensitivity of 0.529 (95% confidence intervals 0.351-0.702) and a positive predictive value of 0.818 (95% confidence intervals 0.597-0.948). These observations offer new opportunities for developing diagnostic tests for PD and related diseases and for testing therapeutic agents aimed at preventing or reversing the aggregation of alpha-syn.	United Arab Emirates Univ, Dept Biochem, Fac Med & Hlth Sci, Al Ain, U Arab Emirates; Univ Lancaster, Dept Biol Sci, Lancaster, England; Belfast City Hosp, No Ireland Reg Histocompatibil & Immunogenet Lab, Belfast BT9 7AD, Antrim, North Ireland; Belfast City Hosp, Movement Disorders Clin, Belfast BT9 7AD, Antrim, North Ireland; Newcastle Gen Hosp, Joint MRC Newcastle Univ Dev Clin Brain Ageing, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	United Arab Emirates University; Lancaster University; Belfast City Hospital; Belfast City Hospital; Newcastle General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	El-Agnaf, OMA (corresponding author), United Arab Emirates Univ, Dept Biochem, Fac Med & Hlth Sci, POB 17666, Al Ain, U Arab Emirates.	o.elagnaf@uaeu.ac.ae	Allsop, David/B-9725-2008	Allsop, David/0000-0002-0513-5575; Schlossmacher, Michael/0000-0002-0394-0300	Alzheimers Research UK [ART-PPG2005A-1] Funding Source: researchfish	Alzheimers Research UK(Alzheimer&apos;s Research UK (ARUK))		Bieschke J, 2000, P NATL ACAD SCI USA, V97, P5468, DOI 10.1073/pnas.97.10.5468; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Cookson MR, 2005, ANNU REV BIOCHEM, V74, P29, DOI 10.1146/annurev.biochem.74.082803.133400; DeMattos RB, 2002, J NEUROCHEM, V81, P229, DOI 10.1046/j.1471-4159.2002.00889.x; DeMattos RB, 2002, SCIENCE, V295, P2264, DOI 10.1126/science.1067568; El-Agnaf OMA, 2000, BIOCHEM BIOPH RES CO, V273, P1003, DOI 10.1006/bbrc.2000.3051; El-Agnaf OMA, 2001, J MOL BIOL, V310, P157, DOI 10.1006/jmbi.2001.4743; El-Agnaf OMA, 2004, FASEB J, V18, P1315, DOI 10.1096/fj.03-1346fje; El-Agnaf OMA, 2003, FASEB J, V17, P1945, DOI 10.1096/fj.03-0098fje; El-Agnaf OMA, 2003, LANCET NEUROL, V2, P461, DOI 10.1016/S1474-4422(03)00481-2; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; LANG AE, 1998, NEW ENGL J MED, V339, P1144; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Li QX, 2002, J ALZHEIMERS DIS, V4, P309, DOI 10.3233/JAD-2002-4406; Martin FL, 2004, PROTEIN PEPTIDE LETT, V11, P229, DOI 10.2174/0929866043407138; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Miller DW, 2004, NEUROLOGY, V62, P1835, DOI 10.1212/01.WNL.0000127517.33208.F4; Pitschke M, 1998, NAT MED, V4, P832, DOI 10.1038/nm0798-832; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Schapira AHV, 1999, BRIT MED J, V318, P311, DOI 10.1136/bmj.318.7179.311; Sharon R, 2003, NEURON, V37, P583, DOI 10.1016/S0896-6273(03)00024-2; Silverberg GD, 2003, LANCET NEUROL, V2, P506, DOI 10.1016/S1474-4422(03)00487-3; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	34	533	564	1	77	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2006	20	3					419	425		10.1096/fj.03-1449com	http://dx.doi.org/10.1096/fj.03-1449com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	074LY	16507759				2022-12-28	WOS:000239815100005
J	Bearzatto, B; Servais, L; Roussel, C; Gall, D; Baba-Aissa, F; Schurmans, S; d'Exaerde, AD; Cheron, G; Schiffmann, SN				Bearzatto, Bertrand; Servais, Laurent; Roussel, Celine; Gall, David; Baba-Aissa, Fawzia; Schurmans, Stephane; d'Exaerde, Alban de Kerchove; Cheron, Guy; Schiffmann, Serge N.			Targeted calretinin expression in granule cells of calretinin-null mice restores normal cerebellar functions	FASEB JOURNAL			English	Article									[Bearzatto, Bertrand; Servais, Laurent; Roussel, Celine; Gall, David; Baba-Aissa, Fawzia; d'Exaerde, Alban de Kerchove; Schiffmann, Serge N.] Univ Libre Bruxelles, Neurophysiol Lab, B-1070 Brussels, Belgium; [Schurmans, Stephane] Univ Libre Bruxelles, IRIBHM, IBMM, B-1070 Brussels, Belgium; [Cheron, Guy] Univ Libre Bruxelles, Lab Movement Biomech, B-1070 Brussels, Belgium; [Cheron, Guy] Univ Mons, Lab Electrophysiol, B-7000 Mons, Belgium	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Universite Libre de Bruxelles; University of Mons	Schiffmann, SN (corresponding author), Univ Libre Bruxelles, Lab Neurophysiol CP601, Route de Lennik 808, B-1070 Brussels, Belgium.	sschiffm@ulb.ac.be	Servais, Laurent/AAL-7384-2020; de Kerchove d'Exaerde, Alban/R-6984-2019; Baba-Aissa, Fawzia/AAD-7811-2020	de Kerchove d'Exaerde, Alban/0000-0002-0682-5877; Schiffmann, Serge/0000-0002-0118-9816; Servais, Laurent/0000-0001-9270-4061					0	46	46	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					380	382		10.1096/fj.05-3785fje	http://dx.doi.org/10.1096/fj.05-3785fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16352645				2022-12-28	WOS:000207915000028
J	Shen, JK; Yang, XR; Xiao, WH; Hackett, SF; Sato, Y; Campochiaro, PA				Shen, JiKui; Yang, XiaoRu; Xiao, Wei-Hong; Hackett, Sean F.; Sato, Yasufumi; Campochiaro, Peter A.			Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization	FASEB JOURNAL			English	Article						angiogenesis; autocrine and paracrine regulation; diabetic retinopathy; ischemic retinopathy; negative feedback	ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; VASCULAR-PERMEABILITY FACTOR; CHOROIDAL NEOVASCULARIZATION; ANGIOGENESIS; INHIBITION; MODEL; EXPRESSION; GENE; MICE	Vasohibin is a recently identified protein that is up-regulated in cultured vascular endothelial cells by vascular endothelial growth factor and fibroblast growth factor 2. It inhibits endothelial cell migration, proliferation, and tube formation, and suppresses angiogenesis in chick chorioallantoic membrane, after subcutaneous implantation of matrigel, and in a tumor xenograft model. This has led to the hypothesis that vasohibin functions as a negative feedback inhibitor of angiogenesis. In this study, we tested that hypothesis in a well-characterized model of retinal neovascularization. In ischemic retina, increased expression of VEGF was accompanied by elevation of vasohibin mRNA and blocking of the increase in vegf mRNA with vegf siRNA significantly attenuated the rise in vasohibin mRNA. In transgenic mice in which the rhodopsin promoter drives expression of VEGF in the retina, there was also a significant increase in vasohibin mRNA. In mice with ischemic retinopathy, there was increased expression of vasohibin in vascular endothelial cells, and vasohibin knockdown caused an increase in neovascularization. Conversely, intraocular injection of recombinant vasohibin or an adenoviral vector containing a vasohibin expression cassette strongly suppressed retinal neovascularization in mice with ischemic retinopathy. Knockdown of vasohibin mRNA in ischemic retina had no significant effect on vegf or vegf receptor 1 mRNA levels but caused a significant elevation in the level of vegf receptor 2 mRNA. These data support the hypothesis that vasohibin acts as a negative feedback regulator of neovascularization in the retina and suggest that suppression of VEGF receptor 2 may play some role in mediating its activity.	Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA; Johns Hopkins Univ, Dept Pulm Dis & Crit Care, Bayview Med Ctr, Baltimore, MD USA; Tohoku Univ, Dept Vasc Biol, Inst Dev Aging & Canc, Sendai, Miyagi 980, Japan	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Tohoku University	Campochiaro, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Ophthalmol, 600 N Wolfe St,Maumenee 719, Baltimore, MD 21287 USA.	pcampo@jhmi.edu	Sato, Yasufumi/AAF-3367-2019		NEI NIH HHS [P30EY1765, EY12609] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY001765, R01EY012609] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; Campochiaro PA, 2003, ONCOGENE, V22, P6537, DOI 10.1038/sj.onc.1206773; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Doll JA, 2003, NAT MED, V9, P774, DOI 10.1038/nm870; Garcia M, 2004, CANCER RES, V64, P5632, DOI 10.1158/0008-5472.CAN-04-0230; Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158; MILLER JW, 1994, AM J PATHOL, V145, P574; Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428; Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; Okamoto N, 1997, AM J PATHOL, V151, P281; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246; SAITO I, 1985, J VIROL, V54, P711, DOI 10.1128/JVI.54.3.711-719.1985; Sawant S, 2004, BIOCHEM BIOPH RES CO, V325, P408, DOI 10.1016/j.bbrc.2004.10.041; Seo MS, 1999, AM J PATHOL, V154, P1743, DOI 10.1016/S0002-9440(10)65430-2; Shimizu K, 2005, BIOCHEM BIOPH RES CO, V327, P700, DOI 10.1016/j.bbrc.2004.12.073; SHIMIZU K, 1981, OPHTHALMOLOGY, V88, P601; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Streck CJ, 2005, J PEDIATR SURG, V40, P236, DOI 10.1016/j.jpedsurg.2004.09.049; Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7; Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Watanabe K, 2004, J CLIN INVEST, V114, P898, DOI 10.1172/JC1200421152; Yamada E, 2001, HISTOL HISTOPATHOL, V16, P87, DOI 10.14670/HH-16.87	30	80	90	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					723	+		10.1096/fj.05-5046fje	http://dx.doi.org/10.1096/fj.05-5046fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16473886				2022-12-28	WOS:000237698700025
J	Soto-Pena, GA; Luna, AL; Acosta-Saavedra, L; Conde-Moo, P; Lopez-Carrillo, L; Cebrian, ME; Bastida, M; Calderon-Aranda, ES; Vega, L				Soto-Pena, Gerson A.; Luna, Ana L.; Acosta-Saavedra, Leonor; Conde-Moo, Patricia; Lopez-Carrillo, Lizbeth; Cebrian, Mariano E.; Bastida, Mariana; Calderon-Aranda, Emma S.; Vega, Libia			Assessment of lymphocyte subpopulations and cytokine secretion in children exposed to arsenic	FASEB JOURNAL			English	Article						cell surface markers; lymphokines; human cells; immunotoxicity	COLONY-STIMULATING FACTOR; CELL-PROLIFERATION; GALLIUM-ARSENIDE; MOUSE SKIN; T-CELLS; GM-CSF; KERATINOCYTES; GROWTH; PROGRESSION; EXPRESSION	Exposure of several human populations to arsenic has been associated with a high incidence of detrimental dermatological and carcinogenic effects. To date, studies examining the immunotoxic effects of arsenic in humans, and specifically in children, are lacking. Therefore, we evaluated several parameters of immunological status in a group of children exposed to arsenic through their drinking water. Peripheral blood mononuclear cells (PBMCs) of 90 children ( 6 to 10 years old) were collected. Proportions of lymphocyte subpopulations, PBMC mitogenic proliferative response, and urinary arsenic levels were evaluated. Increased urine arsenic levels were associated with a reduced proliferative response to phytohemaglutinin (PHA) stimulation (P=0.005), CD4 subpopulation proportion (P=0.092), CD4/CD8 ratio (P=0.056), and IL-2 secretion levels (P=0.003). Increased arsenic exposure was also associated with an increase in GM-CSF secretion by mononucleated cells (P=0.000). We did not observe changes in CD8, B, or NK cell proportions, nor did we observe changes in the secretion of IL-4, IL-10, or IFN-gamma by PHA-activated PBMCs. These data indicate that arsenic exposure could alter the activation processes of T cells, such that an immunosuppression status that favors opportunistic infections and carcinogenesis is produced together with increased GM-CSF secretion that may be associated with chronic inflammation.	CINVESTAV, Secc Externa Toxicol, Mexico City 07360, DF, Mexico; Inst Nacl Salud Publ, Cuernavaca, Morelos, Mexico; Jurisdicc Sanit 5, Secretaria Salubridad & Asistencia, Zimapan, Hidalgo, Mexico	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Nacional de Salud Publica	Vega, L (corresponding author), CINVESTAV, Secc Externa Toxicol, Av IPN 2508, Mexico City 07360, DF, Mexico.	lvega@cinvestav.mx	Vega, Libia/C-3391-2013	Vega, Libia/0000-0002-4993-5267; Conde, Patricia/0000-0002-9346-305X; S Calderon Aranda, Emma/0000-0001-8284-2217				Andres A, 2005, CRIT REV ONCOL HEMAT, V56, P71, DOI 10.1016/j.critrevonc.2004.11.010; ANSEL J, 1990, J INVEST DERMATOL, V94, pS101, DOI 10.1111/1523-1747.ep12876053; Armienta MA, 1997, B ENVIRON CONTAM TOX, V59, P583, DOI 10.1007/s001289900519; BRAUNSTEIN S, 1994, J INVEST DERMATOL, V103, P601, DOI 10.1111/1523-1747.ep12396936; BRONFMAN M, 1988, ARCH INVEST MED, V19, P351; BURNS LA, 1993, J PHARMACOL EXP THER, V265, P178; Del Razo LM, 2001, TOXICOL APPL PHARM, V174, P282, DOI 10.1006/taap.2001.9226; Deng JS, 1998, AM J DERMATOPATH, V20, P143, DOI 10.1097/00000372-199804000-00007; *EPA, 1990, EPASABCASAC90002; Germolec DR, 1998, AM J PATHOL, V153, P1775, DOI 10.1016/S0002-9440(10)65692-1; Germolec DR, 1996, TOXICOL APPL PHARM, V141, P308, DOI 10.1016/S0041-008X(96)80037-8; Germolec DR, 1997, MUTAT RES-REV MUTAT, V386, P209, DOI 10.1016/S1383-5742(97)00006-9; GLICK AB, 1991, MOL CARCINOGEN, V4, P210, DOI 10.1002/mc.2940040308; GONSEBATT ME, 1994, MUTAT RES-ENVIR MUTA, V313, P293, DOI 10.1016/0165-1161(94)90059-0; GONSEBATT ME, 1992, MUTAT RES, V283, P91, DOI 10.1016/0165-7992(92)90139-9; Hayashi T, 1997, INTERNAL MED, V36, P822, DOI 10.2169/internalmedicine.36.822; Hernberg M, 1998, MELANOMA RES, V8, P283, DOI 10.1097/00008390-199806000-00013; KOURY MJ, 1983, EMBO J, V2, P1877, DOI 10.1002/j.1460-2075.1983.tb01674.x; Lim Soon Thye, 2005, Curr Infect Dis Rep, V7, P227, DOI 10.1007/s11908-005-0039-4; LONTZ W, 1995, FREE RADICAL BIO MED, V18, P349, DOI 10.1016/0891-5849(94)E0124-2; Luna AL, 2003, TOXICOL SCI, V72, P377; McCollum G, 2005, J PHARMACOL EXP THER, V313, P877, DOI 10.1124/jpet.104.080713; McPartlin DW, 1999, INT J CLIN PRACT, V53, P562; Meng ZQ, 2000, CHEMOSPHERE, V41, P115, DOI 10.1016/S0045-6535(99)00397-5; MILLER DT, 1987, ANALYST, V112, P1701, DOI 10.1039/an9871201701; Pastore S, 1997, J CLIN INVEST, V99, P3009, DOI 10.1172/JCI119496; Patterson R, 2004, TOXICOL APPL PHARM, V198, P434, DOI 10.1016/j.taap.2003.10.012; Rossman TG, 2004, TOXICOL APPL PHARM, V198, P394, DOI 10.1016/j.taap.2003.10.016; SCHOFER H, 1995, HAUTARZT, V46, P632, DOI 10.1007/s001050050310; SIKORSKI EE, 1989, FUND APPL TOXICOL, V13, P843, DOI 10.1016/0272-0590(89)90338-2; SPALDING JW, 1993, CARCINOGENESIS, V14, P1335, DOI 10.1093/carcin/14.7.1335; Thomas DJ, 2001, TOXICOL APPL PHARM, V176, P127, DOI 10.1006/taap.2001.9258; Tseng CH, 2004, TOXICOL APPL PHARM, V197, P67, DOI 10.1016/j.taap.2004.02.009; UYEMURA K, 1993, J INVEST DERMATOL, V101, P701, DOI 10.1111/1523-1747.ep12371679; VASUNIA KB, 1994, CARCINOGENESIS, V15, P653, DOI 10.1093/carcin/15.4.653; Vega L, 2004, TOXICOLOGY, V199, P121, DOI 10.1016/j.tox.2004.02.012; Vega L, 1999, IMMUNOPHARM IMMUNOT, V21, P203, DOI 10.3109/08923979909052758; Vega L, 2001, TOXICOL APPL PHARM, V172, P225, DOI 10.1006/taap.2001.9152; WIGER K, 2005, IDSSKR NOR LAEGEFORE, V125, P1168; Woo SH, 2005, J CELL BIOCHEM, V95, P120, DOI 10.1002/jcb.20329	40	142	152	1	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					779	+		10.1096/fj.05-4860fje	http://dx.doi.org/10.1096/fj.05-4860fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16461332				2022-12-28	WOS:000237698700037
J	Lemonnier, L; Trebak, M; Lievremont, JP; Bird, GS; Putney, JW				Lemonnier, L; Trebak, M; Lievremont, JP; Bird, GS; Putney, JW			Protection of TRPC7 cation channels from calcium inhibition by closely associated SERCA pumps	FASEB JOURNAL			English	Article						calcium channels; calcium signaling; ion channels; TRPC channels	INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; CAPACITATIVE CA2+ ENTRY; TRANSIENT RECEPTOR; DROSOPHILA TRP; FUNCTIONAL-CHARACTERIZATION; TRISPHOSPHATE RECEPTOR; ENDOPLASMIC-RETICULUM; SIGNALING MECHANISM; MOLECULAR-CLONING; HUMAN HOMOLOG	Numerous studies have demonstrated that members of the transient receptor potential (TRP) superfamily of channels are involved in regulated Ca2+ entry. Additionally, most Ca2+-permeable channels are themselves regulated by Ca2+, often in complex ways. In the current study, we have investigated the regulation of TRPC7, a channel known to be potentially activated by both store-operated mechanisms and non-store-operated mechanisms involving diacylglycerols. Surprisingly, we found that activation of TRPC7 channels by diacylglycerol was blocked by the SERCA pump inhibitor thapsigargin. The structurally related channel, TRPC3, was similarly inhibited. This effect depended on extracellular calcium and on the driving force for Ca2+ entry. The inhibition is not due to calcium entry through store-operated channels but rather results from calcium entry through TRPC7 channels themselves. The effect of thapsigargin was prevented by inhibition of calmodulin and was mimicked by pharmacological disruption of the actin cytoskeleton. Our results suggest the presence of a novel mechanism involving negative regulation of TRPC channels by calcium entering through the channels. Under physiological conditions, this negative feedback by calcium is attenuated by the presence of closely associated SERCA pumps.	NIEHS, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Putney, JW (corresponding author), NIEHS, NIH, Dept Hlth & Human Serv, POB 12233, Res Triangle Pk, NC 27709 USA.	putney@niehs.nih.gov	Bird, Gary/AAI-8186-2021; Lemonnier, Loic/L-7289-2018; Trebak, Mohamed/E-7405-2014; Putney, James W/F-7247-2019	Bird, Gary/0000-0003-1389-8748; Lemonnier, Loic/0000-0001-6200-5382; Putney, James W/0000-0002-3379-4789	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090087, Z01ES090087] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Boulay G, 2002, CELL CALCIUM, V32, P201, DOI 10.1016/S0143416002001550; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Braun FJ, 2001, J BIOL CHEM, V276, P1063, DOI 10.1074/jbc.M008348200; Bugaj V, 2005, J BIOL CHEM, V280, P16790, DOI 10.1074/jbc.M500192200; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Hovnanian A, 2004, BIOCHEM BIOPH RES CO, V322, P1237, DOI 10.1016/j.bbrc.2004.08.067; Lievremont JP, 2004, AM J PHYSIOL-CELL PH, V287, pC1709, DOI 10.1152/ajpcell.00350.2004; Liu XB, 2001, J BIOL CHEM, V276, P29891, DOI 10.1074/jbc.M103283200; Lucas P, 2003, NEURON, V40, P551, DOI 10.1016/S0896-6273(03)00675-5; Luo D, 2001, J BIOL CHEM, V276, P5613, DOI 10.1074/jbc.M007524200; Luo DL, 2001, J BIOL CHEM, V276, P20186, DOI 10.1074/jbc.M100327200; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; McKay RR, 2000, BIOCHEM J, V351, P735, DOI 10.1042/0264-6021:3510735; Moneer Z, 2002, BIOCHEM J, V362, P13, DOI 10.1042/0264-6021:3620013; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Mori Y, 2002, J EXP MED, V195, P673, DOI 10.1084/jem.20011758; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Plant TD, 2003, CELL CALCIUM, V33, P441, DOI 10.1016/S0143-4160(03)00055-1; Riccio A, 2002, J BIOL CHEM, V277, P12302, DOI 10.1074/jbc.M112313200; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Shi J, 2004, J PHYSIOL-LONDON, V561, P415, DOI 10.1113/jphysiol.2004.075051; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Trebak M, 2003, J BIOL CHEM, V278, P16244, DOI 10.1074/jbc.M300544200; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Vazquez G, 2004, BBA-MOL CELL RES, V1742, P21, DOI 10.1016/j.bbamcr.2004.08.015; Vazquez G, 2004, J BIOL CHEM, V279, P40521, DOI 10.1074/jbc.M405280200; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; Xu SZ, 2001, CIRC RES, V88, P84, DOI 10.1161/01.RES.88.1.84; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	39	31	31	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					503	+		10.1096/fj.05-4714fje	http://dx.doi.org/10.1096/fj.05-4714fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16401641				2022-12-28	WOS:000235996000032
J	Haqqani, AS; Nesic, M; Preston, E; Baumann, E; Kelly, J; Stanimirovic, D				Haqqani, AS; Nesic, M; Preston, E; Baumann, E; Kelly, J; Stanimirovic, D			Characterization of vascular protein expression patterns in cerebral ischemia/reperfusion using laser capture microdissection and ICAT-nanoLC-MS/MS	FASEB JOURNAL			English	Article						blood-brain barrier; protein extraction; peptides	BLOOD-BRAIN-BARRIER; ENDOTHELIAL GROWTH-FACTOR; CODED AFFINITY TAG; GENE-EXPRESSION; QUANTITATIVE-ANALYSIS; FOREBRAIN ISCHEMIA; PROTEOMIC ANALYSIS; TEMPORAL PROFILE; IN-VITRO; MATRIX-METALLOPROTEINASE-9	Cerebral ischemia rapidly initiates structural and functional changes in brain vessels, including blood-brain barrier disruption, inflammation, and angiogenesis. Molecular events that accompany these changes were investigated in brain microvessels extracted using laser-capture microdissection (LCM) from Sprague-Dawley rats subjected to a 20 min transient global cerebral ischemia followed by 1, 6, or 24 h reperfusion. Proteins extracted from similar to 300 LCM captured microvessels (20-100 mu m) were ICAT-labeled and analyzed by nanoLC-MS. In-house software was used to identify paired ICAT peaks, which were then sequenced by nanoLC-MS/MS. Pattern analyses using k-means clustering method classified 57 differentially expressed proteins in 7 distinct dynamic patterns. Protein function was assigned using Panther Classification system. Early reperfusion ( 1 h) was characterized by down-regulation of ion pumps, nutrient transporters, and cell structure/motility proteins, and up-regulation of transcription factors, signal transduction molecules and proteins involved in carbohydrate metabolism. The up-regulation of inflammatory cytokines and proteins involved in the extracellular matrix remodeling and anti-oxidative defense was observed in late reperfusion (6-24 h). The up-regulation of IL-1 beta and TGF-1 beta in ischemic brain vessels was confirmed by ELISA, quantitative PCR, and/or immunohistochemistry. A biphasic postischemic ( 1 and 24 h) BBB opening for H-3-sucrose was evident in the same model. Differentially expressed proteins identified in brain vessels during reperfusion are likely involved in orchestrating functional vascular responses to ischemia, including the observed BBB disruption.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	National Research Council Canada	Stanimirovic, D (corresponding author), Natl Res Council Canada, Inst Biol Sci, 1200 Montreal Rd,Bldg M-54, Ottawa, ON K1A 0R6, Canada.	stanimirovic@nrc-cnrc.gc.ca						Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x; Abumiya T, 1999, J CEREBR BLOOD F MET, V19, P1038, DOI 10.1097/00004647-199909000-00012; Aldred S, 2004, CLIN BIOCHEM, V37, P943, DOI 10.1016/j.clinbiochem.2004.09.002; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Bickel DR, 2004, BIOINFORMATICS, V20, P682, DOI 10.1093/bioinformatics/btg468; Cal S, 2000, MOL BIOL CELL, V11, P1457, DOI 10.1091/mbc.11.4.1457; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; del Zoppo GJ, 2003, J CEREBR BLOOD F MET, V23, P879, DOI 10.1097/01.WCB.0000078322.96027.78; DIETRICH WD, 1993, STROKE, V24, P111, DOI 10.1161/01.STR.24.1.111; Dirnagl U, 1997, ADV EXP MED BIOL, V413, P155; Drew PD, 1995, J NEUROIMMUNOL, V63, P157, DOI 10.1016/0165-5728(95)00140-9; Ellison JA, 1999, ANN NY ACAD SCI, V890, P204, DOI 10.1111/j.1749-6632.1999.tb07996.x; Fukuda S, 2004, STROKE, V35, P998, DOI 10.1161/01.STR.0000119383.76447.05; GINSBERG MD, 1989, STROKE, V20, P1627, DOI 10.1161/01.STR.20.12.1627; Goldsmith AP, 2004, J NEUROSCI RES, V78, P647, DOI 10.1002/jnr.20320; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hayashi T, 2003, J CEREBR BLOOD F MET, V23, P166, DOI 10.1097/00004647-200302000-00004; HIROSAWA M, 1993, COMPUT APPL BIOSCI, V9, P161; Ishikawa M, 2004, FRONT BIOSCI-LANDMRK, V9, P1339, DOI 10.2741/1330; Kahlina K, 2004, J BIOL CHEM, V279, P44872, DOI 10.1074/jbc.M402467200; Kendziorski C, 2005, P NATL ACAD SCI USA, V102, P4252, DOI 10.1073/pnas.0500607102; Krupinski J, 1996, STROKE, V27, P852, DOI 10.1161/01.STR.27.5.852; Li C, 2004, MOL CELL PROTEOMICS, V3, P399, DOI 10.1074/mcp.M300133-MCP200; Maier CM, 2004, STROKE, V35, P1169, DOI 10.1161/01.STR.0000125861.55804.f2; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Methy D, 2004, BRAIN RES, V1003, P151, DOI 10.1016/j.brainres.2003.12.031; Mojsilovic-Petrovic J, 2004, J NEUROSCI METH, V133, P39, DOI 10.1016/j.jneumeth.2003.09.026; Mori K, 2002, J NEUROTRAUM, V19, P1261, DOI 10.1089/08977150260338047; Mun-Bryce S, 1998, J CEREBR BLOOD F MET, V18, P1163, DOI 10.1097/00004647-199811000-00001; Novoradovskaya N, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-20; Ohtaki H, 2003, NEUROSCI RES, V45, P313, DOI 10.1016/S0168-0102(02)00238-9; Parente L, 2004, INFLAMM RES, V53, P125, DOI 10.1007/s00011-003-1235-z; Pomfy M, 1992, Funct Dev Morphol, V2, P253; Preston E, 2004, ACTA NEUROPATHOL, V108, P406, DOI 10.1007/s00401-004-0905-4; Preston E, 2002, ACTA NEUROPATHOL, V103, P237, DOI 10.1007/s004010100458; PRESTON E, 1983, J NEUROSCI METH, V9, P45, DOI 10.1016/0165-0270(83)90108-5; PRESTON E, 1993, NEUROSCI LETT, V149, P75, DOI 10.1016/0304-3940(93)90351-K; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Sanchez-Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200; Schaller B, 2004, J CEREBR BLOOD F MET, V24, P351, DOI 10.1097/00004647-200404000-00001; Shekouh AR, 2003, PROTEOMICS, V3, P1988, DOI 10.1002/pmic.200300466; Singh R, 2005, AM J PHYSIOL-CELL PH, V288, pC1179, DOI 10.1152/ajpcell.00258.2004; SMITH ML, 1984, ACTA NEUROPATHOL, V64, P319, DOI 10.1007/BF00690397; Smolka MB, 2001, ANAL BIOCHEM, V297, P25, DOI 10.1006/abio.2001.5318; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Stanimirovic D, 2000, BRAIN PATHOL, V10, P113; Stanimirovic DB, 2001, PROG INFLAM RES, P101; Yamashita K, 1999, BRAIN RES, V836, P139, DOI 10.1016/S0006-8993(99)01626-1; Zang L, 2004, J PROTEOME RES, V3, P604, DOI 10.1021/pr034131l; Zhang WD, 2000, J CEREBR BLOOD F MET, V20, P967, DOI 10.1097/00004647-200006000-00009; Zhang WD, 2003, FASEB J, V17, P2085, DOI 10.1096/fj.02-1131fje; Zhang ZG, 2002, J CEREBR BLOOD F MET, V22, P379, DOI 10.1097/00004647-200204000-00002	52	96	103	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					1809	1821		10.1096/fj.05-3793com	http://dx.doi.org/10.1096/fj.05-3793com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16260651				2022-12-28	WOS:000234053100033
J	de Roos, B; Rucklidge, G; Reid, M; Ross, K; Duncan, G; Navarro, MA; Arbones-Mainar, JM; Guzman-Garcia, MA; Osada, J; Browne, J; Loscher, CE; Roche, HM				de Roos, B; Rucklidge, G; Reid, M; Ross, K; Duncan, G; Navarro, MA; Arbones-Mainar, JM; Guzman-Garcia, MA; Osada, J; Browne, J; Loscher, CE; Roche, HM			Divergent mechanisms of cis9, trans11-and trans10, cis12-conjugated linoleic acid affecting insulin resistance and inflammation in apolipoprotein E knockout mice: a proteomics approach	FASEB JOURNAL			English	Article						dietary fatty acids; atherosclerosis; glucose metabolism; systems biology	EARLY AORTIC ATHEROSCLEROSIS; MIGRATION INHIBITORY FACTOR; HEAT-SHOCK-PROTEIN; FATTY-ACID; LIPID-PEROXIDATION; BODY-COMPOSITION; CELL-FUNCTION; LIVER; SUPPLEMENTATION; CIS-9,TRANS-11	Conjugated linoleic acids (CLA) affect atherogenesis, but mechanisms are not well understood. We explored how two isomers of CLA, cis9, trans11- CLA and trans10, cis12-CLA, affected lipid and glucose metabolism, as well as hepatic protein expression, in apolipoprotein E knockout mice. After 12 wk of intervention, plasma triglyceride, NEFA, and glucose concentrations were significantly higher in the trans10, cis12-CLA group, whereas plasma triglyceride, NEFA, glucose, and insulin concentrations were significantly lower in the cis9, trans11- CLA group, compared with control mice consuming linoleic acid. Proteomics identified significant up- or down-regulation of 113 liver cytosolic proteins by either CLA isomer. Principal component analysis revealed that the treatment effect of cis9, trans11- CLA was mainly explained by the up- regulation of different posttranslational forms of heat shock protein 70 kD. In contrast, the treatment effect of trans10, cis12-CLA was mainly explained by up- regulation of key enzymes in the gluconeogenic, beta-oxidation, and ketogenesic pathways. Correlation analysis again emphasized the divergent effects of both CLA isomers on different pathways, but also revealed a linkage between insulin resistance and increased levels of hepatic serotransferrin. Thus, our systems biology approach provided novel insights into the mechanisms by which individual CLA isomers differentially affect pathways related to atherogenesis, such as insulin resistance and inflammation.	Rowett Res Inst, Aberdeen AB21 9SB, Scotland; Univ Zaragoza, Sch Vet, Dept Biochem, Zaragoza, Spain; St James Hosp, Inst Mol Med, Dept Clin Med, Nutrigenom Res Grp, Dublin 8, Ireland	University of Aberdeen; University of Zaragoza; Trinity College Dublin	de Roos, B (corresponding author), Rowett Res Inst, Greenburn Rd, Aberdeen AB21 9SB, Scotland.	b.deroos@rowett.ac.uk	Arbones-Mainar, Jose M/AGL-8624-2022; Navarro, Ángeles/AAG-6089-2019; Roche, Helen M/AAF-4164-2019	Arbones-Mainar, Jose M/0000-0002-8982-3737; Roche, Helen M/0000-0002-0628-3318; Loscher, Christine/0000-0002-5276-7321	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Albers R, 2003, EUR J CLIN NUTR, V57, P595, DOI 10.1038/sj.ejcn.1601585; Azain MJ, 2000, J NUTR, V130, P1548; Basu S, 2000, CLIN SCI, V99, P511, DOI 10.1042/cs0990511; Brodie AE, 1999, J NUTR, V129, P602; Chen ZP, 2004, ARTERIOSCL THROM VAS, V24, P709, DOI 10.1161/01.ATV.0000119356.35748.9e; Clement L, 2002, J LIPID RES, V43, P1400, DOI 10.1194/jlr.M20008-JLR200; de Roos B, 2005, FASEB J, V19, P813, DOI 10.1096/fj.04-2974fje; Degrace P, 2003, FEBS LETT, V546, P335, DOI 10.1016/S0014-5793(03)00610-0; Ethridge RT, 1998, GASTROENTEROLOGY, V115, P1454, DOI 10.1016/S0016-5085(98)70024-1; Ferrannini E, 2000, LANCET, V355, P2181, DOI 10.1016/S0140-6736(00)02397-7; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; Kritchevsky D, 2004, LIPIDS, V39, P611, DOI 10.1007/s11745-004-1273-8; Kritchevsky D, 2000, J AM COLL NUTR, V19, p472S, DOI 10.1080/07315724.2000.10718950; Latchman DS, 2001, CARDIOVASC RES, V51, P637, DOI 10.1016/S0008-6363(01)00354-6; LEE KN, 1994, ATHEROSCLEROSIS, V108, P19, DOI 10.1016/0021-9150(94)90034-5; Lee KN, 1998, BIOCHEM BIOPH RES CO, V248, P817, DOI 10.1006/bbrc.1998.8994; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; McLeod RS, 2004, AM J CLIN NUTR, V79, p1169S, DOI 10.1093/ajcn/79.6.1169S; Moirand R, 1997, LANCET, V349, P95, DOI 10.1016/S0140-6736(96)06034-5; Moloney F, 2004, AM J CLIN NUTR, V80, P887; Nicolosi RJ, 1997, ARTERY, V22, P266; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; Pan JH, 2004, CIRCULATION, V109, P3149, DOI 10.1161/01.CIR.0000134704.84454.D2; Park Y, 2000, BBA-MOL CELL BIOL L, V1486, P285, DOI 10.1016/S1388-1981(00)00074-3; Park Y, 1997, LIPIDS, V32, P853, DOI 10.1007/s11745-997-0109-x; Parker R, 1999, NETW COMPUT, V10, P12; Perseghin G, 2001, J CLIN ENDOCR METAB, V86, P4776, DOI 10.1210/jc.86.10.4776; Radford NB, 1996, P NATL ACAD SCI USA, V93, P2339, DOI 10.1073/pnas.93.6.2339; Rahman SM, 2001, NUTRITION, V17, P385, DOI 10.1016/S0899-9007(00)00584-0; Riserus U, 2004, AM J CLIN NUTR, V79, p1146S; Riserus U, 2004, AM J CLIN NUTR, V80, P279; Riserus U, 2002, DIABETES CARE, V25, P1516, DOI 10.2337/diacare.25.9.1516; Riserus U, 2002, CIRCULATION, V106, P1925, DOI 10.1161/01.CIR.0000033589.15413.48; Roche HM, 2002, DIABETES, V51, P2037, DOI 10.2337/diabetes.51.7.2037; Roche HM, 2001, NUTR RES REV, V14, P173, DOI [10.1079/095442201108729187, 10.1079/NRR200122]; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shimizu M, 2002, J THORAC CARDIOV SUR, V124, P933, DOI 10.1067/mtc.2002.122305; Smedman A, 2004, CLIN SCI, V106, P67, DOI 10.1042/CS20030105; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Takahashi Y, 2003, BBA-MOL CELL BIOL L, V1631, P265, DOI 10.1016/S1388-1981(03)00038-6; Terpstra AH, 2004, AM J CLIN NUTR, V79, P352; Toomey S, 2003, BIOCHEM SOC T, V31, P1075, DOI 10.1042/BST0311075; Tricon S, 2004, AM J CLIN NUTR, V80, P1626, DOI 10.1093/ajcn/80.6.1626; Tricon S, 2004, AM J CLIN NUTR, V80, P614; Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487; West DB, 1998, AM J PHYSIOL-REG I, V275, pR667; Wilson TA, 2000, NUTR RES, V20, P1795, DOI 10.1016/S0271-5317(00)00268-2; Yotsumoto H, 1998, FOOD RES INT, V31, P403, DOI 10.1016/S0963-9969(98)00103-3; Zhu JH, 2003, ARTERIOSCL THROM VAS, V23, P1055, DOI 10.1161/01.ATV.0000074899.60898.FD	49	68	69	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1746	+		10.1096/fj.05-3953fje	http://dx.doi.org/10.1096/fj.05-3953fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16055499				2022-12-28	WOS:000230923000001
J	Lelliott, CJ; Lopez, M; Curtis, RK; Parker, N; Laudes, M; Yeo, G; Jimenez-Linan, M; Grosse, J; Saha, AK; Wiggins, D; Hauton, D; Brand, MD; O'Rahilly, S; Griffin, JL; Gibbons, GF; Vidal-Puig, A				Lelliott, CJ; Lopez, M; Curtis, RK; Parker, N; Laudes, M; Yeo, G; Jimenez-Linan, M; Grosse, J; Saha, AK; Wiggins, D; Hauton, D; Brand, MD; O'Rahilly, S; Griffin, JL; Gibbons, GF; Vidal-Puig, A			Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis	FASEB JOURNAL			English	Article						fatty acid synthase; malonyl-CoA; metabolomics; metabolic pathways	DENSITY LIPOPROTEIN SECRETION; BREAST-CANCER; NONALCOHOLIC STEATOHEPATITIS; MITOCHONDRIAL DYSFUNCTION; INSULIN-RESISTANCE; GENE-EXPRESSION; MICROARRAY DATA; DISEASE; HEPATOTOXICITY; SPECTROSCOPY	Nonalcoholic steatohepatitis (NASH) is a common feature of the metabolic syndrome and toxic reactions to pharmacological drugs. Tamoxifen, (TMX) a widely used anti-breast cancer drug, can induce NASH and changes in plasma cholesterol levels through mechanisms that are unclear. We studied primary actions of TMX using a short-term treatment ( 5 days) that induces microvesicular hepatic steatosis and marked hypercholesterolemia in male rats. Using a combined approach of gene expression profiling and NMR-based metabolite analysis, we found that TMX-treated livers have increased saturated fatty acid content despite changes in gene expression, indicating decreased de novo lipogenesis and increased fatty acid oxidation. Our results show that TMX predominantly down-regulates FAS expression and activity as indicated by the accumulation of malonyl-CoA, a known inhibitor of mitochondrial beta-oxidation. In the face of a continued supply of exogenous free fatty acids, the blockade of fatty acid oxidation produced by elevated malonyl-CoA is likely to be the major factor leading to steatosis. Use of a combination of metabolomic and transcriptomic analysis has allowed us to identify mechanisms underlying important metabolic side effects of a widely prescribed drug. Given the broader importance of hepatic steatosis, the novel molecular mechanism revealed in this study should be examined in other forms of steatosis and nonalcoholic steatohepatitis.	Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QR, England; Ingenium Pharmaceut AG, Martinsried, Germany; Boston Med Ctr, Diabet Res Unit, Boston, MA USA; Univ Oxford, Nuffield Dept Clin Med, Metab Res Lab, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; MRC, Dunn Human Nutr Unit, Cambridge, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Boston Medical Center; University of Oxford; University of Cambridge; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Vidal-Puig, A (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Hills Rd,Box 232, Cambridge CB2 2QR, England.	ajv22@cam.ac.uk	O'Rahilly, Stephen/ABF-6509-2020; López, Miguel/ABF-4844-2021; Parker, Nadeene/C-1562-2008; Brand, Martin D/A-9423-2012; Lelliott, Christopher J/G-4620-2011; Laudes, Matthias/C-8885-2011	O'Rahilly, Stephen/0000-0003-2199-4449; López, Miguel/0000-0002-7823-1648; Brand, Martin D/0000-0003-4418-6153; Lelliott, Christopher J/0000-0001-8087-4530; Yeo, Giles See How/0000-0001-8823-3615; Vidal-Puig, Antonio/0000-0003-4220-9577; Saha, Asish/0000-0003-1001-5110	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019514] Funding Source: NIH RePORTER; MRC [G0400192] Funding Source: UKRI; Medical Research Council [G0400192] Funding Source: Medline; NIDDK NIH HHS [DK 19514] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome Trust)		BARTLETT SM, 1988, BIOCHEM J, V249, P37, DOI 10.1042/bj2490037; Berson A, 1998, GASTROENTEROLOGY, V114, P764, DOI 10.1016/S0016-5085(98)70590-6; Bollard ME, 2000, MAGNET RESON MED, V44, P201, DOI 10.1002/1522-2594(200008)44:2<201::AID-MRM6>3.0.CO;2-5; Cardoso CMP, 2001, TOXICOL APPL PHARM, V176, P145, DOI 10.1006/taap.2001.9265; Carthew P, 2000, CARCINOGENESIS, V21, P793, DOI 10.1093/carcin/21.4.793; Chitturi S, 2001, SEMIN LIVER DIS, V21, P27, DOI 10.1055/s-2001-12927; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; Day CP, 1998, GASTROENTEROLOGY, V114, P842, DOI 10.1016/S0016-5085(98)70599-2; Doniger SW, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-r7; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fromenty B, 2004, DIABETES METAB, V30, P121, DOI 10.1016/S1262-3636(07)70098-8; FROMENTY B, 1995, PHARMACOL THERAPEUT, V67, P101, DOI 10.1016/0163-7258(95)00012-6; Griffin JL, 2004, PHYSIOL GENOMICS, V17, P140, DOI 10.1152/physiolgenomics.00158.2003; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Jaeschke H, 2002, TOXICOL SCI, V65, P166, DOI 10.1093/toxsci/65.2.166; JORDAN VC, 1977, J ENDOCRINOL, V75, P305, DOI 10.1677/joe.0.0750305; Jordan VC, 2001, ANN NY ACAD SCI, V952, P60, DOI 10.1111/j.1749-6632.2001.tb02728.x; Lelliott CJ, 2002, J CLIN ENDOCR METAB, V87, P728, DOI 10.1210/jc.87.2.728; LUDWIG J, 1980, MAYO CLIN PROC, V55, P434; Marchesini G, 2001, DIABETES, V50, P1844, DOI 10.2337/diabetes.50.8.1844; Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8; MCGARRY JD, 1978, J BIOL CHEM, V253, P8291; Mensenkamp AR, 2001, J HEPATOL, V35, P816, DOI 10.1016/S0168-8278(01)00249-5; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Murata Y, 2003, ONCOL REP, V10, P97; Nebert DW, 2002, LANCET, V360, P1155, DOI 10.1016/S0140-6736(02)11203-7; Nguyen MC, 2001, INT J OBESITY, V25, P296, DOI 10.1038/sj.ijo.0801488; Nishino M, 2003, AM J ROENTGENOL, V180, P129, DOI 10.2214/ajr.180.1.1800129; Noga AA, 2002, J BIOL CHEM, V277, P42358, DOI 10.1074/jbc.M204542200; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Pessayre D, 2002, AM J PHYSIOL-GASTR L, V282, pG193, DOI 10.1152/ajpgi.00426.2001; Rooney OM, 2003, MAGN RESON MED, V50, P925, DOI 10.1002/mrm.10620; SAHA AK, 1995, AM J PHYSIOL, V269, P283; Sanyal AJ, 2001, GASTROENTEROLOGY, V120, P1183, DOI 10.1053/gast.2001.23256; Sekiya M, 2003, HEPATOLOGY, V38, P1529, DOI 10.1016/j.hep.2003.09.028; Tuquet C, 2000, CELL BIOL TOXICOL, V16, P207, DOI 10.1023/A:1007695308257; VidalPuig AJ, 1997, J CLIN INVEST, V99, P2416, DOI 10.1172/JCI119424; WADE GN, 1993, AM J PHYSIOL, V264, pR1219, DOI 10.1152/ajpregu.1993.264.6.R1219; Yahagi N, 2002, J BIOL CHEM, V277, P19353, DOI 10.1074/jbc.M201584200; Younossi ZM, 2002, HEPATOLOGY, V35, P746, DOI 10.1053/jhep.2002.32483; Zhang W, 2000, CANCER RES, V60, P5395	41	69	77	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1108	1119		10.1096/fj.04-3196com	http://dx.doi.org/10.1096/fj.04-3196com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	15985534				2022-12-28	WOS:000230923000039
J	Bentwich, I				Bentwich, I			A postulated role for microRNA in cellular differentiation	FASEB JOURNAL			English	Article						embryogenesis; UTR; genomic module; protein coding genes; microRNA gene cluster	POSTTRANSCRIPTIONAL REGULATION; GERM-CELLS; P-GRANULES; RNAS; TRANSCRIPTOME; SEQUENCES; EXPRESSION; DENSITY; ENCODES; PATTERN	Over the past two decades a variety of mechanisms regulating cellular differentiation have been uncovered. These include signaling by morphogens or membrane-associated ligands and asymmetric segregation of cytoplasmic components. Most of these processes are driven by protein coding genes. Here I describe another possible cellular differentiation mechanism that involves asymmetric segregation of micro RNAs, a group of recently discovered non-protein coding genes that have been shown to be involved in differentiation.-Bentwich, I. A postulated role for microRNA in cellular differentiation.	Rosetta Genom, IL-76706 Rehovot, Israel		Bentwich, I (corresponding author), Rosetta Genom, 10 Plaut St, IL-76706 Rehovot, Israel.	bentwich@rosettagenomics.com						Ambros V, 2003, CURR BIOL, V13, P807, DOI 10.1016/S0960-9822(03)00287-2; [Anonymous], ART GENES ORGANISMS; Barad O, 2004, GENOME RES, V14, P2486, DOI 10.1101/gr.2845604; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Cook T, 2003, BIOESSAYS, V25, P921, DOI 10.1002/bies.10356; CRICK FHC, 1966, SCI AM, V215, P55, DOI 10.1038/scientificamerican1066-55; Davidson E. H., 2001, DEV EVOLUTION; Dubrulle J, 2004, NATURE, V427, P419, DOI 10.1038/nature02216; DURET L, 1993, NUCLEIC ACIDS RES, V21, P2315, DOI 10.1093/nar/21.10.2315; Duret L, 1997, CURR OPIN STRUC BIOL, V7, P399, DOI 10.1016/S0959-440X(97)80058-9; Hobert O, 2004, TRENDS BIOCHEM SCI, V29, P462, DOI 10.1016/j.tibs.2004.07.001; Johnston RJ, 2003, NATURE, V426, P845, DOI 10.1038/nature02255; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Loebel DAF, 2003, DEV BIOL, V264, P1, DOI 10.1016/S0012-1606(03)00390-7; Mattick JS, 2003, BIOESSAYS, V25, P930, DOI 10.1002/bies.10332; Meehan RR, 2003, SEMIN CELL DEV BIOL, V14, P53, DOI 10.1016/S1084-9521(02)00137-4; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; PAGEL M, 1992, P ROY SOC B-BIOL SCI, V249, P119, DOI 10.1098/rspb.1992.0093; Paratore C, 2002, INT J DEV BIOL, V46, P193; Pitt JN, 2000, DEV BIOL, V219, P315, DOI 10.1006/dbio.2000.9607; Podbilewicz B, 2003, DEV CELL, V5, P5, DOI 10.1016/S1534-5807(03)00202-8; Rhoades MW, 2002, CELL, V110, P513, DOI 10.1016/S0092-8674(02)00863-2; Sabourin LA, 2000, CLIN GENET, V57, P16, DOI 10.1034/j.1399-0004.2000.570103.x; Schisa JA, 2001, DEVELOPMENT, V128, P1287; Seitz H, 2003, NAT GENET, V34, P261, DOI 10.1038/ng1171; Shabalina SA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-4-105; Spicher A, 1998, MOL CELL BIOL, V18, P7371, DOI 10.1128/MCB.18.12.7371; Stein LD, 2003, PLOS BIOL, V1, P166, DOI 10.1371/journal.pbio.0000045; Tjaden B, 2002, NUCLEIC ACIDS RES, V30, P3732, DOI 10.1093/nar/gkf505; Versteeg R, 2003, GENOME RES, V13, P1998, DOI 10.1101/gr.1649303; Voas MG, 2004, DEV DYNAM, V229, P162, DOI 10.1002/dvdy.10449; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5	39	34	41	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					875	879		10.1096/fj.04-3609hyp	http://dx.doi.org/10.1096/fj.04-3609hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15923397				2022-12-28	WOS:000230207800034
J	Taleb, S; Lacasa, D; Bastard, JP; Poitou, C; Cancello, R; Pelloux, V; Viguerie, N; Benis, A; Zucker, JD; Bouillot, JL; Coussieu, C; Basdevant, A; Langin, D; Clement, K				Taleb, S; Lacasa, D; Bastard, JP; Poitou, C; Cancello, R; Pelloux, V; Viguerie, N; Benis, A; Zucker, JD; Bouillot, JL; Coussieu, C; Basdevant, A; Langin, D; Clement, K			Cathepsin S, a novel biomarker of adiposity: relevance to atherogenesis	FASEB JOURNAL			English	Article						obesity; atherosclerosis and gene profiling	RECEPTOR ANTAGONIST; CYSTEINE PROTEASES; TISSUE; EXPRESSION; OBESITY; INFLAMMATION; ATHEROSCLEROSIS; DEFICIENCY; ADIPONECTIN; ADIPOCYTES	The molecular mechanisms by which obesity increases the risk of cardiovascular diseases are poorly understood. The purpose of this study was to identify candidate biomarkers overexpressed in adipose tissue of obese subjects that could link expanded fat mass to atherosclerosis. We compared gene expression profile in subcutaneous adipose tissue (scWAT) of 28 obese and 11 lean subjects using microarray technology. This analysis identified 240 genes significantly overexpressed in scWAT of obese subjects. The genes were then ranked according to the correlation between gene expression and body mass index (BMI). In this list, the elastolytic cysteine protease cathepsin S was among the highly correlated genes. RT-PCR and Western blotting confirmed the increase in cathepsin S mRNA ( P= 0.006) and protein ( P < 0.05) in obese scWAT. The circulating concentrations of cathepsin S were also significantly higher in obese than in nonobese subjects ( P < 0.0001). Both cathepsin S mRNA in scWAT and circulating levels were positively correlated with BMI, body fat, and plasma triglyceride levels. In addition, we show that the proinflammatory factors, lipopolysaccharide, interleukin-1 beta, and tumor necrosis factor-alpha increase cathepsin S secretion in human scWAT explants. This study identifies cathepsin S as a novel marker of adiposity. Since this enzyme has been implicated in the development of atherosclerotic lesions, we propose that cathepsin S represents a molecular link between obesity and atherosclerosis.	Hop Hotel Dieu, INSERM Avenir, Dept Nutr, CHRU Pitie Salpetriere,Ctr Rech & Nutr Humaine, F-75004 Paris, France; INSERM Avenir Team, F-75004 Paris, France; INSERM, U680, F-75970 Paris, France; CHRU Tenon Hosp, Dept Biochem, F-75970 Paris, France; Univ Toulouse 3, INSERM, U586, Louis Bugnard Inst, F-31059 Toulouse, France; CHRU Toulouse, F-31059 Toulouse, France; Hop Hotel Dieu, Dept Surg, F-75004 Paris, France; Univ Paris 13, LIM & BIO, F-93000 Bobigny, France; CHRU Pitie Salpetriere, Hop Hotel Dieu, Hormonol Dept, F-75004 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Clement, K (corresponding author), Hop Hotel Dieu, INSERM Avenir, Dept Nutr, CHRU Pitie Salpetriere,Ctr Rech & Nutr Humaine, Pl Parvis Notre Dame, F-75004 Paris, France.	karine.clement@htd.ap-hopparis.fr	ZUCKER, Jean-Daniel/K-3008-2016; Benis, Arriel/M-6262-2016; Taleb, Soraya/K-8176-2017; Clément, karine/R-1120-2017; Viguerie, Nathalie/M-2422-2017	ZUCKER, Jean-Daniel/0000-0002-5597-7922; Benis, Arriel/0000-0002-9125-8300; Taleb, Soraya/0000-0002-6650-619X; Langin, Dominique/0000-0002-2669-7825; Viguerie, Nathalie/0000-0002-1730-9915				Abate N, 2000, J DIABETES COMPLICAT, V14, P154, DOI 10.1016/S1056-8727(00)00067-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; Chiellini C, 2003, J CELL PHYSIOL, V195, P309, DOI 10.1002/jcp.10253; Clement K, 2004, FASEB J, V18, P1657, DOI 10.1096/fj.04-2204com; Curat CA, 2004, DIABETES, V53, P1285, DOI 10.2337/diabetes.53.5.1285; Ferroni Patrizia, 2004, Curr Atheroscler Rep, V6, P424, DOI 10.1007/s11883-004-0082-x; Fruchart JC, 2004, CIRCULATION, V109, P15, DOI 10.1161/01.CIR.0000131513.33892.5b; Goldstein BJ, 2004, J CLIN ENDOCR METAB, V89, P2563, DOI 10.1210/jc.2004-0518; Grundy SM, 2004, J CLIN ENDOCR METAB, V89, P2595, DOI 10.1210/jc.2004-0372; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Jormsjo S, 2002, AM J PATHOL, V161, P939, DOI 10.1016/S0002-9440(10)64254-X; Juge-Aubry CE, 2004, J CLIN ENDOCR METAB, V89, P2652, DOI 10.1210/jc.2003-031219; Juge-Aubry CE, 2003, DIABETES, V52, P1104, DOI 10.2337/diabetes.52.5.1104; Katsuda Shogo, 2003, J Atheroscler Thromb, V10, P267; Katz A, 2000, J CLIN ENDOCR METAB, V85, P2402, DOI 10.1210/jc.85.7.2402; Kos J, 2001, BRIT J CANCER, V85, P1193, DOI 10.1054/bjoc.2001.2057; Lafontan M, 2003, TRENDS PHARMACOL SCI, V24, P276, DOI 10.1016/S0165-6147(03)00132-9; Liu JA, 2004, ARTERIOSCL THROM VAS, V24, P1359, DOI 10.1161/01.ATV.0000134530.27208.41; Liu YM, 2004, J CLIN ENDOCR METAB, V89, P2684, DOI 10.1210/jc.2003-031978; Lyon CJ, 2003, ENDOCRINOLOGY, V144, P2195, DOI 10.1210/en.2003-0285; Meier U, 2004, CLIN CHEM, V50, P1511, DOI 10.1373/clinchem.2004.032482; Muoio DM, 2002, BEST PRACT RES CL EN, V16, P653, DOI 10.1053/beem.2002.0223; Nakajima I, 2002, BIOL CELL, V94, P197, DOI 10.1016/S0248-4900(02)01189-9; Petanceska S, 1996, J BIOL CHEM, V271, P4403; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; SHI GP, 1992, J BIOL CHEM, V267, P7258; Shi GP, 2003, CIRC RES, V92, P493, DOI 10.1161/01.RES.0000060485.20318.96; SHI GP, 1994, J BIOL CHEM, V269, P11530; Shi GP, 1999, J CLIN INVEST, V104, P1191, DOI 10.1172/JCI7709; Singhal A, 2002, CIRCULATION, V106, P1919, DOI 10.1161/01.CIR.0000033219.24717.52; Sukhova GK, 2003, J CLIN INVEST, V111, P897, DOI 10.1172/JCI200314915; Sukhova GK, 1998, J CLIN INVEST, V102, P576, DOI 10.1172/JCI181; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vanhala MJ, 1998, INT J OBESITY, V22, P369, DOI 10.1038/sj.ijo.0800597; Watari M, 2000, J SOC GYNECOL INVEST, V7, P190, DOI 10.1016/S1071-5576(00)00054-X; Willerson JT, 2004, CIRCULATION, V109, P2, DOI 10.1161/01.CIR.0000129535.04194.38; Xu HY, 2002, ENDOCRINOLOGY, V143, P1502, DOI 10.1210/en.143.4.1502; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451	39	115	122	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1540	+		10.1096/fj.05-3673fje	http://dx.doi.org/10.1096/fj.05-3673fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15985526				2022-12-28	WOS:000230207800005
J	McGee, SL; Sparling, D; Olson, AL; Hargreaves, M				McGee, Sean L.; Sparling, David; Olson, Ann-Louise; Hargreaves, Mark			Exercise increases MEF2-and GEF DNA-binding activity in human skeletal muscle	FASEB JOURNAL			English	Article									[Sparling, David; Olson, Ann-Louise] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; [McGee, Sean L.; Hargreaves, Mark] Deakin Univ, Sch Exercise & Nutr Sci, Ctr Phys Act & Nutr, Burwood, NSW, Australia; [McGee, Sean L.; Hargreaves, Mark] Univ Melbourne, Dept Physiol, Melbourne, Vic 3010, Australia	University of Oklahoma System; University of Oklahoma Health Sciences Center; Deakin University; University of Melbourne	Olson, AL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 940 SL Young Blvd,BMSB 964A, Oklahoma City, OK 73104 USA.	ann-olson@ouhsc.edu		Sparling, David/0000-0001-5940-1544; Hargreaves, Mark/0000-0002-3694-5335; McGee, Sean/0000-0001-6953-106X	NIDDK NIH HHS [DK-062341, R01 DK062341] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062341] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))			0	73	77	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					348	349		10.1096/fj.05-4671fje	http://dx.doi.org/10.1096/fj.05-4671fje			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16368714				2022-12-28	WOS:000207915000017
J	Evangelou, E; Trikalinos, TA; Ioannidis, JPA				Evangelou, E; Trikalinos, TA; Ioannidis, JPA			Unavailability of online supplementary scientific information from articles published in major journals	FASEB JOURNAL			English	Article						supplementary information; broken links; internet; scientific journals	WEB PAGE	Printed articles increasingly rely on online supplements to store critical scientific information, but such data may eventually become unavailable. We checked the current availability of online supplementary scientific information published in six top-cited scientific journals ( Science, Nature, Cell, New England Journal of Medicine, Lancet, Proceedings of the National Academy of Sciences USA). Here we show that in 4.7% and 9.6% of articles with online supplementary material, some of the supplements became unavailable within 2 and 5 years of their publication, respectively.	Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece; Tufts New England Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA USA; Fdn Res & Technol Hellas, Biomed Res Inst, Ioannina, Greece	University of Ioannina; Tufts Medical Center; Foundation for Research & Technology - Hellas (FORTH)	Evangelou, E (corresponding author), Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece.	me01760@cc.uoi.gr	Ioannidis, John P. A./G-9836-2011; Trikalinos, Thomas A/A-1217-2009; Evangelou, Evangelos/C-3033-2013	Evangelou, Evangelos/0000-0002-5488-2999				Delamothe T, 1999, BRIT MED J, V318, P888, DOI 10.1136/bmj.318.7188.888; Dellavalle RP, 2003, SCIENCE, V302, P787, DOI 10.1126/science.1088234; Ioannidis JPA, 2002, J CLIN EPIDEMIOL, V55, P619, DOI 10.1016/S0895-4356(02)00393-1; *ISI, 2003, J CIT REP; Koehler W, 1999, J AM SOC INFORM SCI, V50, P162, DOI 10.1002/(SICI)1097-4571(1999)50:2<162::AID-ASI7>3.0.CO;2-B; Koehler W, 2002, J AM SOC INF SCI TEC, V53, P162, DOI 10.1002/asi.10018; Markwell J, 2003, BIOCHEM MOL BIOL EDU, V31, P69, DOI 10.1002/bmb.2003.494031010165	7	47	47	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2005	19	14					1943	1944		10.1096/fj.05-4784lsf	http://dx.doi.org/10.1096/fj.05-4784lsf			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16319137				2022-12-28	WOS:000234405500004
J	Lepidi, S; Abatangelo, G; Vindigni, V; Deriu, GP; Zavan, B; Tonello, C; Cortivo, R				Lepidi, S; Abatangelo, G; Vindigni, V; Deriu, GP; Zavan, B; Tonello, C; Cortivo, R			In vivo regeneration of small-diameter (2 mm) arteries using a polymer scaffold	FASEB JOURNAL			English	Article						vascular prosthesis; tissue engineering; remodeling; surgery	ENDOTHELIAL PROGENITOR CELLS; SAPHENOUS-VEIN; BLOOD-VESSEL; GRAFTS; MUSCLE; BYPASS; PERITONEAL; CONDUITS; VITRO	The difficulty of obtaining significant long-term patency and good wall mechanical strength in vivo has been a significant obstacle in achieving small-diameter vascular prostheses. The aim of the present study was to develop a prosthetic graft that could perform as a small-diameter vascular conduit. Tubular structures of hyaluronan (HYAFF-11 tubules, 2 mm diameter, 1 cm length) were grafted in the abdominal aorta of 30 rats as temporary absorbable guides to promote regeneration of vascular structures. Performance was assessed by histology, immunohistochemistry, and ultra-structural analysis. These experiments resulted in three novel findings: 1) complete endothelialization of the tube's luminal surface occurred; 2) sequential regeneration of vascular components led to complete vascular wall regeneration 15 days after surgery; and 3) the biomaterial used created the ideal environment for the delicate regeneration process during the critical initial phases, yet its biodegradability allowed for complete degradation of the construct four months after implantation, at which time, a new artery remained to connect the artery stumps. This study assesses the feasibility to create a completely biodegradable vascular regeneration guide in vivo, able to sequentially orchestrate vascular regeneration events needed for very small artery reconstruction.	Univ Padua, Dept Histol Microbiol & Med Biotechnol, I-35100 Padua, Italy; Univ Padua, Clin Vasc Surg, I-35100 Padua, Italy; Univ Padua, Clin Plast Surg, I-35100 Padua, Italy	University of Padua; University of Padua; University of Padua	Abatangelo, G (corresponding author), Univ Padua, Dept Histol Microbiol & Med Biotechnol, Via G Colombo 3, I-35100 Padua, Italy.	g.abatangelo@unipd.it	Vindigni, Vincenzo/K-5059-2016	Vindigni, Vincenzo/0000-0001-6638-9010; Lepidi, Sandro/0000-0003-2201-6081				Arts CHP, 2002, EUR J VASC ENDOVASC, V23, P404, DOI 10.1053/ejvs.2002.1604; Bujan J, 2004, BIOTECHNOL APPL BIOC, V39, P17, DOI 10.1042/BA20030111; Campbell JH, 1999, CIRC RES, V85, P1173; Cho SW, 2005, ANN SURG, V241, P506, DOI 10.1097/01.sla.0000154268.12239.ed; Chue WL, 2004, J VASC SURG, V39, P859, DOI 10.1016/j.jvs.2003.03.003; DallaLibera L, 1997, J MUSCLE RES CELL M, V18, P295; Daly CD, 2004, FRONT BIOSCI, V9, P1915, DOI 10.2741/1384; De Lorenzi F, 2002, PLAST RECONSTR SURG, V109, P2023, DOI 10.1097/00006534-200205000-00037; Gleason RL, 2004, FRONT BIOSCI-LANDMRK, V9, P2045, DOI 10.2741/1387; Hsu SH, 2003, ARTIF ORGANS, V27, P1068, DOI 10.1111/j.1525-1594.2003.07141.x; Kakisis JD, 2005, J VASC SURG, V41, P349, DOI 10.1016/j.jvs.2004.12.026; Kaushal S, 2001, NAT MED, V7, P1035, DOI 10.1038/nm0901-1035; Khot UN, 2004, CIRCULATION, V109, P2086, DOI 10.1161/01.CIR.0000127570.20508.5C; Kidane AG, 2004, BIOMACROMOLECULES, V5, P798, DOI 10.1021/bm0344553; Klinkert P, 2004, EUR J VASC ENDOVASC, V27, P357, DOI 10.1016/j.ejvs.2003.12.027; Koike N, 2004, NATURE, V428, P138, DOI 10.1038/428138a; Kurotobi K, 2003, ARTIF ORGANS, V27, P582, DOI 10.1046/j.1525-1594.2003.07016.x; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; Leon Luis, 2003, Expert Rev Cardiovasc Ther, V1, P581; Matsuda T, 2004, ARTIF ORGANS, V28, P64, DOI 10.1111/j.1525-1594.2004.07324.x; McFetridge PS, 2004, ASAIO J, V50, P591, DOI 10.1097/01.MAT.0000144365.22025.9B; Mitchell SL, 2003, CARDIOVASC PATHOL, V12, P59, DOI 10.1016/S1054-8807(02)00183-7; Nanobashvili J, 2004, EUR SURG RES, V36, P74, DOI 10.1159/000076646; Nerem RM, 2003, BIORHEOLOGY, V40, P281; Pawlowski KJ, 2004, FRONT BIOSCI-LANDMRK, V9, P1412, DOI 10.2741/1302; Rashid ST, 2004, CELL PROLIFERAT, V37, P351, DOI 10.1111/j.1365-2184.2004.00318.x; Remuzzi A, 2004, TISSUE ENG, V10, P699, DOI 10.1089/1076327041348347; Remy-Zolghadri M, 2004, J VASC SURG, V39, P613, DOI 10.1016/j.jvs.2003.08.007; Schaner PJ, 2004, J VASC SURG, V40, P146, DOI 10.1016/j.jvs.2004.03.033; Schmidt D, 2004, ANN THORAC SURG, V78, P2094, DOI 10.1016/j.athoracsur.2004.06.052; Thomas AC, 2003, CARDIOVASC PATHOL, V12, P271, DOI 10.1016/S1054-8807(03)00086-3; Tiwari A, 2002, FASEB J, V16, DOI 10.1096/fj.01-0826com; Tonello C, 2003, BIOMATERIALS, V24, P1205, DOI 10.1016/S0142-9612(02)00450-7; Turner NJ, 2004, BIOMATERIALS, V25, P5955, DOI 10.1016/j.biomaterials.2004.02.002; Vorp DA, 2005, FRONT BIOSCI-LANDMRK, V10, P768, DOI 10.2741/1571; Wang H, 2005, ARTERIOSCL THROM VAS, V25, P1817, DOI 10.1161/01.ATV.0000175840.90510.a8; Williams C, 2004, TISSUE ENG, V10, P930, DOI 10.1089/1076327041348536; Wu X, 2004, AM J PHYSIOL-HEART C, V287, pH480, DOI 10.1152/ajpheart.01232.2003; Zhang Z, 2004, BIOMATERIALS, V25, P177, DOI 10.1016/S0142-9612(03)00478-2; [No title captured]	40	38	40	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					103	+		10.1096/fj.05-4802fje	http://dx.doi.org/10.1096/fj.05-4802fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16291641				2022-12-28	WOS:000234053100010
J	Coolen, MW; van Loo, KMJ; van Bakel, NNHM; Ellenbroek, BA; Cools, AR; Martens, GJM				Coolen, MW; van Loo, KMJ; van Bakel, NNHM; Ellenbroek, BA; Cools, AR; Martens, GJM			Reduced Aph-1b expression causes tissue- and substrate-specific changes in gamma-secretase activity in rats with a complex phenotype	FASEB JOURNAL			English	Article						gamma-secretase complex composition; APO-SUS rat model; complex (neuro) developmental phenotype; amyloid-beta precursor protein	AMYLOID PRECURSOR PROTEIN; BETA-APP; ALZHEIMERS-DISEASE; ANIMAL-MODELS; MICE LACKING; MUTANT MICE; PRESENILIN; NICASTRIN; NOTCH; TRAFFICKING	The gamma-secretase enzyme complex displays intramembrane catalytic activity toward many type I transmembrane proteins, including the Alzheimer-linked amyloid-beta-protein precursor (APP) and the neuregulin receptor ErbB4. Active gamma-secretase is a tetrameric protein complex consisting of presenilin-1 ( or -2), nicastrin, PEN-2, and Aph-1a ( or -1b). We have recently discovered that pharmacogenetically bred apomorphine-susceptible Wistar rats ( APO-SUS) have only one or two copies of the Aph-1b gene ( termed I/I and II/II rats, respectively), whereas their phenotypic counterparts ( APO-UNSUS) have three copies ( III/III). As a result, APO-SUS rats display reduced Aph-1b expression and a complex phenotype reminiscent of neurodevelopmental disorders. Here we determined in the I/I and III/III rats the gamma-secretase cleavage activity toward the three APP superfamily members, p75 neurotrophin receptor, ErbB4, and neuregulin-2, and found that the cleavage of only a subset of the substrates was changed. Furthermore, the observed differences were restricted to tissues that normally express relatively high Aph-1b compared with Aph-1a levels. Thus, we provide in vivo evidence that subtle alterations in gamma-secretase subunit composition may lead to a variety of affected ( neuro) developmental signaling pathways and, consequently, a complex phenotype.	Radboud Univ Nijmegen, Dept Mol Anim Physiol, Nijmegen Ctr Mol Life Sci, NL-6525 GA Nijmegen, Netherlands; Radboud Univ Nijmegen, Inst Neurosci, NL-6525 GA Nijmegen, Netherlands; UMC St Radboud, Dept Psychoneuropharmacol, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	Martens, GJM (corresponding author), Radboud Univ Nijmegen, Dept Mol Anim Physiol, Nijmegen Ctr Mol Life Sci, Geert Grootepl Zuid 28, NL-6525 GA Nijmegen, Netherlands.	g.martens@ncmls.ru.nl	van Bakel, Nick/A-3187-2013; Ellenbroek, Bart/C-4570-2012; Martens, Gerard JM/D-1925-2010	Ellenbroek, Bart/0000-0003-1996-4873; Coolen, Marcel/0000-0002-8188-8480; Martens, Gerard/0000-0003-1761-4570				Berezovska O, 2003, J NEUROSCI, V23, P4560; CHU DTW, 1989, DEV BIOL, V136, P104, DOI 10.1016/0012-1606(89)90134-6; COENDERS CJH, 1992, PHYSIOL BEHAV, V52, P321, DOI 10.1016/0031-9384(92)90278-A; Coolen MW, 2005, NEURON, V45, P497, DOI 10.1016/j.neuron.2004.12.054; COOLS AR, 1990, BRAIN RES BULL, V24, P49, DOI 10.1016/0361-9230(90)90288-B; Costa RM, 2003, CURR BIOL, V13, P1348, DOI 10.1016/S0960-9822(03)00492-5; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DHooge R, 1996, NEUROREPORT, V7, P2807, DOI 10.1097/00001756-199611040-00080; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; ELLENBROEK BA, 1995, J NEUROSCI, V15, P7604; Ellenbroek BA, 2002, BEHAV GENET, V32, P349, DOI 10.1023/A:1020214322065; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Gerlai R, 2000, BEHAV BRAIN RES, V109, P219, DOI 10.1016/S0166-4328(99)00175-8; Hawkes C, 2003, MOVEMENT DISORD, V18, P364, DOI 10.1002/mds.10379; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Herrick C. J., 1899, ARCH NEUROLOGY PSYCH, V2, P1; Kelly JP, 1997, PHARMACOL THERAPEUT, V74, P299, DOI 10.1016/S0163-7258(97)00004-1; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Lai MT, 2003, J BIOL CHEM, V278, P22475, DOI 10.1074/jbc.M300974200; Lalonde R, 2002, EXP GERONTOL, V37, P1401, DOI 10.1016/S0531-5565(02)00123-7; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Lee SF, 2004, J BIOL CHEM, V279, P4144, DOI 10.1074/jbc.M309745200; Li T, 2003, J NEUROSCI, V23, P3272; Ma GJ, 2005, J NEUROSCI, V25, P192, DOI 10.1523/JNEUROSCI.3814-04.2005; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; Moberg Paul J, 2003, Curr Psychiatry Rep, V5, P311, DOI 10.1007/s11920-003-0061-x; Montero JC, 2002, BIOCHEM J, V363, P211, DOI 10.1042/0264-6021:3630211; Page K, 1996, P NATL ACAD SCI USA, V93, P14020, DOI 10.1073/pnas.93.24.14020; Periz G, 2004, J NEUROSCI RES, V77, P309, DOI 10.1002/jnr.20203; ROTS NY, 1995, J NEUROENDOCRINOL, V7, P153, DOI 10.1111/j.1365-2826.1995.tb00678.x; Serneels L, 2005, P NATL ACAD SCI USA, V102, P1719, DOI 10.1073/pnas.0408901102; Sester M, 2000, J BIOL CHEM, V275, P3645, DOI 10.1074/jbc.275.5.3645; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Stefansson H, 2002, AM J HUM GENET, V71, P877, DOI 10.1086/342734; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; THINAKARAN G, 1995, J NEUROSCI, V15, P6314; Tisay KT, 2000, J COMP NEUROL, V428, P656, DOI 10.1002/1096-9861(20001225)428:4<656::AID-CNE6>3.0.CO;2-7; Yan XX, 2004, J NEUROSCI, V24, P2942, DOI 10.1523/JNEUROSCI.0092-04.2004; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang YW, 2005, J BIOL CHEM, V280, P17020, DOI 10.1074/jbc.M409467200	45	18	18	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					175	+		10.1096/fj.05-4337fje	http://dx.doi.org/10.1096/fj.05-4337fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16249316				2022-12-28	WOS:000232991100006
J	Maynard, MA; Evans, AJ; Hosomi, T; Hara, S; Jewett, MAS; Ohh, M				Maynard, MA; Evans, AJ; Hosomi, T; Hara, S; Jewett, MAS; Ohh, M			Human HIF-3 alpha 4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma	FASEB JOURNAL			English	Article						HIF-3 alpha 4; VHL; RCC; hypoxia	HYPOXIA-INDUCIBLE FACTOR; TUMOR-SUPPRESSOR PROTEIN; HIPPEL-LINDAU PROTEIN; PAS DOMAIN PROTEIN; GENE-EXPRESSION; FACTOR 1-ALPHA; FACTOR-1; BINDING; TRANSCRIPTION; POLYCYTHEMIA	A universal response to changes in cellular oxygen tension is governed by a family of heterodimeric transcription factors called hypoxia-inducible factor (HIF). Tumor hypoxia, as well as various cancer-causing mutations, has been shown to elevate the level of HIF-1 alpha, signifying a critical role of the HIF pathway in cancer development. The recently identified third member of the human HIF-alpha family, HIF-3 alpha, produces multiple splice variants that contain extra DNA binding elements and protein-protein interaction motifs not found in HIF-1 alpha or HIF-2 alpha. Here we report the molecular cloning of the alternatively spliced human HIF-3 alpha variant HIF-3 alpha 4 and show that it attenuates the ability of HIF-1 to bind hypoxia-responsive elements located within the enhancer/promoter of HIF target genes. The overexpression of HIF-3 alpha 4 suppresses the transcriptional activity of HIF-1 and siRNA-mediated knockdown of the endogenous HIF-3 alpha 4 increases transcription by hypoxia-inducible genes. HIF3 alpha 4 itself is oxygen-regulated, suggesting a novel feedback mechanism of controlling HIF-1 activity. Furthermore, the expression of HIF-3 alpha 4 is dramatically down-regulated in the majority of primary renal carcinomas. These results demonstrate an important dominant-negative regulation of HIF-1-mediated gene transcription by HIF-3 alpha 4 in vivo and underscore its potential significance in renal epithelial oncogenesis.	Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; Princess Margaret Hosp, Univ Hlth Network, Dept Pathol, Toronto, ON M4X 1K9, Canada; Kitasato Univ, Sch Pharmaceut Sci, Dept Publ Hlth & Mol Toxicol, Minato Ku, Tokyo 108, Japan; Univ Toronto, Dept Urol, Toronto, ON, Canada; Univ Toronto, Dept Surg Oncol, Toronto, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Kitasato University; University of Toronto; University of Toronto	Ohh, M (corresponding author), Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	michael.ohh@utoronto.ca						Ang SO, 2002, NAT GENET, V32, P614, DOI 10.1038/ng1019; Bento JC, 2005, HAEMATOLOGICA, V90, P128; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Cario H, 2005, HAEMATOLOGICA, V90, P19; Corless CL, 1997, HUM PATHOL, V28, P459, DOI 10.1016/S0046-8177(97)90035-6; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Eble J, 2004, WHO CLASSIFICATION T; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Gorr TA, 2004, J BIOL CHEM, V279, P36048, DOI 10.1074/jbc.M405077200; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hara S, 2001, BIOCHEM BIOPH RES CO, V287, P808, DOI 10.1006/bbrc.2001.5659; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Makino Y, 2002, J BIOL CHEM, V277, P32405, DOI 10.1074/jbc.C200328200; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; Maynard MA, 2004, AM J NEPHROL, V24, P1, DOI 10.1159/000075346; Maynard MA, 2003, J BIOL CHEM, V278, P11032, DOI 10.1074/jbc.M208681200; Ohh M, 2002, EMBO REP, V3, P177, DOI 10.1093/embo-reports/kvf028; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Pastore Y, 2003, AM J HUM GENET, V73, P412, DOI 10.1086/377108; Ravi R, 2000, GENE DEV, V14, P34; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zimmer M, 2004, MOL CANCER RES, V2, P89; Zundel W, 2000, GENE DEV, V14, P391	31	137	144	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1396	1406		10.1096/fj.05-3788com	http://dx.doi.org/10.1096/fj.05-3788com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16126907				2022-12-28	WOS:000232315700033
J	Zhang, YB; Kilroy, GE; Henagan, TM; Prpic-Uhing, V; Richards, WG; Bannon, AW; Mynatt, RL; Gettys, TW				Zhang, YB; Kilroy, GE; Henagan, TM; Prpic-Uhing, V; Richards, WG; Bannon, AW; Mynatt, RL; Gettys, TW			Targeted deletion of melanocortin receptor subtypes 3 and 4, but not CART, alters nutrient partitioning and compromises behavioral and metabolic responses to leptin	FASEB JOURNAL			English	Article						leptin; melanocortin receptors; uncoupling proteins; adipose tissue	AGOUTI-RELATED PROTEIN; WHITE ADIPOSE-TISSUE; MELANOCORTIN-4 RECEPTOR; FOOD-INTAKE; GENE-EXPRESSION; HYPOTHALAMIC PROOPIOMELANOCORTIN; C57BL/6J MICE; POMC NEURONS; OBESITY; BROWN	Mouse lines with targeted disruption of the cocaine amphetamine-related transcript (CART), melanocortin receptor 3 (MCR3), or melanocortin receptor 4 (MCR4) were used to assess the role of each component in mediating the anorectic and metabolic effects of leptin, and in regulating the partitioning of nutrient energy between fat and protein deposition. Leptin was administered over a 3 day period using either intraperitoneal or intracerebroventricular routes of injection. The absence of MCR4 blocked leptin's ability to increase UCP1 mRNA in both brown and white adipose tissue, but not its ability to reduce food consumption. In contrast, deletion of MCR3 compromised leptin's ability to reduce food consumption, but not its ability to reduce fat deposition or increase UCP1 expression in adipose tissue. Leptin-dependent effects on food consumption and adipocyte gene expression were unaffected by the absence of CART. Repeated measures of body composition over time indicate that the absence of either MCR3 or MCR4, but not CART, increased lipid deposition and produced comparable degrees of adiposity in both lines. Moreover, modest increases in fat content of the diet (4 to 11%) accentuated fat deposition and produced a rapid and comparable 10-12% increase in % body fat in both genotypes. The results indicate that nutrient partitioning, as well as the anorectic and metabolic responses to leptin, are dependent on integrated but separable inputs from the melanocortin 3 and 4 receptor subtypes.	Pennington Biomed Res Ctr, Div Expt Obes, Baton Rouge, LA 70808 USA; Amgen Inc, Thousand Oaks, CA 91320 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Amgen	Gettys, TW (corresponding author), Pennington Biomed Res Ctr, Div Expt Obes, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	gettystw@pbrc.edu	Mynatt, Randall L/N-1980-2017; Gettys, Thomas W/N-1964-2017	Mynatt, Randall L/0000-0003-4399-0019; Gettys, Thomas W/0000-0001-7125-7995; Henagan, Tara/0000-0001-5314-0128	NIDDK NIH HHS [DK 064156, DK 053872, DK60747] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060747, R01DK064156, R01DK053872] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbott CR, 2000, BRAIN RES, V869, P203, DOI 10.1016/S0006-8993(00)02386-6; Albarado DC, 2004, ENDOCRINOLOGY, V145, P243, DOI 10.1210/en.2003-0452; Asnicar MA, 2001, ENDOCRINOLOGY, V142, P4394, DOI 10.1210/en.142.10.4394; Benoit SC, 2000, J NEUROSCI, V20, P3442, DOI 10.1523/JNEUROSCI.20-09-03442.2000; Berman Y, 2001, J BIOL CHEM, V276, P1466, DOI 10.1074/jbc.M008499200; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; Butler AA, 2000, ENDOCRINOLOGY, V141, P3518, DOI 10.1210/en.141.9.3518; Chen AS, 2000, TRANSGENIC RES, V9, P145, DOI 10.1023/A:1008983615045; Chen AS, 2000, NAT GENET, V26, P97, DOI 10.1038/79254; Cheung CC, 1997, ENDOCRINOLOGY, V138, P4489, DOI 10.1210/en.138.10.4489; Collins S, 1996, NATURE, V380, P677, DOI 10.1038/380677a0; Commins SP, 2000, J BIOL CHEM, V275, P33059, DOI 10.1074/jbc.M006328200; Commins SP, 1999, ENDOCRINOLOGY, V140, P292, DOI 10.1210/en.140.1.292; Commins SP, 1999, ENDOCRINOLOGY, V140, P4772, DOI 10.1210/en.140.10.4772; Cone RD, 1999, TRENDS ENDOCRIN MET, V10, P211, DOI 10.1016/S1043-2760(99)00153-8; Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085; da Silva AA, 2004, HYPERTENSION, V43, P1312, DOI 10.1161/01.HYP.0000128421.23499.b9; Dinulescu DM, 2000, J BIOL CHEM, V275, P6695, DOI 10.1074/jbc.275.10.6695; El-Haschimi K, 2000, J CLIN INVEST, V105, P1827, DOI 10.1172/JCI9842; Elias CF, 1998, NEURON, V21, P1375, DOI 10.1016/S0896-6273(00)80656-X; Elias CF, 1999, NEURON, V23, P775, DOI 10.1016/S0896-6273(01)80035-0; Elmquist JK, 1999, NEURON, V22, P221, DOI 10.1016/S0896-6273(00)81084-3; Elmquist JK, 1997, ENDOCRINOLOGY, V138, P839, DOI 10.1210/en.138.2.839; Elmquist JK, 1998, P NATL ACAD SCI USA, V95, P741, DOI 10.1073/pnas.95.2.741; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; GETTYS TW, 1986, AM J PHYSIOL, V251, pE357, DOI 10.1152/ajpendo.1986.251.3.E357; Gettys TW, 1997, ENDOCRINOLOGY, V138, P2697, DOI 10.1210/en.138.7.2697; Graham M, 1997, NAT GENET, V17, P273, DOI 10.1038/ng1197-273; Guerra C, 1998, J CLIN INVEST, V102, P412, DOI 10.1172/JCI3155; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; Haynes WG, 1997, HYPERTENSION, V30, P619, DOI 10.1161/01.HYP.30.3.619; Haynes WG, 1997, J CLIN INVEST, V100, P270, DOI 10.1172/JCI119532; Haynes WG, 1999, HYPERTENSION, V33, P542, DOI 10.1161/01.HYP.33.1.542; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Kask A, 1998, EUR J PHARMACOL, V360, P15, DOI 10.1016/S0014-2999(98)00699-2; Korner J, 1999, NEUROENDOCRINOLOGY, V70, P377, DOI 10.1159/000054499; Kristensen P, 1998, NATURE, V393, P72, DOI 10.1038/29993; Li G, 2004, J ENDOCRINOL, V182, P123, DOI 10.1677/joe.0.1820123; Marsh DJ, 1999, NAT GENET, V21, P119, DOI 10.1038/5070; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; Mountjoy KG, 1999, ENDOCRINOLOGY, V140, P2167, DOI 10.1210/en.140.5.2167; Nillni EA, 2000, J BIOL CHEM, V275, P36124, DOI 10.1074/jbc.M003549200; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Pelleymounter MA, 2000, J PHARMACOL EXP THER, V293, P799; Prpic V, 2003, ENDOCRINOLOGY, V144, P1155, DOI 10.1210/en.2002-220835; Prpic V, 2002, J NUTR, V132, P3325, DOI 10.1093/jn/132.11.3325; Rahmouni K, 2003, J NEUROSCI, V23, P5998, DOI 10.1523/JNEUROSCI.23-14-05998.2003; Satoh N, 1998, NEUROSCI LETT, V249, P107, DOI 10.1016/S0304-3940(98)00401-7; Scarpace PJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE259, DOI 10.1152/ajpendo.1998.275.2.E259; Seeley RJ, 1997, NATURE, V390, P349, DOI 10.1038/37016; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Ste Marie L, 2000, P NATL ACAD SCI USA, V97, P12339, DOI 10.1073/pnas.220409497; Surwit RS, 1998, P NATL ACAD SCI USA, V95, P4061, DOI 10.1073/pnas.95.7.4061; Thornton JE, 1997, ENDOCRINOLOGY, V138, P5063, DOI 10.1210/en.138.11.5063; VanHeek M, 1997, J CLIN INVEST, V99, P385, DOI 10.1172/JCI119171; Watson PM, 2000, AM J PHYSIOL-ENDOC M, V279, pE356, DOI 10.1152/ajpendo.2000.279.2.E356; Williams DL, 2003, ENDOCRINOLOGY, V144, P4692, DOI 10.1210/en.2003-0440; Williams DL, 2000, ENDOCRINOLOGY, V141, P1332, DOI 10.1210/en.141.4.1332; Wilson BD, 1999, ENDOCRINOLOGY, V140, P2387, DOI 10.1210/en.140.5.2387	59	63	66	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1482	1491		10.1096/fj.05-3851com	http://dx.doi.org/10.1096/fj.05-3851com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16126916				2022-12-28	WOS:000232315700042
J	Dudek, EJ; Shang, F; Liu, Q; Valverde, P; Hobbs, M; Taylor, A				Dudek, EJ; Shang, F; Liu, Q; Valverde, P; Hobbs, M; Taylor, A			Selectivity of the ubiquitin pathway for oxidatively modified proteins: relevance to protein precipitation diseases	FASEB JOURNAL			English	Article						cataracts; proteolytic pathways; cellular stress; ubiquitin proteasome pathway	IRON REGULATORY PROTEIN-2; LENS EPITHELIAL-CELLS; PROTEASOME PATHWAY; CONJUGATING ENZYMES; OXIDIZED PROTEINS; HYDROGEN-PEROXIDE; EYE LENS; DEGRADATION; STRESS; SYSTEM	There is now consensus that the accumulation of oxidatively modified proteins is cytotoxic and causally related to several age-related diseases, including the amyloid diseases and age-related cataracts. There is also general agreement that proteolytic pathways provide a quality control mechanism to limit accumulation of damaged proteins. Although many researchers assume that the ubiquitin pathway is involved in recognition and proteolytic removal of oxidatively modified proteins, which are produced upon cellular stress, there has been no direct evidence to support this hypothesis. In this work, we used a novel proteolysis-resistant ubiquitin variant to demonstrate that ubiquitin conjugates isolated from oxidatively stressed mammalian cells are enriched 3.3 - 15-fold for oxidatively modified proteins and that failure to execute ubiquitin-dependent proteolysis renders various cell types more susceptible to oxidative stress-related cytotoxicity. These results were corroborated using several inhibitors of the ubiquitin proteasome pathway, including PS-341, an anticancer drug in clinical use. Taken together the data indicate that the ubiquitin proteolytic pathway recognizes and removes oxidatively modified proteins, and that failure of this system, as occurs upon aging or stress, may be involved in and exacerbate cytotoxicity and age-related syndromes in which accumulation of ubiquitinated and oxidatively modified proteins has an etiologic role.	Tufts Univ, Human Nutr Res Ctr Aging, Lab Nutr & Vis Res, Boston, MA 02111 USA; Tufts Univ, Human Nutr Res Ctr Aging, Vis Res USDA, Boston, MA 02111 USA	Tufts University; United States Department of Agriculture (USDA); Tufts University; United States Department of Agriculture (USDA)	Taylor, A (corresponding author), Tufts Univ, Human Nutr Res Ctr Aging, Lab Nutr & Vis Res, 711 Washington St, Boston, MA 02111 USA.	allen.taylor@tufts.edu	Valverde, Paloma/A-9897-2008		NATIONAL EYE INSTITUTE [R01EY011717, R01EY013250, P30EY013078, R03EY014183, R29EY011717] Funding Source: NIH RePORTER; NEI NIH HHS [EY13078, EY13250, EY14183, EY11717] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMO AM, 1994, J NEUROSCI RES, V38, P358, DOI 10.1002/jnr.490380314; Adamo AM, 1999, J NEUROSCI RES, V55, P523, DOI 10.1002/(SICI)1097-4547(19990215)55:4<523::AID-JNR12>3.0.CO;2-Q; ALLIS CD, 1980, CELL, V20, P55; Beal MF, 2002, FREE RADICAL BIO MED, V32, P797, DOI 10.1016/S0891-5849(02)00780-3; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Berlett BS, 1996, J BIOL CHEM, V271, P4177, DOI 10.1074/jbc.271.8.4177; Bleau G, 1998, ANAL BIOCHEM, V263, P13, DOI 10.1006/abio.1998.2801; BLONDIN J, 1986, Journal of Free Radicals in Biology and Medicine, V2, P275; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; DICE JF, 1993, PHYSIOL REV, V73, P149, DOI 10.1152/physrev.1993.73.1.149; Dringen R, 1999, J NEUROCHEM, V72, P2523, DOI 10.1046/j.1471-4159.1999.0722523.x; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; EISENHAUER DA, 1988, EXP EYE RES, V46, P579, DOI 10.1016/S0014-4835(88)80014-9; El-Agnaf OMA, 2002, BIOCHEM SOC T, V30, P559; Elofsson M, 1999, CHEM BIOL, V6, P811, DOI 10.1016/S1074-5521(99)80128-8; FigueiredoPereira ME, 1997, MOL BIOL REP, V24, P35, DOI 10.1023/A:1006848405975; FINCH JS, 1990, NUCLEIC ACIDS RES, V18, P1907, DOI 10.1093/nar/18.7.1907; Floyd RA, 2002, NEUROBIOL AGING, V23, P795, DOI 10.1016/S0197-4580(02)00019-2; Forman HJ, 2002, AM J RESP CRIT CARE, V166, pS4, DOI 10.1164/rccm.2206007; Frederikse PH, 1996, J BIOL CHEM, V271, P10169, DOI 10.1074/jbc.271.17.10169; Gelman MS, 2002, J BIOL CHEM, V277, P11709, DOI 10.1074/jbc.M111958200; Goellner GM, 2003, INT J BIOCHEM CELL B, V35, P562, DOI 10.1016/S1357-2725(02)00388-6; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Gomes-Marcondes MCC, 2002, CANCER LETT, V180, P69, DOI 10.1016/S0304-3835(02)00006-X; GRAY DA, 2003, SCI AGING KNOWLEDGE, V6, P1; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Guo WM, 2004, INVEST OPHTH VIS SCI, V45, P1194, DOI 10.1167/iovs.03-0830; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; Hitchcock AL, 2003, P NATL ACAD SCI USA, V100, P12735, DOI 10.1073/pnas.2135500100; HUANG LL, 1993, BIOCHIM BIOPHYS ACTA, V1175, P181, DOI 10.1016/0167-4889(93)90021-G; HUANG LL, 1995, EXP EYE RES, V61, P45, DOI 10.1016/S0014-4835(95)80057-3; Hyun DH, 2002, J BIOL CHEM, V277, P28572, DOI 10.1074/jbc.M200666200; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; JAHNGEN JH, 1986, J BIOL CHEM, V261, P3760; JAHNGEN JH, 1990, ARCH BIOCHEM BIOPHYS, V276, P32, DOI 10.1016/0003-9861(90)90006-K; JAHNGENHODGE J, 1992, EXP EYE RES, V55, P897, DOI 10.1016/0014-4835(92)90016-L; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Jellinger KA, 2003, J NEURAL TRANSM-SUPP, P101; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573; Kim BY, 2001, FREE RADICAL BIO MED, V30, P686, DOI 10.1016/S0891-5849(00)00514-1; KOPITO RR, 1999, PHYSIOL REV, V79, P167; LaVaute T, 2001, NAT GENET, V27, P209, DOI 10.1038/84859; MAYER RJ, 1991, J PATHOL, V163, P279, DOI 10.1002/path.1711630402; McBride WH, 2003, ONCOGENE, V22, P5755, DOI 10.1038/sj.onc.1206676; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; Obin M, 1999, J BIOL CHEM, V274, P11789, DOI 10.1074/jbc.274.17.11789; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; Ramanathan M, 1999, NEUROREPORT, V10, P3797, DOI 10.1097/00001756-199912160-00014; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637; RUBINSZTEIN DC, 2003, SCI AGING KNOWLEDGE, V17, pPE26; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297; Shang F, 2004, EXP EYE RES, V78, P1, DOI 10.1016/j.exer.2003.10.003; Shang F, 1997, EXP EYE RES, V64, P21, DOI 10.1006/exer.1996.0176; Shang F, 2001, EXP EYE RES, V73, P229, DOI 10.1006/exer.2001.1029; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; Shang F, 2005, J BIOL CHEM, V280, P20365, DOI 10.1074/jbc.M414356200; SHANG F, 1994, CURR EYE RES, V13, P423, DOI 10.3109/02713689408999870; Shringarpure R, 2003, J BIOL CHEM, V278, P311, DOI 10.1074/jbc.M206279200; SHRINGARPURE R, 2002, PROTEIN TURNOVER PRO; Sitte N, 2000, FASEB J, V14, P2503, DOI 10.1096/fj.00-0210com; Spector A, 1998, INVEST OPHTH VIS SCI, V39, P1188; SPECTOR A, 1981, EXP EYE RES, V33, P673, DOI 10.1016/S0014-4835(81)80107-8; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Taylor A, 2001, NUTRITION, V17, P845, DOI 10.1016/S0899-9007(01)00655-4; Taylor A, 2002, ONCOGENE, V21, P4363, DOI 10.1038/sj.onc.1205557; Taylor A, 1997, MOL ASPECTS MED, V18, P307, DOI 10.1016/S0098-2997(95)00049-6; TAYLOR A, 1999, CRC MOD NUT, P1; Taylor A., 1999, CRC MOD NUT, V1st, P53; Tessier F, 1999, J BIOL CHEM, V274, P20796, DOI 10.1074/jbc.274.30.20796; Vieira O, 2000, FASEB J, V14, P532, DOI 10.1096/fasebj.14.3.532; Wojcik C, 2004, STROKE, V35, P1506, DOI 10.1161/01.STR.0000126891.93919.4e; Wojcik C, 2002, J CELL MOL MED, V6, P25, DOI 10.1111/j.1582-4934.2002.tb00309.x; Zanetti M, 2002, AM J PHYSIOL-HEART C, V283, pH2620, DOI 10.1152/ajpheart.00358.2001; Zhang Y, 2003, GENE DEV, V17, P2733, DOI 10.1101/gad.1156403	83	80	80	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1707	+		10.1096/fj.05-4049fje	http://dx.doi.org/10.1096/fj.05-4049fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16099947				2022-12-28	WOS:000231843700014
J	Bethony, J; Loukas, A; Smout, M; Brooker, S; Mendez, S; Plieskatt, J; Goud, G; Bottazzi, ME; Zhan, B; Wang, Y; Williamson, A; Lustigman, S; Correa-Oliveira, R; Xiao, SH; Hotez, PJ				Bethony, J; Loukas, A; Smout, M; Brooker, S; Mendez, S; Plieskatt, J; Goud, G; Bottazzi, ME; Zhan, B; Wang, Y; Williamson, A; Lustigman, S; Correa-Oliveira, R; Xiao, SH; Hotez, PJ			Antibodies against a secreted protein from hookworm larvae reduce the intensity of hookworm infection in humans and vaccinated laboratory animals	FASEB JOURNAL			English	Article						ancylostoma secreted proteins; morbidity reduction; vaccine	TRANSMITTED HELMINTH INFECTIONS; NECATOR-AMERICANUS; PATHOGENESIS-RELATED-1 PROTEIN; MOLECULAR-CLONING; ENDEMIC AREA; FAMILY; MEBENDAZOLE; EXPRESSION; INHIBITOR; NEMATODES	The development of a vaccine would provide an important new tool for the control of human hookworm infection. On the basis of successful vaccination of laboratory animals with living irradiated, third-stage hookworm larvae (L3), we examined the antibody responses of individuals from hookworm endemic areas of Brazil and China against the most abundant L3 secreted antigens, the ancylostoma secreted proteins, ASP-1 and ASP-2. Logistic regression was used to investigate the effects of antibody isotype responses to ASPs on the risk of an individual harboring heavy hookworm infection. A significant protective association was observed between increasing anti-ASP-2 IgE levels and the risk of heavy hookworm infection. To confirm that ASP-2 is a protective antigen, laboratory dogs were immunized with recombinant ASP-2 formulated with the GlaxoSmithKline Adjuvant, AS03. Sera obtained from the immunized dogs exhibited high geometric mean antibody titers, immunoprecipitated native ASP-2 from L3 extracts and localized the site of ASP-2 expression to the glandular esophagus and body channels exiting to the cuticle. The sera also exhibited an increased ability to inhibit migration of L3 through tissue in vitro relative to sera from AS03-injected controls. Upon L3 challenge, the ASP-2 vaccinated dogs exhibited significant reductions in fecal egg counts and intestinal hookworm burden. These findings provide strong support for the development of an effective recombinant vaccine against hookworm infection in humans.	George Washington Univ, Dept Microbiol & Trop Med, Washington, DC 20037 USA; Queensland Inst Med Res, Div Infect Dis & Immunol, Brisbane, Qld 4006, Australia; Univ Queensland, Australian Ctr Int Trop Hlth & Nutr, Brisbane, Qld 4006, Australia; London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England; New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA; Fiocruz MS, Ctr Pesquisas Rene Rachou, BR-30190 Belo Horizonte, MG, Brazil; Chinese Ctr Dis Control & Prevenet, Inst Parasit Dis, Shanghai, Peoples R China	George Washington University; QIMR Berghofer Medical Research Institute; University of Queensland; University of London; London School of Hygiene & Tropical Medicine; New York Blood Center; Fundacao Oswaldo Cruz; Chinese Center for Disease Control & Prevention; National Institute of Parasitic Diseases, Chinese Center for Disease Control & Prevention	Bethony, J (corresponding author), George Washington Univ, Dept Microbiol & Trop Med, Ross Hall,Room 736,2300 Eye St NW, Washington, DC 20037 USA.	jeff@cpqrr.fiocruz.br; PHotez@gwu.edu	Loukas, Alex/B-7355-2014	Loukas, Alex/0000-0002-0896-8441; Smout, Michael/0000-0001-6937-0112; Plieskatt, Jordan/0000-0002-2333-7234; Hotez, Peter/0000-0001-8770-1042; Bottazzi, Maria Elena/0000-0002-8429-0476; Wolf, Nathaniel/0000-0001-6567-2447	FIC NIH HHS [1K01 TW00009] Funding Source: Medline; Wellcome Trust [073656] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [K01TW000009] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Wellcome Trust(Wellcome TrustEuropean Commission); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Albonico M, 2003, B WORLD HEALTH ORGAN, V81, P343; ALBONICO M, 1995, T ROY SOC TROP MED H, V89, P538, DOI 10.1016/0035-9203(95)90101-9; Asojo OA, 2005, ACTA CRYSTALLOGR F, V61, P391, DOI 10.1107/S1744309105007748; Asojo OA, 2005, J MOL BIOL, V346, P801, DOI 10.1016/j.jmb.2004.12.023; Bethony J, 2002, CLIN INFECT DIS, V35, P1336, DOI 10.1086/344268; Bethony J, 1999, J INFECT DIS, V180, P1665, DOI 10.1086/315069; Brooker S, 2005, EXPERT REV VACCINES, V4, P35, DOI 10.1586/14760584.4.1.35; Brooker S, 2004, ADV PARASIT, V58, P197, DOI 10.1016/S0065-308X(04)58004-1; Bungiro R, 2004, CURR OPIN INFECT DIS, V17, P421, DOI 10.1097/00001432-200410000-00006; CAPRON M, 1994, SCIENCE, V264, P1876, DOI 10.1126/science.8009216; de Silva NR, 2003, TRENDS PARASITOL, V19, P547, DOI 10.1016/j.pt.2003.10.002; Del Valle A, 2003, MOL BIOCHEM PARASIT, V129, P167, DOI 10.1016/S0166-6851(03)00121-X; Dombrowicz D, 2000, J IMMUNOL, V165, P1266, DOI 10.4049/jimmunol.165.3.1266; Geiger SM, 2004, CLIN EXP IMMUNOL, V136, P334, DOI 10.1111/j.1365-2249.2004.02449.x; Goud GN, 2004, J INFECT DIS, V189, P919, DOI 10.1086/381901; Hawdon JM, 1996, J PARASITOL, V82, P642, DOI 10.2307/3283794; Hawdon JM, 1996, J BIOL CHEM, V271, P6672, DOI 10.1074/jbc.271.12.6672; Hawdon JM, 1999, MOL BIOCHEM PARASIT, V99, P149, DOI 10.1016/S0166-6851(99)00011-0; Hawdon JM, 1996, CURR OPIN GENET DEV, V6, P618, DOI 10.1016/S0959-437X(96)80092-X; Hotez PJ, 2005, PLOS MED, V2, P187, DOI 10.1371/journal.pmed.0020067; Hotez PJ, 2002, COMP PARASITOL, V69, P72, DOI 10.1654/1525-2647(2002)069[0072:NHOPCH]2.0.CO;2; Hotez PJ, 2002, J PARASITOL, V88, P684, DOI 10.1645/0022-3395(2002)088[0684:EOVWRF]2.0.CO;2; Hotez PJ, 2004, NEW ENGL J MED, V351, P799, DOI 10.1056/NEJMra032492; Jian X, 2003, EXP PARASITOL, V104, P62, DOI 10.1016/S0014-4894(03)00094-8; Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397; Kooyman FNJ, 2000, PARASITE IMMUNOL, V22, P13; Ledizet Michel, 2005, Current Medicinal Chemistry - Cardiovascular & Hematological Agents, V3, P1, DOI 10.2174/1568016052773315; Loukas A, 2004, J INFECT DIS, V189, P1952, DOI 10.1086/386346; LUSTIGMAN S, 1992, J BIOL CHEM, V267, P17339; MacDonald AJ, 2004, PARASITE IMMUNOL, V26, P53, DOI 10.1111/j.0141-9838.2004.00685.x; McKerrow JH, 1999, PARASITOL TODAY, V15, P123, DOI 10.1016/S0169-4758(99)01411-8; Mendelson S, 2002, J MACH LEARN RES, V2, P1, DOI 10.1162/153244302760185225; Miller T A, 1978, Adv Parasitol, V16, P333, DOI 10.1016/S0065-308X(08)60577-1; MOYLE M, 1994, J BIOL CHEM, V269, P10008; Savioli L, 2002, T ROY SOC TROP MED H, V96, P577, DOI 10.1016/S0035-9203(02)90316-0; Stoltzfus RJ, 1997, NUTR REV, V55, P223, DOI 10.1111/j.1753-4887.1997.tb01609.x; Williamson AL, 2003, PARASITOLOGY, V126, P179, DOI 10.1017/S0031182002002706; World Health Organization, 2002, WHO TRADITIONAL MED, P1; Zhan B, 2003, INT J PARASITOL, V33, P897, DOI 10.1016/S0020-7519(03)00111-5; Zhan B, 2002, MOL BIOCHEM PARASIT, V120, P291, DOI 10.1016/S0166-6851(01)00453-4; Zhan B, 1999, MOL BIOCHEM PARASIT, V98, P143, DOI 10.1016/S0166-6851(98)00157-1	41	130	143	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1743	+		10.1096/fj.05-3936fje	http://dx.doi.org/10.1096/fj.05-3936fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16037096				2022-12-28	WOS:000230923000014
J	Claus, RA; Bunck, AC; Bockmeyer, CL; Brunkhorst, FM; Losche, W; Kinscherf, R; Deigner, HP				Claus, RA; Bunck, AC; Bockmeyer, CL; Brunkhorst, FM; Losche, W; Kinscherf, R; Deigner, HP			Role of increased sphingomyelinase activity in apoptosis and organ failure of patients with severe sepsis	FASEB JOURNAL			English	Article						inflammation; ceramide; endotoxin; oxidative stress; desipramine	ACID SPHINGOMYELINASE; SECRETORY SPHINGOMYELINASE; GLUCOSE-TRANSPORT; GENE-EXPRESSION; CELL-DEATH; CERAMIDE; ACTIVATION; ENDOTHELIUM; DYSFUNCTION; LDL	Numerous studies support the notion that an activation of sphingomyelinases and a subsequent increase of the concentration of the bioactive lipid mediator ceramide are critical in the concert of inflammatory stimuli and to the induction of apoptosis during inflammation. Here we show that patients with severe sepsis exhibit an enhanced sphingolytic activity in comparison with controls [ 262 pmol/(mlxh) vs. 123.6 pmol/( mlxh), P < 0.005]. During the clinical course, a further increase was paralleled by the severity of illness and by fatal outcome. Moreover, we show that oxidative stress may partially account for the increased activity through posttranslational modification of the enzyme. In a murine endotoxic shock model, administration of a low molecular weight inhibitor diminished the rise in enzymatic activity and improved the survival rate. In liver specimen, inhibition of activity correlated with a reduced rate of hepato-cellular apoptosis. Our data support the concept that activation of the plasmatic isoform of sphingomyelinase may play a critical role in the development of apoptosis and organ failure in sepsis. An inhibition of the secreted isoform of sphingomyelinase should be explored further as a potential target in the complicated puzzle of sepsis.	Univ Jena, Div Expt Anesthesiol, Dept Anesthesiol & Intens Care Med, D-07747 Jena, Germany; Heidelberg Univ, Dept Anat & Cell Biol, D-69120 Heidelberg, Germany; Univ E Anglia, Sch Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England	Friedrich Schiller University of Jena; Ruprecht Karls University Heidelberg; University of East Anglia	Claus, RA (corresponding author), Univ Jena, Div Expt Anesthesiol, Dept Anesthesiol & Intens Care Med, Erlanger Allee 101, D-07747 Jena, Germany.	ralf.claus@med.uni-jena.de; h-p.deigner@uea.ac.uk	Bunck, Alexander C/M-6389-2014; Kinscherf, Ralf/AAV-7164-2021; Claus, Ralf A./Q-4035-2016	Bunck, Alexander C/0000-0003-0986-0042; Brunkhorst, Frank Martin/0000-0002-8132-8651; Claus, Ralf A./0000-0001-7232-4088				Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887; Ayala A, 2003, SCAND J INFECT DIS, V35, P593, DOI 10.1080/00365540310015656; Baumruker T, 2002, SEMIN IMMUNOL, V14, P57, DOI 10.1006/smim.2001.0342; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bochud PY, 2003, BMJ-BRIT MED J, V326, P262, DOI 10.1136/bmj.326.7383.262; Cobb JP, 2002, CRIT CARE MED, V30, P2711, DOI 10.1097/00003246-200212000-00016; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Deigner HP, 2001, FASEB J, V15, P807, DOI 10.1096/fj.15.3.807; Drobnik W, 2003, J LIPID RES, V44, P754, DOI 10.1194/jlr.M200401-JLR200; Favory R, 2004, CRIT CARE MED, V32, P495, DOI 10.1097/01.CCM.0000109452.36271.FA; Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010; Goggel R, 2004, NAT MED, V10, P155, DOI 10.1038/nm977; Goni FM, 2002, FEBS LETT, V531, P38, DOI 10.1016/S0014-5793(02)03482-8; Gorski Andrzej, 2003, Med Immunol, V2, P2, DOI 10.1186/1476-9433-2-2; Haberkorn U, 2001, EUR J NUCL MED, V28, P1690, DOI 10.1007/s002590100644; Haberkorn U, 2001, EUR J NUCL MED, V28, P418, DOI 10.1007/s002590100489; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Hotchkiss RS, 1999, P NATL ACAD SCI USA, V96, P14541, DOI 10.1073/pnas.96.25.14541; Hotchkiss RS, 2003, SCAND J INFECT DIS, V35, P585, DOI 10.1080/00365540310015692; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Jones BE, 1999, HEPATOLOGY, V30, P215, DOI 10.1002/hep.510300146; Kinscherf R, 1998, FASEB J, V12, P461, DOI 10.1096/fasebj.12.6.461; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kolzer M, 2004, FEBS LETT, V559, P96, DOI 10.1016/S0014-5793(04)00033-X; Kontush A, 1999, METHOD ENZYMOL, V299, P35; Langmann T, 1999, J LIPID RES, V40, P870; Lightle S, 2003, ARCH BIOCHEM BIOPHYS, V419, P120, DOI 10.1016/j.abb.2003.08.031; Loidl A, 2004, BBA-MOL BASIS DIS, V1690, P150, DOI 10.1016/j.bbadis.2004.06.003; Loidl A, 2003, J BIOL CHEM, V278, P32921, DOI 10.1074/jbc.M306088200; Loidl A, 2002, J LIPID RES, V43, P815; Mahidhara R, 2000, CRIT CARE MED, V28, pN105, DOI 10.1097/00003246-200004001-00013; Marathe S, 1998, J BIOL CHEM, V273, P4081, DOI 10.1074/jbc.273.7.4081; *MEMB AM COLL CHES, 1992, CHEST, V11, P1644; Nakashima I, 2002, ANTIOXID REDOX SIGN, V4, P517, DOI 10.1089/15230860260196326; Oberholzer C, 2001, FASEB J, V15, P879, DOI 10.1096/fj.00-058rev; Papathanassoglou EDE, 2000, CRIT CARE MED, V28, P537, DOI 10.1097/00003246-200002000-00042; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Qiu HW, 2003, J BIOL CHEM, V278, P32744, DOI 10.1074/jbc.M303022200; Riedemann NC, 2003, NAT MED, V9, P517, DOI 10.1038/nm0503-517; Schissel SL, 1998, J BIOL CHEM, V273, P18250, DOI 10.1074/jbc.273.29.18250; Takahashi T, 2002, J PEDIAT HEMATOL ONC, V24, P401, DOI 10.1097/00043426-200206000-00016; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156; Wong ML, 2000, P NATL ACAD SCI USA, V97, P8681, DOI 10.1073/pnas.150098097; Yu SL, 2004, AM J RESP CRIT CARE, V169, P1135, DOI 10.1164/rccm.200211-1278OC; Zhang DX, 2002, AM J PHYSIOL-HEART C, V283, pH1785, DOI 10.1152/ajpheart.00318.2002	45	87	91	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1719	+		10.1096/fj.04-2842fje	http://dx.doi.org/10.1096/fj.04-2842fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16051685				2022-12-28	WOS:000230923000002
J	Perna, AM; Masini, E; Nistri, S; Briganti, V; Chiappini, L; Stefano, P; Bigazzi, M; Pieroni, C; Sacchi, TB; Bani, D				Perna, AM; Masini, E; Nistri, S; Briganti, V; Chiappini, L; Stefano, P; Bigazzi, M; Pieroni, C; Sacchi, TB; Bani, D			Novel drug development opportunity for relaxin in acute myocardial infarction: evidences from a swine model	FASEB JOURNAL			English	Article						cardiac ischemia/reperfusion; adjunctive therapy; cardioprotection	RECOMBINANT HUMAN RELAXIN; REPERFUSION INJURY; ISCHEMIA-REPERFUSION; PREGNANCY HORMONE; NITRIC-OXIDE; PIG HEARTS; IN-VITRO; INVOLVEMENT; NEUTROPHILS; ACTIVATION	The hormone relaxin has been shown to cause coronary vasodilation and to prevent ischemia/reperfusion-induced cardiac injury in rodents. This study provides evidence that relaxin, used as an adjunctive drug to coronary reperfusion, reduces the functional, biochemical, and histopathological signs of myocardial injury in an in vivo swine model of heart ischemia/reperfusion, currently used to test cardiotropic drugs for myocardial infarction. Human recombinant relaxin, given at reperfusion at doses of 1.25, 2.5, and 5 mu g/kg b. wt. after a 30-min ischemia, caused a dose-related reduction of key markers of myocardial damage (serum myoglobin, CK-MB, troponin T) and cardiomyocyte apoptosis (caspase 3, TUNEL assay), as well as of cardiomyocyte contractile dysfunction (myofibril hypercontraction). Compared with the controls, relaxin also increased the uptake of the viability tracer (201)Thallium and improved ventricular performance (cardiac index). Relaxin likely acts by reducing oxygen free radical-induced myocardial injury (malondialdehyde, tissue calcium overload) and inflammatory leukocyte recruitment (myeloperoxidase). The present findings show that human relaxin, given as a drug to counteract reperfusion-induced cardiac injury, affords a clear-cut protection to the heart of swine with induced myocardial infarction. The findings also provide background to future clinical trials with relaxin as adjunctive therapy to catheter-based coronary angioplasty in patients with acute myocardial infarction.	Univ Florence, Dept Anat Histol & Forens Med, I-50139 Florence, Italy; Careggi Hosp, Unit Nucl Med, Florence, Italy; Prosperius Inst, Florence, Italy; Careggi Hosp, Unit Cardiac & Expt Surg, Florence, Italy; Univ Florence, Dept Preclin & Clin Pharmacol, Florence, Italy	University of Florence; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Florence	Bani, D (corresponding author), Univ Florence, Dept Anat Histol & Forens Med, Viale G Pieraccini 6, I-50139 Florence, Italy.	daniele.bani@unifi.it		Bani, Daniele/0000-0001-6302-901X				Bani D, 1997, GEN PHARMACOL-VASC S, V28, P13, DOI 10.1016/S0306-3623(96)00171-1; BANI D, 1995, LAB INVEST, V73, P709; Bani D, 1998, AM J PATHOL, V152, P1367; Becker LB, 2004, CARDIOVASC RES, V61, P461, DOI 10.1016/j.cardiores.2003.10.025; BERMAN DS, 2000, REV PORT CARDIOL S1, V19, P31; Bertini Giovanni, 1993, Journal of Emergency Medicine, V11, P667, DOI 10.1016/0736-4679(93)90624-G; Bigazzi M, 2001, Climacteric, V4, P137, DOI 10.1080/713605086; Claeys MJ, 2004, AM J CARDIOL, V94, P9, DOI 10.1016/j.amjcard.2004.03.021; Dschietzig T, 2003, CELL MOL LIFE SCI, V60, P688, DOI 10.1007/s00018-003-2169-x; Dschietzig T, 2001, FASEB J, V15, P2187, DOI 10.1096/fj.01-0070com; Dschietzig T, 2004, FASEB J, V18, P1536, DOI 10.1096/fj.03-1120fje; EDDIE LW, 1986, LANCET, V1, P1344; Eltzschig HK, 2004, BRIT MED BULL, V70, P71, DOI 10.1093/bmb/ldh025; HALE SL, 1993, CARDIOVASC RES, V27, P2140, DOI 10.1093/cvr/27.12.2140; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Hu FB, 2000, NEW ENGL J MED, V343, P530, DOI 10.1056/NEJM200008243430802; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Masini E, 1997, ENDOCRINOLOGY, V138, P4713, DOI 10.1210/en.138.11.4713; Masini E, 2004, ENDOCRINOLOGY, V145, P1106, DOI 10.1210/en.2003-0833; MASINI E, 1994, J CLIN INVEST, V94, P1974, DOI 10.1172/JCI117549; Nediani C, 1997, J MOL CELL CARDIOL, V29, P2825, DOI 10.1006/jmcc.1997.0516; Nistri S, 2003, FASEB J, V17, P2109, DOI 10.1096/fj.03-0216fje; O'Neill WW, 2004, J AM COLL CARDIOL, V43, P875, DOI 10.1016/j.jacc.2003.12.024; OBYRNE EM, 1978, J CLIN ENDOCR METAB, V47, P1106, DOI 10.1210/jcem-47-5-1106; OSHEROFF PL, 1993, J BIOL CHEM, V268, P15193; SACCHI TB, 1995, BRIT J PHARMACOL, V116, P1589; Samuel CS, 2003, CURR OPIN PHARMACOL, V3, P152, DOI 10.1016/S1471-4892(03)00011-0; Seibold JR, 2000, ANN INTERN MED, V132, P871, DOI 10.7326/0003-4819-132-11-200006060-00004; Seibold JR, 1998, J RHEUMATOL, V25, P302; Sherwood OD, 2004, ENDOCR REV, V25, P205, DOI 10.1210/er.2003-0013; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; STULTS JT, 1990, BIOMED ENVIRON MASS, V19, P655, DOI 10.1002/bms.1200191105; TAYLOR D, 1994, INTERNET WORLD, V5, P8; THORNTON JD, 1992, CIRCULATION, V85, P659, DOI 10.1161/01.CIR.85.2.659; Vinten-Johansen J, 2004, CARDIOVASC RES, V61, P481, DOI 10.1016/j.cardiores.2003.10.011	35	81	87	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1525	+		10.1096/fj.04-3664fje	http://dx.doi.org/10.1096/fj.04-3664fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16009702				2022-12-28	WOS:000230923000027
J	Primo, L; Ferrandi, C; Roca, C; Marchio, S; di Blasio, L; Alessio, M; Bussolino, F				Primo, L; Ferrandi, C; Roca, C; Marchio, S; di Blasio, L; Alessio, M; Bussolino, F			Identification of CD36 molecular features required for its in vitro angiostatic activity	FASEB JOURNAL			English	Article						thrombospondin-1; endothelial cells; VEGF	ENDOTHELIAL GROWTH-FACTOR; PROTEIN-TYROSINE KINASES; TERMINAL DOMAIN; CELL RESPONSES; ANGIOGENESIS; THROMBOSPONDIN-1; INTEGRIN; ACTIVATION; INHIBITION; RECEPTOR	Thrombospondin-1 (TSP-1), a natural inhibitor of angiogenesis, acts directly on endothelial cells (EC) via CD36 to inhibit their migration and morphogenesis induced by basic fibroblast growth factor. Here we show that CD36 triggered by TSP-1 inhibits in vitro angiogenesis stimulated by vascular endothelial growth factor-A ( VEGF-A). To demonstrate that the TSP- 1 inhibitory signal was mediated by CD36, we transduced CD36 in CD36-deficient endothelial cells. Both TSP- 1 and the agonist anti-CD36 mAb SMO, which mimics TSP- 1 activity, reduced the VEGF-A165 induced migration and sprouting of CD36-ECs. To address the mechanisms by which CD36 may exert its angiostatic function, we investigated the functional components of the C-terminal cytoplasmic tail by site-directed mutagenesis. Our results indicate that C464, R467, and K469 of CD36 are required for the inhibitory activity of TSP-1. In contrast, point mutation of C466 did not alter TSP- 1 ability to inhibit EC migration and sprouting. Moreover, we show that activation of CD36 by TSP- 1 down-modulates the VEGF receptor-2 (VEGFR-2) and p38 mitogen-associated protein kinase phosphorylation induced by VEGF-A165, and this effect was specifically abolished by point mutation at C464. These results identify specific amino acids of the C-terminal cytoplasmic tail of CD36 crucial for the in vitro angiostatic activity of TSP- 1 and extend our knowledge of regulation of VEGFR-2-mediated biological activities on ECs.	IRCC, Inst Canc Res & Treatment, I-10060 Candiolo, Italy; Univ Turin, Sch Med, Turin, Italy; Ist Sci San Raffaele, DIBIT, Proteom Lab, I-20132 Milan, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Primo, L (corresponding author), IRCC, Inst Canc Res & Treatment, SP 142,KM 3-95, I-10060 Candiolo, Italy.	luca.primo@ircc.it	Marchiò, Serena/G-9054-2017; di Blasio, Laura/J-7352-2018; Bussolino, Federico/AES-3951-2022; Alessio, Massimo/L-4518-2019; Alessio, Massimo/K-7028-2014; Bussolino, Federico/K-2500-2016	Marchiò, Serena/0000-0001-8214-0776; di Blasio, Laura/0000-0002-1337-7654; Alessio, Massimo/0000-0002-4133-3472; Bussolino, Federico/0000-0002-5348-1341; PRIMO, Luca/0000-0002-1294-0441				Armstrong LC, 2003, MATRIX BIOL, V22, P63, DOI 10.1016/S0945-053X(03)00005-2; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Borges E, 2000, J BIOL CHEM, V275, P39867, DOI 10.1074/jbc.M007040200; BULL HA, 1994, FEBS LETT, V351, P41, DOI 10.1016/0014-5793(94)00814-0; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Calzada MJ, 2004, CIRC RES, V94, P462, DOI 10.1161/01.RES.0000115555.05668.93; Calzada MJ, 2003, J BIOL CHEM, V278, P40679, DOI 10.1074/jbc.M302014200; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chandrasekaran L, 2000, MOL BIOL CELL, V11, P2885, DOI 10.1091/mbc.11.9.2885; Chandrasekaran S, 1999, J BIOL CHEM, V274, P11408, DOI 10.1074/jbc.274.16.11408; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Feitsma K, 2000, J BIOL CHEM, V275, P9396, DOI 10.1074/jbc.275.13.9396; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRAZIER WA, 1998, TUMOR ANGIOGENESIS M; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Grignani F, 1998, CANCER RES, V58, P14; Gruarin P, 2000, BIOCHEM BIOPH RES CO, V275, P446, DOI 10.1006/bbrc.2000.3333; Gruarin P, 1997, BIOCHEM J, V328, P635, DOI 10.1042/bj3280635; Gruarin P, 2000, PARASITE IMMUNOL, V22, P349, DOI 10.1046/j.1365-3024.2000.00313.x; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1998, NAT MED, V4, P13, DOI 10.1038/nm0198-013; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Jimenez B, 2001, ONCOGENE, V20, P3443, DOI 10.1038/sj.onc.1204464; Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341; Lamalice L, 2004, ONCOGENE, V23, P434, DOI 10.1038/sj.onc.1207034; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; Leong KG, 2002, MOL CELL BIOL, V22, P2830, DOI 10.1128/MCB.22.8.2830-2841.2002; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; Malaud E, 2002, BIOCHEM J, V364, P507, DOI 10.1042/BJ20011373; Marchio S, 1999, J BIOL CHEM, V274, P27617, DOI 10.1074/jbc.274.39.27617; Miao WM, 2001, CANCER RES, V61, P7830; Miao WM, 2001, BLOOD, V97, P1689, DOI 10.1182/blood.V97.6.1689; MOSHER DF, 1982, J CELL BIOL, V93, P343, DOI 10.1083/jcb.93.2.343; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PEARCE SFA, 1994, BLOOD, V84, P384; Rousseau S, 2000, J BIOL CHEM, V275, P10661, DOI 10.1074/jbc.275.14.10661; Ruhrberg C, 2001, J CELL SCI, V114, P3215; Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8; Serini G, 2003, NATURE, V424, P391, DOI 10.1038/nature01784; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; SWERLICK RA, 1992, J IMMUNOL, V148, P78; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; Thorne RF, 2000, J BIOL CHEM, V275, P35264, DOI 10.1074/jbc.M003969200; Tolsma SS, 1997, MICROVASC RES, V54, P13, DOI 10.1006/mvre.1997.2015; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349; VOLPERT OV, 1995, BIOCHEM BIOPH RES CO, V217, P326, DOI 10.1006/bbrc.1995.2780; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751; Yauch RL, 2000, BIOCHEM J, V351, P629, DOI 10.1042/0264-6021:3510629; Zhang XA, 2002, MOL BIOL CELL, V13, P1, DOI 10.1091/mbc.01-10-0481	71	61	66	2	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1713	+		10.1096/fj.05-3697fje	http://dx.doi.org/10.1096/fj.05-3697fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16037098				2022-12-28	WOS:000230923000010
J	Suliman, HB; Welty-Wolf, KE; Carraway, MS; Schwartz, DA; Hollingsworth, JW; Piantadosi, CA				Suliman, HB; Welty-Wolf, KE; Carraway, MS; Schwartz, DA; Hollingsworth, JW; Piantadosi, CA			Toll-like receptor 4 mediates mitochondrial DNA damage and biogenic responses after heat-inactivated E. coli	FASEB JOURNAL			English	Article						bacterial infection; inflammation; endotoxin shock; knockout mice; signal transduction; nitric oxide; mitochondrial biogenesis	NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; TOLL-LIKE RECEPTORS; TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS; MOUSE HEPATOCYTES; OXIDATIVE DAMAGE; RELA/P65 SUBUNIT; ADAPTER PROTEIN; GENE-EXPRESSION	An important site of cellular damage in bacterial sepsis is mitochondrial DNA (mtDNA), which we proposed is caused by reactive oxygen and nitrogen species generated by activation of signaling through specific toll-like receptors (TLR). In wild-type (Wt) mice injected with heat-inactivated E. coli, hepatic TLR4 and TLR2 proteins were up-regulated with TLR-dependent increases in transcript levels for tumor necrosis factor (TNF-alpha), interleukin 6, nitric oxide synthase-II (iNOS), and NADPH oxidase 2 (Nox2). The accompanying stress significantly depleted hepatic mtDNA despite eight- and fourfold increases in manganese superoxide dismutase (MnSOD) and mitochondrial transcription factor A (Tfam) expression, respectively. The identical E. coli dose generated significantly less TNF-alpha, NO, and Nox2 in TLR4(-/-) and TLR2/4(-/-) but not in TLR2(-/-) mice. TLR4(-/-) and TLR2/4(-/-) compared with Wt mice were protected from mtDNA oxidation but showed no Tfam up-regulation and little copy number restoration. A critical role in the mtDNA damage was determined for TLR4-mediated iNOS transcription through the MyD88 pathway. In Wt mice, mtDNA depletion was avoided by selective iNOS blockade, and residual mtDNA loss was linked to NF-kappa B-dependent TNF-alpha expression. These data disclose the dual role of TLR4 in mtDNA damage and compensatory mitochondrial biogenic responses after innate immune activation.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Duke University	Piantadosi, CA (corresponding author), Duke Univ, Med Ctr, Dept Med, Box 3315,Room 0590,CR2 Bldg, Durham, NC 27710 USA.	piant001@mc.duke.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101945, Z01ES101946] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL-42444] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Azevedo-Martins AK, 2003, DIABETES, V52, P93, DOI 10.2337/diabetes.52.1.93; Ballinger SW, 2000, CIRC RES, V86, P960, DOI 10.1161/01.RES.86.9.960; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Begbie M, 2000, THROMB HAEMOSTASIS, V84, P216; Brealey David, 2002, Lancet (North American Edition), V360, P219, DOI 10.1016/S0140-6736(02)09459-X; Brookes PS, 2002, FREE RADICAL BIO MED, V33, P755, DOI 10.1016/S0891-5849(02)00901-2; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen BC, 2002, J BIOL CHEM, V277, P24169, DOI 10.1074/jbc.M106014200; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573; CROSS A, 1995, J CLIN INVEST, V96, P676, DOI 10.1172/JCI118110; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; Dishart MK, 1998, J APPL PHYSIOL, V84, P791; Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109; Essani NA, 1996, J IMMUNOL, V156, P2956; Fan J, 2003, J CLIN INVEST, V112, P1234, DOI 10.1172/JCI200318696; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GU GL, 2002, AM J PHYSIOL-GASTR L, V283, pG256; Hatano E, 2001, GASTROENTEROLOGY, V120, P1251, DOI 10.1053/gast.2001.23239; Henneke P, 2002, J IMMUNOL, V169, P3970, DOI 10.4049/jimmunol.169.7.3970; Hornef MW, 2003, J EXP MED, V198, P1225, DOI 10.1084/jem.20022194; Hoshino K, 1999, J IMMUNOL, V162, P3749; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Josse C, 1998, FREE RADICAL BIO MED, V25, P104, DOI 10.1016/S0891-5849(98)00057-4; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kurose I, 1996, HEPATOLOGY, V24, P1185; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Lavon I, 2000, NAT MED, V6, P573, DOI 10.1038/75057; Lemasters JJ, 1999, J BIOENERG BIOMEMBR, V31, P305, DOI 10.1023/A:1005419617371; Lin PH, 2003, FREE RADICAL BIO MED, V35, P1310, DOI 10.1016/j.freeradbiomed.2003.07.002; Liu SB, 2002, INFECT IMMUN, V70, P3433, DOI 10.1128/IAI.70.7.3433-3442.2002; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Matsumura T, 2000, J INTERF CYTOK RES, V20, P915, DOI 10.1089/10799900050163299; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Muir A, 2004, AM J RESP CELL MOL, V30, P777, DOI 10.1165/rcmb.2003-0329OC; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Rogers RJ, 2001, J BIOL CHEM, V276, P20419, DOI 10.1074/jbc.M008915200; Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492; SIMONSON SG, 1994, CIRC SHOCK, V43, P34; Suliman HB, 2004, CARDIOVASC RES, V64, P279, DOI 10.1016/j.cardiores.2004.07.005; Suliman HB, 2004, BLOOD, V104, P43, DOI 10.1182/blood-2003-07-2240; Suliman HB, 2003, J BIOL CHEM, V278, P41510, DOI 10.1074/jbc.M304719200; Suliman HB, 2002, FREE RADICAL BIO MED, V32, P246, DOI 10.1016/S0891-5849(01)00797-3; Suliman HB, 2003, AM J RESP CRIT CARE, V167, P570, DOI 10.1164/rccm.200206-518OC; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; Tsan MF, 2001, AM J PHYSIOL-CELL PH, V280, pC1422; Uchikura K, 2004, AM J PHYSIOL-GASTR L, V287, pG620, DOI 10.1152/ajpgi.00314.2003; Vodovotz Y, 2001, J ENDOTOXIN RES, V7, P365, DOI 10.1179/096805101101532936; VOLPES R, 1992, J HEPATOL, V16, P228, DOI 10.1016/S0168-8278(05)80121-7; Welty-Wolf KE, 1998, AM J RESP CRIT CARE, V158, P610, DOI 10.1164/ajrccm.158.2.9704064; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200	58	83	84	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1531	+		10.1096/fj.04-3500fje	http://dx.doi.org/10.1096/fj.04-3500fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	15994412				2022-12-28	WOS:000230923000031
J	D'Alessio, M; De Nicola, M; Coppola, S; Gualandi, G; Pugliese, L; Cerella, C; Cristofanon, S; Civitareale, P; Ciriolo, MR; Bergamaschi, A; Magrini, A; Ghibelli, L				D'Alessio, M; De Nicola, M; Coppola, S; Gualandi, G; Pugliese, L; Cerella, C; Cristofanon, S; Civitareale, P; Ciriolo, MR; Bergamaschi, A; Magrini, A; Ghibelli, L			Oxidative Bax dimerization promotes its translocation to mitochondria independently of apoptosis	FASEB JOURNAL			English	Article						oxidative stress; glutathione; disulfide	CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; ENDOPLASMIC-RETICULUM; CONFORMATIONAL-CHANGE; CASPASE ACTIVATION; PROAPOPTOTIC BAX; GSH EXTRUSION; CELL-DEATH; GLUTATHIONE; BCL-2	Bax is a cytosolic protein, which in response to stressing apoptotic stimuli, is activated and translocates to mitochondria, thus initiating the intrinsic apoptotic pathway. In spite of many studies and the importance of the issue, the molecular mechanisms that trigger Bax translocation are still obscure. We show by computer simulation that the two cysteine residues of Bax may form disulfide bridges, producing conformational changes that favor Bax translocation. Oxidative, nonapoptogenic treatments produce an up-shift of Bax migration compatible with homodimerization, which is reverted by reducing agents; this is accompanied by translocation to mitochondria. Dimers also appear in pure cytosolic fractions of cell lysates treated with H2O2, showing that Bax dimerization may take place in the cytosol. Bax dimer-enriched lysates support Bax translocation to isolated mitochondria much more efficiently than untreated lysates, indicating that dimerization may promote Bax translocation. The absence of apoptosis in our system allows the demonstration that Bax moves because of oxidations, even in the absence of apoptosis. This provides the first evidence that Bax dimerization and translocation respond to oxidative stimuli, suggesting a novel role for Bax as a sensor of redox imbalance.	Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy; Univ Roma Tor Vergata, Cattedra Med Lavoro, Rome, Italy; Univ Tuscia, Turin, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; Tuscia University	Ghibelli, L (corresponding author), Univ Roma Tor Vergata, Dipartimento Biol, Via Ric Sci 1, I-00133 Rome, Italy.	ghibelli@uniroma2.it	Ciriolo, Maria Rosa/K-6572-2016; Coppola, Simona/A-6638-2015	Coppola, Simona/0000-0001-7851-9409; Cerella, Claudia/0000-0001-9308-8176; Ciriolo, Maria Rosa/0000-0002-7863-9029				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Colussi C, 2000, FASEB J, V14, P2266, DOI 10.1096/fj.00-0074com; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; COPPOLA S, 1995, EXP CELL RES, V221, P462, DOI 10.1006/excr.1995.1397; Coppola S, 2000, BIOCHEM SOC T, V28, P56, DOI 10.1042/bst0280056; D'Alessio M, 2004, FASEB J, V18, P1609, DOI 10.1096/fj.04-1813fje; D'Alessio M, 2003, ANN NY ACAD SCI, V1010, P449, DOI 10.1196/annals.1299.082; De Giorgi F, 2002, FASEB J, V16, P607, DOI 10.1096/fj.01-0269fje; Devadas S, 2003, FREE RADICAL BIO MED, V35, P648, DOI 10.1016/S0891-5849(03)00391-5; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dini L, 1996, EXP CELL RES, V223, P340, DOI 10.1006/excr.1996.0089; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Filomeni G, 2005, ANTIOXID REDOX SIGN, V7, P446, DOI 10.1089/ars.2005.7.446; Filomeni G, 2002, BIOCHEM PHARMACOL, V64, P1057, DOI 10.1016/S0006-2952(02)01176-0; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Gajkowska B, 2004, J MOL HISTOL, V35, P11; Ghibelli L, 1999, FASEB J, V13, P2031, DOI 10.1096/fasebj.13.14.2031; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hampton MB, 1998, ANN NY ACAD SCI, V854, P328, DOI 10.1111/j.1749-6632.1998.tb09913.x; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Hentze H, 2002, J BIOL CHEM, V277, P5588, DOI 10.1074/jbc.M110766200; Hentze H, 1999, HEPATOLOGY, V30, P177, DOI 10.1002/hep.510300111; Hentze H, 2000, AM J PATHOL, V156, P2045, DOI 10.1016/S0002-9440(10)65076-6; Honda T, 2004, CANCER GENE THER, V11, P249, DOI 10.1038/sj.cgt.7700684; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Jungas T, 2002, J BIOL CHEM, V277, P27912, DOI 10.1074/jbc.M110288200; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Krieger E, 2002, PROTEINS, V47, P393, DOI 10.1002/prot.10104; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Murphy KM, 1999, ONCOGENE, V18, P5991, DOI 10.1038/sj.onc.1203001; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; NOSSERI C, 1994, EXP CELL RES, V212, P367, DOI 10.1006/excr.1994.1156; Nouraini S, 2000, MOL CELL BIOL, V20, P1604, DOI 10.1128/MCB.20.5.1604-1615.2000; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; Pan Z, 2001, J BIOL CHEM, V276, P32257, DOI 10.1074/jbc.M100178200; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Sen CK, 1999, CELL DEATH DIFFER, V6, P481, DOI 10.1038/sj.cdd.4400514; Shangary S, 2002, BIOCHEMISTRY-US, V41, P9485, DOI 10.1021/bi025605h; Single B, 1998, CELL DEATH DIFFER, V5, P1001, DOI 10.1038/sj.cdd.4400462; Stefan C, 1997, CHEM RES TOXICOL, V10, P636, DOI 10.1021/tx970006a; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Thomas A, 1996, ONCOGENE, V12, P1055; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; WIEDER ED, 1993, CYTOMETRY, V14, P916, DOI 10.1002/cyto.990140810; WILLIAMS CH, 1962, J BIOL CHEM, V237, P587; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yamaguchi H, 2001, ONCOGENE, V20, P7779, DOI 10.1038/sj.onc.1204984; Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200; Yamaguchi H, 2003, CANCER RES, V63, P1483; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; Zha HB, 1997, J BIOL CHEM, V272, P31482, DOI 10.1074/jbc.272.50.31482; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	72	102	104	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1504	+		10.1096/fj.04-3329fje	http://dx.doi.org/10.1096/fj.04-3329fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15972297				2022-12-28	WOS:000230207800012
J	Mingrone, G; Manco, M; Granato, L; Calvani, M; Scarfone, A; Mora, EV; Greco, AV; Vidal, H; Castagneto, M; Ferrannini, E				Mingrone, G; Manco, M; Granato, L; Calvani, M; Scarfone, A; Mora, EV; Greco, AV; Vidal, H; Castagneto, M; Ferrannini, E			Leptin pulsatility in formerly obese women	FASEB JOURNAL			English	Article						euglycemic-hyperinsulinemic clamp; calorimetric chamber; morbid obesity; biliopancreatic diversion; ACC2 mRNA expression	ACTIVATED PROTEIN-KINASE; ACETYL-COA CARBOXYLASE; HUMAN SKELETAL-MUSCLE; FATTY-ACID OXIDATION; PLASMA LEPTIN; GENE-EXPRESSION; INSULIN-RESISTANCE; BILIOPANCREATIC DIVERSION; ENERGY-EXPENDITURE; BODY-COMPOSITION	Plasma leptin and growth hormone (GH) profile and pulsatility have been studied in morbidly obese subjects before and 14 months after bilio-pancreatic diversion (BPD), a bariatric technique producing massive lipid malabsorption. The maximum leptin diurnal variation (acrophase) decreased (10.27 +/- 1.70 vs. 22.60 +/- 2.79 ng(.)ml(-1); P= 0.001), while its pulsatility index (PI) increased (1.084 +/- 0.005 vs. 1.050 +/- 0.004 ng(.)ml(-1.)min(- 1); P= 0.02) after BPD. Plasma GH acrophase increased ( P= 0.0001) from 0.91 +/- 0.20 to 4.58 +/- 0.80 mu g(.)l(-1.)min(-1) after BPD as well as GH PI (1.70 +/- 0.13 vs. 1.20 +/- 0.04 mu g.l(-1 .)min(-1); P= 0.024). Whole-body glucose uptake ( M), assessed by euglycemic-hyperinsulinemic clamp, almost doubled after BPD (from 0.274 +/- 0.022 to 0.573 +/- 0.027 mmol(.)kg(FFM) (1.)min(-1); P < 0.0001), while 24 h lipid oxidation was significantly (P < 0.0001) reduced (131.94 +/- 35.58 vs. 44.56 +/- 15.10 g). However, the average lipid oxidation was 97.2 +/- 3.1% (P < 0.01) of the metabolizable lipid intake after the bariatric operation, while it was 69.2 +/- 8.5% before. After the operation, skeletal muscle ACC2 mRNA decreased ( P < 0.0001) from 452.82 +/- 76.35 to 182.45 +/- 40.69% of cyclophilin mRNA as did the malonyl-CoA (from 0.28 +/- 0.02 to 0.16 +/- 0.01 nmol(.)g(-1); P < 0.0001). Leptin changes negatively correlated with M changes (R-2= 0.69, P < 0.001). In a stepwise regression (R-2= 0.87, P= 0.0055), only changes in 24 h free fatty acids (B=0.105 +/- 0.018, P= 0.002) and glucose/ insulin ratio (B= 0.247 +/- 0.081, P= 0.029) were the best predictors of leptin variations. In conclusion, the reversion of insulin resistance after BPD might allow reversal of leptin resistance, restoration of leptin pulsatility, and consequent inhibition of ACC2 mRNA expression, translating to a reduced synthesis of malonyl-CoA, which, in turn, results in increased fatty acid oxidation. Finally, since leptin inhibits GH secretion, a reduction of circulating leptin levels might have produced an increase in GH secretion, as observed in our series.	Catholic Univ, Dipartimento Med Interna, Sch Med, CNR Ctr Fisiopatol Shock, I-00168 Rome, Italy; Univ Roma La Sapienza, Dept Comp Sci & Syst, Rome, Italy; INSERM, Unite 449, Lyon, France; Catholic Univ, CNR Ctr Fisiopatol Shock, Dept Surg, Sch Med, Rome, Italy; Univ Pisa, Dept Internal Med, Pisa, Italy; Univ Pisa, CNR, Inst Clin Physiol, Pisa, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Sapienza University Rome; Institut National de la Sante et de la Recherche Medicale (Inserm); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Pisa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); University of Pisa	Mingrone, G (corresponding author), Catholic Univ, Dipartimento Med Interna, Sch Med, CNR Ctr Fisiopatol Shock, Largo A Gemelli 8, I-00168 Rome, Italy.	gmingrone@rm.unicatt.it	Mingrone, Geltrude/AAB-9681-2019; Manco, Melania/M-1058-2013; VIDAL, Hubert/M-6674-2017	Manco, Melania/0000-0002-6581-975X; VIDAL, Hubert/0000-0002-9467-0317; Mingrone, Geltrude/0000-0003-2021-528X				Abu-Elheiga L, 2003, P NATL ACAD SCI USA, V100, P10207, DOI 10.1073/pnas.1733877100; Auboeuf D, 1997, ANAL BIOCHEM, V245, P141, DOI 10.1006/abio.1996.9986; Barbe P, 2001, FASEB J, V15, P13; Boden G, 1997, J CLIN INVEST, V100, P1107, DOI 10.1172/JCI119621; Boden G, 1996, J CLIN ENDOCR METAB, V81, P3419, DOI 10.1210/jc.81.9.3419; Calvani M, 2004, DIABETES, V53, P939, DOI 10.2337/diabetes.53.4.939; Casanueva FF, 1999, FRONT NEUROENDOCRIN, V20, P317, DOI 10.1006/frne.1999.0187; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; De Marinis L, 2004, J CLIN ENDOCR METAB, V89, P174, DOI 10.1210/jc.2002-021308; De Marinis L, 1999, J CLIN ENDOCR METAB, V84, P2386, DOI 10.1210/jc.84.7.2386; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; Dirlewanger M, 2000, INT J OBESITY, V24, P1413, DOI 10.1038/sj.ijo.0801395; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Fabris R, 2004, J CLIN ENDOCR METAB, V89, P1753, DOI 10.1210/jc.2003-031343; Goodwin GW, 1999, AM J PHYSIOL-ENDOC M, V277, pE772, DOI 10.1152/ajpendo.1999.277.4.E772; Granato L, 2004, J APPL PHYSIOL, V96, P1045, DOI 10.1152/japplphysiol.00788.2003; Greco AV, 2002, DIABETES, V51, P144, DOI 10.2337/diabetes.51.1.144; Greco AV, 2002, J INVEST MED, V50, P207, DOI 10.2310/6650.2002.33435; Hardie DG, 2002, BIOCHEM SOC T, V30, P1064, DOI 10.1042/BST0301064; Hauffa B P, 2001, Growth Horm IGF Res, V11 Suppl A, pS1, DOI 10.1016/S1096-6374(01)80002-2; Havel PJ, 2004, DIABETES, V53, pS143, DOI 10.2337/diabetes.53.2007.S143; Havel PJ, 1999, DIABETES, V48, P334, DOI 10.2337/diabetes.48.2.334; HEYMSFIELD SB, 1990, AM J CLIN NUTR, V52, P52, DOI 10.1093/ajcn/52.1.52; HILL JO, 1992, INT J OBESITY, V16, P321; HORTON TJ, 1995, AM J CLIN NUTR, V62, P19, DOI 10.1093/ajcn/62.1.19; Kaltenbach M, 1984, MANGER CORRECTEMENT; Klein S, 1996, DIABETES, V45, P984, DOI 10.2337/diabetes.45.7.984; Kolaczynski JW, 1996, DIABETES, V45, P1511, DOI 10.2337/diabetes.45.11.1511; Kolattukudy P E, 1981, Methods Enzymol, V71 Pt C, P150; Lee Y, 2001, J BIOL CHEM, V276, P5629, DOI 10.1074/jbc.M008553200; Levine JA, 2000, AM J CLIN NUTR, V72, P1451; Levine James A., 1999, Science (Washington D C), V283, P212, DOI 10.1126/science.283.5399.212; Lowell BB, 2005, SCIENCE, V307, P384, DOI 10.1126/science.1104343; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Mizuno T, 1996, HORM METAB RES, V28, P679, DOI 10.1055/s-2007-979877; Mizuno TM, 1996, P NATL ACAD SCI USA, V93, P3434, DOI 10.1073/pnas.93.8.3434; Mueller WM, 1998, ENDOCRINOLOGY, V139, P551, DOI 10.1210/en.139.2.551; MUNSON PJ, 1989, P STAT COMP SECT AM, P295; Muscelli E, 2005, AM J MED, V118, P51, DOI 10.1016/j.amjmed.2004.08.017; Park H, 2002, J BIOL CHEM, V277, P32571, DOI 10.1074/jbc.M201692200; PRESS WH, 1992, NUMERICAL RECIPES C, P537; Reseland JE, 2001, AM J CLIN NUTR, V73, P240; Rosa G, 2003, OBES RES, V11, P1306, DOI 10.1038/oby.2003.177; Rosenbaum M, 1996, J CLIN ENDOCR METAB, V81, P3424, DOI 10.1210/jc.81.9.3424; Saad MF, 1998, DIABETES, V47, P544, DOI 10.2337/diabetes.47.4.544; Schmitz O, 1997, DIABETES METAB, V23, P80; Schoeller DA, 1997, J CLIN INVEST, V100, P1882, DOI 10.1172/JCI119717; SCOPINARO N, 1979, BRIT J SURG, V66, P618, DOI 10.1002/bjs.1800660906; Sinha MK, 1996, BIOCHEM BIOPH RES CO, V228, P733, DOI 10.1006/bbrc.1996.1724; Steinberg GR, 2000, AM J PHYSIOL-ENDOC M, V279, pE1374, DOI 10.1152/ajpendo.2000.279.6.E1374; Steinberg GR, 2002, AM J PHYSIOL-ENDOC M, V283, pE187, DOI 10.1152/ajpendo.00542.2001; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Storlien L, 2004, P NUTR SOC, V63, P363, DOI 10.1079/PNS2004349; Tataranni PA, 1997, ANN NY ACAD SCI, V819, P37, DOI 10.1111/j.1749-6632.1997.tb51797.x; TRAYHURN P, 1995, FEBS LETT, V368, P488, DOI 10.1016/0014-5793(95)00719-P; TREMBLAY A, 1989, AM J CLIN NUTR, V49, P799, DOI 10.1093/ajcn/49.5.799; Ueno N, 2004, ENDOCRINOLOGY, V145, P4176, DOI 10.1210/en.2004-0262; Unger RH, 2002, BBA-MOL CELL BIOL L, V1585, P202, DOI 10.1016/S1388-1981(02)00342-6; WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363; Wellhoener P, 2000, J CLIN ENDOCR METAB, V85, P1267, DOI 10.1210/jc.85.3.1267; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; Xu B, 1999, ENDOCRINOLOGY, V140, P2868, DOI 10.1210/en.140.6.2868; Yildiz BO, 2004, P NATL ACAD SCI USA, V101, P10434, DOI 10.1073/pnas.0403465101	64	14	14	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1380	+		10.1096/fj.04-3453fje	http://dx.doi.org/10.1096/fj.04-3453fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15955844				2022-12-28	WOS:000230207800019
J	Pajusola, K; Kunnapuu, J; Vuorikoski, S; Soronen, J; Andre, H; Pereira, T; Korpisalo, P; Yla-Herttuala, S; Poellinger, L; Alitalo, K				Pajusola, K; Kunnapuu, J; Vuorikoski, S; Soronen, J; Andre, H; Pereira, T; Korpisalo, P; Yla-Herttuala, S; Poellinger, L; Alitalo, K			Stabilized HIF-1 alpha is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated virus gene transfer	FASEB JOURNAL			English	Article						cardiovascular ischemic diseases; pro-angiogenic gene therapy; arteriogenic growth factor	GROWTH-FACTOR; HYPOXIA; EXPRESSION; INDUCTION; HYPERPERMEABILITY; ANGIOPOIETIN-1; PROLIFERATION; LETHALITY; THERAPY; HIF-1	Therapeutic angiogenesis provides a potential alternative for the treatment of cardiovascular ischemic diseases. Vascular endothelial growth factor ( VEGF) is an important component of the angiogenic response to ischemia. Here we used adeno-associated virus (AAV) gene delivery to skeletal muscle to examine the effects of VEGF vs. a stabilized form of hypoxia-inducible factor-1 alpha ( HIF-1 alpha). The recombinant AAVs were injected into mouse tibialis anterior muscle, and their effects were analyzed by immunohistochemistry and functional assays. These analyses showed that stabilized HIF-1 alpha markedly increase capillary sprouting and proliferation, whereas VEGF(164) or VEGF(120) induced only proliferation of endothelial cells without formation of proper capillary structures. The Evans Blue permeability assay indicated that, unlike VEGF, HIF-1 alpha overexpression did not increase vascular leakiness in the transduced muscle. Doppler ultrasound imaging showed that vascular perfusion in the HIF-1 alpha treated muscles was significantly enhanced when compared to the controls and not further improved by co-expression of the arteriogenic growth factors angiopoietin-1 or platelet-derived growth factor-B. Our results show that AAV-mediated transduction of a stabilized form of HIF-1 alpha can circumvent the problems associated with overexpression of individual angiogenic growth factors. HIF-1 alpha should thus offer a potent alternative for pro-angiogenic gene therapy.	Univ Helsinki, Mol Canc Biol Lab, Biomed Helsinki, FIN-00014 Helsinki, Finland; Univ Helsinki, Ludwig Inst Canc Res, Biomed Helsinki, Helsinki, Finland; Univ Kuopio, AI Virtanen Inst, Kuopio, Finland; Univ Kuopio, Dept Med, SF-70210 Kuopio, Finland; Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden	University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki; University of Eastern Finland; University of Eastern Finland; Karolinska Institutet	Alitalo, K (corresponding author), Univ Helsinki, Mol Canc Biol Lab, Biomed Helsinki, POB 63 Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	kari.alitalo@helsinki.fi	Andre, Helder/AAC-5220-2019; Vulli, Jaana/C-1085-2015; Alitalo, Kari K/J-5013-2014; Pereira, Teresa/AAP-8197-2020	Andre, Helder/0000-0002-2926-2376; Vulli, Jaana/0000-0001-9509-1862; Alitalo, Kari K/0000-0002-7331-0902; Pereira, Teresa/0000-0001-8654-2385; Yla-Herttuala, Seppo/0000-0001-7593-2708				An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Bekeredjian R, 2004, AM J MED SCI, V327, P139; Brown M. D., 2003, Angiogenesis, V6, P1, DOI 10.1023/A:1025809808697; Buning H, 2004, CELLS TISSUES ORGANS, V177, P139, DOI 10.1159/000079988; Burgert HG, 2002, CURR TOP MICROBIOL, V269, P273; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 2000, NAT MED, V6, P1102, DOI 10.1038/80430; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chu Danny, 2004, Methods Mol Biol, V246, P213; Clauss M, 1998, TRENDS CARDIOVAS MED, V8, P241, DOI 10.1016/S1050-1738(98)00015-2; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; Dor Y, 2003, ANN NY ACAD SCI, V995, P208, DOI 10.1111/j.1749-6632.2003.tb03224.x; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Gerhardt H, 2003, CELL TISSUE RES, V314, P15, DOI 10.1007/s00441-003-0745-x; Greijer AE, 2004, J CLIN PATHOL, V57, P1009, DOI 10.1136/jcp.2003.015032; Grimm D, 1998, HUM GENE THER, V9, P2745, DOI 10.1089/hum.1998.9.18-2745; Hauck B, 2004, J VIROL, V78, P13678, DOI 10.1128/JVI.78.24.13678-13686.2004; Hewitson KS, 2004, DRUG DISCOV TODAY, V9, P704, DOI 10.1016/S1359-6446(04)03202-7; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; MANALO DJ, 2004, BLOOD; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Paterna JC, 2000, GENE THER, V7, P1304, DOI 10.1038/sj.gt.3301221; Pereira T, 2003, J BIOL CHEM, V278, P6816, DOI 10.1074/jbc.M209297200; Piret JP, 2002, BIOCHEM PHARMACOL, V64, P889, DOI 10.1016/S0006-2952(02)01155-3; Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Ritter T, 2002, BIODRUGS, V16, P3, DOI 10.2165/00063030-200216010-00001; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Springer ML, 1998, MOL CELL, V2, P549, DOI 10.1016/S1097-2765(00)80154-9; Sundberg C, 2001, AM J PATHOL, V158, P1145, DOI 10.1016/S0002-9440(10)64062-X; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 2002, J ANAT, V200, P575, DOI 10.1046/j.1469-7580.2002.00061.x; Tuomisto TT, 2004, ATHEROSCLEROSIS, V174, P111, DOI 10.1016/j.atherosclerosis.2004.01.015; Uutela M, 2004, BLOOD, V104, P3198, DOI 10.1182/blood-2004-04-1485; Yla-Herttuala S, 2003, NAT MED, V9, P694, DOI 10.1038/nm0603-694	40	101	109	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1365	+		10.1096/fj.05-3720fje	http://dx.doi.org/10.1096/fj.05-3720fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15958522				2022-12-28	WOS:000230207800014
J	Gurvich, N; Berman, MG; Wittner, BS; Gentleman, RC; Klein, PS; Green, JBA				Gurvich, N; Berman, MG; Wittner, BS; Gentleman, RC; Klein, PS; Green, JBA			Association of valproate-induced teratogenesis with histone deacetylase inhibition in vivo	FASEB JOURNAL			English	Article						valproic acid; HDAC; trichostatin A; Xenopus laevis; Danio rerio; spina bifida	NEURAL-TUBE DEFECTS; GENE-EXPRESSION; HDAC INHIBITORS; ACID; MOUSE; ACETYLATION; DIFFERENTIATION; ANTICONVULSANT; TARGET; MODEL	Chemically induced birth defects are an important public health and human problem. Here we use Xenopus and zebrafish as models to investigate the mechanism of action of a well-known teratogen, valproic acid (VPA). VPA is a drug used in treatment of epilepsy and bipolar disorder but causes spina bifida if taken during pregnancy. VPA has several biochemical activities, including inhibition of histone deacetylases (HDACs). To investigate the mechanism of action of VPA, we compared its effects in Xenopus and zebrafish embryos with those of known HDAC inhibitors and noninhibitory VPA analogs. We found that VPA and other HDAC inhibitors cause very similar and characteristic developmental defects whereas VPA analogs with poor inhibitory activity in vivo have little teratogenic effect. Unbiased microarray analysis revealed that the effects of VPA and trichostatin A (TSA), a structurally unrelated HDAC inhibitor, are strikingly concordant. The concordance is apparent both by en masse correlation of fold-changes and by detailed similarity of dose-response profiles of individual genes. Together, the results demonstrate that the teratogenic effects of VPA are very likely mediated specifically by inhibition of HDACs.	Univ Penn, Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA USA	University of Pennsylvania; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Howard Hughes Medical Institute; University of Pennsylvania; Harvard University; Harvard Medical School	Green, JBA (corresponding author), Guys Hosp, Univ London Kings Coll, Dept Craniofacial Dev, Floor 28 Guys Tower, London SE1 9RT, England.	jeremy.green@kcl.ac.uk	Green, Jeremy/F-3630-2010	Green, Jeremy/0000-0002-6102-2620	NIEHS NIH HHS [R21ES11710] Funding Source: Medline; NIMH NIH HHS [R01MH64761] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES011710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH064761] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALMOUZNI G, 1994, DEV BIOL, V165, P654, DOI 10.1006/dbio.1994.1283; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blaheta RA, 2002, MED RES REV, V22, P492, DOI 10.1002/med.10017; Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055; Briner W, 2000, NEUROTOXICOL TERATOL, V22, P761, DOI 10.1016/S0892-0362(00)00086-6; Chen F, 2002, CELL, V110, P713, DOI 10.1016/S0092-8674(02)00932-7; DAWSON DA, 1991, TERATOLOGY, V44, P531, DOI 10.1002/tera.1420440507; DAWSON DA, 1987, J APPL TOXICOL, V7, P237, DOI 10.1002/jat.2550070403; Finnell RH, 2002, ANNU REV PHARMACOL, V42, P181, DOI 10.1146/annurev.pharmtox.42.083001.110955; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Glaser KB, 2003, MOL CANCER THER, V2, P151; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Gurvich N, 2004, CANCER RES, V64, P1079, DOI 10.1158/0008-5472.CAN-03-0799; HERRMANN K, 1993, TOXICOL IN VITRO, V7, P41, DOI 10.1016/0887-2333(93)90111-H; Kook H, 2003, J CLIN INVEST, V112, P863, DOI 10.1172/JCI200319137; Kratke R, 1996, TERATOGEN CARCIN MUT, V16, P149; Kultima K, 2004, ENVIRON HEALTH PERSP, V112, P1225, DOI 10.1289/txg.7034; Marks PA, 2003, CURR OPIN PHARMACOL, V3, P344, DOI 10.1016/S1471-4892(03)00084-5; NARUSE I, 1988, TERATOLOGY, V38, P87, DOI 10.1002/tera.1420380113; *NAT AC SCI, 2000, SCI FRONT DEV TOX RI; NAU H, 1994, CIBA F SYMP, V181, P144; NAU H, 1991, PHARMACOL TOXICOL, V69, P310, DOI 10.1111/j.1600-0773.1991.tb01303.x; OBEREMM A, 1992, TERATOGEN CARCIN MUT, V12, P251, DOI 10.1002/tcm.1770120603; Pennati R, 2001, TERATOGEN CARCIN MUT, V21, P121, DOI 10.1002/1520-6866(2001)21:2<121::AID-TCM2>3.0.CO;2-N; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Rebagliati MR, 1998, DEV BIOL, V199, P261, DOI 10.1006/dbio.1998.8935; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Svensson K, 1998, DEVELOPMENT, V125, P61; Tou LQ, 2004, MOL CELL BIOL, V24, P3132, DOI 10.1128/MCB.24.8.3132-3139.2004; Tremolizzo L, 2002, P NATL ACAD SCI USA, V99, P17095, DOI 10.1073/pnas.262658999; van Straaten HWM, 2001, ANAT EMBRYOL, V203, P225, DOI 10.1007/s004290100169; VANSTRAATEN HWM, 1993, DEVELOPMENT, V117, P1163; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Yildirim E, 2003, NEUROSCI LETT, V345, P141, DOI 10.1016/S0304-3940(03)00490-7	35	146	150	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1166	+		10.1096/fj.04-3425fje	http://dx.doi.org/10.1096/fj.04-3425fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15901671				2022-12-28	WOS:000229602600011
J	Aziz, MH; Reagan-Shaw, S; Wu, JQ; Longley, BJ; Ahmad, N				Aziz, MH; Reagan-Shaw, S; Wu, JQ; Longley, BJ; Ahmad, N			Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease?	FASEB JOURNAL			English	Article						ultraviolet; photocarcinogenesis; Survivin	CELL-CYCLE; APOPTOSIS INHIBITOR; HUMAN KERATINOCYTES; ACTINIC KERATOSIS; GREEN TEA; RED WINE; IN-VIVO; SURVIVIN; EXPRESSION; PHOTOCARCINOGENESIS	According to the World Cancer Report, skin cancer constitutes similar to 30% of all newly diagnosed cancers in the world, and solar ultraviolet (UV) radiation (particularly, its UVB component; 290-320 nm) is an established cause of similar to 90% of skin cancers. The available options have proven to be inadequate for the management of skin cancers. Therefore, there is an urgent need to develop mechanism-based novel approaches for prevention/therapy of skin cancer. In this study, we evaluated the chemopreventive effects of resveratrol against UVB radiation-mediated skin tumorigenesis in the SKH-1 hairless mouse model. For our studies, we used a UVB initiation-promotion protocol in which the control mice were subjected to chronic UVB exposure (180 mJ/cm(2), twice weekly, for 28 weeks). The experimental animals received either a pretreatment (30 min before each UVB) or post-treatment (5 min after UVB) of resveratrol (25 or 50 micro mole/0.2 ml acetone/mouse). The mice were followed for skin tumorigenesis and were killed at 24 h after the last UVB exposure, for further studies. The topical application of skin with resveratrol (both pre- and post- treatment) resulted in a highly significant 1) inhibition in tumor incidence, and 2) delay in the onset of tumorigenesis. Interestingly, the post-treatment of resveratrol was found to impart equal protection than the pretreatment; suggesting that resveratrol-mediated responses may not be sunscreen effects. Because Survivin is a critical regulator of survival/death of cells, and its overexpression has been implicated in several cancers, we evaluated its involvement in chemoprevention of UVB-mediated skin carcinogenesis by resveratrol. Our data demonstrated a significant 1) up-regulation of Survivin (both at protein- and mRNA- levels), 2) up-regulation of phospho-Survivin protein, and 3) down-regulation of proapoptotic Smac/DIABLO protein in skin tumors; whereas treatment with resveratrol resulted in the attenuation of these responses. Our study also suggests that resveratrol enhanced apoptosis in UVB-exposure-mediated skin tumors. Our study, for the first time, demonstrated that 1) resveratrol imparts strong chemopreventive effects against UVB exposure-mediated skin carcinogenesis (relevant to human skin cancers), and 2) the chemopreventive effects of resveratrol may, at least in part, be mediated via modulations in Survivin and other associated events. On the basis of our work, it is conceivable to design resveratrol-containing emollient or patch, as well as sunscreen and skin-care products for prevention of skin cancer and other conditions, which are believed to be caused by UV radiation.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Ctr Comprehens Canc, Madison, WI 53706 USA; Univ Wisconsin, Mol & Environm Toxicol Ctr, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ahmad, N (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Ctr Comprehens Canc, 1300 Univ Ave, Madison, WI 53706 USA.	nahmad@wisc.edu	Ahmad, Nihal/AAR-4249-2021	Ahmad, Nihal/0000-0002-4239-9887	NCI NIH HHS [CA-098368] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA098368] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adhami VM, 2003, NEOPLASIA, V5, P74, DOI 10.1016/S1476-5586(03)80019-2; Adhami VM, 2001, BIOCHEM BIOPH RES CO, V288, P579, DOI 10.1006/bbrc.2001.5819; Afaq F, 2003, TOXICOL APPL PHARM, V186, P28, DOI 10.1016/S0041-008X(02)00014-5; Afaq F, 2002, SKIN PHARMACOL APPL, V15, P297, DOI 10.1159/000064533; Afaq F, 2002, FRONT BIOSCI-LANDMRK, V7, pD784, DOI 10.2741/afaq; Ahmad N, 2001, AM J PATHOL, V159, P885, DOI 10.1016/S0002-9440(10)61764-6; Ahmad N, 2001, CLIN CANCER RES, V7, P1466; Ahmad N, 2001, SKIN PHARMACOL APPL, V14, P69, DOI 10.1159/000056336; Allen SM, 2003, CANCER RES, V63, P567; Altieri Dario C, 2003, Methods Mol Biol, V223, P533; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Altieri DC, 2003, ADV CANCER RES, V88, P31, DOI 10.1016/S0065-230X(03)88303-3; Altieri DC, 1999, LAB INVEST, V79, P1327; Ananthaswamy H N, 1998, J Investig Dermatol Symp Proc, V3, P52; Aziz MH, 2004, PHOTOCHEM PHOTOBIOL, V80, P602; Aziz MH, 2003, INT J ONCOL, V23, P17; Balasubramanian S, 1999, ONCOGENE, V18, P1297, DOI 10.1038/sj.onc.1202417; Black HS, 1997, J PHOTOCH PHOTOBIO B, V40, P29, DOI 10.1016/S1011-1344(97)00021-3; Blanc-Brude OP, 2003, CLIN CANCER RES, V9, P2683; Bode A M, 2000, Lancet Oncol, V1, P181, DOI 10.1016/S1470-2045(00)00029-2; Brash DE, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P136; Chiodino C, 1999, J INVEST DERMATOL, V113, P415, DOI 10.1046/j.1523-1747.1999.00711.x; Conney AH, 1999, P SOC EXP BIOL MED, V220, P229, DOI 10.1046/j.1525-1373.1999.d01-39.x; Conney AH, 2004, J CELL BIOCHEM, V91, P277, DOI 10.1002/jcb.20001; DING Z, 2002, SLEEP, V25, P7; Einspahr JG, 2003, RECENT RESULTS CANC, V163, P151; Elmets CA, 2001, J AM ACAD DERMATOL, V44, P425, DOI 10.1067/mjd.2001.112919; Gauthier Y, 2003, BRIT J DERMATOL, V148, P95, DOI 10.1046/j.1365-2133.2003.05024.x; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Grossman D, 1999, LAB INVEST, V79, P1121; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; Grossman D, 2001, J CLIN INVEST, V108, P991, DOI 10.1172/JCI200113345; Hou Z, 2004, MUTAT RES-FUND MOL M, V555, P3, DOI 10.1016/j.mrfmmm.2004.06.040; Hsieh TC, 1999, EXP CELL RES, V249, P109, DOI 10.1006/excr.1999.4471; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Kapadia GJ, 2002, PHARMACOL RES, V45, P499, DOI 10.1006/phrs.2002.0992; Katiyar SK, 1997, JNCI-J NATL CANCER I, V89, P556, DOI 10.1093/jnci/89.8.556; KLIGMAN LH, 1981, JNCI-J NATL CANCER I, V67, P1289; Kopp P, 1998, EUR J ENDOCRINOL, V138, P619, DOI 10.1530/eje.0.1380619; KUFLIK AS, 1994, AM FAM PHYSICIAN, V49, P817; Lo Muzio L, 2001, EXP MOL PATHOL, V70, P249, DOI 10.1006/exmp.2001.2367; Matsumura Y, 2004, TOXICOL APPL PHARM, V195, P298, DOI 10.1016/j.taap.2003.08.019; Matsumura Y, 2002, FRONT BIOSCI-LANDMRK, V7, pD765, DOI 10.2741/matsumur; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Mittal A, 2003, CARCINOGENESIS, V24, P1379, DOI 10.1093/carcin/bgg095; Nahm Walter K, 2004, J Drugs Dermatol, V3, P209; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Ortonne JP, 2002, BRIT J DERMATOL, V146, P20, DOI 10.1046/j.1365-2133.146.s61.6.x; Reagan-Shaw S, 2004, ONCOGENE, V23, P5151, DOI 10.1038/sj.onc.1207666; SOEHNGE H, 1997, FRONT BIOSCI, V2, P538; Soleas GJ, 2002, CLIN BIOCHEM, V35, P119, DOI 10.1016/S0009-9120(02)00275-8; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; STEWARD BW, 2004, REDUCTION EXPOSURE U, P141; Sun AY, 2002, FREE RADICAL BIO MED, V32, P314, DOI 10.1016/S0891-5849(01)00803-6; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Tsao AS, 2004, CA-CANCER J CLIN, V54, P150, DOI 10.3322/canjclin.54.3.150; VONBREUCKMANN F, 2002, ARCH DERMATOL RES, V294, P303; Wall NR, 2003, CANCER RES, V63, P230	59	165	174	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1193	+		10.1096/fj.04-3582fje	http://dx.doi.org/10.1096/fj.04-3582fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15837718				2022-12-28	WOS:000228865300011
J	Bezaire, V; Spriet, LL; Campbell, S; Sabet, N; Gerrits, M; Bonen, A; Harper, ME				Bezaire, V; Spriet, LL; Campbell, S; Sabet, N; Gerrits, M; Bonen, A; Harper, ME			Constitutive UCP3 overexpression at physiological levels increases mouse skeletal muscle capacity for fatty acid transport and oxidation	FASEB JOURNAL			English	Article						metabolic efficiency; fat oxidation; thermogenesis	HUMAN UNCOUPLING PROTEIN-3; CARNITINE PALMITOYLTRANSFERASE-I; HORMONE-SENSITIVE LIPASE; HIGH-ENERGY PHOSPHATES; BROWN ADIPOSE-TISSUE; THYROID-HORMONE; INCREASED EXPRESSION; MESSENGER-RNA; UP-REGULATION; MALONYL-COA	Uncoupling protein 3 (UCP3) expression is directly correlated to fatty acid oxidation in skeletal muscle. UCP3 has been hypothesized to facilitate high rates of fatty acid oxidation, but evidence thus far is lacking. Our aim was to investigate the effects of UCP3 overexpression and ablation on fatty acid uptake and metabolism in muscle of mice having congenic backgrounds. In mice constitutively expressing the UCP3 protein (human form) at levels just over twofold higher than normal (230% of wild-type levels), indirect calorimetry demonstrated no differences in total energy expenditure (VO2), but a shift toward increased fat oxidation compared with wild-type (WT) mice. Metabolic efficiency (gram weight gain/kcal ingested) was similar between Ucp3 overexpressors, WT and Ucp3 (-/-) mice. In muscle of Ucp3-tg mice, plasma membrane fatty acid binding protein (FABPpm) content was increased compared with WT mice. Although hormone-sensitive lipase activity was unchanged across the genotypes, there were increases in carnitine palmitoyltransferase I, beta-hydroxyacylCoA dehydrogenase, and citrate synthase activities and decreases in intramuscular triacylglycerol in muscle of Ucp3-tg mice. There were no differences in muscle mitochondrial content. High-energy phosphates and total muscle carnitine and CoA were also greater in Ucp3-tg compared with WT mice. Taken together, the findings demonstrate an increased capacity for fat oxidation in the absence of significant increases in thermogenesis in Ucp3-tg mice. Findings from Ucp3 (-/-) mice revealed few differences compared with WT mice, consistent with the possibility of compensatory mechanisms. In conjunction with our observed increases in CoA and carnitine in muscle of Ucp3 overexpressors, the findings support the hypothesized role for Ucp3 in facilitating fatty acid oxidation in muscle.	Univ Ottawa, Fac Med, Ottawa, ON, Canada; Univ Guelph, Dept Human Biol & Nutr Sci, Guelph, ON N1G 2W1, Canada	University of Ottawa; University of Guelph	Harper, ME (corresponding author), Univ Ottawa, Fac Med, Ottawa, ON, Canada.	MaryEllen.Harper@uottawa.ca		Harper, Mary-Ellen/0000-0003-3864-5886				ALEXSON SEH, 1988, J BIOL CHEM, V263, P13564; Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; BERGMEYER HU, 1974, METHODS ENZYMATIC AN; Berthon PM, 1998, J APPL PHYSIOL, V85, P148, DOI 10.1152/jappl.1998.85.1.148; Bezaire V, 2001, AM J PHYSIOL-ENDOC M, V281, pE975, DOI 10.1152/ajpendo.2001.281.5.E975; Bonen A, 2003, ACTA PHYSIOL SCAND, V178, P347, DOI 10.1046/j.1365-201X.2003.01157.x; Boss O, 1998, J BIOL CHEM, V273, P5, DOI 10.1074/jbc.273.1.5; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; CEDERBLAD G, 1990, ANAL BIOCHEM, V185, P274, DOI 10.1016/0003-2697(90)90292-H; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; CONTE A, 1991, INT J TISSUE REACT, V13, P33; Cortright RN, 1999, AM J PHYSIOL-ENDOC M, V276, pE217, DOI 10.1152/ajpendo.1999.276.1.E217; Eaton S, 2001, BIOCHEM SOC T, V29, P245, DOI 10.1042/BST0290245; EATON S, 1999, CURRENT VIEWS FATTY; EDSTROM L, 1982, J PHYSIOL-LONDON, V332, P47, DOI 10.1113/jphysiol.1982.sp014399; FRAYN KN, 1980, J LIPID RES, V21, P139; Garcia-Martinez C, 2001, FASEB J, V15, P2033, DOI 10.1096/fj.00-0828fje; Gong DW, 1999, BIOCHEM BIOPH RES CO, V256, P27, DOI 10.1006/bbrc.1999.0239; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; Harper JA, 2002, BIOCHEM J, V361, P49, DOI 10.1042/0264-6021:3610049; Harper ME, 2002, DIABETES, V51, P2459, DOI 10.2337/diabetes.51.8.2459; HARRIS RC, 1974, SCAND J CLIN LAB INV, V33, P109; Himms-Hagen J, 2001, EXP BIOL MED, V226, P78, DOI 10.1177/153537020122600204; Hinz W, 1999, FEBS LETT, V462, P411, DOI 10.1016/S0014-5793(99)01568-9; HOLLOSZY JO, 1967, J BIOL CHEM, V242, P2278; HORIE S, 1986, J BIOCHEM, V99, P1345, DOI 10.1093/oxfordjournals.jbchem.a135602; KUSHMERICK MJ, 1992, P NATL ACAD SCI USA, V89, P7521, DOI 10.1073/pnas.89.16.7521; Langfort J, 1998, ADV EXP MED BIOL, V441, P219; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; Millet L, 1997, J CLIN INVEST, V100, P2665, DOI 10.1172/JCI119811; Moore GBT, 2001, BIOCHEM BIOPH RES CO, V283, P785, DOI 10.1006/bbrc.2001.4848; Moreno M, 2003, FASEB J, V17, P1112, DOI 10.1096/fj.02-0839fje; Nagase I, 1999, FEBS LETT, V461, P319, DOI 10.1016/S0014-5793(99)01477-5; Ruderman NB, 2003, ENDOCRINOLOGY, V144, P5166, DOI 10.1210/en.2003-0849; Russell AP, 2003, PFLUG ARCH EUR J PHY, V445, P563, DOI 10.1007/s00424-002-0943-5; Samec S, 2002, PFLUG ARCH EUR J PHY, V445, P80, DOI 10.1007/s00424-002-0879-9; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; Schrauwen P, 2004, INT J OBESITY, V28, P824, DOI 10.1038/sj.ijo.0802629; Schrauwen P, 2003, FASEB J, V17, P2272, DOI 10.1096/fj.03-0515fje; Schrauwen P, 2001, FASEB J, V15, P2497, DOI 10.1096/fj.01-0400hyp; Short KR, 2001, AM J PHYSIOL-ENDOC M, V280, pE761, DOI 10.1152/ajpendo.2001.280.5.E761; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; Son C, 2004, DIABETOLOGIA, V47, P47, DOI 10.1007/s00125-003-1272-8; SRERE PA, 1969, ARCH BIOCHEM BIOPHYS, V129, P708, DOI 10.1016/0003-9861(69)90231-8; STAVINOHA MA, 2004, IN PRESS AM J PHYSL; Stuart JA, 2001, BIOCHEM J, V356, P779, DOI 10.1042/0264-6021:3560779; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; Wang S, 2003, DIABETES OBES METAB, V5, P295, DOI 10.1046/j.1463-1326.2003.00273.x; Watt MJ, 2003, J PHYSIOL-LONDON, V547, P301, DOI 10.1113/jphysiol.2002.034595; Zhang CY, 1999, FEBS LETT, V449, P129, DOI 10.1016/S0014-5793(99)00441-X	52	108	117	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2005	19	6					977	+		10.1096/fj.04-2765fje	http://dx.doi.org/10.1096/fj.04-2765fje			30	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15814607				2022-12-28	WOS:000228865300026
J	Wang, HW; Babic, AM; Mitchell, HA; Liu, K; Wagner, DD				Wang, HW; Babic, AM; Mitchell, HA; Liu, K; Wagner, DD			Elevated soluble ICAM-1 levels induce immune deficiency and increase adiposity in mice	FASEB JOURNAL			English	Article						adhesion molecule; inflammation; contact hypersensitivity; obesity	INTERCELLULAR-ADHESION MOLECULE-1; ISCHEMIA-REPERFUSION INJURY; TUMOR-NECROSIS-FACTOR; LEUKOCYTE ADHESION; INSULIN-RESISTANCE; LANGERHANS CELLS; OBESITY; ANTIBODIES; ANTI-ICAM-1; EXPRESSION	Elevated soluble intercellular adhesion molecule-1 (sICAM-1) levels have been found in many pathological conditions, including obesity. To determine the effects of elevated sICAM-1 on immune responses and metabolism, we generated a transgenic mouse model overexpressing the extracellular domain of mouse ICAM-1 in the liver. The mice, showing 10-fold higher sICAM-1 levels than wild-type mice, presented elevated neutrophil count. Despite this, after intraperitoneal injection of thioglycollate, neutrophil recruitment into the peritoneal cavity was reduced, and the delayed macrophage recruitment was also affected in the transgenic mice compared with wildtype mice. Inhibition of contact hypersensitivity response in the sICAM-1 transgenic mice was comparable to ICAM-1-deficient mice and characterized by significantly less ear swelling and inflammatory cell infiltration than in wild-type mice. sICAM-1transgenic mice were more susceptible to weight gain on a Western-type diet than wild-type mice, and older animals showed excessive fat accumulation, again reminiscent of ICAM-1-deficient mice. Together, these data indicate that sICAM-1 interferes with ICAM-1-mediated cell-cell interactions, which could produce immune-suppressant effects and alteration of metabolism in persons with high levels of this soluble adhesion receptor.	CBR Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Harvard Medical School	Wagner, DD (corresponding author), CBR Inst Biomed Res, 800 Huntington Ave, Boston, MA 02115 USA.	Wagner@cbr.med.harvard.edu			NHLBI NIH HHS [R37 HL041002, R01 HL53756, R01 HL053756, R37 HL41002] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053756, R37HL041002] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BABIC AM, 2004, IN PRESS MOL MED; Bertry-Coussot L, 2002, J IMMUNOL, V168, P3641, DOI 10.4049/jimmunol.168.7.3641; Biancone L, 1996, J EXP MED, V183, P581, DOI 10.1084/jem.183.2.581; Capra F, 2000, J INFECT DIS, V181, P425, DOI 10.1086/315265; Dong ZM, 1997, P NATL ACAD SCI USA, V94, P7526, DOI 10.1073/pnas.94.14.7526; DUSTIN ML, 1988, J EXP MED, V167, P1323, DOI 10.1084/jem.167.4.1323; Gadek TR, 2002, SCIENCE, V295, P1086, DOI 10.1126/science.295.5557.1086; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; Ito H, 2002, CLIN EXP PHARMACOL P, V29, P399, DOI 10.1046/j.1440-1681.2002.03672.x; KING PD, 1995, J IMMUNOL, V154, P6080; Kumasaka T, 1996, J CLIN INVEST, V97, P2362, DOI 10.1172/JCI118679; Kusterer K, 1998, AM J PHYSIOL-GASTR L, V275, pG377, DOI 10.1152/ajpgi.1998.275.2.G377; Lamas O, 2002, EUR J CLIN NUTR, V56, pS42, DOI 10.1038/sj.ejcn.1601484; Leinonen E, 2003, ATHEROSCLEROSIS, V166, P387, DOI 10.1016/S0021-9150(02)00371-4; Liao F, 1999, J IMMUNOL, V163, P5640; MA J, 1994, CELL IMMUNOL, V158, P389, DOI 10.1006/cimm.1994.1285; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; Matarese G, 2004, TRENDS IMMUNOL, V25, P193, DOI 10.1016/j.it.2004.02.009; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; Moore SI, 2003, INFECT IMMUN, V71, P4182, DOI 10.1128/IAI.71.7.4182-4185.2003; Nieman DC, 1999, J AM DIET ASSOC, V99, P294, DOI 10.1016/S0002-8223(99)00077-2; POBER JS, 1987, J IMMUNOL, V138, P3319; Ridker PM, 1998, LANCET, V351, P88, DOI 10.1016/S0140-6736(97)09032-6; Shahi CN, 1997, AM J CARDIOL, V79, P980, DOI 10.1016/S0002-9149(97)00027-1; Shapiro S, 2003, J NEUROL SCI, V206, P43, DOI 10.1016/S0022-510X(02)00317-9; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Straczkowski M, 2002, METABOLISM, V51, P75, DOI 10.1053/meta.2002.28095; Tedla N, 1998, J IMMUNOL, V161, P5663; UCHIKOSHI F, 1995, TRANSPLANT P, V27, P1527; van den Engel NK, 2000, BLOOD, V95, P1350, DOI 10.1182/blood.V95.4.1350.004k07_1350_1355; vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069; VOLLMAR B, 1995, SURGERY, V117, P195, DOI 10.1016/S0039-6060(05)80085-6; Wang HW, 2002, J IMMUNOL, V169, P5145, DOI 10.4049/jimmunol.169.9.5145; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; Wellen KE, 2003, J CLIN INVEST, V112, P1785, DOI 10.1172/JCI20514; Weyer C, 2002, ATHEROSCLEROSIS, V161, P233, DOI 10.1016/S0021-9150(01)00626-8; Wu KK, 2003, CIRCULATION, V107, P1729, DOI 10.1161/01.CIR.0000064894.97094.4F; Xu H, 2001, EUR J IMMUNOL, V31, P3085, DOI 10.1002/1521-4141(2001010)31:10<3085::AID-IMMU3085>3.0.CO;2-B; XU H, 1994, J EXP MED, V180, P95, DOI 10.1084/jem.180.1.95	43	34	35	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1018	+		10.1096/fj.04-3094fje	http://dx.doi.org/10.1096/fj.04-3094fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15817637				2022-12-28	WOS:000228865300020
J	York, B; Lou, DY; Panettieri, RA; Krymskaya, VP; Vanaman, TC; Noonan, DJ				York, B; Lou, DY; Panettieri, RA; Krymskaya, VP; Vanaman, TC; Noonan, DJ			Cross-talk between tuberin, calmodulin, and estrogen signaling pathways	FASEB JOURNAL			English	Article						lymphangioleiomyomatosis; tuberous sclerosis; hamartin; estrogen receptor alpha	SCLEROSIS; HAMARTIN; RECEPTOR; GENE; PHOSPHORYLATION; ACTIVATION; PROTEINS; LYMPHANGIOLEIOMYOMATOSIS; KINASE; TSC2	Lymphangioleiomyomatosis (LAM) is a rare disease that occurs primarily in women and has been linked to both estrogen-mediated signaling events and mutations associated with the tuberous sclerosis complex 2 gene product tuberin. These two observations fostered the hypothesis that tuberin's impact on estrogen-mediated signaling might be through a direct interaction with the intracellular receptor for estrogen, estrogen receptor alpha (ER alpha). In the study presented here, tuberin was shown to co-immunoprecipitate and directly bind ER alpha through a domain localized within the carboxyl 73 amino acids of tuberin. This domain had previously been shown to serve as a binding domain for the intracellular calcium signaling molecule calmodulin (CaM). Competition binding studies identified a potential competitive relationship for binding of tuberin by ER alpha and CaM. Additionally, tuberin-ER alpha interactions were found to be modulated by the presence of tuberin's predominant intracellular binding partner hamartin, suggesting that tuberin-hamartin interactions negatively impact the ability of tuberin to modulate ER alpha-mediated gene transcription events. Cumulatively, data presented here support the hypothesis that interactions between tuberin, ER alpha, and CaM may play a critical role in the pathology of LAM disease.	Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Kentucky; University of Pennsylvania	Noonan, DJ (corresponding author), Univ Kentucky, Dept Mol & Cellular Biochem, 800 Rose St, Lexington, KY 40536 USA.	dnoonan@pop.uky.edu	panettieri, reynold/AAG-9485-2019		NHLBI NIH HHS [R01 HL055301, P50 HL067663, HL64063, HL071106, HL67321, R01 HL071106, HL55301, R01 HL067321, P01 HL067663, HL67663, R01 HL064063] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055301, R01HL064063, P01HL067663, R01HL071106, R01HL067321, P50HL067663] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aicher LD, 2001, J BIOL CHEM, V276, P21017, DOI 10.1074/jbc.C100136200; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Barkhem Tomas, 2004, Am J Pharmacogenomics, V4, P19, DOI 10.2165/00129785-200404010-00003; Biswas DK, 1998, J BIOL CHEM, V273, P33817, DOI 10.1074/jbc.273.50.33817; Carafoli E, 1999, CALCIUM CELLULAR REG; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Finlay GA, 2004, J BIOL CHEM, V279, P23114, DOI 10.1074/jbc.M401912200; Flores-Delgado G, 2003, MOL CELL ENDOCRINOL, V199, P143, DOI 10.1016/S0303-7207(02)00288-5; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Gomez MR, 1988, TUBEROUS SCLEROSIS; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Govind AP, 2003, MOL CELL BIOCHEM, V253, P233, DOI 10.1023/A:1026068017309; Henry II Kenneth W, 2003, Nucl Recept, V1, P7, DOI 10.1186/1478-1336-1-7; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jadeski LC, 2000, INT J CANCER, V86, P30, DOI 10.1002/(SICI)1097-0215(20000401)86:1<30::AID-IJC5>3.0.CO;2-I; JAMIESON GA, 1979, BIOCHEM BIOPH RES CO, V90, P1048, DOI 10.1016/0006-291X(79)91932-6; Krymskaya VP, 2003, CELL SIGNAL, V15, P729, DOI 10.1016/S0898-6568(03)00040-8; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Li L, 2003, J BIOL CHEM, V278, P1195, DOI 10.1074/jbc.M210708200; Li ZG, 2001, J BIOL CHEM, V276, P17354, DOI 10.1074/jbc.M010238200; Lou Dingyuan, 2001, Molecular Cell Biology Research Communications, V4, P374, DOI 10.1006/mcbr.2001.0307; Murthy V, 2000, AM J PHYSIOL-RENAL, V278, pF737; Nellist M, 2001, HUM MOL GENET, V10, P2889, DOI 10.1093/hmg/10.25.2889; Noonan DJ, 2002, ARCH BIOCHEM BIOPHYS, V398, P132, DOI 10.1006/abbi.2001.2682; Pacheco-Rodriguez G, 2002, CHEST, V121, p56S, DOI 10.1378/chest.121.3_suppl.56S; Pedrero JMG, 2002, MOL ENDOCRINOL, V16, P947; POVEY S, 1994, ANN HUM GENET, V58, P107, DOI 10.1111/j.1469-1809.1994.tb01881.x; ROBERTS PS, 2002, NEW PROSPECTIVES TUB; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; WATTERSON DM, 1976, J BIOL CHEM, V251, P4501; Yamamoto Y, 2002, ARCH BIOCHEM BIOPHYS, V404, P210, DOI 10.1016/S0003-9861(02)00300-4; YU J, 2003, AM J PHYSL LUNG CELL	36	21	22	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2005	19	6					1202	+		10.1096/fj.04-3142fje	http://dx.doi.org/10.1096/fj.04-3142fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15851513				2022-12-28	WOS:000228865300008
J	Li, Y; Zhou, WH; Tong, YG; He, GQ; Song, WH				Li, Yu; Zhou, Weihui; Tong, Yigang; He, Guiqiong; Song, Weihong			Control of APP processing and A beta generation level by BACE1 enzymatic activity and transcription	FASEB JOURNAL			English	Article						BACE1; secretase; transcription; APP processing; amyloid beta; Alzheimer's disease	AMYLOID PRECURSOR PROTEIN; CLEAVING ENZYME; SECRETASE PROTEIN; ASPARTYL PROTEASE; SITE; CLEAVAGE; EXPRESSION; INCREASES; PRESENILIN-1; MATURATION	Deposition of amyloid beta protein (A beta) is one of the characteristic features of Alzheimer's disease (AD) neuropathology. Beta-secretase, a beta-site APP cleaving enzyme 1 (BACE1), is essential for A beta biosynthesis. Although inhibition of BACE1 is considered a valid therapeutic target for AD, the enzymatic dynamics of BACE1 in regulating APP processing and A beta generation has not yet been fully defined. To examine this issue, tightly controlled inducible BACE1 gene expression was established in the neuronal cell line N2ABP1 and the non-neuronal cell line E2BP1 using an ecdysone-inducible system. The BACE1 protein level was increased in a time- and dosage-dependent manner in the inducible BACE1 stable cells by treatment with inducer ponasterone A. The generation of APP CTF beta, the beta-secretase product, increased proportionally with the level of BACE1 protein expression. However, A beta 40/42 production sharply increased to the plateau level with a relatively small increase in BACE1 expression. Although further increasing BACE1 expression increased beta-secretase activity, it had no additional effect on A beta production. Furthermore, we found that BACE1 mRNA levels and BACE1 promoter activity were significantly lower than APP mRNA levels and APP promoter activity. Our data demonstrate that lower BACE transcription is responsible for the minority of APP undergoing the amyloidogenic pathway and relatively lower A beta production in the normal conditions, and that a slight increase in BACE1 can induce a dramatic elevation in A beta production, indicating that the increase in BACE1 can potentially increase neuritic plaque formation in the pathological condition.	Univ British Columbia, Dept Psychiat, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada; Chongqing Univ Med Sci, Dept Pathol, Chongqing, Peoples R China; Chongqing Univ Med Sci, Dept Anat, Chongqing, Peoples R China	University of British Columbia; Chongqing Medical University; Chongqing Medical University	Song, WH (corresponding author), Univ British Columbia, Dept Psychiat, Brain Res Ctr, 2255 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	weihong@interchange.ubc.ca	Song, Weihong/O-7623-2017	Song, Weihong/0000-0001-9928-889X; Tong, Yigang/0000-0002-8503-8045				Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Bodendorf U, 2002, J NEUROCHEM, V80, P799, DOI 10.1046/j.0022-3042.2002.00770.x; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Charlwood J, 2001, J BIOL CHEM, V276, P16739, DOI 10.1074/jbc.M009361200; Christensen MA, 2004, MOL CELL BIOL, V24, P865, DOI 10.1128/MCB.24.2.865-874.2004; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Cruts M, 2001, NEUROSCI LETT, V313, P105, DOI 10.1016/S0304-3940(01)02234-0; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Fukumoto H, 2004, AM J PATHOL, V164, P719, DOI 10.1016/S0002-9440(10)63159-8; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; HE W, 2004, NAT MED; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Huse JT, 2003, J BIOL CHEM, V278, P17141, DOI 10.1074/jbc.M213303200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Hussain I, 2003, J BIOL CHEM, V278, P36264, DOI 10.1074/jbc.M304186200; Kao SC, 2004, J BIOL CHEM, V279, P1942, DOI 10.1074/jbc.M309219200; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; Li QM, 2004, J BIOL CHEM, V279, P10542, DOI 10.1074/jbc.M310001200; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Nicolaou M, 2001, NEUROGENETICS, V3, P203; Ohno M, 2004, NEURON, V41, P27, DOI 10.1016/S0896-6273(03)00810-9; Pastorino L, 2004, MOL CELL NEUROSCI, V25, P642, DOI 10.1016/j.mcn.2003.12.013; Qing H, 2004, FASEB J, V18, P1571, DOI 10.1096/fj.04-1994fje; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Russo C, 2000, NATURE, V405, P531, DOI 10.1038/35014735; Schmechel A, 2004, J BIOL CHEM, V279, P39710, DOI 10.1074/jbc.M402785200; Shi XP, 2001, J BIOL CHEM, V276, P10366, DOI 10.1074/jbc.M009200200; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Sun XL, 2005, FASEB J, V19, P739, DOI 10.1096/fj.04-3426com; Tong Y, 2005, J NEURAL TRANSM, V112, P455, DOI 10.1007/s00702-004-0255-3; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; von Arnim CAF, 2005, J BIOL CHEM, V280, P17777, DOI 10.1074/jbc.M414248200; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Westmeyer GG, 2004, J BIOL CHEM, V279, P53205, DOI 10.1074/jbc.M410378200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	46	106	159	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					285	292		10.1096/fj.05-4986com	http://dx.doi.org/10.1096/fj.05-4986com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449801				2022-12-28	WOS:000237698700014
J	Liu, JB; Chen, QH; Huang, W; Horak, KM; Zheng, HQ; Mestril, R; Wang, XJ				Liu, Jinbao; Chen, Quanhai; Huang, Wei; Horak, Kathleen M.; Zheng, Hanqiao; Mestril, Ruben; Wang, Xuejun			Impairment of the ubiquitin-proteasome system in desminopathy mouse hearts	FASEB JOURNAL			English	Article									[Liu, Jinbao; Chen, Quanhai; Huang, Wei; Horak, Kathleen M.; Zheng, Hanqiao; Wang, Xuejun] Univ S Dakota, Sch Med, Cardiovasc Res Inst, S Dakota Hlth Res Fdn, Sioux Falls, SD 57105 USA; [Liu, Jinbao; Chen, Quanhai; Huang, Wei; Horak, Kathleen M.; Zheng, Hanqiao; Wang, Xuejun] Sioux Valley Hosp & Hlth Syst, Sioux Falls, SD USA; [Liu, Jinbao] Guangzhou Med Coll, Dept Pathophysiol, Guangzhou, Guangdong, Peoples R China; [Huang, Wei] Nanjing Med Univ, Cardiovasc Res Inst, Nanjing, Jiangsu, Peoples R China; [Mestril, Ruben] Loyola Univ, Med Ctr, Cardiovasc Inst, Maywood, IL 60153 USA	University of South Dakota; Guangzhou Medical University; Nanjing Medical University; Loyola University Chicago	Wang, XJ (corresponding author), Univ S Dakota, Sch Med, Cardiovasc Res Inst, S Dakota Hlth Res Fdn, 1100 E 21st St,Suite 700, Sioux Falls, SD 57105 USA.	xwang@usd.edu	Wang, Xuejun/K-8874-2013; Wang, Xuejun/AAT-9490-2021	Wang, Xuejun/0000-0001-9267-1343; Wang, Xuejun/0000-0001-9267-1343; Mestril, Ruben/0000-0003-3631-2236	NHLBI NIH HHS [R01 HL072166, R01-HL-72166] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072166] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))			0	113	116	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					362	364		10.1096/fj.05-4869fje	http://dx.doi.org/10.1096/fj.05-4869fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16371426				2022-12-28	WOS:000207915000022
J	Neumann, J; Gunzer, M; Gutzeit, HO; Ullrich, O; Reymann, KG; Dinkel, K				Neumann, Jens; Gunzer, Matthias; Gutzeit, Herwig O.; Ullrich, Oliver; Reymann, Klaus G.; Dinkel, Klaus			Microglia provide neuroprotection after ischemia	FASEB JOURNAL			English	Article						neuroinflammation; stroke; organotypic cultures; two-photon microscopy; CD11a integrin	INTRACEREBROVENTRICULAR INJECTION; SLICE CULTURES; CELLS MIGRATE; RAT; INJURY; INFLAMMATION; MACROPHAGES; STROKE; NEUROTOXICITY; CYTOTOXICITY	Many neurological insults are accompanied by a marked acute inflammatory reaction, involving the activation of microglia. Using a model of exogenous application of fluorescence-labeled BV2 microglia in pathophysiologically relevant concentrations onto organotypic hippocampal slice cultures, we investigated the specific effects of microglia on neuronal damage after ischemic injury. Neuronal cell death after oxygen-glucose deprivation (OGD) was determined by propidium iodide incorporation and Nissl staining. Migration and interaction with neurons were analyzed by time resolved 3-D two-photon microscopy. We show that microglia protect against OGD-induced neuronal damage and engage in close physical cell-cell contact with neurons in the damaged brain area. Neuroprotection and migration of microglia were not seen with integrin regulator CD11a-deficient microglia or HL-60 granulocytes. The induction of migration and neuron-microglia interaction deep inside the slice was markedly increased under OGD conditions. Lipopolysaccharide-prestimulated microglia failed to provide neuroprotection after OGD. Pharmacological interference with microglia function resulted in a reduced neuroprotection. Microglia proved to be neuroprotective even when applied up to 4 h after OGD, thus defining a "protective time window." In acute injury such as trauma or stroke, appropriately activated microglia may primarily have a neuroprotective role. Anti-inflammatory treatment within the protective time window of microglia would therefore be counterintuitive.	FAN gGmbH, Inst Appl Neurosci, D-39120 Magdeburg, Germany; German Res Ctr Biotechnol, Res Grp Immunodynam, D-38124 Braunschweig, Germany; Tech Univ Dresden, Inst Zool, D-8027 Dresden, Germany; Univ Hosp Magdeburg, Inst Immunol, D-39120 Magdeburg, Germany; Leibniz Inst Neurobiol, Project Grp Neuropharmacol, D-39118 Magdeburg, Germany	Helmholtz Association; Helmholtz-Center for Infection Research; Technische Universitat Dresden; University Hospital Magdeburg; Leibniz Institut fur Neurobiologie (LIN)	Dinkel, K (corresponding author), Jerini AG, Invalidenstr 130, D-10115 Berlin, Germany.	dinkel@jerini.com	Reymann, Klaus G/J-8507-2013; Gunzer, Matthias/AAW-7026-2021	Gunzer, Matthias/0000-0002-5534-6055				BANATI RB, 1994, DEV NEUROSCI-BASEL, V16, P114, DOI 10.1159/000112098; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Batchelor PE, 1999, J NEUROSCI, V19, P1708; Bonde C, 2002, NEUROSCI LETT, V327, P49, DOI 10.1016/S0304-3940(02)00382-8; Czapiga M, 1999, J NEUROSCI RES, V56, P644, DOI 10.1002/(SICI)1097-4547(19990615)56:6<644::AID-JNR10>3.0.CO;2-9; del Zoppo GJ, 2001, ARCH NEUROL-CHICAGO, V58, P669, DOI 10.1001/archneur.58.4.669; Diestel A, 2003, J EXP MED, V198, P1729, DOI 10.1084/jem.20030975; Dinkel K, 2004, P NATL ACAD SCI USA, V101, P331, DOI 10.1073/pnas.0303510101; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; DOWDING AJ, 1991, GLIA, V4, P345, DOI 10.1002/glia.440040403; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; FEUERSTEIN G, 1998, CEREBROVASCULAR DIS; Feuerstein GZ, 2001, ARCH NEUROL-CHICAGO, V58, P672, DOI 10.1001/archneur.58.4.672; Gahwiler BH, 1997, TRENDS NEUROSCI, V20, P471, DOI 10.1016/S0166-2236(97)01122-3; GIULIAN D, 1993, J NEUROSCI, V13, P29; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; Hailer NP, 1997, EUR J NEUROSCI, V9, P863, DOI 10.1111/j.1460-9568.1997.tb01436.x; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Heppner FL, 1998, EUR J NEUROSCI, V10, P3284, DOI 10.1046/j.1460-9568.1998.00379.x; Jiang N, 1995, ANN NEUROL, V38, P935, DOI 10.1002/ana.410380615; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Kim WK, 1998, J NEUROSCI RES, V54, P17, DOI 10.1002/(SICI)1097-4547(19981001)54:1<17::AID-JNR3>3.0.CO;2-K; Kipnis J, 2004, P NATL ACAD SCI USA, V101, P14663, DOI 10.1073/pnas.0404842101; Kitamura Y, 2005, J PHARMACOL SCI, V97, P289, DOI 10.1254/jphs.SC0040129; Kitamura Y, 2004, J PHARMACOL SCI, V94, P203, DOI 10.1254/jphs.94.203; Kohl A, 2003, EXP NEUROL, V181, P1, DOI 10.1016/S0014-4886(02)00049-3; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Laskowski A, 2005, BRAIN RES, V1037, P78, DOI 10.1016/j.brainres.2004.12.035; Lee JC, 2005, GLIA, V50, P168, DOI 10.1002/glia.20164; Lu YZ, 2005, NEUROSCI LETT, V373, P159, DOI 10.1016/j.neulet.2004.10.004; MALLAT M, 1989, DEV BIOL, V133, P309, DOI 10.1016/0012-1606(89)90322-9; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Mitrasinovic OM, 2005, J NEUROSCI, V25, P4442, DOI 10.1523/JNEUROSCI.0514-05.2005; Mizuno T, 1999, BRAIN RES, V849, P58, DOI 10.1016/S0006-8993(99)01984-8; MORIOKA T, 1991, J CEREBR BLOOD F MET, V11, P966, DOI 10.1038/jcbfm.1991.162; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Petrault O, 2005, BRIT J PHARMACOL, V144, P1051, DOI 10.1038/sj.bjp.0706124; Polazzi E, 2002, REV NEUROSCIENCE, V13, P221; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Rogove AD, 1998, CURR BIOL, V8, P19, DOI 10.1016/S0960-9822(98)70016-8; Shaked I, 2005, J NEUROCHEM, V92, P997, DOI 10.1111/j.1471-4159.2004.02954.x; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; STREIT WJ, 1992, NEUROREPORT, V3, P146, DOI 10.1097/00001756-199202000-00006; THERY C, 1993, CLIN NEUROPATHOL, V12, P288; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769	48	216	234	0	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					714	+		10.1096/fj.05-4882fje	http://dx.doi.org/10.1096/fj.05-4882fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16473887				2022-12-28	WOS:000237698700024
J	Rodriguez, M; Zoecklein, L; Gamez, JD; Pavelko, KD; Papke, LM; Nakane, S; Howe, C; Radhakrishnan, S; Hansen, MJ; David, CS; Warrington, AE; Pease, LR				Rodriguez, Moses; Zoecklein, Laurie; Gamez, Jeffrey D.; Pavelko, Kevin D.; Papke, Louisa M.; Nakane, Shunya; Howe, Charles; Radhakrishnan, Suresh; Hansen, Michael J.; David, Chella S.; Warrington, Arthur E.; Pease, Larry R.			STAT4-and STAT6-signaling molecules in a murine model of multiple sclerosis	FASEB JOURNAL			English	Article									[Rodriguez, Moses; Zoecklein, Laurie; Gamez, Jeffrey D.; Pavelko, Kevin D.; Papke, Louisa M.; Nakane, Shunya; Howe, Charles; Warrington, Arthur E.] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA; [Rodriguez, Moses; Radhakrishnan, Suresh; Hansen, Michael J.; David, Chella S.; Pease, Larry R.] Mayo Clin, Dept Immunol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Rodriguez, M (corresponding author), Mayo Clin, Dept Neurol, 200 1st St SW, Rochester, MN 55905 USA.	rodriguez.moses@mayo.edu	Nakane, Shunya/AAF-3715-2022; Nakane, Shunya/AFB-9194-2022; Pavelko, Kevin D/K-7072-2019	Pavelko, Kevin D/0000-0001-7555-1315; Rodriguez, Moses/0000-0001-6328-6497; Howe, Charles/0000-0002-3889-8739	NINDS NIH HHS [R01-NS-32129, R01-NS-24180, P01-NS-38468] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032129, R01NS024180, P01NS038468] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))			0	10	10	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					343	345		10.1096/fj.05-4650fje	http://dx.doi.org/10.1096/fj.05-4650fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16352646				2022-12-28	WOS:000207915000015
J	Edelson, AM				Edelson, AM			Nobel "no-shows"	FASEB JOURNAL			English	Editorial Material											Edelson, AM (corresponding author), 16 Washington Ave, Irvington, NY 10533 USA.	aedelson@verizon.net						ABRAMS I, 1991, INT C PEAC MOV NAT S; ABRAMS I, 1994, C PEAC WAR ISS GEND; BOLLES EB, 2004, EINSTEIN DEFIANT GEN, P95; Einstein A, 1950, OUT MY LATER YEARS; HOFFMANN B, 1972, A EINSTEIN CREATOR R, P149; KYI ASS, 1995, FREEDOM FEAR OTHER W, P180; MIYANMAR, 2005, NY TIMES        1129, P5; PASTERNAK B, 1958, PRIX NOBEL 1958; SAKHAROV A, 1997, PRIX NOBEL NOBEL LEC; SUHR E, 1988, C VONOSSIETZKY EINE, P243; WASSON T, 1987, NOBEL PRIZE WINNERS, P785; 1996, NY TIMES        0113, P2	12	1	1	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					3	6		10.1096/fj.06-0102ufm	http://dx.doi.org/10.1096/fj.06-0102ufm			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16394260				2022-12-28	WOS:000235996000038
J	Fineschi, S; Reith, W; Guerne, PA; Dayer, JM; Chizzolini, C				Fineschi, S; Reith, W; Guerne, PA; Dayer, JM; Chizzolini, C			Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts	FASEB JOURNAL			English	Article						fibrosis; proteasome inhibition; c-Jun	GROWTH-FACTOR-BETA; COL1A2 PROMOTER ACTIVITY; SYSTEMIC-SCLEROSIS; TGF-BETA; MATRIX-METALLOPROTEINASE; EXTRACELLULAR-MATRIX; PROCOLLAGEN GENE; PHORBOL ESTER; EXPRESSION; INDUCTION	Tissue fibrosis results when dysregulation of extracellular matrix (ECM) turnover favors deposition of collagen and other ECM proteins over degradation. Fibrosis may then lead to organ dysfunction and pathology as observed in systemic sclerosis (SSc). In the present study, we investigated the antifibrotic properties of proteasome blockade. A dose- and time-dependent reduction in type-I collagen and tissue inhibitor of metalloproteinase-1 (TIMP-1) production was observed in normal fibroblasts exposed to proteasome inhibitors ( PI). In the same culture conditions, metalloproteinase- 1 (MMP-1) protein and the collagenolytic activity on type I collagen was increased. The steady-state mRNA levels of COL1A1, TIMP-1, and MMP-1 paralleled protein levels. These effects were dominant over the profibrotic properties of TGF-beta and were observed with fibroblasts generated from normal and SSc skin. PI decreased type I collagen mRNA levels with kinetics similar to those observed with DRB, a specific RNA polymerase II inhibitor, thus indicating transcriptional inhibition. Of interest, PI induced c-Jun phosphorylation and c-Jun nuclear accumulation. The specific N-terminal Jun-kinase inhibitor SP-600125 selectively abrogated c-Jun phosphorylation and, in a dose- dependent fashion, the up-regulated synthesis of MMP-1 induced by PI. Finally, PI did not affect fibroblast viability. Thus, the coordinated down-regulation of collagen and TIMP-1 and up-regulation of MMP-1 renders proteasome blockade an attractive strategy for treating conditions as SSc, characterized by excessive fibrosis.	Geneva Univ Hosp, Geneva Sch Med, Dept Internal Med, CH-1211 Geneva 14, Switzerland; Geneva Univ Hosp, Geneva Sch Med, Dept Pathol & Immunol, CH-1211 Geneva 14, Switzerland	University of Geneva	Chizzolini, C (corresponding author), Geneva Univ Hosp, Geneva Sch Med, Dept Internal Med, CH-1211 Geneva 14, Switzerland.	chizzolini@medecine.unige.ch	Chizzolini, Carlo/V-4847-2019					Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; CHAMBERLAIN SH, 1993, J CELL BIOCHEM, V52, P337, DOI 10.1002/jcb.240520310; CHAN D, 1990, BIOCHEM J, V269, P175, DOI 10.1042/bj2690175; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Chizzolini C, 2003, ARTHRITIS RHEUM-US, V48, P2593, DOI 10.1002/art.11129; Chizzolini C, 1998, ARTHRITIS RHEUM-US, V41, P2039; Chizzolini C, 1999, SPRINGER SEMIN IMMUN, V21, P431, DOI 10.1007/BF00870304; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; Clark IM, 1997, BIOCHEM J, V324, P611, DOI 10.1042/bj3240611; Denton CP, 2001, CURR OPIN RHEUMATOL, V13, P505, DOI 10.1097/00002281-200111000-00010; Derouet M, 2004, J BIOL CHEM, V279, P26915, DOI 10.1074/jbc.M313875200; Eckes B, 1999, SPRINGER SEMIN IMMUN, V21, P415, DOI 10.1007/BF00870303; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; Elliott PJ, 2003, J MOL MED, V81, P235, DOI 10.1007/s00109-003-0422-2; Ghosh AK, 2002, EXP BIOL MED, V227, P301, DOI 10.1177/153537020222700502; Hipp MS, 2002, EUR J IMMUNOL, V32, P2208, DOI 10.1002/1521-4141(200208)32:8<2208::AID-IMMU2208>3.0.CO;2-2; Hitraya EG, 1996, ARTHRITIS RHEUM-US, V39, P1347, DOI 10.1002/art.1780390812; Hitraya EG, 1998, ARTHRITIS RHEUM-US, V41, P2048, DOI 10.1002/1529-0131(199811)41:11<2048::AID-ART21>3.0.CO;2-X; Jimenez SA, 2004, ANN INTERN MED, V140, P37, DOI 10.7326/0003-4819-140-1-200401060-00010; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Li DQ, 2004, INVEST OPHTH VIS SCI, V45, P4302, DOI 10.1167/iovs.04-0299; MACKAY AR, 1992, INVAS METAST, V12, P168; McGaha TL, 2002, ARTHRITIS RHEUM, V46, P2748, DOI 10.1002/art.10549; Medsger Jr T. A., 2001, ARTHRITIS ALLIED CON, P1590; Meiners S, 2004, HYPERTENSION, V44, P471, DOI 10.1161/01.HYP.0000142772.71367.65; Mori Y, 2003, ARTHRITIS RHEUM-US, V48, P1964, DOI 10.1002/art.11157; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakayama K, 2001, J IMMUNOL, V167, P1145, DOI 10.4049/jimmunol.167.3.1145; Philpott NJ, 1996, BLOOD, V87, P2244, DOI 10.1182/blood.V87.6.2244.bloodjournal8762244; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Sakai T, 2001, J BONE MINER RES, V16, P1272, DOI 10.1359/jbmr.2001.16.7.1272; SLACK JL, 1995, J CELL BIOCHEM, V58, P380, DOI 10.1002/jcb.240580311; Small GW, 2004, MOL PHARMACOL, V66, P1478, DOI 10.1124/mol.104.003400; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; Tashiro K, 2003, INT J MOL MED, V12, P587; Trojanowska M, 1998, J MOL MED, V76, P266, DOI 10.1007/s001090050216; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vergeer WP, 2000, ARCH BIOCHEM BIOPHYS, V377, P69, DOI 10.1006/abbi.2000.1760; Vincenti MP, 2000, METH MOL B, V151, P121, DOI 10.1385/1-59259-046-2:121; Wendling J, 2003, MOL PHARMACOL, V64, P707, DOI 10.1124/mol.64.3.707; White S.C., 2002, J INT DEV, V14, P725, DOI DOI 10.1002/JID.919; Wu HM, 2002, FEBS LETT, V526, P101, DOI 10.1016/S0014-5793(02)03151-4; Yang Y, 2004, CANCER SCI, V95, P176, DOI 10.1111/j.1349-7006.2004.tb03200.x; Yuan WH, 2001, J BIOL CHEM, V276, P38502, DOI 10.1074/jbc.M107081200; Zhang F, 2003, EXP CELL RES, V291, P275, DOI 10.1016/j.yexcr.2003.07.007	48	51	55	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					562	+		10.1096/fj.05-4870fje	http://dx.doi.org/10.1096/fj.05-4870fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16410344				2022-12-28	WOS:000235996000019
J	Mingorance, A; Sole, M; Muneton, V; Martinez, A; Nieto-Sampedro, M; Soriano, E; del Rio, JA				Mingorance, A; Sole, M; Muneton, V; Martinez, A; Nieto-Sampedro, M; Soriano, E; del Rio, JA			Regeneration of lesioned entorhino-hippocampal axons in vitro by combined degradation of inhibitory proteoglycans and blockade of Nogo-66/NgR signaling	FASEB JOURNAL			English	Article						organotypic cultures; perforant path lesion; chondroitin sulfate; axotomy	MYELIN-ASSOCIATED GLYCOPROTEIN; SPINAL-CORD-INJURY; CHONDROITIN SULFATE PROTEOGLYCANS; RECEPTOR FAMILY-MEMBER; CAJAL-RETZIUS CELLS; NOGO RECEPTOR; NEURITE OUTGROWTH; PATHWAY; CNS; REORGANIZATION	Damaged axons do not regenerate after axotomy in the adult mammalian central nervous system (CNS). This may be due to local inhibitory factors at the site of injury, such as overexpression of chondroitin sulfate (CS) proteoglycans (CSPG), and the presence of myelin-associated inhibitors (MAI). To overcome CSPG- or myelin-induced inhibition, strategies based on extrinsic and intrinsic treatments have been developed. For example, NEP1-40 is a synthetic peptide that promotes axonal regeneration by blocking Nogo-66/NgR interaction and chondroitinase ABC (ChABC), which degrades CS, thereby also promoting axon regrowth. Here, we examined whether the combination of these complementary strategies facilitates regeneration of the lesioned entorhino-hippocampal pathway (EHP) in slice cultures. In this model, overexpressed CSPG and MAI impaired axon regrowth, which mimics regeneration failure in vivo. Both CS cleavage with ChABC and NEP1-40 strongly facilitated the regrowth of entorhinal axons after axotomy, permitting the re-establishment of synaptic contacts with target cells. However, the combined treatment did not improve the regeneration induced by ChABC alone, and the delayed treatment of ChABC, but not NEP1-40, had a less pronounced effect on axonal regrowth compared with acute treatment. These results provide insight into the development of new assays and strategies to enhance axon regeneration in injured cortical connections.	Univ Barcelona, IRB PCB, Dept Cell Biol, Dev & Regenerat CNS, E-08028 Barcelona, Spain; CSIC, Inst Cajal, Regenerat CNS Unit, E-28002 Madrid, Spain; Natl Hosp Parapleg, Toledo, OH USA	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)	del Rio, JA (corresponding author), Univ Barcelona, IRB PCB, Dept Cell Biol, Dev & Regenerat CNS, Barcelona Sci Pk,Josep Samitier 1-5, E-08028 Barcelona, Spain.	jario@pcb.ub.es	Del Rio Fernandez, Jose A/AAD-1121-2020; Mingorance-Le Meur, Ana/A-7147-2008; del rio, jose antonio/L-9232-2014; Soriano, Eduardo/AAB-3216-2019	del rio, jose antonio/0000-0002-5214-4909; Soriano, Eduardo/0000-0002-3204-9285; Mingorance, Ana/0000-0002-6213-6160; Martinez, Albert/0000-0003-0831-9916				Bartsch U, 1995, NEURON, V15, P1375, DOI 10.1016/0896-6273(95)90015-2; Bechmann I, 2000, ANN NY ACAD SCI, V911, P192; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; CASTELLANO B, 1991, J HISTOCHEM CYTOCHEM, V39, P561, DOI 10.1177/39.5.1707903; del Rio JA, 2002, EUR J NEUROSCI, V15, P1881, DOI 10.1046/j.1460-9568.2002.02027.x; Deller T, 2000, ANN NY ACAD SCI, V911, P207; DelRio JA, 1997, NATURE, V385, P70, DOI 10.1038/385070a0; Fournier AE, 2003, J NEUROSCI, V23, P1416, DOI 10.1523/JNEUROSCI.23-04-01416.2003; Hasegawa Y, 2004, J NEUROSCI, V24, P6826, DOI 10.1523/JNEUROSCI.1856-04.2004; He ZG, 2004, ANNU REV NEUROSCI, V27, P341, DOI 10.1146/annurev.neuro.27.070203.144340; Ji BX, 2005, EUR J NEUROSCI, V22, P587, DOI 10.1111/j.1460-9568.2005.04241.x; Laabs T, 2005, CURR OPIN NEUROBIOL, V15, P116, DOI 10.1016/j.conb.2005.01.014; Lee DHS, 2003, NAT REV DRUG DISCOV, V2, P872, DOI 10.1038/nrd1228; Li SX, 2003, J NEUROSCI, V23, P4219; Li WW, 2004, J BIOL CHEM, V279, P43780, DOI 10.1074/jbc.M401803200; Meier S, 2003, FASEB J, V17, P1153, DOI 10.1096/fj.02-0453fje; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; Mingorance A, 2005, MOL CELL NEUROSCI, V29, P471, DOI 10.1016/j.mcn.2005.03.016; Mingorance A, 2004, MOL CELL NEUROSCI, V26, P34, DOI 10.1016/j.mcn.2004.01.001; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; Nieto-Sampedro M, 1999, ADV EXP MED BIOL, V468, P207; Park JB, 2005, NEURON, V45, P345, DOI 10.1016/j.neuron.2004.12.040; Prang P, 2001, EXP NEUROL, V169, P135, DOI 10.1006/exnr.2001.7648; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; Schwab ME, 2004, CURR OPIN NEUROBIOL, V14, P118, DOI 10.1016/j.conb.2004.01.004; Schweigreiter R, 2004, MOL CELL NEUROSCI, V27, P163, DOI 10.1016/j.mcn.2004.06.004; Shao ZH, 2005, NEURON, V45, P353, DOI 10.1016/j.neuron.2004.12.050; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sivasankaran R, 2004, NAT NEUROSCI, V7, P261, DOI 10.1038/nn1193; Steinmetz MP, 2005, J NEUROSCI, V25, P8066, DOI 10.1523/JNEUROSCI.2111-05.2005; Venkatesh K, 2005, J NEUROSCI, V25, P808, DOI 10.1523/JNEUROSCI.4464-04.2005; Vyas AA, 2002, P NATL ACAD SCI USA, V99, P8412, DOI 10.1073/pnas.072211699; Zheng BH, 2003, NEURON, V38, P213, DOI 10.1016/S0896-6273(03)00225-3	33	35	39	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					491	+		10.1096/fj.05-5121fje	http://dx.doi.org/10.1096/fj.05-5121fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16407455				2022-12-28	WOS:000235996000024
J	Mottola, A; Antoniotti, S; Lovisolo, D; Munaron, L				Mottola, A; Antoniotti, S; Lovisolo, D; Munaron, L			Regulation of noncapacitative calcium entry by arachidonic acid and nitric oxide in endothelial cells	FASEB JOURNAL			English	Article						calcium channels; proliferation; signal transduction; angiogenesis; inflammation	ACTIVATED PROTEIN-KINASE; FIBROBLAST-GROWTH-FACTOR; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE A(2); UP-REGULATION; CA2+ ENTRY; IN-VITRO; SYNTHASE; PROLIFERATION; ANGIOGENESIS	Several peptides, including vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), activate the release of arachidonic acid (AA) and nitric oxide ( NO) in endothelial cells (ECs). Both messengers are involved in EC proliferation and vascular permeability and control calcium homeostasis in different ways. Interestingly, it has been recently suggested that NO acts as a downstream mediator of AA-induced calcium entry in smooth muscle cells and isolated mouse parotid cells. In this paper, we have investigated the complex relationships that link intracellular calcium, AA, and NO in cultured endothelial cells. Using different experimental approaches, mainly simultaneous Ca2+ and NO fluorimetric confocal imaging, we provide evidence for a complex pathway leading to noncapacitative calcium entry (NCCE) in bovine aortic endothelial cells (BAECs). In particular, AA is able to induce NCCE through two different pathways: one dependent on eNOS recruitment and NO release, the other NO-independent. Finally, we show that NO increase is involved in the control of BAEC proliferation.	Univ Turin, Dept Anim & Human Biol, I-10123 Turin, Italy; Nanostruct Interfaces & Surfaces Ctr Excellence, Turin, Italy	University of Turin	Munaron, L (corresponding author), Univ Turin, Dept Anim & Human Biol, Via Accademia Albertina 13, I-10123 Turin, Italy.	luca.munaron@unito.it		munaron, luca/0000-0001-9247-4446				Ahern GP, 2002, TRENDS NEUROSCI, V25, P510, DOI 10.1016/S0166-2236(02)02254-3; Antoniotti S, 2003, J CELL PHYSIOL, V197, P370, DOI 10.1002/jcp.10359; Babaei S, 1998, CIRC RES, V82, P1007, DOI 10.1161/01.RES.82.9.1007; BARRETT KE, 1995, NEWS PHYSIOL SCI, V10, P153; Berkels R, 2000, MICROVASC RES, V59, P38, DOI 10.1006/mvre.1999.2191; Boonstra Johannes, 2003, Prog Cell Cycle Res, V5, P181; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; Cirino G, 2003, TRENDS PHARMACOL SCI, V24, P91, DOI 10.1016/S0165-6147(02)00049-4; Cooke JP, 2003, ATHEROSCLEROSIS SUPP, V4, P53, DOI 10.1016/S1567-5688(03)00034-5; DETHLEFSEN SM, 1994, EXP CELL RES, V212, P262, DOI 10.1006/excr.1994.1142; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; Fleming I, 1999, CARDIOVASC RES, V43, P532, DOI 10.1016/S0008-6363(99)00094-2; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Goligorsky MS, 2002, AM J PHYSIOL-RENAL, V283, pF1, DOI 10.1152/ajprenal.00377.2001; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054; Isshiki M, 1999, CELL CALCIUM, V26, P201, DOI 10.1054/ceca.1999.0073; Koyama T, 2002, LIFE SCI, V72, P511, DOI 10.1016/S0024-3205(02)02246-4; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; Lin S, 2000, J BIOL CHEM, V275, P17979, DOI 10.1074/jbc.275.24.17979; Matalon S, 2003, AM J PHYSIOL-LUNG C, V285, pL1184, DOI 10.1152/ajplung.00281.2003; Meissner G, 2004, CELL CALCIUM, V35, P621, DOI 10.1016/j.ceca.2004.01.015; Moneer Z, 2003, BIOCHEM J, V370, P439, DOI 10.1042/BJ20021104; Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411; Munaron L, 2000, J CELL PHYSIOL, V185, P454, DOI 10.1002/1097-4652(200012)185:3<454::AID-JCP17>3.0.CO;2-A; Munaron L, 2004, J CELL MOL MED, V8, P161, DOI 10.1111/j.1582-4934.2004.tb00271.x; Munaron L, 2002, INT J MOL MED, V10, P671; Murohara T, 1999, ARTERIOSCL THROM VAS, V19, P1156, DOI 10.1161/01.ATV.19.5.1156; Nie DT, 2004, SEMIN THROMB HEMOST, V30, P119; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; Pilane CM, 2004, J CELL PHYSIOL, V198, P48, DOI 10.1002/jcp.10382; Pla AF, 2001, CELL CALCIUM, V30, P235, DOI 10.1054/ceca.2001.0234; Rossig L, 1999, J BIOL CHEM, V274, P6823, DOI 10.1074/jbc.274.11.6823; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; Takeuchi K, 2004, CARDIOVASC RES, V62, P194, DOI 10.1016/j.cardiores.2003.12.028; vanderZee R, 1997, CIRCULATION, V95, P1030; Wang H, 2003, J PHARMACOL EXP THER, V307, P753, DOI 10.1124/jpet.103.052787; Wang Y, 2005, J PHARMACOL EXP THER, V314, P522, DOI 10.1124/jpet.105.083477; Watson EL, 2004, CELL SIGNAL, V16, P157, DOI 10.1016/S0898-6568(03)00102-5; Wicher D, 2004, J BIOL CHEM, V279, P50410, DOI 10.1074/jbc.M405800200; Yao X, 2000, FASEB J, V14, P932, DOI 10.1096/fasebj.14.7.932; Yao XQ, 2003, TRENDS PHARMACOL SCI, V24, P263, DOI 10.1016/S0165-6147(03)00122-6; Zhang JL, 2002, AM J PHYSIOL-CELL PH, V283, pC1080, DOI 10.1152/ajpcell.00048.2002; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451; Ziche M, 1997, CIRC RES, V80, P845, DOI 10.1161/01.res.80.6.845; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557	49	32	32	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2075	+		10.1096/fj.05-4110fje	http://dx.doi.org/10.1096/fj.05-4110fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16204355				2022-12-28	WOS:000232991100030
J	Miharada, K; Hiroyama, T; Sudo, K; Nagasawa, T; Nakamura, Y				Miharada, K; Hiroyama, T; Sudo, K; Nagasawa, T; Nakamura, Y			Lipocalin 2 functions as a negative regulator of red blood cell production in an autocrine fashion	FASEB JOURNAL			English	Article						erythropoiesis; apoptosis; homeostasis	TRUNCATED ERYTHROPOIETIN RECEPTOR; GELATINASE-ASSOCIATED LIPOCALIN; HUMAN NEUTROPHIL GELATINASE; ACUTE-PHASE PROTEIN; ERYTHROID-CELLS; SOCS PROTEINS; BONE-MARROW; EXPRESSION; DEATH; NGAL	Members of the lipocalin protein family are typically small, secreted proteins that possess a variety of functions. Although the physiological role of lipocalin 2 remains to be fully elucidated, a few pivotal functions have recently been reported, e. g., regulation of the apoptosis of leukocytes. Unexpectedly, lipocalin 2 is abundantly expressed in erythroid progenitor cells. An in vitro culture experiment demonstrated that lipocalin 2 induces apoptosis and inhibits differentiation of erythroid progenitor cells. During acute anemia the expression of lipocalin 2 was reduced in erythroid cells by a feedback system. Furthermore, injection of recombinant lipocalin 2 into mice suffering from acute anemia retarded the recovery of red blood cell (RBC) numbers, suggesting the importance of reduced expression of lipocalin 2 for the efficient recovery of RBC numbers. These results indicate that lipocalin 2 suppresses RBC production in an autocrine fashion. Hence, anemia arising from pathological conditions, such as chronic inflammation, might be partly due to increased levels of lipocalin 2 secreted from expanded leukocytes and/or macrophages. Also, anemia arising from malignancies might be partly due to the abundant secretion of lipocalin 2 from tumor cells. Thus, lipocalin 2 may represent an attractive therapeutic target for anemia under certain pathological conditions.	RIKEN, BioResource Ctr, Cell Engn Div, Tsukuba, Ibaraki 3050074, Japan; Univ Tsukuba, Inst Clin Med, Div Hematol, Tsukuba, Ibaraki 305, Japan	RIKEN; University of Tsukuba	Nakamura, Y (corresponding author), RIKEN, BioResource Ctr, Cell Engn Div, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.	yukionak@brc.riken.jp	Miharada, Kenichi/C-1397-2014; Nakamura, Yukio/A-5263-2016	Miharada, Kenichi/0000-0001-8073-4001; Nakamura, Yukio/0000-0001-8056-4946				Akerstrom B, 2000, BBA-PROTEIN STRUCT M, V1482, P1, DOI 10.1016/S0167-4838(00)00137-0; BARTSCH S, 1995, FEBS LETT, V357, P255, DOI 10.1016/0014-5793(94)01303-I; Bratt T, 2000, BBA-PROTEIN STRUCT M, V1482, P318, DOI 10.1016/S0167-4838(00)00154-0; Chen XP, 2000, IMMUNITY, V13, P287, DOI 10.1016/S1074-7613(00)00028-5; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104; Flower DR, 1996, BIOCHEM J, V318, P1; Furutani M, 1998, CANCER LETT, V122, P209, DOI 10.1016/S0304-3835(97)00391-1; Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097-2765(02)00708-6; Kjeldsen L, 2000, BBA-PROTEIN STRUCT M, V1482, P272, DOI 10.1016/S0167-4838(00)00152-7; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Liu QS, 1997, MOL REPROD DEV, V46, P507, DOI 10.1002/(SICI)1098-2795(199704)46:4&lt;507::AID-MRD9&gt;3.0.CO;2-S; LIU QS, 1995, J BIOL CHEM, V270, P22565, DOI 10.1074/jbc.270.38.22565; Mishra J, 2004, J AM SOC NEPHROL, V15, P3073, DOI 10.1097/01.ASN.0000145013.44578.45; Motoyama N, 1999, J EXP MED, V189, P1691, DOI 10.1084/jem.189.11.1691; Naka T, 1999, TRENDS BIOCHEM SCI, V24, P394, DOI 10.1016/S0968-0004(99)01454-1; NAKAMURA Y, 1992, SCIENCE, V257, P1138, DOI 10.1126/science.257.5073.1138; NAKAMURA Y, 1994, SCIENCE, V264, P588, DOI 10.1126/science.8160019; Nakamura Y, 2002, MOL CELL BIOL, V22, P5563, DOI 10.1128/MCB.22.15.5563-5574.2002; Nakamura Y, 1998, EXP HEMATOL, V26, P1105; Nielsen BS, 1996, GUT, V38, P414, DOI 10.1136/gut.38.3.414; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NVIDBERG V, 2005, FEBS LETT, V579, P773; Papadaki HA, 2002, BLOOD, V100, P474, DOI 10.1182/blood-2002-01-0136; Stoesz SP, 1998, INT J CANCER, V79, P565, DOI 10.1002/(SICI)1097-0215(19981218)79:6<565::AID-IJC3>3.3.CO;2-6; TRIEBEL S, 1992, FEBS LETT, V314, P386, DOI 10.1016/0014-5793(92)81511-J; Yang J, 2002, MOL CELL, V10, P1045, DOI 10.1016/S1097-2765(02)00710-4; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Zhang J, 2003, BLOOD, V102, P3938, DOI 10.1182/blood-2003-05-1479; Zhu Y, 1994, Curr Opin Hematol, V1, P113	34	61	64	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1881	+		10.1096/fj.05-3809fje	http://dx.doi.org/10.1096/fj.05-3809fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16157692				2022-12-28	WOS:000232315700018
J	Rothman, S				Rothman, S			The constancy of the internal environment: proteins in plasma	FASEB JOURNAL			English	Article						proteins; peptides; blood; exocytosis; endocytosis; membrane transport; protein transport	MEMBRANE; TRANSPORT	The simple fact that there are normal concentrations of various proteins and peptides in blood has broad and surprising implications for how these molecules are released into and removed from the bloodstream by the cells of the body. If, as widely accepted, vesicle transport mechanisms such as exocytosis and endocytosis account for these events, then complex, presently unknown and seemingly unlikely mechanisms must exist to coordinate the rates of separate transport processes. The basis for this conclusion as well as the sole alternative method of transport, movement across permeable membranes, are discussed.	Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Rothman, S (corresponding author), Univ Calif San Francisco, 98 Acacia Ave, Berkeley, CA 94708 USA.	rothman@itsa.ucsf.edu						Alberts B., 2008, MOL BIOL CEL, V5th ed.; GOETZE H, 1978, Biochimica et Biophysica Acta, V512, P214; GONCZ KK, 1995, BBA-BIOMEMBRANES, V1238, P91, DOI 10.1016/0005-2736(95)00128-P; GONCZ KK, 1992, BIOCHIM BIOPHYS ACTA, V1109, P7, DOI 10.1016/0005-2736(92)90181-K; HENRY JB, 2001, CLIN DIAGNOSIS MANAG; Isenman L, 1995, BBA-REV BIOMEMBRANES, V1241, P341, DOI 10.1016/0304-4157(95)00009-7; ISENMAN LD, 1977, P NATL ACAD SCI USA, V74, P4068, DOI 10.1073/pnas.74.9.4068; JACOBS DS, 1996, LAB TEST HDB CONCISE; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; ROTHMAN S, 2001, LESSONS LIVING CELL; ROTHMAN SS, 1995, MEMBRANE PROTEIN TRA, V1; ROTHMAN SS, 1985, PROTEIN SECRETION CR; YOUNG DS, 1993, EFFECTS PREANALYTICA; ZIMMERBERG J, 1987, P NATL ACAD SCI USA, V84, P1585, DOI 10.1073/pnas.84.6.1585	14	3	3	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1383	1388		10.1096/fj.05-3922hyp	http://dx.doi.org/10.1096/fj.05-3922hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16126905				2022-12-28	WOS:000232315700031
J	Zhao, Z; Ho, L; Wang, J; Qin, WP; Festa, ED; Mobbs, C; Hof, P; Rocher, A; Masur, S; Haroutunian, V; Pasinetti, GM				Zhao, Z; Ho, L; Wang, J; Qin, WP; Festa, ED; Mobbs, C; Hof, P; Rocher, A; Masur, S; Haroutunian, V; Pasinetti, GM			Connective tissue growth factor (CTGF) expression in the brain is a downstream effector of insulin resistance-associated promotion of Alzheimer's disease beta-amyloid neuropathology	FASEB JOURNAL			English	Article						diabetes; IDE; secretase; IDE; AKT; MAPK	GAMMA-SECRETASE ACTIVITY; HUMAN MESANGIAL CELLS; DEGRADING ENZYME; NEUROFIBRILLARY TANGLES; EXTRACELLULAR-MATRIX; STEREOLOGIC ANALYSIS; POTENTIAL MECHANISM; DIABETES-MELLITUS; PRECURSOR PROTEIN; NEURITIC PLAQUES	The goal of this study was to further explore potential mechanisms through which diabetogenic dietary conditions that result in promotion of insulin resistance (IR), a feature of non-insulin dependant diabetes mellitus (type-2 diabetes), may influence Alzheimer's disease ( AD). Using genome-wide array technology, we found that connective tissue growth factor ( CTGF), a gene product described previously for its involvement in diabetic fibrosis, is elevated in brain tissue in an established mouse model of diet-induced IR. With this evidence we continued to explore the regulation of CTGF in postmortem AD brain tissue and found that CTGF expression correlated with the progression of AD clinical dementia and amyloid neuritic plaque (NP) neuropathology, but not neurofibrillary tangle (NFT) deposition. Consistent with this evidence, we also found that exposure of Tg2576 mice ( a model AD-type amyloid neuropathology) to a diabetogenic diet that promotes IR results in a similar to 2-fold elevation in CTGF steady-state levels in the brain, coincident with a commensurate promotion of AD-type amyloid plaque burden. Finally, using in vitro cellular models of amyloid precursor protein (APP)-processing and A beta generation/clearance, we confirmed that human recombinant (hr) CTGF may increase A beta(1-40) and A beta(1-42) peptide steady-state levels, possibly through a mechanism that involves gamma-secretase activation and decreased insulin-degrading enzyme (IDE) steady-state levels in a MAP kinase ( MAPK)/ phosphatidylinositol 3-kinase (PI-3K)/protein kinase-B (AKT) 1-dependent manner. The findings in this study tentatively suggest that increased CTGF expression in the brain might be a novel biological predicative factor of AD clinical progression and neuropathology in response to dietary regimens promoting IR conditions.	Mt Sinai Sch Med, Dept Psychiat, Neuroinflammat Res Labs, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Ophthalmol, New York, NY 10029 USA; Bronx Vet Affairs Med Ctr, GRECC, Translat Neurosci Labs, Bronx, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center	Pasinetti, GM (corresponding author), Mt Sinai Sch Med, Dept Psychiat, Neuroinflammat Res Labs, Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA.	giulio.pasinetti@mssm.edu		Pasinetti, Giulio/0000-0002-1524-5196; Mobbs, Charles/0000-0002-5815-8711	NATIONAL INSTITUTE ON AGING [R01AG013799, P01AG002219] Funding Source: NIH RePORTER; NIA NIH HHS [AG13799, AG02219] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adler SG, 2002, AM J KIDNEY DIS, V40, P184, DOI 10.1053/ajkd.2002.33928; Bergen HT, 1999, BRAIN RES, V851, P198, DOI 10.1016/S0006-8993(99)02186-1; BRIGSTOCK DR, 1991, BAILLIERE CLIN ENDOC, V5, P791, DOI 10.1016/S0950-351X(10)80015-1; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Bussiere T, 2003, NEUROSCIENCE, V117, P577, DOI 10.1016/S0306-4522(02)00942-9; Bussiere T, 2002, NEUROSCIENCE, V112, P75, DOI 10.1016/S0306-4522(02)00056-8; Candido R, 2003, CIRC RES, V92, P785, DOI 10.1161/01.RES.0000065620.39919.20; Craft S, 2003, PSYCHONEUROENDOCRINO, V28, P809, DOI 10.1016/S0306-4530(02)00087-2; Craft S, 2004, LANCET NEUROL, V3, P169, DOI 10.1016/S1474-4422(04)00681-7; Crean JKG, 2002, J BIOL CHEM, V277, P44187, DOI 10.1074/jbc.M203715200; Dorris DR, 2002, GENOME RES, V12, P976, DOI 10.1101/gr.227402; Eberlein M, 2001, BRIT J PHARMACOL, V133, P1172, DOI 10.1038/sj.bjp.0704173; Edland SD, 2004, J MOL NEUROSCI, V23, P213, DOI 10.1385/JMN:23:3:213; Evin G, 2002, PEPTIDES, V23, P1285, DOI 10.1016/S0196-9781(02)00063-3; Folger PA, 2001, INVEST OPHTH VIS SCI, V42, P2534; Forette F, 1998, LANCET, V352, P1347, DOI 10.1016/S0140-6736(98)03086-4; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; FUJISAWA Y, 1991, BIOL PSYCHIAT, V30, P1219, DOI 10.1016/0006-3223(91)90158-I; Gasparini L, 2001, J NEUROSCI, V21, P2561, DOI 10.1523/JNEUROSCI.21-08-02561.2001; Haroutunian V, 1998, ARCH NEUROL-CHICAGO, V55, P1185, DOI 10.1001/archneur.55.9.1185; Haroutunian V, 1999, ARCH NEUROL-CHICAGO, V56, P713, DOI 10.1001/archneur.56.6.713; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Hertel M, 2000, EUR J NEUROSCI, V12, P376, DOI 10.1046/j.1460-9568.2000.00930.x; Ho L, 2004, FASEB J, V18, P902, DOI 10.1096/fj.03-0978fje; Hof PR, 2000, J COMP NEUROL, V420, P113, DOI 10.1002/(SICI)1096-9861(20000424)420:1<113::AID-CNE8>3.0.CO;2-N; Kurochkin IV, 2001, TRENDS BIOCHEM SCI, V26, P421, DOI 10.1016/S0968-0004(01)01876-X; Kuusisto J, 1997, BRIT MED J, V315, P1045, DOI 10.1136/bmj.315.7115.1045; Levin-Allerhand J A, 2002, J Nutr Health Aging, V6, P315; Luchsinger JA, 2004, NEUROLOGY, V63, P1187, DOI 10.1212/01.WNL.0000140292.04932.87; Makimura Hideo, 2003, BMC Physiol, V3, P4, DOI 10.1186/1472-6793-3-4; MENEILLY GS, 1993, J AM GERIATR SOC, V41, P710, DOI 10.1111/j.1532-5415.1993.tb07458.x; Meyer JS, 2000, ANN NY ACAD SCI, V903, P411, DOI 10.1111/j.1749-6632.2000.tb06393.x; Mirjany M, 2002, J PHARMACOL EXP THER, V301, P494, DOI 10.1124/jpet.301.2.494; Mirra SS, 1997, NEUROBIOL AGING, V18, pS91, DOI 10.1016/S0197-4580(97)00058-4; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Mizuno TM, 1999, ENDOCRINOLOGY, V140, P4551, DOI 10.1210/en.140.10.4551; Mobbs CV, 2004, NEUROCHEM RES, V29, P1093, DOI 10.1023/B:NERE.0000023596.49140.e0; Murphy M, 1999, J BIOL CHEM, V274, P5830, DOI 10.1074/jbc.274.9.5830; Nimchinsky EA, 2000, J COMP NEUROL, V416, P112, DOI 10.1002/(SICI)1096-9861(20000103)416:1<112::AID-CNE9>3.0.CO;2-K; Ott A, 1999, NEUROLOGY, V53, P1937, DOI 10.1212/WNL.53.9.1937; Paradis V, 2001, HEPATOLOGY, V34, P738, DOI 10.1053/jhep.2001.28055; Peila R, 2004, NEUROLOGY, V63, P228, DOI 10.1212/01.WNL.0000129989.28404.9B; Perez A, 2000, NEUROCHEM RES, V25, P247, DOI 10.1023/A:1007527721160; Petrovitch H, 2000, NEUROBIOL AGING, V21, P57, DOI 10.1016/S0197-4580(00)82479-3; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Qin WP, 2003, J BIOL CHEM, V278, P50970, DOI 10.1074/jbc.M307699200; Ramakrishnan R, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.7.e30; Segarini PR, 2001, J BIOL CHEM, V276, P40659, DOI 10.1074/jbc.M105180200; Skoog I, 1996, LANCET, V347, P1141, DOI 10.1016/S0140-6736(96)90608-X; Spliet WGM, 2003, ACTA NEUROPATHOL, V106, P449, DOI 10.1007/s00401-003-0741-y; Stamer K, 2002, J CELL BIOL, V156, P1051, DOI 10.1083/jcb.200108057; Tandrup T, 1997, J MICROSC-OXFORD, V186, P108, DOI 10.1046/j.1365-2818.1997.2070765.x; Twigg SM, 2002, ENDOCRINOLOGY, V143, P4907, DOI 10.1210/en.2002-220619; Twigg SM, 2001, ENDOCRINOLOGY, V142, P1760, DOI 10.1210/endo.142.5.8141; Ueberham U, 2003, NEUROSCIENCE, V116, P1, DOI 10.1016/S0306-4522(02)00670-X; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Xiang ZM, 2002, GENE EXPRESSION, V10, P271, DOI 10.3727/000000002783992352; Yang M, 2004, FASEB J, V18, P1920, DOI 10.1096/fj.04-2357fje; Zhao LX, 2004, J NEUROSCI, V24, P11120, DOI 10.1523/JNEUROSCI.2860-04.2004	59	34	35	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2005	19	11					2081	+		10.1096/fj.05-4359fje	http://dx.doi.org/10.1096/fj.05-4359fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16186174				2022-12-28	WOS:000232315700005
J	Messina, A; Bortolotto, SK; Cassell, OCS; Kelly, J; Abberton, KM; Morrison, WA				Messina, A; Bortolotto, SK; Cassell, OCS; Kelly, J; Abberton, KM; Morrison, WA			Generation of a vascularized organoid using skeletal muscle as the inductive source	FASEB JOURNAL			English	Article						tissue engineering; rat; adipogenesis; myogenesis; angiogenesis	MESENCHYMAL STEM-CELLS; FIBROBLAST-GROWTH-FACTOR; IN-VIVO; ARTERIOVENOUS SHUNT; BASEMENT-MEMBRANE; BLOOD-VESSELS; BONE-MARROW; TISSUE; TRANSPLANTATION; SKIN	The technology required for creating an in vivo microenvironment and a neovasculature that can grow with and service new tissue is lacking, precluding the possibility of engineering complex three-dimensional organs. We have shown that when an arterio-venous ( AV) loop is constructed in vivo in the rat groin, and placed inside a semisealed chamber, an extensive functional vasculature is generated. To test whether this unusually angiogenic environment supports the survival and growth of implanted tissue or cells, we inserted various preparations of rat and human skeletal muscle. We show that after 6 weeks incubation of muscle tissue, the chamber filled with predominantly well-vascularized recipient-derived adipose tissue, but some new donor-derived skeletal muscle and connective tissue were also evident. When primary cultured myoblasts were inserted into the chamber with the AV loop, they converted to mature striated muscle fibers. Furthermore, we identify novel adipogenesis-inducing properties of skeletal muscle. This represents the first report of a specific three-dimensional tissue grown on its own vascular supply.	Univ Melbourne, Dept Surg, Parkville, Vic 3052, Australia; St Vincents Hosp, Bernard O Brien Inst Microsurg, Fitzroy, Vic 3065, Australia	University of Melbourne; St Vincent's Hospital Melbourne	Messina, A (corresponding author), Bernard O Brien Inst Microsurg, 42 Fitzory St, Fitzroy, Vic 3065, Australia.	messinaa@svhm.org.au		Abberton, Keren/0000-0001-6009-9725				Alsberg E, 2002, P NATL ACAD SCI USA, V99, P12025, DOI 10.1073/pnas.192291499; Auger FA, 2004, BIOTECHNOL APPL BIOC, V39, P263; Barbero A, 2001, J CELL PHYSIOL, V186, P183, DOI 10.1002/1097-4652(200102)186:2<183::AID-JCP1020>3.3.CO;2-H; CARLSON BM, 1968, J MORPHOL, V125, P447, DOI 10.1002/jmor.1051250405; Cassell OCS, 2001, ANN NY ACAD SCI, V944, P429; Chaikof EL, 2002, ANN NY ACAD SCI, V961, P96, DOI 10.1111/j.1749-6632.2002.tb03057.x; CINTI S, 1989, ANAT REC, V224, P466, DOI 10.1002/ar.1092240403; Coraux C, 2003, CURR BIOL, V13, P849, DOI 10.1016/S0960-9822(03)00296-3; Cronin KJ, 2004, PLAST RECONSTR SURG, V113, P260, DOI 10.1097/01.PRS.0000095942.71618.9D; Crosby HA, 2001, GUT, V48, P153, DOI 10.1136/gut.48.2.153; Csete M, 2001, J CELL PHYSIOL, V189, P189, DOI 10.1002/jcp.10016; Cunha G R, 1992, Epithelial Cell Biol, V1, P105; Devine SM, 2001, EXP HEMATOL, V29, P244, DOI 10.1016/S0301-472X(00)00635-4; Eastlick HL, 1943, J EXP ZOOL, V93, P27, DOI 10.1002/jez.1400930103; FONTAINE M, 1995, J PEDIATR SURG, V30, P56, DOI 10.1016/0022-3468(95)90610-X; Germain L, 2000, MED BIOL ENG COMPUT, V38, P232, DOI 10.1007/BF02344782; Griffith LG, 2002, ANN NY ACAD SCI, V961, P83, DOI 10.1111/j.1749-6632.2002.tb03056.x; Gu Y, 2001, CELL TRANSPLANT, V10, P453; Guan JY, 1998, DIABETES, V47, P1020, DOI 10.2337/diabetes.47.7.1020; GUSSONI E, 1992, NATURE, V356, P435, DOI 10.1038/356435a0; Hunt EA, 1932, J EXP ZOOL, V62, P57, DOI 10.1002/jez.1400620103; Irintchev A, 1998, J CELL SCI, V111, P3287; Kaihara S, 2000, TISSUE ENG, V6, P105, DOI 10.1089/107632700320739; Kawaguchi N, 1998, P NATL ACAD SCI USA, V95, P1062, DOI 10.1073/pnas.95.3.1062; Kimura Y, 2003, BIOMATERIALS, V24, P2513, DOI 10.1016/S0142-9612(03)00049-8; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; Koike N, 2004, NATURE, V428, P138, DOI 10.1038/428138a; Liechty KW, 2000, NAT MED, V6, P1282, DOI 10.1038/81395; LOKMIC Z, 2004, ENCY BIOMATERIALS BI; Lucas Paul A., 1995, Wound Repair and Regeneration, V3, P449, DOI 10.1046/j.1524-475X.1995.30409.x; Marler JJ, 1998, ADV DRUG DELIVER REV, V33, P165, DOI 10.1016/S0169-409X(98)00025-8; MATHIEU O, 1981, J MICROSC-OXFORD, V121, P75, DOI 10.1111/j.1365-2818.1981.tb01200.x; Mattioli-Belmonte M, 2003, INT J ARTIF ORGANS, V26, P1077, DOI 10.1177/039139880302601205; Mian RA, 2001, TISSUE ENG, V7, P73, DOI 10.1089/107632700300003305; Ochoa ER, 2002, ANN NY ACAD SCI, V979, P10, DOI 10.1111/j.1749-6632.2002.tb04863.x; Peng HR, 2004, TRANSPL IMMUNOL, V12, P311, DOI 10.1016/j.trim.2003.12.009; Sachlos E., 2003, European Cells & Materials, V5, P29; Smythe GM, 2000, CELL TRANSPLANT, V9, P379, DOI 10.1177/096368970000900309; Soker S, 2000, WORLD J UROL, V18, P10, DOI 10.1007/PL00007070; Tanaka Y, 2000, BRIT J PLAST SURG, V53, P51, DOI 10.1054/bjps.1999.3186; WAKE MC, 1994, CELL TRANSPLANT, V3, P339, DOI 10.1177/096368979400300411; Warejcka DJ, 1996, J SURG RES, V62, P233, DOI 10.1006/jsre.1996.0201; Whitaker MJ, 2001, J PHARM PHARMACOL, V53, P1427, DOI 10.1211/0022357011777963; WILLIAMS D, 2004, MED DEVICE TECHNOL, V15, P8; Xaymardan M, 2002, ANAT RECORD, V267, P28, DOI 10.1002/ar.10072; YOUNG HE, 1995, DEV DYNAM, V202, P137, DOI 10.1002/aja.1002020205; ZACKS SI, 1977, LAB INVEST, V36, P303	47	73	74	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1570	+		10.1096/fj.04-3241fje	http://dx.doi.org/10.1096/fj.04-3241fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16014398				2022-12-28	WOS:000230923000021
J	Lee, WC; Courtenay, A; Troendle, FJ; Stallings- Mann, ML; Dickey, CA; DeLucia, MW; Dickson, DW; Eckman, CB				Lee, WC; Courtenay, A; Troendle, FJ; Stallings- Mann, ML; Dickey, CA; DeLucia, MW; Dickson, DW; Eckman, CB			Enzyme replacement therapy results in substantial improvements in early clinical phenotype in a mouse model of globoid cell leukodystrophy	FASEB JOURNAL			English	Article						Krabbe disease; lysosomal storage disorder; protein therapy; twitcher; blood brain barrier	CENTRAL-NERVOUS-SYSTEM; TWITCHER MOUSE; KRABBE-DISEASE; PSYCHOSINE CYTOTOXICITY; PHORBOL ESTER; MURINE MODEL; TRANSPLANTATION; PATHOLOGY; GALACTOSYLSPHINGOSINE; LEUCODYSTROPHY	Globoid cell leukodystrophy (GLD) or Krabbe disease is a devastating, degenerative neurological disorder caused by mutations in the galactosylceramidase (GALC) gene that severely affect enzyme activity. Currently, treatment options for this disorder are very limited. Enzyme replacement therapy (ERT) has been shown to be effective in lysosomal storage disorders with predominantly peripheral manifestations such as type I Gaucher's and Fabry's disease. Little however is known about the possible benefit of ERT in GLD, which has a substantial central nervous system component. In this study, we examined the effect of peripheral GALC injections in the twitcher mouse model of the disease. Although we were unable to block the precipitous decline that normally occurs just before death, we did observe significant early improvements in motor performance, a substantial attenuation in the initial failure to thrive, and an increase in life span. Immunohistochemical and activity analyses demonstrated GALC uptake in multiple tissues, including the brain. This was associated with a decrease in the abnormal accumulation of the GALC substrate psychosine, which is thought to play a pivotal role in disease pathology. These results indicate that peripheral ERT is likely to be beneficial in GLD.	Mayo Clin, Coll Med, Dept Pharmacol, Jacksonville, FL 32224 USA; Mayo Clin, Coll Med, Dept Neurosci, Jacksonville, FL 32224 USA	Mayo Clinic; Mayo Clinic	Eckman, CB (corresponding author), Mayo Clin, Coll Med, Dept Pharmacol, Birdsall Bldg,Room 327,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	Eckman@mayo.edu	Dickey, Chad A/H-4441-2011	Dickson, Dennis W/0000-0001-7189-7917; Stallings-Mann, Melody/0000-0003-3227-6063; Lee, Chris/0000-0001-9068-5274	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS044230] Funding Source: NIH RePORTER; NINDS NIH HHS [NS44230] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEMBI B, 1994, LANCET, V344, P1679, DOI 10.1016/S0140-6736(94)90462-6; Cohen IJ, 1998, BLOOD CELL MOL DIS, V24, P296, DOI 10.1006/bcmd.1998.0195; De Gasperi R, 2004, GENE THER, V11, P1188, DOI 10.1038/sj.gt.3302282; Desnick RJ, 2002, NAT REV GENET, V3, P954, DOI 10.1038/nrg963; DUCHEN LW, 1980, BRAIN, V103, P695, DOI 10.1093/brain/103.3.695; Dunder U, 2000, FASEB J, V14, P361, DOI 10.1096/fasebj.14.2.361; Eng CM, 2001, NEW ENGL J MED, V345, P9, DOI 10.1056/NEJM200107053450102; GAL AE, 1977, CLIN CHIM ACTA, V77, P53, DOI 10.1016/0009-8981(77)90401-6; HOOGERBRUGGE PM, 1988, J CLIN INVEST, V81, P1790, DOI 10.1172/JCI113521; HOOGERBRUGGE PM, 1988, SCIENCE, V239, P1035, DOI 10.1126/science.3278379; JACOBS JM, 1982, J NEUROL SCI, V55, P285, DOI 10.1016/0022-510X(82)90127-7; Kaye Edward M., 1995, Current Opinion in Pediatrics, V7, P650; KOBAYASHI T, 1980, BRAIN RES, V202, P479, DOI 10.1016/0006-8993(80)90159-6; KOLODNY EH, 1996, HDB CLIN NEUROLOGY, V22, P187; KONDO A, 1987, BRAIN RES, V425, P186, DOI 10.1016/0006-8993(87)90499-9; Krivit W, 2004, SPRINGER SEMIN IMMUN, V26, P119, DOI 10.1007/s00281-004-0166-2; Krivit W, 1998, NEW ENGL J MED, V338, P1119, DOI 10.1056/NEJM199804163381605; Matsuda J, 2001, HUM MOL GENET, V10, P2709, DOI 10.1093/hmg/10.23.2709; Matsumoto A, 1997, DEV BRAIN DYSFUNCT, V10, P142; MIYATAKE T, 1972, BIOCHEM BIOPH RES CO, V48, P538, DOI 10.1016/0006-291X(72)90381-6; NEUFELD EF, 2004, LYSOSOMAL DISORDERS, P327; OLMSTEAD CE, 1987, BEHAV BRAIN RES, V25, P143, DOI 10.1016/0166-4328(87)90007-6; Pedchenko TV, 1999, EXP NEUROL, V158, P459, DOI 10.1006/exnr.1999.7125; Roces DP, 2004, HUM MOL GENET, V13, P1979, DOI 10.1093/hmg/ddh220; Sakai N, 1996, J NEUROCHEM, V66, P1118, DOI 10.1046/j.1471-4159.1996.66031118.x; Schiffmann R, 2001, JAMA-J AM MED ASSOC, V285, P2743, DOI 10.1001/jama.285.21.2743; Scriver C.R., 2001, METABOLIC MOL BASES, P3669; SHAPIRO E, 1991, TREATMENT GENETIC DI, P223; Shen JS, 2001, GENE THER, V8, P1081, DOI 10.1038/sj.gt.3301495; Sly W S, 1978, Prog Clin Biol Res, V23, P547; SUGAMA S, 1990, PEDIATR RES, V28, P473, DOI 10.1203/00006450-199011000-00011; SUGAMA S, 1991, BRAIN DEV-JPN, V13, P104, DOI 10.1016/S0387-7604(12)80116-1; SUZUKI K, 1983, AM J PATHOL, V111, P394; SUZUKI K, 1970, P NATL ACAD SCI USA, V66, P302, DOI 10.1073/pnas.66.2.302; SUZUKI K, 1988, LAB INVEST, V58, P302; SUZUKI K, 1995, MICROSC RES TECHNIQ, V32, P204, DOI 10.1002/jemt.1070320304; SUZUKI K, 1995, BRAIN PATHOL, V5, P249, DOI 10.1111/j.1750-3639.1995.tb00601.x; SUZUKI K, 1989, METABOLIC BASIS INHE, P1699; TANAKA K, 1993, J NEUROPATH EXP NEUR, V52, P490, DOI 10.1097/00005072-199309000-00007; TANAKA K, 1989, BRAIN RES, V482, P347, DOI 10.1016/0006-8993(89)91198-0; Taniike M, 1999, J NEUROPATH EXP NEUR, V58, P644, DOI 10.1097/00005072-199906000-00009; Tohyama J, 2001, NEUROCHEM RES, V26, P667, DOI 10.1023/A:1010991420942; Vanier M, 1976, Adv Exp Med Biol, V68, P115; Wenger D.A., 1997, MOL GENETIC BASIS NE, P421; Wenger DA, 2000, MOL GENET METAB, V70, P1, DOI 10.1006/mgme.2000.2990; Wu YP, 2000, J NEUROPATH EXP NEUR, V59, P628, DOI 10.1093/jnen/59.7.628; YEAGER AM, 1984, SCIENCE, V225, P1052, DOI 10.1126/science.6382609; [No title captured]	48	73	76	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1549	+		10.1096/fj.05-3826fje	http://dx.doi.org/10.1096/fj.05-3826fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15987783				2022-12-28	WOS:000230207800002
J	Ren-Patterson, RF; Kim, DK; Zheng, X; Sherrill, S; Huang, SJ; Tolliver, T; Murphy, DL				Ren-Patterson, RF; Kim, DK; Zheng, X; Sherrill, S; Huang, SJ; Tolliver, T; Murphy, DL			Serotonergic-like progenitor cells propagated from neural stem cells in vitro: survival with SERT protein expression following implantation into brains of mice lacking SERT	FASEB JOURNAL			English	Article						precursor; differentiation; serotonin transporter; uptake	DOPAMINERGIC PHENOTYPE; NEUROTROPHIC FACTOR; NEURONS; DIFFERENTIATION; CNS; MOUSE; TRANSPLANTATION; INDUCTION; MIDBRAIN; THERAPY	Neural stem cells (NSCs) obtained from the midbrain region of embryonic (E14) mice were initially cultured with basic fibroblast growth factor ( bFGF), Sonic hedgehog, and FGF-8 in a serum-free N-2 culture medium to foster differentiation into a serotonergic-like phenotype. During the initial differentiating phase, these progenitor cells expressed En1, Pax3, and Pax5 mRNA. Subsequently, a single serotonin [5- hydroxytryptamine (5-HT)] and tryptophan hydroxylase-positive clone was isolated, which gave rise to cells that developed serotonergic properties. Sixty percent of these progenitor cells expressed the serotonin transporter (SERT), as indicated by specific ligand binding of [I-125]-RTI-55. To further evaluate SERT functionality, we showed that these progenitor cells possessed specific [H-3]-5-HT uptake activity. Implantation of the serotonergic-like progenitors into the hippocampus of adult mice genetically lacking SERT was followed by migration of these cells into adjacent brain regions, and survival of the cells at 8 weeks was accompanied by a gradual increase in density of SERT protein expression, which was not found in vehicle-injected, control mice. These findings suggest that this serotonergic-like NSC model will be a useful contribution to the development of cell biotechnology in regard to the expression of missing genes such as SERT in the adult brain.	NIMH, Clin Sci Lab, NIH, Bethesda, MD 20892 USA; Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Ren-Patterson, RF (corresponding author), NIMH, Clin Sci Lab, NIH, Bldg 10 Room 3D41, Bethesda, MD 20892 USA.	renpatr@intra.nimh.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH000332, ZIAMH000332] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alvarez-Buylla A, 2001, NAT REV NEUROSCI, V2, P287, DOI 10.1038/35067582; Barberi T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870; Bengel D, 1998, MOL PHARMACOL, V53, P649, DOI 10.1124/mol.53.4.649; Brezun JM, 2000, EUR J NEUROSCI, V12, P391, DOI 10.1046/j.1460-9568.2000.00932.x; Chiba S, 2003, CELL TRANSPLANT, V12, P457, DOI 10.3727/000000003108747019; Dziewczapolski G, 2003, EXP NEUROL, V183, P653, DOI 10.1016/S0014-4886(03)00212-7; Eaton M, 1996, EXP NEUROL, V140, P105, DOI 10.1006/exnr.1996.0121; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.neuro.18.1.159; Gage FH, 1998, NATURE, V392, P18; Galter D, 2000, J NEUROSCI RES, V61, P295, DOI 10.1002/1097-4547(20000801)61:3<295::AID-JNR7>3.0.CO;2-4; Hochedlinger K, 2003, NEW ENGL J MED, V349, P275, DOI 10.1056/NEJMra035397; Hynes M, 1999, CURR OPIN NEUROBIOL, V9, P26, DOI 10.1016/S0959-4388(99)80004-X; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Lai ZN, 2002, P NATL ACAD SCI USA, V99, P3651, DOI 10.1073/pnas.062032499; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Lun K, 1998, DEVELOPMENT, V125, P3049; MartinezSerrano A, 1997, TRENDS NEUROSCI, V20, P530, DOI 10.1016/S0166-2236(97)01119-3; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; McKay R, 2002, ANN NY ACAD SCI, V961, P44, DOI 10.1111/j.1749-6632.2002.tb03045.x; Mochizuki H, 1998, J VIROL, V72, P8873, DOI 10.1128/JVI.72.11.8873-8883.1998; Mossner R, 2000, NEUROCHEM INT, V36, P197, DOI 10.1016/S0197-0186(99)00122-9; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Ourednik V, 2001, SCIENCE, V293, P1820, DOI 10.1126/science.1060580; Pfeffer PL, 1998, DEVELOPMENT, V125, P3063; Rosenthal A, 1998, NEURON, V20, P169, DOI 10.1016/S0896-6273(00)80445-6; ROWITCH DH, 1995, MECH DEVELOP, V52, P3, DOI 10.1016/0925-4773(95)00380-J; Rumajogee P, 2002, J NEUROCHEM, V83, P1525, DOI 10.1046/j.1471-4159.2002.01264.x; Salli U, 2004, EXP NEUROL, V188, P351, DOI 10.1016/j.expneurol.2004.04.015; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; Shihabuddin LS, 2004, J NEUROSCI, V24, P10642, DOI 10.1523/JNEUROSCI.3584-04.2004; SILVERTHORN ML, 1995, J PHARMACOL EXP THER, V273, P213; Smidt MP, 1997, P NATL ACAD SCI USA, V94, P13305, DOI 10.1073/pnas.94.24.13305; Snyder EY, 1997, P NATL ACAD SCI USA, V94, P11663, DOI 10.1073/pnas.94.21.11663; Studer L, 1998, NAT NEUROSCI, V1, P290, DOI 10.1038/1105; Stull ND, 2001, EXP NEUROL, V169, P36, DOI 10.1006/exnr.2001.7640; Sugaya K, 2003, CELL MOL LIFE SCI, V60, P1891, DOI 10.1007/s00018-002-3014-y; Svendsen C N, 2000, Prog Brain Res, V127, P13; Tao R, 2000, J PSYCHOPHARMACOL, V14, P100, DOI 10.1177/026988110001400201; Temple S, 2001, NAT REV NEUROSCI, V2, P513, DOI 10.1038/35081577; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; Vogel G, 2000, SCIENCE, V290, P1672, DOI 10.1126/science.290.5497.1672; Wagner J, 1999, NAT BIOTECHNOL, V17, P653, DOI 10.1038/10862; Yang M, 2003, CELL MOL NEUROBIOL, V23, P851, DOI 10.1023/A:1025017423102; Ye WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248; Zhou JW, 2000, BRAIN RES, V877, P37, DOI 10.1016/S0006-8993(00)02624-X	51	6	6	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1537	+		10.1096/fj.04-3657fje	http://dx.doi.org/10.1096/fj.04-3657fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15972295				2022-12-28	WOS:000230207800013
J	Shalli, K; Brown, I; Heys, SD; Schofield, AC				Shalli, K; Brown, I; Heys, SD; Schofield, AC			Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel	FASEB JOURNAL			English	Article						drug resistance; MCF-7 and MDA-MB-231 cells	EXPRESSION; TAXOL; MICROTUBULES; CHEMOTHERAPY; PREDICTION; DYNAMICS; TAXOTERE	Docetaxel is one of the most active drugs used to treat breast cancer. The cellular target of docetaxel is the microtubule, specifically the beta-tubulin subunit, that comprises a series of isotypes and that can modulate function. This study has examined the role of alteration in beta-tubulin isotypes in vitro and has sequenced the beta-tubulin gene to determine if there were mutations, both of which may represent important mechanisms of acquired resistance to docetaxel. Breast cancer cells, MCF-7 (oestrogen-receptor positive) and MDA-MB-231, (oestrogen-receptor negative) were made resistant to docetaxel in vitro. Expression of beta-tubulin isotypes ( class I, II, III, IVa, IVb, and VI) was determined at the RNA and protein level using RT-PCR and western analysis, respectively. DNA sequencing evaluated the beta-tubulin gene. At the mRNA level, class I, II, III, and IVa beta-tubulin mRNA isotypes were over-expressed in docetaxel-resistant MCF-7 cells when compared with the docetaxel-sensitive parental cells. However, class VI beta-tubulin mRNA isotype expression was decreased in resistant cells. In MDA-MB-231 cells, there was a decrease in expression of the class I and class IVa beta-tubulin mRNA. However, there were increased expressions in class II, IVb, and VI beta-tubulin mRNA isotypes in resistant cells. Western analysis has confirmed corresponding increases in beta-tubulin protein levels in MCF- 7 cells. However, in MDA-MB-231 cells, there were decreased protein levels for class II and class III beta-tubulin. This study demonstrates that altered expression of mRNA beta-tubulin isotypes and modulation of beta-tubulin protein levels are associated with acquired docetaxel resistance in breast cancer cells. This allows further understanding and elucidation of mechanisms involved in resistance to docetaxel.	Univ Aberdeen, Sch Med, Coll Life Sci & Med, Aberdeen AB25 2ZD, Scotland; Univ Aberdeen, Sch Med Sci, Coll Life Sci & Med, Aberdeen AB25 2ZD, Scotland	University of Aberdeen; University of Aberdeen	Schofield, AC (corresponding author), Univ Aberdeen, Sch Med, Coll Life Sci & Med, Aberdeen AB25 2ZD, Scotland.	a.schofield@abdn.ac.uk	Shalli, Kawan/CAE-9898-2022; Shalli, Kawan/K-3111-2019		Breast Cancer Now [2001:209] Funding Source: Medline	Breast Cancer Now		Banerjee A, 2002, BIOCHEM BIOPH RES CO, V293, P598, DOI 10.1016/S0006-291X(02)00269-3; Berrieman HK, 2004, LANCET ONCOL, V5, P158, DOI 10.1016/S1470-2045(04)01411-1; BISSETT D, 1993, EUR J CANCER, V29A, P1228, DOI 10.1016/0959-8049(93)90062-K; Bonneterre J, 1999, EUR J CANCER, V35, P1431, DOI 10.1016/S0959-8049(99)00174-4; Brown I, 2004, BREAST CANCER RES, V6, pR601, DOI 10.1186/bcr918; Carles G, 1999, BRIT J CANCER, V80, P1162, DOI 10.1038/sj.bjc.6690481; Chan S, 1999, J CLIN ONCOL, V17, P2341, DOI 10.1200/JCO.1999.17.8.2341; Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8; Derry WB, 1997, BIOCHEMISTRY-US, V36, P3554, DOI 10.1021/bi962724m; Dumontet C, 1996, CELL MOTIL CYTOSKEL, V35, P49, DOI 10.1002/(SICI)1097-0169(1996)35:1<49::AID-CM4>3.0.CO;2-D; Hasegawa S, 2003, CLIN CANCER RES, V9, P2992; HOYLE HD, 1990, J CELL BIOL, V111, P1009, DOI 10.1083/jcb.111.3.1009; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Katsetos CD, 2003, CELL MOTIL CYTOSKEL, V55, P77, DOI 10.1002/cm.10116; Kavallaris M, 1997, J CLIN INVEST, V100, P1282, DOI 10.1172/JCI119642; Liu B, 2001, J SURG RES, V99, P179, DOI 10.1006/jsre.2001.6126; Mason KA, 1997, CLIN CANCER RES, V3, P2431; MCDONALD SL, EUR J CANC, V41, P1086; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Monzo M, 1999, J CLIN ONCOL, V17, P1786, DOI 10.1200/JCO.1999.17.6.1786; Nogales E, 2000, ANNU REV BIOCHEM, V69, P277, DOI 10.1146/annurev.biochem.69.1.277; O'Brien MER, 1999, ANN ONCOL, V10, P205, DOI 10.1023/A:1008370930599; Ogston KN, 2004, BREAST CANCER RES TR, V86, P181, DOI 10.1023/B:BREA.0000032986.00879.d7; PANDA D, 1994, P NATL ACAD SCI USA, V91, P11358, DOI 10.1073/pnas.91.24.11358; Ranganathan S, 1998, BRIT J CANCER, V77, P562, DOI 10.1038/bjc.1998.91; RINGEL I, 1989, JNCI-J NATL CANCER I, V285, P197; SEIDMAN AD, 1993, P AN M AM SOC CLIN, V12, P52; Sjostrom J, 1999, EUR J CANCER, V35, P1194, DOI 10.1016/S0959-8049(99)00122-7; Smith IC, 2002, J CLIN ONCOL, V20, P1456, DOI 10.1200/JCO.20.6.1456; Troester MA, 2004, CANCER RES, V64, P4218, DOI 10.1158/0008-5472.CAN-04-0107; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503	32	93	99	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1299	+		10.1096/fj.04-3178fje	http://dx.doi.org/10.1096/fj.04-3178fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15946994				2022-12-28	WOS:000230207800026
J	Narizhneva, NV; Razorenova, OV; Podrez, EA; Chen, JH; Chandrasekharan, UM; DiCorleto, PE; Plow, EF; Topol, EJ; Byzova, TV				Narizhneva, NV; Razorenova, OV; Podrez, EA; Chen, JH; Chandrasekharan, UM; DiCorleto, PE; Plow, EF; Topol, EJ; Byzova, TV			Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium	FASEB JOURNAL			English	Article						integrin-associated protein; cardiovascular disease; TNF-alpha	INTEGRIN-ASSOCIATED PROTEIN; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; DIFFERENTIAL EXPRESSION; RECEPTOR; INHIBITION; ATHEROSCLEROSIS; IDENTIFICATION; ACTIVATION; DOMAIN	Expression of cell adhesion molecules (CAM) responsible for leukocyte-endothelium interactions plays a crucial role in inflammation and atherogenesis. Up-regulation of vascular CAM-1 (VCAM-1), intracellular CAM-1 (ICAM-1), and E-selectin expression promotes monocyte recruitment to sites of injury and is considered to be a critical step in atherosclerotic plaque development. Factors that trigger this initial response are not well understood. As platelet activation not only promotes thrombosis but also early stages of atherogenesis, we considered the role of thrombospondin-1 (TSP-1), a matricellular protein released in abundance from activated platelets and accumulated in sites of vascular injury, as a regulator of CAM expression. TSP-1 induced expression of VCAM-1 and ICAM-1 on endothelium of various origins, which in turn, resulted in a significant increase of monocyte attachment. This effect could be mimicked by a peptide derived from the C-terminal domain of TSP-1 and known to interact with CD47 on the cell surface. The essential role of CD47 in the cellular responses to TSP-1 was demonstrated further using inhibitory antibodies and knockdown of CD47 with small interfering RNA. Furthermore, we demonstrated that secretion of endogenous TSP-1 and its interaction with CD47 on the cell surface mediates endothelial response to the major proinflammatory agent, tumor necrosis factor alpha (TNF-alpha). Taken together, this study identifies a novel mechanism regulating CAM expression and subsequent monocyte binding to endothelium, which might influence the development of anti-atherosclerosis therapeutic strategies.	Cleveland Clin Fdn, Dept Mol Cardiol, Cardiol & Taussig Canc Ctr, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Byzova, TV (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol, Cardiol & Taussig Canc Ctr, NB50,9500 Euclid Ave, Cleveland, OH 44195 USA.	byzovat@ccf.org	Razorenova, Olga V/A-6400-2014	Topol, Eric/0000-0002-1478-4729; Byzova, Tatiana/0000-0002-2615-875X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000080] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071625, P50HL077107] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR000080, RR-00080] Funding Source: Medline; NHLBI NIH HHS [P50 HL77107, R01 HL071625, P50 HL077107, HL071625.] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Agah A, 2002, AM J PATHOL, V161, P831, DOI 10.1016/S0002-9440(10)64243-5; AIKEN ML, 1986, J CLIN INVEST, V78, P1713, DOI 10.1172/JCI112767; BAENZIGE.NL, 1971, P NATL ACAD SCI USA, V68, P240, DOI 10.1073/pnas.68.1.240; BAGAVANDOSS P, 1990, BIOCHEM BIOPH RES CO, V170, P867, DOI 10.1016/0006-291X(90)92171-U; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Brittain JE, 2001, BLOOD, V97, P2159, DOI 10.1182/blood.V97.7.2159; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Byzova TV, 2002, BLOOD, V99, P4434, DOI 10.1182/blood.V99.12.4434; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; Chen DH, 1999, CIRCULATION, V100, P849, DOI 10.1161/01.CIR.100.8.849; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chiu JJ, 2004, ARTERIOSCL THROM VAS, V24, P73, DOI 10.1161/01.ATV.0000106321.63667.24; Chung J, 1999, BLOOD, V94, P642, DOI 10.1182/blood.V94.2.642.414k35_642_648; Collard CD, 1999, ARTERIOSCL THROM VAS, V19, P2623, DOI 10.1161/01.ATV.19.11.2623; Collins RG, 2000, J EXP MED, V191, P189, DOI 10.1084/jem.191.1.189; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Cybulsky MI, 2001, J CLIN INVEST, V107, P1255, DOI 10.1172/JCI11871; Doyen V, 2003, J EXP MED, V198, P1277, DOI 10.1084/jem.20030705; FAVALORO EJ, 1993, IMMUNOL CELL BIOL, V71, P571, DOI 10.1038/icb.1993.63; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; Freyberg MA, 2001, BIOCHEM BIOPH RES CO, V286, P141, DOI 10.1006/bbrc.2001.5314; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; GAO JF, 1996, ALGEBRA C, V3, P135; Gonzalez-Amaro R, 1998, DRUGS, V56, P977, DOI 10.2165/00003495-199856060-00003; Huo YQ, 2003, NAT MED, V9, P61, DOI 10.1038/nm810; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kootstra NA, 2003, MOL THER, V7, P623, DOI 10.1016/S1525-0016(03)00073-X; KOSFELD MD, 1993, J BIOL CHEM, V268, P8808; Krieglstein CF, 2001, AM J HYPERTENS, V14, p44S, DOI 10.1016/S0895-7061(01)02069-6; Kvansakul M, 2004, EMBO J, V23, P1223, DOI 10.1038/sj.emboj.7600166; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LI WX, 1993, J BIOL CHEM, V268, P16179; Lin TN, 2003, STROKE, V34, P177, DOI 10.1161/01.STR.0000047100.84604.BA; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; Madge LA, 2001, EXP MOL PATHOL, V70, P317, DOI 10.1006/exmp.2001.2368; Maile LA, 2003, CIRC RES, V93, P925, DOI 10.1161/01.RES.0000101754.33652.B7; MORANDI V, 1994, J CELL PHYSIOL, V160, P367, DOI 10.1002/jcp.1041600218; Novina CD, 2004, NATURE, V430, P161, DOI 10.1038/430161a; Peyvandi F, 2003, BLOOD, V102, p314A; REED MJ, 1993, J HISTOCHEM CYTOCHEM, V41, P1467, DOI 10.1177/41.10.8245406; Riessen R, 1998, AM HEART J, V135, P357, DOI 10.1016/S0002-8703(98)70105-X; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Sajid M, 2001, J INVEST MED, V49, P398, DOI 10.2310/6650.2001.33784; Schellings MWM, 2004, CARDIOVASC RES, V64, P24, DOI 10.1016/j.cardiores.2004.06.006; SCHUEPP BJ, 1991, BIOCHEM BIOPH RES CO, V175, P263, DOI 10.1016/S0006-291X(05)81229-X; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; Sengupta K, 2004, MOL CANCER RES, V2, P150; Shi WB, 2000, CIRCULATION, V102, P75, DOI 10.1161/01.CIR.102.1.75; Stenina OI, 2003, CIRCULATION, V107, P3209, DOI 10.1161/01.CIR.0000074223.56882.97; SWERLICK RA, 1991, J INVEST DERMATOL, V97, P190, DOI 10.1111/1523-1747.ep12479643; SWERLICK RA, 1992, J IMMUNOL, V149, P698; Topol EJ, 2001, CIRCULATION, V104, P2641, DOI 10.1161/hc4701.100910; Unger RE, 2002, MICROVASC RES, V64, P384, DOI 10.1006/mvre.2002.2434; VANZANTEN GH, 1994, J CLIN INVEST, V93, P615, DOI 10.1172/JCI117014; Wang XQ, 1999, J CELL BIOL, V147, P389, DOI 10.1083/jcb.147.2.389; WOOD KM, 1993, HISTOPATHOLOGY, V22, P437, DOI 10.1111/j.1365-2559.1993.tb00157.x; Yamauchi Y, 2002, MATRIX BIOL, V21, P441, DOI 10.1016/S0945-053X(02)00036-7; Zapolska-Downar D, 2004, LIFE SCI, V75, P1287, DOI 10.1016/j.lfs.2004.03.005	64	90	94	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1158	+		10.1096/fj.04-3310fje	http://dx.doi.org/10.1096/fj.04-3310fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15833768	Green Accepted			2022-12-28	WOS:000228865300014
J	Grinnell, F				Grinnell, Frederick			Intelligent design: fallacy recapitulates ontogeny	FASEB JOURNAL			English	Article									Univ Texas, SW Med Sch, Dept Cell Biol, Eth Sci & Med Program, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Grinnell, F (corresponding author), Univ Texas, SW Med Sch, Dept Cell Biol, Eth Sci & Med Program, Dallas, TX 75390 USA.	frederick.grinnell@utsouthwestern.edu							0	0	0	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2006	20	3					410	411		10.1096/fj.06-0303ufm	http://dx.doi.org/10.1096/fj.06-0303ufm			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	074LY	16507757				2022-12-28	WOS:000239815100003
J	Bolin, CM; Basha, R; Cox, D; Zawia, NH; Maloney, B; Lahiri, DK; Cardozo-Pelaez, F				Bolin, Celeste M.; Basha, Riyaz; Cox, David; Zawia, Nasser H.; Maloney, Bryan; Lahiri, Debomoy K.; Cardozo-Pelaez, Fernando			Exposure to lead (Pb) and the developmental origin of oxidative DNA damage in the aging brain	FASEB JOURNAL			English	Article						Alzheimer; epigenetic; free radicals; methylation; Ogg1; oxidative stress	AMYLOID PRECURSOR PROTEIN; IRON-RESPONSIVE ELEMENT; ALZHEIMERS-DISEASE; 5'-UNTRANSLATED REGION; GENE-EXPRESSION; MESSENGER-RNA; BIRTH-WEIGHT; CELL-LINES; RAT-BRAIN; REPAIR	Oxidative damage to DNA has been associated with neurodegenerative diseases. Developmental exposure to lead (Pb) has been shown to elevate the Alzheimer's disease (AD) related beta-amyloid peptide (A beta), which is known to generate reactive oxygen species in the aging brain. This study measures the lifetime cerebral 8-hydroxy-2'-deoxyguanosine (oxo(8)dG) levels and the activity of the DNA repair enzyme 8-oxoguanine DNA glycosylase (Ogg1) in rats developmentally exposed to Pb. Oxo(8)dG was transiently modulated early in life (Postnatal day 5), but was later elevated 20 months after exposure to Pb had ceased, while Ogg1 activity was not altered. Furthermore, an age-dependent loss in the inverse correlation between Ogg1 activity and oxo8dG accumulation was observed. The effect of Pb on oxo8dG levels did not occur if animals were exposed to Pb in old age. These increases in DNA damage occurred in the absence of any Pb-induced changes in copper/zinc-superoxide dismutase (SOD1), manganese-SOD (SOD2), and reduced-form glutathion (GSH). These data suggest that oxidative damage and neurodegeneration in the aging brain could be impacted by the developmental disturbances.	Indiana Univ, Sch Med, Dept Psychiat, Inst Psychiat Res,Lab Mol Neurogenet, Indianapolis, IN 46202 USA; Univ Rhode Isl, Dept Biomed & Pharmaceut Sci, NEL, Kingston, RI 02881 USA; Univ Montana, Ctr Environm Hlth Sci, Dept Biomed & Pharmaceut Sci, Missoula, MT 59812 USA	Indiana University System; Indiana University-Purdue University Indianapolis; University of Rhode Island; University of Montana System; University of Montana	Zawia, NH (corresponding author), Indiana Univ, Sch Med, Dept Psychiat, Inst Psychiat Res,Lab Mol Neurogenet, Indianapolis, IN 46202 USA.	nzawia@uri.edu; dlahiri@iupi.edu	Lahiri, Debomoy/AAZ-3322-2020; Maloney, Bryan J/C-4924-2011	Maloney, Bryan J/0000-0003-2364-9649; Basha, Riyaz/0000-0002-4071-0993	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES013022, R29ES008104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018884, R01AG018379] Funding Source: NIH RePORTER; NCRR NIH HHS [RR16457] Funding Source: Medline; NIA NIH HHS [R01 AG18379, R01 AG18884] Funding Source: Medline; NIEHS NIH HHS [ES013022, ES08104] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARKER DJP, 1989, LANCET, V2, P577; Basha MR, 2003, INT J DEV NEUROSCI, V21, P1, DOI 10.1016/S0736-5748(02)00137-5; Basha MR, 2005, J NEUROSCI, V25, P823, DOI 10.1523/JNEUROSCI.4335-04.2005; Bolin C, 2004, J NEUROSCI METH, V136, P69, DOI 10.1016/j.jneumeth.2003.12.025; Bressler J, 1999, NEUROCHEM RES, V24, P595, DOI 10.1023/A:1022596115897; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Cardozo-Pelaez F, 1999, MOVEMENT DISORD, V14, P972, DOI 10.1002/1531-8257(199911)14:6<972::AID-MDS1010>3.0.CO;2-0; Cardozo-Pelaez F, 1998, NEUROBIOL AGING, V19, P311, DOI 10.1016/S0197-4580(98)00067-0; Cardozo-Pelaez F, 2000, FREE RADICAL BIO MED, V28, P779, DOI 10.1016/S0891-5849(00)00172-6; Dorszewska J, 2004, RESP PHYSIOL NEUROBI, V139, P227, DOI 10.1016/j.resp.2003.10.005; Gabbita SP, 1998, J NEUROCHEM, V71, P2034, DOI 10.1046/j.1471-4159.1998.71052034.x; Ge YW, 2004, FASEB J, V18, P1037, DOI 10.1096/fj.03-1379fje; Ge YW, 2004, J NEUROCHEM, V90, P1432, DOI 10.1111/j.1471-4159.2004.02608.x; Guilarte TR, 2000, MOL BRAIN RES, V76, P299, DOI 10.1016/S0169-328X(00)00010-3; Hamilton ML, 2001, P NATL ACAD SCI USA, V98, P10469, DOI 10.1073/pnas.171202698; Hattori M, 1997, NUCLEIC ACIDS RES, V25, P1802, DOI 10.1093/nar/25.9.1802; Hendrie HC, 2001, JAMA-J AM MED ASSOC, V285, P739, DOI 10.1001/jama.285.6.739; Lahiri DK, 2005, FASEB J, V19, P653, DOI 10.1096/fj.04-2900fje; Lahiri DK, 1999, ANN NY ACAD SCI, V893, P331, DOI 10.1111/j.1749-6632.1999.tb07848.x; LOCKITCH G, 1993, CLIN BIOCHEM, V26, P371, DOI 10.1016/0009-9120(93)90113-K; Lovell MA, 1999, J NEUROCHEM, V72, P771, DOI 10.1046/j.1471-4159.1999.0720771.x; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; Maloney B, 2004, FASEB J, V18, P1288, DOI 10.1096/fj.03-1703fje; Moreira EG, 2001, TOXICOLOGY, V169, P145, DOI 10.1016/S0300-483X(01)00497-8; OTTO DA, 1993, NEUROTOXICOLOGY, V14, P191; Rogers JT, 2002, J BIOL CHEM, V277, P45518, DOI 10.1074/jbc.M207435200; Sambamurti K, 2004, FASEB J, V18, P1034, DOI 10.1096/fj.03-1378fje; SANCHEZRAMOS JR, 1994, NEURODEGENERATION, V3, P197; SILBERGELD EK, 1992, FASEB J, V6, P3201, DOI 10.1096/fasebj.6.13.1397842; SPARKS DL, 2003, P NATL ACAD SCI USA, V100, P11193; Stedeford T, 2001, FREE RADICAL BIO MED, V31, P1272, DOI 10.1016/S0891-5849(01)00715-8; Toscano CD, 2002, DEV BRAIN RES, V139, P217, DOI 10.1016/S0165-3806(02)00569-2; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/s001250050157; Venti A, 2004, ANN NY ACAD SCI, V1035, P34, DOI 10.1196/annals.1332.003; WEISS B, 1991, NEUROTOXICOLOGY, V12, P379; Yarbrough DE, 1998, DIABETES CARE, V21, P1652, DOI 10.2337/diacare.21.10.1652; Zawia NH, 1998, DEV BRAIN RES, V107, P291, DOI 10.1016/S0165-3806(98)00023-6; ZAWIA NH, 1994, INT J DEV NEUROSCI, V12, P25, DOI 10.1016/0736-5748(94)90092-2	38	130	139	1	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					788	+		10.1096/fj.05-5091fje	http://dx.doi.org/10.1096/fj.05-5091fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16484331				2022-12-28	WOS:000237698700017
J	Strijdom, H; Jacobs, S; Hattingh, S; Page, C; Lochner, A				Strijdom, Hans; Jacobs, Sean; Hattingh, Suzel; Page, Carine; Lochner, Amanda			Nitric oxide production is higher in rat cardiac microvessel endothelial cells than ventricular cardiomyocytes in baseline and hypoxic conditions: a comparative study	FASEB JOURNAL			English	Article									[Strijdom, Hans; Jacobs, Sean; Hattingh, Suzel; Page, Carine; Lochner, Amanda] Univ Stellenbosch, Fac Hlth Sci, Dept Med Physiol & Biochem, ZA-7505 Tygerberg, South Africa; [Lochner, Amanda] MRC, Cape Heart Grp, Tygerberg, South Africa	Stellenbosch University	Strijdom, H (corresponding author), Univ Stellenbosch, Fac Hlth Sci, Dept Med Physiol & Biochem, POB 19063, ZA-7505 Tygerberg, South Africa.	jgstr@sun.ac.za		Strijdom, Hans/0000-0003-3726-9153					0	21	21	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					314	316		10.1096/fj.05-4225fje	http://dx.doi.org/10.1096/fj.05-4225fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16354719				2022-12-28	WOS:000207915000005
J	Meme, W; Calvo, CF; Froger, N; Ezan, P; Amigou, E; Koulakoff, A; Giaume, C				Meme, W; Calvo, CF; Froger, N; Ezan, P; Amigou, E; Koulakoff, A; Giaume, C			Proinflammatory cytokines released from microglia inhibit gap junctions in astrocytes: potentiation by beta-amyloid	FASEB JOURNAL			English	Article						glial cells; inflammation; Cx43; brain macrophages	CALCIUM-WAVE-PROPAGATION; ALZHEIMERS-DISEASE; IMMUNE FUNCTION; NITRIC-OXIDE; TNF-ALPHA; COMMUNICATION; EXPRESSION; INTERLEUKIN-1-BETA; NEUROTOXICITY; AMPLIFICATION	Brain inflammation is characterized by a reactive gliosis involving the activation of astrocytes and microglia. This process, common to many brain injuries and diseases, underlies important phenotypic changes in these two glial cell types. One characteristic feature of astrocytes is their high level of intercellular communication mediated by gap junctions. Previously, we have reported that astrocyte gap junctional communication (AGJC) and the expression of connexin 43 (Cx43), the main constitutive protein of gap junctions, are inhibited in microglia (MG)-astrocyte cocultures. Here, we report that bacterial lipopolysaccharide activation of microglia increases their inhibitory effect on Cx43 expression and AGJC. This inhibition is mimicked by treating astrocyte cultures with conditioned medium harvested from activated microglia. Interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) were identified as being the main factors responsible for this conditioned medium-mediated activity. Interestingly, an inflammatory response characterized by MG activation and reactive astrocytes occurs in Alzheimer's disease, at sites of beta-amyloid (A beta) deposits. We found that this peptide potentiates the inhibitory effect of a conditioned medium diluted at a concentration that is not effective per se. This potentiation is prevented by treating astrocytes with specific blockers of IL-1 beta and TNF-alpha activities. Thus, the suppression of communication between astrocytes, induced by activated MG could contribute to the proposed role of reactive gliosis in this neurodegenerative disease.	Coll France, INSERM, U587, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France	Giaume, C (corresponding author), Coll France, INSERM, U587, 11 Pl Marcelin Berthelot, F-75005 Paris, France.	christian.giaume@college-de-france.fr		KOULAKOFF, Annette/0000-0002-3143-2215				Akama KT, 2000, J BIOL CHEM, V275, P7918, DOI 10.1074/jbc.275.11.7918; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; Blanc EM, 1998, J NEUROCHEM, V70, P958; Calvo CF, 2000, EUR J NEUROSCI, V12, P2676, DOI 10.1046/j.1460-9568.2000.00145.x; Chandross KJ, 1998, GLIA, V24, P21, DOI 10.1002/(SICI)1098-1136(199809)24:1<21::AID-GLIA3>3.0.CO;2-3; CHANSON M, 2005, BIOCHIM BIOPHYS ACTA, V1771, P197; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Cotrina ML, 1998, J NEUROSCI, V18, P2520; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Duffy HS, 2000, J NEUROSCI, V20; Faustmann PM, 2003, GLIA, V42, P101, DOI 10.1002/glia.10141; Gasic-Milenkovic J, 2003, EUR J NEUROSCI, V17, P813, DOI 10.1046/j.1460-9568.2003.02506.x; Giaume C, 2004, GLIAL NEURONAL SIGNALING, P323; Giaume C, 1996, TRENDS NEUROSCI, V19, P319, DOI 10.1016/0166-2236(96)10046-1; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Haughey NJ, 2003, NEUROMOL MED, V3, P173, DOI 10.1385/NMM:3:3:173; Hinkerohe D, 2005, GLIA, V52, P85, DOI 10.1002/glia.20223; John GR, 2005, GLIA, V49, P161, DOI 10.1002/glia.20109; John GR, 1999, P NATL ACAD SCI USA, V96, P11613, DOI 10.1073/pnas.96.20.11613; Kielian T, 2004, NEUROCHEM INT, V45, P429, DOI 10.1016/j.neuint.2003.09.010; Kirchhoff F, 2001, EUR ARCH PSY CLIN N, V251, P159, DOI 10.1007/s004060170036; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; Meda L, 1999, J NEUROIMMUNOL, V93, P45, DOI 10.1016/S0165-5728(98)00188-X; Medina JM, 1999, ADV EXP MED BIOL, V468, P361; Meme W, 2004, NEUROSCIENCE, V126, P95, DOI 10.1016/j.neuroscience.2004.03.031; Nagy JI, 1996, BRAIN RES, V717, P173, DOI 10.1016/0006-8993(95)01526-4; Nakase T, 2004, BBA-BIOMEMBRANES, V1662, P149, DOI 10.1016/j.bbamem.2004.01.009; Nakase T, 2003, STROKE, V34, P1987, DOI 10.1161/01.STR.0000079814.72027.34; Ozog MA, 2002, J NEUROPATH EXP NEUR, V61, P132, DOI 10.1093/jnen/61.2.132; Rapoport SI, 1999, EUR ARCH PSY CLIN N, V249, P46; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rouach N, 2002, BIOL CELL, V94, P457, DOI 10.1016/S0248-4900(02)00016-3; Rouach N, 2002, EUR J NEUROSCI, V15, P403, DOI 10.1046/j.0953-816x.2001.01868.x; Rouach N, 2000, J CELL BIOL, V149, P1513, DOI 10.1083/jcb.149.7.1513; Scemes E, 2000, MOL NEUROBIOL, V22, P167, DOI 10.1385/MN:22:1-3:167; Schubert P, 2001, MECH AGEING DEV, V123, P47, DOI 10.1016/S0047-6374(01)00343-8; Siushansian R, 2001, J COMP NEUROL, V440, P387, DOI 10.1002/cne.1392; Vega C, 2002, GLIA, V39, P10, DOI 10.1002/glia.10080; Zhang W, 1999, CANCER RES, V59, P1994; Zvalova D, 2004, GLIA, V46, P323, DOI 10.1002/glia.10334	44	153	159	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					494	+		10.1096/fj.05-4297fje	http://dx.doi.org/10.1096/fj.05-4297fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16423877				2022-12-28	WOS:000235996000010
J	De, A; Gambhir, SS				De, A; Gambhir, SS			Noninvasive imaging of protein-protein interactions from live cells and living subjects using bioluminescence resonance energy transfer	FASEB JOURNAL			English	Article						Renilla luciferase; green fluorescent protein; rapamycin and optical CCD imaging	FLUORESCENT INDICATORS; FIREFLY LUCIFERASE; GENE-EXPRESSION; RECEPTOR; COMPLEMENTATION; PHOSPHORYLATION; OLIGOMERIZATION; DISCOVERY; DYNAMICS; GROWTH	This study demonstrates a significant advancement of imaging of a distance-dependent physical process, known as the bioluminescent resonance energy transfer (BRET2) signal in living subjects, by using a cooled charge-coupled device (CCD) camera. A CCD camera-based spectral imaging strategy enables simultaneous visualization and quantitation of BRET signal from live cells and cells implanted in living mice. We used the BRET2 system, which utilizes Renilla luciferase (hRluc) protein and its substrate DeepBlueC (DBC) as an energy donor and a mutant green fluorescent protein (GFP(2)) as the acceptor. To accomplish this objective in this proof-of-principle study, the donor and acceptor proteins were fused to FKBP12 and FRB, respectively, which are known to interact only in the presence of the small molecule mediator rapamycin. Mammalian cells expressing these fusion constructs were imaged using a cooled-CCD camera either directly from culture dishes or by implanting them into mice. By comparing the emission photon yields in the presence and absence of rapamycin, the specific BRET signal was determined. The CCD imaging approach of BRET signal is particularly appealing due to its capacity to seamlessly bridge the gap between in vitro and in vivo studies. This work validates BRET as a powerful tool for interrogating and observing protein-protein interactions directly at limited depths in living mice.	Stanford Univ, Dept Radiol Bioengn, Sch Med, MIPS, Stanford, CA 94305 USA; Stanford Univ, Dept Radiol, Sch Med, BioX Program, Stanford, CA 94305 USA; Stanford Univ, Dept Bioengn, Sch Med, BioX Program, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Gambhir, SS (corresponding author), Stanford Univ, Dept Radiol Bioengn, Sch Med, MIPS, 318 Campus Dr,E150, Stanford, CA 94305 USA.	Sgambhir@stanford.edu			NCI NIH HHS [P50 CA114747, U54 CA119367, 5R01 CA82214] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA119367, P50CA114747, R01CA082214] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arai R, 2002, J BIOSCI BIOENG, V94, P362, DOI 10.1263/jbb.94.362; Bertrand L, 2002, J RECEPT SIGNAL TR R, V22, P533, DOI 10.1081/RRS-120014619; Burack WR, 2005, J BIOL CHEM, V280, P3832, DOI 10.1074/jbc.M410031200; Clemons PA, 1999, CURR OPIN CHEM BIOL, V3, P112, DOI 10.1016/S1367-5931(99)80020-9; Colland F, 2004, BIOCHIMIE, V86, P625, DOI 10.1016/j.biochi.2004.09.014; Contag CH, 1997, PHOTOCHEM PHOTOBIOL, V66, P523, DOI 10.1111/j.1751-1097.1997.tb03184.x; Cotrin SS, 2004, ANAL BIOCHEM, V335, P244, DOI 10.1016/j.ab.2004.09.012; DIONNE P, 2002, LUMINESCENCE BIOTECH, P539; Dues G, 2001, FEBS LETT, V505, P75, DOI 10.1016/S0014-5793(01)02782-X; Eidne KA, 2002, TRENDS ENDOCRIN MET, V13, P415, DOI 10.1016/S1043-2760(02)00669-0; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; Fujita H, 2005, J BIOL CHEM, V280, P5022, DOI 10.1074/jbc.M409701200; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; Germain-Desprez D, 2003, J BIOL CHEM, V278, P22367, DOI 10.1074/jbc.M302234200; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Jensen AA, 2002, EUR J BIOCHEM, V269, P5076, DOI 10.1046/j.1432-1033.2002.03218.x; Kaihara A, 2003, ANAL CHEM, V75, P4176, DOI 10.1021/ac0300800; Keppler A, 2003, NAT BIOTECHNOL, V21, P86, DOI 10.1038/nbt765; Klammt J, 2004, BIOCHEM BIOPH RES CO, V325, P183, DOI 10.1016/j.bbrc.2004.10.018; LEHMING N, 2002, GENOMIC PROTEOMIC, V1, P230; Luker GD, 2002, P NATL ACAD SCI USA, V99, P6961, DOI 10.1073/pnas.092022399; Luker KE, 2004, P NATL ACAD SCI USA, V101, P12288, DOI 10.1073/pnas.0404041101; Luker KE, 2004, METHOD ENZYMOL, V385, P349; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Ozawa T, 2001, ANAL CHEM, V73, P2516, DOI 10.1021/ac0013296; Paulmurugan R, 2004, CANCER RES, V64, P2113, DOI 10.1158/0008-5472.CAN-03-2972; Paulmurugan R, 2003, ANAL CHEM, V75, P1584, DOI 10.1021/ac020731c; Paulmurugan R, 2002, P NATL ACAD SCI USA, V99, P15608, DOI 10.1073/pnas.242594299; Perroy J, 2004, NAT METHODS, V1, P203, DOI 10.1038/NMETH722; Rossi F, 1997, P NATL ACAD SCI USA, V94, P8405, DOI 10.1073/pnas.94.16.8405; Sasaki K, 2003, J BIOL CHEM, V278, P30945, DOI 10.1074/jbc.M212167200; Sato M, 2002, NAT BIOTECHNOL, V20, P287, DOI 10.1038/nbt0302-287; Sato M, 1999, ANAL CHEM, V71, P3948, DOI 10.1021/ac990318d; Schaaf CP, 2004, FASEB J, V18, P267, DOI 10.1096/fj.04-1558fje; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Vrecl M, 2004, J BIOMOL SCREEN, V9, P322, DOI 10.1177/1087057104263212; Wouters FS, 1999, CURR BIOL, V9, P1127, DOI 10.1016/S0960-9822(99)80484-9; Wu JC, 2002, CIRCULATION, V105, P1631, DOI 10.1161/01.CIR.0000014984.95520.AD; Xu XH, 2005, MOL BIOL CELL, V16, P676, DOI 10.1091/mbc.E04-07-0544; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151	40	77	84	1	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2017	+		10.1096/fj.05-4628fje	http://dx.doi.org/10.1096/fj.05-4628fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16204354				2022-12-28	WOS:000232991100029
J	Meex, SJR; van der Kallen, CJH; van Greevenbroek, MMJ; Eurlings, PMH; El Hasnaoui, M; Evelo, CTA; Lindsey, PJ; Luiken, JJFP; Glatz, JFC; de Bruin, TWA				Meex, SJR; van der Kallen, CJH; van Greevenbroek, MMJ; Eurlings, PMH; El Hasnaoui, M; Evelo, CTA; Lindsey, PJ; Luiken, JJFP; Glatz, JFC; de Bruin, TWA			Up-regulation of CD36/FAT in preadipocytes in familial combined hyperlipidemia	FASEB JOURNAL			English	Article						lipid metabolism; fatty acids; metabolic syndrome; gene expression	CHAIN FATTY-ACIDS; CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN; ADIPOSE-TISSUE; GLUCOSE; MUSCLE; LOCUS; IDENTIFICATION; METABOLISM; OXIDATION	Familial combined hyperlipidemia (FCHL) shows many features of the metabolic syndrome. The strong genetic component makes it an excellent model to study the genetic background of metabolic syndrome and insulin resistance. Adipose tissue is believed to contribute to, or even underlie, the FCHL phenotype and is an interesting target tissue for gene expression studies. However, interpretation of adipose tissue gene expression experiments is complex since expression differences cannot only arise as a direct consequence of a genetic trait, but may also reflect an adaptation to metabolic influences at the cellular level. In the present study, we measured gene expression levels in cultured primary human preadipocytes from FCHL and control subjects. Since isolated preadipocytes were allowed to replicate for weeks under standardized conditions, the contribution of previous metabolic influences is rather small whereas genetic defects are preserved and expressed in vitro. The main finding was upregulation of CD36/FAT in FCHL preadipocytes, confirmed in two independent groups of subjects, and a concomitant increase in CD36/FAT-mediated fatty acid uptake. CD36/FAT overexpression has previously been shown to be associated with other insulin-resistant states. The present data suggest that CD36/FAT overexpression in FCHL occurs very early in adipocyte differentiation and may be of genetic origin.	Maastricht Univ, Dept Internal Med, Lab Mol Metab & Endocrinol, POB 616, NL-6200 MD Maastricht, Netherlands; Maastricht Univ, BiGCaT Bioinformat, NL-6200 MD Maastricht, Netherlands; Maastricht Univ, Dept Human Genet, NL-6200 MD Maastricht, Netherlands; Maastricht Univ, Dept Mol Genet, CARIM, NL-6200 MD Maastricht, Netherlands	Maastricht University; Maastricht University; Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC)	Meex, SJR (corresponding author), Maastricht Univ, Dept Internal Med, Lab Mol Metab & Endocrinol, POB 616, NL-6200 MD Maastricht, Netherlands.	steven.meex@intmed.unimaas.nl	Evelo, Chris TA/D-2914-2009; Lindsey, Patrick/AAD-8100-2021	Evelo, Chris TA/0000-0002-5301-3142; van der Kallen, Carla/0000-0003-1468-8793; van Greevenbroek, Marleen/0000-0002-2989-1631; Meex, Steven/0000-0001-8147-9006				ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; Akaike H, 1973, P 2 INT S INF THEOR, P267, DOI DOI 10.1007/978-1-4612-1694-0_15; Allayee H, 2002, CIRC RES, V90, P926, DOI 10.1161/01.RES.0000015885.27134.F0; Aouizerat BE, 1999, AM J HUM GENET, V65, P397, DOI 10.1086/302490; Bonen A, 2004, FASEB J, V18, P1144, DOI 10.1096/fj.03-1065fje; BROWN MS, 1974, P NATL ACAD SCI USA, V71, P788, DOI 10.1073/pnas.71.3.788; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; Coort SLM, 2004, DIABETES, V53, P1655, DOI 10.2337/diabetes.53.7.1655; Coort SLM, 2002, MOL CELL BIOCHEM, V239, P213, DOI 10.1023/A:1020539932353; Eurlings PMH, 2002, J LIPID RES, V43, P930; Gaster M, 2004, DIABETES, V53, P542, DOI 10.2337/diabetes.53.3.542; Georgieva AM, 2004, ARTERIOSCL THROM VAS, V24, P744, DOI 10.1161/01.ATV.0000119681.47218.a4; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; Griffin E, 2001, NAT MED, V7, P840, DOI 10.1038/89969; Hirano K, 2003, TRENDS CARDIOVAS MED, V13, P136, DOI 10.1016/S1050-1738(03)00026-4; Ibrahimi A, 1999, J BIOL CHEM, V274, P26761, DOI 10.1074/jbc.274.38.26761; Keulen ETP, 2001, AM J HYPERTENS, V14, P357, DOI 10.1016/S0895-7061(00)01280-2; Liang CP, 2004, J CLIN INVEST, V113, P764, DOI [10.1172/JCI200419528, 10.1172/JCI19528]; Lindsey JK, 1998, STAT MED, V17, P59, DOI 10.1002/(SICI)1097-0258(19980115)17:1<59::AID-SIM733>3.3.CO;2-Z; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; NIKKILA EA, 1973, LANCET, V1, P954; Pajukanta P, 2004, NAT GENET, V36, P371, DOI 10.1038/ng1320; Pajukanta P, 1998, NAT GENET, V18, P369, DOI 10.1038/ng0498-369; Pajukanta P, 2003, AM J HUM GENET, V72, P903, DOI 10.1086/374177; ROSE HG, 1973, AM J MED, V54, P148, DOI 10.1016/0002-9343(73)90218-0; van der Kallen CJH, 2002, ATHEROSCLEROSIS, V164, P337, DOI 10.1016/S0021-9150(02)00109-0; Voors-Pette C, 2001, ATHEROSCLEROSIS, V157, P481, DOI 10.1016/S0021-9150(00)00752-8	28	14	16	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12								10.1096/fj.04-2403fje	http://dx.doi.org/10.1096/fj.04-2403fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16219805	Bronze, Green Published			2022-12-28	WOS:000232991100023
J	Mutch, DM; Wahli, W; Williamson, G				Mutch, DM; Wahli, W; Williamson, G			Nutrigenomics and nutrigenetics: the emerging faces of nutrition	FASEB JOURNAL			English	Review						coronary heart disease; diabetes; integrative metabolism; metabolomics; nutrient-gene interaction; polymorphism; systems biology	POLYUNSATURATED FATTY-ACIDS; LIPOPROTEIN-LIPASE GENE; PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA-2; ELEMENT-BINDING PROTEIN-1C; CORONARY-HEART-DISEASE; PLASMA-LIPID RESPONSE; PPAR-GAMMA; INSULIN-RESISTANCE; DOCOSAHEXAENOIC ACID; TRIGLYCERIDE LEVELS	The recognition that nutrients have the ability to interact and modulate molecular mechanisms underlying an organism's physiological functions has prompted a revolution in the field of nutrition. Performing population-scaled epidemiological studies in the absence of genetic knowledge may result in erroneous scientific conclusions and misinformed nutritional recommendations. To circumvent such issues and more comprehensively probe the relationship between genes and diet, the field of nutrition has begun to capitalize on both the technologies and supporting analytical software brought forth in the post-genomic era. The creation of nutrigenomics and nutrigenetics, two fields with distinct approaches to elucidate the interaction between diet and genes but with a common ultimate goal to optimize health through the personalization of diet, provide powerful approaches to unravel the complex relationship between nutritional molecules, genetic polymorphisms, and the biological system as a whole. Reluctance to embrace these new fields exists primarily due to the fear that producing overwhelming quantities of biological data within the confines of a single study will submerge the original query; however, the current review aims to position nutrigenomics and nutrigenetics as the emerging faces of nutrition that, when considered with more classical approaches, will provide the necessary stepping stones to achieve the ambitious goal of optimizing an individual's health via nutritional intervention.	Nestle Res Ctr, CH-1000 Lausanne, Switzerland; Univ Lausanne, Ctr Integrat Genom, Lausanne, Switzerland	Nestle SA; University of Lausanne	Mutch, DM (corresponding author), Scripps Res Inst, 10550 N Torrey Pines Rd,MEM 275, La Jolla, CA 92037 USA.	dmmutch_sci@hotmail.com	Wahli, Walter/B-1398-2009; Williamson, Gary/AAE-9665-2019; Wahli, Walter/I-3194-2019	Wahli, Walter/0000-0002-5966-9089; Williamson, Gary/0000-0002-5624-6267; Mutch, David/0000-0002-0908-7259				Agren JJ, 2001, AM J CLIN NUTR, V73, P31; Ames BN, 1999, P NATL ACAD SCI USA, V96, P12216, DOI 10.1073/pnas.96.22.12216; Anderle P, 2004, NUTRITION, V20, P103, DOI 10.1016/j.nut.2003.09.018; Arab L, 2004, P NUTR SOC, V63, P167, DOI 10.1079/PNS2003325; Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101; BAIER LJ, 1995, J CLIN INVEST, V95, P1281, DOI 10.1172/JCI117778; Baier LJ, 1996, J BIOL CHEM, V271, P10892, DOI 10.1074/jbc.271.18.10892; Bellenger J, 2004, FASEB J, V18, P773, DOI 10.1096/fj.03-0950fje; Benowitz NL, 2003, CLIN PHARMACOL THER, V74, P468, DOI 10.1016/j.clpt.2003.07.001; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Berger Alvin, 2002, Lipids Health Dis, V1, P2, DOI 10.1186/1476-511X-1-2; Besnard P, 2002, MOL CELL BIOCHEM, V239, P139, DOI 10.1023/A:1020505512364; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bourre J M, 2004, J Nutr Health Aging, V8, P163; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Browning LM, 2003, P NUTR SOC, V62, P447, DOI 10.1079/PNS2003252; Butcher EC, 2004, NAT BIOTECHNOL, V22, P1253, DOI 10.1038/nbt1017; Cahill DJ, 2003, ADV BIOCHEM ENG BIOT, V83, P177; Calder PC, 1998, CLIN SCI, V94, P303, DOI 10.1042/cs0940303; Calder PC, 2004, CLIN SCI, V107, P1, DOI 10.1042/CS20040119; Carmena-Ramon RF, 1998, ATHEROSCLEROSIS, V139, P107, DOI 10.1016/S0021-9150(98)00064-1; Carr TP, 1996, J NUTR, V126, P1463, DOI 10.1093/jn/126.5.1463; Chang WCL, 1998, J NUTR, V128, P491, DOI 10.1093/jn/128.3.491; CHAO Y, 1991, EUR J CLIN PHARMACOL, V40, pS11, DOI 10.1007/BF01409400; Chilton Robert J, 2004, J Am Osteopath Assoc, V104, pS5; Cleland LG, 2003, DRUGS, V63, P845, DOI 10.2165/00003495-200363090-00001; Clish CB, 2004, OMICS, V8, P3, DOI 10.1089/153623104773547453; Coen M, 2004, J PHARMACEUT BIOMED, V35, P93, DOI 10.1016/j.jpba.2003.12.019; Collett ED, 2001, AM J PHYSIOL-CELL PH, V280, pC1066, DOI 10.1152/ajpcell.2001.280.5.C1066; Corthals GL, 2000, ELECTROPHORESIS, V21, P1104, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1104::AID-ELPS1104>3.3.CO;2-3; Darimont C, 2000, J LIPID RES, V41, P84; Davidson LA, 2004, CANCER RES, V64, P6797, DOI 10.1158/0008-5472.CAN-04-1068; Deckelbaum R. J., 1999, Circulation, V100, P450; Desiere Frank, 2004, Biotechnol Annu Rev, V10, P51, DOI 10.1016/S1387-2656(04)10003-3; Desvergne B, 2004, MOL ENDOCRINOL, V18, P1321, DOI 10.1210/me.2004-0088; Di Minno G, 2002, PATHOPHYSIOL HAEMO T, V32, P361, DOI 10.1159/000073601; Dietrich CG, 2003, GUT, V52, P1788, DOI 10.1136/gut.52.12.1788; Doney A, 2002, BMC GENET, V3, DOI 10.1186/1471-2156-3-21; DONEY AS, 2004, ARTERIOSCLER THROMB; DRESSMAN JB, 1993, J PHARM SCI, V82, P857, DOI 10.1002/jps.2600820902; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Evans D, 2003, J MOL MED-JMM, V81, P264, DOI 10.1007/s00109-003-0426-y; FEINLEIB M, 1975, PREV MED, V4, P518, DOI 10.1016/0091-7435(75)90037-7; Filippi E, 2004, EUR J HUM GENET, V12, P199, DOI 10.1038/sj.ejhg.5201120; Folling A, 1934, H-S Z PHYSIOL CHEM, V227, P169, DOI 10.1515/bchm2.1934.227.1-4.169; German JB, 2004, J NUTR, V134, P2729, DOI 10.1093/jn/134.10.2729; German JB, 2003, J NUTR, V133, p2078S, DOI 10.1093/jn/133.6.2078S; German JB, 2002, J NUTR, V132, P2486, DOI 10.1093/jn/132.9.2486; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Gillies PJ, 2003, J AM DIET ASSOC, V103, pS50, DOI [10.1016/j.jada.2003.09.037, 10.1016/S0002-8223(03)01380-4]; Gillotte-Taylor K, 2002, J BIOL CHEM, V277, P11811, DOI 10.1074/jbc.M108268200; Go VLW, 2003, J NUTR, V133, p3830S, DOI 10.1093/jn/133.11.3830S; Gonzalez B, 2000, PROSTAG LEUKOTR ESS, V62, P299, DOI 10.1054/plef.2000.0158; Goodacre R, 2004, TRENDS BIOTECHNOL, V22, P245, DOI 10.1016/j.tibtech.2004.03.007; Goppert F, 1917, KLIN WOCHENSCHR, V54, P473; Griffin JL, 2004, PHYSIOL GENOMICS, V17, P140, DOI 10.1152/physiolgenomics.00158.2003; Hihi AK, 2002, CELL MOL LIFE SCI, V59, P790, DOI 10.1007/s00018-002-8467-x; Hirai MY, 2004, P NATL ACAD SCI USA, V101, P10205, DOI 10.1073/pnas.0403218101; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Ikeda I, 1996, J NUTR SCI VITAMINOL, V42, P541, DOI 10.3177/jnsv.42.541; Ishikawa T, 2004, PHARMACOGENOMICS, V5, P67, DOI 10.1517/phgs.5.1.67.25683; Jemaa R, 1997, INT J OBESITY, V21, P280, DOI 10.1038/sj.ijo.0800401; JEMAA R, 1995, INT J OBESITY, V19, P270; Jimenez-Sanchez G, 2001, NATURE, V409, P853, DOI 10.1038/35057050; Jump DB, 2002, CURR OPIN LIPIDOL, V13, P155, DOI 10.1097/00041433-200204000-00007; Kaput J, 2004, PHYSIOL GENOMICS, V16, P166, DOI 10.1152/physiolgenomics.00107.2003; Kaput J, 2004, NUTRITION, V20, P26, DOI 10.1016/j.nut.2003.09.005; Kenzelmann M, 2004, GENOMICS, V83, P550, DOI 10.1016/j.ygeno.2003.09.026; Kersten S, 2000, EXS, V89, P141; Knoblauch H, 2002, HUM MOL GENET, V11, P1477, DOI 10.1093/hmg/11.12.1477; Kornman KS, 2004, NUTRITION, V20, P44, DOI 10.1016/j.nut.2003.09.008; Kramer JA, 2003, J NUTR, V133, P57, DOI 10.1093/jn/133.1.57; Krauss RM, 2004, MED CLIN N AM, V88, P897, DOI 10.1016/j.mcna.2004.04.004; Lapillonne A, 2004, CURR OPIN CLIN NUTR, V7, P151, DOI 10.1097/00075197-200403000-00008; Laudes M, 2004, DIABETES, V53, P842, DOI 10.2337/diabetes.53.3.842; Li SX, 2003, DIABETES, V52, P1265, DOI 10.2337/diabetes.52.5.1265; Luan J, 2001, DIABETES, V50, P686, DOI 10.2337/diabetes.50.3.686; Ma YQ, 2003, METABOLISM, V52, P338, DOI 10.1053/meta.2003.50053; Mao-Qiang M, 2004, J INVEST DERMATOL, V123, P305, DOI 10.1111/j.0022-202X.2004.23235.x; Mar R, 2004, CIRC RES, V94, P993, DOI 10.1161/01.RES.0000124922.61830.F0; Marzolini C, 2004, PHARMACOGENOMICS, V5, P273, DOI 10.1517/phgs.5.3.273.29831; Matsusue K, 2003, J CLIN INVEST, V111, P737, DOI 10.1172/JCI200317223; McGladdery SH, 2001, J LIPID RES, V42, P1905; McPherson JD, 2001, NATURE, V409, P934, DOI 10.1038/35057157; Mead JR, 2002, J MOL MED, V80, P753, DOI 10.1007/s00109-002-0384-9; Mendes Pedro, 2002, Brief Bioinform, V3, P134; Miklos GLG, 2004, NAT BIOTECHNOL, V22, P615, DOI 10.1038/nbt965; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Mooser V, 2003, CURR OPIN LIPIDOL, V14, P115, DOI 10.1097/00041433-200304000-00001; Muller M, 2003, NAT REV GENET, V4, P315, DOI 10.1038/nrg1047; Munoz ET, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-30; Mutch DM, 2005, FASEB J, V19, DOI 10.1096/fj.04-2674fje; Nagata R, 2004, J BIOL CHEM, V279, P29031, DOI 10.1074/jbc.M309449200; Narayanan BA, 2003, CANCER RES, V63, P972; Nicholson JK, 2004, NAT BIOTECHNOL, V22, P1268, DOI 10.1038/nbt1015; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Ordovas JM, 2004, P NUTR SOC, V63, P145, DOI 10.1079/PNS2003313; Ordovas JM, 2004, ANNU REV GENOM HUM G, V5, P71, DOI 10.1146/annurev.genom.5.061903.180008; Ordovas JM, 2004, CURR OPIN LIPIDOL, V15, P101, DOI 10.1097/00041433-200404000-00002; Ordovas JM, 2002, BIOCHEM SOC T, V30, P68, DOI 10.1042/BST0300068; Ordovas JM, 2002, AM J CLIN NUTR, V75, P38, DOI 10.1093/ajcn/75.1.38; Ordovas JM, 2000, BRIT J NUTR, V83, pS127; Parillo M, 2004, BRIT J NUTR, V92, P7, DOI 10.1079/BJN20041117; Park EI, 1997, J NUTR, V127, P566, DOI 10.1093/jn/127.4.566; Pratley RE, 2000, J LIPID RES, V41, P2002; Prescott SL, 2004, CURR OPIN CLIN NUTR, V7, P123, DOI 10.1097/00075197-200403000-00004; Rabilloud T, 2002, PROTEOMICS, V2, P3, DOI 10.1002/1615-9861(200201)2:1<3::AID-PROT3>3.3.CO;2-I; Reyes N, 2004, CANCER LETT, V209, P25, DOI 10.1016/j.canlet.2003.12.010; Rieusset J, 2002, MOL ENDOCRINOL, V16, P2628, DOI 10.1210/me.2002-0036; Riva A, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-33; Roberts CK, 2002, CIRCULATION, V106, P2530, DOI 10.1161/01.CIR.0000040584.91836.0D; Roberts MA, 2001, CURR OPIN BIOTECH, V12, P516, DOI 10.1016/S0958-1669(00)00256-1; Rose K, 2004, PROTEOMICS, V4, P2125, DOI 10.1002/pmic.200300718; Ruxton CHS, 2004, J HUM NUTR DIET, V17, P449, DOI 10.1111/j.1365-277X.2007.00770.x; SCRIVER CR, 1988, AM J CLIN NUTR, V48, P1505, DOI 10.1093/ajcn/48.6.1505; Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434; Senti M, 2001, HUM GENET, V109, P385, DOI 10.1007/s004390100584; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Skoglund-Andersson C, 2003, ATHEROSCLEROSIS, V167, P311, DOI 10.1016/S0021-9150(03)00016-9; Smith SR, 2003, DIABETES, V52, P1611, DOI 10.2337/diabetes.52.7.1611; Stulnig TM, 2003, INT ARCH ALLERGY IMM, V132, P310, DOI 10.1159/000074898; Swarbrick MM, 2001, EUR J ENDOCRINOL, V144, P277, DOI 10.1530/eje.0.1440277; Swierczynska M, 2003, J ALLERGY CLIN IMMUN, V112, P995, DOI 10.1016/S0091-6749(03)02015-3; Tai ES, 2005, J NUTR, V135, P397, DOI 10.1093/jn/135.3.397; Tan NS, 2004, BIOCHEM SOC T, V32, P97, DOI 10.1042/BST0320097; Valve R, 1999, J CLIN ENDOCR METAB, V84, P3708, DOI 10.1210/jc.84.10.3708; van der Meer-van Kraaij C, 2005, CARCINOGENESIS, V26, P73, DOI 10.1093/carcin/bgh288; van Ommen B, 2004, NUTRITION, V20, P4, DOI 10.1016/j.nut.2003.09.003; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; WAHLI W, 1995, CHEM BIOL, V2, P261, DOI 10.1016/1074-5521(95)90045-4; Wang QF, 2004, HUM MOL GENET, V13, P1049, DOI 10.1093/hmg/ddh121; Wang YT, 2002, J BIOL CHEM, V277, P5692, DOI 10.1074/jbc.M109977200; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Watkins SM, 2002, J LIPID RES, V43, P1809, DOI 10.1194/jlr.M200169-JLR200; WEST KM, 1971, DIABETES, V20, P99, DOI 10.2337/diab.20.2.99; Wheeler DL, 2001, NUCLEIC ACIDS RES, V29, P11, DOI 10.1093/nar/29.1.11; Willerson JT, 2004, CIRCULATION, V109, P2, DOI 10.1161/01.CIR.0000129535.04194.38; Wood PA, 2004, NUTRITION, V20, P121, DOI 10.1016/j.nut.2003.09.021; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200; Zeisel SH, 2001, J NUTR, V131, P1319, DOI 10.1093/jn/131.4.1319; Zheng KQ, 2004, CHINESE MED J-PEKING, V117, P1288	145	196	220	1	60	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					1602	1616		10.1096/fj.05-3911rev	http://dx.doi.org/10.1096/fj.05-3911rev			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16195369				2022-12-28	WOS:000232991100038
J	Ohki, Y; Heissig, B; Sato, Y; Akiyama, H; Zhu, ZP; Hicklin, DJ; Shimada, K; Ogawa, H; Daida, H; Hattori, K; Ohsaka, A				Ohki, Y; Heissig, B; Sato, Y; Akiyama, H; Zhu, ZP; Hicklin, DJ; Shimada, K; Ogawa, H; Daida, H; Hattori, K; Ohsaka, A			Granulocyte colony-stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils	FASEB JOURNAL			English	Article						angiogenesis; hematopoietic cells; angiogenic factors; VEGF receptors	HEMATOPOIETIC STEM-CELLS; MARROW-DERIVED CELLS; VEGF RECEPTOR FLT-1; FACTOR G-CSF; PROGENITOR CELLS; TUMOR ANGIOGENESIS; IN-VIVO; POSTNATAL NEOVASCULARIZATION; MYOCARDIAL-INFARCTION; HUMAN MONOCYTES	The granulocyte colony-stimulating factor (G-CSF) promotes angiogenesis. However, the exact mechanism is not known. We demonstrate that vascular endothelial growth factor ( VEGF) was released by Gr-1(+) CD11b(-) neutrophils but not Gr-1(-)CD11b(+) monocytes prestimulated with GCSF in vitro and in vivo. Similarly, in vivo, concomitant with an increase in neutrophil numbers in circulation, G-CSF augmented plasma VEGF level in vivo. Local G-CSF administration into ischemic tissue increased capillary density and provided a functional vasculature and contributed to neovascularization of ischemic tissue. Blockade of the VEGF pathway abrogated G-CSF-induced angiogenesis. On the other hand, as we had shown previously, VEGF can induce endothelial progenitor cell ( EPC) mobilization. Here, we show that G-CSF also augmented the number of circulating VEGF receptor-2 (VEGFR2) EPCs as compared with untreated controls. Blocking the VEGF/VEGFR1, but to a much lesser extent, the VEGF/VEGFR2 pathway in GCSF-treated animals delayed tissue revascularization in a hindlimb model. These data clearly show that G-CSF modulates angiogenesis by increasing myelomonocytic cells (VEGFR1(+) neutrophils) and their release of VEGF. Our results indicated that administration of G-CSF into ischemic tissue provides a novel and safe therapeutic strategy to improve neovascularization.	Univ Tokyo, Ctr Med Expt, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan; ImClone Syst Inc, New York, NY USA; Juntendo Univ, Sch Med, Dept Cardiol, Tokyo 113, Japan; Juntendo Univ, Sch Med, Atopy Allergy Res Ctr, Bunkyo Ku, Tokyo 113, Japan; Juntendo Univ, Sch Med, Dept Transfus Med & Stem Cell Regulat, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo; Eli Lilly; Juntendo University; Juntendo University; Juntendo University	Hattori, K (corresponding author), Univ Tokyo, Ctr Med Expt, Inst Med Sci, Minato Ku, 4-6-1,Shirokanedai, Tokyo 1088639, Japan.	khattori@ims.u-tokyo.ac.jp	Heissig, Beate/AAF-6771-2021	Heissig, Beate/0000-0002-0348-5934				Ancelin M, 2004, LAB INVEST, V84, P502, DOI 10.1038/labinvest.3700053; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bautz F, 2000, EXP HEMATOL, V28, P700, DOI 10.1016/S0301-472X(00)00168-5; BOCCHIETTO E, 1993, J CELL PHYSIOL, V155, P89, DOI 10.1002/jcp.1041550112; BUSSOLINO F, 1991, J CLIN INVEST, V87, P986, DOI 10.1172/JCI115107; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; Crivellato E, 2004, LEUKEMIA, V18, P331, DOI 10.1038/sj.leu.2403246; Crosby JR, 2000, CIRC RES, V87, P728, DOI 10.1161/01.RES.87.9.728; Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465; DEHAAS M, 1994, BLOOD, V84, P3885, DOI 10.1182/blood.V84.11.3885.bloodjournal84113885; Eubank TD, 2003, J IMMUNOL, V171, P2637, DOI 10.4049/jimmunol.171.5.2637; Falanga A, 1999, BLOOD, V93, P2506, DOI 10.1182/blood.V93.8.2506.408k31_2506_2514; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Gothert JR, 2004, BLOOD, V104, P1769, DOI 10.1182/blood-2003-11-3952; Gunningham SP, 2001, CANCER RES, V61, P3206; Harada M, 2005, NAT MED, V11, P305, DOI 10.1038/nm1199; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Iba O, 2002, CIRCULATION, V106, P2019, DOI 10.1161/01.CIR.0000031332.45480.79; Kang HJ, 2004, LANCET, V363, P751, DOI 10.1016/S0140-6736(04)15689-4; Kearney JB, 2004, BLOOD, V103, P4527, DOI 10.1182/blood-2003-07-2315; Kitayama Y, 2000, LAB INVEST, V80, P779, DOI 10.1038/labinvest.3780081; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Nakayama T, 2004, J CLIN INVEST, V114, P1317, DOI 10.1172/JCI200422089; Natori T, 2002, BIOCHEM BIOPH RES CO, V297, P1058, DOI 10.1016/S0006-291X(02)02335-5; Ohtsuka M, 2004, FASEB J, V18, P851, DOI 10.1096/fj.03-0637fje; Orlic D, 1998, BLOOD, V91, P3247, DOI 10.1182/blood.V91.9.3247.3247_3247_3254; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Ozawa CR, 2004, J CLIN INVEST, V113, P516, DOI 10.1172/JCI200418420; Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925; Rafii S, 2002, SEMIN CELL DEV BIOL, V13, P61, DOI 10.1006/scdb.2001.0285; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0; Shintani S, 2001, CIRCULATION, V103, P897, DOI 10.1161/01.CIR.103.6.897; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; TAMURA M, 1987, BIOCHEM BIOPH RES CO, V142, P454, DOI 10.1016/0006-291X(87)90296-8; Tateishi-Yuyama E, 2002, LANCET, V360, P427, DOI 10.1016/S0140-6736(02)09670-8; Yamada T, 1996, LAB INVEST, V74, P384; Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22; Yong KL, 1996, BRIT J HAEMATOL, V94, P40, DOI 10.1046/j.1365-2141.1996.d01-1752.x; YUO A, 1989, BLOOD, V74, P2144; Zhang W, 2000, CANCER RES, V60, P6757; Ziegelhoeffer T, 2004, CIRC RES, V94, P230, DOI 10.1161/01.RES.0000110419.50982.1C	51	197	217	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2005	+		10.1096/fj.04-3496fje	http://dx.doi.org/10.1096/fj.04-3496fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16223785				2022-12-28	WOS:000232991100019
J	Takeda, T; Asahi, M; Yamaguchi, O; Hikoso, S; Nakayama, H; Kusakari, Y; Kawai, M; Hongo, K; Higuchi, Y; Kashiwase, K; Watanabe, T; Taniike, M; Nakai, A; Nishida, K; Kurihara, S; Donoviel, DB; Bernstein, A; Tomita, T; Iwatsubo, T; Hori, M; Otsu, K				Takeda, T; Asahi, M; Yamaguchi, O; Hikoso, S; Nakayama, H; Kusakari, Y; Kawai, M; Hongo, K; Higuchi, Y; Kashiwase, K; Watanabe, T; Taniike, M; Nakai, A; Nishida, K; Kurihara, S; Donoviel, DB; Bernstein, A; Tomita, T; Iwatsubo, T; Hori, M; Otsu, K			Presenilin 2 regulates the systolic function of heart by modulating Ca2+ signaling	FASEB JOURNAL			English	Article						ryanodine receptor; sorcin; calcium; excitation-contraction coupling	MULTIDRUG-RESISTANT CELLS; SARCOPLASMIC-RETICULUM; RYANODINE RECEPTOR; RELEASE CHANNELS; PROTEIN; EXPRESSION; SORCIN; LOCALIZATION; STIMULATION	Genetic studies of families with familial Alzheimer's disease have implicated presenilin 2 (PS2) in the pathogenesis of this disease. PS2 is ubiquitously expressed in various tissues including hearts. In this study, we examined cardiac phenotypes of PS2 knockout (PS2KO) mice to elucidate a role of PS2 in hearts. PS2KO mice developed normally with no evidence of cardiac hypertrophy and fibrosis. Invasive hemodynamic analysis revealed that cardiac contractility in PS2KO mice increased compared with that in their littermate controls. A study of isolated papillary muscle showed that peak amplitudes of Ca2+ transients and peak tension were significantly higher in PS2KO mice than those in their littermate controls. PS2KO mouse hearts exhibited no change in expression of calcium regulatory proteins. Since it has been demonstrated that PS2 in brain interacts with sorcin, which serves as a modulator of cardiac ryanodine receptor (RyR2), we tested whether PS2 also interacts with RyR2. Immmunoprecipitation analysis showed that PS2, sorcin, and RyR2 interact with each other in HEK-293 cells overexpressing these proteins or in mouse hearts. Immunohistochemistry of heart muscle indicated that PS2 colocalizes with RyR2 and sorcin at the Z-lines. Elevated Ca2+ attenuated the association of RyR2 with PS2, whereas the association of sorcin with PS2 was enhanced. The enhanced Ca2+ transients and contractility in PS2KO mice were observed at low extracellular [Ca2+] but not at high levels of [Ca2+]. Taken together, our results suggest that PS2 plays an important role in cardiac excitation-contraction coupling by interacting with RyR2.	Osaka Univ, Dept Cardiovasc Med, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Biochem, Grad Sch Med, Suita, Osaka 5650871, Japan; Jikei Univ, Sch Med, Dept Physiol 2, Tokyo 1058461, Japan; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Tokyo, Dept Neuropathol & Neurosci, Grad Sch Pharmaceut Sci, Tokyo 1130033, Japan	Osaka University; Osaka University; Jikei University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Tokyo	Otsu, K (corresponding author), Osaka Univ, Dept Cardiovasc Med, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	kotsu@medone.med.osaka-u.ac.jp	Tomita, Taisuke/L-5427-2015; Hikoso, Shungo/R-4281-2018	Tomita, Taisuke/0000-0002-0075-5943; Hikoso, Shungo/0000-0003-2284-1970; Yamaguchi, Osamu/0000-0002-7461-369X				Asahi M, 2004, P NATL ACAD SCI USA, V101, P9199, DOI 10.1073/pnas.0402596101; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Endo M, 1972, Nihon Seirigaku Zasshi, V34, P88; Guo W, 1996, J BIOL CHEM, V271, P458, DOI 10.1074/jbc.271.1.458; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; HONGO K, 1993, J PHYSIOL-LONDON, V461, P167, DOI 10.1113/jphysiol.1993.sp019507; IMAGAWA T, 1989, J BIOCHEM-TOKYO, V106, P342, DOI 10.1093/oxfordjournals.jbchem.a122855; Iwamoto T, 1998, BIOCHEMISTRY-US, V37, P17230, DOI 10.1021/bi981521q; Ji Y, 1999, ANAL BIOCHEM, V269, P236, DOI 10.1006/abio.1999.4059; KAWAI M, 1994, CELL CALCIUM, V16, P123, DOI 10.1016/0143-4160(94)90007-8; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Leissring MA, 1999, J BIOL CHEM, V274, P32535, DOI 10.1074/jbc.274.46.32535; Lokuta AJ, 1997, J BIOL CHEM, V272, P25333, DOI 10.1074/jbc.272.40.25333; Mattson MP, 2001, BIOCHEM SOC SYMP, V67, P151, DOI 10.1042/bss0670151; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MEYERS MB, 1987, BIOCHEM PHARMACOL, V36, P2373, DOI 10.1016/0006-2952(87)90606-X; MEYERS MB, 1995, J BIOL CHEM, V270, P26411, DOI 10.1074/jbc.270.44.26411; Nakayama H, 2002, FASEB J, V16, P61, DOI 10.1096/fj.02-0474fje; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; Pack-Chung E, 2000, J BIOL CHEM, V275, P14440, DOI 10.1074/jbc.M909882199; Sorrentino V, 1995, Adv Pharmacol, V33, P67, DOI 10.1016/S1054-3589(08)60666-3; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; SUZUKI T, 1986, J BIOL CHEM, V261, P7018; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; TIMERMAN AP, 1994, BIOCHEM BIOPH RES CO, V198, P701, DOI 10.1006/bbrc.1994.1101; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; VANDERBLIEK AM, 1986, EMBO J, V5, P3201, DOI 10.1002/j.1460-2075.1986.tb04630.x; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Yamaguchi O, 2003, P NATL ACAD SCI USA, V100, P15883, DOI 10.1073/pnas.2136717100; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389; Zucchi R, 1997, PHARMACOL REV, V49, P1	36	41	44	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2069	+		10.1096/fj.05-3744fje	http://dx.doi.org/10.1096/fj.05-3744fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16204356				2022-12-28	WOS:000232991100031
J	Imam, SZ; Jankovic, J; Ali, SF; Skinner, JT; Xie, WJ; Conneely, OM; Lee, WD				Imam, SZ; Jankovic, J; Ali, SF; Skinner, JT; Xie, WJ; Conneely, OM; Lee, WD			Nitric oxide mediates increased susceptibility to dopaminergic damage in Nurr1 heterozygous mice	FASEB JOURNAL			English	Article						nitric oxide; dopamine; 3-NT; caspase; transcription; apoptosis	ORPHAN NUCLEAR RECEPTOR; ALPHA-SYNUCLEIN; EXPRESSION INCREASES; METHAMPHETAMINE; APOPTOSIS; DEATH; GENE; OVEREXPRESSION; PEROXYNITRITE; NEUROTOXICITY	Knocking out of Nurr1 gene, a member of nuclear receptor superfamily, causes selective agenesis of dopaminergic neurons in midbrain. Reduced expression of Nurr1 increases the vulnerability of mesencephalic dopamine neurons to dopaminergic toxins. We evaluated the role of nitric oxide as a possible mechanism for this increased susceptibility. Increased expression of neuronal nitric oxide synthase and increased 3-nitrotyrosine were observed in striatum of Nurr1 heterozygous (Nurr1 +/-) mice as compared with wild-type. Increased cytochrome C activation and consecutive release of Smac/DIABLO were also observed in Nurr1 +/- mice. An induction of active Caspase-3 and p53, cleavage of poly-ADP (RNase) polymerase and reduced expression of bcl-2 were observed in Nurr1 +/- mice. Methamphetamine significantly increased these markers in Nurr1 +/- mice as compared with wild-type. The present data therefore suggest that nitric oxide plays a role as a modulating factor for the increased susceptibility, but not the potentiation, of the dopaminergic terminals in Nurr1 +/- mice. We also report that this increased neuronal nitric oxide synthase expression and increased nitration in Nurr1 +/- mice led to the activation of apoptotic cascade via the differential alterations in the DNA binding activity of transcription factors responsible for the propagation of growth arrest as well as apoptosis.	Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; S Texas Vet Hlth Care Syst, San Antonio, TX USA; UT Hlth Sci, Dept Med, San Antonio, TX USA; US FDA, Neurochem Lab, Div Neurotoxicol, NCTR, Jefferson, AR USA; Baylor Coll Med, Dept Cellular & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio; US Food & Drug Administration (FDA); Baylor College of Medicine	Lee, WD (corresponding author), Baylor Coll Med, Dept Neurol, NB 205,6501 Fannin St, Houston, TX 77030 USA.	simam@satx.rr.com; Weidongl@bcm.tmc.edu			NINDS NIH HHS [NS40370, NS043567] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040370, R01NS043567] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Backman C, 2003, BEHAV BRAIN RES, V143, P95, DOI 10.1016/S0166-4328(03)00029-9; Bannon MJ, 2002, P NATL ACAD SCI USA, V99, P6382, DOI 10.1073/pnas.092654299; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Catania MV, 1999, NEUROSCIENCE, V91, P1529, DOI 10.1016/S0306-4522(98)00544-2; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chen W, 2002, CHINESE MED J-PEKING, V115, P446; Cibelli G, 2002, J NEUROSCI RES, V67, P450, DOI 10.1002/jnr.10141; Deng XL, 1999, BRAIN RES, V851, P254, DOI 10.1016/S0006-8993(99)02087-9; Deshmukh M, 1998, APOPTOSIS, V3, P387, DOI 10.1023/A:1009602401251; Elliott MJ, 2002, TUMOR BIOL, V23, P76, DOI 10.1159/000059708; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Greco C, 2001, ANTICANCER RES, V21, P3185; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Hirata H, 1997, J NEUROCHEM, V69, P780; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Imam SZ, 2002, ANN NY ACAD SCI, V965, P204; Imam SZ, 2001, ANN NY ACAD SCI, V939, P366; Imam SZ, 2001, MOL BRAIN RES, V91, P174, DOI 10.1016/S0169-328X(01)00139-5; Imam SZ, 2001, J NEUROCHEM, V76, P745, DOI 10.1046/j.1471-4159.2001.00029.x; Itzhak Y, 1998, J PHARMACOL EXP THER, V284, P1040; Jayanthi S, 2005, P NATL ACAD SCI USA, V102, P868, DOI 10.1073/pnas.0404990102; Jiang CT, 2005, EXP NEUROL, V191, P154, DOI 10.1016/j.expneurol.2004.08.035; Junn E, 2002, NEUROSCI LETT, V320, P146, DOI 10.1016/S0304-3940(02)00016-2; Le W, 1999, J NEUROCHEM, V73, P2218; Liu CT, 1998, CANCER GENE THER, V5, P3; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; MAGES HW, 1994, MOL ENDOCRINOL, V8, P1583, DOI 10.1210/me.8.11.1583; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Ojeda V, 2003, J NEUROSCI RES, V73, P686, DOI 10.1002/jnr.10705; Okano H, 2002, ANTI-CANCER DRUG, V13, P59, DOI 10.1097/00001813-200201000-00007; Paxinou E, 2001, J NEUROSCI, V21, P8053, DOI 10.1523/JNEUROSCI.21-20-08053.2001; Perlmann T, 2004, CELL TISSUE RES, V318, P45, DOI 10.1007/s00441-004-0974-7; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Przedborski S, 2001, J NEUROCHEM, V76, P637, DOI 10.1046/j.1471-4159.2001.00174.x; Sakurada K, 1999, DEVELOPMENT, V126, P4017; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; Schulz JB, 1999, ANN NEUROL, V45, P421, DOI 10.1002/1531-8249(199904)45:4<421::AID-ANA2>3.0.CO;2-Q; SHALL S, 1994, MOL CELL BIOCHEM, V138, P71, DOI 10.1007/BF00928445; Sugars KL, 2001, NUCLEIC ACIDS RES, V29, P4530, DOI 10.1093/nar/29.22.4530; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Yang YL, 2002, J BIOL CHEM, V277, P19482, DOI 10.1074/jbc.M201687200; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248; Zhou WB, 2002, BRAIN RES, V926, P42, DOI 10.1016/S0006-8993(01)03292-9	48	24	24	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1441	1450		10.1096/fj.04-3362com	http://dx.doi.org/10.1096/fj.04-3362com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16126911				2022-12-28	WOS:000232315700037
J	Jay, PY; Rozhitskaya, O; Tarnavski, O; Sherwood, MC; Dorfman, AL; Lu, YL; Ueyama, T; Izumo, S				Jay, PY; Rozhitskaya, O; Tarnavski, O; Sherwood, MC; Dorfman, AL; Lu, YL; Ueyama, T; Izumo, S			Haploinsufficiency of the cardiac transcription factor Nkx2-5 variably affects the expression of putative target genes	FASEB JOURNAL			English	Article						gene regulation; cardiac development; heart failure; heterozygosity	CONGENITAL HEART-DISEASE; HOMEOBOX GENE; NATRIURETIC PEPTIDE; MICE; PROMOTER; TBX5; ARRHYTHMIAS; CSX/NKX2.5; MUTATIONS; LACKING	Heterozygous mutations of the cardiac transcription factor Nkx2-5 cause congenital heart disease. To elucidate the molecular pathways of transcription factor mutant phenotypes or diseases, direct targets are commonly sought in studies of homozygous null mutant animals and by heterologous promoter-reporter gene transactivation assays. The expression of putative target genes in a physiologic range of transcription factor concentration, however, is often not examined. Heterozygous Nkx2-5 knockout (Nkx2-5(+/-)) mice have no more than half-normal levels of Nkx2- 5 protein. We therefore measured the mRNA expression of four putative targets of the cardiac transcription factor Nkx2-5 in wild-type and Nkx2-5(+/-) animals in a variety of developmental and pathologic states. Wild-type and Nkx2-5(+/-) embryonic hearts expressed similar levels of atrial natriuretic factor (ANF), brain natriuretic peptide (BNP), the RNA helicase Csm, and homeodomain only protein HOP. In the failing adult ventricle, ANF and BNP were up-regulated to the same extent in wild- type and Nkx2-5(+/-) myocardium. Csm and HOP were down-regulated in heart failure, and Nkx2-5(+/-) hearts expressed about half-normal levels in healthy and failing states. No consistent relationship existed between the expression of putative transcriptional targets and Nkx2- 5 gene dosage in the physiologically relevant range. Any dependence of gene expression on Nkx2-5(+/-) gene dosage is affected by factors specific to the individual gene and the physiologic context.	Washington Univ, Sch Med, Dept Pediat & Genet, St Louis, MO 63110 USA; Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA	Washington University (WUSTL); Harvard University; Boston Children's Hospital	Jay, PY (corresponding author), Washington Univ, Sch Med, Dept Pediat, 660 S Euclid Ave,Box 8208, St Louis, MO 63110 USA.	jay_p@kids.wustl.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K12HD001487] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL007572] Funding Source: Medline; NICHD NIH HHS [K12-HD001487] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Biben C, 2000, CIRC RES, V87, P888, DOI 10.1161/01.RES.87.10.888; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Chen F, 2002, CELL, V110, P713, DOI 10.1016/S0092-8674(02)00932-7; Durocher D, 1996, MOL CELL BIOL, V16, P4648, DOI 10.1128/mcb.16.9.4648; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Jay PY, 2004, J CLIN INVEST, V113, P1130, DOI 10.1172/JCI200419846; Kirchhoff S, 1998, CURR BIOL, V8, P299, DOI 10.1016/S0960-9822(98)70114-9; Knowles JW, 2001, J CLIN INVEST, V107, P975, DOI 10.1172/JCI11273; Linhares VLF, 2004, CARDIOVASC RES, V64, P402, DOI 10.1016/j.cardiores.2004.09.021; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Magee JA, 2003, CANCER CELL, V3, P273, DOI 10.1016/S1535-6108(03)00047-3; Pashmforoush M, 2004, CELL, V117, P373, DOI 10.1016/S0092-8674(04)00405-2; Quon KC, 2001, GENE DEV, V15, P2917, DOI 10.1101/gad.949001; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; Seidman JG, 2002, J CLIN INVEST, V109, P451, DOI 10.1172/JC1200215043; Shin CH, 2002, CELL, V110, P725, DOI 10.1016/S0092-8674(02)00933-9; Small EA, 2003, DEV BIOL, V261, P116, DOI 10.1016/S0012-1606(03)00306-3; Tamura N, 2000, P NATL ACAD SCI USA, V97, P4239, DOI 10.1073/pnas.070371497; Tanaka M, 2002, COLD SPRING HARB SYM, V67, P317, DOI 10.1101/sqb.2002.67.317; Tanaka M, 1999, DEVELOPMENT, V126, P1269; Tarnavski O, 2004, PHYSIOL GENOMICS, V16, P349, DOI 10.1152/physiolgenomics.00041.2003; Ueyama T, 2003, J BIOL CHEM, V278, P28750, DOI 10.1074/jbc.M300014200; Veitia RA, 2002, BIOESSAYS, V24, P175, DOI 10.1002/bies.10023	25	19	20	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2005	19	8					1495	+		10.1096/fj.04-3064fje	http://dx.doi.org/10.1096/fj.04-3064fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15972800				2022-12-28	WOS:000230207800007
J	Keller, M; Lidington, D; Vogel, L; Peter, BF; Sohn, HY; Pagano, PJ; Pitson, S; Spiegel, S; Pohl, U; Bolz, SS				Keller, Matthias; Lidington, Darcy; Vogel, Lukas; Peter, Bernhard Friedrich; Sohn, Hae-Young; Pagano, Patrick J.; Pitson, Stuart; Spiegel, Sarah; Pohl, Ulrich; Bolz, Steffen-Sebastian			Sphingosine kinase functionally links elevated transmural pressure and increased reactive oxygen species formation in resistance arteries	FASEB JOURNAL			English	Article						smooth muscle; signal transduction; transfection; NADPH oxidase; Ca2+ sensitization	VASCULAR SMOOTH-MUSCLE; RHO-KINASE; CALCIUM SENSITIVITY; MYOGENIC REACTIVITY; NAD(P)H OXIDASE; RHOA/RHO-KINASE; NADPH OXIDASE; ACTIVATION; PATHWAYS; CELLS	Myogenic vasoconstriction, an intrinsic response to elevated transmural pressure (TMP), requires the activation of sphingosine kinase (Sk1) and the generation of reactive oxygen species (ROS). We hypothesized that pressure-induced Sk1 signaling and ROS generation are functionally linked. Using a model of cannulated resistance arteries isolated from the hamster gracilis muscle, we monitored vessel diameter and smooth muscle cell (SMC) Ca-i(2+) (Fura-2) or ROS production (dichlorodihydrofluorescein). Elevation of TMP stimulated the translocation of a GFP- tagged Sk1 fusion protein from the cytosol to the plasma membrane, indicative of enzymatic activation. Concurrently, elevation of TMP initiated a rapid and transient production of ROS, which was enhanced by expression of wild-type Sk1 (hSk(wt)) and inhibited by its dominant-negative mutant (hSk(G82D)). Exogenous sphingosine-1-phosphate (S1P) also stimulated ROS generation is isolated vessels. Chemical (1 mu mol/L DPI), peptide (gp91ds-tat/gp91ds), and genetic (N17Rac) inhibition strategies indicated that NADPH oxidase was the source of the pressure-induced ROS. NADPH oxidase inhibition attenuated myogenic vasoconstriction and reduced the apparent Ca2+ sensitivity of the SMC contractile apparatus, without affecting Ca2+-independent, RhoA-mediated vasoconstriction in response to exogenous S1P. Our results indicate a mandatory role for Sk1/S1P in mediating pressure-induced, NADPH oxidase-derived ROS formation. In turn, ROS generation appears to increase Ca2+ sensitivity, necessary for full myogenic vasoconstriction.	Univ Munich, Inst Physiol, D-80336 Munich, Germany; Univ Munich, Dept Cardiol, D-80336 Munich, Germany; Henry Ford Hlth Syst, Div Hypertens, Detroit, MI USA; Henry Ford Hlth Syst, Div Vasc Res, Detroit, MI USA; Inst Med & Vet Sci, Hanson Inst Human Immunol, Adelaide, SA 5000, Australia; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem, Richmond, VA 23298 USA	University of Munich; University of Munich; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Hanson Institute; Institute Medical & Veterinary Science Australia; Virginia Commonwealth University	Bolz, SS (corresponding author), Univ Munich, Inst Physiol, Schillerstr 44, D-80336 Munich, Germany.	bolz@lmu.de	Pitson, Stuart/B-9342-2009	Pitson, Stuart/0000-0002-9527-2740; Lidington, Darcy/0000-0001-7582-7924				Bokoch GM, 2002, BLOOD, V100, P2692, DOI 10.1182/blood-2002-04-1149; Bolz SS, 2000, CIRCULATION, V102, P2402, DOI 10.1161/01.CIR.102.19.2402; Bolz SS, 2003, J VASC RES, V40, P399, DOI 10.1159/000072830; Bolz SS, 2003, CIRCULATION, V108, P342, DOI 10.1161/01.CIR.0000080324.12530.0D; Bolz SS, 2003, CIRCULATION, V107, P3081, DOI 10.1161/01.CIR.0000074202.19612.8C; Gregg D, 2003, AM J PHYSIOL-CELL PH, V285, pC723, DOI 10.1152/ajpcell.00230.2003; Hill MA, 2001, J APPL PHYSIOL, V91, P973, DOI 10.1152/jappl.2001.91.2.973; Janssen LJ, 2001, AM J PHYSIOL-LUNG C, V280, pL666, DOI 10.1152/ajplung.2001.280.4.L666; Jin LM, 2004, AM J PHYSIOL-HEART C, V287, pH1495, DOI 10.1152/ajpheart.01006.2003; Khan NA, 2003, J NEUROVIROL, V9, P584, DOI 10.1080/714044480; Massett MP, 2002, AM J PHYSIOL-HEART C, V283, pH2282, DOI 10.1152/ajpheart.00544.2002; Nava VE, 2000, FEBS LETT, V473, P81, DOI 10.1016/S0014-5793(00)01510-6; Nowicki PT, 2001, CIRC RES, V89, P114, DOI 10.1161/hh1401.094367; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; Paladugu R, 2003, J VASC SURG, V38, P549, DOI 10.1016/S0741-5214(03)00770-5; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Rey FE, 2001, CIRC RES, V89, P408, DOI 10.1161/hh1701.096037; Schubert R, 2002, AM J PHYSIOL-HEART C, V283, pH2288, DOI 10.1152/ajpheart.00549.2002; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Touyz RM, 2004, HISTOCHEM CELL BIOL, V122, P339, DOI 10.1007/s00418-004-0696-7; Touyz RM, 2002, CIRC RES, V90, P1205, DOI 10.1161/01.RES.0000020404.01971.2F; VAN BJ, 1998, J CELL BIOL, V142, P229; WOJCIAKSTOTHARD B, 2004, AM J PHYSL LUNG CELL; Xiao DL, 2004, AM J PHYSIOL-HEART C, V286, pH1615, DOI 10.1152/ajpheart.00981.2003	26	50	50	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					702	+		10.1096/fj.05-4075fje	http://dx.doi.org/10.1096/fj.05-4075fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16476702				2022-12-28	WOS:000237698700021
J	Jonas, WB; Ives, JA; Rollwagen, F; Denman, DW; Hintz, K; Hammer, M; Crawford, C; Henry, K				Jonas, WB; Ives, JA; Rollwagen, F; Denman, DW; Hintz, K; Hammer, M; Crawford, C; Henry, K			Can specific biological signals be digitized?	FASEB JOURNAL			English	Article						social management of science; controversial science claims; electromagnetic signals; digital biology; thrombin; fibrinogen; coagulation	HUMAN BASOPHIL DEGRANULATION; DILUTE ANTISERUM; IGE; INHIBITION; ACTIVATION; HISTAMINE	At the request of the United States Defense Advanced Research Projects Agency, we attempted to replicate the data of Professor Jacques Benveniste that digital signals recorded on a computer disc produce specific biological effects. The hypothesis was that a digitized thrombin inhibitor signal would inhibit the fibrinogen-thrombin coagulation pathway. Because of the controversies associated with previous research of Prof. Benveniste, we developed a system for the management of social controversy in science that incorporated an expert in social communication and conflict management. The social management approach was an adaptation of interactional communication theory, for management of areas that interfere with the conduct of good science. This process allowed us to successfully complete a coordinated effort by a multidisciplinary team, including Prof. Benveniste, a hematologist, engineer, skeptic, statistician, neuroscientist and conflict management expert. Our team found no replicable effects from digital signals. Jonas, W. B., Ives, J. A., Rollwagen, F., Denman, D. W., Hintz K., Hammer, M., Crawford, C., Henry, K. Can specific biological signals be digitized?	Samueli Inst Informat Biol, Alexandria, VA 22314 USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; Walter Reed Army Inst Res, Washington, DC USA; Univ Maryland, College Pk, MD 20742 USA; George Mason Univ, Fairfax, VA 22030 USA; American Univ, Washington, DC 20016 USA; Def Advance Res Projects Agcy, Arlington, VA USA	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); University System of Maryland; University of Maryland College Park; George Mason University; American University; United States Department of Defense; Defense Advanced Research Projects Agency (DARPA)	Jonas, WB (corresponding author), 1700 Diagonal Rd,Suite 400, Alexandria, VA 22314 USA.	wjonas@siib.org						[Anonymous], 1967, PRAGMATICS HUMAN COM; Belon P, 1999, INFLAMM RES, V48, pS17; Benveniste J, 1999, FASEB J, V13, pA163; Brown V, 2001, INFLAMM RES, V50, pS47; Cissna K.N.L., 1981, RIGOR IMAGINATION ES, P253; COLES P, 1988, NATURE, V334, P372, DOI 10.1038/334372a0; DAVENAS E, 1988, NATURE, V333, P816, DOI 10.1038/333816a0; DESTEPHEN RS, 1988, SMALL GROUP BEHAV, V19, P227, DOI 10.1177/104649648801900204; HAMMER M, 1997, PRACTICE OUTCOMES MO; HAMMER M, 1996, BURZYNSKI ANTINEOPLA; HAMMER M, 1996, MANAGEMENT DISPUTE J; Hammer M. R., 1997, DYNAMIC PROCESSES CR, P9; Hammer Mitchell R, 2004, Integr Cancer Ther, V3, P59, DOI 10.1177/1534735404263448; HIRST SJ, 1993, NATURE, V366, P525, DOI 10.1038/366525a0; Janis, 1989, CRUCIAL DECISIONS; Janis I. L, 1982, GROUPTHINK, V2nd; MADDOX J, 1988, NATURE, V334, P287, DOI 10.1038/334287a0; OVELGONNE JH, 1992, EXPERIENTIA, V48, P504, DOI 10.1007/BF01928175; Rogan R. G., 2002, LAW ENFORCEMENT COMM, P229; SCHIFF M, 1994, MEMORY WATER; STENT GS, 1972, SCI AM, V227, P84, DOI 10.1038/scientificamerican1272-84; Thomas Y, 2000, MED HYPOTHESES, V54, P33, DOI 10.1054/mehy.1999.0891; URESCH J, 1951, COMMUNICATION SOCIAL; Walleczek J., 2000, SELF ORG BIOL DYNAMI; 1988, NATURE LONDON, V333, P787	25	27	29	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					23	28		10.1096/fj.05-3815hyp	http://dx.doi.org/10.1096/fj.05-3815hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16394263				2022-12-28	WOS:000235996000040
J	Eul, B; Rose, F; Krick, S; Savai, R; Goyal, P; Klepetko, W; Grimminger, F; Weissmann, N; Seeger, W; Hanze, J				Eul, B; Rose, F; Krick, S; Savai, R; Goyal, P; Klepetko, W; Grimminger, F; Weissmann, N; Seeger, W; Hanze, J			Impact of HIF-1 alpha and HIF-2 alpha on proliferation and migration of human pulmonary artery fibroblasts in hypoxia	FASEB JOURNAL			English	Article						adventitia; alpha-smooth-muscle actin; remodeling; RNA interference	SMOOTH-MUSCLE-CELLS; GENE-EXPRESSION; CELLULAR PROLIFERATION; INDUCIBLE FACTOR-1-ALPHA; ADVENTITIAL FIBROBLASTS; MOLECULAR-MECHANISMS; RNA INTERFERENCE; FACTOR-I; LUNG; HYPERTENSION	Proliferation of adventitial fibroblasts of small intrapulmonary arteries ( FBPA) has been disclosed as an early event in the development of pulmonary hypertension and cor pulmonale in response to hypoxia. We investigated the role of hypoxia-inducible transcription factors (HIF) in human FBPA exposed to hypoxia. Primary cultures of FBPA displayed a strong mitogenic response to 24 h hypoxia, whereas the rate of apoptosis was significantly suppressed. In addition, the migration of FBPA was strongly increased under hypoxic conditions but not the expression of alpha-smooth muscle actin. Hypoxia induced a marked up-regulation ( protein level) of both HIF-1 alpha and HIF-2 alpha, alongside with nuclear translocation of these transcription factors. Specific inhibition of either HIF-1 alpha or HIF-2 alpha was achieved by RNA interference technology, as proven by HIF-1 alpha and HIF-2 alpha mRNA and protein analysis and expression analysis of HIF downstream target genes. With the use of this approach, the hypoxia-induced proliferative response of the FBPA was found to be solely HIF-2 alpha dependent, whereas the migratory response was significantly reduced by both HIF-1 alpha and HIF-2 alpha interference. In conclusion, HIF up-regulation is essential for hypoxic cellular responses in human pulmonary artery adventitial fibroblasts such as proliferation and migration, mimicking the pulmonary hypertensive phenotype in vivo. Differential HIF subtype dependency was noted, with HIF-2 alpha playing a predominant role, which may offer future intervention strategies.	Univ Giessen, Med Clin 2, Lung Ctr, D-35392 Giessen, Germany; Univ Hosp Vienna, A-1220 Vienna, Austria	Justus Liebig University Giessen; University Hospital Vienna	Hanze, J (corresponding author), Univ Giessen, Med Clin 2, Lung Ctr, Klinikstr 36, D-35392 Giessen, Germany.	joerg.haenze@uglc.de	Goyal, Parag/ABH-1136-2021	Goyal, Parag/0000-0002-5678-8592; Savai, Rajkumar/0000-0003-1538-2091; Seeger, Werner/0000-0003-1946-0894; Grimminger, Friedrich/0000-0001-8725-6276; Weissmann, Norbert/0000-0003-2675-3871				Berg JT, 1998, AM J RESP CRIT CARE, V158, P1920, DOI 10.1164/ajrccm.158.6.9804076; Brusselmans K, 2003, J CLIN INVEST, V111, P1519, DOI 10.1172/JCI200315496; Burgess HA, 2005, AM J PHYSIOL-LUNG C, V288, pL1146, DOI 10.1152/ajplung.00383.2004; Camenisch G, 2001, PFLUG ARCH EUR J PHY, V443, P240, DOI 10.1007/s004240100679; Coulet F, 2003, J BIOL CHEM, V278, P46230, DOI 10.1074/jbc.M305420200; Das M, 2000, AM J RESP CELL MOL, V22, P15, DOI 10.1165/ajrcmb.22.1.3536; Das M, 2002, AM J PHYSIOL-LUNG C, V282, pL976, DOI 10.1152/ajplung.00382.2001; Eddahibi S, 1999, CIRC RES, V84, P329, DOI 10.1161/01.RES.84.3.329; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Faller DV, 1999, CLIN EXP PHARMACOL P, V26, P74, DOI 10.1046/j.1440-1681.1999.02992.x; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Goyal P, 2004, FREE RADICAL BIO MED, V36, P1279, DOI 10.1016/j.freeradbiomed.2004.02.071; Hanze J, 2003, BIOCHEM BIOPH RES CO, V312, P571, DOI 10.1016/j.bbrc.2003.10.153; Iida T, 2002, GENES CELLS, V7, P143, DOI 10.1046/j.1356-9597.2001.00512.x; Kourembanas S, 1997, KIDNEY INT, V51, P438, DOI 10.1038/ki.1997.58; Krick S, 2005, FASEB J, V19, P857, DOI 10.1096/fj.04-2890fje; MICHIELS C, 1994, EXP CELL RES, V213, P43, DOI 10.1006/excr.1994.1171; MIN BH, 1990, J BIOL CHEM, V265, P16667; MURPHY JD, 1991, J PEDIAT, V98, P962; Norman JT, 2000, KIDNEY INT, V58, P2351, DOI 10.1046/j.1523-1755.2000.00419.x; PERKETT EA, 1992, AM J RESP CELL MOL, V6, P82, DOI 10.1165/ajrcmb/6.1.82; Pfeifer M, 1998, RESP PHYSIOL, V111, P201, DOI 10.1016/S0034-5687(97)00102-3; Rose F, 2002, FASEB J, V16, P1660, DOI 10.1096/fj.02-0420fje; Semenza G L, 2000, Respir Res, V1, P159, DOI 10.1186/rr27; Semenza GL, 2004, J APPL PHYSIOL, V96, P1173, DOI 10.1152/japplphysiol.00770.2003; Short M, 2004, AM J PHYSIOL-CELL PH, V286, pC416, DOI 10.1152/ajpcell.00169.2003; Sowter HM, 2003, CANCER RES, V63, P8562; Stenmark KR, 2000, PHYSIOL RES, V49, P503; Stenmark KR, 1997, ANNU REV PHYSIOL, V59, P89, DOI 10.1146/annurev.physiol.59.1.89; Strauss BH, 2000, AM J RESP CELL MOL, V22, P1; SUI GJ, 1988, J PATHOL, V155, P161, DOI 10.1002/path.1711550213; Warnecke C, 2004, FASEB J, V18, P1462, DOI 10.1096/fj.04-1640fje; Welsh DJ, 1998, AM J RESP CRIT CARE, V158, P1757, DOI 10.1164/ajrccm.158.6.9706054; Welsh DJ, 2001, AM J RESP CRIT CARE, V164, P282, DOI 10.1164/ajrccm.164.2.2008054; Wenger RH, 1997, KIDNEY INT, V51, P560, DOI 10.1038/ki.1997.79; Wort SJ, 2001, AM J RESP CELL MOL, V25, P104, DOI 10.1165/ajrcmb.25.1.4331; Yu AY, 1999, J CLIN INVEST, V103, P691, DOI 10.1172/JCI5912	39	46	53	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					163	+		10.1096/fj.05-4104fje	http://dx.doi.org/10.1096/fj.05-4104fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16263938				2022-12-28	WOS:000234053100023
J	Yu, LCH; Flynn, AN; Turner, JR; Buret, AG				Yu, LCH; Flynn, AN; Turner, JR; Buret, AG			SGLT-1-mediated glucose uptake protects intestinal epithelial cells against LPS-induced apoptosis and barrier defects: a novel cellular rescue mechanism?	FASEB JOURNAL			English	Article						enterocytes apoptosis; paracellular permeability; LPS; SGLT-1; glucose	MITOCHONDRIAL PERMEABILITY TRANSITION; DEPENDENT ANION CHANNEL; CYTOCHROME-C RELEASE; BAX TRANSLOCATION; DOWN-REGULATION; BCL-2 FAMILY; IN-VIVO; EXPRESSION; INHIBITION; MYOSIN	Excessive apoptosis induced by enteric microbes leads to epithelial barrier defects. This mechanism has been implicated in the pathogenesis of inflammatory bowel diseases (IBD) and bacterial enteritis. The sodium-dependent glucose cotransporter (SGLT-1) is responsible for active glucose uptake in enterocytes. The aim was to investigate the effects of SGLT-1 glucose uptake on enterocyte apoptosis and barrier defects induced by bacterial lipopolysaccharide (LPS). SGLT-1-transfected Caco-2 cells were treated with LPS ( 50 mu g/mL) in low ( 5 mM) or high ( 25 mM) glucose media. LPS in low glucose induced caspase-3 cleavage, DNA fragmentation, and increased paracellular permeability to dextran in epithelial cells. These phenomena were significantly attenuated in high glucose. LPS increased SGLT-1 activity in high, but not low glucose media. Addition of phloridzin, which competitively binds to SGLT-1, inhibited the cytoprotection mediated by high glucose. Western blot showed that LPS in high glucose increased the levels of anti-apoptotic Bcl-2 and Bcl-XL, and did not change proapoptotic Bax. Differential extraction of membranous vs. cytosolic cell components demonstrated that high glucose inhibits mitochondrial cytochrome c translocation to cytosol. Collectively, SGLT-1-mediated glucose uptake increases anti-apoptotic proteins, and protects enterocytes from LPS-induced apoptosis and barrier defects. The understanding of this novel glucose-mediated rescue mechanism may lead to therapeutic interventions for various enteric diseases.	Univ Calgary, Mucosal Inflammat Res Grp, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	University of Calgary; University of Chicago	Buret, AG (corresponding author), Univ Calgary, Mucosal Inflammat Res Grp, Dept Biol Sci, BI 117,2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	aburet@ucalgary.ca	Turner, Jerrold/H-1502-2019; Turner, Jerrold R/A-6895-2009	Turner, Jerrold R/0000-0003-0627-9455; Yu, Linda Chia-Hui/0000-0003-1461-3249				Abreu MT, 2000, GASTROENTEROLOGY, V119, P1524, DOI 10.1053/gast.2000.20232; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Antonelli A, 2001, BLOOD CELL MOL DIS, V27, P978, DOI 10.1006/bcmd.2001.0470; Bannerman DD, 2004, AM J PATHOL, V165, P1423, DOI 10.1016/S0002-9440(10)63400-1; Berglund JJ, 2001, AM J PHYSIOL-GASTR L, V281, pG1487; Bocker U, 2000, J BIOL CHEM, V275, P12207, DOI 10.1074/jbc.275.16.12207; Bojarski C, 2004, J CELL SCI, V117, P2097, DOI 10.1242/jcs.01071; Caradonna L, 2000, J ENDOTOXIN RES, V6, P205, DOI 10.1177/09680519000060030101; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Cario E, 2000, J IMMUNOL, V164, P966, DOI 10.4049/jimmunol.164.2.966; Chin AC, 2003, P NATL ACAD SCI USA, V100, P11104, DOI 10.1073/pnas.1831452100; Chin AC, 2002, INFECT IMMUN, V70, P3673, DOI 10.1128/IAI.70.7.3673-3680.2002; Courtois F, 2003, AM J CLIN NUTR, V77, P744, DOI 10.1093/ajcn/77.3.744; Darfeuille-Michaud A, 1998, GASTROENTEROLOGY, V115, P1405, DOI 10.1016/S0016-5085(98)70019-8; Deng WL, 2002, GASTROENTEROLOGY, V123, P206, DOI 10.1053/gast.2002.34209; Drewe J, 2001, EUR J CLIN INVEST, V31, P138, DOI 10.1046/j.1365-2362.2001.00792.x; ECKMANN L, 1993, GASTROENTEROLOGY, V105, P1689, DOI 10.1016/0016-5085(93)91064-O; Eguchi Y, 1997, CANCER RES, V57, P1835; Eipel C, 2004, AM J PHYSIOL-GASTR L, V286, pG769, DOI 10.1152/ajpgi.00275.2003; GARDINER KR, 1995, GUT, V36, P897, DOI 10.1136/gut.36.6.897; Giovannini C, 2003, FEBS LETT, V540, P117, DOI 10.1016/S0014-5793(03)00236-9; Gitter AH, 2000, FASEB J, V14, P1749, DOI 10.1096/fj.99-0898com; Hall JL, 2001, DIABETES, V50, P1171, DOI 10.2337/diabetes.50.5.1171; Han XN, 2004, SHOCK, V21, P261, DOI 10.1097/01.shk.0000112346.38599.10; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; Imaeda H, 2002, HISTOCHEM CELL BIOL, V118, P381, DOI 10.1007/s00418-002-0458-3; Jones GB, 2000, ORG LETT, V2, P811, DOI 10.1021/ol0055566; KAN O, 1994, J EXP MED, V180, P917, DOI 10.1084/jem.180.3.917; Kellett GL, 2001, J PHYSIOL-LONDON, V531, P585, DOI 10.1111/j.1469-7793.2001.0585h.x; KIMMICH GA, 1981, AM J PHYSIOL, V241, pC227, DOI 10.1152/ajpcell.1981.241.5.C227; KIMMICH GA, 1984, AM J PHYSIOL, V247, pC74, DOI 10.1152/ajpcell.1984.247.1.C74; Le'Negrate G, 2001, INFECT IMMUN, V69, P5001, DOI 10.1128/IAI.69.8.5001-5009.2001; MADARA JL, 1990, J MEMBRANE BIOL, V116, P177, DOI 10.1007/BF01868675; MADARA JL, 1987, AM J PHYSIOL, V253, pC854, DOI 10.1152/ajpcell.1987.253.6.C854; Malhotra R, 2001, AM J PHYSIOL-CELL PH, V281, pC1596, DOI 10.1152/ajpcell.2001.281.5.C1596; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Mayer B, 2003, NEWS PHYSIOL SCI, V18, P89, DOI 10.1152/nips.01433.2002; Merger M, 2002, GUT, V51, P155, DOI 10.1136/gut.51.2.155; Munoz-Pinedo C, 2003, J BIOL CHEM, V278, P12759, DOI 10.1074/jbc.M212392200; Nazli A, 2004, AM J PATHOL, V164, P947, DOI 10.1016/S0002-9440(10)63182-3; Neut C, 2002, AM J GASTROENTEROL, V97, P939, DOI 10.1111/j.1572-0241.2002.05613.x; OrtizArduan A, 1996, AM J PHYSIOL-RENAL, V271, pF1193; Paesold G, 2002, CELL MICROBIOL, V4, P771, DOI 10.1046/j.1462-5822.2002.00233.x; Pollman MJ, 1999, CIRC RES, V84, P113; Power C, 2001, J SURG RES, V101, P138, DOI 10.1006/jsre.2001.6270; Ramachandran A, 2000, J GASTROEN HEPATOL, V15, P109, DOI 10.1046/j.1440-1746.2000.02059.x; Rao JN, 2003, AM J PHYSIOL-CELL PH, V284, pC848, DOI 10.1152/ajpcell.00371.2002; REGOLI DC, 1981, EUR J PHARMACOL, V71, P105, DOI 10.1016/0014-2999(81)90391-5; Rosenblatt J, 2001, CURR BIOL, V11, P1847, DOI 10.1016/S0960-9822(01)00587-5; Rudkowski JC, 2004, AM J PHYSIOL-LUNG C, V286, pL793, DOI 10.1152/ajplung.00266.2003; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Sato N, 2004, J EXP MED, V200, P601, DOI 10.1084/jem.20040689; Schaffer SW, 2000, AM J PHYSIOL-HEART C, V278, pH1948; Scheepers A, 2004, JPEN-PARENTER ENTER, V28, P364, DOI 10.1177/0148607104028005364; SCHILDBERG FA, 2005, CELL TISSUE RES; Scott KGE, 2002, GASTROENTEROLOGY, V123, P1179, DOI 10.1053/gast.2002.36002; Scovassi AI, 2004, BIOCHEM PHARMACOL, V68, P1041, DOI 10.1016/j.bcp.2004.04.023; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; SUN DQ, 1994, CIRCULATION, V89, P793, DOI 10.1161/01.CIR.89.2.793; THAKKAR NS, 1993, CANCER RES, V53, P2057; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Turner JR, 1997, AM J PHYSIOL-CELL PH, V273, pC1378, DOI 10.1152/ajpcell.1997.273.4.C1378; Turner JR, 1996, J BIOL CHEM, V271, P7738, DOI 10.1074/jbc.271.13.7738; Unno N, 1997, GASTROENTEROLOGY, V113, P1246, DOI 10.1053/gast.1997.v113.pm9322519; Yagi Seiji, 2002, Fukuoka Igaku Zasshi, V93, P38; Yamada T, 2003, AM J PHYSIOL-GASTR L, V284, pG782, DOI 10.1152/ajpgi.00376.2002; Yi XL, 2003, J BIOL CHEM, V278, P16992, DOI 10.1074/jbc.M300039200; Zheng YH, 2004, ONCOGENE, V23, P1239, DOI 10.1038/sj.onc.1207205	69	112	116	1	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					1822	1835		10.1096/fj.05-4226com	http://dx.doi.org/10.1096/fj.05-4226com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16260652				2022-12-28	WOS:000234053100034
J	Hoffmann, J; Feng, Y; vom Hagen, F; Hillenbrand, A; Lin, J; Erber, R; Vajkoczy, P; Gourzoulidou, E; Waldmann, H; Giannis, A; Wolburg, H; Shani, M; Jaeger, V; Weich, HA; Preissner, KT; Hoffmann, S; Deutsch, U; Hammes, HP				Hoffmann, J; Feng, Y; vom Hagen, F; Hillenbrand, A; Lin, J; Erber, R; Vajkoczy, P; Gourzoulidou, E; Waldmann, H; Giannis, A; Wolburg, H; Shani, M; Jaeger, V; Weich, HA; Preissner, KT; Hoffmann, S; Deutsch, U; Hammes, HP			Endothelial survival factors and spatial completion, but not pericyte coverage of retinal capillaries, determine vessel plasticity	FASEB JOURNAL			English	Article						angiogenesis; vessel maturation; retinopathy	EXPERIMENTAL DIABETIC-RETINOPATHY; RECEPTOR TYROSINE KINASES; GROWTH-FACTOR; BLOOD-VESSELS; PDGF-B; MICROVASCULAR PERICYTES; VASCULAR PATTERNS; MESSENGER-RNA; TIE2 RECEPTOR; IN-VITRO	Pericyte loss and capillary regression are characteristic for incipient diabetic retinopathy. Pericyte recruitment is involved in vessel maturation, and ligand-receptor systems contributing to pericyte recruitment are survival factors for endothelial cells in pericyte-free in vitro systems. We studied pericyte recruitment in relation to the susceptibility toward hyperoxia-induced vascular remodeling using the pericyte reporter X-LacZ mouse and the mouse model of retinopathy of prematurity(ROP). Pericytes were found in close proximity to vessels, both during formation of the superficial and the deep capillary layers. When exposure of mice to the ROP was delayed by 24 h, i.e., after the deep retinal layer had formed [at postnatal (p) day 8], preretinal neovascularizations were substantially diminished at p18. Mice with a delayed ROP exposure had 50% reduced avascular zones. Formation of the deep capillary layers at p8 was associated with a combined up-regulation of angiopoietin-1 and PDGF-B, while VEGF was almost unchanged during the transition from a susceptible to a resistant capillary network. Inhibition of Tie-2 function either by soluble Tie-2 or by a sulindac analog, an inhibitor of Tie-2 phosphorylation, resensitized retinal vessels to neovascularizations due to a reduction of the deep capillary network. Inhibition of Tie-2 function had no effect on pericyte recruitment. Our data indicate that the final maturation of the retinal vasculature and its resistance to regressive signals such as hyperoxia depend on the completion of the multilayer structure, in particular the deep capillary layers, and are independent of the coverage by pericytes.	Univ Giessen, Med Clin & Policlin 3, D-35392 Giessen, Germany; Heidelberg Univ, Med Clin 5, Fac Clin Med, D-68167 Mannheim, Germany; Heidelberg Univ, Dept Neurosurg, Fac Med, D-68167 Mannheim, Germany; Univ Dortmund, Fachbereich Organ Chem 3, D-44227 Dortmund, Germany; Max Planck Inst Mol Physiol, Dept Biol Chem, D-44227 Dortmund, Germany; Univ Leipzig, Inst Organ Chem, D-04103 Leipzig, Germany; Univ Tubingen, Inst Pathol, D-72076 Tubingen, Germany; Volcani Ctr, Inst Anim Sci, Bet Dagan, Israel; Gesell Biotechnol Forsch mbH, Dept Cell Culture Technol, D-38124 Braunschweig, Germany; Gesell Biotechnol Forsch mbH, Dept Gene Regulat & Differentiat, D-38124 Braunschweig, Germany; Univ Giessen, Inst Biochem, Fac Med, D-35392 Giessen, Germany; Heidelberg Univ, Med Res Ctr, Univ Clin Mannheim, Fac Med, D-68167 Mannheim, Germany; Univ Munster, Max Planck Inst Vasc Biol, Inst Cell Biol, ZMBE, Munster, Germany; Univ Bern, Theodor Kocher Inst, CH-3012 Bern, Switzerland	Justus Liebig University Giessen; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Dortmund University of Technology; Max Planck Society; Leipzig University; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; Gesellschaft fur Biotechnologische Forschung mbH; Gesellschaft fur Biotechnologische Forschung mbH; Justus Liebig University Giessen; Ruprecht Karls University Heidelberg; Max Planck Society; University of Munster; University of Bern	Hammes, HP (corresponding author), Heidelberg Univ, Klinikum Mannheim, Dept 5, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	hans-peter.hammes@med5.ma.uni-heidelberg.de	Hammes, Hans-Peter/S-3719-2019; Erber, Ralf/B-6790-2008; Erber, Ralf/AAF-3002-2020	Deutsch, Urban/0000-0003-4265-6262				BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917; Beitz J G, 1992, EXS, V61, P85; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; BOADO RJ, 1994, J NEUROSCI RES, V39, P430, DOI 10.1002/jnr.490390410; Bondjers C, 2003, AM J PATHOL, V162, P721, DOI 10.1016/S0002-9440(10)63868-0; Castellon R, 2002, EXP EYE RES, V74, P523, DOI 10.1006/exer.2001.1161; COGAN DG, 1961, ARCH OPHTHALMOL-CHIC, V66, P366, DOI 10.1001/archopht.1961.00960010368014; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DENOFRIO D, 1989, J CELL BIOL, V109, P191, DOI 10.1083/jcb.109.1.191; Enge M, 2002, EMBO J, V21, P4307, DOI 10.1093/emboj/cdf418; ENGERMAN RL, 1976, T AM ACAD OPHTHALMOL, V81, pO710; ENGERMAN RL, 1987, DIABETES, V36, P808, DOI 10.2337/diabetes.36.7.808; ENGERMAN RL, 1989, DIABETES, V38, P1203, DOI 10.2337/diabetes.38.10.1203; Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje; ERBER WN, 1993, PATHOLOGY, V25, P63, DOI 10.3109/00313029309068904; Faude F, 2001, J NEUROCYTOL, V30, P379; Fiedler U, 2003, J BIOL CHEM, V278, P1721, DOI 10.1074/jbc.M208550200; Fruttiger M, 2002, INVEST OPHTH VIS SCI, V43, P522; Gao GQ, 2002, DIABETES, V51, P1218, DOI 10.2337/diabetes.51.4.1218; Gee MS, 2003, AM J PATHOL, V162, P183, DOI 10.1016/S0002-9440(10)63809-6; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Gerhardt H, 2003, CELL TISSUE RES, V314, P15, DOI 10.1007/s00441-003-0745-x; Gourzoulidou E, 2005, CHEMBIOCHEM, V6, P527, DOI 10.1002/cbic.200400192; Hackett SF, 2000, J CELL PHYSIOL, V184, P275, DOI 10.1002/1097-4652(200009)184:3<275::AID-JCP1>3.3.CO;2-Z; HAMMES HP, 1995, DIABETOLOGIA, V38, P269, DOI 10.1007/s001250050280; Hammes HP, 2004, DIABETES, V53, P1104, DOI 10.2337/diabetes.53.4.1104; Hammes HP, 2002, DIABETES, V51, P3107, DOI 10.2337/diabetes.51.10.3107; Hammes HP, 1996, DIABETOLOGIA, V39, P251; HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; Hirschi KK, 1999, CIRC RES, V84, P298, DOI 10.1161/01.RES.84.3.298; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; KOYAMA N, 1994, J CELL PHYSIOL, V158, P1, DOI 10.1002/jcp.1041580102; KUWABARA T, 1960, ARCH OPHTHALMOL-CHIC, V64, P904, DOI 10.1001/archopht.1960.01840010906012; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; MARX M, 1994, J CLIN INVEST, V93, P131, DOI 10.1172/JCI116936; NEHLS V, 1992, CELL TISSUE RES, V270, P469, DOI 10.1007/BF00645048; NEHLS V, 1991, J CELL BIOL, V113, P147, DOI 10.1083/jcb.113.1.147; ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455; Ozerdem U, 2001, DEV DYNAM, V222, P218, DOI 10.1002/dvdy.1200; Papapetropoulos A, 1999, LAB INVEST, V79, P213; Reynolds JD, 2001, PEDIATR DRUGS, V3, P263, DOI 10.2165/00128072-200103040-00003; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Seo MS, 2000, AM J PATHOL, V157, P995, DOI 10.1016/S0002-9440(10)64612-3; Shih SC, 2003, P NATL ACAD SCI USA, V100, P15859, DOI 10.1073/pnas.2136855100; Smith A, 2002, NAT REV DRUG DISCOV, V1, P8, DOI 10.1038/nrd716; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362; Sundberg C, 2002, LAB INVEST, V82, P387, DOI 10.1038/labinvest.3780433; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Thommen R, 1997, J CELL BIOCHEM, V64, P403; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Tidhar A, 2001, DEV DYNAM, V220, P60, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1089>3.0.CO;2-X; Uemura A, 2002, J CLIN INVEST, V110, P1619, DOI 10.1172/JCI200215621	61	32	34	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2035	+		10.1096/fj.04-2109fje	http://dx.doi.org/10.1096/fj.04-2109fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16215210				2022-12-28	WOS:000232991100024
J	Wasilewska-Sampaio, AP; Silveira, MS; Holub, O; Goecking, R; Gomes, FCA; Neto, VM; Linden, R; Ferreira, ST; De Felice, FG				Wasilewska-Sampaio, AP; Silveira, MS; Holub, O; Goecking, R; Gomes, FCA; Neto, VM; Linden, R; Ferreira, ST; De Felice, FG			Neuritogenesis and neuronal differentiation promoted by 2,4-dinitrophenol, a novel anti-amyloidogenic compound	FASEB JOURNAL			English	Article						DNP; central neurons; cAMP; neuritogenesis; tau; differentiation	MICROTUBULE-ASSOCIATED PROTEIN; NERVE GROWTH-FACTOR; TAU-ANTISENSE OLIGONUCLEOTIDES; SPINAL-CORD-INJURY; ALZHEIMERS-DISEASE; CYCLIC-AMP; PC12 CELLS; HIPPOCAMPAL-NEURONS; AXONAL REGENERATION; FUNCTIONAL RECOVERY	Neurite outgrowth is a critical event in neuronal development, formation, and remodeling of synapses, response to injury, and regeneration. We examined the effects of 2,4-dinitrophenol (DNP), a recently described blocker of the aggregation and neurotoxicity of the beta-amyloid peptide, on neurite elongation of central neurons. Morphometric analysis of rat embryo hippocampal and cortical neuronal cultures showed that neurite outgrowth was stimulated by DNP. This effect was accompanied by increases in the neuronal levels of the microtubule-associated protein tau and of cyclic adenosine 3',5' monophosphate (cAMP). DNP also promoted cAMP accumulation, increased tau level, neurite outgrowth, and neuronal differentiation in the mouse neuroblastoma cell line N2A. We show that DNP-induced differentiation requires activation of the extracellular signal-regulated kinase (ERK). The finding that DNP promotes neuritogenesis and neuronal differentiation suggests that, in addition to its anti-amyloidogenic actions, it may be a useful lead compound in the development of novel therapeutic approaches targeting neurite dystrophy and synaptic dysfunction in neurodegenerative pathologies such as Alzheimer's disease.	Univ Fed Rio de Janeiro, Inst Bioquim Med, Programa Bioquim & Biofis Celular, Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Dept Anat, Inst Ciencias Biomed, Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Ferreira, ST (corresponding author), Univ Fed Rio de Janeiro, Inst Bioquim Med, Programa Bioquim & Biofis Celular, Rio De Janeiro, Brazil.	ferreira@bioqmed.ufrj.br	Linden, Rafael/F-2275-2011; Ferreira, Sergio/AAZ-1576-2020; Moura-Neto, VIVALDO/V-9913-2019; Gomes, Flavia/AAX-6354-2021; De Felice, Fernanda G/M-1074-2017; Silveira, Mariana/M-4865-2013; Gomes, Flavia/C-5383-2013	Linden, Rafael/0000-0003-3287-336X; Ferreira, Sergio/0000-0001-7160-9866; Moura-Neto, VIVALDO/0000-0002-6266-043X; Silveira, Mariana/0000-0002-0496-1517; Gomes, Flavia/0000-0003-2966-0638				Ambrosini A, 2000, MOL BRAIN RES, V75, P54, DOI 10.1016/S0169-328X(99)00294-6; Ammer H, 1997, NEUROSCI LETT, V230, P143, DOI 10.1016/S0304-3940(97)00495-3; Avila J, 2004, PHYSIOL REV, V84, P361, DOI 10.1152/physrev.00024.2003; AVILA J, 1994, INT J DEV BIOL, V38, P13; Bhatt DH, 2004, SCIENCE, V305, P254, DOI 10.1126/science.1098439; BLACK MM, 1994, PROG BRAIN RES, V102, P61; BOTELHO LHP, 1988, J BIOL CHEM, V263, P5301; BRE MH, 1990, CELL MOTIL CYTOSKEL, V15, P88, DOI 10.1002/cm.970150205; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; CACERES A, 1991, J NEUROSCI, V11, P1515; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; Cai D, 2001, J NEUROSCI, V21, P4731, DOI 10.1523/JNEUROSCI.21-13-04731.2001; Chalasani SH, 2003, J NEUROSCI, V23, P4601; Christensen AE, 2003, J BIOL CHEM, V278, P35394, DOI 10.1074/jbc.M302179200; CONRAD MJ, 1979, P NATL ACAD SCI USA, V76, P5202, DOI 10.1073/pnas.76.10.5202; De Felice FG, 2004, FASEB J, V18, P1366, DOI 10.1096/fj.04-1764com; De Felice FG, 2001, FASEB J, V15, P1297, DOI 10.1096/fj.00-0676fje; Dehmelt L, 2003, J NEUROSCI, V23, P9479; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; FERREIRA A, 1992, J NEUROSCI RES, V32, P516, DOI 10.1002/jnr.490320407; FERREIRA A, 1989, DEV BRAIN RES, V49, P215, DOI 10.1016/0165-3806(89)90023-0; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; GREENE LA, 1983, J CELL BIOL, V96, P76, DOI 10.1083/jcb.96.1.76; HEIDEMANN SR, 1985, J CELL BIOL, V100, P916, DOI 10.1083/jcb.100.3.916; Heidemann SR, 1996, INT REV CYTOL, V165, P235, DOI 10.1016/S0074-7696(08)62224-X; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; HO PL, 1992, J CELL PHYSIOL, V150, P647, DOI 10.1002/jcp.1041500326; Iida N, 2001, J NEUROSCI, V21, P6459, DOI 10.1523/JNEUROSCI.21-17-06459.2001; Ivins JK, 2004, J NEUROSCI, V24, P1212, DOI 10.1523/JNEUROSCI.4689-03.2004; KAHN JS, 1964, ANAL BIOCHEM, V9, P389, DOI 10.1016/0003-2697(64)90198-8; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Lin SL, 2003, J NEUROCHEM, V87, P1076, DOI 10.1046/j.1471-4159.2003.02076.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu P, 2004, J NEUROSCI, V24, P6402, DOI 10.1523/JNEUROSCI.1492-04.2004; MACCIONI RB, 1989, ARCH BIOCHEM BIOPHYS, V275, P568, DOI 10.1016/0003-9861(89)90403-7; MATUS A, 1991, J CELL SCI, P61; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; Ming GI, 1999, NEURON, V23, P139, DOI 10.1016/S0896-6273(00)80760-6; Moreno-Flores MT, 2003, J NEUROCHEM, V87, P879, DOI 10.1046/j.1471-4159.2003.02051.x; Nakagawa S, 2002, J NEUROSCI, V22, P3673; Nikulina E, 2004, P NATL ACAD SCI USA, V101, P8786, DOI 10.1073/pnas.0402595101; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Pham N, 2000, CURR BIOL, V10, P555, DOI 10.1016/S0960-9822(00)00473-5; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Sanchez S, 2004, NEUROCHEM INT, V44, P231, DOI 10.1016/S0197-0186(03)00150-5; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Selkoe DJ, 2002, SCIENCE, V298, P963; SILVEIRA MS, 2004, IN PRESS BRAIN REPAR; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; Spencer T, 2004, J ANAT, V204, P49, DOI 10.1111/j.1469-7580.2004.00259.x; Takahashi N, 2002, J BIOL CHEM, V277, P16906, DOI 10.1074/jbc.M200585200; TANAKA E, 1995, CELL, V83, P171, DOI 10.1016/0092-8674(95)90158-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUCKER RP, 1990, BRAIN RES REV, V15, P101, DOI 10.1016/0165-0173(90)90013-E; Tuszynski MH, 2002, LANCET NEUROL, V1, P51, DOI 10.1016/S1474-4422(02)00006-6; Tuszynski MH, 2004, PROG BRAIN RES, V146, P441; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WU DK, 1983, J CYCLIC NUCL PROT, V9, P59	65	35	38	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					1627	1636		10.1096/fj.05-3812com	http://dx.doi.org/10.1096/fj.05-3812com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16195371				2022-12-28	WOS:000232991100040
J	Narita, K; Choudhury, A; Dobrenis, K; Sharma, DK; Holicky, EL; Marks, DL; Walkley, SU; Pagano, RE				Narita, K; Choudhury, A; Dobrenis, K; Sharma, DK; Holicky, EL; Marks, DL; Walkley, SU; Pagano, RE			Protein transduction of Rab9 in Niemann-Pick C cells reduces cholesterol storage	FASEB JOURNAL			English	Article						Rab proteins; sphingolipid storage diseases; lipid transport; late endosomes and lysosomes	LOW-DENSITY-LIPOPROTEIN; IN-VIVO; GENE-TRANSFER; DISEASE; ACCUMULATION; TRANSPORT; GLYCOSPHINGOLIPIDS; TRAFFICKING; FIBROBLASTS; ENDOCYTOSIS	Niemann-Pick disease type C ( NPC) is a genetic disorder in which patient cells exhibit lysosomal accumulation of cholesterol and sphingolipids (SLs) caused by defects in either NPC1 or NPC2 proteins. We previously demonstrated that NPC1 human skin fibroblasts overexpressing endosomal Rab proteins (Rab7 or Rab9) showed a correction in the storage disease phenotype. In the current study, we used protein transduction to further investigate Rab9-mediated reduction of stored lipids in NPC cells. Recombinant human Rab9 fused with the herpes simplex virus VP22 protein fragment was overexpressed, purified, and added to culture medium to induce protein transduction. When VP22-Rab9 was transduced into NPC1 fibroblasts, nearly all cells showed significant reduction in cellular free cholesterol levels, with no cytotoxicity up to 5 mu M. A fraction of the VP22-Rab9 that was transduced into the cells was shown to bind to rab GDP dissociation inhibitor, suggesting that this pool of VP22-Rab9 had become prenylated. The reduction in cellular free cholesterol was associated with correction of abnormal intracellular trafficking of BODIPY-lactosylceramide and an increase of sterols in the culture media. The clearance of lysosomal free cholesterol was also associated with a decrease in LDL-receptor levels. In addition, we demonstrated reduction of intracellular cholesterol by VP22-Rab9 transduction in NPC2 fibroblasts and in cultured mouse NPC1 neurons. These observations provide important new information about the correction of membrane traffic in NPC cells by Rab9 overexpression and may lead to new therapeutic approaches for treatment of this disease.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; Mayo Clin & Mayo Fdn, Mol Neurosci Program, Rochester, MN 55905 USA	Mayo Clinic; Yeshiva University; Albert Einstein College of Medicine; Mayo Clinic	Pagano, RE (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW,Stabile 8, Rochester, MN 55905 USA.	pagano.richard@mayo.edu	Narita, Keishi/E-3539-2010	Narita, Keishi/0000-0002-7602-8523	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060934] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-60934] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boenicke L, 2003, J MOL MED-JMM, V81, P205, DOI 10.1007/s00109-003-0421-3; Chen CS, 1999, LANCET, V354, P901, DOI 10.1016/S0140-6736(98)10034-X; Chen CS, 1997, BIOPHYS J, V72, P37, DOI 10.1016/S0006-3495(97)78645-4; Choudhury A, 2004, MOL BIOL CELL, V15, P4500, DOI 10.1091/mbc.E04-05-0432; Choudhury A, 2002, J CLIN INVEST, V109, P1541, DOI 10.1172/JCI200215420; Day GJ, 1998, MOL CELL BIOL, V18, P7444, DOI 10.1128/MCB.18.12.7444; Dolo V, 2000, BBA-MOL CELL BIOL L, V1486, P265, DOI 10.1016/S1388-1981(00)00063-9; Ford KG, 2001, GENE THER, V8, P1, DOI 10.1038/sj.gt.3301383; Frolov A, 2003, J BIOL CHEM, V278, P25517, DOI 10.1074/jbc.M302588200; Gondre M., 1999, Society for Neuroscience Abstracts, V25, P1118; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; Kretz A, 2003, MOL THER, V7, P659, DOI 10.1016/S1525-0016(03)00062-5; KRUTH HS, 1986, J BIOL CHEM, V261, P6769; Lai Z, 2002, J NEUROSCI RES, V67, P363, DOI 10.1002/jnr.10137; Lebrand C, 2002, EMBO J, V21, P1289, DOI 10.1093/emboj/21.6.1289; Marks DL, 2002, TRENDS CELL BIOL, V12, P605, DOI 10.1016/S0962-8924(02)02399-1; MARTIN OC, 1994, J CELL BIOL, V125, P769, DOI 10.1083/jcb.125.4.769; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; Pagano RE, 2000, TRAFFIC, V1, P807, DOI 10.1034/j.1600-0854.2000.011101.x; PATTERSON MC, 2001, NIEMANN PICK DIS TYP, V3; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; Puri V, 2003, J BIOL CHEM, V278, P20961, DOI 10.1074/jbc.M300304200; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; RIEDERER MA, 1995, METHOD ENZYMOL, V257, P15; Schwartz JJ, 2000, CURR OPIN MOL THER, V2, P162; SOKOL J, 1988, J BIOL CHEM, V263, P3411; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; Sun XF, 2001, AM J HUM GENET, V68, P1361, DOI 10.1086/320599; VANIER MT, 1991, DEV NEUROSCI-BASEL, V13, P307, DOI 10.1159/000112178; Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7; Walter M, 2003, J LIPID RES, V44, P243, DOI 10.1194/jlr.M200230-JLR200; Wang Y, 2005, J BIOL CHEM, V280, P11876, DOI 10.1074/jbc.M414676200; Zavaglia D, 2003, MOL THER, V8, P840, DOI 10.1016/j.ymthe.2003.08.001; Zervas M, 2001, J NEUROPATH EXP NEUR, V60, P49, DOI 10.1093/jnen/60.1.49	35	63	63	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2005	19	8					1558	+		10.1096/fj.04-2714fje	http://dx.doi.org/10.1096/fj.04-2714fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15972801				2022-12-28	WOS:000230207800008
J	Duffy, SM; Cruse, G; Lawley, WJ; Bradding, P				Duffy, SM; Cruse, G; Lawley, WJ; Bradding, P			beta(2)-Adrenoceptor regulation of the K+ channel iK(Ca)1 in human mast cells	FASEB JOURNAL			English	Article						salbutamol; ICI 118551; K(Ca)3.1; lung; G protein	HUMAN LUNG; INTERMEDIATE-CONDUCTANCE; DEPENDENT REGULATION; POTASSIUM CHANNELS; ION CHANNELS; ACTIVATION; RELEASE; INHIBITION; SALMETEROL; RESPONSES	Human mast cells express the intermediate conductance Ca2+-activated K+ channel iK(Ca)1, which opens following IgE-dependent activation. This results in cell membrane hyperpolarization and potentiation of both Ca2+ influx and degranulation. Mast cell activation is attenuated following exposure to beta(2)-adrenoceptor agonists such as salbutamol, an effect postulated to operate via intracellular cyclic AMP. In this study, we show that salbutamol closes iK(Ca)1 in mast cells derived from human lung and peripheral blood. Salbutamol (1-10 mu M) inhibited iK(Ca)1 currents following activation with both anti-IgE and the iK(Ca)1 opener I-EBIO, and was reversed by removing salbutamol or by the addition of the selective beta(2)-adrenoceptor antagonist and inverse agonist ICI 118551. Interestingly, ICI 118551 consistently opened iK(Ca)1 in quiescent cells, suggesting that constitutive beta(2)-receptor signaling suppresses channel activity. Manipulation of intracellular cAMP, G alpha i, and G alpha s demonstrates that the beta(2)-adrenergic effects are consistent with a membrane-delimited mechanism involving G alpha s. This is the first demonstration that gating of the iK(Ca)1 channel is regulated by a G protein-coupled receptor and provides a clearly defined mechanism for the mast cell "stabilizing" effect Of beta(2)-agonists. Furthermore, the degree of constitutive beta(2)-receptor "tone" may control the threshold for human mast cell activation through the regulation of iK(Ca)1.	Univ Leicester, Dept Infect Immun & Inflammat, Leicester LE1 7RH, Leics, England	University of Leicester	Bradding, P (corresponding author), Glenfield Gen Hosp, Dept Resp Med, Groby Rd, Leicester LE3 9QP, Leics, England.	pbradding@hotmail.com	Cruse, Glenn/B-4597-2012; Cruse, Glenn/AAZ-1093-2021	Cruse, Glenn/0000-0002-7511-0082; Bradding, Peter/0000-0001-8403-0319				Benovic Jeffrey L., 2002, Journal of Allergy and Clinical Immunology, V110, pS229, DOI 10.1067/mai.2002.129370; Bradding P, 2003, J LEUKOCYTE BIOL, V73, P614, DOI 10.1189/jlb.1202602; Bradding P, 2002, CLIN EXP ALLERGY, V32, P979, DOI 10.1046/j.1365-2222.2002.01419.x; BRADDING P, 2000, ASTHMA RHINITIS, P319; Bradding P, 2003, CURR OPIN ALLERGY CL, V3, P45, DOI 10.1097/01.all.0000053267.39029.fd; CHURCH MK, 1987, BRIT J PHARMACOL, V90, P421, DOI 10.1111/j.1476-5381.1987.tb08972.x; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; Drury DEJ, 1998, BRIT J PHARMACOL, V124, P711, DOI 10.1038/sj.bjp.0701897; Duffy SM, 2004, J ALLERGY CLIN IMMUN, V114, P66, DOI 10.1016/j.jaci.2004.04.005; Duffy SM, 2003, J ALLERGY CLIN IMMUN, V112, P965, DOI 10.1016/j.jaci.2003.07.004; Duffy SM, 2001, J IMMUNOL, V167, P4261, DOI 10.4049/jimmunol.167.8.4261; Duffy SM, 2001, J LEUKOCYTE BIOL, V70, P233; Gerlach AC, 2000, J BIOL CHEM, V275, P585, DOI 10.1074/jbc.275.1.585; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; Giannini D, 1996, CHEST, V110, P1452, DOI 10.1378/chest.110.6.1452; Gong HB, 2002, CIRCULATION, V105, P2497, DOI 10.1161/01.CIR.0000017187.61348.95; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hayashi M, 2004, AM J PHYSIOL-CELL PH, V286, pC635, DOI 10.1152/ajpcell.00283.2003; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Jensen BS, 1999, P NATL ACAD SCI USA, V96, P10917, DOI 10.1073/pnas.96.19.10917; KUME H, 1992, P NATL ACAD SCI USA, V89, P11051, DOI 10.1073/pnas.89.22.11051; KUME H, 1994, J CLIN INVEST, V93, P371, DOI 10.1172/JCI116969; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Liggett Stephen B., 2002, Journal of Allergy and Clinical Immunology, V110, pS223, DOI 10.1067/mai.2002.129945; LIN CS, 1993, J EXP MED, V177, P637, DOI 10.1084/jem.177.3.637; PEACHELL PT, 1988, J IMMUNOL, V140, P571; Pedersen KA, 1999, BBA-BIOMEMBRANES, V1420, P231, DOI 10.1016/S0005-2736(99)00110-8; Peleg S, 2002, NEURON, V33, P87, DOI 10.1016/S0896-6273(01)00567-0; PELLEGRINO M, 2004, PFLUG ARCH EUR J PHY, V436, P749; Roberts JA, 1999, EUR RESPIR J, V14, P275, DOI 10.1034/j.1399-3003.1999.14b07.x; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; Sanmugalingam D, 2000, J LEUKOCYTE BIOL, V68, P38; Swystun VA, 2000, J ALLERGY CLIN IMMUN, V106, P57; Tsuji T, 2004, BIOL PHARM BULL, V27, P1549, DOI 10.1248/bpb.27.1549; von Hahn T, 2001, CELL PHYSIOL BIOCHEM, V11, P219, DOI 10.1159/000051936	36	49	50	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1006	+		10.1096/fj.04-3439fje	http://dx.doi.org/10.1096/fj.04-3439fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15817638				2022-12-28	WOS:000228865300021
J	Archer, JD; Vargas, CC; Anderson, JE				Archer, Jonathan D.; Vargas, Cinthya C.; Anderson, Judy E.			Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort	FASEB JOURNAL			English	Article						nitric oxide; myf5; exercise; utrophin; muscle regeneration	MUSCLE SATELLITE CELLS; CONTRACTION-INDUCED INJURY; OXIDE SYNTHASE TRANSGENE; SKELETAL-MUSCLE; NITRIC-OXIDE; MOUSE MUSCLE; PRECURSOR REPLICATION; GLYCOPROTEIN COMPLEX; MUSCULAR-DYSTROPHY; MYOGENIC CELLS	Although an increase in nitric oxide (NO) in muscle is reported to improve the outcome of deflazacort treatment for mdx mouse muscular dystrophy, the genetic homologue of Duchenne muscular dystrophy (DMD), the impact such treatment on the functional outcomes of the disease, including fiber susceptibility to exercise-induced injury, is not established. Experiments were designed to test whether treatment with deflazacort and L-arginine (a substrate for NO synthase, NOS) would change the extent of fiber injury induced by 24 h of voluntary exercise. The impact of exercise-related injury to induce a secondary regenerative response by muscle was also examined as corroborating evidence of muscle damage. Dystrophic mdx mice were treated for 3 wk with placebo, deflazacort, or deflazacort plus either L-arginine or N-G-nitro-L-arginine methyl ester (a NOS inhibitor). Deflazacort, especially combined with L-arginine, spared quadriceps muscle from injury-induced regeneration (myf5 expression) compared with placebo treatment, despite an increase in membrane permeability immediately after exercise (assessed by Evans blue dye infiltration). Deflazacort alone prevented the typical progressive loss of function (measured as voluntary distance run over 24 h) that was observed 3 months later in placebo-treated mice. Therefore, combined deflazacort plus L-arginine treatment spared mdx dystrophic limb muscle from exercise-induced damage and the need for regeneration and induced a persistent functional improvement in distance run. Results suggest a potential new treatment option for improving the quality of life for boys with DMD.	Univ Manitoba, Fac Med, Dept Human Anat & Cell Sci, Winnipeg, MB R3E 0W3, Canada	University of Manitoba	Anderson, JE (corresponding author), Univ Manitoba, Fac Med, Dept Human Anat & Cell Sci, 730 William Ave, Winnipeg, MB R3E 0W3, Canada.	janders@ms.umanitoba.ca						Ahmad A, 2000, HUM MOL GENET, V9, P2507, DOI 10.1093/hmg/9.17.2507; AMANO F, 1995, FEBS LETT, V368, P425, DOI 10.1016/0014-5793(95)00700-J; Anderson J, 2002, NITRIC OXIDE-BIOL CH, V7, P36, DOI 10.1016/S1089-8603(02)00011-3; Anderson JE, 2000, CELL TRANSPLANT, V9, P551, DOI 10.1177/096368970000900411; Anderson JE, 2000, MOL BIOL CELL, V11, P1859, DOI 10.1091/mbc.11.5.1859; Anderson JE, 2004, CAN J PHYSIOL PHARM, V82, P300, DOI 10.1139/Y04-020; Anderson JE, 2003, NEUROMUSCULAR DISORD, V13, P388, DOI 10.1016/S0960-8966(03)00029-4; Anderson JE, 1998, BIOCHEM CELL BIOL, V76, P13, DOI 10.1139/bcb-76-1-13; Anderson JE, 1998, MUSCLE NERVE, V21, P1153, DOI 10.1002/(SICI)1097-4598(199809)21:9<1153::AID-MUS6>3.0.CO;2-6; Anderson JE, 1996, MUSCLE NERVE, V19, P1576, DOI 10.1002/(SICI)1097-4598(199612)19:12<1576::AID-MUS7>3.0.CO;2-7; ANDERSON JE, 2005, PROGR MUSCULAR DYSTR; Biggar WD, 2004, NEUROMUSCULAR DISORD, V14, P476, DOI 10.1016/j.nmd.2004.05.001; Biggar WD, 2001, J PEDIATR-US, V138, P45, DOI 10.1067/mpd.2001.109601; Blaveri K, 1999, DEV DYNAM, V216, P244, DOI 10.1002/(SICI)1097-0177(199911)216:3<244::AID-DVDY3>3.0.CO;2-9; Bockhold KJ, 1998, MUSCLE NERVE, V21, P173, DOI 10.1002/(SICI)1097-4598(199802)21:2<173::AID-MUS4>3.0.CO;2-8; Chaubourt E, 1999, NEUROBIOL DIS, V6, P499, DOI 10.1006/nbdi.1999.0256; Chaubourt E, 2000, CR ACAD SCI III-VIE, V323, P735, DOI 10.1016/S0764-4469(00)01219-1; Chaubourt E, 2002, J PHYSIOLOGY-PARIS, V96, P43, DOI 10.1016/S0928-4257(01)00079-1; Collins CA, 2005, CELL, V122, P289, DOI 10.1016/j.cell.2005.05.010; Cook JA, 1996, ANAL BIOCHEM, V238, P150, DOI 10.1006/abio.1996.0268; Cousins JC, 2004, J CELL SCI, V117, P3259, DOI 10.1242/jcs.01161; Crawford GE, 2001, HUM MOL GENET, V10, P2745, DOI 10.1093/hmg/10.24.2745; DelloRusso C, 2002, P NATL ACAD SCI USA, V99, P12979, DOI 10.1073/pnas.202300099; Dellorusso C, 2001, J MUSCLE RES CELL M, V22, P467, DOI 10.1023/A:1014587918367; Granchelli JA, 1996, RES COMMUN MOL PATH, V91, P287; Gregorevic P, 2004, NAT MED, V10, P828, DOI 10.1038/nm1085; GROUNDS MD, 1992, CELL TISSUE RES, V267, P99, DOI 10.1007/BF00318695; GROUNDS MD, 1989, CELL TISSUE RES, V255, P385; Heslop L, 2000, J CELL SCI, V113, P2299; Kiechle FL, 1996, ANN CLIN LAB SCI, V26, P501; Konhilas JP, 2005, AM J PHYSIOL-HEART C, V289, pH455, DOI 10.1152/ajpheart.00085.2005; Li S, 2005, GENE THER, V12, P1099, DOI 10.1038/sj.gt.3302505; Liu MJ, 2005, MOL THER, V11, P245, DOI 10.1016/j.ymthe.2004.09.013; Lynch GS, 2004, CLIN EXP PHARMACOL P, V31, P557, DOI 10.1111/j.1440-1681.2004.04026.x; Lynch GS, 2001, J PHYSIOL-LONDON, V535, P591, DOI 10.1111/j.1469-7793.2001.00591.x; Lynch GS, 1997, AM J PHYSIOL-CELL PH, V272, pC2063, DOI 10.1152/ajpcell.1997.272.6.C2063; Lynch GS, 2000, AM J PHYSIOL-CELL PH, V279, pC1290, DOI 10.1152/ajpcell.2000.279.4.C1290; Marzinzig M, 1997, NITRIC OXIDE-BIOL CH, V1, P177, DOI 10.1006/niox.1997.0116; MATSUDA R, 1995, J BIOCHEM-TOKYO, V118, P959, DOI 10.1093/jb/118.5.959; McCarter GC, 2000, J MEMBRANE BIOL, V176, P169, DOI 10.1007/s002320001086; MCGEACHIE JK, 1987, CELL TISSUE RES, V248, P125, DOI 10.1007/BF01239972; McIntosh L, 1998, NMR BIOMED, V11, P1, DOI 10.1002/(SICI)1099-1492(199802)11:1<1::AID-NBM493>3.0.CO;2-D; MCINTOSH LM, 1995, BIOCHEM CELL BIOL, V73, P181, DOI 10.1139/o95-022; McIntosh LM, 1998, ANAT RECORD, V252, P311, DOI 10.1002/(SICI)1097-0185(199810)252:2<311::AID-AR17>3.0.CO;2-Q; MCINTOSH LM, 1994, MUSCLE NERVE, V17, P444, DOI 10.1002/mus.880170413; Morgan JE, 1996, MUSCLE NERVE, V19, P132, DOI 10.1002/(SICI)1097-4598(199602)19:2<132::AID-MUS2>3.0.CO;2-F; Morrison J, 2000, LAB INVEST, V80, P881, DOI 10.1038/labinvest.3780092; Pagel CN, 1999, J NEUROL SCI, V164, P103, DOI 10.1016/S0022-510X(99)00061-1; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Segalat L, 2005, EXP CELL RES, V302, P170, DOI 10.1016/j.yexcr.2004.09.007; Sheehan SM, 2000, MUSCLE NERVE, V23, P239, DOI 10.1002/(SICI)1097-4598(200002)23:2<239::AID-MUS15>3.0.CO;2-U; Shiao T, 2004, HUM MOL GENET, V13, P1873, DOI 10.1093/hmg/ddh204; Squire S, 2002, HUM MOL GENET, V11, P3333, DOI 10.1093/hmg/11.26.3333; St-Pierre SJG, 2004, FASEB J, V18, P1937, DOI 10.1096/fj.04-1859fje; Tatsumi R, 2002, MOL BIOL CELL, V13, P2909, DOI 10.1091/mbc.E02-01-0062; Tatsumi R, 1998, DEV BIOL, V194, P114, DOI 10.1006/dbio.1997.8803; Tatsumi R, 2001, EXP CELL RES, V267, P107, DOI 10.1006/excr.2001.5252; Tidball JG, 2004, MOL GENET METAB, V82, P312, DOI 10.1016/j.ymgme.2004.06.006; Warner LE, 2002, HUM MOL GENET, V11, P1095, DOI 10.1093/hmg/11.9.1095; Wehling M, 2001, J CELL BIOL, V155, P123, DOI 10.1083/jcb.200105110; Wehling-Henricks M, 2005, HUM MOL GENET, V14, P1921, DOI 10.1093/hmg/ddi197; Wehling-Henricks M, 2004, NEUROMUSCULAR DISORD, V14, P483, DOI 10.1016/j.nmd.2004.04.008; Wells KE, 2003, NEUROMUSCULAR DISORD, V13, P21, DOI 10.1016/S0960-8966(02)00191-8; Wozniak AC, 2005, MUSCLE NERVE, V31, P283, DOI 10.1002/mus.20263; Wozniak AC, 2003, J HISTOCHEM CYTOCHEM, V51, P1437, DOI 10.1177/002215540305101104; Yablonka-Reuveni Z, 2006, DEV DYNAM, V235, P203, DOI 10.1002/dvdy.20602; Yue YP, 2003, CIRCULATION, V108, P1626, DOI 10.1161/01.CIR.0000089371.11664.27	67	71	86	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					738	+		10.1096/fj.05-4821fje	http://dx.doi.org/10.1096/fj.05-4821fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16464957				2022-12-28	WOS:000237698700034
J	Kwak, HB; Song, W; Lawler, JM				Kwak, Hyo-Bum; Song, Wook; Lawler, John M.			Exercise training attenuates age-induced elevation in Bax/Bcl-2 ratio, apoptosis, and remodeling in the rat heart	FASEB JOURNAL			English	Article						aging; caspase-3; caspase-9	SPONTANEOUSLY HYPERTENSIVE-RATS; CYTOCHROME-C RELEASE; SKELETAL-MUSCLE; CALORIC RESTRICTION; AGING HEART; FAILURE; CELL; MITOCHONDRIA; MYOCARDIUM; EXPRESSION	Aging is characterized by loss of myocytes, remodeling, and impaired contractile function in the heart. The rate of programmed cell death, or "apoptosis," in the left ventricle increases with age, and contributes to a 30% reduction in myocytes. Aging may preferentially target the Bcl-2 pathway of apoptosis in the heart. Exercise can protect cardiac function of the aging heart, although the mechanisms are poorly understood. We tested the hypothesis that 12 wk of exercise training would attenuate age-induced increases in remodeling, apoptosis, and Bax/Bcl-2 ratio in rat left ventricle. We found that exercise training provided significant protection against loss of cardiac myocytes, reduction in number of myonuclei, reactive hypertrophy of remaining myocytes, and increased connective tissue in left ventricle of the aging rat heart. Exercise training significantly attenuated age- induced increases of apoptosis in the left ventricle, as indicated by lower DNA fragmentation, TUNEL-positive staining, and caspase-3 cleavage, when compared with left ventricles from the age- matched sedentary group. Further, exercise training in the aging reduced caspase-9 levels and Bax/ Bcl-2 ratio by lowering Bax protein expression while increasing Bcl-2 levels. These are the first data to demonstrate protective effects of endurance exercise training against elevated apoptosis and remodeling in the aging heart.	Texas A&M Univ, Redox Biol & Cell Signaling Lab, Dept Hlth & Kinesiol, College Stn, TX 77843 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78284 USA	Texas A&M University System; Texas A&M University College Station; University of Texas System; University of Texas Health San Antonio	Lawler, JM (corresponding author), Texas A&M Univ, Redox Biol & Cell Signaling Lab, Dept Hlth & Kinesiol, College Stn, TX 77843 USA.	jml2621@neo.tamu.edu		Kwak, Hyo Bum/0000-0003-0451-4554				Abou-Raya S, 2004, CLIN INVEST MED, V27, P93; Aguila MB, 2001, MECH AGEING DEV, V122, P77, DOI 10.1016/S0047-6374(00)00215-3; Azhar G, 1999, MECH AGEING DEV, V112, P5, DOI 10.1016/S0047-6374(99)00048-2; Bing Oscar H L, 2002, Heart Fail Rev, V7, P71; Booth FW, 2000, J APPL PHYSIOL, V88, P774, DOI 10.1152/jappl.2000.88.2.774; Brandes RP, 2005, CARDIOVASC RES, V66, P286, DOI 10.1016/j.cardiores.2004.12.027; Burlew Brad S, 2004, Am J Geriatr Cardiol, V13, P29, DOI 10.1111/j.1076-7460.2004.00059.x; CAPASSO JM, 1990, AM J PHYSIOL, V259, pH1086, DOI 10.1152/ajpheart.1990.259.4.H1086; Centurione L, 2003, MECH AGEING DEV, V124, P957, DOI 10.1016/S0047-6374(03)00168-4; Centurione L, 2002, MECH AGEING DEV, V123, P341, DOI 10.1016/S0047-6374(01)00378-5; Chandrashekhar Y, 2004, J AM COLL CARDIOL, V43, P295, DOI 10.1016/j.jacc.2003.09.026; Csiszar A, 2004, PHYSIOL GENOMICS, V17, P21, DOI 10.1152/physiolgenomics.00136.2003; de Souza RR, 2002, BIOGERONTOLOGY, V3, P325, DOI 10.1023/A:1021312027486; Debessa CRG, 2001, MECH AGEING DEV, V122, P1049; Dirks AJ, 2004, FREE RADICAL BIO MED, V36, P27, DOI 10.1016/j.freeradbiomed.2003.10.003; Drew B, 2003, AM J PHYSIOL-REG I, V284, pR474, DOI 10.1152/ajpregu.00455.2002; Du J, 2004, J CLIN INVEST, V113, P115, DOI 10.1172/JCI200418330; Ferder L, 1998, AM J HYPERTENS, V11, P1297, DOI 10.1016/S0895-7061(98)00152-6; FORMAN DE, 1992, J GERONTOL, V47, pM56, DOI 10.1093/geronj/47.2.M56; Hagen TM, 2002, ANN NY ACAD SCI, V959, P491, DOI 10.1111/j.1749-6632.2002.tb02119.x; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Higami Y, 2000, CELL TISSUE RES, V301, P125, DOI 10.1007/s004419900156; Isoyama Shogen, 2002, Heart Fail Rev, V7, P63; Jin HK, 2000, AM J PHYSIOL-HEART C, V279, pH2994, DOI 10.1152/ajpheart.2000.279.6.H2994; Kajstura J, 1996, AM J PHYSIOL-HEART C, V271, pH1215, DOI 10.1152/ajpheart.1996.271.3.H1215; Kang PM, 2004, AM J PHYSIOL-HEART C, V287, pH72, DOI 10.1152/ajpheart.00556.2003; Kass DA, 2004, CIRC RES, V94, P1533, DOI 10.1161/01.RES.0000129254.25507.d6; Kemi M, 2000, TOXICOL PATHOL, V28, P285, DOI 10.1177/019262330002800208; Kobayashi N, 2005, ARTERIOSCL THROM VAS, V25, P2114, DOI 10.1161/01.ATV.0000178993.13222.f2; Lajoie C, 2004, PFLUG ARCH EUR J PHY, V449, P26, DOI 10.1007/s00424-004-1307-0; LAWLER JM, 1993, MED SCI SPORT EXER, V25, P1259; Lee CK, 2002, P NATL ACAD SCI USA, V99, P14988, DOI 10.1073/pnas.232308999; Leeuwenburgh C, 1997, ARCH BIOCHEM BIOPHYS, V346, P74, DOI 10.1006/abbi.1997.0297; Liu JJ, 2000, CARDIOVASC RES, V45, P729, DOI 10.1016/S0008-6363(99)00382-X; Liu LX, 1998, AM J PHYSIOL-REG I, V275, pR315, DOI 10.1152/ajpregu.1998.275.1.R315; Liu PT, 2002, CARDIOVASC RES, V56, P443, DOI 10.1016/S0008-6363(02)00603-X; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P557, DOI 10.1097/00004647-200105000-00010; OLIVETTI G, 1991, CIRC RES, V68, P1560, DOI 10.1161/01.RES.68.6.1560; Phaneuf S, 2002, AM J PHYSIOL-REG I, V282, pR423, DOI 10.1152/ajpregu.00296.2001; Pollack M, 2002, ANN NY ACAD SCI, V959, P93, DOI 10.1111/j.1749-6632.2002.tb02086.x; POWERS SK, 1993, AM J PHYSIOL, V265, pH2094, DOI 10.1152/ajpheart.1993.265.6.H2094; Pugh KG, 2001, DRUG AGING, V18, P263, DOI 10.2165/00002512-200118040-00004; Quindry J, 2005, EXP GERONTOL, V40, P416, DOI 10.1016/j.exger.2005.03.010; Roffe C, 1998, BRIT J BIOMED SCI, V55, P136; Ruetten H, 2001, J AM COLL CARDIOL, V38, P2063, DOI 10.1016/S0735-1097(01)01670-9; Schulman SP, 1996, CIRCULATION, V94, P359, DOI 10.1161/01.CIR.94.3.359; Siu PM, 2005, J APPL PHYSIOL, V99, P204, DOI 10.1152/japplphysiol.00084.2005; Stewart S, 2003, HEART, V89, P49, DOI 10.1136/heart.89.1.49; Sussman MA, 2004, ANNU REV PHYSIOL, V66, P29, DOI 10.1146/annurev.physiol.66.032102.140723; Taylor RP, 2003, ACTA PHYSIOL SCAND, V178, P107, DOI 10.1046/j.1365-201X.2003.01132.x; Torella D, 2004, CIRC RES, V94, P514, DOI 10.1161/01.RES.0000117306.10142.50; Van Remmen H, 2001, EXP GERONTOL, V36, P957; Wanagat J, 2002, J MOL CELL CARDIOL, V34, P17, DOI 10.1006/jmcc.2001.1483; Zhang YP, 2002, MECH AGEING DEV, V123, P245, DOI 10.1016/S0047-6374(01)00349-9	55	117	124	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					791	+		10.1096/fj.05-5116fje	http://dx.doi.org/10.1096/fj.05-5116fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16459353				2022-12-28	WOS:000237698700040
J	Matsukawa, A; Kudoh, S; Sano, G; Maeda, T; Ito, T; Lukacs, NW; Hogaboam, CM; Kunkel, SL; Lira, SA				Matsukawa, Akihiro; Kudoh, Shinji; Sano, Gen-ichiro; Maeda, Takako; Ito, Takaaki; Lukacs, Nicholas W.; Hogaboam, Cory M.; Kunkel, Steven L.; Lira, Sergio A.			Absence of CC chemokine receptor 8 enhances innate immunity during septic peritonitis	FASEB JOURNAL			English	Article									[Matsukawa, Akihiro; Kudoh, Shinji; Maeda, Takako; Ito, Takaaki] Kumamoto Univ, Grad Sch Med Sci, Dept Pathol & Expt Med, Kumamoto 8608556, Japan; [Lukacs, Nicholas W.; Hogaboam, Cory M.; Kunkel, Steven L.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA; [Sano, Gen-ichiro; Lira, Sergio A.] Mt Sinai Sch Med, Immunobiol Ctr, New York, NY USA	Kumamoto University; University of Michigan System; University of Michigan; Icahn School of Medicine at Mount Sinai	Matsukawa, A (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Pathol & Expt Med, 1-1-1 Honjo, Kumamoto 8608556, Japan.	matsu@kaiju.medic.kumamoto-u.ac.jp	hogaboam, cory/M-3578-2014; Hogaboam, Cory M./AAI-1433-2021; Lukacs, Nicholas W/ABH-5583-2020	Hogaboam, Cory M./0000-0003-3366-4850; Matsukawa, Akihiro/0000-0002-5081-6089	NHLBI NIH HHS [P50-HL074024, R01-HL031237] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL074024, R01HL031237] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))			0	21	21	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					302	304		10.1096/fj.04-1728fje	http://dx.doi.org/10.1096/fj.04-1728fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16384913	Green Published			2022-12-28	WOS:000207915000001
J	Serbest, G; Horwitz, J; Jost, M; Barbee, K				Serbest, Gulyeter; Horwitz, Joel; Jost, Monika; Barbee, Kenneth			Mechanisms of cell death and neuroprotection by poloxamer 188 after mechanical trauma	FASEB JOURNAL			English	Article									[Serbest, Gulyeter; Barbee, Kenneth] Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, Philadelphia, PA 19104 USA; [Jost, Monika] Drexel Univ, Coll Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA	Drexel University; Drexel University	Barbee, K (corresponding author), Sch Biomed Engn, 3141 Chestnut St, Philadelphia, PA 19104 USA.	barbee@drexel.edu	Barbee, Kenneth/F-4333-2014						0	74	80	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					308	310		10.1096/fj.05-4024fje	http://dx.doi.org/10.1096/fj.05-4024fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16371428				2022-12-28	WOS:000207915000003
J	Clavreul, N; Adachi, T; Pimental, DR; Ido, Y; Schoneich, C; Cohen, RA				Clavreul, N; Adachi, T; Pimental, DR; Ido, Y; Schoneich, C; Cohen, RA			S-glutathiolation by peroxynitrite of p21ras at cysteine-118 mediates its direct activation and downstream signaling in endothelial cells	FASEB JOURNAL			English	Article						glutathione; oxidized low-density lipoproteins; thiol	GUANINE-NUCLEOTIDE EXCHANGE; NITRIC-OXIDE; OXIDATIVE MODIFICATION; HYDROGEN-PEROXIDE; STRUCTURAL BASIS; RAS; PROTEINS; P21(RAS); IDENTIFICATION; NITROSYLATION	The highly reactive species, peroxynitrite, is produced in endothelial cells in pathological states in which the production of superoxide anion and NO is increased. Here, we show that peroxynitrite added exogenously or generated endogenously in response to exposure to an NO donor or oxidized low-density lipoproteins (oxLDL) increases p21ras activity in bovine aortic endothelial cells. The activation is not dependent on upstream elements but rather is due to direct targeting of p21ras by reversible S-glutathiolation of cysteine thiols as demonstrated by biotin-labeling techniques. The time course of p21ras S-glutathiolation following peroxynitrite corresponds to the increase in its Raf-1 binding activity and translocation to the membrane. Moreover, p21ras S-glutathiolation and activation can be reversed by dithiothreitol, confirming the importance of a disulfide bond. S-glutathiolation also promoted guanine nucleotide exchange of recombinant p21ras. In addition, the oxidant-induced activation of Mek/Erk and PI3 kinase/Akt was abrogated by dominant-negative and Cys-118p21ras mutants, and the latter also prevented S-glutathiolation of p21ras. These results indicate that peroxynitrite arising from NO donors or pathological stimuli such as oxLDL triggers direct S-glutathiolation of p21ras Cys-118, which increases p21ras activity and mediates downstream signaling.	Boston Univ, Med Ctr, Dept Med, Vasc Biol Unit, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Med, Myocardial Biol Unit, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Med, Diabet & Metab Unit, Boston, MA 02118 USA; Keio Univ, Sch Med, Dept Biochem & Integrat Med Biol, Tokyo 108, Japan; Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66045 USA	Boston University; Boston University; Boston University; Keio University; University of Kansas	Cohen, RA (corresponding author), Boston Univ, Med Ctr, Dept Med, Vasc Biol Unit, Boston, MA 02118 USA.	racohen@bu.edu		Ido, Yasuo/0000-0002-3036-9971; /0000-0002-1070-6408	DIVISION OF HEART AND VASCULAR DISEASES [N01HV028178] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL081587, P01HL068758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG012993, R01AG027080] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL-81587, HL-68758, N01-HV-28178] Funding Source: Medline; NIA NIH HHS [AG-27080, P01 AG 12993] Funding Source: Medline	DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adachi T, 2004, NAT MED, V10, P1200, DOI 10.1038/nm1119; Adachi T, 2004, J BIOL CHEM, V279, P29857, DOI 10.1074/jbc.M313320200; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Go YM, 2001, AM J PHYSIOL-HEART C, V281, pH2705, DOI 10.1152/ajpheart.2001.281.6.H2705; Go YM, 1999, AM J PHYSIOL-HEART C, V277, pH1647, DOI 10.1152/ajpheart.1999.277.4.H1647; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Heo J, 2005, J BIOL CHEM, V280, P12438, DOI 10.1074/jbc.M414282200; Heo JY, 2004, BIOCHEMISTRY-US, V43, P2314, DOI 10.1021/bi035275g; Kim JR, 2000, ANAL BIOCHEM, V283, P214, DOI 10.1006/abio.2000.4623; Kirsch M, 1998, J BIOL CHEM, V273, P12716, DOI 10.1074/jbc.273.21.12716; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Kuster GM, 2005, CIRCULATION, V111, P1192, DOI 10.1161/01.CIR.0000157148.59308.F5; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Mallis RJ, 2001, BIOCHEM J, V355, P145, DOI 10.1042/bj3550145; Moellering DR, 2002, BIOCHEM J, V362, P51, DOI 10.1042/0264-6021:3620051; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; Quijano C, 1997, BIOCHEM J, V322, P167, DOI 10.1042/bj3220167; RADI R, 1991, J BIOL CHEM, V266, P4244; Richeson CE, 1998, J AM CHEM SOC, V120, P7211, DOI 10.1021/ja980871x; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; SCHONEICH C, 1995, METHOD ENZYMOL, V251, P45, DOI 10.1016/0076-6879(95)51109-1; Stepp DW, 2002, AM J PHYSIOL-HEART C, V283, pH750, DOI 10.1152/ajpheart.00029.2002; Sullivan DM, 2000, BIOCHEMISTRY-US, V39, P11121, DOI 10.1021/bi0007674; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Yang Y, 2005, P NATL ACAD SCI USA, V102, P117, DOI 10.1073/pnas.0405989102; Zang MW, 2001, J BIOL CHEM, V276, P25157, DOI 10.1074/jbc.M100152200; Zmijewski JW, 2005, AM J PHYSIOL-HEART C, V289, pH852, DOI 10.1152/ajpheart.00015.2005; Zou MH, 2002, DIABETES, V51, P198, DOI 10.2337/diabetes.51.1.198; Zou MH, 2002, J CLIN INVEST, V109, P817, DOI 10.1172/JCI200214442	35	114	115	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					518	+		10.1096/fj.05-4875fje	http://dx.doi.org/10.1096/fj.05-4875fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16415107				2022-12-28	WOS:000235996000017
J	Grossin, L; Cournil-Henrionnet, C; Pinzano, A; Gaborit, N; Dumas, D; Etienne, S; Stoltz, JF; Terlain, B; Netter, P; Mir, LM; Gillet, P				Grossin, L; Cournil-Henrionnet, C; Pinzano, A; Gaborit, N; Dumas, D; Etienne, S; Stoltz, JF; Terlain, B; Netter, P; Mir, LM; Gillet, P			Gene transfer with HSP 70 in rat chondrocytes confers cytoprotection in vitro and during experimental osteoarthritis	FASEB JOURNAL			English	Article						gene delivery; patellar cartilage; apoptosis; MIA	NITRIC-OXIDE SYNTHASE; HEAT-SHOCK PROTEINS; ARTICULAR-CARTILAGE; INDUCED APOPTOSIS; ANIMAL-MODELS; DOSE-RESPONSE; CELL-DEATH; VIVO; EXPRESSION; CASPASE-3	Osteoarthritis is characterized by a gradual degradation of extracellular matrix, resulting from an excess of chondrocyte cell death, mainly due to an increase in apoptotis. Recent studies have revealed the essential role of HSP70 in protecting cells from stressful stimuli. Therefore, overexpressing HSP70 in chondrocytes could represent a good strategy to prevent extracellular matrix destruction. To this end, we have developed a vector carrying HSP70/GFP, and transduced chondrocytes were thus more resistant to cell death induced by mono-iodoacetate (MIA). To overcome the barrier-effect of matrix, we investigated the efficacy of plasmid delivery by electroporation (EP) in rat patellar cartilage. Two days after EP, 50% of patellar chondrocytes were HSP/GFP+. After 3 months, long-term expression of transgene was only depicted in the deep layer (20-30% positive cells). HSP70 overexpression inhibited the natural endochondral ossification in the deep layer, thus leading to a lesser decrease in chondrocyte distribution. Moreover, overexpression of HSP70, after a preventive EP transfer in rat patella, was sufficient to decrease the severity of osteoarthritis-induced lesions, as demonstrated histologically and biochemically. In conclusion, intracellular overexpression of HSP70, through EP delivery, could protect chondrocytes from cellular injuries and thus might be a novel chondroprotective modality in rat OA.-Grossin, L., Cournil-Henrionnet, C., Pinzano, A., Gaborit, N., Dumas, D., Etienne, S., Stoltz, J. F., Terlain, B., Netter, P., Mir, L. M., Gillet, P. Gene transfer with HSP 70 in rat chondrocytes confers cytoprotection in vitro and during experimental osteoarthritis.	Univ Nancy 1, Fac Med Vandoeuvre Nancy, CNRS, UMR 7561, F-54505 Vandoeuvre Les Nancy, France; Inst Gustave Roussy, CNRS, UMR 8121, Villejuif, France; Univ Nancy 1, Fac Med Vandoeuvre Nancy, CNRS, UMR 7563,LEMTA, F-54505 Vandoeuvre Les Nancy, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); Universite de Lorraine	Gillet, P (corresponding author), Univ Nancy 1, Fac Med Vandoeuvre Nancy, CNRS, UMR 7561, Ave Foret Haye,BP184, F-54505 Vandoeuvre Les Nancy, France.	Pierre.Gillet@medecine.uhp-nancy.fr	Gaborit, Nadège A/O-7825-2017; Dumas, Dominique DD/A-5633-2012; PINZANO, Astrid/ABD-5162-2020; MIR, Lluis M/AAJ-9110-2020	PINZANO, Astrid/0000-0002-3867-2676; Cournil, Christel/0000-0002-4827-4276; Christel, HENRIONNET/0000-0001-7484-0377; GILLET, Pierre/0000-0002-0598-7508; GROSSIN, Laurent/0000-0001-6761-0936				Aigner T, 2002, J PATHOL, V198, P1, DOI 10.1002/path.1172; Aigner T, 2002, ARTHRITIS RHEUM-US, V46, P1986, DOI 10.1002/art.10554; ALBINA JE, 1993, J IMMUNOL, V150, P5080; Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602; Bloquel C, 2004, J GENE MED, V6, pS11, DOI 10.1002/jgm.508; BOILEAU C, 2002, FUNDAM CLIN PHARM S1, V16, pA47; Bove SE, 2003, OSTEOARTHR CARTILAGE, V11, P821, DOI 10.1016/S1063-4584(03)00163-8; Concannon CG, 2003, APOPTOSIS, V8, P61, DOI 10.1023/A:1021601103096; Dumond H, 2004, OSTEOARTHR CARTILAGE, V12, P284, DOI 10.1016/j.joca.2003.11.008; Galois L, 2004, OSTEOARTHR CARTILAGE, V12, P779, DOI 10.1016/j.joca.2004.06.008; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; Grogan SP, 2002, J PATHOL, V198, P5, DOI 10.1002/path.1169; Grossin L, 2004, BIORHEOLOGY, V41, P521; Grossin L, 2003, FASEB J, V17, P829, DOI 10.1096/fj.02-0518com; GROSSIN L, 2003, ARTHRITIS RES THE S3, V5, P53; Guingamp C, 1997, ARTHRITIS RHEUM, V40, P1670, DOI 10.1002/art.1780400917; Gutmann B, 2002, NEUROTOX RES, V4, P59, DOI 10.1080/10298420290007637; Hashimoto S, 1998, ARTHRITIS RHEUM-US, V41, P1266, DOI 10.1002/1529-0131(199807)41:7<1266::AID-ART18>3.0.CO;2-Y; Hoehn B, 2001, J CEREBR BLOOD F MET, V21, P1303, DOI 10.1097/00004647-200111000-00006; Janusz MJ, 2001, OSTEOARTHR CARTILAGE, V9, P751, DOI 10.1053/joca.2001.0472; Jouzeau JY, 2000, JOINT BONE SPINE, V67, P565, DOI 10.1016/S1297-319X(00)00214-1; Kiang JG, 1998, PHARMACOL THERAPEUT, V80, P183, DOI 10.1016/S0163-7258(98)00028-X; Kouri-Floras JB, 2002, ULTRASTRUCT PATHOL, V26, P33, DOI 10.1080/01913120252934314; Kuhn K, 2004, OSTEOARTHR CARTILAGE, V12, P1, DOI 10.1016/j.joca.2003.09.015; Lee SW, 2004, ARTHRITIS RHEUM-US, V50, P534, DOI 10.1002/art.20052; Loeuille D, 1997, J RHEUMATOL, V24, P133; Malemud CJ, 2003, CELLS TISSUES ORGANS, V174, P34, DOI 10.1159/000070573; Malhotra R, 1999, J BIOL CHEM, V274, P12567, DOI 10.1074/jbc.274.18.12567; MANKIN HJ, 1971, J BONE JOINT SURG AM, VA 53, P523, DOI 10.2106/00004623-197153030-00009; Matsuo M, 2001, ACTA MED OKAYAMA, V55, P333; Mir LM, 1999, P NATL ACAD SCI USA, V96, P4262, DOI 10.1073/pnas.96.8.4262; Nuttall ME, 2000, J ORTHOPAED RES, V18, P356, DOI 10.1002/jor.1100180306; Okubo S, 2001, CIRCULATION, V103, P877, DOI 10.1161/01.CIR.103.6.877; Pelletier JP, 2003, CLIN EXP RHEUMATOL, V21, P171; Pelletier JP, 2000, ARTHRITIS RHEUM-US, V43, P1290, DOI 10.1002/1529-0131(200006)43:6<1290::AID-ANR11>3.0.CO;2-R; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Saied A, 1997, J BONE MINER RES, V12, P1378, DOI 10.1359/jbmr.1997.12.9.1378; Sharif M, 2004, ARTHRITIS RHEUM-US, V50, P507, DOI 10.1002/art.20020; Sironen RK, 2002, BBA-MOL CELL RES, V1591, P45, DOI 10.1016/S0167-4889(02)00247-1; Sperling O, 2003, NEUROSCI LETT, V351, P137, DOI 10.1016/S0304-3940(03)00858-9; Suzuki K, 1997, J CLIN INVEST, V99, P1645, DOI 10.1172/JCI119327; Takahashi K, 1997, OSTEOARTHR CARTILAGE, V5, P321, DOI 10.1016/S1063-4584(97)80036-2; Takayama S, 2003, ONCOGENE, V22, P9041, DOI 10.1038/sj.onc.1207114; Terauchi R, 2003, ARTHRITIS RHEUM-US, V48, P1562, DOI 10.1002/art.11040; Tiffee JC, 2000, TISSUE CELL, V32, P141, DOI 10.1054/tice.2000.0097; van den Berg WB, 2001, CURR OPIN RHEUMATOL, V13, P452, DOI 10.1097/00002281-200109000-00019; Weiss YG, 2002, J CLIN INVEST, V110, P801, DOI 10.1172/JCI200215888	47	49	53	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					65	75		10.1096/fj.04-2889com	http://dx.doi.org/10.1096/fj.04-2889com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16394269				2022-12-28	WOS:000235996000046
J	Jin, LM; Liu, TY; Lagoda, GA; Champion, HC; Bivalacqua, TJ; Burnett, AL				Jin, LM; Liu, TY; Lagoda, GA; Champion, HC; Bivalacqua, TJ; Burnett, AL			Elevated RhoA/Rho-kinase activity in the aged rat penis: mechanism for age-associated erectile dysfunction	FASEB JOURNAL			English	Article						erection; corpus cavernosum; smooth muscle; myosin light chain phosphatase	NITRIC-OXIDE SYNTHASE; GENE-TRANSFER; MYOSIN PHOSPHATASE; SIGNALING PATHWAY; SMOOTH-MUSCLE; PHOSPHORYLATION; INHIBITION; PROTEIN; PHYSIOLOGY; VASOCONSTRICTION	Epidemiologic studies have shown that aging accounts significantly for the prevalence of erectile dysfunction (ED). The pathophysiology of ED during aging and its underlying molecular mechanisms are largely unknown. We hypothesized that increased RhoA/Rho-kinase signaling is a major factor in the pathogenesis of age-associated ED and the mechanism involves increased penile smooth muscle contractility through inhibition of myosin light chain phosphatase. Male Fischer 344 young (4 month old) and aged (20-22 month old) rats underwent erectile function testing in vivo by measuring intracavernosal pressure (ICP) and mean arterial blood pressure (MAP) upon electrical stimulation of the cavernous nerve. The data demonstrated that erectile function was significantly lower in aged rats than that in young rats at all voltages tested (P < 0.05). Western blot analysis results showed that there were no significant changes in protein expressions of RhoA, Rho-kinase-alpha and -beta isoforms, and myosin light chain phosphatase target subunit (MYPT1); however, membrane-bound RhoA and phosphorylated MYPT1 were increased in aged rat penes by 95 +/- 15 and 56 +/- 8% (P < 0.05), respectively, indicating enhanced RhoA and Rho-kinase activity. Inhibition of Rho-kinase with Y27632 maximally increased ICP/MAP to 0.72 +/- 0.05 in aged rats vs. 0.47 +/- 0.06 in young rats (P < 0.05). Gene transfer of adeno-associated virus (AAV) encoding dominant negative RhoA (T19NRhoA) to penes of aged and young rats for 7 days markedly improved erectile function in aged rats when compared with that in young rats (P < 0.05). These observations were also supported by Rho-kinase activity assay results showing that basal Rho-kinase activity in aged rat penes receiving AAV vehicle treatment was twofold greater than that in young rat penes receiving AAV vehicle treatment, while it was reduced to a level similar to that in young rat penes after gene therapy of T19NRhoA (P < 0.05). Taken together, these data suggest that impaired erectile function during the aging process involves increased RhoA/Rho-kinase signaling, and this pathway may be exploited for the treatment of age-associated ED.	Johns Hopkins Univ, Dept Urol, Baltimore, MD 21287 USA	Johns Hopkins University	Burnett, AL (corresponding author), Johns Hopkins Univ, Dept Urol, 600 N Wolfe St, Baltimore, MD 21287 USA.	aburnett@jhmi.edu			NIDDK NIH HHS [DK-67223, DK-02568] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067223, K08DK002568] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON KE, 1995, PHYSIOL REV, V75, P191, DOI 10.1152/physrev.1995.75.1.191; Aytac IA, 1999, BJU INT, V84, P50; Bivalacqua TJ, 2000, INT J IMPOT RES, V12, pS8, DOI 10.1038/sj.ijir.3900556; Bivalacqua TJ, 2004, P NATL ACAD SCI USA, V101, P9121, DOI 10.1073/pnas.0400520101; Bivalacqua TJ, 2003, J ANDROL, V24, pS17; BURNETT AL, 1995, BIOL REPROD, V52, P485, DOI 10.1095/biolreprod52.3.485; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; Carrier S, 1997, J UROLOGY, V157, P1088, DOI 10.1016/S0022-5347(01)65147-4; Champion HC, 1999, P NATL ACAD SCI USA, V96, P11648, DOI 10.1073/pnas.96.20.11648; Chang S, 2003, INT J IMPOT RES, V15, P53, DOI 10.1038/sj.ijir.3900947; Chitaley K, 2002, BIOCHEM BIOPH RES CO, V298, P427, DOI 10.1016/S0006-291X(02)02458-0; Chitaley K, 2001, NAT MED, V7, P119, DOI 10.1038/83258; Eto M, 2001, J BIOL CHEM, V276, P29072, DOI 10.1074/jbc.M103206200; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; GIVALACQUA TJ, 2003, AM J PHYSIOL-HEART C, V284, pH1408; Gonzalez-Cadavid NF, 2004, EXP GERONTOL, V39, P1705, DOI 10.1016/j.exger.2004.06.022; Jin LM, 2004, AM J PHYSIOL-HEART C, V287, pH1495, DOI 10.1152/ajpheart.01006.2003; Johannes CB, 2000, J UROLOGY, V163, P460, DOI 10.1016/S0022-5347(05)67900-1; Jones R W A, 2002, Expert Opin Pharmacother, V3, P889; Magee TR, 2002, BIOL REPROD, V67, P20, DOI 10.1093/biolreprod/67.1.20; Miao LY, 2001, MECH AGEING DEV, V122, P1757, DOI 10.1016/S0047-6374(01)00297-4; Mills TM, 2002, EUR J PHARMACOL, V439, P173, DOI 10.1016/S0014-2999(02)01408-5; Mills TM, 2001, J APPL PHYSIOL, V91, P1269, DOI 10.1152/jappl.2001.91.3.1269; Ming XF, 2002, MOL CELL BIOL, V22, P8467, DOI 10.1128/MCB.22.24.8467-8477.2002; Musicki B, 2005, J SEX MED, V2, P347, DOI 10.1111/j.1743-6109.2005.20349.x; Rajasekaran M, 2005, J ANDROL, V26, P182; Rajasekaran M, 2002, J ANDROL, V23, P393; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Sawada N, 2001, BIOCHEM BIOPH RES CO, V280, P798, DOI 10.1006/bbrc.2000.4194; Seko T, 2003, CIRC RES, V92, P411, DOI 10.1161/01.RES.0000059987.90200.44; SNYDER RO, 1996, VECTORS GENE THERAPY; van der Loo B, 2000, J EXP MED, V192, P1731, DOI 10.1084/jem.192.12.1731; Wingard CJ, 2003, AM J PHYSIOL-REG I, V285, pR1145, DOI 10.1152/ajpregu.00329.2003	35	79	90	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					536	+		10.1096/fj.05-4232fje	http://dx.doi.org/10.1096/fj.05-4232fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16396994				2022-12-28	WOS:000235996000034
J	Matsumoto, SC; Labovsky, V; Roncoroni, M; Guida, MAC; Gimenez, L; Mitelman, J; Gori, H; Jurgelevicius, R; Grillo, A; Manfredi, P; Levin, MJ; Paveto, C				Matsumoto, SC; Labovsky, V; Roncoroni, M; Guida, MAC; Gimenez, L; Mitelman, J; Gori, H; Jurgelevicius, R; Grillo, A; Manfredi, P; Levin, MJ; Paveto, C			Retinal dysfunction in patients with chronic Chagas' disease is associated to anti-Trypanosoma cruzi antibodies that crossreact with rhodopsin	FASEB JOURNAL			English	Article						electroretinography; rod dysfunction	IDIOPATHIC DILATED CARDIOMYOPATHY; HUMAN BETA-1-ADRENERGIC RECEPTOR; RIBOSOMAL P2-BETA PROTEIN; HEART-DISEASE; MONOCLONAL-ANTIBODY; AMERICAN TRYPANOSOMIASIS; AUTOIMMUNITY HYPOTHESIS; ADRENERGIC-RECEPTOR; P PROTEINS; EPITOPE	To investigate retinal involvement in chronic Chagas' disease, we performed electroretinography and retinal fluorescein angiography studies in chagasic patients. Our results demonstrated a dissociated electrophysiological response characterized by both an abnormal reduction of the electroretinographic b-wave amplitude and a delayed latency, under the dark-adaptated condition. These alterations are compatible with a selective dysfunction of the rods. Antibodies raised against Trypanosoma cruzi that also interact with beta 1-adrenergic receptor blocked light stimulation of cGMP-phosphodiesterase in bovine rod membranes. The specificity from the antibody-rhodopsin interaction was confirmed by Western blot analysis and antigenic competition experiments. Our results suggest an immunomediated rhodopsin blockade. T. cruzi infection probably induces an autoimmune response against rhodopsin in the chronic phase of Chagas' disease through a molecular mimicry mechanism similar to that described previously on cardiac human beta 1-adrenergic and M2-cholinergic receptors, all related to the same subfamily of G-protein-coupled receptors.	Univ Buenos Aires, CONICET, Inst Invest Ingn Genet & Biol Mol, RA-1428 Buenos Aires, DF, Argentina; Hosp Dr Teodoro Alvarez, Dept Neurol, RA-1406 Buenos Aires, DF, Argentina; Hosp Dr Teodoro Alvarez, Dept Ophthalmol, RA-1406 Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Paveto, C (corresponding author), Univ Buenos Aires, CONICET, Inst Invest Ingn Genet & Biol Mol, Vuelta Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	cpaveto@dna.uba.ar						ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; Benoist C, 2001, NAT IMMUNOL, V2, P797, DOI 10.1038/ni0901-797; Bergami PL, 2001, FASEB J, V15, P2602, DOI 10.1096/fj.01-0132com; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cha KW, 2000, P NATL ACAD SCI USA, V97, P3016, DOI 10.1073/pnas.97.7.3016; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; Elies R, 1998, EUR J BIOCHEM, V251, P659, DOI 10.1046/j.1432-1327.1998.2510659.x; Engman DM, 2002, ACTA TROP, V81, P123, DOI 10.1016/S0001-706X(01)00202-9; FARBER DB, 1976, J CYCLIC NUCL PROT, V2, P139; FERRARI I, 1995, J EXP MED, V182, P59, DOI 10.1084/jem.182.1.59; Freedman NJ, 2004, J CLIN INVEST, V113, P1379, DOI 10.1172/JCI200421748; Frohlich SJ, 1998, OPHTHALMOLOGE, V95, P168, DOI 10.1007/s003470050257; Frohlich SJ, 1997, OPHTHALMOLOGE, V94, P206, DOI 10.1007/s003470050103; Galfre G, 1981, Methods Enzymol, V73, P3; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Hargrave PA, 2001, INVEST OPHTH VIS SCI, V42, P3; HOOD DC, 1990, VISUAL NEUROSCI, V5, P379, DOI 10.1017/S0952523800000468; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Kaplan D, 1997, P NATL ACAD SCI USA, V94, P10301, DOI 10.1073/pnas.94.19.10301; KHORANA HG, 1992, J BIOL CHEM, V267, P1; Kierszenbaum F, 1999, CLIN MICROBIOL REV, V12, P210, DOI 10.1128/CMR.12.2.210; Kierszenbaum F, 2003, FEMS IMMUNOL MED MIC, V37, P1, DOI 10.1016/S0928-8244(03)00097-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamb TD, 1996, P NATL ACAD SCI USA, V93, P566, DOI 10.1073/pnas.93.2.566; LEVIN MJ, 1993, PARASITOL TODAY, V9, P381, DOI 10.1016/0169-4758(93)90088-W; LONDESBOROUGH J, 1976, ANAL BIOCHEM, V71, P623, DOI 10.1016/S0003-2697(76)80037-1; Lugones H, 1994, ENFERMEDAD DE CHAGAS, P209; Mahler E, 2004, CLIN EXP IMMUNOL, V136, P527, DOI 10.1111/j.1365-2249.2004.02480.x; Mahler E, 2001, EUR J IMMUNOL, V31, P2210, DOI 10.1002/1521-4141(200107)31:7&lt;2210::AID-IMMU2210&gt;3.0.CO;2-J; MARMOR MF, 1995, DOC OPHTHALMOL, V89, P199, DOI 10.1007/BF01203373; Masuda MO, 1998, FASEB J, V12, P1551, DOI 10.1096/fasebj.12.14.1551; MATSUMOTO SC, 2001, CLIN NEUROPHYSIOL, V112, pS31; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; MESRI EA, 1990, J CLIN MICROBIOL, V28, P1219, DOI 10.1128/JCM.28.6.1219-1224.1990; MIMOUN G, 1991, INT OPHTHALMOL, V15, P4; Mobini R, 2000, HYBRIDOMA, V19, P135, DOI 10.1089/02724570050031176; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PERLMAN I, 1983, BRIT J OPHTHALMOL, V67, P443, DOI 10.1136/bjo.67.7.443; ROMANO C, 1995, INVEST OPHTH VIS SCI, V36, P1968; ROMANO C, 1992, INVEST OPHTH VIS SCI, V4, P396; ROSENBAUM MB, 1994, J CARDIOVASC ELECTR, V5, P367, DOI 10.1111/j.1540-8167.1994.tb01174.x; ROSENBAUM MB, 1964, PROG CARDIOVASC DIS, V7, P199, DOI 10.1016/S0033-0620(64)80020-7; Sakmar TP, 2002, CURR OPIN CELL BIOL, V14, P189, DOI 10.1016/S0955-0674(02)00306-X; SICHI H, 1969, J BIOL CHEM, V244, P178; Sterin-Borda L, 2000, ANN NY ACAD SCI, V917, P273; Stryer L, 1996, P NATL ACAD SCI USA, V93, P557, DOI 10.1073/pnas.93.2.557; Terakita A, 2000, P NATL ACAD SCI USA, V97, P14263, DOI 10.1073/pnas.260349597; Tornow RP, 1998, ACTA ANAT, V162, P163; Trabanino RJ, 2004, BIOPHYS J, V86, P1904, DOI 10.1016/S0006-3495(04)74256-3; Tsukamoto H, 2005, P NATL ACAD SCI USA, V102, P6303, DOI 10.1073/pnas.0500378102; WITT PL, 1984, J GEN PHYSIOL, V84, P51	52	5	5	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					550	+		10.1096/fj.05-4654fje	http://dx.doi.org/10.1096/fj.05-4654fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16423878				2022-12-28	WOS:000235996000011
J	Taylor, KR; Gallo, RL				Taylor, KR; Gallo, RL			Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation	FASEB JOURNAL			English	Review						heparan sulfate; chondroitin sulfate; dermatan sulfate; hyaluronan	HEPARAN-SULFATE PROTEOGLYCANS; FIBROBLAST-GROWTH-FACTOR; HYALURONAN-MEDIATED MOTILITY; TOLL-LIKE RECEPTOR-4; DERMATAN SULFATE; L-SELECTIN; TARGETED DISRUPTION; DENDRITIC CELLS; MICE DEFICIENT; COFACTOR-II	Glycosaminoglycans, linear carbohydrates such as heparan sulfate and hyaluronan, participate in a variety of biological processes including cell-matrix interactions and activation of chemokines, enzymes and growth factors. This review will discuss progress in immunology and the science of wound repair that has revealed the importance of glycosaminoglycans, and their proteoglycans, in the inflammatory process. Heparan sulfate enables growth factor function and modifies enzyme/inhibitor functions, such as antithrombin III and heparin cofactor II. Heparan sulfate also interacts with cytokines/chemokines and participates in leukocyte selectin binding to promote the recruitment of leukocytes. Chondroitin sulfate/dermatan sulfate regulates growth factor activity and is an alternate modulator of heparin cofactor II. In addition, dermatan sulfate induces ICAM-1 expression on endothelial cells and also recruits leukocytes via selectin interactions. Hyaluronan alternatively participates in leukocyte recruitment via interaction with CD44, while activating various inflammatory cells, such as macrophages, through CD44-dependent signaling. Hyaluronan also signals through Toll-like receptor 4 to induce dendritic cell maturation and promote cytokine release by dendritic cells and endothelial cells. Taken together, the field of glycosaminoglycan biology provides new clues and explanations of the process of inflammation and suggests new therapeutic approaches to human disease.-Taylor, K. R., Gallo, R. L. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation.	Univ Calif San Diego, Div Dermatol, San Diego, CA 92103 USA; VA Med Ctr, San Diego, CA USA	University of California System; University of California San Diego	Gallo, RL (corresponding author), Mail Code 9111B,3350 La Jolla Village Dr, La Jolla, CA 92161 USA.	rgallo@vapop.ucsd.edu	Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861				Abrink M, 2004, J BIOL CHEM, V279, P40897, DOI 10.1074/jbc.M405856200; Akama TO, 2000, NAT GENET, V26, P237, DOI 10.1038/79987; Ameye L, 2002, GLYCOBIOLOGY, V12, p107R, DOI 10.1093/glycob/cwf065; Arikawa-Hirasawa E, 2002, AM J HUM GENET, V70, P1368, DOI 10.1086/340390; Arikawa-Hirasawa E, 2001, AM J MED GENET, V106, P254, DOI 10.1002/ajmg.10229.abs; Arikawa-Hirasawa E, 1999, NAT GENET, V23, P354, DOI 10.1038/15537; Bame KJ, 2001, GLYCOBIOLOGY, V11, p91R, DOI 10.1093/glycob/11.6.91R; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; Beg AA, 2002, TRENDS IMMUNOL, V23, P509, DOI 10.1016/S1471-4906(02)02317-7; Bullard KM, 2003, WORLD J SURG, V27, P54, DOI 10.1007/s00268-002-6737-2; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Cano-Gauci DF, 1999, J CELL BIOL, V146, P255; CELLA G, 1992, ANGIOLOGY, V43, P59, DOI 10.1177/000331979204300107; Clasper S, 1999, J BIOL CHEM, V274, P24113, DOI 10.1074/jbc.274.34.24113; Csoka AB, 2001, MATRIX BIOL, V20, P499, DOI 10.1016/S0945-053X(01)00172-X; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; de la Motte CA, 2003, AM J PATHOL, V163, P121, DOI 10.1016/S0002-9440(10)63636-X; DeAngelis PL, 1999, CELL MOL LIFE SCI, V56, P670, DOI 10.1007/s000180050461; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Forlino A, 2005, HUM MOL GENET, V14, P859, DOI 10.1093/hmg/ddi079; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI13561; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; FRASER JRE, 1989, CIBA F SYMP, V143, P41; Fries E, 2003, ACTA BIOCHIM POL, V50, P735; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P44084, DOI 10.1074/jbc.M402131200; Gossec L, 2004, ANN RHEUM DIS, V63, P478, DOI 10.1136/ard.2003.013771; Gotte M, 2003, FASEB J, V17, P575, DOI 10.1096/fj.02-0739rev; Gotte M, 2002, INVEST OPHTH VIS SCI, V43, P1135; Habuchi H, 2004, GLYCOCONJUGATE J, V21, P47, DOI 10.1023/B:GLYC.0000043747.87325.5e; Habuchi O, 2000, BBA-GEN SUBJECTS, V1474, P115, DOI 10.1016/S0304-4165(00)00016-7; HajMohammadi S, 2003, J CLIN INVEST, V111, P989, DOI 10.1172/JCI200315809; Halden Y, 2004, BIOCHEM J, V377, P533, DOI 10.1042/BJ20030729; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HECHT JT, 1995, AM J HUM GENET, V56, P1125; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Huntington JA, 2003, J THROMB HAEMOST, V1, P1535, DOI 10.1046/j.1538-7836.2003.00305.x; Hynes WL, 2000, FEMS MICROBIOL LETT, V183, P201, DOI 10.1111/j.1574-6968.2000.tb08958.x; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Ishiguro K, 2000, DEV DYNAM, V219, P539, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1081>3.0.CO;2-K; Ishiguro K, 2001, J BIOL CHEM, V276, P47483, DOI 10.1074/jbc.M106268200; Itano N, 2002, IUBMB LIFE, V54, P195, DOI 10.1080/15216540214929; Johnson GB, 2002, J IMMUNOL, V168, P5233, DOI 10.4049/jimmunol.168.10.5233; Johnson P, 2000, BIOCHEM PHARMACOL, V59, P455, DOI 10.1016/S0006-2952(99)00266-X; Jones M, 2000, J BIOL CHEM, V275, P7964, DOI 10.1074/jbc.275.11.7964; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Kawashima H, 2003, J BIOL CHEM, V278, P13069, DOI 10.1074/jbc.M212244200; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kawashima H, 2000, J BIOL CHEM, V275, P35448, DOI 10.1074/jbc.M003387200; Kitagawa H, 1997, BIOCHEMISTRY-US, V36, P3998, DOI 10.1021/bi962740j; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; KOSHIISHI I, 1994, BLOOD, V84, P390; Kusche-Gullberg M, 2003, CURR OPIN STRUC BIOL, V13, P605, DOI 10.1016/j.sbi.2003.08.002; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Lesley J, 2004, J BIOL CHEM, V279, P25745, DOI 10.1074/jbc.M313319200; Li JP, 2003, J BIOL CHEM, V278, P28363, DOI 10.1074/jbc.C300219200; Liaw PCY, 2001, J BIOL CHEM, V276, P20959, DOI 10.1074/jbc.M010584200; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; Majors AK, 2003, J BIOL CHEM, V278, P47223, DOI 10.1074/jbc.M304871200; Marshall LJ, 2003, J IMMUNOL, V171, P2057, DOI 10.4049/jimmunol.171.4.2057; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; Merry CLR, 2002, BBA-GEN SUBJECTS, V1573, P319, DOI 10.1016/S0304-4165(02)00399-9; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; Meyer K, 1934, J BIOL CHEM, V107, P629; Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407; Mohamadzadeh M, 1998, J CLIN INVEST, V101, P97, DOI 10.1172/JCI1604; Mummert ME, 2002, J IMMUNOL, V169, P4322, DOI 10.4049/jimmunol.169.8.4322; Nedvetzki S, 2004, P NATL ACAD SCI USA, V101, P18081, DOI 10.1073/pnas.0407378102; Noble PW, 2002, MATRIX BIOL, V21, P25, DOI 10.1016/S0945-053X(01)00184-6; Olutoye OO, 1997, J PEDIATR SURG, V32, P1037, DOI 10.1016/S0022-3468(97)90394-8; Park PW, 2001, NATURE, V411, P98, DOI 10.1038/35075100; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; Penc SF, 1999, J CLIN INVEST, V103, P1329, DOI 10.1172/JCI4742; Petersen F, 1999, J BIOL CHEM, V274, P12376, DOI 10.1074/jbc.274.18.12376; Rabenstein DL, 2002, NAT PROD REP, V19, P312, DOI 10.1039/b100916h; Reed CC, 2002, GLYCOCONJUGATE J, V19, P249, DOI 10.1023/A:1025383913444; Reizes O, 2001, CELL, V106, P105, DOI 10.1016/S0092-8674(01)00415-9; Rhodes KE, 2004, J ANAT, V204, P33, DOI 10.1111/j.1469-7580.2004.00261.x; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; Rose Mark J., 2004, Current Drug Targets - Inflammation and Allergy, V3, P221, DOI 10.2174/1568010043343589; SAMPSON PM, 1992, J CLIN INVEST, V90, P1492, DOI 10.1172/JCI116017; Sanderson RD, 2001, SEMIN CELL DEV BIOL, V12, P89, DOI 10.1006/scdb.2000.0241; Sawai T, 1997, J PEDIATR SURG, V32, P41, DOI 10.1016/S0022-3468(97)90089-0; Sayo T, 2002, J INVEST DERMATOL, V118, P43, DOI 10.1046/j.0022-202x.2001.01613.x; Shikata K, 1999, J PATHOL, V188, P93, DOI 10.1002/(SICI)1096-9896(199905)188:1<93::AID-PATH305>3.0.CO;2-#; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shworak NW, 2002, GLYCOCONJUGATE J, V19, P355, DOI 10.1023/A:1025377206600; Siegelman MH, 1999, J LEUKOCYTE BIOL, V66, P315, DOI 10.1002/jlb.66.2.315; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; Strazynski M, 2004, J BIOL CHEM, V279, P21266, DOI 10.1074/jbc.M309782200; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745; SUGAHARA K, 1992, J BIOL CHEM, V267, P1528; Sugahara K, 2002, IUBMB LIFE, V54, P163, DOI 10.1080/15216540214928; Taylor KR, 2005, J BIOL CHEM, V280, P5300, DOI 10.1074/jbc.m410412200; Taylor KR, 2004, J BIOL CHEM, V279, P17079, DOI 10.1074/jbc.M310859200; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; Termeer C, 2003, TRENDS IMMUNOL, V24, P112, DOI 10.1016/S1471-4906(03)00029-2; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Termeer CC, 2000, J IMMUNOL, V165, P1863, DOI 10.4049/jimmunol.165.4.1863; Thierry V, 2004, OCEAN MODEL, V6, P1, DOI 10.1016/S1463-5003(02)00054-9; Tkachenko E, 2005, CIRC RES, V96, P488, DOI 10.1161/01.RES.0000159708.71142.c8; Tolg C, 2003, ONCOGENE, V22, P6873, DOI 10.1038/sj.onc.1206811; TOLLEFSEN DM, 1986, J BIOL CHEM, V261, P8854; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Trowbridge JM, 2002, J BIOL CHEM, V277, P42815, DOI 10.1074/jbc.M204959200; Trowbridge JM, 2002, GLYCOBIOLOGY, V12, p117R, DOI 10.1093/glycob/cwf066; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Uchimura K, 2002, J BIOL CHEM, V277, P1443, DOI 10.1074/jbc.M104719200; Vink GR, 2005, EUR J HUM GENET, V13, P470, DOI 10.1038/sj.ejhg.5201343; Watanabe H, 1997, P NATL ACAD SCI USA, V94, P6943, DOI 10.1073/pnas.94.13.6943; WATANABE H, 1994, NAT GENET, V7, P154, DOI 10.1038/ng0694-154; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Weigel PH, 2002, IUBMB LIFE, V54, P201, DOI 10.1080/15216540214931; Wilson VA, 2002, GLYCOCONJUGATE J, V19, P347, DOI 10.1023/A:1025325222530; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746; Young MF, 2002, GLYCOCONJUGATE J, V19, P257, DOI 10.1023/A:1025336114352; Zak BM, 2002, BBA-GEN SUBJECTS, V1573, P346, DOI 10.1016/S0304-4165(02)00402-6; Zhuo LS, 2001, J BIOL CHEM, V276, P7693, DOI 10.1074/jbc.C000899200	127	452	470	2	59	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					9	22		10.1096/fj.05-4682rev	http://dx.doi.org/10.1096/fj.05-4682rev			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16394262				2022-12-28	WOS:000235996000039
J	Iribarren, P; Chen, KQ; Hu, JY; Gong, WH; Cho, EH; Lockett, S; Uranchimeg, B; Wang, JM				Iribarren, P; Chen, KQ; Hu, JY; Gong, WH; Cho, EH; Lockett, S; Uranchimeg, B; Wang, JM			CpG-containing oligodeoxynucleotide promotes microglial cell uptake of amyloid beta 1-42 peptide by up-regulating the expression of the G-protein-coupled receptor mFPR2	FASEB JOURNAL			English	Article						Alzheimer's disease; chemotaxis; inflammation; phagocytosis; TLR9	AMYLOID-BETA-PROTEIN; TOLL-LIKE RECEPTOR-9; ANTI-DNA ANTIBODIES; ALZHEIMERS-DISEASE; BACTERIAL-DNA; GENE-THERAPY; MOUSE MODEL; B-CELLS; INFLAMMATION; ACTIVATION	Human G protein-coupled formyl peptide receptor like 1 (FPRL1) and its mouse homologue murine formyl peptide receptor 2 (mFPR2) mediate the chemotactic activity of amyloid beta 1-42 (A beta(42)), a key pathogenic peptide in Alzheimer's disease ( AD). Since mFPR2 is up-regulated in mouse microglia by lipopolysaccharide (LPS), a Toll-like receptor 4 ligand, we investigated the capacity of CpG-containing oligodeoxynucleotide (ODN), a Toll-like receptor (TLR) 9 ligand, to regulate the expression of mFPR2 in mouse microglia. CpG ODN markedly enhanced the expression and function of mFPR2 in microglial cells, which exhibited increased chemotactic responses to mFPR2 agonists, including A beta(42). The effect of CpG ODN is dependent on activation of p38 MAPK. Further studies showed that CpG ODN-treated microglia increased their capacity to endocytose A beta(42) through mFPR2, as this process was abrogated by pertussis toxin, a Gi protein inhibitor, and W peptide, another potent mFPR2 agonist. Our results suggest that TLR9 may play an important role in promoting microglial recognition of A beta(42), thus affecting the pathogenic process of AD.	NCI, Mol Immunoregulat Lab, Canc Res Ctr, Frederick, MD 21702 USA; SAIC Frederick, Basic Res Program, Frederick, MD 21702 USA; SAIC Frederick, Image Anal Lab, Frederick, MD 21702 USA; SAIC Frederick, Dev Therapeut Program, Tumor Hypoxia Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Science Applications International Corporation (SAIC); SAIC-Frederick; Science Applications International Corporation (SAIC); SAIC-Frederick	Wang, JM (corresponding author), NCI, Mol Immunoregulat Lab, Canc Res Ctr, Bldg 560,Room 31-40, Frederick, MD 21702 USA.	wangji@mail.ncifcrf.gov	Cho, Edward/B-3727-2012	Cho, Edward/0000-0002-0278-334X	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01-CO-12400] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Ard MD, 1996, J NEUROSCI RES, V43, P190, DOI 10.1002/(SICI)1097-4547(19960115)43:2<190::AID-JNR7>3.0.CO;2-B; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bessis N, 2004, GENE THER, V11, pS10, DOI 10.1038/sj.gt.3302364; Blesch A, 2004, YONSEI MED J, V45, P28; Boehme KW, 2004, J VIROL, V78, P7867, DOI 10.1128/JVI.78.15.7867-7873.2004; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; Cotter RL, 1999, J LEUKOCYTE BIOL, V65, P416, DOI 10.1002/jlb.65.4.416; Cui YH, 2002, J LEUKOCYTE BIOL, V72, P628; Cui YH, 2002, NEUROBIOL DIS, V10, P366, DOI 10.1006/nbdi.2002.0517; Cui YH, 2002, J IMMUNOL, V168, P434, DOI 10.4049/jimmunol.168.1.434; Dalpke AH, 2002, J IMMUNOL, V168, P4854, DOI 10.4049/jimmunol.168.10.4854; DeWitt DA, 1998, EXP NEUROL, V149, P329, DOI 10.1006/exnr.1997.6738; Dickson DW, 1997, J NEUROPATH EXP NEUR, V56, P321, DOI 10.1097/00005072-199704000-00001; DURAND ML, 1993, NEW ENGL J MED, V328, P21, DOI 10.1056/NEJM199301073280104; Eikelenboom P, 1998, EXP NEUROL, V154, P89, DOI 10.1006/exnr.1998.6920; ElKhoury J, 1996, NATURE, V382, P716; Giulian D, 1999, AM J HUM GENET, V65, P13, DOI 10.1086/302477; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hartt JK, 1999, J EXP MED, V190, P741, DOI 10.1084/jem.190.5.741; Hirsch EC, 2003, ANN NY ACAD SCI, V991, P214; Iribarren P, 2003, J IMMUNOL, V171, P5482, DOI 10.4049/jimmunol.171.10.5482; Iribarren P, 2005, IMMUNOL RES, V31, P165, DOI 10.1385/IR:31:3:165; Kalaria R N, 1999, Curr Opin Hematol, V6, P15, DOI 10.1097/00062752-199901000-00004; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Krug A, 2004, BLOOD, V103, P1433, DOI 10.1182/blood-2003-08-2674; Le YY, 1999, J IMMUNOL, V163, P6777; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Lee Sung Joong, 2002, Current Drug Targets - Inflammation and Allergy, V1, P181; Liu L, 2003, IMMUNOLOGY, V110, P341, DOI 10.1046/j.1365-2567.2003.01739.x; Lombardo JA, 2003, J NEUROSCI, V23, P10879, DOI 10.1523/jneurosci.23-34-10879.2003; Lund J, 2003, J EXP MED, V198, P513, DOI 10.1084/jem.20030162; Macfarlane DE, 1998, J IMMUNOL, V160, P1122; Marshak-Rothstein A, 2004, RHEUM DIS CLIN N AM, V30, P559, DOI 10.1016/j.rdc.2004.04.005; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; McGeer PL, 1999, J LEUKOCYTE BIOL, V65, P409, DOI 10.1002/jlb.65.4.409; Minagar A, 2002, J NEUROL SCI, V202, P13, DOI 10.1016/S0022-510X(02)00207-1; Monsonego A, 2003, SCIENCE, V302, P834, DOI 10.1126/science.1088469; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; PISETSKY DS, 1992, RHEUM DIS CLIN N AM, V18, P437; Pocock JM, 2002, E SCHERING RES FDN W, V39, P105; Rogers J, 2001, NEUROCHEM INT, V39, P333, DOI 10.1016/S0197-0186(01)00040-7; SADIK K, 2003, ALZ DIS ASSOC DIS, V3, pS75; SANO H, 1989, SCAND J IMMUNOL, V30, P51, DOI 10.1111/j.1365-3083.1989.tb01188.x; Scheff SW, 1998, J NEUROPATH EXP NEUR, V57, P1146, DOI 10.1097/00005072-199812000-00006; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SHLOMCHIK MJ, 1993, INT IMMUNOL, V5, P1329, DOI 10.1093/intimm/5.10.1329; Stalder M, 2001, NEUROBIOL AGING, V22, P427, DOI 10.1016/S0197-4580(01)00209-3; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; Tiffany HL, 2001, J BIOL CHEM, V276, P23645, DOI 10.1074/jbc.M101031200; Uchihara T, 1997, STROKE, V28, P1948, DOI 10.1161/01.STR.28.10.1948; Viglianti GA, 2003, IMMUNITY, V19, P837, DOI 10.1016/S1074-7613(03)00323-6; Wegiel J, 1995, BRAIN RES, V705, P225, DOI 10.1016/0006-8993(95)01156-0; WHITLEY RJ, 1990, NEW ENGL J MED, V323, P242, DOI 10.1056/NEJM199007263230406; Wilcock DM, 2003, J NEUROSCI, V23, P3745, DOI 10.1523/jneurosci.23-09-03745.2003; WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yazawa H, 2001, FASEB J, V15, P2454, DOI 10.1096/fj.01-0251com; Yi AK, 1998, J IMMUNOL, V160, P4755; Ying GG, 2004, J IMMUNOL, V172, P7078, DOI 10.4049/jimmunol.172.11.7078	61	68	70	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2032	+		10.1096/fj.05-4578fje	http://dx.doi.org/10.1096/fj.05-4578fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16219804	Bronze			2022-12-28	WOS:000232991100022
J	Infante-Duarte, C; Weber, A; Kratzschmar, K; Prozorovski, T; Pikol, S; Hamann, I; Bellmann-Strobl, J; Aktas, O; Dorr, J; Wuerfel, J; Sturzebecher, CS; Zipp, F				Infante-Duarte, C; Weber, A; Kratzschmar, K; Prozorovski, T; Pikol, S; Hamann, I; Bellmann-Strobl, J; Aktas, O; Dorr, J; Wuerfel, J; Sturzebecher, CS; Zipp, F			Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients	FASEB JOURNAL			English	Article						central nervous system; gene expression	GENE-EXPRESSION; FRACTALKINE CX3CL1; NK CELLS; RECEPTOR; ACTIVATION; CHEMOKINE; ADHESION; CX(3)CR1; BIOLOGY; BETA	Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) characterized by enormous variability in its clinical presentation and course, and for which clear diagnostic parameters are lacking. Here we performed an RNA screen in peripheral mononuclear cells from relapsing-remitting (RR) and primary progressive (PP) MS patients compared with healthy donors (HD) that indicated, among other findings, a role for the chemokine receptor CX(3)CR1 as a diagnostic marker. Gene expression and flow cytometric analyses demonstrated a significantly lower expression of CX(3)CR1 in MS patients compared with healthy individuals. The subpopulation of cells responsible for causing this reduced expression of CX(3)CR1 consisted exclusively of natural killer (NK) cells. Importantly, we found a correlation between disease activity and frequency of CX(3)CR1-positive NK cells in RRMS patients. These findings emphasize the role of NK cells in the development and course of MS and provide evidence for CX(3)CR1 expression as a marker for MS patients and disease activity.	Charite, Neurosci Res Ctr, Inst Neuroimmunol, D-10098 Berlin, Germany; Schering AG, Dept Genom, D-1000 Berlin, Germany; Schering AG, Dept Bioinformat, D-1000 Berlin, Germany; Schering AG, Dept Pharmacogenom, D-1000 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Schering AG; Schering AG; Schering AG	Zipp, F (corresponding author), Charite, Neurosci Res Ctr, Inst Neuroimmunol, D-10098 Berlin, Germany.	frauke.zipp@charite.de	Zipp, Frauke/C-9968-2015; Aktas, Orhan/B-7623-2009	Zipp, Frauke/0000-0002-1231-1928; Aktas, Orhan/0000-0002-2020-9210; Bellmann-Strobl, Judith/0000-0003-2615-1643; Infante Duarte, Carmen/0000-0003-3005-351X				Achiron A, 2004, ANN NEUROL, V55, P410, DOI 10.1002/ana.20008; Amoura Z, 2003, ARTHRITIS RHEUM-US, V48, P3487, DOI 10.1002/art.11350; Baxter AG, 2002, AUTOIMMUNITY, V35, P1, DOI 10.1080/08916930290005864; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; BENCZUR M, 1980, CLIN EXP IMMUNOL, V39, P657; Bomprezzi R, 2003, HUM MOL GENET, V12, P2191, DOI 10.1093/hmg/ddg221; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Echigo T, 2004, J ALLERGY CLIN IMMUN, V113, P940, DOI 10.1016/S0091-6749(04)01061-9; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; Fraticelli P, 2001, J CLIN INVEST, V107, P1173, DOI 10.1172/JCI11517; Hafler DA, 2004, J CLIN INVEST, V113, P788, DOI 10.1172/JCI200421357; Haskell CA, 1999, J BIOL CHEM, V274, P10053, DOI 10.1074/jbc.274.15.10053; Hatori K, 2002, J NEUROSCI RES, V69, P418, DOI 10.1002/jnr.10304; Heusel JW, 2003, CURR OPIN PEDIATR, V15, P586, DOI 10.1097/00008480-200312000-00008; HIRSCH RL, 1985, CLIN IMMUNOL IMMUNOP, V37, P236, DOI 10.1016/0090-1229(85)90155-2; Horwitz DA, 1997, IMMUNOL TODAY, V18, P538, DOI 10.1016/S0167-5699(97)01149-3; Hughes PM, 2002, GLIA, V37, P314, DOI 10.1002/glia.10037; Iglesias AH, 2004, J NEUROIMMUNOL, V150, P163, DOI 10.1016/j.jneuroim.2004.01.017; Kastenbauer S, 2003, J NEUROIMMUNOL, V137, P210, DOI 10.1016/S0165-5728(03)00085-7; Kastrukoff LF, 1998, J NEUROIMMUNOL, V86, P123, DOI 10.1016/S0165-5728(98)00014-9; Kastrukoff LF, 2003, J NEUROIMMUNOL, V145, P103, DOI 10.1016/j.jneuroim.2003.10.001; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Maas K, 2002, J IMMUNOL, V169, P5, DOI 10.4049/jimmunol.169.1.5; Mahadevappa M, 1999, NAT BIOTECHNOL, V17, P1134, DOI 10.1038/15124; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Nanki T, 2002, ARTHRITIS RHEUM, V46, P2878, DOI 10.1002/art.10622; NEIGHBOUR PA, 1982, CLIN EXP IMMUNOL, V49, P11; Neri S, 2001, CLIN DIAGN LAB IMMUN, V8, P1131, DOI 10.1128/CDLI.8.6.1131-1135.2001; Nishimura M, 2002, J IMMUNOL, V168, P6173, DOI 10.4049/jimmunol.168.12.6173; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; O'Connor P, 2002, NEUROLOGY, V59, P998; Ramanathan M, 2001, J NEUROIMMUNOL, V116, P213, DOI 10.1016/S0165-5728(01)00308-3; Ruth JH, 2001, ARTHRITIS RHEUM, V44, P2750, DOI 10.1002/1529-0131(200112)44:12<2750::AID-ART462>3.0.CO;2-C; Takahashi K, 2004, BRAIN, V127, P1917, DOI 10.1093/brain/awh219; Takahashi K, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-23; Umehara H, 2004, ARTERIOSCL THROM VAS, V24, P34, DOI 10.1161/01.ATV.0000095360.62479.1F; VRANES Z, 1989, J NEUROL SCI, V94, P115, DOI 10.1016/0022-510X(89)90222-0; Wandinger KP, 2001, ANN NEUROL, V50, P349, DOI 10.1002/ana.1096; Yoneda O, 2003, EUR J IMMUNOL, V33, P53, DOI 10.1002/immu.200390007	39	57	61	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1902	+		10.1096/fj.05-3832fje	http://dx.doi.org/10.1096/fj.05-3832fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16144955				2022-12-28	WOS:000232315700028
J	Okada, S; Ishii, K; Yamane, J; Iwanami, A; Ikegami, T; Katoh, H; Iwamoto, Y; Nakamura, M; Miyoshi, H; Okano, HJ; Contag, CH; Toyama, Y; Okano, H				Okada, S; Ishii, K; Yamane, J; Iwanami, A; Ikegami, T; Katoh, H; Iwamoto, Y; Nakamura, M; Miyoshi, H; Okano, HJ; Contag, CH; Toyama, Y; Okano, H			In vivo imaging of engrafted neural stem cells: its application in evaluating the optimal timing of transplantation for spinal cord injury	FASEB JOURNAL			English	Article						bioluminescence imaging; neural stem/progenitor cells; delayed transplantation	MAGNETIC-RESONANCE TRACKING; CENTRAL-NERVOUS-SYSTEM; FUNCTIONAL RECOVERY; GENE-EXPRESSION; LENTIVIRAL VECTOR; CONTUSION INJURY; PROGENITOR CELLS; BRAIN; RATS; NANOPARTICLES	Neural stem/progenitor cells (NSPCs) hold promise in neural tissue replacement therapy after spinal cord injury. However, understanding the survival time of grafted NSPCs and determining the extent of migration away from transplantation sites are essential for optimizing treatment regimens. Here, we used in vivo bioluminescence imaging to noninvasively assess the survival and residence time of transplanted NSPCs at the injury sites in living animals, and we used histologic analyses to assess cell integration and morphology. Third-generation lentiviral vectors enabled efficient transduction and stable expression of both luciferase and a variant of green fluorescent protein in primary cultured NSPCs. Signals from these cells were detectable for up to 10 months or more after transplantation into the injured spinal cords of C57BL/6J mice. Histological and functional data supported the imaging data and suggest that the timing of NSPC transplantation may be a key determinant of the fates and function of integrated cells since cell survival and migration depended on the time of transplantation relative to injury. Optimization of cell therapies can be greatly accelerated and refined by imaging, and the methods in the present study can be widely applied to various research fields of regeneration medicine, including transplantation study.	Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Dept Orthopaed Surg, Shinjuku Ku, Tokyo 1608582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Higashi Ku, Fukuoka 8128582, Japan; RIKEN, Tsukuba Inst, Bioresource Ctr, Subteam Manipulat Cell Fate, Ibaraki 3050074, Japan; Stanford Univ, Sch Med, Dept Pediat, James H Clark Ctr,Bio X Program, Stanford, CA 94305 USA; Japan Sci & Technol, CREST, Saitama 3320012, Japan	Keio University; Keio University; Kyushu University; RIKEN; Stanford University; Japan Science & Technology Agency (JST)	Okano, H (corresponding author), Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	hidokano@sc.itc.keio.ac.jp	Okano, Hideyuki/I-7584-2019; Miyoshi, Hiroyuki/G-9808-2013; Nakamura, Masaya/K-4111-2013; Toyama, Yoshiaki/K-5743-2013	ISHII, KEN/0000-0003-0094-7918; Okada, Seiji/0000-0002-5107-8209; Okano, Hirotaka James/0000-0003-4611-7098; Contag, Christopher/0000-0002-1011-8278	NATIONAL CANCER INSTITUTE [R24CA092862] Funding Source: NIH RePORTER; NCI NIH HHS [R24 CA 92862] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Bai Y, 2003, GENE THER, V10, P1446, DOI 10.1038/sj.gt.3302026; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bjorklund A, 2003, LANCET NEUROL, V2, P437, DOI 10.1016/S1474-4422(03)00442-3; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Bulte JWM, 2002, J CEREBR BLOOD F MET, V22, P899, DOI 10.1097/00004647-200208000-00001; Cao YA, 2004, P NATL ACAD SCI USA, V101, P221, DOI 10.1073/pnas.2637010100; Contag CH, 2002, ANNU REV BIOMED ENG, V4, P235, DOI 10.1146/annurev.bioeng.4.111901.093336; Costa GL, 2001, J IMMUNOL, V167, P2379, DOI 10.4049/jimmunol.167.4.2379; Coumans JV, 2001, J NEUROSCI, V21, P9334, DOI 10.1523/JNEUROSCI.21-23-09334.2001; De A, 2003, MOL THER, V7, P681, DOI 10.1016/S1525-0016(03)00070-4; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Graves EE, 2004, CURR MOL MED, V4, P419, DOI 10.2174/1566524043360555; Hallbergson AF, 2003, J CLIN INVEST, V112, P1128, DOI 10.1172/JCI200320098; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Iwanami A, 2005, J NEUROSCI RES, V80, P172, DOI 10.1002/jnr.20435; Iwanami A, 2005, J NEUROSCI RES, V80, P182, DOI 10.1002/jnr.20436; Jendelova P, 2004, J NEUROSCI RES, V76, P232, DOI 10.1002/jnr.20041; Jeong SW, 2003, STROKE, V34, P2258, DOI 10.1161/01.STR.0000083698.20199.1F; Kim DE, 2004, STROKE, V35, P952, DOI 10.1161/01.STR.0000120308.21946.5D; Lee IH, 2004, EXP NEUROL, V187, P509, DOI 10.1016/j.expneurol.2004.02.007; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Llado J, 2004, MOL CELL NEUROSCI, V27, P322, DOI 10.1016/j.mcn.2004.07.010; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; Mandl S, 2002, J CELL BIOCHEM, P239, DOI 10.1002/jcb.10454; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Nakamura M, 2003, EXP NEUROL, V184, P313, DOI 10.1016/S0014-4886(03)00361-3; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341; Okada S, 2004, J NEUROSCI RES, V76, P265, DOI 10.1002/jnr.20044; Okano H, 2002, J NEUROSCI RES, V69, P698, DOI 10.1002/jnr.10343; Pirko I, 2004, FASEB J, V18, P179, DOI 10.1096/fj.02-1124fje; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Rice BW, 2001, J BIOMED OPT, V6, P432, DOI 10.1117/1.1413210; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Shah K, 2003, ONCOGENE, V22, P6865, DOI 10.1038/sj.onc.1206748; Wang XL, 2003, BLOOD, V102, P3478, DOI 10.1182/blood-2003-05-1432	41	180	192	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1839	+		10.1096/fj.05-4082fje	http://dx.doi.org/10.1096/fj.05-4082fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16141363				2022-12-28	WOS:000232315700030
J	Wada, Y; Otu, H; Wu, SQ; Abid, MR; Okada, H; Libermann, T; Kodama, T; Shih, SC; Minami, T; Aird, WC				Wada, Y; Otu, H; Wu, SQ; Abid, MR; Okada, H; Libermann, T; Kodama, T; Shih, SC; Minami, T; Aird, WC			Preconditioning of primary human endothelial cells with inflammatory mediators alters the "set point" of the cell	FASEB JOURNAL			English	Article						endothelium; NF-kappa B; sepsis; thrombin; HUVEC	THROMBIN STIMULATION; ADHESION MOLECULE-1; PROTEIN-KINASE; SEVERE SEPSIS; KAPPA-B; EXPRESSION; ACTIVATION; PROMOTER; THERAPY	Endothelial cells are highly sensitive to changes in the extracellular milieu. Sepsis results in activation of inflammatory and coagulation pathways. We hypothesized that sepsis-associated mediators may alter the response capacity (so-called "set point") of endothelial cells. Human umbilical vein endothelial cells (HUVEC) were preincubated in the presence or absence of tumor necrosis factor (TNF)-alpha, lipopolysaccharide (LPS), hypoxia, hyperthermia, and/or high glucose; treated with or without thrombin for 4 h; and then processed for RNase protection assays of selected activation markers. Priming with TNF-alpha and LPS significantly inhibited thrombin-mediated induction of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, tissue factor, and E-selectin, but not platelet-derived growth factor-A or CD44. In electrophoretic mobility shift assays, thrombin-treated HUVEC demonstrated inducible binding of p65 NF-kappa B, an effect that was significantly blunted by pretreatment of cells with TNF-alpha and LPS. Consistent with these results, TNF-alpha and LPS attenuated the effect of thrombin on I kappa B phosphorylation, total cytoplasmic I kappa B, and nuclear translocation of p65 NF-kappa B. The inhibitory effect of TNF-alpha on thrombin signaling persisted for up to 24 h following removal of the cytokine. Taken together, these data suggest that inflammatory mediators prime endothelial cells to modulate subsequent thrombin response.	Beth Israel Deaconess Med Ctr, Div Mol & Vasc Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Ctr Vasc Biol Res, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo, Japan	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; University of Tokyo	Aird, WC (corresponding author), Beth Israel Deaconess Med Ctr, Div Mol & Vasc Med, RW-663,330 Brookline Ave, Boston, MA 02215 USA.	waird@bidmc.harvard.edu		Otu, Hasan/0000-0002-9253-8152; Libermann, Towia/0000-0002-4006-8179	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060585] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL060585, HL 60585-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abid R, 2004, ARTERIOSCL THROM VAS, V24, P294, DOI 10.1161/01.ATV.0000110502.10593.06; Ahmad S, 2003, AM J RESP CELL MOL, V28, P179, DOI 10.1165/rcmb.2002-0004OC; Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887; Aird WC, 2004, BEST PRACT RES CL HA, V17, P161, DOI 10.1016/j.beha.2004.03.006; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; Barash Y, 2004, BIOINFORMATICS, V20, P839, DOI 10.1093/bioinformatics/btg487; Bernard GR, 2001, CRIT CARE MED, V29, P2051, DOI 10.1097/00003246-200111000-00003; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Che WY, 2002, CIRC RES, V90, P1222, DOI 10.1161/01.RES.0000021127.83364.7D; Cines DB, 1998, BLOOD, V91, P3527; Delikouras A, 2003, EUR J IMMUNOL, V33, P3127, DOI 10.1002/eji.200323566; Ishida I, 2002, J IMMUNOL, V169, P2069, DOI 10.4049/jimmunol.169.4.2069; Kohn G, 2002, SHOCK, V17, P91, DOI 10.1097/00024382-200202000-00002; Minami T, 2004, ARTERIOSCL THROM VAS, V24, P41, DOI 10.1161/01.ATV.0000099880.09014.7D; Minami T, 2003, J BIOL CHEM, V278, P6976, DOI 10.1074/jbc.M208974200; Minami T, 2003, ARTERIOSCL THROM VAS, V23, P2041, DOI 10.1161/01.ATV.0000089326.63053.9A; Minami T, 2001, J BIOL CHEM, V276, P47632, DOI 10.1074/jbc.M108363200; Minami T, 2004, J BIOL CHEM, V279, P50537, DOI 10.1074/jbc.M406454200; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Shih SC, 2002, AM J PATHOL, V161, P35, DOI 10.1016/S0002-9440(10)64154-5; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Wu SQ, 2002, BLOOD, V100, P4454, DOI 10.1182/blood-2002-02-0415; Zhang B, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-16	25	22	25	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1914	+		10.1096/fj.05-4037fje	http://dx.doi.org/10.1096/fj.05-4037fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16172186	Green Accepted, Green Published			2022-12-28	WOS:000232315700010
J	Umeda, S; Suzuki, MT; Okamoto, H; Ono, F; Mizota, A; Terao, K; Yoshikawa, Y; Tanaka, Y; Iwata, T				Umeda, S; Suzuki, MT; Okamoto, H; Ono, F; Mizota, A; Terao, K; Yoshikawa, Y; Tanaka, Y; Iwata, T			Molecular composition of drusen and possible involvement of anti-retinal autoimmunity in two different forms of macular degeneration in cynomolgus monkey (Macaca fascicularis)	FASEB JOURNAL			English	Article						liquid chromatography tandem mass spectroscopy	HIGH-FAT DIET; BRUCHS MEMBRANE; ANIMAL-MODEL; ANNEXIN-V; ANTIBODIES; PROTEINS; AUTOANTIBODIES; PATHOGENESIS; MACULOPATHY; EXPRESSION	We have previously reported a cynomolgus monkey (Macaca fascicularis) pedigree with early onset macular degeneration that develops drusen at 2 yr after birth (1). In this study, the molecular composition of drusen in monkeys affected with late onset and early onset macular degeneration was both characterized. Involvement of anti-retinalautoimmunity in the deposition of drusen and the pathogenesis of the disease was also evaluated. Funduscopic and histological examinations were performed on 278 adult monkeys (mean age = 16.94 yr) for late onset macular degeneration. The molecular composition of drusen was analyzed by immunohistochemistry and/or direct proteome analysis using liquid chromatography tandem mass spectroscopy (LC-MS/ MS). Anti-retinal autoantibodies in sera were screened in 20 affected and 10 age-matched control monkeys by Western blot techniques. Immunogenic molecules were identified by 2D electrophoresis and LC-MS/ MS. Relative antibody titer against each antigen was determined by ELISA in sera from 42 affected (late onset) and 41 normal monkeys. Yellowish-white spots in the macular region were observed in 90 (32%) of the late onset monkeys that were examined. Histological examination demonstrated that drusen or degenerative retinal pigment epithelium (RPE) cells were associated with the pigmentary abnormalities. Drusen in both late and early onset monkeys showed immunoreactivities for apolipoprotein E, amyloid P component, complement component C5, the terminal C5b-9 complement complex, vitronectin, and membrane cofactor protein. LC-MS/MS analyses identified 60 proteins as constituents of drusen, including a number of common components in drusen of human age-related macular degeneration (AMD), such as annexins, crystallins, immunoglobulins, and complement components. Half of the affected monkeys had single or multiple autoantibodies against 38, 40, 50, and 60 kDa retinal proteins. The reacting antigens of 38 and 40 kDa were identified as annexin II and mu-crystallin, respectively. Relative antibody titer against annexin II in affected monkeys was significantly higher than control animals (P<0.01). Significant difference was not observed in antibody titer against mu-crystallin; however, several affected monkeys showed considerably elevated titer (360-610%) compared with the mean for unaffected animals. Monkey drusen both in late and early onset forms of macular degeneration had common components with drusen in human AMD patients, indicating that chronic inflammation mediated by complement activation might also be involved in the formation of drusen in these affected monkeys. The high prevalence of anti-retinalautoantibodies in sera from affected monkeys demonstrated an autoimmune aspect of the pathogenesis of the disease. Although further analyses are required to determine whether and how autoantibodies against annexin II or mu-crystallin relate to the pathogenesis of the disease, it could be hypothesized that immune responses directed against these antigens might trigger chronic activation of the complement cascade at the site of drusen formation.	Natl Hosp Org, Tokyo Med Ctr, Natl Inst Sensory Organs, Meguro Ku, Tokyo 1528902, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biomed Sci, Tokyo 1138657, Japan; Corp Prod & Res Lab Primates, Tsukuba 3050843, Japan; Juntendo Univ, Urayasu Hosp, Dept Ophthalmol, Chiba 2790021, Japan; Natl Inst Biomed Innovat, Tsukuba Primate Res Ctr, Tsukuba 3050843, Japan	University of Tokyo; Juntendo University; National Institute of Health Sciences - Japan	Iwata, T (corresponding author), Natl Hosp Org, Tokyo Med Ctr, Natl Inst Sensory Organs, Meguro Ku, 2-5-1 Higashikgaoka, Tokyo 1528902, Japan.	iwatatakeshi@kankakuki.go.jp						Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950; BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X; BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032; Chen L, 2003, MOL VIS, V9, P151; CIRINO G, 1989, P NATL ACAD SCI USA, V86, P3428, DOI 10.1073/pnas.86.9.3428; COMERA C, 1995, BRIT J PHARMACOL, V115, P1043, DOI 10.1111/j.1476-5381.1995.tb15916.x; Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047; Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899; Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643; Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035; DUBOIS T, 1995, J RHEUMATOL, V22, P1230; DUMONDE DC, 1982, LANCET, V2, P787; GALBRAITH GMP, 1986, J CLIN INVEST, V78, P865, DOI 10.1172/JCI112672; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; GREGORY CY, 1992, EXP EYE RES, V54, P843, DOI 10.1016/0014-4835(92)90147-K; GURNE DH, 1991, OPHTHALMOLOGY, V98, P602; Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477; Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6; HOPE GM, 1992, BRIT J OPHTHALMOL, V76, P11, DOI 10.1136/bjo.76.1.11; ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184; Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417; Kaufman M, 1996, BIOCHEM J, V316, P35, DOI 10.1042/bj3160035; KIM RY, 1992, P NATL ACAD SCI USA, V89, P9292, DOI 10.1073/pnas.89.19.9292; Liu H, 1998, J BIOL CHEM, V273, P12858, DOI 10.1074/jbc.273.21.12858; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; Majji AB, 2000, INVEST OPHTH VIS SCI, V41, P3936; MONACO WA, 1990, OPTOMETRY VISION SCI, V67, P532, DOI 10.1097/00006324-199007000-00011; Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142; Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835; NEWSOME DA, 1986, INVEST OPHTH VIS SCI, V27, P1675; Nicolas MG, 1996, EXP EYE RES, V62, P399, DOI 10.1006/exer.1996.0045; Nicolas MG, 1996, EXP EYE RES, V62, P211, DOI 10.1006/exer.1996.0026; PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033; Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6; RodriguezGarcia MI, 1996, ANN RHEUM DIS, V55, P895, DOI 10.1136/ard.55.12.895; Stafford T J, 1974, Mod Probl Ophthalmol, V12, P214; STAFFORD TJ, 1984, OPHTHALMOLOGY, V91, P513; Suzuki MT, 2003, PRIMATES, V44, P291, DOI 10.1007/s10329-002-0016-6; SUZUKI MT, 1985, EXP ANIM TOKYO, V34, P131, DOI 10.1538/expanim1978.34.2_131; Thirkill CE, 2000, OCUL IMMUNOL INFLAMM, V8, P25, DOI 10.1076/0927-3948(200003)8:1;1-S;FT025; Umeda S, 2005, INVEST OPHTH VIS SCI, V46, P683, DOI 10.1167/iovs.04-1031; Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; WISTOW G, 1991, J MOL EVOL, V32, P262, DOI 10.1007/BF02342749; Yang YH, 1997, INFLAMMATION, V21, P583, DOI 10.1023/A:1027330021479	46	125	133	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1683	+		10.1096/fj.04-3525fje	http://dx.doi.org/10.1096/fj.04-3525fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16099945				2022-12-28	WOS:000231843700018
J	Yamashita, JK; Takano, M; Hiraoka-Kanie, M; Shimazu, C; Peishi, Y; Yanagi, K; Nakano, A; Inoue, E; Kita, F; Nishikawa, SI				Yamashita, JK; Takano, M; Hiraoka-Kanie, M; Shimazu, C; Peishi, Y; Yanagi, K; Nakano, A; Inoue, E; Kita, F; Nishikawa, SI			Prospective identification of cardiac progenitors by a novel single cell-based cardiomyocyte induction	FASEB JOURNAL			English	Article						embryonic stem cells; stroma cells; Flk1; CXCR4; regenerative medicine	EMBRYONIC STEM-CELLS; IN-VITRO DIFFERENTIATION; CHEMOKINE RECEPTOR CXCR4; C-KIT RECEPTOR; STROMAL CELLS; MYOCARDIAL REGENERATION; ENDOTHELIAL-CELLS; ES CELLS; HEART; EXPRESSION	Dissection of cardiomyocyte differentiation process at the cellular level is indispensable in the research for cardiac development and regeneration. Previously, we have established an embryonic stem cell differentiation system that reproduces early vascular development from progenitor cells that express Flk1, a vascular endothelial growth factor receptor, by the combinatory application of 2-dimensional culture and flowcytometry. Here we show that cardiomyocytes can be successfully induced from a single Flk1(+) cell on 2-dimensional culture, enabling the direct observation of differentiating cardiomyocytes and the prospective identification of cardiac progenitor potentials. Flk1+ cells could give rise to cardiomyocytes, as well as endothelial cells, from a single cell by the co-culture on OP9 stroma cells in a fusion-independent manner. Among the cell populations in intermediate stages from Flk1+ cells to cardiomyocytes, Flk1(+)/CXCR4(+)/ vascular endothelial cadherin(-) cells were cardiac-specific progenitors at the single cell level. Noggin, a bone morphogenetic protein inhibitor, abolished cardiomyocyte differentiation by inhibiting the cardiac progenitor induction. However, wnt inhibitors Dkk-1 or Frizzled-8/Fc chimeric protein augmented, but wnt3a inhibited, cardiomyocyte differentiation. In vitro reproduction of cardiomyocyte differentiation process should be a potent tool for the cellular and molecular elucidation of cardiac development, which would provide various targets for cardiac regeneration.	Kyoto Univ, Inst Frontier Med Sci, Stem Cell Res Ctr, Lab Stem Cell Differentiat,Sakyo Ku, Kyoto 6068507, Japan; Jichi Med Sch, Dept Physiol, Minami Kawachi, Tochigi, Japan; Fdn Biomed Res & Innovat, Dept Tissue Engn & Cell Therapy, Kobe, Hyogo, Japan; RIKEN, Lab Stem Cell Biol, Ctr Dev Biol, Kobe, Hyogo, Japan	Kyoto University; Jichi Medical University; Institute for Biomedical Research & Innovation (IBRI); RIKEN	Yamashita, JK (corresponding author), Kyoto Univ, Inst Frontier Med Sci, Stem Cell Res Ctr, Lab Stem Cell Differentiat,Sakyo Ku, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	juny@frontier.kyoto-u.ac.jp						Ara T, 2003, P NATL ACAD SCI USA, V100, P5319, DOI 10.1073/pnas.0730719100; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Boheler KR, 2002, CIRC RES, V91, P189, DOI 10.1161/01.RES.0000027865.61704.32; Caplice NM, 2003, CIRC RES, V92, P6, DOI 10.1161/01.RES.0000052826.35667.40; Caspi O, 2004, ANN NY ACAD SCI, V1015, P285, DOI 10.1196/annals.1302.024; Chien KR, 2004, NATURE, V428, P607, DOI 10.1038/nature02500; Conley BJ, 2004, INT J BIOCHEM CELL B, V36, P555, DOI 10.1016/j.biocel.2003.07.003; Foley A, 2004, TRENDS CARDIOVAS MED, V14, P121, DOI 10.1016/j.tcm.2004.01.003; Fraser ST, 2003, METHOD ENZYMOL, V365, P59; Goodell MA, 2001, ANN NY ACAD SCI, V938, P208; Gros D, 2004, CARDIOVASC RES, V62, P299, DOI 10.1016/j.cardiores.2004.02.010; GULICK J, 1991, J BIOL CHEM, V266, P9180; Hescheler J, 1997, CARDIOVASC RES, V36, P149, DOI 10.1016/S0008-6363(97)00193-4; Hidaka K, 2003, FASEB J, V17, P740, DOI 10.1096/fj.02-0104fje; Hirai H, 2003, BLOOD, V101, P886, DOI 10.1182/blood-2002-02-0655; Hirashima M, 1999, BLOOD, V93, P1253, DOI 10.1182/blood.V93.4.1253.404k31_1253_1263; Kasahara H, 1998, CIRC RES, V82, P936, DOI 10.1161/01.RES.82.9.936; Kataoka H, 1997, DEV GROWTH DIFFER, V39, P729; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; KODAMA H, 1994, EXP HEMATOL, V22, P979; KODAMA H, 1992, J EXP MED, V176, P351, DOI 10.1084/jem.176.2.351; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298; Matsuyoshi N, 1997, P ASSOC AM PHYSICIAN, V109, P362; McGrath KE, 1999, DEV BIOL, V213, P442, DOI 10.1006/dbio.1999.9405; Mummery C, 2003, CIRCULATION, V107, P2733, DOI 10.1161/01.CIR.0000068356.38592.68; Nadal-Ginard B, 2003, CIRC RES, V92, P139, DOI 10.1161/01.RES.0000053618.86362.DF; Nishikawa S, 1998, DEVELOPMENT, V125, P1747; NISHIKAWA SI, 1988, EUR J IMMUNOL, V18, P1767, DOI 10.1002/eji.1830181117; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Oh H, 2004, ANN NY ACAD SCI, V1015, P182, DOI 10.1196/annals.1302.015; Olson EN, 2001, SCIENCE, V291, P2327, DOI 10.1126/science.1060063; Orlic D, 2002, CIRC RES, V91, P1092, DOI 10.1161/01.RES.0000046045.00846.B0; Oswald J, 2004, STEM CELLS, V22, P377, DOI 10.1634/stemcells.22-3-377; Sachinidis A, 2003, CARDIOVASC RES, V58, P278, DOI 10.1016/S0008-6363(03)00248-7; Schroeder T, 2003, P NATL ACAD SCI USA, V100, P4018, DOI 10.1073/pnas.0438008100; Srivastava D, 2000, NATURE, V407, P221, DOI 10.1038/35025190; Stieber J, 2004, TRENDS CARDIOVAS MED, V14, P23, DOI 10.1016/j.tcm.2003.09.006; Sussman MA, 2004, ANNU REV PHYSIOL, V66, P29, DOI 10.1146/annurev.physiol.66.032102.140723; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Tamamura H, 1998, BIOCHEM BIOPH RES CO, V253, P877, DOI 10.1006/bbrc.1998.9871; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tsuneto M, 2003, METHOD ENZYMOL, V365, P98; Wurmser AE, 2004, NATURE, V430, P350, DOI 10.1038/nature02604; Wurmser AE, 2002, NATURE, V416, P485, DOI 10.1038/416485a; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568; Yamashita JK, 2004, INT J HEMATOL, V80, P1, DOI 10.1532/ijh97.04043; Zaffran S, 2002, CIRC RES, V91, P457, DOI 10.1161/01.RES.0000034152.74523.A8	49	117	138	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1534	+		10.1096/fj.04-3540fje	http://dx.doi.org/10.1096/fj.04-3540fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16033809				2022-12-28	WOS:000230923000015
J	Ortega-Gutierrez, S; Molina-Holgado, E; Arevalo-Martin, A; Correa, F; Viso, A; Lopez-Rodriguez, ML; Di Marzo, V; Guaza, C				Ortega-Gutierrez, S; Molina-Holgado, E; Arevalo-Martin, A; Correa, F; Viso, A; Lopez-Rodriguez, ML; Di Marzo, V; Guaza, C			Activation of the endocannabinoid system as a therapeutic approach in a murine model of multiple sclerosis	FASEB JOURNAL			English	Article						Theiler's virus; anandamide; microglia; MS; UCM707	CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; NITRIC-OXIDE SYNTHASE; CANNABINOID RECEPTORS; CONTROL SPASTICITY; ANIMAL-MODEL; VIRAL MODEL; EXPRESSION; ANANDAMIDE; INHIBITORS	Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD) is a well-characterized murine model of human multiple sclerosis ( MS) that closely resembles the chronic and progressive clinical form of the disease. Recent studies have described the involvement of the cannabinoid system in the progression of the disease and the benefits associated with the administration of cannabinoid agonists. With the objective to study whether "indirect" agonists, that is, compounds able to reinforce the physiological endocannabinoid transmission and, therefore, devoid of the psychotropic effects of "direct" agonists, could be suitable agents for the amelioration of MS neurological deficits, we administered the potent and selective anandamide uptake inhibitor UCM707 to TMEV-infected mice. Our results indicate that treatment during established disease significantly improves the motor function of the diseased mice. At the histological level, UCM707 is able to reduce microglial activation, diminish major histocompatibility complex class II antigen expression, and decrease cellular infiltrates in the spinal cord. Additionally, in microglial cells, UCM707 decreases the production of the proinflammatory cytokines tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta, and IL- 6; reduces nitric oxide levels and inducible nitric oxide synthase expression; and is able to potentiate the action of a subeffective dose of the endocannabinoid anandamide. Overall, these results suggest that agents able to activate the endocannabinoid system could constitute a new series of drugs for the treatment of MS.	CSIC, Inst Cajal, Neural Plastic Dept, Neuroimmunol Grp, E-28002 Madrid, Spain; Univ Complutense, Dept Quim Organ 1, E-28040 Madrid, Spain; Hosp Nacl Paraplej, Neuroinflammat Grp, Toledo, OH USA; CSIC, Inst Quim Organ Gen, E-28006 Madrid, Spain; CNR, Ist Chim Biomol, I-80078 Pozzuoli, NA, Italy	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC); Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Organica General (IQOG); Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR)	Guaza, C (corresponding author), CSIC, Inst Cajal, Neural Plastic Dept, Neuroimmunol Grp, Plaza Murillo 2, E-28002 Madrid, Spain.	cgjb@cajal.csic.es	viso, alma/AAN-6044-2020; Arevalo-Martin, Angel/C-1597-2008; Molina-Holgado, Eduardo/C-2714-2008; Ortega-Gutierrez, Silvia/I-1935-2017; Viso, Alma/AAA-4971-2020; Ortega-Gutierrez, Silvia/ABC-7653-2021; Arevalo-Martin, Angel/A-5376-2011; Lopez-Rodriguez, Maria L/S-6342-2016; Di Marzo, Vincenzo/AAD-7742-2019	Molina-Holgado, Eduardo/0000-0001-6693-1682; Ortega-Gutierrez, Silvia/0000-0002-0257-6754; Viso, Alma/0000-0003-2622-4777; Lopez-Rodriguez, Maria L/0000-0001-8607-1085; Di Marzo, Vincenzo/0000-0002-1490-3070; Arevalo-Martin, Angel/0000-0002-0549-6098				Arevalo-Martin A, 2003, J NEUROSCI, V23, P2511; Baker D, 2001, FASEB J, V15, P300, DOI 10.1096/fj.00-0399fje; Baker D, 2000, NATURE, V404, P84, DOI 10.1038/35003583; Becher B, 2000, GLIA, V29, P293; Berrendero F, 2001, SYNAPSE, V41, P195, DOI 10.1002/syn.1075; Biswas KK, 2003, HEPATOLOGY, V38, P1167, DOI 10.1053/jhep.2003.50459; Croxford JL, 2003, J CLIN INVEST, V111, P1231, DOI 10.1172/JCI200317652; DALCANTO MC, 1977, AM J PATHOL, V88, P497; de Lago E, 2004, EUR J PHARMACOL, V484, P249, DOI 10.1016/j.ejphar.2003.11.027; de Lago E, 2002, EUR J PHARMACOL, V449, P99, DOI 10.1016/S0014-2999(02)01996-9; Di Marzo V, 2000, TRENDS PHARMACOL SCI, V21, P195, DOI 10.1016/S0165-6147(00)01487-5; Di Marzo V, 2001, TRENDS PHARMACOL SCI, V22, P346, DOI 10.1016/S0165-6147(00)01712-0; Goodin DS, 2002, NEUROLOGY, V58, P169, DOI 10.1212/WNL.58.2.169; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; Iwahashi T, 1999, CELL IMMUNOL, V194, P186, DOI 10.1006/cimm.1999.1482; Katz-Levy Y, 1999, J CLIN INVEST, V104, P599, DOI 10.1172/JCI7292; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lopez-Rodriguez ML, 2003, J MED CHEM, V46, P1512, DOI 10.1021/jm0210818; LYMAN WD, 1989, J NEUROIMMUNOL, V23, P73, DOI 10.1016/0165-5728(89)90075-1; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; McGavern DB, 1999, EXP NEUROL, V158, P171, DOI 10.1006/exnr.1999.7082; McGavern DB, 2000, BRAIN, V123, P519, DOI 10.1093/brain/123.3.519; Mestre L, 2005, J NEUROCHEM, V92, P1327, DOI 10.1111/j.1471-4159.2004.02979.x; Molina-Holgado E, 2002, J NEUROSCI, V22, P9742, DOI 10.1523/jneurosci.22-22-09742.2002; Molina-Holgado E, 2001, EUR J NEUROSCI, V13, P493, DOI 10.1046/j.0953-816x.2000.01412.x; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; OKUDA Y, 1995, J NEUROIMMUNOL, V62, P103, DOI 10.1016/0165-5728(95)00114-H; Ortar G, 2003, BIOCHEM PHARMACOL, V65, P1473, DOI 10.1016/S0006-2952(03)00109-6; Parkinson JF, 1997, J MOL MED, V75, P174, DOI 10.1007/s001090050102; Pryce G, 2003, BRAIN, V126, P2191, DOI 10.1093/brain/awg224; Ruiz L, 1999, FEBS LETT, V458, P400, DOI 10.1016/S0014-5793(99)01073-X; Sato S, 1997, J NEUROIMMUNOL, V76, P213, DOI 10.1016/S0165-5728(97)00059-3; Walter L, 2004, BRIT J PHARMACOL, V141, P775, DOI 10.1038/sj.bjp.0705667; Wiendl H, 2002, BIODRUGS, V16, P183, DOI 10.2165/00063030-200216030-00003; WIRGUIN I, 1994, IMMUNOPHARMACOLOGY, V28, P209, DOI 10.1016/0162-3109(94)90056-6; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	37	110	113	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1338	+		10.1096/fj.04-2464fje	http://dx.doi.org/10.1096/fj.04-2464fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15941768				2022-12-28	WOS:000230207800028
J	Timmons, JA; Larsson, O; Jansson, E; Fischer, H; Gustafsson, T; Greenhaff, PL; Ridden, P; Rachman, J; Peyrard-Janvid, M; Wahlestedt, C; Sundberg, CJ				Timmons, JA; Larsson, O; Jansson, E; Fischer, H; Gustafsson, T; Greenhaff, PL; Ridden, P; Rachman, J; Peyrard-Janvid, M; Wahlestedt, C; Sundberg, CJ			Human muscle gene expression responses to endurance training provide a novel perspective on Duchenne muscular dystrophy	FASEB JOURNAL			English	Article						gene assay; diabetes transcriptome; aerobic training; DMD	HUMAN SKELETAL-MUSCLE; ALPHA-7-BETA-1 INTEGRIN; INSULIN-RESISTANCE; GLUCOSE-TRANSPORT; EXERCISE; REGENERATION; ACTIVATION; MICE; NORMALIZATION; PROGRESSION	Global gene expression profiling is used to generate novel insight into a variety of disease states. Such studies yield a bewildering number of data points, making it a challenge to validate which genes specifically contribute to a disease phenotype. Aerobic exercise training represents a plausible model for identification of molecular mechanisms that cause metabolic-related changes in human skeletal muscle. We carried out the first transcriptome-wide characterization of human skeletal muscle responses to 6 wk of supervised aerobic exercise training in 8 sedentary volunteers. Biopsy samples before and after training allowed us to identify similar to 470 differentially regulated genes using the Affymetrix U95 platform (80 individual hybridization steps). Gene ontology analysis indicated that extracellular matrix and calcium binding gene families were most up-regulated after training. An electronic reanalysis of a Duchenne muscular dystrophy (DMD) transcript expression dataset allowed us to identify similar to 90 genes modulated in a nearly identical fashion to that observed in the endurance exercise dataset. Trophoblast noncoding RNA, an interfering RNA species, was the singular exception-being up-regulated by exercise and down-regulated in DMD. The common overlap between gene expression datasets may be explained by enhanced alpha(7)beta(1) integrin signaling, and specific genes in this signaling pathway were up-regulated in both datasets. In contrast to these common features, OXPHOS gene expression is subdued in DMD yet elevated by exercise, indicating that more than one major mechanism must exist in human skeletal muscle to sense activity and therefore regulate gene expression. Exercise training modulated diabetes-related genes, suggesting our dataset may contain additional and novel gene expression changes relevant for the anti-diabetic properties of exercise. In conclusion, gene expression profiling after endurance exercise training identified a range of processes responsible for the physiological remodeling of human skeletal muscle tissue, many of which were similarly regulated in DMD. Furthermore, our analysis demonstrates that numerous genes previously suggested as being important for the DMD disease phenotype may principally reflect compensatory integrin signaling.	Karolinska Inst, Ctr Genom & Bioinformat, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Lab Med, Div Clin Physiol, SE-17177 Stockholm, Sweden; Univ Med Sch, Ctr Integrated Syst Biol & Med, Nottingham, England	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of Nottingham	Timmons, JA (corresponding author), Karolinska Inst, Ctr Genom & Bioinformat, SE-17177 Stockholm, Sweden.	Jamie.Timmons@fyfa.ki.se	Gustafsson, Thomas/AAH-1056-2019; Timmons, James A/M-6350-2019; Timmons, James A/J-4698-2014; Sundberg, Carl Johan/B-9356-2013; Larsson, Ola/F-8151-2013; Wahlestedt, Claes/A-7039-2009	Timmons, James A/0000-0002-2255-1220; Timmons, James A/0000-0002-2255-1220; Larsson, Ola/0000-0003-1412-1308; Sundberg, Carl Johan/0000-0002-7000-466X; Gustafsson, Thomas/0000-0002-1559-4206; Greenhaff, Paul/0000-0003-4403-0490				Bakay M, 2002, NEUROMUSCULAR DISORD, V12, pS125, DOI 10.1016/S0960-8966(02)00093-7; Bao S, 1998, DIABETES, V47, P1935, DOI 10.2337/diabetes.47.12.1935; Bengtsson J, 2001, PFLUG ARCH EUR J PHY, V443, P61, DOI 10.1007/s004240100628; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; Bogdanovich S, 2004, J MOL MED, V82, P102, DOI 10.1007/s00109-003-0484-1; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Burkin DJ, 2001, J CELL BIOL, V152, P1207, DOI 10.1083/jcb.152.6.1207; Carpentier M, 2000, PROTEIN SCI, V9, P2386, DOI 10.1110/ps.9.12.2386; Carson JA, 2000, J APPL PHYSIOL, V88, P337, DOI 10.1152/jappl.2000.88.1.337; Casar JC, 2004, J CELL SCI, V117, P73, DOI 10.1242/jcs.00828; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Condorelli G, 2001, DIABETES, V50, P1244, DOI 10.2337/diabetes.50.6.1244; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; De Luca A, 2003, J PHARMACOL EXP THER, V304, P453, DOI 10.1124/jpet.102.041343; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; Francki A, 2003, J CELL BIOCHEM, V88, P802, DOI 10.1002/jcb.10424; Geirsson A, 2003, BIOCHEM BIOPH RES CO, V301, P718, DOI 10.1016/S0006-291X(03)00028-7; Gregorevic P, 2002, AM J PATHOL, V161, P2263, DOI 10.1016/S0002-9440(10)64502-6; Gullberg D, 2003, NATURE, V424, P138, DOI 10.1038/424138a; Haslett JN, 2003, NEUROGENETICS, V4, P163, DOI 10.1007/s10048-003-0148-x; Haslett JN, 2002, P NATL ACAD SCI USA, V99, P15000, DOI 10.1073/pnas.192571199; Henriquez JP, 2002, J CELL SCI, V115, P2041; Hodges BL, 1997, J CELL SCI, V110, P2873; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Irwin WA, 2003, NAT GENET, V35, P367, DOI 10.1038/ng1270; Jones SW, 2004, FASEB J, V18, P1025, DOI 10.1096/fj.03-1228fje; Kamanga-Sollo E, 2003, J CELL PHYSIOL, V197, P225, DOI 10.1002/jcp.10362; Kim SS, 2002, J CELL SCI, V115, P2465; Koskinen SOA, 2000, MUSCLE NERVE, V23, P580, DOI 10.1002/(SICI)1097-4598(200004)23:4<580::AID-MUS18>3.0.CO;2-4; Kwon HS, 2004, DIABETES, V53, P899, DOI 10.2337/diabetes.53.4.899; Larsson O, 2004, CANCER RES, V64, P482, DOI 10.1158/0008-5472.CAN-03-1872; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lluis F, 2001, BLOOD, V97, P1703, DOI 10.1182/blood.V97.6.1703; Manson JE, 2002, NEW ENGL J MED, V347, P716, DOI 10.1056/NEJMoa021067; Mayer U, 2003, J BIOL CHEM, V278, P14587, DOI 10.1074/jbc.R200022200; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Murakami N, 1999, MUSCLE NERVE, V22, P889, DOI 10.1002/(SICI)1097-4598(199907)22:7<889::AID-MUS12>3.0.CO;2-B; Nagarajan UM, 2002, J IMMUNOL, V169, P5078, DOI 10.4049/jimmunol.169.9.5078; Norrbom J, 2004, J APPL PHYSIOL, V96, P189, DOI 10.1152/japplphysiol.00765.2003; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Pattison JS, 2003, PHYSIOL GENOMICS, V15, P34, DOI 10.1152/physiolgenomics.00040.2003; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Ricort JM, 2004, GROWTH HORM IGF RES, V14, P277, DOI 10.1016/j.ghir.2004.02.002; Rudnicki MA, 2003, NAT MED, V9, P1461, DOI 10.1038/nm1203-1461; Schneider MR, 2002, J ENDOCRINOL, V172, P423, DOI 10.1677/joe.0.1720423; Seibaek M, 2003, CLIN CARDIOL, V26, P515, DOI 10.1002/clc.4960261107; Timmons JA, 1998, J CLIN INVEST, V101, P79, DOI 10.1172/JCI1146; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Tyni-Lenne R, 2001, EUR J HEART FAIL, V3, P47, DOI 10.1016/S1388-9842(00)00087-8; Uysal KT, 2000, ENDOCRINOLOGY, V141, P3388, DOI 10.1210/en.141.9.3388; Velazquez L, 2002, J EXP MED, V195, P1599, DOI 10.1084/jem.20011883; Watchko JF, 2002, J APPL PHYSIOL, V93, P407, DOI 10.1152/japplphysiol.01242.2001; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746	58	114	118	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					750	760		10.1096/fj.04-1980com	http://dx.doi.org/10.1096/fj.04-1980com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15857889				2022-12-28	WOS:000229602600031
J	van der Stelt, M; Fox, SH; Hill, M; Crossman, AR; Petrosino, S; Di Marzo, V; Brotchie, JM				van der Stelt, M; Fox, SH; Hill, M; Crossman, AR; Petrosino, S; Di Marzo, V; Brotchie, JM			A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTPlesioned non-human primate models of Parkinson's disease	FASEB JOURNAL			English	Article						basal ganglia; anandamide; rimonabant; 2-AG; CB1	GAMMA-AMINOBUTYRIC-ACID; MPTP-LESIONED PRIMATE; CANNABINOID RECEPTOR AGONIST; TREATED RAT MODEL; UNILATERAL 6-HYDROXYDOPAMINE LESIONS; MESSENGER-RNA EXPRESSION; NIGRA PARS RETICULATA; GLOBUS-PALLIDUS; BASAL GANGLIA; L-DOPA	Endocannabinoids and cannabinoid CB1 receptors play a role in the control of movement by modulating GABA,glutamate, and other neurotransmitters throughout the basal ganglia. Roles for abnormalities in endocannabinoid signaling in Parkinson's disease (PD) and the major side effect of current treatments, levodopa-induced dyskinesia (LID), have been suggested by rodent studies. Here we show that signaling by endocannabinoids contributes to the pathophysiology of parkinsonism and LID in MPTP-lesioned, non-human primate models of Parkinson's disease. In MPTP-lesioned marmosets previously treated with levodopa to establish LID,attenuation of CB1 signaling by systemic administration of rimonabant ( 1 and 3 mg/kg) had anti-parkinsonian actions,equivalent to a 71% increase in motor activity at 3 mg/kg. Rimonabant did not elicit dyskinesia. Co-administration of levodopa (8 mg/kg) and rimonabant ( 1 and 3 mg/k g) resulted in significantly less dyskinesia than levodopa alone, without significantly affecting the anti-parkinsonian action of levodopa. These data suggest that enhanced endocannabinoid signaling may be involved in the pathophysiology of both parkinsonism and LID. To define potential mechanisms by which such a role might be mediated, we determined the levels of the endocannabinoids anandamide and 2-arachidonyl glycerol (2-AG) throughout the basal ganglia in normal and three groups of MPTP-lesioned cynomolgus monkeys (untreated; acutely treated with L-DOPA, non-dyskinetic; long-term treated, with levodopa-induced dyskinesia). In the untreated, MPTP-lesioned primate, parkinsonism was associated with increases in both 2-AG (+88%) and anandamide (+49%) in the striatum, and of 2-AG (+97%) in the substantia nigra, changes that are consistent with the previously suggested role for endocannabinoids in mechanisms attempting to compensate for loss of dopamine in untreated parkinsonism. Increased levels of anandamide (+34%) in the external globus pallidus of MPTP-lesioned animals were normalized by levodopa treatment and may contribute to the generation of parkinsonian symptoms. However, no clear alteration in endocannabinoid levels could be correlated with the expression of LID. These data highlight the potential roles played by endocannabinoids and CB I in PD and LID and suggest the need for further research to pursue the multiple therapeutic opportunities for manipulating this system in movement disorders.	Toronto Western Hosp, Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada; CNR, Ist Chim Biomol, Endocannabinoid Res Grp, Pozzuoli, NA, Italy; Toronto Western Hosp, Movement Disorders Clin, Toronto, ON M5T 2S8, Canada; Univ Manchester, Sch Biol Sci, Div Neurosci, Manchester, Lancs, England	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Manchester	Brotchie, JM (corresponding author), Toronto Western Hosp, Toronto Western Res Inst, MC 11-419,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	vdimarzo@icmib.na.cnr.it; brotchie@uhnres.utoronto.ca	Di Marzo, Vincenzo/AAD-7742-2019	Di Marzo, Vincenzo/0000-0002-1490-3070; Brotchie, Jonathan/0000-0003-2337-0816				AZIZ TZ, 1991, MOVEMENT DISORD, V6, P288, DOI 10.1002/mds.870060404; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; Bezard E, 2003, TRENDS NEUROSCI, V26, P215, DOI 10.1016/S0166-2236(03)00038-9; Bezard E, 2001, J NEUROSCI, V21, P6853, DOI 10.1523/JNEUROSCI.21-17-06853.2001; Bezard E, 2001, NAT REV NEUROSCI, V2, P577, DOI 10.1038/35086062; Brotchie JM, 2003, CURR OPIN PHARMACOL, V3, P54, DOI 10.1016/S1471-4892(02)00011-5; Brotchie JM, 1998, MOVEMENT DISORD, V13, P871, DOI 10.1002/mds.870130603; BROTCHIE JM, 2004, IN PRESS J NEURAL TR; Brown TM, 2003, J NEUROSCI, V23, P11073; Calon F, 2003, MOVEMENT DISORD, V18, P241, DOI 10.1002/mds.10343; Compton DR, 1996, J PHARMACOL EXP THER, V277, P586; CONSROE P, 1986, INT J NEUROSCI, V30, P277, DOI 10.3109/00207458608985678; Costa B, 1999, ACTA PHARMACOL SIN, V20, P1103; CROSSMAN AR, 1990, MOVEMENT DISORD, V5, P100, DOI 10.1002/mds.870050203; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Di Marzo V, 2000, FASEB J, V14, P1432, DOI 10.1096/fj.14.10.1432; Fernandez-Espejo E, 2004, NEUROPSYCHOPHARMACOL, V29, P1134, DOI 10.1038/sj.npp.1300407; Ferrer B, 2003, EUR J NEUROSCI, V18, P1607, DOI 10.1046/j.1460-9568.2003.02896.x; Fox SH, 2002, MOVEMENT DISORD, V17, P1180, DOI 10.1002/mds.10289; Fox SH, 2002, MOVEMENT DISORD, V17, P145, DOI 10.1002/mds.1280; Fox SH, 2001, MOVEMENT DISORD, V16, P642, DOI 10.1002/mds.1148; Gerdeman G, 2001, J NEUROPHYSIOL, V85, P468, DOI 10.1152/jn.2001.85.1.468; Gilgun-Sherki Y, 2003, PHARMACOL TOXICOL, V93, P66, DOI 10.1034/j.1600-0773.2003.930202.x; Giuffrida A, 1999, NAT NEUROSCI, V2, P358, DOI 10.1038/7268; Glass M, 1997, EUR J NEUROSCI, V9, P199, DOI 10.1111/j.1460-9568.1997.tb01390.x; GREENAMYRE JT, 1991, ARCH NEUROL-CHICAGO, V48, P977, DOI 10.1001/archneur.1991.00530210109030; Gubellini P, 2002, J NEUROSCI, V22, P6900; Henry B, 2001, EXP NEUROL, V171, P139, DOI 10.1006/exnr.2001.7727; Henry B, 1999, MOVEMENT DISORD, V14, P744, DOI 10.1002/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7; HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; HERKENHAM M, 1991, BRAIN RES, V547, P267, DOI 10.1016/0006-8993(91)90970-7; Hermann H, 2002, NEUROSCIENCE, V109, P451, DOI 10.1016/S0306-4522(01)00509-7; Hill MP, 2004, CLIN NEUROPHARMACOL, V27, P171, DOI 10.1097/01.wnf.0000135478.70905.3d; Hill MP, 2004, J PHARMACOL EXP THER, V310, P386, DOI 10.1124/jpet.104.066191; Hill MP, 2003, MOVEMENT DISORD, V18, P1301, DOI 10.1002/mds.10542; Hille CJ, 2001, EXP NEUROL, V172, P189, DOI 10.1006/exnr.2001.7763; Kanda T, 1998, ANN NEUROL, V43, P507, DOI 10.1002/ana.410430415; Lastres-Becker I, 2001, EUR J NEUROSCI, V14, P1827, DOI 10.1046/j.0953-816x.2001.01812.x; Lees AJ, 2001, NEUROLOGY, V57, P1687, DOI 10.1212/WNL.57.9.1687; Loschmann PA, 2004, EXP NEUROL, V187, P86, DOI 10.1016/j.expneurol.2004.01.018; Maccarrone M, 2003, J NEUROCHEM, V85, P1018, DOI 10.1046/j.1471-4159.2003.01759.x; Maneuf YP, 1996, EUR J PHARMACOL, V308, P161, DOI 10.1016/0014-2999(96)00326-3; Maneuf YP, 1997, EXP NEUROL, V148, P265, DOI 10.1006/exnr.1997.6645; Maneuf YP, 1996, SYNAPSE, V22, P382; MANEUF YP, 1994, EXP NEUROL, V125, P65, DOI 10.1006/exnr.1994.1007; Meschler JP, 2001, NEUROPHARMACOLOGY, V40, P918, DOI 10.1016/S0028-3908(01)00012-0; Meschler JP, 2001, PSYCHOPHARMACOLOGY, V156, P79, DOI 10.1007/s002130100728; Mesnage V, 2004, CLIN NEUROPHARMACOL, V27, P108, DOI 10.1097/00002826-200405000-00003; Metman LV, 2000, MOVEMENT DISORD, V15, P3, DOI 10.1002/1531-8257(200001)15:1<3::AID-MDS1003>3.0.CO;2-E; Millan MJ, 2004, J PHARMACOL EXP THER, V309, P921, DOI 10.1124/jpet.103.062414; Miller AS, 1998, BRAIN RES, V793, P7, DOI 10.1016/S0006-8993(97)01475-3; Muller-Vahl KR, 2002, PHARMACOPSYCHIATRY, V35, P57, DOI 10.1055/s-2002-25028; Nash JE, 2002, MOVEMENT DISORD, V17, P455, DOI 10.1002/mds.10107; Nash JE, 2004, EXP NEUROL, V188, P471, DOI 10.1016/j.expneurol.2004.05.004; Nash JE, 2000, EXP NEUROL, V165, P136, DOI 10.1006/exnr.2000.7444; Neurath AR, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-6; NUTT JG, 1990, NEUROLOGY, V40, P340; Obeso JA, 2000, ANN NEUROL, V47, pS22; Olanow CW, 2003, NEUROLOGY, V61, pS24, DOI 10.1212/WNL.61.6_suppl_3.S24; PAN HS, 1985, J NEUROCHEM, V45, P1396, DOI 10.1111/j.1471-4159.1985.tb07205.x; Pearce RKB, 1995, MOVEMENT DISORD, V10, P731, DOI 10.1002/mds.870100606; Penney J B Jr, 1986, Mov Disord, V1, P3, DOI 10.1002/mds.870010102; PERTWEE RG, 1991, NEUROPHARMACOLOGY, V30, P237, DOI 10.1016/0028-3908(91)90150-A; PERTWEE RG, 1998, PHARMACOL THERAPEUT, V36, P189; Rajput AH, 2002, MOVEMENT DISORD, V17, P289, DOI 10.1002/mds.10031; Rascol O, 2003, ANN NEUROL, V53, pS3, DOI 10.1002/ana.10513; Rascol O, 2000, NEW ENGL J MED, V342, P1484, DOI 10.1056/NEJM200005183422004; Richter A, 2002, EUR J PHARMACOL, V454, P145, DOI 10.1016/S0014-2999(02)02477-9; ROBERTSON RG, 1991, BRAIN RES, V563, P278, DOI 10.1016/0006-8993(91)91545-C; ROBERTSON RG, 1990, BRAIN RES, V531, P95, DOI 10.1016/0006-8993(90)90762-Z; de Fonseca FR, 2001, NEUROTOX RES, V3, P23, DOI 10.1007/BF03033228; Romero J, 2002, PHARMACOL THERAPEUT, V95, P137, DOI 10.1016/S0163-7258(02)00253-X; Romero J, 1998, LIFE SCI, V63, P351, DOI 10.1016/S0024-3205(98)00283-5; Romero J, 2000, LIFE SCI, V66, P485, DOI 10.1016/S0024-3205(99)00618-9; Rubino T, 2000, SYNAPSE, V35, P8, DOI 10.1002/(SICI)1098-2396(200001)35:1<8::AID-SYN2>3.0.CO;2-Y; SanudoPena MC, 1998, SYNAPSE, V28, P27, DOI 10.1002/(SICI)1098-2396(199801)28:1<27::AID-SYN4>3.0.CO;2-E; SanudoPena MC, 1997, J NEUROPHYSIOL, V77, P1635, DOI 10.1152/jn.1997.77.3.1635; Savola JM, 2003, MOVEMENT DISORD, V18, P872, DOI 10.1002/mds.10464; Segovia G, 2003, MOVEMENT DISORD, V18, P138, DOI 10.1002/mds.10312; Sieradzan KA, 2001, NEUROLOGY, V57, P2108, DOI 10.1212/WNL.57.11.2108; Silverdale MA, 2004, EXP NEUROL, V188, P128, DOI 10.1016/j.expneurol.2004.03.022; Silverdale MA, 2001, EXP NEUROL, V169, P400, DOI 10.1006/exnr.2001.7649; Steece-Collier K, 2000, EXP NEUROL, V163, P239, DOI 10.1006/exnr.2000.7374; Szabo B, 1999, J NEUROCHEM, V73, P1084, DOI 10.1046/j.1471-4159.1999.0731084.x; Szabo B, 2000, NEUROSCIENCE, V97, P89, DOI 10.1016/S0306-4522(00)00036-1; van der Stelt M, 2003, EUR J PHARMACOL, V480, P133, DOI 10.1016/j.ejphar.2003.08.101; Wallmichrath I, 2002, NEUROSCIENCE, V113, P671, DOI 10.1016/S0306-4522(02)00109-4; Wallmichrath I, 2002, N-S ARCH PHARMACOL, V365, P326, DOI 10.1007/s00210-001-0520-z; WICKENS AP, 1993, EUR J PHARMACOL, V250, P205, DOI 10.1016/0014-2999(93)90646-Y; Zeng BY, 1999, NEUROSCI LETT, V276, P71, DOI 10.1016/S0304-3940(99)00762-4	91	163	167	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1140	+		10.1096/fj.04-3010fje	http://dx.doi.org/10.1096/fj.04-3010fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15894565				2022-12-28	WOS:000229602600016
J	Ayash-Rashkovsky, M; Borkow, G; Davis, HL; Moss, RB; Bartholomew, R; Bentwich, Z				Ayash-Rashkovsky, M; Borkow, G; Davis, HL; Moss, RB; Bartholomew, R; Bentwich, Z			Enhanced HIV-1 specific immune response by CpG ODN and HIV-1 immunogen-pulsed dendritic cells confers protection in the Trimera murine model of HIV-1 infection	FASEB JOURNAL			English	Article						vaccines; cytosine-phosphate-guanosine oligonucleotides; small animal model	TOLL-LIKE RECEPTORS; T-HELPER-CELL; GP120-DEPLETED HIV-1; IN-VITRO; IMMUNOSTIMULATORY SEQUENCES; RADIATION CHIMERA; DNA; MOUSE; VACCINATION; VACCINES	We have recently developed a novel small animal model for HIV-1 infection (Ayash-Rashkovsky et al., http://www.fasebi.org/cgi/doi/10.1096/fj.04-3184fje; doi:10.1096/fj.043184fie). The mice were successfully infected with HIV-1 for 4-6 wk with different clades of either T- or M-tropic isolates. HIV-1 infection was accompanied by rapid loss of human CD4+ T cells, decrease in CD4/CD8 ratio, and increased T cell activation. HIV specific human Immoral and cellular immune responses were observed in all HIV-1 infected animals. In the present study, HIV specific human immune responses, both Immoral and cellular, were generated in noninfected Trimera mice, after their immunization with gp120-depleted HIV-1 antigen, presented by autologous human dendritic cells. Addition of CpG ODN to the antigen-pulsed DCs significantly enhanced (by 2- to 30-fold) the Immoral and cellular HIV-1 specific immune responses. Only mice immunized with the HIV-1 immunogen and CpG were completely protected from infection with HIV-1 after challenge with high infection titers of the virus. This novel small animal model for HIV-1 infection may thus serve as an attractive platform for rapid testing of candidate HIV-1 vaccines and of adjuvants and may shorten the time needed for the development and final assessment of protective HIV-1 vaccines in human trials.	Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91010 Jerusalem, Israel; Coley Pharmaceut Grp, Ottawa, ON K2K 3A2, Canada; Immune Response Corp, San Diego, CA USA	Hebrew University of Jerusalem; Coley Pharmaceutical Group	Borkow, G (corresponding author), Rosetta Genom, 10 Plaut St,Sci Pk, IL-76701 Rehovot, Israel.	borkow@agri.huji.ac.il; zbentwich@rosettagenomics.com	Borkow, Gadi/W-4294-2019; Moss, Richard B./S-9218-2019	Moss, Richard B./0000-0003-3611-4221				Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Ayash-Rashkovsky M, 2002, VACCINE, V20, P2684, DOI 10.1016/S0264-410X(02)00202-5; Ayash-Rashkovsky M, 2001, BIOCHEM BIOPH RES CO, V282, P1169, DOI 10.1006/bbrc.2001.4698; Ben-Yedidia T, 1999, INT IMMUNOL, V11, P1043, DOI 10.1093/intimm/11.7.1043; Bender A, 1996, J IMMUNOL METHODS, V196, P121, DOI 10.1016/0022-1759(96)00079-8; Bentwich Z, 1996, CLIN EXP IMMUNOL, V103, P239, DOI 10.1046/j.1365-2249.1996.d01-612.x; Blackwell SE, 2003, J IMMUNOL, V170, P4061, DOI 10.4049/jimmunol.170.8.4061; Bocher WO, 2001, EUR J IMMUNOL, V31, P2071, DOI 10.1002/1521-4141(200107)31:7<2071::AID-IMMU2071>3.0.CO;2-D; Borkow G, 2000, B WORLD HEALTH ORGAN, V78, P1368; Borkow G, 2002, CLIN DIAGN LAB IMMUN, V9, P505, DOI 10.1128/CDLI.9.3.505-507.2002; Borkow G, 2000, J CLIN INVEST, V106, P1053, DOI 10.1172/JCI10182; Burakova T, 1997, TRANSPLANTATION, V63, P1166, DOI 10.1097/00007890-199704270-00018; Dalpke A, 2002, BIOL CHEM, V383, P1491, DOI 10.1515/BC.2002.171; Deml L, 1999, CLIN CHEM LAB MED, V37, P199, DOI 10.1515/CCLM.1999.037; Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037; Dzionek A, 2001, J EXP MED, V194, P1823, DOI 10.1084/jem.194.12.1823; GALUN E, 1995, J INFECT DIS, V172, P25, DOI 10.1093/infdis/172.1.25; Gursel M, 2002, EUR J IMMUNOL, V32, P2617, DOI 10.1002/1521-4141(200209)32:9<2617::AID-IMMU2617>3.0.CO;2-F; Gurunathan S, 2000, CURR OPIN IMMUNOL, V12, P442, DOI 10.1016/S0952-7915(00)00118-7; Hartmann G, 2000, J IMMUNOL, V164, P1617, DOI 10.4049/jimmunol.164.3.1617; Heckelsmiller K, 2002, EUR J IMMUNOL, V32, P3235, DOI 10.1002/1521-4141(200211)32:11<3235::AID-IMMU3235>3.0.CO;2-J; Heckelsmiller K, 2002, J IMMUNOL, V169, P3892, DOI 10.4049/jimmunol.169.7.3892; Heeg K, 2000, INT ARCH ALLERGY IMM, V121, P87, DOI 10.1159/000024303; Heeney JL, 1999, IMMUNOL TODAY, V20, P247, DOI 10.1016/S0167-5699(98)01437-6; Ilan E, 1999, HEPATOLOGY, V29, P553, DOI 10.1002/hep.510290228; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kerkmann M, 2003, J IMMUNOL, V170, P4465, DOI 10.4049/jimmunol.170.9.4465; Kojima Y, 2002, VACCINE, V20, P2857, DOI 10.1016/S0264-410X(02)00238-4; Krieg AM, 2000, IMMUNOL TODAY, V21, P521, DOI 10.1016/S0167-5699(00)01719-9; Krieg AM, 2003, NAT MED, V9, P831, DOI 10.1038/nm0703-831; Krieg AM, 2001, CURR OPIN MOL THER, V3, P15; Krug A, 2003, J IMMUNOL, V170, P3468, DOI 10.4049/jimmunol.170.7.3468; Krug A, 2001, EUR J IMMUNOL, V31, P3026, DOI 10.1002/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H; Lapenta C, 2003, J EXP MED, V198, P361, DOI 10.1084/jem.20021924; LUBIN I, 1991, SCIENCE, V252, P427, DOI 10.1126/science.1826797; LUBIN I, 1994, BLOOD, V83, P2368; Maino VC, 2000, AIDS RES HUM RETROV, V16, P2065, DOI 10.1089/088922200750054819; MARCUS H, 1995, BLOOD, V86, P398, DOI 10.1182/blood.V86.1.398.bloodjournal861398; Mascola Jr, 1999, METH MOLEC MED, V17, P317, DOI 10.1385/0-89603-369-4:317; McMichael AJ, 2001, NATURE, V410, P980, DOI 10.1038/35073658; Medzhitov R, 2001, NAT IMMUNOL, V2, P15, DOI 10.1038/83121; Moss RB, 2000, VACCINE, V18, P1081, DOI 10.1016/S0264-410X(99)00368-0; Moss RB, 1997, VIRAL IMMUNOL, V10, P221, DOI 10.1089/vim.1997.10.221; Moss RB, 2000, J INTERF CYTOK RES, V20, P1131, DOI 10.1089/107999000750053807; Moss RB, 2001, J HUMAN VIROL, V4, P39; Moss RB, 2000, J ACQ IMMUN DEF SYND, V24, P264; Olbrich ARM, 2002, J VIROL, V76, P11397, DOI 10.1128/JVI.76.22.11397-11404.2002; Reisner Y, 1998, TRENDS BIOTECHNOL, V16, P242, DOI 10.1016/S0167-7799(98)01203-7; Robbins GK, 2003, AIDS, V17, P1121, DOI 10.1097/00002030-200305230-00002; Robinson SP, 1999, EUR J IMMUNOL, V29, P2769, DOI 10.1002/(SICI)1521-4141(199909)29:09<2769::AID-IMMU2769>3.0.CO;2-2; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Santini SM, 2000, J EXP MED, V191, P1777, DOI 10.1084/jem.191.10.1777; Segall H, 1996, BLOOD, V88, P721, DOI 10.1182/blood.V88.2.721.bloodjournal882721; Steinman RM, 2002, J CLIN INVEST, V109, P1519, DOI 10.1172/JCI200215962	54	10	10	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1152	+		10.1096/fj.04-3185fje	http://dx.doi.org/10.1096/fj.04-3185fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15833766				2022-12-28	WOS:000228865300015
J	Binz, N; Graham, CE; Simpson, K; Lai, YKY; Shen, WY; Lai, CM; Speed, TP; Rakoczy, PE				Binz, Nicolette; Graham, Caroline E.; Simpson, Ken; Lai, Yvonne K. Y.; Shen, Wei-Yong; Lai, Chooi-May; Speed, Terence P.; Rakoczy, P. Elizabeth			Long-term effect of therapeutic laser photocoagulation on gene expression in the eye	FASEB JOURNAL			English	Article									[Binz, Nicolette; Graham, Caroline E.; Lai, Yvonne K. Y.; Shen, Wei-Yong] Lions Eye Inst, Nedlands, WA 6009, Australia; [Binz, Nicolette; Graham, Caroline E.; Lai, Yvonne K. Y.; Shen, Wei-Yong; Lai, Chooi-May; Rakoczy, P. Elizabeth] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Nedlands, WA 6009, Australia; [Simpson, Ken; Speed, Terence P.] Walter & Eliza Hall Inst Med Res, Div Genet & Bioinformat, Melbourne, Vic 3050, Australia	Lions Eye Institute; University of Western Australia; University of Western Australia; Walter & Eliza Hall Institute	Binz, N (corresponding author), Lions Eye Inst, 2 Verdun St, Nedlands, WA 6009, Australia.	binz@cyllene.uwa.edu.au	Speed, Terence P/B-8085-2009	Speed, Terence P/0000-0002-5403-7998; Walker, Caroline/0000-0001-5917-6519					0	22	25	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					383	385		10.1096/fj.05-3890fje	http://dx.doi.org/10.1096/fj.05-3890fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16354724				2022-12-28	WOS:000207915000029
J	Buytaert, E; Callewaert, G; Hendrickx, N; Scorrano, L; Hartmann, D; Missiaen, L; Vandenheede, JR; Heirman, I; Grooten, J; Agostinis, P				Buytaert, Esther; Callewaert, Geert; Hendrickx, Nico; Scorrano, Luca; Hartmann, Dieter; Missiaen, Ludwig; Vandenheede, Jackie R.; Heirman, Ingeborg; Grooten, Johan; Agostinis, Patrizia			Role of endoplasmic reticulum depletion and multidomain proapoptotic BAX and BAK proteins in shaping cell death after hypericin-mediated photodynamic therapy	FASEB JOURNAL			English	Article							THAPSIGARGIN-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; INTRACELLULAR CA2+; SIGNALING PATHWAYS; HELA-CELLS; BCL-2; CALCIUM; AUTOPHAGY; STORES; ACTIVATION	Both the commitment event and the modality of cell death in photodynamic therapy (PDT) remain poorly defined. We report that PDT with endoplasmic reticulum (ER)-associating hypericin leads to an immediate loss of SERCA2 protein levels, causing disruption of Ca2+ homeostasis and cell death. Protection of SERCA2 protein rescues ER-Ca2+ levels and prevents cell death, suggesting that SERCA2 photodestruction with consequent incapability of the ER to maintain intracellular Ca2+ homeostasis is causal to cell killing. Apoptosis is rapidly initiated after ER-Ca2+ depletion and strictly requires the BAX/BAK gateway at the mitochondria. Bax(-/-)Bak(-/-) double-knockout (DKO) cells are protected from apoptosis but undergo autophagy-associated cell death as revealed by electron microscopy and biochemical analysis. Autophagy inhibitors, but not caspase antagonists, significantly reduce death of DKO cells, suggesting that sustained autophagy is lethal. Thus, following ER photodamage and consequent disruption of Ca2+ homeostasis, BAX and BAK proteins model PDT-mediated cell killing, which is executed through apoptosis in their presence or via an autophagic pathway in their absence.	Catholic Univ Louvain, Dept Mol & Cell Biol, Fac Med, B-1348 Louvain, Belgium; Dulbecco Telethon Inst, Venetian Inst Mol Med, Padua, Italy; Univ Ghent, B-9000 Ghent, Belgium	Universite Catholique Louvain; Fondazione Telethon; Dulbecco Telethon Institute (DTI); Veneto Institute Molecular Medicine; Ghent University	Agostinis, P (corresponding author), Div Biochem, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	Patricia.Agostinis@med.kuleuven.ac.be	Agostinis, Patrizia/AAO-2468-2020; Scorrano, Luca/K-3967-2019; Scorrano, Luca/A-6652-2008; Agostinis, Patrizia/ABI-1177-2020	Scorrano, Luca/0000-0002-8515-8928; Scorrano, Luca/0000-0002-8515-8928; Agostinis, Patrizia/0000-0003-1314-2115				Agostinis P, 2004, PHOTOCH PHOTOBIO SCI, V3, P721, DOI 10.1039/b315237e; Agostinis P, 2002, INT J BIOCHEM CELL B, V34, P221, DOI 10.1016/S1357-2725(01)00126-1; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Chae HJ, 1999, BONE, V25, P453, DOI 10.1016/S8756-3282(99)00196-9; Chen B, 2002, INT J CANCER, V98, P284, DOI 10.1002/ijc.10175; Chiesa A, 2001, BIOCHEM J, V355, P1, DOI 10.1042/0264-6021:3550001; Chiu SM, 2003, BRIT J CANCER, V89, P1590, DOI 10.1038/sj.bjc.6601298; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Delaey EM, 1999, INT J ONCOL, V14, P759; Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628; Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071; Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Granville DJ, 2001, CELL CALCIUM, V30, P343, DOI 10.1054/ceca.2001.0243; Inanami O, 1999, PHOTOCHEM PHOTOBIOL, V70, P650, DOI 10.1562/0031-8655(1999)070<0650:EOBAAF>2.3.CO;2; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kaplan P, 2003, MOL CELL BIOCHEM, V248, P41, DOI 10.1023/A:1024145212616; Kuhn H, 2002, FREE RADICAL BIO MED, V33, P154, DOI 10.1016/S0891-5849(02)00855-9; Lemasters JJ, 2002, ANTIOXID REDOX SIGN, V4, P769, DOI 10.1089/152308602760598918; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; MISSIAEN L, 1994, J BIOL CHEM, V269, P5917; Nguyen HN, 2002, BRAIN RES, V924, P159, DOI 10.1016/S0006-8993(01)03229-2; Nilsson E, 1997, HISTOCHEM J, V29, P857, DOI 10.1023/A:1026441907803; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Oakes SA, 2003, BIOCHEM PHARMACOL, V66, P1335, DOI 10.1016/S0006-2952(03)00482-9; Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Pan Z, 2000, J BIOL CHEM, V275, P19978, DOI 10.1074/jbc.M908329199; Pan Z, 2001, J BIOL CHEM, V276, P32257, DOI 10.1074/jbc.M100178200; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; PENNING LC, 1992, BIOCHIM BIOPHYS ACTA, V1107, P255, DOI 10.1016/0005-2736(92)90412-F; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Rizzuto R, 1995, METHOD ENZYMOL, V260, P417, DOI 10.1016/0076-6879(95)60155-4; RIZZUTO R, 2004, SCI STKE, V215, pRE1, DOI DOI 10.1126/STKE.2152004RE1; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Squier TC, 2000, FRONT BIOSCI-LANDMRK, V5, pD504, DOI 10.2741/Squier; Usuda J, 2003, J BIOL CHEM, V278, P2021, DOI 10.1074/jbc.M205219200; Vantieghem A, 2002, J BIOL CHEM, V277, P37718, DOI 10.1074/jbc.M204348200; Vantieghem A, 1998, FEBS LETT, V440, P19, DOI 10.1016/S0014-5793(98)01416-1; Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445; Wei HF, 1998, J NEUROCHEM, V70, P2305; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Whitacre CM, 2002, CANCER LETT, V179, P43, DOI 10.1016/S0304-3835(01)00853-9; Yamaguchi H, 2003, CANCER RES, V63, P1483; ZDOLSEK JM, 1990, PHOTOCHEM PHOTOBIOL, V51, P67, DOI 10.1111/j.1751-1097.1990.tb01685.x; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	51	188	195	0	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					756	+		10.1096/fj.05-4305fje	http://dx.doi.org/10.1096/fj.05-4305fje			30	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16455754	Green Published			2022-12-28	WOS:000237698700041
J	Malmo, C; Vilasi, S; Iannuzzi, C; Tacchi, S; Cametti, C; Irace, G; Sirangelo, I				Malmo, Clorinda; Vilasi, Silvia; Iannuzzi, Clara; Tacchi, Silvia; Cametti, Cesare; Irace, Gaetano; Sirangelo, Ivana			Tetracycline inhibits W7FW14F apomyoglobin fibril extension and keeps the amyloid protein in a pre-fibrillar, highly cytotoxic state	FASEB JOURNAL			English	Article									[Malmo, Clorinda; Iannuzzi, Clara; Irace, Gaetano; Sirangelo, Ivana] Seconda Univ Napoli, Dipartimento Biochim & Biofis, I-80138 Naples, Italy; [Vilasi, Silvia; Tacchi, Silvia] Univ Perugia, Dipartimento Fis, I-06100 Perugia, Italy; [Cametti, Cesare] Univ Roma La Sapienza, Dipartimento Fis, I-00185 Rome, Italy	Universita della Campania Vanvitelli; University of Perugia; Sapienza University Rome	Sirangelo, I (corresponding author), Seconda Univ Napoli, Dipartimento Biochim & Biofis, Via L De Crecchio 7, I-80138 Naples, Italy.	ivana.sirangelo@unina2.it	Iannuzzi, Clara/H-6764-2012	VILASI, SILVIA/0000-0002-9926-7199; Cametti, Cesare/0000-0003-2077-3660; IANNUZZI, Clara/0000-0003-0092-5997; Sirangelo, Ivana/0000-0002-6408-4990					0	27	28	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					346	347		10.1096/fj.05-4652fje	http://dx.doi.org/10.1096/fj.05-4652fje			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16317065				2022-12-28	WOS:000207915000016
J	Moll, F; Millet, C; Noel, D; Orsetti, B; Bardin, A; Katsaros, D; Jorgensen, C; Garcia, M; Theillet, C; Pujol, P; Francois, V				Moll, F.; Millet, C.; Noel, D.; Orsetti, B.; Bardin, A.; Katsaros, D.; Jorgensen, C.; Garcia, M.; Theillet, C.; Pujol, P.; Francois, V.			Chordin is underexpressed in ovarian tumors and reduces tumor cell motility	FASEB JOURNAL			English	Article						ovarian carcinoma; BMP antagonist	COMPARATIVE GENOMIC HYBRIDIZATION; GROWTH-DIFFERENTIATION FACTOR-9; INCREASED OVULATION RATE; SURFACE EPITHELIUM; BREAST-CANCER; GRANULOSA-CELLS; PRIMARY CULTURE; FAMILY-MEMBERS; MYELOMA CELLS; BONE	Ovarian cancers mostly derive from the monolayer epithelium that covers the ovary. There are currently very few molecular clues to the etiology of this cancer. Bone morphogenetic proteins (BMPs) are required for follicular development and female fertility and are expressed in the ovarian surface epithelium (OSE). We previously reported the expression of human chordin (CHRD), a BMP extracellular regulator, in the ovary. Here we show that CHRD is underexpressed in epithelium ovary cancer and epithelial cancer cell lines as compared with normal tissues and OSE, respectively. Besides, we detected BMP expression in all ovarian cell lines analyzed. To determine the functional relevance of the absence of CHRD mRNA in tumors and cancer cell lines, we studied the effects of CHRD on two cancer cell lines, BG1 and PEO14. Migratory and invasive properties were greatly reduced, whereas cell adhesion to the support was enhanced. In addition, we detected chordin (Chrd) expression in OSE of rat ovaries in a pattern similar to that of BMP4. Altogether, these results suggest that CHRD could participate in regulating BMP activity in normal OSE physiology, and that its mis-expression in OSE may facilitate cancer incidence and/or progression.	CNRS, Inst Genet Humaine, UPR 1142, F-34396 Montpellier 5, France; Univ Turin, Sch Med, Gynaecol Oncol & Breast Canc Unit, Turin, Italy; INSERM, U540, Montpellier, France; INSERM, CRLC Val Aurelle, EMI 229, Montpellier, France; INSERM, U475, Montpellier, France; NCI, LCMB, NIH, Bethesda, MD 20892 USA; Max Planck Inst Biochem, D-8000 Munich, Germany	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; University of Turin; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Max Planck Society	Francois, V (corresponding author), CNRS, Inst Genet Humaine, UPR 1142, 141 Rue Cardonille, F-34396 Montpellier 5, France.	vincent.francois@igh.cnrs.fr	Theillet, Charles/O-7634-2018; Bardin, Amy/AFW-5158-2022; Noel, Daniele/E-5719-2016	Theillet, Charles/0000-0001-5555-2759; Noel, Daniele/0000-0002-3498-3776				Araujo H, 2003, DEVELOPMENT, V130, P3851, DOI 10.1242/dev.00613; AUERSPERG N, 1984, IN VITRO CELL DEV B, V20, P743; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Aunoble B, 2000, INT J ONCOL, V16, P567; Bachiller D, 2003, DEVELOPMENT, V130, P3567, DOI 10.1242/dev.00581; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Bautista S, 1998, GENE CHROMOSOME CANC, V22, P268, DOI 10.1002/(SICI)1098-2264(199808)22:4<268::AID-GCC2>3.0.CO;2-T; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Chen B, 2002, BIOCHEM BIOPH RES CO, V295, P1135, DOI 10.1016/S0006-291X(02)00828-8; Courjal F, 1997, CANCER RES, V57, P4360; Cvetkovic Dusica, 2003, Reprod Biol Endocrinol, V1, P68; Di Pasquale E, 2004, AM J HUM GENET, V75, P106, DOI 10.1086/422103; Dong LW, 1996, J MOL RECOGNIT, V9, P383, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<383::AID-JMR269>3.0.CO;2-Z; Erickson Gregory F, 2003, Reprod Biol Endocrinol, V1, P9, DOI 10.1186/1477-7827-1-9; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; Fuller PJ, 2002, MOL CELL ENDOCRINOL, V191, P89, DOI 10.1016/S0303-7207(02)00059-X; Galloway SM, 2000, NAT GENET, V25, P279, DOI 10.1038/77033; GEISINGER KR, 1989, CANCER-AM CANCER SOC, V63, P280, DOI 10.1002/1097-0142(19890115)63:2<280::AID-CNCR2820630213>3.0.CO;2-N; Glister C, 2005, ENDOCRINOLOGY, V146, P1883, DOI 10.1210/en.2004-1303; Glister C, 2004, REPRODUCTION, V127, P239, DOI 10.1530/rep.1.00090; Guan XY, 2001, CANCER RES, V61, P3806; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Haudenschild DR, 2004, CANCER RES, V64, P8276, DOI 10.1158/0008-5472.CAN-04-2251; Hauptmann S, 2002, HUM PATHOL, V33, P632, DOI 10.1053/hupa.2002.124913; Hayashido Y, 1998, INT J CANCER, V75, P654, DOI 10.1002/(SICI)1097-0215(19980209)75:4<654::AID-IJC26>3.0.CO;2-7; Hjertner O, 2001, BLOOD, V97, P516, DOI 10.1182/blood.V97.2.516; Iantosca MR, 1999, J NEUROSCI RES, V56, P248; IWABUCHI H, 1995, CANCER RES, V55, P6172; Jorgez CJ, 2004, MOL ENDOCRINOL, V18, P953, DOI 10.1210/me.2003-0301; Kawamura C, 2000, BLOOD, V96, P2005, DOI 10.1182/blood.V96.6.2005.h8002005a_2005_2011; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KRUK PA, 1994, EXP CELL RES, V215, P97, DOI 10.1006/excr.1994.1320; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LANGDON SP, 1988, CANCER RES, V48, P6166; Langenfeld EM, 2004, MOL CANCER RES, V2, P141; Larrain J, 2003, EMBO REP, V4, P813, DOI 10.1038/sj.embor.embor902; Millet C, 2001, MECH DEVELOP, V106, P85, DOI 10.1016/S0925-4773(01)00423-3; Moutsatsos IK, 2001, MOL THER, V3, P449, DOI 10.1006/mthe.2001.0291; Mulsant P, 2001, P NATL ACAD SCI USA, V98, P5104, DOI 10.1073/pnas.091577598; Nakayama N, 2001, DEV BIOL, V232, P372, DOI 10.1006/dbio.2001.0200; Ness RB, 1999, JNCI-J NATL CANCER I, V91, P1459, DOI 10.1093/jnci/91.17.1459; Orsetti B, 2004, CANCER RES, V64, P6453, DOI 10.1158/0008-5472.CAN-04-0756; OZAKI T, 1995, CANCER RES, V55, P895; Pangas SA, 2004, J BIOL CHEM, V279, P32281, DOI 10.1074/jbc.M403212200; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Platet N, 2000, MOL ENDOCRINOL, V14, P999, DOI 10.1210/me.14.7.999; Rothhammer T, 2005, CANCER RES, V65, P448; Schindl M, 2003, CLIN CANCER RES, V9, P779; Sengupta S, 2003, FASEB J, V17, P1570, DOI 10.1096/fj.02-1145fje; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shepherd TG, 2003, ENDOCRINOLOGY, V144, P3306, DOI 10.1210/en.2003-0185; Shimasaki S, 1999, P NATL ACAD SCI USA, V96, P7282, DOI 10.1073/pnas.96.13.7282; Smith M, 1999, HUM GENET, V105, P104, DOI 10.1007/s004390051070; Sonoda G, 1997, GENE CHROMOSOME CANC, V20, P320; Souza CJH, 2002, REPRODUCTION, V123, P363, DOI 10.1530/rep.0.1230363; Teixeira FL, 2002, J CLIN ENDOCR METAB, V87, P1337, DOI 10.1210/jc.87.3.1337; Wach S, 2001, ONCOGENE, V20, P7761, DOI 10.1038/sj.onc.1204962; Wilkinson DG, 1992, SITU HYBRIDIZATION P; Yoshida Y, 2001, INT J ONCOL, V18, P913; Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167	61	24	26	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					240	250		10.1096/fj.05-4126com	http://dx.doi.org/10.1096/fj.05-4126com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449796				2022-12-28	WOS:000237698700009
J	Shen, H; Schuster, R; Stringer, KF; Waltz, SE; Lentsch, AB				Shen, H; Schuster, R; Stringer, KF; Waltz, SE; Lentsch, AB			The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth	FASEB JOURNAL			English	Article						cancer; angiogenesis; African-American; endothelial cell	IN-VITRO; ANTIGEN; CANCER; CELLS; RECEPTOR; INTERLEUKIN-8; ANGIOGENESIS; EXPRESSION; BINDING; MOTIF	The Duffy antigen/receptor for chemokines (DARC) is a promiscuous chemokine receptor that binds to members of the CXC chemokine family possessing angiogenic properties. The DARC is expressed on erythrocytes and endothelial cells and is required for Plasmodium vivax infection of erythrocytes. Approximately 70% of African-Americans lack erythrocyte expression of the DARC as a genetic mechanism of protection against malaria infection. African-American men have a 60% greater incidence of prostate cancer and a 2-fold higher mortality rate than Caucasian men. Using a transgenic model of prostate cancer with DARC-deficient mice, we tested the hypothesis that lack of DARC expression on erythrocytes contributes to enhanced prostate tumor growth. In vitro, erythrocytes from wild-type mice but not DARC-deficient mice cleared angiogenic chemokines produced by prostate cancer cells and reduced endothelial cell chemotaxis. In vivo, tumors from DARC-deficient mice had higher intra-tumor concentrations of angiogenic chemokines, increased tumor vessel density, and greatly augmented prostate tumor growth. The data suggest that the DARC functions to clear angiogenic CXC chemokines from the prostate tumor microcirculation and that the lack of erythroid DARC, as occurs in the majority of African-Americans, may be a contributing factor to the increased mortality to prostate cancer in this population.-Shen, H., Schuster, R., Stringer, K. F., Waltz, S. E., Lentsch, A. B. The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth.	Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Lentsch, AB (corresponding author), Univ Cincinnati, Coll Med, Dept Surg, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	alex.lentsch@uc.edu		Waltz, Susan/0000-0003-3572-4642				Addison CL, 2000, J IMMUNOL, V165, P5269, DOI 10.4049/jimmunol.165.9.5269; Addison CL, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-28; Chaudhuri A, 1997, BLOOD, V89, P701, DOI 10.1182/blood.V89.2.701; DARBONNE WC, 1991, J CLIN INVEST, V88, P1362, DOI 10.1172/JCI115442; Dawson TC, 2000, BLOOD, V96, P1681, DOI 10.1182/blood.V96.5.1681.h8001681a_1681_1684; Du JG, 2002, J LEUKOCYTE BIOL, V71, P141; Ferrer FA, 1998, UROLOGY, V51, P161, DOI 10.1016/S0090-4295(97)00491-3; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Hadley TJ, 1997, BLOOD, V89, P3077, DOI 10.1182/blood.V89.9.3077; Kashiwazaki M, 2003, INT IMMUNOL, V15, P1219, DOI 10.1093/intimm/dxg121; Lee JS, 2003, J IMMUNOL, V170, P5244, DOI 10.4049/jimmunol.170.10.5244; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; Modi WS, 1999, MOL BIOL EVOL, V16, P180, DOI 10.1093/oxfordjournals.molbev.a026101; Moore BB, 1999, AM J PATHOL, V154, P1503, DOI 10.1016/S0002-9440(10)65404-1; Ries LAG, 2004, SEER CANC STAT REV; Shen H, 2004, AM J PHYSIOL-CELL PH, V286, pC840, DOI 10.1152/ajpcell.00335.2003; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; SZABO MC, 1995, J BIOL CHEM, V270, P25348, DOI 10.1074/jbc.270.43.25348; TOURNAMILLE C, 1995, NAT GENET, V10, P224, DOI 10.1038/ng0695-224; Veltri RW, 1999, UROLOGY, V53, P139, DOI 10.1016/S0090-4295(98)00455-5	20	98	109	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					59	64		10.1096/fj.05-4764com	http://dx.doi.org/10.1096/fj.05-4764com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16394268				2022-12-28	WOS:000235996000045
J	Cronstein, B				Cronstein, B			Response to RFP: "Rigorous test of intelligent design"	FASEB JOURNAL			English	Editorial Material									NYU, Sch Med, New York, NY 10012 USA	New York University	Cronstein, B (corresponding author), NYU, Sch Med, New York, NY 10012 USA.		Cronstein, Bruce N/D-4678-2011	Cronstein, Bruce N/0000-0002-4295-7383					0	0	0	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2005	19	14					1936	1937		10.1096/fj.05-1202ufm	http://dx.doi.org/10.1096/fj.05-1202ufm			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16319135				2022-12-28	WOS:000234405500002
J	Muciaccia, B; Padula, F; Vicini, E; Gandini, L; Lenzi, A; Stefanini, M				Muciaccia, B; Padula, F; Vicini, E; Gandini, L; Lenzi, A; Stefanini, M			Beta-chemokine receptors 5 and 3 are expressed on the head region of human spermatozoon	FASEB JOURNAL			English	Article						CCR5; CCR3; sperm chemotaxis; Delta 32 mutation; HIV-1 carrier	CHEMOKINE RECEPTORS CCR3; HIV-1 INFECTION; MESSENGER-RNA; SPERM; TRANSMISSION; INDIVIDUALS; CHEMOTAXIS; RESISTANCE; ALLELES; VIRUSES	Induction of human sperm chemotaxis is an established phenomenon, though signaling systems physiologically involved have not been identified. Recently, it has been demonstrated that RANTES is present in the follicular fluid and that this molecule is a chemoactractant for human spermatozoa. However, the presence of beta-chemokine receptors on human spermatozoa has never been reported. By cytometric, Western blotting and immunofluorescence analysis, we demonstrate the presence of CCR5 and CCR3 on ejaculated spermatozoa from healthy subjects. CCR5 was detected in the periacrosomal region of the sperm surface, whereas CCR3 was also present in the postacrosomal cap. Individual variability was observed on CCR5 and CCR3 positive sperm percentages. Presence of Delta 32(+/-) mutation was demonstrated in two subjects expressing CCR5 in half of the ejaculated spermatozoa. Our findings represent the missing information in favor of the possibility that beta-chemokines and their receptors are involved in sperm chemotaxis. Identification of molecular mechanisms of sperm chemotaxis may allow us to identify predictive parameters of sperm fertilizing ability in hypofertile or infertile subjects. Finally, both CCR5 and CCR3 expressed on the sperm cell surface may be involved in HIV-1 adhesion to spermatozoa, thus allowing these cells to perform as virion cellular carriers during sexual transmission of HIV-1 infection.	Univ Roma La Sapienza, Dept Histol & Med Embryol, I-00161 Rome, Italy; Univ Roma La Sapienza, Dept Med Physiopathol, I-00161 Rome, Italy; Univ Roma La Sapienza, Ctr Eccellenza Biol & Med Mol, I-00161 Rome, Italy	Sapienza University Rome; Sapienza University Rome; Sapienza University Rome	Stefanini, M (corresponding author), Univ Roma La Sapienza, Dept Histol & Med Embryol, Via Antonio Scarpa 14, I-00161 Rome, Italy.	mario.stefanini@uniroma1.it	Lenzi, Andrea/I-7711-2015; GANDINI, Loredana/K-3315-2015	Lenzi, Andrea/0000-0002-7711-0465; Vicini, Elena/0000-0003-0399-0145; GANDINI, Loredana/0000-0002-4274-0491				BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; Beaulieu S, 2002, J IMMUNOL, V169, P2925, DOI 10.4049/jimmunol.169.6.2925; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Berger EA, 1997, AIDS, V11, pS3; Blanpain C, 2000, BLOOD, V96, P1638, DOI 10.1182/blood.V96.5.1638.h8001638_1638_1645; BORZY MS, 1988, J ACQ IMMUN DEF SYND, V1, P419; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Dejucq N, 2001, MICROBIOL MOL BIOL R, V65, P208, DOI 10.1128/MMBR.65.2.208-231.2001; Dejucq-Rainsford N, 2004, CURR PHARM DESIGN, V10, P557, DOI 10.2174/1381612043453225; Dragic T, 2001, J GEN VIROL, V82, P1807, DOI 10.1099/0022-1317-82-8-1807; Dulkys Y, 2001, J IMMUNOL, V167, P3443, DOI 10.4049/jimmunol.167.6.3443; DUSSAIX E, 1993, RES VIROLOGY, V144, P487, DOI 10.1016/S0923-2516(06)80064-6; Eisenbach M, 1999, REV REPROD, V4, P56, DOI 10.1530/revreprod/4.1.56; Eisenbach M, 1999, DEV GENET, V25, P87, DOI 10.1002/(SICI)1520-6408(1999)25:2&lt;87::AID-DVG2&gt;3.0.CO;2-4; ERICKSON RP, 1981, J REPROD IMMUNOL, V3, P195, DOI 10.1016/0165-0378(81)90042-5; Fabro G, 2002, BIOL REPROD, V67, P1565, DOI 10.1095/biolreprod.102.006395; Forsythe P, 2003, AM J RESP CELL MOL, V28, P405, DOI 10.1165/rcmb.F265; Garcia-Velasco JA, 1999, FERTIL STERIL, V71, P983, DOI 10.1016/S0015-0282(99)00120-X; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Hendriksen PJM, 1999, THERIOGENOLOGY, V52, P1295, DOI 10.1016/S0093-691X(99)00218-6; Hornung D, 2001, MOL HUM REPROD, V7, P163, DOI 10.1093/molehr/7.2.163; HUANG RD, 1996, FINANCIAL MARKETS I, V5, P1; Isobe T, 2002, HUM REPROD, V17, P1441, DOI 10.1093/humrep/17.6.1441; Januchowski R, 2004, J ANDROL, V25, P757; Kato H, 1999, GENES IMMUN, V1, P97, DOI 10.1038/sj.gene.6363638; Kawano Y, 2001, AM J REPROD IMMUNOL, V45, P1, DOI 10.1111/j.8755-8920.2001.450101.x; Kim LU, 1999, AIDS, V13, P645, DOI 10.1097/00002030-199904160-00004; Larson JL, 1997, BIOL REPROD, V57, P442, DOI 10.1095/biolreprod57.2.442; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; McDermott DH, 1998, LANCET, V352, P866, DOI 10.1016/S0140-6736(98)04158-0; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Muciaccia B, 2005, AIDS, V19, P1424, DOI 10.1097/01.aids.0000180809.04427.04; Oliveira RG, 1999, J REPROD FERTIL, V115, P23, DOI 10.1530/jrf.0.1150023; Oppermann M, 2004, CELL SIGNAL, V16, P1201, DOI 10.1016/j.cellsig.2004.04.007; Quillent C, 1998, LANCET, V351, P14, DOI 10.1016/S0140-6736(97)09185-X; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rottman JB, 1997, AM J PATHOL, V151, P1341; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Suter L, 1997, CYTOMETRY, V27, P161, DOI 10.1002/(SICI)1097-0320(19970201)27:2<161::AID-CYTO8>3.0.CO;2-J; Tamasauskas D, 2001, BLOOD, V97, P3651, DOI 10.1182/blood.V97.11.3651; World Health Organization, 1999, WHO LAB MAN EX HUM S; Zaitseva M, 1997, NAT MED, V3, P1369, DOI 10.1038/nm1297-1369; Zhang Q, 2004, HUM REPROD, V19, P409, DOI 10.1093/humrep/deh085; Zheng Y, 2001, BIOL REPROD, V64, P1730, DOI 10.1095/biolreprod64.6.1730	45	26	29	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					2048	+		10.1096/fj.05-3962fje	http://dx.doi.org/10.1096/fj.05-3962fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16174786				2022-12-28	WOS:000232315700007
J	Hinz, B; Rosch, S; Ramer, R; Tamm, ER; Brune, K				Hinz, B; Rosch, S; Ramer, R; Tamm, ER; Brune, K			Latanoprost induces matrix metalloproteinase-1 expression in human nonpigmented ciliary epithelial cells through a cyclooxygenase-2-dependent mechanism	FASEB JOURNAL			English	Article						COX; MMP; intraocular pressure	PROSTAGLANDIN F-2 ALPHA; UP-REGULATION; CYCLIC-AMP; E-2; RELEASE; IRIS; TRANSCRIPTION; LOCALIZATION; MUSCLES; TIMP-1	Prostaglandins ( PGs) have been implicated in the regulation of intraocular pressure ( IOP) by facilitating the remodeling of tissues involved in aqueous humor outflow. A contribution of cyclooxygenase- 2 ( COX- 2)- dependent PGs to this process was emphasized by a recent study showing an impaired COX- 2 expression in the nonpigmented ciliary epithelium ( NPE) of patients with primary open- angle glaucoma. With the use of human NPE cells ( ODM- 2), the present study therefore investigated the effect of the antiglaucomatous drug latanoprost ( PGF(2 alpha) analog) on the expression of COX- 2 and its association with the induction of matrix metalloproteinases ( MMPs). In NPE cells, latanoprost led to a concentration- and time- dependent increase of COX- 2 mRNA levels. Up- regulation of COX- 2 expression was accompanied by phosphorylations of p38 mitogen- activated protein kinase ( MAPK) and p42/ 44 MAPK and was abrogated by specific inhibitors of both pathways. PGE(2) formation by latanoprost was abolished by the selective COX- 2 inhibitor NS- 398 and by the F- prostaglandin receptor antagonist AL- 8810. Moreover, latanoprost led to a delayed up- regulation of MMP- 1 mRNA, whereas the expression of MMP- 2, MMP- 9, TIMP- 1, and TIMP- 2 remained unchanged. Latanoprost- induced MMP- 1 mRNA and protein expression was abolished by NS- 398 and by COX- 2- silencing small- interfering RNA. In line with this finding, MMP- 1 expression was also induced by PGE2, a major COX- 2 product. As a whole, our results show that MMP- 1 expression by latanoprost requires prior up- regulation of COX- 2. Induction of COX- 2- and subsequent MMP- 1 expression in the NPE may represent a potential mechanism underlying the IOP- lowering and antiglaucomatous action of latanoprost.	Univ Erlangen Nurnberg, Dept Expt & Clin Pharmacol & Toxicol, D-91054 Erlangen, Germany; Univ Regensburg, Inst Human Anat & Embryol, D-8400 Regensburg, Germany	University of Erlangen Nuremberg; University of Regensburg	Hinz, B (corresponding author), Univ Erlangen Nurnberg, Dept Expt & Clin Pharmacol & Toxicol, Fahrstr 17, D-91054 Erlangen, Germany.	hinz@pharmakologie.uni-erlangen.de	Tamm, Ernst/AAB-9772-2019	Tamm, Ernst/0000-0002-6679-8743				ABRAMOVITZ M, 1994, J BIOL CHEM, V269, P2632; Anthony TL, 2002, INVEST OPHTH VIS SCI, V43, P3705; Bazan NG, 2001, NAT MED, V7, P414, DOI 10.1038/86477; Bito LZ, 1997, SURV OPHTHALMOL, V41, pS1, DOI 10.1016/S0039-6257(97)80002-1; Callejas NA, 2001, HEPATOLOGY, V33, P860, DOI 10.1053/jhep.2001.23002; CLOHISY JC, 1994, ENDOCRINOLOGY, V135, P1447, DOI 10.1210/en.135.4.1447; DAVIS P, 1987, J RHEUMATOL, V14, P94; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Gaton DD, 1999, INVEST OPHTH VIS SCI, V40, P363; Hinz B, 2000, BIOCHEM BIOPH RES CO, V278, P790, DOI 10.1006/bbrc.2000.3885; Hinz B, 2000, BIOCHEM BIOPH RES CO, V272, P744, DOI 10.1006/bbrc.2000.2859; Hinz B, 2002, J PHARMACOL EXP THER, V300, P367, DOI 10.1124/jpet.300.2.367; Hinz B, 2004, MOL PHARMACOL, V66, P1643, DOI 10.1124/mol.104.002618; Husain S, 2001, EXP EYE RES, V72, P581, DOI 10.1006/exer.2001.0991; Jeffrey JJ, 1998, BIOL EXTRAC, P15; Kashiwagi K, 2003, BRIT J OPHTHALMOL, V87, P297, DOI 10.1136/bjo.87.3.297; Kashiwagi K, 2002, EXP EYE RES, V74, P41, DOI 10.1006/exer.2001.1104; Kim JW, 2001, INVEST OPHTH VIS SCI, V42, P1514; Lindsey JD, 1996, CURR EYE RES, V15, P869, DOI 10.3109/02713689609017628; Maihofner C, 2001, INVEST OPHTH VIS SCI, V42, P2616; Maldve RE, 2000, J LIPID RES, V41, P873; Minghetti L, 1997, EUR J NEUROSCI, V9, P934, DOI 10.1111/j.1460-9568.1997.tb01444.x; Ottino P, 2001, CURR EYE RES, V23, P77, DOI 10.1076/ceyr.23.2.77.5471; POYER JF, 1995, INVEST OPHTH VIS SCI, V36, P2461; Ramer R, 2003, MOL PHARMACOL, V64, P1189, DOI 10.1124/mol.64.5.1189; Ramer R, 2001, BIOCHEM BIOPH RES CO, V286, P1144, DOI 10.1006/bbrc.2001.5518; RITTIG M, 1990, CELL TISSUE RES, V259, P305, DOI 10.1007/BF00318453; Schlotzer-Schrehardt U, 2002, INVEST OPHTH VIS SCI, V43, P1475; STJERNSCHANTZ J, 1992, Drugs of the Future, V17, P691; Toris CB, 1997, SURV OPHTHALMOL, V41, pS69, DOI 10.1016/S0039-6257(97)80010-0; Tsai SJ, 1997, BIOL REPROD, V57, P1016, DOI 10.1095/biolreprod57.5.1016; VANALPHEN GWHM, 1977, DOC OPHTHALMOL, V42, P397, DOI 10.1007/BF02742255; Wang N, 2001, CURR EYE RES, V22, P198, DOI 10.1076/ceyr.22.3.198.5515; Weinreb R N, 1994, J Glaucoma, V3, P70; Weinreb RN, 2002, INVEST OPHTH VIS SCI, V43, P716; Weinreb RN, 2002, SURV OPHTHALMOL, V47, pS53, DOI 10.1016/S0039-6257(02)00306-5; Weinreb RN, 1997, INVEST OPHTH VIS SCI, V38, P2772; Wu YL, 2001, BIOL REPROD, V65, P1565, DOI 10.1095/biolreprod65.5.1565; Yousufzai SYK, 1996, EXP EYE RES, V63, P305, DOI 10.1006/exer.1996.0119; Zhang YH, 1998, J IMMUNOL, V161, P3071	41	43	45	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1929	+		10.1096/fj.04-3626fje	http://dx.doi.org/10.1096/fj.04-3626fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16076963				2022-12-28	WOS:000231843700025
J	Meaney, S				Meaney, S			Is C-26 hydroxylation an evolutionarily conserved steroid inactivation mechanism?	FASEB JOURNAL			English	Article						brassinolide; ecdysone; 27-hydroxycholesterol; 26-hydroxylase	BILE-ACID SYNTHESIS; DROSOPHILA-MELANOGASTER; SIGNAL-TRANSDUCTION; P450 ENZYMES; CHOLESTEROL; BIOSYNTHESIS; 7-KETOCHOLESTEROL; METABOLISM; ECDYSONE; 27-HYDROXYLASE	Sterols are essential components of virtually all higher eukaryotic organisms, though the exact identity of the dominating sterol varies between species, from the C- 27 of cholesterol in vertebrates to the C- 28 and C- 29 sterols of plants and invertebrates. In addition to their role as structural components of cell membranes these sterols are also converted into a variety of biologically active hormones. This conversion generally involves modifications of the basic structure of the sterol by dealkylation, hydroxylation and/ or isomerization. Recent studies have demonstrated that irreversible inactivation of both plant and insect hormones is achieved by a specific C- 26 hydroxylation. The concept of sterol deactivation by 26- hydroxylation appears to be an example of an evolutionarily conserved mechanism that has persisted despite the widely varying requirements for sterols in the species where it has been detected.	Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Lab Med, Div Clin Chem C174, S-14186 Huddinge, Sweden	Karolinska Institutet; Karolinska University Hospital	Meaney, S (corresponding author), Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Lab Med, Div Clin Chem C174, S-14186 Huddinge, Sweden.	steve.meaney@labmed.ki.se	Meaney, Steve/X-9289-2019	Meaney, Steve/0000-0002-7789-516X				Barenholz Y, 2002, PROG LIPID RES, V41, P1, DOI 10.1016/S0163-7827(01)00016-9; Benveniste P, 2004, ANNU REV PLANT BIOL, V55, P429, DOI 10.1146/annurev.arplant.55.031903.141616; BERGMANN W, 1958, CHOLESTEROL, P435; BJORKHEM I, 1992, J LIPID RES, V33, P455; CLAYTON RB, 1964, J LIPID RES, V5, P3; Clouse SD, 2003, J PLANT GROWTH REGUL, V22, P273, DOI 10.1007/s00344-003-0067-y; Diczfalusy U, 1996, SCAND J CLIN LAB INV, V56, P9; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; Gilbert LI, 2004, MOL CELL ENDOCRINOL, V215, P1, DOI 10.1016/j.mce.2003.11.003; GUSTAFSSON J, 1978, J BIOL CHEM, V253, P199; HASLEWOOD GA, 1967, J LIPID RES, V8, P535; Javitt NB, 2002, J LIPID RES, V43, P665; Kanazawa A, 2001, FISHERIES SCI, V67, P997, DOI 10.1046/j.1444-2906.2001.00354.x; KOOLMAN J, 1979, H-S Z PHYSIOL CHEM, V360, P1351; Kurzchalia TV, 2003, NAT CELL BIOL, V5, P684, DOI 10.1038/ncb0803-684; Lee EY, 2005, BIOCHEM BIOPH RES CO, V328, P929, DOI 10.1016/j.bbrc.2005.01.050; Lyons MA, 2001, LIPIDS, V36, P701, DOI 10.1007/s11745-001-0775-8; Lyons MA, 2001, BBA-MOL CELL BIOL L, V1530, P209, DOI 10.1016/S1388-1981(01)00083-X; Lyons MA, 1999, J LIPID RES, V40, P1846; Matyash V, 2004, PLOS BIOL, V2, P1561, DOI 10.1371/journal.pbio.0020280; Mussig C, 2001, TRENDS ENDOCRIN MET, V12, P398, DOI 10.1016/S1043-2760(01)00477-5; Nakamura M, 2005, J EXP BOT, V56, P833, DOI 10.1093/jxb/eri073; Neff MM, 1999, P NATL ACAD SCI USA, V96, P15316, DOI 10.1073/pnas.96.26.15316; Niwa R, 2004, J BIOL CHEM, V279, P35942, DOI 10.1074/jbc.M404514200; Petryk A, 2003, P NATL ACAD SCI USA, V100, P13773, DOI 10.1073/pnas.2336088100; Pharis RP, 2001, PHYTOCHEMISTRY, V58, P1043, DOI 10.1016/S0031-9422(01)00381-8; POPJAK G, 1977, J AM CHEM SOC, V99, P931, DOI 10.1021/ja00445a041; Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Seto H, 1999, TETRAHEDRON, V55, P8341, DOI 10.1016/S0040-4020(99)00427-5; Soriano IR, 2004, J CHEM ECOL, V30, P1885, DOI 10.1023/B:JOEC.0000045584.56515.11; Thummel CS, 2002, GENE DEV, V16, P3113, DOI 10.1101/gad.1042102; Turk EM, 2003, PLANT PHYSIOL, V133, P1643, DOI 10.1104/pp.103.030882; Une M, 1997, STEROIDS, V62, P458, DOI 10.1016/S0039-128X(97)00012-3; Walters MR, 2004, CELL MOL LIFE SCI, V61, P2309, DOI 10.1007/s00018-004-4065-4; Wang ZY, 2004, TRENDS PLANT SCI, V9, P91, DOI 10.1016/j.tplants.2003.12.009; Warren JT, 2004, INSECT BIOCHEM MOLEC, V34, P991, DOI 10.1016/j.ibmb.2004.06.009; Warren JT, 2002, P NATL ACAD SCI USA, V99, P11043, DOI 10.1073/pnas.162375799; You L, 2004, CHEM-BIOL INTERACT, V147, P233, DOI 10.1016/j.cbi.2004.01.006	39	6	7	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1220	1224		10.1096/fj.04-3304hyp	http://dx.doi.org/10.1096/fj.04-3304hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16051688				2022-12-28	WOS:000231843700028
J	Bernhard, D; Csordas, A; Henderson, B; Rossmann, A; Kind, M; Wick, G				Bernhard, D; Csordas, A; Henderson, B; Rossmann, A; Kind, M; Wick, G			Cigarette smoke metal-catalyzed protein oxidation leads to vascular endothelial cell contraction by depolymerization of microtubules	FASEB JOURNAL			English	Article						cigarette smoke extract; endothelial; atherosclerosis; microtubules; oxidative stress; cytokines/chemokines	SOLUBLE P-SELECTIN; HYDROGEN-PEROXIDE; CARDIOVASCULAR-DISEASE; RISK-FACTORS; ATHEROSCLEROSIS; APOPTOSIS; ASSOCIATION; MECHANISMS; INFLAMMATION; DYSFUNCTION	Smoking is a significant risk factor for development of atherosclerosis. However, the pathophysiology of smoking-mediated vessel wall damage is not understood. With tools ranging from analytical chemistry to cell biology, we show that cigarette smoke contains metals that catalyze the direct oxidation of cellular proteins by smoke oxidants. Oxidation of cellular proteins causes a loss of microtubule function, culminating in microtubule depolymerization and proteasome-dependent degradation of alpha-tubulin. As a consequence of the microtubule collapse, cytoskeletal structures as well as intermediate filaments break down, leading finally to a contraction of vascular endothelial cells. We observed a smoke extract-induced, calpain-dependent degradation of the intracellular form of platelet-endothelial cell adhesion molecule 1/CD31, as well as a release of P-selectin/ CD62P, IL-6, and IL-8 from endothelial cells into the supernatant. Increased levels of soluble CD62P and IL-6 are well known to be associated with smoking in humans. Increased permeability of the vascular endothelium is a crucial event in atherogenesis. This work highlights the compounds and mechanisms by which cigarette smoke induces leakiness of the vascular endothelium.	Innsbruck Med Univ, Vasc Biol Grp, Div Expt Pathophysiol & Immunol, Dept Bioctr, A-6020 Innsbruck, Austria	Medical University of Innsbruck	Bernhard, D (corresponding author), Innsbruck Med Univ, Vasc Biol Grp, Div Expt Pathophysiol & Immunol, Dept Bioctr, Fritz Pregl Str 3-4 OG, A-6020 Innsbruck, Austria.	David.Bernhard@uibk.ac.at		Bernhard, David/0000-0002-2383-6607				Ahmad KA, 2003, ANN NY ACAD SCI, V1010, P365, DOI 10.1196/annals.1299.067; Amberger A, 1997, CELL STRESS CHAPERON, V2, P94, DOI 10.1379/1466-1268(1997)002<0094:CEOIVE>2.3.CO;2; Ambrose JA, 2004, J AM COLL CARDIOL, V43, P1731, DOI 10.1016/j.jacc.2003.12.047; Barbaux SC, 2001, ARTERIOSCL THROM VAS, V21, P1668, DOI 10.1161/hq1001.097022; Bermudez EA, 2002, AM J CARDIOL, V89, P1117, DOI 10.1016/S0002-9149(02)02284-1; Bernhard D, 2003, FASEB J, V17, P2302, DOI 10.1096/fj.03-0312fje; Bernhard D, 2001, CELL DEATH DIFFER, V8, P1014, DOI 10.1038/sj.cdd.4400914; Bernhard David, 2004, Journal of Pharmacological and Toxicological Methods, V50, P45, DOI 10.1016/j.vascn.2004.01.003; Blankenberg S, 2003, ATHEROSCLEROSIS, V170, P191, DOI 10.1016/S0021-9150(03)00097-2; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; Conway DSG, 2002, CIRCULATION, V106, P1962, DOI 10.1161/01.CIR.0000033220.97592.9A; CRAIG WY, 1989, BMJ-BRIT MED J, V298, P784, DOI 10.1136/bmj.298.6676.784; de Maat MPM, 2002, VASC PHARMACOL, V39, P137, DOI 10.1016/S1537-1891(02)00301-4; Durand E, 2004, CIRCULATION, V109, P2503, DOI 10.1161/01.CIR.0000130172.62481.90; Feghali CA, 1997, FRONT BIOSCI, V2, P12; Fernandez-Real JM, 2001, J CLIN ENDOCR METAB, V86, P1154, DOI 10.1210/jc.86.3.1154; FREI B, 1991, BIOCHEM J, V277, P133, DOI 10.1042/bj2770133; GALVEZ BG, 2004, J BIOL CHEM; Heitzer T, 1996, CIRCULATION, V93, P1346, DOI 10.1161/01.CIR.93.7.1346; Herrington DM, 2000, CONTROL CLIN TRIALS, V21, P257, DOI 10.1016/S0197-2456(00)00054-4; HINSHAW DB, 1989, J SURG RES, V46, P339, DOI 10.1016/0022-4804(89)90199-6; HOLDEN WE, 1989, J APPL PHYSIOL, V66, P443, DOI 10.1152/jappl.1989.66.1.443; Kashyap R, 2002, J INVEST MED, V50, P46, DOI 10.2310/6650.2002.33517; KUTTI J, 1990, ADV EXP MED BIOL, V273, P129; LASSILA R, 1992, PROSTAG LEUKOTR ESS, V46, P81, DOI 10.1016/0952-3278(92)90212-2; Lopez-Ongil S, 1999, FREE RADICAL BIO MED, V26, P501, DOI 10.1016/S0891-5849(98)00223-8; MARCY TW, 1987, CLIN CHEST MED, V8, P381; MICHNOVICZ JJ, 1989, METABOLISM, V38, P537, DOI 10.1016/0026-0495(89)90213-8; Mortada WI, 2004, MED SCI MONITOR, V10, pCR112; NIIMI Y, 1994, AM J PHYSIOL, V266, pH1348, DOI 10.1152/ajpheart.1994.266.4.H1348; Penn A, 1996, ENVIRON HEALTH PERSP, V104, P1108, DOI 10.2307/3433125; Podmore ID, 1998, NATURE, V392, P559, DOI 10.1038/33308; RENAUD S, 1990, ADV EXP MED BIOL, V273, P161; Ridker PM, 2001, CIRCULATION, V103, P491, DOI 10.1161/01.CIR.103.4.491; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Selman M, 2003, CHEST, V124, P1185, DOI 10.1378/chest.124.4.1185; Semenov AV, 1999, BIOCHEMISTRY-MOSCOW+, V64, P1326; Stone PCW, 2002, BIOCHEM BIOPH RES CO, V295, P1150, DOI 10.1016/S0006-291X(02)00800-8; Tracy RP, 1997, ARTERIOSCL THROM VAS, V17, P2167, DOI 10.1161/01.ATV.17.10.2167; Valen G, 1999, FREE RADICAL BIO MED, V26, P1480, DOI 10.1016/S0891-5849(99)00009-X; VANHINSBERGH VWM, 1992, ANN NY ACAD SCI, V673, P321; Vayssier-Taussat M, 2001, AM J PHYSIOL-HEART C, V280, pH1293, DOI 10.1152/ajpheart.2001.280.3.H1293; VOEKEL NF, 2000, CHEST, V117, pS241; Weber C, 2004, ARTERIOSCL THROM VAS, V24, P1997, DOI 10.1161/01.ATV.0000142812.03840.6f; Wickenden JA, 2003, AM J RESP CELL MOL, V29, P562, DOI 10.1165/rcmb.2002-0235OC; Wohlfrom M, 2001, CARDIOVASC RES, V49, P169, DOI 10.1016/S0008-6363(00)00245-5; Wong MX, 2004, FEBS LETT, V568, P70, DOI 10.1016/j.febslet.2004.04.094; Zevin S, 2001, J AM COLL CARDIOL, V38, P1633, DOI 10.1016/S0735-1097(01)01616-3	48	88	93	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1096	1107		10.1096/fj.04-3192com	http://dx.doi.org/10.1096/fj.04-3192com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	15985533				2022-12-28	WOS:000230923000038
J	Mahoney, DJ; Parise, G; Melov, S; Safdar, A; Tarnopolsky, MA				Mahoney, DJ; Parise, G; Melov, S; Safdar, A; Tarnopolsky, MA			Analysis of global mRNA expression in human skeletal muscle during recovery from endurance exercise	FASEB JOURNAL			English	Article						ATP; cDNA microarrays	ACTIVATED RECEPTOR-GAMMA; NA+-K+-ATPASE; PYRUVATE-DEHYDROGENASE KINASE-4; LIPID-BINDING PROTEINS; GENE-EXPRESSION; PEROXISOME PROLIFERATOR; SARCOPLASMIC-RETICULUM; OXIDATIVE STRESS; TRANSCRIPTIONAL ACTIVATION; MICROARRAY TECHNOLOGY	To search for novel transcriptional pathways that are activated in skeletal muscle after endurance exercise, we used cDNA microarrays to measure global mRNA expression after an exhaustive bout of high-intensity cycling (similar to 75 min). Healthy, young, sedentary males performed the cycling bout, and skeletal muscle biopsies were taken from the vastus lateralis before, and at 3 and 48 h after exercise. We examined mRNA expression in individual muscle samples from four subjects using cDNA microarrays, used repeated-measures significance analysis of microarray (SAM) to determine statistically significant expression changes, and confirmed selected results using real-time RT-PCR. In total, the expression of 118 genes significantly increased 3 h postcycling and 8 decreased. At 48 h, the expression of 29 genes significantly increased and 5 decreased. Many of these are potentially important novel genes involved in exercise recovery and adaptation, including several involved in 1) metabolism and mitochondrial biogenesis ( FOXO1, PPAR delta, PPAR gamma, nuclear receptor binding protein 2, IL- 6 receptor, ribosomal protein L2, aminolevulinate delta-synthase 2); 2) the oxidant stress response (metalothioneins 1B, 1F, 1G, 1H, 1L, 2A, 3, interferon regulatory factor 1); and 3) electrolyte transport across membranes [Na+- K+- ATPase (beta 3), SERCA3, chloride channel 4]. Others include genes involved in cell stress, proteolysis, apoptosis, growth, differentiation, and transcriptional activation, as well as all three nuclear receptor subfamily 4A family members (Nur77, Nurr1, and Nor1). This study is the first to characterize global mRNA expression during recovery from endurance exercise, and the results provide potential insight into 1) the transcriptional contributions to homeostatic recovery in human skeletal muscle after endurance exercise, and 2) the transcriptional contributions from a single bout of endurance exercise to the adaptive processes that occur after a period of endurance exercise training.	McMaster Univ, Med Ctr, Dept Med Sci, Hamilton, ON, Canada; McMaster Univ, Med Ctr, Dept Kinesiol, Hamilton, ON, Canada; McMaster Univ, Med Ctr, Dept Pediat & Med, Hamilton, ON, Canada; Buck Inst Age Res, Novato, CA 94945 USA	McMaster University; McMaster University; McMaster University; Buck Institute for Research on Aging	Tarnopolsky, MA (corresponding author), McMaster Univ, Med Ctr, Dept Pediat, Rm 4U4,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	tarnopol@mcmaster.ca	Melov, Simon/AAC-9469-2020	Melov, Simon/0000-0001-8554-2834; Safdar, Adeel/0000-0002-7453-7770; Safdar, Adeel/0000-0003-2469-0467	NATIONAL INSTITUTE ON AGING [R01AG018679] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Adhihetty PJ, 2003, EXP PHYSIOL, V88, P99, DOI 10.1113/eph8802505; Ahtikoski AM, 2004, PFLUG ARCH EUR J PHY, V448, P123, DOI 10.1007/s00424-003-1226-5; Aschenbach WG, 2004, SPORTS MED, V34, P91, DOI 10.2165/00007256-200434020-00003; Bakay M, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-4; Barash IA, 2004, AM J PHYSIOL-CELL PH, V286, pC355, DOI 10.1152/ajpcell.00211.2003; BAUMAN JW, 1991, TOXICOL APPL PHARM, V110, P347, DOI 10.1016/S0041-008X(05)80017-1; Beckman KB, 2004, MITOCHONDRION, V4, P453, DOI 10.1016/j.mito.2004.07.029; Bonen A, 1999, AM J PHYSIOL-ENDOC M, V276, pE642, DOI 10.1152/ajpendo.1999.276.4.E642; Cairns SP, 2004, AM J PHYSIOL-CELL PH, V287, pC762, DOI 10.1152/ajpcell.00589.2003; Carson JA, 2001, FASEB J, V15, P207, DOI 10.1096/fj.01-0544fje; Carter SL, 2001, AM J PHYSIOL-ENDOC M, V280, pE898, DOI 10.1152/ajpendo.2001.280.6.E898; Chen YW, 2003, J APPL PHYSIOL, V95, P2485, DOI 10.1152/japplphysiol.01161.2002; Chen YW, 2002, J PHYSIOL-LONDON, V545, P27, DOI 10.1113/jphysiol.2002.021220; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; DOHM GL, 1987, MED SCI SPORT EXER, V19, pS166; Dowell P, 2003, J BIOL CHEM, V278, P45485, DOI 10.1074/jbc.M309069200; Febbraio MA, 2004, DIABETES, V53, P1643, DOI 10.2337/diabetes.53.7.1643; Fehrenbach E, 2003, EXERC IMMUNOL REV, V9, P58; Ferre P, 2004, DIABETES, V53, pS43, DOI 10.2337/diabetes.53.2007.S43; Fischer CP, 2004, AM J PHYSIOL-ENDOC M, V287, pE1189, DOI 10.1152/ajpendo.00206.2004; Fowles JR, 2002, J APPL PHYSIOL, V93, P1703, DOI 10.1152/japplphysiol.00708.2001; Furuyama T, 2003, BIOCHEM J, V375, P365, DOI 10.1042/BJ20030022; Gorla-Bajszczak A, 2000, EUR J ENDOCRINOL, V142, P71, DOI 10.1530/eje.0.1420071; Green HJ, 2004, J APPL PHYSIOL, V97, P143, DOI 10.1152/japplphysiol.00559.2003; Green HJ, 2004, CAN J APPL PHYSIOL, V29, P291, DOI 10.1139/h04-020; Green HJ, 2003, J APPL PHYSIOL, V94, P2034, DOI 10.1152/japplphysiol.00244.2002; Haq F, 2003, MUTAT RES-FUND MOL M, V533, P211, DOI 10.1016/j.mrfmmm.2003.07.014; Heller MJ, 2002, ANNU REV BIOMED ENG, V4, P129, DOI 10.1146/annurev.bioeng.4.020702.153438; Hollander J, 2001, PFLUG ARCH EUR J PHY, V442, P426, DOI 10.1007/s004240100539; Jeukendrup AE, 2003, BIOCHEM SOC T, V31, P1270, DOI 10.1042/BST0311270; Ji LL, 2002, ANN NY ACAD SCI, V959, P82, DOI 10.1111/j.1749-6632.2002.tb02085.x; Johnson NA, 2004, SPORTS MED, V34, P151, DOI 10.2165/00007256-200434030-00002; Kamei Y, 2004, J BIOL CHEM, V279, P41114, DOI 10.1074/jbc.M400674200; Kamei Y, 2003, FEBS LETT, V536, P232, DOI 10.1016/S0014-5793(03)00062-0; Kawamura T, 2004, HYPERTENS RES, V27, P61, DOI 10.1291/hypres.27.61; Kawasaki Masanobu, 1999, American Journal of Physiology, V277, pC948; Keller C, 2001, FASEB J, V15, P2748, DOI 10.1096/fj.01-0507fje; Keller P, 2003, BIOCHEM BIOPH RES CO, V310, P550, DOI 10.1016/j.bbrc.2003.09.048; Kiens B, 2004, J APPL PHYSIOL, V97, P1209, DOI 10.1152/japplphysiol.01278.2003; Kondoh M, 2001, LIFE SCI, V69, P2137, DOI 10.1016/S0024-3205(01)01294-2; Kuo C.-H., 1999, Acta Physiologica Scandinavica, V165, P193, DOI 10.1046/j.1365-201x.1999.00489.x; Kwon HS, 2004, DIABETES, V53, P899, DOI 10.2337/diabetes.53.4.899; Lapsys NM, 2000, J CLIN ENDOCR METAB, V85, P4293, DOI 10.1210/jc.85.11.4293; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; Leppik JA, 2004, J APPL PHYSIOL, V97, P1414, DOI 10.1152/japplphysiol.00964.2003; Li Y, 2004, J BIOTECHNOL, V107, P19, DOI 10.1016/j.jbiotec.2003.09.008; LINDINGER MI, 1988, AM J PHYSIOL, V254, pR117, DOI 10.1152/ajpregu.1988.254.1.R117; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luquet S, 2003, FASEB J, V17, P2299, DOI 10.1096/fj.03-0269fje; Mahoney DJ, 2004, PHYSIOL GENOMICS, V18, P226, DOI 10.1152/physiolgenomics.00067.2004; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; MURAKAMI S, 1998, J PLASMA FUSION RES, V1, P122; Murphy KT, 2004, J PHYSIOL-LONDON, V556, P507, DOI 10.1113/jphysiol.2003.054981; NehlsenCannarella SL, 1997, J APPL PHYSIOL, V82, P1662, DOI 10.1152/jappl.1997.82.5.1662; Neufer PD, 1996, AM J PHYSIOL-CELL PH, V271, pC1828; Norrbom J, 2004, J APPL PHYSIOL, V96, P189, DOI 10.1152/japplphysiol.00765.2003; Norris AW, 2003, J CLIN INVEST, V112, P608, DOI 10.1172/JCI200317305; Ohlendieck K, 1999, PFLUG ARCH EUR J PHY, V438, P700, DOI 10.1007/s004240051096; PENKOVA M, 2005, IN PRESS EXP PH 0107; Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850; Pilegaard H, 2004, P NUTR SOC, V63, P221, DOI 10.1079/PNS2004345; Pilegaard H, 2000, AM J PHYSIOL-ENDOC M, V279, pE806; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Quesada AR, 1996, ARCH BIOCHEM BIOPHYS, V334, P241, DOI 10.1006/abbi.1996.0452; REN JM, 1994, J BIOL CHEM, V269, P14396; Richter EA, 2001, J PHYSIOL-LONDON, V535, P313, DOI 10.1111/j.1469-7793.2001.t01-2-00313.x; Roepstorff C, 2004, P NUTR SOC, V63, P239, DOI 10.1079/PNS2004332; Rome S, 2003, J BIOL CHEM, V278, P18063, DOI 10.1074/jbc.M300293200; Roth SM, 2002, PHYSIOL GENOMICS, V10, P181, DOI 10.1152/physiolgenomics.00028.2002; Ruel M, 2003, J THORAC CARDIOV SUR, V126, P1521, DOI 10.1016/S0022-5223(03)00969-3; Russell AP, 2003, DIABETES, V52, P2874, DOI 10.2337/diabetes.52.12.2874; Stavinoha MA, 2004, AM J PHYSIOL-ENDOC M, V287, pE878, DOI 10.1152/ajpendo.00189.2004; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; Tunstall RJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE66, DOI 10.1152/ajpendo.00475.2001; Tupling AR, 2003, J APPL PHYSIOL, V95, P138, DOI 10.1152/japplphysiol.00483.2002; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vissing K, 2004, FASEB J, V18, P94, DOI 10.1096/fj.04-2084fje; WAHLI W, 1995, CHEM BIOL, V2, P261, DOI 10.1016/1074-5521(95)90045-4; Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294; Winoto A, 2002, CELL, V109, pS57, DOI 10.1016/S0092-8674(02)00710-9; Wittwer M, 2004, ACTA PHYSIOL SCAND, V180, P217, DOI 10.1046/j.0001-6772.2003.01242.x; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; Yasumo H, 2000, BBA-GENE STRUCT EXPR, V1490, P189, DOI 10.1016/S0167-4781(99)00244-4; You HJ, 2002, BBA-GEN SUBJECTS, V1573, P33, DOI 10.1016/S0304-4165(02)00325-2; Zambon AC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r61	87	312	323	2	34	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1498	+		10.1096/fj.04-3149fje	http://dx.doi.org/10.1096/fj.04-3149fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15985525				2022-12-28	WOS:000230207800004
J	Hafizi, S; Ibraimi, F; Dahlback, B				Hafizi, S; Ibraimi, F; Dahlback, B			C1-TEN is a negative regulator of the Akt/PKB signal transduction pathway and inhibits cell survival, proliferation, and migration	FASEB JOURNAL			English	Article						Ax1; phosphatase; receptor tyrosine kinase; tensin	PROTEIN-TYROSINE PHOSPHATASES; LIPID 2ND-MESSENGER; TUMOR-SUPPRESSOR; C1 DOMAIN; KINASE; PTEN; TENSIN; DEPHOSPHORYLATES; GROWTH; JNK	We have previously identified C1 domain-containing phosphatase and TENsin homologue (C1-TEN) as being an intracellular binding partner for Axl receptor tyrosine kinase (RTK). C1-TEN is a tensin-related protein that houses an N-terminal region with predicted structural similarity to PTEN. Here, we report our observations on the effects of ectopic expression of C1-TEN in HEK293 cells, which resulted in profound molecular and phenotypic changes. Stable expression of C1-TEN altered cellular morphology, with less cell spreading and weaker filamentous actin staining. Cells overexpressing C1-TEN were inhibited greatly in their proliferation and migration rates as compared with mock-transfected cells. Furthermore, serum starvation-induced apoptosis caused a twofold increase in caspase 3 activity in C1-TEN-overexpressing cells vs. mock cells. In addition, C1-TEN-overexpressing cells showed a markedly reduced phosphorylation of Akt/PKB kinase and its substrate GSK3, as well as reduced Akt enzymatic activity. No such effects on JNK were observed. Also, serum-stimulated activation of Akt was delayed in C1-TEN-overexpressing cells, while no difference in profile of ERK activation was observed. Furthermore, cells expressing a C1-TEN mutant where the putative phosphatase active site cysteine at position 231 was substituted for a serine displayed full restoration of both cell proliferation and Akt activation. In conclusion, C1-TEN appears to be a novel intracellular phosphatase that negatively regulates the Akt/PKB signaling cascade, and is similar to its relative PTEN in this respect. However, the particular domain organization of C1-TEN may enable it to regulate RTK and other signaling complexes that are linked to Akt/PKB signaling in a unique manner.	Lund Univ, Malmo Univ Hosp, Wallenberg Lab, Sect Clin Chem,Dept Lab Med, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Hafizi, S (corresponding author), Lund Univ, Malmo Univ Hosp, Wallenberg Lab, Sect Clin Chem,Dept Lab Med, SE-20502 Malmo, Sweden.	sassan.hafizi@med.lu.se	Hafizi, Sassan/W-4424-2019	Hafizi, Sassan/0000-0002-4539-0888; Dahlback, Bjorn/0000-0003-1546-0328				Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; Chen HY, 2000, BIOCHEM J, V351, P403, DOI 10.1042/0264-6021:3510403; Chen HY, 2002, P NATL ACAD SCI USA, V99, P733, DOI 10.1073/pnas.022518699; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Goruppi S, 1999, ONCOGENE, V18, P4224, DOI 10.1038/sj.onc.1202788; Hafizi S, 2002, BIOCHEM BIOPH RES CO, V299, P793, DOI 10.1016/S0006-291X(02)02718-3; Johnson JE, 2000, BIOCHEMISTRY-US, V39, P11360, DOI 10.1021/bi000902c; Katz BZ, 2000, BIOCHEM BIOPH RES CO, V272, P717, DOI 10.1006/bbrc.2000.2853; Kikuno R, 1999, DNA Res, V6, P197, DOI 10.1093/dnares/6.3.197; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087; Stenhoff J, 2004, BIOCHEM BIOPH RES CO, V319, P871, DOI 10.1016/j.bbrc.2004.05.070; Taylor GS, 2000, P NATL ACAD SCI USA, V97, P8910, DOI 10.1073/pnas.160255697; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Welsh GI, 1996, TRENDS CELL BIOL, V6, P274, DOI 10.1016/0962-8924(96)10023-4	23	75	78	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2005	19	6					971	+		10.1096/fj.04-2532fje	http://dx.doi.org/10.1096/fj.04-2532fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15817639				2022-12-28	WOS:000228865300022
J	Roderfeld, M; Weiskirchen, R; Wagner, S; Berres, ML; Henkel, C; Grotzinger, J; Gressner, AM; Matern, S; Roeb, E				Roderfeld, Martin; Weiskirchen, Ralf; Wagner, Sandra; Berres, Marie-Luise; Henkel, Corinna; Groetzinger, Joachim; Gressner, Axel M.; Matern, Siegfried; Roeb, Elke			Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice	FASEB JOURNAL			English	Article						liver; fibrosis; MMP-9; TIMP-1; hepatic stellate cells	ESTABLISHED LIVER FIBROSIS; TISSUE INHIBITOR; GENE-EXPRESSION; STELLATE CELLS; RNA EXPRESSION; TGF-BETA; METALLOPROTEINASE-1; RAT; COLLAGENASE; APOPTOSIS	Tissue inhibitor of metalloproteinases-1 (TIMP-1) plays a crucial role in the pathogenesis of hepatic fibrosis and thus may represent an important therapeutic target in the design of anti-fibrotic strategies for chronic liver disease. We present an innovative therapy based on the assignment of inactivated enzymes acting as scavengers for TIMP-1. Hepatic fibrosis was induced in BALB/c mice by repetitive intraperitoneal CCl4 injection. The animals were treated with proteolytic inactive matrix metalloproteinase-9 mutants (E402Q, H401A, E402H/H411E) using adenovirus-mediated gene transfer. Application of these MMP-9 mutants inhibited fibrogenesis, which was indicated by decreasing portal and periportal accumulation of collagen. Total hydroxyproline of liver tissue, the morphometric stage of fibrosis as well as mRNA expression of marker proteins for hepatic fibrosis in livers of E402Q- and H401A-treated mice were significantly reduced. MMP-9 mutants suppressed transdifferentiation of hepatic stellate cells to the myofibroblast like phenotype in vitro and in vivo. Moreover, adenoviral application of the mutants MMP-9-H401A and -E402Q led to increased apoptosis of activated hepatic stellate cells, thought to be the main promoters of hepatic fibrosis. Application of MMP-9 mutants as TIMP-1 scavengers may provide a new therapeutic strategy for hepatic fibrosis.	Univ Giessen, Dept Internal Med 2, D-35385 Giessen, Germany; Univ Kiel, Inst Biochem, D-2300 Kiel, Germany; RWTH Univ Hosp Aachen, Dept Internal Med 3, Aachen, Germany; RWTH Univ Hosp Aachen, Inst Clin Chem & Pathobiochem, Aachen, Germany	Justus Liebig University Giessen; University of Kiel; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital	Roeb, E (corresponding author), Univ Giessen, Dept Internal Med 2, Paul Maimberg Str 5, D-35385 Giessen, Germany.	elke.roeb@innere.med.uni-giessen.de	, Martin/AHD-5202-2022; Weiskirchen, Ralf/O-1734-2018; Berres, Marie-Luise/AAN-5351-2021	, Martin/0000-0002-3232-1277; Weiskirchen, Ralf/0000-0003-3888-0931; 				Abriss B, 2003, J HEPATOL, V38, P169, DOI 10.1016/S0168-8278(02)00361-6; Arthur MJP, 1998, J GASTROEN HEPATOL, V13, pS33; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; BATTS KP, 1995, AM J SURG PATHOL, V19, P1409, DOI 10.1097/00000478-199512000-00007; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Farci P, 2004, GASTROENTEROLOGY, V126, P1740, DOI 10.1053/j.gastro.2004.03.017; Flisiak R, 2002, HEPATO-GASTROENTEROL, V49, P1369; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; FRIEDMAN SL, 2002, SCI MED, V8, P194; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Gressner AM, 2002, FRONT BIOSCI-LANDMRK, V7, pD793, DOI 10.2741/gressner; Herbst H, 1997, AM J PATHOL, V150, P1647; Herrmann J, 2004, ARCH VIROL, V149, P1611, DOI 10.1007/s00705-004-0300-4; HERRON GS, 1986, J BIOL CHEM, V261, P2814; Iimuro Y, 2003, GASTROENTEROLOGY, V124, P445, DOI 10.1053/gast.2003.50063; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; Iredale JP, 2004, GASTROENTEROLOGY, V126, P1199, DOI 10.1053/j.gastro.2004.01.060; Iredale JP, 1996, HEPATOLOGY, V24, P176, DOI 10.1002/hep.510240129; IREDALE JP, 1995, CLIN SCI, V89, P75, DOI 10.1042/cs0890075; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; Issa R, 2004, GASTROENTEROLOGY, V126, P1795, DOI 10.1053/j.gastro.2004.03.009; JAMALL IS, 1981, ANAL BIOCHEM, V112, P70, DOI 10.1016/0003-2697(81)90261-X; Janoschek N, 2004, BIOCHEM BIOPH RES CO, V316, P1107, DOI 10.1016/j.bbrc.2004.02.147; Jiang W, 2005, CHINESE MED J-PEKING, V118, P192; Kasahara A, 1997, J HEPATOL, V26, P574, DOI 10.1016/S0168-8278(97)80423-0; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; KORDULA T, 1992, FEBS LETT, V313, P143, DOI 10.1016/0014-5793(92)81431-K; Kuyvenhoven JP, 2003, THROMB HAEMOSTASIS, V89, P718, DOI 10.1055/s-0037-1613578; Levy C, 2004, AM J GASTROENTEROL, V99, P269, DOI 10.1111/j.1572-0241.2004.04094.x; Liu WB, 2003, WORLD J GASTROENTERO, V9, P316, DOI 10.3748/wjg.v9.i2.316; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; Miyoshi A, 2004, BRIT J CANCER, V90, P1265, DOI 10.1038/sj.bjc.6601685; Morelli AE, 2000, J VIROL, V74, P9617, DOI 10.1128/JVI.74.20.9617-9628.2000; Murphy FR, 2002, J BIOL CHEM, V277, P11069, DOI 10.1074/jbc.M111490200; MURPHY G, 1994, ANN NY ACAD SCI, V732, P31, DOI 10.1111/j.1749-6632.1994.tb24722.x; Nie QH, 2001, WORLD J GASTROENTERO, V7, P363; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Parsons CJ, 2004, HEPATOLOGY, V40, P1106, DOI 10.1002/hep.20425; PETERSON VS, 1995, POLITICAL EXPRESSION, V1, P1; Richards CD, 1997, J IMMUNOL, V159, P2431; Roeb E, 2000, FASEB J, V14, P1671; ROEB E, 1994, FEBS LETT, V349, P45, DOI 10.1016/0014-5793(94)00636-9; ROEB E, 1993, HEPATOLOGY, V18, P1437, DOI 10.1016/0270-9139(93)90236-G; Roeb E, 1997, J HEPATOL, V27, P535, DOI 10.1016/S0168-8278(97)80359-5; Roeb E, 2002, J BIOL CHEM, V277, P50326, DOI 10.1074/jbc.M207446200; SCHAFER S, 1987, HEPATOLOGY, V7, P680, DOI 10.1002/hep.1840070411; Schuppan D, 2001, HEPATOLOGY, V33, P483, DOI 10.1053/jhep.2001.22340; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Siller-Lopez F, 2004, GASTROENTEROLOGY, V126, P1122, DOI 10.1053/j.gastro.2003.12.045; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WALDROP FS, 1982, HISTOCHEMISTRY, V74, P487, DOI 10.1007/BF00496662; Weber LWD, 2003, CRIT REV TOXICOL, V33, P105, DOI 10.1080/713611034; WEISKIRCHEN R, 2000, BMC CELL BIOL, V1; Yoshiji H, 2000, HEPATOLOGY, V32, P1248, DOI 10.1053/jhep.2000.20521; Yoshiji H, 2002, HEPATOLOGY, V36, P850, DOI 10.1053/jhep.2002.35625; Yu Q, 2000, GENE DEV, V14, P163; Zhou XY, 2004, J BIOL CHEM, V279, P23996, DOI 10.1074/jbc.M311668200	60	115	136	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2006	20	3					444	454		10.1096/fj.05-4828com	http://dx.doi.org/10.1096/fj.05-4828com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	074LY	16507762				2022-12-28	WOS:000239815100008
J	Dong, YZ; Tan, JX; Cui, MZ; Zhao, GJ; Mao, GZ; Singh, N; Xu, XM				Dong, Yunzhou; Tan, Jianxin; Cui, Mei-Zhen; Zhao, Guojun; Mao, Guozhang; Singh, Neena; Xu, Xuemin			Calpain inhibitor MDL28170 modulates A beta formation by inhibiting the formation of intermediate A beta(46) and protecting A beta from degradation	FASEB JOURNAL			English	Article									[Dong, Yunzhou; Tan, Jianxin; Cui, Mei-Zhen; Zhao, Guojun; Mao, Guozhang; Xu, Xuemin] Univ Tennessee, Coll Vet Med, Dept Pathobiol, Knoxville, TN 37996 USA; [Singh, Neena] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; Case Western Reserve University	Xu, XM (corresponding author), Univ Tennessee, Coll Vet Med, Dept Pathobiol, 2407 River Dr, Knoxville, TN 37996 USA.	xmx@utk.edu		Cui, Mei-Zhen/0000-0003-4745-6999	NINDS NIH HHS [NS42314] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))			0	22	23	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					331	333		10.1096/fj.05-4524fje	http://dx.doi.org/10.1096/fj.05-4524fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16354722				2022-12-28	WOS:000207915000011
J	Ritz, BW; Lelkes, PI; Gardner, EM				Ritz, Barry W.; Lelkes, Peter I.; Gardner, Elizabeth M.			Functional recovery of peripheral blood mononuclear cells in modeled microgravity	FASEB JOURNAL			English	Article									[Ritz, Barry W.; Gardner, Elizabeth M.] Drexel Univ, Dept Biosci & Biotechnol, Philadelphia, PA 19104 USA; [Lelkes, Peter I.] Drexel Univ, Coll Med, Dept Biomed Engn, Philadelphia, PA 19104 USA	Drexel University; Drexel University	Ritz, BW (corresponding author), Drexel Univ, Dept Biosci & Biotechnol, 3141 Chestnut St,210 Stratton Hall, Philadelphia, PA 19104 USA.	bwr24@drexel.edu	Lelkes, Peter/HGA-2907-2022; Lelkes, Peter I/S-1751-2019						0	15	20	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					305	307		10.1096/fj.04-3122fje	http://dx.doi.org/10.1096/fj.04-3122fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16371429				2022-12-28	WOS:000207915000002
J	Salameh, A; Frenzel, C; Boldt, A; Rassler, B; Glawe, I; Schulte, J; Muhlberg, K; Zimmer, HG; Pfeiffer, D; Dhein, S				Salameh, A.; Frenzel, C.; Boldt, A.; Rassler, B.; Glawe, I.; Schulte, J.; Muehlberg, K.; Zimmer, H. -G.; Pfeiffer, D.; Dhein, S.			Subchronic alpha- and beta-adrenergic regulation of cardiac gap junction protein expression	FASEB JOURNAL			English	Article									[Salameh, A.; Muehlberg, K.; Pfeiffer, D.] Univ Klin Leipzig, Abt Kardiol, Med Klin 1, Leipzig, Germany; [Boldt, A.; Glawe, I.; Schulte, J.; Dhein, S.] Herzzentrum Univ Leipzig, Klin Herzchirurg, Leipzig, Germany; [Rassler, B.; Zimmer, H. -G.] Univ Leipzig, Carl Ludwig Inst Physiol, Leipzig, Germany	Leipzig University; Leipzig University; Leipzig University	Dhein, S (corresponding author), Heart Ctr Leipzig, Clin Cardiac Surg, Struempellstr 39, D-04289 Leipzig, Germany.	dhes@medizin.uni-leipzig.de	Mühlberg, Katja/GLS-0268-2022						0	56	61	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					365	367		10.1096/fj.05-4871fje	http://dx.doi.org/10.1096/fj.05-4871fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16352648				2022-12-28	WOS:000207915000023
J	Sumide, T; Nishida, K; Yamato, M; Ide, T; Hayashida, Y; Watanabe, K; Yang, J; Kohno, C; Kikuchi, A; Maeda, N; Watanabe, H; Okano, T; Tano, Y				Sumide, Taizo; Nishida, Kohji; Yamato, Masayuki; Ide, Takeshi; Hayashida, Yasutaka; Watanabe, Katsuhiko; Yang, Joseph; Kohno, Chinatsu; Kikuchi, Akihiko; Maeda, Naoyuki; Watanabe, Hitoshi; Okano, Teruo; Tano, Yasuo			Functional human corneal endothelial cell sheets harvested from temperature-responsive culture surfaces	FASEB JOURNAL			English	Article									[Sumide, Taizo; Nishida, Kohji; Ide, Takeshi; Hayashida, Yasutaka; Watanabe, Katsuhiko; Maeda, Naoyuki; Watanabe, Hitoshi; Okano, Teruo; Tano, Yasuo] Osaka Univ, Dept Ophthalmol, Sch Med, Suita, Osaka 5650871, Japan; [Yamato, Masayuki; Yang, Joseph; Kohno, Chinatsu; Kikuchi, Akihiko] Tokyo Womens Med Univ, Inst Adv Biomed Engn & Sci, Tokyo, Japan	Osaka University; Tokyo Women's Medical University	Nishida, K (corresponding author), Osaka Univ, Dept Ophthalmol, Sch Med, Room E7,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	knishida@ophthal.med.osaka-u.ac.jp	Okano, Teruo/J-4028-2012	Nishida, Kohji/0000-0001-9069-3610					0	175	190	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					392	394		10.1096/fj.04-3035fje	http://dx.doi.org/10.1096/fj.04-3035fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16339916				2022-12-28	WOS:000207915000032
J	Kondratov, RV; Shamanna, RK; Kondratova, AA; Gorbacheva, VY; Antoch, MP				Kondratov, RV; Shamanna, RK; Kondratova, AA; Gorbacheva, VY; Antoch, MP			Dual role of the CLOCK/BMAL1 circadian complex in transcriptional regulation	FASEB JOURNAL			English	Article						transcriptional activation; stress response	SUDDEN CARDIAC DEATH; CLOCK PROTEIN; SENSITIVITY; MOUSE; PATHWAYS; MAMMALS; GENES	The basic helix-loop-helix (bHLH)-PAS domain containing transcription factors CLOCK and BMAL1 are two major components of the circadian molecular oscillator. It is known that the CLOCK/BMAL1 complex positively regulates the activity of E-box containing promoters. Here we demonstrate that the CLOCK/BMAL1 complex can also suppress the activity of some promoters upon its interaction with CRYPTOCHROME ( CRY). Such a dual function of the circadian transcriptional complex provides a mechanistic explanation for the unpredicted pattern of circadian gene expression in the tissues of Bmal1 null mice. We speculate that the switch from transcriptional activation to transcriptional repression may provide a highly efficient mechanism for circadian control of gene expression. We also show that CLOCK/BMAL1 can interfere with promoter regulation by other, non-circadian, transcription factors including N-MYC and ETS, leading to attenuation or abrogation of transcription of CLOCK/BMAL1-controlled stress-induced genes. We propose that, based upon these results, both circadian repression and activation of the transcription of different target genes are required for circadian responses to various external stimuli, including genotoxic stress induced by anticancer treatment.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Kondratov, RV (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	kondrar@ccf.org; antochm@ccf.org	Kanagal-Shamanna, Rashmi/K-1258-2019	Kanagal-Shamanna, Rashmi/0000-0001-7829-5249; Antoch, mantoch/0000-0003-3001-8511; Kondratov, Roman/0000-0003-3449-745X	NCI NIH HHS [CA102522] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102522] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antoch MP, 2005, CELL CYCLE, V4, P901, DOI 10.4161/cc.4.7.1792; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; Etchegaray JP, 2003, NATURE, V421, P177, DOI 10.1038/nature01314; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Gorbacheva VY, 2005, P NATL ACAD SCI USA, V102, P3407, DOI 10.1073/pnas.0409897102; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Hogenesch JB, 2000, J NEUROSCI, V20, part. no.; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kondratov RV, 2003, GENE DEV, V17, P1921, DOI 10.1101/gad.1099503; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lis Christopher G, 2003, Integr Cancer Ther, V2, P105, DOI 10.1177/1534735403002002002; Lowrey PL, 2004, ANNU REV GENOM HUM G, V5, P407, DOI 10.1146/annurev.genom.5.061903.175925; MULLER JE, 1987, CIRCULATION, V75, P131, DOI 10.1161/01.CIR.75.1.131; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Panda S, 2004, J BIOL RHYTHM, V19, P374, DOI 10.1177/0748730404269008; Panda S, 2002, NATURE, V417, P329, DOI 10.1038/417329a; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Smolensky MH, 1999, CHRONOBIOL INT, V16, P539, DOI 10.3109/07420529908998728; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; WILLICH SN, 1992, AM J CARDIOL, V70, P65, DOI 10.1016/0002-9149(92)91391-G; Yagita K, 2002, EMBO J, V21, P1301, DOI 10.1093/emboj/21.6.1301	26	89	93	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					530	+		10.1096/fj.05-5321fje	http://dx.doi.org/10.1096/fj.05-5321fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16507766				2022-12-28	WOS:000235996000006
J	Bangham, AD				Bangham, AD			Liposomes and the physico-chemical basis of unconsciousness	FASEB JOURNAL			English	Editorial Material							ANESTHETICS				Bangham, AD (corresponding author), 17 High Green, Cambridge CB2 5EG, England.	alecbangham@wwr.co.uk						Bangham A, 2000, BRIT J ANAESTH, V84, P820; BANGHAM AD, 1980, ANESTHESIOLOGY, V53, P135, DOI 10.1097/00000542-198008000-00007; BENNETT P. B., 1967, LIFE SCI, V6, P2527, DOI 10.1016/0024-3205(67)90317-7; BRYSON BA, 2003, SHORT HIST NEARLY EV, P102; HILL MW, 1981, J COMP PHYSIOL, V142, P61, DOI 10.1007/BF00605476; JOHNSON SM, 1969, BIOCHIM BIOPHYS ACTA, V193, P92, DOI 10.1016/0005-2736(69)90062-5; JOHNSON SM, 1970, NATURE, V288, P75; MILLER KW, 1983, LIPOSOME LETT, P251; NICHOLS JW, 1980, BIOCHIM BIOPHYS ACTA, V596, P393; WHITTAKER VP, 1965, J NEUROCHEM, V12, P363, DOI 10.1111/j.1471-4159.1965.tb04237.x	10	3	3	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					1766	1768		10.1096/fj.05-1103ufm	http://dx.doi.org/10.1096/fj.05-1103ufm			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16260644				2022-12-28	WOS:000234053100027
J	Boonyaratanakornkit, JB; Cogoli, A; Li, CF; Schopper, T; Pippia, P; Galleri, G; Meloni, MA; Hughes-Fulford, M				Boonyaratanakornkit, JB; Cogoli, A; Li, CF; Schopper, T; Pippia, P; Galleri, G; Meloni, MA; Hughes-Fulford, M			Key gravity-sensitive signaling pathways drive T-cell activation	FASEB JOURNAL			English	Article						immune response; gene expression; signal transduction; microarray; microgravity	NF-KAPPA-B; PROTEIN-KINASE-C; GENE-EXPRESSION; RECEPTOR; MICROGRAVITY; LYMPHOCYTES; SPACEFLIGHT; TRANSLOCATION; TRANSCRIPTION; CYTOSKELETON	Returning astronauts have experienced altered immune function and increased vulnerability to infection during spaceflights dating back to Apollo and Skylab. Lack of immune response in microgravity occurs at the cellular level. We analyzed differential gene expression to find gravity-dependent genes and pathways. We found inhibited induction of 91 genes in the simulated freefall environment of the random positioning machine. Altered induction of 10 genes regulated by key signaling pathways was verified using real-time RT-PCR. We discovered that impaired induction of early genes regulated primarily by transcription factors NF-kappa B, CREB, ELK, AP-1, and STAT after crosslinking the T-cell receptor contributes to T-cell dysfunction in altered gravity environments. We have previously shown that PKA and PKC are key early regulators in T-cell activation. Since the majority of the genes were regulated by NF-kappa B, CREB, and AP-1, we studied the pathways that regulated these transcription factors. We found that the PKA pathway was down-regulated in vg. In contrast, PI3-K, PKC, and its upstream regulator pLAT were not significantly down-regulated by vectorless gravity. Since NF-kappa B, AP-1, and CREB are all regulated by PKA and are transcription factors predicted by microarray analysis to be involved in the altered gene expression in vectorless gravity, the data suggest that PKA is a key player in the loss of T-cell activation in altered gravity.	Univ Calif San Francisco, Lab Cell Growth, Dept Med, Vet Affairs Med Ctr, San Francisco, CA 94121 USA; Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA; Swiss Fed Inst Technol, CH-8005 Zurich, Switzerland; No Calif Inst Res & Educ, Lab Cell Growth, San Francisco, CA 94121 USA; Univ Sassari, Dept Physiol Biochem & Cellular Sci, I-07100 Sassari, Italy; Univ Calif San Francisco, Lab Cell Growth, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; Swiss Federal Institutes of Technology Domain; ETH Zurich; Northern California Institute for Research & Education; University of Sassari; University of California System; University of California San Francisco	Hughes-Fulford, M (corresponding author), Univ Calif San Francisco, Lab Cell Growth, Dept Med, Vet Affairs Med Ctr, 4150 Clement St,MC151F, San Francisco, CA 94121 USA.	millie.hughes-fulford@med.va.gov	Galleri, Grazia/AAD-3278-2021	Galleri, Grazia/0000-0001-5379-9387; Hughes-Fulford, Millie/0000-0002-0756-068X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000083] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00083-42] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Berry C., 1975, BIOMEDICAL RESULTS A, P43; CERDAN C, 1995, RES IMMUNOL, V146, P164, DOI 10.1016/0923-2494(96)80251-3; CHANDRASEKAR A, 1999, PAP METEOROL GEOPHYS, V50, P65, DOI DOI 10.2467/MRIPAPERS.50.65; COGOLI A, 1993, J LEUKOCYTE BIOL, V53, P569, DOI 10.1002/jlb.53.5.569; Cogoli A, 1997, Gravit Space Biol Bull, V10, P5; COGOLI A, 1984, SCIENCE, V225, P228, DOI 10.1126/science.6729481; Cristillo AD, 2003, BLOOD, V101, P216, DOI 10.1182/blood-2002-03-0697; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Frost LL, 2001, TOXICOL APPL PHARM, V172, P186, DOI 10.1006/taap.2001.9153; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Hamalainen HK, 2001, ANAL BIOCHEM, V299, P63, DOI 10.1006/abio.2001.5369; Hammond TG, 1999, NAT MED, V5, P359, DOI 10.1038/7331; Harrop JA, 1998, J BIOL CHEM, V273, P27548, DOI 10.1074/jbc.273.42.27548; Hatton JP, 1999, FASEB J, V13, pS23, DOI 10.1096/fasebj.13.9001.s23; Hoson T, 1997, PLANTA, V203, pS187, DOI 10.1007/PL00008108; Hughes-Fulford M, 2005, CELL SIGNAL, V17, P1111, DOI 10.1016/j.cellsig.2004.12.016; Hughes-Fulford M, 2003, ADV SPACE RES-SERIES, V32, P1585, DOI 10.1016/S0273-1177(03)90399-1; HUGHESFULFORD M, 2004, SCI STKE, V249, pRE12; HUIJSER RH, 2000, DESKTOP RPM NEW SMAL, P1; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Kim JO, 2003, FEBS LETT, V541, P163, DOI 10.1016/S0014-5793(03)00326-0; Kimzey SL, 1977, BIOMEDICAL RESULTS S, P248; Leach CS, 1977, BIOMEDICAL RESULTS S, P204; Lewis ML, 1998, FASEB J, V12, P1007, DOI 10.1096/fasebj.12.11.1007; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; MESSER G, 1990, Cytokine, V2, P389, DOI 10.1016/1043-4666(90)90046-V; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Pavlidis P, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-10-research0042; Pippia P, 1996, J BIOTECHNOL, V47, P215, DOI 10.1016/0168-1656(96)01387-9; Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576; Raychaudhuri S, 2000, Pac Symp Biocomput, P455; Schraven B, 1999, IMMUNOL TODAY, V20, P431, DOI 10.1016/S0167-5699(99)01519-4; Sciola L, 1999, ADV SPACE RES, V24, P801, DOI 10.1016/S0273-1177(99)00078-2; SHADDUCK RK, 1971, BLOOD-J HEMATOL, V38, P559, DOI 10.1182/blood.V38.5.559.559; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; TIXADOR R, 1985, ACTA ASTRONAUT, V12, P131, DOI 10.1016/0094-5765(85)90082-7; Tjandrawinata RR, 1997, FASEB J, V11, P493, DOI 10.1096/fasebj.11.6.9194530; Unsworth BR, 1998, NAT MED, V4, P901, DOI 10.1038/nm0898-901; WALTENBERGER J, 1998, ANGIOGENESIS, V2, P115; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; Zhang WG, 2000, SEMIN IMMUNOL, V12, P35, DOI 10.1006/smim.2000.0205; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	45	108	118	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2020	+		10.1096/fj.05-3778fje	http://dx.doi.org/10.1096/fj.05-3778fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16210397	Bronze			2022-12-28	WOS:000232991100025
J	Pederson, T				Pederson, T			50 years ago protein synthesis met molecular biology: the discoveries of amino acid activation and transfer RNA	FASEB JOURNAL			English	Editorial Material									Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Pederson, T (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA.	thoru.pederson@umassmed.edu			NIGMS NIH HHS [GM-60551] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060551] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CRICK F H, 1958, Symp Soc Exp Biol, V12, P138; Hoagland M, 2004, NATURE, V431, P249, DOI 10.1038/431249a; HOAGLAND M, 1978, ROOTS LIFE LAYMANS G; HOAGLAND M, 2000, INTIMATE STRANGERS; HOAGLAND M, 1981, SEARCH DNAS SECRETS; Hoagland M. B., 2001, EXPLORING WAY LIFE W; Hoagland MahlonB., 1990, HABIT TRUTH LIFE SCI; HOAGLAND MB, 1956, J BIOL CHEM, V218, P345; HOAGLAND MB, 1955, BIOCHIM BIOPHYS ACTA, V16, P288, DOI 10.1016/0006-3002(55)90218-3; HOAGLAND MB, 1958, J BIOL CHEM, V231, P241; HOAGLAND MB, 1995, WAY LIFE WORKS; ZAMECNIK P, 1978, P NATL ACAD SCI USA, V75, P260; Zamecnik PC, 2004, P NATL ACAD SCI USA, V101, P8150, DOI 10.1073/pnas.0401933101; ZAMECNIK PC, 2002, ANNU REV BIOCHEM, V73, P1	14	4	4	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					1583	1584		10.1096/fj.05-1002ufm	http://dx.doi.org/10.1096/fj.05-1002ufm			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16195365				2022-12-28	WOS:000232991100034
J	Townsend, KP; Pratico, D				Townsend, KP; Pratico, D			Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs	FASEB JOURNAL			English	Review						amyloid beta; APP metabolism; inflammation; central nervous system; NSAIDs; cyclooxygenase; coxibs	PROLIFERATOR-ACTIVATED RECEPTOR; NF-KAPPA-B; AMYLOID PRECURSOR PROTEIN; NEURONAL CYCLOOXYGENASE-2 EXPRESSION; GAMMA-SECRETASE INHIBITOR; TRANSGENIC MICE; MOUSE MODEL; HIPPOCAMPAL-FORMATION; A-BETA-42 PRODUCTION; BETA-42 PRODUCTION	Alzheimer's disease (AD) is the most common form of neurodegenerative disorder with dementia in the elderly. The AD brain pathology is characterized by deposits of amyloid-beta (A beta) peptides and neurofibrillary tangles but also (among other aspects) by signs of a chronic inflammatory process. Epidemiological studies have shown that long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) reduces the risk of developing AD and delays its onset. Classical targets of NSAIDs include cycloxygenase, nuclear factor kappa B, and peroxisome proliferator-activated receptors. Modulation of these pathways, all of which have been implicated in AD pathogenesis, could explain the NSAID effect on AD progression. However, recent studies indicate that a subset of NSAIDs such as ibuprofen, indomethacin, and flurbiprofen may have direct A beta-lowering properties in cell cultures as well as transgenic models of AD-like amyloidosis. A renewed interest in the old and a discovery of new pharmacological properties of these drugs are providing vital insight for future clinical trials. In this review we will summarize how the combination of traditional (anti-inflammatory) and new (anti-amyloidogenic) properties of some NSAIDs is providing unprecedented opportunities for drug discovery and could potentially result in novel therapeutic approaches for the treatment of AD.	Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Pratico, D (corresponding author), 3620 Hamilton Walk,John Morgan Bldg,Room 124, Philadelphia, PA 19104 USA.	domenico@spirit.gcrc.upenn.edu	Pratico, Domenico/ABA-9590-2020		NIA NIH HHS [AG-22512, AG-11542] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG022512, P01AG011542] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aisen PS, 2003, JAMA-J AM MED ASSOC, V289, P2819, DOI 10.1001/jama.289.21.2819; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Anthony JC, 2000, NEUROLOGY, V54, P2066, DOI 10.1212/WNL.54.11.2066; Avramovich Y, 2002, J BIOL CHEM, V277, P31466, DOI 10.1074/jbc.M201308200; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bishop-Bailey D, 2003, FASEB J, V17, P1925, DOI 10.1096/fj.02-1075fje; Boutaud O, 2002, J NEUROCHEM, V82, P1003, DOI 10.1046/j.1471-4159.2002.01064.x; Brune S, 2003, J NEURAL TRANSM, V110, P1041, DOI 10.1007/s00702-003-0018-6; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; Clark CM, 2000, NEURODEGENERATIVE DE, P95, DOI [DOI 10.1155/2016/258, 10.1155/2016/258]; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Combs CK, 2000, J NEUROSCI, V20, P558, DOI 10.1523/JNEUROSCI.20-02-00558.2000; Couzin J, 2004, SCIENCE, V306, P2170; Dinchuk JE, 2003, IMMUNOL LETT, V86, P121, DOI 10.1016/S0165-2478(02)00268-7; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; EBLE JN, 1971, NATURE, V231, P181, DOI 10.1038/231181a0; Eriksen JL, 2003, J CLIN INVEST, V112, P440, DOI 10.1172/JCI200318162; Etminan M, 2003, BMJ-BRIT MED J, V327, P128, DOI 10.1136/bmj.327.7407.128; FERRARI RA, 1990, EUR J PHARMACOL, V179, P25, DOI 10.1016/0014-2999(90)90398-P; Ferrer I, 1998, NEUROPATH APPL NEURO, V24, P271; Gandy S, 2005, J CLIN INVEST, V115, P1121, DOI 10.1172/JCI200525100; Gasparini L, 2004, J NEUROCHEM, V88, P337, DOI 10.1046/j.1471-4159.2003.02154.x; Graham SH, 2003, ARCH NEUROL-CHICAGO, V60, P628, DOI 10.1001/archneur.60.4.628; Harris JR, 2002, MICRON, V33, P609, DOI 10.1016/S0968-4328(02)00029-X; Heneka MT, 2005, BRAIN, V128, P1442, DOI 10.1093/brain/awh452; Ho L, 2001, ARCH NEUROL-CHICAGO, V58, P487, DOI 10.1001/archneur.58.3.487; Ho L, 1999, J NEUROSCI RES, V57, P295; Hoozemans JJM, 2001, ACTA NEUROPATHOL, V101, P2, DOI 10.1007/s004010000251; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; Jantzen PT, 2002, J NEUROSCI, V22, P2246, DOI 10.1523/JNEUROSCI.22-06-02246.2002; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kitamura Y, 1999, BIOCHEM BIOPH RES CO, V254, P582, DOI 10.1006/bbrc.1998.9981; Kojro E, 2005, SUB CELL BIOCHEM, V38, P105; Kowalska A, 2004, POL J PHARMACOL, V56, P171; Lanz TA, 2005, J PHARMACOL EXP THER, V312, P399, DOI 10.1124/jpet.104.073965; Lee RKK, 2000, ANN NY ACAD SCI, V920, P261; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; Lukiw WJ, 1997, J NEUROSCI RES, V50, P937, DOI 10.1002/(SICI)1097-4547(19971215)50:6<937::AID-JNR4>3.0.CO;2-E; Maeshiba Y, 1997, ARZNEIMITTEL-FORSCH, V47, P29; Matsuoka Y, 2001, AM J PATHOL, V158, P1345, DOI 10.1016/S0002-9440(10)64085-0; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; McGeer PL, 2001, ARCH NEUROL-CHICAGO, V58, P1790, DOI 10.1001/archneur.58.11.1790; Morihara T, 2002, J NEUROCHEM, V83, P1009, DOI 10.1046/j.1471-4159.2002.01195.x; *NAT I AG REAG I W, 1997, NEUROBIOL AGING S14, V18, pS11; Netland EE, 1998, NEUROBIOL AGING, V19, P201, DOI 10.1016/S0197-4580(98)00047-5; Oka A, 1997, NEUROREPORT, V8, P1161, DOI 10.1097/00001756-199703240-00020; Pasinetti GM, 1998, J NEUROSCI RES, V54, P1; Pratico D, 2000, NEUROBIOL AGING, V21, P441, DOI 10.1016/S0197-4580(00)00141-X; Prosperi C, 2004, INT J IMMUNOPATH PH, V17, P317, DOI 10.1177/039463200401700312; Quadros A, 2003, NEUROSCI LETT, V353, P66, DOI 10.1016/j.neulet.2003.08.076; Quinn J, 2003, J NEUROIMMUNOL, V137, P32, DOI 10.1016/S0165-5728(03)00037-7; Reid G, 2003, P NATL ACAD SCI USA, V100, P9244, DOI 10.1073/pnas.1033060100; Reines SA, 2004, NEUROLOGY, V62, P66, DOI 10.1212/WNL.62.1.66; RICH JB, 1995, NEUROLOGY, V45, P51, DOI 10.1212/WNL.45.1.51; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; RITSCHEL WA, 1999, HDB BASIC PHARMACOKI, P563; Sagi SA, 2003, J BIOL CHEM, V278, P31825, DOI 10.1074/jbc.M303588200; SAINATI SM, 2000, 6 INT STOCKH S ADV A, V180; Sastre M, 2003, J NEUROSCI, V23, P9796; SAUDER S, 2005, J NEURAL TRANSM; Scharf S, 1999, NEUROLOGY, V53, P197, DOI 10.1212/WNL.53.1.197; Schwab C, 2004, EXP NEUROL, V188, P52, DOI 10.1016/j.expneurol.2004.03.016; Schwab JM, 2003, ARCH NEUROL-CHICAGO, V60, P630, DOI 10.1001/archneur.60.4.630; Searfoss GH, 2003, J BIOL CHEM, V278, P46107, DOI 10.1074/jbc.M307757200; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Skovronsky DM, 2001, J BIOL CHEM, V276, P17036, DOI 10.1074/jbc.M006285200; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Sung S, 2004, AM J PATHOL, V165, P2197, DOI 10.1016/S0002-9440(10)63269-5; Szekely CA, 2004, NEUROEPIDEMIOLOGY, V23, P159, DOI 10.1159/000078501; Takahashi Y, 2003, J BIOL CHEM, V278, P18664, DOI 10.1074/jbc.M301619200; THAL LJ, 2005, NEUROPSYCHOPHARMACOL; Thomas T, 2001, NEUROREPORT, V12, P3263, DOI 10.1097/00001756-200110290-00024; Tomita S, 2000, J BIOL CHEM, V275, P13056, DOI 10.1074/jbc.C000019200; Vamecq J, 1999, LANCET, V354, P141, DOI 10.1016/S0140-6736(98)10364-1; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Weggen S, 2003, J BIOL CHEM, V278, P31831, DOI 10.1074/jbc.M303592200; Xiang ZM, 2002, GENE EXPRESSION, V10, P271, DOI 10.3727/000000002783992352; Yan Q, 2003, J NEUROSCI, V23, P7504; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; Yermakova AV, 1999, J NEUROPATH EXP NEUR, V58, P1135, DOI 10.1097/00005072-199911000-00003; Yermakova AV, 2001, NEUROBIOL AGING, V22, P823, DOI 10.1016/S0197-4580(01)00303-7; Yoshiyama Y, 2001, NEUROREPORT, V12, P2641, DOI 10.1097/00001756-200108280-00011; Zhou Y, 2003, SCIENCE, V302, P1215, DOI 10.1126/science.1090154	88	175	195	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					1592	1601		10.1096/fj.04-3620rev	http://dx.doi.org/10.1096/fj.04-3620rev			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16195368				2022-12-28	WOS:000232991100037
J	Hochstrasser, H; Tomiuk, J; Walter, U; Behnke, S; Spiegel, J; Kruger, R; Georg, B; Riess, O; Berg, D				Hochstrasser, H; Tomiuk, J; Walter, U; Behnke, S; Spiegel, J; Kruger, R; Georg, B; Riess, O; Berg, D			Functional relevance of ceruloplasmin mutations in Parkinson's Disease	FASEB JOURNAL			English	Article						functional analyses; neurodegenerative disease	CENTRAL-NERVOUS-SYSTEM; SUBSTANTIA-NIGRA; BASAL GANGLIA; IRON EFFLUX; IN-VITRO; NEURODEGENERATIVE DISORDERS; COPPER INCORPORATION; LIPID-PEROXIDATION; RAT CERULOPLASMIN; HYDROGEN-PEROXIDE	Increased iron levels of the substantia nigra and the discovery of ceruloplasmin mutations in patients with Parkinson's disease (PD) imply impaired iron metabolism in this neurodegenerative disorder. Ceruloplasmin has ferroxidase activity oxidizing iron(II) to iron(III). In the present study, we analyzed the amount of ceruloplasmin, iron, ferritin, and transferrin and the ceruloplasmin ferroxidase activity in serum of patients with the diagnosis of PD carrying the ceruloplasmin mutations I63T, D544E, and R793H. The impact of these missense mutations on the biosynthesis of holo-ceruloplasmin was investigated in cell culture experiments. Functional relevance was found for the ceruloplasmin mutations I63T and D544E. In vivo, the I63T mutation resulted in half the normal ceruloplasmin concentration and markedly reduced ferroxidase activity in serum from a heteroallelic PD patient. In cell culture, the I63T glycosylphosphatidylinositol (GPI)-linked ceruloplasmin isoform was retained in the endoplasmatic reticulum of human embryonic kidney cells. Furthermore, the D544E polymorphism resulted in significantly reduced serum ceruloplasmin levels and ferroxidase activity in heteroallelic patients and in expression of mainly apo-ceruloplasmin in cell culture. Our studies indicate that altered activity of ceruloplasmin may present a vulnerability factor for iron induced oxidative stress in PD.	Univ Tubingen, Dept Med Genet, D-72076 Tubingen, Germany; Univ Rostock, Dept Neurol, Rostock, Germany; Univ Homburg, Dept Neurol, D-6650 Homburg, Germany; Univ Tubingen, Ctr Neurol, Tubingen, Germany; Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany	Eberhard Karls University of Tubingen; University of Rostock; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Hochstrasser, H (corresponding author), Univ Tubingen, Dept Med Genet, Calwerstr 7, D-72076 Tubingen, Germany.	helmine.hochstrasser@med.uni-tuebingen.de	Berg, Daniela/A-8728-2019; Walter, Uwe/O-4591-2017	Berg, Daniela/0000-0001-5796-5442; Krueger, Rejko/0000-0003-4258-6241; Walter, Uwe/0000-0002-6280-785X				ALDRED AR, 1987, J BIOL CHEM, V262, P2875; Aouffen M, 2004, FREE RADICAL RES, V38, P19, DOI 10.1080/10715760310001624079; Berg D, 2002, NEUROTOX RES, V4, P637, DOI 10.1080/1029842021000045444; Berg D, 2001, J NEUROCHEM, V79, P225, DOI 10.1046/j.1471-4159.2001.00608.x; Bosio S, 2002, BLOOD, V100, P2246, DOI 10.1182/blood-2002-02-0584; Cochran W, 1950, EXPT DESIGNS; Daimon M, 2000, TOHOKU J EXP MED, V191, P119, DOI 10.1620/tjem.191.119; DEXTER DT, 1994, MOVEMENT DISORD, V9, P92, DOI 10.1002/mds.870090115; DEXTER DT, 1989, J NEUROCHEM, V52, P1830, DOI 10.1111/j.1471-4159.1989.tb07264.x; DEXTER DT, 1991, BRAIN, V114, P1953, DOI 10.1093/brain/114.4.1953; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; Erel O, 1998, CLIN CHEM, V44, P2313; FLEMING RE, 1990, J BIOL CHEM, V265, P7701; Forman MS, 2003, TRENDS NEUROSCI, V26, P407, DOI 10.1016/S0166-2236(03)00197-8; Griffiths PD, 1999, BRAIN, V122, P667, DOI 10.1093/brain/122.4.667; Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hellman NE, 2002, J BIOL CHEM, V277, P46632, DOI 10.1074/jbc.M206246200; Hellman NE, 2002, J BIOL CHEM, V277, P1375, DOI 10.1074/jbc.M109123200; Hochstrasser H, 2004, NEUROLOGY, V63, P1912, DOI 10.1212/01.WNL.0000144276.29988.C3; HOLTZMAN NA, 1970, J BIOL CHEM, V245, P2350; HOLTZMAN NA, 1970, J BIOL CHEM, V245, P2354; JACCARD J, 1996, LISREL APPROACHES IN; Jeong SY, 2003, J BIOL CHEM, V278, P27144, DOI 10.1074/jbc.M301988200; Ke Y, 2003, LANCET NEUROL, V2, P246, DOI 10.1016/S1474-4422(03)00353-3; Kim KS, 2002, BIOCHIMIE, V84, P625, DOI 10.1016/S0300-9084(02)01435-9; Klomp LWJ, 1996, HUM MOL GENET, V5, P1989, DOI 10.1093/hmg/5.12.1989; Kohno S, 2000, NEUROGENETICS, V2, P237; KOSCHINSKY ML, 1986, P NATL ACAD SCI USA, V83, P5086, DOI 10.1073/pnas.83.14.5086; Lan J, 1997, J NEURAL TRANSM, V104, P649, DOI 10.1007/BF01291883; Lan J, 1997, J NEURAL TRANSM, V104, P469, DOI 10.1007/BF01277665; Lin AMY, 2002, EXP NEUROL, V176, P328, DOI 10.1006/exnr.2002.7938; Lockhart PJ, 1999, GENE, V236, P251, DOI 10.1016/S0378-1119(99)00276-0; MANN VM, 1994, ANN NEUROL, V36, P876, DOI 10.1002/ana.410360612; Miyajima H, 2001, NEUROLOGY, V57, P2205, DOI 10.1212/WNL.57.12.2205; Miyajima H, 2002, BLOOD CELL MOL DIS, V29, P433, DOI 10.1006/bcmd.2002.0561; Miyajima H, 2003, NEUROPATHOLOGY, V23, P345, DOI 10.1046/j.1440-1789.2003.00521.x; MIYAJIMA H, 1987, NEUROLOGY, V37, P761, DOI 10.1212/WNL.37.5.761; Molina-Arjona JA, 1999, REV NEUROLOGIA, V29, P12, DOI 10.33588/rn.2901.99073; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Patel BN, 1997, J BIOL CHEM, V272, P20185, DOI 10.1074/jbc.272.32.20185; Patel BN, 2002, J NEUROSCI, V22, P6578; Ponka P, 2004, ANN NY ACAD SCI, V1012, P267, DOI 10.1196/annals.1306.022; Qian ZM, 2001, BRAIN RES REV, V35, P287, DOI 10.1016/S0165-0173(01)00056-X; Richardson DR, 1999, J LAB CLIN MED, V134, P454, DOI 10.1016/S0022-2143(99)90166-X; Santiago M, 1997, J NEUROCHEM, V68, P732; Sarkar J, 2003, J BIOL CHEM, V278, P44018, DOI 10.1074/jbc.M304926200; SATO M, 1991, J BIOL CHEM, V266, P5128; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SIAN J, 1994, ANN NEUROL, V36, P348, DOI 10.1002/ana.410360305; SOFIC E, 1992, NEUROSCI LETT, V142, P128, DOI 10.1016/0304-3940(92)90355-B; Sudha K, 2003, NEUROL INDIA, V51, P60; Torsdottir G, 1999, PHARMACOL TOXICOL, V85, P239, DOI 10.1111/j.1600-0773.1999.tb02015.x; Yang F, 1996, AM J RESP CELL MOL, V14, P161, DOI 10.1165/ajrcmb.14.2.8630266; YANG F, 1986, P NATL ACAD SCI USA, V83, P3257, DOI 10.1073/pnas.83.10.3257; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; Youdim MBH, 2004, ANN NY ACAD SCI, V1012, P306, DOI 10.1196/annals.1306.025; Young SP, 1997, FEBS LETT, V411, P93, DOI 10.1016/S0014-5793(97)00478-X	59	68	73	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2005	19	11					1851	+		10.1096/fj.04-3486fje	http://dx.doi.org/10.1096/fj.04-3486fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16150804				2022-12-28	WOS:000232315700021
J	Hong, KM; Burdick, MD; Phillips, RJ; Heber, D; Strieter, RM				Hong, KM; Burdick, MD; Phillips, RJ; Heber, D; Strieter, RM			Characterization of human fibrocytes as circulating adipocyte progenitors and the formation of human adipose tissue in SCID mice	FASEB JOURNAL			English	Article						adipogenesis; chemokine	MESENCHYMAL STEM-CELLS; EXTRACELLULAR-MATRIX SUBSTRATA; PERIPHERAL-BLOOD FIBROCYTES; STROMAL-VASCULAR CELLS; BONE-MARROW STROMA; TGF-BETA; DIFFERENTIATION; ADIPOGENESIS; POPULATION; MODULATION	An increase in fat mass associated with obesity results from recruitment and differentiation of adipocyte progenitor cells. The precise origin of these cells is unknown, although accumulating evidence suggests that circulating stem cells can differentiate into cells of mesenchymal lineage. It is currently unclear whether a progenitor adipocyte population exists in circulation. One potential candidate is the fibrocyte, which may represent a common progenitor cell for several mesenchymal lineages. We demonstrate that these circulating progenitors become adipocytes when cultured under adipogenic conditions, with intracellular lipids accumulation and upregulation of proteins specific for adipocyte differentiation, including leptin, PPAR gamma, and FABP4. cDNA microarray analysis revealed gene clusters that were differentially regulated during adipogenesis of fibrocytes, which were similar to visceral and subcutaneous adipose tissue preadipocyte-to-adipocyte differentiation. Moreover, these progenitors engrafted and formed human adipose tissue following injection into SCID mice. Although fibrocytes express an array of chemokine receptors, we observed an up-regulation of CCR2 expression following fibrocytes differentiation into adipocytes, which was associated with increased chemotactic response to CCL2. This paradigm supports the notion that elevated CCL2 levels in visceral adipose tissue associated with Metabolic Syndrome is a chemotactic niche, whereby fibrocytes can home to and differentiate into adipocytes to perpetuate its tissue formation.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Ctr Human Nutr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Strieter, RM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, 900 Vet Ave,14-154 Warren Hall, Los Angeles, CA 90095 USA.	rstrieter@mednet.ucla.edu						Abe R, 2001, J IMMUNOL, V166, P7556, DOI 10.4049/jimmunol.166.12.7556; Bruun JM, 2005, J CLIN ENDOCR METAB, V90, P2282, DOI 10.1210/jc.2004-1696; BUCALA R, 1994, MOL MED, V1, P71, DOI 10.1007/bf03403533; Chesney J, 2000, Curr Rheumatol Rep, V2, P501, DOI 10.1007/s11926-000-0027-5; Chesney J, 1997, P NATL ACAD SCI USA, V94, P6307, DOI 10.1073/pnas.94.12.6307; Chesney J, 1998, J IMMUNOL, V160, P419; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; D'Ippolito G, 2004, J CELL SCI, V117, P2971, DOI 10.1242/jcs.01103; Fukumura D, 2003, CIRC RES, V93, pE88, DOI 10.1161/01.RES.0000099243.20096.FA; Gaustad KG, 2004, BIOCHEM BIOPH RES CO, V314, P420, DOI 10.1016/j.bbrc.2003.12.109; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Hausman GJ, 1996, J ANIM SCI, V74, P2117; Janderova L, 2003, OBES RES, V11, P65, DOI 10.1038/oby.2003.11; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534-5807(04)00075-9; Metz CN, 2003, CELL MOL LIFE SCI, V60, P1342, DOI 10.1007/s00018-003-2328-0; Mizuno Hiroshi, 2003, Journal of Nippon Medical School, V70, P300; O'Connor KC, 2003, BIOTECHNOL LETT, V25, P1967, DOI 10.1023/B:BILE.0000004386.08923.ab; PETRUSCHKE T, 1994, INT J OBESITY, V18, P532; Phillips RJ, 2004, J CLIN INVEST, V114, P438, DOI 10.1172/jci200420997; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069; SBARBATI R, 1991, BLOOD, V77, P764; Sekiya I, 2004, J BONE MINER RES, V19, P256, DOI 10.1359/JBMR.0301220; Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20-6-530; SILVERMAN KJ, 1988, BIOCHEM BIOPH RES CO, V153, P347, DOI 10.1016/S0006-291X(88)81229-4; Simper D, 2002, CIRCULATION, V106, P1199, DOI 10.1161/01.CIR.0000031525.61826.A8; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; SPIEGELMAN BM, 1983, CELL, V35, P657, DOI 10.1016/0092-8674(83)90098-3; Takahashi K, 2003, J BIOL CHEM, V278, P46654, DOI 10.1074/jbc.M309895200; Theise ND, 2000, HEPATOLOGY, V32, P11, DOI 10.1053/jhep.2000.9124; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Zhou SH, 2004, J BONE MINER RES, V19, P463, DOI 10.1359/JBMR.0301239; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105	36	99	106	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2005	19	11					2029	+		10.1096/fj.05-4295fje	http://dx.doi.org/10.1096/fj.05-4295fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16188961				2022-12-28	WOS:000232315700002
J	Aziz, MA; Sikriwal, D; Singh, S; Jarugula, S; Kumar, PA; Bhatnagar, R				Aziz, MA; Sikriwal, D; Singh, S; Jarugula, S; Kumar, PA; Bhatnagar, R			Transformation of an edible crop with the pagA gene of Bacillus anthracis	FASEB JOURNAL			English	Article						anthrax; protective antigen; chloroplast; biolistics; vaccine	TOXIN B-SUBUNIT; PROTECTIVE ANTIGEN; TRANSGENIC PLANTS; EXPRESSION; VACCINE; IMMUNIZATION; ANTIBODIES; PROMOTERS; INDUCTION; STABILITY	Vaccination against anthrax is the most important strategy to combat the disease. This study describes a generation of edible transgenic crop expressing, functional protective antigen (PA). In vitro studies showed that the plant-expressed antigen is qualitatively similar to recombinant PA. Immunization studies in mouse animal models indicated the generation of PA-specific neutralizing antibodies and stressed the need for improving expression levels to generate higher antibody titers. Genetic engineering of a plant organelle offers immense scope for increasing levels of antigen expression. An AT-rich PA gene (pagA) coding for the 83-kDa PA molecule was thus cloned and expressed in tobacco chloroplasts. Biolistics was used for the transformation of a chloroplast genome under a set of optimized conditions. The expression of the pagA gene with 69% AT content was highly favored by an AT-rich chloroplast genome. A multifold expression level of functional PA was obtained as compared with the nuclear transgenic tobacco plants. This report describes for the first time a comprehensive study on generating transgenic plants expressing PA, which may serve as a source of an edible vaccine against anthrax. Two important achievements of expressing PA in an edible crop and use of chloroplast technology to enhance the expression levels are discussed here.	Jawaharlal Nehru Univ, Ctr Biotechnol, New Delhi 110067, India; Indian Agr Res Inst, Natl Res Ctr Plant Biotechnol, New Delhi 110012, India	Jawaharlal Nehru University, New Delhi; Indian Council of Agricultural Research (ICAR); ICAR - Indian Agricultural Research Institute; ICAR - National Institute For Plant Biotechnology (NIPB)	Bhatnagar, R (corresponding author), Jawaharlal Nehru Univ, Ctr Biotechnol, New Delhi 110067, India.	rakeshbhatnagar@mail.jnu.ac.in	Aziz, Mohammad Azhar/F-7486-2013; Singh, Samer/H-8468-2013; Jarugula, Sridhar/L-9588-2019; P, Anantakumar/D-3605-2009	Aziz, Mohammad Azhar/0000-0002-0798-5063; Singh, Samer/0000-0002-0921-1686; 				Aziz MA, 2002, BIOCHEM BIOPH RES CO, V299, P345, DOI 10.1016/S0006-291X(02)02625-6; Bhatnagar R, 2001, CRIT REV MICROBIOL, V27, P167, DOI 10.1080/20014091096738; Biemelt S, 2003, J VIROL, V77, P9211, DOI 10.1128/JVI.77.17.9211-9220.2003; Bock R, 2004, TRENDS BIOTECHNOL, V22, P311, DOI 10.1016/j.tibtech.2004.03.005; Bock R, 2001, J MOL BIOL, V312, P425, DOI 10.1006/jmbi.2001.4960; Dale PJ, 2002, NAT BIOTECHNOL, V20, P567, DOI 10.1038/nbt0602-567; Daniell H, 2001, J MOL BIOL, V311, P1001, DOI 10.1006/jmbi.2001.4921; Daniell H, 2002, TRENDS PLANT SCI, V7, P84, DOI 10.1016/S1360-1385(01)02193-8; Daniell H, 2001, TRENDS PLANT SCI, V6, P219, DOI 10.1016/S1360-1385(01)01922-7; Fei SZ, 2000, PLANT CELL TISS ORG, V60, P197, DOI 10.1023/A:1006468324616; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; Giddings G, 2000, NAT BIOTECHNOL, V18, P1151, DOI 10.1038/81132; Gu ML, 1999, VACCINE, V17, P340, DOI 10.1016/S0264-410X(98)00210-2; Gupta P, 1999, PROTEIN EXPRES PURIF, V16, P369, DOI 10.1006/prep.1999.1066; HAQ TA, 1995, SCIENCE, V268, P714, DOI 10.1126/science.7732379; HOEKEMA A, 1983, NATURE, V303, P179, DOI 10.1038/303179a0; IACONOCONNORS LC, 1991, INFECT IMMUN, V59, P1961, DOI 10.1128/IAI.59.6.1961-1965.1991; IVINS BE, 1992, INFECT IMMUN, V60, P662, DOI 10.1128/IAI.60.2.662-668.1992; Jani D, 2002, TRANSGENIC RES, V11, P447, DOI 10.1023/A:1020336332392; Komine Y, 2002, P NATL ACAD SCI USA, V99, P4085, DOI 10.1073/pnas.052327599; LEPPLA SH, 1985, MICROBIOLOGY, P62; Losey JE, 1999, NATURE, V399, P214, DOI 10.1038/20338; Maliga P, 2002, CURR OPIN PLANT BIOL, V5, P164, DOI 10.1016/S1369-5266(02)00248-0; Mason HS, 2002, TRENDS MOL MED, V8, P324, DOI 10.1016/S1471-4914(02)02360-2; Muellenhoff M, 2004, J AM ACAD DERMATOL, V50, P136, DOI 10.1016/S0190-9622(03)00407-9; Muniz AE, 2003, J EMERG MED, V25, P271, DOI 10.1016/S0736-4679(03)00201-4; PEZARD C, 1995, INFECT IMMUN, V63, P1369, DOI 10.1128/IAI.63.4.1369-1372.1995; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANFORD JC, 1993, METHOD ENZYMOL, V217, P483; Santos MJD, 2002, VACCINE, V20, P1141, DOI 10.1016/S0264-410X(01)00434-0; SHIMADA H, 1991, NUCLEIC ACIDS RES, V19, P983, DOI 10.1093/nar/19.5.983; Sojikul P, 2003, P NATL ACAD SCI USA, V100, P2209, DOI 10.1073/pnas.0438037100; Staub JM, 2000, NAT BIOTECHNOL, V18, P333, DOI 10.1038/73796; Streatfield SJ, 2003, INT J PARASITOL, V33, P479, DOI 10.1016/S0020-7519(03)00052-3; Streatfield Stephen J, 2003, Expert Rev Vaccines, V2, P763, DOI 10.1586/14760584.2.6.763; Sussman HE, 2003, DRUG DISCOV TODAY, V8, P428, DOI 10.1016/S1359-6446(03)02706-5; VERA A, 1995, CURR GENET, V27, P280, DOI 10.1007/BF00326161; Walmsley AM, 2000, CURR OPIN BIOTECH, V11, P126, DOI 10.1016/S0958-1669(00)00070-7; Wasserman GM, 2003, J OCCUP ENVIRON MED, V45, P222, DOI 10.1097/01.jom.0000058345.05741.6b; Watson J, 2004, VACCINE, V22, P4374, DOI 10.1016/j.vaccine.2004.01.069; Webster DE, 2002, MED J AUSTRALIA, V176, P434; Wein LM, 2003, P NATL ACAD SCI USA, V100, P4346, DOI 10.1073/pnas.0636861100; Welkos S, 2001, MICROBIOL-SGM, V147, P1677, DOI 10.1099/00221287-147-6-1677; Yuki Y, 2003, REV MED VIROL, V13, P293, DOI 10.1002/rmv.398	45	25	29	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1501	+		10.1096/fj.04-3215fje	http://dx.doi.org/10.1096/fj.04-3215fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16030177				2022-12-28	WOS:000230923000018
J	Chopard, A; Arrighi, N; Carnino, A; Marini, JF				Chopard, A; Arrighi, N; Carnino, A; Marini, JF			Changes in dysferlin, proteins from dystrophin glycoprotein complex, costameres, and cytoskeleton in human soleus and vastus lateralis muscles after a long-term bedrest with or without exercise	FASEB JOURNAL			English	Article						human muscles; countermeasures; hypokinesia; hypodynamia	SKELETAL-MUSCLE; FORCE TRANSMISSION; META-VINCULIN; HINDLIMB SUSPENSION; MUSCULAR-DYSTROPHY; MEMBRANE REPAIR; SMOOTH-MUSCLE; BED REST; RAT; SLOW	This study was designed to evaluate the effects of hypokinesia and hypodynamia on cytoskeletal and related protein contents in human skeletal muscles. Twelve proteins: dystrophin and its associated proteins (DGC), dysferlin, talin, vinculin and meta-vinculin, alpha-actinin, desmin, actin, and myosin, were quantitatively analyzed during an 84-day long-term bedrest (LTBR). The preventive or compensatory effects of maximal resistance exercise (MRE) as a countermeasure were evaluated. Most of these proteins are involved in several myopathies, and they play an important role in muscle structure, fiber cohesion, cell integrity maintenance, and force transmission. This is the first comparison of the cytoskeletal protein contents between slow postural soleus ( SOL) and mixed poly-functional vastus lateralis (VL) human muscles. Protein contents were higher in VL than in SOL ( from 12 to 94%). These differences could be mainly explained by the differential mechanical constraints imposed on the muscles, i.e., cytoskeletal protein contents increase with mechanical constraints. After LTBR, proteins belonging to the DGC, dysferlin, and proteins of the costamere exhibited large increases, higher in SOL ( from 67 to 216%) than in VL ( from 32 to 142%). Plasma membrane remodeling during muscle atrophy is probably one of the key points for interpreting these modifications, and mechanisms other than those involved in the resistance of the cytoskeleton to mechanical constraints may be implicated ( membrane repair). MRE compensates the cytoskeletal changes induced by LTBR in SOL, except for gamma-sarcoglycan (+70%) and dysferlin (+108%). The exercise only partly compensated the DGC changes induced in VL, and, as for SOL, dysferlin remained largely increased (+132%). Moreover, vinculin and metavinculin, which exhibited no significant change in VL after LTBR, were increased with MRE during LTBR, reinforcing the pre-LTBR differences between SOL and VL. This knowledge will contribute to the development of efficient space flight countermeasures and rehabilitation methods in clinical situations where musculoskeletal unloading is a component.	Univ Nice, Lab Physiol Adapt Performance Motrice & Sante, UFR 261, STAPS, F-06205 Nice, France	UDICE-French Research Universities; Universite Cote d'Azur	Chopard, A (corresponding author), Univ Nice, Lab Physiol Adapt Performance Motrice & Sante, UFR 261, STAPS, 261 Route Grenoble, F-06205 Nice, France.	achopard@unice.fr	Arrighi, Nicole/AGF-5469-2022; Nicole, ARRIGHI/O-8075-2016					Adams GR, 2003, J APPL PHYSIOL, V95, P2185, DOI 10.1152/japplphysiol.00346.2003; Andersen JL, 1999, J APPL PHYSIOL, V86, P455, DOI 10.1152/jappl.1999.86.2.455; Bansal D, 2004, TRENDS CELL BIOL, V14, P206, DOI 10.1016/j.tcb.2004.03.001; Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689; Bastide B, 2000, BIOCHEM BIOPH RES CO, V270, P442, DOI 10.1006/bbrc.2000.2446; BELKIN AM, 1988, J BIOL CHEM, V263, P6631; Berg HE, 1997, J APPL PHYSIOL, V82, P182, DOI 10.1152/jappl.1997.82.1.182; BERG HE, 1994, AVIAT SPACE ENVIR MD, V65, P752; BERGSTROM J, 1975, SCAND J CLIN LAB INV, V35, P606, DOI 10.3109/00365517509095787; Bezakova G, 2001, J CELL BIOL, V153, P1453, DOI 10.1083/jcb.153.7.1453; BIOLO G, 1995, AM J PHYSIOL-ENDOC M, V268, pE514; CAIOZZO VJ, 1994, J APPL PHYSIOL, V76, P1764, DOI 10.1152/jappl.1994.76.4.1764; Campanaro S, 2002, HUM MOL GENET, V11, P3283, DOI 10.1093/hmg/11.26.3283; Campbell KP, 2003, J BIOL CHEM, V278, P12599, DOI 10.1074/jbc.R300005200; CHESLEY A, 1992, J APPL PHYSIOL, V73, P1383, DOI 10.1152/jappl.1992.73.4.1383; Chopard A, 2002, PFLUG ARCH EUR J PHY, V444, P627, DOI 10.1007/s00424-002-0872-3; Chopard A, 2001, AM J PHYSIOL-REG I, V280, pR323, DOI 10.1152/ajpregu.2001.280.2.R323; Chopard A, 2000, ELECTROPHORESIS, V21, P517, DOI 10.1002/(SICI)1522-2683(20000201)21:3<517::AID-ELPS517>3.0.CO;2-9; DANOWSKI BA, 1992, J CELL BIOL, V118, P1411, DOI 10.1083/jcb.118.6.1411; De la Porte S, 1999, INT REV CYTOL, V191, P99, DOI 10.1016/S0074-7696(08)60158-8; DECHESNE CA, 1985, CIRC RES, V57, P767, DOI 10.1161/01.RES.57.5.767; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; EDGERTON VR, 1995, J APPL PHYSIOL, V78, P1733, DOI 10.1152/jappl.1995.78.5.1733; Ehmsen J, 2002, J CELL SCI, V115, P2801; Ervasti JM, 2003, J BIOL CHEM, V278, P13591, DOI 10.1074/jbc.R200021200; FERAMISCO JR, 1982, J BIOL CHEM, V257, P1024; Ferrando AA, 1997, J APPL PHYSIOL, V82, P807, DOI 10.1152/jappl.1997.82.3.807; FRANZINIARMSTRONG C, 1988, J MUSCLE RES CELL M, V9, P403, DOI 10.1007/BF01774067; GEIGER B, 1979, CELL, V18, P193, DOI 10.1016/0092-8674(79)90368-4; GERMAIN P, 1995, EUR J APPL PHYSIOL O, V71, P342, DOI 10.1007/BF00240415; GIMONA M, 1987, J MUSCLE RES CELL M, V8, P329, DOI 10.1007/BF01568889; Hack AA, 1998, J CELL BIOL, V142, P1279, DOI 10.1083/jcb.142.5.1279; HADDAD F, 1993, J APPL PHYSIOL, V75, P2471, DOI 10.1152/jappl.1993.75.6.2471; HIKIDA RS, 1989, AVIAT SPACE ENVIR MD, V60, P664; Huijing PA, 1999, J BIOMECH, V32, P329, DOI 10.1016/S0021-9290(98)00186-9; Huijing PA, 1998, J EXP BIOL, V201, P683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lemler MS, 2000, AM J PHYSIOL-HEART C, V279, pH1365; Lennon NJ, 2003, J BIOL CHEM, V278, P50466, DOI 10.1074/jbc.M307247200; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; Maeda M, 1997, CIRCULATION, V95, P17, DOI 10.1161/01.CIR.95.1.17; Matsuda C, 2001, HUM MOL GENET, V10, P1761, DOI 10.1093/hmg/10.17.1761; Ohira Y, 1999, J APPL PHYSIOL, V87, P1776, DOI 10.1152/jappl.1999.87.5.1776; PARDO JV, 1983, P NATL ACAD SCI-BIOL, V80, P1008, DOI 10.1073/pnas.80.4.1008; PARDO JV, 1983, J CELL BIOL, V97, P1081, DOI 10.1083/jcb.97.4.1081; PONS F, 1994, J NEUROL SCI, V122, P162, DOI 10.1016/0022-510X(94)90295-X; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Roffino S, 1998, CR ACAD SCI III-VIE, V321, P557, DOI 10.1016/S0764-4469(98)80457-5; Rybakova IN, 2000, J CELL BIOL, V150, P1209, DOI 10.1083/jcb.150.5.1209; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SILICIANO JD, 1982, NATURE, V300, P533, DOI 10.1038/300533a0; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; STREET SF, 1983, J CELL PHYSIOL, V114, P346, DOI 10.1002/jcp.1041140314; TERRACIO L, 1990, J CELL PHYSIOL, V145, P78, DOI 10.1002/jcp.1041450112; THOMASON DB, 1990, J APPL PHYSIOL, V68, P1, DOI 10.1152/jappl.1990.68.1.1; TIDBALL JG, 1986, J CELL BIOL, V103, P1465, DOI 10.1083/jcb.103.4.1465; TIDBALL JG, 1991, J BIOMECH, V24, P43, DOI 10.1016/0021-9290(91)90376-X; Tidball JG, 1999, J BIOL CHEM, V274, P33155, DOI 10.1074/jbc.274.46.33155; TROTTER JA, 1987, ANAT REC, V218, P256, DOI 10.1002/ar.1092180306; Ueda H, 2001, J HISTOCHEM CYTOCHEM, V49, P529, DOI 10.1177/002215540104900413; VIGOREAUX JO, 1994, J MUSCLE RES CELL M, V15, P237; WICKIEWICZ TL, 1983, CLIN ORTHOP RELAT R, P275, DOI 10.1097/00003086-198310000-00042; Widrick JJ, 1999, J PHYSIOL-LONDON, V516, P915, DOI 10.1111/j.1469-7793.1999.0915u.x; Zamora AJ, 1995, ACTA ASTRONAUT, V36, P693, DOI 10.1016/0094-5765(95)00159-X; ZHOU MY, 1995, J APPL PHYSIOL, V78, P1740, DOI 10.1152/jappl.1995.78.5.1740	66	47	51	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1722	+		10.1096/fj.04-3336fje	http://dx.doi.org/10.1096/fj.04-3336fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16046473				2022-12-28	WOS:000230923000006
J	Jbilo, O; Ravinet-Trillou, C; Arnone, M; Buisson, I; Bribes, E; Peleraux, A; Penarier, G; Soubrie, P; Le Fur, G; Galiegue, S; Casellas, P				Jbilo, O; Ravinet-Trillou, C; Arnone, M; Buisson, I; Bribes, E; Peleraux, A; Penarier, G; Soubrie, P; Le Fur, G; Galiegue, S; Casellas, P			The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance	FASEB JOURNAL			English	Article						SR141716; dietary obesity; energy expenditure; DNA chips	ADIPOSE-TISSUE; EXPRESSION; INSULIN; LEPTIN; ADIPOGENESIS; ACTIVATION; FAT	We investigated the molecular events involved in the long-lasting reduction of adipose mass by the selective CB1 antagonist, SR141716. Its effects were assessed at the transcriptional level both in white (WAT) and brown (BAT) adipose tissues in a diet-induced obesity model in mice. Our data clearly indicated that SR141716 reversed the phenotype of obese adipocytes at both macroscopic and genomic levels. First, oral treatment with SR141716 at 10 mg/kg/d for 40 days induced a robust reduction of obesity, as shown by the 50% decrease in adipose mass together with a major restoration of white adipocyte morphology similar to lean animals. Second, we found that the major alterations in gene expression levels induced by obesity in WAT and BAT were mostly reversed in SR141716-treated obese mice. Importantly, the transcriptional patterns of treated obese mice were similar to those obtained in the CB1 receptor knockout mice fed a high-fat regimen and which are resistant to obesity, supporting a CB1 receptor-mediated process. Functional analysis of these modulations indicated that the reduction of adipose mass by the molecule resulted from an enhanced lipolysis through the induction of enzymes of the beta-oxidation and TCA cycle, increased energy expenditure, mainly through futile cycling (calcium and substrate), and a tight regulation of glucose homeostasis. These changes accompanied a significant cellular remodeling and contributed to a reduction of the obesity-related inflammatory status. In addition to a transient reduction of food consumption, increases of both fatty acid oxidation and energy expenditure induced by the molecule summate leading to a sustained weight loss. Altogether, these data strongly indicate that the endocannabinoid system has a major role in the regulation of energy metabolism.	Sanofi Synthelabo Rech, Cent Nervous Syst Res Dept, F-34184 Montpellier, France; Sanofi Synthelabo Rech, Paris, France; Sanofi Synthelabo Rech, Oncol Res Dept, F-34184 Montpellier, France; Sanofi Synthelabo Rech, Cent Nervous Syst Res Dept, Toulouse, France	Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France	Casellas, P (corresponding author), Sanofi Synthelabo Rech, Cent Nervous Syst Res Dept, 371 Rue Prof Joseph Blayac, F-34184 Montpellier, France.	pierre.casellas@sanofi-aventis.com						Beattie JH, 2000, AM J PHYSIOL-REG I, V278, pR1082; Bensaid M, 2003, MOL PHARMACOL, V63, P908, DOI 10.1124/mol.63.4.908; Bernardis LL, 1996, NEUROSCI BIOBEHAV R, V20, P189, DOI 10.1016/0149-7634(95)00015-1; Bouaboula M, 1997, J BIOL CHEM, V272, P22330, DOI 10.1074/jbc.272.35.22330; Breivogel CS, 1997, J PHARMACOL EXP THER, V282, P1632; Cota D, 2003, J CLIN INVEST, V112, P423, DOI 10.1172/JCI17725; Croci T, 1998, BRIT J PHARMACOL, V125, P1393, DOI 10.1038/sj.bjp.0702190; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gomez R, 2002, J NEUROSCI, V22, P9612; Hilairet S, 2003, J BIOL CHEM, V278, P23731, DOI 10.1074/jbc.M212369200; Imamura M, 2002, AM J PHYSIOL-ENDOC M, V283, pE775, DOI 10.1152/ajpendo.00040.2002; Kim KH, 2004, P NATL ACAD SCI USA, V101, P6780, DOI 10.1073/pnas.0305905101; Li JP, 2002, AM J PHYSIOL-ENDOC M, V282, pE1334, DOI 10.1152/ajpendo.00516.2001; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Matias I, 2004, RECENT ADVANCES IN PHARMACOLOGY AND PHYSIOLOGY OF CANNABINOIDS, P217; Mukhopadhyay S, 2000, MOL PHARMACOL, V57, P162; Nadler ST, 2000, P NATL ACAD SCI USA, V97, P11371, DOI 10.1073/pnas.97.21.11371; RAVINET TC, 2003, AM J PHYSIOL-REG I, V284, pR345, DOI DOI 10.1152/AJPREGU.00545.2002; RINALDICARMONA M, 1995, LIFE SCI, V56, P1941, DOI 10.1016/0024-3205(95)00174-5; Rolfe DFS, 1997, PHYSIOL REV, V77, P731, DOI 10.1152/physrev.1997.77.3.731; Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989-5999.2002; SACKS N, 1990, J AM COLL NUTR, V9, P630; Soukas A, 2000, GENE DEV, V14, P963; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Tartare-Deckert S, 2001, J BIOL CHEM, V276, P22231, DOI 10.1074/jbc.M010634200; Trayhurn P, 2001, P NUTR SOC, V60, P329, DOI 10.1079/PNS200194; Trillou CR, 2004, INT J OBESITY, V28, P640, DOI 10.1038/sj.ijo.0802583; Tsou K, 1998, NEUROSCIENCE, V83, P393, DOI 10.1016/S0306-4522(97)00436-3; WILLIAMS SK, 1999, TIS ENGN INTELL UNIT, V1, P143; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Zhou YT, 1999, P NATL ACAD SCI USA, V96, P2391, DOI 10.1073/pnas.96.5.2391	32	290	303	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1567	+		10.1096/fj.04-3177fje	http://dx.doi.org/10.1096/fj.04-3177fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16009704				2022-12-28	WOS:000230923000029
J	Opalenik, SR; Davidson, JM				Opalenik, SR; Davidson, JM			Fibroblast differentiation of bone marrow-derived cells during wound repair	FASEB JOURNAL			English	Article; Proceedings Paper	Annual Meeting of the Wound-Healing-Society	2003	SEATTLE, WA	Wound Healing Soc		wound fibroblast; collagen I; tissue remodeling; stem cells	HEMATOPOIETIC STEM-CELLS; TRANSGENIC MICE; ENGRAFTMENT; PLASTICITY; MOUSE; IDENTIFICATION; PLURIPOTENCY; FIBROCYTES	To examine the ontogeny of the wound fibroblast, bone marrow transplantation was performed to wild-type recipients from transgenic donors that express both the luciferase and beta-galactosidase reporter genes under transcriptional control of the promoter/enhancer for the alpha 2 chain of type I collagen. Polyvinyl alcohol sponges were implanted to elicit a naive granulation tissue response, removed at defined time points, and processed for nucleic acids and histochemistry. Quantitative PCR for the luciferase transgene demonstrated that donor-derived cells were present during inflammation, declined, and rebounded during later stages of tissue remodeling. Furthermore, quantitative RT-PCR revealed that bone marrow-derived collagen transcripts contributed significantly to the total collagen I alpha 2 promoter activation during later stages of repair. beta-galactosidase staining revealed that indeed those cells which expressed the transgene exhibited a fibroblastic phenotype, co-localized with sites of active collagen deposition, and expressed fibroblast specific protein-1. These data strongly support the concept that the adult bone marrow compartment houses progenitors with the potential to migrate to sites of tissue damage, and participate in repair beyond inflammation as fibroblasts. Moreover, that bone marrow-derived fibroblasts make a substantial contribution to the formation of new connective tissue, including type I collagen, during wound repair.	Vanderbilt Univ, Dept Pathol, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Davidson, JM (corresponding author), Vanderbilt Univ, Dept Pathol, C3321 Med Ctr N, Nashville, TN 37232 USA.	jeff.davidson@vanderbilt.edu			NIA NIH HHS [R01-AG06528, R01 AG006528] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG006528] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abe R, 2001, J IMMUNOL, V166, P7556, DOI 10.4049/jimmunol.166.12.7556; Awad HA, 1999, TISSUE ENG, V5, P267, DOI 10.1089/ten.1999.5.267; Badiavas EV, 2003, J CELL PHYSIOL, V196, P245, DOI 10.1002/jcp.10260; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; BUCALA R, 1994, MOL MED, V1, P71, DOI 10.1007/bf03403533; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; Chesney J, 1997, P NATL ACAD SCI USA, V94, P6307, DOI 10.1073/pnas.94.12.6307; Clark R., 1996, Mezhdunarodnyi Sel'skokhozyaistvennyi Zhurnal, P3; Davidson JM, 1998, ARCH DERMATOL RES, V290, pS1, DOI 10.1007/PL00007448; DAVIDSON JM, 1992, INFLAMMATION BASIC P, P809; Dennis JE, 1999, J BONE MINER RES, V14, P700, DOI 10.1359/jbmr.1999.14.5.700; Direkze NC, 2003, STEM CELLS, V21, P514, DOI 10.1634/stemcells.21-5-514; DOWN JD, 1993, EXP HEMATOL, V21, P913; Eckes B., 1996, MOL CELLULAR BIOL WO, P493; Fathke C, 2004, STEM CELLS, V22, P812, DOI 10.1634/stemcells.22-5-812; FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267; Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood-2003-05-1664; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Krause DS, 2002, GENE THER, V9, P754, DOI 10.1038/sj.gt.3301760; OKADA H, 1997, AM J PHYSIOL, V273, P563; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Reyes M, 2001, BLOOD, V98, P2615, DOI 10.1182/blood.V98.9.2615; Schwartz RE, 2002, J CLIN INVEST, V109, P1291, DOI 10.1172/JCI200215182; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; Tao H, 2003, PATHOLOGY, V35, P6, DOI 10.1080/003130202201471; Verfaillie CM, 2002, TRENDS CELL BIOL, V12, P502, DOI 10.1016/S0962-8924(02)02386-3; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wu NJ, 2002, MATRIX BIOL, V21, P149, DOI 10.1016/S0945-053X(01)00192-5; ZIJLMANS JMJM, 1995, P NATL ACAD SCI USA, V92, P8901, DOI 10.1073/pnas.92.19.8901; Zijlmans JMJM, 1998, P NATL ACAD SCI USA, V95, P725, DOI 10.1073/pnas.95.2.725	33	94	98	2	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1561	+		10.1096/fj.04-2978fje	http://dx.doi.org/10.1096/fj.04-2978fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16014399				2022-12-28	WOS:000230923000022
J	Tilkin-Mariame, AF; Cormary, C; Ferro, N; Sarrabayrouse, G; Lajoie-Mazenc, I; Faye, JC; Favre, G				Tilkin-Mariame, AF; Cormary, C; Ferro, N; Sarrabayrouse, G; Lajoie-Mazenc, I; Faye, JC; Favre, G			Geranylgeranyl transferase inhibition stimulates antimelanoma immune response through MHC class I and costimulatory molecule expression	FASEB JOURNAL			English	Article						cancer; immunity; antigen presentation; costimulation; Rho proteins	HUMAN-MELANOMA CELLS; ANTIGEN PRESENTATION; TUMOR-CELLS; IFN-GAMMA; CD80; INDUCTION; IDENTIFICATION; TRANSFORMATION; SURVEILLANCE; DEFICIENCIES	Defective antitumor immune responses are frequent consequences of defects in the expression of major histocompatibility complex (MHC) class I and costimulatory molecules. We demonstrated that statins, inhibitors of HMGCoA reductase, enhance mIFN-gamma induced expression of MHC class I antigens on murine B16F10 melanoma. GGTI-298, a geranylgeranyl transferase I inhibitor, but not FTI-277, a farnesyl transferase inhibitor, mimics this effect of statins. This effect is related to peptide transporter protein TAP1 up-regulation. Simultaneously, GGTI-298 induces the expression of CD80 and CD86 costimulatory molecules. C3 exoenzyme, which selectively inactivates Rho proteins, phenocopies the effects of GGTI-298, indicating a role for Rho proteins in these events. Furthermore, the treatment of B16F10 cells with GGTI-298 or C3 exoenzyme associated with mIFN-gamma induces in vivo tumor growth slowing down in immunocompetent but not in nu/nu syngeneic mice. Both in vivo injections and in vitro restimulation of splenocytes with GGTI-298- and mIFN-gamma- treated B16F10 cells induces an enhancement of specific CD8 T lymphocytes labeled by TRP-2/H-2K(b) tetramers. Finally, these effects are not limited to mouse models since they were also reproduced in two human melanoma cell lines. These observations indicate that protein geranylgeranylation as well as Rho protein are critical for costimulatory and IFN-gamma- dependent MHC class I molecule expression in melanoma.	Inst Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM, U563,CPTP, F-31052 Toulouse, France; Univ Toulouse 3, F-31062 Toulouse, France	UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Tilkin-Mariame, AF (corresponding author), Inst Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM, U563,CPTP, 20-24 Rue Pt St Pierre, F-31052 Toulouse, France.	tilkin@icr.fnclcc.fr	FAVRE, Gilles/K-9189-2014; Lajoie-Mazenc, Isabelle/M-4636-2014	FAVRE, Gilles/0000-0002-2344-1883; 				AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; Allal C, 2000, J BIOL CHEM, V275, P31001, DOI 10.1074/jbc.M005264200; Bernsen MR, 2003, BRIT J CANCER, V88, P424, DOI 10.1038/sj.bjc.6600703; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bloom MB, 1997, J EXP MED, V185, P453, DOI 10.1084/jem.185.3.453; Bohm W, 1998, J IMMUNOL, V161, P897; Botti C, 1998, INT J BIOL MARKER, V13, P51; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cramer LA, 2000, J IMMUNOL, V165, P3190, DOI 10.4049/jimmunol.165.6.3190; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Douin-Echinard V, 2000, CANCER GENE THER, V7, P1543, DOI 10.1038/sj.cgt.7700268; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FERRONE S, 1995, IMMUNOL TODAY, V16, P487, DOI 10.1016/0167-5699(95)80033-6; Fong L, 2000, ANNU REV IMMUNOL, V18, P245, DOI 10.1146/annurev.immunol.18.1.245; Garcia-Lora A, 2003, J CELL PHYSIOL, V195, P346, DOI 10.1002/jcp.10290; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Grangeon C, 2002, CANCER GENE THER, V9, P282, DOI 10.1038/sj.cgt.7700439; Guilloux Y, 2001, CANCER RES, V61, P1107; Johnsen AK, 1999, J IMMUNOL, V163, P4224; Johnson BD, 2003, CELL IMMUNOL, V222, P15, DOI 10.1016/S0008-8749(03)00079-0; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219; Lejeune FJ, 1998, CURR OPIN IMMUNOL, V10, P573, DOI 10.1016/S0952-7915(98)80226-4; Lens SMA, 1998, SEMIN IMMUNOL, V10, P491, DOI 10.1006/smim.1998.0154; Li J, 1996, CANCER IMMUNOL IMMUN, V43, P213, DOI 10.1007/s002620050324; Mazieres J, 2004, CLIN CANCER RES, V10, P2742, DOI 10.1158/1078-0432.CCR-03-0149; McCarthy DO, 2000, CANCER IMMUNOL IMMUN, V49, P85, DOI 10.1007/s002620050606; Miquel K, 1997, CANCER RES, V57, P1846; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Renkvist N, 2001, CANCER IMMUNOL IMMUN, V50, P3, DOI 10.1007/s002620000169; RIVOLTINI L, 1995, CANCER RES, V55, P3149; ROBEY E, 1995, IMMUNOL TODAY, V16, P306, DOI 10.1016/0167-5699(95)80140-5; Rudy W, 1997, INT IMMUNOL, V9, P853, DOI 10.1093/intimm/9.6.853; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Seliger B, 1996, CANCER RES, V56, P1756; Seliger B, 1997, IMMUNOL TODAY, V18, P292, DOI 10.1016/S0167-5699(97)01052-9; Seliger B, 2001, CANCER RES, V61, P1095; Trentin L, 2000, CANCER, V89, P1259, DOI 10.1002/1097-0142(20000915)89:6<1259::AID-CNCR10>3.3.CO;2-7; Tsukada N, 1997, J EXP CLIN CANC RES, V16, P171; Vindelov L, 1990, Methods Cell Biol, V33, P127; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zaks TZ, 1999, J IMMUNOL, V162, P3273; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	44	28	29	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1513	+		10.1096/fj.04-3482fje	http://dx.doi.org/10.1096/fj.04-3482fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15990392				2022-12-28	WOS:000230207800003
J	Fischer, BM; Cuellar, JG; Byrd, AS; Rice, AB; Bonner, JC; Martin, LD; Voynow, JA				Fischer, BM; Cuellar, JG; Byrd, AS; Rice, AB; Bonner, JC; Martin, LD; Voynow, JA			ErbB2 activity is required for airway epithelial repair following neutrophil elastase exposure	FASEB JOURNAL			English	Article; Proceedings Paper	17th Annual North American Cystic Fibrosis Conference	OCT 16-19, 2003	Anaheim, CA			DNA synthesis; protease	EPIDERMAL-GROWTH-FACTOR; CELLS IN-VITRO; TYROSINE KINASE; CYSTIC-FIBROSIS; FACTOR RECEPTOR; BREAST-CANCER; LEUKOCYTE ELASTASE; GENE-EXPRESSION; CARCINOMA-CELLS; MESSENGER-RNA	In cystic fibrosis and chronic bronchitis, airways are chronically injured by exposure to neutrophil elastase ( NE). We sought to identify factors required for epithelial repair following NE exposure. Normal human bronchial epithelial cells were treated with NE ( 50 nM, 22 h) or control vehicle. Following NE treatment, we found a marked and sustained decrease in epithelial proliferation as detected by Ki67 immunostaining. H-3-thymidine incorporation was also initially depressed but increased over 72 h in NE-treated cells, which suggests that DNA synthesis constitutes an early repair process following NE exposure. We hypothesized that ErbB2 receptor tyrosine kinase, a regulator of cancer cell proliferation, was required for epithelial DNA synthesis following NE exposure. Immediately following NE treatment, by flow cytometry analysis, we found a decrease in ErbB2 surface expression. Protein levels of the full-length 185 kD ErbB2 receptor significantly decreased following NE treatment and smaller ErbB2-positive bands, ranging in size from 23 to 40 kD, appeared, which suggests that NE caused ErbB2 degradation. By real-time RT-PCR analysis, we found no change in ErbB2 mRNA expression following NE treatment, which suggests that changes in ErbB2 protein levels were regulated at the post-translational level. Following NE treatment, full-length 185 kD ErbB2 levels increased to pretreatment levels, correlating with the increase in thymidine incorporation during the same time period. Importantly, inhibition of ErbB2 activity with AG825 ( 5 mu M) or Herceptin (3.1 mu M), an ErbB2-neutralizing antibody, blocked thymidine incorporation only in NE-treated cells. These results suggest ErbB2 is a critical factor for epithelial recovery following NE exposure.	Duke Univ, Med Ctr, Div Pediat Pulm Med, Dept Pediat, Durham, NC 27710 USA; NIEHS, Lab Resp Biol, Res Triangle Pk, NC 27709 USA; N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, Raleigh, NC USA	Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; North Carolina State University	Voynow, JA (corresponding author), Duke Univ, Med Ctr, Div Pediat Pulm Med, Dept Pediat, Box 2994, Durham, NC 27710 USA.	voyno001@mc.duke.edu		Byrd, Angela/0000-0002-6743-4343	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073174, R01HL066236] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL073174, HL66236] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMITANI R, 1991, AM J RESP CELL MOL, V4, P26, DOI 10.1165/ajrcmb/4.1.26; Aoshiba K, 2001, AM J PHYSIOL-LUNG C, V281, pL556; BURNETT D, 1995, ARCH BIOCHEM BIOPHYS, V317, P305, DOI 10.1006/abbi.1995.1167; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; Chitano P, 2004, PEDIATR PULM, V38, P456, DOI 10.1002/ppul.20118; Contessa JN, 2002, ONCOGENE, V21, P4032, DOI 10.1038/sj.onc.1205500; Dammann CEL, 2003, AM J RESP CRIT CARE, V167, P1711, DOI 10.1164/rccm.200205-468OC; Davies DE, 1999, ALLERGY, V54, P771; Devaney JM, 2003, FEBS LETT, V544, P129, DOI 10.1016/S0014-5793(03)00482-4; El-Metwally TH, 1999, BIOCHEM BIOPH RES CO, V257, P596, DOI 10.1006/bbrc.1999.0502; Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q; Fischer BM, 1999, AM J RESP CELL MOL, V20, P413, DOI 10.1165/ajrcmb.20.3.3393; Fischer BM, 2003, AM J PHYSIOL-LUNG C, V284, pL671, DOI 10.1152/ajplung.00220.2002; Fischer BM, 2002, AM J RESP CELL MOL, V26, P447, DOI 10.1165/ajrcmb.26.4.4473; Ginzberg HH, 2001, AM J PHYSIOL-GASTR L, V281, pG705, DOI 10.1152/ajpgi.2001.281.3.G705; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28, DOI 10.1164/ajrccm.164.supplement_2.2106061; KERCSMAR CM, 1993, AM J RESP CELL MOL, V8, P56, DOI 10.1165/ajrcmb/8.1.56; KIM KC, 1987, P NATL ACAD SCI USA, V84, P9304, DOI 10.1073/pnas.84.24.9304; Kohri K, 2002, AM J PHYSIOL-LUNG C, V283, pL531, DOI 10.1152/ajplung.00455.2001; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; Le-Barillec K, 1999, J CLIN INVEST, V103, P1039, DOI 10.1172/JCI5779; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liu JB, 2002, AM J RESP CELL MOL, V27, P306, DOI 10.1165/rcmb.4850; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; NAKAMURA H, 1992, J CLIN INVEST, V89, P1478, DOI 10.1172/JCI115738; ORiordan TG, 1997, AM J RESP CRIT CARE, V155, P1522, DOI 10.1164/ajrccm.155.5.9154852; Patel NV, 2000, AM J RESP CELL MOL, V22, P432, DOI 10.1165/ajrcmb.22.4.3854; Perkett Elizabeth Ann, 1995, Current Opinion in Pediatrics, V7, P242, DOI 10.1097/00008480-199506000-00002; Polosa R, 1999, AM J RESP CELL MOL, V20, P914, DOI 10.1165/ajrcmb.20.5.3308; Ramsauer VP, 2003, J BIOL CHEM, V278, P30142, DOI 10.1074/jbc.M303220200; Roh H, 2000, CANCER RES, V60, P560; Sheffield LG, 1998, BIOCHEM BIOPH RES CO, V250, P27, DOI 10.1006/bbrc.1998.9214; Si-Tahar M, 1997, J BIOL CHEM, V272, P11636; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Snedecor GW, 1980, STAT METHODS, V7th; STAL O, 1994, CYTOMETRY, V16, P160, DOI 10.1002/cyto.990160210; STOCKLEY RA, 1979, AM REV RESPIR DIS, V120, P1081; Tikhomirov O, 2001, J BIOL CHEM, V276, P33675, DOI 10.1074/jbc.M101394200; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; Vandivier RW, 2002, J CLIN INVEST, V109, P661, DOI 10.1172/JCI200213572; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; von Bredow C, 2001, EUR RESPIR J, V17, P716, DOI 10.1183/09031936.01.17407160; Voynow JA, 1999, AM J PHYSIOL-LUNG C, V276, pL835; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; You XL, 1998, ONCOGENE, V17, P3177, DOI 10.1038/sj.onc.1202246	47	16	16	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2005	19	7					1374	+		10.1096/fj.04-2675fje	http://dx.doi.org/10.1096/fj.04-2675fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15923396				2022-12-28	WOS:000229602600006
J	Li, L; Bhatia, M; Zhu, YZ; Zhu, YC; Ramnath, RD; Wang, ZJ; Anuar, FBM; Whiteman, M; Salto-Tellez, M; Moore, PK				Li, L; Bhatia, M; Zhu, YZ; Zhu, YC; Ramnath, RD; Wang, ZJ; Anuar, FBM; Whiteman, M; Salto-Tellez, M; Moore, PK			Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse	FASEB JOURNAL			English	Article						cystathionine-gamma-lyase; H2S	CYSTATHIONINE-GAMMA-LYASE; ACUTE-PANCREATITIS; NITRIC-OXIDE; WHOLE-BLOOD; METABOLISM; CYSTEINE; KINASES; SEPSIS; TISSUE; SHOCK	Hydrogen sulfide (H2S) is synthesized in the body from L-Cysteine by several enzymes including cystathionine-gamma-lyase (CSE). To date, there is little information about the potential role of H2S in inflammation. We have now investigated the part played by H2S in endotoxin-induced inflammation in the mouse. E. coli lipopolysaccharide (LPS) administration produced a dose (10 and 20 mg/kg ip)- and time (6 and 24 h)-dependent increase in plasma H2S concentration. LPS (10 mg/kg ip, 6 h) increased plasma H2S concentration from 34.1 +/- 0.7 mu M to 40.9 +/- 0.6 mu M (n=6, P<0.05) while H2S formation from added L-Cysteine was increased in both liver and kidney. CSE gene expression was also increased in both liver (94.2 +/- 2.7%, n=6, P<0.05) and kidney (77.5 +/- 3.2%, n=6, P<0.05). LPS injection also elevated lung (148.2 +/- 2.6%, n=6, P<0.05) and kidney (78.8 +/- 8.2%, n=6, P<0.05) myeloperoxidase (MPO, a marker of tissue neutrophil infiltration) activity alongside histological evidence of lung, liver, and kidney tissue inflammatory damage. Plasma nitrate/nitrite (NOx) concentration was additionally elevated in a time- and dose-dependent manner in LPS-injected animals. To examine directly the possible proinflammatory effect of H2S, mice were administered sodium hydrosulfide (H2S donor drug, 14 mu mol/kg ip) that resulted in marked histological signs of lung inflammation, increased lung and liver MPO activity, and raised plasma TNF-alpha concentration (4.6 +/- 1.4 ng/ml, n=6). In contrast, DL-propargylglycine (CSE inhibitor, 50 mg/kg ip), exhibited marked anti-inflammatory activity as evidenced by reduced lung and liver MPO activity, and ameliorated lung and liver tissue damage. In separate experiments, we also detected significantly higher (150.5 +/- 43.7 mu M c.f. 43.8 +/- 5.1 mu M, n=5, P<0.05) plasma H2S levels in humans with septic shock. These findings suggest that H2S exhibits proinflammatory activity in endotoxic shock and suggest a new approach to the development of novel drugs for this condition.	Natl Univ Singapore, Dept Pharmacol, Singapore 117597, Singapore; Fudan Univ, Shanghai Med Coll, Minist Educ,Key Lab Mol Med, Dept Physiol & Pathophysiol, Shanghai 200032, Peoples R China; Natl Univ Singapore, Dept Biochem, Singapore 117597, Singapore; Natl Univ Singapore Hosp, Dept Pathol, Singapore 119074, Singapore	National University of Singapore; Fudan University; National University of Singapore; National University of Singapore	Moore, PK (corresponding author), Natl Univ Singapore, Dept Pharmacol, Block MD2,18 Med Dr, Singapore 117597, Singapore.	phchead@nus.edu.sg	Whiteman, Matthew/C-6079-2009; Zhu, Yi Zhun/ABG-8449-2021	Whiteman, Matthew/0000-0002-6583-6779; Zhu, Yi Zhun/0000-0001-7700-8041; Ramnath, Raina/0000-0001-8472-5081; Salto-Tellez, Manuel/0000-0001-8586-282X				AWATA S, 1984, BIOCHEM INT, V8, P171; Bhatia M, 2005, FASEB J, V19, P623, DOI 10.1096/fj.04-3023fje; Bhatia M, 1998, P NATL ACAD SCI USA, V95, P4760, DOI 10.1073/pnas.95.8.4760; Cheng YQ, 2004, AM J PHYSIOL-HEART C, V287, pH2316, DOI 10.1152/ajpheart.00331.2004; Gardiner SM, 1999, BRIT J PHARMACOL, V128, P1772, DOI 10.1038/sj.bjp.0702985; GOODWIN LR, 1989, J ANAL TOXICOL, V13, P105, DOI 10.1093/jat/13.2.105; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Haddad JJ, 2002, ANTIOXID REDOX SIGN, V4, P179, DOI 10.1089/152308602753625942; Hui Y, 2003, J INFECTION, V47, P155, DOI 10.1016/S0163-4453(03)00043-4; Ishii I, 2004, BIOCHEM J, V381, P113, DOI 10.1042/BJ20040243; Kamoun P, 2004, AMINO ACIDS, V26, P243, DOI 10.1007/s00726-004-0072-x; Kim SH, 2004, PHARMACOL RES, V49, P433, DOI 10.1016/j.phrs.2003.11.004; KLEBANOFF SJ, 1974, J BIOL CHEM, V249, P3724; KODAMA H, 1983, ARCH BIOCHEM BIOPHYS, V225, P25, DOI 10.1016/0003-9861(83)90003-6; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lyons J, 2001, CRIT CARE MED, V29, P870, DOI 10.1097/00003246-200104000-00036; Malmezat T, 1998, J NUTR, V128, P97, DOI 10.1093/jn/128.1.97; Malmezat T, 2000, AM J PHYSIOL-ENDOC M, V279, pE1391; Mok YYP, 2004, BRIT J PHARMACOL, V143, P881, DOI 10.1038/sj.bjp.0706014; Richardson CJ, 2000, CLIN CHIM ACTA, V293, P115, DOI 10.1016/S0009-8981(99)00245-4; Sorrentino R, 1999, BRIT J PHARMACOL, V127, P1447, DOI 10.1038/sj.bjp.0702666; STIPANUK MH, 1982, BIOCHEM J, V206, P267, DOI 10.1042/bj2060267; Tangerman A, 2002, J CLIN PATHOL, V55, P631, DOI 10.1136/jcp.55.8.631; Thiemermann C, 1997, GEN PHARMACOL-VASC S, V29, P159, DOI 10.1016/S0306-3623(96)00410-7; *US NAT RES COUNC, 1979, HYDR SULF; Wang R, 2003, ANTIOXID REDOX SIGN, V5, P493, DOI 10.1089/152308603768295249; Wang SB, 1999, J BIOL CHEM, V274, P33190, DOI 10.1074/jbc.274.47.33190; WASHTIEN W, 1977, BIOCHEMISTRY-US, V16, P2485, DOI 10.1021/bi00630a026; Yan H, 2004, BIOCHEM BIOPH RES CO, V313, P22, DOI 10.1016/j.bbrc.2003.11.081; Yang GD, 2004, FASEB J, V18, P1782, DOI 10.1096/fj.04-2279fje; Yang GD, 2004, J BIOL CHEM, V279, P49199, DOI 10.1074/jbc.M408997200; Zhang CY, 2003, BIOCHEM BIOPH RES CO, V302, P810, DOI 10.1016/S0006-291X(03)00256-0; Zhao WM, 2002, AM J PHYSIOL-HEART C, V283, pH474, DOI 10.1152/ajpheart.00013.2002; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008	34	653	697	1	106	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1196	+		10.1096/fj.04-3583fje	http://dx.doi.org/10.1096/fj.04-3583fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15863703				2022-12-28	WOS:000228865300001
J	Inoue, K; Takano, H; Shimada, A; Wada, E; Yanagisawa, R; Sakurai, M; Satoh, M; Yoshikawa, T				Inoue, K; Takano, H; Shimada, A; Wada, E; Yanagisawa, R; Sakurai, M; Satoh, M; Yoshikawa, T			Role of metallothionein in coagulatory disturbance and systemic inflammation induced by lipopolysaccharide in mice	FASEB JOURNAL			English	Article						MT; endothelial damage; systemic inflammatory response syndrome; cytokine	TUMOR-NECROSIS-FACTOR; PROTECTIVE ROLE; ACUTE-PHASE; ENDOTOXIN; INTERLEUKIN-6; EXPRESSION; INDUCTION; BIOLOGY; DEATH; GAMMA	Although metallothionein (MT) can be induced by inflammatory mediators, its roles in coagulatory disturbance during inflammation are poorly defined. We determined whether MT protects against coagulatory and fibrinolytic disturbance and systemic inflammation induced by intraperitoneal administration of lipopolysaccharide (LPS) in MT-I/II null (-/-) and wild-type (WT) mice. As compared with WT mice, MT (-/-) mice revealed significant prolongation of prothrombin and activated partial thromboplastin time, a significant increase in the levels of fibrinogen and fibrinogen/fibrin degradation products, and a significant decrease in activated protein C, after LPS treatment. LPS induced inflammatory organ damages in the lung, kidney, and liver in both genotypes of mice. The damages, including neutrophil infiltration, were more prominent in MT (-/-) mice than in WT mice after LPS treatment. In both genotypes of mice, LPS enhanced protein expression of interleukin (IL)-1 beta, IL-6, granulocyte/macrophage-colony-stimulating factor, macrophage inflammatory protein (MIP)-1 alpha, MIP-2, macrophage chemoattractant protein-1, and keratinocyte chemoattractant in the lung, kidney, and liver and circulatory levels of IL-1 beta, IL-6, MIP-2, and KC. In overall trends, however, the levels of these proinflammatory proteins were greater in MT (-/-) mice than in WT mice after LPS challenge. Our results suggest that MT protects against coagulatory and fibrinolytic disturbance and multiple organ damages induced by LPS, at least partly, via the inhibition of the expression of proinflammatory proteins.	Natl Inst Environm Studies, Environm Hlth Sci Div, Tsukuba, Ibaraki 3058506, Japan; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Kyoto, Japan; Tottori Univ, Fac Agr, Dept Vet Pathol, Tottori 680, Japan; Gifu Pharmaceut Univ, Dept Hyg, Gifu, Japan	National Institute for Environmental Studies - Japan; Kyoto Prefectural University of Medicine; Tottori University; Gifu Pharmaceutical University	Takano, H (corresponding author), Natl Inst Environm Studies, Environm Hlth Sci Div, 16-2 Onogawa, Tsukuba, Ibaraki 3058506, Japan.	htakano@nies.go.jp						Alonzi T, 1998, J EXP MED, V187, P461, DOI 10.1084/jem.187.4.461; Badamchian M, 2003, INT IMMUNOPHARMACOL, V3, P1225, DOI 10.1016/S1567-5769(03)00024-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHESTERMAN CN, 1988, BLOOD REV, V2, P88, DOI 10.1016/0268-960X(88)90029-X; Cuzzocrea S, 1999, J IMMUNOL, V163, P5094; De la Fuente M, 2001, FREE RADICAL RES, V35, P73, DOI 10.1080/10715760100300611; DE SK, 1990, J BIOL CHEM, V265, P15267; GANDO S, 1995, INTENS CARE MED, V21, P636, DOI 10.1007/BF01711540; Hambleton Julie, 2002, Hematology Am Soc Hematol Educ Program, P335; HARADA A, 1994, J LEUKOCYTE BIOL, V56, P559, DOI 10.1002/jlb.56.5.559; Heremans H, 2000, AM J RESP CRIT CARE, V161, P110, DOI 10.1164/ajrccm.161.1.9902089; Inoue K, 2004, THROMB HAEMOSTASIS, V91, P1194, DOI 10.1160/TH03-09-0595; Jirillo E, 2002, J ENDOTOXIN RES, V8, P319, DOI 10.1179/096805102125000641; Joyce DE, 2004, CRIT CARE MED, V32, pS280, DOI 10.1097/01.CCM.0000128037.72072.22; Karima R, 1999, MOL MED TODAY, V5, P123, DOI 10.1016/S1357-4310(98)01430-0; Kimura T, 2001, BIOCHEM BIOPH RES CO, V280, P358, DOI 10.1006/bbrc.2000.4085; Klaassen Curtis D., 1998, Journal of Toxicological Sciences, V23, P97; LAZO JS, 1995, ANNU REV PHARMACOL, V35, P635; Lip GYH, 1997, CARDIOVASC RES, V34, P255, DOI 10.1016/S0008-6363(97)00039-4; MICHALSKA AE, 1993, P NATL ACAD SCI USA, V90, P8088, DOI 10.1073/pnas.90.17.8088; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MIN KS, 1991, TOXICOL APPL PHARM, V111, P152, DOI 10.1016/0041-008X(91)90144-4; NABEL EG, 1991, AM J CARDIOL, V68, pC6; Nath R, 2000, TOXICOLOGY, V155, P17, DOI 10.1016/S0300-483X(00)00273-0; NISHIMURA H, 1990, J HISTOCHEM CYTOCHEM, V38, P927, DOI 10.1177/38.7.2355174; Penkowa M, 2003, GLIA, V42, P287, DOI 10.1002/glia.10208; Penkowa M, 2000, GLIA, V32, P247, DOI 10.1002/1098-1136(200012)32:3<247::AID-GLIA50>3.0.CO;2-T; PUTT FA, 1972, MANUAL HISTOPATHOLOG, P94; Reinhart K, 2002, CRIT CARE MED, V30, pS302, DOI 10.1097/00003246-200205001-00021; Rofe AM, 1996, BIOCHEM J, V314, P793, DOI 10.1042/bj3140793; SATO M, 1992, RES COMMUN CHEM PATH, V75, P159; SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T; Takano H, 2004, THORAX, V59, P1057, DOI 10.1136/thx.2004.024232; Takano H, 1997, AM J RESP CRIT CARE, V156, P36, DOI 10.1164/ajrccm.156.1.9610054; Takano H, 2002, AM J RESP CRIT CARE, V165, P1329, DOI 10.1164/rccm.2108122; Takano H, 2000, LAB INVEST, V80, P371, DOI 10.1038/labinvest.3780041; Tohyama C, 1981, Fundam Appl Toxicol, V1, P1; Waelput W, 2001, J EXP MED, V194, P1617, DOI 10.1084/jem.194.11.1617; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; Yamaguchi K, 2000, SHOCK, V14, P535, DOI 10.1097/00024382-200014050-00007; ZHANG ZX, 1995, J BIOL CHEM, V270, P24287, DOI 10.1074/jbc.270.41.24287	41	42	42	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2005	19	14					533	+		10.1096/fj.05-3864fje	http://dx.doi.org/10.1096/fj.05-3864fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16387980				2022-12-28	WOS:000234405500013
J	Yang, SC; Levine, H; Onuchic, JN; Cox, DL				Yang, SC; Levine, H; Onuchic, JN; Cox, DL			Structure of infectious prions: stabilization by domain swapping	FASEB JOURNAL			English	Article						prion; domain swapping; beta-helix; amyloid	MOLECULAR-DYNAMICS; PROTEIN; MECHANISM; SIMULATIONS; OLIGOMER; FIBERS; CORE	A candidate structure for the minimal prion infectious unit is a recently discovered protein oligomer modeled as a beta-helical prion trimer (BPT); BPTs can stack to form cross-beta fibrils and may provide insight into protein aggregates of other amyloid diseases. However, the BPT lacks a clear intermonomer binding mechanism. Here we propose an alternative domain-swapped trimeric prion (DSTP) model and show with molecular dynamics (MD) that the DSTP has more favorable intermonomer hydrogen bonding and proline dihedral strain energy than the BPT. This new structural proposal may be tested by lysine and N terminus fluorescent resonance energy transfer (FRET) either directly on recombinant prion protein amyloid aggregates or on synthetic constructs that contain the proline/lysine-rich hinge region critical for domains to swap. In addition, the domain swapping may provide 1) intrinsic entanglement, which can contribute to the remarkable temperature stability of the infectious prion structure and help explain the absence of PrPSc monomers, 2) insight into why specific prolines are potentially relevant to three inherited forms of prion disease, and 3) a simple explanation of prion strains assuming the strain is encoded in the monomer number of the oligomers.	Univ Calif San Diego, Ctr Theoret Biol Phys, La Jolla, CA 92093 USA; Univ Calif Davis, Dept Phys, Davis, CA 95616 USA	University of California System; University of California San Diego; University of California System; University of California Davis	Cox, DL (corresponding author), Univ Calif San Diego, Ctr Theoret Biol Phys, MC 0374,9500 Gilman Dr, La Jolla, CA 92093 USA.	cox@physics.ucdavis.edu	Levine, Herbert/C-1704-2008; Yang, Sichun/B-1608-2008	Levine, Herbert/0000-0002-8819-9055; Yang, Sichun/0000-0002-1726-0576				BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Bergdoll M, 1997, STRUCTURE, V5, P391, DOI 10.1016/S0969-2126(97)00196-2; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; Govaerts C, 2004, P NATL ACAD SCI USA, V101, P8342, DOI 10.1073/pnas.0402254101; Guo JT, 2004, PROTEINS, V57, P357, DOI 10.1002/prot.20222; Janowski R, 2001, NAT STRUCT BIOL, V8, P316, DOI 10.1038/86188; Kishimoto A, 2004, BIOCHEM BIOPH RES CO, V315, P739, DOI 10.1016/j.bbrc.2004.01.117; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; Lee S, 2003, NAT STRUCT BIOL, V10, P725, DOI 10.1038/nsb961; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Lindskog S, 1997, PHARMACOL THERAPEUT, V74, P1, DOI 10.1016/S0163-7258(96)00198-2; Liu YS, 2001, NAT STRUCT BIOL, V8, P211, DOI 10.1038/84941; Lysek DA, 2004, BIOCHEMISTRY-US, V43, P10393, DOI 10.1021/bi0494828; May BCH, 2004, TRENDS BIOCHEM SCI, V29, P162, DOI 10.1016/j.tibs.2004.02.008; Mobley DL, 2003, BIOPHYS J, V85, P2213, DOI 10.1016/S0006-3495(03)74647-5; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Prusiner SB, 2004, PRION BIOL DIS; Pye VE, 2004, J BIOL CHEM, V279, P40729, DOI 10.1074/jbc.M403751200; Rousseau F, 2003, STRUCTURE, V11, P243, DOI 10.1016/S0969-2126(03)00029-7; Rousseau F, 2001, P NATL ACAD SCI USA, V98, P5596, DOI 10.1073/pnas.101542098; Sinha N, 2001, PROTEIN ENG, V14, P93, DOI 10.1093/protein/14.2.93; Stork M, 2005, BIOPHYS J, V88, P2442, DOI 10.1529/biophysj.104.052415; Sugimoto T, 2003, CHEM ENG TECHNOL, V26, P313, DOI 10.1002/ceat.200390048; Welker E, 2002, J BIOL CHEM, V277, P33477, DOI 10.1074/jbc.M204273200; Wetzel R, 2002, STRUCTURE, V10, P1031, DOI 10.1016/S0969-2126(02)00809-2; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499; Yang SC, 2004, P NATL ACAD SCI USA, V101, P13786, DOI 10.1073/pnas.0403724101	28	36	36	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					1778	1782		10.1096/fj.05-4067hyp	http://dx.doi.org/10.1096/fj.05-4067hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16260647				2022-12-28	WOS:000234053100029
J	Paruch, S; El-Benna, J; Djerdjouri, B; Marullo, S; Perianin, A				Paruch, S; El-Benna, J; Djerdjouri, B; Marullo, S; Perianin, A			A role of p44/42 mitogen-activated protein kinases in formyl-peptide receptor-mediated phospholipase D activity and oxidant production	FASEB JOURNAL			English	Article						MAP kinases; phosphorylation; chemoattractant; superoxide	NEUTROPHIL RESPIRATORY BURST; STIMULATED HUMAN NEUTROPHILS; PHOSPHATIDIC-ACID PRODUCTION; PHORBOL-MYRISTATE ACETATE; SMOOTH-MUSCLE-CELLS; MET-LEU-PHE; MAP KINASE; NADPH OXIDASE; COMPONENT P47(PHOX); NEURITE OUTGROWTH	Phosphatidylcholine-specific phospholipase D (PLD) is a major cellular source of phosphatidic acid and choline, which regulate various physiopathological processes. PLD activation mediated by chemoattractants involves protein phosphorylation. This study provides pharmacological and biochemical evidence of a major role of p44/42 MAP kinases (ERK1/2) in PLD activation induced by the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine ( fMLP). ERK1/ 2 inhibition by the MEK1/2 antagonist U0126 in neutrophilic HL-60 cells or HEK 293T cells stably expressing fMLP receptors abolished fMLP-mediated PLD activity. Conversely, a constitutively activated MEK1 mutant expressed in HEK 293T cells potentiated fMLP-induced PLD activity. Expression of inactive PLD mutants showed that PLD2, but not PLD1, contributed to fMLP-mediated PLD activity. PLD2 co-immunoprecipitated with ERK1/ 2 and became phosphorylated on MAP kinase consensus sites in fMLP-stimulated cells. In cell-free systems, ERK2 gave rise to strong ATP-dependent PLD activity and directly phosphorylated PLD2 that generated two phosphopeptides only after tryptic digestion. Finally, pharmacological inhibition of ERK activation and the inhibition of PLD expression by antisense oligonucleotides in HL-60 cells suggest that the ERK/PLD2 pathway contributes to fMLP-mediated oxidant production. In conclusion, the fMLP-mediated PLD activity is regulated by ERK1/ 2, involving a predominant contribution of PLD2. The ERK/PLD2 coupling may provide potential pharmacological targets to control PLD-associated cellular dysfunctions.	CNRS, UMR 8104, Dept Biol Cellulaire, Inst Cochin,INSERM U567, F-75018 Paris, France; Univ Paris 05, F-75018 Paris, France; INSERM U683, F-75018 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Perianin, A (corresponding author), Hop Cochin, Dept Biol Cellulaire, Pavillon G Roussy 5eme Etage,27,Rue Faubourt St J, F-75014 Paris, France.	perianin@cochin.inserm.fr	Djerdjouri, Bahia/I-2533-2019; Marullo, Stefano/C-6142-2008	Marullo, Stefano/0000-0001-9604-9973				BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; Bechoua S, 2001, J BIOL CHEM, V276, P31752, DOI 10.1074/jbc.M101265200; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRUNET A, 1994, ONCOGENE, V9, P3379; Chen JS, 2004, J BIOL CHEM, V279, P22076, DOI 10.1074/jbc.M311033200; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Dang PMC, 2001, J IMMUNOL, V166, P1206, DOI 10.4049/jimmunol.166.2.1206; DANG PMC, 1995, BIOCHEM BIOPH RES CO, V212, P664, DOI 10.1006/bbrc.1995.2020; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; Djerdjouri B, 1999, BIOCHEM BIOPH RES CO, V264, P371, DOI 10.1006/bbrc.1999.1533; Downey GP, 1998, J IMMUNOL, V160, P434; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; El Marjou M, 2000, LEUKEMIA, V14, P2118; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ElBenna J, 1996, ARCH BIOCHEM BIOPHYS, V334, P395; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Gutkind J. S., 2000, SCI STKE, pre1, DOI DOI 10.1126/STKE.2000.40.RE1; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Kiss Z, 1996, CHEM PHYS LIPIDS, V80, P81, DOI 10.1016/0009-3084(96)02547-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li F, 2005, J PHARMACOL EXP THER, V312, P1043, DOI 10.1124/jpet.104.076588; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; LU DJ, 1993, BLOOD CELLS, V19, P343; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Melendez AJ, 2001, CURR BIOL, V11, P869, DOI 10.1016/S0960-9822(01)00260-3; Muthalif MM, 2000, J PHARMACOL EXP THER, V293, P268; Nakashima S, 1998, BBA-LIPID LIPID MET, V1389, P173, DOI 10.1016/S0005-2760(97)00153-7; Natarajan V, 2001, AM J PHYSIOL-LUNG C, V281, pL435, DOI 10.1152/ajplung.2001.281.2.L435; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLSON SC, 1991, J BIOL CHEM, V266, P17236; Olson SC, 1996, CHEM PHYS LIPIDS, V80, P3, DOI 10.1016/0009-3084(96)02541-8; PAI JK, 1988, J BIOL CHEM, V263, P12472; Palicz A, 2001, J BIOL CHEM, V276, P3090, DOI 10.1074/jbc.M007759200; Pedruzzi E, 1998, CELL SIGNAL, V10, P481, DOI 10.1016/S0898-6568(97)00174-5; PERIANIN A, 1994, FEBS LETT, V342, P135, DOI 10.1016/0014-5793(94)80487-7; Rais S, 1998, CELL SIGNAL, V10, P121, DOI 10.1016/S0898-6568(97)00116-2; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Watanabe H, 2004, J BIOL CHEM, V279, P37870, DOI 10.1074/jbc.M402610200; Watanabe H, 2004, J NEUROCHEM, V89, P142, DOI 10.1111/j.1471-4159.2004.02308.x; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Zhu T, 2002, J BIOL CHEM, V277, P45592, DOI 10.1074/jbc.M201385200	51	24	25	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					142	+		10.1096/fj.05-3881fje	http://dx.doi.org/10.1096/fj.05-3881fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16253958				2022-12-28	WOS:000232991100005
J	Astrakas, LG; Goljer, I; Yasuhara, S; Padfield, KE; Zhang, QH; Gopalan, S; Mindrinos, MN; Dai, G; Yu, YM; Martyn, JAJ; Tompkins, RG; Rahme, LG; Tzika, AA				Astrakas, LG; Goljer, I; Yasuhara, S; Padfield, KE; Zhang, QH; Gopalan, S; Mindrinos, MN; Dai, G; Yu, YM; Martyn, JAJ; Tompkins, RG; Rahme, LG; Tzika, AA			Proton NMR spectroscopy shows lipids accumulate in skeletal muscle in response to burn trauma-induced apoptosis	FASEB JOURNAL			English	Article						magnetic resonance spectroscopy; high-resolution magic angle spinning skeletal muscle; burn trauma; mitochondria; intramyocellular lipids	CONTROLLING MITOCHONDRIAL BIOGENESIS; MAGNETIC-RESONANCE-SPECTROSCOPY; IN-VIVO; INSULIN-RESISTANCE; CELL-DEATH; PROTEIN-TURNOVER; THERMAL-INJURY; BRAIN-TUMORS; GENE-THERAPY; EX-VIVO	Burn trauma triggers hypermetabolism and muscle wasting via increased cellular protein degradation and apoptosis. Proton nuclear magnetic resonance (H-1 NMR) spectroscopy can detect mobile lipids in vivo. To examine the local effects of burn in skeletal muscle, we performed in vivo H-1 NMR on mice 3 days after burn trauma; and ex vivo, high-resolution, magic angle spinning H-1 NMR on intact excised mouse muscle samples before and 1 and 3 days after burn. These samples were then analyzed for apoptotic nuclei using a terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay. To confirm our NMR and cell biology results, we used transcriptome analysis to demonstrate that burn trauma alters the expression of genes involved in lipid metabolism and apoptosis. Our results demonstrate that burn injury results in a localized intramyocellular lipid accumulation, which in turn is accompanied by burn-induced apoptosis and mitochondrial dysfunction, as seen by the up-regulation of apoptotic genes and down-regulation of genes that encode lipid oxidation and the peroxisomal proliferator activator receptor gamma coactivator PGC-1 beta. Moreover, the increased levels of bisallylic methylene fatty acyl protons (2.8 ppm) and vinyl protons (5.4 ppm), in conjunction with the TUNEL assay results, further suggest that burn trauma results in apoptosis. Together, our results provide new insight into the local physiological changes that occur in skeletal muscle after severe burn trauma.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Shriners Burns Inst,Dept Surg,NMR Surg Lab, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA; Varian NMR Syst, Columbia, MD USA; Massachusetts Gen Hosp, Shriners Burns Inst, Dept Anesthesiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Shriners Burns Inst, Dept Crit Care, Boston, MA 02114 USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Stanford University	Tzika, AA (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Shriners Burns Inst,Dept Surg,NMR Surg Lab, 51 Blossom St,Room 261, Boston, MA 02114 USA.	atzika@partners.org	Astrakas, Loukas G/F-5918-2011	Astrakas, Loukas G/0000-0002-4890-4805	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055082, P50GM021700] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM055082, U54GM062119, P50GM021700] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; ASTRAKAS LG, 2003, INT SOC MAGNETIC RES, V11, P1317; Blankenberg FG, 1997, BLOOD, V89, P3778, DOI 10.1182/blood.V89.10.3778.3778_3778_3786; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; Boesch C, 1997, MAGN RESON MED, V37, P484, DOI 10.1002/mrm.1910370403; Bollard ME, 2000, MAGNET RESON MED, V44, P201, DOI 10.1002/1522-2594(200008)44:2<201::AID-MRM6>3.0.CO;2-5; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; COHEN SM, 1979, P NATL ACAD SCI USA, V76, P1603, DOI 10.1073/pnas.76.4.1603; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; FRAHM J, 1989, MAGNET RESON MED, V9, P79, DOI 10.1002/mrm.1910090110; GALSTER AD, 1984, J TRAUMA, V24, P938, DOI 10.1097/00005373-198411000-00003; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GELFAND JA, 1983, ANN SURG, V198, P58, DOI 10.1097/00000658-198307000-00011; Griffin JL, 2003, CANCER RES, V63, P3195; Griffin JL, 2001, MAGNET RESON MED, V46, P249, DOI 10.1002/mrm.1185; Hakumaki JM, 1999, NAT MED, V5, P1323, DOI 10.1038/15279; Hakumaki JM, 2000, TRENDS BIOCHEM SCI, V25, P357, DOI 10.1016/S0968-0004(00)01614-5; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Hasselgren PO, 2000, WORLD J SURG, V24, P1452, DOI 10.1007/s002680010262; HAVEL RJ, 1964, J APPL PHYSIOL, V19, P613, DOI 10.1152/jappl.1964.19.4.613; HELM PA, 1985, ARCH PHYS MED REHAB, V66, P451; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Idriss HT, 2000, MICROSC RES TECHNIQ, V50, P184, DOI 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H; Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Ikezu T, 1997, J BIOL CHEM, V272, P25289, DOI 10.1074/jbc.272.40.25289; Jenkins GM, 2003, CELL MOL LIFE SCI, V60, P701, DOI 10.1007/s00018-003-2239-0; JOHNSON AB, 1992, CLIN SCI, V82, P219, DOI 10.1042/cs0820219; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; KAUPPINEN RA, 1992, J NEUROCHEM, V58, P967, DOI 10.1111/j.1471-4159.1992.tb09350.x; KAUPPINEN RA, 1992, MAGNET RESON MED, V25, P398, DOI 10.1002/mrm.1910250221; KAYAR SR, 1986, EUR J APPL PHYSIOL O, V54, P578, DOI 10.1007/BF00943344; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; KIM MY, 1991, J BIOL CHEM, V266, P484; Krssak M, 1999, DIABETOLOGIA, V42, P113, DOI 10.1007/s001250051123; Lee K, 2000, METAB ENG, V2, P312, DOI 10.1006/mben.2000.0160; Liu GL, 1999, CRIT REV CL LAB SCI, V36, P511, DOI 10.1080/10408369991239240; Lombardi V, 1997, CELL MOL NEUROBIOL, V17, P521, DOI 10.1023/A:1026362922549; MEIBOOM S, 1958, REV SCI INSTRUM, V29, P688, DOI 10.1063/1.1716296; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morvan D, 2002, CANCER RES, V62, P1890; MULLER MJ, 1994, LANCET, V343, P216, DOI 10.1016/S0140-6736(94)90995-4; Negendank W, 1996, ANTICANCER RES, V16, P1533; ODESSEY R, 1982, METABOLISM, V31, P82, DOI 10.1016/0026-0495(82)90049-X; Padfield KE, 2005, P NATL ACAD SCI USA, V102, P5368, DOI 10.1073/pnas.0501211102; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Perseghin G, 1999, DIABETES, V48, P1600, DOI 10.2337/diabetes.48.8.1600; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; Pratt VC, 2001, LIPIDS, V36, P675, DOI 10.1007/s11745-001-0772-y; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Sauer U, 1999, J BACTERIOL, V181, P6679, DOI 10.1128/JB.181.21.6679-6688.1999; Scarpulla RC, 2002, BBA-GENE STRUCT EXPR, V1576, P1, DOI 10.1016/S0167-4781(02)00343-3; SHANGRAW RE, 1982, J SURG RES, V33, P345, DOI 10.1016/0022-4804(82)90048-8; St-Pierre DMM, 1998, ARCH PHYS MED REHAB, V79, P155, DOI 10.1016/S0003-9993(98)90292-1; St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200; Szczepaniak LS, 1999, AM J PHYSIOL-ENDOC M, V276, pE977, DOI 10.1152/ajpendo.1999.276.5.E977; Tawa NE, 1997, J CLIN INVEST, V100, P197, DOI 10.1172/JCI119513; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TOMERA JF, 1988, BURNS, V14, P210, DOI 10.1016/0305-4179(88)90040-X; TREDGET EE, 1992, WORLD J SURG, V16, P68, DOI 10.1007/BF02067117; Tzika AA, 2002, J NEUROSURG, V96, P1023, DOI 10.3171/jns.2002.96.6.1023; Uchida Y, 2003, J INVEST DERMATOL, V120, P662, DOI 10.1046/j.1523-1747.2003.12098.x; Veale MF, 1997, BIOCHEM BIOPH RES CO, V239, P868, DOI 10.1006/bbrc.1997.7566; Vermathen P, 2004, MAGNET RESON MED, V51, P253, DOI 10.1002/mrm.10721; Vit JP, 2003, ONCOGENE, V22, P8645, DOI 10.1038/sj.onc.1207087; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; Wiechert W, 2001, METAB ENG, V3, P195, DOI 10.1006/mben.2001.0187; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yasuhara S, 2000, AM J PHYSIOL-ENDOC M, V279, pE1114, DOI 10.1152/ajpendo.2000.279.5.E1114; Yu YM, 1999, JPEN-PARENTER ENTER, V23, P160, DOI 10.1177/0148607199023003160	73	27	30	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1431	1440		10.1096/fj.04-2005com	http://dx.doi.org/10.1096/fj.04-2005com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16126910				2022-12-28	WOS:000232315700036
J	Bar-Am, O; Weinreb, O; Amit, T; Youdim, MBH				Bar-Am, O; Weinreb, O; Amit, T; Youdim, MBH			Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine	FASEB JOURNAL			English	Article						amyloid precursor protein; brain-derived neurotrophic factor; poly-ADP ribose polymerase	AMYLOID PRECURSOR PROTEIN; ANTI-PARKINSON DRUG; CEREBELLAR GRANULE NEURONS; MAO-B INHIBITOR; MESSENGER-RNA; ALZHEIMERS-DISEASE; KINASE-C; RESPONSIVE ELEMENT; OXIDATIVE STRESS; GENE-EXPRESSION	The anti-Parkinson drug, rasagiline (N-propargyl-(1R)-aminoindan) promotes neuronal survival, via neuroprotective activity related to its propargyl moiety (propargylamine). We have investigated the neurorescue effects of propargylamine, in a progressive neuronal death model, induced by long-term serum deprivation in human SH-SY5Y neuroblastoma cells. Propargylamine (0.1-10 mu M) dose-dependently reduced the levels of the early apoptosis-associated phosphorylated protein, H2A-X (ser 139), as well as decreased the cleavage of caspase-3 and its substrate poly-ADP ribose polymerase (PARP). In addition, the compound markedly reversed the apoptotic effects induced by long-term serum withdrawal, including down-regulation of the antiapoptotic protein, Bcl-2, as well as up-regulation of the proapoptotic proteins, Bax, Bad, and Bim. Real-time RT-PCR demonstrated that propargylamine elevated gene expression levels of Bcl-2, and the neurotrophic factors glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) and reduced Bax gene expression. Serum deprivation increased mRNA and protein levels of holo-amyloid precursor protein (APP), which was markedly decreased by propargylamine. This was accompanied by inducing the release of the nonamyloidogenic alpha-secretase form of soluble APP (sAPP alpha) into the medium. Similar effects on cell survival and APP regulation/processing were demonstrated for rasagiline. These results indicate that both rasagiline and propargylamine possess neurorescue activity, associated with regulation of Bcl-2 family proteins, neurotrophic factors, and APP metabolism.	Technion Israel Inst Technol, Fac Med, Rappaport Family Res Inst, Dept Pharmacol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Eve Topf & USA Natl Parkinson Fdn Ctr Excellence, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Youdim, MBH (corresponding author), Technion Israel Inst Technol, Fac Med, Rappaport Family Res Inst, Dept Pharmacol, POB 9697, IL-31096 Haifa, Israel.	Youdim@tx.technion.ac.il						ABE K, 1991, NEUROSCI LETT, V125, P169, DOI 10.1016/0304-3940(91)90019-P; Akao Y, 2002, J NEUROCHEM, V82, P913, DOI 10.1046/j.1471-4159.2002.01047.x; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Andoh T, 2000, FASEB J, V14, P2144; Atabay C, 1996, J NEUROSCI RES, V43, P465; Atwood CS, 2003, BRAIN RES REV, V43, P1, DOI 10.1016/S0165-0173(03)00174-7; Ba F, 2003, J NEUROSCI METH, V123, P11, DOI 10.1016/S0165-0270(02)00324-2; Bar-Am O, 2004, J NEUROCHEM, V89, P1119, DOI 10.1111/j.1471-4159.2004.02425.x; Belzacq AS, 2003, CURR DRUG TARGETS, V4, P517, DOI 10.2174/1389450033490867; Belzacq AS, 2003, CANCER RES, V63, P541; Berry MD, 2003, PROG NEURO-PSYCHOPH, V27, P197, DOI 10.1016/S0278-5846(03)00015-0; Blandini F, 2004, EXP NEUROL, V187, P455, DOI 10.1016/j.expneurol.2004.03.005; Bonneh-Barkay D, 2005, NEUROPHARMACOLOGY, V48, P406, DOI 10.1016/j.neuropharm.2004.10.016; Charriaut-Marlangue C, 2004, THERAPIE, V59, P185, DOI 10.2515/therapie:2004035; CORDELL B, 1994, ANNU REV PHARMACOL, V34, P69; Cummings BJ, 1996, NEUROBIOL AGING, V17, P921, DOI 10.1016/S0197-4580(96)00170-4; Double KL, 2003, EXP NEUROL, V184, P530, DOI 10.1016/j.expneurol.2003.08.006; Finberg JPM, 1998, NEUROREPORT, V9, P703; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; HALL ED, 1995, EXP NEUROL, V135, P17, DOI 10.1006/exnr.1995.1062; Hoyer A, 2005, J NEURAL TRANSM, V112, P239, DOI 10.1007/s00702-004-0176-1; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; JENDROSKA K, 1995, ACTA NEUROPATHOL, V90, P461, DOI 10.1007/bf00294806; Lemere CA, 1996, NEUROBIOL DIS, V3, P16, DOI 10.1006/nbdi.1996.0003; Lin L, 1998, NEUROREPORT, V9, P547, DOI 10.1097/00001756-199802160-00030; Mandel S, 2005, BRAIN RES REV, V48, P379, DOI 10.1016/j.brainresrev.2004.12.027; Maruyama W, 2004, NEUROCHEM INT, V44, P393, DOI 10.1016/j.neuint.2003.08.005; Maruyama W, 2002, J NEURAL TRANSM, V109, P467, DOI 10.1007/s007020200038; Maruyama W, 2001, ANN NY ACAD SCI, V939, P320; Maruyama W, 2000, ADV RES NEURODEGENER, V8, P171; MARUYAMA W, 2005, IN PRESS J NEURAL TR; MARUYAMA W, 2000, ANN NY ACAD SCI, V939, P320; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; Murer MG, 2001, PROG NEUROBIOL, V63, P71, DOI 10.1016/S0301-0082(00)00014-9; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Ravina BM, 2003, NEUROLOGY, V60, P1234, DOI 10.1212/01.WNL.0000058760.13152.1A; Rogers JT, 2002, J BIOL CHEM, V277, P45518, DOI 10.1074/jbc.M207435200; Russo VC, 2004, ENDOCRINOLOGY, V145, P4103, DOI 10.1210/en.2003-1767; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; SAGI Y, 2001, NEURAL PLAST, V8, P197; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Shaw KTY, 2001, P NATL ACAD SCI USA, V98, P7605, DOI 10.1073/pnas.131152998; Shi J, 2000, NEUROBIOL AGING, V21, P357, DOI 10.1016/S0197-4580(00)00119-6; Shi J, 1998, BRAIN RES, V810, P87, DOI 10.1016/S0006-8993(98)00888-9; Shi J, 1997, BRAIN RES, V772, P247, DOI 10.1016/S0006-8993(97)00827-5; Shoji M, 2000, PSYCHIAT CLIN NEUROS, V54, P45, DOI 10.1046/j.1440-1819.2000.00636.x; Siderowf A, 2004, ARCH NEUROL-CHICAGO, V61, P561; Silva EFDE, 2003, NEUROCHEM RES, V28, P1553, DOI 10.1023/A:1025630627319; SIMONS M, 1995, FEBS LETT, V368, P363, DOI 10.1016/0014-5793(95)00654-R; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; Speiser Z, 1999, J NEURAL TRANSM, V106, P593, DOI 10.1007/s007020050182; Sudoh S, 1996, MOL BRAIN RES, V39, P12, DOI 10.1016/0169-328X(95)00348-V; Suleiman MS, 2001, PHARMACOL THERAPEUT, V89, P29, DOI 10.1016/S0163-7258(00)00102-9; Tabakman R, 2004, BIOESSAYS, V26, P80, DOI 10.1002/bies.10378; Tatton WG, 2002, J PHARMACOL EXP THER, V301, P753, DOI 10.1124/jpet.301.2.753; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Turner PR, 2003, PROG NEUROBIOL, V70, P1, DOI 10.1016/S0301-0082(03)00089-3; Wang L, 2002, GENE THER, V9, P381, DOI 10.1038/sj.gt.3301682; Weiner HL, 2002, NATURE, V420, P879, DOI 10.1038/nature01325; Weinreb O, 2004, FASEB J, V18, P1471, DOI 10.1096/fj.04-1916fje; Weinreb O, 2003, FASEB J, V17, P935, DOI 10.1096/fj.02-0712fje; Weinstock M, 2000, DRUG DEVELOP RES, V50, P216, DOI 10.1002/1098-2299(200007/08)50:3/4<216::AID-DDR4>3.3.CO;2-Q; Westerman MA, 2002, J NEUROSCI, V22, P1858, DOI 10.1523/JNEUROSCI.22-05-01858.2002; Yogev-Falach M, 2003, FASEB J, V17, P2325, DOI 10.1096/fj.03-0078fje; Yogev-Falach M, 2002, FASEB J, V16, P1674, DOI 10.1096/fj.02-0198fje; Yokota M, 1996, J CEREBR BLOOD F MET, V16, P1219, DOI 10.1097/00004647-199611000-00016; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0; Youdim MBH, 2005, J NEUROSCI RES, V79, P172, DOI 10.1002/jnr.20350; Youdim MBH, 2005, TRENDS PHARMACOL SCI, V26, P27, DOI 10.1016/j.tips.2004.11.007; Youdim MBH, 2001, ANN NY ACAD SCI, V939, P450; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LL, 2000, J NEUROSCI RES, V59, P489, DOI 10.1002/(SICI)1097-4547(20000215)59:4<489::AID-JNR3>3.0.CO;2-9	77	140	157	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1899	+		10.1096/fj.05-3794fje	http://dx.doi.org/10.1096/fj.05-3794fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16148027				2022-12-28	WOS:000232315700027
J	Castello, L; Froio, T; Cavallini, G; Biasi, F; Sapino, A; Leonarduzzi, G; Bergamini, E; Poli, G; Chiarpotto, E				Castello, L; Froio, T; Cavallini, G; Biasi, F; Sapino, A; Leonarduzzi, G; Bergamini, E; Poli, G; Chiarpotto, E			Calorie restriction protects against age-related rat aorta sclerosis	FASEB JOURNAL			English	Article						TGF beta 1; ageing; MAPK; oxidative stress; aortic fibrosclerosis	FREE-RADICAL THEORY; GROWTH-FACTOR-BETA; TGF-BETA; AUTOPHAGIC PROTEOLYSIS; DIETARY RESTRICTION; LIPID-PEROXIDATION; OXIDATIVE DAMAGE; PROMOTER-REGION; GENE-EXPRESSION; END-PRODUCT	Many theories have been advanced to account for the ageing process, among which the free radical theory deserves much attention. Numerous studies have also shown an association between tissue fibrosis and oxidative stress. Of note, fibrosis may be considered a significant index of tissue ageing. Calorie restriction (CR) has been demonstrated to maintain many physiological processes in a youthful state until a very advanced age. However the anti-ageing mechanisms of CR are still not fully understood. We thus evaluated the effect of CR on oxidative damage and its relationship with fibrosis during ageing. We found a significant increase of both oxidative stress and fibrosis parameters in the aortae from aged vs. young rats. CR reversed both phenomena. CR also protected against the age-associated increase of Jun-N-terminal kinase and p-38 activities, involved in TGF beta 1 expression and signaling. On the contrary, extracellular regulated kinases did not show any age-related change. CR similarly reversed the age-related increase of AP-1 DNA binding activity and the AP-1-dependent increase of vimentin gene expression. In parallel, CR reversed the age-related morphological alterations of the aorta wall cell composition. These data further support the relationship between oxidative stress and fibrosis in different diseases and during ageing. The protection exerted by CR against fibrosclerosis might be due to a decrease of oxidative stress, with consequent decreased MAPK activity and down-regulation of AP-1 activation and of TGF beta 1 expression and signaling.	Univ Turin, Dept Clin & Biol Sci, I-10043 Turin, Italy; Univ Pisa, Interdepartmental Res Ctr Biol & Pathol Ageing, I-56100 Pisa, Italy; Italian Natl Res Council, Turin, Italy; Univ Turin, Dept Biomed Sci & Human Oncol, I-10124 Turin, Italy	University of Turin; University of Pisa; Consiglio Nazionale delle Ricerche (CNR); University of Turin	Chiarpotto, E (corresponding author), Univ Turin, Dept Clin & Biol Sci, Reg Gonzole 10, I-10043 Turin, Italy.	elena.chiarpotto@unito.it	Leonarduzzi, Gabriella/AAA-6575-2019; Sapino, Anna/AGY-9901-2022; Sapino, Anna/J-4113-2018	Sapino, Anna/0000-0003-3542-9571; Sapino, Anna/0000-0003-3542-9571; LEONARDUZZI, Gabriella Marisa/0000-0002-3422-821X				Abrass CK, 2000, ADV RENAL REPLACE TH, V7, P4, DOI 10.1016/S1073-4449(00)70001-X; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286-4579(99)00250-6; Burt DJ, 2003, DIABETOLOGIA, V46, P531, DOI 10.1007/s00125-003-1075-y; Camandola S, 1997, BIOFACTORS, V6, P173, DOI 10.1002/biof.5520060211; Cavallini G, 2001, EXP GERONTOL, V36, P497, DOI 10.1016/S0531-5565(00)00224-2; Cefalu WT, 1999, TOXICOL SCI, V52, P49, DOI 10.1093/toxsci/52.suppl_1.49; CHIARPOTTO E, 1995, BIOCHEM BIOPH RES CO, V207, P477, DOI 10.1006/bbrc.1995.1213; de Souza RR, 2002, BIOGERONTOLOGY, V3, P325, DOI 10.1023/A:1021312027486; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Donati A, 2001, J GERONTOL A-BIOL, V56, pB375, DOI 10.1093/gerona/56.9.B375; Duffy PH, 2001, AGING-CLIN EXP RES, V13, P263; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Fornieri C, 1999, CONNECT TISSUE RES, V40, P131, DOI 10.3109/03008209909029109; Fulle S, 2004, EXP GERONTOL, V39, P17, DOI 10.1016/j.exger.2003.09.012; Gredilla R, 2001, FASEB J, V15, P1589, DOI 10.1096/fj.00-0764fje; Harman D, 2003, ANTIOXID REDOX SIGN, V5, P557, DOI 10.1089/152308603770310202; Heilbronn LK, 2003, AM J CLIN NUTR, V78, P361, DOI 10.1093/ajcn/78.3.361; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Hutter D, 2000, J GERONTOL A-BIOL, V55, pB125, DOI 10.1093/gerona/55.3.B125; Ikeyama S, 2002, FASEB J, V16, pA1163, DOI 10.1096/fj.01-0409fje; JUNQUEIRA LCU, 1979, HISTOCHEM J, V11, P447, DOI 10.1007/BF01002772; Kim HJ, 2002, MECH AGEING DEV, V123, P1589, DOI 10.1016/S0047-6374(02)00094-5; Kim JW, 2004, J GERONTOL A-BIOL, V59, P876; KIM SJ, 1989, J BIOL CHEM, V264, P402; Knapowski J, 2002, J PHYSIOL PHARMACOL, V53, P135; Kumagai T, 2000, BIOCHEM BIOPH RES CO, V273, P437, DOI 10.1006/bbrc.2000.2967; Lane MA, 1998, J ANTI-AGING MED, V1, P315, DOI DOI 10.1089/rej.1.1998.1.315; Lee J, 1999, FREE RADICAL BIO MED, V26, P260, DOI 10.1016/S0891-5849(98)00195-6; Leonarduzzi G, 1997, FASEB J, V11, P851, DOI 10.1096/fasebj.11.11.9285483; Li ZH, 1997, EXP MOL PATHOL, V64, P1, DOI 10.1006/exmp.1997.2204; Li ZH, 1999, HYPERTENSION, V33, P116, DOI 10.1161/01.HYP.33.1.116; Massague J, 2000, GENE DEV, V14, P627; Mattison JA, 2003, EXP GERONTOL, V38, P35, DOI 10.1016/S0531-5565(02)00146-8; Merry BJ, 2002, INT J BIOCHEM CELL B, V34, P1340, DOI 10.1016/S1357-2725(02)00038-9; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Nitti M, 2002, BIOCHEM BIOPH RES CO, V294, P547, DOI 10.1016/S0006-291X(02)00512-0; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; Parola M, 1996, BIOCHEM BIOPH RES CO, V222, P261, DOI 10.1006/bbrc.1996.0732; Parola M, 1998, J CLIN INVEST, V102, P1942, DOI 10.1172/JCI1413; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Poli G, 1997, FREE RADICAL BIO MED, V22, P287, DOI 10.1016/S0891-5849(96)00327-9; POLI G, 2003, SIGNAL TRANSDUCTION, P180; Poli Giuseppe, 2000, Molecular Aspects of Medicine, V21, P49, DOI 10.1016/S0098-2997(00)00004-2; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raju J, 2003, CANCER RES, V63, P6595; Reddy GK, 1996, CLIN BIOCHEM, V29, P225, DOI 10.1016/0009-9120(96)00003-6; RITTLING SR, 1989, NUCLEIC ACIDS RES, V17, P1619, DOI 10.1093/nar/17.4.1619; Sohal RS, 2002, FREE RADICAL BIO MED, V33, P575, DOI 10.1016/S0891-5849(02)00886-9; Torrens C, 2003, J PHYSIOL-LONDON, V547, P77, DOI 10.1113/jphysiol.2002.026120; UCHIDA K, 1994, METHOD ENZYMOL, V233, P371; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang DS, 2003, BIOCHEM BIOPH RES CO, V310, P236, DOI 10.1016/j.bbrc.2003.09.003; Weigert C, 2000, J AM SOC NEPHROL, V11, P2007, DOI 10.1681/ASN.V11112007; Weindruch R., 1988, RETARDATION AGING DI; Wu YZ, 2003, ONCOGENE, V22, P8891, DOI 10.1038/sj.onc.1206898; Yu BP, 2002, J NUTR SCI VITAMINOL, V48, P257, DOI 10.3177/jnsv.48.257; Zanetti M, 2004, ATHEROSCLEROSIS, V175, P253, DOI 10.1016/j.atherosclerosis.2004.05.001	59	46	47	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1863	+		10.1096/fj.04-2864fje	http://dx.doi.org/10.1096/fj.04-2864fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16150801				2022-12-28	WOS:000232315700023
J	Blumenthal, SB; Kiemer, AK; Tiegs, G; Seyfried, S; Holtje, M; Brandt, B; Holtje, HD; Zahler, S; Vollmar, AM				Blumenthal, SB; Kiemer, AK; Tiegs, G; Seyfried, S; Holtje, M; Brandt, B; Holtje, HD; Zahler, S; Vollmar, AM			Metalloporphyrins inactivate caspase-3 and-8	FASEB JOURNAL			English	Article						porphyrin ring; HO-1 expression; heme-iron	HEME OXYGENASE-1; NITRIC-OXIDE; ZINC-PROTOPORPHYRIN; CELL-DEATH; APOPTOSIS; INHIBITION; INDUCTION; MACROPHAGES; EXPRESSION; REDUCTION	Activation of caspases represents one of the earliest biochemical indicators for apoptotic cell death. Therefore, measurement of caspase activity is a widely used and generally accepted method to determine apoptosis in a wide range of in vivo and in vitro settings. Numerous publications characterize the role of the heme-catabolizing enzyme heme oxygenase-1 (HO-1) in regulating apoptotic processes. Different metalloporphyrins representing inducers and inhibitors of this enzyme are often used, followed by assessment of apoptotic cell death. In the present work, we found that caspase-3-like activity, as well as activity of caspase-8 measured in either Fas (CD95) ligand-treated Jurkat T-lymphocytes or by the use of recombinant caspase-3 or -8, was inhibited by different metalloporphyrins (cobalt(III) protoporphyrin IX, tin and zinc(II) protoporphyrin- IX). Moreover, employing the mouse model of Fas-induced liver apoptosis these properties of porphyrins could also be demonstrated in vivo. The metalloporphyrins were shown to inhibit caspase-3-mediated PARP cleavage. Molecular modeling studies demonstrated that porphyrins can occupy the active site of caspase-3 in an energetically favorable manner and in a binding mode similar to that of known inhibitors. The data shown here introduce metalloporphyrins as direct inhibitors of caspase activity. This finding points to the need for careful employment of metalloporphyrins as modulators of HO.	Univ Munich, Dept Pharm, Ctr Drug Res, D-81377 Munich, Germany; Univ Saarland, Inst Pharmaceut Biol, D-6600 Saarbrucken, Germany; Univ Erlangen Nurnberg, Dept Expt & Clin Pharmacol & Toxicol, D-8520 Erlangen, Germany; Univ Dusseldorf, Inst Pharmaceut Chem, D-4000 Dusseldorf, Germany	University of Munich; Saarland University; University of Erlangen Nuremberg; Heinrich Heine University Dusseldorf	Vollmar, AM (corresponding author), Univ Munich, Dept Pharm, Ctr Drug Res, Butenandtstr 5-13, D-81377 Munich, Germany.	Angelika.Vollmar@cup.uni-muenchen.de	Kiemer, Alexandra K./I-9300-2012	Kiemer, Alexandra K./0000-0002-7224-9900				Akamatsu Y, 2004, FASEB J, V18, P771, DOI 10.1096/fj.03-0921fje; BONNETT R, 2003, COMPR COORDINATION C, V2; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Denault JB, 2002, CHEM REV, V102, P4489, DOI 10.1021/cr010183n; Dirsch VM, 2003, CANCER RES, V63, P8869; Dorman Robert B, 2004, Comp Hepatol, V3 Suppl 1, pS42, DOI 10.1186/1476-5926-2-S1-S42; Erlanson DA, 2003, NAT BIOTECHNOL, V21, P308, DOI 10.1038/nbt786; Fauconneau B, 2002, J NEUROCHEM, V83, P1338, DOI 10.1046/j.1471-4159.2002.01230.x; Gurtu V, 1997, ANAL BIOCHEM, V251, P98, DOI 10.1006/abio.1997.2220; Ito K, 2000, HEPATOLOGY, V31, P416, DOI 10.1002/hep.510310222; Jozkowicz A, 2003, ACTA BIOCHIM POL, V50, P69, DOI 10.18388/abp.2003_3715; Kampfer H, 2001, MOL MED, V7, P488, DOI 10.1007/BF03401854; Kiemer AK, 1998, J BIOL CHEM, V273, P13444, DOI 10.1074/jbc.273.22.13444; Kown MH, 2000, CIRCULATION, V102, P228; Labbe RF, 1999, CLIN CHEM, V45, P2060; Lee D, 2000, J BIOL CHEM, V275, P16007, DOI 10.1074/jbc.275.21.16007; Leist M, 1997, BIOCHEM BIOPH RES CO, V236, P1, DOI 10.1006/bbrc.1997.6890; Liu ZM, 2004, ONCOGENE, V23, P503, DOI 10.1038/sj.onc.1207173; LUO DS, 1994, EUR J PHARM-MOLEC PH, V267, P263, DOI 10.1016/0922-4106(94)90149-X; MAINES MD, 1992, BIOCHIM BIOPHYS ACTA, V1131, P166, DOI 10.1016/0167-4781(92)90072-8; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1981, BIOCHIM BIOPHYS ACTA, V673, P339, DOI 10.1016/0304-4165(81)90465-7; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicotera P, 2004, ONCOGENE, V23, P2757, DOI 10.1038/sj.onc.1207559; Pae HO, 2004, MOL PHARMACOL, V66, P122, DOI 10.1124/mol.66.1.122; Perry DK, 1997, J BIOL CHEM, V272, P18530, DOI 10.1074/jbc.272.30.18530; Petrache I, 2000, AM J PHYSIOL-LUNG C, V278, pL312, DOI 10.1152/ajplung.2000.278.2.L312; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Ryter SW, 2002, MOL CELL BIOCHEM, V234, P249, DOI 10.1023/A:1015957026924; SARDANA MK, 1987, P NATL ACAD SCI USA, V84, P2464, DOI 10.1073/pnas.84.8.2464; Sass G, 2003, HEPATOLOGY, V38, P909, DOI 10.1053/jhep.2003.50386; Serfas L, 1998, ARCH BIOCHEM BIOPHYS, V359, P8, DOI 10.1006/abbi.1998.0887; Shan Y, 2002, ARCH BIOCHEM BIOPHYS, V399, P159, DOI 10.1006/abbi.2001.2742; Shan Y, 2000, ARCH BIOCHEM BIOPHYS, V380, P219, DOI 10.1006/abbi.2000.1921; SMITHKM, 1975, PORPHYRINS METALLOPO; Stennicke HR, 2002, TRENDS BIOCHEM SCI, V27, P94, DOI 10.1016/S0968-0004(01)02045-X; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; STEVENSON DK, 1989, AM J DIS CHILD, V143, P353, DOI 10.1001/archpedi.1989.02150150111027; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Yang G, 2001, BLOOD, V97, P1306, DOI 10.1182/blood.V97.5.1306; Zbinden P, 1998, QUANT STRUCT-ACT REL, V17, P122, DOI 10.1002/(SICI)1521-3838(199804)17:02<122::AID-QSAR122>3.3.CO;2-C; Zhang XC, 2004, J BIOL CHEM, V279, P10677, DOI 10.1074/jbc.M312941200	44	29	30	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1272	1279		10.1096/fj.04-3259com	http://dx.doi.org/10.1096/fj.04-3259com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16051694	Green Submitted			2022-12-28	WOS:000231843700034
J	Fernando, P; Brunette, S; Megeney, LA				Fernando, P; Brunette, S; Megeney, LA			Neural stem cell differentiation is dependent upon endogenous caspase-3 activity	FASEB JOURNAL			English	Article						apoptosis; kinase; neurogenesis	ACTIVATED PROTEIN-KINASE; NEURONAL DIFFERENTIATION; KERATINOCYTE DIFFERENTIATION; MEDIATED ACTIVATION; INDUCED APOPTOSIS; PC12 CELLS; IN-VIVO; ROCK-I; 1 ASK1; CLEAVAGE	Caspase proteases have become the focal point for the development and application of antiapoptotic therapies in a variety of central nervous system diseases. However, this approach is based on the premise that caspase function is limited to invoking cell death signals. Here, we show that caspase-3 activity is elevated in nonapoptotic differentiating neuronal cell populations. Moreover, peptide inhibition of protease activity effectively inhibits the differentiation process in a cultured neurosphere model. These results implicate caspase-3 activation as a conserved feature of neuronal differentiation and suggest that targeted inhibition of this protease in neural cell populations may have unintended consequences.	Ottawa Hlth Res Inst, Mol Med Program, Ottawa, ON, Canada; StemPath Inc, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Megeney, LA (corresponding author), Ottawa Hlth Res Inst, Mol Med Program, 501 Smyth Rd, Ottawa, ON, Canada.	lmegeney@ohri.ca		Fernando, Pasan/0000-0001-8792-9637; Megeney, Lynn/0000-0002-6824-8569				Abraham MC, 2004, TRENDS CELL BIOL, V14, P184, DOI 10.1016/j.tcb.2004.03.002; Bez A, 2003, BRAIN RES, V993, P18, DOI 10.1016/j.brainres.2003.08.061; Bokoch GM, 1998, CELL DEATH DIFFER, V5, P637, DOI 10.1038/sj.cdd.4400405; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chan YM, 2003, EXP NEUROL, V181, P190, DOI 10.1016/S0014-4886(03)00023-2; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Cregan SP, 1999, J NEUROSCI, V19, P7860; Crocker SJ, 2001, EUR J NEUROSCI, V14, P391, DOI 10.1046/j.0953-816x.2001.01653.x; Faigle R, 2004, MOL CELL BIOL, V24, P280, DOI 10.1128/MCB.24.1.280-293.2004; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Fiskum G, 2003, ANN NY ACAD SCI, V991, P111; Flygare J, 2000, EUR J BIOCHEM, V267, P5977, DOI 10.1046/j.1432-1327.2000.01675.x; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gao SY, 2004, NEPHRON EXP NEPHROL, V97, pE49, DOI 10.1159/000078406; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Hansson O, 2000, EXP NEUROL, V164, P102, DOI 10.1006/exnr.2000.7406; Hurelbrink CB, 2001, EXP NEUROL, V171, P46, DOI 10.1006/exnr.2001.7749; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Katz LM, 2001, NEUROREPORT, V12, P3751, DOI 10.1097/00001756-200112040-00029; Kipp M, 2000, J BIOL CHEM, V275, P5031, DOI 10.1074/jbc.275.7.5031; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Kugler S, 2000, CELL DEATH DIFFER, V7, P815, DOI 10.1038/sj.cdd.4400712; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Laplante I, 2004, J NEUROBIOL, V60, P289, DOI 10.1002/neu.20036; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Li H, 2000, STROKE, V31, P176, DOI 10.1161/01.STR.31.1.176; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; McMullan R, 2003, CURR BIOL, V13, P2185, DOI 10.1016/S0960-9822(03)00906-0; Melendez-Vasquez CV, 2004, J NEUROSCI, V24, P3953, DOI 10.1523/JNEUROSCI.4920-03.2004; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nijhawan D, 2000, ANNU REV NEUROSCI, V23, P73, DOI 10.1146/annurev.neuro.23.1.73; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; Okuyama R, 2004, DEV CELL, V6, P551, DOI 10.1016/S1534-5807(04)00098-X; Oomman S, 2004, J COMP NEUROL, V476, P154, DOI 10.1002/cne.20223; Perrelet D, 2000, EUR J NEUROSCI, V12, P2059, DOI 10.1046/j.1460-9568.2000.00098.x; Petrache I, 2003, FASEB J, V17, P407, DOI 10.1096/fj.02-0672com; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; Rohn TT, 2004, EXP CELL RES, V295, P215, DOI 10.1016/j.yexcr.2003.12.029; Sayama K, 2001, J BIOL CHEM, V276, P999, DOI 10.1074/jbc.M003425200; Schierle GS, 1999, NAT MED, V5, P97, DOI 10.1038/4785; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Skerjanc IS, 2000, FEBS LETT, V472, P53, DOI 10.1016/S0014-5793(00)01438-1; Takeda K, 2000, J BIOL CHEM, V275, P9805, DOI 10.1074/jbc.275.13.9805; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Xu DG, 1997, NAT MED, V3, P997, DOI 10.1038/nm0997-997; Yanazume T, 2002, J BIOL CHEM, V277, P8618, DOI 10.1074/jbc.M107924200; Zhang BL, 2003, MOL CELL BIOL, V23, P5716, DOI 10.1128/MCB.23.16.5716-5725.2003	50	163	166	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1671	+		10.1096/fj.04-2981fje	http://dx.doi.org/10.1096/fj.04-2981fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16103108				2022-12-28	WOS:000231843700013
J	Hopfer, U; Fukai, N; Hopfer, H; Wolf, G; Joyce, N; Li, E; Olsen, BR				Hopfer, U; Fukai, N; Hopfer, H; Wolf, G; Joyce, N; Li, E; Olsen, BR			Targeted disruption of Col8a1 and Col8a2 genes in mice leads to anterior segment abnormalities in the eye	FASEB JOURNAL			English	Article						type VIII collagen; corneal endothelial cells; proliferation	POSTERIOR POLYMORPHOUS DYSTROPHY; SHORT-CHAIN COLLAGEN; ENDOTHELIAL-CELL-PROLIFERATION; EPIDERMAL GROWTH-FACTOR; TRIPLE-HELICAL DOMAINS; SMOOTH-MUSCLE-CELLS; VIII COLLAGEN; CORNEAL ENDOTHELIUM; DESCEMETS-MEMBRANE; DIFFERENTIAL EXPRESSION	Collagen VIII is localized in subendothelial and subepithelial extracellular matrices. It is a major component of Descemet's membrane, a thick basement membrane under the corneal endothelium, where it forms a hexagonal lattice structure; a similar structure, albeit less extensive, may be formed in other basement membranes. We have examined the function of collagen VIII in mice by targeted inactivation of the genes encoding the two polypeptide subunits, Co18a1 and Co18a2. Analysis of these mice reveals no major structural defects in most organs, but demonstrates that type VIII collagen is required for normal anterior eye development, particularly the formation of a corneal stroma with the appropriate number of fibroblastic cell layers and Descemet's membrane of appropriate thickness. Complete lack of type VIII collagen leads to dysgenesis of the anterior segment of the eye: a globoid, keratoglobus- like protrusion of the anterior chamber with a thin corneal stroma. Descemet's membrane is markedly thinned. The corneal endothelial cells are enlarged and reduced in number, and show a decreased ability to proliferate in response to different growth factors in vitro. An important function of collagen VIII may therefore be to generate a peri- or subcellular matrix environment that permits or stimulates cell proliferation.	Harvard Univ, Sch Dent Med, Dept Oral & Dev Biol, Boston, MA 02115 USA; Univ Hamburg, Dept Pathol, Hamburg, Germany; Univ Hamburg, Dept Med, Hamburg, Germany; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA; Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA USA; Massachusetts Gen Hosp, Cardiovasc Res Div, Boston, MA 02114 USA	Harvard University; Harvard School of Dental Medicine; University of Hamburg; University of Hamburg; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Schepens Eye Research Institute; Harvard University; Massachusetts General Hospital	Olsen, BR (corresponding author), Harvard Univ, Sch Dent Med, Dept Oral & Dev Biol, 188 Longwood Ave, Boston, MA 02115 USA.	bjorn_olsen@hms.harvard.edu	Hopfer, Helmut/T-5954-2019	Hopfer, Helmut/0000-0003-1755-2170	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036820, R37AR036820, R37AR036819, R01AR036819] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR36819, AR36820] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALITALO K, 1983, J BIOL CHEM, V258, P2653; Aszodi A, 1998, J MOL MED-JMM, V76, P238, DOI 10.1007/s001090050214; BARD JBL, 1988, DEVELOPMENT, V103, P195; Bendeck MP, 1996, CIRC RES, V79, P524, DOI 10.1161/01.RES.79.3.524; BENYA P D, 1980, Renal Physiology, V3, P30; Biswas S, 2001, HUM MOL GENET, V10, P2415, DOI 10.1093/hmg/10.21.2415; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Chakravarti S, 2001, EXP EYE RES, V73, P411, DOI 10.1006/exer.2001.1055; Chen KH, 2001, CORNEA, V20, P731, DOI 10.1097/00003226-200110000-00012; Chen KH, 1999, INVEST OPHTH VIS SCI, V40, P2513; FABRICANT RN, 1981, ARCH OPHTHALMOL-CHIC, V99, P305; Flugel-Koch C, 2002, DEV DYNAM, V225, P111, DOI 10.1002/dvdy.10144; Forsberg E, 1996, P NATL ACAD SCI USA, V93, P6594, DOI 10.1073/pnas.93.13.6594; GOSPODAROWICZ D, 1977, EXP EYE RES, V25, P75, DOI 10.1016/0014-4835(77)90248-2; Gottsch JD, 2003, INVEST OPHTH VIS SCI, V44, P594, DOI 10.1167/iovs.02-0300; Greenhill NS, 2000, MATRIX BIOL, V19, P19, DOI 10.1016/S0945-053X(99)00053-0; Grupcheva CN, 2001, CLIN EXP OPHTHALMOL, V29, P256, DOI 10.1046/j.1442-9071.2001.00432.x; Hay E.D., 1980, International Review of Cytology, V63, P263, DOI 10.1016/S0074-7696(08)61760-X; HENRIQUEZ AS, 1984, SURV OPHTHALMOL, V29, P139, DOI 10.1016/0039-6257(84)90171-1; HEON E, 1995, HUM MOL GENET, V4, P485, DOI 10.1093/hmg/4.3.485; Heon E, 2002, HUM MOL GENET, V11, P1029, DOI 10.1093/hmg/11.9.1029; Hirano S, 2004, BIOCHEM BIOPH RES CO, V317, P437, DOI 10.1016/j.bbrc.2004.03.049; Hou GP, 2000, AM J PATHOL, V156, P467, DOI 10.1016/S0002-9440(10)64751-7; Illidge C, 1998, J BIOL CHEM, V273, P22091, DOI 10.1074/jbc.273.34.22091; IRUELAARISPE ML, 1991, LAB INVEST, V64, P174; IRUELAARISPE ML, 1991, DEV BIOL, V144, P107, DOI 10.1016/0012-1606(91)90483-J; JAKUS MARIE A., 1956, JOUR BIOPHYS AND BIOCHEM CYTOL, V2, P243, DOI 10.1083/jcb.2.4.243; JOHNSON DH, 1982, ARCH OPHTHALMOL-CHIC, V100, P1942, DOI 10.1001/archopht.1982.01030040922011; Jones PL, 2000, MATRIX BIOL, V19, P581, DOI 10.1016/S0945-053X(00)00106-2; KENNEY MC, 1984, EXP EYE RES, V39, P267, DOI 10.1016/0014-4835(84)90015-0; KITTELBERGER R, 1990, CONNECT TISSUE RES, V24, P303, DOI 10.3109/03008209009152157; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEVY SG, 1995, EXP EYE RES, V61, P323, DOI 10.1016/S0014-4835(05)80127-7; Levy SG, 1996, ARCH OPHTHALMOL-CHIC, V114, P1265, DOI 10.1001/archopht.1996.01100140465021; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li QJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1597; LIU CY, 2003, J BIOL CHEM, V28, P28; MacBeath JRE, 1996, BIOCHEM J, V319, P993, DOI 10.1042/bj3190993; MURAGAKI Y, 1991, J BIOL CHEM, V266, P7721; MURAGAKI Y, 1991, EUR J BIOCHEM, V197, P615, DOI 10.1111/j.1432-1033.1991.tb15951.x; MURAGAKI Y, 1992, EUR J BIOCHEM, V207, P895, DOI 10.1111/j.1432-1033.1992.tb17122.x; MURPHY C, 1984, INVEST OPHTH VIS SCI, V25, P1402; PAULUS W, 1991, BRIT J CANCER, V63, P367, DOI 10.1038/bjc.1991.87; PAULUS W, 1992, ACTA HISTOCHEM, P195; PEARCE WG, 1969, BRIT J OPHTHALMOL, V53, P577, DOI 10.1136/bjo.53.9.577; Pellegata NS, 2000, NAT GENET, V25, P91, DOI 10.1038/75664; RAO GN, 1982, INVEST OPHTH VIS SCI, V22, P271; Reneker LW, 2000, DEVELOPMENT, V127, P533; SAGE H, 1982, COLLAGEN REL RES, V2, P465; Saika S, 2001, DEV BIOL, V240, P419, DOI 10.1006/dbio.2001.0480; SAVION N, 1981, J BIOL CHEM, V256, P1149; SAWADA H, 1990, J CELL BIOL, V110, P219, DOI 10.1083/jcb.110.1.219; Semina EV, 2000, GENOMICS, V63, P289, DOI 10.1006/geno.1999.6093; Sibinga NES, 1997, CIRC RES, V80, P532, DOI 10.1161/01.RES.80.4.532; Sinha S, 2001, INT J EXP PATHOL, V82, P295, DOI 10.1046/j.1365-2613.2001.00201.x; Tan ST, 2004, PLAST RECONSTR SURG, V113, P999, DOI 10.1097/01.PRS.0000105683.10752.A6; Tan ST, 2000, PLAST RECONSTR SURG, V106, P529, DOI 10.1097/00006534-200009030-00001; WARING GO, 1982, OPHTHALMOLOGY, V89, P531; Weitkamp B, 1999, FASEB J, V13, P1445, DOI 10.1096/fasebj.13.11.1445; Xu R, 2001, BIOCHEM BIOPH RES CO, V289, P264, DOI 10.1006/bbrc.2001.5970; YAMAGUCHI N, 1991, J BIOL CHEM, V266, P4508; YAMAGUCHI N, 1989, J BIOL CHEM, V264, P16022	62	85	86	2	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1232	1244		10.1096/fj.04-3019com	http://dx.doi.org/10.1096/fj.04-3019com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16051690				2022-12-28	WOS:000231843700030
J	Chen, YY; Deng, YQ; Bao, XY; Reuss, L; Altenberg, GA				Chen, YY; Deng, YQ; Bao, XY; Reuss, L; Altenberg, GA			Mechanism of the defect in gap-junctional communication by expression of a connexin 26 mutant associated with dominant deafness	FASEB JOURNAL			English	Article						channel; genetic disease	NONJUNCTIONAL PLASMA-MEMBRANE; HEMICHANNELS; CHANNELS; INHIBITION; MUTATIONS; CALCIUM; ORGAN; PERMEABILITY; UNDERLIES; CURRENTS	Gap-junctional channels ( connexin oligomers) are large-diameter aqueous pores formed by head-to-head association of two gap-junctional hemichannels, one from each of the adjacent cells. Profound hearing loss of genetic origin is common, and mutations of connexin 26 (Cx26) are the most frequent cause of this disorder. The Cx26 R75W mutant has been associated with disruption of cell-to-cell communication and profound hearing loss, but the mechanism of the gap-junctional defect is unknown. Here, we show that Cx26 R75W forms gap-junctional hemichannels that display altered voltage dependency and reduced permeability, and which cannot form functional gap-junctional channels between neighboring cells. The R75W phenotype is dominant at the gap-junction channel but not at the hemichannel level. Therefore, the absence of gap-junctional communication caused by R75W expression is due to defective gap-junction formation by functional hemichannels.	Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77550 USA; Univ Texas, Med Branch, Membrane Prot Lab, Sealy Ctr Struct Biol, Galveston, TX 77550 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Altenberg, GA (corresponding author), Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77550 USA.	galtenbe@utmb.edu		Altenberg, Guillermo/0000-0002-8932-740X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068586] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM068586] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad S, 2003, BIOCHEM BIOPH RES CO, V307, P362, DOI 10.1016/S0006-291X(03)01166-5; Bao XY, 2004, J BIOL CHEM, V279, P9689, DOI 10.1074/jbc.M311438200; Bao XY, 2004, AM J PHYSIOL-CELL PH, V286, pC647, DOI 10.1152/ajpcell.00295.2003; Beltramello M, 2005, NAT CELL BIOL, V7, P63, DOI 10.1038/ncb1205; Beltramello M, 2003, BIOCHEM BIOPH RES CO, V305, P1024, DOI 10.1016/S0006-291X(03)00868-4; Bruzzone R, 2003, FEBS LETT, V533, P79, DOI 10.1016/S0014-5793(02)03755-9; CALVO J, X CONNEXINS DEAFNESS; Cohen-Salmon M, 2002, CURR BIOL, V12, P1106, DOI 10.1016/S0960-9822(02)00904-1; Contreras JE, 2002, P NATL ACAD SCI USA, V99, P495, DOI 10.1073/pnas.012589799; Corey DP, 2004, NATURE, V432, P723, DOI 10.1038/nature03066; Ebihara L, 1996, BIOPHYS J, V71, P742, DOI 10.1016/S0006-3495(96)79273-1; Eskandari S, 2002, J MEMBRANE BIOL, V185, P93, DOI 10.1007/s00232-001-0115-0; Foote CI, 1998, J CELL BIOL, V140, P1187, DOI 10.1083/jcb.140.5.1187; Forge A, 2003, J COMP NEUROL, V467, P207, DOI 10.1002/cne.10916; Forge A, 2003, CELL COMMUN ADHES, V10, P341, DOI 10.1080/cac.10.4-6.341.346; Forge A, 2002, AUDIOL NEURO-OTOL, V7, P141, DOI 10.1159/000058299; Forge A, 2002, BRIT MED BULL, V63, P5, DOI 10.1093/bmb/63.1.5; Gomez-Hernandez JM, 2003, P NATL ACAD SCI USA, V100, P16030, DOI 10.1073/pnas.2530348100; Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705; Jentsch TJ, 2000, NAT REV NEUROSCI, V1, P21, DOI 10.1038/35036198; John SA, 1999, J BIOL CHEM, V274, P236, DOI 10.1074/jbc.274.1.236; JOHNSTONE BM, 1989, J PHYSIOL-LONDON, V408, P77, DOI 10.1113/jphysiol.1989.sp017448; Kikuchi Toshihiko, 2000, Medical Electron Microscopy, V33, P51, DOI 10.1007/s007950070001; Kudo T, 2003, HUM MOL GENET, V12, P995, DOI 10.1093/hmg/ddg116; Lautermann J, 1998, CELL TISSUE RES, V294, P415, DOI 10.1007/s004410051192; Marziano NK, 2003, HUM MOL GENET, V12, P805, DOI 10.1093/hmg/ddg076; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; Mo L, 1999, J MEMBRANE BIOL, V168, P253, DOI 10.1007/s002329900514; Oh S, 1999, J GEN PHYSIOL, V114, P339, DOI 10.1085/jgp.114.3.339; Oshima A, 2003, J BIOL CHEM, V278, P1807, DOI 10.1074/jbc.M207713200; PAUL DL, 1991, J CELL BIOL, V115, P1077, DOI 10.1083/jcb.115.4.1077; Pfahnl A, 1999, PFLUG ARCH EUR J PHY, V437, P345, DOI 10.1007/s004240050788; Richard G, 1998, HUM GENET, V103, P393, DOI 10.1007/s004390050839; Rizzuto R, 2003, ONCOGENE, V22, P8619, DOI 10.1038/sj.onc.1207105; SANTOS-SACCHI J, 1986, HEARING RES, V21, P205, DOI 10.1016/0378-5955(86)90219-4; Skerrett IM, 2004, FASEB J, V18, P860, DOI 10.1096/fj.03-0763fje; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; Steel KP, 1999, SCIENCE, V285, P1363, DOI 10.1126/science.285.5432.1363; Suchyna TM, 1999, BIOPHYS J, V77, P2968, DOI 10.1016/S0006-3495(99)77129-8; Thomson SC, 2003, KIDNEY BLOOD PRESS R, V26, P10, DOI 10.1159/000069766; Vergara L, 2003, J MEMBRANE BIOL, V196, P173, DOI 10.1007/s00232-003-0636-9; Zhao HB, 2000, J MEMBRANE BIOL, V175, P17, DOI 10.1007/s002320001051	42	36	37	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1516	+		10.1096/fj.04-3491fje	http://dx.doi.org/10.1096/fj.04-3491fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16009703				2022-12-28	WOS:000230923000028
J	Anilkumar, N; Uekita, T; Couchman, JR; Nagase, H; Seiki, M; Itoh, Y				Anilkumar, N; Uekita, T; Couchman, JR; Nagase, H; Seiki, M; Itoh, Y			Palmitoylation at Cys(574) is essential for MT1-MMP to promote cell migration	FASEB JOURNAL			English	Article						cell motility; internalization	TYPE-1 MATRIX-METALLOPROTEINASE; GELATINASE-A; SACCHAROMYCES-CEREVISIAE; TUMOR-CELLS; ACTIVATION; SURFACE; PROTEOLYSIS; RECEPTOR; MMP; OLIGOMERIZATION	MT1-MMP is a type I transmembrane proteinase that promotes cell migration and invasion. Here, we report that MT1-MMP is palmitoylated at Cys(574) in the cytoplasmic domain, and this lipid modification is critical for its promotion of cell migration and clathrin-mediated internalization. The palmitoylation-defective mutant (C574A) failed to promote cell migration and was not internalized through clathrin pathway like wild-type, but it was internalized through the caveolae pathway. Reintroducing a cysteine at different positions in the cytoplasmic tail of the C574A mutant revealed that the position of the palmitoylated cysteine relative to LLY573, a motif that interacts with mu 2 subunit of adaptor protein 2, is critical for the cell motility-promoting activity of MT1-MMP and its clathrin-mediated internalization. Taken together, palmitoylation of MT1-MMP is one of the key posttranslational modifications that determines MT1-MMP-dependent cell migration.	Univ London Imperial Coll Sci & Technol, Kennedy Inst, Div Rheumatol, Dept Matrix Biol,Fac Med, London W6 7LH, England; Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, Tokyo, Japan; Univ London Imperial Coll Sci & Technol, Fac Med, Div Biomed Sci, London, England	Imperial College London; University of Oxford; University of Tokyo; Imperial College London	Itoh, Y (corresponding author), Univ London Imperial Coll Sci & Technol, Kennedy Inst, Div Rheumatol, Dept Matrix Biol,Fac Med, 1 Aspenlea Rd, London W6 7LH, England.	y.itoh@imperial.ac.uk	Seiki, Motoharu/K-9443-2015	Itoh, Yoshifumi/0000-0002-2128-2823	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; Bartels DJ, 1999, MOL CELL BIOL, V19, P6775, DOI 10.1128/mcb.19.10.6775; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Endo K, 2003, J BIOL CHEM, V278, P40764, DOI 10.1074/jbc.M306736200; Galvez BG, 2004, MOL BIOL CELL, V15, P678, DOI 10.1091/mbc.E03-07-0516; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Itoh Y, 2002, ESSAYS BIOCHEM, V38, P21, DOI 10.1042/bse0380021; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Labrecque L, 2004, J BIOL CHEM, V279, P52132, DOI 10.1074/jbc.M409617200; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; Linder ME, 2004, J CELL SCI, V117, P521, DOI 10.1242/jcs.00989; Lobo S, 2002, J BIOL CHEM, V277, P41268, DOI 10.1074/JBC.M206573200; Mazzone M, 2004, J CELL SCI, V117, P6275, DOI 10.1242/jcs.01563; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Osenkowski P, 2004, J CELL PHYSIOL, V200, P2, DOI 10.1002/jcp.20064; Ratnikov BI, 2002, J BIOL CHEM, V277, P7377, DOI 10.1074/jbc.M109580200; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Rozanov DV, 2004, J BIOL CHEM, V279, P4260, DOI 10.1074/jbc.M311569200; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; Stanton H, 1998, J CELL SCI, V111, P2789; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Sugimoto H, 1996, J BIOL CHEM, V271, P7705, DOI 10.1074/jbc.271.13.7705; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wang X, 2004, J BIOL CHEM, V279, P9331, DOI 10.1074/jbc.M312369200; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; Yik JHN, 2002, J BIOL CHEM, V277, P47305, DOI 10.1074/jbc.M208751200; Zucker S, 2003, CURR TOP DEV BIOL, V54, P1, DOI 10.1016/S0070-2153(03)54004-2	44	51	51	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2005	19	8					1326	+		10.1096/fj.04-3651fje	http://dx.doi.org/10.1096/fj.04-3651fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15946988				2022-12-28	WOS:000230207800020
J	Avivi, A; Shams, I; Joel, A; Lache, O; Levy, AP; Nevo, E				Avivi, A; Shams, I; Joel, A; Lache, O; Levy, AP; Nevo, E			Increased blood vessel density provides the mole rat physiological tolerance to its hypoxic subterranean habitat	FASEB JOURNAL			English	Article						subterranean Spalax; VEGF; hypoxia-inducible factor; HuR; hypoxia tolerance	ENDOTHELIAL GROWTH-FACTOR; FACTOR MESSENGER-RNA; INDUCIBLE FACTOR-I; LACTATE-DEHYDROGENASE; SPALAX-EHRENBERGI; EXPRESSION; BINDING; ELEMENT; ELAV; GENE	The blind subterranean mole rat superspecies Spalax ehrenbergi has evolved adaptations that allow it to survive and carry out intensive activities in its highly hypoxic underground sealed burrows. A key component of this adaptation is a higher capillary density in some Spalax tissues, primarily in muscles used in digging and in other energetic activities, resulting in a shorter diffusion distance for oxygen. Vascular endothelial growth factor ( VEGF) is an angiogenic factor that is critical for angiogenesis during development and is found in response to tissue ischemia. We demonstrate here that due to physiological differences, the Spalax muscle regulatory mechanism for VEGF is different than in Rattus muscle. In vivo, the constitutive level of the VEGF mRNA and the mRNA levels of its transcriptional regulator HIF-1 alpha and its mRNA stabilizer HuR are significantly higher in Spalax muscle than in Rattus muscle. Furthermore, as opposed to Rattus, the mRNA levels of HIF-1 alpha, HuR, VEGF, as well as that of LDH-A, the enzyme that catalyzes the production of lactate, an accepted marker of anaerobic metabolism, are not increased in Spalax after hypoxia. However, ex vivo, when oxygenation by blood vessels is no longer relevant, the expression pattern of all these genes is similar in the two rodents under both normoxic and hypoxic conditions. Our studies provide evidence that the highly vascularized muscle in Spalax, the most energy consuming tissue during digging, is resistant to the effects of oxygen deprivation. The significance of these results with respect to ischemic vascular disease is abundantly clear.	Univ Haifa, Inst Evolut, Lab Anim Mol Evolut, IL-31905 Haifa, Israel; Technion Fac Med, Haifa, Israel	University of Haifa; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Avivi, A (corresponding author), Univ Haifa, Inst Evolut, Lab Anim Mol Evolut, IL-31905 Haifa, Israel.	aaron@esti.haifa.ac.il		Shams, Imad/0000-0001-6496-2928				AR A, 1977, RESP PHYSIOL, V30, P201, DOI 10.1016/0034-5687(77)90031-7; ARIELI R, 1991, COMP BIOCHEM PHYS A, V100, P543, DOI 10.1016/0300-9629(91)90367-L; ARIELI R, 1977, PHYSIOL ZOOL, V50, P61, DOI 10.1086/physzool.50.1.30155716; ARIELI R, 1989, EVOLUTION SUBTERRANE, P251; Ashur-Fabian C, 2004, P NATL ACAD SCI USA, V101, P12236, DOI 10.1073/pnas.0404998101; Avivi A, 1999, FEBS LETT, V452, P133, DOI 10.1016/S0014-5793(99)00584-0; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BURLINGTON RF, 1968, NATURE, V219, P1370, DOI 10.1038/2191370a0; Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; Goldberg-Cohen I, 2002, J BIOL CHEM, V277, P13635, DOI 10.1074/jbc.M108703200; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; Hochachka PW, 1996, J APPL PHYSIOL, V81, P1355, DOI 10.1152/jappl.1996.81.3.1355; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Iyer NV, 1998, GENOMICS, V52, P159, DOI 10.1006/geno.1998.5416; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jubb AM, 2004, J CLIN PATHOL, V57, P504, DOI 10.1136/jcp.2003.012963; Jubb AM, 2003, J PATHOL, V200, P577, DOI 10.1002/path.1371; KEREM D, 1973, COMP BIOCHEM PHYSIOL, V45, P731, DOI 10.1016/0300-9629(73)90076-5; Koshikawa N, 2003, ONCOGENE, V22, P6717, DOI 10.1038/sj.onc.1206765; Lai WS, 2001, J BIOL CHEM, V276, P23144, DOI 10.1074/jbc.M100680200; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MARKERT CL, 1975, SCIENCE, V189, P102, DOI 10.1126/science.1138367; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Nevo, 1999, MOSAIC EVOLUTION SUB; Nevo E., 1961, Mammalia Paris, V25, P127, DOI 10.1515/mamm.1961.25.2.127; NEVO E., 2001, ADAPTIVE RAD BLIND S; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Powell FL, 2003, ANNU REV PHYSIOL, V65, P203, DOI 10.1146/annurev.physiol.65.092101.142711; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Shams I, 2004, FASEB J, V18, P307, DOI 10.1096/fj.04-2758fje; Shams I, 2004, P NATL ACAD SCI USA, V101, P9698, DOI 10.1073/pnas.0403540101; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wenger RH, 1996, BIOCHEM BIOPH RES CO, V223, P54, DOI 10.1006/bbrc.1996.0845; Widmer HR, 1997, P NATL ACAD SCI USA, V94, P2062, DOI 10.1073/pnas.94.5.2062; Wiener CM, 1996, BIOCHEM BIOPH RES CO, V225, P485, DOI 10.1006/bbrc.1996.1199	47	58	64	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1314	+		10.1096/fj.04-3414fje	http://dx.doi.org/10.1096/fj.04-3414fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	16000366				2022-12-28	WOS:000230207800018
J	Chakkalakal, JV; Thompson, J; Parks, RJ; Jasmin, BJ				Chakkalakal, JV; Thompson, J; Parks, RJ; Jasmin, BJ			Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies	FASEB JOURNAL			English	Review						DMD; skeletal muscle; molecular therapy; muscle cell survival; dystrophin	MDX MOUSE MUSCLE; CAPACITY ADENOVIRAL VECTOR; HEMATOPOIETIC STEM-CELLS; LONG-TERM PERSISTENCE; SKELETAL-MUSCLE; FULL-LENGTH; GLYCOPROTEIN COMPLEX; GENE-TRANSFER; IN-VIVO; MYOBLAST TRANSPLANTATION	Although the molecular defect causing Duchenne/Becker muscular dystrophy (DMD/BMD) was identified nearly 20 years ago, the development of effective therapeutic strategies has nonetheless remained a daunting challenge. Over the years, a variety of different approaches have been explored in an effort to compensate for the lack of the DMD gene product called dystrophin. This review not only presents some of the most promising molecular, cellular, and pharmacological strategies but also highlights some issues that need to be addressed before considering their implementation. Specifically, we describe current strategies being developed to exogenously deliver healthy copies of the dystrophin gene to dystrophic muscles. We present the findings of several studies that have focused on repairing the mutant dystrophin gene using various approaches. We include a discussion of cell-based therapies that capitalize on the use of myoblast or stem cell transfer. Finally, we summarize the results of several studies that may eventually lead to the development of appropriate drug-based therapies. In this context, we review our current knowledge of the mechanisms regulating expression of utrophin, the autosomal homologue of dystrophin. Given the complexity associated with the dystrophic phenotype, it appears likely that a combinatorial approach involving different therapeutic strategies will be necessary for the appropriate management and eventual treatment of this devastating neuromuscular disease.-Chakkalakal, J. V., Thompson, J., Parks, R. J. Jasmin, B. J. Molecular, cellular, and pharmacological therapies for Duchenne/ Becker muscular dystrophies.	Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; Ottawa Hosp, Ottawa Hlth Res Inst, Program Mol Med, Ottawa, ON, Canada	University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Jasmin, BJ (corresponding author), Univ Ottawa, Fac Med, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	jasmin@uottawa.ca	Chakkalakal, Joe/ABD-2865-2020	Chakkalakal, Joe/0000-0002-8440-7312				Abramovici H, 2003, MOL BIOL CELL, V14, P4499, DOI 10.1091/mbc.E03-03-0190; ACSADI G, 1991, NATURE, V352, P815, DOI 10.1038/352815a0; Acsadi G, 1996, HUM GENE THER, V7, P129, DOI 10.1089/hum.1996.7.2-129; AMALFITANO A, 2001, STRUCTURE MUTATION D, P1; Amalfitano Andrea, 2002, Current Gene Therapy, V2, P111, DOI 10.2174/1566523024605618; Anderson JE, 2000, CELL TRANSPLANT, V9, P551, DOI 10.1177/096368970000900411; Anderson JE, 2003, NEUROMUSCULAR DISORD, V13, P388, DOI 10.1016/S0960-8966(03)00029-4; Anderson JE, 1996, MUSCLE NERVE, V19, P1576, DOI 10.1002/(SICI)1097-4598(199612)19:12<1576::AID-MUS7>3.0.CO;2-7; Asakura A, 2002, J CELL BIOL, V159, P123, DOI 10.1083/jcb.200202092; Bachrach E, 2004, P NATL ACAD SCI USA, V101, P3581, DOI 10.1073/pnas.0400373101; BACKMAN E, 1988, ACTA NEUROL SCAND, V78, P429; Barton-Davis ER, 1999, J CLIN INVEST, V104, P375, DOI 10.1172/JCI7866; Bertoni C, 2003, HUM MOL GENET, V12, P1087, DOI 10.1093/hmg/ddg133; Bertoni C, 2002, HUM GENE THER, V13, P707, DOI 10.1089/104303402317322276; Biggar WD, 2001, J PEDIATR-US, V138, P45, DOI 10.1067/mpd.2001.109601; BLAU HM, 1983, P NATL ACAD SCI-BIOL, V80, P4856, DOI 10.1073/pnas.80.15.4856; Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154; Bonifati MD, 2000, MUSCLE NERVE, V23, P1344, DOI 10.1002/1097-4598(200009)23:9<1344::AID-MUS4>3.3.CO;2-6; BOYCE FM, 1991, P NATL ACAD SCI USA, V88, P1276, DOI 10.1073/pnas.88.4.1276; Bramson JL, 2004, HUM GENE THER, V15, P179, DOI 10.1089/104303404772679986; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Burton EA, 1999, P NATL ACAD SCI USA, V96, P14025, DOI 10.1073/pnas.96.24.14025; BYERS TJ, 1993, NAT GENET, V4, P77, DOI 10.1038/ng0593-77; Camargo FD, 2003, NAT MED, V9, P1520, DOI 10.1038/nm963; Cerletti M, 2003, GENE THER, V10, P750, DOI 10.1038/sj.gt.3301941; Chakkalakal JV, 2004, HUM MOL GENET, V13, P379, DOI 10.1093/hmg/ddh037; Chakkalakal JV, 2003, P NATL ACAD SCI USA, V100, P7791, DOI 10.1073/pnas.0932671100; Chaubourt E, 1999, NEUROBIOL DIS, V6, P499, DOI 10.1006/nbdi.1999.0256; COFFEY AJ, 1992, GENOMICS, V12, P474, DOI 10.1016/0888-7543(92)90437-W; ColeStrauss A, 1996, SCIENCE, V273, P1386, DOI 10.1126/science.273.5280.1386; Cossu G, 1997, HISTOL HISTOPATHOL, V12, P755; COX GA, 1994, NAT GENET, V8, P333, DOI 10.1038/ng1294-333; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; Dalkilic I, 2003, CURR OPIN GENET DEV, V13, P231, DOI 10.1016/S0959-437X(03)00048-0; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; DelloRusso C, 2002, P NATL ACAD SCI USA, V99, P12979, DOI 10.1073/pnas.202300099; DESILVA S, 1987, ARCH NEUROL-CHICAGO, V44, P818, DOI 10.1001/archneur.1987.00520200022012; DSOUZA VN, 1995, HUM MOL GENET, V4, P837, DOI 10.1093/hmg/4.5.837; DUBOWITZ V, 1975, ARCH DIS CHILD, V50, P335, DOI 10.1136/adc.50.5.335; Dudley RWR, 2004, HUM GENE THER, V15, P145, DOI 10.1089/104303404772679959; Dunant P, 2003, MUSCLE NERVE, V27, P624, DOI 10.1002/mus.10341; Durbeej M, 2002, CURR OPIN GENET DEV, V12, P349, DOI 10.1016/S0959-437X(02)00309-X; Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960-8966(91)90039-U; Emery A.E.H., 1993, DUCHENNE MUSCULAR DY; Endesfelder S, 2003, J MOL MED-JMM, V81, P355, DOI 10.1007/s00109-003-0439-6; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FEENER CA, 1989, NATURE, V338, P509, DOI 10.1038/338509a0; FENICHEL GM, 1991, NEUROLOGY, V41, P1874, DOI 10.1212/WNL.41.12.1874; FONG P, 1990, SCIENCE, V250, P673, DOI 10.1126/science.2173137; Gilbert R, 2003, HUM MOL GENET, V12, P1287, DOI 10.1093/hmg/ddg141; Gilbert R, 1998, BIOCHEM BIOPH RES CO, V242, P244, DOI 10.1006/bbrc.1997.7936; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; GORECKI DC, 1992, HUM MOL GENET, V1, P505, DOI 10.1093/hmg/1.7.505; Goyenvalle A, 2004, SCIENCE, V306, P1796, DOI 10.1126/science.1104297; Gramolini AO, 1998, J BIOL CHEM, V273, P736, DOI 10.1074/jbc.273.2.736; Gramolini AO, 1997, J BIOL CHEM, V272, P8117, DOI 10.1074/jbc.272.13.8117; Gramolini AO, 2001, AM J PHYSIOL-CELL PH, V281, pC1300, DOI 10.1152/ajpcell.2001.281.4.C1300; Gramolini AO, 1999, P NATL ACAD SCI USA, V96, P3223, DOI 10.1073/pnas.96.6.3223; GREENBERG DS, 1994, NAT GENET, V8, P340, DOI 10.1038/ng1294-340; Gregorevic P, 2004, NAT MED, V10, P828, DOI 10.1038/nm1085; Gussoni E, 2002, J CLIN INVEST, V110, P807, DOI 10.1172/JCI200216098; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; GUSSONI E, 1992, NATURE, V356, P435, DOI 10.1038/356435a0; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HUNTER JR, 1983, ARCH NEUROL-CHICAGO, V40, P294, DOI 10.1001/archneur.1983.04050050062009; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Iwata Y, 2003, J CELL BIOL, V161, P957, DOI 10.1083/jcb.200301101; Jennekens F G, 1991, Neuromuscul Disord, V1, P389, DOI 10.1016/0960-8966(91)90001-9; Jiang Z, 2004, GENE THER, V11, P1453, DOI 10.1038/sj.gt.3302315; Jiang ZL, 2004, MOL THER, V10, P688, DOI 10.1016/j.ymthe.2004.07.020; Kambadur R, 1997, GENOME RES, V7, P910, DOI 10.1101/gr.7.9.910; KARPATI G, 1993, ANN NEUROL, V34, P8, DOI 10.1002/ana.410340105; KAY MA, 1995, NAT GENET, V11, P191, DOI 10.1038/ng1095-191; Khurana T S, 1991, Neuromuscul Disord, V1, P185, DOI 10.1016/0960-8966(91)90023-L; Khurana TS, 1999, MOL BIOL CELL, V10, P2075, DOI 10.1091/mbc.10.6.2075; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; Krag TOB, 2004, P NATL ACAD SCI USA, V101, P13856, DOI 10.1073/pnas.0405972101; Kren BT, 1998, NAT MED, V4, P285, DOI 10.1038/nm0398-285; Kumar A, 2004, FASEB J, V18, P102, DOI 10.1096/fj.03-0453com; LAW PK, 1979, MUSCLE NERVE, V2, P356, DOI 10.1002/mus.880020506; Liang KW, 2004, GENE THER, V11, P901, DOI 10.1038/sj.gt.3302239; LIDOV HGW, 1995, HUM MOL GENET, V4, P329, DOI 10.1093/hmg/4.3.329; Liu F, 2001, MOL THER, V4, P45, DOI 10.1006/mthe.2001.0419; Lu QL, 2000, J CELL BIOL, V148, P985, DOI 10.1083/jcb.148.5.985; Lu QL, 2003, NAT MED, V9, P1009, DOI 10.1038/nm897; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MATSUMURA K, 1994, J CLIN INVEST, V93, P99, DOI 10.1172/JCI116989; McCroskery S, 2003, J CELL BIOL, V162, P1135, DOI 10.1083/jcb.200207056; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; MENDELL JR, 1995, NEW ENGL J MED, V333, P832, DOI 10.1056/NEJM199509283331303; MENDELL JR, 1989, NEW ENGL J MED, V320, P1592, DOI 10.1056/NEJM198906153202405; Mesa L E, 1991, Neuromuscul Disord, V1, P261, DOI 10.1016/0960-8966(91)90099-E; MOENS P, 1993, J MUSCLE RES CELL M, V14, P446, DOI 10.1007/BF00121296; Moisset PA, 1998, BIOCHEM BIOPH RES CO, V247, P94, DOI 10.1006/bbrc.1998.8739; Mok H, 2005, MOL THER, V11, P66, DOI 10.1016/j.ymthe.2004.09.015; Monaco AP, 1988, GENOMICS, V2, P90, DOI 10.1016/0888-7543(88)90113-9; MONACO AP, 1988, ADV HUM GENET, V17, P61; Muntoni F, 2003, LANCET NEUROL, V2, P731, DOI 10.1016/S1474-4422(03)00585-4; Muruve DA, 2004, J VIROL, V78, P5966, DOI 10.1128/JVI.78.11.5966-5972.2004; Muruve DA, 1999, HUM GENE THER, V10, P965, DOI 10.1089/10430349950018364; Nalbantoglu J, 1999, HUM GENE THER, V10, P1009, DOI 10.1089/10430349950018409; Nguyen T M, 1991, J Cell Biol, V115, P1695, DOI 10.1083/jcb.115.6.1695; Oak SA, 2003, J BIOL CHEM, V278, P39287, DOI 10.1074/jbc.M305551200; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; PALMER E, 1979, NATURE, V277, P148, DOI 10.1038/277148a0; Parks RJ, 1996, P NATL ACAD SCI USA, V93, P13565, DOI 10.1073/pnas.93.24.13565; PARTRIDGE TA, 1978, NATURE, V273, P306, DOI 10.1038/273306a0; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; PHELPS SF, 1995, HUM MOL GENET, V4, P1251, DOI 10.1093/hmg/4.8.1251; Porter JD, 2003, NEUROMUSCULAR DISORD, V13, P223, DOI 10.1016/S0960-8966(02)00242-0; Porter JD, 2002, HUM MOL GENET, V11, P263, DOI 10.1093/hmg/11.3.263; Rando TA, 2000, P NATL ACAD SCI USA, V97, P5363, DOI 10.1073/pnas.97.10.5363; Rando TA, 2002, NEUROMUSCULAR DISORD, V12, pS55, DOI 10.1016/S0960-8966(02)00083-4; Romero NB, 2004, HUM GENE THER, V15, P1065, DOI 10.1089/hum.2004.15.1065; Romero Roberto, 2002, J Matern Fetal Neonatal Med, V12, P1, DOI 10.1080/713605577; Sakamoto M, 2002, BIOCHEM BIOPH RES CO, V293, P1265, DOI 10.1016/S0006-291X(02)00362-5; Santana E, 1998, J INVEST DERMATOL, V111, P1172, DOI 10.1046/j.1523-1747.1998.00403.x; Schaeffer L, 2001, NEURON, V31, P15, DOI 10.1016/S0896-6273(01)00353-1; Skuk D, 1999, EXP NEUROL, V155, P22, DOI 10.1006/exnr.1998.6973; Skuk D, 2000, J NEUROPATH EXP NEUR, V59, P197, DOI 10.1093/jnen/59.3.197; Skuk D, 2002, EXP NEUROL, V175, P112, DOI 10.1006/exnr.2002.7899; Spencer MJ, 2001, CLIN IMMUNOL, V98, P235, DOI 10.1006/clim.2000.4966; St-Pierre SJG, 2004, FASEB J, V18, P1937, DOI 10.1096/fj.04-1859fje; Stupka N, 2004, ACTA NEUROPATHOL, V107, P299, DOI 10.1007/s00401-003-0807-x; THANH LT, 1995, AM J HUM GENET, V56, P725; Tinsley J, 1998, NAT MED, V4, P1441, DOI 10.1038/4033; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; TURNER PR, 1991, J CELL BIOL, V115, P1701, DOI 10.1083/jcb.115.6.1701; Vandebrouck C, 2002, J CELL BIOL, V158, P1089, DOI 10.1083/jcb.200203091; Wagner KR, 2001, ANN NEUROL, V49, P706, DOI 10.1002/ana.1023.abs; Wagner KR, 2002, ANN NEUROL, V52, P832, DOI 10.1002/ana.10385; Wang B, 2000, P NATL ACAD SCI USA, V97, P13714, DOI 10.1073/pnas.240335297; Watchko J, 2002, HUM GENE THER, V13, P1451, DOI 10.1089/10430340260185085; WATKINS SC, 1988, NATURE, V333, P863, DOI 10.1038/333863a0; Weir AP, 2002, J BIOL CHEM, V277, P45285, DOI 10.1074/jbc.M205177200; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363; WORTON RG, 1988, ANNU REV GENET, V22, P601, DOI 10.1146/annurev.ge.22.120188.003125; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; ZATZ M, 1986, AM J MED GENET, V24, P549, DOI 10.1002/ajmg.1320240322; ZATZ M, 1988, AM J MED GENET, V31, P821, DOI 10.1002/ajmg.1320310415; Zhang GF, 2004, HUM GENE THER, V15, P770, DOI 10.1089/1043034041648408; ZUBRZYCKAGAARN EF, 1988, NATURE, V333, P466, DOI 10.1038/333466a0	146	89	108	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					880	891		10.1096/fj.04-1956rev	http://dx.doi.org/10.1096/fj.04-1956rev			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15923398				2022-12-28	WOS:000230207800035
J	Hepple, RT; Baker, DJ; Kaczor, JJ; Krause, DJ				Hepple, RT; Baker, DJ; Kaczor, JJ; Krause, DJ			Long-term caloric restriction abrogates the age-related decline in skeletal muscle aerobic function	FASEB JOURNAL			English	Article						aging; oxygen uptake; mitochondria; rats; sarcopenia	MITOCHONDRIAL PROTON LEAK; DIETARY RESTRICTION; BLOOD-FLOW; F344BNF1-HYBRID RATS; OXIDATIVE CAPACITY; FOOD RESTRICTION; GENE-EXPRESSION; EXERCISE; FISCHER-344; RESPONSES	The purpose of this study was to determine the effect of long-term caloric restriction (CR) on the age-associated decline of skeletal muscle aerobic function. Skeletal muscle maximal aerobic performance (VO(2)max) was assessed in ad libitum (AL) and CR rats aged 8-10 months and 35 months using a pump-perfused hindlimb model to match oxygen delivery to muscle mass between groups. Whereas there was a 46% decline in muscle mass- specific VO2max between 8 10 mo (524 +/- 13 mu mol center dot min(-1)similar to 100 g(-1); mean SE) and 35 mo (281 +/- 54 mu mol(.)min(-1)center dot 100 g(- 1)) in AL rats, not only did CR rats begin at the same point in 8-10 mo old rats (490 +/- 42 mu mol center dot min(-1)center dot 100 g(-1)), we found no decline in 35 mo old CR animals (484 +/- 49 mu mol center dot min(-1)center dot 100g(-1)). Interestingly, although most markers of oxidative capacity began at a lower point in young adult CR animals, CR rats exhibited a higher in situ activity of complex IV at VO2max. This activity allows the young adult CR animals to exhibit normal aerobic capacity despite the lower oxidative enzyme activities. In stark contrast to the 19-41% decline in activities of citrate synthase, complexes I-III, and complex IV in homogenates prepared from the plantaris muscle and mixed region of gastrocnemius muscle with aging in AL rats, no age-related decline was found in CR animals. Thus, our results showed that CR preserves aerobic function in aged skeletal muscles by facilitating a higher in situ function of complex IV and by preventing the age-related decline in mitochondrial oxidative capacity.	Univ Calgary, Fac Kinesiol, Calgary, AB T2N 1N4, Canada; Univ Calgary, Fac Med, Calgary, AB, Canada; McMaster Univ, Dept Pediat, Hamilton, ON, Canada	University of Calgary; University of Calgary; McMaster University	Hepple, RT (corresponding author), Univ Calgary, Fac Kinesiol, 2500 Univ Dr,NW, Calgary, AB T2N 1N4, Canada.	hepple@ucalgary.ca	Kaczor, Jan/A-1990-2008; Kaczor, Jan/AAH-5078-2021; Kaczor, Jan/ABC-6283-2021	Kaczor, Jan/0000-0002-6370-2160; Hepple, Russell/0000-0003-3640-486X				ARMSTRONG RB, 1985, J APPL PHYSIOL, V59, P1322, DOI 10.1152/jappl.1985.59.4.1322; Aspnes LE, 1997, FASEB J, V11, P573, DOI 10.1096/fasebj.11.7.9212081; Bevilacqua L, 2004, AM J PHYSIOL-ENDOC M, V286, pE852, DOI 10.1152/ajpendo.00367.2003; BOREHAM CAG, 1988, J ANAT, V157, P111; Bota DA, 2002, FEBS LETT, V532, P103, DOI 10.1016/S0014-5793(02)03638-4; Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212; Bronikowski AM, 2003, PHYSIOL GENOMICS, V12, P129, DOI 10.1152/physiolgenomics.00082.2002; Brown M, 1996, J GERONTOL A-BIOL, V51, pB117, DOI 10.1093/gerona/51A.2.B117; BUA EA, 2004, FASEB J; DAVIES KJA, 1981, ARCH BIOCHEM BIOPHYS, V209, P539, DOI 10.1016/0003-9861(81)90312-X; Desai VG, 1996, ARCH BIOCHEM BIOPHYS, V333, P145, DOI 10.1006/abbi.1996.0375; Drew B, 2003, AM J PHYSIOL-REG I, V284, pR474, DOI 10.1152/ajpregu.00455.2002; Glantz S.A., 2002, PRIMER BIOSTATISTICS; GOODRICK CL, 1980, GERONTOLOGY, V26, P22, DOI 10.1159/000212390; GORSKI J, 1986, AM J PHYSIOL, V250, pE441, DOI 10.1152/ajpendo.1986.250.4.E441; Gredilla R, 2001, FASEB J, V15, P1589, DOI 10.1096/fj.00-0764fje; HAGBERG JM, 1985, J APPL PHYSIOL, V58, P2041, DOI 10.1152/jappl.1985.58.6.2041; Hagen JL, 2004, J GERONTOL A-BIOL, V59, P1099, DOI 10.1093/gerona/59.11.1099; Hepple RT, 2004, J GERONTOL A-BIOL, V59, P1111, DOI 10.1093/gerona/59.11.1111; Hepple RT, 2004, J APPL PHYSIOL, V96, P2257, DOI 10.1152/japplphysiol.01309.2003; Hepple RT, 2003, J APPL PHYSIOL, V95, P705, DOI 10.1152/japplphysiol.00058.2003; Hepple RT, 2003, J APPL PHYSIOL, V94, P744, DOI 10.1152/japplphysiol.00737.2002; Hepple RT, 2002, J PHYSIOL-LONDON, V541, P1003, DOI 10.1113/jphysiol.2001.013649; Holloszy JO, 1997, J APPL PHYSIOL, V82, P399, DOI 10.1152/jappl.1997.82.2.399; INGRAM DK, 1987, J GERONTOL, V42, P78, DOI 10.1093/geronj/42.1.78; Kanda K, 2002, MICROSC RES TECHNIQ, V59, P301, DOI 10.1002/jemt.10208; Kent-Braun JA, 2002, J APPL PHYSIOL, V93, P1813, DOI 10.1152/japplphysiol.00091.2002; Lal SB, 2001, J GERONTOL A-BIOL, V56, pB116, DOI 10.1093/gerona/56.3.B116; Lee CK, 2002, P NATL ACAD SCI USA, V99, P14988, DOI 10.1073/pnas.232308999; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lee CM, 1998, ANN NY ACAD SCI, V854, P182, DOI 10.1111/j.1749-6632.1998.tb09901.x; Lipman RD, 1996, J GERONTOL A-BIOL, V51, pB54, DOI 10.1093/gerona/51A.1.B54; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; MASORO EJ, 2003, SCI AGING KNOWLEDGE, pRE2; Mathieu-Costello O, 2003, FASEB J, V17, pA1279; Mayhew M, 1998, BIOCHEM BIOPH RES CO, V251, P95, DOI 10.1006/bbrc.1998.9438; MCCARTER R, 1987, J GERONTOL, V42, P432, DOI 10.1093/geronj/42.4.432; McCarter RJM, 1997, AGING-CLIN EXP RES, V9, P73, DOI 10.1007/BF03340130; MCKIERNAN S, 2004, FASEB J; Merry BJ, 2002, INT J BIOCHEM CELL B, V34, P1340, DOI 10.1016/S1357-2725(02)00038-9; Miller RA, 2000, J GERONTOL A-BIOL, V55, pB117, DOI 10.1093/gerona/55.3.B117; MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9; Musch TI, 2004, J APPL PHYSIOL, V96, P81, DOI 10.1152/japplphysiol.00729.2003; OGAWA T, 1992, CIRCULATION, V86, P494, DOI 10.1161/01.CIR.86.2.494; Osborne TB, 1917, SCIENCE, V45, P294, DOI 10.1126/science.45.1160.294; Paterson DH, 2004, J AM GERIATR SOC, V52, P1632, DOI 10.1111/j.1532-5415.2004.52454.x; Payne AM, 2003, J APPL PHYSIOL, V95, P2554, DOI 10.1152/japplphysiol.00758.2003; Poole JG, 2003, AM J PHYSIOL-HEART C, V284, pH1251, DOI 10.1152/ajpheart.00790.2002; Proctor DN, 1998, J APPL PHYSIOL, V85, P68, DOI 10.1152/jappl.1998.85.1.68; Russell JA, 2003, AM J PHYSIOL-HEART C, V285, pH251, DOI 10.1152/ajpheart.01086.2002; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; Sreekumar R, 2002, AM J PHYSIOL-ENDOC M, V283, pE38, DOI 10.1152/ajpendo.00387.2001; Turturro A, 1999, J GERONTOL A-BIOL, V54, pB492, DOI 10.1093/gerona/54.11.B492	53	57	58	1	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1320	+		10.1096/fj.04-3535fje	http://dx.doi.org/10.1096/fj.04-3535fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15955841				2022-12-28	WOS:000230207800016
J	Meshorer, E; Biton, IE; Ben-Shaul, Y; Ben-Ari, S; Assaf, Y; Soreq, H; Cohen, Y				Meshorer, E; Biton, IE; Ben-Shaul, Y; Ben-Ari, S; Assaf, Y; Soreq, H; Cohen, Y			Chronic cholinergic imbalances promote brain diffusion and transport abnormalities	FASEB JOURNAL			English	Article						cholinergic neurotransmission; acetylcholinesterase; blood-brain barrier; aquaporin 4	ACETYLCHOLINESTERASE-TRANSGENIC MICE; POSTTRAUMATIC-STRESS-DISORDER; AQUAPORIN-4 WATER CHANNEL; CEREBRAL-ISCHEMIA; HEAD-INJURY; READTHROUGH ACETYLCHOLINESTERASE; BARRIER PERMEABILITY; ALZHEIMERS-DISEASE; PREFRONTAL CORTEX; UP-REGULATION	Cholinergic imbalances occur after traumatic effects and in the initial stages of neurodegenerative diseases, but their long-lasting effects remained largely unexplained. To address this, we used TgS transgenic mice constitutively overexpressing synaptic acetylcholinesterase (AChE-S) and presenting a complex phenotype of progressive neuro-deterioration. T-1- and T-2- weighted magnetic resonance (MR) brain images appeared similar. However, diffusion-weighted MRI showed decreased baseline water apparent diffusion coefficient in the brains of TgS animals. Furthermore, contrast-enhanced MRI after gadolinium diethylenetriaminepentaacetic acid (Gd- DTPA) injection demonstrated slower recovery of normal signals in the TgS brains than with controls. Perfusion MR imaging and difference T-1 maps calculated from pre- postcontrast T1- weighted MR images indicated accumulation of more Gd- DTPA molecules in the TgS brains than in the parent strain, reflecting impaired blood-brain barrier (BBB) functioning in these transgenic mice. To explore the molecular mechanism(s) underlying these global phenotypes, we performed microarray analysis in the stress-controlling prefrontal cortex of TgS vs. strain-matched wild-type animals. Profound overexpression of numerous ion channels, transporters, and adhesion genes was confirmed by real time RT-PCR tests. Immunohistochemical and immuno-blot analyses revealed corresponding increases in the level and cellular distributions of the chloride channel CLCN3 and the water channel AQP4, both of which contribute to BBB maintenance. Our study attributes to balanced cholinergic neurotransmission, a central role in the brain's maintenance of water diffusion and ion transport, and indicates that chronic impairments in this maintenance facilitate neurodeterioration through interference with BBB function.	Hebrew Univ Jerusalem, Dept Biol Chem, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Israel Ctr Neuronal Computat, IL-91904 Jerusalem, Israel; Tel Aviv Univ, Raymond & Beverly Sackler Fac Exact Sci, Sch Chem, Ramat Aviv, Israel; Wohl Inst Adv Imaging, Tel Aviv Sourasky Med Ctr, Human Brain Imaging Unit, Tel Aviv, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Soreq, H (corresponding author), Hebrew Univ Jerusalem, Dept Biol Chem, IL-91904 Jerusalem, Israel.	soreq@cc.huji.ac.il		Assaf, Yaniv/0000-0001-6828-7595; Soreq, Hermona/0000-0002-0955-526X; Meshorer, Eran/0000-0003-4777-986X				Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x; Andres C, 1997, P NATL ACAD SCI USA, V94, P8173, DOI 10.1073/pnas.94.15.8173; Arreola J, 2002, J PHYSIOL-LONDON, V545, P207, DOI 10.1113/jphysiol.2002.021980; BADAUT J, 2002, J CEREB BLOOD FLOW M, V22, P367, DOI DOI 10.1097/00004647-200204000-00001; Beeri R, 1997, J NEUROCHEM, V69, P2441; BEERI R, 1995, CURR BIOL, V5, P1063, DOI 10.1016/S0960-9822(95)00211-9; Benveniste H, 2002, PROG NEUROBIOL, V67, P393, DOI 10.1016/S0301-0082(02)00020-5; Birikh KR, 2003, P NATL ACAD SCI USA, V100, P283, DOI 10.1073/pnas.0135647100; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Cao H, 1996, BIOCHEM BIOPH RES CO, V227, P266, DOI 10.1006/bbrc.1996.1499; CHEN Y, 2003, P NATL ACAD SCI US; Cho H, 1998, EXP BRAIN RES, V122, P227, DOI 10.1007/s002210050510; Cohen O, 2002, MOL PSYCHIATR, V7, P874, DOI 10.1038/sj.mp.4001103; Darboux I, 1996, EMBO J, V15, P4835, DOI 10.1002/j.1460-2075.1996.tb00864.x; DELAESCALERA S, 1990, EMBO J, V9, P3593, DOI 10.1002/j.1460-2075.1990.tb07570.x; Erb C, 2001, J NEUROCHEM, V77, P638, DOI 10.1046/j.1471-4159.2001.00287.x; Esposito P, 2001, BRAIN RES, V888, P117, DOI 10.1016/S0006-8993(00)03026-2; Farchi N, 2003, J PHYSIOL-LONDON, V546, P165, DOI 10.1113/jphysiol.2002.030841; Forch P, 2001, APOPTOSIS, V6, P463, DOI 10.1023/A:1012441824719; Franklin KBJ, 2001, MOUSE BRAIN STEROTAX; Friedman A, 1996, NAT MED, V2, P1382, DOI 10.1038/nm1296-1382; Grauer E, 2001, LIFE SCI, V68, P985, DOI 10.1016/S0024-3205(00)01000-6; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; HOSSMANN KA, 1995, CEREBROVAS BRAIN MET, V7, P187; Johnson MD, 2002, J BIOL CHEM, V277, P23000, DOI 10.1074/jbc.M201907200; Le Bihan D, 2002, NMR BIOMED, V15, P431, DOI 10.1002/nbm.798; Lu H, 2003, CHINESE MED J-PEKING, V116, P1063; Lupien SJ, 2001, BEHAV BRAIN RES, V127, P137, DOI 10.1016/S0166-4328(01)00361-8; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; McDaniel B, 2001, NEUROIMAGE, V14, P1244, DOI 10.1006/nimg.2001.0934; Meshorer E, 2002, SCIENCE, V295, P508, DOI 10.1126/science.1066752; Mirjany M, 2002, J PHARMACOL EXP THER, V301, P494, DOI 10.1124/jpet.301.2.494; Moghaddam B, 2002, BIOL PSYCHIAT, V51, P775, DOI 10.1016/S0006-3223(01)01362-2; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Nico B, 2001, J CELL SCI, V114, P1297; Omori N, 2002, BRAIN RES, V954, P317, DOI 10.1016/S0006-8993(02)03366-8; Ovadia H, 2001, BRAIN RES, V905, P21, DOI 10.1016/S0006-8993(01)02361-7; Park SE, 2004, CANCER RES, V64, P2652, DOI 10.1158/0008-5472.CAN-04-0649; ROSES AD, 1995, NAT MED, V1, P603, DOI 10.1038/nm0795-603; Schaefer PW, 2000, RADIOLOGY, V217, P331, DOI 10.1148/radiology.217.2.r00nv24331; SCHAEFFER E, 1994, P NATL ACAD SCI USA, V91, P3882, DOI 10.1073/pnas.91.9.3882; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SHARMA HS, 1988, NEUROSCI RES, V5, P224, DOI 10.1016/0168-0102(88)90051-X; Shin LM, 2001, BIOL PSYCHIAT, V50, P932, DOI 10.1016/S0006-3223(01)01215-X; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; Stark D, 1999, MAGNETIC RESONANCE I, V1; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Tomkins O, 2001, CELL MOL NEUROBIOL, V21, P675, DOI 10.1023/A:1015147920283; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Vajda Z, 2002, P NATL ACAD SCI USA, V99, P13131, DOI 10.1073/pnas.192457099; van Eden CG, 2000, PROG BRAIN RES, V126, P49; Venero JL, 2001, PROG NEUROBIOL, V63, P321, DOI 10.1016/S0301-0082(00)00035-6; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Wang GX, 2003, AM J PHYSIOL-HEART C, V285, pH1453, DOI 10.1152/ajpheart.00244.2003; Wen H, 1999, EUR J NEUROSCI, V11, P935, DOI 10.1046/j.1460-9568.1999.00502.x; Wilson JTL, 2003, J NEUROL NEUROSUR PS, V74, P841, DOI 10.1136/jnnp.74.7.841; Yamasue H, 2003, P NATL ACAD SCI USA, V100, P9039, DOI 10.1073/pnas.1530467100; Yongbi MN, 1997, NMR BIOMED, V10, P79, DOI 10.1002/(SICI)1099-1492(199704)10:2<79::AID-NBM449>3.0.CO;2-K; Zhang ZG, 2001, J CEREBR BLOOD F MET, V21, P541, DOI 10.1097/00004647-200105000-00008	62	29	30	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2005	19	8					910	922		10.1096/fj.04-2957com	http://dx.doi.org/10.1096/fj.04-2957com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15923401				2022-12-28	WOS:000230207800038
J	Gotoh, K; Fukagawa, K; Fukagawa, T; Noguchi, H; Kakuma, T; Sakata, T; Yoshimatsu, H				Gotoh, K; Fukagawa, K; Fukagawa, T; Noguchi, H; Kakuma, T; Sakata, T; Yoshimatsu, H			Glucagon-like peptide-1, corticotropin-releasing hormone, and hypothalamic neuronal histamine interact in the leptin-signaling pathway to regulate feeding behavior	FASEB JOURNAL			English	Article						exendin(9-39); tele-methyl histamine; nucleus of the solitary tract	RAT HYPOTHALAMUS; FOOD-INTAKE; RECEPTOR; MICE; NUCLEUS; BRAIN; CELLS	Glucagon-like peptide-1 (GLP-1), corticotropin-releasing hormone (CRH), and hypothalamic neuronal histamine suppress food intake,a target of leptin action in the brain. This study examined the interactions of GLP-1, CRH, and histamine downstream from the leptin-signaling pathway in regulating feeding behavior. Infusion of GLP-1 into the third cerebral ventricle (i3vt) at a dose of 1 mu g significantly decreased the initial 1 h cumulative food intake in rats as compared with phosphate-buffered saline (PBS) controls. The GLP-1-induced suppression of feeding was partially attenuated by intraperitoneal pretreatment with alpha-fluoromethylhistidine (FMH), a specific suicide inhibitor of histidine decarboxylase, which depletes hypothalamic neuronal histamine. Pretreatment with alpha-helical CRH (10 mu g/rat, i3vt), a nonselective CRH antagonist, abolished the GLP-1-induced suppression of feeding completely. I3vt infusion of GLP-1 increased the CRH content and histamine turnover assessed using the pargyline-induced accumulation of tele-methyl histamine(t-MH), a major metabolite of neuronal histamine,in the hypothalamus. The central infusion of CRH also induced the increase of histamine turnover and CRH receptor type 1 was localized on the cell body of histamine neuron. Pretreatment with exendin(9-39), a GLP-1 receptor ant agonist, attenuated the leptin-induced increase in CRH content of the hypothalamus. Finally,i3vt infusion of leptin also increased histamine turnover in the hypothalamus. Pretreatment with exendin(9-39), alpha-helical CRH or both antagonists attenuated the leptin-induced responses of t-MH levels in the hypothalamus. These results suggest that CRH or hypothalamic neuronal histamine mediates the GLP-1-induced suppression of feeding behavior, that CRH mediates GLP-1 signaling to neuronal histamine and that a functional link from GLP-1 to neuronal histamine via CRH constitutes the leptin-signaling pathway regulating feeding behavior.	Oita Univ, Fac Med, Dept Internal Med 1, Oita 8795593, Japan	Oita University	Yoshimatsu, H (corresponding author), Oita Univ, Fac Med, Dept Internal Med 1, Oita 8795593, Japan.	hiroy@med.oita-u.ac.jp						ENG J, 1992, MT SINAI J MED, V59, P147; FUKAGAWA K, 1989, AM J PHYSIOL, V256, pR605, DOI 10.1152/ajpregu.1989.256.3.R605; GOKE R, 1993, J BIOL CHEM, V268, P19650; Goldstone AP, 1997, FEBS LETT, V415, P134, DOI 10.1016/S0014-5793(97)01103-4; Gunn I, 1996, BIOCHEM SOC T, V24, P581, DOI 10.1042/bst0240581; Huang QL, 1998, ENDOCRINOLOGY, V139, P1524, DOI 10.1210/en.139.4.1524; Itateyama E, 2003, EXP BIOL MED, V228, P1132; Larsen PJ, 1997, NEUROSCIENCE, V77, P257, DOI 10.1016/S0306-4522(96)00434-4; Larsen PJ, 1997, ENDOCRINOLOGY, V138, P4445, DOI 10.1210/en.138.10.4445; MacLusky NJ, 2000, ENDOCRINOLOGY, V141, P752, DOI 10.1210/en.141.2.752; Masaki T, 2003, ENDOCRINOLOGY, V144, P2741, DOI 10.1210/en.2003-0031; Navarro M, 1996, J NEUROCHEM, V67, P1982; OISHI R, 1987, J NEUROCHEM, V49, P541, DOI 10.1111/j.1471-4159.1987.tb02898.x; OOHARA A, 1994, J NEUROCHEM, V63, P677; Pinto S, 2004, SCIENCE, V304, P110, DOI 10.1126/science.1089459; Ryan AS, 1998, J CLIN ENDOCR METAB, V83, P2399, DOI 10.1210/jc.83.7.2399; SAKATA T, 1981, PHYSIOL BEHAV, V27, P401, DOI 10.1016/0031-9384(81)90323-1; SAKATA T, 1982, NEURAL BASIS FEEDING, P339; Sarkar S, 2003, BRAIN RES, V985, P163, DOI 10.1016/S0006-8993(03)03117-2; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Scrocchi LA, 1996, NAT MED, V2, P1254, DOI 10.1038/nm1196-1254; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TangChristensen M, 1996, AM J PHYSIOL-REG I, V271, pR848, DOI 10.1152/ajpregu.1996.271.4.R848; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; vanDijk G, 1996, AM J PHYSIOL-REG I, V271, pR1096, DOI 10.1152/ajpregu.1996.271.4.R1096; Yoshimatsu K, 1999, DIABETES, V48, P2286, DOI 10.2337/diabetes.48.12.2286	27	41	44	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1131	+		10.1096/fj.04-2384fje	http://dx.doi.org/10.1096/fj.04-2384fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15894564				2022-12-28	WOS:000229602600015
J	Groten, T; Pierce, AA; Huen, AC; Schnaper, HW				Groten, T; Pierce, AA; Huen, AC; Schnaper, HW			17 beta-estradiol transiently disrupts adherens junctions in endothelial cells	FASEB JOURNAL			English	Article						angiogenesis; vascular endothelial cadherin; vascular endothelial growth factor; Src-family kinases	ESTROGEN-RECEPTOR-ALPHA; NITRIC-OXIDE SYNTHASE; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; VE-CADHERIN; VASCULAR-PERMEABILITY; MICROVASCULAR PERMEABILITY; BETA-CATENIN; PARACELLULAR PERMEABILITY; MOLECULAR-ORGANIZATION	Interendothelial junctions are important regulators of endothelial cell functions such as migration and proliferation, major features in angiogenesis, and endothelial cell monolayer wound healing. 17 beta-estradiol regulates these functions in vivo and in vitro and also increases endothelial monolayer permeability as it results from impaired monolayer integrity and intercellular adhesion. We hypothesized that 17 beta-estradiol affects these cell adhesion-dependent functions in endothelial cells by targeting the adherens junction complex. Here, we show that 17 beta-estradiol increases uterine microvascular endothelial cell monolayer permeability and transiently redistributes interendothelial junction-forming proteins in endothelial cells. Concomitantly, adherens junction proteins are disconnected from the cytoskeleton and alpha-catenin, which links VE-cadherin to the cytoskeleton, is redistributed from the membrane and the adherens junction complex. Furthermore, 17 beta-estradiol increased tyrosine phosphorylation of the adherens junction complex. These effects were inhibited by the estrogen receptor antagonist ICI 182,780 but could be provoked using non-cell membrane-permeable 17 beta-estradiol-BSA in all cells tested, including EA.hy 926 cells, which have been shown unable to stimulate 17 beta-estradiol- dependent gene transcription. Additionally, 17 beta-estradiol treatment enhanced the angiogenic effect of vascular endothelial growth factor in an in vitro angiogenesis model, as a potential implication of the adherens junction disruption. Cotreatment with the Src-family kinase inhibitor PP2 prevented the redistribution and phosphorylation of the adherens junction proteins. Taken together, our data show that adherens junctions in endothelial cells are a downstream target of membrane-associated 17 beta-estradiol signaling, possibly through Src-family kinases.	Northwestern Univ, Dept Pediat, Chicago, IL 60611 USA; Northwestern Univ, Childrens Mem Inst Educ & Res, Chicago, IL 60611 USA; Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Northwestern University	Groten, T (corresponding author), Univ Ulm, Dept Obstet & Gynecol, Prittwitzstr 43, D-89075 Ulm, Germany.	tanja.groten@web.de	Groten, Tanja/G-7339-2018		NHLBI NIH HHS [HL-53918] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053918] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Andriopoulou P, 1999, ARTERIOSCL THROM VAS, V19, P2286, DOI 10.1161/01.ATV.19.10.2286; Baldwin AL, 2001, CRIT REV BIOMED ENG, V29, P247, DOI 10.1615/CritRevBiomedEng.v29.i2.20; Bates DO, 2002, J ANAT, V200, P581, DOI 10.1046/j.1469-7580.2002.00066.x; Bausero P, 2000, AM J PHYSIOL-HEART C, V279, pH2033, DOI 10.1152/ajpheart.2000.279.5.H2033; Bazzoni G, 2001, MICROCIRCULATION, V8, P143, DOI 10.1038/sj.mn.7800084; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Caveda L, 1996, J CLIN INVEST, V98, P886, DOI 10.1172/JCI118870; CHEN WC, 1991, J CELL BIOL, V114, P319, DOI 10.1083/jcb.114.2.319; Chew TL, 2002, J CELL BIOL, V156, P543, DOI 10.1083/jcb.200110161; Cho MM, 1999, AM J PHYSIOL-CELL PH, V276, pC337; Cid MC, 2002, ANN NY ACAD SCI, V966, P143, DOI 10.1111/j.1749-6632.2002.tb04211.x; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; Dejana E, 2000, INT J DEV BIOL, V44, P743; Dejana E, 2001, THROMB HAEMOSTASIS, V86, P308; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Esser S, 1998, J CELL SCI, V111, P1853; Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947; Figtree GA, 2003, CIRCULATION, V107, P120, DOI 10.1161/01.CIR.0000043805.11780.F5; Fujimoto J, 1998, HORM RES, V50, P30, DOI 10.1159/000053121; Gotsch U, 1997, J CELL SCI, V110, P583; Groten T, 2000, MOL HUM REPROD, V6, P1027, DOI 10.1093/molehr/6.11.1027; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Haynes MP, 2002, VASC PHARMACOL, V38, P99, DOI 10.1016/S0306-3623(02)00133-7; Haynes MP, 2003, J BIOL CHEM, V278, P2118, DOI 10.1074/jbc.M210828200; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; Ho KJ, 2002, ARTERIOSCL THROM VAS, V22, P1952, DOI 10.1161/01.ATV.0000041200.85946.4A; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Johns A, 1996, ENDOCRINOLOGY, V137, P4511, DOI 10.1210/en.137.10.4511; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099; Korff T, 1999, J CELL SCI, V112, P3249; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Lampugnani MG, 1997, J CELL SCI, V110, P2065; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; Levin ER, 2002, STEROIDS, V67, P471, DOI 10.1016/S0039-128X(01)00179-9; Li L, 2003, P NATL ACAD SCI USA, V100, P4807, DOI 10.1073/PNAS.0831079100; Martin TA, 2001, CLIN CANCER RES, V7, P734; McIlhenny C, 2002, BRIT J CANCER, V86, P1786, DOI 10.1038/sj.bjc.6600322; MORALES DE, 1995, CIRCULATION, V91, P755, DOI 10.1161/01.CIR.91.3.755; Navarro P, 1995, J BIOL CHEM, V270, P30965, DOI 10.1074/jbc.270.52.30965; Nawroth R, 2002, EMBO J, V21, P4885, DOI 10.1093/emboj/cdf497; Nwariaku FE, 2002, SURGERY, V132, P180, DOI 10.1067/msy.2002.125305; Petzelbauer P, 2000, J INVEST DERM SYMP P, V5, P10, DOI 10.1046/j.1087-0024.2000.00002.x; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Rabiet MJP, 1996, ARTERIOSCL THROM VAS, V16, P488, DOI 10.1161/01.ATV.16.3.488; Rahimi N, 1999, MOL BIOL CELL, V10, P3401, DOI 10.1091/mbc.10.10.3401; Runyan CE, 2003, AM J PHYSIOL-RENAL, V285, pF413, DOI 10.1152/ajprenal.00082.2003; Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930; SHEFFIELD JB, 1987, ANAL BIOCHEM, V166, P49, DOI 10.1016/0003-2697(87)90544-6; Sorby M, 1996, J BIOL CHEM, V271, P10963; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; Suzuki T, 2003, MICROSC RES TECHNIQ, V60, P76, DOI 10.1002/jemt.10246; Vestweber D, 2000, J PATHOL, V190, P281; Vinals F, 1999, MOL CELL BIOL, V19, P2763; Watson CS, 2002, STEROIDS, V67, P429, DOI 10.1016/S0039-128X(01)00172-6; Wong RK, 1999, AM J PHYSIOL-HEART C, V276, pH736; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yuan SY, 2002, VASC PHARMACOL, V39, P213, DOI 10.1016/S1537-1891(03)00010-7	66	41	45	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2005	19	7					1368	+		10.1096/fj.04-2558fje	http://dx.doi.org/10.1096/fj.04-2558fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15928195				2022-12-28	WOS:000229602600003
J	Griol-Charhbili, V; Messadi-Laribi, E; Bascands, JL; Heudes, D; Meneton, P; Giudicelli, JF; Alhenc-Gelas, F; Richer, C				Griol-Charhbili, V; Messadi-Laribi, E; Bascands, JL; Heudes, D; Meneton, P; Giudicelli, JF; Alhenc-Gelas, F; Richer, C			Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia	FASEB JOURNAL			English	Article						myocardial infarction; angiotensin-converting enzyme inhibitor; kallikrein-kinin system; mice	ANGIOTENSIN-CONVERTING ENZYME; BRADYKININ B-2 RECEPTOR; FLOW-DEPENDENT DILATION; GENE KNOCKOUT MICE; NITRIC-OXIDE; ISCHEMIA/REPERFUSION INJURY; INFARCT SIZE; IN-VIVO; CORONARY-OCCLUSION; SIGNALING PATHWAYS	Tissue kallikrein (TK), a major kinin-forming enzyme, is synthesized in the heart and arteries. We tested the hypothesis that TK plays a protective role in myocardial ischemia by performing ischemia-reperfusion (IR) injury, with and without ischemic preconditioning (IPC) or ACE inhibitor (ramiprilat) pretreatment, in vivo in littermate wild-type (WT) or TK-deficient (TK-/-) mice. IR induced similar infarcts in WT and TK-/- IPC reduced infarct size by 65% in WT, and by 40% in TK-/- (P<0.05, TK-/- vs WT). Ramiprilat also reduced infarct size by 29% in WT, but in TK-/- its effect was completely suppressed. Pretreatment of WT with a B2, but not a B1, kinin receptor antagonist reproduced the effects of TK deficiency. However, B2 receptor-deficient mice (B2(-/-)) unexpectedly responded to IPC or ramiprilat like WT mice. But pretreatment of the B2(-/-) mice with a B1 antagonist suppressed the cardioprotective effects of IPC and ramiprilat. In B2(-/-), B1 receptor gene expression was constitutively high. In WT and TK-/- mice, both B2 and B1 mRNA levels increased several fold during IR, and even more during IPC+IR. Thus TK and the B2 receptor play a critical role in the cardioprotection afforded by two experimental maneuvers of potential clinical relevance, IPC and ACE inhibition, during ischemia.	INSERM, U652 367, F-75270 Paris, France; Fac Med Paris Sud, Dept Pharmacol, F-94276 Le Kremlin Bicetre, France; Inst Louis Bugnard, INSERM, U388, IFR31, F-31432 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm)	Richer, C (corresponding author), INSERM, U652, 15 Rue Ecole Med, F-75270 Paris, France.	christine.giudicelli@kb.u-psud.fr	Meneton, Pierre/T-1216-2019; Bascands, Jean-loup/G-3260-2013; Alhenc-Gelas, Francois/F-9511-2017	Bascands, Jean-loup/0000-0002-1667-5913				Bergaya S, 2004, CIRC RES, V94, P1623, DOI 10.1161/01.RES.0000131497.73744.1a; Bergaya S, 2001, CIRC RES, V88, P593, DOI 10.1161/01.RES.88.6.593; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Blaukat A, 2001, J BIOL CHEM, V276, P40431, DOI 10.1074/jbc.M107024200; BORKOWSKI JA, 1995, J BIOL CHEM, V270, P13706, DOI 10.1074/jbc.270.23.13706; Brown NJ, 2000, CIRCULATION, V102, P2190; COHEN MV, 1991, CIRCULATION, V84, P341, DOI 10.1161/01.CIR.84.1.341; Duka I, 2001, CIRC RES, V88, P275, DOI 10.1161/01.RES.88.3.275; ERDOS EG, 1990, HYPERTENSION, V16, P363, DOI 10.1161/01.HYP.16.4.363; GOTO M, 1995, CIRC RES, V77, P611, DOI 10.1161/01.RES.77.3.611; Gougat J, 2004, J PHARMACOL EXP THER, V309, P661, DOI 10.1124/jpet.103.059527; Guo YR, 1998, AM J PHYSIOL-HEART C, V275, pH1375; HARTMAN JC, 1995, ANN THORAC SURG, V60, P789, DOI 10.1016/0003-4975(95)00192-N; HARTMAN JC, 1993, J CARDIOVASC PHARM, V21, P996, DOI 10.1097/00005344-199306000-00022; Hecquet C, 2000, MOL PHARMACOL, V58, P828, DOI 10.1124/mol.58.4.828; Hutter JJ, 1996, CIRCULATION, V94, P1408, DOI 10.1161/01.CIR.94.6.1408; Ignjatovic T, 2004, MOL PHARMACOL, V66, P1310, DOI 10.1124/mol.104.001990; Kanno S, 2000, CIRCULATION, V101, P2742, DOI 10.1161/01.CIR.101.23.2742; KITAKAZE M, 1995, CIRCULATION, V92, P950, DOI 10.1161/01.CIR.92.4.950; Laude K, 2002, CARDIOVASC RES, V55, P466, DOI 10.1016/S0008-6363(02)00277-8; Linz W, 1996, DIABETES, V45, pS51, DOI 10.2337/diab.45.1.S51; Meneton P, 2001, P NATL ACAD SCI USA, V98, P2634, DOI 10.1073/pnas.051619598; Michael LH, 1995, AM J PHYSIOL-HEART C, V269, pH2147, DOI 10.1152/ajpheart.1995.269.6.H2147; Murphy E, 2004, CIRC RES, V94, P7, DOI 10.1161/01.RES.0000108082.76667.F4; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nakano A, 2000, PHARMACOL THERAPEUT, V86, P263, DOI 10.1016/S0163-7258(00)00058-9; NOLLY H, 1994, HYPERTENSION, V23, P919, DOI 10.1161/01.HYP.23.6.919; Oldenburg O, 2004, AM J PHYSIOL-HEART C, V286, pH468, DOI 10.1152/ajpheart.00360.2003; Pan HL, 2000, AM J PHYSIOL-HEART C, V279, pH116; PEARSON PJ, 1990, CIRCULATION, V81, P1921, DOI 10.1161/01.CIR.81.6.1921; Pinto YM, 2000, FASEB J, V14, P1861; Schulz R, 2004, CARDIOVASC RES, V61, P402, DOI 10.1016/j.cardiores.2003.09.019; Slim R, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134968; Trabold F, 2002, HYPERTENSION, V40, P90, DOI 10.1161/01.HYP.0000021747.43346.95; Tricarico C, 2002, ANAL BIOCHEM, V309, P293, DOI 10.1016/S0003-2697(02)00311-1; Tschope C, 2004, CARDIOVASC RES, V61, P559, DOI 10.1016/j.cardiores.2003.10.018; Tschope C, 2000, BRAZ J MED BIOL RES, V33, P701, DOI 10.1590/S0100-879X2000000600011; VANBENTHUYSEN KM, 1987, J CLIN INVEST, V79, P265, DOI 10.1172/JCI112793; WALL TM, 1994, J PHARMACOL EXP THER, V270, P681; Weidenbach R, 2000, BRIT J PHARMACOL, V131, P138, DOI 10.1038/sj.bjp.0703544; WIEMER G, 1991, HYPERTENSION, V18, P558, DOI 10.1161/01.HYP.18.4.558; Yang XP, 1997, HYPERTENSION, V30, P735, DOI 10.1161/01.HYP.30.3.735; Yang XP, 1999, HYPERTENSION, V34, P24, DOI 10.1161/01.HYP.34.1.24; Yang XP, 2001, CIRC RES, V88, P1072, DOI 10.1161/hh1001.090759; Zhu BQ, 2000, J AM COLL CARDIOL, V35, P787, DOI 10.1016/S0735-1097(99)00592-6	45	55	60	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1172	+		10.1096/fj.04-3508fje	http://dx.doi.org/10.1096/fj.04-3508fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15860541				2022-12-28	WOS:000228865300003
J	Piec I; Listrat, A; Alliot, J; Chambon, C; Taylor, RG; Bechet, D				Piec, I; Listrat, A; Alliot, J; Chambon, C; Taylor, RG; Bechet, D			Differential proteome analysis of aging in rat skeletal muscle	FASEB JOURNAL			English	Article						sarcopenia; old; proteomics; stress; cytoskeleton	2-DIMENSIONAL GEL-ELECTROPHORESIS; GENE-EXPRESSION PROFILE; CALORIC RESTRICTION; ENDOPLASMIC-RETICULUM; MASS-SPECTROMETRY; STRIATED-MUSCLE; RHESUS-MONKEYS; FIBER TYPES; OLD RATS; MYBP-C	To identify the mechanisms underlying muscle aging, we have undertaken a high-resolution differential proteomic analysis of gastrocnemius muscle in young adults, mature adults, and old LOU/c/jall rats. Two-dimensional gel electrophoresis and subsequent MALDI-ToF mass spectrometry analyses led to the identification of 40 differentially expressed proteins. Strikingly, most differences characterized old (30-month) animals, whereas young (7-month) and mature (18-month) adults exhibited similar patterns of expression. Important modifications in contractile (actin, myosin light-chains, troponins-T) and cytoskeletal (desmin, tubulin) proteins, and in essential regulatory proteins (gelsolin, myosin binding proteins, CapZ-beta, P23), likely account for dysfunctions in old muscle force generation and speed of contraction. Other features support decreases in cytosolic (triose-phosphate isomerase, enolase, glycerol-3-P dehydrogenase, creatine kinase) and mitochondrial (isocitrate dehydrogenase, cytochrome-c oxidase) energy metabolisms. Muscle aging is often associated with increased oxidative stress. Accordingly, we observed differential regulation of molecular chaperones (hsp20, hsp27, reticuloplasmin ER60) and of proteins implicated in reactive aldehyde detoxification (aldehyde dehydrogenase, glutathione transferase, glyoxalase). We further noticed up-regulation of proteins involved in transcriptional elongation (RNA capping protein) and RNA-editing (Apobec2). Most of these proteins were previously unrecognized as differentially expressed in old muscles, and they represent novel starting points for elucidating the mechanisms of muscle aging.	INRA, Nutr & Prot Metab Lab, Human Nutr Res Ctr, F-63122 Ceyrat, France; Growth & Muscle Metab Lab, Ceyrat, France; Univ Clermont Ferrand, Lab Neuroendocrinol Aging, Aubiere, France; Meat Res Stn, Ceyrat, France	INRAE	Bechet, D (corresponding author), INRA, Nutr & Prot Metab Lab, Human Nutr Res Ctr, UR 551, F-63122 Ceyrat, France.	daniel.bechet@clermont.inra.fr	chambon, christophe/A-1788-2017; Bechet, Daniel/AAU-2874-2020; , Listrat/J-1501-2019; Piec, Isabelle Danielle/GQA-9932-2022	chambon, christophe/0000-0003-0357-9807; Bechet, Daniel/0000-0002-3812-8099; Piec, Isabelle Danielle/0000-0002-0648-1330; Listrat, Anne/0000-0002-6182-1764				Alliot J, 2002, J GERONTOL A-BIOL, V57, pB312, DOI 10.1093/gerona/57.8.B312; BALAGOPAL P, 1997, AM J PHYSIOL, V273, P790; Bejma J, 1999, J APPL PHYSIOL, V87, P465, DOI 10.1152/jappl.1999.87.1.465; Berthier C, 1997, BIOL CELL, V89, P413, DOI 10.1016/S0248-4900(97)89313-6; Bouley J, 2004, PROTEOMICS, V4, P1811, DOI 10.1002/pmic.200300688; Cai D, 2000, ELECTROPHORESIS, V21, P465, DOI 10.1002/(SICI)1522-2683(20000101)21:2<465::AID-ELPS465>3.3.CO;2-X; Carmeli E, 2002, EXP GERONTOL, V37, P477, DOI 10.1016/S0531-5565(01)00220-0; Chang JS, 2003, MECH AGEING DEV, V124, P33, DOI 10.1016/S0047-6374(02)00167-7; Chen JJ, 1996, AGING CLIN EXP RES, V8, P334, DOI 10.1007/BF03339590; Clark KA, 2002, ANNU REV CELL DEV BI, V18, P637, DOI 10.1146/annurev.cellbio.18.012502.105840; Dalle-Donne I, 2001, FREE RADICAL BIO MED, V31, P1624, DOI 10.1016/S0891-5849(01)00749-3; Davydov VV, 2004, EXP GERONTOL, V39, P11, DOI 10.1016/j.exger.2003.08.009; Ek P, 2002, EUR J BIOCHEM, V269, P5016, DOI 10.1046/j.1432-1033.2002.03206.x; Filatov VL, 1999, BIOCHEMISTRY-MOSCOW+, V64, P969; Gilbert R, 1996, J CELL SCI, V109, P101; Gilbert R, 1999, J CELL SCI, V112, P69; Goldring K, 2002, J CELL SCI, V115, P355; Greenlund LJS, 2003, MECH AGEING DEV, V124, P287, DOI 10.1016/S0047-6374(02)00196-3; Hart MC, 1999, J CELL BIOL, V147, P1287, DOI 10.1083/jcb.147.6.1287; HOLLOSZY JO, 1991, MECH AGEING DEV, V60, P199, DOI 10.1016/0047-6374(91)90131-I; Hughes RC, 2001, BIOCHIMIE, V83, P667; Isfort RJ, 2000, ELECTROPHORESIS, V21, P2228, DOI 10.1002/1522-2683(20000601)21:11<2228::AID-ELPS2228>3.0.CO;2-V; Jideama NM, 1996, J BIOL CHEM, V271, P23277, DOI 10.1074/jbc.271.38.23277; Jubrias SA, 1997, PFLUG ARCH EUR J PHY, V434, P246, DOI 10.1007/s004240050392; Kamel HK, 2003, NUTR REV, V61, P157, DOI 10.1301/nr.2003.may.157-167; Kayo T, 2001, P NATL ACAD SCI USA, V98, P5093, DOI 10.1073/pnas.081061898; Kim YJ, 2004, BIOCHEM BIOPH RES CO, V318, P579, DOI 10.1016/j.bbrc.2004.04.068; KLITGAARD H, 1990, ACTA PHYSIOL SCAND, V140, P41, DOI 10.1111/j.1748-1716.1990.tb08974.x; Klumpp S, 2003, BIOCHEM BIOPH RES CO, V306, P110, DOI 10.1016/S0006-291X(03)00920-3; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; LARSSON L, 1994, J PHYSIOL-LONDON, V481, P149, DOI 10.1113/jphysiol.1994.sp020426; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3; Liao W, 1999, BIOCHEM BIOPH RES CO, V260, P398, DOI 10.1006/bbrc.1999.0925; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; Pastoris O, 2000, EXP GERONTOL, V35, P95, DOI 10.1016/S0531-5565(99)00077-7; Payne AM, 2003, J APPL PHYSIOL, V95, P2554, DOI 10.1152/japplphysiol.00758.2003; Renault V, 2002, AGING CELL, V1, P132, DOI 10.1046/j.1474-9728.2002.00017.x; Russell SJ, 2004, J BIOL CHEM, V279, P18861, DOI 10.1074/jbc.M400575200; Sanchez JC, 2001, PROTEOMICS, V1, P136; Sastre J, 2003, FREE RADICAL BIO MED, V35, P1, DOI 10.1016/S0891-5849(03)00184-9; Su T, 2003, P NATL ACAD SCI USA, V100, P7824, DOI 10.1073/pnas.1332160100; Veyrat-Durebex C, 1997, PHYSIOL BEHAV, V62, P1273, DOI 10.1016/S0031-9384(97)00304-1; Vyakarnam A, 1997, MOL CELL BIOL, V17, P4730, DOI 10.1128/MCB.17.8.4730; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Watt Diana J., 2004, Glycoconjugate Journal, V19, P615; Welle S, 2003, PHYSIOL GENOMICS, V14, P149, DOI 10.1152/physiolgenomics.00049.2003; Yan JX, 2001, PROTEOMICS, V1, P424, DOI 10.1002/1615-9861(200103)1:3<424::AID-PROT424>3.3.CO;2-P; Zainal TA, 2000, FASEB J, V14, P1825, DOI 10.1096/fj.99-0881com	50	142	146	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2005	19	6					1143	+		10.1096/fj.04-3084fje	http://dx.doi.org/10.1096/fj.04-3084fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15831715				2022-12-28	WOS:000228865300017
J	Urbich, C; Knau, A; Fichtlscherer, S; Walter, DH; Bruhl, T; Potente, M; Hofmann, WK; de Vos, S; Zeiher, AM; Dimmeler, S				Urbich, C; Knau, A; Fichtlscherer, S; Walter, DH; Bruhl, T; Potente, M; Hofmann, WK; de Vos, S; Zeiher, AM; Dimmeler, S			FOXO-dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial progenitor cells	FASEB JOURNAL			English	Article						forkhead transcription factors; cell death; PI3K/Akt signaling; statins	FORKHEAD TRANSCRIPTION FACTORS; FAMILY-MEMBER BIM; BCL-2 FAMILY; STATIN THERAPY; AKT; PHOSPHORYLATION; GENE; SURVIVAL; ANGIOGENESIS; BINDING	Endothelial progenitor cells (EPCs) contribute to postnatal neovascularization. Risk factors for coronary artery disease reduce the number of EPCs in humans. Since EPC apoptosis might be a potential mechanism to regulate the number of EPCs, we investigated the effects of oxidative stress and HMG-CoA-reductase inhibitors (statins) on EPC apoptosis. Atorvastatin, mevastatin, or VEGF prevented EPC apoptosis induced by H2O2. The antiapoptotic effect was reversed by inhibition of the PI3K/Akt pathway. Forkhead transcription factors (FOXO1, FOXO3a, FOXO4) exert proapoptotic effects and are phosphorylated and, thereby, inactivated by Akt. Therefore, we elucidated the involvement of forkhead transcription factors. Atorvastatin induced the phosphorylation of the predominant forkhead factor FOXO4 in EPCs. In addition, atorvastatin reduced the expression of the proapoptotic forkhead-regulated protein Bim in a PI3K-dependent manner. Consistently, overexpression of FOXO4 activated the Bim promoter as determined by reporter gene expression and stimulated the expression of Bim, resulting in an increased EPC apoptosis. Statins failed to prevent EPC apoptosis induced by overexpression of Bim or noriphosphorylatable FOXO4, suggesting that the protective effects of statins depend on this pathway. In summary, our results show that FOXO-dependent expression of Bim plays a pivotal role for EPC apoptosis. Statins reduce oxidative stress-induced EPC apoptosis, inactivate FOXO4, and down-regulate Bim.	Goethe Univ Frankfurt, Dept Internal Med 3, D-60590 Frankfurt, Germany; Goethe Univ Frankfurt, Dept Hematol & Oncol, D-60590 Frankfurt, Germany; Univ Calif Los Angeles, Sch Med, Dept Hematol & Oncol, Los Angeles, CA USA	Goethe University Frankfurt; Goethe University Frankfurt; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Dimmeler, S (corresponding author), Goethe Univ Frankfurt, Dept Internal Med 3, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	Dimmeler@em.uni-frankfurt.de		Dimmeler, Stefanie/0000-0002-1045-2436; Potente, Michael/0000-0002-5689-0036				Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; ASSMUS B, 2003, CIRC RES, V3, P3; Badorff C, 2002, J CLIN INVEST, V109, P373, DOI 10.1172/JCI200213779; Bhattacharya V, 2000, BLOOD, V95, P581, DOI 10.1182/blood.V95.2.581; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; BRUHL T, 2004, CIRC RES, V5, P5; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen D, 2004, P NATL ACAD SCI USA, V101, P1235, DOI 10.1073/pnas.0308050100; Chen JZ, 2004, INT J BIOCHEM CELL B, V36, P1554, DOI 10.1016/j.biocel.2003.12.015; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; DERNBACH E, 2004, BLOOD, V25, P25; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI13152; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Gehling UM, 2000, BLOOD, V95, P3106; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; He TR, 2004, ARTERIOSCL THROM VAS, V24, P2021, DOI 10.1161/01.ATV.0000142810.27849.8f; Hofmann WK, 2001, BLOOD, V98, P787, DOI 10.1182/blood.V98.3.787; Ito H, 1999, CANCER RES, V59, P5875; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Lefer AM, 1999, CIRCULATION, V100, P178, DOI 10.1161/01.CIR.100.2.178; Liu JW, 2002, CANCER RES, V62, P2976; Llevadot J, 2001, J CLIN INVEST, V108, P399, DOI 10.1172/JCI200113131; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; Murohara T, 2000, J CLIN INVEST, V105, P1527, DOI 10.1172/JCI8296; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Schatteman GC, 2000, J CLIN INVEST, V106, P571, DOI 10.1172/JCI9087; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Sorescu D, 2001, TRENDS CARDIOVAS MED, V11, P124, DOI 10.1016/S1050-1738(01)00097-4; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tepper OM, 2002, CIRCULATION, V106, P2781, DOI 10.1161/01.CIR.0000039526.42991.93; Urbich C, 2000, CIRC RES, V87, P683, DOI 10.1161/01.RES.87.8.683; Urbich C, 2002, CIRC RES, V90, P737, DOI 10.1161/01.RES.0000014081.30867.F8; Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953; Vasa M, 2001, CIRCULATION, V103, P2885, DOI 10.1161/hc2401.092816; VILLUNGER A, 2002, BLOOD, V14, P14; Walter DH, 2002, CIRCULATION, V105, P3017, DOI 10.1161/01.CIR.0000018166.84319.55; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	61	165	186	2	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					974	+		10.1096/fj.04-2727fje	http://dx.doi.org/10.1096/fj.04-2727fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15824087				2022-12-28	WOS:000228865300019
J	Block, ML; Li, G; Qin, L; Wu, X; Pei, Z; Wang, T; Wilson, B; Yang, J; Hong, JS				Block, M. L.; Li, G.; Qin, L.; Wu, X.; Pei, Z.; Wang, T.; Wilson, B.; Yang, J.; Hong, J. S.			Potent regulation of microglia-derived oxidative stress and dopaminergic neuron survival: substance P vs. dynorphin	FASEB JOURNAL			English	Article						microglia; oxidative stress; DA neurotoxicity; superoxide; NADPH oxidase; femtomolar	LIPOPOLYSACCHARIDE-INDUCED NEUROTOXICITY; FEMTOMOLAR CONCENTRATIONS; PARKINSONS-DISEASE; NADPH-OXIDASE; INFLAMMATORY DAMAGE; TETRAZOLIUM SALT; ACTIVATION; RAT; CULTURES; NEUROPROTECTION	Unregulated microglial activation has been implicated as a pivotal factor contributing to Parkinson's disease. Using mesencephalic neuron-glia cultures, we address the novel possibility that peptides endogenous to the substantia nigra (SN), substance P and dynorphin (10(-13)-10(-14) M), are opposing mediators of microglial activation and consequent DA neurotoxicity. Here, we identify that substance P (10-(13)-10(-14) M) is selectively toxic to DA neurons in a microglia-dependent manner. Mechanistically, substance P (10(-13)-10(-14) M) activated microglial NADPH oxidase to produce extracellular superoxide and intracellular reactive oxygen species (ROS). Neuron-glia cultures from mice lacking a functional NADPH oxidase complex (PHOX-/-) were insensitive to substance P (10(-13)-10(-14) M) -induced loss of DA neuron function. Mixed glia cultures from (PHOX-/-) mice failed to show a significant increase in intracellular ROS in response to substance P compared with control cultures (PHOX-/-). Further, dynorphin (10(-14) M) inhibited substance P (10(-13) M) -induced loss of [H-3] DA uptake. Here we demonstrate a tightly regulated mechanism governing microglia-derived oxidative stress, where the neuropeptide balance of dynorphin and substance P is critical to DA neuron survival.	NIEHS, Lab Pharmacol & Chem, Neuropharmacol Sect, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Block, ML (corresponding author), NIEHS, Lab Pharmacol & Chem, Neuropharmacol Sect, POB 12233, Res Triangle Pk, NC 27709 USA.	Block@niehs.nih.gov	Hong, Jau-shyong/F-1920-2019	Hong, Jau-shyong/0000-0002-3056-8401; Block, Michelle/0000-0001-8303-7914	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090082, Z01ES090082] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKIYAMA H, 1989, BRAIN RES, V489, P247, DOI 10.1016/0006-8993(89)90857-3; Block ML, 2004, FASEB J, V18, P1618, DOI 10.1096/fj.04-1945fje; BOWDEN JJ, 1994, P NATL ACAD SCI USA, V91, P8964, DOI 10.1073/pnas.91.19.8964; BROWNSTEIN MJ, 1976, BRAIN RES, V116, P299, DOI 10.1016/0006-8993(76)90907-0; CALVO CF, 1992, J IMMUNOL, V148, P3498; ChancellorFreeland C, 1995, ANN NY ACAD SCI, V771, P472, DOI 10.1111/j.1749-6632.1995.tb44703.x; DAS KP, 1995, J NEUROIMMUNOL, V62, P9, DOI 10.1016/0165-5728(95)00083-E; Delgado M, 1999, J IMMUNOL, V162, P1200; FAITH RE, 1984, CLIN IMMUNOL IMMUNOP, V31, P412, DOI 10.1016/0090-1229(84)90093-X; Fernandez A, 1996, BRAIN, V119, P823, DOI 10.1093/brain/119.3.823; Gao HM, 2003, FASEB J, V17, DOI 10.1096/fj.03-0109fje; Gao HM, 2003, J NEUROSCI, V23, P6181; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; GLADYSHEVA TB, 1989, BIOFIZIKA+, V34, P833; Gozes I, 1999, ANN NY ACAD SCI, V897, P125, DOI 10.1111/j.1749-6632.1999.tb07884.x; GRUBER BL, 1995, BLOOD, V86, P2488; HONG JS, 1977, BRAIN RES, V122, P541, DOI 10.1016/0006-8993(77)90464-4; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Kong LY, 1999, NEUROSCIENCE, V91, P493, DOI 10.1016/S0306-4522(98)00606-X; Kong LY, 2000, J BIOMED SCI, V7, P241; Le YY, 1999, J IMMUNOL, V163, P6777; LEVY R, 1995, EUR J NEUROSCI, V7, P1199, DOI 10.1111/j.1460-9568.1995.tb01110.x; Li GR, 2005, FASEB J, V19, P489, DOI 10.1096/fj.04-2555com; Liu B, 2000, J PHARMACOL EXP THER, V293, P607; Liu B, 2003, METH MOLEC MED, V79, P387; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Liu B, 2001, J PHARMACOL EXP THER, V298, P1133; LOEFFLER DA, 1994, CLIN NEUROPHARMACOL, V17, P370, DOI 10.1097/00002826-199408000-00009; LUBERNAROD J, 1994, J IMMUNOL, V152, P819; Maeda K, 1997, GERONTOLOGY, V43, P11; Marton J, 2003, VALUE HEALTH, V6, P183, DOI 10.1016/S1098-3015(10)63816-8; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; MROZ EA, 1977, BRAIN RES, V125, P305, DOI 10.1016/0006-8993(77)90623-0; Peskin AV, 2000, CLIN CHIM ACTA, V293, P157, DOI 10.1016/S0009-8981(99)00246-6; Qin IY, 2005, FASEB J, V19, P550, DOI 10.1096/fj.04-2857com; QIN L, IN PRESS FASEB J; Qin LY, 2005, ANN NY ACAD SCI, V1053, P107, DOI 10.1196/annals.1344.009; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Rasley A, 2004, J IMMUNOL, V172, P5707, DOI 10.4049/jimmunol.172.9.5707; Ravati A, 2000, BRAIN RES, V866, P23, DOI 10.1016/S0006-8993(00)02210-1; SERRA MC, 1988, J IMMUNOL, V141, P2118; Sowa G, 1997, BIOCHEM PHARMACOL, V53, P823, DOI 10.1016/S0006-2952(97)00006-3; Tan AS, 2000, J IMMUNOL METHODS, V238, P59, DOI 10.1016/S0022-1759(00)00156-3; WALSH DT, 1995, BRIT J PHARMACOL, V114, P1343, DOI 10.1111/j.1476-5381.1995.tb13354.x; Wiedermann FJ, 2002, CRIT CARE MED, V30, P1112, DOI 10.1097/00003246-200205000-00025; WILLIAMSON S A, 1987, Brain Behavior and Immunity, V1, P329, DOI 10.1016/0889-1591(87)90035-3; WILLIAMSON SA, 1988, IMMUNOLOGY, V65, P47; Wu XF, 2005, ANTIOXID REDOX SIGN, V7, P654, DOI 10.1089/ars.2005.7.654; Zhang W, 2005, FASEB J, V19, P533, DOI 10.1096/fj.04-2751com	49	80	87	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					251	258		10.1096/fj.05-4553com	http://dx.doi.org/10.1096/fj.05-4553com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16449797				2022-12-28	WOS:000237698700010
J	Buning, J; Hundorfean, G; Schmitz, M; Zimmer, KP; Strobel, S; Gebert, A; Ludwig, D				Buening, Juergen; Hundorfean, Gheorghe; Schmitz, Martina; Zimmer, Klaus-Peter; Strobel, Stephan; Gebert, Andreas; Ludwig, Diether			Antigen targeting to MHC class II-enriched late endosomes in colonic epithelial cells: trafficking of luminal antigens studied in vivo in Crohn's colitis patients	FASEB JOURNAL			English	Article									[Buening, Juergen; Hundorfean, Gheorghe; Ludwig, Diether] Univ Klinikum Schleswig Holstein, Med Klin 1, D-23538 Lubeck, Germany; [Buening, Juergen; Gebert, Andreas] Univ Lubeck, Inst Anat, Lubeck, Germany; [Schmitz, Martina; Zimmer, Klaus-Peter] Univ Klinikum Munster, Klin & Poliklin Kinderheilkunde, Munster, Germany; [Strobel, Stephan] Univ Plymouth, Peninsula Med Sch, Plymouth PL4 8AA, Devon, England; [Strobel, Stephan] Univ Exeter, Peninsula Med Sch, Plymouth, Devon, England	University of Kiel; Schleswig Holstein University Hospital; University of Lubeck; University of Munster; University of Plymouth; University of Exeter; University of Plymouth	Buning, J (corresponding author), Univ Klinikum Schleswig Holstein, Med Klin 1, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	buening@anat.uni-luebeck.de	Zimmer, Klaus-Peter/AAY-9261-2020; Zimmer, Klaus-Peter/AAY-9351-2020						0	20	21	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					359	361		10.1096/fj.05-4807fje	http://dx.doi.org/10.1096/fj.05-4807fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16373401				2022-12-28	WOS:000207915000021
J	Jeong, YH; Park, CH; Yoo, J; Shin, KY; Ahn, SM; Kim, HS; Lee, SH; Emson, PC; Suh, YH				Jeong, Yun Ha; Park, Cheol Hyoung; Yoo, Jongman; Shin, Ki Young; Ahn, Sung-Min; Kim, Hye-Sun; Lee, Sang Hyung; Emson, Piers C.; Suh, Yoo-Hun			Chronic stress accelerates learning and memory impairments and increases amyloid deposition in APP(V717I)-CT100 transgenic mice, an Alzheimer's disease model	FASEB JOURNAL			English	Article						long-term stress; cognitive impairments; amyloid plaque	CARBOXYL-TERMINAL FRAGMENT; RECEPTOR-LIKE IMMUNOREACTIVITY; PRECURSOR PROTEIN; A-BETA; HIPPOCAMPAL-FORMATION; RETROGRADE-AMNESIA; OLFACTORY FUNCTION; APICAL DENDRITES; BRAIN; LESIONS	Although chronic stress is known to be linked with memory and other neurological disorders, little is known about the relationship between chronic stress and the onset or development of Alzheimer's disease ( AD). In this study, we investigated the effects of long-term stress on the onset and severity of cognitive deficits and pathological changes in APP(V717I)-CT100 mice overexpressing human APP-CT100 containing the London mutation (V717I) after exposure to immobilization stress. We found that chronic immobilization stress accelerated cognitive impairments, as accessed by the Passive avoidance and the Social Transfer of Food Preference (STFP) tests. Moreover, the numbers and densities of vascular and extracellular deposits containing amyloid beta peptide (A beta) and carboxyl-terminal fragments of amyloid precursor protein (APP-CTFs), which are pathologic markers of AD, were significantly elevated in stressed animals, especially in the hippocampus. Moreover, stressed animals, also showed highly elevated levels of neurodegeneration and tau phosphorylation and increased intraneuronal A beta and APP-CTFs immunoreactivities in the hippocampus and in the entorhinal and piriform cortex. This study provides the first evidence that chronic stress accelerates the onset and severity of cognitive deficits and that these are highly correlated with pathological changes, which thus indicates that chronic stress may be an important contributor to the onset and development of AD.	Seoul Natl Univ, Dept Pharmacol, Coll Med, Natl Creat Res Initiat Ctr Alzheimers Dementia, Seoul 110799, South Korea; Seoul Natl Univ, MRC, Neurosci Res Inst, Seoul 110799, South Korea; Seoul Natl Univ, Dept Neurosurg, Coll Med, Seoul 110799, South Korea; Babraham Inst, Neurobiol Programme, Cambridge, England	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Suh, YH (corresponding author), Seoul Natl Univ, Dept Pharmacol, Coll Med, Natl Creat Res Initiat Ctr Alzheimers Dementia, 28 Yeongeon Dong, Seoul 110799, South Korea.	yhsuh@snu.ac.kr	Suh, Yoo-Hun/J-2761-2012; Lee, Sang Hyung/J-5581-2012; Kim, Hye Sun/J-2752-2012	Jeong, Yun Ha/0000-0001-7703-6659				AHIMA R, 1991, J COMP NEUROL, V313, P522, DOI 10.1002/cne.903130312; AHIMA RS, 1990, NEUROSCIENCE, V39, P579, DOI 10.1016/0306-4522(90)90244-X; Alvarez P, 2002, NEUROBIOL LEARN MEM, V78, P470, DOI 10.1006/nlme.2002.4068; Bach JH, 2001, J NEUROCHEM, V78, P109, DOI 10.1046/j.1471-4159.2001.00370.x; Bacon AW, 1998, ANN NY ACAD SCI, V855, P723, DOI 10.1111/j.1749-6632.1998.tb10651.x; Billings LM, 2005, NEURON, V45, P675, DOI 10.1016/j.neuron.2005.01.040; Bunsey M, 1995, HIPPOCAMPUS, V5, P546, DOI 10.1002/hipo.450050606; Chang KA, 2005, J PHARMACOL SCI, V97, P461, DOI 10.1254/jphs.CR0050014; Chong YH, 2001, J BIOL CHEM, V276, P23511, DOI 10.1074/jbc.M009466200; Dewachter I, 2002, LANCET NEUROL, V1, P409, DOI 10.1016/S1474-4422(02)00188-6; Dewachter I, 2002, J NEUROSCI, V22, P3445; Figueiredo HF, 2002, ENDOCRINOLOGY, V143, P2534, DOI 10.1210/en.143.7.2534; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Gupta A, 2002, MED HYPOTHESES, V59, P727, DOI 10.1016/S0306-9877(02)00321-3; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; JACQUELING NC, 2000, LEARNING MEMORY WHAT, P99; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kim CM, 2003, VECTOR-BORNE ZOONOT, V3, P17, DOI 10.1089/153036603765627424; Kim HS, 1998, NEUROREPORT, V9, P3875, DOI 10.1097/00001756-199812010-00020; Kim HS, 2000, FASEB J, V14, P1508, DOI 10.1096/fj.14.11.1508; Kim JH, 2002, J BIOL CHEM, V277, P20256, DOI 10.1074/jbc.M108326200; Kim JJ, 2002, NAT REV NEUROSCI, V3, P453, DOI 10.1038/nrn849; Kim SH, 1996, J NEUROCHEM, V67, P1172; Koo JW, 2003, FASEB J, V17, P1556, DOI 10.1096/fj.02-1032fje; Lambourne SL, 2005, MOL CELL BIOL, V25, P278, DOI 10.1128/MCB.25.1.278-293.2005; LANDFIELD PW, 1978, SCIENCE, V202, P1098, DOI 10.1126/science.715460; LANDFIELD PW, 1994, NEUROBIOL AGING, V15, P579, DOI 10.1016/0197-4580(94)90101-5; LANDFIELD PW, 1981, SCIENCE, V214, P581, DOI 10.1126/science.6270791; Lee JP, 2000, J NEUROSCI RES, V60, P565, DOI 10.1002/(SICI)1097-4547(20000515)60:4<565::AID-JNR16>3.0.CO;2-I; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Lordi B, 1997, PHYSIOL BEHAV, V62, P1087, DOI 10.1016/S0031-9384(97)00261-8; Magarinos AM, 1998, BRAIN RES, V809, P314, DOI 10.1016/S0006-8993(98)00882-8; Magarinos AM, 1997, P NATL ACAD SCI USA, V94, P14002, DOI 10.1073/pnas.94.25.14002; MAGARINOS AM, 1995, NEUROSCIENCE, V69, P89, DOI 10.1016/0306-4522(95)00259-L; McEwen BS, 1995, VITAM HORM, V51, P371, DOI 10.1016/S0083-6729(08)61045-6; McEwen BS, 2002, METABOLISM, V51, P2, DOI 10.1053/meta.2002.33183; McEwen BS, 2000, BRAIN RES, V886, P172, DOI 10.1016/S0006-8993(00)02950-4; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; Mizoguchi K, 2000, J NEUROSCI, V20, P1568; Moceri VM, 2000, NEUROLOGY, V54, P415, DOI 10.1212/WNL.54.2.415; Moceri VM, 2001, EPIDEMIOLOGY, V12, P383, DOI 10.1097/00001648-200107000-00007; MORGAN CD, 1995, J CLIN EXP NEUROPSYC, V17, P793, DOI 10.1080/01688639508405168; MULLAN M, 1993, NEUROBIOL AGING, V14, P407, DOI 10.1016/0197-4580(93)90099-W; Murphy C, 1999, PHYSIOL BEHAV, V66, P177, DOI 10.1016/S0031-9384(98)00262-5; Nacher J, 2004, NEUROSCIENCE, V126, P503, DOI 10.1016/j.neuroscience.2004.03.038; Nordin S, 1996, NEUROPSYCHOLOGY, V10, P113, DOI 10.1037/0894-4105.10.1.113; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Rah JC, 2001, FASEB J, V15, P1463, DOI 10.1096/fj.00-0724fje; Raiha I, 1998, J NEUROL NEUROSUR PS, V65, P785, DOI 10.1136/jnnp.65.5.785; Reagan LP, 1997, J CHEM NEUROANAT, V13, P149, DOI 10.1016/S0891-0618(97)00031-8; SAPOLSKY RM, 1994, ANN NY ACAD SCI, V746, P294; SELKOE DJ, 1997, NAT MED, V3, P67; Shah ZA, 2003, EUR NEUROPSYCHOPHARM, V13, P321, DOI 10.1016/S0924-977X(03)00005-1; Sousa N, 2000, NEUROSCIENCE, V97, P253, DOI 10.1016/S0306-4522(00)00050-6; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; Suh YH, 1997, J NEUROCHEM, V68, P1781; SUTHERLAND RJ, 1989, PSYCHOBIOLOGY, V17, P129; Trojanowski JQ, 1995, FASEB J, V9, P1570, DOI 10.1096/fasebj.9.15.8529836; Vasterling JJ, 2000, J TRAUMA STRESS, V13, P241, DOI 10.1023/A:1007754611030; WATANABE Y, 1992, BRAIN RES, V588, P341, DOI 10.1016/0006-8993(92)91597-8; Weinstock M, 1997, NEUROSCI BIOBEHAV R, V21, P1, DOI 10.1016/S0149-7634(96)00014-0; WINOCUR G, 1990, BEHAV BRAIN RES, V38, P145, DOI 10.1016/0166-4328(90)90012-4; Winocur G, 2001, HIPPOCAMPUS, V11, P18, DOI 10.1002/1098-1063(2001)11:1<18::AID-HIPO1016>3.0.CO;2-5	63	181	186	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					729	+		10.1096/fj.05-4265fje	http://dx.doi.org/10.1096/fj.05-4265fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	044US	16467370				2022-12-28	WOS:000237698700029
J	Sayeed, I; Parvez, S; Winkler-Stuck, K; Seitz, G; Trieu, I; Wallesch, CW; Schonfeld, P; Siemen, D				Sayeed, I; Parvez, S; Winkler-Stuck, K; Seitz, G; Trieu, I; Wallesch, CW; Schonfeld, P; Siemen, D			Patch clamp reveals powerful blockade of the mitochondrial permeability transition pore by the D2-receptor agonist pramipexole	FASEB JOURNAL			English	Article						cyclosporin A; mitochondrion; dopamine agonist; single channel; neuroprotection	DEPENDENT ANION CHANNEL; CELL-DEATH; BRAIN MITOCHONDRIA; RESPIRATORY-CHAIN; SKELETAL-MUSCLE; INHIBITION; DOPAMINE; REPERFUSION; MODULATION; MEMBRANE	The dopamine-D2-agonist pramipexole (PPX) was tested for blocking mitochondrial permeability transition ( PT) in order to give a possible explanation for its neuroprotective effect seen in PPX-treated Parkinson's disease patients. Patch-clamp techniques for studying single-channel currents in the inner mitochondrial membrane and large-amplitude swelling of energized mitochondria were used to study PPX action on the permeability transition pore (PTP), a key player in the mitochondrial route of the apoptotic cascade. Identity of the PTP was proven by measuring the concentration-response relation for cyclosporin A-blockade (IC50= 26 nM). PPX inhibits the PTP reversibly with an IC50 of 500 nM, which is close to the values determined earlier as plasma concentrations after PPX medication in patients. Interaction of PPX with the PTP is further supported by demonstrating that it abolished Ca2+-triggered swelling in functionally intact mitochondria. Blockade of the PTP by PPX was attenuated by increasing concentrations of inorganic phosphate and by acidification. We suggest that PPX could exert part of its neuroprotective effect by inhibition of the PTP and thus, probably, blocking of the mitochondrial pathway of the apoptosis cascade.	Univ Magdeburg, Dept Neurol, D-39120 Magdeburg, Germany; Univ Magdeburg, Dept Biochem, D-39120 Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University	Siemen, D (corresponding author), Univ Magdeburg, Dept Neurol, Leipziger Str 44, D-39120 Magdeburg, Germany.	detlef.siemen@medizin.unimagdeburg.de	Parvez, Suhel/E-6778-2010	Parvez, Suhel/0000-0002-6318-6506				Abramova NA, 2002, J NEUROSCI RES, V67, P494, DOI 10.1002/jnr.10127; Anderson DW, 2001, BRAIN RES, V905, P44, DOI 10.1016/S0006-8993(01)02466-0; Andrabi SA, 2004, FASEB J, V18, P869, DOI 10.1096/fj.03-1031fje; Berman SB, 1999, J NEUROCHEM, V73, P1127, DOI 10.1046/j.1471-4159.1999.0731127.x; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; Brecht HM, 1998, AKTUEL NEUROL, V25, pS310, DOI 10.1055/s-2007-1017756; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Cassarino DS, 1998, J NEUROCHEM, V71, P295; Cesura AM, 2003, J BIOL CHEM, V278, P49812, DOI 10.1074/jbc.M304748200; Chinopoulos C, 2003, J BIOL CHEM, V278, P27382, DOI 10.1074/jbc.M303808200; Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x; de Lau LML, 2004, NEUROLOGY, V63, P1240, DOI 10.1212/01.WNL.0000140706.52798.BE; Di Lisa F, 2003, BASIC RES CARDIOL, V98, P235, DOI 10.1007/s00395-003-0415-x; Fiskum G, 2003, ANN NY ACAD SCI, V991, P111; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; Gu M, 2004, J NEUROCHEM, V91, P1075, DOI 10.1111/j.1471-4159.2004.02804.x; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Halestrap AP, 2004, CARDIOVASC RES, V61, P372, DOI 10.1016/S0008-6363(03)00533-9; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Hansson MJ, 2004, J NEUROCHEM, V89, P715, DOI 10.1111/j.1471-4159.2004.02400.x; Hansson MJ, 2003, BRAIN RES, V960, P99, DOI 10.1016/S0006-8993(02)03798-8; Holloway RG, 2004, ARCH NEUROL-CHICAGO, V61, P1044; HUNTER DR, 1976, J BIOL CHEM, V251, P5069; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; Joyce JN, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-22; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; KINNALLY KW, 1992, J BIOENERG BIOMEMBR, V24, P99, DOI 10.1007/BF00769536; Kitamura Y, 1998, MOL PHARMACOL, V54, P1046, DOI 10.1124/mol.54.6.1046; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kristian T, 2002, J NEUROCHEM, V83, P1297, DOI 10.1046/j.1471-4159.2002.01238.x; Kristian T, 2001, J NEUROTRAUM, V18, P1059, DOI 10.1089/08977150152693755; Le WD, 2000, J NEURAL TRANSM, V107, P1165, DOI 10.1007/s007020070030; Loupatatzis C, 2002, CELL PHYSIOL BIOCHEM, V12, P269, DOI 10.1159/000067897; Marek K, 2002, JAMA-J AM MED ASSOC, V287, P1653; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Michel P.-P., 2002, Rev Neurol (Paris), V158, P24; Pavlov E, 2005, BIOPHYS J, V88, P2614, DOI 10.1529/biophysj.104.057281; Schaper A, 2002, WORLD TODAY, V58, P18; SCHAPIRA AH, 2004, JAMA-J AM MED ASSOC, V291, P2430; Schluter T, 2000, FEBS LETT, V481, P42, DOI 10.1016/S0014-5793(00)01923-2; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; Tatton WG, 1998, ANN NEUROL, V44, pS134, DOI 10.1002/ana.410440720; Tsujimoto Y, 2002, BIOCHIMIE, V84, P187, DOI 10.1016/S0300-9084(02)01370-6; Winkler-Stuck K, 2005, J NEURAL TRANSM, V112, P499, DOI 10.1007/s00702-004-0195-y; Wright CE, 1997, J CLIN PHARMACOL, V37, P520, DOI 10.1002/j.1552-4604.1997.tb04330.x; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zou LL, 1999, LIFE SCI, V64, P1275, DOI 10.1016/S0024-3205(99)00062-4; Zou LL, 2000, NEUROSCI LETT, V281, P167, DOI 10.1016/S0304-3940(00)00853-3	50	55	69	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					556	+		10.1096/fj.05-4748fje	http://dx.doi.org/10.1096/fj.05-4748fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16407457				2022-12-28	WOS:000235996000021
J	Barrier, A; Olaya, N; Chiappini, F; Roser, F; Scatton, O; Artus, C; Franc, B; Dudoit, S; Flahault, A; Debuire, B; Azoulay, D; Lemoine, A				Barrier, A; Olaya, N; Chiappini, F; Roser, F; Scatton, O; Artus, C; Franc, B; Dudoit, S; Flahault, A; Debuire, B; Azoulay, D; Lemoine, A			Ischemic preconditioning modulates the expression of several genes, leading to the overproduction of IL-1Ra, iNOS, and Bcl-2 in a human model of liver ischemia-reperfusion	FASEB JOURNAL			English	Article						preconditioning; liver transplantation; gene expression; apoptosis	INFLOW OCCLUSION; ENDOTHELIAL-CELL; NITRIC-OXIDE; MOUSE-LIVER; APOPTOSIS; INJURY; PROTECTS; INHIBITION; ADENOSINE; AUTOPHAGY	Ischemia triggers an inflammatory response that precipitates cell death during reperfusion. Several studies have shown that tissues are protected by ischemic preconditioning (IP) consisting of 10 min of ischemia followed by 10 min of reperfusion just before ischemia. The molecular basis of this protective effect is poorly understood. We used cDNA arrays (20K) to compare global gene expression in liver biopsies from living human liver donors who underwent IP (n = 7) or not (n = 7) just before liver devascularization. Microarray data were analyzed using paired t test with a type I error rate fixed at alpha = 2.5 10(6) (Bonferroni correction). We found that 60 genes were differentially expressed (36 over- and 24 underexpressed in preconditioning group). After IP, the most significantly overexpressed gene was IL-1R alpha. This was confirmed by immunoblotting. Differentially expressed were genes involved in apoptosis (NOD2, ephrin-A1, and calpain) and in the carbohydrate metabolism. A significant increase in the amount of the anti-apoptotic protein Bcl-2 in preconditioned livers but no change in the cleavage of procaspase-3, -8, and -9 was observed. We also observed an increase in the amount in the inducible nitric oxide synthase. Therefore, the benefits of IP may be associated with the overproduction of IL-1Ra, Bcl-2, and NO countering the proinflammatory and proapoptotic effects generated during ischemia-reperfusion.	Hop Univ Paul Brousse, F-94800 Villejuif, France; INSERM, Serv Biochim & Biol, F-75654 Paris, France; Univ Paris 11, Villejuif, France; Assistance Publ Hop Paris, Paris, France; Univ Calif Berkeley, Div Biostat, Berkeley, CA 94720 USA; Univ Paris 06, INSERM, U444, Hop Tenon, Paris, France; Hop Paul Brousse, Ctr Hepato Biliaire, Villejuif, France; Hop Ambroise Pare, Serv Anat Pathol, Boulogne, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of California System; University of California Berkeley; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP	Lemoine, A (corresponding author), Hop Univ Paul Brousse, F-94800 Villejuif, France.	antoinette.lemoine@pbr.ap-hop-paris.fr	Chiappini, Franck/AAB-9894-2021	Chiappini, Franck/0000-0002-2684-1241				ADAM R, 1992, LANCET, V340, P1373, DOI 10.1016/0140-6736(92)92559-X; Arai M, 2000, HEPATOLOGY, V32, P297, DOI 10.1053/jhep.2000.8896; BELGHITI J, 1992, SURG GYNECOL OBSTET, V175, P271; Bolli R, 1998, CIRCULATION, V98, P824; Bonventre JV, 2002, CURR OPIN NEPHROL HY, V11, P43, DOI 10.1097/00041552-200201000-00007; BORGHISCOARZC G, 1997, LIVER TRANSPLANT SUR, V4, P407; CALNE RY, 1968, BMJ-BRIT MED J, V4, P535, DOI 10.1136/bmj.4.5630.535; Carini R, 2003, GASTROENTEROLOGY, V125, P1480, DOI 10.1016/j.gastro.2003.05.005; Carini R, 2001, HEPATOLOGY, V33, P131, DOI 10.1053/jhep.2001.21050; CHARLOTTE F, 1994, AM J PATHOL, V144, P460; Clavien PA, 2003, ANN SURG, V238, P843, DOI 10.1097/01.sla.0000098620.27623.7d; Clavien PA, 2000, ANN SURG, V232, P155, DOI 10.1097/00000658-200008000-00001; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Cursio R, 1999, FASEB J, V13, P253, DOI 10.1096/fasebj.13.2.253; CYWES R, 1992, ANN SURG, V216, P235, DOI 10.1097/00000658-199209000-00003; Du ZY, 1996, J HEART LUNG TRANSPL, V15, P1258; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Gabay C, 1997, J CLIN INVEST, V99, P2930, DOI 10.1172/JCI119488; GAO WS, 1995, TRANSPLANTATION, V59, P674, DOI 10.1097/00007890-199503150-00005; Gao WS, 1998, HEPATOLOGY, V27, P1652, DOI 10.1002/hep.510270626; Garland JM, 1997, J BIOL CHEM, V272, P4680, DOI 10.1074/jbc.272.8.4680; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Haendeler J, 1996, SHOCK, V6, P405, DOI 10.1097/00024382-199612000-00004; Harada H, 2002, TRANSPLANTATION, V74, P1434, DOI 10.1097/00007890-200211270-00016; HEURTEAUX C, 1995, P NATL ACAD SCI USA, V92, P4666, DOI 10.1073/pnas.92.10.4666; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hotter G, 1996, BIOCHEM BIOPH RES CO, V222, P27, DOI 10.1006/bbrc.1996.0692; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Jaeschke H, 2003, GASTROENTEROLOGY, V125, P1246, DOI 10.1016/S0016-5085(03)01209-5; Kim JS, 2003, GASTROENTEROLOGY, V124, P494, DOI 10.1053/gast.2003.50059; Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620; Kohli V, 1999, GASTROENTEROLOGY, V116, P168, DOI 10.1016/S0016-5085(99)70241-6; Kohli V, 1997, P NATL ACAD SCI USA, V94, P9354, DOI 10.1073/pnas.94.17.9354; Kohli V, 1999, TRANSPLANTATION, V67, P1099, DOI 10.1097/00007890-199904270-00003; Koti RS, 2002, FASEB J, V16, P1654, DOI 10.1096/fj.01-1034fje; Kume M, 2000, BRIT J SURG, V87, P1168, DOI 10.1046/j.1365-2168.2000.01509.x; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Li J, 2004, HUM MOL GENET, V13, P1715, DOI 10.1093/hmg/ddh182; Li SQ, 2004, WORLD J GASTROENTERO, V10, P2580, DOI 10.3748/wjg.v10.i17.2580; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Maedler K, 2004, P NATL ACAD SCI USA, V101, P8138, DOI 10.1073/pnas.0305683101; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; PANG CY, 1995, BIOCHEM PHARMACOL, V49, P1023, DOI 10.1016/0006-2952(94)00467-Z; Peralta C, 1999, HEPATOLOGY, V29, P126, DOI 10.1002/hep.510290104; Peralta C, 2002, AM J PATHOL, V160, P2111, DOI 10.1016/S0002-9440(10)61160-1; Peralta C, 1997, HEPATOLOGY, V25, P934, DOI 10.1002/hep.510250424; Qian T, 1997, AM J PHYSIOL-CELL PH, V273, pC1783, DOI 10.1152/ajpcell.1997.273.6.C1783; RAZ R, 1994, J BIOL CHEM, V269, P24391; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SCHUMER M, 1992, AM J PATHOL, V140, P831; Selzner N, 2003, J HEPATOL, V39, P55, DOI 10.1016/S0168-8278(03)00147-8; Serafin A, 2004, HEPATOLOGY, V39, P688, DOI 10.1002/hep.20089; Serafin A, 2002, AM J PATHOL, V161, P587, DOI 10.1016/S0002-9440(10)64214-9; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Sindram D, 1999, TRANSPLANTATION, V68, P136, DOI 10.1097/00007890-199907150-00025; SUZUKI K, 2001, CIRCULATION S1, V104, P308; TRUMP BF, 1965, LAB INVEST, V14, P2000; Watanabe Y, 2003, HEPATOL RES, V25, P343, DOI 10.1016/S1386-6346(02)00305-4; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Yadav SS, 1999, HEPATOLOGY, V30, P1223, DOI 10.1002/hep.510300513; Yamazoe N, 1998, J ELECTROCERAM, V2, P243, DOI 10.1023/A:1009974506712; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhang Shui-Jun, 2003, Hepatobiliary Pancreat Dis Int, V2, P509	68	53	59	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					1617	1626		10.1096/fj.04-3445com	http://dx.doi.org/10.1096/fj.04-3445com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16195370				2022-12-28	WOS:000232991100039
J	Huang, DM; Hung, Y; Ko, BS; Hsu, SC; Chen, WH; Chien, CL; Tsai, CP; Kuo, CT; Kang, JC; Yang, CS; Mou, CY; Chen, YC				Huang, DM; Hung, Y; Ko, BS; Hsu, SC; Chen, WH; Chien, CL; Tsai, CP; Kuo, CT; Kang, JC; Yang, CS; Mou, CY; Chen, YC			Highly efficient cellular labeling of mesoporous nanoparticles in human mesenchymal stem cells: implication for stem cell tracking	FASEB JOURNAL			English	Article						intracellular internalization; endocytosis; bone marrow; differentiation	IN-VIVO TRACKING; BONE-MARROW; SILICA; DRUG; DELIVERY; RELEASE; TRANSFECTION; IBUPROFEN; PROTEINS; CARRIER	Tracking the distribution of stem cells is crucial to their therapeutic use. However, the usage of current vectors in cellular labeling is restricted by their low internalizing efficiency. Here, we reported a cellular labeling approach with a novel vector composed of mesoporous silica nanoparticles (MSNs) conjugated with fluorescein isothiocyanate in human bone marrow mesenchymal stem cells and 3T3-L1 cells, and the mechanism about fluorescein isothiocyanate-conjugated MSNs (FITC-MSNs) internalization was studied. FITC-MSNs were efficiently internalized into mesenchymal stem cells and 3T3-L1 cells even in short-term incubation. The process displayed a time-and concentration-dependent manner and was dependent on clathrin-mediated endocytosis. In addition, clathrin-dependent endocytosis seemed to play a decisive role on more internalization and longer stay of FITC-MSNs in mesenchymal stem cells than in 3T3-L1 cells. The internalization of FITC-MSNs did not affect the cell viability, proliferation, immunophenotype,and differentiation potential of mesenchymal stem cells, and 3T3-L1 cells. Finally, FITC-MSNs could escape from endolysosomal vesicles and were retained the architectonic integrity after internalization. We conclude that the advantages of biocompatibility, durability, and higher efficiency in internalization suit MSNs to be a better vector for stem cell tracking than others currently used.	Natl Taiwan Univ Hosp, Dept Lab Med, Taipei 100, Taiwan; Natl Hlth Res Inst, Stem Cell Res Ctr, Miaoli, Taiwan; Natl Taiwan Univ, Dept Chem, Taipei 10764, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Dept Anat & Cell Biol, Taipei 10764, Taiwan; Natl Hlth Res Inst, Ctr Nanomed Res, Miaoli, Taiwan	National Taiwan University; National Taiwan University Hospital; National Health Research Institutes - Taiwan; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Health Research Institutes - Taiwan	Chen, YC (corresponding author), Natl Taiwan Univ Hosp, Dept Lab Med, 7,Chung Shan S Rd, Taipei 100, Taiwan.	ycchenmd@ha.mc.ntu.edu.tw	Huang, Dong-Ming/E-3663-2010; Yang, Chung-Shi/E-3999-2010	CHIEN, CHUNG-LIANG/0000-0001-9806-486X; MOU, CHUNG-YUAN/0000-0001-7060-9899; KO, BOR-SHENG/0000-0002-7965-7579; Huang, Dong-Ming/0000-0002-9284-3448				Andersson J, 2004, CHEM MATER, V16, P4160, DOI 10.1021/cm0401490; Bulte JWM, 2001, NAT BIOTECHNOL, V19, P1141, DOI 10.1038/nbt1201-1141; BULTE JWM, 1993, MAGNET RESON MED, V29, P32, DOI 10.1002/mrm.1910290108; Charnay C, 2004, EUR J PHARM BIOPHARM, V57, P533, DOI 10.1016/j.ejpb.2003.12.007; Clark PR, 1999, CURR OPIN MOL THER, V1, P158; Dodd SJ, 1999, BIOPHYS J, V76, P103, DOI 10.1016/S0006-3495(99)77182-1; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Handgretinger R, 1998, BONE MARROW TRANSPL, V21, P987, DOI 10.1038/sj.bmt.1701228; He XX, 2002, J NANOSCI NANOTECHNO, V2, P317, DOI 10.1166/jnn.2002.105; He XX, 2004, J NANOSCI NANOTECHNO, V4, P585, DOI 10.1166/jnn.2004.011; Hill JM, 2003, CIRCULATION, V108, P1009, DOI 10.1161/01.CIR.0000084537.66419.7A; Jendelova P, 2003, MAGNET RESON MED, V50, P767, DOI 10.1002/mrm.10585; Jendelova P, 2004, J NEUROSCI RES, V76, P232, DOI 10.1002/jnr.20041; Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h; Lai CY, 2003, J AM CHEM SOC, V125, P4451, DOI 10.1021/ja028650l; Larson DR, 2003, SCIENCE, V300, P1434, DOI 10.1126/science.1083780; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Luo D, 2000, NAT BIOTECHNOL, V18, P893, DOI 10.1038/78523; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Moore A, 1998, BBA-MOL CELL RES, V1402, P239, DOI 10.1016/S0167-4889(98)00002-0; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Panyam J, 2002, FASEB J, V16, DOI 10.1096/fj.02-0088com; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Radu DR, 2004, J AM CHEM SOC, V126, P13216, DOI 10.1021/ja046275m; Roco MC, 2003, CURR OPIN BIOTECH, V14, P337, DOI 10.1016/S0958-1669(03)00068-5; Rudelius M, 2003, EUR J NUCL MED MOL I, V30, P1038, DOI 10.1007/s00259-002-1110-0; Sahoo SK, 2003, DRUG DISCOV TODAY, V8, P1112, DOI 10.1016/S1359-6446(03)02903-9; Santra S, 2004, CHEM COMMUN, P2810, DOI 10.1039/b411916a; Schoepf U, 1998, BIOTECHNIQUES, V24, P642, DOI 10.2144/98244rr01; Vallet-Regi M, 2001, CHEM MATER, V13, P308, DOI 10.1021/cm0011559; Weissleder R, 1997, J MAGN RESON IMAGING, V7, P258, DOI 10.1002/jmri.1880070140; Wilkinson J M, 2003, Med Device Technol, V14, P29; YEH TC, 1993, MAGN RESON MED, V30, P617, DOI 10.1002/mrm.1910300513	35	268	274	5	84	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2014	+		10.1096/fj.05-4288fje	http://dx.doi.org/10.1096/fj.05-4288fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16230334	Green Submitted			2022-12-28	WOS:000232991100015
J	Wilson, LA; Gemin, A; Espiritu, R; Singh, G				Wilson, LA; Gemin, A; Espiritu, R; Singh, G			ets-1 is transcriptionally up-regulated by H2O2 via an antioxidant response element	FASEB JOURNAL			English	Article						tumor-derived factor; reactive oxygen species; gel shift analysis	LYMPH-NODE METASTASIS; GROWTH-FACTOR; PLASMINOGEN-ACTIVATOR; ENDOTHELIAL-CELLS; NITRIC-OXIDE; OXIDATIVE STRESS; EXPRESSION; GENE; INDUCTION; UROKINASE	Expression of the transcription factor Ets-1 is increasingly associated with the progression of several human cancers. A tumor-derived factor is expected to be involved in the inappropriate up-regulation of ets-1 in tumor and surrounding cells. A link between hydrogen peroxide (H2O2) and increased Ets-1 expression has also been suggested, leading to the proposal that this reactive oxygen species (ROS) may be an important factor in directly regulating the expression of ets-1 in tumor cells. Ets-1 expression in response to H2O2 was examined in an ovarian carcinoma cell model, and the genes promoter region was analyzed in order to identify putative elements involved in redox responsiveness. The up-regulation of Ets-1 by H2O2 was confirmed in the cells tested. Luciferase assays using constructs generated to test the contribution of specific promoter elements indicated that an antioxidant response element (ARE) is primarily involved in the H2O2-mediated induction. Gel shift analysis confirmed the increased binding of an Nrf(2) containing protein complex to the ets-1 ARE after H2O2 treatment. This study has delineated a key element involved in the transcriptional regulation of ets-1 under basal and induced conditions. Ets-1 has obvious deleterious effects in many cancer cells, and thus, the identification of this regulatory pathway has provided possible targets for manipulating its expression.	McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada; McMaster Univ, Dept Pathol & Mol Med, Fac Hlth Sci, Hamilton, ON, Canada	McMaster University; McMaster University	Singh, G (corresponding author), Ctr Canc, 699 Concess St, Hamilton, ON L8V 5C2, Canada.	gurmit.singh@hrcc.on.ca	Singh, Gurmit/C-6744-2014					ANDREWS PA, 1992, CANCER RES, V52, P1895; Behrens P, 2001, J PATHOL, V194, P43, DOI 10.1002/path.844; Behrens P, 2003, INT J CANCER, V107, P183, DOI 10.1002/ijc.11336; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; CHEN JH, 1993, ONCOGENE, V8, P3375; Coulet F, 2003, J BIOL CHEM, V278, P46230, DOI 10.1074/jbc.M305420200; Davidson B, 2001, CLIN CANCER RES, V7, P551; DEVRIES N, 1993, J CELL BIOCHEM, P270; Dhakshinamoorthy S, 2004, J BIOL CHEM, V279, P20096, DOI 10.1074/jbc.M312492200; Dhakshinamoorthy S, 2002, ONCOGENE, V21, P5301, DOI 10.1038/sj.onc.1205642; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Foulds CE, 2004, MOL CELL BIOL, V24, P10954, DOI 10.1128/MCB.24.24.10954-10964.2004; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; Hegen A, 2004, ARTERIOSCL THROM VAS, V24, P1803, DOI 10.1161/01.ATV.0000140819.81839.0e; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Jiang Y, 2001, BIOCHEM BIOPH RES CO, V286, P1123, DOI 10.1006/bbrc.2001.5521; Keehn CA, 2003, MODERN PATHOL, V16, P772, DOI 10.1097/01.MP.0000082395.59356.4F; KESTON AS, 1965, ANAL BIOCHEM, V11, P1, DOI 10.1016/0003-2697(65)90034-5; Kita D, 2001, CANCER RES, V61, P7985; Kitange G, 1999, LAB INVEST, V79, P407; Kitange G, 2000, CANCER, V89, P2292, DOI 10.1002/1097-0142(20001201)89:11<2292::AID-CNCR18>3.0.CO;2-0; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Lindemann RK, 2001, J BIOL CHEM, V276, P46661, DOI 10.1074/jbc.M105816200; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; Mukherjee T, 2003, J CANCER RES CLIN, V129, P430, DOI 10.1007/s00432-003-0457-3; Nakada M, 1999, J NEUROPATH EXP NEUR, V58, P329, DOI 10.1097/00005072-199904000-00003; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; NGUYEN T, 1994, J BIOL CHEM, V269, P13656; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Oikawa M, 2001, BIOCHEM BIOPH RES CO, V289, P39, DOI 10.1006/bbrc.2001.5927; OKA T, 1991, ONCOGENE, V6, P2077; Ordway JM, 2003, MOL CELL BIOL, V23, P4257, DOI 10.1128/MCB.23.12.4257-4266.2003; Pande P, 1999, J PATHOL, V189, P40, DOI 10.1002/(SICI)1096-9896(199909)189:1<40::AID-PATH405>3.0.CO;2-#; Policastro L, 2004, MOL CARCINOGEN, V39, P103, DOI 10.1002/mc.20001; Preston TJ, 2003, EXP CELL RES, V285, P146, DOI 10.1016/S0014-4827(03)00015-6; Radjendirane V, 1999, BIOCHEM PHARMACOL, V58, P597, DOI 10.1016/S0006-2952(99)00143-4; Reichard JF, 2004, BIOCHEM BIOPH RES CO, V322, P842, DOI 10.1016/j.bbrc.2004.07.180; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SETH A, 1990, ONCOGENE, V5, P1761; Shimizu S, 2004, INT J BIOCHEM CELL B, V36, P114, DOI 10.1016/S1357-2725(03)00170-5; Span PN, 2002, ONCOGENE, V21, P8506, DOI 10.1038/sj.onc.1206040; Suzuki H, 1998, BIOCHEM BIOPH RES CO, V249, P542, DOI 10.1006/bbrc.1998.9181; Tokuhara K, 2003, INT SURG, V88, P25; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Watanabe D, 2004, AM J PATHOL, V164, P1827, DOI 10.1016/S0002-9440(10)63741-8; Wilson LA, 2004, MOL CANCER THER, V3, P823; Yamamoto H, 2000, CANCER RES, V60, P134; Yasuda M, 1998, LIFE SCI, V64, P249, DOI 10.1016/S0024-3205(98)00560-8; Zhang YS, 2004, MOL CANCER THER, V3, P885	52	72	72	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2085	+		10.1096/fj.05-4401fje	http://dx.doi.org/10.1096/fj.05-4401fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16234432				2022-12-28	WOS:000232991100014
J	Keiper, T; Al-Fakhri, N; Chavakis, E; Athanasopoulos, AN; Isermann, B; Herzog, S; Saffrich, R; Hersemeyer, K; Bohle, RM; Haendeler, J; Preissner, KT; Santoso, S; Chavakis, T				Keiper, T; Al-Fakhri, N; Chavakis, E; Athanasopoulos, AN; Isermann, B; Herzog, S; Saffrich, R; Hersemeyer, K; Bohle, RM; Haendeler, J; Preissner, KT; Santoso, S; Chavakis, T			The role of junctional adhesion molecule-C (JAM-C) in oxidized LDL-mediated leukocyte recruitment	FASEB JOURNAL			English	Article						atherosclerosis; endothelial cells; inflammation; vascular smooth muscle cells	MIGRATION IN-VITRO; ATHEROSCLEROTIC LESIONS; TRANSENDOTHELIAL MIGRATION; IMMUNOGLOBULIN SUPERFAMILY; LIPID HYDROPEROXIDE; XYLENOL ORANGE; MICE REVEALS; DEFICIENT; INTERACTS; CELLS	The junctional adhesion molecule-C (JAM-C) was recently shown to be a counter receptor for the leukocyte beta 2-integrin Mac-1 (CD11b/CD18), thereby mediating interactions between vascular cells, particularly in inflammatory cell recruitment. Here, we investigated the role of JAM-C in oxidized low-density lipoprotein (LDL)-mediated leukocyte recruitment. As compared with normal arteries, immunostaining of atherosclerotic vessels revealed a high expression of JAM-C in association with neointimal smooth muscle cells and the endothelium. Moreover, JAM-C was strongly up-regulated in the spontaneous early lesions in ApoE -/- mice. In vitro, cultured human arterial smooth muscle cells (HASMC) were found to express JAM-C, and oxLDL, as well as enzymatically modified LDL (eLDL) significantly up-regulated JAM-C on both HASMC and endothelial cells in a time-and dose-dependent manner. Although under quiescent conditions, JAM-C predominantly localized to interendothelial cell-cell contacts in close proximity to zonula occludens-1 (ZO-1), oxLDL treatment induced a disorganization of JAM-C localization that was no more restricted to the interendothelial junctions. JAM-C thereby mediated both leukocyte adhesion and leukocyte transendothelial migration upon oxLDL treatment of endothelial cells, whereas JAM-C on quiescent endothelial cells only mediates leukocyte transmigration. Thus, upon oxLDL stimulation endothelial JAM-C functions as both an adhesion, as well as a transmigration receptor for leukocytes. Taken together, JAM-C is upregulated by oxLDL and may thereby contribute to increased inflammatory cell recruitment during atherosclerosis. JAM-C may therefore provide a novel molecular target for antagonizing interactions between vascular cells in atherosclerosis.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; Heidelberg Univ, Dept Internal Med 1, Heidelberg, Germany; Univ Giessen, Inst Clin Chem & Pathobiochem, Giessen, Germany; Goethe Univ Frankfurt, Dept Internal Med 3, D-6000 Frankfurt, Germany; Heidelberg Univ, Dept Internal Med 5, Heidelberg, Germany; Univ Giessen, Inst Biochem, Giessen, Germany; Univ Giessen, Inst Pathol, Giessen, Germany; Univ Giessen, Inst Clin Immunol & Transfus Med, Giessen, Germany	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ruprecht Karls University Heidelberg; Justus Liebig University Giessen; Goethe University Frankfurt; Ruprecht Karls University Heidelberg; Justus Liebig University Giessen; Justus Liebig University Giessen; Justus Liebig University Giessen	Chavakis, T (corresponding author), NCI, Expt Immunol Branch, NIH, 10 Ctr Dr,Rm 4B17, Bethesda, MD 20892 USA.	chavakist@mail.nih.gov	Chavakis, Triantafyllos/ABE-8845-2020	Saffrich, Rainer/0000-0002-0547-4550; Haendeler, Judith/0000-0001-8507-4540	NATIONAL CANCER INSTITUTE [Z01BC010663, ZIABC010663] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Ancuta P, 2003, J EXP MED, V197, P1701, DOI 10.1084/jem.20022156; Aurrand-Lions M, 2001, BLOOD, V98, P3699, DOI 10.1182/blood.V98.13.3699; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; BOGEN S, 1994, J EXP MED, V179, P1059, DOI 10.1084/jem.179.3.1059; Boisvert WA, 1998, J CLIN INVEST, V101, P353, DOI 10.1172/JCI1195; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; CARLOS TM, 1994, BLOOD, V84, P2068; Chavakis E, 2001, CIRCULATION, V103, P2102; Chavakis T, 2005, BLOOD, V105, P1036, DOI 10.1182/blood-2004-01-0166; Chavakis T, 2004, J BIOL CHEM, V279, P55602, DOI 10.1074/jbc.M404676200; Chavakis T, 2003, J EXP MED, V198, P1507, DOI 10.1084/jem.20030800; Chavakis T, 2003, THROMB HAEMOSTASIS, V89, P13; Cunningham SA, 2002, J BIOL CHEM, V277, P27589, DOI 10.1074/jbc.C200331200; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Ebnet K, 2004, J CELL SCI, V117, P19, DOI 10.1242/jcs.00930; GERRITY RG, 1981, AM J PATHOL, V103, P181; JIANG ZY, 1991, LIPIDS, V26, P853, DOI 10.1007/BF02536169; JIANG ZY, 1992, ANAL BIOCHEM, V202, P384, DOI 10.1016/0003-2697(92)90122-N; Johnson-Leger CA, 2002, BLOOD, V100, P2479, DOI 10.1182/blood-2001-11-0098; Kita T, 2001, ANN NY ACAD SCI, V947, P199; Liang TW, 2002, J IMMUNOL, V168, P1618, DOI 10.4049/jimmunol.168.4.1618; Liao F, 1997, J EXP MED, V185, P1349, DOI 10.1084/jem.185.7.1349; LIBBY P, 1991, LAB INVEST, V64, P5; Mamdouh Z, 2003, NATURE, V421, P748, DOI 10.1038/nature01300; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Muller WA, 2002, LAB INVEST, V82, P521, DOI 10.1038/labinvest.3780446; NAGEH MF, 1997, ARTERIOSCLER THROMB, V80, P810; Naik MU, 2003, BLOOD, V102, P2108, DOI 10.1182/blood-2003-04-1114; Naik MU, 2003, ARTERIOSCL THROM VAS, V23, P2165, DOI 10.1161/01.ATV.0000093982.84451.87; Nakashima Y, 1998, ARTERIOSCL THROM VAS, V18, P842, DOI 10.1161/01.ATV.18.5.842; OBRIEN KD, 1993, J CLIN INVEST, V92, P945, DOI 10.1172/JCI116670; Ostermann G, 2002, NAT IMMUNOL, V3, P151, DOI 10.1038/ni755; Ozaki H, 1999, J IMMUNOL, V163, P553; Palmeri D, 2000, J BIOL CHEM, V275, P19139, DOI 10.1074/jbc.M003189200; Peterson JA, 1998, BLOOD, V92, P2053, DOI 10.1182/blood.V92.6.2053.418k14_2053_2063; Ramos CL, 1999, CIRC RES, V84, P1237, DOI 10.1161/01.RES.84.11.1237; RICHARDSON M, 1994, ARTERIOSCLER THROMB, V14, P760, DOI 10.1161/01.ATV.14.5.760; Rosenfeld ME, 2002, ARTERIOSCL THROM VAS, V22, P361, DOI 10.1161/hq0302.104847; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Santoso S, 2002, J EXP MED, V196, P679, DOI 10.1084/jem.20020267; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Simon DI, 2000, J CLIN INVEST, V105, P293, DOI 10.1172/JCI7811; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STARY HC, 1992, VIRCHOWS ARCH A, V421, P277, DOI 10.1007/BF01660974; STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512; STEWART M, 1995, CURR OPIN CELL BIOL, V7, P690, DOI 10.1016/0955-0674(95)80111-1; SUNDERKOTTER C, 1991, PHARMACOL THERAPEUT, V51, P195, DOI 10.1016/0163-7258(91)90077-Y; Suriyaphol P, 2002, CIRCULATION, V106, P2581, DOI 10.1161/01.CIR.0000038366.11851.D0	49	70	72	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					2078	+		10.1096/fj.05-4196fje	http://dx.doi.org/10.1096/fj.05-4196fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16195363				2022-12-28	WOS:000232315700001
J	Lee, JM; Li, J; Johnson, DA; Stein, TD; Kraft, AD; Calkins, MJ; Jakel, RJ; Johnson, JA				Lee, JM; Li, J; Johnson, DA; Stein, TD; Kraft, AD; Calkins, MJ; Jakel, RJ; Johnson, JA			Nrf2, a multi-organ protector?	FASEB JOURNAL			English	Article						Nrf2; ARE; multi-organ protection	ANTIOXIDANT RESPONSE ELEMENT; PROTEIN-KINASE-C; YA-SUBUNIT GENE; INDUCIBLE EXPRESSION; TRANSCRIPTION FACTOR; OXIDATIVE STRESS; NF-E2-RELATED FACTOR-2; CONFERRING PROTECTION; REGULATORY ELEMENTS; MEDIATED EXPRESSION	NF-E2-related factor 2 (Nrf2) is a basic leucine zipper transcription factor that binds to the promoter sequence "antioxidant responsive element (ARE)" leading to coordinated up-regulation of ARE-driven detoxification and antioxidant genes. Since the expression of a wide array of antioxidant and detoxification genes are positively regulated by the ARE sequence, Nrf2 may serve as a master regulator of the ARE-driven cellular defense system against oxidative stress. In support of this, numerous studies have shown that Nrf2 protects many cell types and organ systems from a broad spectrum of toxic insults and disease pathogenesis. This Nrf2-conferred, multi-organ protection phenomenon raises an interesting question about how a single protein can protect many different organs from various toxic insults. A possible molecular mechanism explaining this phenomenon is that Nrf2 protects many different cell types by coordinately up-regulating classic ARE-driven genes as well as cell type-specific target genes that are required for the defense system of each cell type in its unique environment. This hypothesis is supported by microarray data indicating the protective role of Nrf2 is conveyed through both known ARE-driven genes and novel cell type-specific genes. The widespread nature of Nrf2 may have an important therapeutic potential, allowing prevention of carcinogenesis and neurodegenerative diseases.	Univ Wisconsin, Sch Pharm, Madison, WI 53705 USA; Univ Wisconsin, Mol & Environm Toxicol Ctr, Madison, WI 53705 USA; Univ Wisconsin, Neurosci Training Program, Madison, WI 53705 USA; Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA; Univ Wisconsin, Ctr Neurosci, Madison, WI 53705 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Mol Neurogenet Unit, Charlestown, MA USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Harvard University; Massachusetts General Hospital	Johnson, JA (corresponding author), Univ Wisconsin, Sch Pharm, 6125 Rennebohm Hall,777 Highland Ave, Madison, WI 53705 USA.	jajohnson@pharmacy.wisc.edu		Li, Jiang/0000-0002-7006-1285; Stein, Thor/0000-0001-6954-4477	VA [5I01CX001038-04] Funding Source: Federal RePORTER; NIGMS NIH HHS [T32 GM008692] Funding Source: Medline; CSRD VA [I01 CX001038] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008692] Funding Source: NIH RePORTER; Veterans Affairs [I01CX001038] Funding Source: NIH RePORTER	VA(US Department of Veterans Affairs); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); CSRD VA; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)		Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200; Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; Calkins MJ, 2005, P NATL ACAD SCI USA, V102, P244, DOI 10.1073/pnas.0408487101; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Cho HY, 2004, FASEB J, V18, P1258, DOI 10.1096/fj.03-1127fje; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; Dhakshinamoorthy S, 2004, J BIOL CHEM, V279, P20096, DOI 10.1074/jbc.M312492200; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Dyck PA, 2003, MAMM GENOME, V14, P601, DOI 10.1007/s00335-003-2269-9; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; Fahey JW, 2002, P NATL ACAD SCI USA, V99, P7610, DOI 10.1073/pnas.112203099; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Kang KW, 2002, MOL PHARMACOL, V62, P1001, DOI 10.1124/mol.62.5.1001; Kobayashi A, 2004, METHOD ENZYMOL, V378, P273; Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Lee JM, 2004, P NATL ACAD SCI USA, V101, P9751, DOI 10.1073/pnas.0403620101; Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200; Li J, 2002, J BIOL CHEM, V277, P388, DOI 10.1074/jbc.M109380200; Li J, 2004, PHYSIOL GENOMICS, V18, P261, DOI 10.1152/physiolgenomics.00209.2003; Li N, 2004, J IMMUNOL, V173, P3467, DOI 10.4049/jimmunol.173.5.3467; LI Y, 1992, J BIOL CHEM, V267, P15097; Motohashi H, 2004, P NATL ACAD SCI USA, V101, P6379, DOI 10.1073/pnas.0305902101; MURPHY TH, 1991, J NEUROCHEM, V56, P990, DOI 10.1111/j.1471-4159.1991.tb02019.x; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Ramos-Gomez M, 2003, CARCINOGENESIS, V24, P461, DOI 10.1093/carcin/24.3.461; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; Shih AY, 2003, J NEUROSCI, V23, P3394, DOI 10.1523/jneurosci.23-08-03394.2003; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Yoh K, 2001, KIDNEY INT, V60, P1343, DOI 10.1046/j.1523-1755.2001.00939.x; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200	43	374	392	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1061	1066		10.1096/fj.04-2591hyp	http://dx.doi.org/10.1096/fj.04-2591hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	15985529				2022-12-28	WOS:000230923000034
J	Hirsila, M; Koivunen, P; Xu, L; Seeley, T; Kivirikko, KI; Myllyharju, J				Hirsila, M; Koivunen, P; Xu, L; Seeley, T; Kivirikko, KI; Myllyharju, J			Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway	FASEB JOURNAL			English	Article						hypoxia-inducible transciption factor; prolyl 4-hydroxylase; asparaginyl hydroxylase	DISULFIDE-ISOMERASE SUBUNIT; INDUCIBLE FACTOR-ALPHA; PROLYL 4-HYDROXYLASES; ERYTHROPOIETIN GENE; FACTOR HIF; HYPOXIA; PROTEIN; COLLAGEN; HIF-1-ALPHA; BINDING	/ Hypoxia-inducible transcription factor (HIF) is regulated by two oxygen-dependent events that are catalyzed by the HIF prolyl 4-hydroxylases (HIF-P4Hs) and HIF asparaginyl hydroxylase (FIH). We have purified the three recombinant human HIF-P4Hs to near homogeneity and characterized their catalytic properties and inhibition and those of FIH. The specific activities of the HIF-P4Hs were at least 40-50 mol/ mol/ min, and they and FIH catalyzed an uncoupled decarboxylation of 2-oxoglutarate in the absence of any peptide substrate. The purified HIF-P4Hs showed considerable activities even without added Fe2+, their apparent Km values for iron being markedly lower than that of FIH. Desferrioxamine and several metals were effective inhibitors of FIH, but surprisingly, ineffective inhibitors of the HIF-P4Hs in vitro, especially of HIF-P4H-2. Desferrioxamine and cobalt were more effective in cultured insect cells synthesizing recombinant HIF-P4H-2, but complete inhibition was not achieved and most of the enzyme was inactivated irreversibly. Cobalt also rapidly inactivated HIF-P4Hs during storage at 4 degrees C. The well-known stabilization of HIF-alpha by cobalt and nickel is thus not due to a simple competitive inhibition of HIF-P4Hs. The effective inhibition of FIH by these metals and zinc probably leads to full transcriptional activity of HIF-alpha even in concentrations that produce no stabilization of HIF-alpha.	Oulu Univ, Bioctr, Collagen Res Unit, FIN-90014 Oulu, Finland; Oulu Univ, Dept Med Bichem & Mol Biol, FIN-90014 Oulu, Finland; FibroGen Inc, San Francisco, CA 94080 USA	University of Oulu; University of Oulu; FibroGen	Myllyharju, J (corresponding author), Oulu Univ, Bioctr, Collagen Res Unit, POB 5000, FIN-90014 Oulu, Finland.	johanna.myllyharju@oulu.fi						Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Chun YS, 2001, J CELL SCI, V114, P4051; Chun YS, 2000, BIOCHEM BIOPH RES CO, V268, P652, DOI 10.1006/bbrc.2000.2180; CROSSEN R, 1998, BACULOVIRUS EXPRESSI; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Esposito BP, 2002, ANAL BIOCHEM, V304, P1, DOI 10.1006/abio.2002.5611; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kanaya K, 2003, BIOCHEM BIOPH RES CO, V306, P750, DOI 10.1016/S0006-291X(03)01041-6; Kim W, 2003, CURR OPIN GENET DEV, V13, P55, DOI 10.1016/S0959-437X(02)00010-2; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Koivunen P, 2004, J BIOL CHEM, V279, P9899, DOI 10.1074/jbc.M312254200; Kukkola L, 2003, J BIOL CHEM, V278, P47685, DOI 10.1074/jbc.M306806200; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Li DX, 2004, J BIOL CHEM, V279, P55051, DOI 10.1074/jbc.M410287200; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; McNeill LA, 2002, BIOORG MED CHEM LETT, V12, P1547, DOI 10.1016/S0960-894X(02)00219-6; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006; Rautavuoma K, 2002, J BIOL CHEM, V277, P23084, DOI 10.1074/jbc.M112077200; Salnikow K, 2004, J BIOL CHEM, V279, P40337, DOI 10.1074/jbc.M403057200; Salnikow K, 1999, CARCINOGENESIS, V20, P1819, DOI 10.1093/carcin/20.9.1819; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Stolze IP, 2004, J BIOL CHEM, V279, P42719, DOI 10.1074/jbc.M406713200; Tuckerman JR, 2004, FEBS LETT, V576, P145, DOI 10.1016/j.febslet.2004.09.005; Van den Diepstraten C, 2003, CIRCULATION, V108, P508, DOI 10.1161/01.CIR.0000080883.53863.5C; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; WANG GL, 1993, BLOOD, V82, P3610; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200; Yuan Y, 2001, BIOCHEM BIOPH RES CO, V288, P849, DOI 10.1006/bbrc.2001.5835	43	166	170	1	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1308	+		10.1096/fj.04-3399fje	http://dx.doi.org/10.1096/fj.04-3399fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15941769				2022-12-28	WOS:000230207800027
J	Godbout, JP; Chen, J; Abraham, J; Richwine, AF; Berg, BM; Kelley, KW; Johnson, RW				Godbout, JP; Chen, J; Abraham, J; Richwine, AF; Berg, BM; Kelley, KW; Johnson, RW			Exaggerated neuroinflammation and sickness behavior in aged mice after activation of the peripheral innate immune system	FASEB JOURNAL			English	Article						aging; cytokines; behavior; brain; inflammation	LONG-TERM POTENTIATION; GENE-EXPRESSION; TRANSGENIC MICE; VITAMIN-E; COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; MOUSE MODEL; TNF-ALPHA; BRAIN	Acute cognitive impairment (i.e., delirium) is common in elderly emergency department patients and frequently results from infections that are unrelated to the central nervous system. Since activation of the peripheral innate immune system induces brain microglia to produce inflammatory cytokines that are responsible for behavioral deficits, we investigated if aging exacerbated neuroinflammation and sickness behavior after peripheral injection of lipopolysaccharide (LPS). Microarray analysis revealed a transcriptional profile indicating the presence of primed or activated microglia and increased inflammation in the aged brain. Furthermore, aged mice had a unique gene expression profile in the brain after an intraperitoneal injection of LPS,and the LPS-induced elevation in the brain inflammatory cytokines and oxidative stress was both exaggerated and prolonged compared with adults. Aged mice were anorectic longer and lost more weight than adults after peripheral LPS administration. Moreover, reductions in both locomotor and social behavior remained 24 h later in aged mice, when adults had fully recovered, and the exaggerated neuroinflammatory response in aged mice was not reliably paralleled by increased circulating cytokines in the periphery. Taken together, these data establish that activation of the peripheral innate immune system leads to exacerbated neuroinflammation in the aged as compared with adult mice. This dysregulated link between the peripheral and central innate immune system is likely to be involved in the severe behavioral deficits that frequently occur in older adults with systemic infections.	Univ Illinois, Div Nutr Sci, Urbana, IL 61801 USA; Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Johnson, RW (corresponding author), Univ Illinois, Anim Sci Lab 390, 1207 W Gregory Dr, Urbana, IL 61801 USA.	rwjohn@uiuc.edu		Johnson, Rodney/0000-0002-2376-1852; Kelley, Keith W./0000-0002-6837-8793	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH069148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016710] Funding Source: NIH RePORTER; NIA NIH HHS [AG-16710] Funding Source: Medline; NIMH NIH HHS [MH-069148] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Berg BM, 2004, BRAIN BEHAV IMMUN, V18, P149, DOI 10.1016/S0889-1591(03)00113-2; Blalock EM, 2003, J NEUROSCI, V23, P3807; Blasko I, 2004, AGING CELL, V3, P169, DOI 10.1111/j.1474-9728.2004.00101.x; BLUTHE RM, 1991, EUR J PHARMACOL, V209, P281, DOI 10.1016/0014-2999(91)90184-R; Bluthe RM, 2000, PHYSIOL BEHAV, V70, P367, DOI 10.1016/S0031-9384(00)00269-9; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; BRUGG B, 1995, P NATL ACAD SCI USA, V92, P3032, DOI 10.1073/pnas.92.7.3032; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Capuron L, 2003, BIOL PSYCHIAT, V54, P906, DOI 10.1016/S0006-3223(03)00173-2; Castle SC, 2000, CLIN INFECT DIS, V31, P578, DOI 10.1086/313947; Chorinchath BB, 1996, J IMMUNOL, V156, P1525; Combrinck MI, 2002, NEUROSCIENCE, V112, P7, DOI 10.1016/S0306-4522(02)00030-1; Cunningham C, 2003, EUR J NEUROSCI, V17, P2147, DOI 10.1046/j.1460-9568.2003.02662.x; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Ginaldi L, 2001, MICROBES INFECT, V3, P851, DOI 10.1016/S1286-4579(01)01443-5; Godbout JP, 2004, J NEUROIMMUNOL, V149, P101, DOI 10.1016/j.jneuroim.2003.12.017; Heyser CJ, 1997, P NATL ACAD SCI USA, V94, P1500, DOI 10.1073/pnas.94.4.1500; Holmes C, 2003, J NEUROL NEUROSUR PS, V74, P788, DOI 10.1136/jnnp.74.6.788; JOHNSTON M, 1987, BRIT J MED PSYCHOL, V60, P133, DOI 10.1111/j.2044-8341.1987.tb02723.x; Kalehua AN, 2000, GERONTOLOGY, V46, P115, DOI 10.1159/000022146; Kelley KW, 2003, BRAIN BEHAV IMMUN, V17, pS112; Kheir-Eldin AA, 2001, INT J BIOCHEM CELL B, V33, P475, DOI 10.1016/S1357-2725(01)00032-2; Kiecolt-Glaser JK, 2003, P NATL ACAD SCI USA, V100, P9090, DOI 10.1073/pnas.1531903100; Konsman JP, 2002, TRENDS NEUROSCI, V25, P154, DOI 10.1016/S0166-2236(00)02088-9; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; Li AJ, 1997, BRAIN RES, V748, P30, DOI 10.1016/S0006-8993(96)01283-8; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lue LF, 2001, GLIA, V35, P72, DOI 10.1002/glia.1072; Mattson MP, 2002, PHYSIOL REV, V82, P637, DOI 10.1152/physrev.00004.2002; Morgan TE, 1999, NEUROSCIENCE, V89, P687, DOI 10.1016/S0306-4522(98)00334-0; Morley AA, 2001, BIOGERONTOLOGY, V2, P109, DOI 10.1023/A:1011589218219; Murray CA, 1998, J BIOL CHEM, V273, P12161, DOI 10.1074/jbc.273.20.12161; Musselman DL, 2001, NEW ENGL J MED, V344, P961, DOI 10.1056/NEJM200103293441303; Nguyen MD, 2004, J NEUROSCI, V24, P1340, DOI 10.1523/JNEUROSCI.4786-03.2004; Nicolle MM, 2001, NEUROSCIENCE, V107, P415, DOI 10.1016/S0306-4522(01)00374-8; Perry VH, 2003, NAT REV NEUROSCI, V4, P103, DOI 10.1038/nrn1032; Perry VH, 2004, BRAIN BEHAV IMMUN, V18, P407, DOI 10.1016/j.bbi.2004.01.004; PERRY VH, 1993, GLIA, V7, P60, DOI 10.1002/glia.440070111; Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189; Pollmacher T, 2002, BRAIN BEHAV IMMUN, V16, P525, DOI 10.1016/S0889-1591(02)00004-1; RICHWINE AF, IN PRESS BRAIN BEHAV; Rivest S, 2003, BRAIN BEHAV IMMUN, V17, P13, DOI 10.1016/S0889-1591(02)00055-7; ROBERTS SB, 1994, JAMA-J AM MED ASSOC, V272, P1601, DOI 10.1001/jama.272.20.1601; ROGERS J, 1988, NEUROBIOL AGING, V9, P339, DOI 10.1016/S0197-4580(88)80079-4; Sheffield LG, 1998, NEUROBIOL AGING, V19, P47, DOI 10.1016/S0197-4580(97)00168-1; SIBLEY WA, 1985, LANCET, V1, P1313; Sly LM, 2001, BRAIN RES BULL, V56, P581, DOI 10.1016/S0361-9230(01)00730-4; Streit WJ, 2004, GLIA, V45, P208, DOI 10.1002/glia.10319; Streit WJ, 1997, J MOL MED-JMM, V75, P130, DOI 10.1007/s001090050097; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002; Wilson CJ, 2002, J AM GERIATR SOC, V50, P2041, DOI 10.1046/j.1532-5415.2002.50619.x; Wofford JL, 1996, AM J EMERG MED, V14, P649, DOI 10.1016/S0735-6757(96)90080-7; Xie Z, 2003, EXP NEUROL, V182, P135, DOI 10.1016/S0014-4886(03)00057-8; Ye SM, 2001, J NEUROIMMUNOL, V117, P87, DOI 10.1016/S0165-5728(01)00316-2; Ye SM, 2001, NEUROIMMUNOMODULAT, V9, P183, DOI 10.1159/000049025; Ye SM, 1999, J NEUROIMMUNOL, V93, P139, DOI 10.1016/S0165-5728(98)00217-3; Yirmiya R, 1997, BRAIN RES, V749, P71, DOI 10.1016/S0006-8993(96)01295-4	57	584	597	3	57	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1329	+		10.1096/fj.05-3776fje	http://dx.doi.org/10.1096/fj.05-3776fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15919760				2022-12-28	WOS:000229602600008
J	Sakurai, T; Fujita, Y; Ohto, E; Oguro, A; Atomi, Y				Sakurai, T; Fujita, Y; Ohto, E; Oguro, A; Atomi, Y			The decrease of the cytoskeleton tubulin follows the decrease of the associating molecular chaperone alpha B-crystallin in unloaded soleus muscle atrophy without stretch	FASEB JOURNAL			English	Article						microtubule; small heat shock protein; hindlimb suspension; mechanical stress	HEAT-SHOCK PROTEINS; SKELETAL-MUSCLE; RAT SOLEUS; INTERMEDIATE-FILAMENT; PROTEOMIC ANALYSIS; GENE-EXPRESSION; MESSENGER-RNA; MICROTUBULE; ACTIN; TURNOVER	The cytoskeletal component tubulin/microtubule commonly allows the cell to respond mechanically to the environment. The concentration of free tubulin dimer is autoregulated in the balance of free dimer and polymeric forms of microtubule (MT) protein, having an intrinsic property of "dynamic instability", and through cotranslational beta-tubulin mRNA degradation. Recently, we have demonstrated that alpha B-crystallin is a key molecule of muscle atrophy, since alpha B-crystallin has a chaperone-like-activity that suppresses tubulin aggregation and protects the MT disassembly against both Ca2+ and depolymelizing alkaloid in vitro. Most of the small heat-shock proteins (sHsps), including alpha B-crystallin, are expressed in skeletal muscle. However, no report to date has studied the changes of tubulin/MT during muscle adaptation. Here, we examined changes in tubulin content in rat soleus muscles after hindlimb suspension (HS) with/without passive stretch and the recovery. HS induced rapid decreases of soleus muscle mass, most Hsps ( alpha B-crystallin, Hsp90, Hsp70, Hsp27, and p20) and tubulin contents in soleus muscle, while heat-shock cognate 70-kDa protein (Hsc70) did not decrease. Soleus muscle mass, most Hsps, and tubulin were maintained with passive stretch. After 5 days' recovery, the levels of tubulin and Hsps, but not Hsc70, were restored to control levels. The interactions of alpha B-crystallin and tubulin/MT were observed with immunoprecipitation with an anti-alpha-tubulin antibody and taxol-dependent MT assembly. Other sHsps were also associated with alpha B-crystallin and MT, whereas Hsp90 and Hsp70 did not co-precipitate with them. These data imply an interaction and close relationship between alpha B-crystallin and tubulin/MTs in muscle tissues. The amount of mRNA of alpha B-crystallin decreased with the muscle atrophy level, whereas the gene expression level of beta I-tubulin was maintained during HS. This means a significant role of post-transcriptional regulation in tubulin/MT system in muscle adaptation, whereas alpha B-crystallin and most sHsps are regulated at the transcriptional level. Additional functional contribution of alpha B-crystallin to tubulin/MTs during myotube formation was examined using C2C12 myoblast cultured cells, the alpha B-crystallin expression of which was decreased or increased. It indicated the necessity of alpha B-crystallin during microtubule reorganization. In conclusion, tubulin/MTs were revealed to be early soleus muscle atrophy suggest that the chaperone effect of alpha B-crystallin on the cytoskeleton, which may be also dynamically regulated in the muscle cell, is a key mechanism for muscle adaptation and protection of the atrophy and also muscle differentiation.	Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Meguro Ku, Tokyo 1538902, Japan	University of Tokyo	Atomi, Y (corresponding author), Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Meguro Ku, Tokyo 1538902, Japan.	atomi@idaten.c.u-tokyo.ac.jp	Atomi, Yoriko/AAF-4783-2019	Atomi, Yoriko/0000-0003-3808-6543; Oguro-Ando, Asami/0000-0003-4029-3250				ANTIN PB, 1981, J CELL BIOL, V90, P300, DOI 10.1083/jcb.90.2.300; Appaix F, 2003, EXP PHYSIOL, V88, P175, DOI 10.1113/eph8802511; Arai H, 1997, CELL STRUCT FUNCT, V22, P539, DOI 10.1247/csf.22.539; ATOMI Y, 1991, J BIOCHEM-TOKYO, V110, P812, DOI 10.1093/oxfordjournals.jbchem.a123665; ATOMI Y, 1991, BIOCHEM BIOPH RES CO, V181, P1323, DOI 10.1016/0006-291X(91)92083-V; Atomi Y, 2000, J APPL PHYSIOL, V88, P1355, DOI 10.1152/jappl.2000.88.4.1355; Bluhm WF, 1998, AM J PHYSIOL-HEART C, V275, pH2243, DOI 10.1152/ajpheart.1998.275.6.H2243; BOOTH FW, 1982, J APPL PHYSIOL, V52, P1113; BOOTH FW, 1983, MED SCI SPORT EXER, V15, P415; BOUDRIAU S, 1993, J HISTOCHEM CYTOCHEM, V41, P1013, DOI 10.1177/41.7.8515044; Chang W, 2002, J BIOL CHEM, V277, P30690, DOI 10.1074/jbc.M204930200; Desplanches D, 1997, INT J SPORTS MED, V18, pS259, DOI 10.1055/s-2007-972722; Fujita Y, 2004, J CELL SCI, V117, P1719, DOI 10.1242/jcs.01021; Goldman RD, 1996, J CELL BIOL, V134, P971, DOI 10.1083/jcb.134.4.971; GOLDSPINK DF, 1977, J PHYSIOL-LONDON, V264, P267, DOI 10.1113/jphysiol.1977.sp011667; GOPALAKRISHNAN S, 1992, CURR EYE RES, V11, P929, DOI 10.3109/02713689209033490; GUNDERSEN GG, 1989, J CELL BIOL, V109, P2275, DOI 10.1083/jcb.109.5.2275; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; Isfort RJ, 2002, J CHROMATOGR B, V769, P323, DOI 10.1016/S1570-0232(02)00021-1; Isfort RJ, 2002, PROTEOMICS, V2, P543, DOI 10.1002/1615-9861(200205)2:5<543::AID-PROT543>3.0.CO;2-K; Isfort RJ, 2000, ELECTROPHORESIS, V21, P2228, DOI 10.1002/1522-2683(20000601)21:11<2228::AID-ELPS2228>3.0.CO;2-V; IWAKI T, 1994, J CELL BIOL, V125, P1385, DOI 10.1083/jcb.125.6.1385; Kato K, 1996, J BIOL CHEM, V271, P26989, DOI 10.1074/jbc.271.43.26989; LETERME D, 1994, PFLUG ARCH EUR J PHY, V429, P274, DOI 10.1007/BF00374323; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LOUGHNA P, 1986, J APPL PHYSIOL, V61, P173, DOI 10.1152/jappl.1986.61.1.173; McElhinny AS, 2004, J CELL SCI, V117, P3175, DOI 10.1242/jcs.01158; McKoy G, 1999, J PHYSIOL-LONDON, V516, P583, DOI 10.1111/j.1469-7793.1999.0583v.x; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MOREY ER, 1979, BIOSCIENCE, V29, P168, DOI 10.2307/1307797; Mounier N, 2002, CELL STRESS CHAPERON, V7, P167, DOI 10.1379/1466-1268(2002)007<0167:ACASHS>2.0.CO;2; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; Nikawa T, 2004, FASEB J, V18, P522, DOI 10.1096/fj.03-0419fje; OTEY CA, 1988, CELL MOTIL CYTOSKEL, V9, P337, DOI 10.1002/cm.970090406; Papaseit C, 2000, P NATL ACAD SCI USA, V97, P8364, DOI 10.1073/pnas.140029597; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Perng MD, 1999, J CELL SCI, V112, P2099; Putnam AJ, 2003, AM J PHYSIOL-CELL PH, V284, pC627, DOI 10.1152/ajpcell.00137.2002; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Spencer JA, 2000, J CELL BIOL, V150, P771, DOI 10.1083/jcb.150.4.771; St-Amand J, 2001, FASEB J, V15, P684, DOI 10.1096/fj.00-0150com; Stromer MH, 1998, HISTOL HISTOPATHOL, V13, P283, DOI 10.14670/HH-13.283; Sugiyama Y, 2000, J BIOL CHEM, V275, P1095, DOI 10.1074/jbc.275.2.1095; THEODORAKIS NG, 1992, MOL CELL BIOL, V12, P791, DOI 10.1128/MCB.12.2.791; THOMASON DB, 1990, J APPL PHYSIOL, V68, P1, DOI 10.1152/jappl.1990.68.1.1; TSUTSUI H, 1994, CIRCULATION, V90, P533, DOI 10.1161/01.CIR.90.1.533; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; Yoshioka M, 2003, FASEB J, V17, P1812, DOI 10.1096/fj.02-1200com	48	47	53	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1199	+		10.1096/fj.04-3060fje	http://dx.doi.org/10.1096/fj.04-3060fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15894563				2022-12-28	WOS:000229602600014
J	Andreassi, MG; Cioppa, A; Botto, N; Joksic, G; Manfredi, S; Federici, C; Ostojic, M; Rubino, P; Picano, E				Andreassi, MG; Cioppa, A; Botto, N; Joksic, G; Manfredi, S; Federici, C; Ostojic, M; Rubino, P; Picano, E			Somatic DNA damage in interventional cardiologists: a case control study	FASEB JOURNAL			English	Article						MN assay; professional radiation exposure; low-dose radiation; human lymphocytes	SISTER-CHROMATID EXCHANGES; CHROMOSOMAL-ABERRATIONS; CYTOGENETIC ANALYSIS; IONIZING-RADIATION; LYMPHOCYTES; CANCER; RISK; MICRONUCLEI; BIOMARKERS; PERSONNEL	Interventional cardiologists who work in cardiac catheterization laboratories are exposed to low doses of ionizing radiation that could pose a health hazard. DNA damage is considered to be the main initiating event by which radiation damage to cells results in development of cancer and hereditary disease. The aim of the present study was to assess the effects of chronic low-dose X-ray radiation exposure on somatic DNA damage of interventional cardiologists working in high-volume cardiac catheterization laboratories. For this analysis, we used peripheral lymphocytes and the assay for micronuclei (MNs), which is considered to be a reliable biological dosimeter for radiation exposure. We obtained peripheral blood from 62 physicians (mean age+/-se = 40.6+/-1.5 years): 31 interventional cardiologists (group I, exposed) and 31 age- and sex-matched clinical cardiologists (group II, nonexposed). Interventional cardiologists showed higher MN values (group I=20.5+/-1.6 vs. group II=12.8+/-1.3, P=0.001), although some overlap was apparent in the individual subject analysis. A correlation between years of professional activity and MN frequency value was detectable for interventional cardiologists (r=0.428, P=0.02) but not for clinical cardiologists (r=0.253, P=0.17). The results indicated that, overall, interventional cardiologists working in a high-volume catheterization laboratory have higher levels of somatic DNA damage when compared with clinical cardiologists working outside the catheterization laboratory. The amount of this damage varies and is only weakly related to the duration of professional exposure, which suggests that a dominant modulation of the underlying genetic substrate by environmental factors has a role in determining the harm in individual physicians.	CNR, Inst Clin Physiol, I-54100 Massa, Italy; Vinca Inst Nucl Sci, Belgrade, Serbia Monteneg, Serbia Monteneg	Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); University of Belgrade	Andreassi, MG (corresponding author), CNR, Inst Clin Physiol, Via Aurelia Sud, I-54100 Massa, Italy.	andreas@ifc.cnr.it	Picano, E/G-2261-2014; Botto, Nicoletta/AHD-4957-2022	Joksic, Gordana/0000-0002-7186-301X; Botto, Nicoletta/0000-0002-8336-3610; Andreassi, Maria Grazia/0000-0002-2163-0816; CIOPPA, ANGELO/0000-0003-4324-4227				Andreassi MG, 2003, TRENDS CARDIOVAS MED, V13, P270, DOI 10.1016/S1050-1738(03)00109-9; Andreassi MG, 2002, J AM COLL CARDIOL, V40, P862, DOI 10.1016/S0735-1097(02)02042-9; ANDREASSI MG, 2004, ULTRASOUND, V2, P25; BARQUINERO JF, 1993, MUTAT RES, V286, P275, DOI 10.1016/0027-5107(93)90192-I; Berrington de Gonzalez A, 2004, LANCET, V363, P345, DOI 10.1016/S0140-6736(04)15433-0; BIGATTI P, 1988, MUTAT RES, V204, P343, DOI 10.1016/0165-1218(88)90109-7; Bonassi S, 2004, CYTOGENET GENOME RES, V104, P376, DOI 10.1159/000077519; Bonassi S, 1997, AM J IND MED, V31, P353, DOI 10.1002/(SICI)1097-0274(199703)31:3<353::AID-AJIM12>3.0.CO;2-#; Bozkurt G, 2003, MUTAT RES-GEN TOX EN, V535, P205, DOI 10.1016/S1383-5718(02)00321-2; Brenner DJ, 2003, P NATL ACAD SCI USA, V100, P13761, DOI 10.1073/pnas.2235592100; Cardoso RS, 2001, TERATOGEN CARCIN MUT, V21, P431, DOI 10.1002/tcm.1030; *COMM BIOL EFF ION, 1990, HEALTH EFF EXP LOW L; CORREJA MJ, 2005, IN PRESS INT J CARDI; Fenech M, 2002, TOXICOLOGY, V181, P411, DOI 10.1016/S0300-483X(02)00480-8; FENECH M, 1981, NEW HORIZONS BIOL DO, P373; Finestone A, 2003, ARCH ENVIRON HEALTH, V58, P59, DOI 10.3200/AEOH.58.1.59-62; Garaj-Vrhovac V, 2003, MUTAGENESIS, V18, P265, DOI 10.1093/mutage/18.3.265; Hagmar L, 1998, CANCER RES, V58, P4117; *IAEA, 2001, IAEA TECH REP S, V405; *INT COMM RAD PROT, 1989, 57 ICRP; Jacob K, 2004, CLIN RADIOL, V59, P928, DOI 10.1016/j.crad.2004.04.020; JHA AN, 1991, MUTAT RES, V260, P343, DOI 10.1016/0165-1218(91)90020-M; Kuon E, 2003, BRIT J RADIOL, V76, P406, DOI 10.1259/bjr/82051842; Lee CI, 2004, RADIOLOGY, V231, P393, DOI 10.1148/radiol.2312030767; Limacher MC, 1998, J AM COLL CARDIOL, V31, P892; Maffei F, 2004, MUTAT RES-FUND MOL M, V547, P91, DOI 10.1016/j.mrfmmm.2003.12.003; Maffei F, 2002, MUTAGENESIS, V17, P405, DOI 10.1093/mutage/17.5.405; Maluf SW, 2001, ENVIRON MOL MUTAGEN, V38, P311, DOI 10.1002/em.10029; Markowitz SD, 1997, J CLIN INVEST, V100, P2143, DOI 10.1172/JCI119749; McKetty MH, 1996, HEALTH PHYS, V70, P563, DOI 10.1097/00004032-199604000-00016; Migliore L, 2002, NEUROLOGY, V58, P1809, DOI 10.1212/WNL.58.12.1809; Milacic S, 2004, ENVIRON RES, V95, P2, DOI 10.1016/j.envres.2003.12.006; Miller MC, 2001, TOXICOL LETT, V120, P269, DOI 10.1016/S0378-4274(01)00279-X; NCRP 116. National Council on Radiation Protection and Measurements, 1993, 116 NCRP; PAZYMINO C, 1995, MUTAT RES-ENVIR MUTA, V335, P245, DOI 10.1016/0165-1161(95)00027-5; Picano E, 2004, LANCET, V363, P1909, DOI 10.1016/S0140-6736(04)16373-3; Picano E, 2004, BMJ-BRIT MED J, V328, P578, DOI 10.1136/bmj.328.7439.578; PICANO E, 2004, BRIT MED J, V329, P610; Preston DL, 2003, RADIAT RES, V160, P381, DOI 10.1667/RR3049; Rozgaj R, 1999, OCCUP MED-OXFORD, V49, P353, DOI 10.1093/occmed/49.6.353; Sari-Minodier I, 2002, MUTAT RES-GEN TOX EN, V521, P37, DOI 10.1016/S1383-5718(02)00213-9; SCIOCCHETTI G, 1983, HEALTH PHYS, V45, P385, DOI 10.1097/00004032-198308000-00011; Shiralkar S, 2003, BRIT MED J, V327, P371, DOI 10.1136/bmj.327.7411.371; Smerhovsky Z, 2001, ENVIRON HEALTH PERSP, V109, P41, DOI 10.2307/3434919; Zakeri F, 2004, MUTAT RES-GEN TOX EN, V562, P1, DOI 10.1016/j.mrgentox.2004.04.005; 2001, RADIATION PROTECT, V118	46	78	83	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2005	19	3					998	+		10.1096/fj.04-3287fje	http://dx.doi.org/10.1096/fj.04-3287fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	910AH	15802491				2022-12-28	WOS:000227901300042
J	Al-Lamki, RS; Wang, J; Vandenabeele, P; Bradley, JA; Thiru, S; Luo, DH; Min, W; Pober, JS; Bradley, JR				Al-Lamki, RS; Wang, J; Vandenabeele, P; Bradley, JA; Thiru, S; Luo, DH; Min, W; Pober, JS; Bradley, JR			TNFR1-and TNFR2-mediated signaling pathways in human kidney are cell type-specific and differentially contribute to renal injury	FASEB JOURNAL			English	Article						TNF; ASK1; Etk; apoptosis; proliferation	NECROSIS-FACTOR-RECEPTOR; KINASE; ACTIVATION; TNF; APOPTOSIS; FAMILY; DEATH; ASK1; ETK/BMX	In normal kidney, TNFR1 is expressed in glomerular and peritubular capillary EC, and some tubular cells, and colocalizes with inactive apoptosis signal-regulating kinase-1 (ASK1) phosphorylated at serine 967. Biopsies of rejecting or ischemic renal allografts, which show both tubular cell injury and proliferation, display down-regulation of TNFR1 and activation of ASK1 as well as up-regulation of TNFR2 on tubular cells, where it colocalizes with phosphorylated endothelial/epithelial tyrosine kinase (Etk). We have exploited receptor-selective muteins and evaluated phosphorylation of receptor-specific kinases to study TNF responses in situ. In organ culture, a TNFR1-specific mutein changes phosphorylation of ASK1 to threonine 845, indicative of kinase activation. A TNFR2-specific mutein down-regulates TNFR1 in glomerular EC, up-regulates TNFR2 and Etk in tubular cells, and induces phosphorylation of Etk. Wild-type TNF induces TNFR2 and Etk and activates both ASK1 and Etk but does not down-regulate TNFR1. Wild-type TNF and TNFR1-specific mutein trigger tubular cell apoptosis whereas wild-type TNF and TNFR2-specific mutein induce tubular cells to express proliferating cell nuclear antigen. Differential activation of ASK1 and Etk by regulated TNFRs in patient-derived materials provides an explanation for diverse and opposing responses to TNF at distinct sites, and an in situ bioassay of TNFR signaling.	Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Surg, Cambridge CB2 2QQ, England; State Univ Ghent VIB, Interdept Program Vasc Biol & Transportat, Dept Mol Biomed Res, B-9000 Ghent, Belgium; Yale Univ, Sch Med, Dept Pathol, Boyer Ctr Mol Med, New Haven, CT 06510 USA	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Flanders Institute for Biotechnology (VIB); Ghent University; Yale University	Bradley, JR (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Med, Hills Rd, Cambridge CB2 2QQ, England.	john.bradley@addenbrookes.nhs.uk	Vandenabeele, Peter/C-8597-2009; Vandenabeele, Peter/AAD-5793-2022	Vandenabeele, Peter/0000-0002-6669-8822; Wang, Jun/0000-0003-3667-3760; Bradley, John/0000-0002-7774-8805				Abassi YA, 2003, J BIOL CHEM, V278, P35636, DOI 10.1074/jbc.M306438200; Al-Lamki RS, 2001, LAB INVEST, V81, P1503, DOI 10.1038/labinvest.3780364; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Hamm-Alvarez SF, 2001, AM J PHYSIOL-CELL PH, V280, pC1657, DOI 10.1152/ajpcell.2001.280.6.C1657; Jones SJ, 1999, J IMMUNOL, V162, P1042; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lu F, 2001, CELL RES, V11, P217, DOI 10.1038/sj.cr.7290089; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Pan S, 2002, MOL CELL BIOL, V22, P7512, DOI 10.1128/MCB.22.21.7512-7523.2002; Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SLOWIK MR, 1993, AM J PATHOL, V143, P1724; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; VAN OX, 1994, EUR J BIOCHEM, V220, P771; VAN OX, 1993, NATURE, V361, P266; Zhang HF, 2004, J BIOL CHEM, V279, P44955, DOI 10.1074/jbc.M407617200; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang R, 2003, J CLIN INVEST, V111, P1933, DOI 10.1172/JCI200317790; Zheng LX, 1998, J IMMUNOL, V160, P763	23	119	120	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					1637	1645		10.1096/fj.05-3841com	http://dx.doi.org/10.1096/fj.05-3841com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16195372				2022-12-28	WOS:000232991100041
J	Fu, JD; Li, J; Tweedie, D; Yu, HM; Chen, L; Wang, R; Riordon, DR; Brugh, SA; Wang, SQ; Boheler, KR; Yang, HT				Fu, JD; Li, J; Tweedie, D; Yu, HM; Chen, L; Wang, R; Riordon, DR; Brugh, SA; Wang, SQ; Boheler, KR; Yang, HT			Crucial role of the sarcoplasmic reticulum in the developmental regulation of Ca2+ transients and contraction in cardiomyocytes derived from embryonic stem cells	FASEB JOURNAL			English	Article						cardiomyocyte differentiation; calcium transients; type 2 ryanodine receptor	BETA-ADRENERGIC STIMULATION; CARDIAC MYOCYTES; RYANODINE RECEPTOR; INTRACELLULAR CALCIUM; CHAMBER MYOCARDIUM; MOUSE HEART; RAT; RELEASE; DIFFERENTIATION; CHANNELS	In adult myocardium, excitation-contraction coupling is critically regulated by sarcoplasmic reticulum (SR) Ca2+ release via type 2 ryanodine receptor (RyR2), but generally, it is believed that SR-function is rudimentary in the fetal heart and in embryonic stem (ES) cell-derived cardiomyocytes (ESCMs), a possible source for cell replacement therapies. This study used wild-type (RyR2(+/+)) and RyR2 null ( RyR2(-/-)) ESCMs as an in vitro model of cardiomyogenesis, together with pharmacological approaches and expression profiles of genes relevant for SR function, to elucidate the functional importance of RyR2 and SR on the regulation of Ca2+ transients and contraction during early cardiomyocyte development. During differentiation of RyR2(+/+) ESCMs, SR function developed progressively with increased basal cytosolic free Ca2+ concentration ([ Ca2+] (i)), enhanced frequency and amplitude, and decreased duration of Ca2+ transients that were inhibited by ryanodine and thapsigargin. These functional traits correlated with SR Ca2+ load and the expression of RyR2, SERCA2a, and phospholamban. RyR2-/- ESCMs, comparatively, demonstrated a significantly prolonged time-to-peak and reduced frequency of Ca2+ transients and contractions. beta-adrenergic stimulation of RyR2(+/+) ESCMs increased the frequency and amplitude of Ca2+ transients with differentiation but was much weaker in RyR2(-/-)ESCMs. We conclude that functional SR and control of RyR2-mediated SR Ca2+ release directly contribute to the spontaneous and beta-adrenergic receptor-stimulated contraction of ESCMs, even at very immature stages of development.	Chinese Acad Sci, Mol Cardiol Lab, Inst Hlth Sci, SIBS, Shanghai 200025, Peoples R China; Shanghai Jiao Tong Univ, Sch Med, Shanghai 200025, Peoples R China; Chinese Acad Sci, Key Lab Stem Cell Biol, SIBS, Shanghai 200025, Peoples R China; Chinese Acad Sci, Grad Sch, Shanghai 200025, Peoples R China; NIA, Cardiovasc Sci Lab, Baltimore, MD 21224 USA; Peking Univ, Coll Life Sci, Natl Key Lab Biomembrane & Membrane Biotechnol, Beijing 100871, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Peking University	Yang, HT (corresponding author), Chinese Acad Sci, Mol Cardiol Lab, Inst Hlth Sci, SIBS, 225 Chong Qing Nan Rd,1 Bulg, Shanghai 200025, Peoples R China.	htyang@sibs.ac.cn	Fu, Jidong/E-8173-2012	Wang, Shi-Qiang/0000-0001-7784-4461; Fu, Jidong/0000-0003-2797-5193	NATIONAL INSTITUTE ON AGING [ZIAAG000849, Z01AG000849] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BASSANI JWM, 1995, AM J PHYSIOL-CELL PH, V268, pC1313, DOI 10.1152/ajpcell.1995.268.5.C1313; Bers DM, 2002, FRONT BIOSCI, V7, pD1697, DOI 10.2741/bers; Beutner G, 2001, J BIOL CHEM, V276, P21482, DOI 10.1074/jbc.M101486200; Bogdanov KY, 2001, CIRC RES, V88, P1254, DOI 10.1161/hh1201.092095; Boheler KR, 2002, CIRC RES, V91, P189, DOI 10.1161/01.RES.0000027865.61704.32; Boheler KR, 1999, CELLS TISSUES ORGANS, V165, P237, DOI 10.1159/000016684; Cribbs LL, 2001, CIRC RES, V88, P403; Fabiato A, 1978, Ann N Y Acad Sci, V307, P491, DOI 10.1111/j.1749-6632.1978.tb41979.x; Fijnvandraat AC, 2003, J MOL CELL CARDIOL, V35, P1461, DOI 10.1016/j.yjmcc.2003.09.011; Fijnvandraat AC, 2003, CARDIOVASC RES, V58, P399, DOI 10.1016/S0008-6363(03)00282-7; Freestone NS, 2000, PFLUG ARCH EUR J PHY, V441, P78, DOI 10.1007/s004240000397; Gorza L, 1997, J MOL CELL CARDIOL, V29, P1023, DOI 10.1006/jmcc.1996.0346; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Huser J, 2000, J PHYSIOL-LONDON, V524, P415, DOI 10.1111/j.1469-7793.2000.00415.x; JANCZEWSKI AM, 1995, AM J PHYSIOL-HEART C, V268, pH916, DOI 10.1152/ajpheart.1995.268.2.H916; Liu W, 1999, AM J PHYSIOL-HEART C, V276, pH608, DOI 10.1152/ajpheart.1999.276.2.H608; Liu WR, 2002, LIFE SCI, V71, P1279, DOI 10.1016/S0024-3205(02)01826-X; Lohn M, 2000, CIRC RES, V87, P1034, DOI 10.1161/01.RES.87.11.1034; Maltsev VA, 1999, CIRC RES, V84, P136, DOI 10.1161/01.RES.84.2.136; Mery A, 2005, MOL BIOL CELL, V16, P2414, DOI 10.1091/mbc.E04-10-0883; MOORMAN AFM, 1995, CIRC RES, V76, P616, DOI 10.1161/01.RES.76.4.616; Moorman AFM, 2000, DEV BIOL, V223, P279, DOI 10.1006/dbio.2000.9752; NAKANISHI T, 1988, EXPERIENTIA, V44, P936, DOI 10.1007/BF01939887; PEGG W, 1987, AM J PHYSIOL, V252, pH22, DOI 10.1152/ajpheart.1987.252.1.H22; Sauer H, 2001, AM J PHYSIOL-HEART C, V281, pH411, DOI 10.1152/ajpheart.2001.281.1.H411; Seki S, 2003, CARDIOVASC RES, V58, P535, DOI 10.1016/S0008-6363(03)00255-4; SHAM JSK, 1995, P NATL ACAD SCI USA, V92, P121, DOI 10.1073/pnas.92.1.121; Song LS, 2001, CIRC RES, V88, P794, DOI 10.1161/hh0801.090461; Takahashi A, 1999, PHYSIOL REV, V79, P1089, DOI 10.1152/physrev.1999.79.4.1089; Takeshima H, 2000, MOL CELL, V6, P11, DOI 10.1016/S1097-2765(00)00003-4; Takeshima H, 1998, EMBO J, V17, P3309, DOI 10.1093/emboj/17.12.3309; Terentyev D, 2003, P NATL ACAD SCI USA, V100, P11759, DOI 10.1073/pnas.1932318100; Viatchenko-Karpinski S, 1999, P NATL ACAD SCI USA, V96, P8259, DOI 10.1073/pnas.96.14.8259; Wobus A M, 2002, Methods Mol Biol, V185, P127; Wobus AM, 2005, PHYSIOL REV, V85, P635, DOI 10.1152/physrev.00054.2003; Yang HT, 2002, P NATL ACAD SCI USA, V99, P9225, DOI 10.1073/pnas.142651999; Zhang YM, 2003, AM J PHYSIOL-HEART C, V285, pH2770, DOI 10.1152/ajpheart.01114.2002	38	53	63	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					181	+		10.1096/fj.05-4501fje	http://dx.doi.org/10.1096/fj.05-4501fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	16249315				2022-12-28	WOS:000232991100007
J	Kumarapeli, ARK; Horak, KM; Glasford, JW; Li, J; Chen, QH; Liu, JB; Zheng, HQ; Wang, XJ				Kumarapeli, ARK; Horak, KM; Glasford, JW; Li, J; Chen, QH; Liu, JB; Zheng, HQ; Wang, XJ			A novel transgenic mouse model reveals deregulation of the ubiquitin-proteasome system in the heart by doxorubicin	FASEB JOURNAL			English	Article						proteolysis; peptidase; cardiac function; green fluorescence protein	CARDIOVASCULAR RESEARCH; DILATED CARDIOMYOPATHY; GENETIC-MODIFICATION; DEGRADATION SIGNALS; PROTEIN AGGREGATION; CARDIAC MYOCYTES; CANCER CACHEXIA; QUALITY-CONTROL; 26S PROTEASOME; MICE	Ubiquitin-proteasome system ( UPS) mediated proteolysis is responsible for the degradation of majority of cellular proteins, thereby playing essential roles in maintaining cellular homeostasis and regulating a number of cellular functions. UPS dysfunction was implicated in the pathogenesis of numerous disorders, including neurodegenerative disease, muscular dystrophy, and a subset of cardiomyopathies. However, monitoring in vivo functional changes of the UPS remains a challenge, which hinders the elucidation of UPS pathophysiology. We have recently created a novel transgenic mouse model that ubiquitously expresses a surrogate protein substrate for the UPS. The present study validates its suitability to monitor in vivo changes of UPS proteolytic function in virtually all major organs. Primary culture of cells derived from the adult transgenic mice was also developed and tested for their applications in probing UPS involvement in pathogenesis. Applying these newly established in vivo and in vitro approaches, we have proven in the present study that doxorubicin enhances UPS function in the heart and in cultured cardiomyocytes, suggesting that UPS hyper-function may play an important role in the acute cardiotoxicity of doxorubicin therapy.	S Dakota Res Fdn, Cardiovasc Res Inst, Sioux Falls, SD USA; Univ S Dakota, Sch Med, Div Basic Biomed Sci, Sioux Falls, SD 57105 USA; Guangzhou Med Coll, Dept Pathophysiol, Guangzhou, Guangdong, Peoples R China; Wuhan Univ, Sch Med, Dept Physiol & Pathophysiol, Wuhan 430072, Peoples R China	University of South Dakota; Guangzhou Medical University; Wuhan University	Wang, XJ (corresponding author), Univ S Dakota, Sch Med, Cardiovasc Res Inst, 1100 E 21st St,Suite 700, Sioux Falls, SD 57105 USA.	xwang@usd.edu	Wang, Xuejun/AAT-9490-2021; Wang, Xuejun/K-8874-2013	Wang, Xuejun/0000-0001-9267-1343; Wang, Xuejun/0000-0001-9267-1343; LI, JIE/0000-0003-3902-642X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072166] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL72166, R01 HL072166] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acharyya S, 2004, J CLIN INVEST, V114, P370, DOI 10.1172/jci200420174; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bossy-Wetzel E, 2004, NAT MED, V10, pS2, DOI 10.1038/nm1067; Bulteau AL, 2001, J BIOL CHEM, V276, P30057, DOI 10.1074/jbc.M100142200; Ciftci O, 2001, BLOOD, V97, P2830, DOI 10.1182/blood.V97.9.2830; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; de Vrij FMS, 2004, PROG NEUROBIOL, V74, P249, DOI 10.1016/j.pneurobio.2004.10.001; Dong X, 2004, AM J PHYSIOL-HEART C, V287, pH1417, DOI 10.1152/ajpheart.01233.2003; Dorn GW, 2003, CIRC RES, V92, P1171, DOI 10.1161/01.RES.0000077012.11088.BC; FIELD LJ, 1993, ANNU REV PHYSIOL, V55, P97; Forman MS, 2004, NAT MED, V10, P1055, DOI 10.1038/nm1113; Gilon T, 2000, MOL CELL BIOL, V20, P7214, DOI 10.1128/MCB.20.19.7214-7219.2000; Gilon T, 1998, EMBO J, V17, P2759, DOI 10.1093/emboj/17.10.2759; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Huang WY, 2000, NAT MED, V6, P482, DOI 10.1038/74914; Huber AH, 2001, J BIOL CHEM, V276, P12301, DOI 10.1074/jbc.M010377200; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Kiyomiya K, 1998, LIFE SCI, V62, P1853, DOI 10.1016/S0024-3205(98)00151-9; Kiyomiya KI, 2002, INT J ONCOL, V20, P1205; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Kostin S, 2003, CIRC RES, V92, P715, DOI 10.1161/01.RES.0000067471.95890.5C; Kumarapeli ARK, 2004, J MOL CELL CARDIOL, V37, P1097, DOI 10.1016/j.yjmcc.2004.07.004; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lindsten K, 2003, NAT BIOTECHNOL, V21, P897, DOI 10.1038/nbt851; Liu XW, 2002, AM J PHYSIOL-HEART C, V283, pH254, DOI 10.1152/ajpheart.01023.2001; Liu XW, 2004, AM J PHYSIOL-HEART C, V286, pH933, DOI 10.1152/ajpheart.00759.2003; Luker GD, 2003, NAT MED, V9, P969, DOI 10.1038/nm894; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; Meiners S, 2002, CIRCULATION, V105, P483, DOI 10.1161/hc0402.102951; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; Pasumarthi KBS, 2005, CIRC RES, V96, P110, DOI 10.1161/01.RES.0000152326.91223.4F; Reverte CG, 2001, DEV BIOL, V231, P447, DOI 10.1006/dbio.2001.0153; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Robbins J, 2004, J MOL CELL CARDIOL, V36, P643, DOI 10.1016/j.yjmcc.2004.02.012; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Sarikas A, 2005, CARDIOVASC RES, V66, P33, DOI 10.1016/j.cardiores.2005.01.004; Tisdale MJ, 2000, SCIENCE, V289, P2293, DOI 10.1126/science.289.5488.2293; VARSHAVSKY A, 1991, CELL, V64, P13, DOI 10.1016/0092-8674(91)90202-A; Vikstrom KL, 1998, CIRC RES, V82, P773, DOI 10.1161/01.RES.82.7.773; Vosberg HP, 2005, CARDIOVASC RES, V66, P1, DOI 10.1016/j.cardiores.2005.02.002; Wang XJ, 2003, CIRC RES, V93, P998, DOI 10.1161/01.RES.0000102401.77712.ED; Wang XJ, 2001, CIRC RES, V89, P84, DOI 10.1161/hh1301.092688; Wang XJ, 2001, CIRCULATION, V103, P2402, DOI 10.1161/01.cir.103.19.2402; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weekes J, 2003, PROTEOMICS, V3, P208, DOI 10.1002/pmic.200390029; Yeh ETH, 2002, CIRCULATION, V105, P408, DOI 10.1161/circ.105.4.408; Zhou YY, 2000, AM J PHYSIOL-HEART C, V279, pH429	49	93	96	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2005	19	11					2051	+		10.1096/fj.05-3973fje	http://dx.doi.org/10.1096/fj.05-3973fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16188962				2022-12-28	WOS:000232315700003
J	Mzali, R; Seguin, L; Liot, C; Auger, A; Pacaud, P; Loirand, G; Thibault, C; Pierre, J; Bertoglio, J				Mzali, R; Seguin, L; Liot, C; Auger, A; Pacaud, P; Loirand, G; Thibault, C; Pierre, J; Bertoglio, J			Regulation of Rho signaling pathways in interleukin-2-stimulated human T-lymphocytes	FASEB JOURNAL			English	Article						Rho; GTPases; exchange factors; GTPase activating proteins; cell cycle	GTP-BINDING-PROTEIN; NUCLEOTIDE EXCHANGE FACTOR; ACTIVATING PROTEIN; GTPASES; EXPRESSION; CDC42; RAS; FAMILY; RAC1; ECT2	Rho GTPases are key regulators of many cellular functions, including cytoskeleton organization which is important for cell morphology and mobility, gene expression, cell cycle progression, and cytokinesis. In addition, it has recently been recognized that Rho GTPase activity is required for development of the immune system, as well as for the specialized functions of the peripheral cells that act in the immune response such as antigen presenting cells and lymphocytes. Stimulation of T lymphocytes with interleukin-2 (IL-2) induces clonal expansion of antigen-specific populations and provides a model to study cell cycle entry and cell cycle progression. We have performed gene expression analysis in a model of human T lymphocytes, which proliferate in response to IL-2. In addition to changes in genes relevant to cell cycling and to the antiapoptotic effects of IL-2, we have analyzed expression and variations of more than 300 genes involved in Rho GTPase signaling pathways. We report here that IL-2 regulates the expression of a number of proteins, which participate in the Rho GTPase pathways, including some of the GTPases themselves, GDP/GTP exchange factors, GTPase activating proteins, as well as GDIs and effectors. Our results suggest that regulation of expression of components of the Rho GTPase pathways may be an important mechanism in assembling specific signal transduction cascades that need to be active at certain times during the cell cycle. Some of our findings may also be relevant to the roles of Rho GTPases in T lymphocyte functions and proliferation.	Fac Pharm Paris 11, INSERM, U461, F-92296 Chatenay Malabry, France; Fac Sci, INSERM, U533, Nantes, France; ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Bertoglio, J (corresponding author), Fac Pharm Paris 11, INSERM, U461, 5 Rue Jean Baptiste Clement, F-92296 Chatenay Malabry, France.	j.bertoglio@cep.u-psud.fr	Loirand, Gervaise/K-1834-2014; Pacaud, Pierre/D-6392-2015	Loirand, Gervaise/0000-0002-2306-3931; Thibault-Carpentier, Christelle/0000-0003-1562-1451; SEGUIN, Laetitia/0000-0003-2950-4766; Seguin, Laetitia/0000-0002-9610-7093				Arthur WT, 2002, J BIOL CHEM, V277, P42964, DOI 10.1074/jbc.M207401200; Asselin-Labat ML, 2004, BLOOD, V104, P215, DOI 10.1182/blood-2003-12-4295; Bakker WJ, 2004, J CELL BIOL, V164, P175, DOI 10.1083/jcb.200307056; Beadling Carol, 2002, Med Immunol, V1, P2, DOI 10.1186/1476-9433-1-2; Bellanger JM, 1998, ONCOGENE, V16, P147, DOI 10.1038/sj.onc.1201532; Benvenuti F, 2004, SCIENCE, V305, P1150, DOI 10.1126/science.1099159; Billadeau DD, 1998, J EXP MED, V188, P549, DOI 10.1084/jem.188.3.549; Breslin EM, 2005, BRIT J PHARMACOL, V144, P791, DOI 10.1038/sj.bjp.0706061; Bustelo XR, 2002, BIOESSAYS, V24, P602, DOI 10.1002/bies.10107; Cantrell DA, 2003, IMMUNOL REV, V192, P122, DOI 10.1034/j.1600-065X.2003.00028.x; Chan AML, 1996, ONCOGENE, V12, P1259; Cherry LK, 2004, NAT IMMUNOL, V5, P961, DOI 10.1038/ni1103; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Gesbert F, 1998, J CLIN IMMUNOL, V18, P307, DOI 10.1023/A:1023223614407; Groysman M, 2002, J BIOL CHEM, V277, P50121, DOI 10.1074/jbc.M204299200; Haddad E, 2001, BLOOD, V97, P33, DOI 10.1182/blood.V97.1.33; HORI T, 1987, BLOOD, V70, P1069; Kim JE, 2005, J BIOL CHEM, V280, P5733, DOI 10.1074/jbc.M409298200; Kitamura T, 2001, CELL STRUCT FUNCT, V26, P645, DOI 10.1247/csf.26.645; Kovanen PE, 2003, J BIOL CHEM, V278, P5205, DOI 10.1074/jbc.M209015200; LANG P, 1993, BIOCHEM BIOPH RES CO, V196, P1522, DOI 10.1006/bbrc.1993.2424; LANG P, 1992, J BIOL CHEM, V267, P11677; Li BY, 2000, SCIENCE, V288, P2219, DOI 10.1126/science.288.5474.2219; Liu WM, 2002, BIOINFORMATICS, V18, P1593, DOI 10.1093/bioinformatics/18.12.1593; Lou ZK, 2001, J IMMUNOL, V167, P5749, DOI 10.4049/jimmunol.167.10.5749; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Miletic AV, 2003, CURR OPIN IMMUNOL, V15, P261, DOI 10.1016/S0952-7915(03)00054-2; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Nikolaidou KK, 2004, CURR BIOL, V14, P1822, DOI 10.1016/j.cub.2004.09.080; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Oceguera-Yanez F, 2005, J CELL BIOL, V168, P221, DOI 10.1083/jcb.200408085; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Pellegrin S, 2005, CURR BIOL, V15, P129, DOI 10.1016/j.cub.2005.01.011; REIBEL L, 1991, BIOCHEM BIOPH RES CO, V175, P451, DOI 10.1016/0006-291X(91)91585-Z; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Saito S, 2003, J CELL BIOCHEM, V90, P819, DOI 10.1002/jcb.10688; Salazar MA, 2003, J BIOL CHEM, V278, P49031, DOI 10.1074/jbc.M308104200; Schmidt A, 2002, J BIOL CHEM, V277, P14581, DOI 10.1074/jbc.M111108200; Simpson KJ, 2004, CANCER RES, V64, P8694, DOI 10.1158/0008-5472.CAN-04-2247; Somers WG, 2003, DEV CELL, V4, P29, DOI 10.1016/S1534-5807(02)00402-1; Teramoto H, 2003, ONCOGENE, V22, P2689, DOI 10.1038/sj.onc.1206364; Thompson PW, 2002, J IMMUNOL, V169, P1007, DOI 10.4049/jimmunol.169.2.1007; Toure A, 1998, J BIOL CHEM, V273, P6019, DOI 10.1074/jbc.273.11.6019; Vicente-Manzanares M, 2004, NAT REV IMMUNOL, V4, P110, DOI 10.1038/nri1268; Vicente-Manzanares M, 2003, J IMMUNOL, V171, P1023, DOI 10.4049/jimmunol.171.2.1023; Walmsley MJ, 2003, SCIENCE, V302, P459, DOI 10.1126/science.1089709; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012; Yu H, 2001, J EXP MED, V194, P915, DOI 10.1084/jem.194.7.915; ZALCMAN G, 1995, ONCOGENE, V10, P1935; Zalcman G, 1996, J BIOL CHEM, V271, P30366, DOI 10.1074/jbc.271.48.30366; Zhang D, 2002, IEEE T CIRC SYST VID, V12, P331, DOI 10.1109/TCSVT.2002.1003472	58	15	16	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1911	+		10.1096/fj.05-4030fje	http://dx.doi.org/10.1096/fj.05-4030fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16148026				2022-12-28	WOS:000232315700026
J	Shen, TY; Zong, CH; Hamelberg, D; McCammon, JA; Wolynes, PG				Shen, TY; Zong, CH; Hamelberg, D; McCammon, JA; Wolynes, PG			The folding energy landscape and phosphorylation: modeling the conformational switch of the NFAT regulatory domain	FASEB JOURNAL			English	Article						conformational switch; transcription factor; effective charge; multi-phosphorylation; contact-map PCA	ASSOCIATIVE MEMORY HAMILTONIANS; STRUCTURE-PREDICTION; DYNAMICS; CALCINEURIN; HOMOLOGY; BEHAVIOR	An energy landscape approach predicts the conformational changes of the configurations of the regulatory domain of the protein nuclear factor of activated T cells (NFAT) caused by phosphorylation of specific multiple sites. Structurally local effects and secondary structural changes are modeled using all-atom Brownian dynamics to investigate the changes of the backbone torsional distributions upon phosphorylation. For tertiary and global changes, we employ a coarse-grained model to sample ensembles of conformations both with and without phosphorylation. At the secondary structure level, phosphorylation moderately increases the helical propensity and gives a more rigid local backbone conformation. The tertiary effects of phosphorylation caused by the extensive charge modification are more pronounced and collectively change the conformation of the regulatory domain of NFAT from a flexible globular ensemble to a rather rigid helical bundle, blocking access to the nuclear localization sequence. These studies give computational support to one scenario conjectured from experiments.	Dept Chem & Biochem, La Jolla, CA USA; Ctr Theoret Biol Phys, La Jolla, CA USA; Univ Calif San Diego, Howard Hughes Med Inst, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Pharmacol, San Diego, CA 92103 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Wolynes, PG (corresponding author), 9500 Gilman Dr,Mail Code 0371, La Jolla, CA 92093 USA.	pwolynes@chem.ucsd.edu	McCammon, J. Andrew/AAG-1832-2021; Zong, Chenghang/F-3243-2013; Shen, Tongye/A-9718-2008	Shen, Tongye/0000-0003-1495-3104; Zong, Chenghang/0000-0002-8337-8038; McCammon, J. Andrew/0000-0003-3065-1456				ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; Buck M, 2001, SCIENCE, V291, P2329, DOI 10.1126/science.1060383; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; DAVIS ME, 1991, COMPUT PHYS COMMUN, V62, P187, DOI 10.1016/0010-4655(91)90094-2; Eastwood MP, 2001, IBM J RES DEV, V45, P475, DOI 10.1147/rd.453.0475; FRIEDRICHS MS, 1989, SCIENCE, V246, P371, DOI 10.1126/science.246.4928.371; Hardin C, 2003, P NATL ACAD SCI USA, V100, P1679, DOI 10.1073/pnas.252753899; Hardin C, 2000, P NATL ACAD SCI USA, V97, P14235, DOI 10.1073/pnas.230432197; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; Jolliffe IT., 2002, PRINCIPAL COMPONENT, DOI DOI 10.1007/B98835; Koretke KK, 1996, PROTEIN SCI, V5, P1043; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; MAKAROV AA, 1992, FEBS LETT, V306, P63, DOI 10.1016/0014-5793(92)80838-8; McLachlin DT, 2001, CURR OPIN CHEM BIOL, V5, P591, DOI 10.1016/S1367-5931(00)00250-7; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Papoian GA, 2004, P NATL ACAD SCI USA, V101, P3352, DOI 10.1073/pnas.0307851100; Park S, 2000, P NATL ACAD SCI USA, V97, P7130, DOI 10.1073/pnas.97.13.7130; Qiu D, 1997, J PHYS CHEM A, V101, P3005, DOI 10.1021/jp961992r; Ramelot TA, 2001, J MOL BIOL, V307, P871, DOI 10.1006/jmbi.2001.4535; Schutkowski M, 1998, BIOCHEMISTRY-US, V37, P5566, DOI 10.1021/bi973060z; Shen TY, 2001, J AM CHEM SOC, V123, P9107, DOI 10.1021/ja010190t; Song JX, 2003, J BIOL CHEM, V278, P24714, DOI 10.1074/jbc.M210625200; Tholey A, 2001, BIOCHEMISTRY-US, V40, P225, DOI 10.1021/bi0021277; Volkman BF, 2001, SCIENCE, V291, P2429, DOI 10.1126/science.291.5512.2429	27	44	44	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2005	19	11					1389	1395		10.1096/fj.04-3590hyp	http://dx.doi.org/10.1096/fj.04-3590hyp			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	970NA	16126906				2022-12-28	WOS:000232315700032
J	Mali, RS; Cheng, M; Chintala, SK				Mali, RS; Cheng, M; Chintala, SK			Plasminogen activators promote excitotoxicity-induced retinal damage	FASEB JOURNAL			English	Article						retina; ganglion cells; excitotoxicity; kainic acid; tissue plasminogen activator; urokinase plasminogen activator and non-NMDA receptors	GANGLION-CELL DEATH; ELEVATED GLUTAMATE LEVELS; VITREOUS BODY; KAINIC ACID; NEURONAL DEGENERATION; GRANULE NEURONS; MESSENGER-RNAS; ALBINO-RATS; IN-VIVO; TISSUE	Increased levels of extracellular L-glutamate have been suggested to play a role in retinal damage in a number of blinding diseases such as glaucoma and diabetic retinopathy. Although glutamate can cause retinal damage in part by hyperstimulating its receptors ("excitotoxicity"), the downstream events that lead to retinal damage are poorly understood. In this study, we injected kainic acid (KA), a glutamate receptor agonist that specifically hyperstimulates non-NMDA- type receptors, into the vitreous humor of CD-1 mice and have investigated the role of plasminogen activators (PAs) [tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA)] in excitotoxicity-induced retinal damage. Injection of KA into the vitreous humor led to an up-regulation in tPA and an induction in uPA activity in the retina and this was associated with activation of zymogen plasminogen to active plasmin. Immunocytochemical analysis indicated that retinal ganglion cells (RGCs), constitutively express tPA and release it into the extracellular space upon KA injection. Immunocytochemical analysis also indicated an increase in uPA in the nerve fiber layer after KA injection that was absent in the control retinas. These events were associated with apoptotic death of cells initially in the ganglion cell layer and subsequently in the inner and outer nuclear layer, associated with loss of RGCs and amacrine cells. These phenomena were inhibited when recombinant plasminogen activator inhibitor (rPAI-1) or tPA-STOP were injected into the vitreous humor with KA, whereas a plasmin inhibitor, alpha-2-antiplasmin, failed to attenuate KA-induced retinal damage. Taken together, these results suggest that inhibition of plasminogen activators might attenuate retinal damage in blinding retinal diseases in which hyperstimulation of glutamate receptors is implicated as a causative factor to retinal damage.	Oakland Univ, Eye Res Inst, Rochester, MI 48309 USA	Oakland University	Chintala, SK (corresponding author), Oakland Univ, Eye Res Inst, 409 Dodge Hall, Rochester, MI 48309 USA.	Chintala@oakland.edu			NATIONAL EYE INSTITUTE [R24EY014803, R01EY013643] Funding Source: NIH RePORTER; NEI NIH HHS [EY13643, R01 EY013643, EY014803, R24 EY014803] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ambati J, 1997, ARCH OPHTHALMOL-CHIC, V115, P1161, DOI 10.1001/archopht.1997.01100160331011; Barber AJ, 2003, PROG NEURO-PSYCHOPH, V27, P283, DOI 10.1016/S0278-5846(03)00023-X; Benchenane K, 2004, TRENDS NEUROSCI, V27, P155, DOI 10.1016/j.tins.2003.12.011; BRANDSTATTER JH, 1994, EUR J NEUROSCI, V6, P1100, DOI 10.1111/j.1460-9568.1994.tb00607.x; Brooks DE, 1997, AM J VET RES, V58, P864; Chen SN, 2001, RETINA-J RET VIT DIS, V21, P460, DOI 10.1097/00006982-200110000-00007; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Chintala SK, 2002, J BIOL CHEM, V277, P47461, DOI 10.1074/jbc.M204824200; Christow SP, 1999, EUR J BIOCHEM, V265, P264, DOI 10.1046/j.1432-1327.1999.00729.x; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Das A, 1999, INVEST OPHTH VIS SCI, V40, P809; Dreyer EB, 1996, ARCH OPHTHALMOL-CHIC, V114, P299, DOI 10.1001/archopht.1996.01100130295012; Esser P, 1997, BRIT J OPHTHALMOL, V81, P590, DOI 10.1136/bjo.81.7.590; Fernandez-Monreal M, 2004, MOL CELL NEUROSCI, V25, P594, DOI 10.1016/j.mcn.2003.11.002; Flammer J, 2002, PROG RETIN EYE RES, V21, P359, DOI 10.1016/S1350-9462(02)00008-3; Fletcher EL, 1997, J COMP NEUROL, V380, P449, DOI 10.1002/(SICI)1096-9861(19970421)380:4<449::AID-CNE3>3.0.CO;2-1; FRIEDMAN GC, 1995, J COMP NEUROL, V360, P658; Gualandris A, 1996, J NEUROSCI, V16, P2220; Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232; Hesse L, 2000, RETINA-J RET VIT DIS, V20, P500, DOI 10.1097/00006982-200009000-00011; Hrach CJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P659; Huang YY, 1996, P NATL ACAD SCI USA, V93, P8699, DOI 10.1073/pnas.93.16.8699; IRVINE WD, 1991, ARCH OPHTHALMOL-CHIC, V109, P718, DOI 10.1001/archopht.1991.01080050134044; Izumi Y, 1995, NEUROBIOL DIS, V2, P139, DOI 10.1006/nbdi.1995.0015; IZUMI Y, 1995, J NEUROSCI METH, V60, P219, DOI 10.1016/0165-0270(95)00015-M; JOHNSON MW, 1992, OPHTHALMOLOGY, V99, P515; Kim TW, 2000, ARCH OPHTHALMOL-CHIC, V118, P533; KRYSTOSEK A, 1981, P NATL ACAD SCI-BIOL, V78, P7810, DOI 10.1073/pnas.78.12.7810; KRYSTOSEK A, 1981, SCIENCE, V213, P1532, DOI 10.1126/science.7197054; Lewis H, 1997, OPHTHALMOLOGY, V104, P1847, DOI 10.1016/S0161-6420(97)30018-9; LEWIS H, 1991, AM J OPHTHALMOL, V111, P197, DOI 10.1016/S0002-9394(14)72259-7; Lipton SA, 2003, SURV OPHTHALMOL, V48, pS38, DOI 10.1016/S0039-6257(03)00008-0; LUCAS DR, 1957, ARCH OPHTHALMOL-CHIC, V58, P193; LUTTY GA, 1991, INVEST OPHTH VIS SCI, V32, P237; Majka S, 2001, INVEST OPHTH VIS SCI, V42, P210; Manabe S, 2003, INVEST OPHTH VIS SCI, V44, P385, DOI 10.1167/iovs.02-0187; Masos T, 1997, MOL BRAIN RES, V47, P157, DOI 10.1016/S0169-328X(97)00040-5; MOONEN G, 1982, NATURE, V298, P753, DOI 10.1038/298753a0; MORGAN IG, 1981, NEUROSCI LETT, V21, P275, DOI 10.1016/0304-3940(81)90216-0; Nakajima K, 1996, J NEUROCHEM, V66, P2500; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; OLNEY JW, 1969, J NEUROPATH EXP NEUR, V28, P455, DOI 10.1097/00005072-196907000-00007; Osborne NN, 2004, PROG RETIN EYE RES, V23, P91, DOI 10.1016/j.preteyeres.2003.12.001; Osborne NN, 1996, NEUROCHEM INT, V29, P263, DOI 10.1016/0197-0186(96)00005-8; OSBORNE NN, 1995, INVEST OPHTH VIS SCI, V36, P1692; Osborne NN, 2001, BRIT J OPHTHALMOL, V85, P1252, DOI 10.1136/bjo.85.10.1252; Osborne NN, 1999, SURV OPHTHALMOL, V43, pS102, DOI 10.1016/S0039-6257(99)00044-2; Rogove AD, 1999, J CELL SCI, V112, P4007; Schacke W, 2002, INVEST OPHTH VIS SCI, V43, P2799; SCHWARCZ R, 1977, INVEST OPHTH VIS SCI, V16, P141; SEEDS NW, 1995, SCIENCE, V270, P1992, DOI 10.1126/science.270.5244.1992; SellesNavarro I, 1996, INVEST OPHTH VIS SCI, V37, P2002; Siao CJ, 2002, J NEUROSCI, V22, P3352; SILIPRANDI R, 1992, VISUAL NEUROSCI, V8, P567, DOI 10.1017/S0952523800005666; SISK DR, 1985, GRAEF ARCH CLIN EXP, V223, P250, DOI 10.1007/BF02153655; SISK DR, 1984, INVEST OPHTH VIS SCI, V25, P1124; Sucher NJ, 1997, VISION RES, V37, P3483, DOI 10.1016/S0042-6989(97)00047-3; THANOS S, 1991, EUR J NEUROSCI, V3, P1189, DOI 10.1111/j.1460-9568.1991.tb00054.x; THANOS S, 1993, J NEUROSCI, V13, P455; Thanos S, 2004, EXP EYE RES, V79, P119, DOI 10.1016/j.exer.2004.02.005; Traynelis SF, 2001, NAT MED, V7, P17, DOI 10.1038/83289; TRIPATHI BJ, 1987, OPHTHALMOLOGY, V94, P1434; TRIPATHI RC, 1990, EXP EYE RES, V51, P545, DOI 10.1016/0014-4835(90)90085-9; TRIPATHI RC, 1988, AM J OPHTHALMOL, V106, P719, DOI 10.1016/0002-9394(88)90707-6; Tsirka SE, 1997, J MOL MED, V75, P341, DOI 10.1007/s001090050119; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Tsirka SE, 1996, NATURE, V384, P123, DOI 10.1038/384123b0; Tsirka SE, 1997, J NEUROSCI, V17, P543; Tsirka SE, 1997, P NATL ACAD SCI USA, V94, P9779, DOI 10.1073/pnas.94.18.9779; Vorwerk CK, 1999, SURV OPHTHALMOL, V43, pS142, DOI 10.1016/S0039-6257(99)00017-X; Vorwerk CK, 2004, BRAIN RES BULL, V62, P485, DOI 10.1016/S0361-9230(03)00075-3; Vorwerk CK, 1996, INVEST OPHTH VIS SCI, V37, P1618; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; Yoles E, 1998, ARCH OPHTHALMOL-CHIC, V116, P906, DOI 10.1001/archopht.116.7.906; Zhang X, 2004, INVEST OPHTH VIS SCI, V45, P2374, DOI 10.1167/iovs.03-1239; Zhang X, 2003, MOL VIS, V9, P238	77	41	46	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1280	1289		10.1096/fj.04-3403com	http://dx.doi.org/10.1096/fj.04-3403com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16051695	Green Accepted			2022-12-28	WOS:000231843700035
J	Harfouche, R; Abdel-Malak, NA; Brandes, RP; Karsan, A; Irani, K; Hussain, SNA				Harfouche, R; Abdel-Malak, NA; Brandes, RP; Karsan, A; Irani, K; Hussain, SNA			Roles of reactive oxygen species in angiopoietin-1/tie-2 receptor signaling	FASEB JOURNAL			English	Article						Rac-1; NADPH oxidase; mitogen-activated protein kinases; endothelial cell migration	ENDOTHELIAL GROWTH-FACTOR; NAD(P)H OXIDASE; TYROSINE KINASES; PROTEIN-KINASE; CELL-SURVIVAL; NADPH OXIDASE; ANGIOTENSIN-II; TIE2 RECEPTOR; ACTIVATION; ALPHA	In this study we identified the involvement of reactive oxygen species (ROS) in signaling and biological effects of the angiopoietin-1 (Ang-1)/tie-2 receptor pathway. Exposure of human umbilical vein endothelial cells to Ang-1 ( 50 ng/ml) induced rapid and transient production of ROS, particularly superoxide anions. ROS production was attenuated by preincubation with a peptide (gp91ds-tat) that inhibits the association of the gp91(phox) subunit with the p47(phox) subunit of NADPH oxidase and by the expression of a dominant-negative form of Rac-1 (Rac1N17). These results suggest that ROS production in response to Ang-1 exposure originates mainly from a Rac-1-dependent NADPH oxidase. Overexpression of antioxidants ( superoxide dismutase and catalase) and Rac1N17, as well as preincubation with selective inhibitors of NADPH oxidase augmented basal p38 phosphorylation, inhibited Ang-1-induced PAK-1 phosphorylation and potentiated Ang-1-induced Erk1/2 phosphorylation but had no influence on AKT and SAPK/JNK phosphorylation by Ang-1. Exposure to Ang-1 ( 100 ng/ml) for 5 h induced a threefold increase in endothelial cell migration, a response that was strongly inhibited by overexpression of antioxidants, Rac1N17, and selective NADPH oxidase inhibitors. We conclude that activation of tie-2 receptors by Ang-1 triggers the production of ROS through activation of NADPH oxidase and that ROS generation by Ang-1 promotes endothelial cell migration while negatively regulating Erk1/2 phosphorylation.	Royal Victoria Hosp, Crit Care Div, Montreal, PQ, Canada; Royal Victoria Hosp, Div Resp, Montreal, PQ, Canada; McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada; Goethe Univ Frankfurt, Inst Kardiovask Physiol, D-6000 Frankfurt, Germany; Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; British Columbia Canc Agcy, Dept Med Biophys, Vancouver, BC V5Z 1M9, Canada; British Columbia Canc Agcy, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Johns Hopkins University; University of British Columbia; British Columbia Cancer Agency; British Columbia Cancer Agency	Hussain, SNA (corresponding author), Royal Victoria Hosp, Crit Care Div, Room L3-05,687 Pine Ave W, Montreal, PQ, Canada.	sabah.hussain@muhc.mcgill.ca	Brandes, Ralf P/L-3058-2017; Hussain, Sabah/ABC-5315-2021; Karsan, Aly/K-2067-2015	Brandes, Ralf P/0000-0002-8035-0048; Irani, Kaikobad/0000-0001-9194-7387				Abid MR, 2000, FEBS LETT, V486, P252, DOI 10.1016/S0014-5793(00)02305-X; Aslan M, 2003, ANTIOXID REDOX SIGN, V5, P781, DOI 10.1089/152308603770380089; Bayraktutan U, 2000, ARTERIOSCL THROM VAS, V20, P1903, DOI 10.1161/01.ATV.20.8.1903; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Cascone I, 2003, BLOOD, V102, P2482, DOI 10.1182/blood-2003-03-0670; Cho YJ, 1999, BIOCHEM BIOPH RES CO, V262, P708, DOI 10.1006/bbrc.1999.1274; Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; Donovan D., 2001, Angiogenesis, V4, P113, DOI 10.1023/A:1012218401036; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Frey RS, 2002, CIRC RES, V90, P1012, DOI 10.1161/01.RES.0000017631.28815.8E; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; Harfouche R, 2003, FASEB J, V17, P1523, DOI 10.1096/fj.02-0698fje; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; Kampfer H, 2001, LAB INVEST, V81, P361, DOI 10.1038/labinvest.3780244; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; King K, 2000, HENRY JAMES REV, V21, P1; KOLIZEK TI, 1998, CURR BIOL, V8, P529; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; Kwak HJ, 1999, FEBS LETT, V448, P249, DOI 10.1016/S0014-5793(99)00378-6; Kwon J, 2004, P NATL ACAD SCI USA, V101, P16419, DOI 10.1073/pnas.0407396101; Lassegue B, 2003, AM J PHYSIOL-REG I, V285, pR277, DOI 10.1152/ajpregu.00758.2002; Lee YJ, 2004, J APPL PHYSIOL, V96, P793, DOI 10.1152/japplphysiol.00797.2003; Mahadev K, 2004, CELL SIGNAL, V16, P323, DOI 10.1016/j.cellsig.2003.08.002; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Master Z, 2001, EMBO J, V20, P5919, DOI 10.1093/emboj/20.21.5919; Moldovan L, 2000, CIRC RES, V86, P549, DOI 10.1161/01.RES.86.5.549; Nakatsu MN, 2003, MICROVASC RES, V66, P102, DOI 10.1016/S0026-2862(03)00045-1; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; Papadakis CM, 2000, EUR PHYS J E, V1, P275, DOI 10.1007/s101890050029; Papapetropoulos A, 1999, LAB INVEST, V79, P213; Rey FE, 2001, CIRC RES, V89, P408, DOI 10.1161/hh1701.096037; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Seshiah PN, 2002, CIRC RES, V91, P406, DOI 10.1161/01.RES.0000033523.08033.16; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Usatyuk PV, 2003, ANTIOXID REDOX SIGN, V5, P723, DOI 10.1089/152308603770380025; Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; Weber DS, 2004, CIRC RES, V94, P1219, DOI 10.1161/01.RES.0000126848.54740.4A; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Wu RF, 2003, J BIOL CHEM, V278, P36830, DOI 10.1074/jbc.M302251200; Yamaoka-Tojo M, 2004, CIRC RES, V95, P276, DOI 10.1161/01.RES.0000136522.58649.60	52	97	97	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1728	+		10.1096/fj.04-3621fje	http://dx.doi.org/10.1096/fj.04-3621fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16049136				2022-12-28	WOS:000230923000003
J	Bu, DX; Erl, W; de Martin, R; Hansson, GK; Yan, ZQ				Bu, DX; Erl, W; de Martin, R; Hansson, GK; Yan, ZQ			IKK beta-dependent NF-kappa B pathway controls vascular inflammation and intimal hyperplasia	FASEB JOURNAL			English	Article						nuclear factor-kappa B; angioplastic injury; intima; vascular repair	SMOOTH-MUSCLE-CELLS; KINASE COMPLEX; SYSTEMIC INFLAMMATION; GENE-EXPRESSION; BINDING-SITE; ACTIVATION; ALPHA; INJURY; INHIBITION; CYTOKINE	Nuclear factor-kappaB (NF-kappaB)-mediated vascular inflammation is a prominent characteristic of atherogenesis and restenosis. We noted that angioplastic injury to carotid artery elicited two phases of NF-kappaB activation characterized by an early activation in the arterial media and a late activation coupled with high levels of inhibitor of IkappaB kinase (IKK) activity in intima. These findings prompted us to elucidate the role for the different phases of NF-kappaB activation and IKK in the progress of vascular repair. Our results show that blockade of the early NF-kappaB activation by perivascular administration of pyrrolidine dithiocarbamate transiently attenuates the expression of proinflammatory genes in the injured vessels but does not affect intimal formation. Interruption of IKKbeta by overexpressing a dominant-negative IKKbeta in the injured artery effectively inhibited the late phase of NF-kappaB activation, resulting in down-regulation of inducible nitric oxide synthase, tumor necrosis factor alpha, and monocyte chemoattractant protein-1 expression in conjunction with a 36% reduction in intima size, albeit with a lack of inhibitory effect on the early NF-kappaB activation. Collectively, these findings show that the IKKbeta-mediated late-phase NF-kappaB activation contributes to intimal hyperplasia and the accompanied vascular inflammatory responses.	Karolinska Hosp, Ctr Mol Med, Cardiovasc Res Unit, S-17176 Stockholm, Sweden; Dalian Med Univ, Dalian, Peoples R China; Univ Munich, Inst Prophylaxe Kreislaufrkankheiten, Munich, Germany; Med Univ Vienna, Dept Vasc Biol & Thrombosis Res, Vienna, Austria	Karolinska Institutet; Karolinska University Hospital; Dalian Medical University; University of Munich; Medical University of Vienna	Yan, ZQ (corresponding author), Karolinska Hosp, Ctr Mol Med, Cardiovasc Res Unit, S-17176 Stockholm, Sweden.	zhong-qun.yan@cmm.ki.se	Hansson, Goran K/B-7423-2012	Hansson, Goran/0000-0003-4148-5190				Andreakos E, 2003, ARTHRITIS RHEUM, V48, P1901, DOI 10.1002/art.11044; AUTIERI MV, 1995, BIOCHEM BIOPH RES CO, V213, P827, DOI 10.1006/bbrc.1995.2204; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bourcier T, 1997, J BIOL CHEM, V272, P15817, DOI 10.1074/jbc.272.25.15817; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; Breuss JM, 2002, CIRCULATION, V105, P633, DOI 10.1161/hc0502.102966; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; Danenberg HD, 2002, CIRCULATION, V105, P2917, DOI 10.1161/01.CIR.0000018168.15904.BB; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Denk A, 2001, J BIOL CHEM, V276, P28451, DOI 10.1074/jbc.M102698200; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hawiger J, 1999, BLOOD, V94, P1711, DOI 10.1182/blood.V94.5.1711.417k20_1711_1716; Ialenti A, 2001, N-S ARCH PHARMACOL, V364, P343, DOI 10.1007/s002100100467; Kanters E, 2003, J CLIN INVEST, V112, P1176, DOI 10.1172/JCI18580; Landry DB, 1997, AM J PATHOL, V151, P1085; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Lindner V, 1998, PATHOBIOLOGY, V66, P311, DOI 10.1159/000028039; Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Oitzinger W, 2001, BLOOD, V97, P1611, DOI 10.1182/blood.V97.6.1611; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shintani T, 2002, ANN THORAC SURG, V74, P1132, DOI 10.1016/S0003-4975(02)03921-8; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yan ZQ, 1999, ARTERIOSCL THROM VAS, V19, P2854, DOI 10.1161/01.ATV.19.12.2854; Yan ZQ, 1996, CIRC RES, V79, P38, DOI 10.1161/01.RES.79.1.38; Yoshimura S, 2001, GENE THER, V8, P1635, DOI 10.1038/sj.gt.3301566; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zuckerbraun BS, 2003, J VASC SURG, V38, P812, DOI 10.1016/S0741-5214(03)00427-0	36	40	43	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2005	19	8					1293	+		10.1096/fj.04-2645fje	http://dx.doi.org/10.1096/fj.04-2645fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15939736				2022-12-28	WOS:000230207800032
J	Curfs, DMJ; Knaapen, AM; Pachen, DMFA; Gijbels, MJJ; Lutgens, E; Smook, MLF; Kockx, MM; Daemen, MJAP; van Schooten, FJ				Curfs, DMJ; Knaapen, AM; Pachen, DMFA; Gijbels, MJJ; Lutgens, E; Smook, MLF; Kockx, MM; Daemen, MJAP; van Schooten, FJ			Polycyclic aromatic hydrocarbons induce an inflammatory atherosclerotic plaque phenotype irrespective of their DNA binding properties	FASEB JOURNAL			English	Article						atherosclerosis; chemical carcinogens; DNA adduct formation; inflammation; apoE-KO mice	B6C3F1 MICE; KNOCKOUT MICE; DIOL-EPOXIDES; EXPOSURE; IMMUNOSUPPRESSION; SUPPRESSION; INHIBITION; INVITRO; SPLEEN; CELLS	Although it has been demonstrated that carcinogenic environmental polycyclic aromatic hydrocarbons (PAHs) cause progression of atherosclerosis, the underlying mechanism remains unclear. In the present study, we aimed to investigate whether DNA binding events are critically involved in the progression of PAH-mediated atherogenesis. Apolipoprotein E knockout mice were orally (24 wk, once/wk) exposed to 5 mg/kg benzo[a] pyrene ( B[a] P), or its nonmutagenic, noncarcinogenic structural isoform benzo[e] pyrene ( B[e] P). P-32-postlabeling of lung tissue confirmed the presence of promutagenic PAH-DNA adducts in B[a] P-exposed animals, whereas in B[e] P-exposed and vehicle control animals, these adducts were undetectable. Morphometrical analysis showed that both B[a] P and B[e] P caused an increase in plaque size, whereas location or number of plaques was unaffected. Immunohistochemistry revealed no differences in oxidative DNA damage (8-OHdG) or apoptosis in the plaques. Also plasma lipoprotein levels remained unchanged after PAH-exposure. However, T lymphocytes were increased >= 2-fold in the plaques of B[a]P- and B[e] P- exposed animals. Additionally, B[a] P and to a lesser extent B[e] P exposure resulted in increased TGF beta protein levels in the plaques, that was mainly localized in the plaque macrophages. In vitro studies using the murine macrophage like RAW264.7 cells showed that inhibition of TGF beta resulted in decreased tumor necrosis factor (TNF) alpha release, suggesting that enhanced TGF beta expression in the plaque macrophages contributes to the proinflammatory effects in the vessel wall. In general, this inflammatory reaction in the plaques appeared to be a local response since peripheral blood cell composition ( T cells, B cells, granulocytes, and macrophages) was not changed upon PAH exposure. In conclusion, we showed that both B[a] P and B[e] P cause progression of atherosclerosis, irrespective of their DNA binding properties. Moreover, our data revealed a possible novel mechanism of PAH-mediated atherogenesis, which likely involves a TGF-mediated local inflammatory reaction in the vessel wall.	Univ Maastricht, Dept Hlth Risk Anal & Toxicol, Maastricht, Netherlands; Univ Maastricht, Dept Mol Genet, Maastricht, Netherlands; Univ Maastricht, Dept Pathol, Maastricht, Netherlands; Univ Maastricht, Dept Immunol, Maastricht, Netherlands; Univ Antwerp, Dept Pathol, B-2020 Antwerp, Belgium	Maastricht University; Maastricht University; Maastricht University; Maastricht University; University of Antwerp	van Schooten, FJ (corresponding author), Univ Maastricht, Dept Hlth Risk Anal & Toxicol, Maastricht, Netherlands.	f.vanschooten@grat.unimaas.nl	Lutgens, Esther/E-2919-2010	Lutgens, Esther/0000-0002-2609-5744; Daemen, Mat/0000-0003-1076-199X				ADAMS DH, 1991, J IMMUNOL, V147, P609; BENDITT EP, 1974, CIRCULATION, V50, P650, DOI 10.1161/01.CIR.50.4.650; Binkova B, 2001, INT J HYG ENVIR HEAL, V204, P49, DOI 10.1078/1438-4639-00072; Branen L, 2004, ARTERIOSCL THROM VAS, V24, P2137, DOI 10.1161/01.ATV.0000143933.20616.1b; BURCHIEL SW, 1988, INT J IMMUNOPHARMACO, V10, P369, DOI 10.1016/0192-0561(88)90123-3; Curfs DMJ, 2003, ENVIRON MOL MUTAGEN, V42, P243, DOI 10.1002/em.10200; Curfs DMJ, 2004, AM J PATHOL, V164, P101, DOI 10.1016/S0002-9440(10)63101-X; De Jong WH, 1999, TOXICOL SCI, V50, P214, DOI 10.1093/toxsci/50.2.214; DEAN JH, 1983, CLIN EXP IMMUNOL, V52, P199; DeFlora S, 1997, FASEB J, V11, P1021, DOI 10.1096/fasebj.11.12.9337155; DeFlora S, 1996, MUTAT RES-REV GENET, V366, P197, DOI 10.1016/S0165-1110(96)00043-7; Godschalk RWL, 1998, CARCINOGENESIS, V19, P819, DOI 10.1093/carcin/19.5.819; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Hansson GK, 2001, ARTERIOSCL THROM VAS, V21, P1876, DOI 10.1161/hq1201.100220; HOLLADAY SD, 1995, VET HUM TOXICOL, V37, P99; *INT AG RES CANC, 1983, IARC MON EV CARC RIS, V32, P1; Izzotti A, 2001, FASEB J, V15, P752, DOI 10.1096/fj.00-0312com; Johnson CD, 2003, PHYSIOL GENOMICS, V13, P263, DOI 10.1152/physiolgenomics.00006.2003; LADICS GS, 1991, TOXICOL APPL PHARM, V110, P31, DOI 10.1016/0041-008X(91)90287-O; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Lutgens E, 2002, ARTERIOSCL THROM VAS, V22, P975, DOI 10.1161/01.ATV.0000019729.39500.2F; Mallat Z, 2001, CIRC RES, V89, P930, DOI 10.1161/hh2201.099415; Ross JS, 2001, ANN NY ACAD SCI, V947, P271; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schulick AH, 1998, P NATL ACAD SCI USA, V95, P6983, DOI 10.1073/pnas.95.12.6983; SHERMAN JH, 1993, MOL CARCINOGEN, V8, P264, DOI 10.1002/mc.2940080409; STARY H, 1995, ARTERIOSCLER THROMB, V15, P1513; Stary HC, 1989, ARTERIOSCLER, V99, pI19; THAKKER DR, 1981, CANCER RES, V41, P1389; VAN SF, 1998, FASEB J, V12, P1409; WAKABAYASHI K, 1990, MUTAT RES, V239, P181, DOI 10.1016/0165-1110(90)90005-V; WHITE KL, 1984, CANCER RES, V44, P3388; WHITE KL, 1985, IMMUNOPHARMACOLOGY, V9, P155, DOI 10.1016/0162-3109(85)90011-6; WOOD AW, 1979, J BIOL CHEM, V254, P4408; WOOD AW, 1980, CANCER RES, V40, P1985	36	77	79	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2005	19	8					1290	+		10.1096/fj.04-2269fje	http://dx.doi.org/10.1096/fj.04-2269fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15939734				2022-12-28	WOS:000230207800030
J	Hanlon, PR; Fu, P; Wright, GL; Steenbergen, C; Arcasoy, MO; Murphy, E				Hanlon, PR; Fu, P; Wright, GL; Steenbergen, C; Arcasoy, MO; Murphy, E			Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling	FASEB JOURNAL			English	Article						cardiac; erythropoietin receptor; signal transduction; myocardial infarction	HYPOXIA-INDUCED APOPTOSIS; PKC-EPSILON; ATP CHANNELS; RAT HEARTS; ACTIVATION; PROTECTION; INHIBITOR; TRANSLOCATION; MYOCARDIUM; PATHWAY	Langendorff-perfused rat hearts treated with EPO exhibited significantly improved postischemic recovery of left ventricular developed pressure (LVDP) and reduced infarct size compared with control hearts. Perfusion with the mitogen/extracellular signal- regulated kinase (MEK) inhibitor U0126 just before and concomitant with EPO treatment abolished EPO-induced phosphorylation of the MEK substrate extracellular signal-regulated kinase (ERK) but had no effect of EPO-mediated cardioprotection. EPO treatment of the perfused hearts induced translocation of protein kinase C (PKC) epsilon isoform to the membrane fraction of the hearts and the protective effect of EPO was significantly inhibited by the PKC catalytic inhibitor chelerythrine added before and concomitant with EPO. These data demonstrate that EPO- mediated activation of the PKC signaling pathway before or during ischemia is required for the cardioprotective effect of EPO during ischemia-reperfusion injury. Perfusion with the phosphatidylinositol 3-kinase (PI3K) inhibitors LY294002 or wortmannin just before and concomitant with EPO treatment attenuated EPO-induced phosphorylation of the PI3K substrate Akt but had no effect on EPO-mediated cardioprotection. However, when wortmannin was added during EPO treatment and continued during reperfusion, EPO-mediated cardioprotection was significantly inhibited. We also show that postischemia EPO treatment at the onset of reperfusion significantly improved recovery of LVDP and reduced infarct size. Postischemia cardioprotection by EPO required the PI3K pathway but was not affected by inhibition of PKC at the time of EPO treatment.	Duke Univ, Sch Med, Dept Med, Div Hematol,Med Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University; Duke University	Arcasoy, MO (corresponding author), Duke Univ, Sch Med, Dept Med, Div Hematol,Med Ctr, DUMC Box 3912, Durham, NC 27710 USA.	arcas001@mc.duke.edu			NHLBI NIH HHS [R01 HL039752, HL-39752] Funding Source: Medline; NIDDK NIH HHS [R21 DK-065065] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL039752, R01HL039752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK065065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES010004] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Bianchi R, 2004, P NATL ACAD SCI USA, V101, P823, DOI 10.1073/pnas.0307823100; Cai ZQ, 2004, CIRCULATION, V109, P2050, DOI 10.1161/01.CIR.0000127954.98131.23; Cai ZQ, 2003, CIRCULATION, V108, P79, DOI 10.1161/01.CIR.0000078635.89229.8A; Calvillo L, 2003, P NATL ACAD SCI USA, V100, P4802, DOI 10.1073/pnas.0630444100; Cross HR, 2002, J MOL CELL CARDIOL, V34, P361, DOI 10.1006/jmcc.2001.1518; de Ruijter W, 2003, ANESTH ANALG, V97, P1370, DOI 10.1213/01.ANE.0000081786.74722.DA; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Fryer RM, 2001, J PHARMACOL EXP THER, V296, P642; GANOTE CE, 1985, AM J PATHOL, V120, P129; Hassouna A, 2004, AM J PHYSIOL-CELL PH, V287, pC1418, DOI 10.1152/ajpcell.00144.2004; Hausenloy DJ, 2005, AM J PHYSIOL-HEART C, V288, pH971, DOI 10.1152/ajpheart.00374.2004; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; Inagaki K, 2003, CIRCULATION, V108, P869, DOI 10.1161/01.CIR.0000081943.93653.73; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Kim MH, 2003, BIOCHEM BIOPH RES CO, V309, P1, DOI 10.1016/S0006-291X(03)01525-0; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Lipsic E, 2004, J CARDIOVASC PHARM, V44, P473, DOI 10.1097/01.fjc.0000140209.04675.c3; Liu GS, 1999, J MOL CELL CARDIOL, V31, P1937, DOI 10.1006/jmcc.1999.1026; Liu HP, 2002, AM J PHYSIOL-HEART C, V282, pH1380, DOI 10.1152/ajpheart.00348.2001; LIU YG, 1994, J MOL CELL CARDIOL, V26, P661, DOI 10.1006/jmcc.1994.1078; Matsui T, 2001, CIRCULATION, V104, P330; Moon C, 2003, P NATL ACAD SCI USA, V100, P11612, DOI 10.1073/pnas.1930406100; Ooie T, 2003, CIRC J, V67, P955, DOI 10.1253/circj.67.955; Parsa CJ, 2004, J BIOL CHEM, V279, P20655, DOI 10.1074/jbc.M314099200; Parsa CJ, 2003, J CLIN INVEST, V112, P999, DOI 10.1172/JCI200318200; Ping PP, 1997, CIRC RES, V81, P404, DOI 10.1161/01.RES.81.3.404; Schaffer SW, 2000, AM J PHYSIOL-HEART C, V278, pH1948; Shi Y, 2004, BASIC RES CARDIOL, V99, P173, DOI 10.1007/s00395-004-0455-x; Sun Y, 2004, J CEREBR BLOOD F MET, V24, P259, DOI 10.1097/01.WCB.0000110049.43905.AC; Tong HY, 2000, J BIOL CHEM, V275, P11981, DOI 10.1074/jbc.275.16.11981; Tong HY, 2002, CIRC RES, V90, P377, DOI 10.1161/01.RES.0000012567.95445.55; Tramontano AF, 2003, BIOCHEM BIOPH RES CO, V308, P990, DOI 10.1016/S0006-291X(03)01503-1; van der Meer P, 2004, EUR J HEART FAIL, V6, P853, DOI 10.1016/j.ejheart.2004.03.012; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Vondriska TM, 2001, CIRC RES, V88, P1306, DOI 10.1161/hh1201.092994; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wright GL, 2004, FASEB J, V18, P1031, DOI 10.1096/fj.03-1289fje; Xu PC, 2004, ANESTH ANALG, V99, P993, DOI 10.1213/01.ane.0000131506.38512.7c; Yang CW, 2003, FASEB J, V17, P1754, DOI 10.1096/fj.02-1191fje; Yang XM, 2004, J AM COLL CARDIOL, V44, P1103, DOI 10.1016/j.jacc.2004.05.060	42	98	106	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2005	19	8					1323	+		10.1096/fj.04-3545fje	http://dx.doi.org/10.1096/fj.04-3545fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	15946993				2022-12-28	WOS:000230207800025
J	Barnes, BR; Glnnd, S; Long, YC; Hjalm, G; Andersson, L; Zierath, JR				Barnes, BR; Glnnd, S; Long, YC; Hjalm, G; Andersson, L; Zierath, JR			5 '-AMP-activated protein kinase regulates skeletal muscle glycogen content and ergogenics	FASEB JOURNAL			English	Article						muscle ergogenics; AALPK activity; allosteric regulation; FDL; glycogen supercompensation	GLUCOSE-TRANSPORT; SYNTHASE ACTIVITY; EXERCISE; CONTRACTION; METABOLISM; RATS; ACTIVATION; ISOFORM; INSULIN; PHOSPHORYLATION	5'-AMP-activated protein kinase (AMPK) activity is increased during exercise in an intensity- and glycogen-dependent manner. We previously reported that a mutation in the AMPK gamma 3 subunit (prkag3(225Q)) increases AMPK activity and skeletal muscle glycogen content. Transfection experiments revealed the R225Q mutation is associated with high basal AMPK activity and diminished AMP dependence. Thus, the R225Q mutation can be considered a loss-of-function mutation that abolished allosteric regulation by AMP/ATP, causing increased basal AMPK activity. We used AMPK gamma 3 transgenic (Tg-Prkag3(225Q)) and knockout (Prkag3(-/-)) mice to determine the relationship between AMPK activity, glycogen content, and ergogenics (ability to perform work) in isolated extensor digitorum. longus skeletal muscle after contractions induced by electrical stimulation. Contraction-induced AMPK activity was inversely coupled to glycogen content in wild-type and Tg-Prkag3(225Q) mice, but not in Prkag3(-/-) mice, highlighting a partial feedback control of glycogen on contraction-induced AMPK activity in the presence of a functional AMPK gamma 3 isoform. Skeletal muscle glycogen content was positively correlated to work performance, regardless of genotype. Thus, chronic activation of AMPK by the Prkag-3(225Q) mutation directly influences skeletal muscle ergogenics by enhancing glycogen content. In conclusion, functional studies of the AAPK gamma 3 isoform further support the close connection between glycogen content and exercise performance in skeletal muscle.	Karolinska Inst, Dept Surg Sci, Sect Integrat Physiol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden; Swedish Univ Agr Sci, Dept Mol Biosci, Uppsala, Sweden; Uppsala Univ, Uppsala Biomed Ctr, Swedish Univ Agr Sci, Dept Med Biochem & Microbiol, Uppsala, Sweden; Uppsala Univ, Uppsala Biomed Ctr, Swedish Univ Agr Sci, Dept Anim Breeding & Genet, Uppsala, Sweden	Karolinska Institutet; Karolinska Institutet; Swedish University of Agricultural Sciences; Swedish University of Agricultural Sciences; Uppsala University; Swedish University of Agricultural Sciences; Uppsala University	Zierath, JR (corresponding author), Karolinska Inst, Dept Surg Sci, Sect Integrat Physiol, Von Eulers Vag 4,4th Floor, S-17177 Stockholm, Sweden.	Juleen.Zierath@fyfa.ki.se		Zierath, Juleen/0000-0001-6891-7497				Barnes BR, 2002, DIABETES, V51, P2703, DOI 10.2337/diabetes.51.9.2703; Barnes BR, 2004, J BIOL CHEM, V279, P38441, DOI 10.1074/jbc.M405533200; Bergeron R, 1999, AM J PHYSIOL-ENDOC M, V276, pE938, DOI 10.1152/ajpendo.1999.276.5.E938; BERGSTROM J, 1966, NATURE, V210, P309, DOI 10.1038/210309a0; CARLING D, 1989, BIOCHIM BIOPHYS ACTA, V1012, P81, DOI 10.1016/0167-4889(89)90014-1; CONLEE RK, 1978, AM J PHYSIOL, V235, pR145, DOI 10.1152/ajpregu.1978.235.3.R145; Daniel T, 2002, J BIOL CHEM, V277, P51017, DOI 10.1074/jbc.M207093200; Derave W, 2000, DIABETES, V49, P1281, DOI 10.2337/diabetes.49.8.1281; FELL RD, 1982, J APPL PHYSIOL, V52, P434, DOI 10.1152/jappl.1982.52.2.434; Fogt DL, 2004, AM J PHYSIOL-ENDOC M, V286, pE363, DOI 10.1152/ajpendo.00115.2003; GARETTO LP, 1984, AM J PHYSIOL, V246, pE471, DOI 10.1152/ajpendo.1984.246.6.E471; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Holmes BF, 1999, J APPL PHYSIOL, V87, P1990, DOI 10.1152/jappl.1999.87.5.1990; Hutber CA, 1997, AM J PHYSIOL-ENDOC M, V272, pE262, DOI 10.1152/ajpendo.1997.272.2.E262; Jorgensen SB, 2004, J BIOL CHEM, V279, P1070, DOI 10.1074/jbc.M306205200; Jorgensen SB, 2004, DIABETES, V53, P3074, DOI 10.2337/diabetes.53.12.3074; Milan D, 2000, SCIENCE, V288, P1248, DOI 10.1126/science.288.5469.1248; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Mu J, 2003, BIOCHEM SOC T, V31, P236, DOI 10.1042/bst0310236; Nielsen JN, 2004, P NUTR SOC, V63, P233, DOI 10.1079/PNS2004348; Nielsen JN, 2002, J PHYSIOL-LONDON, V541, P979, DOI 10.1113/jphysiol.2002.018044; Pascoe DD, 1996, SPORTS MED, V21, P98, DOI 10.2165/00007256-199621020-00003; Ryder JW, 2000, J BIOL CHEM, V275, P1457, DOI 10.1074/jbc.275.2.1457; SAHLIN K, 1978, ACTA PHYSIOL SCAND, V104, P370, DOI 10.1111/j.1748-1716.1978.tb06289.x; Song XM, 2002, DIABETOLOGIA, V45, P56, DOI 10.1007/s125-002-8245-8; WALLBERGHENRIKSSON H, 1987, J BIOL CHEM, V262, P7665; WALLBERGHENRIKSSON H, 1984, J APPL PHYSIOL, V57, P1045, DOI 10.1152/jappl.1984.57.4.1045; Wojtaszewski JFP, 2003, BIOCHEM SOC T, V31, P1290; Wojtaszewski JFP, 2002, DIABETES, V51, P284, DOI 10.2337/diabetes.51.2.284; Wojtaszewski JFP, 2003, AM J PHYSIOL-ENDOC M, V284, pE813, DOI 10.1152/ajpendo.00436.2002; YOUNG DA, 1990, DIABETES, V39, P1408, DOI 10.2337/diabetes.39.11.1408	31	56	62	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2005	19	7					773	779		10.1096/fj.04-3221com	http://dx.doi.org/10.1096/fj.04-3221com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15857891				2022-12-28	WOS:000229602600033
J	Sandona, D; Danieli-Betto, D; Germinario, E; Biral, D; Martinello, T; Lioy, A; Tarricone, E; Gastaldello, S; Betto, R				Sandona, D; Danieli-Betto, D; Germinario, E; Biral, D; Martinello, T; Lioy, A; Tarricone, E; Gastaldello, S; Betto, R			The T-tubule membrane ATP-operated P2X(4) receptor influences contractility of skeletal muscle	FASEB JOURNAL			English	Article						extracellular ATP signaling; ATP release; slow- and fast-twitch muscles; twitch potentiation; muscle fatigue	EXTRACELLULAR ATP; P2X(4) RECEPTOR; SARCOPLASMIC-RETICULUM; NUCLEOTIDE RECEPTORS; EXPRESSION; P2Y; ACTIVATION; ADENOSINE; CLONING; RELEASE	Evidence indicates that extracellular ATP may have relevant functions in skeletal muscle, even though the physiological role and distribution of specific signaling pathway elements are not well known. The present work shows that P2X(4) receptor, an extracellular ATP-regulated cell membrane channel permeable to Ca2+, is expressed in several tissues of the rat, including skeletal muscle. A specific antibody detected a protein band of similar to 60 kDa. Immunofluorescence demonstrated that P2X(4) has an intracellular localization, and confocal analysis revealed that the receptor colocalizes with the T-tubule membrane DHP receptor. Considering that the natural agonist of P2X(4) is ATP, we explored if changes of extracellular ATP levels could occur in contracting skeletal muscle to regulate the channel. In vitro experiments showed that substantial ATP is released and rapidly hydrolyzed after electrical stimulation of rat muscle fibers. Results show that the presence of ATP-degrading enzymes (hexokinase/apyrase), inhibitors of P2X receptors or Ca2+-free conditions, all abolished the progressive twitch tension potentiation produced in soleus muscle by low-frequency (0.05 Hz) stimulation. These data reveal that ATP-mediated Ca2+ entry, most likely through P2X(4) receptor, may play an important role in modulating the contractility of skeletal muscle.	CNR, Inst Neurosci, Lab Muscle Biol & Physiopathol, I-35121 Padua, Italy; Univ Padua, Dept Biomed & Expt Sci, I-35100 Padua, Italy; Univ Padua, Dept Human Anat & Physiol, I-35100 Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua	Betto, R (corresponding author), CNR, Inst Neurosci, Lab Muscle Biol & Physiopathol, Viale G Colombo 3, I-35121 Padua, Italy.	romeo.betto@bio.unipd.it	Gastaldello, Stefano/AAM-6768-2020; sandona, dorianna/AAB-9480-2020; Gastaldello, Stefano/AAD-3788-2020	Gastaldello, Stefano/0000-0001-7369-8452; DANIELI, DANIELA/0000-0002-6186-8327; Martinello, Tiziana/0000-0002-5949-6261	NHLBI NIH HHS [HL63903] Funding Source: Medline; Telethon [1286] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063903] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Telethon(Fondazione Telethon); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbracchio MP, 2003, TRENDS PHARMACOL SCI, V24, P52, DOI 10.1016/S0165-6147(02)00038-X; BARTLES JR, 1985, J BIOL CHEM, V260, P2792; Betto R, 1999, J BIOL CHEM, V274, P7907, DOI 10.1074/jbc.274.12.7907; BO XN, 1995, FEBS LETT, V375, P129, DOI 10.1016/0014-5793(95)01203-Q; Bodin P, 2001, NEUROCHEM RES, V26, P959, DOI 10.1023/A:1012388618693; Bogdanov Y, 1998, LIFE SCI, V62, P697, DOI 10.1016/S0024-3205(97)01168-5; BOTTINELLI R, 1994, J PHYSIOL-LONDON, V478, P341, DOI 10.1113/jphysiol.1994.sp020254; Brake AJ, 1996, ANNU REV CELL DEV BI, V12, P519, DOI 10.1146/annurev.cellbio.12.1.519; Buonanno A, 1999, CURR OPIN NEUROBIOL, V9, P110, DOI 10.1016/S0959-4388(99)80014-2; Burnstock G, 2000, BRIT J ANAESTH, V84, P476, DOI 10.1093/oxfordjournals.bja.a013473; Carpenter D, 1999, NEUROSCI LETT, V273, P183, DOI 10.1016/S0304-3940(99)00653-9; Choi RCY, 2001, J NEUROSCI, V21, P9224, DOI 10.1523/JNEUROSCI.21-23-09224.2001; CLOUES R, 1993, PFLUG ARCH EUR J PHY, V424, P152, DOI 10.1007/BF00374606; Collet C, 2002, PFLUG ARCH EUR J PHY, V443, P771, DOI 10.1007/s00424-001-0758-9; Communi D, 2000, CELL SIGNAL, V12, P351, DOI 10.1016/S0898-6568(00)00083-8; CUNHA RA, 1993, PFLUG ARCH EUR J PHY, V424, P503, DOI 10.1007/BF00374914; Danieli-Betto D, 2000, J APPL PHYSIOL, V89, P891, DOI 10.1152/jappl.2000.89.3.891; Delgado J, 1997, BIOCHEM J, V327, P899, DOI 10.1042/bj3270899; Dhulipala PDK, 1998, GENE, V207, P259, DOI 10.1016/S0378-1119(97)00647-1; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Egan TM, 2004, J NEUROSCI, V24, P3413, DOI 10.1523/JNEUROSCI.5429-03.2004; FORRESTER T, 1972, J PHYSIOL-LONDON, V224, P611, DOI 10.1113/jphysiol.1972.sp009915; GarciaGuzman M, 1996, FEBS LETT, V388, P123, DOI 10.1016/0014-5793(96)00499-1; HENNING RH, 1993, BRIT J PHARMACOL, V110, P133, DOI 10.1111/j.1476-5381.1993.tb13782.x; Hong SJ, 1998, J NEUROPHYSIOL, V80, P2550, DOI 10.1152/jn.1998.80.5.2550; Hu B, 2002, J BIOL CHEM, V277, P15752, DOI 10.1074/jbc.M112097200; Hu B, 2001, FASEB J, V15, P2739, DOI 10.1096/fj.01-0445fje; Irwin W, 2002, J BIOL CHEM, V277, P12221, DOI 10.1074/jbc.M108938200; James G, 2002, EUR J PHARMACOL, V447, P247, DOI 10.1016/S0014-2999(02)01756-9; Khakh BS, 1999, J NEUROSCI, V19, P7289, DOI 10.1523/JNEUROSCI.19-17-07289.1999; Kim MS, 2002, ARCH BIOCHEM BIOPHYS, V401, P205; Kirley TL, 1997, J BIOL CHEM, V272, P1076, DOI 10.1074/jbc.272.2.1076; Lazarowski ER, 2003, MOL PHARMACOL, V64, P785, DOI 10.1124/mol.64.4.785; Le KT, 1998, J NEUROSCI, V18, P7152; LI CY, 1993, P NATL ACAD SCI USA, V90, P8264, DOI 10.1073/pnas.90.17.8264; LU Z, 1991, J PHYSIOL-LONDON, V436, P45, DOI 10.1113/jphysiol.1991.sp018538; MARGRETH A, 1993, BIOCHEM BIOPH RES CO, V197, P1303, DOI 10.1006/bbrc.1993.2619; Meyer MP, 1999, DEV DYNAM, V216, P442, DOI 10.1002/(SICI)1097-0177(199912)216:4/5<442::AID-DVDY12>3.0.CO;2-Z; Michel AD, 1997, MOL PHARMACOL, V51, P524; Midrio M, 1997, PFLUG ARCH EUR J PHY, V434, P398, DOI 10.1007/s004240050413; Nori S, 1998, J VASC RES, V35, P179, DOI 10.1159/000025582; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Ryten M, 2002, J CELL BIOL, V158, P345, DOI 10.1083/jcb.200202025; Ryten M, 2001, DEV DYNAM, V221, P331, DOI 10.1002/dvdy.1147; RYTEN M, 2004, FASEB J, V21, P163; SABBADINI RA, 1989, J BIOENERG BIOMEMBR, V21, P163, DOI 10.1007/BF00812068; Sandona D, 2004, BIOCHEM J, V381, P105, DOI 10.1042/BJ20031644; Schiaffino S, 2002, TRENDS PHARMACOL SCI, V23, P569, DOI 10.1016/S0165-6147(02)02111-9; Schwiebert LM, 2002, AM J PHYSIOL-CELL PH, V282, pC289, DOI 10.1152/ajpcell.01387.2000; SEGUELA P, 1996, NEUROSCIENCE, V16, P448; Soto F, 2003, FEBS LETT, V533, P54, DOI 10.1016/S0014-5793(02)03751-1; Soto F, 1996, P NATL ACAD SCI USA, V93, P3684, DOI 10.1073/pnas.93.8.3684; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; Townsend-Nicholson A, 1999, MOL BRAIN RES, V64, P246, DOI 10.1016/S0169-328X(98)00328-3; Urano T, 1997, CANCER RES, V57, P3281; Vizi ES, 2000, J AUTONOM NERV SYST, V81, P278, DOI 10.1016/S0165-1838(00)00129-6; Wells DG, 1995, DEV BIOL, V172, P585, DOI 10.1006/dbio.1995.8062; Yang A, 2004, AM J PHYSIOL-HEART C, V287, pH1096, DOI 10.1152/ajpheart.00079.2004; Zhong Y, 1998, BRIT J PHARMACOL, V125, P771, DOI 10.1038/sj.bjp.0702118; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309	61	36	40	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1184	+		10.1096/fj.04-3333fje	http://dx.doi.org/10.1096/fj.04-3333fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15857823				2022-12-28	WOS:000228865300007
J	Kim, K; Ren, J; Jiang, Y; Ebrahem, Q; Tipps, R; Cristina, K; Xiao, Y; Qiao, J; Taylor, KL; Lum, H; Anand-Apte, B; Xu, Y				Kim, K; Ren, J; Jiang, Y; Ebrahem, Q; Tipps, R; Cristina, K; Xiao, Y; Qiao, J; Taylor, KL; Lum, H; Anand-Apte, B; Xu, Y			GPR4 plays a critical role in endothelial cell function and mediates the effects of sphingosylphosphorylcholine	FASEB JOURNAL			English	Article						angiogenesis; G protein coupled receptor; SPC	PROTEIN-COUPLED RECEPTORS; GROWTH-FACTOR RECEPTOR; LOW-DENSITY-LIPOPROTEIN; SPHINGOSINE 1-PHOSPHATE; LYSOPHOSPHATIDIC ACID; ACTIVATION; MIGRATION; LIGAND; APOPTOSIS; OVARIAN	Angiogenesis is critical for many physiological and pathological processes. We show here that the lipid sphingosylphosphorylcholine (SPC) induces angiogenesis in vivo and GPR4 is required for the biological effects of SPC on endothelial cells (EC). In human umbilical vein EC, down-regulation of GPR4 specifically inhibits SPC-, but not sphingosine-1-phosphate-, or vascular endothelial growth factor (VEGF)-induced tube formation. Re-introduction of GPR4 fully restores the activity of SPC. In microvascular EC, GPR4 plays a pivotal role in cell survival, growth, migration, and tube formation through both SPC-dependent and -independent pathways. The biological effects resulting from SPC/GPR4 interactions involve the activation of both phosphatidylinositol-3 kinase and Akt. Moreover, the effects of SPC on EC require SPC induced trans-phosphorylation and activation of the VEGF receptor 2. These results identify SPC and its receptor, GPR4, as critical regulators of the angiogenic potential of EC.	Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Ophthalm Res, Cole Eye Inst, Cleveland, OH 44195 USA; Rush Univ, Med Ctr, Dept Pharmacol, Chicago, IL 60612 USA; Cleveland Clin Fdn, Ctr Drug Dev & Discovery, Taussig Canc Ctr, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Gynecol & Obstet, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Rush University; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Xu, Y (corresponding author), Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	xuy@ccf.org			NCI NIH HHS [R01-CA89228-01A2] Funding Source: Medline; NEI NIH HHS [R01 EY016490] Funding Source: Medline; NHLBI NIH HHS [R01 HL68804-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089228] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY016490] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068804] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; ADES EW, 1992, J VIROL METHODS, V39, P83, DOI 10.1016/0166-0934(92)90127-Y; Baudhuin LM, 2003, FASEB J, V17, P341, DOI 10.1096/fj.03-0302fje; Bektas M, 2003, BIOCHEMISTRY-US, V42, P12181, DOI 10.1021/bi035051y; BERGER A, 1995, P NATL ACAD SCI USA, V92, P5885, DOI 10.1073/pnas.92.13.5885; Boguslawski G, 2000, BIOCHEM BIOPH RES CO, V272, P603, DOI 10.1006/bbrc.2000.2822; Boguslawski G, 2002, EXP CELL RES, V274, P264, DOI 10.1006/excr.2002.5472; BROOKS PC, 1999, METHODS MOL BIOL, V129; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Dart AM, 1999, CARDIOVASC RES, V43, P308, DOI 10.1016/S0008-6363(99)00150-9; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Folkman J, 2003, SEMIN CANCER BIOL, V13, P159, DOI 10.1016/S1044-579X(02)00133-5; Goppelt-Struebe M, 2000, BIOCHEM J, V345, P217, DOI 10.1042/0264-6021:3450217; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; INOUE N, 1992, CIRC RES, V71, P1410, DOI 10.1161/01.RES.71.6.1410; Karman RJ, 1997, PROSTAG LEUKOTR ESS, V56, P345, DOI 10.1016/S0952-3278(97)90582-2; Kim JH, 2000, IUBMB LIFE, V50, P119, DOI 10.1080/713803698; KUGIYAMA K, 1992, CIRC RES, V71, P1422, DOI 10.1161/01.RES.71.6.1422; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lin P, 2003, J BIOL CHEM, V278, P14379, DOI 10.1074/jbc.M209101200; Lu J, 2002, J LIPID RES, V43, P463; Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905; Lum H, 2003, AM J PHYSIOL-HEART C, V285, pH1786, DOI 10.1152/ajpheart.00359.2003; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Murata Y, 1996, J INVEST DERMATOL, V106, P1242, DOI 10.1111/1523-1747.ep12348937; Murugesan G, 1996, J CLIN INVEST, V97, P2736, DOI 10.1172/JCI118728; Niedernberg A, 2003, BRIT J PHARMACOL, V138, P481, DOI 10.1038/sj.bjp.0705055; Nofer JR, 2001, J BIOL CHEM, V276, P34480, DOI 10.1074/jbc.M103782200; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Radu CG, 2004, P NATL ACAD SCI USA, V101, P245, DOI 10.1073/pnas.2536801100; Rodriguez-Lafrasse C, 1999, NEUROCHEM RES, V24, P199, DOI 10.1023/A:1022501702403; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sengupta S, 2003, FASEB J, V17, P1570, DOI 10.1096/fj.02-1145fje; Sin WC, 2004, ONCOGENE, V23, P6299, DOI 10.1038/sj.onc.1207838; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; STRASBERG PM, 1988, BIOCHEM CELL BIOL, V66, P1322, DOI 10.1139/o88-153; Sun LY, 1996, J INVEST DERMATOL, V106, P232, DOI 10.1111/1523-1747.ep12340570; Uhlenbrock K, 2002, CELL SIGNAL, V14, P941, DOI 10.1016/S0898-6568(02)00041-4; Wettschureck N, 2002, J MOL MED, V80, P629, DOI 10.1007/s00109-002-0370-2; Xiao YJ, 2001, ANAL BIOCHEM, V290, P302, DOI 10.1006/abio.2001.5000; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Xu Yan, 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P23, DOI 10.2174/1568008033340414; Zhong B, 2003, BLOOD, V101, P3240, DOI 10.1182/blood-2001-12-0180; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	46	57	66	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					819	+		10.1096/fj.04-2988fje	http://dx.doi.org/10.1096/fj.04-2988fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15857892				2022-12-28	WOS:000227591900027
J	Layland, J; Cave, AC; Warren, C; Grieve, DJ; Sparks, E; Kentish, JC; Solaro, RJ; Shah, AM				Layland, J; Cave, AC; Warren, C; Grieve, DJ; Sparks, E; Kentish, JC; Solaro, RJ; Shah, AM			Protection against endotoxemia-induced contractile dysfunction in mice with cardiac-specific expression of slow skeletal troponin I	FASEB JOURNAL			English	Article						myocardial contractility; myofilament Ca2+ responsiveness	CALCIUM SENSITIVITY; VENTRICULAR MYOCYTES; MYOFILAMENT RESPONSE; NITRIC-OXIDE; PHOSPHORYLATION; CA2+; RELAXATION; ACTIVATION; PROTEINS; HEARTS	Gram negative endotoxemia is associated with an intrinsic impairment of cardiomyocyte contraction, in part due to a reduction in myofilament Ca2+ responsiveness. Endotoxemic rat hearts show increased cardiac troponin I (cTnI) phosphorylation at serines 23 and 24, residues required for the protein kinase A (PKA)-dependent reduction of myofilament Ca2+ sensitivity after beta-adrenoceptor stimulation. To investigate the functional significance of increased TnI phosphorylation in endotoxemia, we studied the contractile effects of systemic bacterial lipopolysaccharide (LPS) treatment in transgenic mice (TG) with cardiac-specific replacement of cTnI by slow skeletal TnI (ssTnI, which lacks the PKA phosphorylation sites) and matched nontransgenic littermates (NTG) on a CD1 background. In wild-type CD1 mice treated with LPS (6 mg/kg ip), after 16-18 h there was a significant reduction in the maximum rates of left ventricular pressure development and pressure decline in isolated Langendorff-perfused hearts compared with saline-treated controls and a decrease in isolated myocyte unloaded sarcomere shortening from 6.1 +/- 0.2 to 3.9 +/- 0.2% (1 Hz, 32 degrees C, P<0.05). Similarly, in NTG myocytes, endotoxemia reduced myocyte shortening by 42% from 6.7 0.2 to 3.9 +/- 0.1% (P<0.05) with no change in intracellular Ca2+ transients. However, in the TG group, LPS reduced myocyte shortening by only 13% from 7.5 +/- 0.2 to 6.5 +/- 0.2% (P<0.05). LPS treatment significantly reduced the positive inotropic effect of isoproterenol in NTG myocytes but not in TG myocytes, even though isoproterenol-induced increases in Ca2+ transient amplitude were similar in both groups. Only LPS-treated NTG hearts showed a significant increase in cTnI phosphorylation. Investigation of the sarcomere shortening-Ca2+ relationship in Triton-skinned cardiomyocytes revealed a significant reduction in myofilament Ca2+ sensitivity after LPS treatment in NTG myocytes, an effect that was substantially attenuated in TG myocytes. In conclusion, the replacement of cTnI with ssTnI in the heart provides significant protection against endotoxemia-induced cardiac contractile dysfunction, most probably by preserving myofilament Ca2+ responsiveness due to prevention of phosphorylation of TnI at PKA-sensitive sites.	Kings Coll London, GKT Sch Med, Dept Cardiol, Div Cardiovasc, London SE5 9PJ, England; Univ Illinois, Chicago, IL USA	University of London; King's College London; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Shah, AM (corresponding author), Kings Coll London, GKT Sch Med, Dept Cardiol, Div Cardiovasc, Bessemer Rd, London SE5 9PJ, England.	ajay.shah@kcl.ac.uk	Warren, Gordon/A-9794-2008; Grieve, David/F-5035-2010	Warren, Gordon/0000-0002-7073-8524; Shah, Ajay/0000-0002-6547-0631	NHLBI NIH HHS [R37 HL-22231] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN DG, 1985, J MOL CELL CARDIOL, V17, P821, DOI 10.1016/S0022-2828(85)80097-3; BLUMENTHAL DK, 1978, J BIOL CHEM, V253, P334; CAPOGROSSI MC, 1986, J GEN PHYSIOL, V88, P589, DOI 10.1085/jgp.88.5.589; F'entzke RC, 1999, J PHYSIOL-LONDON, V517, P143, DOI 10.1111/j.1469-7793.1999.0143z.x; FRITZ JD, 1989, ANAL BIOCHEM, V180, P205, DOI 10.1016/0003-2697(89)90116-4; Gao WD, 1997, CIRC RES, V80, P393, DOI 10.1161/01.res.0000435855.49359.47; Grocott-Mason RM, 1998, INTENS CARE MED, V24, P286, DOI 10.1007/s001340050570; Kaye DM, 1999, BIOCHEM BIOPH RES CO, V256, P398, DOI 10.1006/bbrc.1999.0346; KENTISH JC, 1991, PFLUG ARCH EUR J PHY, V419, P310, DOI 10.1007/BF00371112; Kentish JC, 2001, CIRC RES, V88, P1059, DOI 10.1161/hh1001.091640; Khadour FH, 2002, AM J PHYSIOL-HEART C, V283, pH1108, DOI 10.1152/ajpheart.00549.2001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Layland J, 2002, J PHYSIOL-LONDON, V540, P457, DOI 10.1113/jphysiol.2001.014126; Layland J, 2004, J PHYSIOL-LONDON, V556, P835, DOI 10.1113/jphysiol.2004.061176; Lim CC, 2001, AM J PHYSIOL-HEART C, V281, pH969, DOI 10.1152/ajpheart.2001.281.2.H969; LINCOLN TM, 1978, J BIOL CHEM, V253, P337; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; Pena JR, 2004, CARDIOVASC RES, V61, P756, DOI 10.1016/j.cardiores.2003.12.019; PFITZER G, 1982, FEBS LETT, V149, P171, DOI 10.1016/0014-5793(82)81095-8; Powers FM, 1998, J MOL CELL CARDIOL, V30, P967, DOI 10.1006/jmcc.1998.0661; Rigby SL, 1998, AM J PHYSIOL-HEART C, V274, pH580, DOI 10.1152/ajpheart.1998.274.2.H580; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; SHAH AM, 1994, CIRC RES, V74, P970, DOI 10.1161/01.RES.74.5.970; SOLARO RJ, 2001, HDB PHYSL, P264; STAHL TJ, 1990, AM J PHYSIOL, V258, pH625, DOI 10.1152/ajpheart.1990.258.3.H625; Tavernier B, 2001, FASEB J, V15, P294, DOI 10.1096/fj.00-0433fje; Tavernier B, 2001, AM J RESP CRIT CARE, V163, P362, DOI 10.1164/ajrccm.163.2.2002128; Tavernier B, 1998, CARDIOVASC RES, V38, P472, DOI 10.1016/S0008-6363(98)00028-5; Terracciano CMN, 1998, J PHYSIOL-LONDON, V512, P651, DOI 10.1111/j.1469-7793.1998.651bd.x; Vila-Petroff MG, 1999, CIRC RES, V84, P1020, DOI 10.1161/01.RES.84.9.1020; Wu LL, 2001, AM J PHYSIOL-REG I, V281, pR408, DOI 10.1152/ajpregu.2001.281.2.R408; Yasuda S, 1997, CIRC RES, V81, P1011; YATES LD, 1983, J MOL BIOL, V168, P123, DOI 10.1016/S0022-2836(83)80326-X; Yuasa K, 1999, J BIOL CHEM, V274, P37429, DOI 10.1074/jbc.274.52.37429; ZHONG JM, 1997, AM J PHYSIOL-HEART C, V273, pH2312	36	126	128	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1137	+		10.1096/fj.04-2519fje	http://dx.doi.org/10.1096/fj.04-2519fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15601671				2022-12-28	WOS:000228865300006
J	Kilic, E; Kilic, U; Soliz, J; Bassetti, CL; Gassmann, M; Hermann, DM				Kilic, E; Kilic, U; Soliz, J; Bassetti, CL; Gassmann, M; Hermann, DM			Brain-derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1/-2 and Akt pathways	FASEB JOURNAL			English	Article						neuroprotection; mitogen-activated protein kinase; phosphatidyl inositol-3 kinase; NO synthase	MICE OVEREXPRESSING ERYTHROPOIETIN; ARTERY-OCCLUSION; RETINAL DEGENERATION; NEURONAL APOPTOSIS; NITRIC-OXIDE; CELL-DEATH; INJURY; KINASE; NEUROPROTECTION; EXPRESSION	Apart from its hematopoietic function, erythropoietin (Epo) exerts neuroprotective functions in brain hypoxia and ischemia. To examine the mechanisms mediating Epo's neuroprotective activity in vivo, we made use of our transgenic mouse line tg21 that constitutively expresses human Epo in brain without inducing excessive erythrocytosis. We show that human Epo is expressed in tg21 brains and that cortical and striatal neurons carry the Epo receptor. After middle cerebral artery occlusion, human Epo potently protected brains of tg21 mice against ischemic injury, both when severe (90 min) and mild (30 min) ischemia was imposed. Histochemical studies revealed that Epo induced an activation of JAK-2, ERK-1/-2, and Akt pathways in the ischemic brain. This activation was associated with elevated Bcl-X-L and decreased NO synthase-1 and -2 levels in neurons. Intracerebroventricular injections of selective inhibitors of ERK-1/-2 (PD98059) or Akt (wortmannin) pathways revealed that both ERK-1/-2 and Akt were required for Epo's neuroprotective function, antagonization of either pathway completely abolishing tissue protection. On the other hand, ERK-1/-2 and Akt blockade did not reverse the neuronal NO synthase-1/-2 inhibition, indicating that Epo down-regulates these NO synthases in an ERK-1/-2 and Akt independent manner. On the basis of our data, the dual activation of ERK-1/-2 and Akt is crucial for Epo's neuroprotective activity.	Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland; Univ Zurich, Inst Vet Physiol, Vetsuisse Fac, Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich	Kilic, E (corresponding author), Univ Zurich Hosp, Dept Neurol, Frauenklin Str 26, CH-8091 Zurich, Switzerland.	ertugrul.kilic@usz.ch	Hermann, Dirk/GZB-9350-2022; Hermann, Dirk M/AAP-5538-2020; Hermann, Dirk M./AAT-3652-2021; Soliz, Jorge/AAA-9752-2022; Kilic, Ertugrul/W-4563-2018	Hermann, Dirk M./0000-0003-0198-3152; Kilic, Ertugrul/0000-0001-6494-8923; Soliz, Jorge/0000-0002-2335-5862; Bassetti, Claudio/0000-0002-4535-0245; Gassmann, Max/0000-0003-2750-8878				Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chong ZZ, 2003, J NEUROSCI RES, V71, P659, DOI 10.1002/jnr.10528; Chong ZZ, 2003, J CEREBR BLOOD F MET, V23, P320, DOI 10.1097/01.WCB.0000050061.57184.AE; DALKARA T, 1994, BRAIN PATHOL, V4, P49; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Gassmann M, 2003, ADV EXP MED BIOL, V543, P323; Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723; Grimm C, 2005, SEMIN CELL DEV BIOL, V16, P531, DOI 10.1016/j.semcdb.2005.03.004; Grimm C, 2004, J NEUROSCI, V24, P5651, DOI 10.1523/JNEUROSCI.1288-04.2004; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Hermann DM, 2001, NEUROBIOL DIS, V8, P655, DOI 10.1006/nbdi.2001.0399; Hermann DM, 2001, NEUROSCIENCE, V104, P947, DOI 10.1016/S0306-4522(01)00125-7; Hirt L, 2004, STROKE, V35, P1738, DOI 10.1161/01.STR.0000131480.03994.b1; Hopfl G, 2004, AM J PHYSIOL-REG I, V286, pR608, DOI 10.1152/ajpregu.00538.2003; Hudson JQ, 2002, PHARMACOTHERAPY, V22, p141S, DOI 10.1592/phco.22.14.141S.33397; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; Jacobs-Helber SM, 2000, BLOOD, V96, P933, DOI 10.1182/blood.V96.3.933.015k52_933_940; Kilic E, 2005, FASEB J, V19, P2026, DOI 10.1096/fj.05-3941fje; Kilic E, 2002, ANN NEUROL, V52, P617, DOI 10.1002/ana.10356; Kilic U, 2005, J PINEAL RES, V38, P67, DOI 10.1111/j.1600-079X.2004.00178.x; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Macdougall Iain C, 2003, Curr Hematol Rep, V2, P459; Maeda K, 1999, NEUROBIOL DIS, V6, P101, DOI 10.1006/nbdi.1998.0235; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; Nagata Y, 1998, BLOOD, V92, P1859, DOI 10.1182/blood.V92.6.1859.418k37_1859_1869; Okuno S, 2004, J NEUROSCI, V24, P7879, DOI 10.1523/JNEUROSCI.1745-04.2004; Ruscher K, 2002, J NEUROSCI, V22, P10291, DOI 10.1523/jneurosci.22-23-10291.2002; Ruschitzka FT, 2000, P NATL ACAD SCI USA, V97, P11609, DOI 10.1073/pnas.97.21.11609; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Squadrito F, 1999, BRIT J PHARMACOL, V127, P482, DOI 10.1038/sj.bjp.0702521; Wang YM, 2005, BRAIN, V128, P52, DOI 10.1093/brain/awh325; Wenger RH, 1998, INT J MOL MED, V2, P317; Wiessner C, 2001, J CEREBR BLOOD F MET, V21, P857, DOI 10.1097/00004647-200107000-00011	37	239	269	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2005	19	12					2026	+		10.1096/fj.05-3941fje	http://dx.doi.org/10.1096/fj.05-3941fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	980CI	15556972				2022-12-28	WOS:000232991100027
J	Nunes, AF; Saraiva, MJ; Sousa, MM				Nunes, AF; Saraiva, MJ; Sousa, MM			Transthyretin knockouts are a new mouse model for increased neuropeptide Y	FASEB JOURNAL			English	Article						lipoprotein lipase; peptidylglycine alpha-amidating monooxygenase; peripheral nerve; depression	VASOACTIVE INTESTINAL POLYPEPTIDE; DORSAL-ROOT GANGLIA; MESSENGER-RNA; LIPOPROTEIN-LIPASE; EXPRESSION; PEPTIDE; CELLS; MONOOXYGENASE; RECEPTOR; BEHAVIOR	Transthyretin (TTR) has access to the brain and nerve through the blood and cerebrospinal fluid. To investigate TTR function in nervous system homeostasis, differential gene expression in wild-type (WT) and TTR knockout ( KO) mice was assessed. Peptidylglycine alpha-amidating monooxygenase (PAM), the rate-limiting enzyme in neuropeptide maturation, is overexpressed in the peripheral (PNS) and central nervous system (CNS) of TTR KOs that, consequently, display increased neuropeptide Y (NPY) levels. NPY acts on energy homeostasis by increasing white adipose tissue lipoprotein lipase (LPL) and decreasing thermogenesis; accordingly, we show increased LPL expression and activity in white adipose tissue, PNS, and CNS as well as decreased body temperature in TTR KOs. Associated to increased NPY levels, TTR KOs display increased carbohydrate consumption and preference. In neuronal cells, absence of TTR is related to increased PAM activity, NPY levels and LPL expression, reinforcing that TTR is involved in neuropeptide maturation and that increased NPY correlates with LPL overexpression in the nervous system. Furthermore, we provide molecular insights to the reduced depressive behavior of TTR KOs, as NPY is anti-depressant. Our findings demonstrate that TTR KOs are a model for increased NPY and that TTR plays a role in nervous system physiology.	Inst Mol & Cellular Biol, Mol Neurobiol Grp, P-4150180 Oporto, Portugal; Univ Porto, ICBAS, P-4100 Oporto, Portugal	Universidade do Porto; Universidade do Porto	Sousa, MM (corresponding author), Inst Mol & Cellular Biol, Mol Neurobiol Grp, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.	msousa@ibmc.up.pt	Sousa, Monica/K-4367-2013; Saraiva, Maria João/K-3907-2013	Sousa, Monica/0000-0002-4524-2260; Saraiva, Maria João/0000-0002-3360-6899				BILLINGTON CJ, 1994, AM J PHYSIOL, V266, pR1765, DOI 10.1152/ajpregu.1994.266.6.R1765; Chen XL, 1997, AM J PHYSIOL-HEART C, V273, pH1737, DOI 10.1152/ajpheart.1997.273.4.H1737; Cougnon-Aptel N, 1999, NEUROSCI LETT, V259, P45, DOI 10.1016/S0304-3940(98)00900-8; EPISKOPOU V, 1993, P NATL ACAD SCI USA, V90, P2375, DOI 10.1073/pnas.90.6.2375; ERNSTROM U, 1995, FEBS LETT, V360, P177, DOI 10.1016/0014-5793(95)00095-Q; ESTEBAN J, 1989, LIFE SCI, V45, P2395, DOI 10.1016/0024-3205(89)90002-7; FORD TA, 1993, J MOL NEUROSCI, V4, P97, DOI 10.1007/BF02782122; Fraboulet S, 1996, ENDOCRINOLOGY, V137, P5493, DOI 10.1210/en.137.12.5493; Heilig M, 2004, NEUROPEPTIDES, V38, P213, DOI 10.1016/j.npep.2004.05.002; HEILIG M, 1988, EUR J PHARMACOL, V147, P465, DOI 10.1016/0014-2999(88)90182-3; Herzog H, 2003, EUR J PHARMACOL, V480, P21, DOI 10.1016/j.ejphar.2003.08.089; Hiruma H, 2000, BRAIN RES, V883, P184, DOI 10.1016/S0006-8993(00)02892-4; Huey PU, 2002, J LIPID RES, V43, P19; Huey PU, 1998, J LIPID RES, V39, P2135; Inui A, 1998, P ASSOC AM PHYSICIAN, V110, P171; Kohno K, 1997, AM J PATHOL, V150, P1497; Liz MA, 2004, J BIOL CHEM, V279, P21431, DOI 10.1074/jbc.M402212200; MAINS RE, 1987, ANN NY ACAD SCI, V493, P278, DOI 10.1111/j.1749-6632.1987.tb27213.x; Pedrazzini T, 2003, CELL MOL LIFE SCI, V60, P350, DOI 10.1007/s000180300029; Prigge ST, 2000, CELL MOL LIFE SCI, V57, P1236, DOI 10.1007/PL00000763; PULFORD D, 2002, SOC NEUR 32 ANN M WA; RAZ A, 1969, J BIOL CHEM, V244, P3230; Redrobe JP, 2002, NEUROPSYCHOPHARMACOL, V26, P615, DOI 10.1016/S0893-133X(01)00403-1; Rovere C, 1996, J BIOL CHEM, V271, P11368, DOI 10.1074/jbc.271.19.11368; Saegusa T, 2003, J VET MED SCI, V65, P1365, DOI 10.1292/jvms.65.1365; Serot JM, 1997, J NEUROL NEUROSUR PS, V63, P506, DOI 10.1136/jnnp.63.4.506; Shi TJS, 1999, NEUROSCIENCE, V93, P741; SOPRANO DR, 1985, J BIOL CHEM, V260, P1793; Sousa JC, 2004, J NEUROCHEM, V88, P1052, DOI 10.1046/j.1471-4159.2003.02309.x; Sousa MM, 2003, PROG NEUROBIOL, V71, P385, DOI 10.1016/j.pneurobio.2003.11.002; Sousa MM, 2000, J LIPID RES, V41, P58; Sousa MM, 2000, LAB INVEST, V80, P1101, DOI 10.1038/labinvest.3780116; SPINDEL ER, 1987, GEN COMP ENDOCR, V67, P67, DOI 10.1016/0016-6480(87)90206-1; STENFORS C, 1989, J NEUROSCI RES, V24, P445, DOI 10.1002/jnr.490240315; Stogner KA, 2000, EUR J PHARMACOL, V387, pR9, DOI 10.1016/S0014-2999(99)00800-6; Sunman JA, 2004, MOL CARCINOGEN, V41, P231, DOI 10.1002/mc.20060; THEODORSSONNORHEIM E, 1987, LIFE SCI, V41, P845, DOI 10.1016/0024-3205(87)90177-9; Thiele TE, 1998, NATURE, V396, P366, DOI 10.1038/24614; Thorsell A, 2000, P NATL ACAD SCI USA, V97, P12852, DOI 10.1073/pnas.220232997; Valenzuela RF, 2000, J NEUROL SCI, V173, P140, DOI 10.1016/S0022-510X(99)00316-0; Vasquez PAJ, 2000, BEHAV BRAIN RES, V111, P115, DOI 10.1016/S0166-4328(00)00142-X; White DM, 1996, NEUROSCIENCE, V73, P881, DOI 10.1016/0306-4522(96)00055-3; WIDDOWSON PS, 1992, J NEUROCHEM, V59, P73, DOI 10.1111/j.1471-4159.1992.tb08877.x; WIDERLOV E, 1988, J PSYCHIATR RES, V22, P69, DOI 10.1016/0022-3956(88)90030-1; ZACHRISSON O, 1995, NEUROSCI LETT, V194, P89, DOI 10.1016/0304-3940(95)11735-F	45	64	70	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2005	19	13					166	+		10.1096/fj.05-4106fje	http://dx.doi.org/10.1096/fj.05-4106fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	994TC	16263939				2022-12-28	WOS:000234053100022
J	Kunzelmann, K; Sun, J; Markovich, D; Konig, J; Murle, B; Mall, M; Schreiber, R				Kunzelmann, K; Sun, J; Markovich, D; Konig, J; Murle, B; Mall, M; Schreiber, R			Control of ion transport in mammalian airways by protease activated receptors type 2 (PAR-2)	FASEB JOURNAL			English	Article						airway epithelium; trypsin; tryptase	CYSTIC-FIBROSIS MOUSE; CL-SECRETION; INFLAMMATION; INHIBITION; MODULATION; EXPRESSION; EPITHELIUM; CHANNELS	Protease-activated receptors (PARs) are widely distributed in human airways. They couple to G-proteins and are activated after proteolytic cleavage of the N terminus of the receptor. Evidence is growing that PAR subtype 2 plays a pivotal role in inflammatory airway diseases, such as allergic asthma or bronchitis. However, nothing is known about the effects of PAR-2 on electrolyte transport in the native airways. PAR-2 is expressed in airway epithelial cells, where they are activated by mast cell tryptase, neutrophil proteinase 3, or trypsin. Recent studies produced conflicting results about the functional consequence of PAR-2 stimulation. Here we report that stimulation of PAR-2 receptors in mouse and human airways leads to a change in electrolyte transport and a shift from absorption to secretion. Although PAR-2 appears to be expressed on both sides of the epithelium, only basolateral stimulation results in inhibition of amiloride sensitive Na+ conductance and stimulation of both luminal Cl- channels and basolateral K+ channels. The present data indicate that these changes occur through activation of phospholipase C and increase in intracellular Ca2+, which activates basolateral SK4 K+ channels and luminal Ca2+-dependent Cl- channels. In addition, the present data suggest a PAR-2 mediated release of prostaglandin E2, which may contribute to the secretory response. In conclusion, these results provide further evidence for a role of PAR-2 in inflammatory airway disease: stimulation of these receptors may cause accumulation of airway surface liquid, which, however, may help to flush noxious stimuli away from the affected airways.	Univ Regensburg, Inst Physiol, D-93053 Regensburg, Germany; Univ Queensland, Sch Biomed Sci, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia; Heidelberg Univ, Kinderklin 3, Mukoviszidose Zentrum, Heidelberg, Germany	University of Regensburg; University of Queensland; Ruprecht Karls University Heidelberg	Kunzelmann, K (corresponding author), Univ Regensburg, Inst Physiol, Univ Str 31, D-93053 Regensburg, Germany.	uqkkunze@mailbox.uq.edu.au	Markovich, Daniel/F-7884-2012; Mall, Marcus A./AAA-1498-2022; Schreiber, Robert/Q-7550-2019	Mall, Marcus A./0000-0002-4057-2199; Kunzelmann, Karl/0000-0002-4583-7037				Cenac N, 2003, J IMMUNOL, V170, P4296, DOI 10.4049/jimmunol.170.8.4296; Cenac N, 2002, AM J PATHOL, V161, P1903, DOI 10.1016/S0002-9440(10)64466-5; Chambers LS, 2001, AM J PHYSIOL-LUNG C, V281, pL1369, DOI 10.1152/ajplung.2001.281.6.L1369; Cicala C, 2001, BRIT J PHARMACOL, V132, P1229, DOI 10.1038/sj.bjp.0703934; Cocks TM, 2001, PULM PHARMACOL THER, V14, P183, DOI 10.1006/pupt.2001.0285; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Cottrell GS, 2004, J BIOL CHEM, V279, P13532, DOI 10.1074/jbc.M312090200; Cuffe JE, 2002, J PHYSIOL-LONDON, V539, P209, DOI 10.1113/jphysiol.2001.013159; D'Andrea MR, 1998, J HISTOCHEM CYTOCHEM, V46, P157; Danahay H, 2001, AM J PHYSIOL-CELL PH, V280, pC1455, DOI 10.1152/ajpcell.2001.280.6.C1455; Ellis CA, 1999, AM J PHYSIOL-CELL PH, V276, pC38, DOI 10.1152/ajpcell.1999.276.1.C38; Fiorucci S, 2001, P NATL ACAD SCI USA, V98, P13936, DOI 10.1073/pnas.241377298; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; KAWABATA A, 2004, IN PRESS J PHARM EXP; Knight DA, 2001, J ALLERGY CLIN IMMUN, V108, P797, DOI 10.1067/mai.2001.119025; KOSLOWSKY T, 1994, PFLUG ARCH EUR J PHY, V428, P597, DOI 10.1007/BF00374583; Kunzelmann K, 2004, FASEB J, V18, P142, DOI 10.1096/fj.04-2314fje; Lan RS, 2004, AM J PHYSIOL-LUNG C, V286, pL388, DOI 10.1152/ajplung.00286.2003; Lan RS, 2001, BRIT J PHARMACOL, V132, P93, DOI 10.1038/sj.bjp.0703776; Lindner JR, 2000, J IMMUNOL, V165, P6504, DOI 10.4049/jimmunol.165.11.6504; Ma HP, 2002, J BIOL CHEM, V277, P7641, DOI 10.1074/jbc.C100737200; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Mall M, 2003, PEDIATR RES, V53, P608, DOI 10.1203/01.PDR.0000057204.51420.DC; Mall M, 2000, AM J RESP CELL MOL, V23, P283, DOI 10.1165/ajrcmb.23.3.4060; MALL M, 2002, AM J PHYSIOL, V282, P200; Nguyen C, 2003, CAN J PHYSIOL PHARM, V81, P920, DOI 10.1139/Y03-080; Nguyen TD, 1999, J CLIN INVEST, V103, P261, DOI 10.1172/JCI2539; Oceandy D, 2003, J MEMBRANE BIOL, V192, P159, DOI 10.1007/s00232-002-1072-y; Oceandy D, 2002, HUM MOL GENET, V11, P1059, DOI 10.1093/hmg/11.9.1059; Reed DE, 2003, J PHYSIOL-LONDON, V547, P531, DOI 10.1113/jphysiol.2002.032011; Ricciardolo FLM, 2000, AM J RESP CRIT CARE, V161, P1672, DOI 10.1164/ajrccm.161.5.9907133; Risse PA, 2004, LIFE SCI, V75, P991, DOI 10.1016/j.lfs.2004.02.008; Rochelle LG, 2000, AM J PHYSIOL-LUNG C, V279, pL14, DOI 10.1152/ajplung.2000.279.1.L14; Schmidlin F, 2001, AM J RESP CRIT CARE, V164, P1276, DOI 10.1164/ajrccm.164.7.2101157; Vergnolle N, 2004, BRIT J PHARMACOL, V141, P1264, DOI 10.1038/sj.bjp.0705750; Vergnolle N, 1998, P NATL ACAD SCI USA, V95, P7766, DOI 10.1073/pnas.95.13.7766; Witko-Sarsat V, 1999, AM J RESP CELL MOL, V20, P729, DOI 10.1165/ajrcmb.20.4.3371; Yue G, 2002, J BIOL CHEM, V277, P11965, DOI 10.1074/jbc.M108951200	38	89	90	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					969	+		10.1096/fj.04-2469fje	http://dx.doi.org/10.1096/fj.04-2469fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15809358				2022-12-28	WOS:000228865300031
